PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Elbehti, A; Nitschke, W; Tron, P; Michel, C; Lemesle-Meunier, D				Elbehti, A; Nitschke, W; Tron, P; Michel, C; Lemesle-Meunier, D			Redox components of cytochrome bc-type enzymes in acidophilic prokaryotes I. Characterization of the cytochrome bc(1)-type complex of the acidophilic ferrous ion-oxidizing bacterium Thiobacillus ferrooxidans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TYPE CYTOCHROMES; BLUE COPPER PROTEIN; IRON-SULFUR CLUSTER; ELECTRON-TRANSFER; RESPIRATORY-CHAIN; PURIFICATION; OXIDATION; INHIBITORS; MEMBRANE; MITOCHONDRIA	The redox components of the cytochrome bc(1) complex from the acidophilic chemolithotrophic organism Thiobacillus ferrooxidans were investigated by potentiometric and spectroscopic techniques. Optical redox titrations demonstrated the presence of two b-type hemes with differing redox midpoint potentials at pH 7.4 (-169 and +20 mV for b(L) and b(H), respectively). At pH 3.5, by contrast, both hemes appeared to titrate at about +20 mV, Antimycin A, 2-heptyl-4-hydroxyquinoline N-oxide, and stigmatellin induced distinguishable shifts of the b hemes' alpha-bands, providing evidence for the binding of antimycin A and 2-heptyl-4-hydroxyquinoline N-oxide near heme b(H) (located on the cytosolic side of the membrane) and of stigmatellin near heme b(L) (located on the periplasmic side of the membrane). The inhibitors stigmatellin, 5-(n-undecyl)-6-hydroxy-4,7-dioxobenzothiazole, and 2,5-dibromo-3-methyl-6-isopropyl-p-benzoquinone affected the EPR spectrum of the Rieske iron-sulfur center in a way that differs from what has been observed for cytochrome bc(1) or b(6)f complexes. The results obtained demonstrate that the T. ferrooxidans complex, although showing most of the features characteristic for be, complexes, contains unique properties that are most probably related to the chemolithotrophicity and/or acidophilicity of its parent organism. A speculative model for reverse electron transfer through the T, ferrooxidans complex is proposed.	CNRS, Inst Biol Struct & Microbiol, Lab Bioenerget & Ingn Prot, F-13402 Marseille 20, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite	Lemesle-Meunier, D (corresponding author), CNRS, Inst Biol Struct & Microbiol, Lab Bioenerget & Ingn Prot, 31 Chemin Joseph Aiguier, F-13402 Marseille 20, France.	lemesle@ibsm.cnrs-mrs.fr	Nitschke, Wolfgang/C-4812-2012	Nitschke, Wolfgang/0000-0003-2084-3032; MICHEL, Caroline/0000-0002-0515-4637				Appia-Ayme C, 1998, FEMS MICROBIOL LETT, V167, P171, DOI 10.1111/j.1574-6968.1998.tb13224.x; APPIAAYME C, 1998, THESIS U MARSEILLE 2; BODO C, 1974, CAN J MICROBIOL, V20, P1647, DOI 10.1139/m74-256; BRANDT U, 1988, EUR J BIOCHEM, V173, P499, DOI 10.1111/j.1432-1033.1988.tb14026.x; BRANDT U, 1994, CRIT REV BIOCHEM MOL, V29, P165, DOI 10.3109/10409239409086800; BROWN RC, 1973, AM J CLIN PATHOL, V60, P234; BRUNGNA M, 1999, J BIOL CHEM, V274, P16766; CAVAZZA C, 1995, FEMS MICROBIOL LETT, V130, P193; Cavazza C, 1996, EUR J BIOCHEM, V242, P308, DOI 10.1111/j.1432-1033.1996.0308r.x; COBLEY JG, 1975, FEBS LETT, V60, P29, DOI 10.1016/0014-5793(75)80411-X; COX JC, 1978, BIOCHEM J, V174, P497, DOI 10.1042/bj1740497; COX JC, 1979, BIOCHEM J, V178, P195, DOI 10.1042/bj1780195; DEVRIES S, 1979, BIOCHIM BIOPHYS ACTA, V546, P316, DOI 10.1016/0005-2728(79)90049-5; DUTTON PL, 1971, BIOCHIM BIOPHYS ACTA, V226, P63, DOI 10.1016/0005-2728(71)90178-2; Elbehti A, 1996, FEMS MICROBIOL LETT, V136, P51; ELBEHTI A, 1997, BIOMINE; EWART DK, 1991, ADV INORG CHEM, V36, P103, DOI 10.1016/S0898-8838(08)60038-0; FUKUMORI Y, 1988, FEMS MICROBIOL LETT, V50, P169; INGLEDEW WJ, 1982, BIOCHIM BIOPHYS ACTA, V683, P89, DOI 10.1016/0304-4173(82)90007-6; INGLEDEW WJ, 1980, BIOCHIM BIOPHYS ACTA, V590, P141, DOI 10.1016/0005-2728(80)90020-1; KAI M, 1992, J BIOCHEM-TOKYO, V112, P816; KAMENSKII YA, 1985, BIOL MEMBR, V2, P100; KAMENSKY Y, 1985, FEBS LETT, V181, P95, DOI 10.1016/0014-5793(85)81120-0; KELLY DP, 1971, ANNU REV MICROBIOL, V25, P177, DOI 10.1146/annurev.mi.25.100171.001141; LIEBL U, 1990, FEBS LETT, V261, P427, DOI 10.1016/0014-5793(90)80608-L; LINK TA, 1993, J BIOENERG BIOMEMBR, V25, P221, DOI 10.1007/BF00762584; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUURA K, 1983, J BIOL CHEM, V258, P1571; MEUNIERLEMESLE D, 1989, BIOCHIMIE PARIS, V71, P1145; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; NUNZI F, 1993, BIOCHIM BIOPHYS ACTA, V1162, P28, DOI 10.1016/0167-4838(93)90123-9; OHNISHI T, 1988, EUR J BIOCHEM, V176, P385, DOI 10.1111/j.1432-1033.1988.tb14293.x; PECK HD, 1968, ANNU REV MICROBIOL, V22, P489, DOI 10.1146/annurev.mi.22.100168.002421; PETTIGREW GW, 1988, BIOCHEM J, V252, P427, DOI 10.1042/bj2520427; RIEDEL A, 1991, J BIOL CHEM, V266, P17838; SATO A, 1989, BIOCHIM BIOPHYS ACTA, V976, P129, DOI 10.1016/S0005-2728(89)80221-X; SHAFIA F, 1969, J BACTERIOL, V97, P256, DOI 10.1128/JB.97.1.256-260.1969; SHORT SA, 1969, J BACTERIOL, V99, P142, DOI 10.1128/JB.99.1.142-150.1969; SILVERMAN MP, 1959, J BACTERIOL, V77, P642, DOI 10.1128/JB.77.5.642-647.1959; SLATER EC, 1973, BIOCHIM BIOPHYS ACTA, V301, P129, DOI 10.1016/0304-4173(73)90002-5; TAMEGAI H, 1994, FEMS MICROBIOL LETT, V119, P147; THIKONOVA GB, 1967, BIOKIMYA, V32, P725; TRUMPOWER BL, 1990, MICROBIOL REV, V54, P101, DOI 10.1128/MMBR.54.2.101-129.1990; TSAI AL, 1985, BIOCHIM BIOPHYS ACTA, V806, P418, DOI 10.1016/0005-2728(85)90249-X; VALKOVAVALCHANOVA MB, 1994, FEMS MICROBIOL LETT, V121, P61, DOI 10.1016/0378-1097(94)90146-5; VONJAGOW G, 1985, FEBS LETT, V185, P311, DOI 10.1016/0014-5793(85)80929-7; VONJAGOW G, 1981, FEBS LETT, V136, P19, DOI 10.1016/0014-5793(81)81206-9	47	36	38	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16760	16765		10.1074/jbc.274.24.16760	http://dx.doi.org/10.1074/jbc.274.24.16760			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358017	hybrid			2022-12-25	WOS:000080780400016
J	Miyake, S; Mullane-Robinson, KP; Lill, NL; Douillard, P; Band, H				Miyake, S; Mullane-Robinson, KP; Lill, NL; Douillard, P; Band, H			Cbl-mediated negative regulation of platelet-derived growth factor receptor-dependent cell proliferation - A critical role for Cbl tyrosine kinase-binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTOONCOGENE C-CBL; FACTOR-ALPHA RECEPTOR; FACTOR BETA-RECEPTOR; ACTIVATED T-CELLS; EGF RECEPTOR; SIGNAL-TRANSDUCTION; V-CBL; PHOSPHORYLATION; PROTEIN; RAS	The Cbl proto-oncogene product has emerged as a novel negative regulator of receptor and non-receptor tyrosine kinases, Our previous observations that Cbl overexpression in NIH3T3 cells enhanced the ubiquitination and degradation of the platelet-derived growth factor receptor-alpha (PDGFR alpha) and that the expression of oncogenic Cbl mutants up-regulated the PDGFRa signaling machinery strongly suggested that Cbl negatively regulates PDGFR alpha signaling. Here, we show that, similar to PDGFR alpha, selective stimulation of PDGFR beta induces Cbl phosphorylation, and its physical association with the receptor. Overexpression of wild type Cbl in NIH3T3 cells led to an enhancement of the ligand-dependent ubiquitination and subsequent degradation of the PDGFR beta, as observed with PDGFR alpha. We show that Cbl-dependent negative regulation of PDGFR alpha and beta results in a reduction of PDGF-induced cell proliferation and protection against apoptosis. A point mutation (G306E) that inactivates the tyrosine kinase binding domain in the N-terminal transforming region of Cbl compromised the PDGF-inducible tyrosine phosphorylation of Cbl although this mutant could still associate with the PDGFR. More importantly, the G306E mutation abrogated the ability of Cbl to enhance the ligand-induced ubiquitination and degradation of the PDGFR and to inhibit the PDGF-dependent cell proliferation and protection from apoptosis. These results demonstrate that Cbl can negatively regulate PDGFR-dependent biological responses and that this function requires the conserved tyrosine kinase binding domain of Cbl.	Harvard Univ, Brigham & Womens Hosp, Sch Med,Dept Med,Div Rheumatol Immunol & Allergy, Lymphocyte Biol Sect, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Band, H (corresponding author), Smith Bldg,Room 538C,1 Jimmy Fund Way, Boston, MA 02115 USA.				NATIONAL CANCER INSTITUTE [R01CA075075, R01CA076118] Funding Source: NIH RePORTER; NCI NIH HHS [CA76118, CA75075] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andoniou CE, 1996, ONCOGENE, V12, P1981; Bazenet CE, 1996, MOL CELL BIOL, V16, P6926; BLAKE TJ, 1991, ONCOGENE, V6, P653; Bonita DP, 1997, MOL CELL BIOL, V17, P4597, DOI 10.1128/MCB.17.8.4597; Claesson-Welsh Lena, 1994, Progress in Growth Factor Research, V5, P37, DOI 10.1016/0955-2235(94)90016-7; Deckert M, 1998, J BIOL CHEM, V273, P8867, DOI 10.1074/jbc.273.15.8867; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Feshchenko EA, 1998, J BIOL CHEM, V273, P8323, DOI 10.1074/jbc.273.14.8323; FLIER JS, 1989, NEW ENGL J MED, V321, P1383, DOI 10.1056/NEJM198911163212007; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; Gelderloos JA, 1998, J BIOL CHEM, V273, P5908, DOI 10.1074/jbc.273.10.5908; Hime GR, 1997, ONCOGENE, V14, P2709, DOI 10.1038/sj.onc.1201223; Hooshmand-Rad R, 1998, J CELL SCI, V111, P607; Langdon WY, 1995, AUST NZ J MED, V25, P859, DOI 10.1111/j.1445-5994.1995.tb02892.x; Liu YC, 1998, CELL SIGNAL, V10, P377, DOI 10.1016/S0898-6568(97)00179-4; Liu YC, 1997, J BIOL CHEM, V272, P168; Lupher ML, 1998, J BIOL CHEM, V273, P35273, DOI 10.1074/jbc.273.52.35273; Lupher ML, 1998, INT J BIOCHEM CELL B, V30, P439, DOI 10.1016/S1357-2725(97)00075-7; Lupher ML, 1996, J BIOL CHEM, V271, P24063, DOI 10.1074/jbc.271.39.24063; Lupher ML, 1997, J BIOL CHEM, V272, P33140, DOI 10.1074/jbc.272.52.33140; Marengere LEM, 1997, J IMMUNOL, V159, P70; Meisner H, 1997, MOL CELL BIOL, V17, P2217, DOI 10.1128/MCB.17.4.2217; Meng WY, 1999, NATURE, V398, P84, DOI 10.1038/18050; Miyake S, 1997, CRIT REV ONCOGENESIS, V8, P189, DOI 10.1615/CritRevOncog.v8.i2-3.30; Miyake S, 1998, P NATL ACAD SCI USA, V95, P7927, DOI 10.1073/pnas.95.14.7927; MORI S, 1992, J BIOL CHEM, V267, P6429; MORI S, 1993, J BIOL CHEM, V268, P577; Murphy MA, 1998, MOL CELL BIOL, V18, P4872, DOI 10.1128/MCB.18.8.4872; Naramura M, 1998, P NATL ACAD SCI USA, V95, P15547, DOI 10.1073/pnas.95.26.15547; Ojaniemi M, 1998, ONCOGENE, V16, P3159, DOI 10.1038/sj.onc.1201859; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; Rellahan BL, 1997, J BIOL CHEM, V272, P30806, DOI 10.1074/jbc.272.49.30806; SEIFERT RA, 1993, J BIOL CHEM, V268, P4473; Smit L, 1997, CRIT REV ONCOGENESIS, V8, P359, DOI 10.1615/CritRevOncog.v8.i4.50; Thien CBF, 1997, ONCOGENE, V14, P2239, DOI 10.1038/sj.onc.1201193; Thien CBF, 1997, ONCOGENE, V15, P2909, DOI 10.1038/sj.onc.1201468; Ueno H, 1997, J BIOL CHEM, V272, P8739, DOI 10.1074/jbc.272.13.8739; Walker F, 1998, MOL CELL BIOL, V18, P7192, DOI 10.1128/MCB.18.12.7192; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556	40	146	149	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16619	16628		10.1074/jbc.274.23.16619	http://dx.doi.org/10.1074/jbc.274.23.16619			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347229	hybrid			2022-12-25	WOS:000080668600089
J	Stumm, G; Schlegel, J; Schafer, T; Wurz, C; Mennel, HD; Krieg, JC; Vedder, H				Stumm, G; Schlegel, J; Schafer, T; Wurz, C; Mennel, HD; Krieg, JC; Vedder, H			Amphetamines induce apoptosis and regulation of bcl-x splice variants in neocortical neurons	FASEB JOURNAL			English	Article						drug abuse; neurotoxicity; bcl gene family	DISMUTASE TRANSGENIC MICE; MDMA ECSTASY; 3,4-METHYLENEDIOXYMETHAMPHETAMINE MDMA; METHAMPHETAMINE; CELLS; ABUSE; BRAIN; TRANSCRIPTION; DEATH; JUN	Amphetamine analogs have emerged as popular recreational drugs of abuse. The number of reports of these substances producing severe acute toxicity and death is increasing, In 'Ecstasy'-associated deaths, focal necrosis in the liver and individual myocytic necrosis has been reported. Furthermore, serotonergic and dopaminergic neuronal cell damage has been observed in experimental amphetamine intoxication in laboratory animals, Here we demonstrate that subchronic exposure to D-amphetamine, methamphetamine, methylenedioxyamphetamine, and methylenedioxymethamphetamine ('Ecstasy') results in significant neurotoxicity in rat neocortical neurons in vitro, This neuronal cell death is accompanied by endonucleosomal DNA cleavage and differential expression of anti- and proapoptotic bcl-x(L/S) splice variants. In addition, we observed pronounced induction of cell stress-associated transcription factor c-jun and translation initiation inhibitor p97 after amphetamine treatment. These data support that the neurotoxic effects of different amphetamines are extended to rat neocortical neurons and that apoptotic pathways are involved in amphetamine-induced neurotoxicity.	Univ Marburg, Dept Neuropathol, Marburg, Germany; Univ Marburg, Inst Forens Med, Marburg, Germany; Univ Marburg, Dept Psychiat, Marburg, Germany	Philipps University Marburg; Philipps University Marburg; Philipps University Marburg	Stumm, G (corresponding author), Univ Hosp Marburg, Dept Psychiat, Rudolf-Bultmann Str 8, D-35039 Marburg, Germany.	stumm@mailer.uni-marburg.de		Schlegel, Jurgen/0000-0002-5544-2717				BELL DS, 1973, ARCH GEN PSYCHIAT, V29, P35; BUDOWLE B, 1991, AM J HUM GENET, V48, P137; Cadet JL, 1997, SYNAPSE, V25, P176; CERRUTI C, 1995, CLIN EXP PHARMACOL P, V22, P381, DOI 10.1111/j.1440-1681.1995.tb02025.x; GREEN AR, 1995, PSYCHOPHARMACOLOGY, V119, P247, DOI 10.1007/BF02246288; Herdegen T, 1997, TRENDS NEUROSCI, V20, P227, DOI 10.1016/S0166-2236(96)01000-4; Hirata H, 1997, BRAIN RES, V768, P345, DOI 10.1016/S0006-8993(97)00798-1; Hirata H, 1998, MOL BRAIN RES, V58, P209, DOI 10.1016/S0169-328X(98)00055-2; Huang NK, 1997, LIFE SCI, V61, P2219, DOI 10.1016/S0024-3205(97)00924-7; Imataka H, 1997, EMBO J, V16, P817, DOI 10.1093/emboj/16.4.817; Jayanthi S, 1998, ANN NY ACAD SCI, V844, P92, DOI 10.1111/j.1749-6632.1998.tb08224.x; KIESSLING M, 1993, J CEREBR BLOOD F MET, V13, P914, DOI 10.1038/jcbfm.1993.114; McCann UD, 1998, LANCET, V352, P1433, DOI 10.1016/S0140-6736(98)04329-3; MCGUIRE PK, 1994, BRIT J PSYCHIAT, V165, P391, DOI 10.1192/bjp.165.3.391; Milroy CM, 1996, J CLIN PATHOL, V49, P149, DOI 10.1136/jcp.49.2.149; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Parsadanian AS, 1998, J NEUROSCI, V18, P1009; RICAURTE G, 1985, SCIENCE, V229, P986, DOI 10.1126/science.4023719; RICAURTE GA, 1992, ANN NY ACAD SCI, V648, P371; Robinson TE, 1997, J NEUROSCI, V17, P8491; SCHIFANO F, 1991, LANCET, V338, P1335, DOI 10.1016/0140-6736(91)92633-D; Seiden L S, 1996, NIDA Res Monogr, V163, P251; Simantov R, 1997, FASEB J, V11, P141, DOI 10.1096/fasebj.11.2.9039956; STEELE TD, 1994, ADDICTION, V89, P539, DOI 10.1111/j.1360-0443.1994.tb03330.x; Stewart JL, 1997, J ANAL TOXICOL, V21, P515, DOI 10.1093/jat/21.6.515; TAKEMOTO O, 1995, STROKE, V26, P1639, DOI 10.1161/01.STR.26.9.1639; VEDDER H, 1993, BRAIN RES, V605, P18, DOI 10.1016/0006-8993(93)91351-R; WAGNER GC, 1985, RES COMMUN CHEM PATH, V47, P221; Yamamoto H, 1996, ANN NY ACAD SCI, V801, P327, DOI 10.1111/j.1749-6632.1996.tb17453.x; ZIMMERMAN EF, 1991, PEDIATR ANN, V20, P541, DOI 10.3928/0090-4481-19911001-05	31	138	146	1	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	1999	13	9					1065	1072		10.1096/fasebj.13.9.1065	http://dx.doi.org/10.1096/fasebj.13.9.1065			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	200NZ	10336889	Bronze			2022-12-25	WOS:000080547700011
J	Eto, A; Saido, TC; Fukushima, K; Tomioka, S; Imai, S; Nisizawa, T; Hanada, N				Eto, A; Saido, TC; Fukushima, K; Tomioka, S; Imai, S; Nisizawa, T; Hanada, N			Inhibitory effect of a self-derived peptide on glucosyltransferase of Streptococcus mutans - Possible novel anticaries measures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE-ANALYSIS; ALPHA-AMYLASE; NUCLEOTIDE-SEQUENCE; OPTICAL BIOSENSOR; GLUCAN SYNTHESIS; GTF GENES; SOBRINUS; BINDING; SITE; DOMAIN	Glucosyltransferase (GTF) plays an important role in the development of dental caries. We examined the possible presence of self-inhibitory segments within the enzyme molecule for the purpose of developing anticaries measures through GTF inhibition. Twenty-two synthetic peptides derived from various regions presumably responsible for insoluble-glucan synthesis were studied with respect to their effects on catalytic activity. One of them, which is identical in amino acid sequence to residues 1176-1194, significantly and specifically inhibited both sucrose hydrolysis and glucosyl transfer to glucan by GTF-I, Double-reciprocal analysis revealed that the inhibition is noncompetitive. Scramble peptides, composed of the identical amino acids in randomized sequence, had no effect on GTF-I activity. Furthermore, the peptide is tightly bound to the enzyme once complexed, even in the presence of sodium dodecyl sulfate (SDS). Kinetic analysis using an optical evanescent resonant mirror cuvette system demonstrated that the enzyme-peptide interaction was biphasic. These results indicate that the peptide directly interacts with the enzyme with high affinity and inhibits its activity in a sequence-specific manner. This peptide itself could possibly be an effective agent for prevention of dental caries, although its effectiveness may be improved by further modification.	Natl Inst Infect Dis, Dept Oral Sci, Shinjuku Ku, Tokyo 1628640, Japan; RIKEN, Brain Sci Inst, Lab Proteolyt Neurosci, Wako, Saitama 3510198, Japan; Nihon Univ, Sch Dent, Dept Microbiol, Matsudo, Chiba 2718587, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1138657, Japan	National Institute of Infectious Diseases (NIID); RIKEN; Nihon University; University of Tokyo	Hanada, N (corresponding author), Natl Inst Infect Dis, Dept Oral Sci, Shinjuku Ku, 1-23-1 Toyama, Tokyo 1628640, Japan.		Saido, Takaomi C/N-5472-2015; Sado, Takaomi/AAN-2759-2021; Hanada, Nobuhiro/C-5308-2011	Saido, Takaomi C/0000-0003-1970-6903; Sado, Takaomi/0000-0003-1970-6903; 				AOKI H, 1986, INFECT IMMUN, V53, P587, DOI 10.1128/IAI.53.3.587-594.1986; Edwards PR, 1997, ANAL BIOCHEM, V246, P1, DOI 10.1006/abio.1996.9922; EDWARDS PR, 1995, ANAL BIOCHEM, V231, P210, DOI 10.1006/abio.1995.1522; ETO A, 1995, J BIOL CHEM, V270, P25115, DOI 10.1074/jbc.270.42.25115; FERRETTI JJ, 1987, J BACTERIOL, V169, P4271, DOI 10.1128/jb.169.9.4271-4278.1987; FUKUSHIMA K, 1992, INFECT IMMUN, V60, P2815, DOI 10.1128/IAI.60.7.2815-2822.1992; Hall DR, 1997, ANAL BIOCHEM, V253, P145, DOI 10.1006/abio.1997.2358; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; HANADA N, 1989, INFECT IMMUN, V57, P2079, DOI 10.1128/IAI.57.7.2079-2085.1989; HANADA N, 1988, INFECT IMMUN, V56, P1999, DOI 10.1128/IAI.56.8.1999-2005.1988; HANADA N, 1993, INFECT IMMUN, V61, P2096, DOI 10.1128/IAI.61.5.2096-2103.1993; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; KATO C, 1991, FEMS MICROBIOL LETT, V79, P153, DOI 10.1111/j.1574-6968.1991.tb04521.x; KATO C, 1992, BIOCHEM BIOPH RES CO, V189, P1184, DOI 10.1016/0006-291X(92)92329-V; KATO C, 1990, FEMS MICROBIOL LETT, V72, P299, DOI 10.1111/j.1574-6968.1990.tb03906.x; KURAMITSU HK, 1993, CRIT REV ORAL BIOL M, V4, P159, DOI 10.1177/10454411930040020201; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOESCHE WJ, 1986, MICROBIOL REV, V50, P353, DOI 10.1128/MMBR.50.4.353-380.1986; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MOOSER G, 1991, J BIOL CHEM, V266, P8916; MOOSER G, 1988, INFECT IMMUN, V56, P880, DOI 10.1128/IAI.56.4.880-884.1988; Nunomura W, 1997, J BIOL CHEM, V272, P30322, DOI 10.1074/jbc.272.48.30322; RARICK HM, 1992, SCIENCE, V256, P1031, DOI 10.1126/science.1317058; ROGERS JC, 1983, J BIOL CHEM, V258, P8169; Russell R. R., 1990, ARCH ORAL BIOL, V35, P53; SAIDO TC, 1992, J BIOCHEM, V111, P81, DOI 10.1093/oxfordjournals.jbchem.a123723; SHIROZA T, 1987, J BACTERIOL, V169, P4263, DOI 10.1128/jb.169.9.4263-4270.1987; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; VERTESY L, 1984, EUR J BIOCHEM, V141, P505, DOI 10.1111/j.1432-1033.1984.tb08221.x; WIEGAND G, 1995, J MOL BIOL, V247, P99, DOI 10.1006/jmbi.1994.0125; Yagisawa H, 1998, J BIOL CHEM, V273, P417, DOI 10.1074/jbc.273.1.417; YAMASHITA Y, 1993, INFECT IMMUN, V61, P3811, DOI 10.1128/IAI.61.9.3811-3817.1993; YAMASHITA Y, 1989, J BACTERIOL, V171, P6265, DOI 10.1128/jb.171.11.6265-6270.1989	33	11	12	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15797	15802		10.1074/jbc.274.22.15797	http://dx.doi.org/10.1074/jbc.274.22.15797			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336482	hybrid			2022-12-25	WOS:000080560100071
J	Hamada, K; Kumazaki, T; Satoh, S				Hamada, K; Kumazaki, T; Satoh, S			Effect of transforming RNA on the synthesis of a protein with a secretory signal sequence in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL NUCLEAR-RNA; RECOGNITION PARTICLE; ENDOPLASMIC-RETICULUM; 7SL RNA; MESSENGER-RNA; MALIGNANT TRANSFORMATION; TRANSLATION INITIATION; POLY(A) TAIL; SECONDARY STRUCTURE; ELONGATION ARREST	U5 small nuclear RNA itself can act as a clastogenic and transforming agent when transfected into cells. In the previous work, the 3' half of the U5 small nuclear RNA first stem structure (designated RNA3S) was capable of driving normal cells into tumorigenic cells when expressed with a poly(A) tail (RNA3S(+)). This transformation critically depended upon the polypurine sequence GGAGAGGAA in RNA3S(+), In this work, we first examined the pre-beta-lactamase and luciferase (model secretory and nonsecretory proteins) translation with the in vitro synthesized RNA3S in rabbit reticulocyte lysate, The capped RNA3S with a poly(A) tail suppressed the translation. In addition, the polypurine sequence played a crucial role in affecting the secretory protein synthesis, indicating a primary action of RNA3S(+). Further studies revealed that the oligodeoxynucleotides, corresponding to the polypurine and its antisense sequences, directly contacted 28 S rRNA in ribosome and 7SL RNA in signal recognition particle, respectively, and differentially affected the nascent chain elongation of secretory protein synthesis. These results suggest that RNA3S(+) blocks a physiological regulatory function played by signal recognition particle and the ribosome in the secretory protein synthesis and support the idea that the transformation might result from a repressed cellular activity.	Hiroshima Univ, Res Inst Radiat Biol & Med, Div Cell Biol, Minami Ku, Hiroshima 7340037, Japan; Inst Bioregulat Co Ltd, Naka Ku, Yokohama, Kanagawa 2310013, Japan	Hiroshima University	Hamada, K (corresponding author), Hiroshima Univ, Res Inst Radiat Biol & Med, Div Cell Biol, Minami Ku, 1-2-3 Kasumi, Hiroshima 7340037, Japan.							ANDREAZZOLI M, 1991, EMBO J, V10, P767, DOI 10.1002/j.1460-2075.1991.tb08008.x; ANDREWS DW, 1987, EMBO J, V6, P3471, DOI 10.1002/j.1460-2075.1987.tb02671.x; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BRANLANT C, 1983, NUCLEIC ACIDS RES, V11, P8359, DOI 10.1093/nar/11.23.8359; Bridges BA, 1997, BIOESSAYS, V19, P347, DOI 10.1002/bies.950190412; Cairns J, 1998, GENETICS, V148, P1433; CAIRNS J, 1988, NATURE, V335, P142, DOI 10.1038/335142a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FARBER E, 1991, CANCER RES, V51, P2751; FARBER E, 1987, LAB INVEST, V56, P4; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GALLIE DR, 1991, GENE DEV, V5, P2108, DOI 10.1101/gad.5.11.2108; GILMORE R, 1982, J CELL BIOL, V95, P470, DOI 10.1083/jcb.95.2.470; HALL BG, 1990, GENETICS, V126, P5; HALL BG, 1995, P NATL ACAD SCI USA, V92, P5669, DOI 10.1073/pnas.92.12.5669; HAMADA K, 1989, MOL CELL BIOL, V9, P4345, DOI 10.1128/MCB.9.10.4345; Hamada K, 1997, MOL CARCINOGEN, V20, P175; HAMADA K, 1992, MUTAT RES, V267, P97, DOI 10.1016/0027-5107(92)90114-H; HELDIN CH, 1984, CELL, V37, P9, DOI 10.1016/0092-8674(84)90296-4; HYNES RO, 1976, BIOCHIM BIOPHYS ACTA, V458, P73, DOI 10.1016/0304-419X(76)90015-9; ISFORT RJ, 1994, CARCINOGENESIS, V15, P1203, DOI 10.1093/carcin/15.6.1203; JACKSON RJ, 1983, METHOD ENZYMOL, V96, P50; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; MADER S, 1995, MOL CELL BIOL, V15, P4990; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MEYER DI, 1982, NATURE, V297, P647, DOI 10.1038/297647a0; MULLER M, 1982, J BIOL CHEM, V257, P1860; NEWBOLD RF, 1982, NATURE, V299, P633, DOI 10.1038/299633a0; NOLLER HF, 1991, ANNU REV BIOCHEM, V60, P191, DOI 10.1146/annurev.biochem.60.1.191; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; ROTHMAN JE, 1977, NATURE, V269, P775, DOI 10.1038/269775a0; SAMBROOK J, 1989, MOL CLONING LAB MANU, P207; SCHLENSTEDT G, 1990, J BIOL CHEM, V265, P13960; Schwab ED, 1996, MED HYPOTHESES, V47, P235, DOI 10.1016/S0306-9877(96)90086-9; SHAPIRO JA, 1984, MOL GEN GENET, V194, P79, DOI 10.1007/BF00383501; SIEGEL V, 1988, CELL, V52, P39, DOI 10.1016/0092-8674(88)90529-6; SIEGEL V, 1986, NATURE, V320, P81, DOI 10.1038/320081a0; SIEGEL V, 1985, J CELL BIOL, V100, P1913, DOI 10.1083/jcb.100.6.1913; STRAUSS BS, 1992, CANCER RES, V52, P249; Tarun SZ, 1996, EMBO J, V15, P7168, DOI 10.1002/j.1460-2075.1996.tb01108.x; TARUN SZ, 1995, GENE DEV, V9, P2997, DOI 10.1101/gad.9.23.2997; Trosko James E., 1998, Frontiers in Bioscience, V3, pD208; ULLU E, 1984, EMBO J, V3, P3303, DOI 10.1002/j.1460-2075.1984.tb02294.x; ULLU E, 1984, NATURE, V312, P171, DOI 10.1038/312171a0; ULLU E, 1982, CELL, V29, P195, DOI 10.1016/0092-8674(82)90103-9; VAHERI A, 1978, BIOCHIM BIOPHYS ACTA, V516, P1, DOI 10.1016/0304-419X(78)90002-1; WALTER P, 1980, P NATL ACAD SCI-BIOL, V77, P7112, DOI 10.1073/pnas.77.12.7112; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; WALTER P, 1982, NATURE, V299, P691, DOI 10.1038/299691a0; WEINBERG RA, 1989, CANCER RES, V49, P3713; WIECH H, 1991, FEBS LETT, V285, P182, DOI 10.1016/0014-5793(91)80800-I; WOLIN SL, 1989, J CELL BIOL, V109, P2617, DOI 10.1083/jcb.109.6.2617; WOOD KV, 1984, BIOCHEM BIOPH RES CO, V124, P592, DOI 10.1016/0006-291X(84)91595-X; ZWIEB C, 1989, PROG NUCLEIC ACID RE, V37, P207; ZWIEB C, 1985, NUCLEIC ACIDS RES, V13, P6105, DOI 10.1093/nar/13.17.6105	58	2	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15786	15796		10.1074/jbc.274.22.15786	http://dx.doi.org/10.1074/jbc.274.22.15786			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336481	hybrid			2022-12-25	WOS:000080560100070
J	Andersson, H; Kappeler, F; Hauri, HP				Andersson, H; Kappeler, F; Hauri, HP			Protein targeting to endoplasmic reticulum by dilysine signals involves direct retention in addition to retrieval	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EARLY SECRETORY PATHWAY; GOLGI-APPARATUS; TRANSMEMBRANE PROTEINS; CIS-GOLGI; BETA-COP; ERGIC-53; TRANSPORT; COATOMER; ER; COMPARTMENT	Dilysine signals confer localization of type I membrane proteins to the endoplasmic reticulum (ER). According to the prevailing model these signals target proteins to the ER by COP I-mediated retrieval from post-ER compartments, whereas the actual retention mechanism in the ER is unknown. We expressed chimeric membrane proteins with a C-terminal -Lys-Lys-Ala-Ala (KKAA) or -Lys-Lys-Phe-Phe (KKFF) dilysine signal in Lec-1 cells. Unlike KKFF constructs, which had access to post-ER compartments, the KKAA chimeras were localized to the ER by confocal microscopy and mere neither processed by cis-Golgi-specific enzymes in vivo nor included into ER-derived transport vesicles in an in vitro budding assay, suggesting that KKAA-bearing proteins are permanently retained in the ER. The ER localization was nonsaturable and exclusively mediated by the dilysine signal because mutating the lysines to alanines led to cell surface expression of the chimeras. Although the KKAA signal avidly binds COP I in vitro, the ER retention by this signal does not depend on intact COP I in vivo because it was not affected in an epsilon-COP-deficient cell line. me propose that dilysine ER targeting signals can mediate ER retention in addition to retrieval.	Univ Basel, Bioctr, Dept Pharmacol, CH-4056 Basel, Switzerland	University of Basel	Hauri, HP (corresponding author), Univ Basel, Bioctr, Dept Pharmacol, Klingelbergstr 70, CH-4056 Basel, Switzerland.							CARRERA AC, 1987, EUR J IMMUNOL, V17, P179, DOI 10.1002/eji.1830170205; Cosson P, 1996, EMBO J, V15, P1792, DOI 10.1002/j.1460-2075.1996.tb00528.x; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; DAHLLOF B, 1991, J BIOL CHEM, V266, P1804; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; GAYNOR EC, 1994, J CELL BIOL, V127, P653, DOI 10.1083/jcb.127.3.653; Guo Q, 1996, J BIOL CHEM, V271, P11191, DOI 10.1074/jbc.271.19.11191; HAURI H-P, 1992, Current Opinion in Cell Biology, V4, P600, DOI 10.1016/0955-0674(92)90078-Q; Itin C, 1996, MOL BIOL CELL, V7, P483, DOI 10.1091/mbc.7.3.483; ITIN C, 1995, J CELL BIOL, V131, P57, DOI 10.1083/jcb.131.1.57; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KAPPELER F, 1994, J BIOL CHEM, V269, P6279; Kappeler F, 1997, J BIOL CHEM, V272, P31801, DOI 10.1074/jbc.272.50.31801; Klumperman J, 1998, J CELL SCI, V111, P3411; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; Lewis MJ, 1996, CELL, V85, P205, DOI 10.1016/S0092-8674(00)81097-1; Munro S, 1998, TRENDS CELL BIOL, V8, P11, DOI 10.1016/S0962-8924(97)01197-5; Nichols WC, 1998, CELL, V93, P61, DOI 10.1016/S0092-8674(00)81146-0; Nishimura N, 1997, SCIENCE, V277, P556, DOI 10.1126/science.277.5325.556; OPRINS A, 1993, J CELL BIOL, V121, P49, DOI 10.1083/jcb.121.1.49; ORCI L, 1994, P NATL ACAD SCI USA, V91, P11924, DOI 10.1073/pnas.91.25.11924; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Rowe T, 1996, J CELL BIOL, V135, P895, DOI 10.1083/jcb.135.4.895; ROWE T, 1995, METHOD ENZYMOL, V257, P49; SATTENTAU QJ, 1989, J EXP MED, V170, P1319, DOI 10.1084/jem.170.4.1319; SCHWANINGER R, 1992, J CELL BIOL, V119, P1077, DOI 10.1083/jcb.119.5.1077; SCHWEIZER A, 1991, J CELL BIOL, V113, P45, DOI 10.1083/jcb.113.1.45; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; STANLEY P, 1975, CELL, V6, P121, DOI 10.1016/0092-8674(75)90002-1; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; Tisdale EJ, 1997, J CELL BIOL, V137, P581, DOI 10.1083/jcb.137.3.581; TOWNSLEY FM, 1994, EUR J CELL BIOL, V64, P121; Vollenweider F, 1998, J CELL BIOL, V142, P377, DOI 10.1083/jcb.142.2.377; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0	36	106	110	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					15080	15084		10.1074/jbc.274.21.15080	http://dx.doi.org/10.1074/jbc.274.21.15080			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329713	hybrid			2022-12-25	WOS:000081965200078
J	Schmidt, M; Voss, M; Weernink, PAO; Wetzel, J; Amano, M; Kaibuchi, K; Jakobs, KH				Schmidt, M; Voss, M; Weernink, PAO; Wetzel, J; Amano, M; Kaibuchi, K; Jakobs, KH			A role for rho-kinase in rho-controlled phospholipase D stimulation by the m3 muscarinic acetylcholine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION-FACTOR; GTP-BINDING PROTEIN; DIFFICILE TOXIN-B; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; RAT-BRAIN; TYROSINE PHOSPHORYLATION; SERINE/THREONINE KINASE; AGONIST STIMULATION; D DEFINES; ACTIVATION	Stimulation of phospholipase D (PLD) by membrane receptors is now recognized as a major signal transduction pathway involved in diverse cellular functions. Rho proteins control receptor signaling to PLD, and these GTPases have been shown to directly stimulate purified recombinant PLD1 enzymes in vitro. Here we report that stimulation of PLD activity, measured in the presence of phosphatidylinositol 4,5-bisphosphate, by RhoA in membranes of HEK-293 cells expressing the m3 muscarinic acetylcholine receptor (mAChR) is phosphorylation-dependent. Therefore, the possible involvement of the RhoA-stimulated serine/threonine kinase, Rho-kinase, was investigated. Overexpression of Rho-kinase and constitutively active Rho-kinase (Rho-kinase-CAT) but not of kinase-deficient Rho-kinase-CAT markedly increased m3 mAChR-mediated but not protein kinase C-mediated PLD stimulation, similar to overexpression of RhoA Expression of the Rho-inactivating C3 transferase abrogated the stimulatory effect of wild-type Rho-kinase, but not of Rho-kinase-CAT. Recombinant Rho-kinase CAT mimicked the phosphorylation-dependent PLD stimulation by RhoA in HEK-293 cell membranes. Finally, the Rho-kinase inhibitor HA-1077 largely inhibited RhoA-induced PLD stimulation in membranes as well as PLD stimulation by the m3 mAChR but not by protein kinase C in intact HEK-293 cells. me conclude that Rho-kinase is involved in Rho-dependent PLD stimulation by the G protein-coupled m3 mAChR in HEK-293 cells. Thus, our findings identify Rho-kinase as a novel player in the receptor-controlled PLD signaling pathway.	Univ Essen Gesamthsch Klinikum, Inst Pharmakol, D-45122 Essen, Germany; Nara Inst Sci & Technol, Div Signal Transduct, Nara 63001, Japan	University of Duisburg Essen; Nara Institute of Science & Technology	Schmidt, M (corresponding author), Univ Essen Gesamthsch Klinikum, Inst Pharmakol, Hufelandstr 55, D-45122 Essen, Germany.		Schmidt, Martina/C-5339-2018; Amano, Mutsuki/M-4820-2014	Schmidt, Martina/0000-0003-3075-0630; Amano, Mutsuki/0000-0002-0662-1524				AKTORIES K, 1993, GTPASES BIOL, V1, P87; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Asano T, 1998, CARDIOVASC DRUG REV, V16, P76, DOI 10.1111/j.1527-3466.1998.tb00346.x; Bae CD, 1998, J BIOL CHEM, V273, P11596, DOI 10.1074/jbc.273.19.11596; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; Chen YG, 1997, J CELL BIOL, V138, P495, DOI 10.1083/jcb.138.3.495; Chung JK, 1997, J BIOL CHEM, V272, P15980, DOI 10.1074/jbc.272.25.15980; COCKCROFT S, 1997, PROG LIPID RES, V35, P345; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; Cross MJ, 1996, CURR BIOL, V6, P588, DOI 10.1016/S0960-9822(02)00545-6; Exton JH, 1997, J BIOL CHEM, V272, P15579, DOI 10.1074/jbc.272.25.15579; Fensome A, 1996, CURR BIOL, V6, P730, DOI 10.1016/S0960-9822(09)00454-0; Fensome A, 1998, J BIOL CHEM, V273, P13157, DOI 10.1074/jbc.273.21.13157; GENY B, 1995, EUR J BIOCHEM, V231, P31, DOI 10.1111/j.1432-1033.1995.tb20666.x; GOSH S, 1996, J BIOL CHEM, V271, P8472; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; Hammond SM, 1997, J BIOL CHEM, V272, P3860, DOI 10.1074/jbc.272.6.3860; Hess JA, 1997, J BIOL CHEM, V272, P1615, DOI 10.1074/jbc.272.3.1615; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; Jenco JM, 1998, BIOCHEMISTRY-US, V37, P4901, DOI 10.1021/bi972776r; Keller J, 1997, FEBS LETT, V403, P299, DOI 10.1016/S0014-5793(97)00067-7; Kim JH, 1996, J BIOL CHEM, V271, P25213, DOI 10.1074/jbc.271.41.25213; Kodaki T, 1997, J BIOL CHEM, V272, P11408; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; Lopez I, 1998, J BIOL CHEM, V273, P12846, DOI 10.1074/jbc.273.21.12846; Malcolm KC, 1996, J BIOL CHEM, V271, P13135, DOI 10.1074/jbc.271.22.13135; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; Min DS, 1998, J BIOL CHEM, V273, P7044, DOI 10.1074/jbc.273.12.7044; MORITZ A, 1992, J BIOL CHEM, V267, P7207; Morris AJ, 1996, TRENDS PHARMACOL SCI, V17, P182, DOI 10.1016/0165-6147(96)10016-X; Nakagawa O, 1996, FEBS LETT, V392, P189, DOI 10.1016/0014-5793(96)00811-3; Park SK, 1997, J BIOL CHEM, V272, P29263, DOI 10.1074/jbc.272.46.29263; PERTILE P, 1995, J BIOL CHEM, V270, P5130, DOI 10.1074/jbc.270.10.5130; Provost JJ, 1996, BIOCHEM J, V319, P285, DOI 10.1042/bj3190285; Rizzo MA, 1999, J BIOL CHEM, V274, P1131, DOI 10.1074/jbc.274.2.1131; Rumenapp U, 1997, EUR J BIOCHEM, V248, P407, DOI 10.1111/j.1432-1033.1997.00407.x; RUMENAPP U, 1995, EUR J BIOCHEM, V234, P240, DOI 10.1111/j.1432-1033.1995.240_c.x; Schmidt M, 1996, J BIOL CHEM, V271, P2422, DOI 10.1074/jbc.271.5.2422; Schmidt M, 1998, J BIOL CHEM, V273, P7413, DOI 10.1074/jbc.273.13.7413; Schmidt M, 1996, EUR J BIOCHEM, V240, P707, DOI 10.1111/j.1432-1033.1996.0707h.x; Schmidt M, 1996, N-S ARCH PHARMACOL, V354, P87, DOI 10.1007/BF00178707; SCHMIDT M, 1994, EUR J BIOCHEM, V225, P667, DOI 10.1111/j.1432-1033.1994.00667.x; Slaaby R, 1998, J BIOL CHEM, V273, P33722, DOI 10.1074/jbc.273.50.33722; Sung TC, 1999, J BIOL CHEM, V274, P494, DOI 10.1074/jbc.274.1.494; Sung TC, 1997, EMBO J, V16, P4519, DOI 10.1093/emboj/16.15.4519; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Vinggaard AM, 1997, CELL SIGNAL, V9, P189, DOI 10.1016/S0898-6568(96)00140-4; Winstel R, 1996, P NATL ACAD SCI USA, V93, P2105, DOI 10.1073/pnas.93.5.2105	55	79	85	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					14648	14654		10.1074/jbc.274.21.14648	http://dx.doi.org/10.1074/jbc.274.21.14648			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329658	hybrid			2022-12-25	WOS:000081965200023
J	Vidugiriene, J; Sharma, DK; Smith, TK; Baumann, NA; Menon, AK				Vidugiriene, J; Sharma, DK; Smith, TK; Baumann, NA; Menon, AK			Segregation of glycosylphosphatidylinositol biosynthetic reactions in a subcompartment of the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOSYL-PHOSPHATIDYLINOSITOL ANCHOR; VARIANT SURFACE GLYCOPROTEIN; MEMBRANE-PROTEINS; MAMMALIAN-CELLS; GPI-ANCHOR; RAT-LIVER; GLUCOSAMINYL PHOSPHATIDYLINOSITOL; GLYCOPHOSPHATIDYLINOSITOL ANCHORS; STRUCTURAL CHARACTERIZATION; INTRACELLULAR-TRANSPORT	Glycosylphosphatidylinositols (GPIs) are synthesized in the endoplasmic reticulum (ER) via the sequential addition of monosaccharides, fatty acid, and phosphoethanolamine(s) to phosphatidylinositol (PI), While attempting to establish a mammalian cell-free system for GPI biosynthesis, we found that the assembly of mannosylated GPI species was impaired when purified ER preparations were substituted for unfractionated cell lysates as the enzyme source. To explore this problem we analyzed the distribution of the various GPI biosynthetic reactions in subcellular fractions prepared from homogenates of mammalian cells. The results indicate the following: (i) the initial reaction of GPI assembly, i.e, the transfer of GlcNAc to PI to form GlcNAc-PI, is uniformly distributed in the ER; (ii) the second step of the pathway, i.e. de-N-acetylation of GlcNAc-PI to yield GlcN-PI, is largely confined to a subcompartment of the ER that appears to be associated with mitochondria; (iii) the mitochondria-associated ER subcompartment is enriched in enzymatic activities involved in the conversion of GlcN-PI to H5 (a singly mannosylated GPI structure containing one phosphoethanolamine side chain; and (iv) the mitochondria-associated ER subcompartment, unlike bulk ER, is capable of the de novo synthesis of H5 from UDP-GlcNAc and PI. The confinement of these GPI biosynthetic reactions to a domain of the ER provides another example of the compositional and functional heterogeneity of the ER, The implications of these findings for GPI assembly are discussed.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ Dundee, Dept Biochem, Dundee DD1 4HN, Scotland	University of Wisconsin System; University of Wisconsin Madison; University of Dundee	Menon, AK (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.			Menon, Anant Kumar/0000-0001-6924-2698	NIGMS NIH HHS [GM5427] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEIJON C, 1990, J BIOL CHEM, V265, P14691; ACHLEITNER G, 1995, J BIOL CHEM, V270, P29836; AMTHAUER R, 1992, P NATL ACAD SCI USA, V89, P6124, DOI 10.1073/pnas.89.13.6124; ARDAIL D, 1993, J BIOL CHEM, V268, P25985; COSTELLO LC, 1992, J BIOL CHEM, V267, P8599; CUI Z, 1993, J BIOL CHEM, V268, P16655; DELUCA AW, 1994, GLYCOBIOLOGY, V4, P909, DOI 10.1093/glycob/4.6.909; DOERING TL, 1989, J BIOL CHEM, V264, P11168; Doerrler WT, 1996, J BIOL CHEM, V271, P27031, DOI 10.1074/jbc.271.43.27031; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; Field M. C., 1992, LIPID MODIFICATION P, P155; GAIGG B, 1995, BBA-BIOMEMBRANES, V1234, P214, DOI 10.1016/0005-2736(94)00287-Y; Graham John M., 1993, V19, P1; HIROSE S, 1992, J BIOL CHEM, V267, P16968; HIROSE S, 1992, P NATL ACAD SCI USA, V89, P6025, DOI 10.1073/pnas.89.13.6025; KAMITANI T, 1992, J BIOL CHEM, V267, P24611; KATZ J, 1983, BIOCHEM J, V214, P795, DOI 10.1042/bj2140795; KODUKULA K, 1991, J BIOL CHEM, V266, P4464; LOW MG, 1986, TRENDS BIOCHEM SCI, V11, P212, DOI 10.1016/0968-0004(86)90009-5; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; MEIER PJ, 1981, BIOCHIM BIOPHYS ACTA, V646, P283, DOI 10.1016/0005-2736(81)90335-7; MENON A, 1995, TRENDS CELL BIOL, V5, P355, DOI 10.1016/S0962-8924(00)89069-8; MENON AK, 1993, EMBO J, V12, P1907, DOI 10.1002/j.1460-2075.1993.tb05839.x; MENON AK, 1990, J BIOL CHEM, V265, P9033; MENON AK, 1990, EMBO J, V9, P4249, DOI 10.1002/j.1460-2075.1990.tb07873.x; Menon AK, 1997, BIOCHEM SOC T, V25, P861, DOI 10.1042/bst0250861; MENON AK, 1998, GPI ANCH BIOM; Nakamura N, 1997, J BIOL CHEM, V272, P15834, DOI 10.1074/jbc.272.25.15834; PICKETT CB, 1980, EXP CELL RES, V128, P343, DOI 10.1016/0014-4827(80)90070-1; PUOTI A, 1993, J BIOL CHEM, V268, P7215; PUOTI A, 1991, J BIOL CHEM, V266, P21051; PUOTI A, 1992, J BIOL CHEM, V267, P22673; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; Rooney E, 1996, J BIOL CHEM, V271, P29304, DOI 10.1074/jbc.271.46.29304; RUSH JS, 1995, J CELL BIOL, V130, P529, DOI 10.1083/jcb.130.3.529; Saito K, 1996, FEBS LETT, V395, P262, DOI 10.1016/0014-5793(96)01049-6; Sharma DK, 1997, BIOCHEM J, V328, P171; SHARMA DK, 1997, THESIS U DUNDEE DUND; SHIAO YJ, 1995, J BIOL CHEM, V270, P11190, DOI 10.1074/jbc.270.19.11190; SHORE GC, 1977, J CELL BIOL, V72, P714, DOI 10.1083/jcb.72.3.714; Simpson PB, 1996, J BIOL CHEM, V271, P33493, DOI 10.1074/jbc.271.52.33493; Simpson PB, 1997, J BIOL CHEM, V272, P22654, DOI 10.1074/jbc.272.36.22654; SITIA R, 1992, MOL BIOL CELL, V3, P1067, DOI 10.1091/mbc.3.10.1067; Smith TK, 1996, J BIOL CHEM, V271, P6476, DOI 10.1074/jbc.271.11.6476; SRERE PA, 1987, ANNU REV BIOCHEM, V56, P89, DOI 10.1146/annurev.bi.56.070187.000513; STEVENS VL, 1995, BIOCHEM J, V310, P361, DOI 10.1042/bj3100361; STEVENS VL, 1994, J BIOL CHEM, V269, P31397; Stevens VL, 1996, BIOCHEM J, V313, P253, DOI 10.1042/bj3130253; Takahashi M, 1996, EMBO J, V15, P4254, DOI 10.1002/j.1460-2075.1996.tb00800.x; TAKEDA J, 1995, TRENDS BIOCHEM SCI, V20, P367, DOI 10.1016/S0968-0004(00)89078-7; UDENFRIEND S, 1995, ANNU REV BIOCHEM, V64, P563, DOI 10.1146/annurev.bi.64.070195.003023; UEDA E, 1993, J BIOL CHEM, V268, P9998; URAKAZE M, 1992, J BIOL CHEM, V267, P6459; VANCE JE, 1990, J BIOL CHEM, V265, P7248; Vertel B M, 1992, Semin Cell Biol, V3, P325, DOI 10.1016/1043-4682(92)90019-R; VIDUGIRIENE J, 1995, EMBO J, V14, P4686, DOI 10.1002/j.1460-2075.1995.tb00150.x; VIDUGIRIENE J, 1995, METHOD ENZYMOL, V250, P513; VIDUGIRIENE J, 1993, J CELL BIOL, V121, P987, DOI 10.1083/jcb.121.5.987; VIDUGIRIENE J, 1994, J CELL BIOL, V127, P333, DOI 10.1083/jcb.127.2.333; Voelker DR, 1997, BBA-LIPID LIPID MET, V1348, P236, DOI 10.1016/S0005-2760(97)00101-X; VOELKER DR, 1993, J BIOL CHEM, V268, P7069; WASSLER M, 1993, J CELL BIOL, V123, P285, DOI 10.1083/jcb.123.2.285	64	54	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					15203	15212		10.1074/jbc.274.21.15203	http://dx.doi.org/10.1074/jbc.274.21.15203			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329729	hybrid			2022-12-25	WOS:000081965200094
J	Yao, YJ; Ping, XL; Zhang, H; Chen, FF; Lee, PK; Ahsan, H; Chen, CJ; Lee, PH; Pleacocke, M; Santella, RM; Tsou, HC				Yao, YJ; Ping, XL; Zhang, H; Chen, FF; Lee, PK; Ahsan, H; Chen, CJ; Lee, PH; Pleacocke, M; Santella, RM; Tsou, HC			PTEN/MMAC1 mutations in hepatocellular carcinomas	ONCOGENE			English	Article						PTEN/MMAC1; mutation; liver; tumor	BANNAYAN-ZONANA-SYNDROME; TUMOR-SUPPRESSOR GENE; HEPATITIS-B VIRUS; COWDEN-DISEASE; GERMLINE MUTATIONS; AFLATOXIN EXPOSURE; PROSTATE-CANCER; P53 MUTATIONS; BREAST-CANCER; HUMAN LIVER	Mutations in the PTEN/MMAC1 gene have been identified in several types of human cancers and cancer cell lines, including brain, endometrial, prostate, breast, thyroid, and melanoma. In this study, we screened a total of 96 hepatocellular carcinoma (HCC) samples from Taiwan, where HCC is the leading cancer in males and third leading cancer in females, for mutations in the PTEN/MMAC1 gene. Complete sequence analysis of these samples demonstrated a missense mutation in exon 5 (K144I) and exon 7 (V255A) from HCC samples B6-21 and B6-2, respectively. A putative splice site mutation was also detected in intron 3 from sample B6-2. Both B6-21 and B6-2 were previously shown to contain missense mutations in the coding sequences of the p53 gene. Functional studies with the two missense mutations demonstrated that while mutation V255A in exon 7 resulted in a loss of phosphatase activity, mutation K144I in exon 5 retained its phosphatase activity. Additionally, we identified a silent mutation (P96P) in exon 5 of the PTEN/MMAC1 gene from HCC sample B6-22. These data provide the first evidence that the PTEN/MMAC1 gene is mutated in a subset of HCC samples.	Columbia Univ Coll Phys & Surg, Sch Publ Hlth, Dept Dermatol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Sch Publ Hlth, Div Environm Hlth Sci, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Sch Publ Hlth, Div Epidemiol, New York, NY 10032 USA; Natl Taiwan Univ, Coll Publ Hlth, Inst Epidemiol, Taipei 10764, Taiwan; Natl Taiwan Univ, Coll Publ Hlth, Dept Surg, Taipei 10764, Taiwan	Columbia University; Columbia University; Columbia University; National Taiwan University; National Taiwan University	Tsou, HC (corresponding author), Columbia Presbyterian Hosp, Dept Dermatol, 630 W 168th St,VC1526, New York, NY 10032 USA.		Chen, Chien-Jen/C-6976-2008; Chen, Chien-Jen/N-4723-2019	LEE, PO-HUANG/0000-0001-5831-035X	NATIONAL CANCER INSTITUTE [R01CA070519] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR044535] Funding Source: NIH RePORTER; NCI NIH HHS [CA70519] Funding Source: Medline; NIAMS NIH HHS [P0-30 AR44535] Funding Source: Medline; NIA NIH HHS [AG00760] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AGUILAR F, 1994, SCIENCE, V264, P1317, DOI 10.1126/science.8191284; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; BUETOW KH, 1992, P NATL ACAD SCI USA, V89, P9622, DOI 10.1073/pnas.89.20.9622; Cairns P, 1997, CANCER RES, V57, P4997; Chen CJ, 1996, HEPATOLOGY, V24, P38, DOI 10.1002/hep.510240108; Chen CJ, 1997, J GASTROEN HEPATOL, V12, pS294, DOI 10.1111/j.1440-1746.1997.tb00513.x; COONEY KA, 1998, UNPUB; Dahia PLM, 1997, CANCER RES, V57, P4710; FUJIMOTO Y, 1994, CANCER RES, V54, P281; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Guldberg P, 1997, CANCER RES, V57, P3660; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Liu WG, 1997, NAT GENET, V16, P328, DOI 10.1038/ng0897-328; Lunn RM, 1997, CANCER RES, V57, P3471; Lynch ED, 1997, AM J HUM GENET, V61, P1254, DOI 10.1086/301639; Marsh DJ, 1998, HUM MOL GENET, V7, P507, DOI 10.1093/hmg/7.3.507; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; Miyoshi Y, 1998, CANCER RES, V58, P2524; Montesano R, 1997, JNCI-J NATL CANCER I, V89, P1844, DOI 10.1093/jnci/89.24.1844; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Nelen MR, 1997, HUM MOL GENET, V6, P1383, DOI 10.1093/hmg/6.8.1383; NISHIDA N, 1994, CANCER RES, V54, P3107; PEERS FG, 1976, INT J CANCER, V17, P167, DOI 10.1002/ijc.2910170204; Peng Shian-Yang, 1993, Journal of the Formosan Medical Association, V92, P866; Rhei E, 1997, CANCER RES, V57, P3657; Risinger JI, 1997, CANCER RES, V57, P4736; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Teng DHF, 1997, CANCER RES, V57, P5221; Tsou HC, 1998, HUM GENET, V102, P467, DOI 10.1007/s004390050723; Tsou HC, 1997, AM J HUM GENET, V61, P1036, DOI 10.1086/301607; YEH FS, 1989, CANCER RES, V49, P2506; ZHANG YJ, 1993, BIOCHEM BIOPH RES CO, V196, P1010, DOI 10.1006/bbrc.1993.2350	36	105	116	1	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 20	1999	18	20					3181	3185		10.1038/sj.onc.1202659	http://dx.doi.org/10.1038/sj.onc.1202659			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	197WB	10340391				2022-12-25	WOS:000080388000015
J	Bab, I; Smith, E; Gavish, H; Attar-Namdar, M; Chorev, M; Chen, YC; Muhlrad, A; Birnbaum, MJ; Stein, G; Frenkel, B				Bab, I; Smith, E; Gavish, H; Attar-Namdar, M; Chorev, M; Chen, YC; Muhlrad, A; Birnbaum, MJ; Stein, G; Frenkel, B			Biosynthesis of osteogenic growth peptide via alternative translational initiation at AUG(85) of histone H4 mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL-CHARACTERIZATION; EUKARYOTIC RIBOSOMES; MAMMALIAN-CELLS; MESSENGER-RNA; EXPRESSION; GENE; SEQUENCE; RAT; UPSTREAM; DNA	The osteogenic growth peptide (OGP) is an extracellular mitogen identical to the histone H4 (H4) COOH-terminal residues 90-103, which regulates osteogenesis and hematopoiesis, By Northern analysis, OGP mRNA is indistinguishable from H4 mRNA. Indeed, cells transfected with a construct encoding [His(102)]H4 secreted the corresponding [His(13)]OGP. These results suggest production of OGP from H4 genes. Cells transfected with H4-chloramphenicol acetyltransferase (CAT) fusion genes expressed both "long" and "short" CAT proteins. The short CAT was retained following an ATG --> TTG mutation of the H4 ATG initiation codon, but not following mutation of the in-frame internal ATG(85) codon, which, unlike ATG(1), resides within a perfect context for translational initiation. These results suggest that a PreOGP is translated starting at AUG(85). The translational initiation at AUG(85) could be inhibited by optimizing the nucleotide sequence surrounding ATG(1) to maximally support upstream translational initiation, thus implicating leaky ribosomal scanning in usage of the internal AUG. Conversion of the predicted PreOGP to OGP was shown in a cell lysate system using synthetic [His(102)]H4-(85-103) as substrate. Together, our results demonstrate that H4 gene expression diverges at the translational level into the simultaneous parallel production of both H4, a nuclear structural protein, and OGP, an extracellular regulatory peptide.	Univ So Calif, Sch Med, Inst Med Genet, Los Angeles, CA 90033 USA; Hebrew Univ Jerusalem, Fac Med Dent, Bone Lab, IL-91120 Jerusalem, Israel; Univ So Calif, Sch Med, Dept Orthopaed Surg, Los Angeles, CA 90033 USA; Univ So Calif, Sch Med, Dept Biochem, Los Angeles, CA 90033 USA; Univ So Calif, Sch Med, Dept Mol Biol, Los Angeles, CA 90033 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Div Bone & Mineral Metab, Boston, MA 02215 USA; Merrimack Coll, Dept Biol, N Andover, MA 01845 USA; Univ Massachusetts, Med Ctr, Dept Cell Biol, Worcester, MA 01655 USA	University of Southern California; Hebrew University of Jerusalem; University of Southern California; University of Southern California; University of Southern California; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Merrimack College; University of Massachusetts System; University of Massachusetts Worcester	Frenkel, B (corresponding author), Univ So Calif, Sch Med, Inst Med Genet, 2250 Alcazar St,CSC-IGM240, Los Angeles, CA 90033 USA.		Bab, Itai A/C-2613-2009					Akhmanova A, 1996, FEBS LETT, V388, P219, DOI 10.1016/0014-5793(96)00551-0; BAB I, 1992, EMBO J, V11, P1867, DOI 10.1002/j.1460-2075.1992.tb05238.x; BARANY G, 1979, PEPTIDES, V1, P1; Brinkmeier ML, 1998, MOL ENDOCRINOL, V12, P622, DOI 10.1210/me.12.5.622; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Class R, 1996, AM J CLIN ONCOL-CANC, V19, P522, DOI 10.1097/00000421-199610000-00019; Doenecke D, 1997, HISTOCHEM CELL BIOL, V107, P1, DOI 10.1007/s004180050083; Frenkel B, 1996, ENDOCRINOLOGY, V137, P1080, DOI 10.1210/en.137.3.1080; Gan WN, 1998, J BIOL CHEM, V273, P5006, DOI 10.1074/jbc.273.9.5006; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Greenberg Z, 1997, J CELL BIOCHEM, V65, P359, DOI 10.1002/(SICI)1097-4644(19970601)65:3<359::AID-JCB6>3.0.CO;2-R; GREENBERG Z, 1995, J CLIN ENDOCR METAB, V80, P2330, DOI 10.1210/jc.80.8.2330; Gurevitch O, 1996, BLOOD, V88, P4719, DOI 10.1182/blood.V88.12.4719.bloodjournal88124719; KHARCHENKO E P, 1987, Byulleten' Eksperimental'noi Biologii i Meditsiny, V103, P418; Kim HS, 1996, BIOCHEM BIOPH RES CO, V229, P381, DOI 10.1006/bbrc.1996.1814; Kogerman P, 1998, CLIN EXP METASTAS, V16, P83; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1991, GENE EXPRESSION, V1, P111; KOZAK M, 1989, MOL CELL BIOL, V9, P5073, DOI 10.1128/MCB.9.11.5073; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LATHE R, 1985, J MOL BIOL, V183, P1, DOI 10.1016/0022-2836(85)90276-1; Louters LL, 1996, BIOCHIMIE, V78, P39, DOI 10.1016/0300-9084(96)81327-7; Maiyar AC, 1996, J BIOL CHEM, V271, P12414, DOI 10.1074/jbc.271.21.12414; MAJESKA RJ, 1980, ENDOCRINOLOGY, V107, P1494, DOI 10.1210/endo-107-5-1494; MEIER VS, 1989, NUCLEIC ACIDS RES, V17, P795, DOI 10.1093/nar/17.2.795; Merrick WC., 1996, TRANSLATION CONTROL, P31; MULTIGNER L, 1992, NATURE, V360, P33, DOI 10.1038/360033a0; PAULI U, 1987, SCIENCE, V236, P1308, DOI 10.1126/science.3035717; ROBINSON D, 1995, J BONE MINER RES, V10, P690; Schuur ER, 1996, J BIOL CHEM, V271, P7043, DOI 10.1074/jbc.271.12.7043; Watabe Y, 1996, J BIOL CHEM, V271, P25126, DOI 10.1074/jbc.271.41.25126; Wells D., 1989, Nucleic Acids Research, V17, P311; WOLFE SA, 1989, BIOCHIM BIOPHYS ACTA, V1007, P140, DOI 10.1016/0167-4781(89)90032-8	35	44	52	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					14474	14481		10.1074/jbc.274.20.14474	http://dx.doi.org/10.1074/jbc.274.20.14474			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318873	hybrid			2022-12-25	WOS:000080322200102
J	Harari, D; Tzahar, E; Romano, J; Shelly, M; Pierce, JH; Andrews, GC; Yarden, Y				Harari, D; Tzahar, E; Romano, J; Shelly, M; Pierce, JH; Andrews, GC; Yarden, Y			Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor tyrosine kinase	ONCOGENE			English	Article						growth factor; oncogene; pancreas; signal transduction; tyrosine kinase	NEU DIFFERENTIATION FACTOR; SIGNAL-TRANSDUCTION; CARDIAC DEVELOPMENT; CELLULAR-RESPONSE; FACTOR FAMILY; EGF DOMAIN; HEREGULIN; LIGAND; BINDING; ACTIVATION	The ErbB/HER family of receptor tyrosine kinases consists of four receptors that bind a large number of growth factor ligands sharing an epidermal growth factor- (EGF)-like motif, Whereas ErbB-1 binds seven different ligands whose prototype is EGF, the three families of neuregulins (NRGs) activate ErbB-3 and/or ErbB-4. Here we characterize a fourth neuregulin, NRG-4, that acts through ErbB-4. The predicted pro-NRG-4 is a transmembrane protein carrying a unique EGF-like motif and a short cytoplasmic domain. A synthetic peptide encompassing the full-length EGF-like domain can induce growth of interleukin-dependent cells ectopically expressing ErbB-4, but not cells expressing the other three ErbB proteins or their combinations. Consistent with specificity to ErbB-4, NRG-4 can displace an ErbB-4-bound NRG-1 and can activate signaling downstream of this receptor, Expression of NRG-4 mRNA was detected in the adult pancreas and weakly in muscle; other tissues displayed no detectable NRG-4 mRNA. The primary structure and the pattern of expression of NRG-4, together with the strict specificity of this growth factor to ErbB-4, suggest a physiological role distinct from that of the known ErbB ligands.	Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel; NCI, Bethesda, MD 20892 USA; Pfizer Inc, Cent Res, Groton, CT 06340 USA	Weizmann Institute of Science; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Pfizer	Yarden, Y (corresponding author), Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel.		YARDEN, YOSEF/K-1467-2012	shelly, maya/0000-0002-2211-1751				Alimandi M, 1997, EMBO J, V16, P5608, DOI 10.1093/emboj/16.18.5608; BARBACCI EG, 1995, J BIOL CHEM, V270, P9585, DOI 10.1074/jbc.270.16.9585; Ben-Baruch Noa, 1998, P145; Burden S, 1997, NEURON, V18, P847, DOI 10.1016/S0896-6273(00)80324-4; Busfield SJ, 1997, MOL CELL BIOL, V17, P4007, DOI 10.1128/MCB.17.7.4007; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; Carraway KL, 1997, NATURE, V387, P512, DOI 10.1038/387512a0; CHAN SDH, 1995, J BIOL CHEM, V270, P22608, DOI 10.1074/jbc.270.38.22608; Chang H, 1997, NATURE, V387, P509, DOI 10.1038/387509a0; Chen XM, 1996, J BIOL CHEM, V271, P7620, DOI 10.1074/jbc.271.13.7620; Cohen BD, 1996, J BIOL CHEM, V271, P30897, DOI 10.1074/jbc.271.48.30897; Elenius K, 1997, EMBO J, V16, P1268, DOI 10.1093/emboj/16.6.1268; Erickson SL, 1997, DEVELOPMENT, V124, P4999; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; GREGORY H, 1979, GASTROENTEROLOGY, V77, P313; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; Higashiyama S, 1997, J BIOCHEM-TOKYO, V122, P675; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; Jones JT, 1998, J BIOL CHEM, V273, P11667, DOI 10.1074/jbc.273.19.11667; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KARUNAGARAN D, 1995, J BIOL CHEM, V270, P9982, DOI 10.1074/jbc.270.17.9982; Klapper LN, 1997, ONCOGENE, V14, P2099, DOI 10.1038/sj.onc.1201029; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; LIN YZ, 1988, BIOCHEMISTRY-US, V27, P5640, DOI 10.1021/bi00415a037; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MARQUARDT H, 1984, SCIENCE, V223, P1079, DOI 10.1126/science.6320373; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; Pinkas-Kramarski R, 1998, MOL CELL BIOL, V18, P6090, DOI 10.1128/MCB.18.10.6090; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PinkasKramarski R, 1997, ONCOGENE, V15, P2803, DOI 10.1038/sj.onc.1201466; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; Reddy CC, 1996, NAT BIOTECHNOL, V14, P1696, DOI 10.1038/nbt1296-1696; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Riese DJ, 1996, ONCOGENE, V12, P345; Riese DJ, 1996, J BIOL CHEM, V271, P20047, DOI 10.1074/jbc.271.33.20047; Riethmacher D, 1997, NATURE, V389, P725, DOI 10.1038/39593; SAMUEL K, 1990, P NATL ACAD SCI USA, V87, P2264; Shelly M, 1998, J BIOL CHEM, V273, P10496, DOI 10.1074/jbc.273.17.10496; SHING Y, 1993, SCIENCE, V259, P1604, DOI 10.1126/science.8456283; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; Smith T.F., 1981, ADV APPL MATH, V2, P482, DOI DOI 10.1016/0196-8858(81)90046-4; TAM JP, 1983, J AM CHEM SOC, V105, P6442, DOI 10.1021/ja00359a014; TOYODA H, 1995, J BIOL CHEM, V270, P7495, DOI 10.1074/jbc.270.13.7495; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Tzahar E, 1998, BBA-REV CANCER, V1377, pM25, DOI 10.1016/S0304-419X(97)00032-2; Tzahar E, 1997, EMBO J, V16, P4938, DOI 10.1093/emboj/16.16.4938; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; Wang LM, 1998, P NATL ACAD SCI USA, V95, P6809, DOI 10.1073/pnas.95.12.6809; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; Yung Y, 1997, FEBS LETT, V408, P292, DOI 10.1016/S0014-5793(97)00442-0; Zhang DX, 1997, P NATL ACAD SCI USA, V94, P9562, DOI 10.1073/pnas.94.18.9562	60	236	275	0	10	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 29	1999	18	17					2681	2689		10.1038/sj.onc.1202631	http://dx.doi.org/10.1038/sj.onc.1202631			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FH	10348342				2022-12-25	WOS:000080124900003
J	Strathdee, G; MacKean, MJ; Illand, M; Brown, R				Strathdee, G; MacKean, MJ; Illand, M; Brown, R			A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer	ONCOGENE			English	Article						mismatch repair; methylation; cisplatin; drug resistance; ovarian cancer	DNA MISMATCH REPAIR; NONPOLYPOSIS COLORECTAL-CANCER; MICROSATELLITE INSTABILITY; TUMOR-CELLS; HMSH2 GENE; CISPLATIN; HYPERMETHYLATION; NEOPLASMS; MUTATION	Experimental evidence from several sources has identified a link between mismatch repair deficiency and cytotoxic drug resistance, Selection for cisplatin resistance in the human ovarian cancer cell line A2780, results in loss of expression of the mismatch repair protein hMLH1 in most (90%) of the resultant cisplatin-resistant cell lines, Here me demonstrate that the cisplatin sensitive parental cell line displays methylation of the promoter of only one hMLH1 allele, but that the resistant cell lines all exhibit hyper-methylation of the promoters of both hMLH1 alleles, Full methylation of all sites tested was found to be invariably associated with loss of hMLH1 expression, whereas a partial increase in methylation appears compatible with either loss or maintenance of expression, In addition treatment of two of the resistant cell lines with 5-azacytidine, a known inhibitor of methylation, results in re-expression of hMLH1, Clonogenic assays demonstrate that the 5-azacytidine treated cells show increased sensitivity to cisplatin, Furthermore, 12.5% (3/24) of ovarian tumours show hypermethylation of the hMLH1 promoter, Expression of hMLH1 is absent in the tumours that are hypermethylated, while all the unmethylated tumours still express the protein, This analysis suggests that methylation of the hMLH1 promoter may be a common mechanism for loss of hMLH1 expression, and possibly for cisplatin-resistance, in ovarian cancer.	Univ Glasgow, CRC, Dept Med Oncol, Beatson Labs, Glasgow G61 1BD, Lanark, Scotland	Beatson Institute; University of Glasgow	Brown, R (corresponding author), Univ Glasgow, CRC, Dept Med Oncol, Beatson Labs, Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.			Strathdee, Gordon/0000-0001-9681-8429				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Aebi S, 1996, CANCER RES, V56, P3087; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; Brown R, 1997, ONCOGENE, V15, P45, DOI 10.1038/sj.onc.1201167; Eshleman James R., 1995, Current Opinion in Oncology, V7, P83; Fink D, 1996, CANCER RES, V56, P4881; Fink D, 1998, CLIN CANCER RES, V4, P1; Fink D, 1997, INT J ONCOL, V11, P539; FROST P, 1990, CANCER RES, V50, P4572; Fujita M, 1995, INT J CANCER, V64, P361, DOI 10.1002/ijc.2910640602; Hatta Y, 1997, INT J ONCOL, V11, P465; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Kane MF, 1997, CANCER RES, V57, P808; Kaye SB, 1996, ANN ONCOL, V7, P9; KING BL, 1995, BRIT J CANCER, V72, P376, DOI 10.1038/bjc.1995.341; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; LYNCH HT, 1993, GASTROENTEROLOGY, V104, P1535, DOI 10.1016/0016-5085(93)90368-M; Modrich P, 1997, J BIOL CHEM, V272, P24727, DOI 10.1074/jbc.272.40.24727; NEIJT JP, 1997, TXB MED ONCOLOGY, P87; NYCE J, 1989, CANCER RES, V49, P5829; Prolla TA, 1998, NAT GENET, V18, P276, DOI 10.1038/ng0398-276; Reitmair AH, 1996, CANCER RES, V56, P3842; Thibodeau SN, 1996, CANCER RES, V56, P4836; Zingg JM, 1997, CARCINOGENESIS, V18, P869, DOI 10.1093/carcin/18.5.869	25	290	312	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 8	1999	18	14					2335	2341		10.1038/sj.onc.1202540	http://dx.doi.org/10.1038/sj.onc.1202540			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184DT	10327053				2022-12-25	WOS:000079595500005
J	Mayer, T; Meyer, M; Janning, A; Schiedel, AC; Barnekow, A				Mayer, T; Meyer, M; Janning, A; Schiedel, AC; Barnekow, A			A mutant form of the rho protein can restore stress fibers and adhesion plaques in v-src transformed fibroblasts	ONCOGENE			English	Article						rho proteins; transformed fibroblasts; v-src	ROUS-SARCOMA VIRUS; INTRACELLULAR-LOCALIZATION; ACTIN CYTOSKELETON; TYROSINE KINASES; ONCOGENE PRODUCT; CELLS; PHOSPHORYLATION; GTPASES; FAMILY; SIGNAL	The organization of polymerized actin in the mammalian cell is regulated by several members of the rho family. Three rho proteins, cdc42, rac and rho act in a cascade to organize the intracellular actin cytoskeleton. Rho proteins are involved in the formation of actin stress fibers and adhesion plaques in fibroblasts. During transformation of mammalian cells by oncogenes the cytoskeleton is rearranged and stress fibers and adhesion plaques are disintegrated. In this paper we investigate the function of the rho protein in RR1022 rat fibroblasts transformed by the Rous sarcoma virus. Two activated mutants of the rho protein, rho G14V and rho Q63L, and a dominant negative mutant, rho N117I, were stably transfected into RR1022 cells. The resulting cell lines were analysed for the organization of polymerized actin and adhesion plaques. Cells expressing rho Q63L, but not rho wt, rho G14V or rho N117I, showed an altered morphology. These cells displayed a flat, fibroblast like shape when compared with the RR1022 ancestor cells. Immunofluorescence analyses revealed that actin stress fibers and adhesion plaques were rearranged in these cells. We conclude from these data that an active rho protein can restore elements of the actin cytoskeleton in transformed cells by overriding the tyrosine kinase phosphorylation induced by the pp60(v-src).	Muenster Univ, Dept Expt Tumorbiol, D-48149 Muenster, Germany		Mayer, T (corresponding author), Muenster Univ, Dept Expt Tumorbiol, Badestr 9, D-48149 Muenster, Germany.			Mayer, Thomas/0000-0001-6954-2287; Schiedel, Anke/0000-0002-8114-3139				ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARNEKOW A, 1984, MOL CELL BIOL, V4, P1179, DOI 10.1128/MCB.4.6.1179; BARNEKOW A, 1987, COMP BIOCHEM PHYS B, V87, P663, DOI 10.1016/0305-0491(87)90371-3; BARNEKOW A, 1991, BEHRING I MITT, V8, P67; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BROTT BK, 1991, P NATL ACAD SCI USA, V88, P755, DOI 10.1073/pnas.88.3.755; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; CHANG JH, 1995, J CELL BIOL, V130, P355, DOI 10.1083/jcb.130.2.355; DECLUE JE, 1987, MOL CELL BIOL, V7, P371, DOI 10.1128/MCB.7.1.371; EATON S, 1995, J CELL BIOL, V131, P151, DOI 10.1083/jcb.131.1.151; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FRAME MC, 1994, MOL BIOL CELL, V5, P1177, DOI 10.1091/mbc.5.11.1177; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HALL A, 1992, MOL BIOL CELL, V3, P475, DOI 10.1091/mbc.3.5.475; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HIRST R, 1986, P NATL ACAD SCI USA, V83, P6470, DOI 10.1073/pnas.83.17.6470; HORVATH AR, 1990, ONCOGENE, V5, P1349; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; KELLIE S, 1986, J CELL SCI, V82, P129; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; Leung T, 1996, MOL CELL BIOL, V16, P5313; MADAULE P, 1985, CELL, V41, P31, DOI 10.1016/0092-8674(85)90058-3; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NUSRAT A, 1995, P NATL ACAD SCI USA, V92, P10629, DOI 10.1073/pnas.92.23.10629; PASQUALE EB, 1986, P NATL ACAD SCI USA, V83, P5507, DOI 10.1073/pnas.83.15.5507; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RIDLEY AJ, 1994, EMBO J, V13, P2610; ROHRSCHNEIDER L, 1985, MOL CELL BIOL, V5, P3097, DOI 10.1128/MCB.5.11.3097; SCHIEDEL AC, 1995, FEBS LETT, V376, P113, DOI 10.1016/0014-5793(95)01258-0; Seabra MC, 1996, J BIOL CHEM, V271, P14398, DOI 10.1074/jbc.271.24.14398; SEFTON BM, 1981, CELL, V24, P165, DOI 10.1016/0092-8674(81)90512-2; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; STOKER AW, 1986, J VIROL, V58, P876, DOI 10.1128/JVI.58.3.876-883.1986; STOSSEL TP, 1989, J BIOL CHEM, V264, P18261; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; TROULIARIS S, 1995, J VIROL, V69, P6010, DOI 10.1128/JVI.69.10.6010-6020.1995; TURNER CE, 1991, J CELL BIOL, V115, P201, DOI 10.1083/jcb.115.1.201; WANG HCR, 1992, MOL BIOL CELL, V3, P1329, DOI 10.1091/mbc.3.12.1329; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; WYKE AW, 1993, CELL GROWTH DIFFER, V4, P671; WYKE AW, 1995, CELL GROWTH DIFFER, V6, P1225	50	35	36	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 25	1999	18	12					2117	2128		10.1038/sj.onc.1202537	http://dx.doi.org/10.1038/sj.onc.1202537			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	179TX	10321736				2022-12-25	WOS:000079346200009
J	Hatton, JP; Gaubert, F; Lewis, ML; Darsel, Y; Ohlmann, P; Cazenave, JP; Schmitt, D				Hatton, JP; Gaubert, F; Lewis, ML; Darsel, Y; Ohlmann, P; Cazenave, JP; Schmitt, D			The kinetics of translocation and cellular quantity of protein kinase C in human leukocytes are modified during spaceflight	FASEB JOURNAL			English	Article; Proceedings Paper	Symposium of the European-Space-Agency/National-Aeronautics-and-Space-Administration Workshop on Cell and Molecular Biology Research in Space	JUN, 1998	BELGIUM NATL ACAD SCI, LEUVEN, BELGIUM	European Space Agcy, NASA	BELGIUM NATL ACAD SCI	microgravity; translocation	SIGNAL-TRANSDUCTION; PHORBOL ESTERS; MICROGRAVITY; ACTIVATION; LYMPHOCYTES; CELLS; MICROASSAY; RECEPTORS; RESPONSES; GRAVITY	Protein kinase C (PKC) is a family of serine/threonine kinases that play an important role in mediating intracellular signal transduction in eukaryotes, U937 cells were exposed to microgravity during a space shuttle flight and stimulated with a radiolabeled phorbol ester ([H-3]PDBu) to both specifically label and activate translocation of PKC from the cytosol to the particulate fraction of the cell. Although significant translocation of PKC occurred at all g levels, the kinetics of translocation in flight were significantly different from those on the ground. In addition, the total quantity of [H-3]PDBu binding PKC was increased in flight compared to cells at 1 g on the ground, whereas the quantity in hypergravity (1.4 g) was decreased with respect to 1 g, Similarly, in purified human peripheral blood T cells the quantity of PKC delta varied in inverse proportion to the g level for some experimental treatments, In addition to these novel findings, the results confirm earlier studies which showed that PKC is sensitive to changes in gravitational acceleration. The mechanisms of cellular gravisensitivity are poorly understood but the demonstrated sensitivity of PKC to this stimulus provides us with a useful means of measuring the effect of altered gravity levels on early cell activation events.	Etablissement Tranfus Sanguine, INSERM, U311, F-67065 Strasbourg, France; CHU Rangueil, INSERM, U151, F-31054 Toulouse, France; Univ Alabama, Huntsville, AL 35899 USA; CHU Rangueil, Immunol Lab, F-31054 Toulouse, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Alabama System; University of Alabama Huntsville; CHU de Toulouse	Hatton, JP (corresponding author), Etablissement Tranfus Sanguine, INSERM, U311, F-67065 Strasbourg, France.	jason.hatton@etss.u-strasbg.fr	Cazenave, Jean-Pierre/AAE-2935-2019					ALBRECHTBUEHLER G, 1997, FRONTIERS BIOL SCI S, P54; Banerjee A, 1996, ANN NY ACAD SCI, V793, P226, DOI 10.1111/j.1749-6632.1996.tb33517.x; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; Cogoli A, 1991, Adv Space Biol Med, V1, P183; COGOLI A, 1984, SCIENCE, V225, P228, DOI 10.1126/science.6729481; DEGROOT RP, 1991, EXP CELL RES, V197, P87, DOI 10.1016/0014-4827(91)90483-B; GAUBERT F, 1998, THESIS U P SABATIER; GENZEL P, 1988, ESA, P21; GMUNDER FK, 1990, BIOL CELL, V70, P33, DOI 10.1016/0248-4900(90)90358-A; Hashemi BB, 1998, FASEB J, V12, pA626; Hatton JP, 1998, J CELL BIOCHEM, V70, P252, DOI 10.1002/(SICI)1097-4644(19980801)70:2<252::AID-JCB11>3.0.CO;2-P; HATTON JP, 1997, FRONTIERS BIOL SCI S, P82; Hofmann J, 1997, FASEB J, V11, P649, DOI 10.1096/fasebj.11.8.9240967; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; HughesFulford M, 1996, EXP CELL RES, V224, P103, DOI 10.1006/excr.1996.0116; Johnson JA, 1996, J BIOL CHEM, V271, P24962, DOI 10.1074/jbc.271.40.24962; KAPUSCINSKI J, 1977, ANAL BIOCHEM, V83, P252, DOI 10.1016/0003-2697(77)90533-4; Keenan C, 1997, IMMUNOLOGY, V90, P557, DOI 10.1046/j.1365-2567.1997.00198.x; Kiang JG, 1996, THYROID, V6, P475, DOI 10.1089/thy.1996.6.475; KILEY SC, 1995, J CELL SCI, V108, P1003; Kiley SC, 1997, CELL GROWTH DIFFER, V8, P231; Lewis ML, 1998, FASEB J, V12, P1007, DOI 10.1096/fasebj.12.11.1007; LIMOUSE M, 1991, EXP CELL RES, V197, P82, DOI 10.1016/0014-4827(91)90482-A; Mochly-Rosen D, 1998, FASEB J, V12, P35; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; Moore D, 1996, BIOL MED RES SPACE, P1; PARKER PJ, 1994, PROTEIN KINASE C, P3; PELECH SL, 1986, BIOCHEMISTRY-US, V25, P8348, DOI 10.1021/bi00374a002; Pippia P, 1996, J BIOTECHNOL, V47, P215, DOI 10.1016/0168-1656(96)01387-9; Schmitt DA, 1996, FASEB J, V10, P1627, DOI 10.1096/fasebj.10.14.9002555; SHOYAB M, 1980, NATURE, V288, P451, DOI 10.1038/288451a0; TABONY J, 1990, NATURE, V346, P448, DOI 10.1038/346448a0; TABONY J, 1996, NANOBIOLOGY, V4, P117; TSUTSUMI A, 1993, J IMMUNOL, V150, P1746; Wang Y, 1997, J CLIN INVEST, V99, P2890, DOI 10.1172/JCI119483; WOODS KM, 1994, EXP CELL RES, V211, P171, DOI 10.1006/excr.1994.1074	36	48	50	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.		1999	13			S			S23	S33		10.1096/fasebj.13.9001.s23	http://dx.doi.org/10.1096/fasebj.13.9001.s23			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	198CF	10352142				2022-12-25	WOS:000080403800004
J	Burma, S; Kurimasa, A; Xie, GF; Taya, Y; Araki, R; Abe, M; Crissman, HA; Ouyang, H; Li, GC; Chen, DJ				Burma, S; Kurimasa, A; Xie, GF; Taya, Y; Araki, R; Abe, M; Crissman, HA; Ouyang, H; Li, GC; Chen, DJ			DNA-dependent protein kinase-independent activation of p53 in response to DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IONIZING-RADIATION; CATALYTIC SUBUNIT; PHOSPHORYLATION; CELLS; CHECKPOINTS; EXPRESSION; MICE	Phosphorylation at serine 15 of the human p53 tumor suppressor protein is induced by DNA damage and correlates with accumulation of p53 and its activation as a transcription factor. The DNA-dependent protein kinase (DNA-PK) can phosphorylate serine 15 of human p53 and the homologous serine 18 of murine p53 in vitro, Contradictory reports exist about the requirement for DNA-PK in vivo for p53 activation and cell cycle arrest in response to ionizing radiation. While primary SCID (severe combined immunodeficiency) cells, that have defective DNA-PK, show normal p53 activation and cell cycle arrest, a transcriptionally inert form of p53 is induced in the SCID cell line SCGR11. In order to unambiguously define the role of the DNA-PK catalytic subunit (DNA-PKcs) in p53 activation, we examined p53 phosphorylation in mouse embryonic fibroblasts (MEFs) from DNA-PKcs-null mice. We found a similar pattern of serine 18 phosphorylation and accumulation of p53 in response to irradiation in both control and DNA-PKcs-null MEFs, The induced p53 was capable of sequence-specific DNA binding even in the absence of DNA-PKcs. Transactivation of the cyclin-dependent-kinase inhibitor p21, a downstream target of p53, and the G(1) cell cycle checkpoint were also found to be normal in the DNA-PKcs -/- MEFs. Our results demonstrate that DNA-PKcs, unlike the related ATM protein, is not essential for the activation of p53 and G(1) cell cycle arrest in response to ionizing radiation.	Univ Calif Los Alamos Natl Lab, Div Life Sci, Los Alamos, NM 87545 USA; Natl Canc Ctr, Res Inst, Tokyo 1040045, Japan; Natl Inst Radiol Sci, Chiba 2638555, Japan; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA	United States Department of Energy (DOE); Los Alamos National Laboratory; National Cancer Center - Japan; National Institutes for Quantum Science & Technology; Memorial Sloan Kettering Cancer Center	Chen, DJ (corresponding author), Lawrence Berkeley Natl Lab, Div Life Sci, MS 74,1 Cyclotron Rd, Berkeley, CA 94720 USA.			Abe, Masumi/0000-0003-1550-2006	NCI NIH HHS [CA-50519, CA-56909, CA078497] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056909, R37CA050519, R01CA078497, R01CA050519] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Araki R, 1997, P NATL ACAD SCI USA, V94, P2438, DOI 10.1073/pnas.94.6.2438; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chan DW, 1998, INT J RADIAT BIOL, V74, P217, DOI 10.1080/095530098141591; CRISSMAN HA, 1987, EXP CELL RES, V173, P256, DOI 10.1016/0014-4827(87)90350-8; DAnna JA, 1997, RADIAT RES, V148, P260, DOI 10.2307/3579611; Guidos CJ, 1996, GENE DEV, V10, P2038, DOI 10.1101/gad.10.16.2038; Gurley KE, 1996, CARCINOGENESIS, V17, P2537, DOI 10.1093/carcin/17.12.2537; Huang LC, 1996, CANCER RES, V56, P2940; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; Jackson SP, 1997, INT J BIOCHEM CELL B, V29, P935, DOI 10.1016/S1357-2725(97)00006-X; Jongmans W, 1996, ONCOGENE, V13, P1133; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kurimasa A, 1999, P NATL ACAD SCI USA, V96, P1403, DOI 10.1073/pnas.96.4.1403; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; McLure KG, 1998, EMBO J, V17, P3342, DOI 10.1093/emboj/17.12.3342; Peterson SR, 1997, J BIOL CHEM, V272, P10227; PETERSON SR, 1995, P NATL ACAD SCI USA, V92, P3171, DOI 10.1073/pnas.92.8.3171; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Rathmell WK, 1997, CANCER RES, V57, P68; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343	25	68	70	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17139	17143		10.1074/jbc.274.24.17139	http://dx.doi.org/10.1074/jbc.274.24.17139			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358069	hybrid			2022-12-25	WOS:000080780400068
J	Morrison, RF; Farmer, SR				Morrison, RF; Farmer, SR			Role of PPAR gamma in regulating a cascade expression of cyclin-dependent kinase inhibitors, p18(INK4c) and p21(Waf1/Cip1), during adipogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN-ALPHA; ADIPOCYTE DIFFERENTIATION; CELL-CYCLE; 3T3-L1 PREADIPOCYTES; TRANSCRIPTIONAL ACTIVATION; TRANSLATIONAL CONTROL; ECTOPIC EXPRESSION; GENE-EXPRESSION; GROWTH-ARREST; PROLIFERATION	Molecular mechanisms coupling growth arrest and cell differentiation were examined during adipogenesis, Data are presented that document a cascade expression of members of two independent families of cyclin-dependent kinase inhibitors that define distinct states of growth arrest during 3T3-L1 preadipocyte differentiation. Exit from the cell cycle into a pre-differentiation state of post-mitotic growth arrest was characterized by significant increases in p21 and p27, During onset of irreversible growth arrest associated with terminal differentiation, the level of p21 declined with a concomitant, dramatic increase in p18 and a sustained level of p27, The expression of p18 and p21, regulated at the level of protein and mRNA accumulation, was directly coupled to differentiation. Stable cell lines were engineered to express adipogenic transcription factors to examine the active role of trans-acting elements in regulating these cell cycle inhibitors. Ectopic expression of peroxisome proliferator-activated receptor (PPAR) gamma in non-precursor fibroblastic cell lines resulted in conversion to adipocytes and a coordinated increase in p18 and p21 mRNA and protein expression in a PPAR gamma ligand-associated manner. These data demonstrate a role for PPAR gamma in mediating the differentiation-dependent cascade expression of cyclin-dependent kinase inhibitors, thereby providing a molecular mechanism coupling growth arrest and adipocyte differentiation.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA	Boston University	Farmer, SR (corresponding author), Boston Univ, Sch Med, Dept Biochem, 715 Albany St, Boston, MA 02118 USA.	farmer@med-biochem.bu.edu		Farmer, Stephen/0000-0003-2483-2795	NATIONAL CANCER INSTITUTE [F32CA069765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051586, R56DK051586, P30DK046200] Funding Source: NIH RePORTER; NCI NIH HHS [1F32CA69765-01A1] Funding Source: Medline; NIDDK NIH HHS [DK51586, DK46200] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altiok S, 1997, GENE DEV, V11, P1987, DOI 10.1101/gad.11.15.1987; BORTELL R, 1992, J CELL BIOCHEM, V50, P62, DOI 10.1002/jcb.240500111; Brun RP, 1996, CURR OPIN CELL BIOL, V8, P826, DOI 10.1016/S0955-0674(96)80084-6; Brun RP, 1996, GENE DEV, V10, P974, DOI 10.1101/gad.10.8.974; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Chellappan SP, 1998, CURR TOP MICROBIOL, V227, P57; Constance CM, 1996, MOL CELL BIOL, V16, P3878; CORNELIUS P, 1994, ANNU REV NUTR, V14, P99, DOI 10.1146/annurev.nu.14.070194.000531; Franklin DS, 1996, MOL BIOL CELL, V7, P1587, DOI 10.1091/mbc.7.10.1587; FREYTAG SO, 1994, GENE DEV, V8, P1654, DOI 10.1101/gad.8.14.1654; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; Gregoire FM, 1998, PHYSIOL REV, V78, P783, DOI 10.1152/physrev.1998.78.3.783; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; Koh KN, 1998, J MOL CELL CARDIOL, V30, P463, DOI 10.1006/jmcc.1997.0611; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LIN FT, 1992, GENE DEV, V6, P533, DOI 10.1101/gad.6.4.533; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Matsumura I, 1997, MOL CELL BIOL, V17, P2933, DOI 10.1128/MCB.17.5.2933; Moitra J, 1998, GENE DEV, V12, P3168, DOI 10.1101/gad.12.20.3168; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Phelps DE, 1998, CELL GROWTH DIFFER, V9, P595; Phelps DE, 1998, MOL CELL BIOL, V18, P2334, DOI 10.1128/MCB.18.4.2334; Richon VM, 1997, J BIOL CHEM, V272, P10117, DOI 10.1074/jbc.272.15.10117; SCOTT RE, 1982, P NATL ACAD SCI-BIOL, V79, P845, DOI 10.1073/pnas.79.3.845; Shao DL, 1997, J BIOL CHEM, V272, P21473, DOI 10.1074/jbc.272.34.21473; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; SMYTH MJ, 1993, J CELL SCI, V106, P1; STEPHENS JM, 1992, J MOL ENDOCRINOL, V9, P61, DOI 10.1677/jme.0.0090061; STUDENT AK, 1980, J BIOL CHEM, V255, P4745; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; Timchenko NA, 1997, MOL CELL BIOL, V17, P7353, DOI 10.1128/MCB.17.12.7353; TONTONOZ P, 1994, NUCLEIC ACIDS RES, V22, P5628, DOI 10.1093/nar/22.25.5628; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wu ZD, 1998, J CLIN INVEST, V101, P22, DOI 10.1172/JCI1244; WU ZD, 1995, GENE DEV, V9, P2350, DOI 10.1101/gad.9.19.2350; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168	45	255	263	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17088	17097		10.1074/jbc.274.24.17088	http://dx.doi.org/10.1074/jbc.274.24.17088			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358062	hybrid			2022-12-25	WOS:000080780400061
J	Tang, ED; Nunez, G; Barr, FG; Guan, KL				Tang, ED; Nunez, G; Barr, FG; Guan, KL			Negative regulation of the forkhead transcription factor FKHR by Akt	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; INSULIN-RESPONSE SEQUENCE; ALVEOLAR RHABDOMYOSARCOMA; CAENORHABDITIS-ELEGANS; PHOSPHATIDYLINOSITOL 3-KINASE; FUSION PROTEIN; C-AKT; ACTIVATION; PHOSPHORYLATION; EXPRESSION	The FKHR gene was first identified from its disruption by the t(2;13) chromosomal translocation seen in the pediatric tumor alveolar rhabdomyosarcoma. It encodes for a member of the forkhead family of transcription factors. Recently, a homolog of FKHR in the nematode Caenorhabditis elegans was identified called DAF-16, which is a downstream target of two Akt homologs in an insulin-related signaling pathway. We have examined the possible role of Akt in the regulation of FKHR, We find that FKHR can bind in vitro to the insulin-responsive sequence (IRS) in the insulinlike growth factor-binding protein 1 promoter and can activate transcription from a reporter plasmid containing multiple copies of the IRS. Expression of active but not inactive Akt can suppress FKHR-mediated transcriptional activation. Akt can phosphorylate FKHR in vitro on three phosphoacceptor sites, at least a subset of which can also be phosphorylated by Akt in vivo. Importantly, mutation of these three sites to alanine residues enhances the transcriptional activity of FKHR and renders it resistant to inhibition by Akt, Expression of an Akt-resistant mutant of FKHR causes apoptosis in 293T cells in a manner dependent on DNA binding. These results suggest that FKHR may be a direct nuclear regulatory target for Akt in both metabolic and cell survival pathways.	Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Inst Gerontol, Ann Arbor, MI 48109 USA; Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Pennsylvania	Tang, ED (corresponding author), Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA.		Nuñez, Gabriel/A-7160-2014					Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BENNICELLI JL, 1995, ONCOGENE, V11, P119; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Cichy SB, 1998, J BIOL CHEM, V273, P6482, DOI 10.1074/jbc.273.11.6482; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; CLEVIDENCE DE, 1993, P NATL ACAD SCI USA, V90, P3948, DOI 10.1073/pnas.90.9.3948; Coffer PJ, 1998, BIOCHEM J, V335, P1; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HROMAS R, 1993, BLOOD, V81, P2854; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; SASAKI H, 1993, DEVELOPMENT, V118, P47; SUBLETT JE, 1995, ONCOGENE, V11, P545; UNTERMAN TG, 1994, BIOCHEM BIOPH RES CO, V203, P1835, DOI 10.1006/bbrc.1994.2401; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147; Yenush L, 1998, MOL CELL BIOL, V18, P6784, DOI 10.1128/MCB.18.11.6784	29	645	681	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16741	16746		10.1074/jbc.274.24.16741	http://dx.doi.org/10.1074/jbc.274.24.16741			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358014	hybrid			2022-12-25	WOS:000080780400013
J	Yoshida, Y; Nakano, Y; Nezu, T; Yamashita, Y; Koga, T				Yoshida, Y; Nakano, Y; Nezu, T; Yamashita, Y; Koga, T			A novel NDP-6-deoxyhexosyl-4-ulose reductase in the pathway for the synthesis of thymidine diphosphate-D-fucose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTINOBACILLUS-ACTINOMYCETEMCOMITANS SEROTYPES; O-ANTIGEN VARIATION; PERIODONTAL-DISEASE; POLYSACCHARIDE SYNTHESIS; SHIGELLA-FLEXNERI; GENE-CLUSTER; SEQUENCE; RHAMNOSE; LIPOPOLYSACCHARIDE; IDENTIFICATION	The serotype-specific polysaccharide antigen of Actinobacillus actinomycetemcomitans Y4 (serotype b) consists of D-fucose and L-rhamnose. Thymidine diphosphate (dTDP)-D-fucose is the activated nucleotide sugar form of D-fucose, which has been identified as a constituent of structural polysaccharides in only a few bacteria. In this paper, we show that three dTDP-D-fucose synthetic enzymes are encoded by genes in the gene cluster responsible for the synthesis of serotype b-specific polysaccharide in A. actinomycetemcomitans. The first and second steps of the dTDP-D-fucose synthetic pathway are catalyzed by D-glucose-l-phosphate thymidylyltransferase and dTDP-D-glucose 4,6-dehydratase, which are encoded by rmlA and rmlB in the gene cluster, respectively. These two reactions are common to the well studied dTDP-L-rhamnose synthetic pathway. However, the enzyme catalyzing the last step of the dTDP-D-fucose synthetic pathway has never been reported. We identified the fed gene encoding a dTDP-4-keto-6-deoxy-D-glucose reductase, After purifying the three enzymes, their enzymatic activities were analyzed by reversed-phase high performance liquid chromatography, In addition, nuclear magnetic resonance analysis and gas-liquid chromatography analysis proved that the fed gene product converts dTDP-4-keto-6-deoxy-D-glucose to dTDP-D-fucose. Moreover, kinetic analysis of the enzyme indicated that the K-m values for dTDP-4-keto-6-deoxy-D-glucose and NADPH are 97.3 and 28.7 mu M, respectively, and that the enzyme follows the sequential mechanism. This paper is the first report on the dTDP-D-fucose synthetic pathway and dTDP-4-keto-6-deoxy-D-glucose reductase.	Kyushu Univ, Dept Prevent Dent, Fac Dent, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Fac Dent, Dept Prosthet Dent 1, Fukuoka 8128582, Japan	Kyushu University; Kyushu University	Nakano, Y (corresponding author), Kyushu Univ, Dept Prevent Dent, Fac Dent, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	yosh@dent.kyushu-u.ac.jp	Nakano, Yoshio/J-3182-2013	Nakano, Yoshio/0000-0001-9848-3124				AMANN E, 1988, GENE, V69, P301, DOI 10.1016/0378-1119(88)90440-4; AMANO K, 1989, INFECT IMMUN, V57, P2942, DOI 10.1128/IAI.57.10.2942-2946.1989; ARAKAWA Y, 1995, J BACTERIOL, V177, P1788, DOI 10.1128/jb.177.7.1788-1796.1995; ASIKAINEN S, 1991, ORAL MICROBIOL IMMUN, V6, P115, DOI 10.1111/j.1399-302X.1991.tb00462.x; Cleland W. W, 1970, ENZYMES, V2, P1; EBERSOLE JL, 1994, J CLIN PERIODONTOL, V21, P65, DOI 10.1111/j.1600-051X.1994.tb00282.x; GMUR R, 1993, ORAL MICROBIOL IMMUN, V8, P116, DOI 10.1111/j.1399-302X.1993.tb00556.x; JIANG XM, 1991, MOL MICROBIOL, V5, P695, DOI 10.1111/j.1365-2958.1991.tb00741.x; KAPLAN AH, 1989, REV INFECT DIS, V11, P46; KOGA T, 1991, PERIODONTAL DIS PATH, P117; KOPLIN R, 1993, J BACTERIOL, V175, P7789; KOTOWYCZ G, 1973, CHEM REV, V73, P669, DOI 10.1021/cr60286a004; LEONTEIN K, 1978, CARBOHYD RES, V62, P359, DOI 10.1016/S0008-6215(00)80882-4; LINDQUIST L, 1993, EUR J BIOCHEM, V211, P763, DOI 10.1111/j.1432-1033.1993.tb17607.x; LU H, 1993, INFECT IMMUN, V61, P2400, DOI 10.1128/IAI.61.6.2400-2407.1993; MARUMO K, 1992, EUR J BIOCHEM, V204, P539, DOI 10.1111/j.1432-1033.1992.tb16665.x; MELO A, 1968, J BIOL CHEM, V243, P1475; MELO A, 1968, J BIOL CHEM, V243, P1467; Meyer DH, 1997, TRENDS MICROBIOL, V5, P224, DOI 10.1016/S0966-842X(97)01055-X; MORONA R, 1994, J BACTERIOL, V176, P733, DOI 10.1128/jb.176.3.733-747.1994; PAGE RC, 1991, INFECT IMMUN, V59, P3451, DOI 10.1128/IAI.59.10.3451-3462.1991; RAJAKUMAR K, 1994, J BACTERIOL, V176, P2362, DOI 10.1128/JB.176.8.2362-2373.1994; REEVES P, 1995, TRENDS MICROBIOL, V3, P381, DOI 10.1016/S0966-842X(00)88983-0; REEVES P, 1993, TRENDS GENET, V9, P17, DOI 10.1016/0168-9525(93)90067-R; Reeves PR, 1996, TRENDS MICROBIOL, V4, P495, DOI 10.1016/S0966-842X(97)82912-5; Roberts IS, 1996, ANNU REV MICROBIOL, V50, P285, DOI 10.1146/annurev.micro.50.1.285; SAARELA M, 1992, ORAL MICROBIOL IMMUN, V7, P277, DOI 10.1111/j.1399-302X.1992.tb00588.x; Sambrook J, 1989, MOL CLONING LAB MANN; SATO N, 1993, CARBOHYD RES, V245, P105, DOI 10.1016/0008-6215(93)80063-K; SCRUTTON NS, 1990, NATURE, V343, P38, DOI 10.1038/343038a0; SEGEL IH, 1975, ENZYME KINETICS, P957; SHIBAEV VN, 1986, ADV CARBOHYD CHEM BI, V44, P277; SHIBUYA N, 1991, J BIOL CHEM, V266, P16318; SLOTS J, 1986, J CLIN PERIODONTOL, V13, P570, DOI 10.1111/j.1600-051X.1986.tb00849.x; STEVENSON G, 1994, J BACTERIOL, V176, P4144, DOI 10.1128/JB.176.13.4144-4156.1994; SUZUKI J, 1991, AGR BIOL CHEM TOKYO, V55, P283, DOI 10.1080/00021369.1991.10870520; TAKESHITA S, 1987, GENE, V61, P63, DOI 10.1016/0378-1119(87)90365-9; Tonetti M, 1996, J BIOL CHEM, V271, P27274, DOI 10.1074/jbc.271.44.27274; Tsukioka Y, 1997, J BACTERIOL, V179, P1126, DOI 10.1128/jb.179.4.1126-1134.1997; VERMA N, 1989, J BACTERIOL, V171, P5694, DOI 10.1128/jb.171.10.5694-5701.1989; WINN AM, 1993, CARBOHYD RES, V247, P249, DOI 10.1016/0008-6215(93)84257-7; Yoshida Y, 1998, INFECT IMMUN, V66, P107, DOI 10.1128/IAI.66.1.107-114.1998; ZAMBON JJ, 1983, INFECT IMMUN, V41, P19, DOI 10.1128/IAI.41.1.19-27.1983	43	38	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16933	16939		10.1074/jbc.274.24.16933	http://dx.doi.org/10.1074/jbc.274.24.16933			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358040	hybrid			2022-12-25	WOS:000080780400039
J	Howard, OMZ; Shirakawa, AK; Turpin, JA; Maynard, A; Tobin, GJ; Carrington, M; Oppenheim, JJ; Dean, M				Howard, OMZ; Shirakawa, AK; Turpin, JA; Maynard, A; Tobin, GJ; Carrington, M; Oppenheim, JJ; Dean, M			Naturally occurring CCR5 extracellular and transmembrane domain variants affect HIV-1 co-receptor and ligand binding function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CHEMOKINE-RECEPTOR; ENVELOPE GLYCOPROTEINS; DISEASE PROGRESSION; ENTRY; INFECTION; CORECEPTOR; ASSOCIATION; INHIBITION; MACROPHAGE	Analysis of CCR5 variants in human immunodeficiency virus, type 1 (HIV-1), high risk cohorts led to the identification of multiple single amino acid substitutions in the amino-terminal third of the HIV-1 co-receptor CCR5 suggesting the possibility of protective and permissive genotypes; unfortunately, the low frequency of these mutations did not led to correlation with function. Therefore, we used analytical methods to assess the functional and structural significance of six of these variant receptors in vitro. These studies showed three categories of effects on CCR5 function. 1) Mutations in the first extracellular domain of CCR5 severely reduce specific ligand binding and chemokine-induced chemotaxis. 2) An extracellular domain variant, A29S, when co-expressed with CD4, supported HIV-1 infection whereas the others do not. 3) The transmembrane region variants of CCR5 support monotropic HIV-1 infection that is blocked by addition of some receptor agonists, Mutations in the first and second transmembrane domains increase RANTES (regulated on activation normal T-cell expressed) binding affinity but did not affect MIP1 beta binding affinity presumably based on differences in ligand-receptor interaction sites. Furthermore, the CCR5 transmembrane mutants do not respond to RANTES with the classical bell-shaped chemotactic response curve, suggesting that they are resistant to RANTES-induced desensitization. These data demonstrate that single amino acid changes in the extracellular domains of CCR5 can have profound effects on both HIV-1 coreceptor and specific ligand-induced functions, whereas mutations in the transmembrane domain only affect the response to chemokine ligands.	NCI, Intramural Res Support Program, SAIC Frederick, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA; NCI, Mol Immunoregulat Lab, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA; NCI, Lab Genom Divers, Div Basic Sci, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA; SW Res Inst, Frederick, MD 21701 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Howard, OMZ (corresponding author), POB B, Frederick, MD 21702 USA.		Dean, Michael/R-7501-2019; Dean, Michael C/G-8172-2012; Howard, O M Zack/B-6117-2012	Dean, Michael C/0000-0003-2234-0631; Howard, O M Zack/0000-0002-0505-7052	NCI NIH HHS [N01-CO-56000] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC009369, Z01BC005652] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO056000] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alkhatib G, 1997, VIROLOGY, V234, P340, DOI 10.1006/viro.1997.8673; Alkhatib G, 1997, J BIOL CHEM, V272, P20420, DOI 10.1074/jbc.272.33.20420; Atchison RE, 1996, SCIENCE, V274, P1924, DOI 10.1126/science.274.5294.1924; Bazan HA, 1998, J VIROL, V72, P4485, DOI 10.1128/JVI.72.5.4485-4491.1998; Bieniasz Paul D., 1998, Frontiers in Bioscience, V3, pD44; Bjorndal A, 1997, J VIROL, V71, P7478; Bohm SK, 1997, BIOCHEM J, V322, P1; BOKOCH GM, 1995, BLOOD, V86, P1649, DOI 10.1182/blood.V86.5.1649.bloodjournal8651649; Carrington M, 1997, AM J HUM GENET, V61, P1261, DOI 10.1086/301645; Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; Choe H, 1998, J VIROL, V72, P6113, DOI 10.1128/JVI.72.7.6113-6118.1998; Combadiere C, 1996, J LEUKOCYTE BIOL, V60, P147, DOI 10.1002/jlb.60.1.147; Combadiere C, 1998, J BIOL CHEM, V273, P23799, DOI 10.1074/jbc.273.37.23799; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Elsner J, 1997, EUR J IMMUNOL, V27, P2892, DOI 10.1002/eji.1830271122; Farzan M, 1998, J VIROL, V72, P1160, DOI 10.1128/JVI.72.2.1160-1164.1998; Garred P, 1998, J RHEUMATOL, V25, P1462; Gong WH, 1998, J BIOL CHEM, V273, P4289, DOI 10.1074/jbc.273.8.4289; Grimm MC, 1998, J EXP MED, V188, P317, DOI 10.1084/jem.188.2.317; Haribabu B, 1997, J BIOL CHEM, V272, P28726, DOI 10.1074/jbc.272.45.28726; He JL, 1997, NATURE, V385, P645, DOI 10.1038/385645a0; Hill CM, 1998, VIROLOGY, V248, P357, DOI 10.1006/viro.1998.9283; Horuk R, 1998, J BIOL CHEM, V273, P386, DOI 10.1074/jbc.273.1.386; Howard OMZ, 1998, J MED CHEM, V41, P2184, DOI 10.1021/jm9801253; Howard OMZ, 1998, J LEUKOCYTE BIOL, V64, P6, DOI 10.1002/jlb.64.1.6; HOWARD OMZ, 1995, BIOCHEM J, V306, P217, DOI 10.1042/bj3060217; Kim JY, 1997, J BIOL CHEM, V272, P27313, DOI 10.1074/jbc.272.43.27313; Kuhmann SE, 1997, J VIROL, V71, P8642, DOI 10.1128/JVI.71.11.8642-8656.1997; LEONARD EJ, 1995, CURRENT PROTOCOLS IM, V13; LUI R, 1996, CELL, V86, P367; Mack M, 1998, J EXP MED, V187, P1215, DOI 10.1084/jem.187.8.1215; McDermott DH, 1998, LANCET, V352, P866, DOI 10.1016/S0140-6736(98)04158-0; Moore JP, 1997, CURR OPIN IMMUNOL, V9, P551, DOI 10.1016/S0952-7915(97)80110-0; Nibbs RJB, 1997, J BIOL CHEM, V272, P12495, DOI 10.1074/jbc.272.19.12495; Pakianathan DR, 1997, BIOCHEMISTRY-US, V36, P9642, DOI 10.1021/bi970593z; Pease JE, 1998, J BIOL CHEM, V273, P19972, DOI 10.1074/jbc.273.32.19972; Rabut GEE, 1998, J VIROL, V72, P3464, DOI 10.1128/JVI.72.4.3464-3468.1998; Ruffing N, 1998, CELL IMMUNOL, V189, P160, DOI 10.1006/cimm.1998.1379; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Samson M, 1997, J BIOL CHEM, V272, P24934, DOI 10.1074/jbc.272.40.24934; Shieh JTC, 1998, J VIROL, V72, P4243, DOI 10.1128/JVI.72.5.4243-4249.1998; Smith MW, 1997, SCIENCE, V277, P959, DOI 10.1126/science.277.5328.959; Sozzani S, 1997, J LEUKOCYTE BIOL, V62, P30, DOI 10.1002/jlb.62.1.30; Tournamille C, 1997, J BIOL CHEM, V272, P16274, DOI 10.1074/jbc.272.26.16274; Wu LJ, 1997, J EXP MED, V186, P1373, DOI 10.1084/jem.186.8.1373; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L; Zhou YH, 1998, J IMMUNOL, V160, P4018	47	64	66	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16228	16234		10.1074/jbc.274.23.16228	http://dx.doi.org/10.1074/jbc.274.23.16228			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347178	hybrid			2022-12-25	WOS:000080668600038
J	Myung, CS; Yasuda, H; Liu, WW; Harden, TK; Garrison, JC				Myung, CS; Yasuda, H; Liu, WW; Harden, TK; Garrison, JC			Role of isoprenoid lipids on the heterotrimeric G protein gamma subunit in determining effector activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACULOVIRUS EXPRESSION SYSTEM; PHOSPHOLIPASE-C ISOZYMES; BETA-ADRENERGIC-RECEPTOR; TRIMERIC G-PROTEINS; ADENYLYL-CYCLASE; ALPHA-SUBUNIT; TISSUE DISTRIBUTION; CRYSTAL-STRUCTURE; PRENYL GROUP; SF9 CELLS	Post-translational prenylation of heterotrimeric G protein gamma subunits is essential for high affinity alpha-beta gamma and alpha-beta gamma-receptor interactions, suggesting that the prenyl group is an important domain in the beta gamma dimer. To determine the role of the prenyl modification in the interaction of beta gamma dimers with effecters, the CAAX (where A indicates alipathic amino acid) motifs in the gamma(1), gamma(2), and y(11) subunits were altered to direct modification with different prenyl groups. Six recombinant beta gamma dimers were overexpressed in baculovirus-infected Sf9 insect cells, purified, and examined for their ability to stimulate three phospholipase C-beta isozymes and type II adenylyl cyclase, The native beta(1)gamma(2) dimer (gamma subunit modified with geranylgeranyl) is more potent and effective in activating phospholipase C-beta than either the beta(1)gamma(1) (farnesyl) or the beta(1)gamma(11) (farnesyl) dimers. However, farnesyl modification of the gamma subunit in the beta(1)gamma(2) dimer (beta(1)gamma(2-L71S)) caused a decrement in its ability to activate phospholipase C-beta. In contrast, both the beta 1 gamma(1-S74L) (geranylgeranyl) and the beta(1)gamma(11-S73L) (geranylgeranyl) dimers were more active than the native forms. The beta(1)gamma(2) dimer activates type II adenylyl cyclase about 12-fold; however, neither the beta(1)gamma(1) nor the beta(1)gamma(11) dimers activate the enzyme. As was the case with phospholipase C-P, the beta(1)gamma(2-L71S) dimer was less able to activate adenylyl cyclase than the native beta(1)gamma(2) dimer. Interestingly, neither the beta(1)gamma(1-S74L) nor the beta(1)gamma(11-S73L) dimers stimulated adenylyl cyclase. The results suggest that both the amino acid sequence of the gamma subunit and its prenyl group play a role in determining the activity of the beta gamma-effector complex.	Univ Virginia, Hlth Sci Ctr, Dept Pharmacol, Charlottesville, VA 22908 USA; Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA	University of Virginia; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Garrison, JC (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Pharmacol, Box 448, Charlottesville, VA 22908 USA.			Myung, Chang-Seon/0000-0002-6292-2911	NCI NIH HHS [P01-CA-40042] Funding Source: Medline; NIDDK NIH HHS [R01-DK-19952] Funding Source: Medline; NIGMS NIH HHS [GM-29536] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA040042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019952] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029536, R37GM029536] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLOOM H, 1987, ELECTROPHORESIS, V8, P93; BOYER JL, 1992, J BIOL CHEM, V267, P25451; BOYER JL, 1994, J BIOL CHEM, V269, P2814; BROOKER G, 1976, SCIENCE, V194, P270, DOI 10.1126/science.184530; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; CASEY PJ, 1994, CURR OPIN CELL BIOL, V6, P219, DOI 10.1016/0955-0674(94)90139-2; CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; Dessauer CW, 1996, J BIOL CHEM, V271, P16967, DOI 10.1074/jbc.271.28.16967; DIETRICH A, 1994, EUR J BIOCHEM, V219, P171, DOI 10.1111/j.1432-1033.1994.tb19927.x; FEDER D, 1986, EMBO J, V5, P1509, DOI 10.1002/j.1460-2075.1986.tb04390.x; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; Fletcher JE, 1998, J BIOL CHEM, V273, P636, DOI 10.1074/jbc.273.1.636; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; Gautam N, 1998, CELL SIGNAL, V10, P447, DOI 10.1016/S0898-6568(98)00006-0; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRABER SG, 1994, METHOD ENZYMOL, V237, P212; GRABER SG, 1996, METH NEUROSCI, V29, P207; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; JACOBOWITZ O, 1994, P NATL ACAD SCI USA, V91, P10630, DOI 10.1073/pnas.91.22.10630; Jones PG, 1998, BBA-MOL CELL RES, V1402, P288, DOI 10.1016/S0167-4889(98)00017-2; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KISSELEV O, 1995, J BIOL CHEM, V270, P25356, DOI 10.1074/jbc.270.43.25356; KISSELEV OG, 1994, J BIOL CHEM, V269, P21399; Kuang YN, 1996, P NATL ACAD SCI USA, V93, P2964, DOI 10.1073/pnas.93.7.2964; LEE SB, 1993, J BIOL CHEM, V268, P25952; Lindorfer MA, 1996, J BIOL CHEM, V271, P18582, DOI 10.1074/jbc.271.31.18582; Loew A, 1998, STRUCT FOLD DES, V6, P1007, DOI 10.1016/S0969-2126(98)00102-6; Long SB, 1998, BIOCHEMISTRY-US, V37, P9612, DOI 10.1021/bi980708e; MARSHALL CJ, 1993, SCIENCE, V259, P1865, DOI 10.1126/science.8456312; Matsuda T, 1998, BIOCHEMISTRY-US, V37, P9843, DOI 10.1021/bi973194c; MOOMAW JF, 1992, J BIOL CHEM, V267, P17438; Morishita R, 1998, FEBS LETT, V428, P85, DOI 10.1016/S0014-5793(98)00498-0; MORISHITA R, 1995, J BIOL CHEM, V270, P29469, DOI 10.1074/jbc.270.49.29469; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; MOTULSKY HJ, 1987, FASEB J, V1, P365, DOI 10.1096/fasebj.1.5.3315805; MUNTZ KH, 1992, MOL BIOL CELL, V3, P49, DOI 10.1091/mbc.3.1.49; Myung CS, 1999, ANAL BIOCHEM, V270, P303, DOI 10.1006/abio.1999.4086; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; OHGURO H, 1991, EMBO J, V10, P3669, DOI 10.1002/j.1460-2075.1991.tb04934.x; Panchenko MP, 1998, J BIOL CHEM, V273, P28298, DOI 10.1074/jbc.273.43.28298; PARK DG, 1993, J BIOL CHEM, V268, P4573; PARK DG, 1993, J BIOL CHEM, V268, P3710; Park HW, 1997, SCIENCE, V275, P1800, DOI 10.1126/science.275.5307.1800; PATERSON A, 1995, CELL SIGNAL, V7, P709, DOI 10.1016/0898-6568(95)00039-R; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; RAY K, 1995, J BIOL CHEM, V270, P21765, DOI 10.1074/jbc.270.37.21765; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; RHEE SG, 1992, J BIOL CHEM, V267, P12393; RUBENSTEIN RC, 1991, BIOCHEMISTRY-US, V30, P10769, DOI 10.1021/bi00108a023; Sankaran B, 1998, J BIOL CHEM, V273, P7148, DOI 10.1074/jbc.273.12.7148; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; Siffert W, 1998, NAT GENET, V18, P45, DOI 10.1038/ng0198-45; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; TANG WJ, 1995, SCIENCE, V268, P1769, DOI 10.1126/science.7792604; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TAUSSIG R, 1993, J BIOL CHEM, V268, P9; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; UEDA N, 1994, J BIOL CHEM, V269, P4388; Waldo GL, 1996, BIOCHEM J, V316, P559, DOI 10.1042/bj3160559; Watson AJ, 1996, J BIOL CHEM, V271, P28154, DOI 10.1074/jbc.271.45.28154; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; WU DQ, 1993, J BIOL CHEM, V268, P3704; Yasuda H, 1998, J BIOL CHEM, V273, P21958, DOI 10.1074/jbc.273.34.21958; Yasuda H, 1996, J BIOL CHEM, V271, P18588, DOI 10.1074/jbc.271.31.18588; YOKOYAMA K, 1993, J BIOL CHEM, V268, P4055	74	67	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16595	16603		10.1074/jbc.274.23.16595	http://dx.doi.org/10.1074/jbc.274.23.16595			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347226	hybrid, Green Published			2022-12-25	WOS:000080668600086
J	Riethmuller, C; Gorren, ACF; Pitters, E; Hemmens, B; Habisch, HJ; Heales, SJR; Schmidt, K; Werner, ER; Mayer, B				Riethmuller, C; Gorren, ACF; Pitters, E; Hemmens, B; Habisch, HJ; Heales, SJR; Schmidt, K; Werner, ER; Mayer, B			Activation of neuronal nitric-oxide synthase by the 5-methyl analog of tetrahydrobiopterin - Functional, evidence against reductive oxygen activation by the pterin cofactor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-ARGININE; SUBUNIT DIMERIZATION; ELECTRON-TRANSFER; INSECT CELLS; BINDING; HEME; ENZYME; DIMER; SUBSTRATE; INTERMEDIATE	Tetrahydrobiopterin ((6R) -5,6,7,8-tetrahydro-L-biopterin (H(4)biopterin)) is an essential cofactor of nitric-oxide synthases (NOSs), but its role in enzyme function is not known. Binding of the pterin affects the electronic structure of the prosthetic heme group in the oxygenase domain and results in a pronounced stabilization of the active homodimeric structure of the protein. However, these allosteric effects are also produced by the potent pterin antagonist of NOS, 4-amino-H(4)biopterin, suggesting that the natural cofactor has an additional, as yet unknown catalytic function. Here we show that the 5-methyl analog of H(4)biopterin, which does not react with O(2), is a functionally active pterin cofactor of neuronal NOS. Activation of the H(4)biopterin-free enzyme occurred in a biphasic manner with half-maximally effective concentrations of approximately 0.2 mu M and 10 mM 5-methyl-H(4)biopterin. Thus, the affinity of the 5-methyl compound was 3 orders of magnitude lower than that of the natural cofactor, allowing the direct demonstration of the functional anticooperativity of the two pterin binding sites of dimeric NOS. In contrast to H(4)biopterin, which inactivates nitric oxide (NO) through nonenzymatic superoxide formation, up to 1 mM of the 5-methyl derivative did not consume O(2) and had no effect on NO steady-state concentrations measured electrochemically with a Clark-type NO electrode. Therefore, reconstitution with 5-methyl-H(4)biopterin allowed, for the first time, the detection of enzymatic NO formation in the absence of superoxide or NO scavengers. These results unequivocally identify free NO as a NOS product and indicate that reductive O(2) activation by the pterin cofactor is not essential to NO biosynthesis.	Graz Univ, Inst Pharmakol & Toxikol, A-8010 Graz, Austria; UCL Natl Hosp Neurol & Neurosurg, Dept Clin Biochem, London WC1N 3BG, England; Univ Innsbruck, Inst Med Chem & Biochem, A-6020 Innsbruck, Austria	University of Graz; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of Innsbruck	Mayer, B (corresponding author), Graz Univ, Inst Pharmakol & Toxikol, Univ Pl 2, A-8010 Graz, Austria.	mayer@kfunigraz.ac.at	Mayer, Bernd/B-9391-2008	Habisch, Hansjorg/0000-0001-5537-506X; Gorren, Antonius Cornelis Franciscus/0000-0003-3476-6162; Werner, Ernst R./0000-0003-1948-3391; Mayer, Bernd/0000-0002-2921-3494				BAEK KJ, 1993, J BIOL CHEM, V268, P21120; Bec N, 1998, J BIOL CHEM, V273, P13502, DOI 10.1074/jbc.273.22.13502; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; Gorren ACF, 1997, BIOCHEMISTRY-US, V36, P4360, DOI 10.1021/bi962381s; Gorren ACF, 1996, BIOCHEMISTRY-US, V35, P16735, DOI 10.1021/bi961931j; HARTENECK C, 1994, BIOCHEM J, V304, P683, DOI 10.1042/bj3040683; HEINZEL B, 1992, BIOCHEM J, V281, P627, DOI 10.1042/bj2810627; HEVEL JM, 1992, BIOCHEMISTRY-US, V31, P7160, DOI 10.1021/bi00146a019; HYLAND K, 1985, J CHROMATOGR, V343, P35, DOI 10.1016/S0378-4347(00)84565-X; KLATT P, 1994, J BIOL CHEM, V269, P13861; KLATT P, 1995, EMBO J, V14, P3687, DOI 10.1002/j.1460-2075.1995.tb00038.x; KLATT P, 1993, J BIOL CHEM, V268, P14781; Klatt P, 1996, J BIOL CHEM, V271, P7336, DOI 10.1074/jbc.271.13.7336; KUKOVETZ WR, 1989, J CARDIOVASC PHARM, V14, pS40, DOI 10.1097/00005344-198914110-00008; List BM, 1996, BIOCHEM J, V315, P57, DOI 10.1042/bj3150057; MARLETTA MA, 1988, BIOCHEMISTRY-US, V27, P8706, DOI 10.1021/bi00424a003; MAYER B, 1995, N-S ARCH PHARMACOL, V351, P453; MAYER B, 1995, J BIOL CHEM, V270, P655, DOI 10.1074/jbc.270.2.655; MAYER B, 1994, NEUROPHARMACOLOGY, V33, P1253, DOI 10.1016/0028-3908(94)90024-8; MAYER B, 1991, FEBS LETT, V288, P187, DOI 10.1016/0014-5793(91)81031-3; Mayer B, 1997, TRENDS BIOCHEM SCI, V22, P477, DOI 10.1016/S0968-0004(97)01147-X; Mayer B, 1997, BIOCHEMISTRY-US, V36, P8422, DOI 10.1021/bi970144z; MCMILLAN K, 1995, BIOCHEMISTRY-US, V34, P3686, DOI 10.1021/bi00011a025; MURPHY ME, 1991, P NATL ACAD SCI USA, V88, P10860, DOI 10.1073/pnas.88.23.10860; Perry JM, 1998, P NATL ACAD SCI USA, V95, P11101, DOI 10.1073/pnas.95.19.11101; Pfeiffer S, 1997, BIOCHEM J, V328, P349, DOI 10.1042/bj3280349; Presta A, 1998, BIOCHEMISTRY-US, V37, P298, DOI 10.1021/bi971944c; RodriguezCrespo I, 1996, J BIOL CHEM, V271, P11462, DOI 10.1074/jbc.271.19.11462; SCHMIDT HHHW, 1991, P NATL ACAD SCI USA, V88, P365, DOI 10.1073/pnas.88.2.365; Schmidt HHHW, 1996, P NATL ACAD SCI USA, V93, P14492, DOI 10.1073/pnas.93.25.14492; Siddhanta U, 1998, J BIOL CHEM, V273, P18950, DOI 10.1074/jbc.273.30.18950; Siddhanta U, 1996, J BIOL CHEM, V271, P7309, DOI 10.1074/jbc.271.13.7309; STUEHR DJ, 1991, J BIOL CHEM, V266, P6259; Stuehr DJ, 1997, ANNU REV PHARMACOL, V37, P339, DOI 10.1146/annurev.pharmtox.37.1.339; Vasquez-Vivar J, 1998, P NATL ACAD SCI USA, V95, P9220, DOI 10.1073/pnas.95.16.9220; WERNER ER, 1994, BIOCHEM J, V304, P189, DOI 10.1042/bj3040189; Werner ER, 1996, BIOCHEM J, V320, P193, DOI 10.1042/bj3200193; Xia Y, 1997, P NATL ACAD SCI USA, V94, P12705, DOI 10.1073/pnas.94.23.12705	39	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16047	16051		10.1074/jbc.274.23.16047	http://dx.doi.org/10.1074/jbc.274.23.16047			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347155	hybrid			2022-12-25	WOS:000080668600015
J	Diderich, JA; Schepper, M; van Hoek, P; Luttik, MAH; van Dijken, JP; Pronk, JT; Klaassen, P; Boelens, HFM; de Mattos, RJT; van Dam, K; Kruckeberg, AL				Diderich, JA; Schepper, M; van Hoek, P; Luttik, MAH; van Dijken, JP; Pronk, JT; Klaassen, P; Boelens, HFM; de Mattos, RJT; van Dam, K; Kruckeberg, AL			Glucose uptake kinetics and transcription of HXT genes chemostat cultures of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDIVIDUAL HEXOSE TRANSPORTERS; ESCHERICHIA-COLI; PHYSIOLOGICAL CHARACTERIZATION; SUGAR-TRANSPORT; YEAST; EXPRESSION; AFFINITY; REPRESSION; PROTEIN; GROWTH	The kinetics of glucose transport and the transcription of all 20 members of the HXT hexose transporter gene family were studied in relation to the steady state in situ carbon metabolism of Saccharomyces cerevisiae CEN.PK113-7D grown in chemostat cultures. Cells were cultivated at a dilution rate of 0.10 h(-1) under various nutrient-limited conditions (anaerobically glucose- or nitrogen-limited or aerobically glucose-, galactose-, fructose-, ethanol-, or nitrogen-limited), or at dilution rates ranging between 0.05 and 0.38 h(-1) in aerobic glucose-limited cultures. Transcription of HXT1-HXT7 was correlated with the extracellular glucose concentration in the cultures. Transcription of GAL2, encoding the galactose transporter, was only detected in galactose-limited cultures. SNF3 and RGT2, two members of the HXT family that encode glucose sensors, were transcribed at low levels. HXT8-HXT17 transcripts were detected at very low levels. A consistent relationship was observed between the expression of individual HXT genes and the glucose transport kinetics determined from zero-trans influx of C-14-glucose during 5 s, This relationship was in broad agreement with the transport kinetics of Hxt1-Hxt7 and Gal2 deduced in previous studies on single-HXT strains. At lower dilution rates the glucose transport capacity estimated from zero-trans influx experiments and the residual glucose concentration exceeded the measured in situ glucose consumption rate. At high dilution rates, however, the estimated glucose transport capacity was too low to account for the in situ glucose consumption rate.	Univ Amsterdam, EC Slater Inst, NL-1018 TV Amsterdam, Netherlands; Delft Univ Technol, Kluyver Lab Biotechnol, NL-2628 BC Delft, Netherlands; Gist Brocades BV, NL-2600 MA Delft, Netherlands; Univ Amsterdam, Dept Chem Engn, NL-1018 WV Amsterdam, Netherlands	University of Amsterdam; Delft University of Technology; University of Amsterdam	Kruckeberg, AL (corresponding author), Free Univ Amsterdam, Fac Biol, Dept Mol Cell Physiol, de Boelelaan 1087, NL-1081 HV Amsterdam, Netherlands.		Diderich, Jasper/AAH-3373-2019	Luttik, Marijke/0000-0002-9798-8072; Diderich, Jasper/0000-0003-2675-9712; Pronk, Jack/0000-0002-5617-4611				ADAMS J, 1985, GENETICS, V110, P173; Bergmeyer HU, 1974, METHODS ENZYMATIC AN; BISSON LF, 1993, CRIT REV BIOCHEM MOL, V28, P259, DOI 10.3109/10409239309078437; BISSON LF, 1988, J BACTERIOL, V170, P4838, DOI 10.1128/jb.170.10.4838-4845.1988; Boles E, 1997, FEMS MICROBIOL REV, V21, P85, DOI 10.1016/S0168-6445(97)00052-1; Brown CJ, 1998, MOL BIOL EVOL, V15, P931, DOI 10.1093/oxfordjournals.molbev.a026009; CELENZA JL, 1988, P NATL ACAD SCI USA, V85, P2130, DOI 10.1073/pnas.85.7.2130; CIRIACY M, 1997, YEAST SUGAR METABOLI, P45; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Gancedo JM, 1998, MICROBIOL MOL BIOL R, V62, P334, DOI 10.1128/MMBR.62.2.334-361.1998; HELLING RB, 1987, GENETICS, V116, P349; HUIBREGTSE JM, 1993, J BIOL CHEM, V268, P22219; KOU SC, 1970, J BACTERIOL, V103, P671, DOI 10.1128/JB.103.3.671-678.1970; Kruckeberg AL, 1996, ARCH MICROBIOL, V166, P283, DOI 10.1007/s002030050385; LAGUNAS R, 1993, FEMS MICROBIOL LETT, V104, P229, DOI 10.1016/0378-1097(93)90598-V; LEWIS DA, 1991, MOL CELL BIOL, V11, P3804, DOI 10.1128/MCB.11.7.3804; Liang H, 1996, MOL BIOL CELL, V7, P1953, DOI 10.1091/mbc.7.12.1953; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANIATIS T, 1982, MOL CLONING LABORATO, P199; Mathias LJ, 1997, TRENDS POLYM SCI, V5, P2; MEIJER M, 1998, THESIS U UTRECHT; Meijer MMC, 1996, BBA-BIOENERGETICS, V1277, P209, DOI 10.1016/S0005-2728(96)00098-9; NEIGEBORN L, 1986, MOL CELL BIOL, V6, P3569, DOI 10.1128/MCB.6.11.3569; NOORMAN HJ, 1991, J GEN MICROBIOL, V137, P2171, DOI 10.1099/00221287-137-9-2171; Ozcan S, 1996, MOL CELL BIOL, V16, P5536; Ozcan S, 1998, EMBO J, V17, P2566, DOI 10.1093/emboj/17.9.2566; OZCAN S, 1994, EUR J BIOCHEM, V224, P605, DOI 10.1111/j.1432-1033.1994.00605.x; OZCAN S, 1995, MOL CELL BIOL, V15, P1564; Ozcan S, 1996, P NATL ACAD SCI USA, V93, P12428, DOI 10.1073/pnas.93.22.12428; PIRT SJ, 1975, PRINCIPLES MICROBE C, P29; POSTMA E, 1989, YEAST, V5, P159, DOI 10.1002/yea.320050305; REIFENBERGER E, 1995, MOL MICROBIOL, V16, P157, DOI 10.1111/j.1365-2958.1995.tb02400.x; Reifenberger E, 1997, EUR J BIOCHEM, V245, P324, DOI 10.1111/j.1432-1033.1997.00324.x; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SCHULZE U, 1995, THESIS U TU DENMARK; SEBER GAF, 1989, NONLINEAR REGRESSION, P683; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Smits HP, 1996, YEAST, V12, P439, DOI 10.1002/(SICI)1097-0061(199604)12:5<439::AID-YEA925>3.3.CO;2-N; Teusink B, 1998, J BACTERIOL, V180, P556, DOI 10.1128/JB.180.3.556-562.1998; THEODORIS G, 1994, GENETICS, V137, P957; Travisano M, 1996, GENETICS, V143, P15; TSCHOPP JF, 1986, J BACTERIOL, V166, P313, DOI 10.1128/jb.166.1.313-318.1986; Van Hoek P, 1998, APPL ENVIRON MICROB, V64, P2133; VANURK H, 1988, YEAST, V4, P283, DOI 10.1002/yea.320040406; VERDUYN C, 1990, J GEN MICROBIOL, V136, P395, DOI 10.1099/00221287-136-3-395; VERDUYN C, 1992, YEAST, V8, P501, DOI 10.1002/yea.320080703; VERDUYN C, 1984, J MICROBIOL METH, V2, P15, DOI 10.1016/0167-7012(84)90027-7; WALSH MC, 1994, J BACTERIOL, V176, P953, DOI 10.1128/JB.176.4.953-958.1994; Weikert C, 1997, MICROBIOL-UK, V143, P1567, DOI 10.1099/00221287-143-5-1567; WENDELL DL, 1993, J BACTERIOL, V175, P7689, DOI 10.1128/JB.175.23.7689-7696.1993; WENZEL TJ, 1995, NUCLEIC ACIDS RES, V23, P883, DOI 10.1093/nar/23.5.883; WEUSTHUIS RA, 1994, MICROBIOL REV, V58, P616, DOI 10.1128/MMBR.58.4.616-630.1994; WEUSTHUIS RA, 1994, MICROBIOL-UK, V140, P1723, DOI 10.1099/13500872-140-7-1723	53	169	173	0	17	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15350	15359		10.1074/jbc.274.22.15350	http://dx.doi.org/10.1074/jbc.274.22.15350			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336421	hybrid			2022-12-25	WOS:000080560100010
J	Navarre, WW; Ton-That, H; Faull, KF; Schneewind, O				Navarre, WW; Ton-That, H; Faull, KF; Schneewind, O			Multiple enzymatic activities of the murein hydrolase from staphylococcal phage phi 11 - Identification of a D-alanyl-glycine endopeptidase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-POSITIVE BACTERIA; BETA-LYTIC PROTEASE; L-ALANINE AMIDASE; CELL-WALL; SURFACE-PROTEINS; STREPTOCOCCUS-PNEUMONIAE; LISTERIA-MONOCYTOGENES; ACHROMOBACTER-LYTICUS; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING	Bacteriophage muralytic enzymes degrade the cell wall envelope of staphylococci to release phage particles from the bacterial cytoplasm, Murein hydrolases of staphylococcal phages phi 11, 80 alpha, 187, Twort, and phi PVL harbor a central domain that displays sequence homology to known N-acetylmuramyl-L-alanyl amidases; however, their precise cleavage sites on the staphylococcal peptidoglycan have thus far not been determined, Here we examined the properties of the phi 11 enzyme to hydrolyze either the staphylococcal cell wall or purified cell wall anchor structures attached to surface protein. Our results show that the phi 11 enzyme has D-alanyl-glycyl endopeptidase as well as N-acetylmuramyl-L-alanyl amidase activity. Analysis of a deletion mutant lacking the amidase homologous sequence, phi 11(Delta 181-381), revealed that the D-alanyl-glycyl endopeptidase activity is contained within the N-terminal 180 amino acid residues of the polypeptide chain. Sequences similar to this N-terminal domain are found in the murein hydrolases of staphylococcal phages but not in those of phages that infect other Gram-positive bacteria such as Listeria or Bacillus.	Univ Calif Los Angeles, Sch Med, Dept Microbiol & Immunol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Schneewind, O (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Microbiol & Immunol, 10833 Le Conte Ave, Los Angeles, CA 90095 USA.	olafs@ucla.edu	Ton-That, Hung/AAB-6155-2020	Navarre, William/0000-0002-9293-9220; Ton-That, Hung/0000-0003-1611-0469	NIAID NIH HHS [AI 38897, AI 33985] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI033985, R01AI038897] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ackermann H. W., 1987, VIRUSES PROKARYOTES, V2; Baba T, 1996, EMBO J, V15, P4789, DOI 10.1002/j.1460-2075.1996.tb00859.x; Baba T, 1998, EMBO J, V17, P4639, DOI 10.1093/emboj/17.16.4639; Bon J, 1997, CAN J MICROBIOL, V43, P612, DOI 10.1139/m97-087; Braun L, 1997, MOL MICROBIOL, V25, P285, DOI 10.1046/j.1365-2958.1997.4621825.x; BROWDER HP, 1965, BIOCHEM BIOPH RES CO, V19, P383, DOI 10.1016/0006-291X(65)90473-0; Creighton T. E., 1993, PROTEINS STRUCTURES; DAWSON IM, 1949, NATURE BACTERIAL SUR, P119; DEJONGE BLM, 1992, J BIOL CHEM, V267, P11248; DIAZ E, 1992, J BACTERIOL, V174, P5516; DIAZ E, 1991, J BIOL CHEM, V266, P5464; DIAZ E, 1990, P NATL ACAD SCI USA, V87, P8125, DOI 10.1073/pnas.87.20.8125; GARCIA E, 1988, P NATL ACAD SCI USA, V85, P914, DOI 10.1073/pnas.85.3.914; GARCIA JL, 1994, J BACTERIOL, V176, P4066, DOI 10.1128/JB.176.13.4066-4072.1994; GHUYSEN J. M., 1965, BIOCHEMISTRY, V4, P2245, DOI 10.1021/bi00886a043; GHUYSEN J. M., 1965, BIOCHEMISTRY, V4, P2237, DOI 10.1021/bi00886a042; Ghuysen J-M., 1966, METHOD ENZYMOL, P685, DOI DOI 10.1016/0076-6879(66)08124-2; GHUYSEN JM, 1963, BIOCHEMISTRY-US, V2, P1110, DOI 10.1021/bi00905a035; GHUYSEN JM, 1991, ANNU REV MICROBIOL, V45, P37, DOI 10.1146/annurev.mi.45.100191.000345; GHUYSEN JM, 1963, BIOCHEMISTRY-US, V2, P1119, DOI 10.1021/bi00905a036; GHUYSEN JM, 1968, BACTERIOL REV, V32, P425, DOI 10.1128/MMBR.32.4_Pt_2.425-464.1968; GHUYSEN JM, 1994, BACTERIA CELL ALL; GLAUNER B, 1988, ANAL BIOCHEM, V172, P451, DOI 10.1016/0003-2697(88)90468-X; Gupta S K, 1995, J Comput Biol, V2, P459, DOI 10.1089/cmb.1995.2.459; HIGASHI Y, 1970, J BIOL CHEM, V245, P3683; HIGASHI Y, 1970, J BIOL CHEM, V245, P3697; HIGASHI Y, 1967, P NATL ACAD SCI USA, V57, P1878, DOI 10.1073/pnas.57.6.1878; HOLTJE JV, 1975, J BIOL CHEM, V250, P6072; Kaneko J, 1998, GENE, V215, P57, DOI 10.1016/S0378-1119(98)00278-9; Li SL, 1998, J BIOCHEM-TOKYO, V124, P332, DOI 10.1093/oxfordjournals.jbchem.a022116; Li SL, 1997, J BIOCHEM-TOKYO, V122, P772; LI SL, 1990, J BACTERIOL, V172, P6506, DOI 10.1128/jb.172.11.6506-6511.1990; Loessner MJ, 1997, J BACTERIOL, V179, P2845, DOI 10.1128/jb.179.9.2845-2851.1997; Loessner MJ, 1998, FEMS MICROBIOL LETT, V162, P265, DOI 10.1016/S0378-1097(98)00131-1; LOESSNER MJ, 1995, MOL MICROBIOL, V16, P1231, DOI 10.1111/j.1365-2958.1995.tb02345.x; MUNOZ E, 1966, BIOCHEMISTRY-US, V5, P3748, DOI 10.1021/bi00876a004; NAKAGAWA J, 1984, J BIOL CHEM, V259, P3937; Navarre WW, 1998, J BIOL CHEM, V273, P29135, DOI 10.1074/jbc.273.44.29135; Navarre WW, 1999, MICROBIOL MOL BIOL R, V63, P174, DOI 10.1128/MMBR.63.1.174-229.1999; NAVARRE WW, 1994, MOL MICROBIOL, V14, P115, DOI 10.1111/j.1365-2958.1994.tb01271.x; OSHIDA T, 1995, P NATL ACAD SCI USA, V92, P285, DOI 10.1073/pnas.92.1.285; PETIT JF, 1966, BIOCHEMISTRY-US, V5, P2764, DOI 10.1021/bi00872a037; Quintela JC, 1999, J BACTERIOL, V181, P334, DOI 10.1128/JB.181.1.334-337.1999; QUINTELA JC, 1995, J BACTERIOL, V177, P4947, DOI 10.1128/jb.177.17.4947-4962.1995; Ramadurai L, 1997, J BACTERIOL, V179, P3625, DOI 10.1128/jb.179.11.3625-3631.1997; ROMERO A, 1990, J BACTERIOL, V172, P5064, DOI 10.1128/jb.172.9.5064-5070.1990; SANCHEZPUELLES JM, 1990, GENE, V89, P69, DOI 10.1016/0378-1119(90)90207-8; SCHINDLER CA, 1964, P NATL ACAD SCI USA, V51, P414, DOI 10.1073/pnas.51.3.414; SCHLEIFER KH, 1972, BACTERIOL REV, V36, P407, DOI 10.1128/MMBR.36.4.407-477.1972; SCHNEEWIND O, 1995, SCIENCE, V268, P103, DOI 10.1126/science.7701329; SCHNEEWIND O, 1993, EMBO J, V12, P4803, DOI 10.1002/j.1460-2075.1993.tb06169.x; SCHNEEWIND O, 1992, CELL, V70, P267, DOI 10.1016/0092-8674(92)90101-H; Shockman GD., 1994, BACTERIAL CELL WALL, P131, DOI 10.1016/S0167-7306(08)60410-X; SLOAN GL, 1977, BIOCHEM J, V167, P293, DOI 10.1042/bj1670293; STROMINGER JL, 1967, SCIENCE, V156, P213, DOI 10.1126/science.156.3772.213; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; TIPPER DJ, 1969, BIOCHEMISTRY-US, V8, P2183, DOI 10.1021/bi00833a060; TIPPER DJ, 1967, BIOCHEMISTRY-US, V6, P906, DOI 10.1021/bi00855a035; TIPPER DJ, 1965, P NATL ACAD SCI USA, V54, P1133, DOI 10.1073/pnas.54.4.1133; TIPPER DJ, 1965, BIOCHEMISTRY-US, V4, P468, DOI 10.1021/bi00879a015; TIPPER DJ, 1969, J BACTERIOL, V97, P837, DOI 10.1128/JB.97.2.837-847.1969; TIPPER DJ, 1969, BIOCHEMISTRY-US, V8, P2192, DOI 10.1021/bi00833a061; TIPPER DJ, 1968, J BIOL CHEM, V243, P3169; TonThat H, 1997, J BIOL CHEM, V272, P22285, DOI 10.1074/jbc.272.35.22285; WANG X, 1991, GENE, V102, P105; YOUNG RY, 1992, MICROBIOL REV, V56, P430, DOI 10.1128/MMBR.56.3.430-481.1992	66	137	158	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15847	15856		10.1074/jbc.274.22.15847	http://dx.doi.org/10.1074/jbc.274.22.15847			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336488	hybrid			2022-12-25	WOS:000080560100077
J	Shinde, U; Fu, X; Inouye, M				Shinde, U; Fu, X; Inouye, M			A pathway for conformational diversity in proteins mediated by intramolecular chaperones	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBTILISIN BPN'; PRO-SEQUENCE; ESCHERICHIA-COLI; FUNCTIONAL-ANALYSIS; PROPEPTIDE; PEPTIDE; REQUIREMENT; SPECIFICITY; MECHANISM; CATALYSIS	Conformational diversity within unique amino acid sequences is observed in diseases like scrapie and Alzheimer's disease. The molecular basis of such diversity is unknown. Similar phenomena occur in subtilisin, a serine protease homologous with eukaryotic pro-hormone convertases, The subtilisin propeptide functions as an intramolecular chaperone (IMC) that imparts steric information during folding but is not required for enzymatic activity. Point mutations within IMCs alter folding, resulting in structural conformers that specifically interact with their cognate IMCs in a process termed "protein memory." Here, we show a mechanism that mediates conformational diversity in subtilisin. During maturation, while the IMC is autocleaved and subsequently degraded by the active site of subtilisin, enzymatic properties of this site differ significantly before and after cleavage. Although subtilisin folded by Ile(-48) --> Thr IMC (IMCI-48T) acquires an "altered" enzymatically active conformation (SUb(I-48T)) significantly different from wild-type subtilisin (Sub(WT)), both precursors undergo autocleavage at similar rates. IMC cleavage initiates conformational changes during which the IMC continues its chaperoning function subsequent to its cleavage from subtilisin. Structural imprinting resulting in conformational diversity originates during this reorganization stage and is a late folding event catalyzed by autocleavage of the IMC.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Inouye, M (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, 675 Hoes Ln, Piscataway, NJ 08854 USA.	inouye@rwja.umdnj.edu						ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BAKER D, 1992, NATURE, V356, P263, DOI 10.1038/356263a0; BRYAN P, 1992, BIOCHEMISTRY-US, V31, P4937, DOI 10.1021/bi00136a003; CHANG SC, 1994, J BIOL CHEM, V269, P3548; CLARK JL, 1969, P NATL ACAD SCI USA, V62, P278, DOI 10.1073/pnas.62.1.278; EDER J, 1995, MOL MICROBIOL, V16, P609, DOI 10.1111/j.1365-2958.1995.tb02423.x; EDER J, 1993, BIOCHEMISTRY-US, V32, P18, DOI 10.1021/bi00052a004; EDER J, 1993, J MOL BIOL, V233, P293, DOI 10.1006/jmbi.1993.1507; EDER J, 1995, INTRAMOLECULAR CHAPE, P35; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; GALLAGHER T, 1995, STRUCTURE, V3, P907, DOI 10.1016/S0969-2126(01)00225-8; GRAY AM, 1990, SCIENCE, V247, P1328, DOI 10.1126/science.2315700; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; IKEMURA H, 1988, J BIOL CHEM, V263, P12959; IKEMURA H, 1987, J BIOL CHEM, V262, P7859; INOUYE M, 1991, ENZYME, V45, P314, DOI 10.1159/000468904; Jain SC, 1998, J MOL BIOL, V284, P137, DOI 10.1006/jmbi.1998.2161; KOBAYASHI T, 1992, J MOL BIOL, V226, P931, DOI 10.1016/0022-2836(92)91042-N; LI YY, 1994, J BIOL CHEM, V269, P4169; LI YY, 1995, J BIOL CHEM, V270, P25127, DOI 10.1074/jbc.270.42.25127; LONGSTAFF C, 1990, BIOCHEMISTRY-US, V29, P7339, DOI 10.1021/bi00483a025; MAHONEY WC, 1980, J BIOL CHEM, V255, P1199; Miranker AD, 1996, CURR OPIN STRUC BIOL, V6, P31, DOI 10.1016/S0959-440X(96)80092-3; OLAITAN SA, 1968, J BIOL CHEM, V243, P5296; PHILIPP M, 1983, MOL CELL BIOCHEM, V51, P5, DOI 10.1007/BF00215583; PHILO JS, 1993, BIOCHEMISTRY-US, V32, P10812, DOI 10.1021/bi00091a036; POLGAR L, 1967, BIOCHEMISTRY-US, V6, P610, DOI 10.1021/bi00854a032; Prusiner SB, 1998, CELL, V93, P337, DOI 10.1016/S0092-8674(00)81163-0; RUSSELL AJ, 1987, NATURE, V328, P496, DOI 10.1038/328496a0; RUSSELL AJ, 1987, J MOL BIOL, V193, P803, DOI 10.1016/0022-2836(87)90360-3; SHINDE U, 1993, P NATL ACAD SCI USA, V90, P6924, DOI 10.1073/pnas.90.15.6924; SHINDE U, 1993, TRENDS BIOCHEM SCI, V18, P442, DOI 10.1016/0968-0004(93)90146-E; SHINDE U, 1995, J MOL BIOL, V252, P25, DOI 10.1006/jmbi.1995.0472; SHINDE U, 1995, J MOL BIOL, V247, P390, DOI 10.1006/jmbi.1994.0147; SHINDE U, 1997, MOL CHAPERONES PROTE, P467; Shinde UP, 1997, NATURE, V389, P520, DOI 10.1038/39097; SILEN JL, 1989, NATURE, V341, P462, DOI 10.1038/341462a0; SMITH SM, 1989, J BIOL CHEM, V264, P20487; SOHL JL, 1995, INTRAMOLECULAR CHAPE, P61; SORENSEN P, 1993, BIOCHEMISTRY-US, V32, P12160; SUTER U, 1992, J NEUROSCI, V12, P306; VANDENHAZEL HB, 1995, J BIOL CHEM, V270, P8602, DOI 10.1074/jbc.270.15.8602; VOORBERG J, 1993, EMBO J, V12, P749, DOI 10.1002/j.1460-2075.1993.tb05709.x; Weiner M, 1995, MOL BIOL CURRENT INN; WELLS JA, 1988, TRENDS BIOCHEM SCI, V13, P291, DOI 10.1016/0968-0004(88)90121-1; WRIGHT CS, 1969, NATURE, V221, P235, DOI 10.1038/221235a0; ZHU X, 1992, BIOCH LIFE SCI ADV, V11, P35; ZHU XL, 1989, NATURE, V339, P483, DOI 10.1038/339483a0	48	66	70	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15615	15621		10.1074/jbc.274.22.15615	http://dx.doi.org/10.1074/jbc.274.22.15615			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336458	hybrid			2022-12-25	WOS:000080560100047
J	Yu, R; Hinkle, PM				Yu, R; Hinkle, PM			Signal transduction and hormone-dependent internalization of the thyrotropin-releasing hormone receptor in cells lacking G(q) and G(11)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C INHIBITOR; BETA-ADRENERGIC-RECEPTOR; PROTEIN-COUPLED RECEPTORS; ARRESTIN/CLATHRIN INTERACTION; BETA(2)-ADRENERGIC RECEPTOR; STIMULATED INTERNALIZATION; NUCLEOTIDE-BINDING; CARBOXYL-TERMINUS; XENOPUS OOCYTES; ARRESTIN	The thyrotropin-releasing hormone (TRH) receptor was expressed in embryonic fibroblasts from mice lacking the a subunits of G(q) and G(11) (Fq/11 cells) to determine whether G protein coupling is necessary for agonist-dependent receptor internalization. Neither TRH nor agonists acting on endogenous receptors increased intracellular calcium unless the cells were co-transfected with the alpha subunit of G(q). In contrast, temperature-dependent internalization of [H-3]MeTRH in Fq/11 cells was the same whether G(q)alpha was expressed or not. A rhodamine-labeled TRH analog and fluorescein-labeled transferrin co-localized in endocytic vesicles in Fq/11 cells, indicating that endocytosis took place via the normal clathrin pathway. Cotransfection with beta-arrestin or V53D beta-arrestin increased TRH-dependent receptor sequestration. Fq/11 cells were co-transfected with the TRH receptor and a green fluorescent protein (GFP)-beta-arrestin conjugate. GFP-beta-arrestin was uniformly distributed in the cytoplasm of untreated cells and quickly translocated to the periphery of the cells when TRH was added. A truncated TRH receptor that lacks potential phosphorylation sites in the cytoplasmic carboxyl terminus signaled but did not internalize or cause membrane localization of GFP-beta-arrestin. These results prove that calcium signaling by the TRH receptor requires coupling to a G protein in the G(q) family, but TRH-dependent binding of beta-arrestin and sequestration do not.	Univ Rochester, Med Ctr, Sch Med & Dent, Dept Physiol & Pharmacol, Rochester, NY 14642 USA; Univ Rochester, Ctr Canc, Sch Med & Dent, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Hinkle, PM (corresponding author), Univ Rochester, Med Ctr, Sch Med & Dent, Dept Physiol & Pharmacol, Box 711,601 Elmwood Ave, Rochester, NY 14642 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019974] Funding Source: NIH RePORTER; NCI NIH HHS [CA 11098] Funding Source: Medline; NIDDK NIH HHS [DK19974] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASHWORTH R, 1995, P NATL ACAD SCI USA, V92, P512, DOI 10.1073/pnas.92.2.512; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; BENYA RV, 1994, MOL PHARMACOL, V46, P495; Bhowmick N, 1998, ENDOCRINOLOGY, V139, P3185, DOI 10.1210/en.139.7.3185; Bohm SK, 1997, BIOCHEM J, V322, P1; CLARK RB, 1985, J CYCLIC NUCL PROT, V10, P97; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; DELAPENA P, 1995, J BIOL CHEM, V270, P3554, DOI 10.1074/jbc.270.8.3554; Drmota T, 1998, J BIOL CHEM, V273, P24000, DOI 10.1074/jbc.273.37.24000; Drmota T, 1998, J BIOL CHEM, V273, P21699, DOI 10.1074/jbc.273.34.21699; FALCKPEDERSEN E, 1994, MOL PHARMACOL, V45, P684; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Ferguson SSG, 1996, CAN J PHYSIOL PHARM, V74, P1095, DOI 10.1139/y96-124; GOLLASCH M, 1993, P NATL ACAD SCI USA, V90, P6265, DOI 10.1073/pnas.90.13.6265; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Goodman OB, 1997, J BIOL CHEM, V272, P15017, DOI 10.1074/jbc.272.23.15017; Hildebrandt JP, 1997, BRIT J PHARMACOL, V120, P841, DOI 10.1038/sj.bjp.0700991; HINKLE PM, 1989, MOL ENDOCRINOL, V3, P1337, DOI 10.1210/mend-3-9-1337; Hipkin RW, 1997, J BIOL CHEM, V272, P13869, DOI 10.1074/jbc.272.21.13869; Jan CR, 1998, LIFE SCI, V63, P895, DOI 10.1016/S0024-3205(98)00346-4; Koenig JA, 1996, MOL PHARMACOL, V49, P351; Koenig JA, 1997, TRENDS PHARMACOL SCI, V18, P276, DOI 10.1016/S0165-6147(97)01091-2; Krupnick JG, 1997, J BIOL CHEM, V272, P15011, DOI 10.1074/jbc.272.23.15011; Lee KB, 1998, J BIOL CHEM, V273, P12967, DOI 10.1074/jbc.273.21.12967; LI PZ, 1992, MOL ENDOCRINOL, V6, P1393, DOI 10.1210/me.6.9.1393; MAHAN LC, 1985, P NATL ACAD SCI USA, V82, P129, DOI 10.1073/pnas.82.1.129; Mao JH, 1998, J BIOL CHEM, V273, P27118, DOI 10.1074/jbc.273.42.27118; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; Muto Y, 1997, J PHARMACOL EXP THER, V282, P1379; NELSON EJ, 1994, ENDOCRINOLOGY, V135, P1084, DOI 10.1210/en.135.3.1084; NUSSENZVEIG DR, 1993, MOL ENDOCRINOL, V7, P1105, DOI 10.1210/me.7.9.1105; NUSSENZVEIG DR, 1993, J BIOL CHEM, V268, P2389; Offermanns S, 1998, EMBO J, V17, P4304, DOI 10.1093/emboj/17.15.4304; Petrou C, 1997, J BIOL CHEM, V272, P2326; QUICK MW, 1994, J BIOL CHEM, V269, P30164; Roettger BF, 1997, MOL PHARMACOL, V51, P357; SLEPAK VZ, 1993, J BIOL CHEM, V268, P21889; THOMPSON AK, 1991, J BIOL CHEM, V266, P23856; Yu R, 1997, J BIOL CHEM, V272, P28301, DOI 10.1074/jbc.272.45.28301; Yu R, 1997, MOL PHARMACOL, V51, P785, DOI 10.1124/mol.51.5.785	40	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15745	15750		10.1074/jbc.274.22.15745	http://dx.doi.org/10.1074/jbc.274.22.15745			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336475	hybrid			2022-12-25	WOS:000080560100064
J	Bae, SH; Lee, JN; Fitzky, BU; Seong, JY; Paik, YK				Bae, SH; Lee, JN; Fitzky, BU; Seong, JY; Paik, YK			Cholesterol biosynthesis from lanosterol - Molecular cloning, tissue distribution, expression, chromosomal localization, and regulation of rat 7-dehydrocholesterol reductase, a Smith-Lemli-Opitz syndrome-related protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLEAVAGE-ACTIVATING PROTEIN; SONIC-HEDGEHOG; STEROL DELTA(7)-REDUCTASE; DELTA-7-STEROL REDUCTASE; SACCHAROMYCES-CEREVISIAE; MICROSOMAL-ENZYMES; ASSAY-METHOD; KINASE-C; GENE; PURIFICATION	The cDNA encoding the 471-amino acid rat 7-dehydrocholesterol reductase (DHCR), an enzyme that has been implicated in both cholesterol biosynthesis and developmental abnormalities (e.g. Smith-Lemli-Opitz syndrome) in mammals, has been cloned and sequenced, and the primary structure of the enzyme has been deduced. The DHCR gene was mapped to chromosome 8q2.1 by fluorescence in situ hybridization, Rat DHCR, calculated molecular mass of 54.15-kDa polypeptide, shares a close amino acid identity with mouse and human DHCRs (96 and 87%, respectively) as compared with its other related proteins (e.g. fungal sterol Delta(14)-reductase) and exhibits high hydrophobicity (>68%) with 9 transmembrane domains. Five putative sterol-sensing domains were predicted to be localized in transmembrane domains 4-8, which are highly homologous to those found in 3-hydroxymethylglutaryl-CoA reductase, sterol regulatory element-binding protein cleavage-activating protein, and patched protein. The polypeptide encoded by DHCR cDNA was expressed in yeast as a 55.45-kDa myc-tagged fusion protein, which was recognized with anti-myc monoclonal antibody 9E10 and shown to possess full DHCR activity with respect to dependence on NADPH and sensitivity to DHCR inhibitors. Northern blot analysis indicates that the highest expression of DHCR mRNA was detected in liver, followed by kidney and brain. In rat brains, the highest level of mRNA encoding DHCR was detected in the midbrain, followed by the spinal cord and medulla, Feeding fats 5% cholestyramine plus 0.1% lovastatin in chow resulted in both approximately a 3-fold induction of DHCR mRNA and a 5-fold increase of the enzymic activity in the liver. When rats were fed 0.1% (w/w) AY-9944 (in chow) for 14-days, a complete inhibition of DHCR activity and a significant reduction in serum total cholesterol level mere observed. However, the level of hepatic DHCR mRNA fell only slightly, suggesting that AY-9944 may act more rapidly at the protein level than at the level of transcription of the DHCR gene under these conditions.	Yonsei Univ, Med Res Ctr, Dept Biochem, Sudaemoon Ku, Seoul 120749, South Korea; Inst Biochem Pharmakol, A-6020 Innsbruck, Austria; Dept Biochem, A-6020 Innsbruck, Austria; Bioprod Res Ctr, A-6020 Innsbruck, Austria	Yonsei University	Paik, YK (corresponding author), Yonsei Univ, Med Res Ctr, Dept Biochem, Sudaemoon Ku, 134 Shinchon Dong, Seoul 120749, South Korea.	paikyk@bubble.yonsei.ac.kr	Bae, Sung-Ho/AAK-7350-2020	Seong, Je Kyung/0000-0003-1177-6958				ALLEY TL, 1995, AM J HUM GENET, V56, P1411; Anderson AJ, 1998, AM J MED GENET, V78, P413, DOI 10.1002/(SICI)1096-8628(19980806)78:5<413::AID-AJMG4>3.0.CO;2-M; Bae SH, 1997, BIOCHEM J, V326, P609, DOI 10.1042/bj3260609; BAUSE E, 1983, BIOCHEM J, V209, P331, DOI 10.1042/bj2090331; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Chambers CM, 1997, AM J MED GENET, V68, P322, DOI 10.1002/(SICI)1096-8628(19970131)68:3<322::AID-AJMG14>3.0.CO;2-V; CHEN WN, 1991, YEAST, V7, P305, DOI 10.1002/yea.320070313; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Cho SY, 1998, MOL CELLS, V8, P233; COOPER JA, 1984, J BIOL CHEM, V259, P7835; Cooper MK, 1998, SCIENCE, V280, P1603, DOI 10.1126/science.280.5369.1603; DVORNIK D, 1968, J LIPID RES, V9, P587; Fitzky BU, 1998, P NATL ACAD SCI USA, V95, P8181, DOI 10.1073/pnas.95.14.8181; FitzPatrick DR, 1998, AM J MED GENET, V75, P145, DOI 10.1002/(SICI)1096-8628(19980113)75:2<145::AID-AJMG5>3.0.CO;2-S; GAVEL Y, 1990, PROTEIN ENG, V3, P433, DOI 10.1093/protein/3.5.433; GAYLOR JL, 1981, BIOCH ISOPRENOIDS, V1, P482; Gemmill RM, 1998, P NATL ACAD SCI USA, V95, P9572, DOI 10.1073/pnas.95.16.9572; GRAND RJA, 1989, BIOCHEM J, V258, P625, DOI 10.1042/bj2580625; Honda A, 1998, J LIPID RES, V39, P44; HUNTER T, 1982, J BIOL CHEM, V257, P4843; IRONS M, 1994, AM J MED GENET, V50, P347, DOI 10.1002/ajmg.1320500409; KANG MK, 1995, J BIOCHEM-TOKYO, V117, P819, DOI 10.1093/oxfordjournals.jbchem.a124781; Kelley RI, 1996, AM J MED GENET, V66, P478, DOI 10.1002/(SICI)1096-8628(19961230)66:4<478::AID-AJMG22>3.0.CO;2-Q; KIM CK, 1995, BBA-LIPID LIPID MET, V1259, P39, DOI 10.1016/0005-2760(95)00128-Y; KISHIMOTO A, 1985, J BIOL CHEM, V260, P2492; Kolf-Clauw M, 1998, J LAB CLIN MED, V131, P222, DOI 10.1016/S0022-2143(98)90093-2; KolfClauw M, 1997, TERATOLOGY, V56, P188, DOI 10.1002/(SICI)1096-9926(199709)56:3<188::AID-TERA2>3.0.CO;2-Y; KolfClauw M, 1996, TERATOLOGY, V54, P115, DOI 10.1002/(SICI)1096-9926(199609)54:3<115::AID-TERA1>3.0.CO;2-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAI MH, 1994, GENE, V140, P41; Lanoue L, 1997, AM J MED GENET, V73, P24; Lecain E, 1996, J BIOL CHEM, V271, P10866, DOI 10.1074/jbc.271.18.10866; Lee EY, 1999, BIOCHEM PHARMACOL, V57, P579, DOI 10.1016/S0006-2952(98)00321-9; Lee JN, 1997, J BIOCHEM MOL BIOL, V30, P370; Loftus SK, 1997, SCIENCE, V277, P232, DOI 10.1126/science.277.5323.232; MACKNESS MI, 1992, LIPOPROTEIN ANAL PRA, P1; MATSUDA Y, 1992, CYTOGENET CELL GENET, V61, P282, DOI 10.1159/000133423; MILETICH JP, 1990, J BIOL CHEM, V265, P11397; Moebius FF, 1998, P NATL ACAD SCI USA, V95, P1899, DOI 10.1073/pnas.95.4.1899; Nohturfft A, 1998, P NATL ACAD SCI USA, V95, P12848, DOI 10.1073/pnas.95.22.12848; Nohturfft A, 1998, J BIOL CHEM, V273, P17243, DOI 10.1074/jbc.273.27.17243; PAIK YK, 1986, J BIOL CHEM, V261, P6470; PAIK YK, 1984, J BIOL CHEM, V259, P3413; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; Porter JA, 1996, CELL, V86, P21, DOI 10.1016/S0092-8674(00)80074-4; ROUX C, 1980, J NUTR, V110, P2310, DOI 10.1093/jn/110.11.2310; SAMBROOK J, 1989, MOL CLONING LAB MANA; Shefer S, 1997, METABOLISM, V46, P844, DOI 10.1016/S0026-0495(97)90133-5; Silve S, 1998, BBA-LIPID LIPID MET, V1392, P233, DOI 10.1016/S0005-2760(98)00041-1; SMITH DW, 1964, J PEDIATR-US, V64, P210, DOI 10.1016/S0022-3476(64)80264-X; Tabin CJ, 1997, TRENDS CELL BIOL, V7, P442, DOI 10.1016/S0962-8924(97)01159-8; TINT GS, 1995, J LIPID RES, V36, P89; TINT GS, 1994, NEW ENGL J MED, V330, P107, DOI 10.1056/NEJM199401133300205; TRZASKOS JM, 1986, J BIOL CHEM, V261, P6937; Wassif CA, 1998, AM J HUM GENET, V63, P55, DOI 10.1086/301936; Waterham HR, 1998, AM J HUM GENET, V63, P329, DOI 10.1086/301982; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x; Xu GR, 1998, METABOLISM, V47, P878, DOI 10.1016/S0026-0495(98)90130-5	60	58	61	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					14624	14631		10.1074/jbc.274.21.14624	http://dx.doi.org/10.1074/jbc.274.21.14624			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329655	hybrid			2022-12-25	WOS:000081965200020
J	Leng, XH; Nishi, T; Forgac, M				Leng, XH; Nishi, T; Forgac, M			Transmembrane topography of the 100-kDa a subunit (Vph1p) of the yeast vacuolar proton translocating ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COATED VESICLE (H+)-ATPASE; SITE-DIRECTED MUTAGENESIS; H+-ATPASE; ESCHERICHIA-COLI; ALPHA-SUBUNIT; SACCHAROMYCES-CEREVISIAE; STRUCTURAL-CHANGES; MEMBRANE TOPOLOGY; CDNA SEQUENCE; GENE ENCODES	The membrane topography of the yeast vacuolar proton-translocating ATPase a subunit (Vph1p) has been investigated using cysteine scanning mutagenesis. A Cys-less form of Vph1p lacking the seven endogenous cysteines was constructed and shown to have 80% of wild type activity. Single cysteine residues were introduced at 13 sites within the Cys-less mutant, with 12 mutants showing greater than 70% of wild type activity. To evaluate their disposition with respect to the membrane, vacuoles were treated in the presence or absence of the impermeant sulfhydryl reagent 4-acetamido-4'-maleimidylstilbene-2,2'-disulfonic acid (AMS) followed by the membrane permeable sulfhydryl reagent 3-(N-maleimidylpropionyl) biocytin (MPB). Three of the 12 active cysteine mutants were not labeled by MPB. The mutants E3C, D89C, T161C, S266C, N447C, K450C, and S703C were labeled by MPB in an AMS-protectable manner, suggesting a cytoplasmic orientation, whereas G602C and S840C showed minimal protection by AMS, suggesting a lumenal orientation. Factor Xa cleavage sites were introduced at His-499, Leu-560, and Pro-606. Cleavage at 560 was observed in the absence of detergent, suggesting a cytoplasmic orientation for this site. Based on these results, we propose a model of the a subunit containing nine transmembrane segments, with the amino terminus facing the cytoplasm and the carboxyl terminus facing the lumen.	Tufts Univ, Sch Med, Dept Cellular & Mol Physiol, Boston, MA 02111 USA	Tufts University	Forgac, M (corresponding author), Tufts Univ, Sch Med, Dept Cellular & Mol Physiol, 136 Harrison Ave, Boston, MA 02111 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034928] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034478, R37GM034478] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 34928] Funding Source: Medline; NIGMS NIH HHS [R01 GM034478, GM34478] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI I, 1990, J BIOL CHEM, V265, P960; ANRAKU Y, 1992, J BIOENERG BIOMEMBR, V24, P395, DOI 10.1007/BF00762532; ARAI H, 1988, J BIOL CHEM, V263, P8796; Ausubel F.M., 1992, SHORT PROTOCOLS MOL; BOWMAN BJ, 1992, J BIOENERG BIOMEMBR, V24, P361, DOI 10.1007/BF00762529; BOWMAN EJ, 1988, J BIOL CHEM, V263, P13994; CAIN BD, 1988, J BIOL CHEM, V263, P6606; CAIN BD, 1986, J BIOL CHEM, V261, P43; CAIN BD, 1989, J BIOL CHEM, V264, P3292; Capaldi RA, 1996, J BIOENERG BIOMEMBR, V28, P397, DOI 10.1007/BF02113980; CHATTERJEE D, 1992, P NATL ACAD SCI USA, V89, P6257, DOI 10.1073/pnas.89.14.6257; Cross RL, 1996, J BIOENERG BIOMEMBR, V28, P403, DOI 10.1007/BF02113981; FENG Y, 1992, J BIOL CHEM, V267, P5817; Fillingame RH, 1997, J EXP BIOL, V200, P217; FORGAC M, 1992, J BIOENERG BIOMEMBR, V24, P341, DOI 10.1007/BF00762527; Futai M, 1996, J BIOENERG BIOMEMBR, V28, P409, DOI 10.1007/BF02113982; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GLUCK SL, 1992, J BIOENERG BIOMEMBR, V24, P351, DOI 10.1007/BF00762528; GUTHRIE C, 1991, METHOD ENZYMOL, V194, P13; Hirata R, 1997, J BIOL CHEM, V272, P4795, DOI 10.1074/jbc.272.8.4795; KAKINUMA Y, 1981, J BIOL CHEM, V256, P859; KANE PM, 1995, J BIOL CHEM, V270, P17025; KANE PM, 1992, J BIOL CHEM, V267, P447; KANE PM, 1992, J BIOENERG BIOMEMBR, V24, P383, DOI 10.1007/BF00762531; KIBAK H, 1992, J BIOENERG BIOMEMBR, V24, P415, DOI 10.1007/BF00762534; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leng XH, 1996, J BIOL CHEM, V271, P22487, DOI 10.1074/jbc.271.37.22487; Leng XH, 1998, J BIOL CHEM, V273, P6717, DOI 10.1074/jbc.273.12.6717; Liu Q, 1996, J BIOL CHEM, V271, P2018, DOI 10.1074/jbc.271.4.2018; Long JC, 1998, J BIOL CHEM, V273, P16235, DOI 10.1074/jbc.273.26.16235; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANDEL M, 1988, P NATL ACAD SCI USA, V85, P5521, DOI 10.1073/pnas.85.15.5521; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; MANOLSON MF, 1994, J BIOL CHEM, V269, P14064; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; NELSON N, 1992, J BIOENERG BIOMEMBR, V24, P407, DOI 10.1007/BF00762533; Pedersen PL, 1996, J BIOENERG BIOMEMBR, V28, P389, DOI 10.1007/BF02113979; PERIN MS, 1991, J BIOL CHEM, V266, P3877; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; SWALLOW CJ, 1990, J BIOL CHEM, V265, P7645; SZE H, 1992, J BIOENERG BIOMEMBR, V24, P371, DOI 10.1007/BF00762530; Valiyaveetil FI, 1997, J BIOL CHEM, V272, P32635, DOI 10.1074/jbc.272.51.32635; Valiyaveetil FI, 1998, J BIOL CHEM, V273, P16241, DOI 10.1074/jbc.273.26.16241; VIK SB, 1994, J BIOL CHEM, V269, P30364; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; YAMASHIRO CT, 1990, MOL CELL BIOL, V10, P3737, DOI 10.1128/MCB.10.7.3737; ZIMNIAK L, 1988, J BIOL CHEM, V263, P9102	49	87	89	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					14655	14661		10.1074/jbc.274.21.14655	http://dx.doi.org/10.1074/jbc.274.21.14655			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329659	hybrid			2022-12-25	WOS:000081965200024
J	Mizzen, CA; Dou, YL; Liu, YG; Cook, RG; Gorovsky, MA; Allis, CD				Mizzen, CA; Dou, YL; Liu, YG; Cook, RG; Gorovsky, MA; Allis, CD			Identification and mutation of phosphorylation sites in a linker histone - Phosphorylation of macronuclear H1 is not essential for viability in tetrahymena	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE-GEL ELECTROPHORESIS; TRANSCRIPTION IN-VIVO; RNA POLYMERASE-II; AMITOTIC MACRONUCLEUS; CHROMATIN STRUCTURE; SEQUENCE; GENE; CONDENSATION; ACETYLATION; PYRIFORMIS	Linker histone phosphorylation has been suggested to play roles in both chromosome condensation and transcriptional regulation, In the ciliated protozoan Tetrahymena, in contrast to many eukaryotes, histone H1 of macronuclei is highly phosphorylated during interphase. Macronuclei divide amitotically without overt chromosome condensation in this organism, suggesting that requirements for phosphorylation of macronuclear H1 may be limited to transcriptional regulation. Here we report the major sites of phosphorylation of macronuclear H1 in Tetrahymena thermophila. Five phosphorylation sites, present in a single cluster, were identified by sequencing P-32-labeled peptides isolated from tryptic peptide maps. Phosphothreonine was detected within two TPVK motifs and one TPTK motif that resemble established p34(cdc2) kinase consensus sequences. Phosphoserine was detected at two non-proline-directed sites that do not resemble known kinase consensus sequences. Phosphorylation at the two noncanonical sites appears to be hierarchical because it was observed only when a nearby p34cdc2 Site was also phosphorylated. Cells expressing macronuclear H1 containing alanine substitutions at all five of these phosphorylation sites were viable even though macronuclear H1 phosphorylation was abolished. These data suggest that the five sites identified comprise the entire collection of sites utilized by Tetrahymena and demonstrate that phosphorylation of macronuclear H1, like the protein itself, is not essential for viability in Tetrahymena.	Univ Virginia, Hlth Sci Ctr, Dept Mol Genet & Biochem, Charlottesville, VA 22908 USA; Univ Rochester, Dept Biol, Rochester, NY 14627 USA; Baylor Coll Med, Dept Microbiol & Immunol, Houston, TX 77030 USA	University of Virginia; University of Rochester; Baylor College of Medicine	Allis, CD (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Mol Genet & Biochem, Box 440, Charlottesville, VA 22908 USA.	allis@virginia.edu			NIGMS NIH HHS [GM40922, GM21793] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021793, R01GM040922] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARENTS G, 1993, P NATL ACAD SCI USA, V90, P10489, DOI 10.1073/pnas.90.22.10489; Balhorn R, 1975, Methods Enzymol, V40, P138; BOUVET P, 1994, GENE DEV, V8, P1147, DOI 10.1101/gad.8.10.1147; BRADBURY EM, 1992, BIOESSAYS, V14, P9; CALZONE FJ, 1983, J BIOL CHEM, V258, P6899; Chadee DN, 1997, J BIOL CHEM, V272, P8113, DOI 10.1074/jbc.272.13.8113; CROSTON GE, 1991, SCIENCE, V251, P643, DOI 10.1126/science.1899487; GAERTIG J, 1994, NUCLEIC ACIDS RES, V22, P5391, DOI 10.1093/nar/22.24.5391; GLOVER CVC, 1981, CELL, V23, P73, DOI 10.1016/0092-8674(81)90271-3; Gorovsky M A, 1975, Methods Cell Biol, V9, P311, DOI 10.1016/S0091-679X(08)60080-1; GOROVSKY MA, 1974, J CELL BIOL, V61, P134, DOI 10.1083/jcb.61.1.134; GOROVSKY MA, 1973, J PROTOZOOL, V20, P19, DOI 10.1111/j.1550-7408.1973.tb05995.x; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; HAYASHI T, 1987, J BIOCHEM-TOKYO, V102, P369, DOI 10.1093/oxfordjournals.jbchem.a122063; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAYBOURN PJ, 1991, SCIENCE, V254, P238, DOI 10.1126/science.1718039; Lee HL, 1998, EMBO J, V17, P1454, DOI 10.1093/emboj/17.5.1454; LENNOX RW, 1989, METHOD ENZYMOL, V170, P532; LU MJ, 1994, CHROMOSOMA, V103, P111; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Mizzen CA, 1998, CELL MOL LIFE SCI, V54, P6, DOI 10.1007/s000180050121; OHSUMI K, 1993, SCIENCE, V262, P2033, DOI 10.1126/science.8266099; PAULSON JR, 1980, EUR J BIOCHEM, V111, P189; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; ROTH SY, 1988, J CELL BIOL, V107, P2473, DOI 10.1083/jcb.107.6.2473; ROTH SY, 1991, EMBO J, V10, P2069, DOI 10.1002/j.1460-2075.1991.tb07738.x; SHEN XT, 1995, CELL, V82, P47, DOI 10.1016/0092-8674(95)90051-9; Shen XT, 1996, CELL, V86, P475, DOI 10.1016/S0092-8674(00)80120-8; Sweet MT, 1997, J BIOL CHEM, V272, P916, DOI 10.1074/jbc.272.2.916; van Holde KE, 1989, CHROMATIN, P69; WEST MHP, 1984, ELECTROPHORESIS, V5, P133, DOI 10.1002/elps.1150050302; Wolffe A, 1998, CHROMATIN - STRUCTURE AND FUNCTION, 3RD EDITION, P1, DOI 10.1016/B978-012761914-9/50003-9; Wolffe AP, 1997, BIOESSAYS, V19, P249, DOI 10.1002/bies.950190311; WU M, 1994, MOL CELL BIOL, V14, P10, DOI 10.1128/MCB.14.1.10; WU M, 1986, P NATL ACAD SCI USA, V83, P8674, DOI 10.1073/pnas.83.22.8674; Zlatanova J, 1996, PROG NUCLEIC ACID RE, V52, P217, DOI 10.1016/S0079-6603(08)60968-X	36	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					14533	14536		10.1074/jbc.274.21.14533	http://dx.doi.org/10.1074/jbc.274.21.14533			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329641	hybrid			2022-12-25	WOS:000081965200006
J	Walmsley, AR; Batten, MR; Lad, U; Bulleid, NJ				Walmsley, AR; Batten, MR; Lad, U; Bulleid, NJ			Intracellular retention of procollagen within the endoplasmic reticulum is mediated by prolyl 4-hydroxylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; CARBOXYL-TERMINAL PROPEPTIDE; MOLECULAR CHAPERONE; III PROCOLLAGEN; OSTEOGENESIS IMPERFECTA; I PROCOLLAGEN; HELICAL PROCOLLAGEN; CIS-HYDROXYPROLINE; QUALITY-CONTROL; CHICK-EMBRYOS	The correct folding and assembly of proteins within the endoplasmic reticulum (ER) are prerequisites for subsequent transport from this organelle to the Gels apparatus. The mechanisms underlying the ability of the cell to recognize and retain unassembled or mal-folded proteins generally require binding to molecular chaperones within the ER. One classic example of this process occurs during the biosynthesis of procollagen. Here partially folded intermediates are retained and prevented from secretion, leading to a build up of unfolded chains within the cell. The accumulation of these partially folded intermediates occurs during vitamin C deficiency due to incomplete proline hydroxylation, as vitamin C is an essential co-factor of the enzyme prolyl 4-hydroxylase. in this report we show that this retention is tightly regulated with little or no secretion occurring under conditions preventing proline hydroxylation. me studied the molecular mechanism underlying retention by determining which proteins associate with partially folded procollagen intermediates within the ER. By using a combination of cross-linking and sucrose gradient analysis, we show that the major protein binding to procollagen during its biosynthesis is prolyl 4-hydroxylase, and no binding to other ER resident proteins including Hsp47 was detected. This binding is regulated by the folding status rather than the extent of hydroxylation of the chains demonstrating that this enzyme can recognize and retain unfolded procollagen chains and can release these chains for further transport once they have folded correctly.	Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England	University of Manchester	Bulleid, NJ (corresponding author), Univ Manchester, Sch Biol Sci, 2-205 Stopford Bldg, Manchester M13 9PT, Lancs, England.			Bulleid, Neil/0000-0002-9839-5279				Allen S, 1997, BIOCHEM J, V328, P113, DOI 10.1042/bj3280113; BERG RA, 1973, BIOCHEMISTRY-US, V12, P3395, DOI 10.1021/bi00742a005; Bulleid NJ, 1997, EMBO J, V16, P6694, DOI 10.1093/emboj/16.22.6694; Bulleid NJ, 1996, BIOCHEM J, V317, P195, DOI 10.1042/bj3170195; CHEAH KSE, 1979, BIOCHEM J, V182, P81, DOI 10.1042/bj1820081; CHESSLER SD, 1992, J BIOL CHEM, V267, P7751; CHESSLER SD, 1993, J BIOL CHEM, V268, P18226; ENGEL J, 1991, ANNU REV BIOPHYS BIO, V20, P137, DOI 10.1146/annurev.biophys.20.1.137; FERTALA A, 1994, BIOCHEM J, V298, P31, DOI 10.1042/bj2980031; FESSLER LI, 1981, J BIOL CHEM, V256, P2531; FOURIE AM, 1994, J BIOL CHEM, V269, P30470; GEDDIS AE, 1993, MATRIX, V13, P399, DOI 10.1016/S0934-8832(11)80045-4; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; Hosokawa N, 1998, J BIOCHEM-TOKYO, V124, P654, DOI 10.1093/oxfordjournals.jbchem.a022162; JAIN N, 1994, BIOCHEM J, V304, P61, DOI 10.1042/bj3040061; JOHN DCA, 1993, EMBO J, V12, P1587, DOI 10.1002/j.1460-2075.1993.tb05803.x; JUVA K, 1969, J BIOL CHEM, V244, P6486; KAO WWY, 1979, J BIOL CHEM, V254, P2234; Kivirikko K. I., 1992, POSTTRANSLATIONAL MO, P1; LAMANDE SR, 1995, J BIOL CHEM, V270, P8642, DOI 10.1074/jbc.270.15.8642; LANE JM, 1971, BIOCHIM BIOPHYS ACTA, V236, P517, DOI 10.1016/0005-2795(71)90235-2; LEES JF, 1994, J BIOL CHEM, V269, P24354; Lees JF, 1997, EMBO J, V16, P908, DOI 10.1093/emboj/16.5.908; McLaughlin SH, 1998, BIOCHEM J, V331, P793, DOI 10.1042/bj3310793; McLaughlin SH, 1998, MATRIX BIOL, V16, P369, DOI 10.1016/S0945-053X(98)90010-5; Nagata K, 1996, TRENDS BIOCHEM SCI, V21, P23, DOI 10.1016/0968-0004(96)80881-4; NAKAI A, 1992, J CELL BIOL, V117, P903, DOI 10.1083/jcb.117.4.903; NATSUME T, 1994, J BIOL CHEM, V269, P31224; Oliver JD, 1997, SCIENCE, V275, P86, DOI 10.1126/science.275.5296.86; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; PROCKOP DJ, 1989, AM J MED GENET, V34, P60, DOI 10.1002/ajmg.1320340112; Reddy P, 1996, EMBO J, V15, P2077, DOI 10.1002/j.1460-2075.1996.tb00561.x; SAGA S, 1987, J CELL BIOL, V105, P517, DOI 10.1083/jcb.105.1.517; Satoh M, 1996, J CELL BIOL, V133, P469, DOI 10.1083/jcb.133.2.469; SUPERTIFURGA A, 1989, HUM GENET, V82, P104, DOI 10.1007/BF00284038; TUDERMAN L, 1975, EUR J BIOCHEM, V52, P9, DOI 10.1111/j.1432-1033.1975.tb03967.x; UITTO J, 1975, SCIENCE, V190, P1202, DOI 10.1126/science.1198105; UITTO J, 1972, BIOCHIM BIOPHYS ACTA, V278, P601, DOI 10.1016/0005-2795(72)90023-2; UITTO J, 1974, EUR J BIOCHEM, V43, P221, DOI 10.1111/j.1432-1033.1974.tb03403.x; VUORI K, 1992, EMBO J, V11, P4213, DOI 10.1002/j.1460-2075.1992.tb05515.x; WALLIS GA, 1989, J BIOL CHEM, V265, P18628; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; WILSON R, 1995, BIOCHEM J, V307, P679, DOI 10.1042/bj3070679; Wilson R, 1998, J BIOL CHEM, V273, P9637, DOI 10.1074/jbc.273.16.9637	44	79	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					14884	14892		10.1074/jbc.274.21.14884	http://dx.doi.org/10.1074/jbc.274.21.14884			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329688	hybrid			2022-12-25	WOS:000081965200053
J	Cabannes, E; Khan, G; Aillet, F; Jarrett, RF; Hay, RT				Cabannes, E; Khan, G; Aillet, F; Jarrett, RF; Hay, RT			Mutations in the IkBa gene in Hodgkin's disease suggest a tumour suppressor role for I kappa B alpha	ONCOGENE			English	Article						Hodgkin's lymphoma; tumour suppressor; I kappa B alpha; NF-kappa B	REED-STERNBERG CELLS; TRANSCRIPTION FACTORS; EXPRESSION; ACTIVATION; PROTEINS; KINASE; MICE; ONCOGENESIS; LINES; BETA	The NF-kappa B/Rel family of transcription factors regulates wide variety of genes whose products play a fundamental role in inflammatory and immune responses. The implication of NF-kappa B/Rel proteins and their I kappa B regulatory subunits in the control of cellular growth and oncogenesis, was suggested by the induction of fatal lymphomas in birds by the v-rel oncoprotein, and the rearrangement and amplification of several genes encoding the NF-kappa B/Rel/I kappa B signal transduction factors in human malignancies, primarily of lymphoid origin. Hodgkin's disease (HD) is a lymphoma characterized by a low frequency of malignant Hodgkin and Reed-Sternberg (H/RS) cells in a reactive background of nonneoplastic cells. The peculiar activated phenotype of Hodgkin and Reed-Sternberg cells and their pattern of cytokine secretion are believed to be a consequence of constitutive activation of the NF-kappa B transcription factor. Here, we report the detection of mutations of the 1k Ba gene, in two HD-derived cell lines and in two out of eight biopsy samples from patients with relapsed Hodgkin's disease. The presence of defective I kappa B alpha is thus likely to explain the constitutive activation of NF-kappa B in these cells and suggests that I kappa B alpha is a tumour suppressor controlling the oncogenic activation of NF-kappa B in Hodgkin and Reed-Sternberg cells.	Univ St Andrews, Sch Biomed Sci, St Andrews KY16 9ST, Fife, Scotland; Univ Glasgow, Sch Vet, Dept Vet Pathol, LRF Virus Ctr, Glasgow G61 1QH, Lanark, Scotland	University of St Andrews; University of Glasgow	Hay, RT (corresponding author), Univ St Andrews, Sch Biomed Sci, Biomol Sci Bldg, St Andrews KY16 9ST, Fife, Scotland.		Hay, Ronald T/F-9338-2011; Khan, Gulfaraz/AAC-2859-2022; Hay, Ronald/S-3233-2019; Jarrett, Ruth F/A-5570-2012	Hay, Ronald T/0000-0001-7113-9024; Khan, Gulfaraz/0000-0001-6836-1783; Hay, Ronald/0000-0001-7113-9024; 				ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Bargou RC, 1996, BLOOD, V87, P4340, DOI 10.1182/blood.V87.10.4340.bloodjournal87104340; BEAUPARLANT P, 1994, ONCOGENE, V9, P3189; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; DIEHL V, 1996, BAILLIERES CLIN HAEM, V9; DREXLER HG, 1993, LEUKEMIA LYMPHOMA, V9, P1, DOI 10.3109/10428199309148499; Gilmore TD, 1996, ONCOGENE, V13, P1367; GILMORE TD, 1995, DNA PROVIRUS, P109; Gruss HJ, 1996, BAILLIERE CLIN HAEM, V9, P417, DOI 10.1016/S0950-3536(96)80019-9; Gruss HJ, 1997, IMMUNOL TODAY, V18, P156, DOI 10.1016/S0167-5699(97)84661-0; GRUSS HJ, 1992, CANCER RES, V52, P3353; Gruss HJ, 1996, LEUKEMIA LYMPHOMA, V20, P397, DOI 10.3109/10428199609052421; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; Hirano F, 1998, MOL CELL BIOL, V18, P2596, DOI 10.1128/MCB.18.5.2596; ITO CY, 1995, GENOMICS, V29, P490, DOI 10.1006/geno.1995.9977; JAFFRAY E, 1995, MOL CELL BIOL, V15, P2166; JUNG M, 1995, SCIENCE, V268, P1619, DOI 10.1126/science.7777860; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; Klement JF, 1996, MOL CELL BIOL, V16, P2341; Krappmann D, 1999, ONCOGENE, V18, P943, DOI 10.1038/sj.onc.1202351; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; Lin L, 1998, CELL, V92, P819, DOI 10.1016/S0092-8674(00)81409-9; Luque I, 1997, SEMIN CANCER BIOL, V8, P103, DOI 10.1006/scbi.1997.0061; Mosialos G, 1997, SEMIN CANCER BIOL, V8, P121, DOI 10.1006/scbi.1997.0063; Sonenshein GE, 1997, SEMIN CANCER BIOL, V8, P113, DOI 10.1006/scbi.1997.0062; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; Sylla BS, 1998, P NATL ACAD SCI USA, V95, P10106, DOI 10.1073/pnas.95.17.10106; TROELSTRA C, 1993, NUCLEIC ACIDS RES, V21, P419, DOI 10.1093/nar/21.3.419; Verma IM, 1997, P NATL ACAD SCI USA, V94, P11758, DOI 10.1073/pnas.94.22.11758; Whiteside ST, 1997, SEMIN CANCER BIOL, V8, P75, DOI 10.1006/scbi.1997.0058; Wood KM, 1998, ONCOGENE, V16, P2131, DOI 10.1038/sj.onc.1201735	37	266	272	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 20	1999	18	20					3063	3070		10.1038/sj.onc.1202893	http://dx.doi.org/10.1038/sj.onc.1202893			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	197WB	10340377				2022-12-25	WOS:000080388000001
J	Veillette, A; Soussou, D; Latour, S; Davidson, D; Gervais, FG				Veillette, A; Soussou, D; Latour, S; Davidson, D; Gervais, FG			Interactions of CD45-associated protein with the antigen receptor signaling machinery in T-lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHATASE CD45; AMINO-TERMINAL DOMAIN; KINASE P56LCK; CELL RESPONSIVENESS; SH3 DOMAINS; ASSOCIATION; EXPRESSION; P56(LCK); ZAP-70; LCK	CD45 is a transmembrane protein tyrosine phosphatase playing an essential role during T-cell activation This function relates to the ability of CD45 to regulate p56(lck), a cytoplasmic protein tyrosine kinase necessary for T-cell antigen receptor (TCR) signaling. Previous studies have demonstrated that CD45 is constitutively associated in T-lymphocytes with a transmembrane molecule termed CD45-AP (or lymphocyte phosphatase-associated phosphoprotein), Even though the exact role of this polypeptide is unclear, recent analyses of mice lacking CD45-AP have indicated that its expression is also required for optimal T-cell activation. Herein, we wished to understand better the function of CD45-AP. The results of our studies showed that in T-cells, CD45-AP is part of a multimolecular complex that includes not only CD45, but also TCR, the CD4 and CD8 coreceptors, and p56(lck). The association of CD45-AP with TCR, CD4, and CD8 seemed to occur via the shared ability of these molecules to bind CD45. However, binding of CD45-AP to p56(lck) could take place in the absence of other lymphoid-specific components, suggesting that it can be direct, Structure-function analyses demonstrated that such an interaction was mediated by an acidic segment in the cytoplasmic region of CD45-AP and by the kinase domain of p56(lck). Interestingly, the ability of CD45-AP to interact with Lck in the absence of other lymphoid-specific molecules was proportional to the degree of catalytic activation of p56(lck). Together, these findings suggest that CD45-AP is an adaptor molecule involved in orchestrating interactions among components of the antigen, receptor signaling machinery. Moreover, they raise the possibility that one of the functions of CD45-AP is to recognize activated Lck molecules and bring them into the vicinity of CD45.	McGill Univ, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Med, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Oncol, Montreal, PQ H3G 1Y6, Canada; Montreal Gen Hosp, Dept Med, Montreal, PQ H3G 1A4, Canada; Montreal Gen Hosp, Dept Oncol, Montreal, PQ H3G 1A4, Canada	McGill University; McGill University; McGill University; McGill University; McGill University; McGill University	Veillette, A (corresponding author), McGill Univ, McGill Canc Ctr, Rm 715,McIntyre Med Sci Bldg,3655 Drummond St, Montreal, PQ H3G 1Y6, Canada.		Latour, Sylvain/H-3652-2017	Latour, Sylvain/0000-0001-8238-4391				ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; Bonnard M, 1997, CELL IMMUNOL, V175, P1, DOI 10.1006/cimm.1996.1044; Bruyns E, 1995, J BIOL CHEM, V270, P31372; BURNS CM, 1994, J BIOL CHEM, V269, P13594; CARON L, 1992, MOL CELL BIOL, V12, P2720, DOI 10.1128/MCB.12.6.2720; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; Chow L M, 1995, Semin Immunol, V7, P207, DOI 10.1006/smim.1995.0026; CHOW LML, 1994, ONCOGENE, V9, P3437; CHOW LML, 1993, NATURE, V365, P156, DOI 10.1038/365156a0; DAVIDSON D, 1992, J EXP MED, V175, P1483, DOI 10.1084/jem.175.6.1483; Davidson D, 1997, J BIOL CHEM, V272, P23455, DOI 10.1074/jbc.272.37.23455; DIANZANI U, 1992, EUR J IMMUNOL, V22, P365, DOI 10.1002/eji.1830220212; DIANZANI U, 1990, EUR J IMMUNOL, V20, P2249, DOI 10.1002/eji.1830201014; Doro U, 1996, MOL CELL BIOL, V16, P4996; Fournel M, 1996, J EXP MED, V183, P301, DOI 10.1084/jem.183.1.301; FURUKAWA T, 1994, P NATL ACAD SCI USA, V91, P10928, DOI 10.1073/pnas.91.23.10928; Gervais FG, 1997, J BIOL CHEM, V272, P12754, DOI 10.1074/jbc.272.19.12754; GERVAIS FG, 1993, MOL CELL BIOL, V13, P7112, DOI 10.1128/MCB.13.11.7112; GERVAIS FG, 1995, MOL CELL BIOL, V15, P2393; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; Kitamura K, 1997, EUR J IMMUNOL, V27, P383, DOI 10.1002/eji.1830270207; KITAMURA K, 1995, J BIOL CHEM, V270, P21151, DOI 10.1074/jbc.270.36.21151; KORETZKY GA, 1993, J BIOL CHEM, V268, P8958; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; Latour S, 1996, J BIOL CHEM, V271, P22782, DOI 10.1074/jbc.271.37.22782; Leitenberg D, 1996, J EXP MED, V183, P249, DOI 10.1084/jem.183.1.249; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; Matsuda A, 1998, J EXP MED, V187, P1863, DOI 10.1084/jem.187.11.1863; MCFARLAND EDC, 1995, J BIOL CHEM, V270, P28103; McFarland EDC, 1997, BIOCHEMISTRY-US, V36, P7169, DOI 10.1021/bi970013y; Ng DHW, 1996, J BIOL CHEM, V271, P1295, DOI 10.1074/jbc.271.3.1295; NOVAK TJ, 1994, IMMUNITY, V1, P109, DOI 10.1016/1074-7613(94)90104-X; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; RESKEKUNZ AB, 1985, EUR J IMMUNOL, V15, P1048, DOI 10.1002/eji.1830151017; REYNOLDS PJ, 1992, ONCOGENE, V7, P1949; ROSS SE, 1994, BIOCHEM BIOPH RES CO, V198, P88, DOI 10.1006/bbrc.1994.1013; SCHRAVEN B, 1991, EUR J IMMUNOL, V21, P2469, DOI 10.1002/eji.1830211025; SCHRAVEN B, 1994, J BIOL CHEM, V269, P29102; SCHRAVEN B, 1990, NATURE, V345, P71, DOI 10.1038/345071a0; SCHRAVEN B, 1992, EUR J IMMUNOL, V22, P1857, DOI 10.1002/eji.1830220727; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; Shimizu Y, 1997, AM J HEMATOL, V54, P1, DOI 10.1002/(SICI)1096-8652(199701)54:1<1::AID-AJH1>3.0.CO;2-1; TAKEDA A, 1994, J BIOL CHEM, V269, P2357; Thomas M L, 1995, Semin Immunol, V7, P279, DOI 10.1006/smim.1995.0032; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; VANOERS NSC, 1994, IMMUNITY, V1, P675, DOI 10.1016/1074-7613(94)90038-8; VEILLETTE A, 1992, ONCOGENE, V7, P971; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VOLAREVIC S, 1990, P NATL ACAD SCI USA, V87, P7085, DOI 10.1073/pnas.87.18.7085; VOLAREVIC S, 1992, J EXP MED, V176, P835, DOI 10.1084/jem.176.3.835; VORONOVA AF, 1986, NATURE, V319, P682, DOI 10.1038/319682a0; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; WEAVER CT, 1991, MOL CELL BIOL, V11, P4415, DOI 10.1128/MCB.11.9.4415; WEIL R, 1995, J BIOL CHEM, V270, P2791, DOI 10.1074/jbc.270.6.2791; Weiss A, 1995, ANN NY ACAD SCI, V766, P149, DOI 10.1111/j.1749-6632.1995.tb26658.x	57	25	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					14392	14399		10.1074/jbc.274.20.14392	http://dx.doi.org/10.1074/jbc.274.20.14392			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318863	hybrid			2022-12-25	WOS:000080322200092
J	Arosa, FA; de Jesus, O; Porto, G; Carmo, AM; de Sousa, M				Arosa, FA; de Jesus, O; Porto, G; Carmo, AM; de Sousa, M			Calreticulin is expressed on the cell surface of activated human peripheral blood T lymphocytes in association with major histocompatibility complex class I molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-I; CALCIUM-BINDING PROTEIN; N-LINKED GLYCANS; ENDOPLASMIC-RETICULUM; TRANSFERRIN RECEPTOR; IMMATURE THYMOCYTES; LIGAND-BINDING; KDEL RECEPTOR; TAP COMPLEXES; HEAVY-CHAINS	Calreticulin is an endoplasmic reticulum resident molecule known to be involved in the folding and assembly of major histocompatibility complex (MHC) class I molecules. In the present study, expression of calreticulin was analyzed in human peripheral blood T lymphocytes. Pulse-chase experiments in [S-35]methionine-labeled T cell blasts showed that calreticulin was associated with several proteins in the endoplasmic reticulum and suggested that it was expressed at the cell surface. Indeed, the 60-kDa calreticulin was labeled by cell surface biotinylation and precipitated from the surface of activated T cells together with a protein with an apparent molecular mass of 46 kDa. Cell surface expression of calreticulin by activated T lymphocytes was further confirmed by immunofluorescence and flow cytometry, studies that showed that both CD8+ and CD4+ T cells expressed calreticulin in the plasma membrane. Low amounts of cell surface calreticulin were detected in resting T lymphocytes. By sequential immunoprecipitation using the conformation independent monoclonal antibody HC-10, we provided evidence that the cell surface 46-kDa protein co-precipitated with calreticulin is unfolded MHC I. These results show for the first time that after T cell activation, significant amounts of calreticulin are expressed on the T cell surface, where they are found in physical association with a pool of beta(2)-free MHC class I molecules.	Univ Porto, Inst Mol & Cell Biol, Lab Mol Immunol, P-4150 Porto, Portugal; Santo Antonio Gen Hosp, Dept Hematol, P-4050 Porto, Portugal	Universidade do Porto	Arosa, FA (corresponding author), Univ Porto, Inst Mol & Cell Biol, Lab Mol Immunol, Rua Campo Alegre 823, P-4150 Porto, Portugal.		Carmo, Alexandre/B-5191-2011; Porto, Graca/J-7939-2013; Arosa, Fernando A./E-5640-2010	Carmo, Alexandre/0000-0002-2508-9799; Porto, Graca/0000-0002-1923-4638; Arosa, Fernando A./0000-0002-7209-4507; de sousa, maria/0000-0002-4552-185X				Arosa FA, 1997, CLIN EXP IMMUNOL, V107, P548, DOI 10.1046/j.1365-2249.1997.d01-967.x; AROSA FA, 1994, SCAND J IMMUNOL, V39, P426, DOI 10.1111/j.1365-3083.1994.tb03396.x; Basu S, 1999, J EXP MED, V189, P797, DOI 10.1084/jem.189.5.797; BURNS K, 1992, J BIOL CHEM, V267, P19039; CHEN A, 1994, J IMMUNOL, V153, P1430; CONRAD ME, 1993, GASTROENTEROLOGY, V104, P1700, DOI 10.1016/0016-5085(93)90648-V; Conrad ME, 1996, J CLIN INVEST, V98, P1449, DOI 10.1172/JCI118933; Coppolino MG, 1998, INT J BIOCHEM CELL B, V30, P553, DOI 10.1016/S1357-2725(97)00153-2; de Sousa Maria, 1998, Journal of Hepatology, V28, P1, DOI 10.1016/S0168-8278(98)80367-X; DEMARIA S, 1992, CELL IMMUNOL, V142, P103, DOI 10.1016/0008-8749(92)90272-Q; Denning GM, 1997, BLOOD, V90, P372; DUPUIS M, 1993, J EXP MED, V177, P1, DOI 10.1084/jem.177.1.1; Feder JN, 1998, P NATL ACAD SCI USA, V95, P1472, DOI 10.1073/pnas.95.4.1472; GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P403, DOI 10.1146/annurev.immunol.11.1.403; GRIFFITHS G, 1994, J CELL BIOL, V127, P1557, DOI 10.1083/jcb.127.6.1557; Gross CN, 1998, J BIOL CHEM, V273, P22068, DOI 10.1074/jbc.273.34.22068; Harris MR, 1998, J IMMUNOL, V160, P5404; Krause KH, 1997, CELL, V88, P439, DOI 10.1016/S0092-8674(00)81884-X; Lebron JA, 1998, CELL, V93, P111, DOI 10.1016/S0092-8674(00)81151-4; Llewellyn DH, 1997, BIOCHEM BIOPH RES CO, V240, P36, DOI 10.1006/bbrc.1997.7607; MACHY P, 1982, P NATL ACAD SCI-BIOL, V79, P4148, DOI 10.1073/pnas.79.13.4148; MACHY P, 1987, NATURE, V328, P724, DOI 10.1038/328724a0; MALHOTRA R, 1993, IMMUNOLOGY, V78, P341; MCCAULIFFE DP, 1990, J CLIN INVEST, V85, P1379, DOI 10.1172/JCI114582; MCCAULIFFE DP, 1993, J INVEST DERMATOL, V100, P73; McDonnell JM, 1996, J BIOL CHEM, V271, P7891, DOI 10.1074/jbc.271.14.7891; MONOS DS, 1983, J IMMUNOL, V131, P341; NASH PD, 1994, MOL CELL BIOCHEM, V135, P71, DOI 10.1007/BF00925962; NAUSEEF WM, 1995, J BIOL CHEM, V270, P4741, DOI 10.1074/jbc.270.9.4741; Noessner Elfriede, 1995, Journal of Experimental Medicine, V181, P327; Oliver JD, 1996, J BIOL CHEM, V271, P13691, DOI 10.1074/jbc.271.23.13691; OLSSON L, 1994, P NATL ACAD SCI USA, V91, P9086, DOI 10.1073/pnas.91.19.9086; OPAS M, 1991, J CELL PHYSIOL, V149, P160, DOI 10.1002/jcp.1041490120; Ortmann B, 1997, SCIENCE, V277, P1306, DOI 10.1126/science.277.5330.1306; ORTMANN B, 1994, NATURE, V368, P864, DOI 10.1038/368864a0; PARHAM P, 1979, J IMMUNOL, V123, P343; PERNIS B, 1985, IMMUNOL TODAY, V6, P45, DOI 10.1016/0167-5699(85)90046-5; PETERSON JR, 1995, MOL BIOL CELL, V6, P1173, DOI 10.1091/mbc.6.9.1173; Pickl WF, 1996, IMMUNOLOGY, V88, P104, DOI 10.1046/j.1365-2567.1996.d01-644.x; ROJIANI MV, 1991, BIOCHEMISTRY-US, V30, P9859, DOI 10.1021/bi00105a008; Sadasivan B, 1996, IMMUNITY, V5, P103, DOI 10.1016/S1074-7613(00)80487-2; SCHNABL E, 1990, J EXP MED, V171, P1431, DOI 10.1084/jem.171.5.1431; Sim RB, 1998, IMMUNOBIOLOGY, V199, P208, DOI 10.1016/S0171-2985(98)80028-4; Solheim JC, 1997, J IMMUNOL, V158, P541; Solheim JC, 1997, J IMMUNOL, V158, P2236; SONNICHSEN B, 1994, J CELL SCI, V107, P2705; SONTHEIMER RD, 1995, J INVEST MED, V43, P362; STAM NJ, 1986, J IMMUNOL, V137, P2299; Stuart GR, 1997, IMMUNOPHARMACOLOGY, V38, P73, DOI 10.1016/S0162-3109(97)00076-3; SUGITA M, 1994, J EXP MED, V180, P2163, DOI 10.1084/jem.180.6.2163; SUH WK, 1994, SCIENCE, V264, P1322, DOI 10.1126/science.8191286; TOWNSLEY FM, 1993, EMBO J, V12, P2821, DOI 10.1002/j.1460-2075.1993.tb05943.x; TSE DB, 1984, J EXP MED, V159, P193, DOI 10.1084/jem.159.1.193; VanLeeuwen JEM, 1997, J BIOL CHEM, V272, P4179, DOI 10.1074/jbc.272.7.4179; VanLeeuwen JEM, 1996, J BIOL CHEM, V271, P25345, DOI 10.1074/jbc.271.41.25345; VanLeeuwen JEM, 1996, P NATL ACAD SCI USA, V93, P13997, DOI 10.1073/pnas.93.24.13997; WHITE TK, 1995, J BIOL CHEM, V270, P15926, DOI 10.1074/jbc.270.27.15926; Wiest DL, 1997, P NATL ACAD SCI USA, V94, P1884, DOI 10.1073/pnas.94.5.1884; WIEST DL, 1995, EMBO J, V14, P3425, DOI 10.1002/j.1460-2075.1995.tb07348.x; Zhang J, 1998, J IMMUNOL, V161, P2930; Zhang Q, 1998, J IMMUNOL, V160, P831; ZHU JH, 1994, CLIN INVEST MED, V17, P196; Zhu Q, 1997, BIOCHEM BIOPH RES CO, V232, P354, DOI 10.1006/bbrc.1997.6195	63	110	118	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16917	16922		10.1074/jbc.274.24.16917	http://dx.doi.org/10.1074/jbc.274.24.16917			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358038	hybrid			2022-12-25	WOS:000080780400037
J	Rieke, CJ; Mulichak, AM; Garavito, RM; Smith, WL				Rieke, CJ; Mulichak, AM; Garavito, RM; Smith, WL			The role of arginine 120 of human prostaglandin endoperoxide H synthase-2 in the interaction with fatty acid substrates and inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; TIME-DEPENDENT INHIBITION; SELECTIVE-INHIBITION; DIFFERENTIAL INHIBITION; CRYSTAL-STRUCTURE; ARACHIDONIC-ACID; GENE-EXPRESSION; G/H SYNTHASE-1; HEME-BINDING; CYCLOOXYGENASE-2	Arg-120 is located near the mouth of the hydrophobic channel that forms the cyclooxygenase active site of prostaglandin endoperoxide H synthases (PGHSs)-1 and -2, Replacement of Arg-120 of ovine PGHS-1 with a glutamine increases the apparent K-m of PGHS-1 for arachidonate by 1,000-fold (Bhattacharyya, D. K., Lecomte, M., Rieke, C. J., Garavito, R. M., and Smith, W. L. (1996) J, Biol, Chem, 271, 2179-2184). This and other evidence indicate that the guanido group of Arg-120 forms an ionic bond with the carboxylate group of arachidonate and that this interaction is an important contributor to the overall strength of arachidonate binding to PGHS-1. In contrast, we report here that R120Q human PGHS-2 (hPGHS-2) and native hPGHS-2 have very similar kinetic properties, but R120L hPGHS-2 catalyzes the oxygenation of arachidonate inefficiently. Our data indicate that the guanido group of Arg-120 of hPGHS-2 interacts with arachidonate through a hydrogen bond rather than an ionic bond and that this interaction is much less important for arachidonate binding to PGHS-2 than to PGHS-1. The K-m values of PGHS-1 and -2 for arachidonate are the same, and all but one of the core residues of the active sites of the two isozymes are identical. Thus, the results of our studies of Arg-120 of PGHS-1 and -2 imply that interactions involved in the binding of arachidonate to PGHS-1 and -2 are quite different and that residues within the hydrophobic cyclooxygenase channel must contribute more significantly to arachidonate binding to PGHS-S than to PGHS-1. As observed previously with R120Q PGHS-1, flurbiprofen was an ineffective inhibitor of R120Q hPGHS-2, PGHS-2-specific inhibitors including NS398, DuP-697, and SC58125 had IC50 values for the R120Q mutant that were up to 1,000-fold less than those observed for native hPGHS-2; thus, the positively charged guanido group of Arg-120 interferes with the binding of these compounds. NS398 did not cause time-dependent inhibition of R120Q hPGHS-2, whereas DuP-697 and SC58125 were time-dependent inhibitors. Thus, Arg-120 is important for the time-dependent inhibition of hPGHS-2 by NS398 but not by DuP-697 or SC58125.	Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA	Michigan State University	Smith, WL (corresponding author), Michigan State Univ, Dept Biochem, 513 Biochem Bldg, E Lansing, MI 48824 USA.				NIGMS NIH HHS [P01GM57323] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM057323] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bhattacharyya DK, 1996, J BIOL CHEM, V271, P2179, DOI 10.1074/jbc.271.4.2179; Callan OH, 1996, J BIOL CHEM, V271, P3548; COPELAND RA, 1994, P NATL ACAD SCI USA, V91, P11202, DOI 10.1073/pnas.91.23.11202; DEWITT DL, 1990, J BIOL CHEM, V265, P5192; EVETT GE, 1993, ARCH BIOCHEM BIOPHYS, V306, P169, DOI 10.1006/abbi.1993.1496; FOEGH ML, 1989, PROSTAGLANDINS CLIN, P131; Gan QF, 1996, J BIOL CHEM, V271, P25412, DOI 10.1074/jbc.271.41.25412; Gierse JK, 1996, J BIOL CHEM, V271, P15810, DOI 10.1074/jbc.271.26.15810; Greig GM, 1997, MOL PHARMACOL, V52, P829, DOI 10.1124/mol.52.5.829; Guan ZH, 1998, J BIOL CHEM, V273, P12901, DOI 10.1074/jbc.273.21.12901; Guo QP, 1996, J BIOL CHEM, V271, P19134, DOI 10.1074/jbc.271.32.19134; HULKOWER KI, 1994, ARTHRITIS RHEUM-US, V37, P653, DOI 10.1002/art.1780370508; JONES DA, 1993, J BIOL CHEM, V268, P9049; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KULMACZ RJ, 1987, PROSTAGLANDINS, V34, P225, DOI 10.1016/0090-6980(87)90246-2; KULMACZ RJ, 1985, J BIOL CHEM, V260, P2572; Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0; LANEUVILLE O, 1994, J PHARMACOL EXP THER, V271, P927; LECOMTE M, 1994, J BIOL CHEM, V269, P13207; LOLL PJ, 1995, NAT STRUCT BIOL, V2, P637, DOI 10.1038/nsb0895-637; Luong C, 1996, NAT STRUCT BIOL, V3, P927, DOI 10.1038/nsb1196-927; MANCINI JA, 1995, J BIOL CHEM, V270, P29372, DOI 10.1074/jbc.270.49.29372; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MASFERRER JL, 1994, P NATL ACAD SCI USA, V91, P3228, DOI 10.1073/pnas.91.8.3228; MEADE EA, 1993, J BIOL CHEM, V268, P6610; OTTO JC, 1994, J BIOL CHEM, V269, P19868; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; RAZ A, 1990, ADV PROSTAG THROMB L, V20, P22; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIMOKAWA T, 1991, J BIOL CHEM, V266, P6168; SHIMOKAWA T, 1992, J BIOL CHEM, V267, P12387; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; So OY, 1998, J BIOL CHEM, V273, P5801, DOI 10.1074/jbc.273.10.5801; STEGEMAN R, 1999, IN PRESS ACTA CRYSTA; Wong E, 1997, J BIOL CHEM, V272, P9280; Xiao GS, 1997, BIOCHEMISTRY-US, V36, P1836, DOI 10.1021/bi962476u; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; Xie WL, 1996, J BIOL CHEM, V271, P31742, DOI 10.1074/jbc.271.49.31742	38	87	90	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17109	17114		10.1074/jbc.274.24.17109	http://dx.doi.org/10.1074/jbc.274.24.17109			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358065	hybrid			2022-12-25	WOS:000080780400064
J	Brewer, G				Brewer, G			Evidence for a 3 '-5 ' decay pathway for c-myc mRNA in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; CODING REGION; DEGRADATION; PURIFICATION; TURNOVER; PROTEIN; INVITRO; YEAST; EXORIBONUCLEASE; EXOSOME	Many mBNAs in mammalian cells decay via a sequential pathway involving rapid conversion of polyadenylated molecules to a poly(A)-deficient state followed by rapid degradation of the poly(A)-deficient molecules. However, the rapidity of this latter step(s) has precluded further analyses of the decay pathways involved. Decay intermediates derived from degradation of poly(A)-deficient molecules could offer clues regarding decay pathways, but these intermediates have not been readily detected. Cell-free mRNA decay systems have proven useful in analyses of decay pathways because decay intermediates are rather stable in vitro. Cell-free systems indicate that many mRNAs decay by a sequential 3'-5' pathway because 3'-terminal decay intermediates form following deadenylation. However, if 3'-terminal, in vitro decay intermediates reflect a biologically significant aspect of mRNA turnover, then similar intermediates should be present in cells. Here, I have compared the in vivo and in vitro decay of mRNA encoded by the c-myc proto-oncogene. Its decay both in vivo and in vitro occurs by rapid removal of the poly(A) tract and generation of a 3'-terminal decay intermediate. These data strongly suggest that a 3'-5' pathway contributes to turnover of c-myc mRNA in cells. It is likely that 3'-5' decay represents a major turnover pathway in mammalian cells.	Wake Forest Univ, Sch Med, Dept Microbiol & Immunol, Winston Salem, NC 27157 USA	Wake Forest University	Brewer, G (corresponding author), Wake Forest Univ, Sch Med, Dept Microbiol & Immunol, Winston Salem, NC 27157 USA.				NATIONAL CANCER INSTITUTE [R01CA052443] Funding Source: NIH RePORTER; NCI NIH HHS [CA52443] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson JSJ, 1998, EMBO J, V17, P1497, DOI 10.1093/emboj/17.5.1497; Bashkirov VI, 1997, J CELL BIOL, V136, P761, DOI 10.1083/jcb.136.4.761; BEELMAN CA, 1995, CELL, V81, P179, DOI 10.1016/0092-8674(95)90326-7; BERNSTEIN PL, 1992, GENE DEV, V6, P642, DOI 10.1101/gad.6.4.642; BREWER G, 1988, MOL CELL BIOL, V8, P1697, DOI 10.1128/MCB.8.4.1697; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; BREWER G, 1990, METHOD ENZYMOL, V181, P202; Brewer G, 1998, J BIOL CHEM, V273, P34770, DOI 10.1074/jbc.273.52.34770; BREWER G, 1989, MOL CELL BIOL, V9, P1996, DOI 10.1128/MCB.9.5.1996; BREWER G, 1992, PROMEGA NOTES, V40, P11; CARUCCIO N, 1994, J BIOL CHEM, V269, P31814; Couttet P, 1997, P NATL ACAD SCI USA, V94, P5628, DOI 10.1073/pnas.94.11.5628; DEAN A, 1983, P NATL ACAD SCI-BIOL, V80, P5515, DOI 10.1073/pnas.80.18.5515; DEMARIA CT, 1997, PROGR MOL SUBCELLULA, P65; DONOVAN WP, 1986, P NATL ACAD SCI USA, V83, P120, DOI 10.1073/pnas.83.1.120; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HSU CL, 1993, MOL CELL BIOL, V13, P4826, DOI 10.1128/MCB.13.8.4826; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; Korner CG, 1997, J BIOL CHEM, V272, P10448; Korner CG, 1998, EMBO J, V17, P5427, DOI 10.1093/emboj/17.18.5427; Lee CH, 1998, J BIOL CHEM, V273, P25261, DOI 10.1074/jbc.273.39.25261; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; Mitchell P, 1997, CELL, V91, P457, DOI 10.1016/S0092-8674(00)80432-8; MUHLRAD D, 1994, NATURE, V370, P578, DOI 10.1038/370578a0; PROKIPCAK RD, 1994, J BIOL CHEM, V269, P9261; ROSS J, 1986, MOL CELL BIOL, V6, P4362, DOI 10.1128/MCB.6.12.4362; ROSS J, 1995, MICROBIOL REV, V59, P16; ROSS J, 1993, CONTROL MESSENGER RN, P417; RuizEchevarria MJ, 1996, TRENDS BIOCHEM SCI, V21, P433, DOI 10.1016/S0968-0004(96)10055-4; SCHIAVI SC, 1992, BIOCHIM BIOPHYS ACTA, V1114, P95, DOI 10.1016/0304-419X(92)90009-N; SWARTWOUT SG, 1989, MOL CELL BIOL, V9, P288, DOI 10.1128/MCB.9.1.288	31	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16174	16179		10.1074/jbc.274.23.16174	http://dx.doi.org/10.1074/jbc.274.23.16174			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347171	hybrid			2022-12-25	WOS:000080668600031
J	Fang, N; Koretzky, GA				Fang, N; Koretzky, GA			SLP-76 and Vav function in separate, but overlapping pathways to augment interleukin-2 promoter activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; CELL ANTIGEN RECEPTOR; ACCESSORY MOLECULE CD28; ACTIVATED T-CELLS; SIGNAL-TRANSDUCTION; PROTOONCOGENE PRODUCT; TRANSCRIPTION FACTORS; GENE-EXPRESSION; NUCLEAR FACTOR; IL-2 PROMOTER	SLP-76 and Vav, two hematopoietic cell specific molecules, are critical for T cell development and activation. Following T cell antigen receptor stimulation, SLP-76 and Vav both undergo tyrosine phosphorylation and associate with each other via the SH2 domain of Vav and phosphorylated tyrosines of SLP-76, Furthermore, SLP-76 and Vav have a synergistic effect on interleukin (IL)-2 promoter activity in T cells. In this report, we show that two tyrosines, Tyr-113 and Tyr-128, of SLP-76 are required for its binding to Vav, both in vitro and in intact cells. Surprisingly, we find also that the interaction between SLP-76 and Vav is not required for their cooperation in augmenting IL-2 promoter activity, as the two molecules appear to function in different signaling pathways upstream of IL-2 gene expression. Overexpression of SLP-76 in the Jurkat T cell line potentiates the activities of both nuclear factor of activated T cells and AP-1 transcription factors, In contrast, overexpression of Vav leads to enhanced nuclear factor of activated T cells activity without affecting AP-1, Additionally, overexpression of Vav, but not SLP-76, augments CD28-induced IL-2 promoter activity. These findings suggest that the synergy between SLP-76 and Vav in regulating IL-2 gene expression reflects the cooperation between different signaling pathways.	Univ Iowa, Coll Med, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Grad Program Immunol, Iowa City, IA 52242 USA	University of Iowa; University of Iowa	Koretzky, GA (corresponding author), Univ Iowa, Coll Med, Dept Internal Med, 540 EMRB, Iowa City, IA 52242 USA.		Koretzky, Gary/AAU-5381-2021		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053256] Funding Source: NIH RePORTER; NIGMS NIH HHS [R0IGM53256] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON JP, 1995, SCIENCE, V270, P932, DOI 10.1126/science.270.5238.932; ALTMAN A, 1990, CRIT REV IMMUNOL, V10, P347; BOGUSKI MS, 1992, NATURE, V358, P113, DOI 10.1038/358113a0; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; Cantrell D, 1998, TRENDS CELL BIOL, V8, P180, DOI 10.1016/S0962-8924(98)01264-1; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; Clements JL, 1998, SCIENCE, V281, P416, DOI 10.1126/science.281.5375.416; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; DaSilva AJ, 1997, P NATL ACAD SCI USA, V94, P7493, DOI 10.1073/pnas.94.14.7493; Deckert M, 1996, IMMUNITY, V5, P591, DOI 10.1016/S1074-7613(00)80273-3; Fang N, 1996, J IMMUNOL, V157, P3769; Fischer KD, 1998, CURR BIOL, V8, P554, DOI 10.1016/S0960-9822(98)70224-6; Fischer KD, 1998, SEMIN IMMUNOL, V10, P317, DOI 10.1006/smim.1998.0124; FRASER JD, 1992, MOL CELL BIOL, V12, P4357, DOI 10.1128/MCB.12.10.4357; FRASER JD, 1991, SCIENCE, V251, P313, DOI 10.1126/science.1846244; Genot E, 1996, EMBO J, V15, P3923, DOI 10.1002/j.1460-2075.1996.tb00766.x; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Holsinger LJ, 1998, CURR BIOL, V8, P563, DOI 10.1016/S0960-9822(98)70225-8; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; JAIN J, 1992, J IMMUNOL, V148, P1240; Kabelitz D, 1995, Curr Top Microbiol Immunol, V200, P1; Kalli K, 1998, MOL CELL BIOL, V18, P3140, DOI 10.1128/MCB.18.6.3140; KATZAV S, 1994, J BIOL CHEM, V269, P32579; Klasen S, 1998, INT IMMUNOL, V10, P481, DOI 10.1093/intimm/10.4.481; Liu SK, 1999, CURR BIOL, V9, P67, DOI 10.1016/S0960-9822(99)80017-7; Liu YC, 1998, CELL SIGNAL, V10, P377, DOI 10.1016/S0898-6568(97)00179-4; Luo C, 1996, J EXP MED, V184, P141, DOI 10.1084/jem.184.1.141; Maggirwar SB, 1997, MOL CELL BIOL, V17, P2605, DOI 10.1128/MCB.17.5.2605; Motto DG, 1996, J EXP MED, V183, P1937, DOI 10.1084/jem.183.4.1937; Musci MA, 1997, J IMMUNOL, V159, P1639; Musci MA, 1997, J BIOL CHEM, V272, P11674, DOI 10.1074/jbc.272.18.11674; PASTOR MI, 1995, CANCER SURV, V22, P75; PASTOR MI, 1995, IMMUNOL TODAY, V16, P159, DOI 10.1016/0167-5699(95)80134-0; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Peterson EJ, 1998, CURR OPIN IMMUNOL, V10, P337, DOI 10.1016/S0952-7915(98)80173-8; Pivniouk V, 1998, CELL, V94, P229, DOI 10.1016/S0092-8674(00)81422-1; Raab M, 1997, IMMUNITY, V6, P155, DOI 10.1016/S1074-7613(00)80422-7; RAMOSMORALES F, 1994, ONCOGENE, V9, P1917; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; ROBEY E, 1995, IMMUNOL TODAY, V16, P306, DOI 10.1016/0167-5699(95)80140-5; Rudd CE, 1996, IMMUNITY, V4, P527, DOI 10.1016/S1074-7613(00)80479-3; Shapiro VS, 1997, MOL CELL BIOL, V17, P4051, DOI 10.1128/MCB.17.7.4051; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; Tuosto L, 1996, J EXP MED, V184, P1161, DOI 10.1084/jem.184.3.1161; VONBOEHMER H, 1995, CLIN IMMUNOL IMMUNOP, V76, pS145, DOI 10.1016/S0090-1229(95)90018-7; Wardenburg JB, 1996, J BIOL CHEM, V271, P19641, DOI 10.1074/jbc.271.33.19641; Wardenburg JB, 1998, IMMUNITY, V9, P607, DOI 10.1016/S1074-7613(00)80658-5; WEISS A, 1992, COLD SPRING HARB SYM, V57, P107, DOI 10.1101/SQB.1992.057.01.014; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284; WHITEHURST CE, 1992, J IMMUNOL, V148, P3230; Wu J, 1997, J EXP MED, V185, P1877, DOI 10.1084/jem.185.10.1877; WU J, 1995, MOL CELL BIOL, V15, P4337; Wu J, 1996, IMMUNITY, V4, P593, DOI 10.1016/S1074-7613(00)80485-9; Yablonski D, 1998, SCIENCE, V281, P413, DOI 10.1126/science.281.5375.413; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0	59	65	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16206	16212		10.1074/jbc.274.23.16206	http://dx.doi.org/10.1074/jbc.274.23.16206			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347175	hybrid			2022-12-25	WOS:000080668600035
J	Martin, JL; Baxter, RC				Martin, JL; Baxter, RC			Oncogenic ras causes resistance to the growth inhibitor insulin-like growth factor binding protein-3 (IGFBP-3) in breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FIBROBLASTS; FACTOR-I; IGF-I; RETINOIC ACID; HUMAN-PLASMA; MECHANISM; PROLIFERATION; PURIFICATION; ESTRADIOL; RECEPTORS	Insulin-like growth factor binding protein-3 (IG-FBP-3) inhibits proliferation and promotes apoptosis in normal and malignant cells. In MCF-10A human mammary epithelial cells, 30 ng/ml human plasma-derived IGFBP-3 inhibited DNA synthesis to 70% of control. This inhibition appeared IGF-independent, since neither an IGF-receptor antibody nor IGFBP-6 inhibited DNA synthesis. Malignant transformation of MCF-10A cells by transfection with Ha-ras oncogene abolished the inhibitory effect of IGFBP-3, concomitant with an increase in IGFBP-3 secretion and cell association of approximately 60 and 300%, respectively. When mitogen-activated protein (MAP) kinase activation was partially inhibited using PD 98059, IGFBP-3 sensitivity in ras-transfected cells was restored, with a significant inhibitory effect at 10 ng/ml IGFBP-3. PD 98059 had no effect on IGFBP-3 secretion or cell association by ras-transfected or parent MCF-10A cells. Hs578T, a tumor-derived breast cancer cell line that expresses activated Ha-ras, similarly has a high level of secreted and cell-associated IGFBP-3. In the absence of PD 98059, DNA synthesis by Hs578T cells was reduced to 70% of control by 1000 ng/ml IGFBP-S. PD 98059 increased sensitivity to IGFBP-3, so that this level of inhibition was achieved with 100 ng/ml IGFBP-3. These results suggest that MAP kinase activation by oncogenic ras expression causes IGFBP-3 resistance, a possible factor in the dysregulation of breast cancer cell growth.	Univ Sydney, Royal N Shore Hosp, Kolling Inst Med Res, St Leonards, NSW 2065, Australia	Royal North Shore Hospital; University of Sydney; Kolling Institute of Medical Research	Martin, JL (corresponding author), Univ Sydney, Royal N Shore Hosp, Kolling Inst Med Res, St Leonards, NSW 2065, Australia.		Baxter, Robert C/F-3927-2012	Baxter, Robert C/0000-0001-5061-2142				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; AngellozNicoud P, 1996, GROWTH REGULAT, V6, P130; BASOLO F, 1991, MOL CARCINOGEN, V4, P25, DOI 10.1002/mc.2940040106; BAXTER RC, 1986, J CLIN INVEST, V78, P1504, DOI 10.1172/JCI112742; BINOUX M, 1993, ADV EXP MED BIOL, V343, P293; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Chan JM, 1998, SCIENCE, V279, P563, DOI 10.1126/science.279.5350.563; CLARK GJ, 1995, BREAST CANCER RES TR, V35, P133, DOI 10.1007/BF00694753; CONOVER CA, 1992, ENDOCRINOLOGY, V130, P3191, DOI 10.1210/en.130.6.3191; DEMELLOW JSM, 1988, BIOCHEM BIOPH RES CO, V156, P199, DOI 10.1016/S0006-291X(88)80824-6; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; Firth SM, 1998, BIOCHEM BIOPH RES CO, V246, P325, DOI 10.1006/bbrc.1998.8615; Gill ZP, 1997, J BIOL CHEM, V272, P25602, DOI 10.1074/jbc.272.41.25602; GOLDSTEIN S, 1991, P NATL ACAD SCI USA, V88, P9680, DOI 10.1073/pnas.88.21.9680; Gucev ZS, 1996, CANCER RES, V56, P1545; Hankinson SE, 1998, LANCET, V351, P1393, DOI 10.1016/S0140-6736(97)10384-1; Huynh H, 1996, J BIOL CHEM, V271, P1016, DOI 10.1074/jbc.271.2.1016; JACOBS S, 1986, ENDOCRINOLOGY, V118, P223, DOI 10.1210/endo-118-1-223; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KRAUS MH, 1984, P NATL ACAD SCI-BIOL, V81, P5384, DOI 10.1073/pnas.81.17.5384; Leal SM, 1997, J BIOL CHEM, V272, P20572, DOI 10.1074/jbc.272.33.20572; MARTIN JL, 1992, GROWTH REGULAT, V2, P88; MARTIN JL, 1990, J BIOL CHEM, V265, P4124; MARTIN JL, 1986, J BIOL CHEM, V261, P8754; MARTIN JL, 1995, ENDOCRINOLOGY, V136, P1219, DOI 10.1210/en.136.3.1219; MARTIN JL, 1992, ENDOCRINOLOGY, V131, P1703, DOI 10.1210/en.131.4.1703; OH Y, 1993, J BIOL CHEM, V268, P26045; OH YM, 1993, J BIOL CHEM, V268, P14964; PRATT SE, 1994, BIOCHEM BIOPH RES CO, V198, P292, DOI 10.1006/bbrc.1994.1041; Rajah R, 1997, J BIOL CHEM, V272, P12181, DOI 10.1074/jbc.272.18.12181; Salahifar H, 1997, ENDOCRINOLOGY, V138, P1683, DOI 10.1210/en.138.4.1683; SOULE HD, 1990, CANCER RES, V50, P6075; SUIKKARI AM, 1991, J CLIN ENDOCR METAB, V73, P1377, DOI 10.1210/jcem-73-6-1377	33	62	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16407	16411		10.1074/jbc.274.23.16407	http://dx.doi.org/10.1074/jbc.274.23.16407			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347201	hybrid			2022-12-25	WOS:000080668600061
J	Boix, E; Nikolovski, Z; Moiseyev, GP; Rosenberg, HF; Cuchillo, CM; Nogues, MV				Boix, E; Nikolovski, Z; Moiseyev, GP; Rosenberg, HF; Cuchillo, CM; Nogues, MV			Kinetic and product distribution analysis of human eosinophil cationic protein indicates a subsite arrangement that favors exonuclease-type activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE PANCREATIC RIBONUCLEASE; SITE-DIRECTED MUTAGENESIS; CRYSTAL-STRUCTURE; CATALYTIC PROPERTIES; SECONDARY STRUCTURE; MASS-SPECTROMETRY; MOLECULAR-CLONING; GRANULE PROTEINS; BINDING SUBSITES; NEUROTOXIN	With the use of a high yield prokaryotic expression system, large amounts of human eosinophil cationic protein (ECP) have been obtained. This has allowed a thorough kinetic study of the ribonuclease activity of this protein. The catalytic efficiencies for oligouridylic acids of the type (Up)(n)U>p, mononucleotides U>p and C>p, and dinucleoside monophosphates CpA, UpA, and UpG have been interpreted by the specific subsites distribution in ECP, The distribution of products derived from digestion of high molecular mass substrates, such as poly(U) and poly(C), by ECP was compared with that of RNase A The characteristic cleavage pattern of polynucleotides by ECP suggests that an exonuclease-like mechanism is predominantly favored in comparison to the endonuclease catalytic mechanism of RNase A. Comparative molecular modeling with bovine pancreatic RNase A-substrate analog crystal complexes revealed important differences in the subsite structure, whereas the secondary phosphate-binding site (p(2)) is lacking, the secondary base subsite (B-2) is severely impaired, and there are new interactions at the p(o), B-o, and p(-1) sites, located upstream of the P-O-5' cleavable phosphodiester bond, that are not found in RNase A. The differences in the multisubsites structure could explain the reduced catalytic efficiency of ECP and the shift from an endonuclease to an exonuclease-type mechanism.	Univ Autonoma Barcelona, Dept Bioquim & Biol Mol, Fac Ciencies, Bellaterra 08193, Spain; NIAID, Host Def Lab, NIH, Bethesda, MD 20892 USA	Autonomous University of Barcelona; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Nogues, MV (corresponding author), Univ Autonoma Barcelona, Dept Bioquim & Biol Mol, Fac Ciencies, Bellaterra 08193, Spain.		Boix, Ester/B-9038-2012; Nogues, M. Victoria/H-6100-2015	Boix, Ester/0000-0003-1790-2142; Nogues, M. Victoria/0000-0002-7104-0961	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000649] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABAGYAN R, 1994, J COMPUT CHEM, V15, P488, DOI 10.1002/jcc.540150503; ABUGHAZALEH RI, 1992, J LEUKOCYTE BIOL, V52, P611, DOI 10.1002/jlb.52.6.611; Ackerman Steven J., 1993, P33; ALONSO J, 1986, ARCH BIOCHEM BIOPHYS, V246, P681, DOI 10.1016/0003-9861(86)90324-3; ARNOTT S, 1976, J MOL BIOL, V106, P735, DOI 10.1016/0022-2836(76)90262-X; BEINTEMA JJ, 1988, BIOCHEMISTRY-US, V27, P4530, DOI 10.1021/bi00412a046; BIRDSALL DL, 1992, J BIOL CHEM, V267, P22230; BOIX E, 1994, J BIOL CHEM, V269, P2529; Boix E, 1996, J MOL BIOL, V257, P992, DOI 10.1006/jmbi.1996.0218; BRAVO J, 1994, ANAL BIOCHEM, V219, P82, DOI 10.1006/abio.1994.1234; Cuchillo C. M., 1997, RIBONUCLEASES STRUCT, P272; CURRAN TP, 1993, BIOCHEMISTRY-US, V32, P2307, DOI 10.1021/bi00060a023; DELCARDAYRE SB, 1994, BIOCHEMISTRY-US, V33, P6031, DOI 10.1021/bi00186a001; DELLORENS R, 1989, PROTEIN ENG, V2, P417, DOI 10.1093/protein/2.6.417; DELROSAR.EJ, 1969, BIOCHEMISTRY-US, V8, P1884, DOI 10.1021/bi00833a017; Domachowske JB, 1997, J LEUKOCYTE BIOL, V62, P363, DOI 10.1002/jlb.62.3.363; Domachowske JB, 1998, J INFECT DIS, V177, P1458, DOI 10.1086/515322; Domachowske JB, 1998, NUCLEIC ACIDS RES, V26, P3358, DOI 10.1093/nar/26.14.3358; FOLLMANN H., 1967, EUR J BIOCHEM, V1, P243, DOI 10.1111/j.1432-1033.1967.tb00068.x; FONTECILLACAMPS JC, 1994, J BIOL CHEM, V269, P21526; GILLILAND GL, 1994, PROTEIN PEPTIDE LETT, V1, P60; GLEICH GJ, 1986, P NATL ACAD SCI USA, V83, P3146, DOI 10.1073/pnas.83.10.3146; Grantham R., 1981, NUCLEIC ACIDS RES, V9, P43; GULLBERG U, 1986, BIOCHEM BIOPH RES CO, V139, P1239, DOI 10.1016/S0006-291X(86)80310-2; Hahner S, 1997, NUCLEIC ACIDS RES, V25, P1957, DOI 10.1093/nar/25.10.1957; HAMANN KJ, 1990, GENOMICS, V7, P535, DOI 10.1016/0888-7543(90)90197-3; IMAZAWA M, 1968, J BIOCHEM-TOKYO, V64, P595, DOI 10.1093/oxfordjournals.jbchem.a128936; IRIE M, 1984, J BIOCHEM-TOKYO, V96, P89, DOI 10.1093/oxfordjournals.jbchem.a134833; KOLBANOVSKAYA EY, 1993, MOL BIOL+, V27, P821; LEHRER RI, 1989, J IMMUNOL, V142, P4428; LI JRT, 1974, ARCH BIOCHEM BIOPHYS, V161, P227, DOI 10.1016/0003-9861(74)90255-0; LIBONATI M, 1992, MOL CELL BIOCHEM, V117, P139; MCPHERSON A, 1986, J MOL BIOL, V189, P305, DOI 10.1016/0022-2836(86)90512-7; MITSUI Y, 1978, BIOCHIM BIOPHYS ACTA, V535, P299, DOI 10.1016/0005-2795(78)90096-X; MOISEEV GP, 1982, BIOORG KHIM+, V8, P1197; MOLINA HA, 1988, AM J TROP MED HYG, V38, P327, DOI 10.4269/ajtmh.1988.38.327; Mosimann SC, 1996, J MOL BIOL, V260, P540, DOI 10.1006/jmbi.1996.0420; Moussaoui M, 1996, J BIOL CHEM, V271, P4687; Moussaoui M, 1998, J BIOL CHEM, V273, P25565, DOI 10.1074/jbc.273.40.25565; NEWTON DL, 1994, J NEUROSCI, V14, P538; NOGUES MV, 1995, BBA-PROTEIN STRUCT M, V1253, P16, DOI 10.1016/0167-4838(95)00138-K; Nogues MV, 1998, CELL MOL LIFE SCI, V54, P766, DOI 10.1007/s000180050205; OLSSON I, 1977, LAB INVEST, V36, P493; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; ROSENBERG HF, 1995, J BIOL CHEM, V270, P7876, DOI 10.1074/jbc.270.14.7876; ROSENBERG HF, 1989, P NATL ACAD SCI USA, V86, P4460, DOI 10.1073/pnas.86.12.4460; ROSENBERG HF, 1995, NAT GENET, V10, P219, DOI 10.1038/ng0695-219; ROSENBERG HF, 1989, J EXP MED, V170, P163, DOI 10.1084/jem.170.1.163; Sambrook J., 2002, MOL CLONING LAB MANU; SHAPIRO R, 1991, BIOCHEMISTRY-US, V30, P2246, DOI 10.1021/bi00222a030; SLIFMAN NR, 1986, J IMMUNOL, V137, P2913; SNYDER MR, 1997, RIBONUCLEASES STRUCT, P425; Sorrentino S, 1997, FEBS LETT, V404, P1, DOI 10.1016/S0014-5793(97)00086-0; SORRENTINO S, 1991, FEBS LETT, V288, P23, DOI 10.1016/0014-5793(91)80994-E; SORRENTINO S, 1992, J BIOL CHEM, V267, P14859; SORRENTINO S, 1994, ARCH BIOCHEM BIOPHYS, V312, P340, DOI 10.1006/abbi.1994.1318; Spry CJ, 1988, EOSINOPHILS COMPREHE; STEYAERT J, 1994, PROTEINS, V18, P318, DOI 10.1002/prot.340180403; TARRAGONAFIOL A, 1993, PROTEIN ENG, V6, P901, DOI 10.1093/protein/6.8.901; Trulson A, 1997, BRIT J HAEMATOL, V98, P312, DOI 10.1046/j.1365-2141.1997.2203035.x; VICENTINI AM, 1990, BIOCHEMISTRY-US, V29, P8827, DOI 10.1021/bi00489a046; WANG BH, 1994, ANAL CHEM, V66, P1918, DOI 10.1021/ac00083a023; Yakovlev G, 1997, J BIOMOL STRUCT DYN, V15, P243, DOI 10.1080/07391102.1997.10508189; YAKOVLEV GI, 1985, FEBS LETT, V179, P217, DOI 10.1016/0014-5793(85)80521-4; YOUNG JD, 1986, NATURE, V321, P613, DOI 10.1038/321613a0; YOUNG PR, 1978, J MOL BIOL, V126, P467, DOI 10.1016/0022-2836(78)90053-0; ZEGERS I, 1994, PROTEIN SCI, V3, P2322, DOI 10.1002/pro.5560031217; Zhang JZ, 1998, P NATL ACAD SCI USA, V95, P3708, DOI 10.1073/pnas.95.7.3708	68	67	69	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15605	15614		10.1074/jbc.274.22.15605	http://dx.doi.org/10.1074/jbc.274.22.15605			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336457	hybrid			2022-12-25	WOS:000080560100046
J	Li, QJ; Vaingankar, SM; Green, HM; Martins-Green, M				Li, QJ; Vaingankar, SM; Green, HM; Martins-Green, M			Activation of the 9E3/cCAF chemokine by phorbol esters occurs via multiple signal transduction pathways that converge to MEK1/ERK2 and activate the Elk1 transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ROUS-SARCOMA VIRUS; NF-KAPPA-B; GROWTH-FACTOR RECEPTOR; MAP KINASE; PLATELET PROTEIN; TUMOR PROMOTERS; DOWN-REGULATION; SKIN TUMORS; GENE	Using primary fibroblasts in culture, we have investigated the signal transduction mechanisms by which phorbol esters, a class of tumor promoters, activate the 9E3 gene and its chemokine product the chicken chemotactic and angiogenic factor. This gene is highly stimulated by phorbol 12,13-dibutyrate (PDBu) via three pathways: (i) a small contribution through protein kinase C (the commonly recognized pathway for these tumor promoters), (ii) a contribution involving tyrosine kinases, and (iii) a larger contribution via pathways that can be interrupted by dexamethasone, All three of these pathways converge into the mitogen-activated protein kinases, MEK1/ERK2, Using a luciferase reporter system, we show that although both the AP-1 and PDRIIkB (a NF kappa B-like factor in chickens) response elements are capable of activation in these normal cells, regions of the 9E3 promoter containing them are unresponsive to PDBu stimulation. In contrast, we show for the first time that activation by PDBu occurs through a segment of the promoter containing Elk1 response elements; deletion and mutation of these elements abrogates 9E3/ chicken chemotactic and angiogenic factor expression. Electrophoretic mobility shift assays and functional studies using PathDetect systems show that stimulation of the cells by phorbol esters leads to activation of the Elk1 transcription factor, which binds to its element in the 9E3 promoter.	Univ Calif Riverside, Dept Biol, Riverside, CA 92521 USA	University of California System; University of California Riverside	Martins-Green, M (corresponding author), Univ Calif Riverside, Dept Biol, Riverside, CA 92521 USA.	mmgreen@ucrac1.ucr.edu			NIGMS NIH HHS [GM48436] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM048436] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ATKINS KB, 1995, CELL GROWTH DIFFER, V6, P713; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BARKER K, 1990, MOL CELL BIOL, V10, P3813, DOI 10.1128/MCB.10.7.3813; Barrie AP, 1997, J BIOL CHEM, V272, P19666, DOI 10.1074/jbc.272.32.19666; BEDARD PA, 1987, P NATL ACAD SCI USA, V84, P6715, DOI 10.1073/pnas.84.19.6715; BISSELL MJ, 1979, P NATL ACAD SCI USA, V76, P348, DOI 10.1073/pnas.76.1.348; BISSELL MJ, 1977, J SUPRAMOL STR CELL, V6, P1, DOI 10.1002/jss.400060102; BLOBEL GA, 1991, P NATL ACAD SCI USA, V88, P1162, DOI 10.1073/pnas.88.4.1162; BLUMBERG PM, 1980, CRC CR REV TOXICOL, V8, P153, DOI 10.3109/10408448009037493; Cabannes E, 1997, ONCOGENE, V15, P29, DOI 10.1038/sj.onc.1201162; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; Cannon RE, 1997, MOL CARCINOGEN, V20, P108, DOI 10.1002/(SICI)1098-2744(199709)20:1<108::AID-MC12>3.0.CO;2-5; CHAO TSO, 1994, J BIOL CHEM, V269, P7337; Cobb M H, 1996, Adv Pharmacol, V36, P49, DOI 10.1016/S1054-3589(08)60576-1; Cohen RA, 1996, NEUROCASE, V2, P93; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; DEHBI M, 1992, MOL CELL BIOL, V12, P1490, DOI 10.1128/MCB.12.4.1490; DIAZMECO MT, 1993, MOL CELL BIOL, V13, P4770, DOI 10.1128/MCB.13.8.4770; DIGIOVANNI J, 1993, CARCINOGENESIS, V14, P319, DOI 10.1093/carcin/14.2.319; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Farina AR, 1997, CELL GROWTH DIFFER, V8, P789; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Force T, 1998, HYPERTENSION, V31, P152, DOI 10.1161/01.HYP.31.1.152; FOURNIER A, 1989, BIOCHEM BIOPH RES CO, V161, P556, DOI 10.1016/0006-291X(89)92635-1; Gatti A, 1997, EUR J BIOCHEM, V249, P92, DOI 10.1111/j.1432-1033.1997.t01-1-00092.x; GUAN KL, 1994, CELL SIGNAL, V6, P581, DOI 10.1016/0898-6568(94)90041-8; GULBINS E, 1994, MOL CELL BIOL, V14, P4749, DOI 10.1128/MCB.14.7.4749; Gutkind JS, 1997, LIFE SCI, V60, P999; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; HISCOTT J, 1993, MOL CELL BIOL, V13, P6231, DOI 10.1128/MCB.13.10.6231; HORUK R, 1996, CHEMOATTRACTANT LIGA; Howard OMZ, 1996, TRENDS BIOTECHNOL, V14, P46, DOI 10.1016/0167-7799(96)80920-6; Imai S, 1997, MOL BIOL CELL, V8, P2407, DOI 10.1091/mbc.8.12.2407; Iversen Olav Hilmar, 1995, Critical Reviews in Oncogenesis, V6, P357; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; Jenkins TD, 1997, J BIOL CHEM, V272, P24433, DOI 10.1074/jbc.272.39.24433; JIANG GQ, 1995, MOL CELL BIOL, V15, P5131; KLIGMAN AM, 1994, CANCER LETT, V87, P171, DOI 10.1016/0304-3835(94)90219-4; Knoepp SM, 1996, J BIOL CHEM, V271, P1678, DOI 10.1074/jbc.271.3.1678; KRANE SM, 1993, BRIT J RHEUMATOL, V32, P3; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; Kujoth GC, 1998, CELL GROWTH DIFFER, V9, P523; LACEY M, 1986, NATURE, V322, P609, DOI 10.1038/322609a0; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; Liu YZ, 1997, BIOCHEM J, V322, P155, DOI 10.1042/bj3220155; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; Martins-Green M., 1997, Cytokine and Growth Factor Reviews, V8, P221, DOI 10.1016/S1359-6101(97)00016-6; Martins-Green M, 1998, CYTOKINE, V10, P522, DOI 10.1006/cyto.1997.0311; Martins-Green M, 1998, CYTOKINE, V10, P819, DOI 10.1006/cyto.1998.0383; MARTINSGREEN M, 1994, CANCER RES, V54, P4334; MartinsGreen M, 1996, CYTOKINE, V8, P448, DOI 10.1006/cyto.1996.0061; MARTINSGREEN M, 1990, J CELL BIOL, V110, P581, DOI 10.1083/jcb.110.3.581; MARTINSGREEN M, 1992, J CELL SCI, V101, P701; MARUYAMA IN, 1991, P NATL ACAD SCI USA, V88, P5729, DOI 10.1073/pnas.88.13.5729; Mukaida N, 1992, Cytokines, V4, P41; MUKAIDA N, 1994, J BIOL CHEM, V269, P13289; NEWTON AC, 1995, CURR BIOL, V5, P973, DOI 10.1016/S0960-9822(95)00191-6; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OHMICHI M, 1994, J BIOL CHEM, V269, P3783; Ohtsuka T, 1996, J BIOL CHEM, V271, P1651, DOI 10.1074/jbc.271.3.1651; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; Pircher TJ, 1997, MOL CELL ENDOCRINOL, V133, P169, DOI 10.1016/S0303-7207(97)00164-0; Puceat M, 1996, MOL CELL BIOCHEM, V157, P65; RICHMOND A, 1996, CHEMOATTRACTANT LIGA, P87; Rider LG, 1996, J IMMUNOL, V157, P2374; Sanders JL, 1996, J BONE MINER RES, V11, P1862; Schwachtgen JL, 1998, BLOOD, V92, P1247, DOI 10.1182/blood.V92.4.1247.416k08_1247_1258; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SIEWEKE MH, 1994, CRIT REV ONCOGENESIS, V5, P297, DOI 10.1615/CritRevOncog.v5.i2-3.90; SIEWEKE MH, 1989, CANCER RES, V49, P6419; STALKER A, 1991, AM J ANAT, V190, P19, DOI 10.1002/aja.1001900104; SUGANO S, 1987, CELL, V49, P321, DOI 10.1016/0092-8674(87)90284-4; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; Vaingankar SM, 1998, J BIOL CHEM, V273, P5226, DOI 10.1074/jbc.273.9.5226; VANLINT J, 1995, J BIOL CHEM, V270, P1455, DOI 10.1074/jbc.270.3.1455; Wu GD, 1997, J BIOL CHEM, V272, P2396; XIAN WJ, 1995, CELL GROWTH DIFFER, V6, P1447; Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710	81	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15454	15465		10.1074/jbc.274.22.15454	http://dx.doi.org/10.1074/jbc.274.22.15454			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336436	hybrid			2022-12-25	WOS:000080560100025
J	Tanabe, K; Nakanish, H; Maeda, H; Nishioku, T; Hashimoto, K; Liou, SY; Akamine, A; Yamamoto, K				Tanabe, K; Nakanish, H; Maeda, H; Nishioku, T; Hashimoto, K; Liou, SY; Akamine, A; Yamamoto, K			A predominant apoptotic death pathway of neuronal PC12 cells induced by activated microglia is displaced by a non-apoptotic death pathway following blockage of caspase-3-dependent cascade	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; N-ACETYLCYSTEINE; CYTOCHROME-C; CATHEPSIN-D; CULTURED MICROGLIA; INTERFERON-GAMMA; BCL-2; INHIBITION; PROTEASES; RECEPTOR	Activated microglia have been implicated in the regulation of neuronal cell death, However, the biochemical mechanism for neuronal death triggered by activated microglia is still unclear, When treated with activated microglia, neuronal PC12 cells undergo apoptosis accompanied by caspase-3-like protease activation and DNA fragmentation, Apoptotic bodies formed were subsequently phagocytosed by neighboring activated microglia. Pretreatment of the cells with the caspase-3-like protease inhibitor N-acetyl-Asp-Glu-Val-Asp-aldehyde did not reverse this cell death. Although Bcl-2 overexpression in the cells caused the inhibition of caspase-3-like protease activity and DNA fragmentation and the effective interference of apoptosis induced by deprivation of trophic factors, it could not suppress the activated microglia-induced neuronal death, At the electron microscopic level, degenerating cells with high levels of Bcl-2 were characterized by slightly condensed chromatins forming irregular-shaped masses, severely disintegrated perikarya, and marked vacuolation. Various protease inhibitors tested did not inhibit this cell death, whereas the radical oxygen species scavenger N-acetyl-L-cysteine significantly suppressed this death. Altogether, our study provides an alternative death pathway for the activated microglia-induced neuronal death by blockage of the caspase-3 protease cascade.	Kyushu Univ, Fac Dent, Dept Pharmacol, Fukuoka 8128582, Japan; Kyushu Univ, Fac Dent, Dept Conservat Dent 2, Fukuoka 8128582, Japan; Nippon Glaxo Ltd, Tsukuba Res Labs, Tsukuba, Ibaraki 3004247, Japan	Kyushu University; Kyushu University; Eisai Co Ltd; GlaxoSmithKline	Yamamoto, K (corresponding author), Kyushu Univ, Fac Dent, Dept Pharmacol, Fukuoka 8128582, Japan.							ALBRECHT H, 1994, FEBS LETT, V351, P45, DOI 10.1016/0014-5793(94)00817-5; ALLSOPP TE, 1993, CELL, V73, P295, DOI 10.1016/0092-8674(93)90230-N; Atabay C, 1996, J NEUROSCI RES, V43, P465; BATISTATOU A, 1993, J NEUROSCI, V13, P4422; BETZCORRADIN S, 1993, GLIA, V7, P255; Bladier C, 1997, CELL GROWTH DIFFER, V8, P589; Borner C, 1996, J BIOL CHEM, V271, P12695, DOI 10.1074/jbc.271.22.12695; CHAO CC, 1995, J LEUKOCYTE BIOL, V58, P65, DOI 10.1002/jlb.58.1.65; Chen DF, 1997, NATURE, V385, P434, DOI 10.1038/385434a0; COLTON CA, 1994, ANN NY ACAD SCI, V738, P54; COSSARIZZA A, 1995, EXP CELL RES, V220, P232, DOI 10.1006/excr.1995.1311; Deiss LP, 1996, EMBO J, V15, P3861, DOI 10.1002/j.1460-2075.1996.tb00760.x; FERRARI G, 1995, J NEUROSCI, V15, P2857; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; Gardner AM, 1997, FREE RADICAL BIO MED, V22, P73, DOI 10.1016/S0891-5849(96)00235-3; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; Higuchi M, 1998, ONCOGENE, V17, P2753, DOI 10.1038/sj.onc.1202211; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Islam KN, 1997, FREE RADICAL BIO MED, V22, P1007, DOI 10.1016/S0891-5849(96)00493-5; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Lafon C, 1996, CELL GROWTH DIFFER, V7, P1095; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; McGeer PL, 1995, BRAIN RES REV, V21, P195, DOI 10.1016/0165-0173(95)00011-9; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; Nakanishi H, 1997, J NEUROCHEM, V68, P739; Navikas V, 1996, J NEUROSCI RES, V45, P322, DOI 10.1002/(SICI)1097-4547(19960815)45:4<322::AID-JNR1>3.0.CO;2-B; Nuovo GJ, 1996, MOL MED, V2, P358, DOI 10.1007/BF03401633; Offen D, 1998, P NATL ACAD SCI USA, V95, P5789, DOI 10.1073/pnas.95.10.5789; OReilly LA, 1996, EMBO J, V15, P6979, DOI 10.1002/j.1460-2075.1996.tb01090.x; PIETENPOL JA, 1994, CANCER RES, V54, P3714; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; SARIN A, 1993, J EXP MED, V178, P1693, DOI 10.1084/jem.178.5.1693; Sastradipura DF, 1998, J NEUROCHEM, V70, P2045; SEUBERT P, 1988, BRAIN RES, V460, P189, DOI 10.1016/0006-8993(88)91222-X; SEUBERT P, 1989, BRAIN RES, V492, P366, DOI 10.1016/0006-8993(89)90921-9; Shimizu S, 1996, ONCOGENE, V13, P21; SIMAN R, 1988, NEURON, V1, P279, DOI 10.1016/0896-6273(88)90076-1; SLATER AFG, 1995, BBA-MOL BASIS DIS, V1271, P59, DOI 10.1016/0925-4439(95)00010-2; SQUIER MKT, 1994, J CELL PHYSIOL, V159, P229, DOI 10.1002/jcp.1041590206; Stefanis L, 1996, J BIOL CHEM, V271, P30663, DOI 10.1074/jbc.271.48.30663; Takai N, 1998, J NEUROSCI RES, V54, P214, DOI 10.1002/(SICI)1097-4547(19981015)54:2<214::AID-JNR9>3.0.CO;2-H; Tanabe H, 1997, EUR J NEUROSCI, V9, P848, DOI 10.1111/j.1460-9568.1997.tb01434.x; Toyoshima F, 1997, J CELL BIOL, V139, P1005, DOI 10.1083/jcb.139.4.1005; Uhlmann EJ, 1996, CANCER RES, V56, P2506; Vairo G, 1996, ONCOGENE, V13, P1511; Vercammen D, 1998, J EXP MED, V188, P919, DOI 10.1084/jem.188.5.919; Vercammen D, 1998, J EXP MED, V187, P1477, DOI 10.1084/jem.187.9.1477; Wu GS, 1998, ONCOGENE, V16, P2177, DOI 10.1038/sj.onc.1201755; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; Zhang KZ, 1996, P NATL ACAD SCI USA, V93, P4504, DOI 10.1073/pnas.93.9.4504; ZHONG LT, 1993, P NATL ACAD SCI USA, V90, P4533, DOI 10.1073/pnas.90.10.4533; ZIELASEK J, 1992, CELL IMMUNOL, V141, P111, DOI 10.1016/0008-8749(92)90131-8	58	39	39	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15725	15731		10.1074/jbc.274.22.15725	http://dx.doi.org/10.1074/jbc.274.22.15725			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336472	hybrid			2022-12-25	WOS:000080560100061
J	Gonen, H; Bercovich, B; Orian, A; Carrano, A; Takizawa, C; Yamanaka, K; Pagano, M; Iwai, K; Ciechanover, A				Gonen, H; Bercovich, B; Orian, A; Carrano, A; Takizawa, C; Yamanaka, K; Pagano, M; Iwai, K; Ciechanover, A			Identification of the ubiquitin carrier proteins, E2s, involved in signal-induced conjugation and subsequent degradation of I kappa B alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE GENE; KINASE COMPLEX; PROTEASOME PATHWAY; SCAFFOLD PROTEIN; ENZYMES; PHOSPHORYLATION; ACTIVATION; YEAST; PROTEOLYSIS; LIGASE	The last step in the activation of the transcription factor NF-kappa B is signal-induced, ubiquitin- and proteasome-mediated degradation of the inhibitor I kappa B alpha. Although most of the components involved in the activation and degradation pathways have been identified, the ubiquitin carrier proteins (E2) have remained elusive. Here we show that the two highly homologous members of the UBCH5 family, UBCH5b and UBCH5c, and CDC34/UBC3, the mammalian homolog of yeast Cdc34/Ubc3, are the E2 enzymes involved in the process. The conjugation reaction they catalyze in vitro is specific, as they do not recognize the S32A,S36A mutant species of I kappa B alpha that cannot be phosphorylated and conjugated following an extracellular signal. Furthermore, the reaction is specifically inhibited by a doubly phosphorylated peptide that spans the ubiquitin ligase recognition domain of the inhibitor. Cys-to-Ala mutant species of the enzymes that cannot bind ubiquitin inhibit tumor necrosis factor a-induced degradation of the inhibitor in vivo. Not surprisingly, they have a similar effect in a cell-free system as well. Although it is clear that the E2 enzymes are not entirely specific to I kappa B alpha, they are also not involved in the conjugation and degradation of the bulk of cellular proteins, thus exhibiting some degree of specificity that is mediated probably via their association with a defined subset of ubiquitin-protein ligases. The mechanisms that underlie the involvement of two different E2 species in I kappa B alpha conjugation are not clear at present. It is possible that different conjugating machineries operate under different physiological conditions or in different cells.	Technion Israel Inst Technol, Fac Med, Dept Biochem, IL-31096 Haifa, Israel; Bruce Rappaport Fac Med, Dept Biochem, IL-31096 Haifa, Israel; Bruce Rappaport Fac Med, Rappaport Family Inst Res Med Sci, IL-31096 Haifa, Israel; NYU, Med Ctr, Dept Pathol, New York, NY 10016 USA; NYU, Med Ctr, Kaplan Comprehens Canc Ctr, New York, NY 10016 USA; Kyoto Univ, Grad Sch Med, Dept Immunol & Cell Biol, Sankyo Ku, Kyoto 6068501, Japan	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; New York University; New York University; Kyoto University	Ciechanover, A (corresponding author), Technion Israel Inst Technol, Fac Med, Dept Biochem, Efron St,Bat Galim,POB 9649, IL-31096 Haifa, Israel.		Yamanaka, Koji/ABD-1034-2020; Yamanaka, Koji/H-5806-2011; IWAI, KAZUHIRO/GSN-7385-2022; Ciechanover, Aaron J/C-9166-2017	Yamanaka, Koji/0000-0003-4655-0035; Yamanaka, Koji/0000-0003-4655-0035; Iwai, Kazuhiro/0000-0001-5620-5951; pagano, michele/0000-0003-3210-2442				Abu Hatoum O, 1998, MOL CELL BIOL, V18, P5670, DOI 10.1128/MCB.18.10.5670; ALKALAY I, 1995, P NATL ACAD SCI USA, V92, P10599, DOI 10.1073/pnas.92.23.10599; Aristarkhov A, 1996, P NATL ACAD SCI USA, V93, P4294, DOI 10.1073/pnas.93.9.4294; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; BLUMENFELD N, 1994, J BIOL CHEM, V269, P9574; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Cohen L, 1998, NATURE, V395, P292, DOI 10.1038/26254; Coux O, 1998, J BIOL CHEM, V273, P8820, DOI 10.1074/jbc.273.15.8820; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; Gonen H, 1996, J BIOL CHEM, V271, P302, DOI 10.1074/jbc.271.1.302; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; GROPPER R, 1991, J BIOL CHEM, V266, P3602; GUAN JL, 1984, CELL, V37, P779, DOI 10.1016/0092-8674(84)90413-6; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HERSHKO A, 1987, P NATL ACAD SCI USA, V84, P1829, DOI 10.1073/pnas.84.7.1829; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; IWAI K, 1995, EMBO J, V14, P5350, DOI 10.1002/j.1460-2075.1995.tb00219.x; Jensen JP, 1995, J BIOL CHEM, V270, P30408, DOI 10.1074/jbc.270.51.30408; KAISER P, 1994, J BIOL CHEM, V269, P8797; Kalchman MA, 1996, J BIOL CHEM, V271, P19385, DOI 10.1074/jbc.271.32.19385; Krek W, 1998, CURR OPIN GENET DEV, V8, P36, DOI 10.1016/S0959-437X(98)80059-2; Kumar S, 1997, J BIOL CHEM, V272, P13548, DOI 10.1074/jbc.272.21.13548; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Nuber U, 1996, J BIOL CHEM, V271, P2795, DOI 10.1074/jbc.271.5.2795; Patton EE, 1998, GENE DEV, V12, P692, DOI 10.1101/gad.12.5.692; Peters JM, 1998, CURR OPIN CELL BIOL, V10, P759, DOI 10.1016/S0955-0674(98)80119-1; PETERS JM, 1998, UBIQUITIN BIOL CELL, P1; PLON SE, 1993, P NATL ACAD SCI USA, V90, P10484, DOI 10.1073/pnas.90.22.10484; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; Song A, 1998, MOL CELL BIOL, V18, P4994, DOI 10.1128/MCB.18.9.4994; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; TABOR S, 1990, CURRENT PROTOCOLS MO; Tashiro K, 1997, P NATL ACAD SCI USA, V94, P7862, DOI 10.1073/pnas.94.15.7862; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Wing SS, 1996, MOL CELL BIOL, V16, P4064; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yaron A, 1997, EMBO J, V16, P6486, DOI 10.1093/emboj/16.21.6486; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159	50	97	104	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					14823	14830		10.1074/jbc.274.21.14823	http://dx.doi.org/10.1074/jbc.274.21.14823			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329681	hybrid			2022-12-25	WOS:000081965200046
J	Illana, B; Lazaro, JM; Gutierrez, C; Meijer, WJJ; Blanco, L; Salas, M				Illana, B; Lazaro, JM; Gutierrez, C; Meijer, WJJ; Blanco, L; Salas, M			Phage phi 29 terminal protein residues Asn(80) and Tyr(82) are recognition elements of the replication origins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRIMED DNA-REPLICATION; BACILLUS-SUBTILIS; BACTERIOPHAGE PHI-29; SECONDARY-STRUCTURE; INITIATION; INVITRO; PHAGE-PHI-29; COMPLEX; POLYMERASE; TEMPLATE	Initiation of phage phi 29 DNA replication starts with the recognition of the origin of replication, located at both ends of the linear DNA, by a heterodimer formed by the phi 29 terminal protein (TP) and the phi 29 DNA polymerase. The parental TP, covalently linked to the DNA ends, is one of the main components of the replication origin. Here we provide evidence that recognition of the origin is mediated through interactions between the TP of the TP/DNA polymerase heterodimer, called primer TP, and the parental TP, Based on amino acid sequence comparisons, various phi 29 TP mutants were generated at conserved amino acid residues from positions 61 to 87, In vitro phi 29 DNA amplification analysis revealed that residues Asn(80) and Tyr(82) are essential for functional interaction between primer and parental TP required for recognition of the origin of replication. Although these mutant TPs can form functional heterodimers with phi 29 DNA polymerase that are able to recognize the origin of replication, these heterodimers are not able to recognize an origin containing a mutant TP.	Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, Consejo Super Invest Cientif, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Salas, M (corresponding author), Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, Consejo Super Invest Cientif, E-28049 Madrid, Spain.	msalas@cbm.uam.es	Gutierrez, Crisanto/ABH-8782-2020; Salas, Margarita/J-9873-2014; Blanco, Luis/I-1848-2015	Salas, Margarita/0000-0001-5939-3441; Meijer, Wilfried/0000-0003-1842-0049; Gutierrez, Crisanto/0000-0001-8905-8222	NIGMS NIH HHS [5RO1 GM27242-19] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027242] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BJORNSTI MA, 1982, J VIROL, V41, P508, DOI 10.1128/JVI.41.2.508-517.1982; BLANCO L, 1987, J VIROL, V61, P3983, DOI 10.1128/JVI.61.12.3983-3991.1987; BLANCO L, 1984, P NATL ACAD SCI-BIOL, V81, P5325, DOI 10.1073/pnas.81.17.5325; BLANCO L, 1994, P NATL ACAD SCI USA, V91, P12198, DOI 10.1073/pnas.91.25.12198; BORDO D, 1991, J MOL BIOL, V217, P721, DOI 10.1016/0022-2836(91)90528-E; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DUNSWORTHBROWNE M, 1980, NUCLEIC ACIDS RES, V8, P543, DOI 10.1093/nar/8.3.543; GARCIA JA, 1984, P NATL ACAD SCI-BIOL, V81, P80, DOI 10.1073/pnas.81.1.80; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GRIMES S, 1989, J MOL BIOL, V209, P101, DOI 10.1016/0022-2836(89)90173-3; GUTIERREZ C, 1991, J MOL BIOL, V222, P983, DOI 10.1016/0022-2836(91)90589-X; GUTIERREZ C, 1994, EMBO J, V13, P269, DOI 10.1002/j.1460-2075.1994.tb06257.x; GUTIERREZ J, 1986, VIROLOGY, V155, P474, DOI 10.1016/0042-6822(86)90209-6; HAY RT, 1996, REPLICATION EUKARYOT, P699; HERMOSO JM, 1985, NUCLEIC ACIDS RES, V13, P7715, DOI 10.1093/nar/13.21.7715; HIROKAWA H, 1972, P NATL ACAD SCI USA, V69, P1555, DOI 10.1073/pnas.69.6.1555; INCIARTE MR, 1980, J VIROL, V34, P187, DOI 10.1128/JVI.34.1.187-199.1980; KORNBERG A, 1992, DNA REPLICATION, P103; Mendez J, 1997, EMBO J, V16, P2519, DOI 10.1093/emboj/16.9.2519; MENDEZ J, 1992, P NATL ACAD SCI USA, V89, P9579, DOI 10.1073/pnas.89.20.9579; PENALVA MA, 1982, P NATL ACAD SCI-BIOL, V79, P5522, DOI 10.1073/pnas.79.18.5522; PRONK R, 1992, CHROMOSOMA, V102, pS39, DOI 10.1007/BF02451784; RONDA C, 1983, J VIROL, V48, P721, DOI 10.1128/JVI.48.3.721-730.1983; SALAS M, 1991, ANNU REV BIOCHEM, V60, P39, DOI 10.1146/annurev.bi.60.070191.000351; SALAS M, 1978, J MOL BIOL, V119, P269, DOI 10.1016/0022-2836(78)90438-2; SALAS M, 1996, REPLICATION EUKARYOT, P131; SALAS M, 1983, MECHANISMS DNA REPLI, P203; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAACK J, 1990, GENE DEV, V4, P1197, DOI 10.1101/gad.4.7.1197; SERRANO M, 1990, SCIENCE, V248, P1012, DOI 10.1126/science.2111580; SOGO JM, 1989, METHOD ENZYMOL, V170, P142; SOGO JM, 1982, VIROLOGY, V116, P1, DOI 10.1016/0042-6822(82)90398-1; SOGO JM, 1987, ELECTRON MICROS, P61; VANDERVLIET PC, 1996, REPLICATION EUKARYOT, P87; VLCEK C, 1986, GENE, V46, P215, DOI 10.1016/0378-1119(86)90406-3; ZABALLOS A, 1989, GENE, V83, P187, DOI 10.1016/0378-1119(89)90104-2; ZABALLOS A, 1987, GENE, V58, P67, DOI 10.1016/0378-1119(87)90030-8	38	11	11	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					15073	15079		10.1074/jbc.274.21.15073	http://dx.doi.org/10.1074/jbc.274.21.15073			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329712	hybrid			2022-12-25	WOS:000081965200077
J	Inohara, N; Koseki, T; del Peso, L; Hu, YM; Yee, C; Chen, S; Carrio, R; Merino, J; Liu, D; Ni, J; Nunez, G				Inohara, N; Koseki, T; del Peso, L; Hu, YM; Yee, C; Chen, S; Carrio, R; Merino, J; Liu, D; Ni, J; Nunez, G			Nod1, an Apaf-1-like activator of caspase-9 and nuclear factor-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE-RICH REPEATS; CELL-DEATH; CYTOCHROME-C; DISEASE RESISTANCE; CED-3 ACTIVATION; PROTEIN-KINASE; APOPTOSIS; RECEPTOR; COMPLEX; FAMILY	Ced-4 and Apaf-1 belong to a major class of apoptosis regulators that contain caspase-recruitment (CARD) and nucleotide-binding oligomerization domains. Nod1, a protein with an NH2-terminal CARD-linked to a nucleotide-binding domain and a COOH-terminal segment with multiple leucine-rich repeats, was identified. Nod-1 was found to bind to multiple caspases with long prodomains, but specifically activated caspase-9 and promoted caspase-9-induced apoptosis. As reported for Apaf-1, Nod1 required both the CARD and P-loop for function. Unlike Apaf-1, Nod1 induced activation of nuclear factor-kappa-B (NF-kappa B) and bound RICK, a CARD-containing kinase that also induces NF-KB activation. Nod1 mutants inhibited NF-KB activity induced by RICK, but not that resulting from tumor necrosis factor-cu stimulation. Thus, Nod1 is a leucine-rich repeat-containing Apaf-1-like molecule that can regulate both apoptosis and NF-kappa B activation pathways.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; Univ Cantabria, Dept Biol Mol, Unidad Inmunol, Santander 39011, Spain; Human Genome Sci, Rockville, MD 20850 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Universidad de Cantabria; GlaxoSmithKline; Human Genome Sciences Inc	Nunez, G (corresponding author), Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA.		del Peso, Luis/K-9391-2014; Nuñez, Gabriel/A-7160-2014	del Peso, Luis/0000-0003-4014-5688; Carrio, Roberto/0000-0001-5527-8403	NCI NIH HHS [K04 CA64421, R01 CA64556] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064556, K04CA064421] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Bodmer JL, 1997, IMMUNITY, V6, P79, DOI 10.1016/S1074-7613(00)80244-7; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Chaudhary D, 1998, J BIOL CHEM, V273, P17708, DOI 10.1074/jbc.273.28.17708; Chin KC, 1997, P NATL ACAD SCI USA, V94, P2501, DOI 10.1073/pnas.94.6.2501; Chinnaiyan AM, 1997, NATURE, V388, P728, DOI 10.1038/41913; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; Chou JJ, 1998, CELL, V94, P171, DOI 10.1016/S0092-8674(00)81417-8; del Peso L, 1998, J BIOL CHEM, V273, P33495, DOI 10.1074/jbc.273.50.33495; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hu YM, 1998, J BIOL CHEM, V273, P33489, DOI 10.1074/jbc.273.50.33489; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Inohara N, 1997, P NATL ACAD SCI USA, V94, P10717, DOI 10.1073/pnas.94.20.10717; Inohara N, 1998, J BIOL CHEM, V273, P8705, DOI 10.1074/jbc.273.15.8705; Inohara N, 1998, J BIOL CHEM, V273, P12296, DOI 10.1074/jbc.273.20.12296; Inohara N, 1998, J BIOL CHEM, V273, P32479, DOI 10.1074/jbc.273.49.32479; Inohara N, 1998, EMBO J, V17, P2526, DOI 10.1093/emboj/17.9.2526; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; KOBE B, 1995, CURR OPIN STRUC BIOL, V5, P409, DOI 10.1016/0959-440X(95)80105-7; Koseki T, 1998, P NATL ACAD SCI USA, V95, P5156, DOI 10.1073/pnas.95.9.5156; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; McCarthy JV, 1998, J BIOL CHEM, V273, P16968, DOI 10.1074/jbc.273.27.16968; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P12740, DOI 10.1073/pnas.91.26.12740; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; OPIPARI AW, 1990, J BIOL CHEM, V265, P14705; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Parniske M, 1997, CELL, V91, P821, DOI 10.1016/S0092-8674(00)80470-5; Peter ME, 1997, P NATL ACAD SCI USA, V94, P12736, DOI 10.1073/pnas.94.24.12736; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; SAKSELA K, 1993, MOL CELL BIOL, V13, P3698, DOI 10.1128/MCB.13.6.3698; Spector MS, 1997, NATURE, V385, P653, DOI 10.1038/385653a0; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; STASKAWICZ BJ, 1995, SCIENCE, V268, P661, DOI 10.1126/science.7732374; Thome M, 1998, CURR BIOL, V8, P885, DOI 10.1016/S0960-9822(07)00352-1; van der Biezen EA, 1998, CURR BIOL, V8, pR226, DOI 10.1016/S0960-9822(98)70145-9; Verma IM, 1997, P NATL ACAD SCI USA, V94, P11758, DOI 10.1073/pnas.94.22.11758; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Wu DY, 1997, J BIOL CHEM, V272, P21449, DOI 10.1074/jbc.272.34.21449; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239; Yang XL, 1998, SCIENCE, V281, P1355, DOI 10.1126/science.281.5381.1355; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	55	595	639	2	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					14560	14567		10.1074/jbc.274.21.14560	http://dx.doi.org/10.1074/jbc.274.21.14560			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329646	hybrid			2022-12-25	WOS:000081965200011
J	Loden, M; Nielsen, NH; Roos, G; Emdin, SO; Landberg, G				Loden, M; Nielsen, NH; Roos, G; Emdin, SO; Landberg, G			Cyclin E dependent kinase activity in human breast cancer in relation to cyclin E, p27 and p21 expression and retinoblastoma protein phosphorylation	ONCOGENE			English	Article						breast cancer; cyclin E; p27; p21; retinoblastoma protein; kinase activity	UBIQUITIN-PROTEASOME PATHWAY; CELL-CYCLE; INHIBITOR P27; P53 PROTEIN; FUNCTIONAL INACTIVATION; E OVEREXPRESSION; ABNORMAL P53; MICE LACKING; G(1) CYCLINS; P27(KIP1)	The cell cycle machinery is regulated by cyclin dependent kinases and sets of activating and inhibitory proteins, The G1-S control mechanism is often deregulated in tumours supposedly leading to increased kinase activity, phosphorylation of substrates and subsequent S phase entrance. Increased kinase activity has been proposed to be essential in cell cycle aberrations, but few studies have actually shown enhanced kinase activity related to specific cell cycle defects in primary tumours, In the present study we have determined the cyclin E dependent kinase activity (cyclin E-kinase) in 59 primary breast cancers, using an H1-kinase assay, and related the activity to the expression of cyclin E, p27 and p21, In a subgroup of 48 tumours, we further characterized the association between cyclin E-kinase, in vivo phosphorylation of the retinoblastoma protein (pRb) and proliferation. The cyclin E-kinase correlated significantly with cyclin E content and inversely with p27 and p21 expression. P27, but not p21, was associated with low cyclin E-kinase in specimens with normal/low levels of cyclin E, At elevated cyclin E levels, suppression of cyclin E-kinase seemed to require high levels of both p21 and p27, The cyclin E-kinase correlated with the phosphorylation status of pRb as well as with proliferation. Surprisingly, pRb phosphorylation did not correlate with proliferation. Our results support that pRb is a substrate for cyclin E-kinase in primary breast cancer and that deregulation of cyclin E and p27 act through increased CDK-kinase activity, but cyclin E associated events beside pRb phosphorylation might be rate-limiting for entrance into S phase.	Umea Univ, Dept Pathol, S-90187 Umea, Sweden; Umea Univ, Dept Surg, S-90187 Umea, Sweden; Umea Univ, Dept Oncol, S-90187 Umea, Sweden	Umea University; Umea University; Umea University	Landberg, G (corresponding author), Umea Univ, Dept Pathol, S-90187 Umea, Sweden.							Bartek J, 1997, EXP CELL RES, V237, P1, DOI 10.1006/excr.1997.3776; Bukholm IK, 1997, J PATHOL, V181, P140, DOI 10.1002/(SICI)1096-9896(199702)181:2<140::AID-PATH745>3.0.CO;2-A; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; Ellis PA, 1997, BRIT J CANCER, V76, P480, DOI 10.1038/bjc.1997.413; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Ferrando AA, 1996, HUM GENET, V97, P91; Fredersdorf S, 1997, P NATL ACAD SCI USA, V94, P6380, DOI 10.1073/pnas.94.12.6380; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Jiang M, 1997, INT J CANCER, V74, P529, DOI 10.1002/(SICI)1097-0215(19971021)74:5<529::AID-IJC9>3.0.CO;2-5; KEYOMARSI K, 1995, ONCOGENE, V11, P941; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Landberg G, 1997, APMIS, V105, P575, DOI 10.1111/j.1699-0463.1997.tb05056.x; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; LUKAS J, 1995, CANCER RES, V55, P4818; Lukas J, 1997, AM J PATHOL, V150, P167; LUKAS J, 1997, GENE DEV, V11, P1492; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; MOUSSES S, 1995, HUM MOL GENET, V4, P1089, DOI 10.1093/hmg/4.6.1089; Nevins JR, 1997, J CELL PHYSIOL, V173, P233, DOI 10.1002/(SICI)1097-4652(199711)173:2<233::AID-JCP27>3.0.CO;2-F; Nielsen NH, 1996, BRIT J CANCER, V74, P874, DOI 10.1038/bjc.1996.451; Nielsen NH, 1997, ONCOGENE, V14, P295, DOI 10.1038/sj.onc.1200833; NIELSEN NH, 1999, IN PRESS BREAST CANC; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; Sgambato A, 1996, CANCER RES, V56, P1389; Sgambato A, 1997, CELL GROWTH DIFFER, V8, P393; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Spataro V, 1998, BRIT J CANCER, V77, P448, DOI 10.1038/bjc.1998.71; Tan P, 1997, CANCER RES, V57, P1259; Wakasugi E, 1997, AM J CLIN PATHOL, V107, P684; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Yasui W, 1996, VIRCHOWS ARCH, V429, P13; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; Zhao JY, 1998, GENE DEV, V12, P456, DOI 10.1101/gad.12.4.456	48	47	48	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 22	1999	18	16					2557	2566		10.1038/sj.onc.1202488	http://dx.doi.org/10.1038/sj.onc.1202488			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	189LU	10353599				2022-12-25	WOS:000079907100003
J	Nath, A; Conant, K; Chen, PQ; Scott, C; Major, EO				Nath, A; Conant, K; Chen, PQ; Scott, C; Major, EO			Transient exposure to HIV-1 Tat protein results in cytokine production in macrophages and astrocytes - A hit and run phenomenon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TUMOR-NECROSIS-FACTOR; FACTOR-ALPHA; GENE-EXPRESSION; GLIAL-CELLS; T-CELLS; INDUCTION; DISEASE; INTERLEUKIN-6; DEMENTIA	The pathological correlates of dementia due to human immunodeficiency virus (HIV) infection are glial cell activation and cytokine dysregulation, These findings occur in the setting of small numbers of productively infected cells within the brain. We determined whether exposure of susceptible cells to Tat protein of HIV could result in the production of select proinflammatory cytokines. In a dose-responsive manner, Tat induced interleukin (IL)-1 beta production in monocytic cells, while astrocytic cells showed an increase in mRNA for IL-1 beta, but had a translation block for IL-1 beta protein production. Conversely, IL-6 protein and mRNA productions were strongly induced in astrocytic cells and minimally in monocytic cells. IL-IP and IL-6 production were independent of tumor necrosis factor-alpha production. An exposure to Tat for a few minutes was sufficient for sustained releases of cytokines for several hours. This prolonged cytokine production is likely maintained by a positive feed back loop of Tat-induced nuclear factor kappa B activation and cytokine production that is independent of extracellular calcium. Thus a transient exposure may be sufficient to initiate a cascade of events resulting in cerebral dysfunction and a "hit and run" approach may be in effect. Hence cross-sectional measurement of viral load in the brain may not be a useful indicator of the role of viral products in the neuropathogenesis of HIV dementia.	Univ Kentucky, Dept Neurol, Kentucky Clin, Lexington, KY 40536 USA; Univ Kentucky, Dept Microbiol, Lexington, KY 40536 USA; Univ Kentucky, Dept Immunol, Lexington, KY 40536 USA; NINDS, Lab Mol Med & Neurosci, NIH, Bethesda, MD 20892 USA; Univ Manitoba, Dept Med Microbiol, Winnipeg, MB R3E OW3, Canada	University of Kentucky; University of Kentucky; University of Kentucky; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); University of Manitoba	Nath, A (corresponding author), Univ Kentucky, Dept Neurol, Kentucky Clin, Rm L-445, Lexington, KY 40536 USA.							AKIRA S, 1992, IMMUNOL REV, V313, P47; BENVENISTE EN, 1990, J NEUROIMMUNOL, V30, P201, DOI 10.1016/0165-5728(90)90104-U; CAMPBELL IL, 1993, P NATL ACAD SCI USA, V90, P10061, DOI 10.1073/pnas.90.21.10061; Chang HC, 1997, AIDS, V11, P1421, DOI 10.1097/00002030-199712000-00006; Chen PQ, 1997, J BIOL CHEM, V272, P22385, DOI 10.1074/jbc.272.36.22385; Cheng J, 1998, NEUROSCIENCE, V82, P97, DOI 10.1016/S0306-4522(97)00174-7; Conant K, 1996, J VIROL, V70, P1384, DOI 10.1128/JVI.70.3.1384-1389.1996; Conant K, 1998, P NATL ACAD SCI USA, V95, P3117, DOI 10.1073/pnas.95.6.3117; DACUNHA A, 1993, BRAIN RES, V631, P39, DOI 10.1016/0006-8993(93)91183-S; DINARELLO CA, 1987, IMMUNOL LETT, V16, P227, DOI 10.1016/0165-2478(87)90151-9; Dollard SC, 1995, NEUROPATH APPL NEURO, V21, P518, DOI 10.1111/j.1365-2990.1995.tb01098.x; ENSOLI B, 1993, J VIROL, V67, P277, DOI 10.1128/JVI.67.1.277-287.1993; FURER M, 1993, CELL ADHES COMMUN, V1, P223, DOI 10.3109/15419069309097256; GENIS P, 1992, J EXP MED, V176, P1703, DOI 10.1084/jem.176.6.1703; GLASS JD, 1993, NEUROLOGY, V43, P2230, DOI 10.1212/WNL.43.11.2230; Haughey N. J., 1998, Journal of Neurovirology, V4, P353; HOFMAN FM, 1994, J NEUROIMMUNOL, V54, P19, DOI 10.1016/0165-5728(94)90226-7; Hull M, 1996, NEUROBIOL AGING, V17, P795; Johnson RT, 1996, ANN NEUROL, V39, P392, DOI 10.1002/ana.410390319; Jones M, 1998, J NEUROPATH EXP NEUR, V57, P563, DOI 10.1097/00005072-199806000-00004; Lafrenie RM, 1997, J IMMUNOL, V159, P4077; LEE SC, 1993, J NEUROIMMUNOL, V46, P19, DOI 10.1016/0165-5728(93)90229-R; LOWENTHAL JW, 1989, P NATL ACAD SCI USA, V86, P2331, DOI 10.1073/pnas.86.7.2331; Ma MH, 1997, J VIROL, V71, P2495, DOI 10.1128/JVI.71.3.2495-2499.1997; MAGNUSON DSK, 1995, ANN NEUROL, V37, P373, DOI 10.1002/ana.410370314; MERRILL JE, 1991, FASEB J, V5, P2391, DOI 10.1096/fasebj.5.10.2065887; Nath A, 1998, PROG NEUROBIOL, V54, P19, DOI 10.1016/S0301-0082(97)00053-1; Navia BA, 1998, NEUROLOGY, V51, P221, DOI 10.1212/WNL.51.1.221; New DR, 1998, J BIOL CHEM, V273, P17852, DOI 10.1074/jbc.273.28.17852; NORRIS JG, 1994, J IMMUNOL, V152, P841; NUMEROF RP, 1990, CELL IMMUNOL, V130, P118, DOI 10.1016/0008-8749(90)90166-O; PHILIPPON V, 1994, VIROLOGY, V205, P519, DOI 10.1006/viro.1994.1673; POLI G, 1992, PATHOBIOLOGY, V60, P246, DOI 10.1159/000163729; RAUTONEN N, 1994, AIDS, V8, P1504, DOI 10.1097/00002030-199410000-00023; TARDIEU M, 1992, ANN NEUROL, V32, P11, DOI 10.1002/ana.410320104; VITKOVIC L, 1991, AIDS RES HUM RETROV, V7, P723, DOI 10.1089/aid.1991.7.723; WESSELINGH SL, 1993, ANN NEUROL, V33, P576, DOI 10.1002/ana.410330604; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; Wiley CA, 1996, AIDS, V10, P943; YAMAMURA M, 1991, SCIENCE, V254, P277, DOI 10.1126/science.1925582	40	296	305	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17098	17102		10.1074/jbc.274.24.17098	http://dx.doi.org/10.1074/jbc.274.24.17098			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358063	hybrid			2022-12-25	WOS:000080780400062
J	Ardehali, H; Printz, RL; Whitesell, RR; May, JM; Granner, DK				Ardehali, H; Printz, RL; Whitesell, RR; May, JM; Granner, DK			Functional interaction between the N- and C-terminal halves of human hexokinase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BRAIN HEXOKINASE; DEPENDENT DIABETES-MELLITUS; RATE-LIMITING STEP; GLUCOSE-TRANSPORT; SKELETAL-MUSCLE; MAMMALIAN HEXOKINASES; CRYSTAL-STRUCTURE; REGULATORY SITE; BINDING-SITE; INSULIN	Mammalian hexokinases (HKs) I-III are composed of two highly homologous similar to 50-kDa halves. Studies of HKI indicate that the C-terminal half of the molecule is active and is sensitive to inhibition by glucose B-phosphate (G6P), whereas the N-terminal half binds G6P but is devoid of catalytic activity. In contrast, both the N- and C-terminal halves of HKII (N-HKII and C-HKII, respectively) are catalytically active, and when expressed as discrete proteins both are inhibited by G6P, However, C-HKII has a significantly higher K-i for G6P (K-iG6P) than N-HKII. We here address the question of whether the high K-iG6P of the C-terminal half (C-half) of HKII is decreased by interaction with the N-terminal half (N-half) in the context of the intact enzyme. A chimeric protein consisting of the N-half of HKI and the C-half of HKII was prepared. Because the N-half of HKI is unable to phosphorylate glucose, the catalytic activity of this chimeric enzyme depends entirely on the C-HKII component. The K-iG6P of this chimeric enzyme is similar to that of HKI and is significantly lower than that of C-HKII. When a conserved amino acid (Asp(209)) required for glucose binding is mutated in the N-half of this chimeric protein, a significantly higher K-iG6P (similar to that of C-HKII) is observed. However, mutation of a second conserved amino acid (Ser(155)), also involved in catalysis but not required for glucose binding, does not increase the K-iG6P of the chimeric enzyme. This resembles the behavior of HKII, in which a D209A mutation results in an increase in the K-iG6P of the enzyme, whereas a S155A mutation does not. These results suggest an interaction in which glucose binding by the N-half causes the activity of the C-half to be regulated by significantly lower concentrations of G6P.	Vanderbilt Univ, Dept Mol Physiol & Biophys, Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Med, Sch Med, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Granner, DK (corresponding author), Vanderbilt Univ, Dept Mol Physiol & Biophys, Sch Med, 707 Light Hall, Nashville, TN 37232 USA.				NIDDK NIH HHS [DK20593, DK46867] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK020593, R01DK046867, P60DK020593] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aleshin AE, 1998, FEBS LETT, V434, P42, DOI 10.1016/S0014-5793(98)00952-1; Aleshin AE, 1998, J MOL BIOL, V282, P345, DOI 10.1006/jmbi.1998.2017; Aleshin AE, 1998, STRUCTURE, V6, P39, DOI 10.1016/S0969-2126(98)00006-9; ANDERSON CM, 1978, J MOL BIOL, V123, P207, DOI 10.1016/0022-2836(78)90321-2; ANDERSON CM, 1978, J MOL BIOL, V123, P15, DOI 10.1016/0022-2836(78)90374-1; Ardehali H, 1996, J BIOL CHEM, V271, P1849, DOI 10.1074/jbc.271.4.1849; ARORA KK, 1993, J BIOL CHEM, V268, P18259; ARORA KK, 1991, J BIOL CHEM, V266, P5359; BAIJAL M, 1992, ARCH BIOCHEM BIOPHYS, V298, P271, DOI 10.1016/0003-9861(92)90123-E; Baque S, 1998, DIABETES, V47, P1392, DOI 10.2337/diabetes.47.9.1392; BEECHEM JM, 1992, METHOD ENZYMOL, V210, P37; BEECHEM JM, 1985, ANNU REV BIOCHEM, V54, P43, DOI 10.1146/annurev.biochem.54.1.43; Beechem JM., 2002, TOPICS FLUORESCENCE, P241, DOI DOI 10.1007/0-306-47058-6_5; BENNETT WS, 1980, J MOL BIOL, V140, P211, DOI 10.1016/0022-2836(80)90103-5; Bonadonna RC, 1996, DIABETES, V45, P915, DOI 10.2337/diabetes.45.7.915; CROFFORD OB, 1965, J BIOL CHEM, V240, P3237; CROFFORD OB, 1965, J BIOL CHEM, V240, P14; Fang TY, 1998, J BIOL CHEM, V273, P19548, DOI 10.1074/jbc.273.31.19548; GARFINKEL D, 1984, AM J PHYSIOL, V247, pR527, DOI 10.1152/ajpregu.1984.247.3.R527; GROSSBARD L, 1966, J BIOL CHEM, V241, P3546; KASHIWAYA Y, 1994, J BIOL CHEM, V269, P25502; KATZ A, 1988, AM J PHYSIOL, V255, pE942, DOI 10.1152/ajpendo.1988.255.6.E942; Kelley DE, 1996, J CLIN INVEST, V97, P2705, DOI 10.1172/JCI118724; KIPNIS DM, 1959, J BIOL CHEM, V234, P165; Kruszynska YT, 1998, DIABETES, V47, P1107, DOI 10.2337/diabetes.47.7.1107; KUBO K, 1986, AM J PHYSIOL, V250, pE100, DOI 10.1152/ajpendo.1986.250.1.E100; LANGE AJ, 1991, BIOCHEM J, V277, P159, DOI 10.1042/bj2770159; MEHTA A, 1988, J BIOL CHEM, V263, P15492; MORGAN HE, 1961, J BIOL CHEM, V236, P253; Mulichak AM, 1998, NAT STRUCT BIOL, V5, P555, DOI 10.1038/811; PRINTZ RL, 1993, J BIOL CHEM, V268, P5209; ROTHMAN DL, 1995, P NATL ACAD SCI USA, V92, P983, DOI 10.1073/pnas.92.4.983; STEITZ TA, 1977, J BIOL CHEM, V252, P4494; Tsai HJ, 1996, ARCH BIOCHEM BIOPHYS, V329, P17, DOI 10.1006/abbi.1996.0186; WHITE TK, 1989, ARCH BIOCHEM BIOPHYS, V274, P375, DOI 10.1016/0003-9861(89)90451-7; WHITE TK, 1987, ARCH BIOCHEM BIOPHYS, V259, P402, DOI 10.1016/0003-9861(87)90506-6; WHITESELL RR, 1995, J CEREBR BLOOD F MET, V15, P814, DOI 10.1038/jcbfm.1995.102; WHITESELL RR, 1993, J CELL PHYSIOL, V157, P509, DOI 10.1002/jcp.1041570310; WILSON JE, 1995, REV PHYSIOL BIOCH P, V126, P65, DOI 10.1007/BFb0049776	39	26	27	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					15986	15989		10.1074/jbc.274.23.15986	http://dx.doi.org/10.1074/jbc.274.23.15986			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347146	hybrid			2022-12-25	WOS:000080668600006
J	Lopez-Coronado, JM; Belles, JM; Lesage, F; Serrano, R; Rodriguez, PL				Lopez-Coronado, JM; Belles, JM; Lesage, F; Serrano, R; Rodriguez, PL			A novel mammalian lithium-sensitive enzyme with a dual enzymatic activity, 3 '-phosphoadenosine 5 '-phosphate phosphatase and inositol-polyphosphate 1-phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3'(2'),5'-BISPHOSPHATE NUCLEOTIDASE; SALT TOLERANCE; YEAST; GENE; SULFOTRANSFERASE; INHIBITION; TOXICITY; FAMILY; PAPS	We report the molecular cloning in Rattus norvegicus of a novel mammalian enzyme (RnPIP), which shows both 3'-phosphoadenosine 5'-phosphate (PAP) phosphatase and inositol-polyphosphate l-phosphatase activities. This enzyme is the first PAP phosphatase characterized at the molecular level in mammals, and it represents the first member of a novel family of dual specificity enzymes. The phosphatase activity is strictly dependent on Mg2+, and it is inhibited by Ca2+ and Li+ ions. Lithium chloride inhibits the hydrolysis of both PAP and inositol-1,4-bisphosphate at submillimolar concentration; therefore, it is possible that the inhibition of the human homologue of RnPIP by lithium ions is related to the pharmacological action of lithium. We propose that the PAP phosphatase activity of RnPIP is crucial for the function of enzymes sensitive to inhibition by PAP, such as sulfotransferase and RNA processing enzymes. Finally, an unexpected connection between PAP and inositol-1,4-bisphosphate metabolism emerges from this work.	Univ Politecn Valencia, CSIC, Inst Biol Mol & Celular Plantas, E-46022 Valencia, Spain; Inst Pharmacol Mol & Cellulaire, CNRS, UPR 411, F-06560 Valbonne, France	Consejo Superior de Investigaciones Cientificas (CSIC); Universitat Politecnica de Valencia; CSIC-UPV - Instituto de Biologia Molecular y Celular de Plantas (IBMCP); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Rodriguez, PL (corresponding author), Univ Politecn Valencia, CSIC, Inst Biol Mol & Celular Plantas, E-46022 Valencia, Spain.		Bellés, José María/H-4734-2015; Lesage, Florian/D-5097-2011; Lesage, Florian/P-9780-2019; Rodriguez, Pedro L./K-4605-2014	Bellés, José María/0000-0003-0362-9616; Lesage, Florian/0000-0002-4406-7106; Lesage, Florian/0000-0002-4406-7106; Rodriguez, Pedro L./0000-0002-5886-9425				BAYKOV AA, 1988, ANAL BIOCHEM, V171, P266, DOI 10.1016/0003-2697(88)90484-8; BRUNNGRABER EG, 1958, J BIOL CHEM, V233, P472; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Dichtl B, 1997, EMBO J, V16, P7184, DOI 10.1093/emboj/16.23.7184; GLASER HU, 1993, EMBO J, V12, P3105, DOI 10.1002/j.1460-2075.1993.tb05979.x; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HALLCHER LM, 1980, J BIOL CHEM, V255, P896; Jenkinson S, 1995, Methods Mol Biol, V41, P151; Klaassen CD, 1997, FASEB J, V11, P404, DOI 10.1096/fasebj.11.6.9194521; Kurima K, 1998, P NATL ACAD SCI USA, V95, P8681, DOI 10.1073/pnas.95.15.8681; LESAGE F, 1994, NUCLEIC ACIDS RES, V22, P3685, DOI 10.1093/nar/22.18.3685; MAJERUS PW, 1992, ANNU REV BIOCHEM, V61, P225, DOI 10.1146/annurev.bi.61.070192.001301; MARCUS F, 1980, J BIOL CHEM, V255, P2481; MURGUIA JR, 1995, SCIENCE, V267, P232; Murguia JR, 1996, J BIOL CHEM, V271, P29029, DOI 10.1074/jbc.271.46.29029; Quintero FJ, 1996, PLANT CELL, V8, P529, DOI 10.1105/tpc.8.3.529; RAMASWAMY SG, 1987, J BIOL CHEM, V262, P10044; RENSDOMIANO SS, 1987, J NEUROCHEM, V48, P1411, DOI 10.1111/j.1471-4159.1987.tb05679.x; Roth J. A., 1982, SULFATE METABOLISM S, P107; SCHWENN JD, 1988, ARCH MICROBIOL, V150, P313, DOI 10.1007/BF00408300; Thomas W., 1992, Human Molecular Genetics, V1, P138, DOI 10.1093/hmg/1.2.138-a; Weinshilboum RM, 1997, FASEB J, V11, P3, DOI 10.1096/fasebj.11.1.9034160; YORK JD, 1995, P NATL ACAD SCI USA, V92, P5149, DOI 10.1073/pnas.92.11.5149	23	56	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16034	16039		10.1074/jbc.274.23.16034	http://dx.doi.org/10.1074/jbc.274.23.16034			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347153	hybrid			2022-12-25	WOS:000080668600013
J	Sawant, SG; Gregoire, V; Dhar, S; Umbricht, CB; Cvilic, S; Sukumar, S; Pandita, TK				Sawant, SG; Gregoire, V; Dhar, S; Umbricht, CB; Cvilic, S; Sukumar, S; Pandita, TK			Telomerase activity as a measure for monitoring radiocurability of tumor cells	FASEB JOURNAL			English	Article						cell kill; ionizing radiation; tumor growth	LIFE-SPAN; CANCER; MARKER; IMMORTALITY	Radiotherapy plays a key role in the treatment of many tumors. It is difficult to determine what fraction of tumor cells survives after treatment with ionizing radiation. A convenient and sensitive biochemical assay could be efficacious in determining the potential success of radiotherapy. Since telomerase activity is frequently associated with the malignant phenotype, we sought to determine whether a correlation existed between ionizing radiation-induced cell killing and telomerase activity. We evaluated telomerase activity in two telomerase-positive and one telomerase-negative human cell line exposed to ionizing radiation. Telomerase activity was determined using a PCR-based telomeric repeat amplification protocol coupled with ELISA We found ionizing radiation treatment to decrease the telomerase activity (in plateau phase cells of RKO, HeLa; and growing cells of RKO) in a dose-dependent manner, which correlated with cell death in in vitro tests as well as during tumor regression in nude mice. In contrast, growing HeLa cells after 24 h postradiation treatment showed an increase in telomerase activity, but there was no increase in the levels of mRNA of hTERT. To assess the sensitivity of the telomerase activity assay, we performed mixing experiments of HeLa and AG1522 cell. extracts. These studies showed that telomerase activity could be detected in lysate equal to a single HeLa cell when mixed with 10,000 AG1522 cells. Our results indicate that even a few surviving neoplastic cells can be detected by telomerase activity assay. Therefore, detection of telomerase activity may be a useful monitor of radiotherapeutic efficacy and an early predictor of outcome.	Columbia Univ, Coll Phys & Surg VC11 213, Ctr Radiol Res, New York, NY 10032 USA; St Luc Univ Hosp, Dept Radiat Oncol, Brussels, Belgium; Johns Hopkins Oncol Ctr, Baltimore, MD 21205 USA	Columbia University; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Johns Hopkins University; Johns Hopkins Medicine	Pandita, TK (corresponding author), Columbia Univ, Coll Phys & Surg VC11 213, Ctr Radiol Res, 630 W 168th St, New York, NY 10032 USA.		Pandita, Tej K/AAM-9188-2020		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034746] Funding Source: NIH RePORTER; NINDS NIH HHS [NS34746] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; Blackburn EH, 1995, TELOMERES; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Brandt-Rauf PW, 1998, PHARMACOL THERAPEUT, V77, P135, DOI 10.1016/S0163-7258(97)00111-3; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; FRANKENBERGSCHWAGER M, 1990, RADIAT ENVIRON BIOPH, V29, P273, DOI 10.1007/BF01210408; HARLEY CB, 1994, COLD SPRING HARB SYM, V59, P307, DOI 10.1101/SQB.1994.059.01.035; Hiyama E, 1996, INT J ONCOL, V9, P453; HIYAMA K, 1995, J IMMUNOL, V155, P3711; Holt SE, 1996, MOL CELL BIOL, V16, P2932; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Lee DH, 1998, CLIN CANCER RES, V4, P535; Meeker AK, 1997, BIOCHEMISTRY-MOSCOW+, V62, P1323; MEYERSON M, 1997, CELL, V90, P85; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; MOYZIS RK, 1988, P NATL ACAD SCI USA, V85, P6622, DOI 10.1073/pnas.85.18.6622; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Ohyashiki K, 1997, CANCER RES, V57, P2100; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; Pandita TK, 1996, RADIAT RES, V145, P730, DOI 10.2307/3579364; Pandita TK, 1996, ONCOGENE, V13, P1423; Ramirez RD, 1997, J INVEST DERMATOL, V108, P113, DOI 10.1111/1523-1747.ep12285654; Scates DK, 1997, BRIT J UROL, V80, P263, DOI 10.1046/j.1464-410X.1997.00248.x; Shay JW, 1997, J CLIN PATHOL, V50, P106, DOI 10.1136/jcp.50.2.106; Sidransky D, 1997, SCIENCE, V278, P1054, DOI 10.1126/science.278.5340.1054; Smilenov LB, 1998, ONCOGENE, V17, P2137, DOI 10.1038/sj.onc.1202138; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; WATSON JD, 1992, NAT, V239, P197; WILLEY JC, 1991, CANCER RES, V51, P5370; Wisman GBA, 1998, J CLIN ONCOL, V16, P2238, DOI 10.1200/JCO.1998.16.6.2238	30	40	52	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	1999	13	9					1047	1054		10.1096/fasebj.13.9.1047	http://dx.doi.org/10.1096/fasebj.13.9.1047			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	200NZ	10336887				2022-12-25	WOS:000080547700009
J	Vandenburgh, H; Chromiak, J; Shansky, J; Del Tatto, M; Lemaire, J				Vandenburgh, H; Chromiak, J; Shansky, J; Del Tatto, M; Lemaire, J			Space travel directly induces skeletal muscle atrophy	FASEB JOURNAL			English	Article						protein turnover; skeletal myofiber; spaceflight; TCA	GROWTH-FACTOR-I; PROTEIN-TURNOVER; MECHANICAL STIMULATION; SUSPENDED RATS; TISSUE-CULTURE; IGF-I; HORMONE; SPACEFLIGHT; EXERCISE; INVITRO	Space travel causes rapid and pronounced skeletal muscle wasting in humans that reduces their long-term flight capabilities, To develop effective countermeasures, the basis of this atrophy needs to be better understood. Space travel may cause muscle atrophy indirectly by altering circulating levels of factors such as growth hormone, glucocorticoids, and anabolic steroids and/or by a direct effect on the muscle fibers themselves. To determine whether skeletal muscle cells are directly affected by space travel, tissue-cultured avian skeletal muscle cells were tissue engineered into bioartificial muscles and flown in perfusion bioreactors for 9 to 10 days aboard the Space Transportation System (STS, i.e., Space Shuttle). Significant muscle fiber atrophy occurred due to a decrease in protein synthesis rates without alterations in protein degradation, Return of the muscle cells to Earth stimulated protein synthesis rates of both muscle-specific and extracellular matrix proteins relative to ground controls. These results show for the first time that skeletal muscle fibers are directly responsive to space travel and should be a target for countermeasure development.	Brown Univ, Sch Med, Dept Pathol, Providence, RI 02906 USA; Miriam Hosp, Providence, RI 02906 USA; Brown Univ, Dept Mol Pharmacol Physiol & Biotechnol, Providence, RI 02912 USA	Brown University; Lifespan Health Rhode Island; Miriam Hospital; Brown University	Vandenburgh, H (corresponding author), Brown Univ, Sch Med, Dept Pathol, 164 Summit Ave, Providence, RI 02906 USA.							BOOTH FW, 1985, FED PROC, V44, P2293; CERNY LC, 1986, J CELL BIOL, V103, P2153, DOI 10.1083/jcb.103.6.2153; CHROMIAK JA, 1992, AM J PHYSIOL, V262, pC1471, DOI 10.1152/ajpcell.1992.262.6.C1471; Chromiak JA, 1998, IN VITRO CELL DEV-AN, V34, P694; CHROMIAK JA, 1994, J CELL PHYSIOL, V159, P407, DOI 10.1002/jcp.1041590304; Davis TA, 1996, J LEUKOCYTE BIOL, V60, P69, DOI 10.1002/jlb.60.1.69; EDGERTON VR, 1995, J APPL PHYSIOL, V78, P1733, DOI 10.1152/jappl.1995.78.5.1733; Ferrando AA, 1996, AM J PHYSIOL-ENDOC M, V270, pE627, DOI 10.1152/ajpendo.1996.270.4.E627; GOLDSPINK DF, 1983, BIOCHEM J, V210, P89, DOI 10.1042/bj2100089; GRIGORYEV AI, 1990, KOSM BIOL AVIAK MED, V5, P3; GRINDELAND RE, 1994, AM J PHYSIOL, V267, pR316, DOI 10.1152/ajpregu.1994.267.1.R316; Hintz RL, 1996, ENDOCRIN METAB CLIN, V25, P759, DOI 10.1016/S0889-8529(05)70352-2; Hymer WC, 1996, J APPL PHYSIOL, V80, P955, DOI 10.1152/jappl.1996.80.3.955; KU Z, 1994, AM J PHYSIOL, V267, pC115, DOI 10.1152/ajpcell.1994.267.1.C115; Lewis ML, 1998, FASEB J, V12, P1007, DOI 10.1096/fasebj.12.11.1007; LINDERMAN JK, 1994, AM J PHYSIOL, V267, pR365, DOI 10.1152/ajpregu.1994.267.2.R365; MCMILLAN DN, 1987, PROSTAGLANDINS, V34, P841, DOI 10.1016/0090-6980(87)90065-7; Meling TR, 1996, AM J MED SCI, V311, P153, DOI 10.1097/00000441-199604000-00001; MIR B, 1990, FASEB J, V4, P64; PERRONE CE, 1995, J BIOL CHEM, V270, P2099, DOI 10.1074/jbc.270.5.2099; REDMOND EM, 1995, IN VITRO CELL DEV-AN, V31, P601; Rooyackers OE, 1997, ANNU REV NUTR, V17, P457, DOI 10.1146/annurev.nutr.17.1.457; Roy R R, 1996, Exerc Sport Sci Rev, V24, P399; Roy RR, 1996, J APPL PHYSIOL, V81, P302, DOI 10.1152/jappl.1996.81.1.302; Schmitt DA, 1996, FASEB J, V10, P1627, DOI 10.1096/fasebj.10.14.9002555; Shansky J, 1997, IN VITRO CELL DEV-AN, V33, P659, DOI 10.1007/s11626-997-0118-y; STEFFEN JM, 1986, AM J PHYSIOL, V251, pR1059, DOI 10.1152/ajpregu.1986.251.6.R1059; Stein TP, 1997, AM J PHYSIOL-ENDOC M, V272, pE688, DOI 10.1152/ajpendo.1997.272.4.E688; Stewart D.M, 1972, REGULATION ORGAN TIS, P77; VandenBurgh H, 1998, HUM GENE THER, V9, P2555, DOI 10.1089/hum.1998.9.17-2555; VANDENBURGH H, 1980, J BIOL CHEM, V255, P5826; Vandenburgh H, 1996, HUM GENE THER, V7, P2195, DOI 10.1089/hum.1996.7.17-2195; VANDENBURGH HH, 1990, AM J PHYSIOL, V259, pC232, DOI 10.1152/ajpcell.1990.259.2.C232; VANDENBURGH HH, 1989, AM J PHYSIOL, V256, pC674, DOI 10.1152/ajpcell.1989.256.3.C674; VANDENBURGH HH, 1991, FASEB J, V5, P2860, DOI 10.1096/fasebj.5.13.1916108; VANDENBURGH HH, 1992, AM J PHYSIOL, V262, pR350, DOI 10.1152/ajpregu.1992.262.3.R350; Vandenburgh HH, 1996, AM J PHYSIOL-CELL PH, V270, pC1284, DOI 10.1152/ajpcell.1996.270.5.C1284; VANDENBURGH HH, 1988, IN VITRO CELL DEV B, V24, P166, DOI 10.1007/BF02623542; VANDENBURGH HH, 1991, AM J PHYSIOL, V260, pC475, DOI 10.1152/ajpcell.1991.260.3.C475; VANDENBURGH HH, 1987, MED SCI SPORT EXER, V19, pS142; VANDENBURGH HH, 1998, METHODS MOL MED TISS, P205; Viru A, 1985, HORMONES MUSCULAR AC; WONG TS, 1990, J APPL PHYSIOL, V69, P1709, DOI 10.1152/jappl.1990.69.5.1709	43	89	95	1	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	1999	13	9					1031	1038		10.1096/fasebj.13.9.1031	http://dx.doi.org/10.1096/fasebj.13.9.1031			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	200NZ	10336885				2022-12-25	WOS:000080547700007
J	Berneburg, M; Grether-Beck, S; Kurten, V; Ruzicka, T; Briviba, K; Sies, H; Krutmann, J				Berneburg, M; Grether-Beck, S; Kurten, V; Ruzicka, T; Briviba, K; Sies, H; Krutmann, J			Singlet oxygen mediates the UVA-induced generation of the photoaging-associated mitochondrial common deletion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE-SCALE DELETIONS; OXIDATIVE DAMAGE; HUMAN SKIN; DNA-DAMAGE; STRAND BREAKS; EXPRESSION; CELLS; COLLAGENASE; RADIATION; MUTATIONS	Mutations of mitochondrial (mt) DNA accumulate during normal aging. The most frequent mutation is a 4,977-base pair deletion also called the common deletion, which is increased in photoaged skin. Oxidative stress may play a major role in the generation of large scale mtDNA deletions, but direct proof for this has been elusive. We therefore assessed whether the common deletion can be generated in vitro through UV irradiation and whether reactive oxygen species are involved in this process, Normal human fibroblasts were repetitively exposed to sublethal doses of UVA radiation and assayed for the common deletion employing a semiquantitative polymerase chain reaction technique. There was a time/dose-dependent generation of the common deletion, attributable to the generation of singlet oxygen, since the common deletion was diminished when irradiating in the presence of singlet oxygen quenchers, but increased when enhancing singlet oxygen half-life by deuterium oxide. The induction of the common deletion by UVA irradiation was mimicked by treatment of unirradiated cells with singlet oxygen produced by the thermodecomposition of an endoperoxide. These studies provide evidence for the involvement of reactive oxygen species in the generation of aging-associated mtDNA lesions in human cells and indicate a previously unrecognized role of singlet oxygen in photoaging of human skin.	Univ Dusseldorf, Dept Dermatol, D-40225 Dusseldorf, Germany; Univ Dusseldorf, Inst Physiol Chem 1, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf	Krutmann, J (corresponding author), Univ Dusseldorf, Dept Dermatol, Moorenstr 5, D-40225 Dusseldorf, Germany.		Sies, Helmut/B-7266-2008; Sies, Helmut/ABE-7355-2020	Sies, Helmut/0000-0002-1000-3198; Briviba, Karlis/0000-0003-3338-7515				AMES BN, 1995, BBA-MOL BASIS DIS, V1271, P165, DOI 10.1016/0925-4439(95)00024-X; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; Arkin MR, 1997, CHEM BIOL, V4, P389, DOI 10.1016/S1074-5521(97)90129-0; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; Berneburg M, 1997, PHOTOCHEM PHOTOBIOL, V66, P271, DOI 10.1111/j.1751-1097.1997.tb08654.x; Birch-Machin MA, 1998, J INVEST DERMATOL, V110, P149, DOI 10.1046/j.1523-1747.1998.00099.x; BOURGERON T, 1993, J BIOL CHEM, V268, P19369; CORTOPASSI GA, 1992, P NATL ACAD SCI USA, V89, P7370, DOI 10.1073/pnas.89.16.7370; DEVASAGAYAM TPA, 1991, BIOCHEMISTRY-US, V30, P6283, DOI 10.1021/bi00239a029; DI MASCIO P, 1989, J AM CHEM SOC, V111, P2909, DOI 10.1021/ja00190a027; DRIGGERS WJ, 1993, J BIOL CHEM, V268, P22042; FLOYD RA, 1989, ARCH BIOCHEM BIOPHYS, V273, P106, DOI 10.1016/0003-9861(89)90167-7; Frederick JE, 1992, BIOL RESPONSES ULTRA, P7; GATTERMANN N, 1995, LEUKEMIA, V9, P1704; GretherBeck S, 1996, P NATL ACAD SCI USA, V93, P14586, DOI 10.1073/pnas.93.25.14586; GREWE M, 1994, LANCET, V343, P25, DOI 10.1016/S0140-6736(94)90879-6; Hanson KM, 1998, P NATL ACAD SCI USA, V95, P10576, DOI 10.1073/pnas.95.18.10576; HENNINGER HP, 1993, BIOL CHEM H-S, V374, P625, DOI 10.1515/bchm3.1993.374.7-12.625; HOLT IJ, 1989, ANN NEUROL, V26, P699, DOI 10.1002/ana.410260603; Hou JH, 1996, BIOCHEM J, V318, P1065, DOI 10.1042/bj3181065; IKEBE S, 1990, BIOCHEM BIOPH RES CO, V170, P1044, DOI 10.1016/0006-291X(90)90497-B; Ito K, 1997, BIOL CHEM, V378, P1307; KADOWAKI T, 1994, NEW ENGL J MED, V330, P962, DOI 10.1056/NEJM199404073301403; Kogelnik AM, 1998, NUCLEIC ACIDS RES, V26, P112, DOI 10.1093/nar/26.1.112; LEDOUX SP, 1992, CARCINOGENESIS, V13, P1967, DOI 10.1093/carcin/13.11.1967; MADSEN CS, 1993, P NATL ACAD SCI USA, V90, P7671, DOI 10.1073/pnas.90.16.7671; MITA S, 1990, NUCLEIC ACIDS RES, V18, P561, DOI 10.1093/nar/18.3.561; MODAK SB, 1993, CANCER RES, V53, P4505; RICHTER C, 1995, INT J BIOCHEM CELL B, V27, P647, DOI 10.1016/1357-2725(95)00025-K; SCHARFFETTERKOCHANEK K, 1993, FEBS LETT, V331, P304, DOI 10.1016/0014-5793(93)80357-Z; SCHON EA, 1989, SCIENCE, V244, P346, DOI 10.1126/science.2711184; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; SHOFFNER JM, 1989, P NATL ACAD SCI USA, V86, P7952, DOI 10.1073/pnas.86.20.7952; Sies H, 1996, J PHOTOCH PHOTOBIO B, V32, P97, DOI 10.1016/1011-1344(95)07192-X; WALLACE DC, 1990, PEDIATR RES, V28, P525, DOI 10.1203/00006450-199011000-00023; Wei Yau-Huei, 1998, Proceedings of the National Science Council Republic of China Part B Life Sciences, V22, P55; Williams MD, 1998, J BIOL CHEM, V273, P28510, DOI 10.1074/jbc.273.43.28510; WLASCHEK M, 1995, J INVEST DERMATOL, V104, P194, DOI 10.1111/1523-1747.ep12612751; Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514; YANG JH, 1995, ARCH DERMATOL RES, V287, P641; YANG JH, 1994, ARCH DERMATOL RES, V286, P386, DOI 10.1007/BF00371798; ZHANG C, 1992, FEBS LETT, V297, P34, DOI 10.1016/0014-5793(92)80321-7	42	282	299	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15345	15349		10.1074/jbc.274.22.15345	http://dx.doi.org/10.1074/jbc.274.22.15345			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336420	hybrid			2022-12-25	WOS:000080560100009
J	Klatt, P; Molina, EP; Lamas, S				Klatt, P; Molina, EP; Lamas, S			Nitric oxide inhibits c-Jun DNA binding by specifically targeted S-glutathionylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; REDOX REGULATION; NITROSATIVE STRESS; SERUM-ALBUMIN; SULFENIC ACID; IN-VITRO; THIOLS; AP-1; NITROSOGLUTATHIONE; TRANSCRIPTION	This study addresses potential molecular mechanisms underlying the inhibition of the transcription factor c-Jun by nitric oxide. We show that in the presence of the physiological sulfhydryl glutathione nitric oxide modifies the two cysteine residues contained in the DNA binding module of c-Jun in a selective and distinct way. Although nitric oxide induced the formation of an intermolecular disulfide bridge between cysteine residues in the leucine zipper site of c-Jun monomers, this same radical directed the covalent incorporation of stoichiometric amounts of glutathione to a single conserved cysteine residue in the DNA-binding site of the protein. We found that covalent dimerization of c-Jun apparently did not affect its DNA binding activity, whereas the formation of a mixed disulfide with glutathione correlated well with the inhibition of transcription factor binding to DNA. Furthermore, we provide experimental evidence that nitric oxide-induced S-glutathionylation and inhibition of c-Jun involves the formation of S-nitrosoglutathione. In conclusion, our results support the reversible formation of a mixed disulfide between glutathione and c-Jun as a potential mechanism by which nitrosative stress may be transduced into a functional response at the level of transcription.	CSIC, Ctr Invest Biol, Dept Estructura & Func Proteinas, Inst Reina Sofia Invest Nefrol, E-28006 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Lamas, S (corresponding author), CSIC, Ctr Invest Biol, Dept Estructura & Func Proteinas, Inst Reina Sofia Invest Nefrol, Calle Velazquez 144, E-28006 Madrid, Spain.	pklatt@cib.csic.es; slamas@cib.csic.es	Lamas, Santiago/G-7308-2015; Pineda-Molina, Estela/K-9969-2014	Lamas, Santiago/0000-0001-5166-4155; Pineda-Molina, Estela/0000-0002-4266-0192				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; BANNISTER AJ, 1991, ONCOGENE, V6, P1243; Becker K, 1998, NAT STRUCT BIOL, V5, P267, DOI 10.1038/nsb0498-267; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; Brendeford EM, 1998, FEBS LETT, V425, P52, DOI 10.1016/S0014-5793(98)00196-3; Chandra A, 1997, BIOCHEMISTRY-US, V36, P15801, DOI 10.1021/bi9714722; Christopherson KS, 1997, J CLIN INVEST, V100, P2424, DOI 10.1172/JCI119783; Conant K, 1998, J NEUROIMMUNOL, V88, P39, DOI 10.1016/S0165-5728(98)00069-1; Cotgreave IA, 1998, BIOCHEM BIOPH RES CO, V242, P1, DOI 10.1006/bbrc.1997.7812; DEMASTER EG, 1995, BIOCHEMISTRY-US, V34, P11494, DOI 10.1021/bi00036a023; Ellis HR, 1997, BIOCHEMISTRY-US, V36, P15013, DOI 10.1021/bi972191x; FURCHGOTT RF, 1995, ANNU REV PHARMACOL, V35, P1; Galter Dagmar, 1994, European Journal of Biochemistry, V221, P639; GILBERT HF, 1995, METHOD ENZYMOL, V251, P8, DOI 10.1016/0076-6879(95)51107-5; Gorren ACF, 1996, ARCH BIOCHEM BIOPHYS, V330, P219, DOI 10.1006/abbi.1996.0247; GREEN LC, 1982, ANAL BIOCHEM, V162, P156; Hardison R, 1978, Methods Cell Biol, V17, P235, DOI 10.1016/S0091-679X(08)61146-2; Hausladen A, 1998, P NATL ACAD SCI USA, V95, P14100, DOI 10.1073/pnas.95.24.14100; Hausladen A, 1996, CELL, V86, P719, DOI 10.1016/S0092-8674(00)80147-6; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; KHARITONOV VG, 1995, J BIOL CHEM, V270, P28158; Liu ZG, 1998, J PHARMACOL EXP THER, V284, P526; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; Matthews JR, 1996, NUCLEIC ACIDS RES, V24, P2236, DOI 10.1093/nar/24.12.2236; Mayer B, 1998, J BIOL CHEM, V273, P3264, DOI 10.1074/jbc.273.6.3264; Mayer B, 1997, TRENDS BIOCHEM SCI, V22, P477, DOI 10.1016/S0968-0004(97)01147-X; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MEYER DJ, 1994, FEBS LETT, V345, P177, DOI 10.1016/0014-5793(94)00429-3; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; Nicotera P, 1997, TRENDS PHARMACOL SCI, V18, P189, DOI 10.1016/S0165-6147(97)90619-2; Nikitovic D, 1998, BIOCHEM BIOPH RES CO, V242, P109, DOI 10.1006/bbrc.1997.7930; Nikitovic D, 1996, J BIOL CHEM, V271, P19180, DOI 10.1074/jbc.271.32.19180; OEHLER T, 1993, ONCOGENE, V8, P1141; Oliveira L, 1999, J BIOL CHEM, V274, P516, DOI 10.1074/jbc.274.1.516; Padgett CM, 1998, ARCH BIOCHEM BIOPHYS, V358, P232, DOI 10.1006/abbi.1998.0859; PARK EM, 1988, BIOCHIM BIOPHYS ACTA, V964, P151, DOI 10.1016/0304-4165(88)90161-4; REED DJ, 1980, ANAL BIOCHEM, V106, P55, DOI 10.1016/0003-2697(80)90118-9; SCHARFSTEIN JS, 1994, J CLIN INVEST, V94, P1432, DOI 10.1172/JCI117480; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; Schmidt K, 1997, N-S ARCH PHARMACOL, V355, P457, DOI 10.1007/PL00004969; SCHUMAN EM, 1994, ANNU REV NEUROSCI, V17, P153, DOI 10.1146/annurev.neuro.17.1.153; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; SIES H, 1975, EUR J BIOCHEM, V57, P503, DOI 10.1111/j.1432-1033.1975.tb02325.x; Singh SP, 1996, P NATL ACAD SCI USA, V93, P14428, DOI 10.1073/pnas.93.25.14428; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; Stamler JS, 1998, NAT STRUCT BIOL, V5, P247, DOI 10.1038/nsb0498-247; Stamler JS, 1997, NEURON, V18, P691, DOI 10.1016/S0896-6273(00)80310-4; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; Sun Y, 1996, FREE RADICAL BIO MED, V21, P335, DOI 10.1016/0891-5849(96)00109-8; Tabuchi A, 1996, J BIOL CHEM, V271, P31061, DOI 10.1074/jbc.271.49.31061; TABUCHI A, 1994, FEBS LETT, V351, P123, DOI 10.1016/0014-5793(94)00839-6; THOMAS JA, 1994, METHOD ENZYMOL, V233, P385; THOMAS JA, 1995, ARCH BIOCHEM BIOPHYS, V319, P1, DOI 10.1006/abbi.1995.1261; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; Wink DA, 1998, FREE RADICAL BIO MED, V25, P434, DOI 10.1016/S0891-5849(98)00092-6; Wink DA, 1997, J BIOL CHEM, V272, P11147; Wong PSY, 1998, BIOCHEMISTRY-US, V37, P5362, DOI 10.1021/bi973153g; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; XANTHOUDAKIS S, 1994, METHOD ENZYMOL, V234, P163; ZIEGLER DM, 1985, ANNU REV BIOCHEM, V54, P305, DOI 10.1146/annurev.bi.54.070185.001513	60	137	138	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15857	15864		10.1074/jbc.274.22.15857	http://dx.doi.org/10.1074/jbc.274.22.15857			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336489	hybrid, Green Published			2022-12-25	WOS:000080560100078
J	Wood, WM; Dowding, JM; Gordon, DF; Ridgway, EC				Wood, WM; Dowding, JM; Gordon, DF; Ridgway, EC			An upstream regulator of the glycoprotein hormone cu-subunit gene mediates pituitary cell type activation and repression by different mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC ENHANCER; ALPHA-SUBUNIT; GROWTH-HORMONE; TRANSCRIPTION FACTOR; PROMOTER ACTIVITY; HOMEODOMAIN PROTEINS; EXPRESSION; PIT-1; ELEMENTS; LIM	Targeting of alpha-subunit gene expression within the pituitary is influenced by an upstream regulatory region that directs high level expression to thyrotropes and gonadotropes of transgenic mice. The same region also enhanced the activity of the proximal promoter in transfections of pituitary-derived alpha-TSH and alpha-T3 cells. We have localized the activating sequences to a 125-bp region that contains consensus sites for factors that also play a role in proximal promoter activity. Proteins present in alpha-TSH and alpha-T3 cells as well as those from GH3 somatotrope-derived cells interact with this region. The upstream area inhibited proximal alpha-promoter activity by 80% when transfected into GH3 cells. Repression in GH3 cells was mediated through a different mechanism than enhancement, as supported by the following evidence. Reversing the orientation of the area resulted in a loss of proximal promoter activation in alpha-TSH and alpha-T3 cells but did not relieve repression in GH3 cells. Mutation of proximal sites shown to be important for activation had no effect on repression. Finally, bidirectional deletional analysis revealed that multiple elements are involved in activation and repression and, together with the DNA binding studies, suggests that these processes may be mediated through closely juxtaposed or even overlapping elements, thus perhaps defining a new class of bifunctional gene regulatory sequence.	Univ Colorado, Hlth Sci Ctr, Dept Med Endocrinol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Div Endocrinol Diabet & Metab, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Wood, WM (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Med Endocrinol, B-151,4200 E 9th Ave, Denver, CO 80262 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047407] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 47407, DK 36842] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agulnick AD, 1996, NATURE, V384, P270, DOI 10.1038/384270a0; ANDERSEN B, 1990, J BIOL CHEM, V265, P21874; BACH I, 1995, P NATL ACAD SCI USA, V92, P2720, DOI 10.1073/pnas.92.7.2720; Bach I, 1997, GENE DEV, V11, P1370, DOI 10.1101/gad.11.11.1370; BARNHART KM, 1994, MOL ENDOCRINOL, V8, P878, DOI 10.1210/me.8.7.878; BOKAR JA, 1989, MOL CELL BIOL, V9, P5113, DOI 10.1128/MCB.9.11.5113; Bradford AP, 1997, MOL CELL BIOL, V17, P1065, DOI 10.1128/MCB.17.3.1065; Brinkmeier ML, 1998, MOL ENDOCRINOL, V12, P622, DOI 10.1210/me.12.5.622; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; GORDON DF, 1993, MOL CELL ENDOCRINOL, V96, P75, DOI 10.1016/0303-7207(93)90097-4; Gordon DF, 1997, J BIOL CHEM, V272, P24339, DOI 10.1074/jbc.272.39.24339; HAMERNIK DL, 1992, MOL ENDOCRINOL, V6, P1745, DOI 10.1210/me.6.10.1745; HAUGEN BR, 1994, MOL ENDOCRINOL, V8, P1574, DOI 10.1210/me.8.11.1574; HECKERT LL, 1995, J BIOL CHEM, V270, P26497, DOI 10.1074/jbc.270.44.26497; HORN F, 1992, MOL CELL BIOL, V12, P2143, DOI 10.1128/MCB.12.5.2143; HOWARD PW, 1995, J BIOL CHEM, V270, P20930, DOI 10.1074/jbc.270.36.20930; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; ISHIBASHI M, 1987, J CLIN ENDOCR METAB, V64, P1187, DOI 10.1210/jcem-64-6-1187; JACKSON SM, 1995, MOL ENDOCRINOL, V9, P278, DOI 10.1210/me.9.3.278; Jurata LW, 1996, P NATL ACAD SCI USA, V93, P11693, DOI 10.1073/pnas.93.21.11693; KENDALL SK, 1994, MOL ENDOCRINOL, V8, P1420, DOI 10.1210/me.8.10.1420; MAXWELL IH, 1989, BIOTECHNIQUES, V7, P276; Morcillo P, 1997, GENE DEV, V11, P2729, DOI 10.1101/gad.11.20.2729; REN SC, 1993, BLOOD, V81, P1058; RHODES SJ, 1993, GENE DEV, V7, P913, DOI 10.1101/gad.7.6.913; ROBERSON MS, 1994, MOL CELL BIOL, V14, P2985, DOI 10.1128/MCB.14.5.2985; Sarapura VD, 1998, MOL CELL ENDOCRINOL, V146, P77, DOI 10.1016/S0303-7207(98)00195-6; SARAPURA VD, 1992, THYROID, V2, P31, DOI 10.1089/thy.1992.2.31; SARAPURA VD, 1990, ENDOCRINOLOGY, V127, P1352, DOI 10.1210/endo-127-3-1352; SCHAUFELE F, 1990, J BIOL CHEM, V265, P17189; SCHODERBEK WE, 1992, MOL ENDOCRINOL, V6, P893, DOI 10.1210/me.6.6.893; SCHOENHERR CJ, 1995, CURR OPIN NEUROBIOL, V5, P566, DOI 10.1016/0959-4388(95)80060-3; SEIDAH NG, 1994, DNA CELL BIOL, V13, P1163, DOI 10.1089/dna.1994.13.1163; SILVER BJ, 1987, P NATL ACAD SCI USA, V84, P2198, DOI 10.1073/pnas.84.8.2198; SIMMONS DM, 1990, GENE DEV, V4, P695, DOI 10.1101/gad.4.5.695; STEGER DJ, 1994, MOL CELL BIOL, V14, P5592, DOI 10.1128/MCB.14.8.5592; STEGER DJ, 1991, MOL ENDOCRINOL, V5, P243, DOI 10.1210/mend-5-2-243; SWANSON LW, 1992, PROG BRAIN RES, V92, P97, DOI 10.1016/S0079-6123(08)61167-X; TANSEY WP, 1991, J BIOL CHEM, V266, P9805; Treier M, 1998, GENE DEV, V12, P1691, DOI 10.1101/gad.12.11.1691; WALDMAN IA, 1997, EMBO J, V16, P3145; WHITE MC, 1986, CLIN ENDOCRINOL, V25, P173, DOI 10.1111/j.1365-2265.1986.tb01679.x; Wood WM, 1998, MOL CELL ENDOCRINOL, V142, P141, DOI 10.1016/S0303-7207(98)00110-5; WOOD WM, 1989, J BIOL CHEM, V264, P14840; Wood WM, 1996, J BIOL CHEM, V271, P24213, DOI 10.1074/jbc.271.39.24213	45	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15526	15532		10.1074/jbc.274.22.15526	http://dx.doi.org/10.1074/jbc.274.22.15526			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336446	hybrid			2022-12-25	WOS:000080560100035
J	McAbee, DD; Jiang, X				McAbee, DD; Jiang, X			Copper and zinc ions differentially block asialoglycoprotein receptor-mediated endocytosis in isolated rat hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GALACTOSYL RECEPTORS; MOLECULAR-BIOLOGY; HOLO-LACTOFERRIN; APO-LACTOFERRIN; FATTY ACYLATION; BINDING; IRON; CELLS; SUBPOPULATION; INACTIVATION	Asialoglycoprotein receptors on hepatocytes lose endocytic and ligand binding activity when hepatocytes are exposed to iron ions. Here, we report the effects of zinc and copper ions on the endocytic and ligand binding activity of asialoglycoprotein receptors on isolated rat hepatocytes. Treatment of cells at 37 degrees C for 2 h with ZnCl2 (0-220 mu M) or CuCl2 (0-225 mu M) reversibly blocked sustained endocytosis of I-125-asialoorosomucoid by up to 93% (t(1/2) = 62 min) and 99% (t(1/2) = 54 min), respectively. Cells remained viable during such treatments. Zinc- and copper-treated cells lost similar to 50% of their surface asialoglycoprotein receptor ligand binding activity; zinc-treated cells accumulated inactive asialoglycoprotein receptors intracellularly, whereas copper-treated cells accumulated inactive receptors on their surfaces. Cells treated at 4 degrees C with metal did not lose surface asialoglycoprotein receptor activity. Exposure of cells to copper ions, but not to zinc ions, blocked internalization of prebound 125I-asialoorosomucoid, but degradation of internalized ligand and pinocytosis of the fluid-phase marker Lucifer Yellow were not blocked by metal treatment. Zinc ions reduced diferric transferrin binding and endocytosis on hepatocytes by similar to 33%; copper ions had no inhibitory effects. These findings are the first demonstration of a specific inhibition of receptor-mediated endocytosis by non-iron transition metals.	Calif State Univ Long Beach, Dept Chem & Biochem, Long Beach, CA 90840 USA	California State University System; California State University Long Beach	McAbee, DD (corresponding author), Calif State Univ Long Beach, Dept Chem & Biochem, 1250 Bellflower Blvd, Long Beach, CA 90840 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043355] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 43355] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bennatt DJ, 1997, BIOCHEMISTRY-US, V36, P8359, DOI 10.1021/bi963078u; Bennatt DJ, 1997, BIOCHEMISTRY-US, V36, P8367, DOI 10.1021/bi963079m; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; DeSilva DM, 1996, PHYSIOL REV, V76, P31, DOI 10.1152/physrev.1996.76.1.31; Eide D, 1997, CURR OPIN CELL BIOL, V9, P573, DOI 10.1016/S0955-0674(97)80036-1; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; Linder Maria C., 1996, American Journal of Clinical Nutrition, V63, p797S; Mason A. Z., 1995, METAL SPECIATION BIO, P479; MCABEE DD, 1991, J CELL BIOCHEM, V45, P59, DOI 10.1002/jcb.240450113; MCABEE DD, 1988, BIOCHEMISTRY-US, V27, P2061, DOI 10.1021/bi00406a037; MCABEE DD, 1993, BIOCHEMISTRY-US, V32, P13749, DOI 10.1021/bi00212a046; MCABEE DD, 1991, J BIOL CHEM, V266, P23624; MCABEE DD, 1987, J BIOL CHEM, V262, P1942; McAbee DD, 1998, BIOCHEM J, V331, P719, DOI 10.1042/bj3310719; McAbee DD, 1997, J CELL PHYSIOL, V171, P75; OKA JA, 1989, J BIOL CHEM, V264, P12016; Palmiter RD, 1998, P NATL ACAD SCI USA, V95, P8428, DOI 10.1073/pnas.95.15.8428; QIAN YC, 1995, AM J PHYSIOL-CELL PH, V269, pC892, DOI 10.1152/ajpcell.1995.269.4.C892; SCHACHTE.H, 1970, J BIOL CHEM, V245, P1090; SEGLEN PO, 1973, EXP CELL RES, V82, P391, DOI 10.1016/0014-4827(73)90357-1; STADTMAN ER, 1993, ANNU REV BIOCHEM, V62, P797, DOI 10.1146/annurev.bi.62.070193.004053; Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048; TROWBRIDGE IS, 1992, J INORG BIOCHEM, V47, P209, DOI 10.1016/0162-0134(92)84066-V; Weigel P H, 1993, Subcell Biochem, V19, P125; WEIGEL PH, 1983, ANAL BIOCHEM, V133, P437, DOI 10.1016/0003-2697(83)90106-9; WEIGEL PH, 1994, MOL BIOL CELL, V5, P227, DOI 10.1091/mbc.5.2.227; Weigel PH, 1998, BIOCHEM BIOPH RES CO, V246, P563, DOI 10.1006/bbrc.1998.8491; Zeng FY, 1996, J BIOL CHEM, V271, P32454, DOI 10.1074/jbc.271.50.32454; ZENG FY, 1995, J BIOL CHEM, V270, P21382, DOI 10.1074/jbc.270.36.21382	29	12	12	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					14750	14758		10.1074/jbc.274.21.14750	http://dx.doi.org/10.1074/jbc.274.21.14750			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329671	hybrid			2022-12-25	WOS:000081965200036
J	Steenhuis, JJ; Hutchison, RS; Barry, BA				Steenhuis, JJ; Hutchison, RS; Barry, BA			Alterations in carboxylate ligation at the active site of photosystem II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYNTHETIC OXYGEN EVOLUTION; DIFFERENCE FT-IR; EVOLVING MANGANESE CLUSTER; TEMPERATURE-DEPENDENCE; CRYSTAL-STRUCTURES; ELECTRON-TRANSFER; AB-INITIO; COMPLEX; OXIDATION; PROTEIN	Photosystem II (PSII) is the photosynthetic enzyme catalyzing the oxidation of water and reduction of plastoquinone (Q). This reaction occurs at a catalytic site containing four manganese atoms and cycling among five oxidation states, the S-n states, where n refers to the number of oxidizing equivalents stored. Biochemical and spectroscopic techniques have been used previously to conclude that aspartate 170 in the D1 subunit influences the structure and function of the PSII active site (Boerner, R. J., Nguyen, A. P., Barry, B. A., and Debus, R, J. (1992) Biochemistry 31, 6660-6672). Substitution of glutamate for aspartate 170 resulted in an assembled manganese cluster, which was capable of enzymatic turnover, but at lower steady-state oxygen evolution rates. Here, we obtained the difference (light-minus-dark) Fourier transform IR spectrum associated with the S(2)Q(-)-minus-S(1)Q transition by illumination of oxygen-evolving wild-type and DE170D1 PSII preparations at 200 K. These spectra are known to be dominated by contributions from carboxylic acid and carboxylate residues that are close to or ligating the manganese cluster. Substitution of glutamate for aspartate 170 results in alterations in the S(2)Q(-)-minus-S(1)Q spectrum; the alterations are consistent with a change in carboxylate coordination to manganese or calcium. In particular, the spectra are consistent with a shift from bridging/bidentate carboxylates in wild-type PSII to unidentate carboxylate ligation in DE170D1 PSII.	Univ Minnesota, Dept Biochem Mol Biol & Biophys, St Paul, MN 55108 USA	University of Minnesota System; University of Minnesota Twin Cities	Barry, BA (corresponding author), Univ Minnesota, Dept Biochem Mol Biol & Biophys, 1479 Gortner Ave, St Paul, MN 55108 USA.							AASA R, 1987, FEBS LETT, V221, P245, DOI 10.1016/0014-5793(87)80934-1; BARRY BA, 1995, METHOD ENZYMOL, V258, P303; BARRY BA, 1987, P NATL ACAD SCI USA, V84, P7099, DOI 10.1073/pnas.84.20.7099; BELLAMY LJ, 1980, INFRARED SPECTRA COM, P183; BERNARD MT, 1995, J BIOL CHEM, V270, P1589, DOI 10.1074/jbc.270.4.1589; BOERNER RJ, 1992, BIOCHEMISTRY-US, V31, P6660, DOI 10.1021/bi00144a005; BRITT RD, 1996, ADV PHOTOSYNTH, V4, P137; BUTLER WF, 1984, BIOPHYS J, V45, P947, DOI 10.1016/S0006-3495(84)84241-1; CASEY JL, 1984, BIOCHIM BIOPHYS ACTA, V767, P21, DOI 10.1016/0005-2728(84)90075-6; DEBUS RJ, 1992, BIOCHIM BIOPHYS ACTA, V1102, P269, DOI 10.1016/0005-2728(92)90133-M; DEERFIELD DW, 1995, PROTEINS, V21, P244, DOI 10.1002/prot.340210307; DEPAULA JC, 1986, BIOCHEMISTRY-US, V25, P6487, DOI 10.1021/bi00369a022; DEPAULA JC, 1985, BIOCHEMISTRY-US, V24, P8114, DOI 10.1021/bi00348a042; Diner BA, 1991, CURR OPIN STRUC BIOL, V1, P546, DOI 10.1016/S0959-440X(05)80076-4; DISMUKES GC, 1981, P NATL ACAD SCI-BIOL, V78, P274, DOI 10.1073/pnas.78.1.274; FLETT MS, 1962, SPECTROCHIM ACTA, V18, P1537, DOI 10.1016/S0371-1951(62)80282-3; Ghirardi ML, 1998, BIOCHEMISTRY-US, V37, P13559, DOI 10.1021/bi980358w; Kim S, 1998, BBA-BIOENERGETICS, V1366, P330, DOI 10.1016/S0005-2728(98)00134-0; Kim SY, 1998, BIOPHYS J, V74, P2588, DOI 10.1016/S0006-3495(98)77965-2; LIBSON AM, 1994, BIOCHEMISTRY-US, V33, P8007, DOI 10.1021/bi00192a004; MACDONALD GM, 1995, J BIOL CHEM, V270, P8420, DOI 10.1074/jbc.270.15.8420; MACDONALD GM, 1992, BIOCHEMISTRY-US, V31, P9848, DOI 10.1021/bi00155a043; MACDONALD GM, 1994, BIOCHEMISTRY-US, V33, P4393, DOI 10.1021/bi00180a037; MILLER AF, 1991, BIOCHIM BIOPHYS ACTA, V1056, P1, DOI 10.1016/S0005-2728(05)80067-2; Nakamoto K., 1986, INFRARED RAMAN SPECT, P191; Nara M, 1996, J PHYS CHEM-US, V100, P19812, DOI 10.1021/jp9615924; NAVERRETE JTL, 1994, BIOPOLYMERS, V34, P1065; NIXON PJ, 1992, BIOCHEMISTRY-US, V31, P942, DOI 10.1021/bi00118a041; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; NOREN GH, 1991, BIOCHEMISTRY-US, V30, P3943, DOI 10.1021/bi00230a020; PAKRASI HB, 1992, PHOTOSYSTEMS STRUCTU, P231; Patzlaff JS, 1996, BIOCHEMISTRY-US, V35, P7802, DOI 10.1021/bi960056z; PECORARO VL, 1988, PHOTOCHEM PHOTOBIOL, V48, P249; RAMIREZ FJ, 1995, SPECTROCHIM ACTA A, V51, P293, DOI 10.1016/0584-8539(94)00188-H; ROSENZWEIG AC, 1993, NATURE, V366, P537, DOI 10.1038/366537a0; ROSENZWEIG AC, 1995, CHEM BIOL, V2, P409, DOI 10.1016/1074-5521(95)90222-8; SAUER K, 1992, MANGANESE REDOX ENZY, P141; Smith JC, 1997, INORG CHIM ACTA, V255, P99, DOI 10.1016/S0020-1693(96)05350-9; Steenhuis JJ, 1996, J AM CHEM SOC, V118, P11927, DOI 10.1021/ja961691v; Steenhuis JJ, 1998, J PHYS CHEM B, V102, P4, DOI 10.1021/jp9730609; Steenhuis JJ, 1997, J PHYS CHEM B, V101, P6652, DOI 10.1021/jp971260e; STYRING S, 1988, BIOCHIM BIOPHYS ACTA, V933, P378, DOI 10.1016/0005-2728(88)90046-1; STYRING S, 1987, BIOCHEMISTRY-US, V26, P2401, DOI 10.1021/bi00383a001; WIEGHARDT K, 1988, J AM CHEM SOC, V110, P7398, DOI 10.1021/ja00230a021; YACHANDRA VK, 1993, SCIENCE, V260, P675, DOI 10.1126/science.8480177; YOCUM CF, 1992, MANGANESE REDOX ENZY, P71	46	21	21	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					14609	14616		10.1074/jbc.274.21.14609	http://dx.doi.org/10.1074/jbc.274.21.14609			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329653	hybrid			2022-12-25	WOS:000081965200018
J	Fazili, Z; Sun, WP; Mittelstaedt, S; Cohen, C; Xu, XX				Fazili, Z; Sun, WP; Mittelstaedt, S; Cohen, C; Xu, XX			Disabled-2 inactivation is an early step in ovarian tumorigenicity	ONCOGENE			English	Article						ovarian cancer; breast cancer; Disabled-2 (Dab2); immunohistology; expression	ABL TYROSINE KINASE; DROSOPHILA-ABL; SIGNAL-TRANSDUCTION; HUMAN CANCER; SH3 DOMAIN; BREAST; GENE; PROTEINS; MOUSE; GRB2	Disabled-2 (Dab2) functions in mitogenic signal transduction pathway, and is frequently activated by homozygous gene deletion in tumors, suggesting that Dab2 is a candidate tumor suppressor. Here, we surveyed the expression of Dab2 and report that Dab2 is expressed in a variety of tissues, and the level of expression is particularly high in ovary and breast. Dab2 expression was also detected in immortalized breast and ovarian epithelial cells. However, in more than a dozen established tumor cell lines derived from breast and ovarian epithelial tumors examined by Western blotting, Dab2 expression was undetectable in 90% of these cell lines. Histological staining of human ovarian tissues with specific anti-Dab2 antibodies indicated that Dab2 is highly expressed in the surface epithelial layer, In an immunohistological study of 26 ovarian carcinomas, 22 (85%) of the tumors were found to lose the expression of Dab2 in the tumor cells, which are epithelial origin. Loss of Dab2 expression is not correlated with tumor grade, suggesting that Dab2 is lost in an early stage of tumorigenicity. indeed, loss of Dab2 correlates closely with morphological transformation of the surface epithelial cells. Additionally, loss of Dab2 protein occurs in hyperproliferative, but histological benign ovarian epithelium, suggesting that loss of Dab2 occurs in premalignant lesions. Thus, this study indicates that the loss of Dab2 expression is correlated with tumorigenicity of the cells disregarding the grade of the tumors, and loss of Dab2 expression is an early event in ovarian malignancies.	Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Winship Canc Ctr, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Pathol, Atlanta, GA 30322 USA	Emory University; Emory University; Emory University	Xu, XX (corresponding author), Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA.				NATIONAL CANCER INSTITUTE [R01CA075389, R55CA070783] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA75389, R55 CA70783] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albertsen HM, 1996, GENOMICS, V33, P207, DOI 10.1006/geno.1996.0185; BAST RC, 1993, CANCER, V71, P1597, DOI 10.1002/cncr.2820710426; BELL DA, 1991, HUM PATHOL, V22, P750, DOI 10.1016/0046-8177(91)90205-4; Berchuck A, 1997, BIOCHEM PHARMACOL, V54, P541, DOI 10.1016/S0006-2952(97)00061-0; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; BOS JL, 1989, CANCER RES, V49, P4682; BUDAY L, 1995, ONCOGENE, V11, P1327; CHERNIACK AD, 1995, J BIOL CHEM, V270, P1485, DOI 10.1074/jbc.270.4.1485; CLARK GJ, 1995, BREAST CANCER RES TR, V35, P133, DOI 10.1007/BF00694753; DArcangelo G, 1997, J NEUROSCI, V17, P23, DOI 10.1523/JNEUROSCI.17-01-00023.1997; FAZILI Z, 1998, UNPUB DISABLED 2 GEN; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GERTLER FB, 1989, CELL, V58, P103, DOI 10.1016/0092-8674(89)90407-8; GERTLER FB, 1993, GENE DEV, V7, P441, DOI 10.1101/gad.7.3.441; GODWIN AK, 1993, CANCER-AM CANCER SOC, V71, P530; HOFFMANN FM, 1991, TRENDS GENET, V7, P351, DOI 10.1016/0168-9525(91)90254-F; Howell BW, 1997, EMBO J, V16, P121, DOI 10.1093/emboj/16.1.121; Howell BW, 1997, NATURE, V389, P733, DOI 10.1038/39607; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MOK SC, 1994, GYNECOL ONCOL, V52, P247, DOI 10.1006/gyno.1994.1040; Mok SC, 1998, ONCOGENE, V16, P2381, DOI 10.1038/sj.onc.1201769; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Sheldon M, 1997, NATURE, V389, P730, DOI 10.1038/39601; STENBACK F, 1985, EUR J OBSTET GYN R B, V20, P357, DOI 10.1016/0028-2243(85)90059-0; SZABO CI, 1995, HUM MOL GENET, V4, P1811, DOI 10.1093/hmg/4.suppl_1.1811; Ware ML, 1997, NEURON, V19, P239, DOI 10.1016/S0896-6273(00)80936-8; WATERS SB, 1995, MOL CELL BIOL, V15, P2791; WINGO PA, 1995, CA-CANCER J CLIN, V45, P8, DOI 10.3322/canjclin.45.1.8; WITTEKIND M, 1994, BIOCHEMISTRY-US, V33, P13531, DOI 10.1021/bi00250a004; WONG KK, 1993, INT J ONCOL, V3, P13; XU XX, 1995, J BIOL CHEM, V270, P14184, DOI 10.1074/jbc.270.23.14184; Xu XX, 1998, ONCOGENE, V16, P1561, DOI 10.1038/sj.onc.1201678; ZHENG J, 1995, J NATL CANCER I, V15, P1146; ZHOU DJ, 1988, CANCER, V62, P1573, DOI 10.1002/1097-0142(19881015)62:8<1573::AID-CNCR2820620819>3.0.CO;2-M	37	114	118	2	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 20	1999	18	20					3104	3113		10.1038/sj.onc.1202649	http://dx.doi.org/10.1038/sj.onc.1202649			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	197WB	10340382				2022-12-25	WOS:000080388000006
J	Kurokawa, K; Tanaka, T; Kato, J				Kurokawa, K; Tanaka, T; Kato, J			p19(ARF) prevents G1 cyclin-dependent kinase activation by interacting with MDM2 and activating p53 in mouse fibroblasts	ONCOGENE			English	Article						p19(ARF); G1 cyclin-cdks; G1 arrest; MDM2; p53; p21(Cip1)	CELL-CYCLE; ONCOPROTEIN MDM2; TUMOR-SUPPRESSOR; CDK INHIBITORS; RETINOBLASTOMA PROTEIN; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; MAMMALIAN-CELLS; CANCER; PRODUCT	p19(ARF) encoded by the INK4a tumor suppressor gene locus functions upstream of p53 to induce cell cycle arrest, p19(ARF) can interact with MDM2 and p53 in cells ectopically overexpressing these three components, but the biochemical cascades from p19(ARF) to cell cycle arrest has not been fully elucidated, In this study, we generated stably transfected NIH3T3 cells that express exogenous p19(ARF); under the control of a heavy metal-inducible metalothionine promoter. Cells arrested in G1 by ectopically expressed p19(ARF) contained considerably reduced G1 cyclin dependent kinase (cdk2 and cdk4) activities, The expression of cyclin A (a regulatory subunit of cdk2) markedly decreased, while cyclin D1, the major cdk4 partner in fibroblasts, expressed at a slightly higher level and formed complexes with cdk2 and cdk6 in addition to cdk4. Induction of p19(ARF) activated p53 by increasing its stability; and allowed the expression of p21(Cip1) which bound to all of the cyclin D1-cdk complexes (cyclin D1-cdk2, -cdk4, and -cdk6) thereby inhibiting their kinase activities. p19(ARF) formed complexes with several cellular proteins including mouse MDM2. The majority of MDM2 was found in the complex with p19(ARF), while no p53 was detected in association with p19(ARF). Thus, we propose that p19(ARF) neutralizes MDM2 by sequestration from p53, which results in activation of p53, inhibition of G1 cyclin-cdk activities, and G1 arrest.	Nara Inst Sci & Technol, Grad Sch Biol Sci, Nara 6300101, Japan	Nara Institute of Science & Technology	Kato, J (corresponding author), Nara Inst Sci & Technol, Grad Sch Biol Sci, 8916-5 Takayama, Nara 6300101, Japan.		Kurokawa, Kazuo/E-9130-2013; Tanaka, Toshiaki/C-5567-2013; Shingakujyutsu, Kurokawaken/G-1378-2011	Kurokawa, Kazuo/0000-0003-3549-4795; Tanaka, Toshiaki/0000-0002-9448-1452; 				Brown DR, 1998, EMBO J, V17, P2513, DOI 10.1093/emboj/17.9.2513; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cook DM, 1996, ONCOGENE, V13, P1789; DellaValle V, 1997, ONCOGENE, V15, P2475, DOI 10.1038/sj.onc.1201417; Dunphy William G., 1994, Trends in Cell Biology, V4, P202; GOTTLIEB MT, 1996, BIOCHIM BIOPHYS ACTA, V1287, P77; Haber DA, 1997, CELL, V91, P555, DOI 10.1016/S0092-8674(00)80441-9; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LENG P, 1995, INT J ONCOL, V6, P251; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LUNA RMD, 1995, NATURE, V378, P203; MAO L, 1995, CANCER RES, V55, P2995; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Piette J, 1997, ONCOGENE, V15, P1001, DOI 10.1038/sj.onc.1201432; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Quelle DE, 1997, P NATL ACAD SCI USA, V94, P669, DOI 10.1073/pnas.94.2.669; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHEAFF RJ, 1995, CURR BIOL, V5, P28, DOI 10.1016/S0960-9822(95)00009-1; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; STONE S, 1995, CANCER RES, V55, P2988; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	41	35	35	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 29	1999	18	17					2718	2727		10.1038/sj.onc.1202628	http://dx.doi.org/10.1038/sj.onc.1202628			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FH	10348346				2022-12-25	WOS:000080124900007
J	Nakamura, N; Fujii, M; Tsukahara, T; Arai, M; Ohashi, T; Wakao, H; Kannagi, M; Yamamoto, N				Nakamura, N; Fujii, M; Tsukahara, T; Arai, M; Ohashi, T; Wakao, H; Kannagi, M; Yamamoto, N			Human T-cell leukemia virus type 1 Tax protein induces the expression of STAT1 and STAT5 genes in T-cells	ONCOGENE			English	Article						HTLV-1; tax; STAT; transformation	DNA-BINDING ACTIVITY; CONSTITUTIVE ACTIVATION; TRANSCRIPTION FACTOR; TRANSACTIVATOR GENE; MOLECULAR-CLONING; ABL ONCOGENE; HTLV-I; INTERLEUKIN-2; PATHWAY; LINES	Human T-cell leukemia virus type 1 (HTLV-1) Tax transforms normal T-cells in the presence of interleukin (IL)-2 in vitro. STAT is a family of transcription factors that play a pivotal role in cytokine-induced functions of a various type of cells. We investigated the involvement of STATs in the transformation of T-cells by HTLV-1, HTLV-1-transformed T-cell lines expressed higher amounts of STAT1, STAT3 and STAT5 RNA and proteins than virus-negative T cells. The expression of STAT1 and STAT5 in a human T-cell line was induced by Tax, IL-2 induced the DNA binding activity of STAT3 and STAT5 of a HTLV-1-transformed cell line and then stimulated its proliferation. In contrast, IL-2 did neither in a cell line lacking STAT3 and STAT5. The expression of STAT1, STAT3 and STAT5 mRNAs were also induced by a T-cell mitogen in normal human peripheral blood mononuclear cells, Our results suggest that the induction of STAT1 and STAT5 by Tax enhances cytokine-induced functions of virus-infected T-cells, hence the induction may play a role in IL-2-dependent transformation steps of T-cells by HTLV-1.	Tokyo Med & Dent Univ, Dept Immunotherapeut, Bunkyo Ku, Tokyo 113, Japan; Tokyo Med & Dent Univ, Dept Microbiol, Bunkyo Ku, Tokyo 113, Japan; Niigata Univ, Sch Med, Dept Virol, Niigata 9518510, Japan; Helix Res Inst, Chiba 292, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Niigata University	Fujii, M (corresponding author), Tokyo Med & Dent Univ, Dept Immunotherapeut, Bunkyo Ku, Yushima, Tokyo 113, Japan.		WAKAO, Hiroshi/A-4242-2012; Ohashi, Takashi/C-4671-2012	Ohashi, Takashi/0000-0002-3769-4224				AKAGI T, 1993, J VIROL, V67, P1211, DOI 10.1128/JVI.67.3.1211-1217.1993; AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; CANN AJ, 1985, NATURE, V318, P571, DOI 10.1038/318571a0; Cao XM, 1996, MOL CELL BIOL, V16, P1595; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; Darnell JE, 1996, RECENT PROG HORM RES, V51, P391; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJII M, 1991, ONCOGENE, V6, P1023; GOUILLEUX F, 1995, ENDOCRINOLOGY, V136, P5700, DOI 10.1210/en.136.12.5700; GouilleuxGruart V, 1996, BLOOD, V87, P1692; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; JOHNSTON JA, 1995, P NATL ACAD SCI USA, V92, P8705, DOI 10.1073/pnas.92.19.8705; KIM SJ, 1990, J EXP MED, V172, P121, DOI 10.1084/jem.172.1.121; KOBAYASHI N, 1984, EMBO J, V3, P1339, DOI 10.1002/j.1460-2075.1984.tb01974.x; LEE B, 1989, TOHOKU J EXP MED, V157, P1, DOI 10.1620/tjem.157.1; Lin JX, 1996, J BIOL CHEM, V271, P10738, DOI 10.1074/jbc.271.18.10738; Lindholm PF, 1996, J VIROL, V70, P2525, DOI 10.1128/JVI.70.4.2525-2532.1996; Low KG, 1997, J VIROL, V71, P1956, DOI 10.1128/JVI.71.3.1956-1962.1997; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; MIURA S, 1991, MOL CELL BIOL, V11, P1313, DOI 10.1128/MCB.11.3.1313; MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0; NAGATA K, 1989, J VIROL, V63, P3220, DOI 10.1128/JVI.63.8.3220-3226.1989; OHASHI T, 1995, BLOOD, V85, P1454, DOI 10.1182/blood.V85.6.1454.bloodjournal8561454; OHTANI K, 1989, NUCLEIC ACIDS RES, V17, P1589, DOI 10.1093/nar/17.4.1589; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; Schmitt I, 1998, J VIROL, V72, P633, DOI 10.1128/JVI.72.1.633-640.1998; SEIKI M, 1986, EMBO J, V5, P561, DOI 10.1002/j.1460-2075.1986.tb04247.x; Shuai K, 1996, ONCOGENE, V13, P247; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; SUGAMURA K, 1984, INT J CANCER, V34, P221, DOI 10.1002/ijc.2910340213; SUGAMURA K, 1986, Cancer Reviews, V1, P96; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; Takemoto S, 1997, P NATL ACAD SCI USA, V94, P13897, DOI 10.1073/pnas.94.25.13897; TSUCHIYA H, 1993, J VIROL, V67, P7001, DOI 10.1128/JVI.67.12.7001-7007.1993; UCHIJIMA M, 1994, J BIOL CHEM, V269, P14946; UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481; WAKAO H, 1995, EMBO J, V14, P2527, DOI 10.1002/j.1460-2075.1995.tb07250.x; WAKAO H, 1995, EMBO J, V14, P854, DOI 10.1002/j.1460-2075.1995.tb07064.x; WeberNordt RM, 1996, BLOOD, V88, P809; YAMAMOTO N, 1982, SCIENCE, V217, P737, DOI 10.1126/science.6980467; YAMASHITA I, 1994, BLOOD, V84, P1573; YOSHIDA M, 1995, CURR TOP MICROBIOL, V193, P79; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555	50	26	26	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 29	1999	18	17					2667	2675		10.1038/sj.onc.1202608	http://dx.doi.org/10.1038/sj.onc.1202608			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FH	10348340				2022-12-25	WOS:000080124900001
J	Sun, SY; Yue, P; Wu, GS; El-Deiry, WS; Shroot, B; Hong, WK; Lotan, R				Sun, SY; Yue, P; Wu, GS; El-Deiry, WS; Shroot, B; Hong, WK; Lotan, R			Mechanisms of apoptosis induced by the synthetic retinoid CD437 in human non-small cell lung carcinoma cells	ONCOGENE			English	Article						retinoids; CD437; lung cancer; p53; apoptosis	P53 GENE-MUTATIONS; GROWTH ARREST; IN-VIVO; CANCER; DEATH; ACID; INDUCTION; LINES; PATHWAY; IDENTIFICATION	The novel synthetic retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) has been shown to induce apoptosis in various tumor cell lines including human non-small cell lung carcinoma (NSCLC) cells, which are resistant to the natural all-trans retinoic acid and to many synthetic receptor-selective retinoids, Although the mechanism of this effect was not elucidated, it was found to be independent of nuclear retinoid receptors, In the present study, we analysed the mechanisms by which CD437 induces apoptosis in two human NSCLC cell lines: H460 with wild-type p53 and H1792 with mutant p53. Both cell lines underwent apoptosis after exposure to CD437, although the cell line with wild-type p53 (H460) was more sensitive to the induction of apoptosis, CD437 increased the activity of caspase in both cell lines, however, the effect was much more pronounced in the H460 cells, The caspase inhibitors (Z-DEVD-FMK and Z-VAD-FMK) suppressed CD437-induced CPP32-like caspase activation and apoptosis in both cell lines, CD437 induced the expression of the p53 gene and its target genes, p21, Bas, and Killer/DR5, only in the H460 cells. These results suggest that CD437-induced apoptosis is more extensive in NSCLC cells that express wild-type p53, possibly due to the involvement of the p53 regulated genes Killer/DR5, and Bar although CD437 can also induce apoptosis by means of a p53-independent mechanism. Both pathways of CD437-induced apoptosis appear to involve activation of CPP32-like caspase.	Univ Texas, MD Anderson Cancer Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Clin Canc Prevent, Houston, TX 77030 USA; Univ Penn, Sch Med, Howard Hughes Med Inst, Lab Mol Oncol & Cell Cycle Regulat, Philadelphia, PA 19104 USA; Galderma Res & Dev, Sophia Antipolis, France	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Howard Hughes Medical Institute; University of Pennsylvania; Galderma R&D SNC	Sun, SY (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Thorac Head & Neck Med Oncol, 1515 Holcombe Blvd,Box 108, Houston, TX 77030 USA.		El-Deiry, Wafik/AAJ-6080-2020	El-Deiry, Wafik/0000-0002-9577-8266	NATIONAL CANCER INSTITUTE [U19CA068437] Funding Source: NIH RePORTER; NCI NIH HHS [U19 CA68437] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adachi H, 1998, AM J RESP CELL MOL, V18, P323, DOI 10.1165/ajrcmb.18.3.2974; Benner S E, 1995, Oncology (Williston Park), V9, P205; BERNARD BA, 1992, BIOCHEM BIOPH RES CO, V186, P977, DOI 10.1016/0006-291X(92)90842-9; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHEN YQ, 1995, CANCER RES, V55, P4536; DE LUCA LM, 1991, FASEB J, V5, P2924; ELDEIRY WS, 1994, CANCER RES, V54, P1169; FAN SJ, 1994, CANCER RES, V54, P5824; GERADTS J, 1993, CELL GROWTH DIFFER, V4, P799; GomezManzano C, 1997, J NATL CANCER I, V89, P1036, DOI 10.1093/jnci/89.14.1036; HARPER JW, 1993, CELL, V75, P805; Hsu CA, 1997, BLOOD, V89, P4470, DOI 10.1182/blood.V89.12.4470; KORSMEYER SJ, 1993, SEMIN CANCER BIOL, V4, P327; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LEHMANN JM, 1991, CANCER RES, V51, P4804; Li Y, 1998, MOL CELL BIOL, V18, P4719, DOI 10.1128/MCB.18.8.4719; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; LOTAN R, 1995, J NATL CANCER I, V87, P1655, DOI 10.1093/jnci/87.22.1655; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU S, 1994, P AM ASSOC CANC RES, V35, pA1517; MARTIN SJ, 1995, CRIT REV ONCOL HEMAT, V18, P137, DOI 10.1016/1040-8428(94)00124-C; MICHIELI P, 1994, CANCER RES, V54, P3391; MITSUDOMI T, 1992, ONCOGENE, V7, P171; MIYASHITA T, 1995, CELL, V80, P293; Nagy L, 1998, CELL DEATH DIFFER, V5, P11, DOI 10.1038/sj.cdd.4400337; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Oridate N, 1997, INT J CANCER, V70, P484, DOI 10.1002/(SICI)1097-0215(19970207)70:4<484::AID-IJC21>3.0.CO;2-E; Patel T, 1996, FASEB J, V10, P587, DOI 10.1096/fasebj.10.5.8621058; Piedrafita FJ, 1997, MOL CELL BIOL, V17, P6348, DOI 10.1128/MCB.17.11.6348; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Schadendorf D, 1996, J CELL BIOL, V135, P1889, DOI 10.1083/jcb.135.6.1889; SHAO ZM, 1995, ONCOGENE, V11, P493; SHEIKH MS, 1994, ONCOGENE, V9, P3407; Shimamura A, 1996, CLIN CANCER RES, V2, P435; Sun SY, 1997, J CELL PHYSIOL, V173, P279, DOI 10.1002/(SICI)1097-4652(199711)173:2<279::AID-JCP36>3.0.CO;2-8; Sun SY, 1997, CANCER RES, V57, P4931; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Zou CP, 1998, CLIN CANCER RES, V4, P1345	39	113	115	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	1999	18	14					2357	2365		10.1038/sj.onc.1202543	http://dx.doi.org/10.1038/sj.onc.1202543			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184DT	10327056				2022-12-25	WOS:000079595500008
J	Gao, J; Serrero, G				Gao, J; Serrero, G			Adipose differentiation related protein (ADRP) expressed in transfected COS-7 cells selectively stimulates long chain fatty acid uptake	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER PLASMA-MEMBRANES; RAT HEART MYOCYTES; BINDING-PROTEIN; GENE-EXPRESSION; TRANSCRIPTIONAL REGULATION; ADIPOCYTE DIFFERENTIATION; OLEATE; TRANSPORT; METABOLISM; PERMEATION	Adipose differentiation related protein (ADRP) is a 50-kDa novel protein cloned from a mouse 1246 adipocyte cDNA library, rapidly induced during adipocyte differentiation. We have examined ADRP function, and we show here that ADRP facilitates fatty acid uptake in COS cells transfected with ADRP cDNA We demonstrate that uptake of long chain fatty acids was significantly stimulated in a time-dependent fashion in ADRP-expressing COS-7 cells compared with empty vector-transfected control cells. Oleic acid uptake velocity increased significantly in a dose-dependent manner in ADRP-expressing COS-7 cells compared with control cells. The transport K-m was 0.051 mu M, and V-max was 57.97 pmol/10(5) cells/min in ADRP-expressing cells, and K-m was 0.093 mu M and V-max was 20.13 pmol/10(5) cells/min in control cells. The oleate uptake measured at 4 degrees C was only 10% that at 37 degrees C, ADRP also stimulated uptake of palmitate and arachidonate but had no effect on uptake of medium chain fatty acid such as octanoic acid and glucose. These data suggest that ADRP specifically enhances uptake of long chain fatty acids by increasing the initial rate of uptake and provide novel information about ADRP function as a saturable transport component for long chain fatty acids.	Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA; Univ Maryland, Program Oncol, Marlene & Stewart Greenebaum Canc Ctr, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Serrero, G (corresponding author), Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, 20 N Pine St, Baltimore, MD 21201 USA.				NIDDK NIH HHS [R01DK 51463] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051463] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; ABUMRAD NA, 1981, J BIOL CHEM, V256, P9183; AMRI EZ, 1994, J LIPID RES, V35, P930; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BLACK PN, 1994, BBA-LIPID LIPID MET, V1210, P123, DOI 10.1016/0005-2760(94)90113-9; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brasaemle DL, 1997, J LIPID RES, V38, P2249; DEGRELLA RF, 1980, J BIOL CHEM, V255, P9731; DEGRELLA RF, 1980, J BIOL CHEM, V255, P9739; DISTEL RJ, 1992, J BIOL CHEM, V267, P5937; FUJII S, 1987, LIPIDS, V22, P544, DOI 10.1007/BF02540374; GRIMALDI PA, 1992, P NATL ACAD SCI USA, V89, P10930, DOI 10.1073/pnas.89.22.10930; HEIMBERG M, 1978, P251; JIANG HP, 1992, P NATL ACAD SCI USA, V89, P7856, DOI 10.1073/pnas.89.17.7856; KAHN CR, 1989, MOL ENDOCRINOL, V3, P840, DOI 10.1210/mend-3-5-840; KLIP A, 1990, DIABETES CARE, V13, P228, DOI 10.2337/diacare.13.3.228; KLOTZ IM, 1946, J AM CHEM SOC, V68, P1486, DOI 10.1021/ja01212a030; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; NOGUCHI T, 1985, J BIOL CHEM, V260, P4393; NOY N, 1986, BIOCHEMISTRY-US, V25, P2013, DOI 10.1021/bi00356a027; RUDNEY H, 1986, ANNU REV NUTR, V6, P245, DOI 10.1146/annurev.nu.06.070186.001333; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; Schroeder F, 1998, CHEM PHYS LIPIDS, V92, P1, DOI 10.1016/S0009-3084(98)00003-6; SCHWIETERMAN W, 1988, P NATL ACAD SCI USA, V85, P359, DOI 10.1073/pnas.85.2.359; SORRENTINO D, 1988, J CLIN INVEST, V82, P928, DOI 10.1172/JCI113700; SPECTOR A A, 1978, P229; Spiegelman B M, 1986, Prog Clin Biol Res, V226, P445; Steiner S, 1996, BIOCHEM BIOPH RES CO, V218, P777, DOI 10.1006/bbrc.1996.0138; STREMMEL W, 1985, P NATL ACAD SCI USA, V82, P4, DOI 10.1073/pnas.82.1.4; STREMMEL W, 1986, P NATL ACAD SCI USA, V83, P3086, DOI 10.1073/pnas.83.10.3086; STREMMEL W, 1986, P NATL ACAD SCI USA, V83, P3584, DOI 10.1073/pnas.83.11.3584; STUMP DD, 1992, J HEPATOL, V16, P304, DOI 10.1016/S0168-8278(05)80661-0; TRIGATTI BL, 1991, J BIOL CHEM, V266, P22621; Ye H, 1998, BIOCHEM J, V330, P803, DOI 10.1042/bj3300803; ZHOU SL, 1992, J BIOL CHEM, V267, P14456	35	189	195	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16825	16830		10.1074/jbc.274.24.16825	http://dx.doi.org/10.1074/jbc.274.24.16825			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358026	hybrid			2022-12-25	WOS:000080780400025
J	Hermolin, J; Dmitriev, OY; Zhang, Y; Fillingame, RH				Hermolin, J; Dmitriev, OY; Zhang, Y; Fillingame, RH			Defining the domain of binding of F-1 subunit epsilon with the polar loop of F-0 subunit c in the Escherichia coli ATP synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLING H+ TRANSPORT; ALPHA-SUBUNIT; CROSS-LINKING; PROTON TRANSLOCATION; ENERGY TRANSDUCTION; F0F1-ATP SYNTHASE; GAMMA-SUBUNIT; 2ND STALK; F-ATPASE; ROTATION	We have previously shown that the E31C-substituted epsilon subunit of F-1 can be cross-linked by disulfide bond formation to the Q42C-substituted c subunit of F-0 in the Escherichia coli F1F0-ATP synthase complex (Zhang, Y., and Fillingame, R. H. (1995) J. Biol. Chem. 270, 24609-24614). The interactions of subunits epsilon and c are thought to be central to the coupling of H+ transport through F-1 to ATP synthesis in F-1, To further define the domains of interaction, we have introduced additional Cys into subunit epsilon and subunit c and tested for cross-link formation following sulfhydryl oxidation, The results show that Cys, in a continuous stretch of residues 26-33 in subunit epsilon, can be cross-linked to Cys at positions 40, 42, and 44 in the polar loop region of subunit c. The results are interpreted, and the subunit interaction is modeled using the NMR and x-ray diffraction structures of the monomeric subunits together with information on the packing arrangement of subunit c in a ring of 12 subunits, In the model, residues 26-33 form a turn of antiparallel beta-sheet which packs between the polar loop regions of adjacent subunit c at the cytoplasmic surface of the c(12) oligomer.	Univ Wisconsin, Dept Biomol Chem, Sch Med, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Fillingame, RH (corresponding author), Univ Wisconsin, Dept Biomol Chem, Sch Med, 587 Med Sci Bldg, Madison, WI 53706 USA.		Dmitriev, Oleg/AAB-7830-2019; Zhang, Ying E/G-3657-2015	Zhang, Ying E/0000-0003-2753-7601	NIGMS NIH HHS [GM23105] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023105, R37GM023105] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AGGELER R, 1990, BIOCHEMISTRY-US, V29, P10387, DOI 10.1021/bi00497a013; AGGELER R, 1995, BBA-BIOENERGETICS, V1230, P62, DOI 10.1016/0005-2728(95)00040-P; BIRKENHAGER R, 1995, EUR J BIOCHEM, V230, P58, DOI 10.1111/j.1432-1033.1995.tb20534.x; Bulygin VV, 1998, J BIOL CHEM, V273, P31765, DOI 10.1074/jbc.273.48.31765; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; Dunn SD, 1998, J BIOL CHEM, V273, P8646, DOI 10.1074/jbc.273.15.8646; Elston T, 1998, NATURE, V391, P510, DOI 10.1038/35185; Engelbrecht S, 1997, FEBS LETT, V414, P485, DOI 10.1016/S0014-5793(97)00997-6; Fillingame RH, 1997, J EXP BIOL, V200, P217; Fillingame RH, 1998, BBA-BIOENERGETICS, V1365, P135, DOI 10.1016/S0005-2728(98)00053-X; FOSTER DL, 1982, J BIOL CHEM, V257, P2009; FRAGA D, 1994, J BIOL CHEM, V269, P7532; GIRVIN ME, 1989, BIOCHEMISTRY-US, V28, P4340, DOI 10.1021/bi00436a032; Girvin ME, 1998, BIOCHEMISTRY-US, V37, P8817, DOI 10.1021/bi980511m; Hasler K, 1998, FEBS LETT, V426, P301, DOI 10.1016/S0014-5793(98)00358-5; HATCH LP, 1995, J BIOL CHEM, V270, P29407, DOI 10.1074/jbc.270.49.29407; Jiang WP, 1998, P NATL ACAD SCI USA, V95, P6607, DOI 10.1073/pnas.95.12.6607; Jones PC, 1998, J BIOL CHEM, V273, P29701, DOI 10.1074/jbc.273.45.29701; Jones PC, 1998, J BIOL CHEM, V273, P17178, DOI 10.1074/jbc.273.27.17178; Kato-Yamada Y, 1998, J BIOL CHEM, V273, P19375, DOI 10.1074/jbc.273.31.19375; Kinosita K, 1998, CELL, V93, P21, DOI 10.1016/S0092-8674(00)81142-3; KUKI M, 1988, J BIOL CHEM, V263, P17437; LAROE DJ, 1992, J BACTERIOL, V174, P633, DOI 10.1128/jb.174.2.633-637.1992; Licher T, 1998, FEBS LETT, V431, P419, DOI 10.1016/S0014-5793(98)00807-2; Long JC, 1998, J BIOL CHEM, V273, P16235, DOI 10.1074/jbc.273.26.16235; MOSHER ME, 1985, J BIOL CHEM, V260, P4807; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; Rodgers AJW, 1998, J BIOL CHEM, V273, P29406, DOI 10.1074/jbc.273.45.29406; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schulenberg B, 1997, EUR J BIOCHEM, V249, P134, DOI 10.1111/j.1432-1033.1997.t01-1-00134.x; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; Singh S, 1996, FEBS LETT, V397, P30, DOI 10.1016/S0014-5793(96)01127-1; Takeyasu K, 1996, FEBS LETT, V392, P110, DOI 10.1016/0014-5793(96)00796-X; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Uhlin U, 1997, STRUCTURE, V5, P1219, DOI 10.1016/S0969-2126(97)00272-4; Valiyaveetil FI, 1997, J BIOL CHEM, V272, P32635, DOI 10.1074/jbc.272.51.32635; Valiyaveetil FI, 1998, J BIOL CHEM, V273, P16241, DOI 10.1074/jbc.273.26.16241; VIK SB, 1994, J BIOL CHEM, V269, P30364; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X; Walker JE, 1998, ANGEW CHEM INT EDIT, V37, P2309, DOI 10.1002/(SICI)1521-3773(19980918)37:17<2308::AID-ANIE2308>3.0.CO;2-W; Wang HY, 1998, NATURE, V396, P279, DOI 10.1038/24409; Watts SD, 1997, J BIOL CHEM, V272, P15065, DOI 10.1074/jbc.272.24.15065; WATTS SD, 1995, FEBS LETT, V368, P235, DOI 10.1016/0014-5793(95)00658-V; Watts SD, 1996, J BIOL CHEM, V271, P28341, DOI 10.1074/jbc.271.45.28341; Wilkens S, 1997, NAT STRUCT BIOL, V4, P198, DOI 10.1038/nsb0397-198; Wilkens S, 1998, NATURE, V393, P29, DOI 10.1038/29908; WILKENS S, 1995, NAT STRUCT BIOL, V2, P961, DOI 10.1038/nsb1195-961; Yasuda R, 1998, CELL, V93, P1117, DOI 10.1016/S0092-8674(00)81456-7; ZHANG Y, 1995, J BIOL CHEM, V270, P24609, DOI 10.1074/jbc.270.41.24609; ZHANG Y, 1994, J BIOL CHEM, V269, P10221	53	52	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17011	17016		10.1074/jbc.274.24.17011	http://dx.doi.org/10.1074/jbc.274.24.17011			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358051	hybrid			2022-12-25	WOS:000080780400050
J	Liu, JY; Jiang, T; Zhang, JP; Liang, DC				Liu, JY; Jiang, T; Zhang, JP; Liang, DC			Crystal structure of allophycocyanin from red algae Porphyra yezoensis at 2.2-angstrom resolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYANOBACTERIUM MASTIGOCLADUS-LAMINOSUS; AMINO-ACID-SEQUENCES; ANGSTROM RESOLUTION; C-PHYCOCYANIN; FREMYELLA-DIPLOSIPHON; BETA-SUBUNIT; X-RAY; CRYSTALLIZATION; REFINEMENT; PHYCOERYTHRIN	The crystal structure of allophycocyanin from red algae Porphyra yezoensis (APC-PY) at 2.2-Angstrom resolution has been determined by the molecular replacement method. The crystal belongs to space group R32 with cell parameters a = b = 105.3 Angstrom, c = 189.4 Angstrom, alpha = beta = 90 degrees, gamma = 120 degrees, After several cycles of refinement using program X-PLOR and model building based on the electron density map, the crystallographic R-factor converged to 19.3% (R-free factor is 26.9%) in the range of 10.0 to 2.2 Angstrom The r.m.s. deviations of bond length and angles are 0.015 Angstrom and 2.9 degrees, respectively. In the crystal, two APC-PY trimers associate face to face into a hexamer, The assembly of two trimers within the hexamer is similar to that of C-phycocyanin (C-PC) and R-phycoerythrin (R-PE) hexamers, but the assembly tightness of the two trimers to the hexamer is not so high as that in C-PC and R-PE hexamers, The chromophore-protein interactions and possible pathway of energy transfer were discussed. Phycocyanobilin 1 alpha 84 of APC-PY forms 5 hydrogen bonds with 3 residues in subunit 2 beta of another monomer, In R-PE and C-PC, chromophore 1 alpha 84 only forms 1 hydrogen bond with 2 beta 77 residue in subunit 2 beta. This result may support and explain great spectrum difference exists between APC trimer and monomer.	Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Chaoyang Dist, Peoples R China	Chinese Academy of Sciences; Institute of Biophysics, CAS	Liang, DC (corresponding author), Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, 15 Datun Rd, Beijing 100101, Chaoyang Dist, Peoples R China.	dcliang@sun5.ibp.ac.cn						APT KE, 1993, PLANT MOL BIOL, V21, P27, DOI 10.1007/BF00039615; BREJC K, 1995, J MOL BIOL, V249, P424, DOI 10.1006/jmbi.1995.0307; BRUNGER AT, 1990, XPLOR VERSION 2 1; Chang WR, 1996, J MOL BIOL, V262, P721, DOI 10.1006/jmbi.1996.0547; CSATORDAY K, 1984, BIOCHEMISTRY-US, V23, P6466, DOI 10.1021/bi00321a029; DEXTER DL, 1953, J CHEM PHYS, V21, P836, DOI 10.1063/1.1699044; DUERRING M, 1991, J MOL BIOL, V217, P577, DOI 10.1016/0022-2836(91)90759-Y; DUERRING M, 1990, J MOL BIOL, V211, P633, DOI 10.1016/0022-2836(90)90270-V; FICNER R, 1993, EUR J BIOCHEM, V218, P103, DOI 10.1111/j.1432-1033.1993.tb18356.x; FICNER R, 1992, J MOL BIOL, V228, P935, DOI 10.1016/0022-2836(92)90876-L; Forster T., 1965, MODERN QUANTUM CHEM, V3, P93; GLAZER AN, 1984, BIOCHIM BIOPHYS ACTA, V768, P29, DOI 10.1016/0304-4173(84)90006-5; HOUMARD J, 1988, J BACTERIOL, V170, P5512, DOI 10.1128/jb.170.12.5512-5521.1988; HOUMARD J, 1986, MOL GEN GENET, V205, P404, DOI 10.1007/BF00338074; Jiang T, 1999, PROTEINS, V34, P224; KARSHIKOV A, 1991, PROTEIN ENG, V4, P681, DOI 10.1093/protein/4.6.681; Liu JY, 1998, ACTA CRYSTALLOGR D, V54, P662, DOI 10.1107/S0907444997017824; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MACCOLL R, 1983, ARCH BIOCHEM BIOPHYS, V223, P24, DOI 10.1016/0003-9861(83)90567-2; MINAMI Y, 1985, FEBS LETT, V191, P216, DOI 10.1016/0014-5793(85)80011-9; NAVAZA J, 1984, ACTA CRYSTALLOGR A, V50, P157; OFFNER GD, 1983, J BIOL CHEM, V258, P9931; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; SCHIRMER T, 1985, J MOL BIOL, V184, P257, DOI 10.1016/0022-2836(85)90379-1; SCHIRMER T, 1986, J MOL BIOL, V188, P651, DOI 10.1016/S0022-2836(86)80013-4; SCHIRMER T, 1987, J MOL BIOL, V196, P677, DOI 10.1016/0022-2836(87)90040-4; SIDLER W, 1981, H-S Z PHYSIOL CHEM, V362, P611, DOI 10.1515/bchm2.1981.362.1.611	27	61	70	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16945	16952		10.1074/jbc.274.24.16945	http://dx.doi.org/10.1074/jbc.274.24.16945			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358042	hybrid			2022-12-25	WOS:000080780400041
J	Matskevitch, I; Wagner, CA; Stegen, C; Broer, S; Noll, B; Risler, T; Kwon, HM; Handler, JS; Waldegger, S; Busch, AE; Lang, F				Matskevitch, I; Wagner, CA; Stegen, C; Broer, S; Noll, B; Risler, T; Kwon, HM; Handler, JS; Waldegger, S; Busch, AE; Lang, F			Functional characterization of the betaine/gamma-aminobutyric acid transporter BGT-1 expressed in Xenopus oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VOLUME REGULATORY MECHANISMS; BRAIN GABA TRANSPORTER; RAT-BRAIN; MOLECULAR-CLONING; MOUSE-BRAIN; CDNA; HETEROGENEITY; CHANNELS; CELLS	Betaine is an osmolyte accumulated in cells during osmotic cell shrinkage. The canine transporter mediating cellular accumulation of the osmolyte betaine and the neurotransmitter gamma-aminobutyric acid (BGT-1) was expressed in Xenopus oocytes and analyzed by two-electrode voltage clamp and tracer flux studies. Exposure of oocytes expressing BGT-1 to betaine or gamma-aminobutyric acid (GABA) depolarized the cell membrane in the current clamp mode and induced an inward current under voltage clamp conditions. At 1 mM substrate the induced currents decreased in the following order: betaine GABA > diaminobutyric acid = beta-alanine > proline quinidine > dimethylglycine > glycine > sarcosine. Both the V-max and K-m of GABA- and betaine-induced currents were voltage-dependent, and GABA- and betaine-induced currents and radioactive tracer uptake were strictly Na+-dependent but only partially dependent on the presence of Cl-. The apparent affinity of GABA decreased with decreasing Naf concentrations. The K-m of Na+ also depended on the GABA and Cl- concentration. A decrease of the Cl- concentration reduced the apparent affinity for Na+ and GABA, and a decrease of the Na+ concentration reduced the apparent affinity for Cl- and GABA. A comparison of Na-22(+)-, Cl-36(-)-, and C-14-labeled GABA and C-14-labeled betaine fluxes and GABA- and betaine-induced currents yielded a coupling ratio of Na+/Cl-/organic substrate of 3:1:1 or 3:2:1, Based on the data, a transport model of ordered binding is proposed in which GABA binds first, Na+ second, and Cl- third. In conclusion, BGT-1 displays significant functional differences from the other members of the GABA transporter family.	Univ Tubingen, Inst Physiol 1, Dept Physiol, D-72076 Tubingen, Germany; Univ Tubingen, Dept Biochem, D-72076 Tubingen, Germany; Univ Tubingen, Dept Internal Med, D-72076 Tubingen, Germany; Johns Hopkins Univ, Sch Med, Dept Internal Med, Baltimore, MD 21205 USA; IM Sechenov Evolutionary Physiol & Biochem Inst, St Petersburg 194223, Russia	Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Johns Hopkins University; North-Western State Medical University named after I.I. Mechnikov; Russian Academy of Sciences; Sechenov Institute of Evolutionary Physiology & Biochemistry	Lang, F (corresponding author), Univ Tubingen, Inst Physiol 1, Dept Physiol, Gmelinstr 5, D-72076 Tubingen, Germany.		Lee-Kwon, Whaseon/D-6021-2011; Broer, Stefan/A-1286-2008	Broer, Stefan/0000-0002-8040-1634				BORDEN LA, 1992, J BIOL CHEM, V267, P21098; Borden LA, 1996, NEUROCHEM INT, V29, P335, DOI 10.1016/0197-0186(95)00158-1; BORDEN LA, 1995, J NEUROCHEM, V64, P977; BURG MB, 1995, AM J PHYSIOL-RENAL, V268, pF983, DOI 10.1152/ajprenal.1995.268.6.F983; Burg MB, 1996, FASEB J, V10, P1598, DOI 10.1096/fasebj.10.14.9002551; BURG MB, 1994, J EXP ZOOL, V268, P171, DOI 10.1002/jez.1402680216; Busch AE, 1996, J PHYSIOL-LONDON, V491, P735, DOI 10.1113/jphysiol.1996.sp021253; Cammack JN, 1996, P NATL ACAD SCI USA, V93, P723, DOI 10.1073/pnas.93.2.723; CAMMACK JN, 1994, NEURON, V13, P949, DOI 10.1016/0896-6273(94)90260-7; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HANDLER JS, 1993, AM J PHYSIOL, V265, pC1449, DOI 10.1152/ajpcell.1993.265.6.C1449; KAVANAUGH MP, 1992, J BIOL CHEM, V267, P22007; KWON HM, 1992, J BIOL CHEM, V267, P6297; Lang F, 1998, PHYSIOL REV, V78, P247, DOI 10.1152/physrev.1998.78.1.247; Lang F, 1998, CELL PHYSIOL BIOCHEM, V8, P1, DOI 10.1159/000016269; LIU QR, 1993, J BIOL CHEM, V268, P2106; LIU QR, 1992, P NATL ACAD SCI USA, V89, P6639, DOI 10.1073/pnas.89.14.6639; LOPEZCORCUERA B, 1992, J BIOL CHEM, V267, P17491; MAGER S, 1993, NEURON, V10, P177, DOI 10.1016/0896-6273(93)90309-F; PENG HB, 1991, METHOD CELL BIOL, V36, P657; Quick MW, 1997, J NEUROSCI, V17, P2967; RASOLA A, 1995, FEBS LETT, V373, P229, DOI 10.1016/0014-5793(95)01052-G; Risso S, 1996, J PHYSIOL-LONDON, V490, P691, DOI 10.1113/jphysiol.1996.sp021178; SMITH KE, 1992, MOL PHARMACOL, V42, P563; Sonders MS, 1996, CURR OPIN NEUROBIOL, V6, P294, DOI 10.1016/S0959-4388(96)80111-5; Su A, 1996, BIOPHYS J, V70, P762, DOI 10.1016/S0006-3495(96)79616-9; UCHIDA S, 1992, P NATL ACAD SCI USA, V89, P8230, DOI 10.1073/pnas.89.17.8230; YAMAUCHI A, 1992, J BIOL CHEM, V267, P649	28	57	60	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16709	16716		10.1074/jbc.274.24.16709	http://dx.doi.org/10.1074/jbc.274.24.16709			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358010	hybrid			2022-12-25	WOS:000080780400009
J	Wright, K; Kolios, G; Westwick, J; Ward, SG				Wright, K; Kolios, G; Westwick, J; Ward, SG			Cytokine-induced apoptosis in epithelial HT-29 cells is independent of nitric oxide formation - Evidence for an interleukin-13-driven phosphatidylinositol 3-kinase-dependent survival mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLAMMATORY BOWEL-DISEASE; TUMOR-NECROSIS-FACTOR; PROTEIN-KINASE AKT; HUMAN B-CELLS; SIGNAL-TRANSDUCTION; KAPPA-B; MEDIATED APOPTOSIS; ULCERATIVE-COLITIS; SYNTHASE ACTIVITY; IGE SYNTHESIS	A combination of the pro-inflammatory cytokines interleukin (IL)-1 alpha, interferon (IFN)-gamma, and tumor necrosis factor (TNF)-alpha induces nitric oxide synthase mRNA expression and nitric oxide (NO) generation in the human colon carcinoma cell line HT-29, This can be inhibited by pretreatment with IL-13 via a phosphatidylinositol (PI) 3-kinase-dependent mechanism (Wright, K., Ward, S. G., Kolios, G., and Westwick, J. (1997) J. Biol. Chem. 272, 12626-12633), Since NO has been implicated in regulating mechanisms leading to cell death, while activation of PI 3-kinase-dependent signaling cascades are thought to be involved with promoting cell survival events, we have investigated the outcome of these cytokine treatments on apoptosis and cell survival of HT-29 cells. Initiation of apoptosis can be achieved by the combinations of IFN-gamma/TNF-alpha, IFN-gamma/CD95, IL-1 alpha/IFN-gamma, and IL-1 alpha/IFN-gamma/TNF-alpha to varying extents. Induction of apoptotic markers by HT-29 cells in response to cytokine treatment is not dependent on NO production. Pretreatment with IL-13 protects against IL-1 alpha/IFN-gamma/TNF-alpha- and IFN-gamma/TNF-alpha- as well as IFN-gamma/CD95-induced (but not IL-1 alpha/IFN-gamma-induced) cell death. In addition, IFN-gamma/TNF-alpha and IL-1 alpha/IFN-gamma/TNF-alpha stimulate activation of caspase-8 and caspase-3, which IL-13 pretreatment was able to partially inhibit and delay. IL-13 also stimulates activation of the major PI 3-kinase effector, protein kinase B, The PI 3-kinase inhibitors wortmannin and LY294002 inhibit IL-13 stimulation of protein kinase B as well as the cell survival effects of IL-13, These data demonstrate that cytokine-induced apoptosis of HT-29 cells is NO-independent and that the activation of a PI 8-kinase-dependent signaling cascade by IL-13 is a key signal responsible for the inhibition of apoptosis.	Univ Bath, Dept Pharm& Pharmacol, Bath BA2 7AY, Avon, England	University of Bath	Ward, SG (corresponding author), Univ Bath, Dept Pharm& Pharmacol, Bath BA2 7AY, Avon, England.		Wright, Karen Leslie/C-7959-2011; Kolios, George/N-6641-2013; Ward, Stephen/AAE-4341-2020	Wright, Karen Leslie/0000-0003-0040-9247; Kolios, George/0000-0002-2066-4782; Ward, Stephen G./0000-0002-6795-6002				ABREUMARTIN MT, 1995, J IMMUNOL, V155, P4147; Aggarwal S, 1999, J IMMUNOL, V162, P2154; ALBINA JE, 1993, J IMMUNOL, V150, P5080; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; ANKARCRONA M, 1994, EXP CELL RES, V213, P172, DOI 10.1006/excr.1994.1187; AVERSA G, 1993, J EXP MED, V178, P2213, DOI 10.1084/jem.178.6.2213; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Brune B, 1998, EUR J PHARMACOL, V351, P261, DOI 10.1016/S0014-2999(98)00274-X; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; COCKS BG, 1993, INT IMMUNOL, V5, P657, DOI 10.1093/intimm/5.6.657; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEFRANCE T, 1994, J EXP MED, V179, P135, DOI 10.1084/jem.179.1.135; delPeso L, 1997, SCIENCE, V278, P687; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; Downward J, 1998, SCIENCE, V279, P673, DOI 10.1126/science.279.5351.673; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; FEHSEL K, 1995, J IMMUNOL, V155, P2858; GARDINER KR, 1995, GUT, V37, P530, DOI 10.1136/gut.37.4.530; GENARO AM, 1995, J CLIN INVEST, V95, P1884, DOI 10.1172/JCI117869; GOLD MR, 1994, J BIOL CHEM, V269, P5403; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; Iwamoto M, 1996, J PATHOL, V180, P152; KANETO H, 1995, DIABETES, V44, P733, DOI 10.2337/diabetes.44.7.733; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kim YM, 1997, J BIOL CHEM, V272, P1402, DOI 10.1074/jbc.272.2.1402; Kolios G, 1999, EUR J IMMUNOL, V29, P530, DOI 10.1002/(SICI)1521-4141(199902)29:02<530::AID-IMMU530>3.0.CO;2-Y; Kolios G, 1998, GUT, V43, P56, DOI 10.1136/gut.43.1.56; Kolios G, 1996, BRIT J PHARMACOL, V119, P351, DOI 10.1111/j.1476-5381.1996.tb15993.x; KOLIOS G, 1995, BRIT J PHARMACOL, V116, P2866, DOI 10.1111/j.1476-5381.1995.tb15938.x; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI JH, 1994, J BIOL CHEM, V269, P30077; LEFORT S, 1995, FEBS LETT, V366, P122, DOI 10.1016/0014-5793(95)00512-8; Lomo J, 1997, BLOOD, V89, P4415; MALEFYT RD, 1993, J IMMUNOL, V151, P6370; Manna SK, 1998, J IMMUNOL, V161, P2863; Mannick JB, 1997, J BIOL CHEM, V272, P24125, DOI 10.1074/jbc.272.39.24125; McCafferty DM, 1997, GASTROENTEROLOGY, V112, P1022, DOI 10.1053/gast.1997.v112.pm9041266; MCKENZIE ANJ, 1993, P NATL ACAD SCI USA, V90, P3735, DOI 10.1073/pnas.90.8.3735; McKenzie SJ, 1996, J CLIN INVEST, V98, P136, DOI 10.1172/JCI118757; Messmer UK, 1996, J BIOL CHEM, V271, P20192, DOI 10.1074/jbc.271.33.20192; MINTY A, 1993, NATURE, V362, P248, DOI 10.1038/362248a0; MISKO TP, 1993, ANAL BIOCHEM, V214, P11, DOI 10.1006/abio.1993.1449; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; Obiri NI, 1997, J IMMUNOL, V158, P756; Ossina NK, 1997, J BIOL CHEM, V272, P16351, DOI 10.1074/jbc.272.26.16351; Parry RV, 1997, EUR J IMMUNOL, V27, P2495, DOI 10.1002/eji.1830271006; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; PUSHKAREVA M, 1995, IMMUNOL TODAY, V16, P294, DOI 10.1016/0167-5699(95)80184-7; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; SARIH M, 1993, BIOCHEM BIOPH RES CO, V191, P503, DOI 10.1006/bbrc.1993.1246; SCHUTZE S, 1994, J LEUKOCYTE BIOL, V56, P533, DOI 10.1002/jlb.56.5.533; Singer II, 1996, GASTROENTEROLOGY, V111, P871, DOI 10.1016/S0016-5085(96)70055-0; Strater J, 1997, GASTROENTEROLOGY, V113, P160, DOI 10.1016/S0016-5085(97)70091-X; Veldman RJ, 1998, BIOCHEM BIOPH RES CO, V247, P802, DOI 10.1006/bbrc.1998.8896; Villa P, 1997, TRENDS BIOCHEM SCI, V22, P388, DOI 10.1016/S0968-0004(97)01107-9; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wright K, 1997, J BIOL CHEM, V272, P12626, DOI 10.1074/jbc.272.19.12626; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Yamashita K, 1999, BLOOD, V93, P674, DOI 10.1182/blood.V93.2.674.402k26_674_685; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zamorano J, 1996, J IMMUNOL, V157, P4926	67	75	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17193	17201		10.1074/jbc.274.24.17193	http://dx.doi.org/10.1074/jbc.274.24.17193			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358077	hybrid			2022-12-25	WOS:000080780400076
J	Barrientos, A; Moraes, CT				Barrientos, A; Moraes, CT			Titrating the effects of mitochondrial complex I impairment in the cell physiology	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEREDITARY OPTIC NEUROPATHY; RESPIRATORY NADH DEHYDROGENASE; DEPENDENT LIPID-PEROXIDATION; DNA-ENCODED SUBUNITS; PERMEABILITY TRANSITION; XENOMITOCHONDRIAL CYBRIDS; SUPEROXIDE FORMATION; HEART-MITOCHONDRIA; FLUORESCENT-PROBE; SKIN FIBROBLASTS	The mitochondrial oxidative phosphorylation system consists of five multimeric enzymes (complexes I-V). NADH dehydrogenase or complex I (CI) is affected in most of the mitochondrial diseases and in some neuro degenerative disorders. We have studied the physiological consequences of a partial CI inhibition at the cellular level. We used a genetic model (40% CI-inhibited human-ape xenomitochondrial cybrids) and a drug-induced model (0-100% CI-inhibited cells using different concentrations of rotenone). We observed a quantitative correlation between the level of CI impairment and cell respiration, cell growth, free radical production, lipid peroxidation, mitochondrial membrane potential, and apoptosis. We showed that cell death was quantitatively associated with free radical production rather than with a decrease in respiratory chain function. The results obtained with human xenomitochondrial cybrid cells were compatible with those observed in rotenone-induced 40% CI-inhibited cells. At high concentrations (5-6-fold higher than the concentration necessary for 100% CI inhibition), rotenone showed a second toxic effect at the level of microtubule assembly, which also led to apoptosis, The correlation found among all the parameters studied helped clarify the physiological consequences of partial CI inhibitions at the cellular level.	Univ Miami, Sch Med, Dept Neurol, Miami, FL 33136 USA; Univ Miami, Sch Med, Dept Cell Biol & Anat, Miami, FL 33136 USA	University of Miami; University of Miami	Moraes, CT (corresponding author), Univ Miami, Sch Med, Dept Neurol, 1501 NW 9th Ave, Miami, FL 33136 USA.		Moraes, Carlos/AAT-3818-2021		NEI NIH HHS [EY10804] Funding Source: Medline; NIGMS NIH HHS [GM55766] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY010804] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Barrientos A, 1998, J BIOL CHEM, V273, P14210, DOI 10.1074/jbc.273.23.14210; BEYER RE, 1992, BIOCHEM CELL BIOL, V70, P390, DOI 10.1139/o92-061; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; BRINKLEY BR, 1974, EXP CELL RES, V85, P41, DOI 10.1016/0014-4827(74)90210-9; Buchet K, 1998, J BIOL CHEM, V273, P22983, DOI 10.1074/jbc.273.36.22983; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; CATHCART R, 1983, ANAL BIOCHEM, V134, P111, DOI 10.1016/0003-2697(83)90270-1; CHANCE B, 1963, J BIOL CHEM, V238, P418; CHIUEH CC, 1984, PSYCHOPHARMACOL BULL, V20, P548; CHOMYN A, 1986, SCIENCE, V234, P614, DOI 10.1126/science.3764430; CLEETER MWJ, 1992, J NEUROCHEM, V58, P786, DOI 10.1111/j.1471-4159.1992.tb09789.x; DYKENS JA, 1994, J NEUROCHEM, V63, P584; FIGUERAS MJ, 1973, EUR J CANCER, V9, P529, DOI 10.1016/0014-2964(73)90140-0; FOURNIER N, 1987, J BIOENERG BIOMEMBR, V19, P297, DOI 10.1007/BF00762419; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; Hale AJ, 1996, EUR J BIOCHEM, V236, P1, DOI 10.1111/j.1432-1033.1996.00001.x; Hao HL, 1996, J BIOL CHEM, V271, P2347, DOI 10.1074/jbc.271.4.2347; HASEGAWA E, 1990, BIOCHEM BIOPH RES CO, V170, P1049, DOI 10.1016/0006-291X(90)90498-C; HEDLEY D, 1992, CYTOMETRY, V13, P686, DOI 10.1002/cyto.990130704; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Hofhaus G, 1996, J BIOL CHEM, V271, P13155, DOI 10.1074/jbc.271.22.13155; HOFHAUS G, 1995, MOL CELL BIOL, V15, P964; HOFHAUS G, 1993, EMBO J, V12, P3043, DOI 10.1002/j.1460-2075.1993.tb05973.x; IMBERTI R, 1992, RES COMMUN CHEM PATH, V78, P27; Jun AS, 1996, MOL CELL BIOL, V16, P771; Kenyon L, 1997, P NATL ACAD SCI USA, V94, P9131, DOI 10.1073/pnas.94.17.9131; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; KUYPERS FA, 1987, BIOCHIM BIOPHYS ACTA, V921, P266, DOI 10.1016/0005-2760(87)90027-0; LAGANIERE S, 1993, GERONTOLOGY, V39, P7, DOI 10.1159/000213509; LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561; Luo XP, 1997, J CLIN INVEST, V99, P2877, DOI 10.1172/JCI119481; Marchetti P, 1996, CANCER RES, V56, P2033; MARGULIS L, 1973, INT REV CYTOL, V34, P333, DOI 10.1016/S0074-7696(08)61939-7; Mazat JP, 1997, MOL CELL BIOCHEM, V174, P143, DOI 10.1023/A:1006875517267; MEISNER HM, 1966, EXP CELL RES, V42, P291, DOI 10.1016/0014-4827(66)90292-8; PARADIES G, 1991, ARCH BIOCHEM BIOPHYS, V284, P332, DOI 10.1016/0003-9861(91)90304-2; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Petit PX, 1996, FEBS LETT, V396, P7, DOI 10.1016/0014-5793(96)00988-X; PETRONILLI V, 1993, J BIOL CHEM, V268, P1011; Pitkanen S, 1996, J CLIN INVEST, V98, P345, DOI 10.1172/JCI118798; PRYOR WA, 1982, ANN NY ACAD SCI, V393, P1, DOI 10.1111/j.1749-6632.1982.tb31228.x; RAMSAY RR, 1992, BIOCHEM BIOPH RES CO, V189, P47, DOI 10.1016/0006-291X(92)91523-S; RICHTER C, 1988, FREE RADICAL BIO MED, V4, P365, DOI 10.1016/0891-5849(88)90088-3; ROBINSON BH, 1993, BIOCHIM BIOPHYS ACTA, V1182, P231, DOI 10.1016/0925-4439(93)90064-8; ROBINSON BH, 1985, AM J HUM GENET, V37, P938; Salvioli S, 1997, FEBS LETT, V411, P77, DOI 10.1016/S0014-5793(97)00669-8; SCOTT ID, 1980, BIOCHEM J, V192, P873, DOI 10.1042/bj1920873; Seaton TA, 1997, BRAIN RES, V777, P110; Seaton TA, 1998, BRAIN RES, V809, P12, DOI 10.1016/S0006-8993(98)00790-2; SHAPIRA AHV, 1989, LANCET, V1, P1269; Simbula G, 1997, AM J PHYSIOL-CELL PH, V273, pC479, DOI 10.1152/ajpcell.1997.273.2.C479; SINGER TP, 1994, BBA-BIOENERGETICS, V1187, P198, DOI 10.1016/0005-2728(94)90110-4; SMILEY ST, 1991, P NATL ACAD SCI USA, V88, P3671, DOI 10.1073/pnas.88.9.3671; Swerdlow RH, 1996, ANN NEUROL, V40, P663, DOI 10.1002/ana.410400417; TAKAYANAGI R, 1980, BIOCHEM J, V192, P853, DOI 10.1042/bj1920853; TAKESHIGE K, 1979, BIOCHEM J, V180, P129, DOI 10.1042/bj1800129; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; WALKER JE, 1992, Q REV BIOPHYS, V25, P253, DOI 10.1017/S003358350000425X; WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231; WOLVETANG EJ, 1994, FEBS LETT, V339, P40, DOI 10.1016/0014-5793(94)80380-3; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; Zamzami N, 1996, FEBS LETT, V384, P53, DOI 10.1016/0014-5793(96)00280-3	64	302	307	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16188	16197		10.1074/jbc.274.23.16188	http://dx.doi.org/10.1074/jbc.274.23.16188			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347173	hybrid			2022-12-25	WOS:000080668600033
J	Bird, TH; Du, SY; Bauer, CE				Bird, TH; Du, SY; Bauer, CE			Autophosphorylation, phosphotransfer, and DNA-binding properties of the RegB RegA two-component regulatory system in Rhodobacter capsulatus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYNTHESIS GENE-EXPRESSION; SIGNAL-TRANSDUCTION SYSTEM; ESCHERICHIA-COLI; TRANSCRIPTIONAL ACTIVATOR; RESPONSE REGULATORS; BACILLUS-SUBTILIS; OXYGEN REGULATION; PHOSPHORYLATION; DOMAIN; PROTEINS	In the purple, photosynthetic bacterium, Rhodobacter capsulatus, the RegB/RegA two-component system is required for activation of several anaerobic processes, such as synthesis of the photosynthetic apparatus and assimilation of CO2 and N-2. It is believed that RegB is an integral membrane histidine kinase that monitors the external environment. Under anaerobic growth conditions, it transduces a signal through phosphorylation of the response regulator, RegA, which then induces target gene expression. We used an in vitro assay to characterize the phosphorylation of wild-type RegA and a mutant variant (RegA*) that is responsible for abnormally high photosynthesis gene expression under both aerobic and anaerobic growth conditions. Phosphorylation assays indicate that phosphorylated RegA* (RegA*similar to P) is much more stable than RegA similar to P, indicating that it may be locked in a conformation that is resistant to dephosphorylation, DNase I footprint assays also indicate that unphosphorylated RegA* has a much higher affinity for specific DNA binding sites than the wild-type protein. Phosphorylation of RegA* increases DNA binding 2,5-fold, whereas phosphorylation of RegA increases DNA binding more than 16-fold. Collectively, these results support the hypothesis that RegA* is a constitutively active variant that does not require phosphorylation to assume a structural conformation required to bind DNA.	Indiana Univ, Dept Biol, Bloomington, IN 47405 USA	Indiana University System; Indiana University Bloomington	Bauer, CE (corresponding author), Indiana Univ, Dept Biol, Jordan Hall, Bloomington, IN 47405 USA.				NIGMS NIH HHS [GM40941, GM00618, R01 GM040941, R37 GM040941] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM040941, K04GM000618, R01GM040941, R37GM040941] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILALOV I, 1996, BIOCHEMISTRY-US, V35, P11053; Bauer CE, 1996, CELL, V85, P5, DOI 10.1016/S0092-8674(00)81074-0; BAUER CE, 1995, ANOXYGENIC PHOTOSYNT, P1221; Bird TH, 1996, J MOL BIOL, V256, P436, DOI 10.1006/jmbi.1996.0099; COHENBAZIRE G, 1957, J CELL COMPAR PHYSL, V49, P25, DOI 10.1002/jcp.1030490104; Du SY, 1998, J BIOL CHEM, V273, P18509, DOI 10.1074/jbc.273.29.18509; Elsen S, 1998, J BIOL CHEM, V273, P30762, DOI 10.1074/jbc.273.46.30762; FIEDLER U, 1995, EMBO J, V14, P3696, DOI 10.1002/j.1460-2075.1995.tb00039.x; GRIMSLEY JK, 1994, J BIOL CHEM, V269, P16977; GU BH, 1994, MOL MICROBIOL, V13, P51, DOI 10.1111/j.1365-2958.1994.tb00401.x; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; HUALA E, 1992, J BACTERIOL, V174, P1428, DOI 10.1128/jb.174.4.1428-1431.1992; IGO MM, 1989, GENE DEV, V3, P1725, DOI 10.1101/gad.3.11.1725; INOUE K, 1995, BIOCHEMISTRY-US, V34, P391, DOI 10.1021/bi00002a002; Joshi HM, 1996, P NATL ACAD SCI USA, V93, P14515, DOI 10.1073/pnas.93.25.14515; KAHN D, 1991, MOL MICROBIOL, V5, P987, DOI 10.1111/j.1365-2958.1991.tb00774.x; LUKAT GS, 1992, P NATL ACAD SCI USA, V89, P718, DOI 10.1073/pnas.89.2.718; MAKINO K, 1989, J MOL BIOL, V210, P551, DOI 10.1016/0022-2836(89)90131-9; MAKINO K, 1994, PHOSPHATE MICROORGAN; MASUDA S, 1998, IN PRESS P 11 INT C; MCCLEARY WR, 1994, J BIOL CHEM, V269, P31567; MOSLEY CS, 1994, J BACTERIOL, V176, P7566, DOI 10.1128/JB.176.24.7566-7573.1994; NAKASHIMA K, 1991, J BIOL CHEM, V266, P10775; NARRO ML, 1990, J BACTERIOL, V172, P4549, DOI 10.1128/jb.172.8.4549-4554.1990; Ponnampalam SN, 1997, J BIOL CHEM, V272, P18391, DOI 10.1074/jbc.272.29.18391; Qian YL, 1996, J BACTERIOL, V178, P12, DOI 10.1128/jb.178.1.12-18.1996; SCOPES RK, 1974, ANAL BIOCHEM, V59, P277, DOI 10.1016/0003-2697(74)90034-7; SGANGA MW, 1992, CELL, V68, P945, DOI 10.1016/0092-8674(92)90037-D; Stock J.B., 1995, 2 COMPONENT SIGNAL T, P25; STUDIER RW, 1990, METHOD ENZYMOL, V53, P450; TARDAT B, 1993, MOL MICROBIOL, V9, P53, DOI 10.1111/j.1365-2958.1993.tb01668.x; Tiwari RP, 1996, MICROBIOL-UK, V142, P1693, DOI 10.1099/13500872-142-7-1693; VOLZ K, 1991, J BIOL CHEM, V266, P15511; VOLZ K, 1993, BIOCHEMISTRY-US, V32, P11741, DOI 10.1021/bi00095a001; WEGLENSKI P, 1989, J BACTERIOL, V264, P4479; WEISS V, 1992, P NATL ACAD SCI USA, V89, P5088, DOI 10.1073/pnas.89.11.5088; WEISS V, 1988, P NATL ACAD SCI USA, V85, P8919, DOI 10.1073/pnas.85.23.8919	37	55	57	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16343	16348		10.1074/jbc.274.23.16343	http://dx.doi.org/10.1074/jbc.274.23.16343			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347192	hybrid			2022-12-25	WOS:000080668600052
J	Czaplewski, LG; McKeating, J; Craven, CJ; Higgins, LD; Appay, V; Brown, A; Dudgeon, T; Howard, LA; Meyers, T; Owen, J; Palan, SR; Tan, P; Wilson, G; Woods, NR; Heyworth, CM; Lord, BI; Brotherton, D; Christison, R; Craig, S; Cribbes, S; Edwards, RM; Evans, SJ; Gilbert, R; Morgan, P; Randle, E; Schofield, N; Varley, PG; Fisher, J; Waltho, JP; Hunter, MG				Czaplewski, LG; McKeating, J; Craven, CJ; Higgins, LD; Appay, V; Brown, A; Dudgeon, T; Howard, LA; Meyers, T; Owen, J; Palan, SR; Tan, P; Wilson, G; Woods, NR; Heyworth, CM; Lord, BI; Brotherton, D; Christison, R; Craig, S; Cribbes, S; Edwards, RM; Evans, SJ; Gilbert, R; Morgan, P; Randle, E; Schofield, N; Varley, PG; Fisher, J; Waltho, JP; Hunter, MG			Identification of amino acid residues critical for aggregation of human CC chemokines macrophage inflammatory protein (MIP)-1 alpha, MIP-1 beta, and RANTES - Characterization of active disaggregated chemokine variants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENETICALLY-ENGINEERED VARIANT; RANDOMIZED PHASE-II; 3-DIMENSIONAL STRUCTURE; FUNCTIONAL EXPRESSION; HEMATOPOIETIC-CELLS; NMR-SPECTROSCOPY; BREAST-CANCER; STEM-CELLS; PROTEIN-1-ALPHA; MIP-1-ALPHA	Human CC chemokines macrophage inflammatory protein (MIP)-1 alpha, MIP-1 beta, and RANTES (regulated on activation normal T cell expressed) self-associate to form high-molecular mass aggregates. To explore the biological significance of chemokine aggregation, nonaggregating variants were sought. The phenotypes of 105 hMIP-1 alpha variants generated by systematic mutagenesis and expression in yeast were determined, hMIP-1 alpha residues Asp(26) and Glu(66) were critical to the self-association process. Substitution at either residue resulted in the formation of essentially homogenous tetramers at 0.5 mg/ml. Substitution of identical or analogous residues in homologous positions in both hMIP-1 beta and RANTES demonstrated that they were also critical to aggregation. Our analysis suggests that a single charged residue at either position 26 or 66 is insufficient to support extensive aggregation and that two charged residues must be present. Solution of the three-dimensional NMR structure of hMIP-1 alpha has enabled comparison of these residues in hMIP-1 beta and RANTES. Aggregated and disaggregated forms of hMIP-1 alpha, hMIP-1 beta, and RANTES generally have equivalent G-protein-coupled receptor-mediated biological potencies. We have therefore generated novel reagents to evaluate the role of hMIP-1 alpha, hMIP-1 beta, and RANTES aggregation in vitro and in vivo. The disaggregated chemokines retained their human immunodeficiency virus (HIV) inhibitory activities. Surprisingly, high concentrations of RANTES, but not disaggregated RANTES variants, enhanced infection of cells by both M- and T-tropic HIV isolates/strains. This observation has important implications for potential therapeutic uses of chemokines implying that disaggregated forms may be necessary for safe clinical investigation.	British Biotech Pharmaceut Ltd, Oxford OX4 5LY, England; Univ Reading, Sch Anim & Microbial Sci, Reading RG6 2AJ, Berks, England; Univ Sheffield, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England; Christie Hosp NHS Trust, Paterson Inst Canc Res, CRC, Dept Expt Haematol, Manchester M20 9BX, Lancs, England; Univ Leeds, Sch Chem, Leeds LS2 9JT, W Yorkshire, England	University of Reading; University of Sheffield; Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research; University of Leeds	Czaplewski, LG (corresponding author), British Biotech Pharmaceut Ltd, Watlington Rd, Oxford OX4 5LY, England.		Appay, Victor/M-4830-2017; Appay, Victor/AAM-7701-2021	Appay, Victor/0000-0001-5434-3963; McKeating, Jane/0000-0002-7229-5886				ALBERT J, 1990, AIDS, V4, P107, DOI 10.1097/00002030-199002000-00002; Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; AVALOS BR, 1994, BLOOD, V84, P1790, DOI 10.1182/blood.V84.6.1790.bloodjournal8461790; Bernstein SH, 1997, BRIT J HAEMATOL, V99, P888, DOI 10.1046/j.1365-2141.1997.4913294.x; BILLETER M, 1992, J BIOMOL NMR, V2, P257, DOI 10.1007/BF01875320; Buckle AM, 1997, METHOD ENZYMOL, V287, P127; CANQUE B, 1994, BLOOD, V84, pA480; CHUNG CW, 1995, BIOCHEMISTRY-US, V34, P9307, DOI 10.1021/bi00029a005; CLEMENTS JM, 1992, CYTOKINE, V4, P76, DOI 10.1016/1043-4666(92)90040-X; Clemons MJ, 1998, BLOOD, V92, P1532, DOI 10.1182/blood.V92.5.1532.417k18_1532_1540; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P1689, DOI 10.1021/bi00459a004; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Combadiere C, 1996, J LEUKOCYTE BIOL, V60, P147, DOI 10.1002/jlb.60.1.147; CONNOR RI, 1994, AIDS RES HUM RETROV, V10, P321, DOI 10.1089/aid.1994.10.321; CRAIG S, 1993, Patent No. 13206; Dealwis C, 1998, P NATL ACAD SCI USA, V95, P6941, DOI 10.1073/pnas.95.12.6941; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; FAIRBROTHER WJ, 1994, J MOL BIOL, V242, P252, DOI 10.1006/jmbi.1994.1577; GAO JL, 1993, J EXP MED, V177, P1421, DOI 10.1084/jem.177.5.1421; GEITZ D, 1992, NUCLEIC ACIDS RES, V20, P1425; GRAHAM GJ, 1994, J BIOL CHEM, V269, P4974; HUNTER MG, 1995, BLOOD, V86, P4400, DOI 10.1182/blood.V86.12.4400.bloodjournal86124400; KORDEL J, 1992, BIOCHEMISTRY-US, V31, P4856; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAROCHE Y, 1994, BIO-TECHNOL, V12, P1119, DOI 10.1038/nbt1194-1119; Laurence JS, 1998, BIOCHEMISTRY-US, V37, P9346, DOI 10.1021/bi980329l; LODI PJ, 1994, SCIENCE, V263, P1762, DOI 10.1126/science.8134838; LORD BI, 1992, BLOOD, V79, P2605; LORD BI, 1995, BLOOD, V85, P3412, DOI 10.1182/blood.V85.12.3412.bloodjournal85123412; Lubkowski J, 1997, NAT STRUCT BIOL, V4, P64, DOI 10.1038/nsb0197-64; MACURA S, 1981, J MAGN RESON, V43, P259, DOI 10.1016/0022-2364(81)90037-8; MANTEL C, 1993, P NATL ACAD SCI USA, V90, P2232, DOI 10.1073/pnas.90.6.2232; Marshall E, 1998, EUR J CANCER, V34, P1023, DOI 10.1016/S0959-8049(97)10141-1; Meunier S, 1997, BIOCHEMISTRY-US, V36, P4412, DOI 10.1021/bi9627929; MILLER MD, 1992, CRIT REV IMMUNOL, V12, P17; NILGES M, 1988, FEBS LETT, V239, P129, DOI 10.1016/0014-5793(88)80559-3; PARKINSON EK, 1993, J INVEST DERMATOL, V101, P113, DOI 10.1111/1523-1747.ep12363603; PASCAL SM, 1994, J MAGN RESON SER B, V103, P197, DOI 10.1006/jmrb.1994.1031; PATEL SR, 1993, BIOCHEMISTRY-US, V32, P5466, DOI 10.1021/bi00071a024; RAJARATHNAM K, 1994, SCIENCE, V264, P90, DOI 10.1126/science.8140420; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; Sherman F., 1986, METHODS YEAST GENETI; SKELTON NJ, 1995, BIOCHEMISTRY-US, V34, P5329, DOI 10.1021/bi00016a004; SPOONCER E, 1986, DIFFERENTIATION, V31, P111, DOI 10.1111/j.1432-0436.1986.tb00391.x; STCHARLES R, 1989, J BIOL CHEM, V264, P2092; Varley PG, 1997, EUR BIOPHYS J BIOPHY, V25, P437, DOI 10.1007/s002490050058; VERFAILLIE CM, 1994, J EXP MED, V179, P643, DOI 10.1084/jem.179.2.643; vonLuettichau I, 1996, CYTOKINE, V8, P89, DOI 10.1006/cyto.1996.0012; Ward SG, 1998, BIOCHEM J, V333, P457, DOI 10.1042/bj3330457; Whitehead Brian, 1997, V60, P29; Williams SL, 1997, CYTOKINES CELL MOL T, V3, P41; WOLPE SD, 1989, FASEB J, V3, P2565, DOI 10.1096/fasebj.3.14.2687068; Wuthrich K, 1986, NMR PROTEINS NUCL AC; ZHANG YJ, 1995, MOL CELL BIOL, V15, P4851	55	139	144	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16077	16084		10.1074/jbc.274.23.16077	http://dx.doi.org/10.1074/jbc.274.23.16077			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347159	hybrid			2022-12-25	WOS:000080668600019
J	Deacon, K; Blank, JL				Deacon, K; Blank, JL			MEK kinase 3 directly activates MKK6 and MKK7, specific activators of the p38 and c-Jun NH2-terminal kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; N-TERMINAL KINASE; PROTEIN-KINASE; MAP KINASE; MOLECULAR-CLONING; DIFFERENTIAL ACTIVATION; SELECTIVE ACTIVATION; CELLULAR STRESSES; JNK; PHOSPHORYLATION	Mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase kinase kinase 3 (MEKK3) activates the c-Jun NH2-terminal kinase (JNK) pathway, although no substrates for MEKK3 have been identified. We have examined the regulation by MEKK3 of MAPK kinase 7 (MKK7) and MKK6, two novel MAPK kinases specific for JNK and p38, respectively. Coexpression of MKK7 with MEKK3 in COS-7 cells enhanced MKK7 autophosphorylation and its ability to activate recombinant JNK1 in vitro. MKK6 autophosphorylation and in vitro activation of p38 alpha were also observed following coexpression of MKK6 with MEKK3. MEKK2, a closely related homologue of MEKK3, also activated MKK7 and MKK6 in COS-7 cells. Importantly, immunoprecipitates of either MEKK3 or MEKK2 directly activated recombinant MKK7 and MKK6 in vitro. These data identify MEKK3 as a MAPK kinase kinase specific for MKK7 and MKK6 in the JNK and p38 pathways. We have also examined whether MEKK3 or MEKK2 activates p38 in intact cells using MAPK-activated protein kinase-2 (MAPKAPK2) as an affinity ligand and substrate. Anisomycin, sorbitol, or the expression of MEKK3 in HEK293 cells enhanced MAPKAPK2 phosphorylation, whereas MEKK2 was less effective. Furthermore, MAPKAPK2 phosphorylation induced by MEKK3 or cellular stress was abolished by the p38 inhibitor SB-203580, suggesting that MEKK3 is coupled to p38 activation in intact cells.	Univ Leicester, Sch Med, Dept Cell Physiol & Pharmacol, Leicester LE1 9HN, Leics, England	University of Leicester	Blank, JL (corresponding author), Univ Leicester, Sch Med, Dept Cell Physiol & Pharmacol, POB 138,Med Sci Bldg,Univ Rd, Leicester LE1 9HN, Leics, England.							BENLEVY R, 1995, EMBO J, V14, P5920, DOI 10.1002/j.1460-2075.1995.tb00280.x; Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Clerk A, 1998, J BIOL CHEM, V273, P7228, DOI 10.1074/jbc.273.13.7228; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; Deacon K, 1997, J BIOL CHEM, V272, P14489, DOI 10.1074/jbc.272.22.14489; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; DUAM G, 1994, TRENDS BIOCHEM SCI, V19, P474; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Fanger GR, 1998, J BIOL CHEM, V273, P3476, DOI 10.1074/jbc.273.6.3476; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; GAUN Z, 1998, J BIOL CHEM, V273, P28670; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Hirai S, 1997, J BIOL CHEM, V272, P15167, DOI 10.1074/jbc.272.24.15167; Hirai S, 1998, J BIOL CHEM, V273, P7406, DOI 10.1074/jbc.273.13.7406; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Holland PM, 1997, J BIOL CHEM, V272, P24994, DOI 10.1074/jbc.272.40.24994; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ishizuka T, 1996, J BIOL CHEM, V271, P12762, DOI 10.1074/jbc.271.22.12762; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Lu XH, 1997, J BIOL CHEM, V272, P24751, DOI 10.1074/jbc.272.40.24751; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Moriguchi T, 1997, EMBO J, V16, P7045, DOI 10.1093/emboj/16.23.7045; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Takekawa M, 1997, EMBO J, V16, P4973, DOI 10.1093/emboj/16.16.4973; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Wang XHS, 1996, J BIOL CHEM, V271, P31607; Wang XS, 1997, J BIOL CHEM, V272, P23668, DOI 10.1074/jbc.272.38.23668; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; WINSTON BW, 1995, P NATL ACAD SCI USA, V92, P1614, DOI 10.1073/pnas.92.5.1614; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xu SC, 1996, P NATL ACAD SCI USA, V93, P5291, DOI 10.1073/pnas.93.11.5291; Xu X, 1996, ONCOGENE, V13, P135; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; YAN MH, 1994, NATURE, V372, P798; YAN MH, 1994, J BIOL CHEM, V269, P19067; ZHENG CF, 1993, J BIOL CHEM, V268, P11435; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	62	78	84	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16604	16610		10.1074/jbc.274.23.16604	http://dx.doi.org/10.1074/jbc.274.23.16604			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347227	hybrid			2022-12-25	WOS:000080668600087
J	Deshpande, T; Takagi, T; Hao, LN; Buratowski, S; Charbonneau, H				Deshpande, T; Takagi, T; Hao, LN; Buratowski, S; Charbonneau, H			Human PIR1 of the protein-tyrosine phosphatase superfamily has RNA 5 '-triphosphatase and diphosphatase activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICULAR STOMATITIS-VIRUS; CAPPING ENZYME BINDS; MESSENGER-RNA; NUCLEOSIDE TRIPHOSPHATASE; SACCHAROMYCES-CEREVISIAE; TUMOR-SUPPRESSOR; TERMINAL DOMAIN; LEF-4 SUBUNIT; POLYMERASE-II; BACULOVIRUS	A human cDNA was isolated encoding a protein with significant sequence similarity (41% identity) to the BVP RNA 5'-phosphatase from the Autographa californica nuclear polyhedrosis virus. This protein is a member of the protein-tyrosine phosphatase (PTP) superfamily and is identical to PIR1, shown by Yuan et al. (Yuan, Y., Da-Ming, L., and Sun, H. (1998) J. Biol. Chem. 272, 20347-20353) to be a nuclear protein that can associate with RNA or ribonucleoprotein complexes, We demonstrate that PIR1 removes two phosphates from the 5'-triphosphate end of RNA, but not from mononucleotide triphosphates, The specific activity of PIR1 with RNA is several orders of magnitude greater than that with the best protein substrates examined, suggesting that RNA is its physiological substrate. A 120-amino acid segment C-terminal to the PTP domain is not required for RNA phosphatase activity. We propose that PIR1 and its closest homologs, which include the metazoan mRNA capping enzymes, constitute a subgroup of the PTP family that use RNA as a substrate.	Purdue Univ, Dept Biochem, W Lafayette, IN 47907 USA; Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Harvard University; Harvard Medical School	Charbonneau, H (corresponding author), Purdue Univ, Dept Biochem, 1153 Biochem, W Lafayette, IN 47907 USA.	charb@biochem.purdue.edu			NATIONAL CANCER INSTITUTE [R01CA059935, R29CA059935] Funding Source: NIH RePORTER; NCI NIH HHS [CA59935] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM G, 1975, CELL, V5, P51, DOI 10.1016/0092-8674(75)90091-4; Barford D, 1998, ANNU REV BIOPH BIOM, V27, P133, DOI 10.1146/annurev.biophys.27.1.133; Bisaillon M, 1997, VIROLOGY, V236, P1, DOI 10.1006/viro.1997.8698; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DENU JM, 1995, P NATL ACAD SCI USA, V92, P5910, DOI 10.1073/pnas.92.13.5910; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Fisher CL, 1997, BIOTECHNIQUES, V23, P570, DOI 10.2144/97234bm01; Gross CH, 1998, J VIROL, V72, P7057, DOI 10.1128/JVI.72.9.7057-7063.1998; Gross CH, 1998, J VIROL, V72, P10020, DOI 10.1128/JVI.72.12.10020-10028.1998; GUAN KL, 1991, J BIOL CHEM, V266, P17026; Guarino LA, 1998, J VIROL, V72, P10003, DOI 10.1128/JVI.72.12.10003-10010.1998; GUPTA KC, 1980, J VIROL, V33, P292, DOI 10.1128/JVI.33.1.292-303.1980; HAKES DJ, 1993, P NATL ACAD SCI USA, V90, P4017, DOI 10.1073/pnas.90.9.4017; Ho CK, 1998, J BIOL CHEM, V273, P34151, DOI 10.1074/jbc.273.51.34151; Ho CK, 1998, MOL CELL BIOL, V18, P5189, DOI 10.1128/MCB.18.9.5189; Ho CK, 1998, J BIOL CHEM, V273, P9577, DOI 10.1074/jbc.273.16.9577; ITOH N, 1984, J BIOL CHEM, V259, P3930; Jin JP, 1998, J VIROL, V72, P10011, DOI 10.1128/JVI.72.12.10011-10019.1998; KIM D, 1993, VIROLOGY, V195, P587, DOI 10.1006/viro.1993.1410; LI YH, 1995, J VIROL, V69, P4533, DOI 10.1128/JVI.69.7.4533-4537.1995; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; McCracken S, 1997, GENE DEV, V11, P3306, DOI 10.1101/gad.11.24.3306; MIZUMOTO K, 1987, PROG NUCLEIC ACID RE, V34, P1, DOI 10.1016/S0079-6603(08)60491-2; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; SHATKIN AJ, 1976, CELL, V9, P645, DOI 10.1016/0092-8674(76)90128-8; SHENG ZQ, 1993, J BIOL CHEM, V268, P4728; Shuman S, 1997, VIROLOGY, V227, P1, DOI 10.1006/viro.1996.8305; SHUMAN S, 1995, PROG NUCLEIC ACID RE, V50, P101, DOI 10.1016/S0079-6603(08)60812-0; SHUMAN S, 1980, J BIOL CHEM, V255, P1588; Takagi T, 1998, P NATL ACAD SCI USA, V95, P9808, DOI 10.1073/pnas.95.17.9808; Takagi T, 1997, CELL, V89, P867, DOI 10.1016/S0092-8674(00)80272-X; Taylor GS, 1997, J BIOL CHEM, V272, P24054, DOI 10.1074/jbc.272.38.24054; TONKS NK, 1988, J BIOL CHEM, V263, P6731; Tsukamoto T, 1998, BIOCHEM BIOPH RES CO, V243, P101, DOI 10.1006/bbrc.1997.8038; Wang SP, 1997, P NATL ACAD SCI USA, V94, P9573, DOI 10.1073/pnas.94.18.9573; Wen YX, 1998, P NATL ACAD SCI USA, V95, P12226, DOI 10.1073/pnas.95.21.12226; Yamada-Okabe T, 1998, NUCLEIC ACIDS RES, V26, P1700, DOI 10.1093/nar/26.7.1700; Yuan Y, 1998, J BIOL CHEM, V273, P20347, DOI 10.1074/jbc.273.32.20347; YUE Z, 1997, P NATL ACAD SCI USA, V94, P12758	39	59	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16590	16594		10.1074/jbc.274.23.16590	http://dx.doi.org/10.1074/jbc.274.23.16590			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347225	hybrid			2022-12-25	WOS:000080668600085
J	Posch, M; Sutterluety, H; Skern, T; Seiser, C				Posch, M; Sutterluety, H; Skern, T; Seiser, C			Characterization of the translation-dependent step during iron-regulated decay of transferrin receptor mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA DEGRADATION; ELEMENT-BINDING-PROTEIN; 3' UNTRANSLATED REGION; AU-RICH ELEMENTS; MOUSE THYMIDINE KINASE; RESPONSIVE-ELEMENT; C-FOS; ACONITASE ACTIVITY; NITRIC-OXIDE; AUTOREGULATED INSTABILITY	Iron regulates the stability of the mRNA encoding the transferrin receptor (TfR). When iron is scarce, iron regulatory proteins (IRPs) stabilize TfR mRNA by binding to the 3'-untranslated region. High levels of iron induce degradation of TfR mRNA; the translation inhibitor cycloheximide prevents this. To distinguish between cotranslational mRNA decay and a trans effect of translation inhibitors, we designed a reporter system exploiting the properties of the selectable marker gene thymidine kinase (TK), The 3'-untranslated region of human transferrin receptor, which contains all elements necessary for iron-dependent regulation of mRNA stability, was fused to the TK cDNA. In stably transfected mouse fibroblasts, the expression of the reporter gene was perfectly regulated by iron. Introduction of stop codons in the TK coding sequence or insertion of stable stem-loop structures in the leader sequence did not affect on the iron-dependent regulation of the reporter mRNA This implies that global translation inhibitors stabilize TfR mRNA in trans. Cycloheximide prevented the destabilization of TfR mRNA only in the presence of active IRPs. Inhibition of IRP inactivation by cycloheximide or by the specific proteasome inhibitor MG132 correlated with the stabilization of TfR mRNA These observations suggest that inhibition of translation by cycloheximide interferes with the rate-limiting step of iron-induced TfR mRNA decay in a transacting mechanism by blocking IRP inactivation.	Univ Vienna, Vienna Bioctr, Inst Mol Biol, A-1030 Vienna, Austria; Univ Vienna, Fac Med, Inst Biochem, A-1030 Vienna, Austria	University of Vienna; Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA); University of Vienna	Seiser, C (corresponding author), Univ Vienna, Vienna Bioctr, Inst Mol Biol, Dr Bohr Gasse 9, A-1030 Vienna, Austria.		Skern, Tim/AAC-1732-2022	Skern, Tim/0000-0001-8865-5500; Seiser, Christian/0000-0002-7046-9352; Sutterluty-Fall, Hedwig/0000-0001-9249-9299				AHARON T, 1993, MOL CELL BIOL, V13, P1971, DOI 10.1128/MCB.13.3.1971; BHONSALE SS, 1992, GENE DEV, V6, P1927; BINDER R, 1994, EMBO J, V13, P1969, DOI 10.1002/j.1460-2075.1994.tb06466.x; BREWER G, 1988, MOL CELL BIOL, V8, P1697, DOI 10.1128/MCB.8.4.1697; BRIDGES KR, 1984, J BIOL CHEM, V259, P2970; CASEY JL, 1989, EMBO J, V8, P3693, DOI 10.1002/j.1460-2075.1989.tb08544.x; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; CHEN CYA, 1995, MOL CELL BIOL, V15, P5777; CHEN CYA, 1994, MOL CELL BIOL, V14, P8471, DOI 10.1128/MCB.14.12.8471; CHEN CYA, 1994, MOL CELL BIOL, V14, P416, DOI 10.1128/MCB.14.1.416; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CLEVELAND DW, 1988, TRENDS BIOCHEM SCI, V13, P339, DOI 10.1016/0968-0004(88)90103-X; CONSTABLE A, 1992, P NATL ACAD SCI USA, V89, P4554, DOI 10.1073/pnas.89.10.4554; COX TC, 1991, EMBO J, V10, P1891, DOI 10.1002/j.1460-2075.1991.tb07715.x; DANDEKAR T, 1991, EMBO J, V10, P1903, DOI 10.1002/j.1460-2075.1991.tb07716.x; DRAPIER JC, 1994, ADV EXP MED BIOL, V356, P141; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; Gehring NH, 1999, J BIOL CHEM, V274, P6219, DOI 10.1074/jbc.274.10.6219; GOESSLING LS, 1992, SCIENCE, V256, P670, DOI 10.1126/science.1316633; GOESSLING LS, 1994, J BIOL CHEM, V269, P4343; GOOSSEN B, 1990, EMBO J, V9, P4127, DOI 10.1002/j.1460-2075.1990.tb07635.x; GRAVES RA, 1987, CELL, V48, P615, DOI 10.1016/0092-8674(87)90240-6; Gray NK, 1996, P NATL ACAD SCI USA, V93, P4925, DOI 10.1073/pnas.93.10.4925; GRAY NK, 1993, EUR J BIOCHEM, V218, P657, DOI 10.1111/j.1432-1033.1993.tb18420.x; GUO B, 1994, J BIOL CHEM, V269, P24252; GUO B, 1995, J BIOL CHEM, V270, P21645, DOI 10.1074/jbc.270.37.21645; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P7536, DOI 10.1073/pnas.89.16.7536; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P11735, DOI 10.1073/pnas.89.24.11735; Hanson ES, 1999, J BIOL CHEM, V274, P5047, DOI 10.1074/jbc.274.8.5047; Hanson ES, 1998, J BIOL CHEM, V273, P7588, DOI 10.1074/jbc.273.13.7588; HENDERSON BR, 1993, J BIOL CHEM, V268, P27327; HENDERSON BR, 1995, J BIOL CHEM, V270, P20509, DOI 10.1074/jbc.270.35.20509; HIRLING H, 1994, EMBO J, V13, P453, DOI 10.1002/j.1460-2075.1994.tb06280.x; HOFBAUER R, 1987, NUCLEIC ACIDS RES, V15, P741, DOI 10.1093/nar/15.2.741; Iwai K, 1998, P NATL ACAD SCI USA, V95, P4924, DOI 10.1073/pnas.95.9.4924; IWAI K, 1995, EMBO J, V14, P5350, DOI 10.1002/j.1460-2075.1995.tb00219.x; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; KAPTAIN S, 1991, P NATL ACAD SCI USA, V88, P10109, DOI 10.1073/pnas.88.22.10109; Ke YH, 1998, J BIOL CHEM, V273, P23637, DOI 10.1074/jbc.273.37.23637; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KOELLER DM, 1989, P NATL ACAD SCI USA, V86, P3574, DOI 10.1073/pnas.86.10.3574; KOELLER DM, 1991, P NATL ACAD SCI USA, V88, P7778, DOI 10.1073/pnas.88.17.7778; Kohler SA, 1995, J BIOL CHEM, V270, P30781, DOI 10.1074/jbc.270.51.30781; KUHN LC, 1992, J INORG BIOCHEM, V47, P183, DOI 10.1016/0162-0134(92)84064-T; KUHN LC, 1984, CELL, V37, P95, DOI 10.1016/0092-8674(84)90304-0; LAIRDOFFRINGA IA, 1990, MOL CELL BIOL, V10, P6132, DOI 10.1128/MCB.10.12.6132; LANG V, 1994, J BIOL CHEM, V269, P6117; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; LEIBOLD EA, 1992, ANNU REV NUTR, V12, P345, DOI 10.1146/annurev.nu.12.070192.002021; LOUACHE F, 1984, J BIOL CHEM, V259, P1576; MARZLUFF WF, 1988, TRENDS BIOCHEM SCI, V13, P49, DOI 10.1016/0968-0004(88)90027-8; Menotti E, 1998, J BIOL CHEM, V273, P1821, DOI 10.1074/jbc.273.3.1821; MUHLRAD D, 1995, MOL CELL BIOL, V15, P2145; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; MULLNER EW, 1988, CELL, V53, P815, DOI 10.1016/0092-8674(88)90098-0; OWEN D, 1987, EMBO J, V6, P1287, DOI 10.1002/j.1460-2075.1987.tb02366.x; PACHTER JS, 1987, CELL, V51, P283, DOI 10.1016/0092-8674(87)90155-3; PANTOPOULOS K, 1995, P NATL ACAD SCI USA, V92, P1267, DOI 10.1073/pnas.92.5.1267; Pantopoulos K, 1996, MOL CELL BIOL, V16, P3781; PANTOPOULOS K, 1995, RNA, V1, P155; ROUAULT TA, 1988, SCIENCE, V241, P1207, DOI 10.1126/science.3413484; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SAGLIOCCO FA, 1994, J BIOL CHEM, V269, P18630; SAMANIEGO F, 1994, J BIOL CHEM, V269, P30904; Schalinske KL, 1997, P NATL ACAD SCI USA, V94, P10681, DOI 10.1073/pnas.94.20.10681; Schlegl J, 1997, RNA, V3, P1159; SEISER C, 1993, J BIOL CHEM, V268, P13074; SEISER C, 1995, J BIOL CHEM, V270, P29400, DOI 10.1074/jbc.270.49.29400; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHERLEY JL, 1988, J BIOL CHEM, V263, P375; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; STEARNE PA, 1985, J IMMUNOL, V134, P3474; STOECKLIN G, 1994, J BIOL CHEM, V269, P28591; Sutterluety H, 1996, J MOL BIOL, V259, P383, DOI 10.1006/jmbi.1996.0327; Toth I, 1999, J BIOL CHEM, V274, P4467, DOI 10.1074/jbc.274.7.4467; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; WALDEN WE, 1989, J BIOL CHEM, V264, P13765; WARD JH, 1982, J BIOL CHEM, V257, P317; WARD JH, 1984, J BIOL CHEM, V259, P3235; WEISS G, 1993, EMBO J, V12, P3651, DOI 10.1002/j.1460-2075.1993.tb06039.x; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; WINSTALL E, 1995, MOL CELL BIOL, V15, P3796; YEN TJ, 1988, NATURE, V334, P580, DOI 10.1038/334580a0	83	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16611	16618		10.1074/jbc.274.23.16611	http://dx.doi.org/10.1074/jbc.274.23.16611			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347228	hybrid			2022-12-25	WOS:000080668600088
J	Bayliss, MT; Osborne, D; Woodhouse, S; Davidson, C				Bayliss, MT; Osborne, D; Woodhouse, S; Davidson, C			Sulfation of chondroitin sulfate in human articular cartilage - The effect of age, topographical position, and zone of cartilage on tissue composition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODIES; DERMATAN SULFATE; JOINT FLUID; PROTEOGLYCAN; DISEASE; OSTEOARTHRITIS; AGGRECAN	The chondroitin ABC lyase digestion products of normal human femoral condyle articular cartilage and of purified aggrecan were analyzed for their mono- and nonsulfated disaccharide composition, Changes in the total tissue chemistry were most pronounced during the period from birth to 20 years of age, when the -[GlcA beta,3GalNAc6]- disaccharide content increased from approximately 50% to 85% of the total disaccharide content and there was a concomitant decrease in the content of the 4-sulfated disaccharide, In general, the disaccharide content of the deeper layers of immature cartilage were richer in the 4-sulfated residue than the upper regions of the tissue. As the tissue aged and decreased in thickness, the disaccharide composition became more evenly 6-sulfated. The newly synthesized chondroitin sulfate chains had a similar composition to the endogenous chains and also underwent the same age and zonal changes, The monoclonal antisera 3B3(+) and 2B6(+) were used to immunolocalize the unsaturated 6- and 4-sulfated residues generated at the reducing termini of the chondroitin sulfate chains by digestion with chondroitin ABC lyase, and these analyses indicated that the sulfation pattern at this position did not necessarily reflect the internal disaccharide composition of the chains. In summary, the sulfation pattern of chondroitin sulfate disaccharides from human normal articular cartilage varies with the age of the specimen, the position (topography) on the joint surface, and the zone of cartilage analyzed, Furthermore, these changes in composition are a consequence of both extracellular, post-translational processing of the core protein of aggrecan and changes in the sulfotransferase activity of the chondrocyte.	Univ London Royal Vet Coll, London NW1 0TU, England; Lilly Res Ctr Ltd, Windlesham GU20 6PH, Surrey, England; Univ Cambridge, Wellcome CRC Inst, Cambridge CB2 1QR, England	University of London; University of London Royal Veterinary College; Eli Lilly; University of Cambridge	Bayliss, MT (corresponding author), Univ London Royal Vet Coll, Royal Coll St, London NW1 0TU, England.							ALI SY, 1981, SEMIN ARTHRITIS RHEU, V11, P56, DOI 10.1016/0049-0172(81)90039-1; BAYLISS MT, 1985, BIOCHEM J, V232, P111, DOI 10.1042/bj2320111; BAYLISS MT, 1990, BIOCHEM SOC T, V18, P799, DOI 10.1042/bst0180799; BROCKLEHURST R, 1984, J BONE JOINT SURG AM, V66A, P95, DOI 10.2106/00004623-198466010-00013; Brown MP, 1998, AM J VET RES, V59, P786; CARNEY SL, 1986, ANAL BIOCHEM, V156, P38, DOI 10.1016/0003-2697(86)90150-8; CATERSON B, 1990, J CELL SCI, V97, P411; CHRISTNER JE, 1980, J BIOL CHEM, V255, P7102; DEUTSCH W, 1994, SPRACHE KOGNIT, V13, P230; Dudhia J, 1996, BIOCHEM J, V313, P933, DOI 10.1042/bj3130933; FEIZI T, 1985, NATURE, V314, P53, DOI 10.1038/314053a0; HARDINGHAM T, 1990, SEMIN ARTHRITIS RHEU, V20, P12, DOI 10.1016/0049-0172(90)90044-G; HASCALL VC, 1970, J BIOL CHEM, V245, P4920; HAZELL PK, 1995, ARTHRITIS RHEUM, V38, P953, DOI 10.1002/art.1780380711; LEMPERG R, 1974, CALC TISS RES, V15, P237, DOI 10.1007/BF02059060; LEWIS S, 1995, ACTA ORTHOP SCA S266, V66, P142; LOHMANDER S, 1977, ARCH BIOCHEM BIOPHYS, V180, P93, DOI 10.1016/0003-9861(77)90012-1; MANKIN HJ, 1970, J BONE JOINT SURG AM, VA 52, P424, DOI 10.2106/00004623-197052030-00002; Maroudas A., 1979, ADULT ARTICULAR CART; MICHELACCI YM, 1979, CONNECT TISSUE RES, V7, P29, DOI 10.3109/03008207909152350; MORALES TI, 1991, ARCH BIOCHEM BIOPHYS, V286, P99, DOI 10.1016/0003-9861(91)90013-9; MOURAO PAS, 1976, BIOCHIM BIOPHYS ACTA, V428, P19, DOI 10.1016/0304-4165(76)90104-5; MURATA K, 1979, J BIOCHEM-TOKYO, V86, P371, DOI 10.1093/oxfordjournals.jbchem.a132535; MURATA K, 1997, CONNECT TISSUE RES, V5, P109; Plaas AHK, 1998, J BIOL CHEM, V273, P12642, DOI 10.1074/jbc.273.20.12642; Plaas AHK, 1997, J BIOL CHEM, V272, P20603, DOI 10.1074/jbc.272.33.20603; Platt D, 1998, EQUINE VET J, V30, P43, DOI 10.1111/j.2042-3306.1998.tb04087.x; ROSENBERG LC, 1985, J BIOL CHEM, V260, P6304; ROUGHLEY PJ, 1980, J BIOL CHEM, V255, P217; SCHUMACHER BL, 1994, ARCH BIOCHEM BIOPHYS, V311, P144, DOI 10.1006/abbi.1994.1219; SHIBATA S, 1992, J BIOL CHEM, V267, P6548; SHINMEI M, 1992, ARTHRITIS RHEUM, V35, P1304, DOI 10.1002/art.1780351110; SLATER RR, 1995, ARTHRITIS RHEUM-US, V38, P655, DOI 10.1002/art.1780380513	33	160	163	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15892	15900		10.1074/jbc.274.22.15892	http://dx.doi.org/10.1074/jbc.274.22.15892			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336494	hybrid			2022-12-25	WOS:000080560100083
J	Bhattacharya, M; Peri, K; Ribeiro-da-Silva, A; Almazan, G; Shichi, H; Hou, X; Varma, DR; Chemtob, S				Bhattacharya, M; Peri, K; Ribeiro-da-Silva, A; Almazan, G; Shichi, H; Hou, X; Varma, DR; Chemtob, S			Localization of functional prostaglandin E-2 receptors EP3 and EP4 in the nuclear envelope	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; RAT-LIVER; ENDOPLASMIC-RETICULUM; PROSTANOID RECEPTOR; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; CELLS; EXPRESSION; ACTIVATION; SUBTYPES	The effects of prostaglandin E-2 are thought to be mediated via G protein-coupled plasma membrane receptors, termed EP. However recent data implied that prostanoids may also act intracellularly. We investigated if the ubiquitous EP3 and the EP4 receptors are localized in nuclear membranes. Radioligand binding studies on isolated nuclear membrane fractions of neonatal porcine brain and adult rat liver revealed the presence of EP3 and EP4. A perinuclear localization of EP3 alpha and EP4 receptors was visualized by indirect immunocytofluorescence and confocal microscopy in porcine cerebral microvascular endothelial cells and in transfected HEK 293 cells that stably overexpress these receptors. Immunoelectron microscopy clearly revealed EP3 alpha and EP4 receptors localization in the nuclear envelope of endothelial cells; this is the first demonstration of the nuclear localization of these receptors. Data also reveal that nuclear EP receptors are functional as they affect transcription of genes such as inducible nitric-oxide synthase and intranuclear calcium transients; this appears to involve pertussis toxin-sensitive G proteins. These results define a possible molecular mechanism of action of nuclear EP3 receptors.	Univ Montreal, Hop St Justine, Res Ctr, Montreal, PQ H3T 1C5, Canada; McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada; Wayne State Univ, Sch Med, Dept Ophthalmol, Detroit, MI 48201 USA; Univ Montreal, Hop St Justine, Dept Pediat, Montreal, PQ H3T 1C5, Canada; Univ Montreal, Hop St Justine, Dept Ophthalmol, Montreal, PQ H3T 1C5, Canada; Univ Montreal, Hop St Justine, Dept Pharmacol, Montreal, PQ H3T 1C5, Canada	Universite de Montreal; McGill University; Wayne State University; Universite de Montreal; Universite de Montreal; Universite de Montreal	Chemtob, S (corresponding author), Univ Montreal, Hop St Justine, Res Ctr, 3175 Cote St Catherine, Montreal, PQ H3T 1C5, Canada.		Ribeiro-da-Silva, Alfredo/K-4783-2012	Ribeiro-da-Silva, Alfredo/0000-0002-4125-0255				ADACHI H, 1993, EUR J BIOCHEM, V217, P37, DOI 10.1111/j.1432-1033.1993.tb18215.x; ADAM M, 1994, FEBS LETT, V338, P170, DOI 10.1016/0014-5793(94)80358-7; Baldassare JJ, 1997, J BIOL CHEM, V272, P4911, DOI 10.1074/jbc.272.8.4911; BARSONY J, 1990, P NATL ACAD SCI USA, V87, P1188, DOI 10.1073/pnas.87.3.1188; BASTIEN L, 1994, J BIOL CHEM, V269, P11873; Baylink TM, 1996, J BONE MINER RES, V11, P1413; Bhattacharya M, 1998, P NATL ACAD SCI USA, V95, P15792, DOI 10.1073/pnas.95.26.15792; Boie Y, 1997, EUR J PHARMACOL, V340, P227, DOI 10.1016/S0014-2999(97)01383-6; BOOZ GW, 1992, ENDOCRINOLOGY, V130, P3641, DOI 10.1210/en.130.6.3641; Chemtob S, 1996, ACTA PAEDIATR, V85, P517, DOI 10.1111/j.1651-2227.1996.tb14077.x; Coffey RJ, 1997, P NATL ACAD SCI USA, V94, P657, DOI 10.1073/pnas.94.2.657; COLEMAN RA, 1994, PHARMACOL REV, V46, P205; CROZE EM, 1984, J CELL PHYSIOL, V119, P46, DOI 10.1002/jcp.1041190109; DALE B, 1994, P ROY SOC B-BIOL SCI, V255, P119, DOI 10.1098/rspb.1994.0017; DiRosa M, 1996, PROSTAG LEUKOTR ESS, V54, P229, DOI 10.1016/S0952-3278(96)90053-8; DIVECHA N, 1993, CELL, V74, P405, DOI 10.1016/0092-8674(93)80041-C; Doke A., 1996, Pediatric Research, V39, p205A; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Dumont I, 1998, AM J PHYSIOL-REG I, V275, pR1812, DOI 10.1152/ajpregu.1998.275.6.R1812; FIGUEIREDO BC, 1993, MOL BRAIN RES, V17, P258, DOI 10.1016/0169-328X(93)90010-M; Gerasimenko OV, 1996, PFLUG ARCH EUR J PHY, V432, P1, DOI 10.1007/s004240050098; GOETZL EJ, 1995, FASEB J, V9, P1051, DOI 10.1096/fasebj.9.11.7649404; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; Hertz R, 1996, EUR J BIOCHEM, V235, P242, DOI 10.1111/j.1432-1033.1996.00242.x; HESCHELER J, 1988, EMBO J, V7, P613; KANAI N, 1995, SCIENCE, V268, P866, DOI 10.1126/science.7754369; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; LAHAIE I, 1998, AM J PHYSIOL, V274, P1406; LEFFLER CW, 1985, PROSTAGLANDINS, V30, P811, DOI 10.1016/0090-6980(85)90009-7; LEPRETRE N, 1994, J BIOL CHEM, V269, P29546; LI DY, 1994, BRIT J PHARMACOL, V112, P59, DOI 10.1111/j.1476-5381.1994.tb13029.x; LIND GJ, 1993, INVEST OPHTH VIS SCI, V34, P2943; Lu D, 1998, ENDOCRINOLOGY, V139, P365, DOI 10.1210/en.139.1.365; Malviya AN, 1998, CELL, V92, P17, DOI 10.1016/S0092-8674(00)80895-8; Minghetti L, 1997, GLIA, V19, P152, DOI 10.1002/(SICI)1098-1136(199702)19:2<152::AID-GLIA6>3.0.CO;2-2; MORITA I, 1995, J BIOL CHEM, V270, P10902, DOI 10.1074/jbc.270.18.10902; NAMBA T, 1993, NATURE, V365, P166, DOI 10.1038/365166a0; NeuschaferRube F, 1997, FEBS LETT, V401, P185, DOI 10.1016/S0014-5793(96)01468-8; NICOTERA P, 1989, P NATL ACAD SCI USA, V86, P453, DOI 10.1073/pnas.86.2.453; NOORDLIE RC, 1966, METHOD ENZYMOL, V9, P619; PERI KG, 1995, J BIOL CHEM, V270, P24615, DOI 10.1074/jbc.270.41.24615; PICKEL V, 1993, IMMUNOHISTOCHEMISTRY; RIBEIRODASILVA A, 1993, IMMUNOHISTOCHEMISTRY; RUBIN BS, 1986, BRAIN RES, V383, P60, DOI 10.1016/0006-8993(86)90008-9; SAFFITZ JE, 1994, FASEB J, V8, P252, DOI 10.1096/fasebj.8.2.8119495; Sambrook J., 2002, MOL CLONING LAB MANU; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; SIMONSON MS, 1994, EXP CELL RES, V215, P137, DOI 10.1006/excr.1994.1325; Spencer AG, 1998, J BIOL CHEM, V273, P9886, DOI 10.1074/jbc.273.16.9886; TAKAGI H, 1994, NITRIC OXIDE ROLES N, P44; TAKEI Y, 1994, J BIOCHEM-TOKYO, V115, P578, DOI 10.1093/oxfordjournals.jbchem.a124378; VIRGOLINI I, 1988, PROSTAGLANDINS, V36, P807, DOI 10.1016/0090-6980(88)90058-5; Yano T, 1997, BIOCHEM PHARMACOL, V53, P1757, DOI 10.1016/S0006-2952(96)00869-6; ZHAO C, 1995, J OCUL PHARMACOL TH, V11, P421, DOI 10.1089/jop.1995.11.421	54	208	211	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15719	15724		10.1074/jbc.274.22.15719	http://dx.doi.org/10.1074/jbc.274.22.15719			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336471	hybrid			2022-12-25	WOS:000080560100060
J	Fay, PJ; Koshibu, K; Mastri, M				Fay, PJ; Koshibu, K; Mastri, M			The A1 and A2 subunits of factor VIIIa synergistically stimulate factor IXa catalytic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-C; PORCINE FACTOR-VIII; COAGULATION FACTOR-VIII; LIGHT-CHAIN; COFACTOR ACTIVITY; INTERACTIVE SITE; BINDING-SITE; CLEAVAGE; PROTEOLYSIS; IDENTIFICATION	Factor VIIIa, the protein cofactor for factor IXa, is comprised of A1, A2, and A3-C1-C2 subunits. Recently, we showed that isolated A2 subunit enhanced the k(cat) for factor IXa-catalyzed activation of factor X by similar to 100-fold (similar to 1 min(-1)), whereas isolated A1 or A3-C1-C2 subunits showed no effect on this rate (Fay, P. J., and Koshibu, K. J. (1998) J, Biol, Chem, 273, 19049-19054), However, A1 subunit increased the A2-dependent stimulation by similar to 10-fold. The K-m for factor X in the presence of A2 subunit was unaffected by A1 subunit, whereas the k(cat) observed in the presence of saturating A1 and A2 subunits (similar to 15 min(-1)) represented 5-10% of the value observed for native factor VIIIa (similar to 200 min(-1)). An anti-A1 subunit antibody that blocks the association of A2 eliminated the A1-dependent contribution to factor IXa activity, Inclusion of both A1 and A2 subunits resulted in greater increases in the fluorescence anisotropy of fluorescein-Phe-Phe-Arg factor IXa than that observed for A2 subunit alone and approached values obtained with factor VIIIa, These results indicate that A1 subunit alters the A2 subunit-dependent modulation of the active site of factor IXa to synergistically increase cofactor activity, yielding an overall increase in k(cat) of over 1000-fold compared with factor IXa alone.	Univ Rochester, Med Ctr, Vasc Med Unit, Sch Med & Dent,Dept Med, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Fay, PJ (corresponding author), Univ Rochester, Med Ctr, Vasc Med Unit, Sch Med & Dent,Dept Med, POB 610,601 Elmwood Ave, Rochester, NY 14642 USA.			Koshibu, Kyoko/0000-0002-9809-0299	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038199, P01HL030616] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 30616, HL 38199] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASILLAS G, 1971, COAGULATION, V4, P107; CURTIS JE, 1994, J BIOL CHEM, V269, P6246; DONATH MJSH, 1995, J BIOL CHEM, V270, P3648, DOI 10.1074/jbc.270.8.3648; DUFFY EJ, 1992, J BIOL CHEM, V267, P17006; FAY PJ, 1993, J BIOL CHEM, V268, P17861; Fay PJ, 1998, J BIOL CHEM, V273, P19049, DOI 10.1074/jbc.273.30.19049; FAY PJ, 1994, J BIOL CHEM, V269, P20522; FAY PJ, 1991, J BIOL CHEM, V266, P20139; FAY PJ, 1991, J BIOL CHEM, V266, P8957; FOSTER PA, 1990, BLOOD, V75, P1999; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPHEAR BJ, 1992, BLOOD, V80, P3120; Lapan KA, 1997, J BIOL CHEM, V272, P2082; Lenting PJ, 1996, J BIOL CHEM, V271, P1935, DOI 10.1074/jbc.271.4.1935; LENTING PJ, 1994, J BIOL CHEM, V269, P7150; LOLLAR P, 1990, J BIOL CHEM, V265, P1688; LOLLAR P, 1993, METHOD ENZYMOL, V222, P128; LOLLAR P, 1989, BIOCHEMISTRY-US, V28, P666, DOI 10.1021/bi00428a038; LOLLAR P, 1992, J BIOL CHEM, V267, P23652; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028; OBRIEN DP, 1992, BIOCHEMISTRY-US, V31, P2805, DOI 10.1021/bi00125a022; OBrien LM, 1997, BLOOD, V90, P3943, DOI 10.1182/blood.V90.10.3943; OBRIEN LM, 1995, J BIOL CHEM, V270, P27087, DOI 10.1074/jbc.270.45.27087; PERSSON E, 1995, BIOCHEMISTRY-US, V34, P12775, DOI 10.1021/bi00039a038; PITTMAN DD, 1992, BLOOD, V79, P389; REGAN LM, 1995, J BIOL CHEM, V270, P8546, DOI 10.1074/jbc.270.15.8546; Regan LM, 1996, J BIOL CHEM, V271, P3982; REGAN LM, 1994, J BIOL CHEM, V269, P9445; Sudhakar K, 1996, J BIOL CHEM, V271, P23015, DOI 10.1074/jbc.271.38.23015; Sudhakar K, 1998, BIOCHEMISTRY-US, V37, P6874, DOI 10.1021/bi980084c	31	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15401	15406		10.1074/jbc.274.22.15401	http://dx.doi.org/10.1074/jbc.274.22.15401			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336428	hybrid			2022-12-25	WOS:000080560100017
J	Habura, A; Tikhonenko, I; Chisholm, RL; Koonce, MP				Habura, A; Tikhonenko, I; Chisholm, RL; Koonce, MP			Interaction mapping of a dynein heavy chain - Identification of dimerization and intermediate-chain binding domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-ARM DYNEIN; CYTOPLASMIC DYNEIN; MOLECULAR ANALYSIS; MOTOR PROTEINS; SEQUENCE-ANALYSIS; ALPHA-DYNEIN; DICTYOSTELIUM; DYNACTIN; COMPLEX; GENES	Cytoplasmic dynein is a multisubunit microtubule-based motor protein that is involved in several eukaryotic cell motilities, Two dynein heavy chains each form a motor domain that connects to a common cargo-binding tail. Although this tail domain is composed of multiple polypeptides, subunit organization within this region is poorly understood. Here we present an in vitro dissection of the tail-forming region of the dynein heavy chain from Dictyostelium. Our work identifies a sequence important for dimerization and for binding the dynein intermediate chain. The core of this motif localizes within an similar to 150-amino acid region that is strongly conserved among other cytoplasmic dyneins, This level of conservation does not extend to the axonemal dynein heavy chains, suggesting functional differences between the two. Dimerization appears to occur through a different mechanism than the heavy chain-intermediate chain interaction. We corroborate the in vitro interactions with in vivo expression of heavy chain fragments in Dictyostelium. Fragments lacking the interaction domain express well, without an obvious phenotype. On the other hand, the region crucial for both interactions appears to be lethal when overexpressed.	New York State Dept Hlth, Wadsworth Ctr Labs & Res, Div Mol Med, Albany, NY 12201 USA; Northwestern Univ, Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA; SUNY Albany, Dept Biomed Sci, Albany, NY 12201 USA	State University of New York (SUNY) System; Wadsworth Center; Northwestern University; State University of New York (SUNY) System; State University of New York (SUNY) Albany	Koonce, MP (corresponding author), New York State Dept Hlth, Wadsworth Ctr Labs & Res, Div Mol Med, Empire State Plaza,POB 509, Albany, NY 12201 USA.	Michael.Koonce@wadsworth.org	Chisholm, Rex L/B-3418-2009	Chisholm, Rex L/0000-0002-5638-3990	NIGMS NIH HHS [GM51532] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051532, R29GM051532] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bruno KS, 1996, P NATL ACAD SCI USA, V93, P4775, DOI 10.1073/pnas.93.10.4775; Efimov VP, 1998, GENETICS, V149, P101; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Gee MA, 1997, NATURE, V390, P636, DOI 10.1038/37663; GIBBONS IR, 1995, CELL MOTIL CYTOSKEL, V32, P136, DOI 10.1002/cm.970320214; GILL SR, 1994, MOL BIOL CELL, V5, P645, DOI 10.1091/mbc.5.6.645; HOLZBAUR ELF, 1994, ANNU REV CELL BIOL, V10, P339, DOI 10.1146/annurev.cb.10.110194.002011; HUGHES SM, 1995, J CELL SCI, V108, P17; KARKI S, 1995, J BIOL CHEM, V270, P28806, DOI 10.1074/jbc.270.48.28806; Kaufman L., 1990, FINDING GROUPS DATA, DOI 10.1002/9780470316801; KING SM, 1995, J BIOL CHEM, V270, P11445, DOI 10.1074/jbc.270.19.11445; KING SM, 1991, J BIOL CHEM, V266, P8401; KOONCE MP, 1992, J CELL BIOL, V119, P1597, DOI 10.1083/jcb.119.6.1597; Koonce MP, 1997, J BIOL CHEM, V272, P19714, DOI 10.1074/jbc.272.32.19714; Koonce MP, 1996, MOL BIOL CELL, V7, P935, DOI 10.1091/mbc.7.6.935; Koonce MP, 1998, CELL MOTIL CYTOSKEL, V39, P63, DOI 10.1002/(SICI)1097-0169(1998)39:1<63::AID-CM6>3.0.CO;2-H; KOONCE MP, 1990, CELL MOTIL CYTOSKEL, V15, P51, DOI 10.1002/cm.970150108; LIN KH, 1991, BIOTECHNIQUES, V11, P748; Mazumdar M, 1996, P NATL ACAD SCI USA, V93, P6552, DOI 10.1073/pnas.93.13.6552; Milisav I, 1998, CELL MOTIL CYTOSKEL, V39, P261, DOI 10.1002/(SICI)1097-0169(1998)39:4<261::AID-CM2>3.0.CO;2-6; MITCHELL DR, 1994, J CELL SCI, V107, P635; Mitchell DR, 1997, CELL MOTIL CYTOSKEL, V37, P120, DOI 10.1002/(SICI)1097-0169(1997)37:2<120::AID-CM4>3.3.CO;2-G; MOCZ G, 1993, BIOCHEMISTRY-US, V32, P3456, DOI 10.1021/bi00064a032; Nurminsky DI, 1998, MOL CELL BIOL, V18, P6816, DOI 10.1128/MCB.18.11.6816; Porter ME, 1996, CURR OPIN CELL BIOL, V8, P10, DOI 10.1016/S0955-0674(96)80042-1; SAKAKIBARA H, 1991, J CELL BIOL, V113, P615, DOI 10.1083/jcb.113.3.615; Sambrook J., 1989, MOL CLONING, pA1; Samso M, 1998, J MOL BIOL, V276, P927, DOI 10.1006/jmbi.1997.1584; SCHLIWA M, 1981, J CELL BIOL, V90, P222, DOI 10.1083/jcb.90.1.222; SCHROER TA, 1994, CURR OPIN CELL BIOL, V6, P69, DOI 10.1016/0955-0674(94)90118-X; Steffen W, 1997, MOL BIOL CELL, V8, P2077, DOI 10.1091/mbc.8.10.2077; Steffen W, 1996, J STRUCT BIOL, V117, P227, DOI 10.1006/jsbi.1996.0087; Sweeney HL, 1996, ANNU REV PHYSIOL, V58, P751, DOI 10.1146/annurev.ph.58.030196.003535; Trivinos-Lagos L., 1993, Molecular Biology of the Cell, V4, p47A; VALLEE R, 1993, P NATL ACAD SCI USA, V90, P8769, DOI 10.1073/pnas.90.19.8769; Vallee RB, 1996, SCIENCE, V271, P1539, DOI 10.1126/science.271.5255.1539; VAUGHAN KT, 1995, J CELL BIOL, V131, P1507, DOI 10.1083/jcb.131.6.1507; WILKERSON CG, 1994, J CELL SCI, V107, P497; WITMAN G B, 1992, Current Opinion in Cell Biology, V4, P74	39	61	61	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15447	15453		10.1074/jbc.274.22.15447	http://dx.doi.org/10.1074/jbc.274.22.15447			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336435	hybrid			2022-12-25	WOS:000080560100024
J	Kim, DG; Chi, SS; Lee, KH; Rhee, SY; Kwon, YH; Chung, CH; Kwon, HM; Kang, MS				Kim, DG; Chi, SS; Lee, KH; Rhee, SY; Kwon, YH; Chung, CH; Kwon, HM; Kang, MS			Neuregulin stimulates myogenic differentiation in an autocrine manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICK EMBRYONIC MYOBLASTS; MAMMARY EPITHELIAL-CELLS; SKELETAL-MUSCLE; MEMBRANE-FUSION; ERBB3 RECEPTORS; PRECURSOR CELLS; EXPRESSION; GROWTH; HEREGULIN; MYOD	During myogenesis, mononucleated myoblasts form multinucleated myotubes by membrane fusion. Efficiency of this intercellular process can be maximized by a simultaneous progress, with a time window, of other neighboring myoblasts in the differentiation program. This phenomenon has been described as the community effect. It proposes the existence of a molecule that acts as a differentiation-inducing signal to a group of identical cells. Here,we show that neuregulin is a strong candidate for this molecule in myoblast differentiation. The expression of neuregulin increased rapidly but transiently at early stage of differentiation of rat L6 cells. Neuregulin showed a potent differentiation-promoting activity in membrane fusion and expression of myosin heavy chain. The antibodies raised against neuregulin and its cognate receptor ErbB3, which were capable of neutralizing the signal pathway, inhibited myotube formation and expression of myosin heavy chain in both L6 cells and primary rat myoblasts. The progress of differentiation was mostly halted after the expression of myogenin and cell cycle arrest. These results suggest that the activation of an autocrine signaling of neuregulin may provide a basic mechanism for the community effect observed in the differentiation of the embryonic muscle cells.	Dankook Univ, Dept Mol Biol, Yongsan Gu, Seoul 140714, South Korea; Seoul Natl Univ, Dept Mol Biol, Seoul 151742, South Korea; Seoul Natl Univ, Res Ctr Cell Differentiat, Seoul 151742, South Korea; Kyung Hee Univ, Dept Biol, Seoul 130701, South Korea	Dankook University; Seoul National University (SNU); Seoul National University (SNU); Kyung Hee University	Kwon, HM (corresponding author), Dankook Univ, Dept Mol Biol, Yongsan Gu, 8 Hannam Dong, Seoul 140714, South Korea.							ALBERTS B, 1994, MOL BIOL CELL, P724; Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; Anastasi S, 1997, J CELL BIOL, V137, P1057, DOI 10.1083/jcb.137.5.1057; Andres V, 1996, J CELL BIOL, V132, P657, DOI 10.1083/jcb.132.4.657; BAEK HJ, 1994, DEV BIOL, V165, P178, DOI 10.1006/dbio.1994.1244; BENBARUCH N, 1994, P SOC EXP BIOL MED, V206, P221; Britsch S, 1998, GENE DEV, V12, P1825, DOI 10.1101/gad.12.12.1825; BUCKINGHAM M, 1992, TRENDS GENET, V8, P144, DOI 10.1016/0168-9525(92)90373-C; Burden S, 1997, NEURON, V18, P847, DOI 10.1016/S0896-6273(00)80324-4; COSSU G, 1995, P NATL ACAD SCI USA, V92, P2254, DOI 10.1073/pnas.92.6.2254; DONG Z, 1995, NEURON, V15, P585, DOI 10.1016/0896-6273(95)90147-7; Florini JR, 1996, ENDOCR REV, V17, P481, DOI 10.1210/edrv-17-5-481; Florini JR, 1996, J BIOL CHEM, V271, P12699, DOI 10.1074/jbc.271.22.12699; FOSTER RF, 1987, DEV BIOL, V122, P11, DOI 10.1016/0012-1606(87)90327-7; FRANK D, 1991, DEVELOPMENT, V113, P1387; GOODEARL ADJ, 1995, J CELL BIOL, V130, P1423, DOI 10.1083/jcb.130.6.1423; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; GUO K, 1995, MOL CELL BIOL, V15, P3823; GURDON JB, 1988, NATURE, V336, P772, DOI 10.1038/336772a0; GURDON JB, 1993, CELL, V75, P831, DOI 10.1016/0092-8674(93)90526-V; GURDON JB, 1993, CURR BIOL, V3, P1, DOI 10.1016/0960-9822(93)90139-F; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Hannon K, 1996, J CELL BIOL, V132, P1151, DOI 10.1083/jcb.132.6.1151; HOLT CE, 1994, P NATL ACAD SCI USA, V91, P10844, DOI 10.1073/pnas.91.23.10844; HOPWOOD ND, 1989, EMBO J, V8, P3409, DOI 10.1002/j.1460-2075.1989.tb08505.x; JO SA, 1995, NATURE, V373, P158, DOI 10.1038/373158a0; KATO K, 1993, P NATL ACAD SCI USA, V90, P1310, DOI 10.1073/pnas.90.4.1310; Lawrence PA, 1996, CELL, V85, P951, DOI 10.1016/S0092-8674(00)81297-0; Lee KH, 1997, BIOCHEM J, V324, P237, DOI 10.1042/bj3240237; LU HS, 1995, J BIOL CHEM, V270, P4784, DOI 10.1074/jbc.270.9.4784; MARTE BM, 1995, MOL ENDOCRINOL, V9, P14, DOI 10.1210/me.9.1.14; MARTE BM, 1995, ONCOGENE, V10, P167; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; MOSCOSO LM, 1995, DEV BIOL, V172, P158, DOI 10.1006/dbio.1995.0012; Neumann C, 1997, BIOESSAYS, V19, P721, DOI 10.1002/bies.950190813; OTT MO, 1991, DEVELOPMENT, V111, P1097; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; Redfield A, 1997, J CELL BIOL, V138, P1323, DOI 10.1083/jcb.138.6.1323; Rosenbaum C, 1997, EXP NEUROL, V148, P604, DOI 10.1006/exnr.1997.6696; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; Velasco JA, 1998, MOL CARCINOGEN, V21, P156, DOI 10.1002/(SICI)1098-2744(199803)21:3<156::AID-MC2>3.0.CO;2-K	43	60	62	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15395	15400		10.1074/jbc.274.22.15395	http://dx.doi.org/10.1074/jbc.274.22.15395			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336427	hybrid			2022-12-25	WOS:000080560100016
J	Lu, PJ; Sundquist, K; Baeckstrom, D; Poulsom, R; Hanby, A; Meier-Ewert, S; Jones, T; Mitchell, M; Pitha-Rowe, P; Freemont, P; Taylor-Papadimitriou, J				Lu, PJ; Sundquist, K; Baeckstrom, D; Poulsom, R; Hanby, A; Meier-Ewert, S; Jones, T; Mitchell, M; Pitha-Rowe, P; Freemont, P; Taylor-Papadimitriou, J			A novel gene (PLU-1) containing highly conserved putative DNA chromatin binding motifs is specifically up-regulated in breast cancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY EPITHELIAL-CELLS; ESCAPES X-INACTIVATION; MONOCLONAL-ANTIBODY; NUCLEAR RECEPTOR; PROTEINS; MORPHOGENESIS; HYBRIDIZATION; EXPRESSION; SEQUENCE; COACTIVATORS	A novel human gene (PLU-1) has been identified which shows a highly restricted expression in normal adult tissues but which is consistently expressed in breast cancers, A fragment of the PLU-1 cDNA was identified by differentially screening a fetal brain library with cDNAs prepared from ce-1 cells (a human mammary epithelial cell line overexpressing c-ErbB2) treated or untreated with the antibody 4D5, which inhibits c-ErbB2 phosphorylation. Clones covering the full cDNA sequence of 6.4 kilobases were isolated from a breast cancer cDNA library. Although expression of PLU-1 in ce-1 cells is regulated by signaling from c-ErbB2, the gene is expressed in all the breast cancer cell lines examined, in cells cultured from primary breast cancers, and in the invasive and in situ components of primary breast cancers. Translation of the open reading frame predicts a protein of 1544 amino acids, which contains three PHD/LAP motifs, a specific DNA-binding domain found in a Drosophila protein (dri) and novel domains showing extensive homology with other human and non human gene products. Transient transfection of cell lines with MYC-tagged PLU-1 showed the protein to be localized in the nucleus and associated with discrete foci. The presence of the dri motif and PHD/LAP fingers together with the clear nuclear localization and consistent expression in breast cancers, suggest a role for PLU-1 in regulating gene expression in breast cancers.	Johns Hopkins Univ, Oncol Grp, Baltimore, MD 21231 USA; Imperial Canc Res Fund, Lab Epithelial Cell Biol, London WC2A 3PX, England; Imperial Canc Res Fund, Lab Situ Hybridizat & Histopathol, London WC2A 3PX, England; Imperial Canc Res Fund, Genome Anal Lab, London WC2A 3PX, England; Imperial Canc Res Fund, Lab Mol Struct & Funct, London WC2A 3PX, England; Imperial Canc Res Fund, Lab Human Cytogenet, London WC2A 3PX, England; Imperial Canc Res Fund, Lab Computat Genome Anal, London WC2A 3PX, England; Guys Hosp, Imperial Canc Res Fund, Breast Pathol Lab, London SE1 9RT, England	Johns Hopkins University; Cancer Research UK; Cancer Research UK; Cancer Research UK; The Genome Analysis Centre (TGAC); Cancer Research UK; Cancer Research UK; Cancer Research UK; Cancer Research UK; Guy's & St Thomas' NHS Foundation Trust	Taylor-Papadimitriou, J (corresponding author), Guys Hosp, Imperial Canc Res Fund, Breast Canc Biol Grp, 3rd Floor,Thomas Guy House,St Thomas St, London SE1 9RT, England.		Corbett-Jones, Tania A/E-4891-2013; Jones, Tania/C-8912-2011	Corbett-Jones, Tania A/0000-0002-0067-3382; Jones, Tania/0000-0002-0067-3382; Freemont, Paul/0000-0002-5658-8486	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049043] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK49043] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; AGULNIK AI, 1994, HUM MOL GENET, V3, P879, DOI 10.1093/hmg/3.6.879; ALIMANDI M, 1995, ONCOGENE, V10, P1813; BARTEK J, 1991, P NATL ACAD SCI USA, V88, P3520, DOI 10.1073/pnas.88.9.3520; Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DSOUZA B, 1993, ONCOGENE, V8, P1797; DUNNE J, 1995, GENOMICS, V30, P207, DOI 10.1006/geno.1995.9884; FATTAEY AR, 1993, ONCOGENE, V8, P3149; Gregory SL, 1996, MOL CELL BIOL, V16, P792; GRESS TM, 1992, MAMM GENOME, V3, P609, DOI 10.1007/BF00352477; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Huang NW, 1998, EMBO J, V17, P3398, DOI 10.1093/emboj/17.12.3398; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KUMAR R, 1991, MOL CELL BIOL, V11, P979, DOI 10.1128/MCB.11.2.979; LU PJ, 1995, J CELL BIOL, V129, P1363, DOI 10.1083/jcb.129.5.1363; Nagase T, 1996, DNA Res, V3, P321, DOI 10.1093/dnares/3.5.321; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; Poulsom R, 1998, EUR J HISTOCHEM, V42, P121; SAHA V, 1995, P NATL ACAD SCI USA, V92, P9737, DOI 10.1073/pnas.92.21.9737; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Schnitzler G, 1998, CELL, V94, P17, DOI 10.1016/S0092-8674(00)81217-9; SEGATTO O, 1990, New Biologist, V2, P187; SENIOR PV, 1988, DEVELOPMENT, V104, P431; SHEARER M, 1992, INT J CANCER, V51, P602, DOI 10.1002/ijc.2910510417; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; TAKEUCHI T, 1995, GENE DEV, V9, P211; TAYLORPAPADIMITRIOU J, 1993, CANCER SURV, V16, P59; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Wang LM, 1998, P NATL ACAD SCI USA, V95, P6809, DOI 10.1073/pnas.95.12.6809; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; WU JS, 1994, HUM MOL GENET, V3, P153, DOI 10.1093/hmg/3.1.153	37	186	216	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15633	15645		10.1074/jbc.274.22.15633	http://dx.doi.org/10.1074/jbc.274.22.15633			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336460	hybrid			2022-12-25	WOS:000080560100049
J	Saba, RI; Ruysschaert, JM; Herchuelz, A; Goormaghtigh, E				Saba, RI; Ruysschaert, JM; Herchuelz, A; Goormaghtigh, E			Fourier transform infrared spectroscopy study of the secondary and tertiary structure of the reconstituted Na+/Ca2+ exchanger 70-kDa polypeptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CALCIUM EXCHANGER; MEMBRANE H+-ATPASE; NA-CA EXCHANGE; LOW-DENSITY-LIPOPROTEIN; PLASMA-MEMBRANE; PARTIAL-PURIFICATION; NA+-CA-2+ EXCHANGE; NEUROSPORA-CRASSA; P-GLYCOPROTEIN; CONFORMATIONAL-CHANGES	The secondary structure of the purified 70-kDa protein Na+/Ca2+ exchanger, functionally reconstituted into asolectin lipid vesicles, was examined by Fourier transform infrared attenuated total reflection spectroscopy. Fourier transform infrared attenuated total reflection spectroscopy provided evidence that the protein is composed of 44% alpha-helices, 25% beta-sheets, 16% beta-turns, and 15% random structures, notably the proportion of alpha-helices is greater than that corresponding to the transmembrane domains predicted by exchanger hydropathy profile. Polarized infrared spectroscopy showed that the orientation of helices is almost perpendicular to the membrane. Tertiary structure modifications, induced by addition of Ca2+, were evaluated by deuterium/hydrogen exchange kinetic measurements for the reconstituted exchanger. This approach was previously proven as a useful tool for detection of tertiary structure modifications induced by an interaction between a protein and its specific ligand, Deuterium/hydrogen exchange kinetic measurements indicated that, in the absence of Ca2+, a large fraction of the protein (40%) is inaccessible to solvent. Addition of Ca2+ increased to 55% the inaccessibility to solvent, representing a major conformational change characterized by the shielding of at least 93 amino acids.	Free Univ Brussels, Fac Med, Lab Pharmacodynamie & Therapeut, B-1070 Brussels, Belgium; Free Univ Brussels, Fac Sci, Chim Phys Macromol Interfaces Lab, B-1050 Brussels, Belgium	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Saba, RI (corresponding author), Free Univ Brussels, Fac Med, Lab Pharmacodynamie & Therapeut, CP 617,Route Lennik 808,Bat GE, B-1070 Brussels, Belgium.			Goormaghtigh, Erik/0000-0002-2071-2262				ACETO JF, 1992, ARCH BIOCHEM BIOPHYS, V298, P553, DOI 10.1016/0003-9861(92)90449-7; ADDISON R, 1986, J BIOL CHEM, V261, P4896; ADDISON R, 1982, J BIOL CHEM, V257, P421; ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; Barth A, 1997, J BIOL CHEM, V272, P25507, DOI 10.1074/jbc.272.41.25507; BARZILAI A, 1984, P NATL ACAD SCI-BIOL, V81, P6521, DOI 10.1073/pnas.81.20.6521; BERS DM, 1989, CIRC RES, V65, P334, DOI 10.1161/01.RES.65.2.334; CABIAUX V, 1989, J BIOL CHEM, V264, P4928; CHALLOU N, 1994, BIOCHEMISTRY-US, V33, P3902; CHEON J, 1988, J BIOL CHEM, V263, P2309; DEJONGH HHJ, 1995, BIOCHEMISTRY-US, V34, P172, DOI 10.1021/bi00001a021; DIPOLO R, 1987, BIOCHIM BIOPHYS ACTA, V897, P347, DOI 10.1016/0005-2736(87)90432-9; DIPOLO R, 1986, BIOCHIM BIOPHYS ACTA, V854, P298, DOI 10.1016/0005-2736(86)90123-9; DIPOLO R, 1979, J GEN PHYSIOL, V73, P91, DOI 10.1085/jgp.73.1.91; DURKIN JT, 1991, ARCH BIOCHEM BIOPHYS, V290, P369, DOI 10.1016/0003-9861(91)90553-U; FISCHBARG J, 1993, P NATL ACAD SCI USA, V90, P11658, DOI 10.1073/pnas.90.24.11658; GOORMAGHTIGH E, 1993, BIOCHEMISTRY-US, V32, P6104, DOI 10.1021/bi00074a023; GOORMAGHTIGH E, 1994, SPECTROCHIM ACTA A, V50, P2137; Goormaghtigh E, 1994, Subcell Biochem, V23, P405; GOORMAGHTIGH E, 1994, J BIOL CHEM, V269, P27409; GOORMAGHTIGH E, 1990, EUR J BIOCHEM, V193, P409, DOI 10.1111/j.1432-1033.1990.tb19354.x; Goormaghtigh E, 1994, Subcell Biochem, V23, P329; GOORMAGHTIGH E, 1989, BIOCHIM BIOPHYS ACTA, V1006, P147, DOI 10.1016/0005-2760(89)90338-X; GOORMAGHTIGH E, 1991, EUR J BIOCHEM, V195, P421, DOI 10.1111/j.1432-1033.1991.tb15721.x; GOORMAGHTIGH E, 1990, MOL DESCRIPTION BIOL, P285; GORNETSCHELNOKOW U, 1994, EMBO J, V13, P338, DOI 10.1002/j.1460-2075.1994.tb06266.x; HAGER KM, 1986, P NATL ACAD SCI USA, V83, P7693, DOI 10.1073/pnas.83.20.7693; Hale CC, 1997, BIOCHEM BIOPH RES CO, V236, P113, DOI 10.1006/bbrc.1997.6912; HALE CC, 1984, P NATL ACAD SCI-BIOL, V81, P6569, DOI 10.1073/pnas.81.21.6569; Harrick N.J., 1967, INTERNAL REFLEXION S; Heimburg T, 1997, J BIOL CHEM, V272, P25685, DOI 10.1074/jbc.272.41.25685; HILGEMANN DW, 1986, J GEN PHYSIOL, V87, P675, DOI 10.1085/jgp.87.5.675; HILGEMANN DW, 1991, ANN NY ACAD SCI, V639, P126, DOI 10.1111/j.1749-6632.1991.tb17296.x; KHANANSHVILI D, 1990, BIOCHEMISTRY-US, V29, P2437, DOI 10.1021/bi00462a001; KHANANSHVILI D, 1991, J BIOL CHEM, V266, P13764; MILANICK MA, 1991, AM J PHYSIOL, V261, pC185, DOI 10.1152/ajpcell.1991.261.1.C185; MIYAMOTO H, 1980, J BIOL CHEM, V255, P2656; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; Philipson K D, 1993, Int Rev Cytol, V137C, P199; PHILIPSON KD, 1988, BIOCHIM BIOPHYS ACTA, V945, P298, DOI 10.1016/0005-2736(88)90492-0; PHILIPSON KD, 1987, BIOCHIM BIOPHYS ACTA, V897, P152, DOI 10.1016/0005-2736(87)90323-3; PHILIPSON KD, 1987, BIOCHIM BIOPHYS ACTA, V899, P60; Raussens V, 1997, J BIOL CHEM, V272, P262; RAUSSENS V, 1997, THESIS U LIBRE BRUXE; REEVES JP, 1990, INTRACELLULAR CALCIU, P305; Saba RI, 1999, BIOCHEM J, V338, P139, DOI 10.1042/0264-6021:3380139; SARKADI B, 1992, J BIOL CHEM, V267, P4854; SHAPIRO AB, 1994, J BIOL CHEM, V269, P3745; SOLDATI L, 1985, J BIOL CHEM, V260, P3321; Sonveaux N, 1996, J BIOL CHEM, V271, P24617, DOI 10.1074/jbc.271.40.24617; STREHLER EE, 1991, J MEMBRANE BIOL, V120, P1, DOI 10.1007/BF01868586; SUSI H, 1967, J BIOL CHEM, V242, P5460; SWEADNER KJ, 1992, ANN NY ACAD SCI, V671, P217, DOI 10.1111/j.1749-6632.1992.tb43798.x; UNWIN N, 1993, J MOL BIOL, V229, P1101, DOI 10.1006/jmbi.1993.1107; VERMURI R, 1988, BIOCHIM BIOPHYS ACTA, V937, P258; VIGNERON L, 1995, J BIOL CHEM, V270, P17685, DOI 10.1074/jbc.270.30.17685; WAKABAYASHI S, 1982, BIOCHIM BIOPHYS ACTA, V693, P125, DOI 10.1016/0005-2736(82)90478-3; WEISS MS, 1991, FEBS LETT, V280, P379, DOI 10.1016/0014-5793(91)80336-2	59	21	24	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15510	15518		10.1074/jbc.274.22.15510	http://dx.doi.org/10.1074/jbc.274.22.15510			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336444	hybrid			2022-12-25	WOS:000080560100033
J	Shih, SC; Mullen, A; Abrams, K; Mukhopadhyay, D; Claffey, KP				Shih, SC; Mullen, A; Abrams, K; Mukhopadhyay, D; Claffey, KP			Role of protein kinase C isoforms in phorbol ester-induced vascular endothelial growth factor expression in human glioblastoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE; SELECTIVE INHIBITOR; GLUCOSE-TRANSPORT; ZETA-ISOFORM; KAPPA-B; ACTIVATION; POTENT; GENE	Aberrant expression of the potent angiogenic cytokine, vascular endothelial growth factor (VEGF), has been demonstrated to be associated with most human solid tumors. Both transcriptional and post-transcriptional mechanisms have been shown to modulate VEGF expression in a multitude of cell types. Here we report that when protein kinase C (PKC) pathways were activated in human glioblastoma U373 cells by phorbol 12-myristate 13-acetate (PMA), VEGF mRNA expression was up-regulated via a post-transcriptional mRNA stabilization mechanism. PMA treatment exhibited no increase in VEGF-specific transcriptional activation as determined by run-off transcription assays and VEGF promoter-luciferase reporter assays. However, PMA increased VEGF mRNA half-life from 0.8 to 3.6 h which was blocked by PKC inhibitors but not by protein kinase A or cyclic nucleotide-dependent protein kinase inhibitors. When U373 cells were transfected with antisense oligonucleotide sequences to the translation start sites of PKC-alpha, -beta, -gamma, -delta, -epsilon, or -zeta isoforms, both PKC-alpha and -zeta antisense oligonucleotides showed substantial inhibition of PMA-induced VEGF mRNA. In addition, overexpression of PKC-zeta resulted in a strong constitutive up-regulation of VEGF mRNA expression. This study demonstrates for the first time that specific PKC isoforms regulate VEGF mRNA expression through post-transcriptional mechanisms.	Univ Connecticut, Ctr Hlth, Dept Physiol, Farmington, CT 06030 USA; Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02215 USA	University of Connecticut; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Claffey, KP (corresponding author), Univ Connecticut, Ctr Hlth, Dept Physiol, 263 Farmington Ave, Farmington, CT 06030 USA.				NCI NIH HHS [CA64436] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064436, R29CA064436] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bandyopadhyay G, 1997, J BIOL CHEM, V272, P2551; Berra E, 1997, MOL CELL BIOL, V17, P4346, DOI 10.1128/MCB.17.8.4346; BOULIS NM, 1990, BRAIN RES, V525, P198, DOI 10.1016/0006-8993(90)90864-8; Casabona G, 1997, PROG NEURO-PSYCHOPH, V21, P407, DOI 10.1016/S0278-5846(97)00011-0; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; Claffey KP, 1998, MOL BIOL CELL, V9, P469, DOI 10.1091/mbc.9.2.469; Claffey KP, 1996, CANCER METAST REV, V15, P165, DOI 10.1007/BF00437469; CRABOS M, 1991, BIOCHEM BIOPH RES CO, V178, P878, DOI 10.1016/0006-291X(91)90973-B; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; Huang CS, 1997, J BIOL CHEM, V272, P4187, DOI 10.1074/jbc.272.7.4187; IJICHI A, 1995, GLIA, V14, P87, DOI 10.1002/glia.440140203; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; JONES KT, 1994, J CELL PHYSIOL, V159, P324, DOI 10.1002/jcp.1041590215; KIESER A, 1994, ONCOGENE, V9, P963; Kim SJ, 1997, BIOCHEM BIOPH RES CO, V237, P336, DOI 10.1006/bbrc.1997.7061; LOZANO J, 1994, J BIOL CHEM, V269, P19200; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Mukhopadhyay D, 1997, MOL CELL BIOL, V17, P5629, DOI 10.1128/MCB.17.9.5629; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; Namiki A, 1995, J BIOL CHEM, V270, P31189, DOI 10.1074/jbc.270.52.31189; Nave BT, 1996, BIOCHEM J, V318, P203, DOI 10.1042/bj3180203; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Pal S, 1998, J BIOL CHEM, V273, P26277, DOI 10.1074/jbc.273.41.26277; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SENGER DR, 1993, CANCER METAST REV, V12, P303, DOI 10.1007/BF00665960; TAMAOKI T, 1990, BIO-TECHNOL, V8, P732, DOI 10.1038/nbt0890-732; TISCHER E, 1991, J BIOL CHEM, V266, P11947; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; USHMOROV AG, 1994, CARCINOGENESIS, V15, P2739, DOI 10.1093/carcin/15.12.2739; vanDijk MCM, 1997, BIOCHEM J, V323, P693, DOI 10.1042/bj3230693; VISNJIC D, 1995, BIOCHEM J, V310, P163, DOI 10.1042/bj3100163; WAYS DK, 1992, J BIOL CHEM, V267, P4799	33	87	94	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15407	15414		10.1074/jbc.274.22.15407	http://dx.doi.org/10.1074/jbc.274.22.15407			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336429	hybrid			2022-12-25	WOS:000080560100018
J	Zhou, ZM; Peng, SB; Crider, BP; Andersen, P; Xie, XS; Stone, DK				Zhou, ZM; Peng, SB; Crider, BP; Andersen, P; Xie, XS; Stone, DK			Recombinant SFD isoforms activate vacuolar proton pumps	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLATHRIN-COATED VESICLES; MOLECULAR CHARACTERIZATION; SACCHAROMYCES-CEREVISIAE; TRANSLOCATING COMPLEX; RECONSTITUTION; SUBUNIT; ATPASE; (H+)-ATPASE; EXPRESSION; PROTEINS	The vacuolar proton pump of clathrin-coated vesicles is composed of two general sectors, a cytosolic, ATP hydrolytic domain (V-1) and an intramembranous proton channel, V-0. V-1 is comprised of 8-9 subunits including polypeptides of 50 and 57 kDa, termed SFD (Sub Fifty-eight-kDa Doublet). Although SFD is essential to the activation of ATPase and proton pumping activities catalyzed by holoenzyme, its constituent polypeptides have not been separated to determine their respective roles in ATPase functions. Recent molecular characterization of these subunits revealed that they are isoforms that arise through an alternative splicing mechanism (Zhou,., Peng, S.-B., Crider, B.P., Slaughter, C., Xie, X.S., and Stone, D.K. (1998) J. Biol. Chem. 273, 5878-5884). To determine the functional characteristics of the 57-kDa (SFD alpha)(1) and 50-kDa (SFD beta) isoforms, we expressed these proteins in Escherichia coli. We determined that purified recombinant proteins, rSFD alpha and rSFD beta, when reassembled with SFD-depleted holoenzyme, are functionally interchangeable in restoration of ATPase and proton pumping activities. In addition, we determined that the V-pump of chromaffin granules has only the SFDa isoform in its native state and that rSFD alpha and rSFD beta are equally effective in restoring ATPase and proton pumping activities to SFD-depleted enzyme. Finally, we found that SFD alpha and SFD beta structurally interact not only with V-1, but also with V-0, indicating that these activator subunits may play both structural and functional roles in coupling ATP hydrolysis to proton flow.	Univ Texas, SW Med Ctr, Dept Internal Med, Div Mol Transport, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Stone, DK (corresponding author), Univ Texas, SW Med Ctr, Dept Internal Med, Div Mol Transport, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.				NIDDK NIH HHS [R01DK-33627] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033627] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALAWQATI Q, 1995, CURR OPIN CELL BIOL, V7, P504, DOI 10.1016/0955-0674(95)80006-9; Boekema EJ, 1997, P NATL ACAD SCI USA, V94, P14291, DOI 10.1073/pnas.94.26.14291; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CRIDER BP, 1994, J BIOL CHEM, V269, P17379; Crider BP, 1997, J BIOL CHEM, V272, P10721; Graf R, 1996, J BIOL CHEM, V271, P20908, DOI 10.1074/jbc.271.34.20908; Harvey WR, 1997, J EXP BIOL, V200, P203; HO MN, 1993, J BIOL CHEM, V268, P18286; Junge W, 1997, TRENDS BIOCHEM SCI, V22, P420, DOI 10.1016/S0968-0004(97)01129-8; KANE PM, 1995, J BIOL CHEM, V270, P17025; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.biochem.59.1.415; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU Q, 1994, J BIOL CHEM, V269, P31592; MATTSSON JP, 1994, J BIOL CHEM, V269, P24979; MEYERS M, 1993, J BIOL CHEM, V268, P9184; NANDI PK, 1982, P NATL ACAD SCI-BIOL, V79, P5881, DOI 10.1073/pnas.79.19.5881; Peng SB, 1999, J BIOL CHEM, V274, P2549, DOI 10.1074/jbc.274.4.2549; PENG SB, 1995, J BIOL CHEM, V270, P16926; PHAN HL, 1994, EMBO J, V13, P1706, DOI 10.1002/j.1460-2075.1994.tb06435.x; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; STONE DK, 1984, J BIOL CHEM, V259, P2701; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; THURIEAU C, 1988, DNA-J MOLEC CELL BIO, V7, P663, DOI 10.1089/dna.1988.7.663; XIE XS, 1986, J BIOL CHEM, V261, P2492; XIE XS, 1989, J BIOL CHEM, V264, P18870; XIE XS, 1994, J BIOL CHEM, V269, P25809; XIE XS, 1986, P NATL ACAD SCI USA, V83, P8913, DOI 10.1073/pnas.83.23.8913; XIE XS, 1993, J BIOL CHEM, V268, P25063; ZANG K, 1992, J BIOL CHEM, V267, P9701; Zhou ZM, 1998, J BIOL CHEM, V273, P5878, DOI 10.1074/jbc.273.10.5878	30	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15913	15919		10.1074/jbc.274.22.15913	http://dx.doi.org/10.1074/jbc.274.22.15913			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336497	hybrid			2022-12-25	WOS:000080560100086
J	He, XY; Merz, G; Mehta, P; Schulz, H; Yang, SY				He, XY; Merz, G; Mehta, P; Schulz, H; Yang, SY			Human brain short chain L-3-hydroxyacyl coenzyme A dehydrogenase is a single-domain multifunctional enzyme - Characterization of a novel 17 beta-hydroxysteroid dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE-BINDING PROTEIN; AMYLOID-BETA PEPTIDE; EXPRESSION CLONING; STRUCTURAL ORGANIZATION; ALZHEIMERS-DISEASE; MOLECULAR-CLONING; A DEHYDROGENASE; CELLS; REDUCTASE; RAT	Human brain short chain L-3-hydroxyacyl-CoA dehydrogenase (SCHAD) was found to catalyze the oxidation of 17 beta-estradiol and dihydroandrosterone as well as alcohols. Mitochondria have been demonstrated to be the proper location of this NAD(+)-dependent dehydrogenase in cells, although its primary structure is identical to an amyloid beta-peptide binding protein reportedly associated with the endoplasmic reticulum (ERAB). This fatty acid beta-oxidation enzyme was identified as a novel 17 beta-hydroxysteroid dehydrogenase responsible for the inactivation of sex steroid hormones. The catalytic rate constant of the purified enzyme was estimated to be 0.66 min(-1) with apparent K-m values of 43 and 50 mu M for 17 beta-estradiol and NAD(+), respectively. The catalytic efficiency of this enzyme for the oxidation of 17 beta-estradiol was comparable with that of peroxisomal 17 beta-hydroxysteroid dehydrogenase type 4, As a result, the human SCHAD gene product, a single-domain multifunctional enzyme, appears to function in two different pathways of lipid metabolism. Because the catalytic functions of human brain short chain L-3-hydroxyacyl-CoA dehydrogenase could weaken the protective effects of estrogen and generate aldehydes in neurons, it is proposed that a high concentration of this enzyme in brain is a potential risk factor for Alzheimer's disease.	New York State Inst Basic Res Dev Disabil, Dept Pharmacol, Staten Isl, NY 10314 USA; New York State Inst Basic Res Dev Disabil, Dept Pathol Neurobiol, Staten Isl, NY 10314 USA; New York State Inst Basic Res Dev Disabil, Dept Immunol, Staten Isl, NY 10314 USA; CUNY City Coll, Dept Chem, New York, NY 10031 USA	Institute for Basic Research in Developmental Disabilities; Institute for Basic Research in Developmental Disabilities; Institute for Basic Research in Developmental Disabilities; City University of New York (CUNY) System; City College of New York (CUNY)	Yang, SY (corresponding author), New York State Inst Basic Res Dev Disabil, Dept Pharmacol, 1050 Forest Hill Rd, Staten Isl, NY 10314 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030847] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK047392] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL30847] Funding Source: Medline; NIDDK NIH HHS [DK47392] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMSKI J, 1995, BIOCHEM J, V311, P437, DOI 10.1042/bj3110437; Beyreuther K, 1997, NATURE, V389, P677, DOI 10.1038/39479; Binstock J F, 1981, Methods Enzymol, V71 Pt C, P403; Biswas MG, 1997, J BIOL CHEM, V272, P15959, DOI 10.1074/jbc.272.25.15959; BLACKSHEAR PJ, 1984, METHOD ENZYMOL, V104, P237; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN Z, 1993, BIOCHEMISTRY-US, V32, P3342, DOI 10.1021/bi00064a017; Cornish-Bowden A., 1995, ANAL ENZYME KINETIC; DIENAIDENOUBHAN.M, 1996, EUR J BIOCHEM, V240, P660; Fomitcheva J, 1998, J BIOL CHEM, V273, P22664, DOI 10.1074/jbc.273.35.22664; GEISSLER WM, 1994, NAT GENET, V7, P34, DOI 10.1038/ng0594-34; Goodman YD, 1996, J NEUROCHEM, V66, P1836; He XY, 1998, J BIOL CHEM, V273, P10741, DOI 10.1074/jbc.273.17.10741; He XY, 1998, BBA-LIPID LIPID MET, V1392, P119, DOI 10.1016/S0005-2760(98)00031-9; He XY, 1999, BBA-MOL CELL BIOL L, V1437, P119, DOI 10.1016/S1388-1981(98)00005-5; Henderson Victor W., 1997, American Journal of Medicine, V103, p11S, DOI 10.1016/S0002-9343(97)00261-1; JOHNSON GD, 1981, J IMMUNOL METHODS, V43, P349, DOI 10.1016/0022-1759(81)90183-6; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; Kawata M, 1995, NEUROSCI RES, V24, P1, DOI 10.1016/0168-0102(96)81278-8; Kobayashi A, 1996, J BIOCHEM-TOKYO, V119, P775, DOI 10.1093/oxfordjournals.jbchem.a021307; Labrie F, 1998, STEROIDS, V63, P322, DOI 10.1016/S0039-128X(98)00007-5; Labrie F, 1997, STEROIDS, V62, P148, DOI 10.1016/S0039-128X(96)00174-2; Leenders F, 1996, J BIOL CHEM, V271, P5438, DOI 10.1074/jbc.271.10.5438; LIN SX, 1992, J BIOL CHEM, V267, P16182; Nokelainen P, 1998, MOL ENDOCRINOL, V12, P1048, DOI 10.1210/me.12.7.1048; OGAWA H, 1995, P NATL ACAD SCI USA, V92, P11899, DOI 10.1073/pnas.92.25.11899; Oppermann UCT, 1997, BIOCHEMISTRY-US, V36, P34, DOI 10.1021/bi961803v; Pai JT, 1998, J BIOL CHEM, V273, P26138, DOI 10.1074/jbc.273.40.26138; Pelletier G, 1995, BRAIN RES, V704, P233, DOI 10.1016/0006-8993(95)01119-6; PELTOKETO H, 1988, FEBS LETT, V239, P73, DOI 10.1016/0014-5793(88)80548-9; SCHIEBER A, 1992, EUR J BIOCHEM, V206, P491, DOI 10.1111/j.1432-1033.1992.tb16952.x; Segel IH, 1975, ENZYME KINETICS BEHA; Suzuki K, 1998, J BIOCHEM-TOKYO, V123, P353; Torroja L, 1998, J CELL BIOL, V141, P1009, DOI 10.1083/jcb.141.4.1009; Vredendaal PJCM, 1998, MAMM GENOME, V9, P763, DOI 10.1007/s003359900860; Woolley CS, 1997, J NEUROSCI, V17, P1848; WU L, 1993, J BIOL CHEM, V268, P12964; Xu HX, 1998, NAT MED, V4, P447, DOI 10.1038/nm0498-447; Yan SD, 1997, NATURE, V389, P689	39	110	117	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					15014	15019		10.1074/jbc.274.21.15014	http://dx.doi.org/10.1074/jbc.274.21.15014			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329704	hybrid			2022-12-25	WOS:000081965200069
J	Luan, P; Balch, WE; Emr, SD; Burd, CG				Luan, P; Balch, WE; Emr, SD; Burd, CG			Molecular dissection of guanine nucleotide dissociation inhibitor function in vivo - Rab-independent binding to membranes and role of Rab recycling factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; SECRETORY PATHWAY; GDP/GTP EXCHANGE; GOLGI TRANSPORT; YEAST HOMOLOG; BOVINE BRAIN; GDP; PROTEIN; GTP; GTPASES	Guanine nucleotide dissociation inhibitor (GDI) is an essential protein required for the recycling of Rab GTPases mediating the targeting and fusion of vesicles in the exocytic and endocytic pathways. Using site-directed mutagenesis of yeast GDI1, we demonstrate that amino acid residues required for Rab recognition in vitro are critical for function in vivo in Saccharomyces cerevisiae. Analysis of the effects of Rab-binding mutants on function in vivo reveals that only a small pool of recycling Rab protein is essential for growth, and that the rates of recycling of distinct Rabs are differentially sensitive to GDI. Furthermore, we find that membrane association of Gdi1p is Rab-independent. Mutant Gdi1 proteins unable to bind Rabs were able to associate with cellular membranes as efficiently as wild-type Gdi1p, yet caused a striking loss of the endogenous cytosolic Gdi1p-Rab pools leading to dominant inhibition of growth when expressed at levels of the normal, endogenous pool. These results demonstrate a potential role for a new recycling factor in the retrieval of Rab-GDP from membranes, and illustrate the importance of multiple effecters in regulating GDI function in Rab delivery and retrieval from membranes.	Scripps Res Inst, Dept Cell Biol IMM 11, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol Biol IMM 11, La Jolla, CA 92037 USA; Univ Calif San Diego, Sch Med, Howard Hughes Med Inst, Div Cellular & Mol Med, La Jolla, CA 92093 USA	Scripps Research Institute; Scripps Research Institute; Howard Hughes Medical Institute; University of California System; University of California San Diego	Balch, WE (corresponding author), Scripps Res Inst, Dept Cell Biol IMM 11, La Jolla, CA 92037 USA.	webalch@scripps.edu		Burd, Christopher/0000-0003-1831-8706	NCI NIH HHS [CA 58689] Funding Source: Medline; NIGMS NIH HHS [GM33301] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA058689] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033301] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; Chen W, 1998, MOL BIOL CELL, V9, P3241, DOI 10.1091/mbc.9.11.3241; Collins RN, 1997, J BIOL CHEM, V272, P18281, DOI 10.1074/jbc.272.29.18281; D'Adamo P, 1998, NAT GENET, V19, P134, DOI 10.1038/487; DASCHER C, 1994, J BIOL CHEM, V269, P1437; DiracSvejstrup AB, 1997, EMBO J, V16, P465, DOI 10.1093/emboj/16.3.465; ELAZAR Z, 1994, J BIOL CHEM, V269, P794; GARRETT MD, 1994, EMBO J, V13, P1718, DOI 10.1002/j.1460-2075.1994.tb06436.x; Gaynor EC, 1997, J CELL BIOL, V136, P789, DOI 10.1083/jcb.136.4.789; GAYNOR EC, 1994, J CELL BIOL, V127, P653, DOI 10.1083/jcb.127.3.653; HAAS A, 1995, EMBO J, V14, P5258, DOI 10.1002/j.1460-2075.1995.tb00210.x; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HORAZDOVSKY BF, 1993, J BIOL CHEM, V268, P4953; HORAZDOVSKY BF, 1994, EMBO J, V13, P1297, DOI 10.1002/j.1460-2075.1994.tb06382.x; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JANOUEIXLEROSEY I, 1995, J BIOL CHEM, V270, P14801, DOI 10.1074/jbc.270.24.14801; Jedd G, 1997, J CELL BIOL, V137, P563, DOI 10.1083/jcb.137.3.563; KLIONSKY DJ, 1988, MOL CELL BIOL, V8, P2105, DOI 10.1128/MCB.8.5.2105; Lazar T, 1997, TRENDS BIOCHEM SCI, V22, P468, DOI 10.1016/S0968-0004(97)01150-X; McLauchlan H, 1998, CURR BIOL, V8, P34, DOI 10.1016/S0960-9822(98)70018-1; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; NUOFFER C, 1994, J CELL BIOL, V125, P225, DOI 10.1083/jcb.125.2.225; OSSIG R, 1995, EMBO J, V14, P3645, DOI 10.1002/j.1460-2075.1995.tb00034.x; PETER F, 1994, J CELL BIOL, V126, P1393, DOI 10.1083/jcb.126.6.1393; PFEFFER SR, 1995, J BIOL CHEM, V270, P17057, DOI 10.1074/jbc.270.29.17057; Rybin V, 1996, NATURE, V383, P266, DOI 10.1038/383266a0; SASAKI T, 1991, MOL CELL BIOL, V11, P2909, DOI 10.1128/MCB.11.5.2909; SASAKI T, 1990, J BIOL CHEM, V265, P2333; Schalk I, 1996, NATURE, V381, P42, DOI 10.1038/381042a0; SCHALK IJ, 1994, J MOL BIOL, V244, P469, DOI 10.1006/jmbi.1994.1744; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; Sherman F, 1979, METHODS YEAST GENETI; SHISHEVA A, 1994, J BIOL CHEM, V269, P23865; SHISHEVA A, 1995, EUR J CELL BIOL, V68, P143; SINGERKRUGER B, 1994, J CELL BIOL, V125, P283, DOI 10.1083/jcb.125.2.283; SOLDATI T, 1994, NATURE, V369, P76, DOI 10.1038/369076a0; SOLDATI T, 1993, MOL BIOL CELL, V4, P425, DOI 10.1091/mbc.4.4.425; ULLRICH O, 1994, NATURE, V368, P157, DOI 10.1038/368157a0; ULLRICH O, 1993, J BIOL CHEM, V268, P18143; WALDHERR M, 1993, NAT GENET, V3, P193, DOI 10.1038/ng0393-193; Wendland B, 1996, J CELL BIOL, V135, P1485, DOI 10.1083/jcb.135.6.1485; WICHMANN H, 1992, CELL, V71, P1131, DOI 10.1016/S0092-8674(05)80062-5; Wu SK, 1998, J BIOL CHEM, V273, P26931, DOI 10.1074/jbc.273.41.26931; Wu SK, 1996, TRENDS BIOCHEM SCI, V21, P472, DOI 10.1016/S0968-0004(96)10062-1; YANG CZ, 1994, J BIOL CHEM, V269, P31891	47	46	47	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					14806	14817		10.1074/jbc.274.21.14806	http://dx.doi.org/10.1074/jbc.274.21.14806			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329679	hybrid			2022-12-25	WOS:000081965200044
J	Mizuno, T; Nakata, M; Naiki, H; Michikawa, M; Wang, R; Haass, C; Yanagisawa, K				Mizuno, T; Nakata, M; Naiki, H; Michikawa, M; Wang, R; Haass, C; Yanagisawa, K			Cholesterol-dependent generation of a seeding amyloid beta-protein in cell culture	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; SCRAPIE ISOFORM; PRION PROTEIN; MDCK CELLS; IN-VITRO; FIBRIL FORMATION; CAVEOLAE; PEPTIDE; GANGLIOSIDES	Deposition of aggregated amyloid beta-protein (A beta), a proteolytic cleavage product of the amyloid precursor protein (1), is a critical step in the development of Alzheimer's disease (2). However, we are far from understanding the molecular mechanisms underlying the initiation of A beta polymerization in vivo. Here, we report that a seeding A beta, which catalyzes the fibrillogenesis of soluble A beta, is generated from the apically missorted amyloid precursor protein in cultured epithelial cells. Furthermore, the generation of this A beta depends exclusively on the presence of cholesterol in the cells. Taken together with mass spectrometric analysis of this novel A beta and our recent study (3), it is suggested that a conformationally altered form of A beta, which acts as a "seed" for amyloid fibril formation, is generated in intracellular cholesterol-rich microdomains.	Natl Inst Longev Sci, Dept Dementia Res, Obu 4748522, Japan; Peptide Inst Inc, Prot Res Fdn, Osaka 562, Japan; Fukui Med Univ, Dept Pathol, Fukui 9101193, Japan; Rockefeller Univ, Lab Mass Spectrometry, New York, NY 10021 USA; Cent Inst Mental Hlth, Dept Mol Biol, D-68159 Mannheim, Germany	University of Fukui; Rockefeller University; Central Institute of Mental Health	Yanagisawa, K (corresponding author), Natl Inst Longev Sci, Dept Dementia Res, Gengo 36-3, Obu 4748522, Japan.		Wang, Rong/A-8721-2009; Naiki, Hironobu/G-5599-2014					Bouillot C, 1996, J BIOL CHEM, V271, P7640, DOI 10.1074/jbc.271.13.7640; Carrell RW, 1997, LANCET, V350, P134, DOI 10.1016/S0140-6736(97)02073-4; ChooSmith LP, 1997, FEBS LETT, V402, P95, DOI 10.1016/S0014-5793(96)01504-9; ChooSmith LP, 1997, J BIOL CHEM, V272, P22987, DOI 10.1074/jbc.272.37.22987; DESTROOPER B, 1995, J BIOL CHEM, V270, P4058, DOI 10.1074/jbc.270.8.4058; HAASS C, 1995, J CELL BIOL, V128, P537, DOI 10.1083/jcb.128.4.537; HAASS C, 1994, P NATL ACAD SCI USA, V91, P1564, DOI 10.1073/pnas.91.4.1564; Harper JD, 1997, ANNU REV BIOCHEM, V66, P385, DOI 10.1146/annurev.biochem.66.1.385; Ikezu T, 1998, J BIOL CHEM, V273, P10485, DOI 10.1074/jbc.273.17.10485; Kaneko K, 1997, P NATL ACAD SCI USA, V94, P2333, DOI 10.1073/pnas.94.6.2333; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kim K., 1988, NEUROSCI RES COMMUN, V2, P121; Lansbury PT, 1997, NEURON, V19, P1151, DOI 10.1016/S0896-6273(00)80406-7; Lee SJ, 1998, NAT MED, V4, P730, DOI 10.1038/nm0698-730; McLaurin J, 1996, J BIOL CHEM, V271, P26482, DOI 10.1074/jbc.271.43.26482; Mizuno T, 1998, BBA-BIOMEMBRANES, V1373, P119, DOI 10.1016/S0005-2736(98)00097-2; Naiki H, 1997, BIOCHEMISTRY-US, V36, P6243, DOI 10.1021/bi9624705; Naiki H, 1996, LAB INVEST, V74, P374; Naslavsky N, 1997, J BIOL CHEM, V272, P6324, DOI 10.1074/jbc.272.10.6324; PARTON RG, 1994, J HISTOCHEM CYTOCHEM, V42, P155, DOI 10.1177/42.2.8288861; PODLISNY MB, 1995, J BIOL CHEM, V270, P9564, DOI 10.1074/jbc.270.16.9564; Prusiner SB, 1997, SCIENCE, V278, P245, DOI 10.1126/science.278.5336.245; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Simons M, 1998, P NATL ACAD SCI USA, V95, P6460, DOI 10.1073/pnas.95.11.6460; SUZUKI N, 1994, AM J PATHOL, V145, P452; TARABOULOS A, 1995, J CELL BIOL, V129, P121, DOI 10.1083/jcb.129.1.121; VAN A, 1995, FEBS LETT, V369, P18; Vey M, 1996, P NATL ACAD SCI USA, V93, P14945, DOI 10.1073/pnas.93.25.14945; Wang R, 1996, J BIOL CHEM, V271, P31894, DOI 10.1074/jbc.271.50.31894; YANAGISAWA K, 1995, NAT MED, V1, P1062, DOI 10.1038/nm1095-1062	31	101	107	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					15110	15114		10.1074/jbc.274.21.15110	http://dx.doi.org/10.1074/jbc.274.21.15110			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329717	hybrid			2022-12-25	WOS:000081965200082
J	Nardini, M; Ridder, IS; Rozeboom, HJ; Kalk, KH; Rink, R; Janssen, DB; Dijkstra, BW				Nardini, M; Ridder, IS; Rozeboom, HJ; Kalk, KH; Rink, R; Janssen, DB; Dijkstra, BW			The X-ray structure of epoxide hydrolase from Agrobacterium radiobacter AD1 - An enzyme to detoxify harmful epoxides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HALOALKANE DEHALOGENASE; CATALYTIC MECHANISM; PROTEIN STRUCTURES; CRYSTAL-STRUCTURE; DIFFRACTION DATA; PROGRAM PACKAGE; MOLSCRIPT; LIPASE; ERRORS; FOLD	Epoxide hydrolases catalyze the cofactor-independent hydrolysis of reactive and toxic epoxides, They play an essential role in the detoxification of various xenobiotics in higher organisms and in the bacterial degradation of several environmental pollutants. The first x-ray structure of one of these, from Agrobacterium radiobacter AD1, has been determined by isomorphous replacement at 2.1-Angstrom resolution. The enzyme shows a two domain structure with the core having the alpha/beta hydrolase-fold topology. The catalytic residues, Asp(107) and His(275), are located in a predominantly hydrophobic environment between the two domains. A tunnel connects the back of the active-site cavity with the surface of the enzyme and provides access to the active site for the catalytic water molecule, which in the crystal structure, has been found at hydrogen bond distance to His275. Because of a crystallographic contact, the active site has become accessible for the Gln(134) side chain, which occupies a position mimicking a bound substrate. The structure suggests Tyr(152)/Tyr(215) as the residues involved in substrate binding, stabilization of the transition state, and possibly protonation of the epoxide oxygen.	Univ Groningen, Biophys Chem Lab, NL-9747 AG Groningen, Netherlands; Univ Groningen, BIOSON Res Inst, NL-9747 AG Groningen, Netherlands; Univ Groningen, Dept Chem, Biochem Lab, NL-9747 AG Groningen, Netherlands	University of Groningen; University of Groningen; University of Groningen	Dijkstra, BW (corresponding author), Univ Groningen, Biophys Chem Lab, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.		Nardini, Marco/B-7842-2017; Dijkstra, Bauke W./H-4308-2019	Nardini, Marco/0000-0002-3718-2165; Dijkstra, Bauke W./0000-0001-9731-6586; Rozeboom, Henriette/0000-0002-1656-6477; Ridder, Ivo Steven/0000-0002-1669-4161				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; ARAND M, 1994, FEBS LETT, V338, P251, DOI 10.1016/0014-5793(94)80278-5; Archelas A, 1998, TRENDS BIOTECHNOL, V16, P108, DOI 10.1016/S0167-7799(97)01161-X; BELL PA, 1993, J BIOL CHEM, V268, P14011; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; BRUNGER AT, 1992, XPLOR SYSTEM XRAY CR; EGLOFF MP, 1995, BIOCHEMISTRY-US, V34, P2751, DOI 10.1021/bi00009a003; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FRANKEN SM, 1991, EMBO J, V10, P1297, DOI 10.1002/j.1460-2075.1991.tb07647.x; Furey W, 1997, METHOD ENZYMOL, V277, P590, DOI 10.1016/S0076-6879(97)77033-2; HECHT HJ, 1994, NAT STRUCT BIOL, V1, P532, DOI 10.1038/nsb0894-532; HERANDEZ O, 1982, METABOLIC BASIS DETO, P207; HOL WGJ, 1978, NATURE, V273, P443, DOI 10.1038/273443a0; HOLM L, 1994, PROTEINS, V19, P165, DOI 10.1002/prot.340190302; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; JACOBS MHJ, 1991, EUR J BIOCHEM, V202, P1217, DOI 10.1111/j.1432-1033.1991.tb16493.x; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KERR BM, 1990, DRUG METAB DISPOS, V18, P540; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P842, DOI 10.1107/S0907444995016477; KLEYWEGT GJ, 1995, STRUCTURE, V15, P535; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krooshof GH, 1997, BIOCHEMISTRY-US, V36, P9571, DOI 10.1021/bi971014t; LACOURCIERE GM, 1994, CHEM RES TOXICOL, V7, P121, DOI 10.1021/tx00038a001; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; McGaughey GB, 1998, J BIOL CHEM, V273, P15458, DOI 10.1074/jbc.273.25.15458; Misawa E, 1998, EUR J BIOCHEM, V253, P173, DOI 10.1046/j.1432-1327.1998.2530173.x; Navaza J, 1997, METHOD ENZYMOL, V276, P581, DOI 10.1016/S0076-6879(97)76079-8; NOBLE MEM, 1993, FEBS LETT, V331, P123, DOI 10.1016/0014-5793(93)80310-Q; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; RAMAKRISHNAN C, 1965, J MOL BIOL, V7, P95; Rink R, 1997, J BIOL CHEM, V272, P14650, DOI 10.1074/jbc.272.23.14650; Spelberg JHL, 1998, TETRAHEDRON-ASYMMETR, V9, P459, DOI 10.1016/S0957-4166(98)00003-2; VERSCHUEREN KHG, 1993, J MOL BIOL, V232, P856, DOI 10.1006/jmbi.1993.1436; VERSCHUEREN KHG, 1993, NATURE, V363, P693, DOI 10.1038/363693a0; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0	39	146	154	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					14579	14586		10.1074/jbc.274.21.14579	http://dx.doi.org/10.1074/jbc.274.21.14579			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329649	Green Published, hybrid			2022-12-25	WOS:000081965200014
J	Perisic, O; Paterson, HF; Mosedale, G; Lara-Gonzalez, S; Williams, RL				Perisic, O; Paterson, HF; Mosedale, G; Lara-Gonzalez, S; Williams, RL			Mapping the phospholipid-binding surface and translocation determinants of the C2 domain from cytosolic phospholipase A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; GREEN FLUORESCENT PROTEIN; ARACHIDONIC-ACID; CRYSTAL-STRUCTURE; MEMBRANE PENETRATION; NUCLEAR-ENVELOPE; CALCIUM; SYNAPTOTAGMIN; SPECIFICITY; CELLS	Cytosolic phospholipase A(2) (cPLA(2)) plays a key role in the generation of arachidonic acid, a precursor of potent inflammatory mediators, Intact cPLA(2) is known to translocate in a calcium-dependent manner from the cytosol to the nuclear envelope and endoplasmic reticulum, We show here that the C2 domain of cPLA(2) alone is sufficient for this calcium-dependent translocation in living cells, We have identified sets of exposed hydrophobic residues in loops known as calcium-binding region (CBR) 1 and CBR3, which surround the C2 domain calcium-binding sites, whose mutation dramatically decreased phospholipid binding in vitro without significantly affecting calcium binding. Mutation of a residue that binds calcium ions (D43N) also eliminated phospholipid binding. The same mutations that prevent phospholipid binding of the isolated C2 domain in vitro abolished the calcium-dependent translocation of cPLA(2) to internal membranes in vivo, suggesting that the membrane targeting is driven largely by direct interactions with the phospholipid bilayer, Using fluorescence quenching by spin-labeled phospholipids for a series of mutants containing a single tryptophan residue at various positions in the cPLA(2) C2 domain, we show that two of the calcium-binding loops, CBR1 and CBR3, penetrate in a calcium-dependent manner into the hydrophobic core of the phospholipid bilayer, establishing an anchor for docking the domain onto the membrane.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England; Inst Canc Res, Chester Beatty Labs, Canc Res Campaign, Ctr Cell & Mol Biol, London SW3 6JB, England	MRC Laboratory Molecular Biology; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Williams, RL (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	rlw@mrc-lmb.cam.ac.uk		Lara-Gonzalez, Samuel/0000-0002-3313-0165; Perisic, Olga/0000-0002-3842-2896; Williams, Roger/0000-0001-7754-4207	MRC [MC_U105184308] Funding Source: UKRI; Medical Research Council [MC_U105184308] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Balboa MA, 1998, J BIOL CHEM, V273, P7684, DOI 10.1074/jbc.273.13.7684; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; Chae YK, 1998, J BIOL CHEM, V273, P25659, DOI 10.1074/jbc.273.40.25659; Chapman ER, 1998, J BIOL CHEM, V273, P13995, DOI 10.1074/jbc.273.22.13995; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; Davletov B, 1998, J BIOL CHEM, V273, P19093, DOI 10.1074/jbc.273.30.19093; Edwards AS, 1997, BIOCHEMISTRY-US, V36, P15615, DOI 10.1021/bi9718752; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Essen LO, 1997, BIOCHEMISTRY-US, V36, P2753, DOI 10.1021/bi962466t; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; Fujimoto K, 1996, J CELL SCI, V109, P2453; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; HAYAKAWA M, 1993, J BIOL CHEM, V268, P11290; Hixon MS, 1998, BIOCHEMISTRY-US, V37, P8516, DOI 10.1021/bi980416d; Irvine R, 1998, CURR BIOL, V8, pR557, DOI 10.1016/S0960-9822(07)00360-0; KRAMER RM, 1997, FEBS LETT, V210, P19; KRAMER RM, 1994, SIGNAL ACTIVATED PHO, P13; LESLIE CC, 1990, BIOCHIM BIOPHYS ACTA, V1045, P261, DOI 10.1016/0005-2760(90)90129-L; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; Levine TP, 1998, CURR BIOL, V8, P729, DOI 10.1016/S0960-9822(98)70296-9; Lichtenbergova L, 1998, BIOCHEMISTRY-US, V37, P14128, DOI 10.1021/bi980888s; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LONDON E, 1981, BIOCHEMISTRY-US, V20, P1932, DOI 10.1021/bi00510a032; Medkova M, 1998, J BIOL CHEM, V273, P17544, DOI 10.1074/jbc.273.28.17544; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Mosior M, 1998, J BIOL CHEM, V273, P2184, DOI 10.1074/jbc.273.4.2184; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; Nalefski EA, 1998, J BIOL CHEM, V273, P1365, DOI 10.1074/jbc.273.3.1365; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; Nalefski EA, 1997, BIOCHEMISTRY-US, V36, P12011, DOI 10.1021/bi9717340; Pappa H, 1998, STRUCT FOLD DES, V6, P885, DOI 10.1016/S0969-2126(98)00090-2; PEARSON RH, 1979, NATURE, V281, P499, DOI 10.1038/281499a0; Perisic O, 1998, J BIOL CHEM, V273, P1596, DOI 10.1074/jbc.273.3.1596; PETERSGOLDEN M, 1993, BIOCHEM BIOPH RES CO, V196, P147, DOI 10.1006/bbrc.1993.2227; Plant PJ, 1997, J BIOL CHEM, V272, P32329, DOI 10.1074/jbc.272.51.32329; Ponting CP, 1996, PROTEIN SCI, V5, P162; Qin ZH, 1996, BIOCHEMISTRY-US, V35, P2917, DOI 10.1021/bi9521452; Qiu ZH, 1998, J BIOL CHEM, V273, P8203, DOI 10.1074/jbc.273.14.8203; REGIER MK, 1993, ARCH BIOCHEM BIOPHYS, V301, P439, DOI 10.1006/abbi.1993.1168; Sakai N, 1997, J CELL BIOL, V139, P1465, DOI 10.1083/jcb.139.6.1465; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; SHARP JD, 1991, J BIOL CHEM, V266, P14850; Siemering KR, 1996, CURR BIOL, V6, P1653, DOI 10.1016/S0960-9822(02)70789-6; SierraHonigmann R, 1996, LAB INVEST, V74, P684; Sutton RB, 1998, STRUCTURE, V6, P1395, DOI 10.1016/S0969-2126(98)00139-7; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; SWAIRJO MA, 1995, NAT STRUCT BIOL, V2, P968, DOI 10.1038/nsb1195-968; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622; WILLIAMSON P, 1992, BIOCHEMISTRY-US, V31, P6355, DOI 10.1021/bi00142a027; Xu GY, 1998, J MOL BIOL, V280, P485, DOI 10.1006/jmbi.1998.1874	51	113	116	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					14979	14987		10.1074/jbc.274.21.14979	http://dx.doi.org/10.1074/jbc.274.21.14979			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329700	hybrid			2022-12-25	WOS:000081965200065
J	Robertson, GP; Goldberg, EK; Lugo, TG; Fountain, JW				Robertson, GP; Goldberg, EK; Lugo, TG; Fountain, JW			Functional localization of a melanoma tumor suppressor gene to a small (<= 2 Mb) region on 11q23	ONCOGENE			English	Article						melanoma; tumor suppressor gene; chromosome 11 (11q23); functional cloning; DNA-damage checkpoint control gene (CHK1)	HUMAN PROSTATE-CANCER; MALIGNANT-MELANOMA; CHROMOSOME 11Q; BREAST-CANCER; ATAXIA-TELANGIECTASIA; OVARIAN-CANCER; ALLELIC LOSSES; HUMAN GENOME; HETEROZYGOSITY; MAP	We have previously demonstrated the existence of a melanoma tumor suppressor gene(s) on the long arm of chromosome 11 through suppression of tumorigenicity assays. Although loss of heterozygosity studies also support this finding, only a large critical region (44 cM) has been identified to date on 11q22-25, To further localize a tumor suppressor gene(s) within this region, we have now generated and characterized nine melanoma microcell hybrids, each retaining an introduced fragment of 11q, Of the nine hybrids, four were suppressed for tumor formation in nude mice, while five formed tumors at the same rate as the parental melanoma cell line (UACC 903), Molecular analysis of the hybrids with 118 microsatellite markers narrowed the location of a putative suppressor gene to a small (less than or equal to 2 Mb) candidate region on 11q23 between the markers D11S1786 and D11S2077 and within the larger region frequently deleted in melanoma tumors and cell fines. While multiple tumor suppressor genes are likely to reside on 11q22-25, the presence of this region in all four suppressed hybrids supports the simplest model that a single locus is responsible for the suppressed phenotype observed in UACC 903.	Univ So Calif, Inst Med Genet, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA; Univ Calif Riverside, Div Biomed Sci, Riverside, CA 92521 USA	University of Southern California; University of California System; University of California Riverside	Fountain, JW (corresponding author), Univ So Calif, Inst Med Genet, Dept Biochem & Mol Biol, 2250 Alcazar St,CSC-IGM240, Los Angeles, CA 90033 USA.		Robertson, Gavin P./A-6106-2017	Robertson, Gavin P./0000-0003-0152-2997	NATIONAL CANCER INSTITUTE [R01CA066021] Funding Source: NIH RePORTER; NCI NIH HHS [CA66021] Funding Source: Medline; CIT NIH HHS [CCT0197] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); CIT NIH HHS		Arai Y, 1996, GENOMICS, V35, P196, DOI 10.1006/geno.1996.0339; BARCH MJ, 1991, ACT CYTOGENETICS LAB, P180; Baysal BE, 1997, GENOMICS, V44, P214, DOI 10.1006/geno.1997.4880; Chandrasekharappa SC, 1997, SCIENCE, V276, P404, DOI 10.1126/science.276.5311.404; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; Dahiya R, 1997, INT J CANCER, V72, P283, DOI 10.1002/(SICI)1097-0215(19970717)72:2<283::AID-IJC14>3.0.CO;2-H; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; Evans Glen A., 1996, American Journal of Human Genetics, V59, pA66; FOULKES WD, 1993, BRIT J CANCER, V67, P268, DOI 10.1038/bjc.1993.51; FOUNTAIN JW, 1998, GENETIC FACTORS CUTA, P475; Gabra H, 1996, CANCER RES, V56, P950; GUDMUNDSSON J, 1995, BRIT J CANCER, V72, P696, DOI 10.1038/bjc.1995.396; HAMPTON GM, 1994, CANCER RES, V54, P4586; HERBST RA, 1995, CANCER RES, V55, P2494; IIZUKA M, 1995, GENE CHROMOSOME CANC, V13, P40; JAMES MR, 1994, NAT GENET, V8, P70, DOI 10.1038/ng0994-70; Kawana Y, 1997, PROSTATE, V32, P205; KELDYSH PL, 1993, GENE CHROMOSOME CANC, V6, P45, DOI 10.1002/gcc.2870060109; KILLARY AM, 1995, METHOD ENZYMOL, V254, P133; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Li LM, 1997, CELL, V88, P143, DOI 10.1016/S0092-8674(00)81866-8; LUGO TG, 1987, MOL CELL BIOL, V7, P2814, DOI 10.1128/MCB.7.8.2814; Manickam P, 1997, HUM GENET, V101, P102, DOI 10.1007/s004390050595; MORTON NE, 1991, P NATL ACAD SCI USA, V88, P7474, DOI 10.1073/pnas.88.17.7474; Murakami Y, 1998, P NATL ACAD SCI USA, V95, P8153, DOI 10.1073/pnas.95.14.8153; NEGRINI M, 1995, CANCER RES, V55, P3003; RASIO D, 1995, CANCER RES, V55, P6053; Robertson G, 1996, CANCER RES, V56, P4487; Robertson GP, 1997, CYTOGENET CELL GENET, V79, P53, DOI 10.1159/000134682; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SAXON PJ, 1986, EMBO J, V5, P3461, DOI 10.1002/j.1460-2075.1986.tb04670.x; SHAW ME, 1995, GENE CHROMOSOME CANC, V13, P1, DOI 10.1002/gcc.2870130102; THOMPSON FH, 1995, CANCER GENET CYTOGEN, V83, P93, DOI 10.1016/0165-4608(95)00057-V; TOMLINSON IPM, 1995, J CLIN PATHOL, V48, P424, DOI 10.1136/jcp.48.5.424; TOMLINSON IPM, 1993, GENE CHROMOSOME CANC, V7, P169, DOI 10.1002/gcc.2870070310; Tomlinson IPM, 1996, EUR J CANCER, V32A, P1797, DOI 10.1016/0959-8049(96)00198-0; TRASK B, 1990, FLUORESCENCE IN SITU, P383; VANAGAITE L, 1995, HUM GENET, V95, P451; WALKER GJ, 1995, GENE CHROMOSOME CANC, V12, P134, DOI 10.1002/gcc.2870120208; Wang SS, 1998, SCIENCE, V282, P284, DOI 10.1126/science.282.5387.284; WINQVIST R, 1995, CANCER RES, V55, P2660	41	21	21	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 20	1999	18	20					3173	3180		10.1038/sj.onc.1202664	http://dx.doi.org/10.1038/sj.onc.1202664			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	197WB	10340390				2022-12-25	WOS:000080388000014
J	Bowler, WB; Dixon, CJ; Halleux, C; Maier, R; Bilbe, G; Fraser, WD; Gallagher, JA; Hipskind, RA				Bowler, WB; Dixon, CJ; Halleux, C; Maier, R; Bilbe, G; Fraser, WD; Gallagher, JA; Hipskind, RA			Signaling in human osteoblasts by extracellular nucleotides - Their weak induction of the c-fos proto-oncogene via Ca2+ mobilization is strongly potentiated by a parathyroid hormone/cAMP-dependent protein kinase pathway independently of mitogen-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE FACTOR; SMOOTH-MUSCLE CELLS; GROWTH-FACTOR; GENE-TRANSCRIPTION; OSTEOSARCOMA CELLS; MAP KINASE; PURINERGIC RECEPTORS; CALCIUM INFLUX; IN-VIVO; ATP	Extracellular nucleotides acting through specific P2 receptors activate intracellular signaling cascades. Consistent with the expression of G protein-coupled P2Y receptors in skeletal tissue, the human osteosarcoma cell line SaOS-2 and primary osteoblasts express P2Y(1) and P2Y(2) receptors, respectively. Their activation by nucleotide agonists (ADP and ATP for P2Y(1); ATP and UTP for P2Y(2)) elevates [Ca2+](i) and moderately induces expression of the c-fos proto-oncogene. A synergistic effect on c-fos induction is observed by combining ATP and parathyroid hormone, a key bone cell regulator. Parathyroid hormone elevates intracellular cAMP levels and correspondingly activates a stably integrated reporter gene driven by the Ca2+/cAMP-responsive element of the human c-fos promoter. Nucleotides have little effect on either cAMP levels or this reporter, instead activating luciferase controlled by the full c-fos promoter. This induction is reproduced by a stably integrated serum response element reporter independently of mitogen-activated protein kinase activation and ternary complex factor phosphorylation. This novel example of synergy between the cAMP-dependent protein kinase/CaCRE signaling module and a non-mitogen-activated protein kinase/ternary complex factor pathway that targets the serum response element shows that extracellular ATP, via P2Y receptors, can potentiate strong responses to ubiquitous growth and differentiative factors.	Univ Liverpool, Human Bone Cell Res Grp, Liverpool L69 3GE, Merseyside, England; Univ Liverpool, Dept Human Anat & Cell Biol, Liverpool L69 3GE, Merseyside, England; Univ Liverpool, Dept Clin Chem, Liverpool L69 3GE, Merseyside, England; Novartis Pharma AG, CH-4002 Basel, Switzerland; Inst Genet Mol Montpellier, CNRS, UMR 5535, F-34293 Montpellier 5, France	University of Liverpool; University of Liverpool; University of Liverpool; Novartis; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier	Bowler, WB (corresponding author), Univ Liverpool, Human Bone Cell Res Grp, Liverpool L69 3GE, Merseyside, England.	wbb@liv.ac.uk						ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; BOARDER MR, 1995, TRENDS PHARMACOL SCI, V16, P133, DOI 10.1016/S0165-6147(00)89001-X; BONNI A, 1995, MOL CELL NEUROSCI, V6, P168, DOI 10.1006/mcne.1995.1015; BOWLER WB, 1995, J BONE MINER RES, V10, P1137; Bowler WB, 1998, BONE, V22, P195, DOI 10.1016/S8756-3282(97)00280-9; Chaudhary LR, 1997, BIOCHEM BIOPH RES CO, V238, P134, DOI 10.1006/bbrc.1997.7256; COLLART MA, 1991, MOL CELL BIOL, V11, P2826, DOI 10.1128/MCB.11.5.2826; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; Dixon CJ, 1997, BRIT J PHARMACOL, V120, P777; DUBYAK G R, 1990, Comprehensive Therapy, V16, P57; ENDHO H, 1997, BIOCHEM BIOPH RES CO, V235, P99; Evans DB, 1996, J BONE MINER RES, V11, P1066; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; GALLAGHER JA, 1996, METHODS MOL MED, V1, P233; Ginty DD, 1997, NEURON, V18, P183, DOI 10.1016/S0896-6273(00)80258-5; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Gudermann T, 1997, ANNU REV NEUROSCI, V20, P399, DOI 10.1146/annurev.neuro.20.1.399; HARDEN TK, 1995, ANNU REV PHARMACOL, V35, P541, DOI 10.1146/annurev.pharmtox.35.1.541; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HIPSKIND RA, 1994, MOL CELL BIOL, V14, P6219, DOI 10.1128/MCB.14.9.6219; HIPSKIND RA, 1991, J BIOL CHEM, V266, P19583; HIPSKIND RA, 1994, GENE DEV, V8, P1803, DOI 10.1101/gad.8.15.1803; HIPSKIND RA, 1998, FRONT BIOSCI, V3, P804, DOI DOI 10.2741/A323; HUANG NN, 1989, P NATL ACAD SCI USA, V86, P7904, DOI 10.1073/pnas.86.20.7904; Hurley MM, 1996, J BONE MINER RES, V11, P1256; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; KUMAGAI H, 1991, J BONE MINER RES, V6, P697; LEE G, 1994, MOL CELL BIOL, V14, P4579, DOI 10.1128/MCB.14.7.4579; LEE K, 1994, ENDOCRINOLOGY, V134, P441, DOI 10.1210/en.134.1.441; MACDONALD BR, 1986, ENDOCRINOLOGY, V118, P2445, DOI 10.1210/endo-118-6-2445; MIRANTI CK, 1995, MOL CELL BIOL, V15, P3672; MISRA RP, 1994, J BIOL CHEM, V269, P25483; Neary JT, 1998, NEUROSCI LETT, V242, P159, DOI 10.1016/S0304-3940(98)00067-6; OREILLY DS, 1986, J ENDOCRINOL, V111, P501, DOI 10.1677/joe.0.1110501; Patel V, 1996, BIOCHEM J, V320, P221, DOI 10.1042/bj3200221; Post SR, 1998, J BIOL CHEM, V273, P23093, DOI 10.1074/jbc.273.36.23093; RAISZ LG, 1963, NATURE, V197, P1015, DOI 10.1038/1971015a0; REIMER WJ, 1992, AM J PHYSIOL, V263, pC1040, DOI 10.1152/ajpcell.1992.263.5.C1040; ROBB S, 1994, EMBO J, V13, P1325, DOI 10.1002/j.1460-2075.1994.tb06385.x; ROBERTSON LM, 1995, NEURON, V14, P241, DOI 10.1016/0896-6273(95)90282-1; RODAN SB, 1987, CANCER RES, V47, P4961; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SCHOFL C, 1991, BIOCHEM J, V274, P15, DOI 10.1042/bj2740015; SCHOFL C, 1992, J BONE MINER RES, V6, P697; Soltoff SP, 1998, J BIOL CHEM, V273, P2653, DOI 10.1074/jbc.273.5.2653; Stein GS, 1996, PHYSIOL REV, V76, P593, DOI 10.1152/physrev.1996.76.2.593; THOMAS AP, 1992, TECHNIQUES CALCIUM R, P1; Tornquist K, 1996, J CELL PHYSIOL, V166, P241; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; VERHEIJEN MHG, 1995, ENDOCRINOLOGY, V136, P3331, DOI 10.1210/en.136.8.3331; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WANG DJ, 1992, J CELL PHYSIOL, V153, P221, DOI 10.1002/jcp.1041530202; Wang Y, 1996, MOL CELL BIOL, V16, P5915; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; Wu LW, 1997, J CLIN ENDOCR METAB, V82, P1126, DOI 10.1210/jc.82.4.1126; Xia ZG, 1996, J NEUROSCI, V16, P5425; Yu SM, 1996, MOL PHARMACOL, V50, P1000	70	95	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					14315	14324		10.1074/jbc.274.20.14315	http://dx.doi.org/10.1074/jbc.274.20.14315			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318853	hybrid			2022-12-25	WOS:000080322200082
J	Schoenwaelder, SM; Burridge, K				Schoenwaelder, SM; Burridge, K			Evidence for a calpeptin-sensitive protein-tyrosine phosphatase upstream of the small GTPase Rho - A novel role for the calpain inhibitor calpeptin in the inhibition of protein-tyrosine phosphatases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; STRESS FIBER FORMATION; SWISS 3T3 CELLS; INTEGRIN-MEDIATED ADHESION; TUMOR-SUPPRESSOR PTEN; ACTIN CYTOSKELETON; INTRACELLULAR CAMP; BINDING PROTEIN; MESANGIAL CELLS; HUMAN PLATELETS	Activation of the thiol protease calpain results in proteolysis of focal adhesion-associated proteins and severing of cytoskeletal-integrin links. We employed a commonly used inhibitor of calpain, calpeptin, to examine a role for this protease in the reorganization of the cytoskeleton under a variety of conditions. Calpeptin induced stress fiber formation in both forskolin-treated REF-52 fibroblasts and serum-starved Swiss 3T3 fibroblasts. Surprisingly, calpeptin was the only calpain inhibitor of several tested with the ability to induce these effects, suggesting that calpeptin may act on targets besides calpain. Here we show that calpeptin inhibits tyrosine phosphatases, enhancing tyrosine phosphorylation particularly of paxillin, Calpeptin preferentially inhibits membrane-associated phosphatase activity. Consistent with this observation, in vitro phosphatase assays using purified glutathione S-transferase fusion proteins demonstrated a preference for the transmembrane protein-tyrosine phosphatase-alpha over the cytosolic protein-tyrosine phosphatase-1B. Furthermore, unlike wide spectrum inhibitors of tyrosine phosphatases such as pervanadate, calpeptin appeared to inhibit a subset of phosphatases. Calpeptin-induced assembly of stress fibers was inhibited by botulinum toxin C3, indicating that calpeptin is acting on a phosphatase upstream of the small GTPase Rho, a protein that controls stress fiber and focal adhesion assembly. Not only does this work reveal that calpeptin is an inhibitor of protein-tyrosine phosphatases, but it suggests that calpeptin will be a valuable tool to identify the phosphatase activity upstream of Rho.	Univ N Carolina, Dept Cell Biol & Anat, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Schoenwaelder, SM (corresponding author), Univ N Carolina, Dept Cell Biol & Anat, 108 Taylor Hall, CB 7090, Chapel Hill, NC 27599 USA.	drsms@med.unc.edu	Schoenwaelder, Simone/E-9506-2011; Jackson, Shaun P/E-9633-2011	Schoenwaelder, Simone/0000-0003-0465-5840	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL045100] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029860] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45100] Funding Source: Medline; NIGMS NIH HHS [GM29860] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arregui CO, 1998, J CELL BIOL, V143, P861, DOI 10.1083/jcb.143.3.861; BARRY ST, 1994, J CELL SCI, V107, P2033; BECKERLE MC, 1987, CELL, V51, P569, DOI 10.1016/0092-8674(87)90126-7; Burridge K, 1997, TRENDS CELL BIOL, V7, P342, DOI 10.1016/S0962-8924(97)01127-6; BURRIDGE K, 1995, ANAL BIOCHEM, V232, P56, DOI 10.1006/abio.1995.9961; Busca R, 1998, MOL BIOL CELL, V9, P1367, DOI 10.1091/mbc.9.6.1367; CHRZANOWSKAWODNICKA M, 1994, J CELL SCI, V107, P3643; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; Cooray P, 1996, BIOCHEM J, V318, P41, DOI 10.1042/bj3180041; DEFILIPPI P, 1995, EXP CELL RES, V221, P141, DOI 10.1006/excr.1995.1361; Dong JM, 1998, J BIOL CHEM, V273, P22554, DOI 10.1074/jbc.273.35.22554; Fauman EB, 1996, TRENDS BIOCHEM SCI, V21, P413, DOI 10.1016/S0968-0004(96)10059-1; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; Flinn HM, 1996, J CELL SCI, V109, P1133; FOX JEB, 1985, J BIOL CHEM, V260, P1060; FOX JEB, 1995, THROMB HAEMOSTASIS, V73, P987; FRANGIONI JV, 1993, EMBO J, V12, P4843, DOI 10.1002/j.1460-2075.1993.tb06174.x; GLASS WF, 1993, J CELL PHYSIOL, V157, P296; GORDON JA, 1991, METHOD ENZYMOL, V201, P477; Gu MX, 1996, J BIOL CHEM, V271, P27751, DOI 10.1074/jbc.271.44.27751; GUAN KL, 1991, J BIOL CHEM, V266, P17026; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Han JD, 1996, J BIOL CHEM, V271, P29211, DOI 10.1074/jbc.271.46.29211; Hopkin K, 1998, SCIENCE, V282, P1027, DOI 10.1126/science.282.5391.1027; Huttenlocher A, 1997, J BIOL CHEM, V272, P32719, DOI 10.1074/jbc.272.52.32719; Huyer G, 1997, J BIOL CHEM, V272, P843, DOI 10.1074/jbc.272.2.843; KISHIMOTO A, 1983, J BIOL CHEM, V258, P1156; Koyama Y, 1996, BIOCHEM BIOPH RES CO, V218, P331, DOI 10.1006/bbrc.1996.0058; KREISBERG JI, 1985, AM J PHYSIOL, V249, pF227, DOI 10.1152/ajprenal.1985.249.2.F227; Kreisberg JI, 1997, AM J PHYSIOL-RENAL, V273, pF283, DOI 10.1152/ajprenal.1997.273.2.F283; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMB NJC, 1988, J CELL BIOL, V106, P1955, DOI 10.1083/jcb.106.6.1955; LAMPUGNANI MG, 1990, LAB INVEST, V63, P521; Lang P, 1996, EMBO J, V15, P510, DOI 10.1002/j.1460-2075.1996.tb00383.x; Laudanna C, 1997, J BIOL CHEM, V272, P24141, DOI 10.1074/jbc.272.39.24141; Li JP, 1996, BBA-MOL CELL RES, V1312, P223, DOI 10.1016/0167-4889(96)00038-9; Liu F, 1998, CURR BIOL, V8, P173, DOI 10.1016/S0960-9822(98)70066-1; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; MEHDI S, 1991, TRENDS BIOCHEM SCI, V16, P150, DOI 10.1016/0968-0004(91)90058-4; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; NOBES CD, 1995, J CELL SCI, V108, P225; ODA A, 1993, J BIOL CHEM, V268, P12603; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; Potter DA, 1998, J CELL BIOL, V141, P647, DOI 10.1083/jcb.141.3.647; RANKIN S, 1994, FEBS LETT, V354, P315, DOI 10.1016/0014-5793(94)01148-6; Retta SF, 1996, EXP CELL RES, V229, P307, DOI 10.1006/excr.1996.0376; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Saras J, 1997, J BIOL CHEM, V272, P24333, DOI 10.1074/jbc.272.39.24333; Schneider GB, 1998, CELL ADHES COMMUN, V5, P207, DOI 10.3109/15419069809040292; Schoenwaelder SM, 1997, J BIOL CHEM, V272, P24876, DOI 10.1074/jbc.272.40.24876; Schoenwaelder SM, 1997, J BIOL CHEM, V272, P1694, DOI 10.1074/jbc.272.3.1694; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P27610; SEUFFERLEIN T, 1995, J BIOL CHEM, V270, P24343, DOI 10.1074/jbc.270.41.24343; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Troyer DA, 1996, J AM SOC NEPHROL, V7, P415; TSUJINAKA T, 1988, BIOCHEM BIOPH RES CO, V153, P1201, DOI 10.1016/S0006-291X(88)81355-X; TURNER CE, 1989, J BIOL CHEM, V264, P11938; Wang F, 1997, BIOCHEM J, V324, P481, DOI 10.1042/bj3240481; WANG YL, 1990, ACTA PHARMACOL SIN, V11, P39; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125; Yuan YP, 1996, J BIOL CHEM, V271, P27090, DOI 10.1074/jbc.271.43.27090; ZACHARY I, 1993, J BIOL CHEM, V268, P22060; Zhong CL, 1998, J CELL BIOL, V141, P539, DOI 10.1083/jcb.141.2.539	69	94	97	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					14359	14367		10.1074/jbc.274.20.14359	http://dx.doi.org/10.1074/jbc.274.20.14359			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318859	hybrid			2022-12-25	WOS:000080322200088
J	Ravagnan, L; Marzo, I; Costantini, P; Susin, SA; Zamzami, N; Petit, PX; Hirsch, F; Goulbern, M; Poupon, MF; Miccoli, L; Xie, ZH; Reed, JC; Kroemer, G				Ravagnan, L; Marzo, I; Costantini, P; Susin, SA; Zamzami, N; Petit, PX; Hirsch, F; Goulbern, M; Poupon, MF; Miccoli, L; Xie, ZH; Reed, JC; Kroemer, G			Lonidamine triggers apoptosis via a direct, Bcl-2-inhibited effect on the mitochondrial permeability transition pore	ONCOGENE			English	Article						lonidamine; mitochondrial megachannel; permeability transition; programmed cell death	CERAMIDE-INDUCED APOPTOSIS; PROGRAMMED CELL-DEATH; ASCITES TUMOR-CELLS; CYTOCHROME-C; NUCLEAR APOPTOSIS; BENZODIAZEPINE RECEPTOR; NEUROBLASTOMA-CELLS; ENERGY-METABOLISM; OXIDATIVE STRESS; DIVALENT-CATIONS	The molecular mode of action of lonidamine, a therapeutic agent employed in cancer chemotherapy, has been elusive. Here we provide evidence that lonidamine (LND) acts on mitochondria to induce apoptosis, LND provokes a disruption of the mitochondrial transmembrane potential which precedes signs of nuclear apoptosis and cytolysis, The mitochondrial and cytocidal effects of LND are not prevented by inhibitors of caspases or of mRNA or protein synthesis. However, they are prevented by transfection-enforced overexpression of Bcl-2, an oncoprotein which inhibits apoptosis by stabilizing the mitochondrial membrane barrier function. Accordingly, the cell death-inducing effect of LND is amplified by simultaneous addition of PK11195, an isoquinoline ligand of the peripheral benzodiazepine receptor which antagonizes the cytoprotective effect of Bcl-2, When added to isolated nuclei, LND fails to provoke DNA degradation unless mitochondria are added simultaneously. In isolated mitochondria, LND causes the dissipation of the mitochondrial inner transmembrane potential and the release of apoptogenic factors capable of inducing nuclear apoptosis in vitro. Thus the mitochondrion is the subcellular target of LND. All effects of LND on isolated mitochondria are counteracted by cyclosporin A, an inhibitor of the mitochondrial PT pore. We therefore tested the effect of LND on the purified PT pore reconstituted into liposomes, LND permeabilizes liposomal membranes containing the PT pore. This effect is prevented by addition of recombinant Bcl-2 protein but not by a mutant Bcl-2 protein that has lost its apoptosis-inhibitory function. Altogether these data indicate that LND represents a novel type of anti-cancer agent which induces apoptosis via a direct effect on the mitochondrial PT pore.	CNRS, Unite Propre Rech 420, F-94801 Villejuif, France; INRA, Ctr Rech Jouy En Josas, F-78352 Jouy En Josas, France; Inst Curie, CNRS, Unite Mixte Rech 147, F-75248 Paris, France; Burnham Inst, La Jolla, CA 92037 USA	Centre National de la Recherche Scientifique (CNRS); INRAE; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sanford Burnham Prebys Medical Discovery Institute	Kroemer, G (corresponding author), CNRS, Unite Propre Rech 420, 19 Rue Guy Moquet, F-94801 Villejuif, France.		KROEMER, Guido/B-4263-2013; PETIT, Patrice/A-4453-2008; Marzo, Isabel/E-6918-2016; Petit, patrice/AAF-6774-2020; Kroemer, Guido/AAY-9859-2020; Susin, Santos A/Q-6754-2017; miccoli, laurent/N-6638-2018; Petit, Patrice X./A-3692-2009	KROEMER, Guido/0000-0002-9334-4405; Marzo, Isabel/0000-0002-2315-9079; Susin, Santos A/0000-0002-3366-1628; miccoli, laurent/0000-0002-5242-4388; Petit, Patrice X./0000-0002-5038-9101				Angioli R, 1997, INT J ONCOL, V11, P777; Backway KL, 1997, CANCER RES, V57, P2446; BENHORIN H, 1995, CANCER RES, V55, P2814; BERNARDI P, 1992, J BIOL CHEM, V267, P2934; BERNARDI P, 1993, J BIOL CHEM, V268, P1005; Beutner G, 1996, FEBS LETT, V396, P189, DOI 10.1016/0014-5793(96)01092-7; BRENNER C, 1998, IN PRESS METH ENZYMO; BRENNER C, 1998, IN PRESS FEBS LETT; Brunet CL, 1998, CELL DEATH DIFFER, V5, P107, DOI 10.1038/sj.cdd.4400334; BUSTAMANTE E, 1981, J BIOL CHEM, V256, P8699; CASTIGLIONE S, 1993, BIOCHEM PHARMACOL, V46, P330, DOI 10.1016/0006-2952(93)90423-T; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; CONNERN CP, 1994, BIOCHEM J, V302, P321, DOI 10.1042/bj3020321; Costantini P, 1996, J BIOL CHEM, V271, P6746, DOI 10.1074/jbc.271.12.6746; De Cesare M, 1998, BRIT J CANCER, V77, P434, DOI 10.1038/bjc.1998.69; Decaudin D, 1997, CANCER RES, V57, P62; DelBufalo D, 1996, J CLIN INVEST, V98, P1165, DOI 10.1172/JCI118900; DeLena M, 1997, J CLIN ONCOL, V15, P3208, DOI 10.1200/JCO.1997.15.10.3208; Dogliotti L, 1998, CANCER CHEMOTH PHARM, V41, P333, DOI 10.1007/s002800050747; Dudak SD, 1996, ANTICANCER RES, V16, P3665; Fanciulli M, 1996, ONCOL RES, V8, P111; FLORIDI A, 1981, CANCER RES, V41, P4661; Fulda S, 1998, CANCER RES, V58, P4453; Fulda S, 1997, CANCER RES, V57, P3823; HAEFFNER A, 1999, IN PRESS EUR J IMMUN; Herr I, 1997, EMBO J, V16, P6200, DOI 10.1093/emboj/16.20.6200; Hirsch T, 1998, EXP CELL RES, V241, P426, DOI 10.1006/excr.1998.4084; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Kantrow SP, 1997, BIOCHEM BIOPH RES CO, V232, P669, DOI 10.1006/bbrc.1997.6353; Kim CN, 1997, CANCER RES, V57, P3115; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Kroemer Guido, 1997, P1111; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Macho A, 1997, J IMMUNOL, V158, P4612; Mancini M, 1998, J CELL BIOL, V140, P1485, DOI 10.1083/jcb.140.6.1485; Marchetti P, 1996, J IMMUNOL, V157, P4830; Marchetti P, 1996, CANCER RES, V56, P2033; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; MCENERY MW, 1992, P NATL ACAD SCI USA, V89, P3170, DOI 10.1073/pnas.89.8.3170; Miccoli L, 1998, J NATL CANCER I, V90, P1400, DOI 10.1093/jnci/90.18.1400; OUDARD S, 1995, INT J CANCER, V62, P216, DOI 10.1002/ijc.2910620218; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Petit PX, 1998, FEBS LETT, V426, P111, DOI 10.1016/S0014-5793(98)00318-4; PETRONILLI V, 1993, J BIOL CHEM, V268, P21939; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Pratesi G, 1996, CANCER CHEMOTH PHARM, V38, P123, DOI 10.1007/s002800050459; Pulselli R, 1996, ANTICANCER RES, V16, P419; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Shimizu S, 1998, P NATL ACAD SCI USA, V95, P1455, DOI 10.1073/pnas.95.4.1455; Susin SA, 1997, EXP CELL RES, V236, P397, DOI 10.1006/excr.1997.3733; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; SZABO I, 1992, J BIOL CHEM, V267, P2940; Testi R, 1996, TRENDS BIOCHEM SCI, V21, P468, DOI 10.1016/S0968-0004(96)10056-6; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zamzami N, 1998, ONCOGENE, V16, P1055, DOI 10.1038/sj.onc.1201864; Zamzami N, 1998, ONCOGENE, V16, P2265, DOI 10.1038/sj.onc.1201989; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	66	176	183	1	24	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 22	1999	18	16					2537	2546		10.1038/sj.onc.1202625	http://dx.doi.org/10.1038/sj.onc.1202625			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	189LU	10353597				2022-12-25	WOS:000079907100001
J	Velcich, A; Corner, G; Palumbo, L; Augenlicht, L				Velcich, A; Corner, G; Palumbo, L; Augenlicht, L			Altered phenotype of HT29 colonic adenocarcinoma cells following expression of the DCC gene	ONCOGENE			English	Article						DCC; MUC2 expression; colon cancer	TUMOR-SUPPRESSOR GENE; INTESTINAL MUCIN GENE; II COLORECTAL-CANCER; CARCINOMA CELLS; MESSENGER-RNA; ALLELIC LOSS; CHROMOSOME 18Q; MUTANT MICE; DIFFERENTIATION; APOPTOSIS	On 18q, frequently deleted in late stage colorectal cancers, a gene, Deleted in Colon Cancer (DCC), has been identified and postulated to play a role as a tumor suppressor gene. DCC is retained in the majority of mucinous tumors, which produce high levels of mucins, and seems to be preferentially expressed in intestinal goblet cells. To investigate whether DCC is related to mucin expression and can modulate the transformed phenotype, we introduced a full-length DCC cDNA into HT29 cells, which can be induced in vitro to express MUC2, the gene that encodes the major colonic mucin, Expression of DCC did not modulate constitutive or induced expression of MUC2, nor did DCC induce a mature goblet cell phenotype, However, HT29 clones expressing high and low levels of DCC protein showed a significant decrease in cell proliferation and tumorigenicity. Furthermore, increased shedding and an elevated rate of spontaneous apoptosis were associated with higher levels of expression of DCC, In summary, while restoration of DCC expression in a human colon carcinoma cell line did not influence expression of differentiation markers, DCC expression did affect the growth and tumorigenic properties of the cells suggesting that DCC can modulate the malignant phenotype of colon cancer.	Montefiore Med Ctr, Albert Einstein Canc Ctr, Dept Oncol, Bronx, NY 10467 USA	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine	Velcich, A (corresponding author), Montefiore Med Ctr, Albert Einstein Canc Ctr, Dept Oncol, 111 E 210th St, Bronx, NY 10467 USA.				NCI NIH HHS [CA-68965, CA-55913] Funding Source: Medline; PHS HHS [P30-13330] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068965, R29CA055913] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUGENLICHT LH, 1991, P NATL ACAD SCI USA, V88, P3286, DOI 10.1073/pnas.88.8.3286; BEDI A, 1995, CANCER RES, V55, P1811; BURSCH W, 1990, CARCINOGENESIS, V11, P847, DOI 10.1093/carcin/11.5.847; Carethers JM, 1998, GASTROENTEROLOGY, V114, P1188, DOI 10.1016/S0016-5085(98)70424-X; Chan SSY, 1996, CELL, V87, P187, DOI 10.1016/S0092-8674(00)81337-9; CHANG SK, 1994, GASTROENTEROLOGY, V107, P28, DOI 10.1016/0016-5085(94)90057-4; CHO KR, 1994, GENOMICS, V19, P525, DOI 10.1006/geno.1994.1102; CHO KR, 1995, CURR OPIN GENET DEV, V5, P72, DOI 10.1016/S0959-437X(95)90056-X; COLONY PC, 1983, DEV BIOL, V97, P349, DOI 10.1016/0012-1606(83)90092-1; COLONY PC, 1989, CELL MOL BIOL COLON, P1; Derynck R, 1996, CELL, V87, P173, DOI 10.1016/S0092-8674(00)81335-5; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Fazeli A, 1997, NATURE, V386, P796, DOI 10.1038/386796a0; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fearon ER, 1996, BBA-REV CANCER, V1288, pM17, DOI 10.1016/0304-419X(96)00023-6; GENDLER SJ, 1995, ANNU REV PHYSIOL, V57, P607, DOI 10.1146/annurev.ph.57.030195.003135; Gotley DC, 1996, ONCOGENE, V13, P787; GUM JR, 1994, J BIOL CHEM, V269, P2440; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HEDRICK L, 1994, GENE DEV, V8, P1174, DOI 10.1101/gad.8.10.1174; HEERDT BG, 1994, CANCER RES, V54, P3288; Heerdt BG, 1996, CELL GROWTH DIFFER, V7, P101; ITOH F, 1993, INT J CANCER, V53, P260, DOI 10.1002/ijc.2910530215; JEN J, 1994, NEW ENGL J MED, V331, P213, DOI 10.1056/NEJM199407283310401; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; KIM SH, 1993, J CELL BIOL, V123, P877, DOI 10.1083/jcb.123.4.877; KLINGELHUTZ AJ, 1995, ONCOGENE, V10, P1581; Kolodziej PA, 1996, CELL, V87, P197, DOI 10.1016/S0092-8674(00)81338-0; LABOISSE CL, 1989, CELL MOL BIOL COLON, P28; Martinez-Lopez E, 1998, GASTROENTEROLOGY, V114, P1180, DOI 10.1016/S0016-5085(98)70423-8; Mehlen P, 1998, NATURE, V395, P801, DOI 10.1038/27441; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OOKAWA K, 1993, INT J CANCER, V53, P382, DOI 10.1002/ijc.2910530307; PIERCEALL WE, 1994, J CELL BIOL, V124, P1017, DOI 10.1083/jcb.124.6.1017; REALE MA, 1994, CANCER RES, V54, P4493; Reale MA, 1996, CLIN CANCER RES, V2, P1097; Reyes-Mugica M, 1998, LAB INVEST, V78, P669; REYESMUGICA M, 1997, CANCER RES, P382; RIEFERCHRIST KM, 1997, FRONT BIOSCI, V15, P438; Riggins GJ, 1996, NAT GENET, V13, P347, DOI 10.1038/ng0796-347; SCHAEFFER WI, 1976, CANCER LETT, V1, P259; Shibata D, 1996, NEW ENGL J MED, V335, P1727, DOI 10.1056/NEJM199612053352303; Shoemaker AR, 1997, CANCER RES, V57, P1999; Smits R, 1997, CARCINOGENESIS, V18, P321, DOI 10.1093/carcin/18.2.321; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; TANAKA K, 1991, NATURE, V349, P340, DOI 10.1038/349340a0; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; Velcich A, 1997, J BIOL CHEM, V272, P7968, DOI 10.1074/jbc.272.12.7968; VELCICH A, 1993, J BIOL CHEM, V268, P13956; VELCICH A, 1995, CELL GROWTH DIFFER, V6, P749; VIELMETTER J, 1994, J CELL BIOL, V127, P2009, DOI 10.1083/jcb.127.6.2009; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268; Zhu YA, 1998, CELL, V94, P703, DOI 10.1016/S0092-8674(00)81730-4	56	32	35	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	1999	18	16					2599	2606		10.1038/sj.onc.1202610	http://dx.doi.org/10.1038/sj.onc.1202610			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	189LU	10353603				2022-12-25	WOS:000079907100007
J	Maeda, A; Scharenberg, AM; Tsukada, S; Bolen, JB; Kinet, JP; Kurosaki, T				Maeda, A; Scharenberg, AM; Tsukada, S; Bolen, JB; Kinet, JP; Kurosaki, T			Paired immunoglobulin-like receptor B (PIR-B) inhibits BCR-induced activation of Syk and Btk by SHP-1	ONCOGENE			English	Article						PIR-B; ITIM; SHP-1; SHP-2; tyrosine phosphorylation	CELL ANTIGEN RECEPTOR; TYROSINE-PHOSPHATASE SHP-1; SIGNAL-TRANSDUCTION; PHOSPHOLIPASE C-GAMMA-2; CA2+ MOBILIZATION; DISTINCT PATHWAYS; KINASE LYN; INVOLVEMENT; LYMPHOCYTES; REQUIREMENT	Coligation of paired immunoglobulin-like receptor B (PIR-B) with B cell antigen receptor (BCR) blocks antigen-induced B cell activation. This inhibition is mediated in part by recruitment of SHP-1 and SHP-2 to the phosphorylated ITIMs in the cytoplasmic domain of PIR-B; however the molecular target(s) of these phosphatases remain elusive. Here,ve show that PIR-B ligation inhibits the BCR-induced tyrosine phosphorylation of Ig alpha/Ig beta, Syk, Btk and phospholipase C (PLC)-gamma 2 Overexpression of a catalgtically inactive form of SHP-1 prevents the PIR-B-mediated inhibition: of tyrosine phosphorylation of Syk, Btk, and PLC-gamma 2. Dephosphorylation of Syk and Btk mediated by SHP-1 leads to a decrease of their kinase activity, which in turn inhibits tyrosine phosphorylation of PLC-gamma 2. Furthermore, we define a requirement for Lan in mediating tyrosine phosphorylation of PIR-B, Based on these results, we propose a model of PIR-B-mediated inhibitory signaling in which coligation of PIR-B and BCR results in phosphorylation of ITIMs by Lyn, subsequent recruitment of SHP-1, and a resulting inhibition of the BCR-induced inositol 1,4,5-trisphosphate generation by dephosphorylation of Syk and Btk.	Kansai Med Univ, Dept Mol Genet, Inst Liver Res, Moriguchi, Osaka 5708506, Japan; Beth Israel Hosp, Lab Allergy & Immunol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Hoechst Marion Roussel, Bridgewater, NJ 08807 USA	Kansai Medical University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Kurosaki, T (corresponding author), Kansai Med Univ, Dept Mol Genet, Inst Liver Res, Moriguchi, Osaka 5708506, Japan.		Maeda, Akito/AAX-6252-2020; Kurosaki, Tomohiro/D-1306-2009	Kurosaki, Tomohiro/0000-0002-6352-304X; Maeda, Akito/0000-0001-8776-9135				BABA Y, IN PRESS BLOOD; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; Binstadt BA, 1996, IMMUNITY, V5, P629, DOI 10.1016/S1074-7613(00)80276-9; Blery M, 1998, P NATL ACAD SCI USA, V95, P2446, DOI 10.1073/pnas.95.5.2446; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; Burshtyn DN, 1996, IMMUNITY, V4, P77, DOI 10.1016/S1074-7613(00)80300-3; Chan VWF, 1997, IMMUNITY, V7, P69, DOI 10.1016/S1074-7613(00)80511-7; DeFranco AL, 1997, CURR OPIN IMMUNOL, V9, P296, DOI 10.1016/S0952-7915(97)80074-X; Fluckiger AC, 1998, EMBO J, V17, P1973, DOI 10.1093/emboj/17.7.1973; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Gupta N, 1997, J EXP MED, V186, P473, DOI 10.1084/jem.186.3.473; Hayami K, 1997, J BIOL CHEM, V272, P7320, DOI 10.1074/jbc.272.11.7320; Hippen KL, 1997, IMMUNITY, V7, P49, DOI 10.1016/S1074-7613(00)80509-9; Kubagawa H, 1997, P NATL ACAD SCI USA, V94, P5261, DOI 10.1073/pnas.94.10.5261; KUROSAKI T, 1994, J EXP MED, V179, P1725, DOI 10.1084/jem.179.5.1725; Kurosaki T, 1997, CURR OPIN IMMUNOL, V9, P309, DOI 10.1016/S0952-7915(97)80075-1; Maeda A, 1998, J EXP MED, V187, P1355, DOI 10.1084/jem.187.8.1355; Nadler MJS, 1997, J BIOL CHEM, V272, P20038, DOI 10.1074/jbc.272.32.20038; Nishizumi H, 1998, J EXP MED, V187, P1343, DOI 10.1084/jem.187.8.1343; Ono M, 1997, CELL, V90, P293, DOI 10.1016/S0092-8674(00)80337-2; ORourke L, 1997, CURR OPIN IMMUNOL, V9, P324, DOI 10.1016/S0952-7915(97)80077-5; PLEIMAN CM, 1994, IMMUNOL TODAY, V15, P393, DOI 10.1016/0167-5699(94)90267-4; PUTNEY JW, 1993, CELL, V75, P199, DOI 10.1016/0092-8674(93)80061-I; Reth M, 1997, ANNU REV IMMUNOL, V15, P453, DOI 10.1146/annurev.immunol.15.1.453; SANCHEZ M, 1993, J EXP MED, V178, P1049, DOI 10.1084/jem.178.3.1049; SAOUAF SJ, 1994, P NATL ACAD SCI USA, V91, P9524, DOI 10.1073/pnas.91.20.9524; Scharenberg AM, 1998, EMBO J, V17, P1961, DOI 10.1093/emboj/17.7.1961; Sugawara H, 1997, EMBO J, V16, P3078, DOI 10.1093/emboj/16.11.3078; TAKATA M, 1995, J EXP MED, V182, P907, DOI 10.1084/jem.182.4.907; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; Wang JY, 1996, J EXP MED, V184, P831, DOI 10.1084/jem.184.3.831; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118	34	118	122	1	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 8	1999	18	14					2291	2297		10.1038/sj.onc.1202552	http://dx.doi.org/10.1038/sj.onc.1202552			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184DT	10327049	Bronze			2022-12-25	WOS:000079595500001
J	Garbe, J; Wong, M; Wigington, D; Yaswen, P; Stampfer, MR				Garbe, J; Wong, M; Wigington, D; Yaswen, P; Stampfer, MR			Viral oncogenes accelerate conversion to immortality of cultured conditionally immortal human mammary epithelial cells	ONCOGENE			English	Article						immortalization; telomerase; p53; TGF beta; human papillomavirus; SV40T	HUMAN PAPILLOMAVIRUS TYPE-16; LARGE T-ANTIGEN; TELOMERASE ACTIVITY; HUMAN FIBROBLASTS; BREAST-CANCER; P16 INACTIVATION; TUMOR-ANTIGEN; P53 GENE; E6; PROTEIN	Our recent studies on the process of immortalization of cultured human mammary epithelial cells (HMEC) have uncovered a previously undescribed, apparently epigenetic step, termed conversion. When first isolated, clonally derived HMEC lines of indefinite lifespan showed little or no telomerase activity or ability to maintain growth in the presence of TGF beta. Cell populations whose mean terminal restriction fragment length had declined to <3 kb also exhibited slow heterogeneous growth, and contained many non-proliferative cells. With continued passage, these conditionally immortal cell populations very gradually converted to a fully immortal phenotype of good growth+/-TGF beta, expression of high levels of telomerase activity, and stabilization of telomere length. We now show that exposure of the early passage conditionally immortal 184A1 HMEC line to the viral oncogenes human papillomavirus type 16 (HPV16)-E6, -E7, or SV40T, results in either immediate (E6) or rapid (E7; SV40T) conversion of these telomerase negative, TGF beta sensitive conditionally immortal cells to the fully immortal phenotype. Unlike conditional immortal 184A1, the HPV16-E7 and SV40T exposed cells were able to maintain growth in TGF beta prior to expression of high levels of telomerase activity. A mutated HPV16-E6 oncogene, unable to inactivate p53, was still capable of rapidly converting conditional immortal 184A1. Our studies provide further evidence that the transforming potential of these viral oncogenes may involve activities beyond their inactivation of p53 and pRB functions. These additional activities may greatly accelerate a step in HMEC immortal transformation, conversion, that would be rate-limiting in the absence of viral oncogene exposure.	Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Stampfer, MR (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Bldg 934, Berkeley, CA 94720 USA.				NATIONAL CANCER INSTITUTE [R37CA024844, R01CA024844] Funding Source: NIH RePORTER; NCI NIH HHS [CA-24844] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; Bacchetti S, 1996, CANCER SURV, V28, P197; BAND V, 1990, CANCER RES, V50, P7351; BAND V, 1991, J VIROL, V65, P6671, DOI 10.1128/JVI.65.12.6671-6676.1991; Band V, 1998, INT J ONCOL, V12, P499; BARTEK J, 1991, P NATL ACAD SCI USA, V88, P3520, DOI 10.1073/pnas.88.9.3520; Belair CD, 1997, P NATL ACAD SCI USA, V94, P13677, DOI 10.1073/pnas.94.25.13677; Bodnar AG, 1996, EXP CELL RES, V228, P58, DOI 10.1006/excr.1996.0299; Brenner AJ, 1998, ONCOGENE, V17, P199, DOI 10.1038/sj.onc.1201919; BRENNER AJ, 1995, CANCER RES, V55, P2892; Chiu CP, 1997, P SOC EXP BIOL MED, V214, P99; CHOO CK, 1993, EXP CELL RES, V208, P161, DOI 10.1006/excr.1993.1234; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; Dalal S, 1996, J VIROL, V70, P683, DOI 10.1128/JVI.70.2.683-688.1996; Ethier SP, 1996, J MAMMARY GLAND BIOL, V1, P111, DOI 10.1007/BF02096306; FINER MH, 1994, BLOOD, V83, P43; Gollahon LS, 1996, ONCOGENE, V12, P715; HAMMOND SL, 1984, P NATL ACAD SCI-BIOL, V81, P5435, DOI 10.1073/pnas.81.17.5435; HARRIS CC, 1987, CANCER RES, V47, P1; HARTMANN A, 1995, ONCOGENE, V10, P681; Holt SE, 1997, EUR J CANCER, V33, P761, DOI 10.1016/S0959-8049(97)00066-X; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KLINGELHUTZ AJ, 1994, MOL CELL BIOL, V14, P961, DOI 10.1128/MCB.14.2.961; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; Mal A, 1996, NATURE, V380, P262, DOI 10.1038/380262a0; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; RENAN MJ, 1993, MOL CARCINOGEN, V7, P139; Sandhu C, 1997, MOL CELL BIOL, V17, P2458, DOI 10.1128/MCB.17.5.2458; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SHAY JW, 1993, EXP CELL RES, V209, P45, DOI 10.1006/excr.1993.1283; SHAY JW, 1993, ONCOGENE, V8, P1407; SHAY JW, 1993, BREAST CANCER RES TR, V25, P83, DOI 10.1007/BF00662404; Sjogren S, 1996, J NATL CANCER I, V88, P173, DOI 10.1093/jnci/88.3-4.173; STAMPFER M, 1994, CANC SURVEYS, V18, P7; Stampfer M, 1985, J TISSUE CULTURE MET, V9, P107; Stampfer MR, 1997, MOL BIOL CELL, V8, P2391, DOI 10.1091/mbc.8.12.2391; STAMPFER MR, 1993, EXP CELL RES, V208, P175, DOI 10.1006/excr.1993.1236; STAMPFER MR, 1982, IN VITRO CELL DEV B, V18, P531; STAMPFER MR, 1985, P NATL ACAD SCI USA, V82, P2394, DOI 10.1073/pnas.82.8.2394; STAMPFER MR, 1988, BREAST CANCER CELLUL, P1; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; THOR AD, 1992, JNCI-J NATL CANCER I, V84, P845, DOI 10.1093/jnci/84.11.845; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; VIALLET J, 1994, EXP CELL RES, V212, P36, DOI 10.1006/excr.1994.1115; WALEN KH, 1989, CANCER GENET CYTOGEN, V37, P249, DOI 10.1016/0165-4608(89)90056-3; WAZER DE, 1995, P NATL ACAD SCI USA, V92, P3687, DOI 10.1073/pnas.92.9.3687; Woodworth CD, 1996, CELL GROWTH DIFFER, V7, P811; ZerfassThome K, 1996, ONCOGENE, V13, P2323	53	41	42	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 1	1999	18	13					2169	2180		10.1038/sj.onc.1202523	http://dx.doi.org/10.1038/sj.onc.1202523			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	182YE	10327063				2022-12-25	WOS:000079525100001
J	Gaponenko, V; Abusamhadneh, E; Abbott, MB; Finley, N; Gasmi-Seabrook, G; Solaro, RJ; Rance, M; Rosevear, PR				Gaponenko, V; Abusamhadneh, E; Abbott, MB; Finley, N; Gasmi-Seabrook, G; Solaro, RJ; Rance, M; Rosevear, PR			Effects of troponin I phosphorylation on conformational exchange in the regulatory domain of cardiac troponil C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMICAL-SHIFT ANISOTROPY; N-15 NMR RELAXATION; BACKBONE DYNAMICS; SITE; INTERFERENCE; COMPLEX	Conformational exchange has been demonstrated within the regulatory domain of calcium-saturated cardiac troponin C when bound to the NH2-terminal domain of cardiac troponin I-(1-80), and cardiac troponin I-(1-80)DD, having serine residues 23 and 24 mutated to aspartate to mimic the phosphorylated form of the protein. Binding of cardiac troponin I-(1-80) decreases conformational exchange for residues 29, 32, and 34. Comparison of average transverse cross correlation rates show that both the NH2- and COOH-terminal domains of cardiac troponin C tumble with similar correlation times when bound to cardiac troponin I-(1-80). In contrast, the NH2- and COOH-terminal domains in free cardiac troponin C and cardiac troponin C bound cardiac troponin I-(1-80)DD tumble independently. These results suggest that the nonphosphorylated cardiac specific NH2 terminus of cardiac troponin I interacts with the NH2-terminal domain of cardiac troponin C.	Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA; Univ Illinois, Coll Med, Dept Physiol & Biophys, Chicago, IL 60612 USA	University of Cincinnati; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Rance, M (corresponding author), Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA.		Gaponenko, Vadim/K-9729-2019	Gaponenko, Vadim/0000-0002-7891-9223	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049934] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044324] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040089] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 49934] Funding Source: Medline; NIAMS NIH HHS [AR 44324] Funding Source: Medline; NIGMS NIH HHS [GM 40089] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRITO RMM, 1991, BIOCHEMISTRY-US, V30, P10236, DOI 10.1021/bi00106a023; Dohet C, 1995, FEBS LETT, V377, P131, DOI 10.1016/0014-5793(95)01319-9; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Gagne SM, 1998, BIOCHEM CELL BIOL, V76, P302, DOI 10.1139/bcb-76-2-3-302; HERZBERG O, 1986, J BIOL CHEM, V261, P2638; KLEERKOPER Q, 1995, BIOCHEMISTRY-US, V34, P13343, DOI 10.1021/bi00041a010; Kroenke CD, 1998, J AM CHEM SOC, V120, P7905, DOI 10.1021/ja980832l; KRUDY GA, 1994, J BIOL CHEM, V269, P23731; Paakkonen K, 1998, J BIOL CHEM, V273, P15633, DOI 10.1074/jbc.273.25.15633; PALMER AG, 1991, J AM CHEM SOC, V113, P4371, DOI 10.1021/ja00012a001; PUTKEY JA, 1993, J BIOL CHEM, V268, P6827; Reiffert SU, 1998, BIOCHEMISTRY-US, V37, P13516, DOI 10.1021/bi980280j; ROBERTSON SP, 1982, J BIOL CHEM, V257, P260; SIA KS, 1997, J BIOL CHEM, V272, P18216; Solaro RJ, 1998, CIRC RES, V83, P471, DOI 10.1161/01.RES.83.5.471; Tjandra N, 1995, J AM CHEM SOC, V117, P12562, DOI 10.1021/ja00155a020; Tjandra N, 1996, J AM CHEM SOC, V118, P6986, DOI 10.1021/ja960510m; VANEERD JP, 1976, CALCIUM TRANSPORT CO, P427; Vassylyev DG, 1998, P NATL ACAD SCI USA, V95, P4847, DOI 10.1073/pnas.95.9.4847	19	60	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16681	16684		10.1074/jbc.274.24.16681	http://dx.doi.org/10.1074/jbc.274.24.16681			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358006	hybrid			2022-12-25	WOS:000080780400005
J	Rund, S; Lindner, B; Brade, H; Holst, O				Rund, S; Lindner, B; Brade, H; Holst, O			Structural analysis of the lipopolysaccharide from Chlamydia trachomatis serotype L2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENUS-SPECIFIC EPITOPE; ESCHERICHIA-COLI; KDO; ENDOTOXIN; STRAIN; ACID; TWAR	The lipopolysaccharide (LPS) of Chlamydia trachomatis L2 was isolated from tissue culture-grown elementary bodies using a modified phenol/water procedure followed by extraction with phenol/chloroform/light petroleum. From a total of 5 x 10(4) cm(2) of infected monolayers, 22.3 mg of LPS were obtained. Compositional analysis indicated the presence of 3-deoxy-D-manno-oct-2-ulopyranosonic acid (Kdo), GlcN, phosphorus, and fatty acids in a molar ratio of 2.8:2:2.1:4.5. Matrix-assisted laser-desorption ionization mass spectrometry performed on the de-O-acylated LPS gave a major molecular ion peak at mit 1781.1 corresponding to a molecule of 3 Kdo, 2 GlcN, 2 phosphates, and two 3-hydroxyeicosanoic acid residues. The structure of deacylated LPS obtained after successive treatment with hydrazine and potassium hydroxide was determined by 600 MHz NMR spectroscopy as Kdo alpha 2 --> 8Kdo alpha 2 --> 4Kdo alpha 2 --> 6D --> GlcpN beta 1 --> 6D-GlcpN alpha 1, 4-bisphosphate. These data, together with those published recently on the acylation pattern of chlamydial lipid A (Qureshi, N,, Kaltashov, I., Walker, K,, Doroshenko, V,, Cotter, R, J,, Takayama, K, Sievert, T, R,, Rice, P, A., Lin, J,-S, L,, and Golenbock, D, T, (1997) J, Biol, Chem, 272, 10594-10600) allow us to present for the first time the complete structure of a major molecular species of a chlamydial LPS.	Res Ctr Borstel, Ctr Med & Biosci, Div Med & Biochem Microbiol, D-23845 Borstel, Germany; Res Ctr Borstel, Ctr Med & Biosci, Div Biophys, D-23845 Borstel, Germany	Forschungszentrum Borstel; Forschungszentrum Borstel	Brade, H (corresponding author), Res Ctr Borstel, Ctr Med & Biosci, Div Med & Biochem Microbiol, D-23845 Borstel, Germany.		Lindner, Buko/G-9731-2014					BIRNBAUM GI, 1987, J CARBOHYD CHEM, V6, P17, DOI 10.1080/07328308708058858; BOCK K, 1992, CARBOHYD RES, V229, P213, DOI 10.1016/S0008-6215(00)90571-8; BRADE H, 1987, P NATL ACAD SCI USA, V84, P2508, DOI 10.1073/pnas.84.8.2508; Brade H., 1999, ENDOTOXIN HLTH DIS; BRADE L, 1986, INFECT IMMUN, V54, P568, DOI 10.1128/IAI.54.2.568-574.1986; HOLST O, 1995, EUR J BIOCHEM, V229, P194, DOI 10.1111/j.1432-1033.1995.tb20455.x; HOLST O, 1993, EUR J BIOCHEM, V214, P703, DOI 10.1111/j.1432-1033.1993.tb17971.x; HOLST O, 1994, EUR J BIOCHEM, V222, P183, DOI 10.1111/j.1432-1033.1994.tb18856.x; INGALLS RR, 1995, INFECT IMMUN, V63, P3125, DOI 10.1128/IAI.63.8.3125-3130.1995; KUO CC, 1995, CLIN MICROBIOL REV, V8, P451, DOI 10.1128/CMR.8.4.451; MOULDER JW, 1991, MICROBIOL REV, V55, P143, DOI 10.1128/MMBR.55.1.143-190.1991; NANO FE, 1985, SCIENCE, V228, P742, DOI 10.1126/science.2581315; NURMINEN M, 1983, SCIENCE, V220, P1279, DOI 10.1126/science.6344216; NURMINEN M, 1985, INFECT IMMUN, V48, P573, DOI 10.1128/IAI.48.2.573-575.1985; PRYTULLA S, 1991, CARBOHYD RES, V215, P345, DOI 10.1016/0008-6215(91)84033-B; Qureshi N, 1997, J BIOL CHEM, V272, P10594; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; SAIKKU P, 1988, LANCET, V2, P983, DOI 10.1016/S0140-6736(88)90741-6; SCHACHTER J, 1980, ANNU REV MICROBIOL, V34, P285, DOI 10.1146/annurev.mi.34.100180.001441; Storz J, 1971, CHLAMYDIA CHLAMYDIA; WENMAN WM, 1982, NATURE, V269, P68; WESTPHAL O., 1965, METHOD CARBOHYD CHEM, V5, P83; WOLLENWEBER HW, 1990, J MICROBIOL METH, V11, P195, DOI 10.1016/0167-7012(90)90056-C	23	89	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16819	16824		10.1074/jbc.274.24.16819	http://dx.doi.org/10.1074/jbc.274.24.16819			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358025	hybrid			2022-12-25	WOS:000080780400024
J	Ferguson, PL; Flintoff, WF				Ferguson, PL; Flintoff, WF			Topological and functional analysis of the human reduced folate carrier by hemagglutinin epitope insertion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; GREEN FLUORESCENT PROTEIN; TRANSMEMBRANE CONDUCTANCE REGULATOR; RESISTANCE-ASSOCIATED PROTEIN; GENE FUSION APPROACH; METHOTREXATE UPTAKE; MEMBRANE TOPOLOGY; BINDING-PROTEIN; TRANSPORT-DEFICIENT; N-GLYCOSYLATION	The membrane topology of the human reduced folate carrier protein (591 amino acids) was assessed by single insertions of the hemagglutinin epitope into nine sites of the protein. Reduced folate carrier-deficient Chinese hamster ovary cells expressing each of these constructs were probed with anti-hemagglutinin epitope monoclonal antibodies to assess whether the insertion was exposed to the external environment or to the cytoplasm. The results are consistent with the 12-transmembrane topology predicted for this protein. The hemagglutinin epitope insertion mutants were also tested for their effects on the function of the reduced folate carrier. For these studies, each of the constructs had a carboxyl-terminal fusion of the enhanced green fluorescent protein to monitor and quantitate expression. Insertions into the external loop between transmembrane regions 7 and 8 (Pro-297), the cytoplasmic loop between transmembrane regions 6 and 7 (Ser-225), and near the cytoplasmic amino and carboxyl termini (Pro-SO and Gly-492, respectively) had minor effects on methotrexate binding and uptake. The insertion into the cytoplasmic loop between transmembrane regions 10 and 11 (Gln-385) greatly reduced both binding and uptake of methotrexate, whereas the insertion into the external loop between transmembrane regions 11 and 12 (Pro-427) selectively interfered with uptake but not binding.	Univ Western Ontario, Dept Microbiol & Immunol, London, ON N6A 5C1, Canada	Western University (University of Western Ontario)	Flintoff, WF (corresponding author), Univ Western Ontario, Dept Microbiol & Immunol, London, ON N6A 5C1, Canada.							Antony AC, 1996, ANNU REV NUTR, V16, P501, DOI 10.1146/annurev.nu.16.070196.002441; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHANEY WG, 1986, SOMAT CELL MOLEC GEN, V12, P237, DOI 10.1007/BF01570782; CHANG XB, 1994, J BIOL CHEM, V269, P18572; CUBITT AB, 1995, TRENDS BIOCHEM SCI, V20, P448, DOI 10.1016/S0968-0004(00)89099-4; Dan N, 1996, J BIOL CHEM, V271, P30717, DOI 10.1074/jbc.271.48.30717; DIXON KH, 1994, J BIOL CHEM, V269, P17; EHRMANN M, 1990, P NATL ACAD SCI USA, V87, P7574, DOI 10.1073/pnas.87.19.7574; ELWOOD PC, 1989, J BIOL CHEM, V264, P14893; Fiedler B, 1996, J BIOL CHEM, V271, P29312, DOI 10.1074/jbc.271.46.29312; FLINTOFF WF, 1976, SOMAT CELL GENET, V2, P245, DOI 10.1007/BF01538963; FLINTOFF WF, 1983, ARCH BIOCHEM BIOPHYS, V223, P433, DOI 10.1016/0003-9861(83)90607-0; Girotti M, 1996, J CELL SCI, V109, P2915; GOSWITZ VC, 1995, PROTEIN SCI, V4, P534; Hampton RY, 1996, P NATL ACAD SCI USA, V93, P828, DOI 10.1073/pnas.93.2.828; HENDERSON GB, 1990, ANNU REV NUTR, V10, P319, DOI [10.1146/annurev.nutr.10.1.319, 10.1146/annurev.nu.10.070190.001535]; HENDERSON GB, 1984, J BIOL CHEM, V259, P4558; HENDERSON GB, 1990, CANCER RES, V50, P1709; HENN DK, 1995, P NATL ACAD SCI USA, V92, P7425, DOI 10.1073/pnas.92.16.7425; Howard M, 1995, AM J PHYSIOL-CELL PH, V269, pC1565, DOI 10.1152/ajpcell.1995.269.6.C1565; HRESKO RC, 1994, J BIOL CHEM, V269, P20482; Kast C, 1997, J BIOL CHEM, V272, P26479, DOI 10.1074/jbc.272.42.26479; KAST C, 1995, BIOCHEMISTRY-US, V34, P4402, DOI 10.1021/bi00013a032; Kast C, 1998, BIOCHEMISTRY-US, V37, P2305, DOI 10.1021/bi972332v; Kast C, 1996, J BIOL CHEM, V271, P9240, DOI 10.1074/jbc.271.16.9240; LACEY SW, 1989, J CLIN INVEST, V84, P715, DOI 10.1172/JCI114220; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; MATHERLY LH, 1994, BIOCHEM PHARMACOL, V47, P1094, DOI 10.1016/0006-2952(94)90423-5; MATHERLY LH, 1991, CANCER RES, V51, P3420; MCCORMICK JI, 1979, EUR J CANCER, V15, P1377, DOI 10.1016/0014-2964(79)90115-4; MOSCOW JA, 1995, CANCER RES, V55, P3790; Moyer BD, 1998, J BIOL CHEM, V273, P21759, DOI 10.1074/jbc.273.34.21759; Nikiforovich GV, 1998, PROTEIN ENG, V11, P279, DOI 10.1093/protein/11.4.279; NIMAN HL, 1983, P NATL ACAD SCI-BIOL, V80, P4949, DOI 10.1073/pnas.80.16.4949; Presley JF, 1997, NATURE, V389, P81, DOI 10.1038/38001; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P7853, DOI 10.1021/bi00420a040; RATNAM M, 1989, BIOCHEMISTRY-US, V28, P8249, DOI 10.1021/bi00446a042; REAVES B, 1994, FEBS LETT, V351, P448, DOI 10.1016/0014-5793(94)00813-2; Roy K, 1998, J BIOL CHEM, V273, P2526, DOI 10.1074/jbc.273.5.2526; SADASIVAN E, 1989, J BIOL CHEM, V264, P5806; SAMBROOK J, 1989, MOL CLONING, V9, P14; SIROTNAK FM, 1985, CANCER RES, V45, P3992; Tusnady GE, 1997, FEBS LETT, V402, P1, DOI 10.1016/S0014-5793(96)01478-0; UNDERHILL TM, 1989, MOL CELL BIOL, V9, P1754, DOI 10.1128/MCB.9.4.1754; UNDERHILL TM, 1989, SOMAT CELL MOLEC GEN, V15, P49, DOI 10.1007/BF01534669; WILLIAMS FMR, 1994, J BIOL CHEM, V269, P5810; WILLIAMS FMR, 1995, J BIOL CHEM, V270, P2987, DOI 10.1074/jbc.270.7.2987; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WONG SC, 1995, J BIOL CHEM, V270, P17468, DOI 10.1074/jbc.270.29.17468; Wong SC, 1998, BBA-BIOMEMBRANES, V1375, P6, DOI 10.1016/S0005-2736(98)00118-7; YANG CH, 1988, J BIOL CHEM, V263, P9703; Zhao R, 1998, J BIOL CHEM, V273, P19065, DOI 10.1074/jbc.273.30.19065; Zhao RB, 1998, J BIOL CHEM, V273, P7873, DOI 10.1074/jbc.273.14.7873; [No title captured]	56	71	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16269	16278		10.1074/jbc.274.23.16269	http://dx.doi.org/10.1074/jbc.274.23.16269			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347183	hybrid			2022-12-25	WOS:000080668600043
J	Greene, B; King, J				Greene, B; King, J			In vitro unfolding refolding of wild type phage P22 scaffolding protein reveals capsid-binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMPLEX VIRUS TYPE-1; BACTERIOPHAGE P22; IN-VITRO; COAT PROTEIN; AMINO-ACIDS; PROCAPSIDS; SUBUNITS; HEAD; PURIFICATION; PRECURSOR	The scaffolding proteins of double-stranded DNA viruses are required for the polymerization of capsid subunits into properly sized closed shells but are absent from the mature virions, Phage P22 scaffolding subunits are elongated 33-kDa molecules that copolymerize with coat subunits into icosahedral precursor shells and subsequently exit from the precursor shell through channels in the procapsid lattice to participate in further rounds of polymerization and dissociation. Purified scaffolding subunits could be refolded in vitro after denaturation by high temperature or guanidine hydrochloride solutions. The lack of coincidence of fluorescence and circular dichroism signals indicated the presence of at least one partially folded intermediate, suggesting that the protein consisted of multiple domains. Proteolytic fragments containing the C terminus were competent for copolymerization with capsid subunits into procapsid shells in vitro, whereas the N terminus was not needed for this function. Proteolysis of partially denatured scaffolding subunits indicated that it was the capsid-binding C-terminal domain that unfolded at low temperatures and guanidinium concentrations. The minimal stability of the coat-binding domain may reflect its role in the conformational switching needed for icosahedral shell assembly.	MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Greene, B (corresponding author), Univ Calif San Francisco, George Williams Hooper Fdn, San Francisco, CA 94143 USA.				NIGMS NIH HHS [GM17890] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM017890] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAZINET C, 1990, J MOL BIOL, V216, P701, DOI 10.1016/0022-2836(90)90393-Z; BAZINET C, 1988, J MOL BIOL, V202, P77, DOI 10.1016/0022-2836(88)90520-7; BeaudetMiller M, 1996, J VIROL, V70, P8081, DOI 10.1128/JVI.70.11.8081-8088.1996; BOND JS, 1993, PROTEOLYTIC ENZYMES; BRAND L, 1972, ANNU REV BIOCHEM, V41, P843, DOI 10.1146/annurev.bi.41.070172.004211; CASIENS S, 1988, BACTERIOPHAGES, V1, P15; CASJENS S, 1985, J VIROL, V53, P174, DOI 10.1128/JVI.53.1.174-179.1985; CASPAR DLD, 1980, BIOPHYS J, V32, P103, DOI 10.1016/S0006-3495(80)84929-0; CLEVELAND DW, 1977, J MOL BIOL, V116, P227, DOI 10.1016/0022-2836(77)90214-5; CREIGHTON TE, 1987, PROTEIN ENG, P83; EARNSHAW W, 1976, J MOL BIOL, V104, P387, DOI 10.1016/0022-2836(76)90278-3; EPPLER K, 1991, VIROLOGY, V183, P519, DOI 10.1016/0042-6822(91)90981-G; FULLER MT, 1981, VIROLOGY, V112, P529, DOI 10.1016/0042-6822(81)90300-7; FULLER MT, 1982, J MOL BIOL, V156, P633, DOI 10.1016/0022-2836(82)90270-4; GALISTEO ML, 1993, BIOPHYS J, V65, P227, DOI 10.1016/S0006-3495(93)81073-7; Greene B, 1996, VIROLOGY, V225, P82, DOI 10.1006/viro.1996.0577; Greene B, 1999, J BIOL CHEM, V274, P16141, DOI 10.1074/jbc.274.23.16141; GREENE B, 1994, VIROLOGY, V205, P188, DOI 10.1006/viro.1994.1634; GUO PX, 1991, VIROLOGY, V183, P366, DOI 10.1016/0042-6822(91)90149-6; HARRISON SC, 1984, TRENDS BIOCHEM SCI, V9, P345, DOI 10.1016/0968-0004(84)90057-4; Hong Z, 1996, J VIROL, V70, P533, DOI 10.1128/JVI.70.1.533-540.1996; HORWITZ M S, 1991, P771; KING J, 1978, CELL, V15, P551, DOI 10.1016/0092-8674(78)90023-5; KING J, 1974, NATURE, V251, P112, DOI 10.1038/251112a0; KING J, 1996, STRUCTURAL BIOL VIRU, P288; LAEMMLI UK, 1970, J MOL BIOL, V49, P99, DOI 10.1016/0022-2836(70)90379-7; LEE CS, 1995, J VIROL, V69, P5024, DOI 10.1128/JVI.69.8.5024-5032.1995; LIDDINGTON RC, 1991, NATURE, V354, P278, DOI 10.1038/354278a0; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MATUSICKKUMAR L, 1995, J VIROL, V69, P4347, DOI 10.1128/JVI.69.7.4347-4356.1995; MITRAKI A, 1993, J BIOL CHEM, V268, P20071; MURIALDO H, 1978, MICROBIOL REV, V42, P529, DOI 10.1128/MMBR.42.3.529-576.1978; Parker MH, 1997, PROTEIN SCI, V6, P1583, DOI 10.1002/pro.5560060722; Parker MH, 1998, J MOL BIOL, V281, P69, DOI 10.1006/jmbi.1998.1917; Parker MH, 1997, J MOL BIOL, V268, P655, DOI 10.1006/jmbi.1997.0995; PRASAD BVV, 1993, J MOL BIOL, V231, P65, DOI 10.1006/jmbi.1993.1257; PRESTON VG, 1983, J VIROL, V45, P1056, DOI 10.1128/JVI.45.3.1056-1064.1983; Preston VG, 1997, J GEN VIROL, V78, P1633, DOI 10.1099/0022-1317-78-7-1633; PREVELIGE PE, 1988, J MOL BIOL, V202, P743, DOI 10.1016/0022-2836(88)90555-4; PREVELIGE PE, 1993, BIOPHYS J, V64, P824, DOI 10.1016/S0006-3495(93)81443-7; PTITSYN OB, 1987, J PROTEIN CHEM, V6, P273; PTITSYN OB, 1990, FEBS LETT, V262, P20, DOI 10.1016/0014-5793(90)80143-7; RIXON FJ, 1993, SEMIN VIROL, V4, P135, DOI 10.1006/smvy.1993.1009; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; SCHWEERS O, 1994, J BIOL CHEM, V269, P24290; SPEED MA, 1995, PROTEIN SCI, V4, P900; TESCHKE CM, 1995, BIOCHEMISTRY-US, V34, P6815, DOI 10.1021/bi00020a028; TESCHKE CM, 1993, BIOCHEMISTRY-US, V32, P10658, DOI 10.1021/bi00091a016; TESCHKE CM, 1993, BIOCHEMISTRY-US, V32, P10839, DOI 10.1021/bi00091a040; THOMAS GJ, 1982, BIOCHEMISTRY-US, V21, P3866, DOI 10.1021/bi00259a023; THOMSEN DR, 1995, J VIROL, V69, P3690, DOI 10.1128/JVI.69.6.3690-3703.1995; Thuman-Commike PA, 1998, BIOPHYS J, V74, P559, DOI 10.1016/S0006-3495(98)77814-2; ThumanCommike PA, 1996, J MOL BIOL, V260, P85, DOI 10.1006/jmbi.1996.0383; TRAUB F, 1984, J VIROL, V49, P892, DOI 10.1128/JVI.49.3.892-901.1984; Trus BL, 1996, J MOL BIOL, V263, P447, DOI 10.1016/S0022-2836(96)80018-0; Tuma R, 1996, BIOCHEMISTRY-US, V35, P4619, DOI 10.1021/bi952793l; VANDRIEL R, 1980, J MOL BIOL, V138, P27, DOI 10.1016/S0022-2836(80)80003-9; VOTER WA, 1982, J ULTRA MOL STRUCT R, V80, P374, DOI 10.1016/S0022-5320(82)80051-8; Wood LJ, 1997, J VIROL, V71, P179, DOI 10.1128/JVI.71.1.179-190.1997; WYCKOFF E, 1985, J VIROL, V53, P192, DOI 10.1128/JVI.53.1.192-197.1985; ZIEGELHOFFER T, 1992, J BIOL CHEM, V267, P455	61	15	15	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16135	16140		10.1074/jbc.274.23.16135	http://dx.doi.org/10.1074/jbc.274.23.16135			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347165	hybrid			2022-12-25	WOS:000080668600025
J	Heinlein, CA; Ting, HJ; Yeh, SY; Chang, CS				Heinlein, CA; Ting, HJ; Yeh, SY; Chang, CS			Identification of ARA70 as a ligand-enhanced coactivator for the peroxisome proliferator-activated receptor gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOID-X-RECEPTOR; PPAR-GAMMA; NUCLEAR RECEPTOR; INDEPENDENT ACTIVATION; ESTROGEN-RECEPTOR; ANDROGEN RECEPTOR; GENE-EXPRESSION; DIFFERENTIATION; INSULIN; BINDING	In an effort to understand transcriptional regulation by the peroxisome proliferator-activated receptor gamma (PPAR gamma), we have investigated its potential interaction with coregulators and have identified ARA70 as a ligand-enhanced coactivator. ARA70 was initially described as a coactivator for the androgen receptor (AR) and is expressed in a range of tissues including adipose tissue (Yeh, S., and Chang, C. (1996) Proc. Natl. Acad. Sci. U.S. A. 93, 5517-5521), Here we show that ARA70 and PPAR gamma specifically interact by coimmunoprecipitation and in a mammalian two-hybrid assay. PPAR gamma and ARA70 interact in the absence of the PPAR gamma ligand 15-deoxy-Delta 12,14-prostaglandin J2, although the addition of exogenous ligand enhances this interaction. Similarly, in transient transfection of DU145 cells, cotransfection of PPAR gamma and ARA70 induces transcription from re porter constructs driven by either three copies of an isolated PPAR response element or the natural promoter of the adipocyte fatty acid-binding protein 2 in the absence of exogenous 15-deoxy-Delta 12,14-prostaglandin J2. However, this PPAR gamma-ARA70 transactivation is enhanced by the addition of ligand. Thus, ARA70 can function as a ligand-enhanced coactivator of PPAR gamma. Finally, we show that AR can squelch PPAR gamma-ARA70 transactivation, which suggests that cross-talk may occur between PPAR gamma- and AR-mediated responses in adipocytes.	Univ Rochester, Med Ctr, Dept Pathol, George Whipple Lab Canc Res, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Urol, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Radiat Oncol, Rochester, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester	Chang, CS (corresponding author), Univ Rochester, Med Ctr, Dept Pathol, George Whipple Lab Canc Res, Box 626,601 Elmwood Ave, Rochester, NY 14642 USA.			Ting, Huei-Ju/0000-0003-3709-5755	NATIONAL CANCER INSTITUTE [R01CA077532] Funding Source: NIH RePORTER; NCI NIH HHS [CA77532, CA55638, CA68568] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; Bai WL, 1997, J BIOL CHEM, V272, P10457; Bjorntorp Per, 1997, Human Reproduction (Oxford), V12, P21; Brodie AE, 1996, BIOCHEM BIOPH RES CO, V228, P655, DOI 10.1006/bbrc.1996.1713; Brun RP, 1996, GENE DEV, V10, P974, DOI 10.1101/gad.10.8.974; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; CHALWA A, 1994, ENDOCRINOLOGY, V135, P798; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Chu RY, 1996, J BIOL CHEM, V271, P27670, DOI 10.1074/jbc.271.44.27670; DiRenzo J, 1997, MOL CELL BIOL, V17, P2166, DOI 10.1128/MCB.17.4.2166; Dowell P, 1997, J BIOL CHEM, V272, P33435, DOI 10.1074/jbc.272.52.33435; DUNAIF A, 1995, AM J MED S1A, V98, P33; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Fujimoto N, 1999, J BIOL CHEM, V274, P8316, DOI 10.1074/jbc.274.12.8316; GEARING KL, 1993, P NATL ACAD SCI USA, V90, P1440, DOI 10.1073/pnas.90.4.1440; HAUG A, 1986, ACTA ENDOCRINOL-COP, V113, P133, DOI 10.1530/acta.0.1130133; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HOLMANG A, 1990, AM J PHYSIOL, V259, pE555, DOI 10.1152/ajpendo.1990.259.4.E555; JOW L, 1995, J BIOL CHEM, V270, P3836, DOI 10.1074/jbc.270.8.3836; KIMURA N, 1993, J HISTOCHEM CYTOCHEM, V41, P671, DOI 10.1177/41.5.8468448; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; Kopelman PG, 1997, BRIT MED BULL, V53, P322, DOI 10.1093/oxfordjournals.bmb.a011616; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Mizukami J, 1997, BIOCHEM BIOPH RES CO, V240, P61, DOI 10.1006/bbrc.1997.7602; MUERHOFF AS, 1992, J BIOL CHEM, V267, P19051; Mukherjee R, 1997, NATURE, V386, P407, DOI 10.1038/386407a0; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; ONATE SA, 1995, SCIENCE, V270, P1354; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Qi JS, 1997, MOL CELL BIOL, V17, P7195, DOI 10.1128/MCB.17.12.7195; REBUFFESCRIVE M, 1991, INT J OBESITY, V15, P791; Reginato MJ, 1998, J BIOL CHEM, V273, P1855, DOI 10.1074/jbc.273.4.1855; Saez E, 1998, NAT MED, V4, P1058, DOI 10.1038/2042; Sarraf P, 1998, NAT MED, V4, P1046, DOI 10.1038/2030; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; Schoonjans K, 1996, J LIPID RES, V37, P907; Tontonoz P, 1997, P NATL ACAD SCI USA, V94, P237, DOI 10.1073/pnas.94.1.237; TONTONOZ P, 1995, MOL CELL BIOL, V15, P351, DOI 10.1128/MCB.15.1.351; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Werman A, 1997, J BIOL CHEM, V272, P20230, DOI 10.1074/jbc.272.32.20230; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517; Zhang B, 1996, J BIOL CHEM, V271, P31771, DOI 10.1074/jbc.271.50.31771; Zhu YJ, 1997, J BIOL CHEM, V272, P25500, DOI 10.1074/jbc.272.41.25500	52	111	117	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16147	16152		10.1074/jbc.274.23.16147	http://dx.doi.org/10.1074/jbc.274.23.16147			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347167	hybrid			2022-12-25	WOS:000080668600027
J	Middlemas, DS; Kihl, BK; Zhou, JF; Zhu, XY				Middlemas, DS; Kihl, BK; Zhou, JF; Zhu, XY			Brain-derived neurotrophic factor promotes survival and chemoprotection of human neuroblastoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; TYROSINE KINASE RECEPTOR; TRK PROTOONCOGENE PRODUCT; NGF-DEPENDENT SURVIVAL; PHOSPHOLIPASE C-GAMMA-1; SIGNAL-TRANSDUCTION; PROTEIN-KINASE; IN-VITRO; PHOSPHATIDYLINOSITOL-3 KINASE; NEURONAL DIFFERENTIATION	Brain-derived neurotrophic factor (BDNF) promotes neuronal survival and protection against neuronal damage. We addressed whether BDNF might promote survival and chemoprotection in neuroblastoma (NB) using a drug-sensitive human NE cell line. All-trans-retinoic acid (ATRA) induces a striking phenotypic differentiation of NB1643 cells, and exogenous BDNF treatment promotes survival of these differentiated cells. ATRA induces TRKB expression, and exogenous BDNF stimulates both autophosphorylation of TRKB and induction of the immediate early gene, FOS, in these cells. BDNF mRNA is expressed in NB1643 cells, Because the time course of TRKB induction closely parallels phenotypic differentiation of these cells, it seems probable that ATRA induces differentiation of NB1643 cells by establishing an autocrine loop involving BDNF and TRKB, Exogenous BDNF treatment resulted in a further increase in neurite outgrowth, which again suggests that an autocrine loop is involved in differentiation of NB1643 cells in response to ATRA, We then tested whether BDNF might afford drug resistance in NE and found that BDNF does indeed protect in this NE model against cisplatin, a DNA-damaging agent actually used in the treatment of NE.	St Jude Childrens Res Hosp, Dept Mol Pharmacol, Memphis, TN 38105 USA	St Jude Children's Research Hospital	Middlemas, DS (corresponding author), St Jude Childrens Res Hosp, Dept Mol Pharmacol, 332 N Lauderdale St, Memphis, TN 38105 USA.				NATIONAL CANCER INSTITUTE [R29CA071628, P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [1 R29 CA 71628, CA 21765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACHESON A, 1995, NATURE, V374, P450, DOI 10.1038/374450a0; Alcantara S, 1997, J NEUROSCI, V17, P3623; Baxter GT, 1997, J NEUROSCI, V17, P2683; BORRELLO MG, 1993, INT J CANCER, V54, P540, DOI 10.1002/ijc.2910540404; BOZYCZKOCOYNE D, 1993, J NEUROSCI METH, V50, P205, DOI 10.1016/0165-0270(93)90009-G; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BUTLER WB, 1984, ANAL BIOCHEM, V141, P70, DOI 10.1016/0003-2697(84)90426-3; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; CHENG B, 1994, BRAIN RES, V640, P56, DOI 10.1016/0006-8993(94)91857-0; COOPER MJ, 1990, CELL GROWTH DIFFER, V1, P149; CROM WR, 1981, CANCER CHEMOTH PHARM, V6, P95; DUGICHDJORDJEVIC MM, 1995, NEUROSCIENCE, V66, P861, DOI 10.1016/0306-4522(94)00631-E; Easton JB, 1999, J BIOL CHEM, V274, P11321, DOI 10.1074/jbc.274.16.11321; FRISEN J, 1993, P NATL ACAD SCI USA, V90, P4971, DOI 10.1073/pnas.90.11.4971; FRISEN J, 1992, P NATL ACAD SCI USA, V89, P11282, DOI 10.1073/pnas.89.23.11282; GHOSH A, 1994, SCIENCE, V263, P1618, DOI 10.1126/science.7907431; Giannini G, 1997, J BIOL CHEM, V272, P26693, DOI 10.1074/jbc.272.42.26693; GREENE LA, 1978, J CELL BIOL, V78, P747, DOI 10.1083/jcb.78.3.747; GURWELL JA, 1993, DEV BRAIN RES, V76, P293, DOI 10.1016/0165-3806(93)90222-V; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; Harlow E., 1988, ANTIBODIES LAB MANUA; IRELAND CM, 1994, ANTICANCER RES, V14, P2397; Israel MA, 1994, ATLAS HUMAN TUMOR CE, P42; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1993, NEURON, V11, P321, DOI 10.1016/0896-6273(93)90187-V; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KIMURA K, 1994, J BIOL CHEM, V269, P18961; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KLEIN R, 1992, NEURON, V8, P947, DOI 10.1016/0896-6273(92)90209-V; KLEIN R, 1994, FASEB J, V8, P738, DOI 10.1096/fasebj.8.10.8050673; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; KLEIN R, 1993, CELL, V75, P113, DOI 10.1016/0092-8674(93)90683-H; KLEIN R, 1990, DEVELOPMENT, V109, P845; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; KOGNER P, 1993, CANCER RES, V53, P2044; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LAVENIUS E, 1995, CELL GROWTH DIFFER, V6, P727; LICHTENFELS R, 1994, J IMMUNOL METHODS, V172, P227, DOI 10.1016/0022-1759(94)90110-4; LOEB DM, 1994, J BIOL CHEM, V269, P8901; Lucarelli E, 1994, Prog Clin Biol Res, V385, P185; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MATSUMOTO K, 1995, CANCER RES, V55, P1798; MATSUSHIMA H, 1993, MOL CELL BIOL, V13, P7447, DOI 10.1128/MCB.13.12.7447; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MERLIO JP, 1993, NEURON, V10, P151, DOI 10.1016/0896-6273(93)90307-D; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; MIDDLEMAS DS, 1994, J BIOL CHEM, V269, P5458; MIDDLEMAS DS, 1993, METHODS NEUROSCI, V12, P139; NAKAGAWARA A, 1992, CANCER RES, V52, P1364; NAKAGAWARA A, 1994, MOL CELL BIOL, V14, P759, DOI 10.1128/MCB.14.1.759; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; OBERMEIER A, 1993, EMBO J, V12, P933, DOI 10.1002/j.1460-2075.1993.tb05734.x; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; OHMICHI M, 1992, NEURON, V9, P769, DOI 10.1016/0896-6273(92)90039-G; PAPADOPOULOS NG, 1994, J IMMUNOL METHODS, V177, P101, DOI 10.1016/0022-1759(94)90147-3; PENG X, 1995, NEURON, V15, P395, DOI 10.1016/0896-6273(95)90043-8; Pinon LGP, 1996, DEVELOPMENT, V122, P3255; POLUHA W, 1995, ONCOGENE, V10, P185; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; REECE PA, 1987, CLIN PHARMACOL THER, V42, P320, DOI 10.1038/clpt.1987.155; RODRIGUEZTEBAR A, 1991, DEVELOPMENT, V112, P813; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; ROSS RA, 1983, J NATL CANCER I, V71, P741; Sambrook J, 1989, MOL CLONING LAB MANU, V1-3; Scala S, 1996, CANCER RES, V56, P3737; SMEYNE RJ, 1994, NATURE, V368, P246, DOI 10.1038/368246a0; SOPPET D, 1991, CELL, V65, P895, DOI 10.1016/0092-8674(91)90396-G; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; SUZUKI T, 1993, J NATL CANCER I, V85, P377, DOI 10.1093/jnci/85.5.377; Thompson J, 1997, CLIN CANCER RES, V3, P423; TRICHE TJ, 1983, HUM PATHOL, V14, P569; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; VETTER ML, 1991, P NATL ACAD SCI USA, V88, P5650, DOI 10.1073/pnas.88.13.5650; VONHOLST A, 1995, MOL CELL NEUROSCI, V6, P185; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; ZAR JH, 1984, BIOSTAT ANAL, P292	80	60	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16451	16460		10.1074/jbc.274.23.16451	http://dx.doi.org/10.1074/jbc.274.23.16451			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347207	hybrid			2022-12-25	WOS:000080668600067
J	Ravandi, A; Kuksis, A; Shaikh, NA				Ravandi, A; Kuksis, A; Shaikh, NA			Glycated phosphatidylethanolamine promotes macrophage uptake of low density lipoprotein and accumulation of cholesteryl esters and triacylglycerols	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE-DERIVED MACROPHAGES; DIABETIC-PATIENTS; ADVANCED GLYCOSYLATION; ANIONIC PHOSPHOLIPIDS; SCAVENGER RECEPTORS; FLUOROMETRIC ASSAY; MASS-SPECTROMETRY; CORE ALDEHYDES; LDL-RECEPTOR; IN-VIVO	Non-enzymatic glycation of low density lipoprotein (LDL) has been suggested to be responsible for the increase in susceptibility to atherogenesis of diabetic individuals. Although the association of lipid glycation with this process has been investigated, the effect of specific lipid glycation products on LDL metabolism has not been addressed. This study reports that glucosylated phosphatidylethanolamine (Glc-PtdEtn), the major LDL lipid glycation product, promotes LDL uptake and cholesteryl ester (CE) and triacylglycerol (TG) accumulation by THP-1 macrophages. Incubation of THP-1 macrophages at a concentration of 100 mu g/ml protein LDL specifically enriched (10 nmol/mg LDL protein) with synthetically prepared Glc-PtdEtn resulted in a significant increase in CE and TG accumulation when compared with LDL enriched in non-glucosylated PtdEtn, After a 24-h incubation with LDL containing Glc-PtdEtn, the macrophages contained 2-fold higher CE (10.11 +/- 1.54 mu g/mg cell protein) and TG (285.32 +/- 4.38 mu g/mg cell protein) compared with LDL specifically enriched in non-glucosylated PtdEtn (CE, 3.97 +/- 0.95, p < 0.01 and TG, 185.57 +/- 3.58 mu g/mg cell protein, p < 0.01), The corresponding values obtained with LDL containing glycated protein and lipid were similar to those of LDL containing Glc-PtdEtn (CE, 11.9 +/- 1.35 and TG, 280.78 +/- 3.98 mu g/mg cell protein). The accumulation of both neutral lipids was further significantly increased by incubating the macrophages with Glc-PtdEtn LDL exposed to copper oxidation, By utilizing the fluorescent probe, 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate (DiI), a 1.6-fold increase was seen in Glc-PtdEtn + LDL uptake when compared with control LDL, Competition studies revealed that acetylated LDL is not a good competitor for DiI Glc-PtdEtn LDL (5-6% inhibition), whereas glycated LDL gave an 80% inhibition, and LDL + Glc-PtdEtn gave 93% inhibition of uptake by macrophages, These results indicate that glucosylation of PtdEtn in LDL accounts for the entire effect of LDL glycation on macrophage uptake and CE and TG accumulation and, therefore, the increased atherogenic potential of LDL in hyperglycemia.	Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 1L6, Canada; Special Diagnost Inc, Toronto, ON M5G 1L6, Canada	University of Toronto; University of Toronto	Kuksis, A (corresponding author), Univ Toronto, Banting & Best Dept Med Res, 112 Coll St, Toronto, ON M5G 1L6, Canada.		Ravandi, Amir/O-7552-2019					Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; AVIRAM M, 1992, BIOCHEM BIOPH RES CO, V185, P465, DOI 10.1016/S0006-291X(05)81008-3; AVIRAM M, 1993, J CLIN INVEST, V91, P1942, DOI 10.1172/JCI116413; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; BUCALA R, 1993, P NATL ACAD SCI USA, V90, P6434, DOI 10.1073/pnas.90.14.6434; Engelmann B, 1996, BIOCHEM J, V315, P781, DOI 10.1042/bj3150781; Fluiter K, 1997, BIOCHEM J, V326, P515, DOI 10.1042/bj3260515; FOLCH J, 1957, J BIOL CHEM, V226, P497; GONEN B, 1981, DIABETES, V30, P875, DOI 10.2337/diabetes.30.10.875; GREENSPAN P, 1995, BBA-LIPID LIPID MET, V1257, P257, DOI 10.1016/0005-2760(95)00088-T; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; KLEIN RL, 1990, DIABETOLOGIA, V33, P299, DOI 10.1007/BF00403324; KLEIN RL, 1992, DIABETES, V41, P1301, DOI 10.2337/diabetes.41.10.1301; KOBAYASHI K, 1995, HORM METAB RES, V27, P356, DOI 10.1055/s-2007-979978; Kritharides L, 1998, ARTERIOSCL THROM VAS, V18, P1589, DOI 10.1161/01.ATV.18.10.1589; KUKSIS A, 1981, J CHROMATOGR, V224, P1, DOI 10.1016/S0378-4347(00)80133-4; KUKSIS A, 1980, J CHROMATOGR, V2, P1; LOPESVIRELLA MF, 1988, DIABETES, V37, P550, DOI 10.2337/diabetes.37.5.550; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lyons TJ, 1997, CURR OPIN LIPIDOL, V8, P174, DOI 10.1097/00041433-199706000-00008; LYONS TJ, 1987, DIABETOLOGIA, V30, P916, DOI 10.1007/BF00295874; MULLARKEY CJ, 1990, BIOCHEM BIOPH RES CO, V173, P932, DOI 10.1016/S0006-291X(05)80875-7; NEEPER M, 1992, J BIOL CHEM, V267, P14998; OTTNAD E, 1995, P NATL ACAD SCI USA, V92, P1391, DOI 10.1073/pnas.92.5.1391; PITAS RE, 1983, ARTERIOSCLEROSIS, V3, P2, DOI 10.1161/01.ATV.3.1.2; RABINI RA, 1994, CLIN BIOCHEM, V27, P381, DOI 10.1016/0009-9120(94)90042-6; Ravandi A, 1998, CLIN CHEM, V44, pA73; RAVANDI A, 1995, J BIOCHEM BIOPH METH, V30, P271, DOI 10.1016/0165-022X(95)00015-7; Ravandi A, 1997, LIPIDS, V32, P989, DOI 10.1007/s11745-997-0129-6; Ravandi A, 1996, FEBS LETT, V381, P77, DOI 10.1016/0014-5793(96)00064-6; RAVANDI A, 1995, LIPIDS, V30, P885, DOI 10.1007/BF02537478; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; Ryeom SW, 1996, J BIOL CHEM, V271, P20536, DOI 10.1074/jbc.271.34.20536; SAKURAI T, 1991, BIOCHEM BIOPH RES CO, V177, P433, DOI 10.1016/0006-291X(91)92002-2; Sambrano GR, 1997, ARTERIOSCL THROM VAS, V17, P3442, DOI 10.1161/01.ATV.17.12.3442; SASAKI J, 1982, BIOCHIM BIOPHYS ACTA, V713, P199, DOI 10.1016/0005-2760(82)90237-5; SOBENIN IA, 1993, ATHEROSCLEROSIS, V100, P41, DOI 10.1016/0021-9150(93)90066-4; STEPHAN ZF, 1993, J LIPID RES, V34, P325; Teupser D, 1996, BBA-LIPID LIPID MET, V1303, P193, DOI 10.1016/0005-2760(96)00094-X; VLASSARA H, 1986, J EXP MED, V164, P1301, DOI 10.1084/jem.164.4.1301; Watson AD, 1997, J BIOL CHEM, V272, P13597, DOI 10.1074/jbc.272.21.13597	41	35	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16494	16500		10.1074/jbc.274.23.16494	http://dx.doi.org/10.1074/jbc.274.23.16494			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347212	hybrid			2022-12-25	WOS:000080668600072
J	Saha, N; Schwer, B; Shuman, S				Saha, N; Schwer, B; Shuman, S			Characterization of human, Schizosaccharomyces pombe, and Candida albicans mRNA cap methyltransferases and complete replacement of the yeast capping apparatus by mammalian enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; CARBOXY-TERMINAL DOMAIN; MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; GUANYLYLTRANSFERASE ACTIVITIES; NUCLEOSIDE TRIPHOSPHATASE; MUTATIONAL ANALYSIS; 5'-CAPPING ENZYME; ESCHERICHIA-COLI; ACTIVE-SITE	Human and fission yeast cDNAs encoding mRNA (guanine-N7) methyltransferase were identified based on similarity of the human (Hcm1p; 476 amino acids) and Schizosaccharomyces pombe (Pcm1p; 389 amino acids) polypeptides to the cap methyltransferase of Saccharomyces cerevisiae (Abd1p), Expression of PCM1 or HCM1 in S. cerevisiae complemented the lethal phenotype resulting from deletion of the ABD1 gene, as did expression of the NH2-terminal deletion mutants PCM1(94-389) and HCM1(121-476), The CCM1 gene encoding Candida albicans cap methyltransferase (Ccm1p; 474 amino acids) was isolated from a C, albicans genomic library by selection for complementation of the conditional growth phenotype of S, cerevisiae abd1-ts mutants. Human cap methyltransferase was expressed in bacteria, purified, and characterized. Recombinant Hcm1p catalyzed quantitative S-adenosylmethionine-dependent conversion of GpppA-capped poly(A) to m7GpppA-capped poly(A), We identified by alanine-scanning mutagenesis eight amino acids (Asp-203, Gly-207, Asp-211, Asp-227, Arg-239, Tyr-289, Phe-291, and Phe-354) that are essential for human cap methyltransferase function in vivo, All eight residues are conserved in other cellular cap methyltransferases. Five of the mutant human proteins (D203A, R239A, Y289A, F291A, and F354A) were expressed in bacteria and found to be defective in cap methylation in vitro. Concordance of mutational effects on Hcm1p, Abd1p, and vaccinia capping enzyme underscores a conserved structural basis for cap methylation in DNA viruses, yeast, and metazoans, This is in contrast to the structural and mechanistic divergence of the RNA triphosphatase components of the yeast and metazoan capping systems. Nevertheless, we demonstrate that the entire three-component yeast capping apparatus, consisting of RNA 5'-triphosphatase (Cet1p), RNA guanylyltransferase (Ceg1p), and Abd1p could be replaced in vivo by the two-component mammalian apparatus consisting of a bifunctional triphosphatase-guanylyltransferase Mce1p and the methyltransferase Hcm1(121-476)p. Isogenic yeast strains with fungal versus mammalian capping systems should facilitate rational screens for antifungal drugs that target cap formation in vivo.	Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Cornell University	Shuman, S (corresponding author), Sloan Kettering Inst, Program Mol Biol, 1275 York Ave, New York, NY 10021 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052470] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52470] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Cho EJ, 1997, GENE DEV, V11, P3319, DOI 10.1101/gad.11.24.3319; ENSINGER MJ, 1976, J BIOL CHEM, V251, P5283; FIKES JD, 1990, NATURE, V346, P291, DOI 10.1038/346291a0; FRESCO LD, 1994, P NATL ACAD SCI USA, V91, P6624, DOI 10.1073/pnas.91.14.6624; Gross CH, 1998, J VIROL, V72, P10020, DOI 10.1128/JVI.72.12.10020-10028.1998; HIGMAN MA, 1994, J BIOL CHEM, V269, P14974; Ho CK, 1998, J BIOL CHEM, V273, P34151, DOI 10.1074/jbc.273.51.34151; Ho CK, 1996, J VIROL, V70, P6658, DOI 10.1128/JVI.70.10.6658-6664.1996; Ho CK, 1998, MOL CELL BIOL, V18, P5189, DOI 10.1128/MCB.18.9.5189; Ho CK, 1998, J BIOL CHEM, V273, P9577, DOI 10.1074/jbc.273.16.9577; Janbon G, 1997, YEAST, V13, P985, DOI 10.1002/(SICI)1097-0061(199708)13:10<985::AID-YEA153>3.0.CO;2-T; Jin JP, 1998, J VIROL, V72, P10011, DOI 10.1128/JVI.72.12.10011-10019.1998; MAO XD, 1994, J BIOL CHEM, V269, P24472; Mao XD, 1996, BIOCHEMISTRY-US, V35, P6900, DOI 10.1021/bi960221a; MAO XD, 1995, MOL CELL BIOL, V15, P4167; Mao XD, 1996, MOL CELL BIOL, V16, P475; McCracken S, 1997, GENE DEV, V11, P3306, DOI 10.1101/gad.11.24.3306; MIZUMOTO K, 1979, P NATL ACAD SCI USA, V76, P4961, DOI 10.1073/pnas.76.10.4961; Myette JR, 1996, J BIOL CHEM, V271, P11936, DOI 10.1074/jbc.271.20.11936; Pillutla RC, 1998, J BIOL CHEM, V273, P21443, DOI 10.1074/jbc.273.34.21443; SHIBAGAKI Y, 1995, J BIOCHEM, V118, P1303, DOI 10.1093/oxfordjournals.jbchem.a125023; SHUMAN S, 1994, P NATL ACAD SCI USA, V91, P12046, DOI 10.1073/pnas.91.25.12046; SHUMAN S, 1995, PROG NUCLEIC ACID RE, V50, P101, DOI 10.1016/S0079-6603(08)60812-0; Silva E, 1998, MOL CELL BIOL, V18, P4612, DOI 10.1128/MCB.18.8.4612; Takagi T, 1998, P NATL ACAD SCI USA, V95, P9808, DOI 10.1073/pnas.95.17.9808; Takagi T, 1997, CELL, V89, P867, DOI 10.1016/S0092-8674(00)80272-X; Tsukamoto T, 1998, BIOCHEM BIOPH RES CO, V251, P27, DOI 10.1006/bbrc.1998.9402; Tsukamoto T, 1997, BIOCHEM BIOPH RES CO, V239, P116, DOI 10.1006/bbrc.1997.7439; VENKATESAN S, 1980, J BIOL CHEM, V255, P2829; Wang SP, 1997, P NATL ACAD SCI USA, V94, P9573, DOI 10.1073/pnas.94.18.9573; Wang SP, 1997, J BIOL CHEM, V272, P14683, DOI 10.1074/jbc.272.23.14683; Wen YX, 1998, P NATL ACAD SCI USA, V95, P12226, DOI 10.1073/pnas.95.21.12226; Yamada-Okabe T, 1998, NUCLEIC ACIDS RES, V26, P1700, DOI 10.1093/nar/26.7.1700; Yamada-Okabe T, 1998, FEBS LETT, V435, P49, DOI 10.1016/S0014-5793(98)01037-0; Yu L, 1996, J VIROL, V70, P6162, DOI 10.1128/JVI.70.9.6162-6168.1996; Yu L, 1997, J VIROL, V71, P9837, DOI 10.1128/JVI.71.12.9837-9843.1997; Yue ZY, 1997, P NATL ACAD SCI USA, V94, P12898, DOI 10.1073/pnas.94.24.12898	37	67	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16553	16562		10.1074/jbc.274.23.16553	http://dx.doi.org/10.1074/jbc.274.23.16553			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347220	hybrid			2022-12-25	WOS:000080668600080
J	Jimenez-Lara, AM; Aranda, A				Jimenez-Lara, AM; Aranda, A			The vitamin D receptor binds in a transcriptionally inactive form and without a defined polarity on a retinoic acid response element	FASEB JOURNAL			English	Article						retinoid receptor; half-site; heterodimer; retinoid X receptor	NUCLEAR RECEPTOR; THYROID-HORMONE; DIRECT REPEATS; HISTONE DEACETYLASE; LIGAND SENSITIVITY; CO-REPRESSOR; BETA-GENE; HETERODIMERS; TRANSACTIVATION; COMPLEX	Heterodimers of the vitamin D receptor (VDR) with the retinoid X receptor (RXR) bind in a transcriptionally unproductive manner to the retinoic acid response element present in the retinoic acid receptor-Pe promoter. This element is composed of a direct repeat (DR) of the sequence PuGTTCA spaced by five nucleotides, However, the same sequence separated by three nucleotides (DR3) acts as a strong vitamin D response element. Here we show that the polarity of binding of the heterodimers to the DR3 was 5'-RXR-VDR-3', whereas on the DR5, both heterodimeric partners bind indistinctly to the 5' or 3' hemi-sites, These results suggest that the response elements can allosterically regulate the conformation of the receptors to determine positive or negative regulation of gene expression. Despite the altered polarity, the DRS-bound heterodimer was able to recruit the nuclear receptor coactivator ACTR in a vitamin D-dependent fashion. Furthermore, binding of the corepressor SMRT (silencing mediator of retinoid and thyroid hormone receptors) to the RXR/VDR heterodimer on a DR5 was not observed. Binding of RXR/VDR heterodimers to DRs with different transcriptional outcomes may generate selectivity and provide a greater complexity and flexibility to the vitamin D responses.	UAM, CSIC, Inst Invest Biomed, Madrid 29029, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Aranda, A (corresponding author), UAM, CSIC, Inst Invest Biomed, Arturo Duperier 4, Madrid 29029, Spain.		Jiménez-Lara, Ana-María/ABF-5639-2020; Aranda, Ana/ABG-8820-2020	Jiménez-Lara, Ana-María/0000-0001-6471-9741; Aranda, Ana/0000-0002-8338-9589				BAKER AR, 1988, P NATL ACAD SCI USA, V85, P3294, DOI 10.1073/pnas.85.10.3294; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHEN JD, 1995, NATURE, V377, P455; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; GarciaVillalba P, 1996, MOL CELL BIOL, V16, P318; Gill RK, 1998, MOL ENDOCRINOL, V12, P57, DOI 10.1210/mend.12.1.0048; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; JIMENEZLARA AM, 1999, IN PRESS ENDOCRINOLO; KATO S, 1995, MOL CELL BIOL, V15, P5858; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; Lemon BD, 1996, MOL CELL BIOL, V16, P1006; MADER S, 1993, EMBO J, V12, P5029, DOI 10.1002/j.1460-2075.1993.tb06196.x; MADER S, 1993, J BIOL CHEM, V268, P591; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; Masuyama H, 1997, MOL ENDOCRINOL, V11, P1507, DOI 10.1210/me.11.10.1507; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; Polly P, 1997, J CELL BIOCHEM, V67, P287, DOI 10.1002/(SICI)1097-4644(19971201)67:3<287::AID-JCB1>3.0.CO;2-S; QUELO I, 1994, DNA CELL BIOL, V13, P1181, DOI 10.1089/dna.1994.13.1181; Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787; SCHRADER M, 1995, MOL CELL BIOL, V15, P1154; SCHRADER M, 1994, NATURE, V370, P382, DOI 10.1038/370382a0; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; TOWERS TL, 1993, P NATL ACAD SCI USA, V90, P6310, DOI 10.1073/pnas.90.13.6310; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; Zamir I, 1997, GENE DEV, V11, P835, DOI 10.1101/gad.11.7.835; ZECHEL C, 1994, EMBO J, V13, P1425, DOI 10.1002/j.1460-2075.1994.tb06396.x; ZECHEL C, 1994, EMBO J, V13, P1414, DOI 10.1002/j.1460-2075.1994.tb06395.x	37	19	19	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	1999	13	9					1073	1081		10.1096/fasebj.13.9.1073	http://dx.doi.org/10.1096/fasebj.13.9.1073			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	200NZ	10336890				2022-12-25	WOS:000080547700012
J	Blanchoin, L; Pollard, TD				Blanchoin, L; Pollard, TD			Mechanism of interaction of Acanthamoeba actophorin (ADF/cofilin) with actin filaments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPOLYMERIZING FACTOR COFILIN; F-ACTIN; ADP-ACTIN; INORGANIC-PHOSPHATE; PHALLOIDIN BINDING; NUCLEOTIDE-BINDING; KINETIC-ANALYSIS; ARP2/3 COMPLEX; RATE CONSTANTS; YEAST COFILIN	We characterized the interaction of Acanthamoeba actophorin, a member of ADF/cofilin family, with filaments of amoeba and rabbit skeletal muscle actin. The affinity is about 10 times higher for muscle actin filaments (K-d = 0.5 mu M) than amoeba actin filaments (K-d = 5 mu M) even though the affinity for muscle and amoeba Mg-ADP-actin monomers (K-d = 0.1 mu M) is the same (Blanchoin, L., and Pollard, T. D. (1998) J, Biol, Chem. 273, 25106-25111), Actophorin binds slowly (k(+) = 0.03 mu M-1 s(-1)) to and dissociates from amoeba actin filaments in a simple bimolecular reaction, but binding to muscle actin filaments is cooperative. Actophorin severs filaments in a concentration-dependent fashion. Phosphate or BeF3 bound to ADP-actin filaments inhibit actophorin binding. Actophorin increases the rate of phosphate release from actin filaments more than 10-fold. The time course of the interaction of actophorin with filaments measured by quenching of the fluorescence of pyrenyl-actin or fluorescence anisotropy of rhodamine-actophorin is complicated, because severing, depolymerization, and repolymerization follows binding. The 50-fold higher affinity of actophorin for Mg-ADP-actin monomers (K-d = 0.1 mu M) than ADP-actin filaments provides the thermodynamic basis for driving disassembly of filaments that have hydrolyzed ATP and dissociated gamma-phosphate.	Salk Inst Biol Studies, Struct Biol Lab, La Jolla, CA 92037 USA	Salk Institute	Pollard, TD (corresponding author), Salk Inst Biol Studies, Struct Biol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.				PHS HHS [NIH 26388] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AIZAWA H, 1995, J BIOL CHEM, V270, P10923, DOI 10.1074/jbc.270.18.10923; Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; Blanchoin L, 1996, J BIOL CHEM, V271, P12380, DOI 10.1074/jbc.271.21.12380; Blanchoin L, 1998, J BIOL CHEM, V273, P25106, DOI 10.1074/jbc.273.39.25106; CARLIER MF, 1988, J BIOL CHEM, V263, P817; Carlier MF, 1998, CURR OPIN CELL BIOL, V10, P45, DOI 10.1016/S0955-0674(98)80085-9; Carlier MF, 1997, J CELL BIOL, V136, P1307, DOI 10.1083/jcb.136.6.1307; COMBEAU C, 1988, J BIOL CHEM, V263, P17429; COOPER JA, 1986, J BIOL CHEM, V261, P477; DANCKER P, 1990, BIOCHIM BIOPHYS ACTA, V1035, P197, DOI 10.1016/0304-4165(90)90116-E; De La Cruz EM, 1996, BIOCHEMISTRY-US, V35, P14054, DOI 10.1021/bi961047t; DE LA CRUZ EM, 1995, BIOCHEMISTRY-US, V34, P5452, DOI 10.1021/bi00016a016; DE LA CRUZ EM, 1994, BIOCHEMISTRY-US, V33, P14387, DOI 10.1021/bi00252a003; Didry D, 1998, J BIOL CHEM, V273, P25602, DOI 10.1074/jbc.273.40.25602; Du JY, 1998, BIOCHEMISTRY-US, V37, P13276, DOI 10.1021/bi981117r; HAWKINS M, 1993, BIOCHEMISTRY-US, V32, P9985, DOI 10.1021/bi00089a014; HAYDEN SM, 1993, BIOCHEMISTRY-US, V32, P9994, DOI 10.1021/bi00089a015; KINOSIAN HJ, 1993, J BIOL CHEM, V268, P8683; Kinosian HJ, 1996, BIOCHEMISTRY-US, V35, P16550, DOI 10.1021/bi961891j; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; KUHLMAN PA, 1994, FEBS LETT, V339, P297, DOI 10.1016/0014-5793(94)80434-6; Lappalainen P, 1997, EMBO J, V16, P5520, DOI 10.1093/emboj/16.18.5520; MABUCHI I, 1983, J CELL BIOL, V97, P1612, DOI 10.1083/jcb.97.5.1612; MACIVER SK, 1991, J CELL BIOL, V115, P1611, DOI 10.1083/jcb.115.6.1611; Maciver SK, 1998, EUR J BIOCHEM, V256, P388, DOI 10.1046/j.1432-1327.1998.2560388.x; Maciver SK, 1998, CURR OPIN CELL BIOL, V10, P140, DOI 10.1016/S0955-0674(98)80097-5; MACLEANFLETCHER S, 1980, CELL, V20, P329, DOI 10.1016/0092-8674(80)90619-4; MAEKAWA S, 1984, J BIOCH, V95, P337; McGough A, 1997, J CELL BIOL, V138, P771, DOI 10.1083/jcb.138.4.771; Melki R, 1996, BIOCHEMISTRY-US, V35, P12038, DOI 10.1021/bi961325o; MOON A, 1995, MOL BIOL CELL, V6, P1423, DOI 10.1091/mbc.6.11.1423; MOON AL, 1993, J CELL BIOL, V120, P421, DOI 10.1083/jcb.120.2.421; MORIYAMA K, 1990, J BIOL CHEM, V265, P5768; Mossakowska M, 1996, J MUSCLE RES CELL M, V17, P383, DOI 10.1007/BF00123355; Mullins RD, 1998, P NATL ACAD SCI USA, V95, P6181, DOI 10.1073/pnas.95.11.6181; NISHIDA E, 1984, J BIOCHEM-TOKYO, V95, P387, DOI 10.1093/oxfordjournals.jbchem.a134619; POLLARD TD, 1986, J CELL BIOL, V103, P2747, DOI 10.1083/jcb.103.6.2747; POLLARD TD, 1984, J CELL BIOL, V99, P769, DOI 10.1083/jcb.99.3.769; QUIRK S, 1993, BIOCHEMISTRY-US, V32, P8525, DOI 10.1021/bi00084a019; Ressad F, 1998, J BIOL CHEM, V273, P20894, DOI 10.1074/jbc.273.33.20894; Rosenblatt J, 1997, J CELL BIOL, V136, P1323, DOI 10.1083/jcb.136.6.1323; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; THERIOT JA, 1991, NATURE, V352, P126, DOI 10.1038/352126a0; WANG YL, 1985, J CELL BIOL, V101, P597, DOI 10.1083/jcb.101.2.597; WEBB MR, 1992, P NATL ACAD SCI USA, V89, P4884, DOI 10.1073/pnas.89.11.4884; Welch MD, 1998, SCIENCE, V281, P105, DOI 10.1126/science.281.5373.105; Wriggers W, 1997, BIOPHYS J, V73, P624, DOI 10.1016/S0006-3495(97)78098-6; Xu JY, 1998, J BIOL CHEM, V273, P9570, DOI 10.1074/jbc.273.16.9570; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735; YONEZAWA N, 1985, J BIOL CHEM, V260, P4410	51	226	234	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15538	15546		10.1074/jbc.274.22.15538	http://dx.doi.org/10.1074/jbc.274.22.15538			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336448	hybrid			2022-12-25	WOS:000080560100037
J	Chu, ZL; Shin, YA; Yang, JM; DiDonato, JA; Ballard, DW				Chu, ZL; Shin, YA; Yang, JM; DiDonato, JA; Ballard, DW			IKK gamma mediates the interaction of cellular I kappa B kinases with the tax transforming protein of human T cell leukemia virus type 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HTLV-I; TRANSCRIPTIONAL ACTIVATOR; SIGNAL-TRANSDUCTION; COMPLEX; ALPHA; LINE; IDENTIFICATION; EXPRESSION; PATHWAYS; BINDING	The Tax oncoprotein of human T cell leukemia virus type 1 constitutively activates transcription factor NF-kappa B by a mechanism involving Tax-induced phosphorylation of I kappa B alpha, a labile cytoplasmic inhibitor of NF-kappa B. To trigger this signaling cascade, Tax associates stably with and persistently activates a cellular I kappa B kinase (IKK) containing both catalytic (IKK alpha and IKK beta) and noncatalytic (IKK gamma) subunits. We now demonstrate that IKK gamma enables Tax to dock with the IKK beta catalytic subunit, resulting in chronic I kappa B kinase activation. Mutations in either IKK gamma or Tax that prevent formation of these higher order Tax.IKK complexes also interfere with the ability of Tax to induce IKK beta catalytic function in vivo. Deletion mapping studies indicate that amino acids 1-100 of IKK gamma are required for this Tax targeting function. Together, these findings identify IKK gamma as an adaptor protein that directs the stable formation of pathologic Tax.IKK complexes in virally infected T cells.	Vanderbilt Univ, Sch Med, Howard Hughes Med Inst, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Nashville, TN 37232 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA	Howard Hughes Medical Institute; Vanderbilt University; Vanderbilt University; Cleveland Clinic Foundation	Ballard, DW (corresponding author), Vanderbilt Univ, Sch Med, Howard Hughes Med Inst, 802 Rudolph Light Hall, Nashville, TN 37232 USA.		Hazen, Stanley L/ABD-5845-2021		NCI NIH HHS [T32 CA09385] Funding Source: Medline; NIAID NIH HHS [R01AI33839] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009385] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033839] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; Baumann B, 1998, J BIOL CHEM, V273, P11448, DOI 10.1074/jbc.273.19.11448; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Chu ZL, 1998, J BIOL CHEM, V273, P15891, DOI 10.1074/jbc.273.26.15891; Courtois G, 1997, MOL CELL BIOL, V17, P1441, DOI 10.1128/MCB.17.3.1441; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; KOEFFLER HP, 1984, BLOOD, V64, P482; Li YG, 1999, P NATL ACAD SCI USA, V96, P1042, DOI 10.1073/pnas.96.3.1042; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; Nemoto S, 1998, MOL CELL BIOL, V18, P7336, DOI 10.1128/MCB.18.12.7336; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; SODROSKI J, 1985, SCIENCE, V228, P1430, DOI 10.1126/science.2990028; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; Uchiyama T, 1997, ANNU REV IMMUNOL, V15, P15, DOI 10.1146/annurev.immunol.15.1.15; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070	30	154	160	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15297	15300		10.1074/jbc.274.22.15297	http://dx.doi.org/10.1074/jbc.274.22.15297			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336413	hybrid			2022-12-25	WOS:000080560100002
J	Smith, TJ; Jennings, TA; Sciaky, D; Cao, HJ				Smith, TJ; Jennings, TA; Sciaky, D; Cao, HJ			Prostaglandin-endoperoxide H synthase-2 expression in human thyroid epithelium - Evidence for constitutive expression in vivo and in cultured KAT-50 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN COLON-CANCER; HUMAN ORBITAL FIBROBLASTS; HUMAN-SKIN FIBROBLASTS; NF-KAPPA-B; MESSENGER-RNA; CYCLOOXYGENASE-2 EXPRESSION; GLYCOSAMINOGLYCAN SYNTHESIS; INDUCIBLE CYCLOOXYGENASE; LEUKOREGULIN INDUCTION; PANCREATIC-ISLET	zProstaglandin-endoperoxide H synthase (PGHS) (EC 1.14.99.1) expression was examined in human thyroid tissue and in KAT-50, a well differentiated human thyroid epithelial cell line. PGHS-1 is found constitutively expressed in most healthy tissues, whereas PGHS-2 is highly inducible and currently thought to be expressed, with few exceptions, only in diseased tissues. Surprisingly, PGHS-2 mRNA and protein were easily detected in normal thyroid tissue. KAT-50 cells express high levels of constitutive PGHS-2 mRNA and protein under basal culture conditions, Compounds usually associated with PGHS-8 induction, including interleukin-1 beta (IL-beta), phorbol la-myristate 13-acetate, and serum transiently down-regulated PGHS-2 expression. Human PGHS-2 promoter constructs (-1840/+123 and -831/+123) fused to a luciferase reporter and transfected into untreated KAT-50 cells exhibited substantial activity. NS-398, a highly selective inhibitor of PGHS-2 could inhibit substantial basal prostaglandin E-2 production, Exogenous IL-1 receptor antagonist or IL-1 alpha neutralizing antibodies could attenuate constitutive PGHS-2 expression in KAT-50 cells, suggesting that endogenous IL-1 alpha synthesis was driving PGHS-2 expression, Our findings suggest that normal thyroid epithelium expresses high constitutive levels of PGHS-2 in situ and in vitro and this enzyme is active in the generation of prostaglandin E-2. Thus, unprovoked PGHS-2 expression might be considerably more widespread in healthy tissues than is currently believed.	Albany Med Coll, Dept Med, Div Mol & Cellular Med, Albany, NY 12208 USA; Albany Med Coll, Dept Biochem & Mol Biol, Albany, NY 12208 USA; Albany Med Coll, Dept Pathol, Albany, NY 12208 USA; Samuel S Stratton Vet Affairs Med Ctr, Albany, NY 12208 USA	Albany Medical College; Albany Medical College; Albany Medical College	Smith, TJ (corresponding author), Albany Med Coll, Dept Med, Div Mol & Cellular Med, A-175,47 New Scotland Ave, Albany, NY 12208 USA.		Smith, Terry/ABG-1360-2020	Smith, Terry/0000-0002-6279-9685	NATIONAL EYE INSTITUTE [R01EY008976, R01EY011708] Funding Source: NIH RePORTER; NEI NIH HHS [EY11708, EY08976] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		APPLEBY SB, 1994, BIOCHEM J, V302, P723, DOI 10.1042/bj3020723; Asano K, 1996, AM J PHYSIOL-LUNG C, V271, pL126, DOI 10.1152/ajplung.1996.271.1.L126; Atwa MA, 1996, EUR J ENDOCRINOL, V135, P322, DOI 10.1530/eje.0.1350322; BETZ M, 1991, J IMMUNOL, V146, P108; CAO CY, 1995, BRAIN RES, V697, P187, DOI 10.1016/0006-8993(95)00839-I; Cao HJ, 1998, J BIOL CHEM, V273, P29615, DOI 10.1074/jbc.273.45.29615; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CROFFORD LJ, 1994, J CLIN INVEST, V93, P1095, DOI 10.1172/JCI117060; DARGENIO DZ, 1992, ADAPT 2 PROGRAM SIMU; Davies Terry F., 1996, P525; DICERBO A, 1992, J CLIN ENDOCR METAB, V74, P585, DOI 10.1210/jc.74.3.585; DINCHUK JE, 1995, NATURE, V378, P406, DOI 10.1038/378406a0; DiPaola R, 1997, J CLIN ENDOCR METAB, V82, P670, DOI 10.1210/jc.82.2.670; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; FOX BS, 1993, IMMUNOMETHODS, V2, P255; FUNK CD, 1991, FASEB J, V5, P2304, DOI 10.1096/fasebj.5.9.1907252; FUTAKI N, 1994, PROSTAGLANDINS, V47, P55, DOI 10.1016/0090-6980(94)90074-4; Gallois C, 1998, J BIOL CHEM, V273, P23183, DOI 10.1074/jbc.273.36.23183; HARRIS RC, 1994, J CLIN INVEST, V94, P2504, DOI 10.1172/JCI117620; HEMPEL SL, 1994, J CLIN INVEST, V93, P391, DOI 10.1172/JCI116971; Hla T, 1996, PROSTAG OTH LIPID M, V51, P81, DOI 10.1016/0090-6980(95)00158-1; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; HU ZQ, 1995, J IMMUNOL, V155, P2134; Huff R., 1995, Inflammation Research, V44, pS145, DOI 10.1007/BF01778304; KARGMAN SL, 1995, CANCER RES, V55, P2556; KOSAKA T, 1994, EUR J BIOCHEM, V221, P889, DOI 10.1111/j.1432-1033.1994.tb18804.x; KUJUBU DA, 1992, J BIOL CHEM, V267, P7991; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; Kwon G, 1998, DIABETES, V47, P583, DOI 10.2337/diabetes.47.4.583; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; Liu XH, 1996, CANCER RES, V56, P5125; MASFERRER JL, 1992, P NATL ACAD SCI USA, V89, P3917, DOI 10.1073/pnas.89.9.3917; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; MORITA I, 1995, J BIOL CHEM, V270, P10902, DOI 10.1074/jbc.270.18.10902; Narko K, 1997, ENDOCRINOLOGY, V138, P3638, DOI 10.1210/en.138.9.3638; Narko K, 1997, J BIOL CHEM, V272, P21455, DOI 10.1074/jbc.272.34.21455; OBANION MK, 1991, J BIOL CHEM, V266, P23261; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Parker J, 1997, EXP CELL RES, V236, P321, DOI 10.1006/excr.1997.3741; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; RANKIN JHG, 1976, AM J PHYSIOL, V231, P754, DOI 10.1152/ajplegacy.1976.231.3.754; RAPOPORT B, 1978, ENDOCRINOLOGY, V102, P175, DOI 10.1210/endo-102-1-175; RISTIMAKI A, 1994, J BIOL CHEM, V269, P11769; Robertson RP, 1998, DIABETES, V47, P1379, DOI 10.2337/diabetes.47.9.1379; ROBERTSON RP, 1974, J CLIN INVEST, V54, P310, DOI 10.1172/JCI107766; ROPER RL, 1990, J IMMUNOL, V145, P2644; SCHREY MP, 1995, BRIT J CANCER, V72, P1412, DOI 10.1038/bjc.1995.523; SEIBERT K, 1994, P NATL ACAD SCI USA, V91, P12013, DOI 10.1073/pnas.91.25.12013; Sheng HM, 1997, J CLIN INVEST, V99, P2254, DOI 10.1172/JCI119400; Siegle I, 1998, ARTHRITIS RHEUM-US, V41, P122, DOI 10.1002/1529-0131(199801)41:1<122::AID-ART15>3.3.CO;2-#; Smith RS, 1997, AM J PATHOL, V151, P317; Smith TJ, 1998, RHEUM DIS CLIN N AM, V24, P501, DOI 10.1016/S0889-857X(05)70023-5; Smith TJ, 1997, ENDOCRINOLOGY, V138, P5576, DOI 10.1210/en.138.12.5576; SMITH TJ, 1994, P NATL ACAD SCI USA, V91, P5094, DOI 10.1073/pnas.91.11.5094; SMITH TJ, 1984, J CLIN INVEST, V74, P2157, DOI 10.1172/JCI111642; SMITH TJ, 1988, METABOLISM, V37, P179, DOI 10.1016/S0026-0495(98)90015-4; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Sorli CH, 1998, P NATL ACAD SCI USA, V95, P1788, DOI 10.1073/pnas.95.4.1788; TAHARA K, 1991, J BIOL CHEM, V266, P440; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Venkataraman GM, 1998, THYROID, V8, P63, DOI 10.1089/thy.1998.8.63; WANG HS, 1995, J CLIN ENDOCR METAB, V80, P3553, DOI 10.1210/jc.80.12.3553; Wang HS, 1996, J BIOL CHEM, V271, P22718, DOI 10.1074/jbc.271.37.22718; Williams CS, 1997, J CLIN INVEST, V100, P1325, DOI 10.1172/JCI119651; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; YAMAGATA K, 1993, NEURON, V11, P371, DOI 10.1016/0896-6273(93)90192-T; Yang XH, 1997, BBA-GENE STRUCT EXPR, V1350, P287, DOI 10.1016/S0167-4781(96)00225-4; YOKOYAMA C, 1989, BIOCHEM BIOPH RES CO, V165, P888, DOI 10.1016/S0006-291X(89)80049-X; Young DA, 1998, P NATL ACAD SCI USA, V95, P8904, DOI 10.1073/pnas.95.15.8904	70	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15622	15632		10.1074/jbc.274.22.15622	http://dx.doi.org/10.1074/jbc.274.22.15622			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336459	hybrid			2022-12-25	WOS:000080560100048
J	Ehrnsperger, M; Lilie, H; Gaestel, M; Buchner, J				Ehrnsperger, M; Lilie, H; Gaestel, M; Buchner, J			The dynamics of Hsp25 quaternary structure - Structure and function of different oligomeric species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; ALPHA-B-CRYSTALLIN; EHRLICH ASCITES TUMOR; A-CRYSTALLIN; ACTIN POLYMERIZATION; STRESS PROTEINS; EXPRESSION; AGGREGATION; CELLS; PHOSPHORYLATION	Small heat shock proteins (sHsps), including alpha-crystallin, represent a conserved and ubiquitous family of proteins. They form large oligomers, ranging in size from 140 to more than 800 kDa, which seem to be important for the interaction with non-native proteins as molecular chaperones. Here we analyzed the stability and oligomeric structure of murine Hsp25 and its correlation with function. Upon unfolding, the tertiary and quaternary structure of Hsp25 is rapidly lost, whereas the secondary structure remains remarkably stable. Unfolding is completely reversible, leading to native hexadecameric structures. These oligomers are in a concentration-dependent equilibrium with tetramers and dimers, indicating that tetramers assembled from dimers represent the basic building blocks of Hsp25 oligomers. At high temperatures, the Hsp25 complexes increase in molecular mass, consistent with the appearance of "heat shock granules" in vivo after heat treatment. This high molecular mass "heat shock form" of Hsp25 is in a slow equilibrium with hexadecameric Hsp25. Thus, it does not represent an off-pathway reaction. Interestingly, the heat shock form exhibits unchanged chaperone activity even after incubation at 80 degrees C. We conclude that Hsp25 is a dynamic tetramer of tetramers with a unique ability to refold and reassemble into its active quaternary structure after denaturation. So-called heat shock granules, which have been reported to appear in response to stress, seem to represent a novel functional species of Hsp25.	Univ Regensburg, Inst Biophys & Phys Biochem, D-93040 Regensburg, Germany; Univ Halle Wittenberg, Inst Biotechnol, D-06120 Halle, Germany; Univ Halle Wittenberg, Innovationskolleg Zellspezialisieriung, D-06120 Halle, Germany	University of Regensburg; Martin Luther University Halle Wittenberg; Martin Luther University Halle Wittenberg	Buchner, J (corresponding author), Univ Regensburg, Inst Biophys & Phys Biochem, Univ Str 31, D-93040 Regensburg, Germany.	johannes.buchner@ch.tum.de	Gaestel, Matthias/A-6560-2013; Buchner, Johannes/A-2651-2010	Gaestel, Matthias/0000-0002-4944-4652; Buchner, Johannes/0000-0003-1282-7737				Aquino DA, 1997, J NEUROPATH EXP NEUR, V56, P664; ARRIGO AP, 1987, DEV BIOL, V122, P39, DOI 10.1016/0012-1606(87)90330-7; ARRIGO AP, 1988, MOL CELL BIOL, V8, P5059, DOI 10.1128/MCB.8.12.5059; Arrigo AP, 1994, BIOL HEAT SHOCK PROT, P335; Bassi FA, 1995, BIOPHYS J, V69, P2720, DOI 10.1016/S0006-3495(95)80143-8; BEHLKE J, 1991, FEBS LETT, V288, P119, DOI 10.1016/0014-5793(91)81016-2; BENNDORF R, 1994, J BIOL CHEM, V269, P20780; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chang ZY, 1996, J BIOL CHEM, V271, P7218, DOI 10.1074/jbc.271.12.7218; CHIESA R, 1990, FEBS LETT, V268, P222, DOI 10.1016/0014-5793(90)81013-E; CIOCCA DR, 1993, JNCI-J NATL CANCER I, V85, P1558, DOI 10.1093/jnci/85.19.1558; COLLIER NC, 1988, J CELL BIOL, V106, P1131, DOI 10.1083/jcb.106.4.1131; de Jong WW, 1998, INT J BIOL MACROMOL, V22, P151, DOI 10.1016/S0141-8130(98)00013-0; DUDICH IV, 1995, BBA-PROTEIN STRUCT M, V1253, P163, DOI 10.1016/0167-4838(95)00135-X; Ehrnsperger M, 1998, ANAL BIOCHEM, V259, P218, DOI 10.1006/abio.1998.2630; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; EHRNSPERGER M, 1997, MOL CHAPERONES LIFE, P533; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P509, DOI 10.1021/bi00002a015; GAESTEL M, 1989, EUR J BIOCHEM, V179, P209, DOI 10.1111/j.1432-1033.1989.tb14542.x; Gesierich U, 1996, FEBS LETT, V393, P151, DOI 10.1016/0014-5793(96)00867-8; Haley DA, 1998, J MOL BIOL, V277, P27, DOI 10.1006/jmbi.1997.1611; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; JAKOB U, 1993, J BIOL CHEM, V268, P1517; KAMPINGA HH, 1994, BIOCHEM BIOPH RES CO, V204, P1170, DOI 10.1006/bbrc.1994.2586; KANTOROW M, 1995, J BIOL CHEM, V270, P17215, DOI 10.1074/jbc.270.29.17215; KATO K, 1992, J BIOL CHEM, V267, P7718; Kim KK, 1998, NATURE, V394, P595, DOI 10.1038/29106; Kim R, 1998, P NATL ACAD SCI USA, V95, P9129, DOI 10.1073/pnas.95.16.9129; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; KNAUF U, 1992, FEBS LETT, V309, P297, DOI 10.1016/0014-5793(92)80793-G; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; Lee GJ, 1997, EMBO J, V16, P659, DOI 10.1093/emboj/16.3.659; Leroux MR, 1997, J BIOL CHEM, V272, P12847, DOI 10.1074/jbc.272.19.12847; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; Mehlen P, 1997, BIOCHEM BIOPH RES CO, V241, P187, DOI 10.1006/bbrc.1997.7635; MEHLEN P, 1994, EUR J BIOCHEM, V221, P327, DOI 10.1111/j.1432-1033.1994.tb18744.x; MERCK KB, 1992, BIOCHIM BIOPHYS ACTA, V1130, P267, DOI 10.1016/0167-4781(92)90439-7; MERCK KB, 1993, J BIOL CHEM, V268, P1046; MIRON T, 1991, J CELL BIOL, V114, P255, DOI 10.1083/jcb.114.2.255; NICHOLL ID, 1994, EMBO J, V13, P945, DOI 10.1002/j.1460-2075.1994.tb06339.x; NOVER L, 1989, MOL CELL BIOL, V9, P1298, DOI 10.1128/MCB.9.3.1298; OSTERYOUNG KW, 1994, J BIOL CHEM, V269, P28676; RENKAWEK K, 1994, ACTA NEUROPATHOL, V87, P155, DOI 10.1007/BF00296185; ROSSI JM, 1989, J CELL BIOL, V108, P425, DOI 10.1083/jcb.108.2.425; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; STEGE GJJ, 1995, J CELL PHYSIOL, V164, P579, DOI 10.1002/jcp.1041640316; Sun TX, 1998, J BIOL CHEM, V273, P286, DOI 10.1074/jbc.273.1.286; SUREWICZ WK, 1995, BIOCHEMISTRY-US, V34, P9655, DOI 10.1021/bi00030a001; VIERLING E, 1997, GUIDBOOK MOL CHAPERO, P277; WANG KY, 1995, INVEST OPHTH VIS SCI, V36, P311; Waters ER, 1996, J EXP BOT, V47, P325, DOI 10.1093/jxb/47.3.325; WISTOW G, 1993, EXP EYE RES, V56, P729, DOI 10.1006/exer.1993.1090; ZANTEMA A, 1992, J BIOL CHEM, V267, P12936	55	145	148	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					14867	14874		10.1074/jbc.274.21.14867	http://dx.doi.org/10.1074/jbc.274.21.14867			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329686	hybrid			2022-12-25	WOS:000081965200051
J	Fortini, P; Parlanti, E; Sidorkina, OM; Laval, J; Dogliotti, E				Fortini, P; Parlanti, E; Sidorkina, OM; Laval, J; Dogliotti, E			The type of DNA glycosylase determines the base excision repair pathway in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APURINIC APYRIMIDINIC SITES; COLI FPG PROTEIN; ESCHERICHIA-COLI; POLYMERASE-BETA; NUCLEAR ANTIGEN; SACCHAROMYCES-CEREVISIAE; PURIFIED PROTEINS; HUMAN HOMOLOG; FREE-RADICALS; ABASIC SITES	The base excision repair (BER) of modified nucleotides is initiated by damage-specific DNA glycosylases. The repair of the resulting apurinic/apyrimidinic site involves the replacement of either a single nucleotide (short patch BER) or of several nucleotides (long patch BER). The mechanism that controls the selection of either BER pathway is unknown. We tested the hypothesis that the type of base damage present on DNA, by determining the specific DNA glycosylase in charge of its excision, drives the repair of the resulting abasic site intermediate to either BER branch. In mammalian cells hypoxanthine (HX) and 1,N-6-ethenoadenine (epsilon A) are both substrates for the monofunctional 3-methyladenine DNA glycosylase, the ANPG protein, whereas 7,8-dihydro-8-oxoguanine (8-oxoG) is removed by the bifunctional DNA glycosylase/beta-lyase 8-oxoG-DNA glycosylase (OGG1). Circular plasmid molecules containing a single HX, EA, Or 8-oxoG were constructed. In vitro repair assays with HeLa cell extracts revealed that EX and epsilon A are repaired via both short and long patch BER, whereas 8-oxoG is repaired mainly via the short patch pathway The preferential repair of 8-oxoG by short patch BER was confirmed by the low efficiency of repair of this lesion by DNA polymerase beta-deficient mouse cells as compared with their wild-type counterpart. These data fit into a model where the intrinsic properties of the DNA glycosylase that recognizes the lesion selects the branch of BER that will restore the intact DNA template.	Ist Super Sanita, Comparat Toxicol & Ecotoxicol Lab, I-00161 Rome, Italy; Inst Gustave Roussy, CNRS, UMR 1772, Grp Reparat ADN, F-94805 Villejuif, France	Istituto Superiore di Sanita (ISS); Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Dogliotti, E (corresponding author), Ist Super Sanita, Comparat Toxicol & Ecotoxicol Lab, Viale Regina Elena 299, I-00161 Rome, Italy.		Fortini, Paola/K-1197-2018; Parlanti, Eleonora/AAC-5978-2021	Fortini, Paola/0000-0001-6206-8498; 				Aburatani H, 1997, CANCER RES, V57, P2151; Arai K, 1997, ONCOGENE, V14, P2857, DOI 10.1038/sj.onc.1201139; BAILLY V, 1989, BIOCHEM J, V262, P581, DOI 10.1042/bj2620581; Biade S, 1998, J BIOL CHEM, V273, P898, DOI 10.1074/jbc.273.2.898; Bjoras M, 1997, EMBO J, V16, P6314, DOI 10.1093/emboj/16.20.6314; BOITEUX S, 1990, J BIOL CHEM, V265, P3916; CZECZOT H, 1991, J BACTERIOL, V173, P3419, DOI 10.1128/jb.173.11.3419-3424.1991; Dianov G, 1998, J BIOL CHEM, V273, P33811, DOI 10.1074/jbc.273.50.33811; DIZDAROGLU M, 1993, BIOCHEMISTRY-US, V32, P12105, DOI 10.1021/bi00096a022; DOGLIOTTI E, 1997, BASE EXCISION REPAIR, P81; Fortini P, 1998, BIOCHEMISTRY-US, V37, P3575, DOI 10.1021/bi972999h; FROSINA G, 1994, BIOCHEM J, V304, P699, DOI 10.1042/bj3040699; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; Jaiswal M, 1998, NUCLEIC ACIDS RES, V26, P2184, DOI 10.1093/nar/26.9.2184; Jonsson ZO, 1997, BIOESSAYS, V19, P967, DOI 10.1002/bies.950191106; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Klungland A, 1999, MOL CELL, V3, P33, DOI 10.1016/S1097-2765(00)80172-0; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; Laval J, 1998, MUTAT RES-FUND MOL M, V402, P93, DOI 10.1016/S0027-5107(97)00286-8; Lu RZ, 1997, CURR BIOL, V7, P397, DOI 10.1016/S0960-9822(06)00187-4; MATSUMOTO Y, 1994, MOL CELL BIOL, V14, P6187, DOI 10.1128/MCB.14.9.6187; Nicholl ID, 1997, BIOCHEMISTRY-US, V36, P7557, DOI 10.1021/bi962950w; OCONNOR TR, 1989, P NATL ACAD SCI USA, V86, P5222, DOI 10.1073/pnas.86.14.5222; Radicella JP, 1997, P NATL ACAD SCI USA, V94, P8010, DOI 10.1073/pnas.94.15.8010; Ramana CV, 1998, P NATL ACAD SCI USA, V95, P5061, DOI 10.1073/pnas.95.9.5061; Reardon JT, 1997, P NATL ACAD SCI USA, V94, P9463, DOI 10.1073/pnas.94.17.9463; RoldanArjona T, 1997, P NATL ACAD SCI USA, V94, P8016, DOI 10.1073/pnas.94.15.8016; Rosenquist TA, 1997, P NATL ACAD SCI USA, V94, P7429, DOI 10.1073/pnas.94.14.7429; ROTHWELL DG, 1997, BASE EXCISION REPAIR, P67; SAPARBAEV M, 1995, NUCLEIC ACIDS RES, V23, P3750, DOI 10.1093/nar/23.18.3750; SAPARBAEV M, 1994, P NATL ACAD SCI USA, V91, P5873, DOI 10.1073/pnas.91.13.5873; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SINGER B, 1992, P NATL ACAD SCI USA, V89, P9386, DOI 10.1073/pnas.89.20.9386; SINGHAL RK, 1995, J BIOL CHEM, V270, P949, DOI 10.1074/jbc.270.2.949; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; Srivastava DK, 1998, J BIOL CHEM, V273, P21203, DOI 10.1074/jbc.273.33.21203; Stucki M, 1998, ONCOGENE, V17, P835, DOI 10.1038/sj.onc.1202001; Wilson SH, 1998, MUTAT RES-DNA REPAIR, V407, P203, DOI 10.1016/S0921-8777(98)00002-0	38	189	194	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					15230	15236		10.1074/jbc.274.21.15230	http://dx.doi.org/10.1074/jbc.274.21.15230			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329732	hybrid			2022-12-25	WOS:000081965200097
J	Kudo, N; Taoka, H; Toda, T; Yoshida, M; Horinouchi, S				Kudo, N; Taoka, H; Toda, T; Yoshida, M; Horinouchi, S			A novel nuclear export signal sensitive to oxidative stress in the fission yeast transcription factor Pap1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORDER CHROMOSOME STRUCTURE; BREFELDIN-A RESISTANCE; REV ACTIVATION DOMAIN; SCHIZOSACCHAROMYCES-POMBE; LEPTOMYCIN-B; SACCHAROMYCES-CEREVISIAE; MAP KINASE; CELL-CYCLE; NUCLEOCYTOPLASMIC TRANSPORT; MUTATIONAL ANALYSIS	Pap1, a fission yeast AP-l-like transcription factor, is negatively regulated by CRM1/exportin 1, the nuclear export factor. Pap1 was localized normally in the cytoplasm but was accumulated in the nucleus when Crm1 was inactivated by a temperature sensitive mutation or by treatment with leptomycin B, a specific export inhibitor. Deletion of the C-terminal cysteine-rich domain (CRD) resulted in nuclear accumulation of Pap1, while a glutathione S-transferase-green fluorescent protein-CRD fusion protein was localized in the cytoplasm in a Crm1-dependent manner. Deletion and mutational analyses identified several important amino acids in a 19-amino acid region in the CRD as a nuclear export signal (NES), Strikingly, a cysteine residue (Cys-532), in addition to two leucines and an isoleucine, was important for the NES function and the presence of at least one of the two cysteine residues was essential. Unlike classical NESs such as the human immunodeficiency virus Rev NES, the Pap1 NES lost the function upon treatment with oxidants such as diethyl maleate. The oxidative stress response is conserved through evolution, as green fluorescent protein-fused proteins bearing the Pap1 NES expressed in mammalian cells responded to diethyl maleate. These results show that the hydrophobic amino acid-rich region containing two important cysteines in Pap1 serves as a novel NES, which is sensitive to oxidative stress.	Univ Tokyo, Grad Sch Agr & Life Sci, Dept Biotechnol, Bunkyo Ku, Tokyo 113, Japan; Imperial Canc Res Fund, Lab Cell Regulat, London WC2A 3PX, England	University of Tokyo; Cancer Research UK	Yoshida, M (corresponding author), Univ Tokyo, Grad Sch Agr & Life Sci, Dept Biotechnol, Bunkyo Ku, Tokyo 113, Japan.	ayoshida@hongo.ecc.u-tokyo.ac.jp	Kudo, Nobuaki/AAU-7196-2021; Yoshida, Minoru/C-8049-2014	Yoshida, Minoru/0000-0002-4376-5674; Kudo, Nobuaki/0000-0001-8134-1242				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ADACHI Y, 1989, J CELL BIOL, V108, P1195, DOI 10.1083/jcb.108.4.1195; Alfa C., 1993, EXPT FISSION YEAST L, P133; ArenzanaSeisdedos F, 1997, J CELL SCI, V110, P369; BASI G, 1993, GENE, V123, P131, DOI 10.1016/0378-1119(93)90552-E; Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; BOSSIER P, 1993, J BIOL CHEM, V268, P23640; Casso D, 1996, MOL GEN GENET, V252, P518, DOI 10.1007/BF02172398; Engel K, 1998, EMBO J, V17, P3363, DOI 10.1093/emboj/17.12.3363; Fernandes L, 1997, MOL CELL BIOL, V17, P6982, DOI 10.1128/MCB.17.12.6982; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1996, J BIOL CHEM, V271, P20024, DOI 10.1074/jbc.271.33.20024; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0; Hagting A, 1998, EMBO J, V17, P4127, DOI 10.1093/emboj/17.14.4127; HAMAMOTO T, 1983, J ANTIBIOT, V36, P639, DOI 10.7164/antibiotics.36.639; HIRATA D, 1994, MOL GEN GENET, V242, P250, DOI 10.1007/BF00280413; Kato T, 1996, FEBS LETT, V378, P207, DOI 10.1016/0014-5793(95)01442-X; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Kudo N, 1997, J BIOL CHEM, V272, P29742, DOI 10.1074/jbc.272.47.29742; Kuge S, 1998, GENES CELLS, V3, P521, DOI 10.1046/j.1365-2443.1998.00209.x; KUGE S, 1994, EMBO J, V13, P655, DOI 10.1002/j.1460-2075.1994.tb06304.x; Kuge S, 1997, EMBO J, V16, P1710, DOI 10.1093/emboj/16.7.1710; KULLIK I, 1995, J BACTERIOL, V177, P1285, DOI 10.1128/jb.177.5.1285-1291.1995; Kumada K, 1996, MOL GEN GENET, V250, P59, DOI 10.1007/s004380050051; Lee J, 1997, J BIOL CHEM, V272, P23042, DOI 10.1074/jbc.272.37.23042; Li YZ, 1998, P NATL ACAD SCI USA, V95, P4864, DOI 10.1073/pnas.95.9.4864; MALIM MH, 1991, J VIROL, V65, P4248, DOI 10.1128/JVI.65.8.4248-4254.1991; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; MILLAR JBA, 1995, GENE DEV, V9, P2117, DOI 10.1101/gad.9.17.2117; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P6532, DOI 10.1073/pnas.92.14.6532; MOYEROWLEY WS, 1989, GENE DEV, V3, P283, DOI 10.1101/gad.3.3.283; NAGAO K, 1995, J BACTERIOL, V177, P1536, DOI 10.1128/jb.177.6.1536-1543.1995; NAKAGAWA CW, 1995, J BIOCHEM-TOKYO, V118, P109, DOI 10.1093/oxfordjournals.jbchem.a124864; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; NISHI K, 1994, J BIOL CHEM, V269, P6320; NISHI K, 1992, MOL MICROBIOL, V6, P761, DOI 10.1111/j.1365-2958.1992.tb01526.x; NUNOSHIBA T, 1994, NUCLEIC ACIDS RES, V22, P2958, DOI 10.1093/nar/22.15.2958; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Pemberton LF, 1998, CURR OPIN CELL BIOL, V10, P392, DOI 10.1016/S0955-0674(98)80016-1; SCHNELL N, 1992, CURR GENET, V21, P269, DOI 10.1007/BF00351681; SHIOZAKI K, 1995, NATURE, V378, P739, DOI 10.1038/378739a0; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Sun Y, 1996, FREE RADICAL BIO MED, V21, P335, DOI 10.1016/0891-5849(96)00109-8; Takeuchi T, 1997, FEBS LETT, V416, P339, DOI 10.1016/S0014-5793(97)01233-7; TODA T, 1991, GENE DEV, V5, P60, DOI 10.1101/gad.5.1.60; TODA T, 1992, MOL CELL BIOL, V12, P5474, DOI 10.1128/MCB.12.12.5474; Toone WM, 1998, GENE DEV, V12, P1453, DOI 10.1101/gad.12.10.1453; Toyoshima F, 1998, EMBO J, V17, P2728, DOI 10.1093/emboj/17.10.2728; TURI TG, 1995, BIOCHEM BIOPH RES CO, V213, P410, DOI 10.1006/bbrc.1995.2147; Ullman KS, 1997, CELL, V90, P967, DOI 10.1016/S0092-8674(00)80361-X; WEMMIE A, 1994, J BIOL CHEM, V269, P14690; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; WU AL, 1993, J BIOL CHEM, V268, P18850; WU AL, 1994, MOL CELL BIOL, V14, P5832, DOI 10.1128/MCB.14.9.5832; Yang J, 1998, GENE DEV, V12, P2131, DOI 10.1101/gad.12.14.2131; Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087; YOSHIDA M, 1990, EXP CELL RES, V187, P150, DOI 10.1016/0014-4827(90)90129-X	61	117	120	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					15151	15158		10.1074/jbc.274.21.15151	http://dx.doi.org/10.1074/jbc.274.21.15151			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329722	hybrid			2022-12-25	WOS:000081965200087
J	Kwok, Y; Zeng, QP; Hurley, LH				Kwok, Y; Zeng, QP; Hurley, LH			Structural insight into a quinolone-topoisomerase II-DNA complex - Further evidence for a 2 : 2 quinobenzoxazine-Mg2+ self-assembly model formed in the presence of topoisomerase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED ALKYLATION; ANTINEOPLASTIC AGENTS; ANTITUMOR ACTIVITIES; MECHANISM; CLEAVAGE; BINDING; DRUGS; PSOROSPERMIN; GYRASE; ANTIBACTERIALS	Quinobenzoxazine A-62176, developed from the antibacterial fluoroquinolones, is active in vitro and in vivo against murine and human tumors. It has been previously claimed that A-62176 is a catalytic inhibitor of mammalian topoisomerase II that does not stabilize the cleaved complex. However, at low drug concentrations and pH 6-7, we have found that A-62176 can enhance the formation of the cleaved complex at certain sites. Using a photocleavage assay, mismatched sequences, and competition experiments between psorospermin and A-62176, we pinpointed the drug binding site on the DNA base pairs between positions +1 and +2 relative to the cleaved phosphodiester bonds. A 2:2 quinobenzoxazine-Mg2+ self-assembly model was previously proposed, in which one drug molecule intercalates into the DNA helix and the second drug molecule is externally bound, held to the first molecule and DNA by two Mg2+ bridges, The results of competition experiments between psorospermin and A-62176, as well as between psorospermin and A-62176 and norfloxacin, are consistent with this model and provide the first evidence that this 2:2 quinobenzoxazine-Mg2+ complex is assembled in the presence of topoisomerase II. These results also have parallel implications for the mode of binding of the quinolone antibiotics to the bacterial gyrase-DNA complex.	Univ Texas, Coll Pharm, Drugs Dynam Inst, Austin, TX 78712 USA	University of Texas System; University of Texas Austin	Hurley, LH (corresponding author), Univ Texas, Coll Pharm, Drugs Dynam Inst, Austin, TX 78712 USA.				NCI NIH HHS [CA-49751] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA049751, R35CA049751] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARNOTT S, 1980, NATURE, V287, P561, DOI 10.1038/287561a0; Bigioni M, 1996, BIOCHEMISTRY-US, V35, P153, DOI 10.1021/bi951736p; BOND PJ, 1975, P NATL ACAD SCI USA, V72, P4825, DOI 10.1073/pnas.72.12.4825; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; CHU DTW, 1987, J HETEROCYCLIC CHEM, V24, P453, DOI 10.1002/jhet.5570240228; CHU DTW, 1992, DRUG EXP CLIN RES, V18, P275; CHU DTW, 1994, DRUG EXP CLIN RES, V20, P177; CLEMENT JJ, 1995, CANCER RES, V55, P830; CORBETT AH, 1993, CHEM RES TOXICOL, V6, P585, DOI 10.1021/tx00035a001; DARPA P, 1989, BIOCHIM BIOPHYS ACTA, V989, P163, DOI 10.1016/0304-419X(89)90041-3; FAN JY, 1995, J MED CHEM, V38, P408, DOI 10.1021/jm00003a003; FREUDENREICH CH, 1994, P NATL ACAD SCI USA, V91, P11007, DOI 10.1073/pnas.91.23.11007; Hansen M, 1996, J AM CHEM SOC, V118, P5553; Kingma PS, 1998, J BIOL CHEM, V273, P17999, DOI 10.1074/jbc.273.29.17999; Kwok Y, 1998, J BIOL CHEM, V273, P33020, DOI 10.1074/jbc.273.49.33020; Kwok Y, 1998, P NATL ACAD SCI USA, V95, P13531, DOI 10.1073/pnas.95.23.13531; LEE MP, 1989, J BIOL CHEM, V264, P21779; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; Marians KJ, 1997, J BIOL CHEM, V272, P9401; Maxam A M, 1980, Methods Enzymol, V65, P499; Osheroff N, 1994, Adv Pharmacol, V29B, P105; PALU G, 1992, P NATL ACAD SCI USA, V89, P9671, DOI 10.1073/pnas.89.20.9671; Palumbo M, 1993, Trends Microbiol, V1, P232, DOI 10.1016/0966-842X(93)90138-H; PERMANA PA, 1994, BIOCHEMISTRY-US, V33, P11333, DOI 10.1021/bi00203a031; POMMIER Y, 1993, CANCER CHEMOTH PHARM, V32, P103, DOI 10.1007/BF00685611; Pommier Yves, 1997, P153; ROBINSON MJ, 1991, J BIOL CHEM, V266, P14585; SHEN LL, 1989, BIOCHEMISTRY-US, V28, P3886, DOI 10.1021/bi00435a039; SHEN LL, 1989, BIOCHEMISTRY-US, V28, P3879, DOI 10.1021/bi00435a038; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WATT PM, 1994, BIOCHEM J, V303, P681, DOI 10.1042/bj3030681	31	28	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17226	17235		10.1074/jbc.274.24.17226	http://dx.doi.org/10.1074/jbc.274.24.17226			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358081	hybrid			2022-12-25	WOS:000080780400080
J	Lehtonen, JYA; Horiuchi, M; Daviet, L; Akishita, M; Dzau, VJ				Lehtonen, JYA; Horiuchi, M; Daviet, L; Akishita, M; Dzau, VJ			Activation of the de novo biosynthesis of sphingolipids mediates angiotensin II type 2 receptor-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED NEURONS; SERINE PALMITOYLTRANSFERASE; CERAMIDE BIOSYNTHESIS; TYROSINE-PHOSPHATASE; FUSARIUM-MONILIFORME; CELL-PROLIFERATION; SPHINGOID BASES; WEHI-231 CELLS; INHIBITION; DEATH	This study examines the role of sphingolipids in mediating the apoptosis of PC12W cells induced by the angiotensin II type 2 (AT(2)) receptor. PC12W cells express abundant AT(2) receptor but not angiotensin II type 1 receptor and undergo apoptosis when stimulated by angiotensin II. AT(2) receptor-induced ceramide accumulation preceded the onset of caspase 3 activation and DNA fragmentation. AT(2) receptor-induced ceramide accumulation did not result from the degradation of complex sphingolipids (SL) such as sphingomyelin or glycosphingolipids, as no changes in neutral or acidic sphingomyelinase activities, sphingomyelin level, nor in cellular glycolipid composition were observed. AT(2) receptor activated serine palmitoyltransferase with a maximum time of 24 h after angiotensin II stimulation. The AT(2) receptor-induced accumulation of ceramide was blocked by inhibitors of the de novo pathway of SL synthesis, beta-chloro-L-alanine and fumonisin B-1. Inhibition of the de novo biosynthesis of SLs by fumonisin B-1 and beta-chloro-L-alanine completely abrogated the AT(2) receptor-mediated apoptosis, Pertussis toxin and orthovanadate blocked AT(2) receptor-mediated ceramide production. Taken together our data demonstrate that in PC12W cells the stimulation of AT(2) receptor induces the activation of de novo pathway, and a metabolite of this pathway, possibly ceramide, mediates AT(2) receptor-induced apoptosis.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Dzau, VJ (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, 75 Francis St, Boston, MA 02115 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL035610, R01HL035610, R01HL046631, R01HL035252] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL35610, HL35252, HL46631] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bedecs K, 1997, BIOCHEM J, V325, P449, DOI 10.1042/bj3250449; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Booz GW, 1996, HYPERTENSION, V28, P635, DOI 10.1161/01.HYP.28.4.635; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; DOSTAL DE, 1992, AM J PHYSIOL, V263, pC851, DOI 10.1152/ajpcell.1992.263.4.C851; DRESSLER KA, 1990, J BIOL CHEM, V265, P14917; Gamard CJ, 1997, J BIOL CHEM, V272, P16474, DOI 10.1074/jbc.272.26.16474; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Horiuchi M, 1997, J BIOL CHEM, V272, P19022, DOI 10.1074/jbc.272.30.19022; KAMBAYASHI Y, 1993, J BIOL CHEM, V268, P24543; MANDON EC, 1991, EUR J BIOCHEM, V198, P667, DOI 10.1111/j.1432-1033.1991.tb16065.x; MEDLOCK KA, 1988, BIOCHEMISTRY-US, V27, P7079, DOI 10.1021/bi00418a061; MERRILL AH, 1993, J BIOL CHEM, V268, P27299; MERRILL AH, 1992, METHOD ENZYMOL, V209, P427; MERRILL AH, 1986, J BIOL CHEM, V261, P3764; Michel C, 1997, J BIOL CHEM, V272, P22432, DOI 10.1074/jbc.272.36.22432; MUKOYAMA M, 1993, J BIOL CHEM, V268, P24539; NikolovaKarakashian M, 1997, J BIOL CHEM, V272, P18718, DOI 10.1074/jbc.272.30.18718; OLIVERA A, 1994, ANAL BIOCHEM, V223, P306, DOI 10.1006/abio.1994.1589; QUINTANS J, 1994, BIOCHEM BIOPH RES CO, V202, P710, DOI 10.1006/bbrc.1994.1988; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; SCHROEDER JJ, 1994, J BIOL CHEM, V269, P3475; Smith ER, 1997, J BIOL CHEM, V272, P5640, DOI 10.1074/jbc.272.9.5640; SPETH RC, 1990, BIOCHEM BIOPH RES CO, V169, P997, DOI 10.1016/0006-291X(90)91993-3; STOLL M, 1995, J CLIN INVEST, V95, P651, DOI 10.1172/JCI117710; Tepper AD, 1997, J BIOL CHEM, V272, P24308, DOI 10.1074/jbc.272.39.24308; TILLY JL, 1993, J CELL PHYSIOL, V154, P519, DOI 10.1002/jcp.1041540310; Tsuzuki S, 1996, BIOCHEM BIOPH RES CO, V228, P825, DOI 10.1006/bbrc.1996.1739; Van Brocklyn JR, 1998, J CELL BIOL, V142, P229, DOI 10.1083/jcb.142.1.229; VANECHTEN G, 1990, J BIOL CHEM, V265, P9333; WANG E, 1991, J BIOL CHEM, V266, P14486; Wiesner DA, 1997, J BIOL CHEM, V272, P9868; WILLIAMS MA, 1980, J NEUROCHEM, V35, P266, DOI 10.1111/j.1471-4159.1980.tb12515.x; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xu J, 1998, J BIOL CHEM, V273, P16521, DOI 10.1074/jbc.273.26.16521; Yamada T, 1996, P NATL ACAD SCI USA, V93, P156, DOI 10.1073/pnas.93.1.156	36	88	93	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16901	16906		10.1074/jbc.274.24.16901	http://dx.doi.org/10.1074/jbc.274.24.16901			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358036	hybrid			2022-12-25	WOS:000080780400035
J	Olayioye, MA; Beuvink, I; Horsch, K; Daly, JM; Hynes, NE				Olayioye, MA; Beuvink, I; Horsch, K; Daly, JM; Hynes, NE			ErbB receptor-induced activation of Stat transcription factors is mediated by Src tyrosine kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; MAMMARY EPITHELIAL-CELLS; DNA-BINDING ACTIVITY; C-SRC; PHOSPHATIDYLINOSITOL 3-KINASE; FAMILY KINASES; V-SRC; SIGNAL-TRANSDUCTION; INTERFERON RECEPTOR; BREAST-CANCER	Epidermal growth factor (EGF) binding to its receptor, ErbB1, triggers various signal transduction pathways, one of which leads to the activation of signal transducer and activator of transcription (Stat) factors. The mechanism underlying ErbB1-induced Stat activation and whether Stats are downstream targets of other ErbB receptors have not been explored. In this report we show that ErbB2, ErbB3, and ErbB4 do not potentiate Stat5 phosphorylation by EGF, However, neu differentiation factor-induced heterodimers of ErbB2 and ErbB4 activated Stat5. In A431 cells, Stat1, Stat3, and Stat5, were constitutively complexed with ErbB1 and rapidly phosphorylated on tyrosine in response to EGF. Neither mutation of the conserved tyrosine residue (Tyr(694)) nor inactivation of the Stat5a SH2 domain disrupted this association. However, an intact SH2 domain was necessary for EGF-induced Stat5a phosphorylation, In contrast to prolactin, which induced only Tyr(694) phosphorylation of Stat5a, EGF promoted phosphorylation on Tyr(694) and additional tyrosine residue(s). Janus kinases (Jaks) were also constitutively associated with ErbB receptors and were phosphorylated in response to EGF-related ligands, However, we provide evidence that EGF- and neu differentiation factor-induced Stat activation are dependent on Src but not Jak kinases. Upon EGF stimulation, c-Src was rapidly recruited to Stat/ ErbB receptor complexes. Pharmacological Src kinase inhibitors and a dominant negative c-Src ablated both Stat and Jak tyrosine phosphorylation, However, dominant negative Jaks did not affect EGF-induced Stat phosphorylation, Taken together, the experiments establish two independent roles for Src kinases: (i) key molecules in ErbB receptor-mediated Stat signaling and (ii) potential upstream regulators of Jak kinases.	Friedrich Miescher Inst, CH-4002 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research	Hynes, NE (corresponding author), Friedrich Miescher Inst, POB 2543, CH-4002 Basel, Switzerland.	hynes@fmi.ch						BELSCHES AP, 1997, FRONT BIOSCI, V2, P501; Biscardi JS, 1998, MOL CARCINOGEN, V21, P261, DOI 10.1002/(SICI)1098-2744(199804)21:4<261::AID-MC5>3.0.CO;2-N; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Burden S, 1997, NEURON, V18, P847, DOI 10.1016/S0896-6273(00)80324-4; Campbell GS, 1997, J BIOL CHEM, V272, P2591, DOI 10.1074/jbc.272.5.2591; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Cella N, 1998, MOL CELL BIOL, V18, P1783, DOI 10.1128/MCB.18.4.1783; Chaturvedi P, 1998, ONCOGENE, V16, P1749, DOI 10.1038/sj.onc.1201972; Chaturvedi P, 1997, MOL CELL BIOL, V17, P3295, DOI 10.1128/MCB.17.6.3295; DALY JM, 1999, IN PRESS ONCOGENE; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; David M, 1996, J BIOL CHEM, V271, P9185, DOI 10.1074/jbc.271.16.9185; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; FLIER JS, 1989, NEW ENGL J MED, V321, P1383, DOI 10.1056/NEJM198911163212007; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; GRONER B, 1995, CURR OPIN GENET DEV, V5, P587, DOI 10.1016/0959-437X(95)80027-1; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HARWERTH IM, 1992, J BIOL CHEM, V267, P15160; Horvath CM, 1997, CURR OPIN CELL BIOL, V9, P233, DOI 10.1016/S0955-0674(97)80067-1; HYNES NE, 1989, J CELL BIOCHEM, V39, P167, DOI 10.1002/jcb.240390208; JOHNSTON JA, 1995, J BIOL CHEM, V270, P28527, DOI 10.1074/jbc.270.48.28527; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KIM HH, 1994, J BIOL CHEM, V269, P24747; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; Leaman DW, 1996, MOL CELL BIOL, V16, P369; Leaman DW, 1996, FASEB J, V10, P1578, DOI 10.1096/fasebj.10.14.9002549; Li XX, 1997, MOL CELL BIOL, V17, P2048, DOI 10.1128/MCB.17.4.2048; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; MISSBACH M, 1999, IN PRESS BONE NY; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P1801; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P271; Olayioye MA, 1998, MOL CELL BIOL, V18, P5042, DOI 10.1128/MCB.18.9.5042; OSHEROV N, 1994, EUR J BIOCHEM, V225, P1047, DOI 10.1111/j.1432-1033.1994.1047b.x; Park OK, 1996, P NATL ACAD SCI USA, V93, P13704, DOI 10.1073/pnas.93.24.13704; Pfeffer LM, 1997, SCIENCE, V276, P1418, DOI 10.1126/science.276.5317.1418; QUELLE FW, 1995, J BIOL CHEM, V270, P20775, DOI 10.1074/jbc.270.35.20775; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; RUFFJAMISON S, 1995, P NATL ACAD SCI USA, V92, P4215, DOI 10.1073/pnas.92.10.4215; Sakatsume M, 1998, J BIOL CHEM, V273, P3021, DOI 10.1074/jbc.273.5.3021; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; Stancato LF, 1997, MOL CELL BIOL, V17, P3833, DOI 10.1128/MCB.17.7.3833; STOVER DR, 1995, J BIOL CHEM, V270, P15591, DOI 10.1074/jbc.270.26.15591; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; VANDERKUUR J, 1995, J BIOL CHEM, V270, P7587, DOI 10.1074/jbc.270.13.7587; Venema RC, 1998, J BIOL CHEM, V273, P30795, DOI 10.1074/jbc.273.46.30795; Vignais ML, 1996, MOL CELL BIOL, V16, P1759; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; Wartmann M, 1996, J BIOL CHEM, V271, P31863, DOI 10.1074/jbc.271.50.31863; WASILENKO WJ, 1991, MOL CELL BIOL, V11, P309, DOI 10.1128/MCB.11.1.309; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	63	296	305	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17209	17218		10.1074/jbc.274.24.17209	http://dx.doi.org/10.1074/jbc.274.24.17209			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358079	hybrid			2022-12-25	WOS:000080780400078
J	Lee, J; Godon, C; Lagniel, G; Spector, D; Garin, J; Labarre, J; Toledano, MB				Lee, J; Godon, C; Lagniel, G; Spector, D; Garin, J; Labarre, J; Toledano, MB			Yap1 and Skn7 control two specialized oxidative stress response regulons in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIOL-SPECIFIC ANTIOXIDANT; PENTOSE-PHOSPHATE PATHWAY; SACCHAROMYCES-CEREVISIAE; HYDROGEN-PEROXIDE; TRANSCRIPTION FACTOR; BUDDING YEAST; SUPEROXIDE-DISMUTASE; METAL RESISTANCE; BZIP PROTEINS; TARGET GENE	Yap1 and Skn7 are two yeast transcriptional regulators that co-operate to activate thioredoxin (TRX2) and thioredoxin reductase (TRR1) in response to redox stress signals. Although they are both important for re sistance to H2O2, only Yap1 is important for cadmium resistance, whereas Skn7 has a negative effect upon this response. The respective roles of Yap1 and Skn7 in the induction of defense genes by H2O2 were analyzed by two-dimensional gel electrophoresis. Yap1 controls a large oxidative stress response regulon of at least 32 proteins. Fifteen of these proteins also require the presence of Skn7 for their induction by H2O2. Although about half of the Yap1 target genes do not contain a consensus Yap1 recognition motif, the control of one such gene, TSA1, involves the binding of Yap1 and Skn7 to its promoter in vitro. The co-operative control of the oxidative stress response by Yap1 and Skn7 delineates two gene subsets. Remarkably, these two gene subsets separate antioxidant scavenging enzymes from the metabolic pathways regenerating the main cellular reducing power, glutathione and NADPH. Such a specialization may explain, at least in part, the dissociated function of Yap1 and Skn7 in H2O2 and cadmium resistance.	CEA Saclay, Serv Biochim & Genet Mol, F-91191 Gif Sur Yvette, France; Rutgers State Univ, Coll Pharm, Dept Pharmacol & Toxicol, Piscataway, NJ 08855 USA; CEA, Dept Biol Mol & Struct, F-38054 Grenoble, France	CEA; UDICE-French Research Universities; Universite Paris Saclay; Rutgers State University New Brunswick; CEA	Toledano, MB (corresponding author), CEA Saclay, Serv Biochim & Genet Mol, Batiment 142, F-91191 Gif Sur Yvette, France.							BABIYCHUK E, 1995, J BIOL CHEM, V270, P26224, DOI 10.1074/jbc.270.44.26224; Brennan RJ, 1996, MUTAT RES-FUND MOL M, V356, P171, DOI 10.1016/0027-5107(96)00051-6; BROWN JL, 1993, J BACTERIOL, V175, P6908, DOI 10.1128/jb.175.21.6908-6915.1993; BROWN JL, 1994, EMBO J, V13, P5186, DOI 10.1002/j.1460-2075.1994.tb06849.x; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; CHAE HZ, 1994, BIOFACTORS, V4, P177; COLLINSON LP, 1992, J GEN MICROBIOL, V138, P329, DOI 10.1099/00221287-138-2-329; DEMPLE B, 1991, ANNU REV GENET, V25, P315, DOI 10.1146/annurev.ge.25.120191.001531; Fernandes L, 1997, MOL CELL BIOL, V17, P6982, DOI 10.1128/MCB.17.12.6982; FLATTERYOBRIEN J, 1993, J GEN MICROBIOL, V139, P501, DOI 10.1099/00221287-139-3-501; Godon C, 1998, J BIOL CHEM, V273, P22480, DOI 10.1074/jbc.273.35.22480; GRALLA EB, 1991, J BACTERIOL, V173, P5918, DOI 10.1128/jb.173.18.5918-5920.1991; GRANDORI R, 1994, PROTEIN SCI, V3, P2185, DOI 10.1002/pro.5560031204; Grant CM, 1996, CURR GENET, V29, P511, DOI 10.1007/BF02426954; Grant CM, 1996, MOL MICROBIOL, V21, P171, DOI 10.1046/j.1365-2958.1996.6351340.x; GUTHRIE C, 1991, METHOD ENZYMOL, V194, P182; HALLIWELL B, 1994, NUTR REV, V52, P253; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HIRATA D, 1994, MOL GEN GENET, V242, P250, DOI 10.1007/BF00280413; IZAWA S, 1995, FEBS LETT, V368, P73, DOI 10.1016/0014-5793(95)00603-7; Izawa S, 1996, BIOCHEM J, V320, P61, DOI 10.1042/bj3200061; JAMIESON DJ, 1992, J BACTERIOL, V174, P6678, DOI 10.1128/JB.174.20.6678-6681.1992; Juhnke H, 1996, MOL GEN GENET, V252, P456, DOI 10.1007/BF02173011; Ketela T, 1998, MOL GEN GENET, V259, P372, DOI 10.1007/s004380050824; KREMS B, 1995, CURR GENET, V27, P427, DOI 10.1007/BF00311211; Krems B, 1996, CURR GENET, V29, P327, DOI 10.1007/s002940050053; Kuge S, 1998, GENES CELLS, V3, P521, DOI 10.1046/j.1365-2443.1998.00209.x; KUGE S, 1994, EMBO J, V13, P655, DOI 10.1002/j.1460-2075.1994.tb06304.x; Kuge S, 1997, EMBO J, V16, P1710, DOI 10.1093/emboj/16.7.1710; KULLIK I, 1994, REDOX REPORT, V1, P1; KWON SJ, 1994, BIOCHEM BIOPH RES CO, V201, P8, DOI 10.1006/bbrc.1994.1662; Lee J, 1999, J BIOL CHEM, V274, P4537, DOI 10.1074/jbc.274.8.4537; Li ZS, 1996, J BIOL CHEM, V271, P6509, DOI 10.1074/jbc.271.11.6509; Li ZS, 1997, P NATL ACAD SCI USA, V94, P42, DOI 10.1073/pnas.94.1.42; MORGAN BA, 1995, EMBO J, V14, P5679, DOI 10.1002/j.1460-2075.1995.tb00255.x; Morgan BA, 1997, EMBO J, V16, P1035, DOI 10.1093/emboj/16.5.1035; MOYEROWLEY WS, 1989, GENE DEV, V3, P283, DOI 10.1101/gad.3.3.283; Netto LES, 1996, J BIOL CHEM, V271, P15315, DOI 10.1074/jbc.271.26.15315; NOGAE I, 1990, GENE, V96, P161, DOI 10.1016/0378-1119(90)90248-P; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAAFFGERSTENSCHLAGER I, 1993, CURR GENET, V24, P373, DOI 10.1007/BF00351843; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SCHNELL N, 1992, CURR GENET, V21, P269, DOI 10.1007/BF00351681; SIKORSKI RS, 1989, GENETICS, V122, P19; SINGHAL RK, 1987, FASEB J, V1, P220, DOI 10.1096/fasebj.1.3.2887478; STEPHEN DWS, 1995, MOL MICROBIOL, V16, P415, DOI 10.1111/j.1365-2958.1995.tb02407.x; Stephen DWS, 1996, FEMS MICROBIOL LETT, V141, P207, DOI 10.1111/j.1574-6968.1996.tb08386.x; STORZ G, 1990, TRENDS GENET, V6, P363, DOI 10.1016/0168-9525(90)90278-E; SZCZYPKA MS, 1994, J BIOL CHEM, V269, P22853; TOLEDANO MB, 1994, CELL, V78, P897, DOI 10.1016/S0092-8674(94)90702-1; VANLOON APGM, 1986, P NATL ACAD SCI USA, V83, P3820; WEMMIE JA, 1994, J BIOL CHEM, V269, P32592; WU AL, 1993, J BIOL CHEM, V268, P18850; WU AL, 1994, MOL CELL BIOL, V14, P5832, DOI 10.1128/MCB.14.9.5832; Zheng M, 1998, SCIENCE, V279, P1718, DOI 10.1126/science.279.5357.1718	56	453	469	0	57	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16040	16046		10.1074/jbc.274.23.16040	http://dx.doi.org/10.1074/jbc.274.23.16040			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347154	hybrid			2022-12-25	WOS:000080668600014
J	Miura, D; Manabe, K; Ozono, K; Saito, M; Gao, QZ; Norman, AW; Ishizuka, S				Miura, D; Manabe, K; Ozono, K; Saito, M; Gao, QZ; Norman, AW; Ishizuka, S			Antagonistic action of novel 1 alpha,25-dihydroxyvitamin D-3-26,23-lactone analogs on differentiation of human leukemia cells (HL-60) induced by 1 alpha,25-dihydroxyvitamin D-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITAMIN-D-RECEPTOR; BIOLOGICAL-ACTIVITY ASSESSMENT; 1,25-DIHYDROXYVITAMIN D-3; 24-HYDROXYLASE GENE; RAT; IDENTIFICATION; METABOLITES; RESPONSES; GROWTH; LINE	We examined the effects of two novel 1 alpha,25-dihydroxyvitamin D-3-26,23-lactone (1 alpha,25-lactone) analogues on human promyelocytic leukemia cell (HL-60) differentiation using the evaluation system of the vitamin D nuclear receptor (VDR)/vitamin D-responsive element (DRE)-mediated genomic action stimulated by 1 alpha,25-dihydroxyvitamin D-3 (1 alpha,25(OH)(2)D-3) and its analogues. We found that the 1 alpha,25-lactone analogues (23S)-25-dehydro-1 alpha-hydroxyvitamin-D-3-26,23-lactone (TEI-9647), and (23R)-25-dehydro-1 alpha-hydroxyvitamin-D3-26,23-lactone (TEI-9648) bound much more strongly to the VDR than the natural (23S,25R)-1 alpha,25(OH)(2)D-3-26,23-lactone, but did not induce cell differentiation even at high concentrations (10(-6) M). Intriguingly, the differentiation of HL-60 cells induced by 1 alpha,25(OH)(2)D-3 was inhibited by either TEI-9647 or TEI-9648 but not by the natural lactone. In contrast, retinoic acid or 12-O-tetradecanoylphorbol-13- acetate-induced HL-60 cell differentiation was not blocked by TEI-9647 or TEI-9648. In separate studies, TEI-9647 (10(-7) M) was found to be an effective antagonist of both 1 alpha,25(OH)(2)D-3 (10(-8) M) mediated induction of p21(WAF1,CIP1) in HL-60 cells and activation of the luciferase reporter assay in COS-7 cells transfected with cDNA containing the DRE of the rat 25(OH)D-3-24-hydroxylase gene and cDNA of the human VDR. Collectively the results strongly suggest that our novel 1 alpha,25-1actone analogues, TEI-9647 and TEI-9648, are specific antagonists of 1 alpha,25(OH)(2)D-3 action, specifically VDR/DRE-mediated genomic action. As such, they represent the first examples of antagonists, which act on the nuclear VDR.	Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA; Univ Calif Riverside, Div Biomed Sci, Riverside, CA 92521 USA; Osaka Med Ctr Maternal & Child Hlth, Dept Environm Med Res Inst, Osaka 5941101, Japan; Teijin Inst Biomed Res, Dept Bone & Calcium Metab, Tokyo 1918512, Japan; Teijin Inst Biomed Res, Safety Res Dept, Tokyo 1918512, Japan	University of California System; University of California Riverside; University of California System; University of California Riverside	Norman, AW (corresponding author), Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA.							ABE E, 1981, P NATL ACAD SCI-BIOL, V78, P4990, DOI 10.1073/pnas.78.8.4990; Baudino TA, 1998, J BIOL CHEM, V273, P16434, DOI 10.1074/jbc.273.26.16434; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BINDERUP L, 1991, BIOCHEM PHARMACOL, V42, P1569, DOI 10.1016/0006-2952(91)90426-6; BOUILLON R, 1995, ENDOCR REV, V16, P200, DOI 10.1210/er.16.2.200; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; CADE C, 1987, ENDOCRINOLOGY, V120, P1490, DOI 10.1210/endo-120-4-1490; COLLINS SJ, 1979, J EXP MED, V149, P969, DOI 10.1084/jem.149.4.969; COLLINS SJ, 1987, BLOOD, V70, P1233; EISMAN JA, 1976, ARCH BIOCHEM BIOPHYS, V176, P235, DOI 10.1016/0003-9861(76)90161-2; Gill RK, 1998, MOL ENDOCRINOL, V12, P57, DOI 10.1210/mend.12.1.0048; Haussler MR, 1998, J BONE MINER RES, V13, P325, DOI 10.1359/jbmr.1998.13.3.325; HAUSSLER MR, 1986, ANNU REV NUTR, V6, P527, DOI 10.1146/annurev.nu.06.070186.002523; HONDA A, 1993, BIOCHEM J, V295, P509, DOI 10.1042/bj2950509; HONDA A, 1992, J STEROID BIOCHEM, V41, P109, DOI 10.1016/0960-0760(92)90231-7; INABA M, 1989, BIOCHIM BIOPHYS ACTA, V1010, P20, DOI 10.1016/0167-4889(89)90179-1; INABA M, 1991, ARCH BIOCHEM BIOPHYS, V284, P257, DOI 10.1016/0003-9861(91)90293-R; ISHIZUKA S, 1984, BIOCHEMISTRY-US, V23, P1473, DOI 10.1021/bi00302a021; ISHIZUKA S, 1984, J STEROID BIOCHEM, V20, P611; ISHIZUKA S, 1987, J BIOL CHEM, V262, P7165; ISHIZUKA S, 1981, FEBS LETT, V134, P207, DOI 10.1016/0014-5793(81)80603-5; ISHIZUKA S, 1985, ARCH BIOCHEM BIOPHYS, V242, P82, DOI 10.1016/0003-9861(85)90482-5; ISHIZUKA S, 1990, ENDOCRINOLOGY, V127, P695, DOI 10.1210/endo-127-2-695; ISHIZUKA S, 1988, ENDOCRINOLOGY, V123, P781, DOI 10.1210/endo-123-2-781; ISHIZUKA S, 1988, MOL CELL ENDOCRINOL, V55, P7; ISHIZUKA S, 1997, VITAMIN D CHEM BIOL, P683; ISHIZUKA S, 1988, VITAMIN D MOL CELLUL, P143; KIYOKI M, 1985, BIOCHEM BIOPH RES CO, V127, P693, DOI 10.1016/S0006-291X(85)80217-5; LEE YS, 1989, J BIOL CHEM, V264, P13701; LEMIRE JM, 1995, J NUTR, V125, pS1704, DOI 10.1093/jn/125.suppl_6.1704S; Liu YY, 1997, J BIOL CHEM, V272, P3336, DOI 10.1074/jbc.272.6.3336; MANABE K, 1997, VITAMIN D CHEM BIOL, P79; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; NEMERE I, 1991, HDB PHYSL; NEVEU I, 1994, J NEUROSCI RES, V38, P214, DOI 10.1002/jnr.490380212; NORMAN AW, 1980, SCIENCE, V209, P823, DOI 10.1126/science.6250216; NORMAN AW, 1993, J BIOL CHEM, V268, P20022; Norman AW, 1997, MOL ENDOCRINOL, V11, P1518, DOI 10.1210/me.11.10.1518; Ohyama Y, 1996, J BIOL CHEM, V271, P30381, DOI 10.1074/jbc.271.48.30381; OHYAMA Y, 1994, J BIOL CHEM, V269, P10545; ONISKO BL, 1980, BIOCHEMISTRY-US, V19, P4124, DOI 10.1021/bi00558a034; Pike J. W., 1997, Vitamin D., P105; REDDY GS, 1987, J BONE MINER RES S, V2, P36; ROVERA G, 1979, P NATL ACAD SCI USA, V76, P2779, DOI 10.1073/pnas.76.6.2779; SONG X, 1997, ENDOCRINOLOGY, V139, P457; WION D, 1991, J NEUROSCI RES, V28, P110, DOI 10.1002/jnr.490280111; YOSHIDA M, 1984, J PHARMACOBIO-DYNAM, V7, P962; Zanello LP, 1997, J BIOL CHEM, V272, P22617, DOI 10.1074/jbc.272.36.22617; ZHOU JY, 1989, BLOOD, V74, P82; ZIEROLD C, 1995, J BIOL CHEM, V270, P1675, DOI 10.1074/jbc.270.4.1675	51	105	110	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16392	16399		10.1074/jbc.274.23.16392	http://dx.doi.org/10.1074/jbc.274.23.16392			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347199	hybrid			2022-12-25	WOS:000080668600059
J	Taniura, H; Matsumoto, K; Yoshikawa, K				Taniura, H; Matsumoto, K; Yoshikawa, K			Physical and functional interactions of neuronal growth suppressor necdin with p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRADER-WILLI-SYNDROME; EMBRYONAL CARCINOMA-CELLS; NUCLEAR-PROTEIN; P53-MEDIATED APOPTOSIS; TUMOR SUPPRESSION; GENE; EXPRESSION; MOUSE; ONCOPROTEIN; REGION	Necdin is expressed in virtually all postmitotic neurons, and ectopic expression of this protein suppresses cell proliferation. Necdin, like the retinoblastoma protein, interacts with cell cycle promoting proteins such as simian virus 40 large T antigen, adenovirus E1A, and the transcription factor E2F1. Here we demonstrate that necdin interacts with the tumor suppressor protein p53 as well. The yeast two-hybrid and in vitro binding analyses revealed that necdin bound to a narrow region (amino acids 35-62) located between the MDM2-binding site and the proline-rich region in the amino-terminal domain of p53, The electrophoretic mobility shift assay showed that necdin supershifted a complex between p53 and its binding DNA, implying that the p53-necdin complex is competent for DNA binding. In p53-deficient osteosarcoma SAOS-2 cells, necdin markedly suppressed p53-dependent activation of the p21/WAF promoter. Necdin and p53 inhibited cell growth in an additive manner as assessed by the colony formation of SAOS-2 cells, suggesting that necdin does not affect p53-mediated growth suppression. On the other hand, necdin inhibited p53-induced apoptosis of osteosarcoma U2OS cells. Thus, necdin can be a growth suppressor that targets p53 and modulates its biological functions in postmitotic neurons.	Osaka Univ, Inst Prot Res, Div Regulat Macromol Funct, Osaka 5650871, Japan	Osaka University	Taniura, H (corresponding author), Osaka Univ, Inst Prot Res, Div Regulat Macromol Funct, Yamadaoka 3-2, Osaka 5650871, Japan.	hideo@protein.osaka-u.ac.jp						ADAMS PD, 1995, SEMIN CANCER BIOL, V6, P99, DOI 10.1006/scbi.1995.0013; AIZAWA T, 1992, DEV BRAIN RES, V68, P265, DOI 10.1016/0165-3806(92)90069-9; ARMSTRONG JF, 1995, CURR BIOL, V5, P931, DOI 10.1016/S0960-9822(95)00183-7; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; BROWN DR, 1993, MOL CELL BIOL, V13, P6849, DOI 10.1128/MCB.13.11.6849; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; Eizenberg O, 1996, MOL CELL BIOL, V16, P5178; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Garkavtsev I, 1998, NATURE, V391, P295, DOI 10.1038/34675; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAUPT Y, 1995, ONCOGENE, V10, P1563; HAYASHI Y, 1995, BIOCHEM BIOPH RES CO, V213, P317, DOI 10.1006/bbrc.1995.2132; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Jay P, 1997, NAT GENET, V17, P357, DOI 10.1038/ng1197-357; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; Jordan J, 1997, J NEUROSCI, V17, P1397; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; MacDonald HR, 1997, HUM MOL GENET, V6, P1873, DOI 10.1093/hmg/6.11.1873; MAHESWARAN S, 1995, GENE DEV, V9, P2143, DOI 10.1101/gad.9.17.2143; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MARUYAMA K, 1991, BIOCHEM BIOPH RES CO, V178, P291, DOI 10.1016/0006-291X(91)91812-Q; Matsuzawa S, 1998, EMBO J, V17, P2736, DOI 10.1093/emboj/17.10.2736; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Nakada Y, 1998, GENE, V213, P65, DOI 10.1016/S0378-1119(98)00206-6; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; SAH VP, 1995, NAT GENET, V10, P175, DOI 10.1038/ng0695-175; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SLACK RS, 1993, ONCOGENE, V8, P1585; Taniura H, 1998, J BIOL CHEM, V273, P720, DOI 10.1074/jbc.273.2.720; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; Uetsuki T, 1996, J BIOL CHEM, V271, P918, DOI 10.1074/jbc.271.2.918; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Xiang H, 1996, J NEUROSCI, V16, P6753; Xiang H, 1998, J NEUROSCI, V18, P1363	40	121	132	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16242	16248		10.1074/jbc.274.23.16242	http://dx.doi.org/10.1074/jbc.274.23.16242			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347180	hybrid			2022-12-25	WOS:000080668600040
J	Hebb, MO; Denovan-Wright, EM; Robertson, HA				Hebb, MO; Denovan-Wright, EM; Robertson, HA			Expression of the Huntington's disease gene is regulated in astrocytes in the arcuate nucleus of the hypothalamus of postpartum rats	FASEB JOURNAL			English	Article						glia; lactation; Sprague-Dawley; epidermal growth factor receptor	HORMONE-RELEASING HORMONE; GROWTH-FACTOR-ALPHA; ACIDIC PROTEIN IMMUNOREACTIVITY; ESTRADIOL VALERATE; EMBRYONIC LETHALITY; PEROXIDASE-ACTIVITY; FEMALE RAT; TGF-ALPHA; NEURONS; ESTROGEN	Huntington's disease (HD) is one of a number of neurodegenerative disorders caused by expansion of polyglutamine-encoding CAG repeats within specific genes. Huntingtin, the protein product of the HD gene, is widely expressed in neural and nonneural human and rodent tissue. The function of the wild-type or mutated form of huntingtin is currently unknown. We have observed that relative to naive and male animals, huntingtin protein was significantly increased in the arcuate nucleus of postpartum rats. Using an oligonucleotide probe, in sih and Northern blot hybridization confirmed the expression of hunting-tin mRNA, Quantification of the in situ hybridization signal in the arcuate nucleus revealed an approximate sevenfold increase in the expression of huntingtin mRNA in postpartum, lactating animals compared with naive female or male animals. Emulsion autoradiography and immunohistochemistry revealed that the cells with elevated huntingtin expression had a stellate conformation that morphologically resembled astrocytes. Dual label immunofluorescence immunohistochemistry demonstrated the colocalization of huntingin and glial fibrillary acidic protein in these cells, confirming that they were astrocytes, Astrocytes expressing huntingtin were consistently found in close apposition to neuronal soma, suggesting interactions between these cell types. During the perinatal and postnatal period, the hypothalamus undergoes alterations in metabolic function. Our results support the idea of glia-induced metabolic changes in the hypothalamus, These results provide the first demonstration of naturally occurring changes in the expression of the Huntington's disease gene in the brain and suggest that huntingtin may play an important role in the processes that regulate neuroendocrine function.	Dalhousie Univ, Dept Pharmacol, Mol Neurobiol Lab, Halifax, NS B3H 4H7, Canada	Dalhousie University	Robertson, HA (corresponding author), Dalhousie Univ, Dept Pharmacol, Mol Neurobiol Lab, Sir Charles Tupper Med Bldg, Halifax, NS B3H 4H7, Canada.							ANDERSON WA, 1975, J CELL BIOL, V64, P668, DOI 10.1083/jcb.64.3.668; BRAWER JR, 1978, ENDOCRINOLOGY, V103, P501, DOI 10.1210/endo-103-2-501; CARLOCK L, 1995, NEUROREPORT, V6, P1121, DOI 10.1097/00001756-199505300-00012; Chowen JA, 1996, CELL MOL NEUROBIOL, V16, P297, DOI 10.1007/BF02088097; Ferrer I, 1996, PROG NEUROBIOL, V49, P99; Folstein S.E., 1989, HUNTINGTONS DIS DISO; GARCIASEGURA LM, 1986, BRAIN RES, V366, P131, DOI 10.1016/0006-8993(86)91287-4; GARCIASEGURA LM, 1989, DEV BRAIN RES, V47, P298, DOI 10.1016/0165-3806(89)90186-7; HOFFMAN GE, 1994, BRAIN RES, V654, P207, DOI 10.1016/0006-8993(94)90481-2; KEEFE DL, 1991, AM J OBSTET GYNECOL, V164, P959; KING JC, 1994, ENDOCRINOLOGY, V134, P1340, DOI 10.1210/en.134.3.1340; LI SH, 1993, NEURON, V11, P985, DOI 10.1016/0896-6273(93)90127-D; LIN BY, 1994, HUM MOL GENET, V3, P85, DOI 10.1093/hmg/3.1.85; LIN BY, 1993, HUM MOL GENET, V2, P1541, DOI 10.1093/hmg/2.10.1541; Liu YF, 1997, J BIOL CHEM, V272, P8121, DOI 10.1074/jbc.272.13.8121; LYTTLE CR, 1977, NATURE, V268, P337, DOI 10.1038/268337a0; Ma YJ, 1997, ENDOCRINOLOGY, V138, P19, DOI 10.1210/en.138.1.19; MA YJ, 1994, J NEUROSCI, V14, P5644; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; MOORE KE, 1987, BIOL REPROD, V36, P47, DOI 10.1095/biolreprod36.1.47; NASIR J, 1995, CELL, V81, P811, DOI 10.1016/0092-8674(95)90542-1; OJEDA SR, 1992, FRONT NEUROENDOCRIN, V13, P120; OJEDA SR, 1990, P NATL ACAD SCI USA, V87, P9698, DOI 10.1073/pnas.87.24.9698; OLMOS G, 1989, NEUROSCIENCE, V32, P663, DOI 10.1016/0306-4522(89)90288-1; PFAFF D, 1973, J COMP NEUROL, V151, P121, DOI 10.1002/cne.901510204; Sambrook J., 2002, MOL CLONING LAB MANU; SCHIPPER HM, 1990, BRAIN RES, V507, P200, DOI 10.1016/0006-8993(90)90273-E; TATTER SB, 1995, NEUROREPORT, V6, P1125, DOI 10.1097/00001756-199505300-00013; TORRESALEMAN I, 1992, GLIA, V6, P180, DOI 10.1002/glia.440060305; TRANQUE PA, 1987, BRAIN RES, V406, P348, DOI 10.1016/0006-8993(87)90805-5; TROTTIER Y, 1995, NAT GENET, V10, P104, DOI 10.1038/ng0595-104; TROTTIER Y, 1995, NATURE, V378, P403, DOI 10.1038/378403a0; WITKIN JW, 1991, ENDOCRINOLOGY, V129, P1083, DOI 10.1210/endo-129-2-1083; WITKIN JW, 1985, PEPTIDES, V6, P263, DOI 10.1016/0196-9781(85)90050-6; ZEITLIN S, 1995, NAT GENET, V11, P155, DOI 10.1038/ng1095-155	35	28	28	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	1999	13	9					1099	1106		10.1096/fasebj.13.9.1099	http://dx.doi.org/10.1096/fasebj.13.9.1099			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	200NZ	10336893				2022-12-25	WOS:000080547700015
J	Bae, H; Cabrera-Vera, TM; Depree, KM; Graber, SG; Hamm, HE				Bae, H; Cabrera-Vera, TM; Depree, KM; Graber, SG; Hamm, HE			Two amino acids within the alpha 4 helix of G alpha(i1) mediate coupling with 5-hydroxytryptamine(1B) receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN GAMMA-SUBUNIT; GUANINE-NUCLEOTIDE-BINDING; HETEROTRIMERIC G-PROTEINS; A1 ADENOSINE RECEPTORS; RECOMBINANT G-PROTEINS; TRIMERIC G-PROTEINS; BETA-GAMMA; CRYSTAL-STRUCTURE; ADENYLYL-CYCLASE; PROTEOLYTIC DIGESTION	We previously reported that residues 299-318 in Ga-i1 participate in the selective interaction between Ga-i1 and the 5-hydroxytryptamine(1B) (5-HT1B) receptor (Bae, H., Anderson, K., Flood, L. A., Skiba, N. P., Hamm, H. E., and Graber, S. G. (1997) J. Biol. Chem. 272, 32071-32077). The present study more precisely defines which residues within this domain are critical for 5-HT1B receptor-mediated G protein activation. A series of Ga-i1/G alpha(t) chimeras and point mutations were reconstituted with G beta gamma and Sf9 cell membranes containing the 5-HT1B receptor. Functional coupling to 5-HT1B receptors was assessed by 1) [S-35]GTP gamma S binding and 2) agonist affinity shift assays. Replacement of the alpha 4 helix of Ga-i1 (residues 299-308) with the corresponding sequence from G alpha(t) produced a chimera (Chi22) that only weakly coupled to the 5-HT1B receptor. In contrast, substitution of residues within the alpha 4-beta 6 loop region of Ga-i1 (residues 309-318) with the corresponding sequence in G alpha(t) either permitted full 5-HT1B receptor coupling to the chimera (Chi24) or only minimally reduced coupling to the chimeric protein (Chi25), Two mutations within the alpha 4 helix of Ga-i1 (Q304K and E308L) reduced agonist-stimulated [S-35]GTP gamma S binding, and the effects of these mutations were additive. The opposite substitutions within Chi22 (K300Q and L304E) restored Ga-i1 receptor coupling, and again the effects of the two mutations were additive. Mutations of other residues within the alpha 4 helix of Ga-i1 had minimal to no effect on 5-HT1B coupling behavior. These data provide evidence that alpha 4 helix residues in G alpha(i) participate in directing specific receptor interactions and suggest that Gln(304) and Glu(308) of Ga-i1 act in concert to mediate the ability of the 5-HT1B receptor to couple specifically to inhibitory G proteins.	Northwestern Univ, Inst Neurosci, Chicago, IL 60611 USA; W Virginia Univ, Dept Pharmacol & Toxicol, Morgantown, WV 26506 USA	Northwestern University; West Virginia University	Hamm, HE (corresponding author), Northwestern Univ, Inst Neurosci, 320 E Super,Searle Bldg,Rm 5-555, Chicago, IL 60611 USA.		Hamm, Heidi E/G-2374-2014; Bae, Hyunsu/ABH-6248-2020	Bae, Hyunsu/0000-0002-0299-3582	NATIONAL CANCER INSTITUTE [T32CA070085] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY010291] Funding Source: NIH RePORTER; NCI NIH HHS [5T32CA70085-02] Funding Source: Medline; NEI NIH HHS [EY10291] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ASANO T, 1985, J BIOL CHEM, V260, P2653; Bae H, 1997, J BIOL CHEM, V272, P32071, DOI 10.1074/jbc.272.51.32071; BORNANCIN F, 1989, EUR J BIOCHEM, V184, P687, DOI 10.1111/j.1432-1033.1989.tb15068.x; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; BOYER JL, 1994, J BIOL CHEM, V269, P2814; Clawges HM, 1997, BIOCHEMISTRY-US, V36, P12930, DOI 10.1021/bi970112b; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; ENGEL G, 1986, N-S ARCH PHARMACOL, V332, P1, DOI 10.1007/BF00633189; FERGUSON KM, 1986, J BIOL CHEM, V261, P7393; Figler RA, 1996, MOL PHARMACOL, V50, P1587; GARCIA PD, 1995, EMBO J, V14, P4460, DOI 10.1002/j.1460-2075.1995.tb00125.x; Goadsby PJ, 1998, CLIN NEUROSCI, V5, P18; GRABER SG, 1992, J BIOL CHEM, V267, P1271; Gudermann T, 1996, ANNU REV PHARMACOL, V36, P429; HAMBLIN MW, 1991, MOL PHARMACOL, V40, P143; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; Hamm HE, 1996, CURR OPIN CELL BIOL, V8, P189, DOI 10.1016/S0955-0674(96)80065-2; KISSELEV O, 1995, P NATL ACAD SCI USA, V92, P9102, DOI 10.1073/pnas.92.20.9102; KISSELEV O, 1995, J BIOL CHEM, V270, P25356, DOI 10.1074/jbc.270.43.25356; KISSELEV OG, 1994, J BIOL CHEM, V269, P21399; Kostenis E, 1997, J BIOL CHEM, V272, P19107, DOI 10.1074/jbc.272.31.19107; Kostenis E, 1997, BIOCHEMISTRY-US, V36, P1487, DOI 10.1021/bi962554d; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; KUBOTA A, 1994, BIOCHEM BIOPH RES CO, V204, P176, DOI 10.1006/bbrc.1994.2442; KUROSE H, 1991, BIOCHEMISTRY-US, V30, P3335, DOI 10.1021/bi00227a024; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LAUGWITZ KL, 1993, NEURON, V10, P233, DOI 10.1016/0896-6273(93)90314-H; LEE CH, 1995, MOL PHARMACOL, V47, P218; Lichtarge O, 1996, P NATL ACAD SCI USA, V93, P7507, DOI 10.1073/pnas.93.15.7507; LIU J, 1995, P NATL ACAD SCI USA, V92, P11642, DOI 10.1073/pnas.92.25.11642; MAZZONI MR, 1991, J BIOL CHEM, V266, P14072; Mazzoni MR, 1996, J BIOL CHEM, V271, P30034, DOI 10.1074/jbc.271.47.30034; MIDDLEMISS DN, 1988, EUR J PHARMACOL, V157, P101, DOI 10.1016/0014-2999(88)90476-1; MIGEON JC, 1994, J BIOL CHEM, V269, P9767; MUNSHI R, 1991, J BIOL CHEM, V266, P22285; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; Onrust R, 1997, SCIENCE, V275, P381, DOI 10.1126/science.275.5298.381; POBINER BF, 1991, MOL PHARMACOL, V40, P156; RASENICK MM, 1994, J BIOL CHEM, V269, P21519; RAYMOND JR, 1993, BIOCHEMISTRY-US, V32, P11064, DOI 10.1021/bi00092a016; Skiba NP, 1996, J BIOL CHEM, V271, P413, DOI 10.1074/jbc.271.1.413; Sunahara RK, 1997, SCIENCE, V278, P1943, DOI 10.1126/science.278.5345.1943; Taylor JM, 1996, J BIOL CHEM, V271, P3336; TAYLOR JM, 1994, J BIOL CHEM, V269, P27618; THOMAS TC, 1993, P NATL ACAD SCI USA, V90, P10295, DOI 10.1073/pnas.90.21.10295; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; Yasuda H, 1996, J BIOL CHEM, V271, P18588, DOI 10.1074/jbc.271.31.18588	51	41	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					14963	14971		10.1074/jbc.274.21.14963	http://dx.doi.org/10.1074/jbc.274.21.14963			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329698	Green Published, hybrid			2022-12-25	WOS:000081965200063
J	Johnsson, E; Areschoug, T; Mestecky, J; Lindahl, G				Johnsson, E; Areschoug, T; Mestecky, J; Lindahl, G			An IgA-binding peptide derived from a streptococcal surface protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-B STREPTOCOCCI; GROUP-A STREPTOCOCCI; IMMUNOGLOBULIN-A; MOLECULAR CHARACTERIZATION; BETA-ANTIGEN; COILED COILS; FC-RECEPTORS; IDENTIFICATION; PYOGENES; REGION	Surface proteins that bind to the Fc part of human IgA are expressed by many strains of Streptococcus pyogenes, a major human pathogen. Studies of these proteins have been complicated by their size and by their ability to bind human plasma proteins other than IgA. Here, we describe a synthetic 50-residue peptide, derived from streptococcal protein Sir22, that binds human IgA but not any of the other plasma proteins known to bind to Sir22. The peptide binds serum IgA and secretory IgA and binds IgA of both subclasses. Evidence is presented that the peptide folds correctly both in solution and when it is immobilized and that it readily renatures after denaturation, Together, these data indicate that the peptide corresponds to a protein domain that binds IgA with high specificity. This is the first report of an IgA-binding domain that retains its properties in isolated form.	Univ Lund, Dept Lab Med, S-22362 Lund, Sweden; Univ Alabama, Dept Microbiol, Birmingham, AL 35294 USA	Lund University; University of Alabama System; University of Alabama Birmingham	Lindahl, G (corresponding author), Univ Lund, Dept Lab Med, Solvegatan 23, S-22362 Lund, Sweden.							AKERSTROM B, 1994, MOL IMMUNOL, V31, P393, DOI 10.1016/0161-5890(94)90117-1; AKERSTROM B, 1992, J IMMUNOL, V148, P3238; BESSEN DE, 1994, INFECT IMMUN, V62, P1968, DOI 10.1128/IAI.62.5.1968-1974.1994; BESSEN DE, 1992, INFECT IMMUN, V60, P124, DOI 10.1128/IAI.60.1.124-135.1992; Carayannopoulos L, 1996, J EXP MED, V183, P1579, DOI 10.1084/jem.183.4.1579; CEDERVALL T, 1995, SCAND J IMMUNOL, V42, P433, DOI 10.1111/j.1365-3083.1995.tb03677.x; FRICK IM, 1994, MOL MICROBIOL, V12, P143, DOI 10.1111/j.1365-2958.1994.tb01003.x; FRITHZ E, 1989, MOL MICROBIOL, V3, P1111, DOI 10.1111/j.1365-2958.1989.tb00261.x; HEDEN LO, 1991, EUR J IMMUNOL, V21, P1481, DOI 10.1002/eji.1830210623; JERLSTROM PG, 1991, MOL MICROBIOL, V5, P843, DOI 10.1111/j.1365-2958.1991.tb00757.x; Jerlstrom PG, 1996, INFECT IMMUN, V64, P2787; JOHNSSON E, 1994, J IMMUNOL, V153, P3557; Johnsson E, 1998, J IMMUNOL, V161, P4894; Johnsson E, 1996, J IMMUNOL, V157, P3021; Kammerer RA, 1998, P NATL ACAD SCI USA, V95, P13419, DOI 10.1073/pnas.95.23.13419; LINDAHL G, 1989, MOL MICROBIOL, V3, P239, DOI 10.1111/j.1365-2958.1989.tb01813.x; LINDAHL G, 1990, EUR J IMMUNOL, V20, P2241, DOI 10.1002/eji.1830201013; MESTECKY J, 1985, METHOD ENZYMOL, V116, P37; Morton HC, 1996, CRIT REV IMMUNOL, V16, P423; Raghavan M, 1996, ANNU REV CELL DEV BI, V12, P181, DOI 10.1146/annurev.cellbio.12.1.181; RUSSELLJONES GJ, 1984, J EXP MED, V160, P1467, DOI 10.1084/jem.160.5.1467; SCHALEN C, 1980, ACTA PATH MICRO IM C, V88, P271; STENBERG L, 1994, J BIOL CHEM, V269, P13458; SU JY, 1994, BIOCHEMISTRY-US, V33, P15501, DOI 10.1021/bi00255a032; Thern A, 1998, J IMMUNOL, V160, P860; THERN A, 1995, J IMMUNOL, V154, P375	26	27	28	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					14521	14524		10.1074/jbc.274.21.14521	http://dx.doi.org/10.1074/jbc.274.21.14521			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329638	hybrid			2022-12-25	WOS:000081965200003
J	Mikkola, I; Bruun, JA; Bjorkoy, G; Holm, T; Johansen, T				Mikkola, I; Bruun, JA; Bjorkoy, G; Holm, T; Johansen, T			Phosphorylation of the transactivation domain of Pax6 by extracellular signal-regulated kinase and p38 mitogen-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMEOBOX-CONTAINING GENE; HYDROLYZING PHOSPHOLIPASE-C; NIH 3T3 CELLS; MAP KINASE; PAIRED-DOMAIN; TRANSCRIPTION FACTOR; DNA-BINDING; EYE DEVELOPMENT; MEDIATED PHOSPHORYLATION; TRANSDUCTION PATHWAY	The transcription factor Pax6 is required for normal development of the central nervous system, the eyes, nose, and pancreas. Here we show that the transactivation domain (TAD) of zebrafish Pax6 is phosphorylated in vitro by the mitogen-activated protein kinases (MAPKs) extracellular-signal regulated kinase (ERK) and p38 kinase but not by Jun N-terminal kinase (JNK). Three of four putative proline-dependent kinase phosphorylation sites are phosphorylated in vitro. Of these sites, the serine 413 (Ser(413)) is evolutionary conserved from sea urchin to man. Ser(413) is also phosphorylated in vivo upon activation of ERK or p38 kinase. Substitution of Ser(413) with alanine strongly decreased the transactivation potential of the Pax6 TAD whereas substitution with glutamate increased the transactivation. Reporter gene assays with wild-type and mutant Pax6 revealed that transactivation by the full-length Pax6 protein from paired domain-binding sites was strongly enhanced (le-fold) following co-transfection with activated p38 kinase. This enhancement was largely dependent on the Ser(413) site. ERK activation, however, produced a 3-fold increase in transactivation which was partly independent of the Ser(413) site. These findings provide a starting point for further studies aimed at elucidating a post-translational regulation of Pax6 following activation of MAPK signaling pathways.	Univ Tromso, Inst Med Biol, Dept Biochem, N-9037 Tromso, Norway	UiT The Arctic University of Tromso	Johansen, T (corresponding author), Univ Tromso, Inst Med Biol, Dept Biochem, N-9037 Tromso, Norway.	terjej@fagmed.uit.no	Johansen, Terje/N-2971-2015; Johansen, Terje/AAY-1753-2021	Johansen, Terje/0000-0003-1451-9578; Johansen, Terje/0000-0003-1451-9578; Bruun, Jack-Ansgar/0000-0003-0614-2790; Mikkola, Ingvild/0000-0001-6442-7626				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Bennicelli JL, 1996, P NATL ACAD SCI USA, V93, P5455, DOI 10.1073/pnas.93.11.5455; Bjorkoy G, 1997, J BIOL CHEM, V272, P11557; BJORKOY G, 1995, J BIOL CHEM, V270, P21299; Callaerts P, 1997, ANNU REV NEUROSCI, V20, P483, DOI 10.1146/annurev.neuro.20.1.483; CARRIERE C, 1995, CELL GROWTH DIFFER, V6, P1531; CARRIERE C, 1993, MOL CELL BIOL, V13, P7257, DOI 10.1128/MCB.13.12.7257; CHALEPAKIS G, 1994, P NATL ACAD SCI USA, V91, P12745, DOI 10.1073/pnas.91.26.12745; Chow CW, 1997, SCIENCE, V278, P1638, DOI 10.1126/science.278.5343.1638; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CZERNY T, 1995, MOL CELL BIOL, V15, P2858; CZERNY T, 1993, GENE DEV, V7, P2048, DOI 10.1101/gad.7.10.2048; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dorfler P, 1996, EMBO J, V15, P1971, DOI 10.1002/j.1460-2075.1996.tb00548.x; EPSTEIN J, 1994, J BIOL CHEM, V269, P8355; EPSTEIN JA, 1994, GENE DEV, V8, P2022, DOI 10.1101/gad.8.17.2022; Fortin AS, 1997, HUM MOL GENET, V6, P1781, DOI 10.1093/hmg/6.11.1781; Glardon S, 1997, DEVELOPMENT, V124, P817; Glardon S, 1998, DEVELOPMENT, V125, P2701; GLASER T, 1994, NAT GENET, V7, P463, DOI 10.1038/ng0894-463; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; GUPTA S, 1994, FEBS LETT, V353, P281, DOI 10.1016/0014-5793(94)01052-8; HALDER G, 1995, CURR OPIN GENET DEV, V5, P602, DOI 10.1016/0959-437X(95)80029-8; HALDER G, 1995, SCIENCE, V267, P1788, DOI 10.1126/science.7892602; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HANSON I, 1995, TRENDS GENET, V11, P268, DOI 10.1016/S0168-9525(00)89073-3; Hemesath TJ, 1998, NATURE, V391, P298, DOI 10.1038/34681; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Kato Y, 1998, NATURE, V395, P713, DOI 10.1038/27234; KRAUSS S, 1991, EMBO J, V10, P3609, DOI 10.1002/j.1460-2075.1991.tb04927.x; KRAUSS S, 1991, NATURE, V353, P267, DOI 10.1038/353267a0; Kurozumi K, 1998, GENES CELLS, V3, P257, DOI 10.1046/j.1365-2443.1998.00186.x; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; Loosli F, 1996, P NATL ACAD SCI USA, V93, P2658, DOI 10.1073/pnas.93.7.2658; MACDONALD R, 1994, NEURON, V13, P1039, DOI 10.1016/0896-6273(94)90044-2; Mao C, 1996, ONCOGENE, V12, P863; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MARTIN P, 1992, ONCOGENE, V7, P1721; MIKKOLA I, 1992, J NEUROBIOL, V23, P933, DOI 10.1002/neu.480230802; Niu HF, 1998, GENE DEV, V12, P1953, DOI 10.1101/gad.12.13.1953; NOLL M, 1993, CURR OPIN GENET DEV, V3, P595, DOI 10.1016/0959-437X(93)90095-7; Nornes S, 1996, J BIOL CHEM, V271, P26914, DOI 10.1074/jbc.271.43.26914; Nornes S, 1998, MECH DEVELOP, V77, P185, DOI 10.1016/S0925-4773(98)00156-7; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; Price ER, 1998, J BIOL CHEM, V273, P17983, DOI 10.1074/jbc.273.29.17983; Quinn JC, 1996, GENE DEV, V10, P435, DOI 10.1101/gad.10.4.435; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Singh S, 1998, J BIOL CHEM, V273, P21531, DOI 10.1074/jbc.273.34.21531; Sjottem E, 1996, J VIROL, V70, P188; Sprague GF, 1998, GENE DEV, V12, P2817, DOI 10.1101/gad.12.18.2817; StOnge L, 1997, NATURE, V387, P406, DOI 10.1038/387406a0; STRACHAN T, 1994, CURR OPIN GENET DEV, V4, P427, DOI 10.1016/0959-437X(94)90032-9; Tan PB, 1998, CELL, V93, P569, DOI 10.1016/S0092-8674(00)81186-1; Tang HK, 1998, J BIOL CHEM, V273, P7210, DOI 10.1074/jbc.273.13.7210; Tomarev SI, 1997, P NATL ACAD SCI USA, V94, P2421, DOI 10.1073/pnas.94.6.2421; TON CCT, 1991, CELL, V67, P1059, DOI 10.1016/0092-8674(91)90284-6; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TURQUE N, 1994, MOL ENDOCRINOL, V8, P929, DOI 10.1210/me.8.7.929; UNDERHILL DA, 1995, P NATL ACAD SCI USA, V92, P3692, DOI 10.1073/pnas.92.9.3692; Underhill DA, 1997, J BIOL CHEM, V272, P14175, DOI 10.1074/jbc.272.22.14175; WALTHER C, 1991, DEVELOPMENT, V113, P1435; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; WESTWICK JK, 1995, METHOD ENZYMOL, V255, P342; WILSON DS, 1995, CELL, V82, P709, DOI 10.1016/0092-8674(95)90468-9; WISHART DS, 1994, COMPUT APPL BIOSCI, V10, P121; XU WG, 1995, CELL, V80, P639, DOI 10.1016/0092-8674(95)90518-9; Yang BS, 1996, MOL CELL BIOL, V16, P538; Yang SH, 1998, EMBO J, V17, P1740, DOI 10.1093/emboj/17.6.1740; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	76	93	96	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					15115	15126		10.1074/jbc.274.21.15115	http://dx.doi.org/10.1074/jbc.274.21.15115			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329718	hybrid			2022-12-25	WOS:000081965200083
J	Portnoy, ME; Rosenzweig, AC; Rae, T; Huffman, DL; O'Halloran, TV; Culotta, VC				Portnoy, ME; Rosenzweig, AC; Rae, T; Huffman, DL; O'Halloran, TV; Culotta, VC			Structure-function analyses of the ATX1 metallochaperone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COPPER-TRANSPORTING ATPASE; CEREVISIAE LYS7 GENE; SACCHAROMYCES-CEREVISIAE; SUPEROXIDE-DISMUTASE; PHYSIOLOGICAL-ROLE; WILSON-DISEASE; IRON TRANSPORT; YEAST; PROTEIN; HOMEOSTASIS	Saccharomyces cerevisiae Atx1p represents a member of the family of metallochaperone molecules that escort copper to distinct intracellular targets, Atx1p specifically delivers copper to the Ccc2p copper transporter in the Golgi. Additionally, when overproduced, Atx1p substitutes for superoxide dismutase 1 in preventing oxidative damage; however the mechanistic overlap between these functions is unresolved. The crystal structure of Atx1p has been solved recently, By examining a surface electrostatic potential distribution, multiple conserved lysines are revealed on one face of Atx1p. An additional conserved lysine (Lys(65)) lies in close proximity to the metal binding site. Through site-directed mutagenesis, residues in the metal binding region including Lys65 were found to be necessary for both copper delivery to Ccc2p and for Atx1p antioxidant activity. Copper trafficking to Ccc2p also relied on the lysine rich face of Atx1p. Surprisingly however, elimination of these lysines did not inhibit the antioxidant activity of Atx1p, We provide evidence that Atx1p does not suppress oxidative damage by a metallochaperone mechanism but may directly consume superoxide. Purified Cu-Atx1p reacts noncatalytically with superoxide anion in vitro. We conclude that the copper-trafficking and antioxidant functions of Atx1p arise from chemically and structurally distinct attributes of this metallochaperone.	Johns Hopkins Univ, Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Publ Hlth, Dept Biochem, Baltimore, MD 21205 USA; Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA; Northwestern Univ, Dept Chem, Evanston, IL 60208 USA	Johns Hopkins University; Johns Hopkins University; Northwestern University; Northwestern University	Culotta, VC (corresponding author), Johns Hopkins Univ, Sch Publ Hlth, Dept Environm Hlth Sci, 615 N Wolfe St,Rm 7023, Baltimore, MD 21205 USA.		O'Halloran, Thomas/ABE-6125-2021	O'Halloran, Thomas/0000-0001-8732-5059	NCI NIH HHS [T32CA 09110] Funding Source: Medline; NIEHS NIH HHS [ES 08996] Funding Source: Medline; NIGMS NIH HHS [R01 GM054111, GM54111] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009110] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008996] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054111] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amaravadi R, 1997, HUM GENET, V99, P329, DOI 10.1007/s004390050367; BILINSKI T, 1985, BIOCHEM BIOPH RES CO, V130, P533, DOI 10.1016/0006-291X(85)90449-8; BULL PC, 1994, TRENDS GENET, V10, P246, DOI 10.1016/0168-9525(94)90172-4; Corson LB, 1998, P NATL ACAD SCI USA, V95, P6361, DOI 10.1073/pnas.95.11.6361; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; CULOTTA VC, 1995, J BIOL CHEM, V270, P29991; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; DANCIS A, 1994, J BIOL CHEM, V269, P25660; FRIDOVICH I, 1985, CRC HDB METHODS OXYG, P213; FU DD, 1995, YEAST, V11, P283, DOI 10.1002/yea.320110310; Gamonet F, 1998, EUR J BIOCHEM, V251, P716, DOI 10.1046/j.1432-1327.1998.2510716.x; Gitschier J, 1998, NAT STRUCT BIOL, V5, P47, DOI 10.1038/nsb0198-47; Glerum DM, 1996, J BIOL CHEM, V271, P14504, DOI 10.1074/jbc.271.24.14504; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; Himelblau E, 1998, PLANT PHYSIOL, V117, P1227, DOI 10.1104/pp.117.4.1227; HORECKA J, 1995, GENE, V162, P87, DOI 10.1016/0378-1119(95)00325-Z; Hung IH, 1998, J BIOL CHEM, V273, P1749, DOI 10.1074/jbc.273.3.1749; Klomp LWJ, 1997, J BIOL CHEM, V272, P9221, DOI 10.1074/jbc.272.14.9221; LIN SJ, 1995, P NATL ACAD SCI USA, V92, P3784, DOI 10.1073/pnas.92.9.3784; Lin SJ, 1997, J BIOL CHEM, V272, P9215; LIN SJ, 1997, THESIS J HOPKINS U; Linder M. C., 1991, BIOCH COPPER, V1-13; LIU XF, 1992, J BIOL CHEM, V267, P18298; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nishihara E, 1998, NEUROREPORT, V9, P3259, DOI 10.1097/00001756-199810050-00023; Pufahl RA, 1997, SCIENCE, V278, P853, DOI 10.1126/science.278.5339.853; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; ROSENZWEIG AC, 1999, IN PRESS STRUCTURE L; Sherman F., 1978, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; Steele RA, 1997, BIOCHEMISTRY-US, V36, P6885, DOI 10.1021/bi9631632; Valentine JS, 1997, SCIENCE, V278, P817, DOI 10.1126/science.278.5339.817; Wakabayashi T, 1998, FEBS LETT, V440, P141, DOI 10.1016/S0014-5793(98)01431-8; YamaguchiIwai Y, 1996, EMBO J, V15, P3377, DOI 10.1002/j.1460-2075.1996.tb00703.x; Yuan DS, 1997, J BIOL CHEM, V272, P25787, DOI 10.1074/jbc.272.41.25787; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632	37	120	121	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					15041	15045		10.1074/jbc.274.21.15041	http://dx.doi.org/10.1074/jbc.274.21.15041			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329707	hybrid			2022-12-25	WOS:000081965200072
J	Sunwoo, JB; Sun, PC; Gupta, VK; Schmidt, AP; El-Mofty, S; Scholnick, SB				Sunwoo, JB; Sun, PC; Gupta, VK; Schmidt, AP; El-Mofty, S; Scholnick, SB			Localization of a putative tumor suppressor gene in the sub-telomeric region of chromosome 8p	ONCOGENE			English	Article						deletion mapping; 8p23; squamous cell carcinoma; tumor suppressor gene	SQUAMOUS-CELL CARCINOMAS; ARM 8P; SUPRAGLOTTIC LARYNX; ALLELIC IMBALANCE; FREQUENT LOSS; CANCER; DELETION; LOCI; HEAD; 3P	Several regions of chromsome arm 8p are frequently deleted in a variety of human malignancies including those of the prostate, head and neck, lung, and colon, suggesting that there is more than one tumor suppressor gene on this chromosome arm. Both laryngeal and oral squamous cell carcinomas exhibit three distinct and nonoverlapping regions of deletion on 8p, We have further refined the localization of the putative suppressor in 8p23 by using eight microsatellite loci to create a high resolution deletion map of 150 squamous cell carcinomas of the larynx and oral cavity, These new data demonstrate that there are two distinct classes of deletion within this relatively small region of the chromosome and suggest two possible locations for the gene within the D8S264 to D8S1788 interval. We also determined that there is little difference between the allelic loss frequencies of microsatellites mapping near the telomeric ends of other chromosome arms and loci mapping to more centromere proximal regions of the same arm. These data suggest that the high allelic loss frequencies seen at 8p23 loci are not the result of a generalized instability of chromosome ends and are instead consistent with the activation of a specific suppressor gene.	Washington Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Scholnick, SB (corresponding author), Washington Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, St Louis, MO 63110 USA.			Sunwoo, John/0000-0002-8393-4196	NATIONAL CANCER INSTITUTE [R01CA058473] Funding Source: NIH RePORTER; NCI NIH HHS [CA58473] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CAIRNS P, 1994, CANCER RES, V54, P1422; FUJIWARA Y, 1993, CANCER RES, V53, P1172; Gotta M, 1996, EXPERIENTIA, V52, P1136, DOI 10.1007/BF01952113; Gustafson CE, 1996, CANCER RES, V56, P5238; Leach RJ, 1996, CYTOGENET CELL GENET, V75, P71, DOI 10.1159/000134460; MACGROGAN D, 1994, GENE CHROMOSOME CANC, V10, P151, DOI 10.1002/gcc.2870100302; MACOSKA JA, 1995, CANCER RES, V55, P5390; MAESTRO R, 1993, CANCER RES, V53, P5775; Ranta S, 1996, GENOME RES, V6, P351, DOI 10.1101/gr.6.5.351; SCHOLNICK SB, 1994, CANCER, V73, P2472, DOI 10.1002/1097-0142(19940515)73:10<2472::AID-CNCR2820731005>3.0.CO;2-B; Scholnick SB, 1996, J NATL CANCER I, V88, P1676, DOI 10.1093/jnci/88.22.1676; Scholnick SB, 1998, OTOLARYNG HEAD NECK, V118, P363, DOI 10.1016/S0194-5998(98)70316-X; Spanknebel KA, 1997, AM J HUM GENET, V61, pA83; Sunwoo JB, 1996, GENE CHROMOSOME CANC, V16, P164, DOI 10.1002/(SICI)1098-2264(199607)16:3<164::AID-GCC2>3.0.CO;2-X; Tanaka K, 1996, ONCOGENE, V12, P405; Washburn J., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P515; Wu CL, 1997, GENE CHROMOSOME CANC, V20, P347, DOI 10.1002/(SICI)1098-2264(199712)20:4<347::AID-GCC5>3.0.CO;2-1; YAREMKO ML, 1994, GENE CHROMOSOME CANC, V10, P1, DOI 10.1002/gcc.2870100102; YOO GH, 1994, CANCER RES, V54, P4603	19	38	41	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 22	1999	18	16					2651	2655		10.1038/sj.onc.1202838	http://dx.doi.org/10.1038/sj.onc.1202838			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	189LU	10353609				2022-12-25	WOS:000079907100013
J	Masse, E; Drolet, M				Masse, E; Drolet, M			Relaxation of transcription-induced negative supercoiling is an essential function of Escherichia coli DNA topoisomerase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							R-LOOP FORMATION; GYRASE GENES; MUTANTS; TEMPLATE; MUTATIONS; VITRO	It has been suggested that the essential function of DNA topoisomerase I in Escherichia coli is to prevent chromosomal DNA from reaching an unacceptably high level of global negative supercoliing. However, other in vivo studies have shown that DNA topoisomerase I is very effective in removing local negative supercoliing generated during transcription elongation. To determine whether topoisomerase I is essential for controlling global or local DNA supercoliing, we have prepared a set of topA null mutant strains in combination with different plasmid DNAs. Although we found a correlation between the severity of the growth defect with both transcription-induced and global supercoliing, near to complete growth inhibition correlated only with transcription-induced supercoliing. This result strongly suggests that the major function of DNA topoisomerase I is to relax local negative supercoliing generated during transcription elongation.	Univ Montreal, Dept Microbiol & Immunol, Montreal, PQ H3C 3J7, Canada	Universite de Montreal	Drolet, M (corresponding author), Univ Montreal, Dept Microbiol & Immunol, CP 6128,Succursale Centreville, Montreal, PQ H3C 3J7, Canada.	Marc.Drolet@umontreal.ca	Drolet, Marc/M-1328-2019					COOK DN, 1992, P NATL ACAD SCI USA, V89, P10603, DOI 10.1073/pnas.89.22.10603; DINARDO S, 1982, CELL, V31, P43, DOI 10.1016/0092-8674(82)90403-2; DRLICA K, 1992, MOL MICROBIOL, V6, P425, DOI 10.1111/j.1365-2958.1992.tb01486.x; DROLET M, 1995, P NATL ACAD SCI USA, V92, P3526, DOI 10.1073/pnas.92.8.3526; DROLET M, 1994, J BIOL CHEM, V269, P2068; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; LYNCH AS, 1993, J BACTERIOL, V175, P1645, DOI 10.1128/JB.175.6.1645-1655.1993; Masse E, 1999, J BIOL CHEM, V274, P16659, DOI 10.1074/jbc.274.23.16659; Miller J.H., 1992, SHORT COURSE BACTERI, P150; Phoenix P, 1997, J BIOL CHEM, V272, P1473, DOI 10.1074/jbc.272.3.1473; PRUSS GJ, 1985, J MOL BIOL, V185, P51, DOI 10.1016/0022-2836(85)90182-2; PRUSS GJ, 1982, CELL, V31, P35, DOI 10.1016/0092-8674(82)90402-0; RECORD MT, 1996, CELLULAR MOL BIOL, V1, P792; Sambrook J., 2002, MOL CLONING LAB MANU; SINGER M, 1989, MICROBIOL REV, V53, P1; TSAO YP, 1989, CELL, V56, P111, DOI 10.1016/0092-8674(89)90989-6; WU HY, 1988, CELL, V53, P433, DOI 10.1016/0092-8674(88)90163-8	17	61	63	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16654	16658		10.1074/jbc.274.23.16654	http://dx.doi.org/10.1074/jbc.274.23.16654			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347233	hybrid			2022-12-25	WOS:000080668600093
J	Shulga, N; James, P; Craig, EA; Goldfarb, DS				Shulga, N; James, P; Craig, EA; Goldfarb, DS			A nuclear export signal prevents Saccharomyces cerevisiae Hsp70 Ssb1p from stimulating nuclear localization signal-directed nuclear transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHOCK COGNATE PROTEIN; HEAT-SHOCK; KARYOPHILIC PROTEINS; YEAST; IMPORT; BINDING; COMPLEX; PATHWAY; TRANSLOCATION; DEGRADATION	Hsp70 has been implicated in nuclear localization signal (NLS)-directed nuclear transport. Saccharomyces cerevisiae contains distinct SSA and SSB gene families of cytosolic Hsp70s. The nucleocytoplasmic localization of Ssa1p and Ssb1p was investigated using green fluorescent protein (GFP) fusions. Whereas GFP-Ssa1p localized both to the nucleus and cytoplasm, GFP-Ssb1p appeared only in the cytosol. The C-terminal domain of Ssb1p contains a leucine-rich nuclear export signal (NES) that is necessary and sufficient to direct nuclear export. The accumulation of GFP-Ssb1p in the nuclei of xpo1-1 cells suggests that Ssb1p shuttles across the nuclear envelope. Elevated levels of SSA1 but not SSB1 suppressed the NLS-GFP nuclear localization defects of nup188-Delta cells. Studies with Ssa1p/Ssb1p chimeras revealed that the Ssb1p NES is sufficient and necessary to inhibit the function of Ssa- or Ssb-type Hsp70s in nuclear transport. Thus, NES-less Ssb1p stimulates nuclear transport in nup188-Delta cells and NES-containing Ssa1p does not. We conclude that the differential function of Ssa1p and Ssb1p in nuclear transport is due to the NES-directed export of the Ssb1p and not to functional differences in their ATPase or peptide binding domains.	Univ Rochester, Dept Biol, Rochester, NY 14627 USA; Univ Wisconsin, Dept Biomol Chem, Madison, WI 53706 USA	University of Rochester; University of Wisconsin System; University of Wisconsin Madison	Goldfarb, DS (corresponding author), Univ Rochester, Dept Biol, Rochester, NY 14627 USA.	dasg@uhura.cc.rochester.edu						Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; Brodsky JL, 1998, FEBS LETT, V435, P183, DOI 10.1016/S0014-5793(98)01065-5; Craig E, 1995, COLD SPRING HARB SYM, V60, P441, DOI 10.1101/SQB.1995.060.01.049; CRAIG EA, 1985, MOL CELL BIOL, V5, P3517, DOI 10.1128/MCB.5.12.3517; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; Fritz CC, 1996, CURR BIOL, V6, P848, DOI 10.1016/S0960-9822(02)00608-5; Gorlich D, 1997, CURR OPIN CELL BIOL, V9, P412, DOI 10.1016/S0955-0674(97)80015-4; HALLADAY JT, 1995, MOL CELL BIOL, V15, P4890; Hightower LE, 1994, BIOL HEAT SHOCK PROT, P179; IMAMOTO N, 1992, J CELL BIOL, V119, P1047, DOI 10.1083/jcb.119.5.1047; IMAMOTOSONOBE N, 1990, J BIOL CHEM, V265, P16504; James P, 1997, SCIENCE, V275, P387, DOI 10.1126/science.275.5298.387; JEOUNG DI, 1991, GENE DEV, V5, P2235, DOI 10.1101/gad.5.12a.2235; Lamian V, 1996, EXP CELL RES, V228, P84, DOI 10.1006/excr.1996.0302; MANDELL RB, 1992, EXP CELL RES, V198, P164, DOI 10.1016/0014-4827(92)90163-3; MANDELL RB, 1990, J CELL BIOL, V111, P1775, DOI 10.1083/jcb.111.5.1775; Mathew A, 1998, MOL CELL BIOL, V18, P5091, DOI 10.1128/MCB.18.9.5091; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; MELCHIOR F, 1995, CURR OPIN CELL BIOL, V7, P310, DOI 10.1016/0955-0674(95)80084-0; MILARSKI KL, 1989, J CELL BIOL, V109, P1947, DOI 10.1083/jcb.109.5.1947; MORIMOTO RI, 1994, BIOL HEAT SHOCK PROT, P1; Nehrbass U, 1996, J CELL BIOL, V133, P1153, DOI 10.1083/jcb.133.6.1153; NELSON RJ, 1992, CELL, V71, P97, DOI 10.1016/0092-8674(92)90269-I; Niedenthal RK, 1996, YEAST, V12, P773, DOI 10.1002/(SICI)1097-0061(19960630)12:8<773::AID-YEA972>3.3.CO;2-C; NILSSON B, 1987, PROTEIN ENG, V1, P107, DOI 10.1093/protein/1.2.107; OHBA M, 1994, FEBS LETT, V351, P263; Ohba M, 1997, FEBS LETT, V409, P307, DOI 10.1016/S0014-5793(97)00535-8; OKUNO Y, 1993, EXP CELL RES, V206, P134, DOI 10.1006/excr.1993.1129; PELHAM HRB, 1984, EMBO J, V3, P3095, DOI 10.1002/j.1460-2075.1984.tb02264.x; Pfund C, 1998, EMBO J, V17, P3981, DOI 10.1093/emboj/17.14.3981; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; Rivett AJ, 1998, CURR OPIN IMMUNOL, V10, P110, DOI 10.1016/S0952-7915(98)80040-X; Roberts PM, 1998, METHOD CELL BIOL, V53, P545; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SHI YG, 1992, MOL CELL BIOL, V12, P2186, DOI 10.1128/MCB.12.5.2186; Shi YH, 1998, GENE DEV, V12, P654, DOI 10.1101/gad.12.5.654; Shulga N, 1996, J CELL BIOL, V135, P329, DOI 10.1083/jcb.135.2.329; SIKORSKI RS, 1989, GENETICS, V122, P19; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; STONE DE, 1990, MOL CELL BIOL, V10, P1622, DOI 10.1128/MCB.10.4.1622; TAKENAKA IM, 1995, J BIOL CHEM, V270, P19839, DOI 10.1074/jbc.270.34.19839; VELAZQUEZ JM, 1984, CELL, V36, P655, DOI 10.1016/0092-8674(84)90345-3; VOJTEK AB, 1995, METHOD ENZYMOL, V255, P331; Wozniak RW, 1998, TRENDS CELL BIOL, V8, P184, DOI 10.1016/S0962-8924(98)01248-3; YANG J, 1994, MOL CELL BIOL, V14, P5088, DOI 10.1128/MCB.14.8.5088; Yoneda Y, 1997, J BIOCHEM, V121, P811; Zhang MJ, 1998, BIOCHEM BIOPH RES CO, V243, P113, DOI 10.1006/bbrc.1997.8070; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606; [No title captured]	50	52	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16501	16507		10.1074/jbc.274.23.16501	http://dx.doi.org/10.1074/jbc.274.23.16501			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347213	hybrid			2022-12-25	WOS:000080668600073
J	Uriarte, M; Marina, A; Ramon-Maiques, S; Fita, I; Rubio, V				Uriarte, M; Marina, A; Ramon-Maiques, S; Fita, I; Rubio, V			The carbamoyl-phosphate synthetase of Pyrococcus furiosus is enzymologically and structurally a carbamate kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE GENOME SEQUENCE; ESCHERICHIA-COLI; ARGININE-DEIMINASE; ARCHAEON; BINDING; EXPRESSION; SUBUNIT; ENZYME; ARCHAEBACTERIA; BIOSYNTHESIS	The hyperthermophiles Pyrococcus furiosus and Pyrococcus abyssi make pyrimidines and arginine from carbamoyl phosphate (CP) synthesized by an enzyme that differs from other carbamoyl-phosphate synthetases and that resembles carbamate kinase (CK) in polypeptide mass, amino acid sequence, and oligomeric organization, This enzyme was reported to use ammonia, bicarbonate, and two ATP molecules as carbamoyl-phosphate synthetases to make CP and to exhibit bicarbonate-dependent ATPase activity. We have reexamined these findings using the enzyme of P, furiosus expressed in Escherichia coli from the corresponding gene cloned in a plasmid, We show that the enzyme uses chemically made carbamate rather than ammonia and bicarbonate and catalyzes a reaction with the stoichiometry and equilibrium that are typical for CK, Furthermore, the enzyme catalyzes actively full reversion of the CK reaction and exhibits little bicarbonate-dependent ATPase, In addition, it cross-reacts with antibodies raised against CK from Enterococcus faecium, and its three-dimensional structure, judged by x-ray crystallography of enzyme crystals, is very similar to that of CK, Thus, the enzyme is, in all respects other than its function in vivo, a CK, Because in other organisms the function of CK is to make ATP from ADP and CP derived from arginine catabolism, this is the first example of using CK for making rather than using CP, The reasons for this use and the adaptation of the enzyme to this new function are discussed.	CSIC, Inst biomed Valencia, Valencia 46010, Spain; CSIC, Ctr Invest & Desarrollo, ES-08034 Barcelona, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biomedicina de Valencia (IBV); Consejo Superior de Investigaciones Cientificas (CSIC)	Rubio, V (corresponding author), CSIC, Inst biomed Valencia, C Jaime Roig 11, Valencia 46010, Spain.	rubio@ibv.csic.es	Marina, Alberto/H-6264-2011; Ramon-Maiques, Santiago/R-2533-2019; Rubio, Vicente/K-7919-2014	Marina, Alberto/0000-0002-1334-5273; Rubio, Vicente/0000-0001-8124-1196; Ramon-Maiques, Santiago/0000-0001-9674-8088				ABDELAL AT, 1979, ANNU REV MICROBIOL, V33, P139, DOI 10.1146/annurev.mi.33.100179.001035; ALLEN CM, 1964, BIOCHEMISTRY-US, V3, P1238, DOI 10.1021/bi00897a010; ANDERSON PM, 1965, BIOCHEMISTRY-US, V4, P2803, DOI 10.1021/bi00888a034; BAUR H, 1989, EUR J BIOCHEM, V179, P53, DOI 10.1111/j.1432-1033.1989.tb14520.x; BERGMEYER HU, 1986, METHOD ENZYMAT AN, V7, P346; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CAPLOW M, 1968, J AM CHEM SOC, V90, P6795, DOI 10.1021/ja01026a041; CHILDRESS JJ, 1993, NATURE, V362, P147, DOI 10.1038/362147a0; DAVIES GE, 1970, P NATL ACAD SCI USA, V66, P651, DOI 10.1073/pnas.66.3.651; DELTITO BJD, 1995, J BACTERIOL, V177, P7086, DOI 10.1128/jb.177.24.7086-7091.1995; Durbecq V, 1997, P NATL ACAD SCI USA, V94, P12803, DOI 10.1073/pnas.94.24.12803; FIALA G, 1986, ARCH MICROBIOL, V145, P56, DOI 10.1007/BF00413027; Gaastra W, 1984, Methods Mol Biol, V1, P349, DOI 10.1385/0-89603-062-8:349; Gomori G, 1942, J LAB CLIN MED, V27, P955; GUTHOHRL.G, 1969, EUR J BIOCHEM, V8, P207, DOI 10.1111/j.1432-1033.1969.tb00516.x; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JOHNSTONE A, 1987, IMMUNOCHEMISTRY PRAC; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kawarabayasi Y, 1998, DNA Res, V5, P55, DOI 10.1093/dnares/5.2.55; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; Knodler LA, 1998, J BIOL CHEM, V273, P4470, DOI 10.1074/jbc.273.8.4470; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEGENDRE N, 1993, PRACTICAL GUIDE PROT, P71; Legrain C, 1997, EUR J BIOCHEM, V247, P1046, DOI 10.1111/j.1432-1033.1997.01046.x; LEGRAIN C, 1995, MICROBIOL-SGM, V141, P1093, DOI 10.1099/13500872-141-5-1093; LILLEY MD, 1993, NATURE, V364, P45, DOI 10.1038/364045a0; Marina A, 1999, PROTEIN SCI, V8, P934; Marina A, 1998, EUR J BIOCHEM, V253, P280, DOI 10.1046/j.1432-1327.1998.2530280.x; Marshall M, 1970, METHOD ENZYMOL, V17, P229; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MEISTER A, 1989, ADV ENZYMOL RAMB, V62, P315; METZENBERG RL, 1958, J BIOL CHEM, V233, P1560; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NUZUM CT, 1975, UREA CYCLE, P325; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; Purcarea C, 1996, EUR J BIOCHEM, V236, P189, DOI 10.1111/j.1432-1033.1996.00189.x; Purcarea C, 1997, J BACTERIOL, V179, P4143, DOI 10.1128/jb.179.13.4143-4157.1997; PURCAREA C, 1995, THESIS U PARIS SUD P; ROSSMAN MG, 1972, MOL REPLACEMENT METH; RUBIO V, 1991, BIOCHEMISTRY-US, V30, P1068, DOI 10.1021/bi00218a027; Rubio V, 1998, EUR J BIOCHEM, V255, P262, DOI 10.1046/j.1432-1327.1998.2550262.x; RUBIO V, 1994, CARBON DIOXIDE FIXAT, P249; SANDLER SJ, 1994, J BACTERIOL, V176, P3661, DOI 10.1128/JB.176.12.3661-3672.1994; SIMMER JP, 1990, J BIOL CHEM, V265, P10395; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; Thoden JB, 1997, BIOCHEMISTRY-US, V36, P6305, DOI 10.1021/bi970503q; THORNE KJI, 1963, J BIOL CHEM, V238, P2992; VANDECASTEELE M, 1990, J GEN MICROBIOL, V136, P1177, DOI 10.1099/00221287-136-7-1177; WALDROP GL, 1994, BIOCHEMISTRY-US, V33, P10249, DOI 10.1021/bi00200a004	51	30	31	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16295	16303		10.1074/jbc.274.23.16295	http://dx.doi.org/10.1074/jbc.274.23.16295			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347186	hybrid			2022-12-25	WOS:000080668600046
J	Chen, CY; Faller, DV				Chen, CY; Faller, DV			Selective inhibition of protein kinase C isozymes by Fas ligation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL ACTIVATION; KAPPA-B ACTIVATION; SIGNAL-TRANSDUCTION; INDUCED APOPTOSIS; RECEPTOR SUPERFAMILY; MOLECULAR-CLONING; SURFACE ANTIGEN; DEATH DOMAIN; CERAMIDE; LYMPHOCYTES	Activation of protein kinase C (PKC) can protect cells from apoptosis induced by various agents, including Fas ligation. To elucidate a possible interaction between Fas-mediated apoptotic signals and activation-related protective signals, we investigated the impact of Fas ligation on PKC activity. We demonstrate that engagement of Fas on human lymphoid Jurkat cells triggered apoptosis, and Fas ligation resulted in partial blockade of cellular PKC activity. The phorbol 12-myristate 13-acetate-mediated translocation of PKC theta from the cytoplasm to the membrane was inhibited by treatment with anti-Fas antibody, whereas the translocation of PKC alpha or epsilon was not affected. In vitro kinase assay of PKC alpha or epsilon phosphotransferase activity demonstrated that Fas ligation inhibited the ability of PKC alpha to phosphorylate histone H1 as substrate but did not inhibit epsilon isozyme activity. This inhibition of PKC alpha activity mediated by Fas ligation was reversed by okadaic acid, a phosphatase inhibitor, suggesting the involvement of a member of the protein phosphatase 2A subfamily in this component of Fas signaling, Identical patterns of PKC isozyme inhibition were obtained using mouse thymoma cells over-expressing the fog gene (LF(+)), These results suggest that the selective inhibition of a potentially protective, PKC-mediated pathway by Fas activation may, to some extent, contribute to Fas-induced apoptotic signaling.	Boston Univ, Sch Med, Canc Res Ctr, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Pediat, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Microbiol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02118 USA	Boston University; Boston University; Boston University; Boston University; Boston University; Boston University	Faller, DV (corresponding author), Boston Univ, Sch Med, Canc Res Ctr, 80 E Concord St K-701, Boston, MA 02118 USA.				NATIONAL CANCER INSTITUTE [R01CA050459] Funding Source: NIH RePORTER; NCI NIH HHS [CA50459] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abbas AK, 1996, CELL, V84, P655, DOI 10.1016/S0092-8674(00)81042-9; BaierBitterlich G, 1996, MOL CELL BIOL, V16, P1842; BERRY N, 1990, EUR J BIOCHEM, V189, P205, DOI 10.1111/j.1432-1033.1990.tb15478.x; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; CANTRELL DA, 1985, P NATL ACAD SCI USA, V82, P8158, DOI 10.1073/pnas.82.23.8158; CHEN CY, 1995, ONCOGENE, V11, P1487; Chen CY, 1998, J BIOL CHEM, V273, P16700, DOI 10.1074/jbc.273.27.16700; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; COWLING GJ, 1994, PHILOS T ROY SOC B, V345, P257, DOI 10.1098/rstb.1994.0103; Datta R, 1997, J BIOL CHEM, V272, P20317, DOI 10.1074/jbc.272.33.20317; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DIAZMECO MT, 1993, MOL CELL BIOL, V13, P4770, DOI 10.1128/MCB.13.8.4770; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; EASTMAN A, 1994, CANCER RES, V54, P2812; Emoto Y, 1996, BLOOD, V87, P1990; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Gamard CJ, 1997, J BIOL CHEM, V272, P16474, DOI 10.1074/jbc.272.26.16474; GENOT EM, 1995, J BIOL CHEM, V270, P9833, DOI 10.1074/jbc.270.17.9833; Gubina E, 1998, BLOOD, V91, P823, DOI 10.1182/blood.V91.3.823.823_823_829; Gulbins E, 1998, J LEUKOCYTE BIOL, V63, P253, DOI 10.1002/jlb.63.2.253; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JONES MJ, 1995, J BIOL CHEM, V270, P5007, DOI 10.1074/jbc.270.10.5007; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; KIM MY, 1991, J BIOL CHEM, V266, P484; KISHIMOTO A, 1989, J BIOL CHEM, V264, P4088; KOVACS B, 1995, J IMMUNOL, V155, P5543; Lee JY, 1996, J BIOL CHEM, V271, P13169, DOI 10.1074/jbc.271.22.13169; MCCONKEY DJ, 1989, J BIOL CHEM, V264, P13399; Meller N, 1996, MOL CELL BIOL, V16, P5782; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; Monks CRF, 1997, NATURE, V385, P83, DOI 10.1038/385083a0; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, IMMUNOL TODAY, V16, P39, DOI 10.1016/0167-5699(95)80069-7; NEWTON AC, 1995, CURR BIOL, V5, P973, DOI 10.1016/S0960-9822(95)00191-6; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OEHM A, 1992, J BIOL CHEM, V267, P10709; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; RAJOTTE D, 1992, J BIOL CHEM, V267, P9980; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; Sawai H, 1997, J BIOL CHEM, V272, P2452; SINGER GG, 1994, IMMUNITY, V1, P365, DOI 10.1016/1074-7613(94)90067-1; Smith BL, 1996, J BIOL CHEM, V271, P16753, DOI 10.1074/jbc.271.28.16753; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TOMEI LD, 1988, BIOCHEM BIOPH RES CO, V155, P324, DOI 10.1016/S0006-291X(88)81088-X; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WEISS A, 1986, ANNU REV IMMUNOL, V4, P593, DOI 10.1146/annurev.iy.04.040186.003113; WHELAN RD, ONCOGENE, V16, P1939; WOLFF RA, 1994, J BIOL CHEM, V269, P19605	60	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15320	15328		10.1074/jbc.274.22.15320	http://dx.doi.org/10.1074/jbc.274.22.15320			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336417	hybrid			2022-12-25	WOS:000080560100006
J	Lopes, LR; Hoyal, CR; Knaus, UG; Babior, BM				Lopes, LR; Hoyal, CR; Knaus, UG; Babior, BM			Activation of the leukocyte NADPH oxidase by protein kinase C in a partially recombinant cell-free system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY BURST OXIDASE; CHRONIC GRANULOMATOUS-DISEASE; DEPENDENT SUPEROXIDE PRODUCTION; SODIUM DODECYL-SULFATE; GTP-BINDING PROTEIN; HUMAN-NEUTROPHILS; ANIONIC AMPHIPHILE; PHOSPHORYLATION; TRANSLOCATION; COMPONENTS	The leukocyte NADPH oxidase is an enzyme present in phagocytes and B lymphocytes that when activated catalyzes the production of O-2(radical anion) from oxygen at the expense of NADPH. A correlation between the activation of the oxidase and the phosphorylation of p47(PHOX), a cytosolic oxidase component, is well recognized in whole cells, and direct evidence for a relationship between the phosphorylation of this oxidase component and the activation of the oxidase has been obtained in a number of cell-free systems containing neutrophil membrane and cytosol. Using superoxide dismutase-inhibitable cytochrome c reduction to quantify O-2(radical anion) production, we now show that p47(PHOX) phosphorylated by protein kinase C activates the NADPH oxidase not only in a cell-free system containing neutrophil membrane and cytosol, but also in a system in which the cytosol is replaced by the recombinant proteins p67(PHOX), Rac2, and phosphorylated p47(PHOX), suggesting that neutrophil plasma membrane plus those three cytosolic proteins are both necessary and sufficient for oxidase activation. In both the cytosol-containing and recombinant cell-free systems, however, activation by SDS yielded greater rates of O-2(radical anion) production than activation by protein kinase C-phosphorylated p47PHOX, indicating that a system that employs protein kinase C-phosphorylated p47PHOX as the sole activating agent, although more physiological than the SDS-activated system, is nevertheless incomplete.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Lopes, LR (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA.		Lopes, Lucia R/B-9063-2012	Lopes, Lucia R/0000-0003-0530-7805	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024227, R37AI024227, R01AI028479] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00833] Funding Source: Medline; NIAID NIH HHS [AI-24227, AI-28479] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABO A, 1992, J BIOL CHEM, V267, P16767; BABIOR BM, 1984, CLIN RES, V32, pA550; BORREGAARD N, 1983, J CELL BIOL, V97, P52, DOI 10.1083/jcb.97.1.52; BROMBERG Y, 1984, CELL IMMUNOL, V88, P213, DOI 10.1016/0008-8749(84)90066-2; BROMBERG Y, 1985, J BIOL CHEM, V260, P3539; BROMBERG Y, 1994, J BIOL CHEM, V269, P7055; CHANOCK SJ, 1994, J BIOL CHEM, V269, P24519; COX JA, 1985, J CLIN INVEST, V76, P1932, DOI 10.1172/JCI112190; CROSS AR, 1982, BIOCHEM J, V204, P479, DOI 10.1042/bj2040479; Dana R, 1998, J BIOL CHEM, V273, P441, DOI 10.1074/jbc.273.1.441; ElBenna J, 1995, BLOOD CELL MOL DIS, V21, P201, DOI 10.1006/bcmd.1995.0023; FAUST LP, 1995, J CLIN INVEST, V96, P1499, DOI 10.1172/JCI118187; Hata K, 1998, J BIOL CHEM, V273, P4232, DOI 10.1074/jbc.273.7.4232; HAYAKAWA T, 1986, J BIOL CHEM, V261, P9109; HEYWORTH PG, 1990, BIOCHIM BIOPHYS ACTA, V1052, P299, DOI 10.1016/0167-4889(90)90225-3; HEYWORTH PG, 1991, J CLIN INVEST, V87, P352, DOI 10.1172/JCI114993; IYER SS, 1994, J BIOL CHEM, V269, P22405; KLEINBERG ME, 1990, J BIOL CHEM, V265, P15577; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KNAUS UG, 1992, J BIOL CHEM, V267, P23575; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETO TL, 1991, J BIOL CHEM, V266, P19812; MCPHAIL LC, 1985, J CLIN INVEST, V75, P1735, DOI 10.1172/JCI111884; MCPHAIL LC, 1995, P NATL ACAD SCI USA, V92, P7931, DOI 10.1073/pnas.92.17.7931; OKAMURA N, 1988, J BIOL CHEM, V263, P6777; PARK JW, 1994, BIOCHEMISTRY-US, V33, P2907, DOI 10.1021/bi00176a021; PARK JW, 1992, J BIOL CHEM, V267, P17327; Park JW, 1997, J BIOL CHEM, V272, P11035; QUINN MT, 1993, J BIOL CHEM, V268, P20983; SEGAL AW, 1985, NATURE, V316, P547, DOI 10.1038/316547a0; SHPUNGIN S, 1989, J BIOL CHEM, V264, P9195; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOMEYA A, 1993, FEBS LETT, V330, P215, DOI 10.1016/0014-5793(93)80276-Z; STEINBECK MJ, 1991, J BIOL CHEM, V266, P16336; TOUBIN HT, 1979, P NATL ACAD SCI USA, V76, P4350; Tsunawaki S, 1996, J EXP MED, V184, P893, DOI 10.1084/jem.184.3.893; TYAGI SR, 1992, BIOCHEMISTRY-US, V31, P2765, DOI 10.1021/bi00125a017	37	43	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15533	15537		10.1074/jbc.274.22.15533	http://dx.doi.org/10.1074/jbc.274.22.15533			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336447	hybrid			2022-12-25	WOS:000080560100036
J	Rulli, SJ; Horiba, MN; Skripnikova, E; Rabon, EC				Rulli, SJ; Horiba, MN; Skripnikova, E; Rabon, EC			Glu-857 moderates K+-dependent stimulation and SCH 28080-dependent inhibition of the gastric H,K-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA,K-ATPASE ALPHA-SUBUNIT; SITE-DIRECTED MUTAGENESIS; AMINO-ACID-SEQUENCE; CATION-BINDING-SITE; SARCOPLASMIC-RETICULUM; FUNCTIONAL EXPRESSION; BETA-SUBUNIT; TRANSMEMBRANE DOMAIN; MEMBRANE TOPOLOGY; H+/K+-ATPASE	The rabbit H,K-ATPase alpha- and beta-subunits were transiently expressed in HEK293 T cells. The co-expression of the H,K-ATPase alpha- and P-subunits was essential for the functional H,K-ATPase. The K+-stimulated H,K-ATPase activity of 0.82 +/- 0.2 mu mol/mg/h saturated with a K-0.5 (KCI) of 0.6 +/- 0.1 mM, whereas the 2-methyl-8-(phenylmethoxy)imidazo[1,2a]pyridine-3-acetonitrile (SCH 28080)-inhibited ATPase of 0.62 +/- 0.07 mu mol/mg/h saturated with a K-i (SCH 28080) of 1.0 +/- 0.3 mu M. Site mutations were introduced at the N,N-dicyclohexylcarbodiimide-reactive residue, Glu-857, to evaluate the role of this residue in ATPase function, Variations in the side chain size and charge of this residue did not inhibit the specific activity of the H,K-ATPase, but reversal of the side chain charge by substitution of Lys or Arg for Glu produced a reciprocal change in the sensitivity of the H,K-ATPase to K+ and SCH 28080. The K-0.5 for K+ stimulated ATPase was decreased to 0.2 +/- .05 and 0.2 +/- .03 mM, respectively, in Lys-857 and Arg-857 site mutants, whereas the K-i for SCH 28080-dependent inhibition was increased to 6.5 +/- 1.4 and 5.9 +/- 1.5 mu M, respectively. The H,K-ATPase kinetics were unaffected by the introduction of Ala at this site, but Leu produced a modest reciprocal effect. These data indicate that Glu-857 is not an essential residue for cation dependent activity but that the residue influences the kinetics of both K+ and SCH 28080-mediated functions. This finding suggests a possible role of this residue in the conformational equilibrium of the H,K-ATPase.	Tulane Univ, Med Ctr, Dept Physiol, New Orleans, LA 70112 USA; Dept Vet Affairs, New Orleans, LA 70112 USA	Tulane University	Rabon, EC (corresponding author), Tulane Univ, Med Ctr, Dept Physiol, SL39,1430 Tulane Ave, New Orleans, LA 70112 USA.							ARGUELLO JM, 1991, J BIOL CHEM, V266, P14627; ARGUELLO JM, 1994, J BIOL CHEM, V269, P6892; ARGUELLO JM, 1995, J BIOL CHEM, V270, P22764, DOI 10.1074/jbc.270.39.22764; Arguello JM, 1996, J BIOL CHEM, V271, P24610, DOI 10.1074/jbc.271.40.24610; Asano S, 1996, J BIOL CHEM, V271, P2740, DOI 10.1074/jbc.271.5.2740; BAMBERG K, 1992, BIOCHIM BIOPHYS ACTA, V1131, P69, DOI 10.1016/0167-4781(92)90100-E; BAYLE D, 1995, J BIOL CHEM, V270, P25678, DOI 10.1074/jbc.270.43.25678; Bayle D, 1997, J RECEPT SIGNAL TR R, V17, P29, DOI 10.3109/10799899709036593; Beggah A, 1996, J BIOL CHEM, V271, P20895, DOI 10.1074/jbc.271.34.20895; Beggah AT, 1997, J BIOL CHEM, V272, P10318; BESANCON M, 1993, BIOCHEMISTRY-US, V32, P2345, DOI 10.1021/bi00060a028; Boxenbaum N, 1998, J BIOL CHEM, V273, P23086, DOI 10.1074/jbc.273.36.23086; CAPASSO JM, 1992, J BIOL CHEM, V267, P1150; CLARKE DM, 1990, J BIOL CHEM, V265, P6262; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; CROWSON MS, 1992, J BIOL CHEM, V267, P13740; DEANCOS JG, 1988, BIOCHEMISTRY-US, V27, P1793; FENG JN, 1995, CELL MOL BIOL RES, V41, P29; Geering K, 1996, J CELL BIOL, V133, P1193, DOI 10.1083/jcb.133.6.1193; GOLDSHLEGER R, 1995, BIOCHEMISTRY-US, V34, P8668, DOI 10.1021/bi00027a016; GOLDSHLEGER R, 1992, P NATL ACAD SCI USA, V89, P6911, DOI 10.1073/pnas.89.15.6911; GORGA FR, 1985, BIOCHEMISTRY-US, V24, P6783, DOI 10.1021/bi00345a009; GRISHIN AV, 1994, FEBS LETT, V349, P144, DOI 10.1016/0014-5793(94)00655-5; HALL K, 1991, BIOCHIM BIOPHYS ACTA, V1077, P173, DOI 10.1016/0167-4838(91)90055-5; JAISSER F, 1993, J CELL BIOL, V123, P1421, DOI 10.1083/jcb.123.6.1421; JEWELLMOTZ EA, 1993, BIOCHEMISTRY-US, V32, P13523, DOI 10.1021/bi00212a018; KARLISH SJD, 1990, P NATL ACAD SCI USA, V87, P4566, DOI 10.1073/pnas.87.12.4566; Klaassen CHW, 1997, BIOCHEM J, V321, P419, DOI 10.1042/bj3210419; Klaassen CHW, 1997, ANN NY ACAD SCI, V834, P101, DOI 10.1111/j.1749-6632.1997.tb52230.x; Kone BC, 1998, J BIOL CHEM, V273, P2543, DOI 10.1074/jbc.273.5.2543; Kuntzweiler TA, 1996, J BIOL CHEM, V271, P29682, DOI 10.1074/jbc.271.47.29682; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE HC, 1978, BIOCHIM BIOPHYS ACTA, V508, P339, DOI 10.1016/0005-2736(78)90336-X; Lutsenko S, 1997, J BIOL CHEM, V272, P5249, DOI 10.1074/jbc.272.8.5249; LUTSENKO S, 1995, P NATL ACAD SCI USA, V92, P7936, DOI 10.1073/pnas.92.17.7936; LUTSENKO S, 1994, J BIOL CHEM, V269, P4555; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MAEDA M, 1988, BIOCHEM BIOPH RES CO, V157, P203, DOI 10.1016/S0006-291X(88)80033-0; MERCIER F, 1991, FASEB J, V5, pA749; NEWMAN PR, 1990, DNA CELL BIOL, V9, P749, DOI 10.1089/dna.1990.9.749; OKAMOTO CT, 1990, BIOCHIM BIOPHYS ACTA, V1037, P360, DOI 10.1016/0167-4838(90)90038-H; PEDEMONTE CH, 1986, J BIOL CHEM, V261, P6660; PICK U, 1979, BIOCHEMISTRY-US, V18, P108, DOI 10.1021/bi00568a017; RABON EC, 1993, J BIOL CHEM, V268, P8012; Rabon EC, 1996, J BIOL CHEM, V271, P32137, DOI 10.1074/jbc.271.50.32137; RABON EC, 1990, BIOCHIM BIOPHYS ACTA, V1039, P277, DOI 10.1016/0167-4838(90)90260-M; RABON EC, 1990, J BIOL CHEM, V265, P1594; SACHS G, 1976, J BIOL CHEM, V251, P7690; SHAINSKAYA A, 1994, J BIOL CHEM, V269, P10780; Shainskaya A, 1998, J BIOL CHEM, V273, P7311, DOI 10.1074/jbc.273.13.7311; SHIN JM, 1994, J BIOL CHEM, V269, P22533; SHULL GE, 1986, J BIOL CHEM, V261, P6788; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; Swarts HGP, 1996, J BIOL CHEM, V271, P29764, DOI 10.1074/jbc.271.47.29764; VANHUYSSE JW, 1993, BIOCHEMISTRY-US, V32, P819, DOI 10.1021/bi00054a012; VANHUYSSE JW, 1993, CELL MOL BIOL RES, V39, P497; YODA A, 1970, BIOCHEM BIOPH RES CO, V40, P880, DOI 10.1016/0006-291X(70)90985-X	58	4	4	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					15245	15250		10.1074/jbc.274.21.15245	http://dx.doi.org/10.1074/jbc.274.21.15245			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329734	hybrid			2022-12-25	WOS:000081965200099
J	Rumbaugh, JA; Henricksen, LA; DeMott, MS; Bambara, RA				Rumbaugh, JA; Henricksen, LA; DeMott, MS; Bambara, RA			Cleavage of substrates with mismatched nucleotides by flap endonuclease-1 - Implications for mammalian Okazaki fragment processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SV40 DNA-REPLICATION; BASE EXCISION-REPAIR; SINGLE-STRANDED-DNA; CALF RTH-1 NUCLEASE; SIMIAN VIRUS-40 DNA; 3' EXONUCLEASE; SCHIZOSACCHAROMYCES-POMBE; PURIFIED PROTEINS; POLYMERASE-ALPHA; YEAST	Flap endonuclease-l (FEN1) is proposed to participate in removal of the initiator RNA of mammalian Okazaki fragments by two pathways. In one pathway, RNase HI removes most of the RNA, leaving a single ribonucleotide adjacent to the DNA FEN1 removes this ribonucleotide exonucleolytically. In the other pathway, FEN1 removes the entire primer endonucleolytically after displacement of the 5'-end region of the Okazaki fragment. Cleavage would occur beyond the RNA, a short distance into the DNA, The initiator RNA and an adjacent short region of DNA are synthesized by DNA polymerase alpha/primase. Because the fidelity of DNA polymerase a is lower than that of the DNA polymerases that complete DNA extension, mismatches occur relatively frequently near the 5'-ends of Okazaki fragments. We have examined the ability of FEN1 to repair such errors. Results show that mismatched bases up to 15 nucleotides from the 5'-end of an annealed DNA strand change the pattern of FEN1 cleavage. Instead of removing terminal nucleotides sequentially, FEN1 appears to cleave a portion of the mismatched strand endonucleolytically. We propose that a mismatch destabilizes the helical structure over a nearby area. This allows FEN1 to cleave more efficiently, facilitating removal of the mismatch. If mismatches were not introduced during synthesis of the Okazaki fragment, helical disruption would not occur, nor would unnecessary degradation of the 5'-end of the fragment.	Univ Rochester, Sch Med & Dent, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Ctr Canc, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Bambara, RA (corresponding author), Univ Rochester, Sch Med & Dent, Med Ctr, Dept Biochem & Biophys, Box 712,601 Elmwood Ave, Rochester, NY 14642 USA.				NCI NIH HHS [CA11198] Funding Source: Medline; NIGMS NIH HHS [GM18961, GM24441] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA011198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024441] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; Barnes CJ, 1996, J BIOL CHEM, V271, P29624, DOI 10.1074/jbc.271.47.29624; BUDD ME, 1995, J BIOL CHEM, V270, P26766, DOI 10.1074/jbc.270.45.26766; Budd ME, 1997, MOL CELL BIOL, V17, P2136, DOI 10.1128/MCB.17.4.2136; Ceska TA, 1996, NATURE, V382, P90, DOI 10.1038/382090a0; DeMott MS, 1996, J BIOL CHEM, V271, P30068, DOI 10.1074/jbc.271.47.30068; DeMott MS, 1998, J BIOL CHEM, V273, P27492, DOI 10.1074/jbc.273.42.27492; Frank P, 1998, FEBS LETT, V421, P23, DOI 10.1016/S0014-5793(97)01528-7; Freudenreich CH, 1998, SCIENCE, V279, P853, DOI 10.1126/science.279.5352.853; FRIEDBERG EC, 1996, DNA REPLICATION EUKA; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; HIRAOKA LR, 1995, GENOMICS, V25, P220, DOI 10.1016/0888-7543(95)80129-A; Huang L, 1996, BIOCHEMISTRY-US, V35, P9266, DOI 10.1021/bi9603074; JOHNSON RE, 1995, SCIENCE, V269, P238, DOI 10.1126/science.7618086; KENNY MK, 1989, P NATL ACAD SCI USA, V86, P9757, DOI 10.1073/pnas.86.24.9757; Kim K, 1998, J BIOL CHEM, V273, P8842, DOI 10.1074/jbc.273.15.8842; KIM Y, 1995, NATURE, V376, P612, DOI 10.1038/376612a0; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Kornberg A., 1992, DNA REPLICATION; KUNKEL TA, 1992, BIOESSAYS, V14, P303, DOI 10.1002/bies.950140503; Lehmann AR, 1996, MUTAT RES-DNA REPAIR, V363, P147, DOI 10.1016/0921-8777(96)00017-1; LINDAHL T, 1995, PHILOS T ROY SOC B, V347, P57, DOI 10.1098/rstb.1995.0009; LONGLEY MJ, 1990, NUCLEIC ACIDS RES, V18, P7317, DOI 10.1093/nar/18.24.7317; Mueser TC, 1996, CELL, V85, P1101, DOI 10.1016/S0092-8674(00)81310-0; MURANTE RS, 1994, J BIOL CHEM, V269, P1191; Murante RS, 1996, J BIOL CHEM, V271, P25888, DOI 10.1074/jbc.271.42.25888; Murante RS, 1995, J BIOL CHEM, V270, P30377, DOI 10.1074/jbc.270.51.30377; MURRAY JM, 1994, MOL CELL BIOL, V14, P4878, DOI 10.1128/MCB.14.7.4878; NETHANEL T, 1992, J VIROL, V66, P6634, DOI 10.1128/JVI.66.11.6634-6640.1992; PERRINO FW, 1990, BIOCHEMISTRY-US, V29, P5526; REAGAN MS, 1995, J BACTERIOL, V177, P364, DOI 10.1128/jb.177.2.364-371.1995; ROBERTS JD, 1991, P NATL ACAD SCI USA, V88, P3465, DOI 10.1073/pnas.88.8.3465; Rumbaugh JA, 1997, J BIOL CHEM, V272, P22591, DOI 10.1074/jbc.272.36.22591; Sambrook J., 2002, MOL CLONING LAB MANU; SIEGAL G, 1992, P NATL ACAD SCI USA, V89, P9377, DOI 10.1073/pnas.89.20.9377; SOMMERS CH, 1995, J BIOL CHEM, V270, P4193, DOI 10.1074/jbc.270.9.4193; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1961; TURCHI JJ, 1993, J BIOL CHEM, V268, P15136; TURCHI JJ, 1994, P NATL ACAD SCI USA, V91, P9803, DOI 10.1073/pnas.91.21.9803; WAGA S, 1994, J BIOL CHEM, V269, P10923; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523	44	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					14602	14608		10.1074/jbc.274.21.14602	http://dx.doi.org/10.1074/jbc.274.21.14602			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329652	hybrid			2022-12-25	WOS:000081965200017
J	Lazarova, DL; Spengler, BA; Biedler, JL; Ross, RA				Lazarova, DL; Spengler, BA; Biedler, JL; Ross, RA			HuD, a neuronal-specific RNA-binding protein, is a putative regulator of N-myc pre-mRNA processing/stability in malignant human neuroblasts	ONCOGENE			English	Article						HuD; N-myc; human neuroblastoma; RNA-binding protein	3' UNTRANSLATED REGION; ENCEPHALOMYELITIS SENSORY NEURONOPATHY; FACTOR MESSENGER-RNAS; CELL-LINES; NUCLEOTIDE-SEQUENCE; GENE-EXPRESSION; BLASTOMA CELLS; SEX-LETHAL; IN-VITRO; RICH	N-myc gene copy numbers and transcription rates are similar in N (neuroblastic, tumorigenic) and S (nonneuronal, non-tumorigenic) neuroblastoma cells with chromosomally integrated amplified N-myc genes. However, er, N cells show significantly higher N-myc mRNA levels than S cells. Therefore, post-transcriptional control of N-myc gene expression must differ between these cell types, Since no differences in N-myc mRNA half-life were found between N and S cells from two cell lines, steady-state levels of N-myc pre-mRNA processing intermediates were analysed. Results suggest that the differences in N-myc expression arise primarily at the nuclear post-transcriptional level. The neuronal-specific RNA-binding Hu proteins are present in cytoplasmic acid nuclear fractions of N cells and one of them, HuD, binds specifically to both exonic and intronic N-myc RNA sequences. In sense and antisense HuD-transfected N cells, there are coordinate changes in HuD and N-myc expression le,els, Thus, we propose that HuD plays a role in the nuclear processing/stability of N-myc pre-mRNA in N-type neuroblastoma cells.	Fordham Univ, Dept Biol Sci, Bronx, NY 10458 USA	Fordham University	Ross, RA (corresponding author), Fordham Univ, Dept Biol Sci, 441 E Fordham Rd, Bronx, NY 10458 USA.							BABISS LE, 1990, MOL CELL BIOL, V10, P6700, DOI 10.1128/MCB.10.12.6700; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BERGER SL, 1994, NUCLEIC ACIDS RES, V22, P3218, DOI 10.1093/nar/22.15.3218; BIEDLER JL, 1978, CANCER RES, V38, P3751; BRAWERMAN G, 1989, CELL, V57, P9, DOI 10.1016/0092-8674(89)90166-9; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BRODEUR GM, 1981, CANCER RES, V41, P4678; Chagnovich D, 1996, J BIOL CHEM, V271, P33587, DOI 10.1074/jbc.271.52.33587; Chagnovich D, 1996, J BIOL CHEM, V271, P33580, DOI 10.1074/jbc.271.52.33580; CHEN QY, 1995, MOL CELL BIOL, V15, P2010; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CICCARONE V, 1989, CANCER RES, V49, P219; CRIST WM, 1991, NEW ENGL J MED, V324, P461, DOI 10.1056/NEJM199102143240706; DALMAU J, 1991, NEUROLOGY, V41, P1757, DOI 10.1212/WNL.41.11.1757; DALMAU J, 1992, AM J PATHOL, V141, P881; ERBA HP, 1986, NUCLEIC ACIDS RES, V14, P5275, DOI 10.1093/nar/14.13.5275; Favaloro J, 1980, Methods Enzymol, V65, P718; Gao FB, 1996, J CELL SCI, V109, P579; GAO FB, 1994, P NATL ACAD SCI USA, V91, P11207, DOI 10.1073/pnas.91.23.11207; GOOD PJ, 1995, P NATL ACAD SCI USA, V92, P4557, DOI 10.1073/pnas.92.10.4557; Graveley BR, 1996, MOL CELL BIOL, V16, P4942; HIRVONEN H, 1989, J CELL BIOL, V108, P1093, DOI 10.1083/jcb.108.3.1093; HORMIGO A, 1994, J NEUROIMMUNOL, V55, P205, DOI 10.1016/0165-5728(94)90011-6; IKEGAKI N, 1986, P NATL ACAD SCI USA, V83, P5929, DOI 10.1073/pnas.83.16.5929; Jain RG, 1997, MOL CELL BIOL, V17, P954, DOI 10.1128/MCB.17.2.954; KING PH, 1994, J NEUROSCI, V14, P1943; KOHL NE, 1983, CELL, V35, P359, DOI 10.1016/0092-8674(83)90169-1; Kostyk SK, 1996, NEUROREPORT, V7, P1549, DOI 10.1097/00001756-199607080-00003; Koushika SP, 1996, CURR BIOL, V6, P1634, DOI 10.1016/S0960-9822(02)70787-2; KRYSTAL G, 1988, MOL CELL BIOL, V8, P3373, DOI 10.1128/MCB.8.8.3373; KRYSTAL GW, 1990, MOL CELL BIOL, V10, P4180, DOI 10.1128/MCB.10.8.4180; LEVINE TD, 1993, MOL CELL BIOL, V13, P3494, DOI 10.1128/MCB.13.6.3494; LIU J, 1995, NEUROLOGY, V45, P544, DOI 10.1212/WNL.45.3.544; Lou H, 1996, GENE DEV, V10, P208, DOI 10.1101/gad.10.2.208; MANLEY GT, 1995, ANN NEUROL, V38, P102, DOI 10.1002/ana.410380117; MARUSICH MF, 1992, DEV BIOL, V149, P295, DOI 10.1016/0012-1606(92)90285-O; MARUSICH MF, 1994, J NEUROBIOL, V25, P143, DOI 10.1002/neu.480250206; MCCULLOUGH AJ, 1993, MOL CELL BIOL, V13, P7689, DOI 10.1128/MCB.13.12.7689; MULLER WEG, 1992, J MOL BIOL, V226, P721, DOI 10.1016/0022-2836(92)90628-W; Okano HJ, 1997, J NEUROSCI, V17, P3024; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; RETTIG WJ, 1987, CANCER RES, V47, P1383; ROSS RA, 1995, CELL GROWTH DIFFER, V6, P449; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SAKAI K, 1994, BIOCHEM BIOPH RES CO, V199, P1200, DOI 10.1006/bbrc.1994.1358; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SEEGER RC, 1977, CANCER RES, V37, P1364; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SINGH R, 1995, SCIENCE, V268, P1173, DOI 10.1126/science.7761834; Sivak L. E., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P187; Spengler BA, 1997, ONCOL RES, V9, P467; STANTON LW, 1986, P NATL ACAD SCI USA, V83, P1772, DOI 10.1073/pnas.83.6.1772; SZABO A, 1991, CELL, V67, P325, DOI 10.1016/0092-8674(91)90184-Z; Tora M, 1997, NEUROLOGY, V48, P735, DOI 10.1212/WNL.48.3.735; Wakamatsu Y, 1997, DEVELOPMENT, V124, P3449; Wang JW, 1997, J BIOL CHEM, V272, P22227, DOI 10.1074/jbc.272.35.22227	56	45	46	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 29	1999	18	17					2703	2710		10.1038/sj.onc.1202621	http://dx.doi.org/10.1038/sj.onc.1202621			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FH	10348344				2022-12-25	WOS:000080124900005
J	Bartsch, D; Hahn, SA; Danichevski, KD; Ramaswamy, A; Bastian, D; Galehdari, H; Barth, P; Schmiegel, W; Simon, B; Rothmund, M				Bartsch, D; Hahn, SA; Danichevski, KD; Ramaswamy, A; Bastian, D; Galehdari, H; Barth, P; Schmiegel, W; Simon, B; Rothmund, M			Mutations of the DPC4/Smad4 gene in neuroendocrine pancreatic tumors	ONCOGENE			English	Article						non-functioning neuroendocrine pancreatic; carcinoma; gastrinoma; insulinoma; DPC4/Smad4; tumor-suppressor genes	DPC4 GENE; SUPPRESSOR GENE; IN-VIVO; GASTRINOMAS; ADENOCARCINOMA; CARCINOMA; NEOPLASIA; 18Q21.1; CANCERS; MEN1	Tumors of the endocrine pancreas are extremely rare, and molecular mechanisms leading to their development are not well understood, ii candidate tumor suppressor gene, DPC4, located at 18q21, has recently been shown to be inactivated in half of pancreatic adenocarcinoma xenografts, The close anatomical relationship of the exocrine and endocrine pancreas prompted us to determine the role of DPC4 in the tumorigenesis of 25 pancreatic islet cell tumors (II insulinomas, nine nonfunctioning endocrine carcinomas, three gastrinomas, two vipomas). A mutation screening of the highly conserved COOH-terminal domain of DPC4 (exons 8-11) was performed by single-strand conformational variant (SSCP) analysis and a PCR-based deletion assay. Five of nine (55%) non-functioning endocrine pancreatic carcinomas revealed either point mutations, small intragenic deletions or homozygous deletion of DPC4 sequences compared to none of the insulinomas, gastrinomas or vipomas, These results suggest that DPC4 is an important target gene promoting tumorigenesis of non-functioning neuroendocrine pancreatic carcinomas.	Univ Marburg, Dept Surg, D-35043 Marburg, Germany; Univ Marburg, Dept Pathol, D-35043 Marburg, Germany; Univ Marburg, Dept Internal Med, D-35043 Marburg, Germany; Setchenov Med Acad, Moscow 109507, Russia; Ruhr Univ Bochum, Dept Internal Med, D-44892 Bochum, Germany	Philipps University Marburg; Philipps University Marburg; Philipps University Marburg; Ruhr University Bochum	Bartsch, D (corresponding author), Univ Marburg, Dept Surg, Baldringerstr, D-35043 Marburg, Germany.		Hahn, Stephan A./AAV-6062-2021; Hahn, Stephan/E-3880-2010	Hahn, Stephan A./0000-0003-0855-9741; Hahn, Stephan/0000-0003-0855-9741				Barrett MT, 1996, CANCER RES, V56, P4351; BARTSCH D, 1995, GENE CHROMOSOME CANC, V14, P189, DOI 10.1002/gcc.2870140306; Chandrasekharappa SC, 1997, SCIENCE, V276, P404, DOI 10.1126/science.276.5311.404; EDIS AJ, 1984, MANUAL ENDOCRINE SUR; EVERS BM, 1994, ANN SURG, V219, P596, DOI 10.1097/00000658-199406000-00002; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hahn SA, 1998, CANCER RES, V58, P1124; Hahn SA, 1996, CANCER RES, V56, P490; HAHN SA, 1995, CANCER RES, V55, P4670; Hoque ATMS, 1997, GUT, V40, P120, DOI 10.1136/gut.40.1.120; Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086; Kim SK, 1996, CANCER RES, V56, P2519; Kong XT, 1997, CANCER RES, V57, P3772; Lei JY, 1996, ONCOGENE, V13, P2459; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; McGrogan D, 1997, ONCOGENE, V15, P1111; Muscarella P, 1998, CANCER RES, V58, P237; Nagatake M, 1996, CANCER RES, V56, P2718; Schutte M, 1996, CANCER RES, V56, P2527; Takagi Y, 1996, GASTROENTEROLOGY, V111, P1369, DOI 10.1053/gast.1996.v111.pm8898652; THIAGALINGAM S, 1996, NAT GENET, V13, P342; Trump D, 1996, QJM-INT J MED, V89, P653; YASHIRO T, 1993, SURGERY, V114, P758; YOSHIMOTO K, 1992, CANCER RES, V53, P1057; Zhuang ZP, 1997, CANCER RES, V57, P4682	25	95	99	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 8	1999	18	14					2367	2371		10.1038/sj.onc.1202585	http://dx.doi.org/10.1038/sj.onc.1202585			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184DT	10327057				2022-12-25	WOS:000079595500009
J	Cook, JL; Zhang, Z; Alam, J; Re, RN				Cook, JL; Zhang, Z; Alam, J; Re, RN			Effects of chromosomal integration site upon p53 interactions with DNA consensus sequence homologies	ONCOGENE			English	Article						p53; consensus sequence; chromatin; stable transfection	GENE-EXPRESSION; BINDING-SITE; WILD-TYPE; TRANSCRIPTIONAL ACTIVATION; MCK PROMOTER; CELL-LINES; REPRESSION	In the present study, we report that, despite the presence of one perfect p53 consensus sequence homology (designated SCL CS) and four half-sites within the 3'-untranslated region of the stem cell leukemia (SCL) gene, the native endogenous gene is not regulated by p53, We employ a tet-repressible system to show that, under conditions in which the WAF1 mRNA steady-state level is upregulated fourfold by p53, the SCL mRNA level is not altered, In a previous report, ne demonstrated that p53 interactions with the SCL CS can upregulate downstream reporter gene activity 43-fold in transient reporter assays, This disparity prompted us to explore the differences between p53 regulation of SCL CS activity in organized (chromosomally integrated) and disorganized (non-replicating episomal plasmid) chromatin. We show that p53 can increase (between 3-80-fold), decrease (between 5-33-fold) or have no effect upon transactivation of an SCL CS/reporter fusion gene depending upon chromosomal integration site. Most studies used to characterize p53 binding sites employ transient transfection assays. Our results suggest that characterization of consensus sequence homologies by assay of transiently transfected cells mag be inaccurate.	Alton Ochsner Med Fdn & Ochsner Clin, Div Res, New Orleans, LA 70121 USA	Ochsner Health System	Cook, JL (corresponding author), Alton Ochsner Med Fdn & Ochsner Clin, Div Res, 1516 Jefferson Hwy, New Orleans, LA 70121 USA.		Alam, Jawed/F-2596-2010	Alam, Jawed/0000-0001-6520-482X				ACKLANDBERGLUND CE, 1995, BIOTECHNIQUES, V18, P196; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BI SC, 1994, CANCER RES, V54, P582; Chin PL, 1997, ONCOGENE, V15, P87, DOI 10.1038/sj.onc.1201161; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOK JL, 1995, ONCOGENE, V11, P723; DEB SP, 1994, ONCOGENE, V9, P1341; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; FURTH PA, 1994, P NATL ACAD SCI USA, V91, P9302, DOI 10.1073/pnas.91.20.9302; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HOWE JR, 1995, J BIOL CHEM, V270, P14168, DOI 10.1074/jbc.270.23.14168; Jackson P, 1997, FEBS LETT, V406, P271, DOI 10.1016/S0014-5793(97)00283-4; Jackson P, 1998, ONCOGENE, V16, P283, DOI 10.1038/sj.onc.1201491; Kristjuhan A, 1995, EUR J BIOCHEM, V234, P827, DOI 10.1111/j.1432-1033.1995.827_a.x; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; Metcalfe AMJ, 1997, NUCLEIC ACIDS RES, V25, P983, DOI 10.1093/nar/25.5.983; Morris GF, 1996, P NATL ACAD SCI USA, V93, P895, DOI 10.1073/pnas.93.2.895; OConnor DJ, 1995, EMBO J, V14, P6184, DOI 10.1002/j.1460-2075.1995.tb00309.x; OSIFCHIN NE, 1994, J BIOL CHEM, V269, P6383; PARK DJ, 1994, ONCOGENE, V9, P1899; PENNIE WD, 1995, MOL CELL BIOL, V15, P2125; PONTE P, 1984, NUCLEIC ACIDS RES, V12, P1687, DOI 10.1093/nar/12.3.1687; RAIMOND J, 1995, FEBS LETT, V363, P165, DOI 10.1016/0014-5793(95)00310-6; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584	28	6	6	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 8	1999	18	14					2373	2379		10.1038/sj.onc.1202566	http://dx.doi.org/10.1038/sj.onc.1202566			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184DT	10327058				2022-12-25	WOS:000079595500010
J	Metcalfe, S; Weeds, A; Okorokov, AL; Milner, J; Cockman, M; Pope, B				Metcalfe, S; Weeds, A; Okorokov, AL; Milner, J; Cockman, M; Pope, B			Wild-type p53 protein shows calcium-dependent binding to F-actin	ONCOGENE			English	Article						p53; actin; calcium	TUMOR-SUPPRESSOR P53; MUTANT P53; DISRUPTION; CLEAVAGE; CELLS	Nuclear localization of p53 is required for p53 to detect and respond to DNA strand abnormalities and breaks following DNA damage. This leads to activation of the tumour suppressive functions of p53 resulting in either cell cycle arrest and DNA repair; or apoptosis, Critical functional changes in DNA which require strand breaks, including gene rearrangement, may transiently mimic DNA damage: here it is important not to trigger a p53 response. The fine control of p53 in these different circumstances is unknown but may include transient sequestering of p53 in the cytoplasm, Reversible nuclear-cytoplasmic shuttling is an intrinsic property of p53 (Middeler et al,, 1997) associated with cell cycle-related changes in p53's subcellular distribution, Takahashi and Suzuki (1994) described p53 inactivation by shuttling to the cytoplasm and Katsumoto et al, (1995) found wildtype p53 to be closely associated,vith cytoplasmic actin filaments during DNA synthesis. Here we show that, in the presence of free calcium ions, p53 binds directly to F-actin with a dissocation constant of about 10 mu M. Thus, part of the regulatory machinery in normal cell cycling may involve p53-actin interactions regulated by calcium fluxes and the dynamic turnover of F-actin.	Addenbrookes Hosp, Dept Surg, Cambridge CB2 2QQ, England; MRC, Mol Biol Lab, Cambridge CB2 2QQ, England; Univ York, YCRC P53 Lab, York YO1 5DD, N Yorkshire, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; MRC Laboratory Molecular Biology; University of York - UK	Metcalfe, S (corresponding author), Addenbrookes Hosp, Dept Surg, Hills Rd,Box 202, Cambridge CB2 2QQ, England.		Cockman, Matthew/V-9619-2019	Cockman, Matthew/0000-0002-3310-4821; Okorokov, Andrei/0000-0003-2477-3254				Ayscough KR, 1998, CURR OPIN CELL BIOL, V10, P102, DOI 10.1016/S0955-0674(98)80092-6; Comer KA, 1998, ONCOGENE, V16, P1299, DOI 10.1038/sj.onc.1201645; FOURIE AM, 1997, J BIOL CHEM, V272, P1947; GANNON JV, 1991, NATURE, V349, P802; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Guenal I, 1997, J CELL SCI, V110, P489; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; HOUK TW, 1974, ANAL BIOCHEM, V62, P66, DOI 10.1016/0003-2697(74)90367-4; Katsumoto T, 1995, BIOL CELL, V84, P167, DOI 10.1016/0248-4900(96)89426-3; Klotzsche O, 1998, ONCOGENE, V16, P3423, DOI 10.1038/sj.onc.1202155; Madden SL, 1997, ONCOGENE, V15, P1079, DOI 10.1038/sj.onc.1201091; Maki CG, 1996, CANCER RES, V56, P2649; Middeler G, 1997, ONCOGENE, V14, P1407, DOI 10.1038/sj.onc.1200949; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; Molinari M, 1996, ONCOGENE, V13, P2077; POPE B, 1994, FEBS LETT, V338, P58, DOI 10.1016/0014-5793(94)80116-9; Pope BJ, 1997, BIOCHEMISTRY-US, V36, P15848, DOI 10.1021/bi972192p; Rubtsova SN, 1998, FEBS LETT, V430, P353, DOI 10.1016/S0014-5793(98)00692-9; TAKAHASHI K, 1994, ONCOGENE, V9, P183; TAYLOR RS, 1976, BIOCHEM J, V159, P301, DOI 10.1042/bj1590301; WAY M, 1992, J CELL BIOL, V116, P1135, DOI 10.1083/jcb.116.5.1135; Whitesell L, 1998, MOL CELL BIOL, V18, P1517, DOI 10.1128/MCB.18.3.1517	22	39	39	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 8	1999	18	14					2351	2355		10.1038/sj.onc.1202559	http://dx.doi.org/10.1038/sj.onc.1202559			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184DT	10327055				2022-12-25	WOS:000079595500007
J	Yang, HK; Kang, SH; Kim, YS; Won, K; Bang, YJ; Kim, SJ				Yang, HK; Kang, SH; Kim, YS; Won, K; Bang, YJ; Kim, SJ			Truncation of the TGF-beta type II receptor gene results in insensitivity to TGF-beta in human gastric cancer cells	ONCOGENE			English	Article						transforming growth factor-beta; cancer; mutation; carcinogenesis; receptor	MICROSATELLITE INSTABILITY; COLORECTAL CANCERS; GROWTH-INHIBITION; MUTATIONS; COLON; EXPRESSION; KINASE	The transforming growth factor-beta (TGF-beta receptor system has been implicated in the development of resistance to the growth-inhibitory effects of TGF-beta. It has been reported that resistance to TGF-beta correlates with inactivation of the TGF-beta type II receptor (RII). In the present report, we examine the genetic changes in the TGF-beta RII gene of human gastric cancer cell lines, SNU-5 and SNU-668, which we had previously reported to express truncated TGF-beta RII transcripts. By independent PCR and Southern hybridization analysis of genomic DNA, we found that the genomic sequence of TGF-beta RII is truncated after exon 2 in SNU-5 and after exon 3 in SNU-668. This was confirmed by sequencing the TGF-beta RII cDNA cloned from a SNU-5 cDNA library. Predicted TGF-beta RII protein of SNU-5 cells based on sequencing data contains only a part of extracellular domain of TGF-beta RII. We demonstrate that cotransfection of 3TP-Lux and wild type TGF-beta RII restores the TGF-beta responsiveness in SNU-5 cells, suggesting that genetic changes in the TGF-beta RII gene of SNU-5 cells are responsible for the loss of sensitivity to TGF-beta. This is the first report demonstrating that truncation of the TGF-beta RII gene is an alternative mechanism to inactivate the TGF-beta signal transduction pathways.	NCI, Lab Cell Regulat & Carcinogenesis, Bethesda, MD 20892 USA; Seoul Natl Univ, Coll Med, Canc Res Ctr, Seoul, South Korea	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Seoul National University (SNU)	Kim, SJ (corresponding author), NCI, Lab Cell Regulat & Carcinogenesis, Bethesda, MD 20892 USA.		Yang, Han-Kwang/J-2767-2012; Bang, Yung Jue/J-2759-2012	Bang, Yung Jue/0000-0001-6000-4597				BIOBIN GP, 1996, LAB INVEST, V74, P513; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; GARRIGUEANTAR L, 1995, CANCER RES, V55, P3892; HAHM KB, IN PRESS; INAGAKI M, 1993, P NATL ACAD SCI USA, V90, P5359, DOI 10.1073/pnas.90.11.5359; Kim David H., 1996, Journal of Biomedical Science, V3, P143, DOI 10.1007/BF02253095; KIMCHI A, 1988, SCIENCE, V240, P196, DOI 10.1126/science.2895499; LIN HY, 1994, CELL MOL BIOL, V40, P337; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; Lu SL, 1996, CANCER RES, V56, P4595; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Markowitz Sanford D., 1996, Cytokine and Growth Factor Reviews, V7, P93, DOI 10.1016/1359-6101(96)00001-9; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MYEROFF LL, 1995, CANCER RES, V55, P5545; Ohue M, 1996, INT J CANCER, V68, P203, DOI 10.1002/(SICI)1097-0215(19961009)68:2<203::AID-IJC11>3.0.CO;2-B; Park JG, 1997, INT J CANCER, V70, P443, DOI 10.1002/(SICI)1097-0215(19970207)70:4<443::AID-IJC12>3.0.CO;2-G; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; PARSONS R, 1995, CANCER RES, V55, P5548; PEPTIN MC, 1996, BIOCHEM BIOPH RES CO, V220, P289; Renault B, 1996, HUM GENET, V98, P601, DOI 10.1007/s004390050267; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; SPORN MB, 1985, NATURE, V313, P747; SUN LZ, 1994, J BIOL CHEM, V269, P26449; Takenoshita S, 1997, ONCOGENE, V14, P1255, DOI 10.1038/sj.onc.1200938; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0	28	31	33	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 1	1999	18	13					2213	2219		10.1038/sj.onc.1202535	http://dx.doi.org/10.1038/sj.onc.1202535			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	182YE	10327067	Bronze			2022-12-25	WOS:000079525100005
J	Hughes-Fulford, M; Gilbertson, V				Hughes-Fulford, M; Gilbertson, V			Osteoblast fibronectin mRNA, protein synthesis, and matrix are unchanged after exposure to microgravity	FASEB JOURNAL			English	Article; Proceedings Paper	Symposium of the European-Space-Agency/National-Aeronautics-and-Space-Administration Workshop on Cell and Molecular Biology Research in Space	JUN, 1998	BELGIUM NATL ACAD SCI, LEUVEN, BELGIUM	European Space Agcy, NASA	BELGIUM NATL ACAD SCI	growth activation; spaceflight; mRNA expression	MESSENGER-RNA EXPRESSION; GENE-EXPRESSION; SHAPE CHANGES; CELL-SHAPE; DIFFERENTIATION; BONE	The well-defined osteoblast line, MC3T3-E1 was used to examine fibronectin (FN) mRNA levels, protein synthesis, and extracellular FN matrix accumulation after growth activation in spaceflight. These osteoblasts produce FN extracellular matrix (ECM) known to regulate adhesion, differentiation, and function in adherent cells. Changes in bone ECM and osteoblast cell shape occur in spaceflight. To determine whether altered FN matrix is a factor in causing these changes in spaceflight, quiescent osteoblasts were launched into microgravity and were then sera activated with and without a 1-gravity field. Synthesis of FN mRNA, protein, and matrix were measured after activation in microgravity, FN mRNA synthesis is significantly reduced in microgravity (0-G) when compared to ground (GR) osteoblasts flown in a centrifuge simulating earth's gravity (1-G) field 2.5 h after activation. However, 27.5 h after activation there were no significant differences in mRNA synthesis. A small but significant reduction of FN protein was found in the 0-G samples 2.5 h after activation. Total FN protein 27.5 h after activation showed no significant difference between any of the gravity conditions, however, there was a fourfold increase in absolute amount of protein synthesized during the incubation. Using immunofluorescence, we found no significant differences in the amount or in the orientation of the FN matrix after 27.5 h in microgravity, These results demonstrate that FN is made by sera-activated osteoblasts even during exposure to microgravity. These data also suggest that after a total period of 43 h of spaceflight FN transcription, translation, or altered matrix assembly is not responsible for the altered cell shape or altered matrix formation of osteoblasts.	Vet Adm Med Ctr, Lab Cell Growth & Differentiat, San Francisco, CA 94121 USA; Univ Calif San Francisco, Med Ctr, San Francisco, CA 94121 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco	Hughes-Fulford, M (corresponding author), Vet Adm Med Ctr, Lab Cell Growth 151F, 4150 Clement St, San Francisco, CA 94121 USA.	milliehf@spacedu.com		Hughes-Fulford, Millie/0000-0002-0756-068X				ADAMS JC, 1993, DEVELOPMENT, V117, P1183; BENZEEV A, 1991, BIOESSAYS, V13, P207, DOI 10.1002/bies.950130502; BOONSTRA J, 1997, ESA PUBLICATION; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; Fitzgerald J, 1996, EXP CELL RES, V228, P168, DOI 10.1006/excr.1996.0313; Fitzgerald J, 1999, FASEB J, V13, P553, DOI 10.1096/fasebj.13.3.553; Globus RK, 1998, J CELL SCI, V111, P1385; GUIGNANDON A, 1995, CELL STRUCT FUNCT, V20, P369, DOI 10.1247/csf.20.369; HUGHESFULFORD M, 1993, RECEPTOR, V3, P145; HUGHESFULFORD M, 1991, EXP GERONTOL, V26, P247, DOI 10.1016/0531-5565(91)90017-G; HUGHESFULFORD M, 1999, IN PRESS EFFECT MICR; INGBER DE, 1990, P NATL ACAD SCI USA, V87, P3579, DOI 10.1073/pnas.87.9.3579; KACENA MA, 1997, GRAVITATIONAL SPACE, V11, P15; Kodama HA., 1981, JPN J ORAL BIOL, V23, P899, DOI DOI 10.2330/JORALBIOSCI1965.23.899; Leong J, 1996, EXP CELL RES, V224, P79, DOI 10.1006/excr.1996.0113; MACK PB, 1971, AEROSPACE MED, V42, P828; MCNAMEE HP, 1993, J CELL BIOL, V121, P673, DOI 10.1083/jcb.121.3.673; Moursi AM, 1996, J CELL SCI, V109, P1369; Nicogossian AE., 1989, SPACE PHYSL MED, V2nd/4th Edition; ROBERTS WE, 1987, AM J PHYSIOL, V252, pR247, DOI 10.1152/ajpregu.1987.252.2.R247; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; Tjandrawinata RR, 1997, FASEB J, V11, P493, DOI 10.1096/fasebj.11.6.9194530; TURNER RT, 1985, P SOC EXP BIOL MED, V180, P544; VOSE GP, 1974, AM J ROENTGENOL, V121, P1; WEISS RE, 1980, P NATL ACAD SCI-BIOL, V77, P2074, DOI 10.1073/pnas.77.4.2074; WINNARD RG, 1995, J BONE MINER RES, V10, P1969	28	22	25	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.		1999	13			S			S121	S127						7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	198CF	10352153				2022-12-25	WOS:000080403800015
J	Leuschner, WD; Hoch, W				Leuschner, WD; Hoch, W			Subtype-specific assembly of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor subunits is mediated by their N-terminal domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; INHIBITORY GLYCINE RECEPTOR; D-ASPARTATE RECEPTOR; GLUTAMATE-RECEPTOR; BINDING-PROTEINS; CA2+ PERMEABILITY; AMPA RECEPTORS; TRANSMEMBRANE SEGMENT; FUNCTIONAL EXPRESSION; TETRAMERIC STRUCTURE	Glutamate receptors (GluR) are oligomeric protein complexes formed by the assembly of four or perhaps five subunits, The rules that govern the selectivity of this process are not well understood. Here, we expressed combinations of subunits from two related GluR subfamilies in COS7 cells, the alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) and kainate receptors. By co-immunoprecipitation experiments, we assessed the ability of AMPA receptor subunits to assemble into multimeric complexes. Subunits GluR1-4 associated with indistinguishable efficiency with each other, whereas the kainate receptor subunits GluR6 and 7 showed a much lower degree of association with GluR1, Using chimeric receptors and truncation fragments of subunits, we show that this assembly specificity is determined by N-terminal regions of these subunits and that the most N-terminal domain of GluR2 together with a membrane anchor efficiently associates with GLuR1.	Max Planck Inst Entwicklungsbiol, Biochem Abt, D-72076 Tubingen, Germany	Max Planck Society	Hoch, W (corresponding author), Max Planck Inst Entwicklungsbiol, Biochem Abt, Spemannstr 35, D-72076 Tubingen, Germany.	werner.hoch@tuebingen.mpg.de						ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Angulo MC, 1997, J NEUROSCI, V17, P6685; BABILA T, 1994, NEURON, V12, P615, DOI 10.1016/0896-6273(94)90217-8; BECKER CM, 1989, J NEUROCHEM, V53, P124, DOI 10.1111/j.1471-4159.1989.tb07303.x; BENNETT JA, 1995, NEURON, V14, P373, DOI 10.1016/0896-6273(95)90293-7; BONIFACINO JS, 1990, CELL, V63, P503, DOI 10.1016/0092-8674(90)90447-M; BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; BROSE N, 1994, J BIOL CHEM, V269, P16780; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COSSON P, 1992, SCIENCE, V258, P659, DOI 10.1126/science.1329208; Dong HL, 1997, NATURE, V386, P279, DOI 10.1038/386279a0; ECKERSKORN C, 1988, EUR J BIOCHEM, V176, P509, DOI 10.1111/j.1432-1033.1988.tb14308.x; FERNS M, 1992, NEURON, V8, P1079, DOI 10.1016/0896-6273(92)90129-2; FERNS MJ, 1993, NEURON, V11, P491, DOI 10.1016/0896-6273(93)90153-I; FerrerMontiel AV, 1996, P NATL ACAD SCI USA, V93, P2741, DOI 10.1073/pnas.93.7.2741; GREEN WN, 1993, CELL, V74, P57, DOI 10.1016/0092-8674(93)90294-Z; GREEN WN, 1995, TRENDS NEUROSCI, V18, P280, DOI 10.1016/0166-2236(95)93915-K; GU Y, 1991, J CELL BIOL, V114, P799, DOI 10.1083/jcb.114.4.799; GU Y, 1990, NEURON, V5, P147, DOI 10.1016/0896-6273(90)90305-Y; Hackam AS, 1997, J BIOL CHEM, V272, P13750, DOI 10.1074/jbc.272.21.13750; Hackam AS, 1998, J NEUROCHEM, V70, P40; Hall RA, 1997, J NEUROCHEM, V68, P625; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HOLLMANN M, 1994, NEURON, V13, P1331, DOI 10.1016/0896-6273(94)90419-7; Hopf C, 1998, EUR J BIOCHEM, V253, P382, DOI 10.1046/j.1432-1327.1998.2530382.x; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KREIENKAMP HJ, 1995, NEURON, V14, P635, DOI 10.1016/0896-6273(95)90320-8; KUHSE J, 1993, NEURON, V11, P1049, DOI 10.1016/0896-6273(93)90218-G; KURYATOV A, 1994, NEURON, V12, P1291, DOI 10.1016/0896-6273(94)90445-6; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBOLEZ B, 1992, NEURON, V9, P247, DOI 10.1016/0896-6273(92)90164-9; Lampinen M, 1998, EMBO J, V17, P4704, DOI 10.1093/emboj/17.16.4704; Langosch D, 1996, J MOL BIOL, V263, P525, DOI 10.1006/jmbi.1996.0595; Laube B, 1998, J NEUROSCI, V18, P2954; Leonard AS, 1998, J BIOL CHEM, V273, P19518, DOI 10.1074/jbc.273.31.19518; LERMA J, 1994, EUR J NEUROSCI, V6, P1080, DOI 10.1111/j.1460-9568.1994.tb00605.x; Lissin DV, 1998, P NATL ACAD SCI USA, V95, P7097, DOI 10.1073/pnas.95.12.7097; Mano I, 1998, NEUROREPORT, V9, P327, DOI 10.1097/00001756-199801260-00027; Michaelis EK, 1998, PROG NEUROBIOL, V54, P369, DOI 10.1016/S0301-0082(97)00055-5; MIYASHIRO K, 1994, P NATL ACAD SCI USA, V91, P10800, DOI 10.1073/pnas.91.23.10800; NAKANISHI N, 1992, P NATL ACAD SCI USA, V89, P8552, DOI 10.1073/pnas.89.18.8552; Nishimune A, 1998, NEURON, V21, P87, DOI 10.1016/S0896-6273(00)80517-6; Osten P, 1998, NEURON, V21, P99, DOI 10.1016/S0896-6273(00)80518-8; Premkumar LS, 1997, J GEN PHYSIOL, V110, P485, DOI 10.1085/jgp.110.5.485; PUCHALSKI RB, 1994, NEURON, V13, P131, DOI 10.1016/0896-6273(94)90464-2; Rosenmund C, 1998, SCIENCE, V280, P1596, DOI 10.1126/science.280.5369.1596; Sahara Y, 1997, J NEUROSCI, V17, P6611; SHEN NV, 1993, NEURON, V11, P67; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; Srivastava S, 1998, NEURON, V21, P581, DOI 10.1016/S0896-6273(00)80568-1; STERNBACH Y, 1994, NEURON, V13, P1345, DOI 10.1016/0896-6273(94)90420-0; Swanson GT, 1997, J NEUROSCI, V17, P58, DOI 10.1523/JNEUROSCI.17-01-00058.1997; Tsang TC, 1996, BIOTECHNIQUES, V20, P51; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; VERDOORN TA, 1991, SCIENCE, V252, P1715, DOI 10.1126/science.1710829; Villmann C, 1997, J NEUROSCI, V17, P7634, DOI 10.1523/jneurosci.17-20-07634.1997; Wang ZZ, 1996, J BIOL CHEM, V271, P27575, DOI 10.1074/jbc.271.44.27575; WENTHOLD RJ, 1994, J BIOL CHEM, V269, P1332; WENTHOLD RJ, 1992, J BIOL CHEM, V267, P501; Wenthold RJ, 1996, J NEUROSCI, V16, P1982; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WO ZG, 1994, P NATL ACAD SCI USA, V91, P7154, DOI 10.1073/pnas.91.15.7154; Wood MW, 1997, J BIOL CHEM, V272, P3532, DOI 10.1074/jbc.272.6.3532; Wu TY, 1996, BIOCHEM J, V319, P731, DOI 10.1042/bj3190731; Xia J, 1999, NEURON, V22, P179, DOI 10.1016/S0896-6273(00)80689-3; ZHANG D, 1995, NEUROSCIENCE, V67, P177, DOI 10.1016/0306-4522(94)00627-H	70	93	101	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16907	16916		10.1074/jbc.274.24.16907	http://dx.doi.org/10.1074/jbc.274.24.16907			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358037	hybrid			2022-12-25	WOS:000080780400036
J	Rena, G; Guo, SD; Cichy, SC; Unterman, TG; Cohen, P				Rena, G; Guo, SD; Cichy, SC; Unterman, TG; Cohen, P			Phosphorylation of the transcription factor forkhead family member FKHR by protein kinase B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; P70 S6 KINASE; CAENORHABDITIS-ELEGANS; MAPKAP KINASE-1; ACTIVATION; INSULIN; INHIBITION; GENE; PATHWAY; SIGNALS	Protein kinase B lies "downstream" of phosphatidylinositide (PtdIns) 3-kinase and is thought to mediate many of the intracellular actions of insulin and other growth factors. Here we show that FKHR, a human homologue of the DAF16 transcription factor in Caenorhabditis elegans, is rapidly phosphorylated by human protein kinase B alpha (PKB alpha) at Thr-24, Ser-256, and Ser-319 in vitro and at a much faster rate than BAD, which is thought to be a physiological substrate for PKB, The same three sites, which all lie in the canonical PKB consensus sequences (Arg-Xaa-Arg-Xaa-Xaa-(Ser/Thr)), became phosphorylated when FKHR was cotransfected with either PKB or PDK1 (an upstream activator of PKB), All three residues became phosphorylated when 293 cells were stimulated with insulin-like growth factor 1 (IGF-1), The IGF-1-induced phosphorylation was abolished by the PtdIns 3-kinase inhibitor wortmannin but not by PD 98059 (an inhibitor of the mitogen-activated protein kinase cascade) or by rapamycin, These results indicate that FKHR is a physiological substrate of PKB and that it may mediate some of the physiological effects of PKB on gene expression. DAF16 is known to be a component of a signaling pathway that has been partially dissected genetically and includes homologues of the insulin/IGF-1 receptor, PtdIns 8-kinase and PKB, The conservation of Thr-24, Ser-256, and Ser-319 and the sequences surrounding them in DAF16 therefore suggests that DAF16 is also a direct substrate for PKB in C, elegans.	Univ Dundee, Dept Biochem, Med Res Council Prot Phosphorylat Unit, Dundee DD1 5EH, Scotland; Univ Illinois, Coll Med, Chicago, IL 60612 USA; Chicago Area Vet Hlth Care Syst, W Side Div, Chicago, IL 60612 USA	University of Dundee; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Rena, G (corresponding author), Univ Dundee, Dept Biochem, Med Res Council Prot Phosphorylat Unit, Dundee DD1 5EH, Scotland.		Rena, Graham/AAV-7985-2021	Rena, Graham/0000-0002-9121-1350				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Anderson MJ, 1998, GENOMICS, V47, P187, DOI 10.1006/geno.1997.5122; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Barthel A, 1997, ENDOCRINOLOGY, V138, P3559, DOI 10.1210/en.138.8.3559; BIGGS WH, 1999, IN PRESS P NATL ACAD; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Casamayor A, 1999, CURR BIOL, V9, P186, DOI 10.1016/S0960-9822(99)80088-8; Cichy SB, 1998, J BIOL CHEM, V273, P6482, DOI 10.1074/jbc.273.11.6482; Cohen P, 1997, FEBS LETT, V410, P3, DOI 10.1016/S0014-5793(97)00490-0; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Currie RA, 1999, BIOCHEM J, V337, P575, DOI 10.1042/0264-6021:3370575; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Deprez J, 1997, J BIOL CHEM, V272, P17269, DOI 10.1074/jbc.272.28.17269; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; Hajduch E, 1998, DIABETES, V47, P1006, DOI 10.2337/diabetes.47.7.1006; Hillion J, 1997, BLOOD, V90, P3714, DOI 10.1182/blood.V90.9.3714; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; LEIGHTON IA, 1995, FEBS LETT, V375, P289, DOI 10.1016/0014-5793(95)01170-J; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; PETRITSCH C, 1995, EUR J BIOCHEM, V230, P431, DOI 10.1111/j.1432-1033.1995.0431h.x; Rena G, 1998, NUCLEIC ACIDS RES, V26, P3867, DOI 10.1093/nar/26.16.3867; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; Shaw M, 1997, FEBS LETT, V416, P307, DOI 10.1016/S0014-5793(97)01235-0; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Sutherland C, 1998, J BIOL CHEM, V273, P3198, DOI 10.1074/jbc.273.6.3198; Thomas G, 1997, CURR OPIN CELL BIOL, V9, P782, DOI 10.1016/S0955-0674(97)80078-6; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; Wood WB, 1998, CELL, V95, P147, DOI 10.1016/S0092-8674(00)81744-4	38	586	608	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17179	17183		10.1074/jbc.274.24.17179	http://dx.doi.org/10.1074/jbc.274.24.17179			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358075	hybrid			2022-12-25	WOS:000080780400074
J	Roussel, A; Canaan, S; Egloff, MP; Riviere, M; Dupuis, L; Verger, R; Cambillau, C				Roussel, A; Canaan, S; Egloff, MP; Riviere, M; Dupuis, L; Verger, R; Cambillau, C			Crystal structure of human gastric lipase and model of lysosomal acid lipase, two lipolytic enzymes of medical interest	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTER STORAGE-DISEASE; CANDIDA-RUGOSA LIPASE; INTERFACIAL ACTIVATION; ENZYMATIC-ACTIVITY; MOLECULAR-CLONING; WOLMAN-DISEASE; INSECT CELLS; HYDROLASE; PURIFICATION; EXPRESSION	Fat digestion in humans requires not only the classical pancreatic lipase but also gastric lipase, which is stable and active despite the highly acidic stomach environment. We report here the structure of recombinant human gastric lipase at 3.0-Angstrom resolution, the first structure to be described within the mammalian acid lipase family. This globular enzyme (379 residues) consists of a core domain belonging to the alpha/beta hydrolase-fold family and a "cap" domain, which is analogous to that present in serine carboxypeptidases. It possesses a classical catalytic triad (Ser-153, His-353, Asp-324) and an oxyanion hole (NH groups of G1n-154 and Leu-67), Four N-glycosylation sites were identified on the electron density maps. The catalytic serine is deeply buried under a segment consisting of 30 residues, which can be defined as a lid and belonging to the cap domain. The displacement of the lid is necessary for the substrates to have access to Ser-153, A phosphonate inhibitor was positioned in the active site that clearly suggests the location of the hydrophobic substrate binding site. The lysosomal acid lipase was modeled by homology, and possible explanations for some previously reported mutations leading to the cholesterol ester storage disease are given based on the present model.	CNRS IFR1 UPR 9025, Lab Lipolyse Enzymat, F-13402 Marseille 20, France; CNRS IFR1 UPR 9039, F-13402 Marseille 20, France	Centre National de la Recherche Scientifique (CNRS)	Cambillau, C (corresponding author), CNRS IFR1 UPR 9025, Lab Lipolyse Enzymat, 31 Chemin Joseph Aiguier, F-13402 Marseille 20, France.	cambillau@afmb.cnrs-mrs.fr	berti, liliane/F-5878-2011					AMEIS D, 1994, EUR J BIOCHEM, V219, P905, DOI 10.1111/j.1432-1033.1994.tb18572.x; AMEIS D, 1995, J LIPID RES, V36, P241; ANDERSON RA, 1991, J BIOL CHEM, V266, P22479; ANDERSON RA, 1994, P NATL ACAD SCI USA, V91, P2718, DOI 10.1073/pnas.91.7.2718; AOUBALA M, 1994, BBA-LIPID LIPID MET, V1213, P319, DOI 10.1016/0005-2760(94)00058-1; ASLANIDIS C, 1994, GENOMICS, V20, P329, DOI 10.1006/geno.1994.1180; Aslanidis C, 1996, GENOMICS, V33, P85, DOI 10.1006/geno.1996.0162; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BODMER MW, 1987, BIOCHIM BIOPHYS ACTA, V909, P237, DOI 10.1016/0167-4781(87)90083-2; BRENNER S, 1988, NATURE, V334, P528, DOI 10.1038/334528a0; BRUNGER AT, 1992, X PLOR VERSION 3 1; BRZOZOWSKI AM, 1991, NATURE, V351, P491, DOI 10.1038/351491a0; BURKE JA, 1972, SCIENCE, V176, P309, DOI 10.1126/science.176.4032.309; Canaan S, 1998, PROTEIN EXPRES PURIF, V14, P23, DOI 10.1006/prep.1998.0946; CARRIERE F, 1993, GASTROENTEROLOGY, V105, P876, DOI 10.1016/0016-5085(93)90908-U; CARRIERE F, 1994, LIPASES THEIR STRUCT, P181; De Caro J, 1998, BBA-PROTEIN STRUCT M, V1386, P39, DOI 10.1016/S0167-4838(98)00058-2; DEREWENDA ZS, 1992, J MOL BIOL, V227, P818, DOI 10.1016/0022-2836(92)90225-9; EGLOFF MP, 1995, BIOCHEMISTRY-US, V34, P2751, DOI 10.1021/bi00009a003; GARGOURI Y, 1986, GASTROENTEROLOGY, V91, P919, DOI 10.1016/0016-5085(86)90695-5; GARGOURI Y, 1988, J BIOL CHEM, V263, P2159; GOLDSTEIN JL, 1977, ANNU REV BIOCHEM, V46, P897, DOI 10.1146/annurev.bi.46.070177.004341; GROCHULSKI P, 1994, BIOCHEMISTRY-US, V33, P3494, DOI 10.1021/bi00178a005; GROCHULSKI P, 1994, PROTEIN SCI, V3, P82; Hamosh, 1990, LINGUAL GASTRIC LIPA; Kleywegt GJ, 1994, 1 MAP FINAL MODEL, P59; KLIMA H, 1993, J CLIN INVEST, V92, P2713, DOI 10.1172/JCI116888; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRAUT J, 1977, ANNU REV BIOCHEM, V46, P331, DOI 10.1146/annurev.bi.46.070177.001555; Lang DA, 1998, EUR J BIOCHEM, V254, P333, DOI 10.1046/j.1432-1327.1998.2540333.x; LAPEY A, 1974, J PEDIATR-US, V84, P328, DOI 10.1016/S0022-3476(74)80712-2; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIAO DI, 1992, BIOCHEMISTRY-US, V31, P9796, DOI 10.1021/bi00155a037; Lohse P, 1997, J LIPID RES, V38, P1896; Lohse P, 1997, J LIPID RES, V38, P892; Longhi S, 1997, PROTEIN SCI, V6, P275; MARTINEZ C, 1994, BIOCHEMISTRY-US, V33, P83, DOI 10.1021/bi00167a011; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MOREAU H, 1992, J MOL BIOL, V225, P147, DOI 10.1016/0022-2836(92)91032-K; MOREAU H, 1989, HISTOCHEMISTRY, V91, P419, DOI 10.1007/BF00493829; MULLER DPR, 1975, GUT, V16, P838; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nicolas A, 1996, BIOCHEMISTRY-US, V35, P398, DOI 10.1021/bi9515578; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; Pagani F, 1996, HUM MOL GENET, V5, P1611, DOI 10.1093/hmg/5.10.1611; PAGANO NJ, 1994, MECH COMPOS MATER, V1, P3; Pariyarath R, 1996, FEBS LETT, V397, P79, DOI 10.1016/S0014-5793(96)01134-9; PATRICK AD, 1969, NATURE, V222, P1087; PETERSEN SB, 1994, LIPASES THEIR STRUCT, P23; Roussel A, 1998, PROTEINS, V32, P523; Roussel A, 1991, SILICON GRAPHICS GEO, P86; RUDENKO G, 1995, STRUCTURE, V3, P1249, DOI 10.1016/S0969-2126(01)00260-X; SEEDORF U, 1995, ARTERIOSCL THROM VAS, V15, P773, DOI 10.1161/01.ATV.15.6.773; Suzuki A, 1997, GASTROENTEROLOGY, V112, P2048, DOI 10.1053/gast.1997.v112.pm9178698; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Uppenberg J, 1995, BIOCHEMISTRY-US, V34, P16838, DOI 10.1021/bi00051a035; VANTILBEURGH H, 1993, NATURE, V362, P814, DOI 10.1038/362814a0; WickerPlanquart C, 1996, PROTEIN ENG, V9, P1225, DOI 10.1093/protein/9.12.1225	61	132	145	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16995	17002		10.1074/jbc.274.24.16995	http://dx.doi.org/10.1074/jbc.274.24.16995			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358049	hybrid			2022-12-25	WOS:000080780400048
J	Ujita, M; McAuliffe, J; Hindsgaul, O; Sasaki, K; Fukuda, MN; Fukuda, M				Ujita, M; McAuliffe, J; Hindsgaul, O; Sasaki, K; Fukuda, MN; Fukuda, M			Poly-N-acetyllactosamine synthesis in branched N-glycans is controlled by complemental branch specificity of i-extension enzyme and beta 1,4-galactosyltransferase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; BLOOD-GROUP-I; ASPARAGINE-LINKED OLIGOSACCHARIDES; LYSOSOMAL MEMBRANE-GLYCOPROTEINS; HUMAN-ERYTHROCYTE-MEMBRANE; L-SELECTIN; CARBOHYDRATE STRUCTURE; SUGAR CHAINS; KIDNEY CELLS; HL-60 CELLS	Poly-N-acetyllactosamine is a unique carbohydrate that can carry various functional oligosaccharides, such as sialyl Lewis X. It has been shown that the amount of poly-N-acetyllactosamine is increased in N-glycans, when they contain Gal beta 1 --> 4GlcNAc beta 1 --> 6(Gal beta 1 --> 4GlcNAc beta 1 --> 2)Man alpha 1 --> branched structure. To determine how this increased synthesis of poly-N-acetyllactosamines takes place, the branched acceptor was incubated with a mixture of i-extension enzyme (iGnT) and beta 1,4-galactosyltransferase I(beta 4Gal-TI), First, N-acetyllactosamine repeats were more readily added to the branched acceptor than the summation of poly-N-acetyllactosamines formed individually on each unbranched acceptor. Surprisingly, poly-N-acetyllactosamine was more efficiently formed on Gal beta 1 --> 4GlcNAc beta 1 --> 2Man alpha --> R side chain than in Gal beta 1 --> 4GlcNAc beta 1 --> 6Man alpha --> R, due to preferential action of iGnT on Gal beta 1 --> 4GlcNAc beta 1 --> 2Man alpha --> R side chain. On the other hand, galactosylation was much more efficient on pl,G-linked GlcNAc than beta 1,a-linked GlcNAc, preferentially forming Gal beta 1 --> 4GlcNAc beta 1 --> 6(GlcNA beta 1 --> 2)Man alpha 1 --> 6Man beta --> R. Starting with this preformed acceptor, N-acetyllactosamine repeats were added almost equally to Gal beta 1 --> 4GlcNAc beta 1 --> 6Man alpha --> R and Gal beta 1 --> 4GlcNA beta 1 --> 2Man alpha --> R side chains. Taken together, these results indicate that the complemental branch specificity of iGnT and beta 4Gal-TI leads to efficient and equal addition of N-acetyllactosamine repeats on both side chains of GlcNAc beta 1 --> 6(GlcNAc beta 1 --> 2)Man alpha 1 --> 6Man beta --> R structure, which is consistent with the structures found in nature. The results also suggest that the addition of Gal beta 1 --> 4GlcNA beta 1 --> 6 side chain on Gal beta 1 --> 4GlcNAc beta 1 --> 2Man --> R side chain converts the acceptor to one that is much more favorable for iGnT and beta 4Gal-TI.	Burnham Inst, Ctr Canc Res, Glycobiol Program, La Jolla, CA 92037 USA; Kyowa Hakko Kogyo Co Ltd, Tokyo Res Labs, Machida, Tokyo 194, Japan	Sanford Burnham Prebys Medical Discovery Institute; Kyowa Kirin Ltd	Ujita, M (corresponding author), Burnham Inst, Ctr Canc Res, Glycobiol Program, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NATIONAL CANCER INSTITUTE [R01CA048737, P01CA071932] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA71932, R01 CA48737] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Angata K, 1998, J BIOL CHEM, V273, P28524, DOI 10.1074/jbc.273.43.28524; Bakker H, 1997, J BIOL CHEM, V272, P18580, DOI 10.1074/jbc.272.30.18580; BIERHUIZEN MFA, 1993, GENE DEV, V7, P468, DOI 10.1101/gad.7.3.468; BLANKEN WM, 1982, EUR J BIOCHEM, V127, P547, DOI 10.1111/j.1432-1033.1982.tb06906.x; BOCK K, 1992, CARBOHYD RES, V228, P1, DOI 10.1016/S0008-6215(00)90544-5; Cho SK, 1997, J BIOL CHEM, V272, P13622, DOI 10.1074/jbc.272.21.13622; CUMMINGS RD, 1984, J BIOL CHEM, V259, P6253; DABROWSKI U, 1984, J BIOL CHEM, V259, P7648; DEMETRIOU M, 1995, J CELL BIOL, V130, P383, DOI 10.1083/jcb.130.2.383; DENNIS JW, 1987, SCIENCE, V236, P582, DOI 10.1126/science.2953071; FUKUDA M, 1988, J BIOL CHEM, V263, P5314; FUKUDA M, 1984, J BIOL CHEM, V259, P8260; FUKUDA M, 1984, J BIOL CHEM, V259, P4782; FUKUDA M, 1986, J BIOL CHEM, V261, P2796; FUKUDA M, 1979, J BIOL CHEM, V254, P3700; FUKUDA M, 1984, J BIOL CHEM, V259, P925; Fukuda M., 1994, MOL GLYCOBIOLOGY, P1; FUKUDA MN, 1981, J BIOL CHEM, V256, P3900; FUKUDA MN, 1982, J BIOL CHEM, V257, P446; FUKUDA MN, 1992, CRC HDB ENDOGLYCOSID, P55; GLASGOW LR, 1977, J BIOL CHEM, V252, P8615; HANISCH FG, 1989, J BIOL CHEM, V264, P872; HEMMERICH S, 1995, J BIOL CHEM, V270, P12035, DOI 10.1074/jbc.270.20.12035; HOKKE CH, 1995, EUR J BIOCHEM, V228, P981, DOI 10.1111/j.1432-1033.1995.tb20350.x; HOKKE CH, 1991, FEBS LETT, V286, P18, DOI 10.1016/0014-5793(91)80931-R; HUBBARD SC, 1987, J BIOL CHEM, V262, P16403; IMAI Y, 1993, NATURE, V361, P555; JARNEFELT J, 1978, J BIOL CHEM, V253, P8006; KRUSIUS T, 1978, EUR J BIOCHEM, V92, P289, DOI 10.1111/j.1432-1033.1978.tb12747.x; LEE N, 1990, J BIOL CHEM, V265, P20476; LOWE BJ, 1994, MOL GLYCOBIOLOGY, P163; MCEVER RP, 1995, J BIOL CHEM, V270, P11025, DOI 10.1074/jbc.270.19.11025; MIZOGUCHI A, 1984, J BIOL CHEM, V259, P1949; MURAMATSU T, 1979, CELL, V18, P183, DOI 10.1016/0092-8674(79)90367-2; Nakayama J, 1996, J BIOL CHEM, V271, P1829, DOI 10.1074/jbc.271.4.1829; Ohyama C, 1999, EMBO J, V18, P1516, DOI 10.1093/emboj/18.6.1516; PIERCE M, 1986, J BIOL CHEM, V261, P772; Rosen SD, 1996, CURR BIOL, V6, P261, DOI 10.1016/S0960-9822(02)00473-6; SAITOH O, 1992, J BIOL CHEM, V267, P5700; SASAKI H, 1987, J BIOL CHEM, V262, P12059; Sasaki K, 1997, P NATL ACAD SCI USA, V94, P14294, DOI 10.1073/pnas.94.26.14294; Sato T, 1998, P NATL ACAD SCI USA, V95, P472, DOI 10.1073/pnas.95.2.472; SCHACHTER H, 1991, Glycobiology, V1, P453, DOI 10.1093/glycob/1.5.453; Schwientek T, 1998, J BIOL CHEM, V273, P29331, DOI 10.1074/jbc.273.45.29331; SMITH DF, 1990, J BIOL CHEM, V265, P6225; SRIVASTAVA G, 1992, CARBOHYD RES, V224, P83, DOI 10.1016/0008-6215(92)84095-A; Taguchi T, 1997, GLYCOBIOLOGY, V7, P31, DOI 10.1093/glycob/7.1.31; TAKEUCHI M, 1988, J BIOL CHEM, V263, P3657; Tsuboi S, 1996, J BIOL CHEM, V271, P27213, DOI 10.1074/jbc.271.44.27213; Ujita M, 1998, J BIOL CHEM, V273, P34843, DOI 10.1074/jbc.273.52.34843; Ujita M, 1999, J BIOL CHEM, V274, P9296, DOI 10.1074/jbc.274.14.9296; VANDENEIJNDEN DH, 1988, J BIOL CHEM, V263, P12461; WATSON E, 1994, GLYCOBIOLOGY, V4, P227, DOI 10.1093/glycob/4.2.227; Wilkins PP, 1996, J BIOL CHEM, V271, P18732, DOI 10.1074/jbc.271.31.18732; YAMASHITA K, 1984, J BIOL CHEM, V259, P834; ZDEBSKA E, 1983, CARBOHYD RES, V120, P113, DOI 10.1016/0008-6215(83)88011-2; Zhou DP, 1999, P NATL ACAD SCI USA, V96, P406, DOI 10.1073/pnas.96.2.406	57	52	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16717	16726		10.1074/jbc.274.24.16717	http://dx.doi.org/10.1074/jbc.274.24.16717			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358011	hybrid			2022-12-25	WOS:000080780400010
J	Yao, XL; Cowan, MJ; Gladwin, MT; Lawrence, MM; Angus, CW; Shelhamer, JH				Yao, XL; Cowan, MJ; Gladwin, MT; Lawrence, MM; Angus, CW; Shelhamer, JH			Dexamethasone alters arachidonate release from human epithelial cells by induction of p11 protein synthesis and inhibition of phospholipase A(2) activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-II PHOSPHOLIPASE-A2; CA2+-SENSITIVE CYTOSOLIC PHOSPHOLIPASE-A2; LIPID 2ND MESSENGERS; RAT MESANGIAL CELLS; BINDING PROTEINS; GENE-EXPRESSION; SUBSTRATE; CLONING; FAMILY; RNA	The effect of the glucocorticosteroid, dexamethasone, on arachidonic acid (AA) release and on protein levels of p11 and cytosolic phospholipase A(2) (cPLA(2)) was studied in two epithelial cell lines, HeLa cells and BEAS-2B cells. Dexamethasone treatment of HeLa cells and BEAS-2B cells increased cellular pll protein and mRNA levels in a time- and dose-dependent manner. It had little effect on levels of cPLA(2) protein. In order to determine if increased pll protein expression resulted in increased interaction between p11 and cPLA(2), anti-cPLA(2) antibodies were used to immunoprecipitate p11.cPLA(2) complexes and Western blots of the immunoprecipitate were used to detect p11, In cells treated with dexamethasone, more p11 was detected in the anti-cPLA(2) immunoprecipitate compared with control cells. Dexamethasone treatment of HeLa cells prelabeled with [H-3]AA decreased the release of [H-3]AA under basal conditions and after stimulation with the calcium ionophore A23187 (10(-6) M). In order to determine if altering the p11 protein levels in HeLa cells independent of glucocorticosteroid treatment could also produce an effect on [H-3]AA release, cells were stably transfected with plasmids expressing either p11 antisense mRNA or p11 mRNA Cloned HeLa cells expressing p11 antisense mRNA exhibited less cellular p11 protein compared with control cells and greater [H-3]AA release compared with cells transfected with a control vector. Cloned HeLa cells stably transfected with a p11 expression vector exhibited increased p11 cellular protein and diminished [H-3]AA release under basal conditions and in response to A23187, Therefore, dexamethasone alteration of epithelial cell AA release may be due in part to induction of p11 protein expression.	NIH, Ctr Clin, Dept Crit Care Med, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Clinical Center (CC)	Shelhamer, JH (corresponding author), NIH, Ctr Clin, Dept Crit Care Med, Bldg 10,Rm 7-D-43, Bethesda, MD 20892 USA.							BLACKWELL GJ, 1978, BRIT J PHARMACOL, V62, P79, DOI 10.1111/j.1476-5381.1978.tb07009.x; BUHL WJ, 1992, EICOSANOIDS, V5, pS26; Chen YJ, 1998, BBA-LIPID LIPID MET, V1394, P57, DOI 10.1016/S0005-2760(98)00098-8; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; CROFFORD LJ, 1994, J CLIN INVEST, V93, P1095, DOI 10.1172/JCI117060; CROXTALL JD, 1994, BIOCHEM PHARMACOL, V48, P1729, DOI 10.1016/0006-2952(94)90458-8; CRUMPTON MJ, 1990, NATURE, V345, P212, DOI 10.1038/345212a0; DAVIDSON FF, 1987, J BIOL CHEM, V262, P1698; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; DENNIS EA, 1991, FASEB J, V5, P2068, DOI 10.1096/fasebj.5.7.1901288; ERIKSON E, 1984, MOL CELL BIOL, V4, P77, DOI 10.1128/MCB.4.1.77; FLOWER R, 1989, BIOCHEM SOC T, V17, P276, DOI 10.1042/bst0170276; FULLER PJ, 1989, J IMMUNOL, V143, P1015; GERKE V, 1985, EMBO J, V4, P2917, DOI 10.1002/j.1460-2075.1985.tb04023.x; GERKE V, 1984, EMBO J, V3, P227, DOI 10.1002/j.1460-2075.1984.tb01789.x; GLENNEY J, 1986, J BIOL CHEM, V261, P7247; GLENNEY JR, 1987, J CELL BIOL, V104, P503, DOI 10.1083/jcb.104.3.503; HOECK WG, 1993, P NATL ACAD SCI USA, V90, P4475, DOI 10.1073/pnas.90.10.4475; HONG SL, 1976, P NATL ACAD SCI USA, V73, P1730, DOI 10.1073/pnas.73.5.1730; KLEE CB, 1988, BIOCHEMISTRY-US, V27, P6645, DOI 10.1021/bi00418a001; KLIGMAN D, 1988, TRENDS BIOCHEM SCI, V13, P437, DOI 10.1016/0968-0004(88)90218-6; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; LISCOVITCH M, 1994, CELL, V77, P329, DOI 10.1016/0092-8674(94)90148-1; Mahajan DK, 1997, FERTIL STERIL, V68, P967, DOI 10.1016/S0015-0282(97)00189-1; MAYER RJ, 1993, FASEB J, V7, P339, DOI 10.1096/fasebj.7.2.8440410; MOORE BW, 1965, BIOCHEM BIOPH RES CO, V19, P739, DOI 10.1016/0006-291X(65)90320-7; MUKHERJEE AB, 1994, BIOCHEM PHARMACOL, V48, P1, DOI 10.1016/0006-2952(94)90216-X; NAKANO T, 1990, J BIOL CHEM, V265, P12745; NAKANO T, 1990, FEBS LETT, V273, P23, DOI 10.1016/0014-5793(90)81042-M; Newton R, 1998, J BIOL CHEM, V273, P32312, DOI 10.1074/jbc.273.48.32312; Newton R, 1996, LIFE SCI, V60, P67, DOI 10.1016/S0024-3205(96)00590-5; OBANION MK, 1992, P NATL ACAD SCI USA, V89, P4888, DOI 10.1073/pnas.89.11.4888; Ristimaki A, 1996, BIOCHEM J, V318, P325, DOI 10.1042/bj3180325; SCHALKWIJK C, 1991, BIOCHEM BIOPH RES CO, V180, P46, DOI 10.1016/S0006-291X(05)81252-5; SHARP JD, 1991, J BIOL CHEM, V266, P14850; Tischfield JA, 1997, J BIOL CHEM, V272, P17247, DOI 10.1074/jbc.272.28.17247; Vervoordeldonk MJBM, 1996, BIOCHEM J, V315, P435, DOI 10.1042/bj3150435; VERVOORDELDONK MJBM, 1994, BBA-MOL CELL RES, V1224, P541, DOI 10.1016/0167-4889(94)90292-5; WALLNER BP, 1986, NATURE, V320, P77, DOI 10.1038/320077a0; Wijkander J, 1997, BIOCHEM J, V325, P405, DOI 10.1042/bj3250405; WU CC, 1995, P NATL ACAD SCI USA, V92, P3473, DOI 10.1073/pnas.92.8.3473; Wu T, 1997, J BIOL CHEM, V272, P17145, DOI 10.1074/jbc.272.27.17145; YANG J, 1994, P NATL ACAD SCI USA, V91, P529, DOI 10.1073/pnas.91.2.529	44	83	86	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17202	17208		10.1074/jbc.274.24.17202	http://dx.doi.org/10.1074/jbc.274.24.17202			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358078	hybrid			2022-12-25	WOS:000080780400077
J	Kanaya, E; Nakajima, N; Morikawa, K; Okada, K; Shimura, Y				Kanaya, E; Nakajima, N; Morikawa, K; Okada, K; Shimura, Y			Characterization of the transcriptional activator CBF1 from Arabidopsis thaliana - Evidence for cold denaturation in regions outside of the dna binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ETHYLENE-RESPONSIVE ELEMENT; HOMEOTIC GENE APETALA2; CIS-ACTING ELEMENT; ABSCISIC-ACID; LOW-TEMPERATURE; PROTEIN INTERACTS; AP2 DOMAIN; EXPRESSION; DROUGHT; AINTEGUMENTA	A transcriptional activator, CBF1, from Arabidopsis thaliana, which has the AP2 domain for DNA binding and regulates the cold acclimation response, was overexpressed in Escherichia coli, purified, and characterized, Analyses of the interaction between CBF1 and the C-repeat/dehydration-responsive element by fluorescence measurement showed that CBF1 binds to C-repeat/dehydration-responsive element as a monomer irrespective of the temperature. CD spectra of the intact and truncated CBF1 proteins (1-213, 41-213, 41-157, and 41-146) were measured to examine the temperature-dependent changes of the secondary structure of CBF1. The results suggested that the CBF1 protein has regions exhibiting reversible cold denaturation in the range between 30 and -5 degrees C and also has a region exhibiting thermal denaturation between 40 and 60 degrees C. This cold denaturation occurred in both the N-terminal and acidic regions. The thermal denaturation occurred in the region encompassing the AP2 domain. The difference between the retention time of CBF1 at 4 degrees C and that at 25 degrees C in gel filtration, and the decrease of the sedimentation coefficient, s(20,w), caused by the temperature change from 25 to 3 degrees C, strongly suggested that the cold denaturation was accompanied by the extension of the molecule. The possible cold denaturation observed here might be a physiologically important structural response of CBF1 to cold stress.	Biomed Engn Res Inst, Osaka 5650874, Japan; Kyoto Univ, Grad Sch Sci, Dept Bot, Kyoto 6068502, Japan	Kyoto University	Kanaya, E (corresponding author), Biomed Engn Res Inst, 6-2-3 Furuedai, Osaka 5650874, Japan.							ANTONINO LC, 1991, P NATL ACAD SCI USA, V88, P7715, DOI 10.1073/pnas.88.17.7715; BAKER SS, 1994, PLANT MOL BIOL, V24, P701, DOI 10.1007/BF00029852; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; BLAIR WS, 1994, MOL CELL BIOL, V14, P7226, DOI 10.1128/MCB.14.11.7226; Buttner M, 1997, P NATL ACAD SCI USA, V94, P5961, DOI 10.1073/pnas.94.11.5961; Elliott RC, 1996, PLANT CELL, V8, P155, DOI 10.1105/tpc.8.2.155; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; Gilmour SJ, 1998, PLANT J, V16, P433, DOI 10.1046/j.1365-313x.1998.00310.x; Goodwin T. W., 1946, BIOCHEM JOUR, V40, P628; GOSTI F, 1995, MOL GEN GENET, V246, P10, DOI 10.1007/BF00290128; Greenblatt J, 1996, METHOD ENZYMOL, V274, P120; GROVES WE, 1968, ANAL BIOCHEM, V22, P195, DOI 10.1016/0003-2697(68)90307-2; GUILTINAN MJ, 1990, SCIENCE, V250, P267, DOI 10.1126/science.2145628; HOPE IA, 1988, NATURE, V333, P635, DOI 10.1038/333635a0; HOPKINS F. GOWLAND, 1930, NATURE [LONDON], V126, P383, DOI 10.1038/126383a0; Jaglo-Ottosen KR, 1998, SCIENCE, V280, P104, DOI 10.1126/science.280.5360.104; Jiang C, 1996, PLANT MOL BIOL, V30, P679, DOI 10.1007/BF00049344; JOFUKU KD, 1994, PLANT CELL, V6, P1211, DOI 10.1105/tpc.6.9.1211; KAUZMANN W, 1959, ADV PROTEIN CHEM, V14, P1, DOI 10.1016/S0065-3233(08)60608-7; KELLY RC, 1976, J BIOL CHEM, V251, P7240; KITAKUNI E, 1994, PROTEIN SCI, V3, P831; Klucher KM, 1996, PLANT CELL, V8, P137, DOI 10.1105/tpc.8.2.137; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laue T., 1993, ANAL ULTRACENTRIFUGA, P90; Leblanc B, 1994, Methods Mol Biol, V30, P1; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MAHAPATRA SS, 1989, PLANT PHYSIOL, V89, P375; MARCOTTE WR, 1988, NATURE, V335, P454, DOI 10.1038/335454a0; MARCOTTE WR, 1989, PLANT CELL, V1, P969, DOI 10.2307/3868997; Maxam A M, 1980, Methods Enzymol, V65, P499; Medina J, 1999, PLANT PHYSIOL, V119, P463, DOI 10.1104/pp.119.2.463; Miller J. H., 1972, EXPT MOL GENETICS, P433; Moose SP, 1996, GENE DEV, V10, P3018, DOI 10.1101/gad.10.23.3018; MUNDY J, 1990, P NATL ACAD SCI USA, V87, P1406, DOI 10.1073/pnas.87.4.1406; MURATA N, 1992, NATURE, V356, P710, DOI 10.1038/356710a0; NORDIN K, 1991, PLANT MOL BIOL, V16, P1061, DOI 10.1007/BF00016077; OHARE P, 1988, EMBO J, V7, P4231, DOI 10.1002/j.1460-2075.1988.tb03320.x; OHMETAKAGI M, 1995, PLANT CELL, V7, P173, DOI 10.1105/tpc.7.2.173; Okamuro JK, 1997, P NATL ACAD SCI USA, V94, P7076, DOI 10.1073/pnas.94.13.7076; PRESTON CM, 1988, CELL, V52, P425, DOI 10.1016/S0092-8674(88)80035-7; PRIVALOV PL, 1986, J MOL BIOL, V190, P487, DOI 10.1016/0022-2836(86)90017-3; PRIVALOV PL, 1990, CRIT REV BIOCHEM MOL, V25, P281, DOI 10.3109/10409239009090612; ROBEN SM, 1992, MOL CELL BIOL, V12, P444; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Shinozaki K, 1996, CURR OPIN BIOTECH, V7, P161, DOI 10.1016/S0958-1669(96)80007-3; Stockinger EJ, 1997, P NATL ACAD SCI USA, V94, P1035, DOI 10.1073/pnas.94.3.1035; TRUANT R, 1993, J BIOL CHEM, V268, P2284; VANHOLDE KE, 1985, PHYSICAL BIOCH, P225; WAXMAN E, 1993, BIOCHEMISTRY-US, V32, P3005, DOI 10.1021/bi00063a011; WEIGEL D, 1995, PLANT CELL, V7, P388, DOI 10.1105/tpc.7.4.388; Wilson K, 1996, PLANT CELL, V8, P659, DOI 10.1105/tpc.8.4.659; WU CSC, 1981, BIOCHEMISTRY-US, V20, P566, DOI 10.1021/bi00506a019; Xin ZG, 1998, P NATL ACAD SCI USA, V95, P7799, DOI 10.1073/pnas.95.13.7799; YAMAGUCHISHINOZAKI K, 1994, PLANT CELL, V6, P251, DOI 10.1105/tpc.6.2.251	56	20	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16068	16076		10.1074/jbc.274.23.16068	http://dx.doi.org/10.1074/jbc.274.23.16068			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347158	hybrid			2022-12-25	WOS:000080668600018
J	Liu, YF; Ghahremani, MH; Rasenick, MM; Jakobs, KH; Albert, PR				Liu, YF; Ghahremani, MH; Rasenick, MM; Jakobs, KH; Albert, PR			Stimulation of cAMP synthesis by G(i)-coupled receptors upon ablation of distinct G alpha(i) protein expression - G(i) subtype specificity of the 5-HT1A receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; MAMMALIAN ADENYLYL CYCLASES; SIGNAL-TRANSDUCTION; COUPLED RECEPTORS; CELL-LINES; MOLECULAR-CLONING; RAT HIPPOCAMPUS; PHOSPHOLIPASE-C; GI-PROTEIN; INHIBITION	The three G alpha(i) subunits were independently depleted from rat pituitary GH4C1 cells by stable transfection of each G alpha(i) antisense rat cDNA construct. Depletion of any G alpha(i) subunit eliminated receptor-induced inhibition of basal cAMP production, indicating that all Ga, subunits are required for this response. By contrast, receptor-mediated inhibition of vasoactive intestinal peptide (VIP)-stimulated cAMP production was blocked by selective depletions for responses induced by the transfected serotonin 1A (5-HT1A) (G alpha(i2) or G alpha(i3)) or endogenous muscarinic-M4 (G alpha(i1) or G alpha(i2)) receptors. Strikingly, receptor activation in G alpha(i1)-depleted clones (for the 5-HT1A receptor) or G alpha(i3)-depleted clones (for the muscarinic receptor) induced a pertussis toxin-sensitive increase in basal cAMP production, whereas the inhibitory action on VIP-stimulated cAMP synthesis remained. Finally, in G alpha(i2)-depleted clones, activation of 5-HT1A receptors increased VIP-stimulated cAMP synthesis. Thus, 5-HT1A and muscarinic M4 receptor may couple dominantly to G alpha(i1) and G alpha(i3), respectively, to inhibit cAMP production. Upon removal of these G alpha(i) subunits to reduce inhibitory coupling, stimulatory receptor coupling is revealed that may involve G beta gamma-induced activation of adenylyl cyclase II, a G(i)-stimulated cyclase that is predominantly expressed in GH4C1 cells. Thus G(i)-coupled receptor activation involves integration of both inhibitory and stimulatory outputs that can be modulated by specific changes in alpha(i) subunit expression level.	McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada; Univ Illinois, Dept Physiol, Chicago, IL 60612 USA; Univ Illinois, Dept Biophys, Chicago, IL 60612 USA; Univ Illinois, Dept Psychiat, Chicago, IL 60612 USA; Univ Essen Gesamthsch, Inst Pharmakol, D-45122 Essen, Germany; Univ Ottawa, Neurosci Res Inst, Ottawa, ON K1H 8M5, Canada	McGill University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Duisburg Essen; University of Ottawa	Albert, PR (corresponding author), Univ Ottawa, Neurosci Res Inst, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.		Ghahremani, Mohammad H/F-1615-2013; Albert, Paul/E-4804-2010	Ghahremani, Mohammad H/0000-0001-5051-6214; Albert, Paul/0000-0002-1809-3554				ALBERT PR, 1994, TRENDS PHARMACOL SCI, V15, P250, DOI 10.1016/0165-6147(94)90320-4; ALBERT PR, 1994, VITAM HORM, V48, P59, DOI 10.1016/S0083-6729(08)60496-3; ALBERT PR, 1990, J BIOL CHEM, V265, P5825; ALBERT PR, 1997, P SOC NEUROSCI, V23, P289; Baker LP, 1999, J NEUROSCI, V19, P180, DOI 10.1523/JNEUROSCI.19-01-00180.1999; Bayewitch ML, 1998, J BIOL CHEM, V273, P2273, DOI 10.1074/jbc.273.4.2273; BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; CADOGAN AK, 1994, J NEUROCHEM, V62, P1816; CARLSON KE, 1989, J BIOL CHEM, V264, P13298; CHEN JQ, 1993, J BIOL CHEM, V268, P12253; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; Degtiar VE, 1997, J PHYSIOL-LONDON, V502, P321, DOI 10.1111/j.1469-7793.1997.321bk.x; DELLACQUA ML, 1993, J BIOL CHEM, V268, P5676; DUMUIS A, 1988, MOL PHARMACOL, V33, P178; DUZIC E, 1992, J BIOL CHEM, V267, P24045; EASON MG, 1992, J BIOL CHEM, V267, P15795; FARGIN A, 1991, CELL SIGNAL, V3, P547, DOI 10.1016/0898-6568(91)90031-O; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; Ghahremani MH, 1999, J BIOL CHEM, V274, P9238, DOI 10.1074/jbc.274.14.9238; GIERSCHIK P, 1989, J BIOL CHEM, V264, P21470; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOETZL EJ, 1994, J BIOL CHEM, V269, P809; GREEN A, 1990, J BIOL CHEM, V265, P5206; Gudermann T, 1997, ANNU REV NEUROSCI, V20, P399, DOI 10.1146/annurev.neuro.20.1.399; HADCOCK JR, 1990, J BIOL CHEM, V265, P14784; JONES DT, 1987, J BIOL CHEM, V262, P14241; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; Law SF, 1997, J PHARMACOL EXP THER, V281, P1476; LAW SF, 1991, J BIOL CHEM, V266, P17885; LIU YF, 1991, J BIOL CHEM, V266, P23689; LIU YF, 1994, J BIOL CHEM, V269, P13880; LUSTIG KD, 1993, J BIOL CHEM, V268, P13900; Marjamaki A, 1997, J BIOL CHEM, V272, P16466, DOI 10.1074/jbc.272.26.16466; MARKSTEIN R, 1986, N-S ARCH PHARMACOL, V333, P335, DOI 10.1007/BF00500006; MILLIGAN G, 1991, J BIOL CHEM, V266, P6447; MILLIGAN G, 1993, TRENDS PHARMACOL SCI, V14, P413, DOI 10.1016/0165-6147(93)90064-Q; MONTMAYEUR JP, 1993, MOL ENDOCRINOL, V7, P161, DOI 10.1210/me.7.2.161; PINKASKRAMARSKI R, 1990, NEUROSCI LETT, V108, P335, DOI 10.1016/0304-3940(90)90663-T; SENOGLES SE, 1994, J BIOL CHEM, V269, P23120; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093	46	56	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16444	16450		10.1074/jbc.274.23.16444	http://dx.doi.org/10.1074/jbc.274.23.16444			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347206	hybrid			2022-12-25	WOS:000080668600066
J	O'Rourke, JP; Newbound, GC; Hutt, JA; DeWille, J				O'Rourke, JP; Newbound, GC; Hutt, JA; DeWille, J			CCAAT/enhancer-binding protein delta regulates mammary epithelial cell G(0) growth arrest and apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C/EBP FAMILY MEMBERS; BREAST-CANCER CELLS; TRANSCRIPTION FACTOR; GENE-TRANSCRIPTION; TUMOR-SUPPRESSOR; CYCLIN D1; 3T3-L1 ADIPOCYTES; MAMMALIAN-CELLS; CDK INHIBITOR; EXPRESSION	CCAAT/enhancer-binding proteins (C/EBPs) are a highly conserved family of DNA-binding proteins that regulate cell-specific growth, differentiation, and apoptosis. Here, we show that induction of C/EBP delta gene expression during G(0) growth arrest is a general property of mammary-derived cell lines. C/EBP delta is not induced during G(0) growth arrest in 3T3 or IEC18 cells. C/EBP delta induction is G(0)-specific in mouse mammary epithelial cells; C/EBP delta gene expression is not induced by growth arrest in the G(1), S, or G(2) phase of the cell cycle. C/EBP delta antisense-expressing cells (AS1 cells) maintain elevated cyclin D1 and phosphorylated retinoblastoma protein levels and exhibit delayed G(0) growth arrest and apoptosis in response to serum and growth factor withdrawal. Conversely, C/EBP delta-overexpressing cells exhibited a rapid decline in cyclin D1 and phosphorylated retinoblastoma protein levels, a rapid increase in the cyclin-dependent kinase inhibitor p27, and accelerated G(0) growth arrest and apoptosis in response to serum and growth factor withdrawal. When C/EBP delta levels were rescued in AS1 cells by transfection with a C/EBP delta "sense" construct, normal G(0) growth arrest and apoptosis were restored. These results demonstrate that C/EBP delta plays a key role in the regulation of G(0) growth arrest and apoptosis in mammary epithelial cells.	Ohio State Univ, Ohio State Comprehens Canc Ctr, Dept Vet Biosci, Columbus, OH 43210 USA; Ohio State Univ, Ohio State Comprehens Canc Ctr, Ohio State Biochem Program, Columbus, OH 43210 USA; Ohio State Univ, Ohio State Comprehens Canc Ctr, Div Mol Biol & Canc Genet, Columbus, OH 43210 USA	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	DeWille, J (corresponding author), Ohio State Univ, Ohio State Comprehens Canc Ctr, Dept Vet Biosci, Columbus, OH 43210 USA.				NATIONAL CANCER INSTITUTE [P30CA016058, R29CA057607, R01CA057607] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [K01RR000136] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA16058, CA 57607] Funding Source: Medline; NCRR NIH HHS [RR00136CA] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Boudreau F, 1996, EXP CELL RES, V222, P1, DOI 10.1006/excr.1996.0001; Breed DR, 1997, ENDOCRINOLOGY, V138, P5527, DOI 10.1210/en.138.12.5527; CANTWELL CA, 1998, GENE DEV, V18, P2108; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Chen PL, 1996, P NATL ACAD SCI USA, V93, P465, DOI 10.1073/pnas.93.1.465; Chinery R, 1997, NAT MED, V3, P1233, DOI 10.1038/nm1197-1233; Choi YH, 1997, J BIOL CHEM, V272, P28479, DOI 10.1074/jbc.272.45.28479; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Colangelo AM, 1998, P NATL ACAD SCI USA, V95, P10920, DOI 10.1073/pnas.95.18.10920; COOPER G, 1997, CELL MOL APPROACH, P561; Cram EJ, 1998, J BIOL CHEM, V273, P2008, DOI 10.1074/jbc.273.4.2008; Flodby P, 1996, J BIOL CHEM, V271, P24753, DOI 10.1074/jbc.271.40.24753; FLODBY P, 1993, EXP CELL RES, V208, P248, DOI 10.1006/excr.1993.1244; Gigliotti AP, 1998, J CELL PHYSIOL, V174, P232, DOI 10.1002/(SICI)1097-4652(199802)174:2<232::AID-JCP10>3.0.CO;2-E; Harvat BL, 1997, ONCOGENE, V14, P2111, DOI 10.1038/sj.onc.1201055; Helbing CC, 1997, CANCER RES, V57, P1255; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HSU W, 1994, MOL CELL BIOL, V14, P268, DOI 10.1128/MCB.14.1.268; HURST HC, 1994, PROTEIN PROFILE, V1, P123; Johnson D, 1998, ONCOGENE, V16, P2017, DOI 10.1038/sj.onc.1201727; Katayose Y, 1997, CANCER RES, V57, P5441; Lacorte JM, 1997, J BIOL CHEM, V272, P23578, DOI 10.1074/jbc.272.38.23578; MACDOUGALD OA, 1994, J BIOL CHEM, V269, P19041; MACDOUGALD OA, 1995, J BIOL CHEM, V270, P647, DOI 10.1074/jbc.270.2.647; MERLO GR, 1993, ANN NY ACAD SCI, V698, P108, DOI 10.1111/j.1749-6632.1993.tb17195.x; MERLO GR, 1995, J CELL BIOL, V128, P1185, DOI 10.1083/jcb.128.6.1185; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Morisaki H, 1997, BIOCHEM BIOPH RES CO, V240, P386, DOI 10.1006/bbrc.1997.7590; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; NISHIO Y, 1993, MOL CELL BIOL, V13, P1854, DOI 10.1128/MCB.13.3.1854; ORourke J, 1997, J BIOL CHEM, V272, P6291, DOI 10.1074/jbc.272.10.6291; Pause A, 1998, P NATL ACAD SCI USA, V95, P993, DOI 10.1073/pnas.95.3.993; PITTMAN N, 1995, J BIOL CHEM, V270, P28848, DOI 10.1074/jbc.270.48.28848; Robinson GW, 1998, GENE DEV, V12, P1907, DOI 10.1101/gad.12.12.1907; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; Sabatakos G, 1998, BIOCHEM J, V334, P205, DOI 10.1042/bj3340205; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; SCOTT LM, 1992, BLOOD, V80, P1725; Seagroves TN, 1998, GENE DEV, V12, P1917, DOI 10.1101/gad.12.12.1917; Sgambato A, 1996, CANCER RES, V56, P1389; Sgambato A, 1998, CANCER RES, V58, P3448; Shao NS, 1996, ONCOGENE, V13, P1; Shuman JD, 1997, J BIOL CHEM, V272, P12793, DOI 10.1074/jbc.272.19.12793; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; Sterneck E, 1997, GENE DEV, V11, P2153, DOI 10.1101/gad.11.17.2153; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; TANAKA T, 1995, CELL, V80, P353, DOI 10.1016/0092-8674(95)90418-2; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; TOPPER YJ, 1980, PHYSIOL REV, V60, P1049, DOI 10.1152/physrev.1980.60.4.1049; Umayahara Y, 1997, J BIOL CHEM, V272, P31793, DOI 10.1074/jbc.272.50.31793; Wang XT, 1997, ONCOGENE, V15, P2991, DOI 10.1038/sj.onc.1201450; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; Yamada T, 1997, J BIOCHEM-TOKYO, V121, P731; Yamanaka R, 1997, P NATL ACAD SCI USA, V94, P13187, DOI 10.1073/pnas.94.24.13187; Yin M, 1996, J BIOL CHEM, V271, P17974, DOI 10.1074/jbc.271.30.17974; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982; Zwijsen RML, 1996, MOL CELL BIOL, V16, P2554	59	61	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16582	16589		10.1074/jbc.274.23.16582	http://dx.doi.org/10.1074/jbc.274.23.16582			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347224	hybrid			2022-12-25	WOS:000080668600084
J	Sharma, DK; Vidugiriene, J; Bangs, JD; Menon, AK				Sharma, DK; Vidugiriene, J; Bangs, JD; Menon, AK			A cell-free assay for glycosylphosphatidylinositol anchoring in African trypanosomes - Demonstration of a transamidation reaction mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOSYL-PHOSPHATIDYLINOSITOL ANCHOR; TERMINAL SIGNAL PEPTIDE; SURFACE GLYCOPROTEIN; MEMBRANE-PROTEINS; GPI ANCHOR; DEVELOPMENTAL VARIATION; BRUCEI; BIOSYNTHESIS; PURIFICATION; ATTACHMENT	We established an in vitro assay for the addition of glycosyl-phosphatidylinositol (GPI) anchors to proteins using procyclic trypanosomes engineered to express GPI-anchored variant surface glycoprotein (VSG), The assay is based on the premise that small nucleophiles, such as hydrazine, can substitute for the GPI moiety and effect displacement of the membrane anchor of a GPI-anchored protein or pro-protein causing release of the protein into the aqueous medium. Cell membranes containing pulse-radiolabeled VSG were incubated with hydrazine, and the VSG released from the membranes was measured by carbonate extraction, immunoprecipitation, and SDS-polyacrylamide gel electrophoresis/fluorography, Release of VSG was time- and temperature-dependent, was stimulated by hydrazine, and occurred only for VSG molecules situated in early compartments of the secretory pathway. No nucleophile-induced VSG release was seen in membranes prepared from cells expressing a VSG variant with a conventional transmembrane anchor (i.e. a nonfunctional GPI signal sequence). Pro-VSG was shown to be a substrate in the reaction by assaying membranes prepared from cells treated with mannosamine, a GPI biosynthesis inhibitor. When a biotinylated derivative of hydrazine was used instead of hydrazine, the released VSG could be precipitated with streptavidin-agarose, indicating that the biotin moiety was covalently incorporated into the protein. Hydrazine was shown to block the C terminus of the released VSG hydrazide because the released material, unlike a truncated form of VSG lacking a GPI signal sequence, was not susceptible to proteolysis by carboxypeptidases, These results firmly establish that the released material in our assay is VSG hydrazide and strengthen the proof that CPI anchoring proceeds via a transamidation reaction mechanism. The reaction could be inhibited with sulfhydryl alkylating reagents, suggesting that the transamidase enzyme contains a functionally important sulfhydryl residue.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Vilnius State Univ, Dept Biochem, Vilnius, Lithuania; Univ Wisconsin, Sch Med, Dept Med Microbiol & Immunol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; Vilnius University; University of Wisconsin System; University of Wisconsin Madison	Sharma, DK (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.			Menon, Anant Kumar/0000-0001-6924-2698	NIAID NIH HHS [AI35739, R01 AI035739] Funding Source: Medline; NIGMS NIH HHS [R01 GM055427, GM55427] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035739, R29AI035739] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055427] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABE Y, 1993, J BIOL CHEM, V268, P3525; AMTHAUER R, 1993, P NATL ACAD SCI USA, V90, P3973, DOI 10.1073/pnas.90.9.3973; AMTHAUER R, 1992, P NATL ACAD SCI USA, V89, P6124, DOI 10.1073/pnas.89.13.6124; Andrews DW, 1996, TRENDS BIOCHEM SCI, V21, P365; Bangs JD, 1997, EMBO J, V16, P4285, DOI 10.1093/emboj/16.14.4285; Benghezal M, 1996, EMBO J, V15, P6575, DOI 10.1002/j.1460-2075.1996.tb01048.x; CLAYTON CE, 1989, J BIOL CHEM, V264, P15088; CONZELMANN A, 1988, EMBO J, V7, P2233, DOI 10.1002/j.1460-2075.1988.tb03063.x; Doering TL, 1997, BIOCHEM J, V328, P669; EVANS EA, 1986, P NATL ACAD SCI USA, V83, P581, DOI 10.1073/pnas.83.3.581; Field M. C., 1992, LIPID MODIFICATION P, P155; FIELD MC, 1991, J BIOL CHEM, V266, P8392; FIELD MC, 1992, J BIOL CHEM, V267, P5324; GUTHER MLS, 1994, J BIOL CHEM, V269, P18694; HAMBURGER D, 1995, J CELL BIOL, V129, P629, DOI 10.1083/jcb.129.3.629; HERELD D, 1988, POST TRANSLATIONAL M, P9; HOWELL S, 1994, J BIOL CHEM, V269, P16993; Kelley RJ, 1999, MOL BIOCHEM PARASIT, V98, P17, DOI 10.1016/S0166-6851(98)00155-8; KODUKULA K, 1991, J BIOL CHEM, V266, P4464; KODUKULA K, 1995, METHOD ENZYMOL, V250, P536; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LISANTI MP, 1991, EMBO J, V10, P1969, DOI 10.1002/j.1460-2075.1991.tb07726.x; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MAXWELL SE, 1995, P NATL ACAD SCI USA, V92, P1550, DOI 10.1073/pnas.92.5.1550; MAXWELL SE, 1995, J BIOL CHEM, V270, P19576, DOI 10.1074/jbc.270.33.19576; MAYOR S, 1991, J CELL BIOL, V114, P61, DOI 10.1083/jcb.114.1.61; McDowell MA, 1998, BIOCHEM J, V335, P681, DOI 10.1042/bj3350681; MENON AK, 1990, EMBO J, V9, P4249, DOI 10.1002/j.1460-2075.1990.tb07873.x; MENSAWILMOT K, 1995, METHOD ENZYMOL, V250, P641; NICCHITTA CV, 1989, J CELL BIOL, V108, P789, DOI 10.1083/jcb.108.3.789; RALTON JE, 1993, J BIOL CHEM, V268, P24183; RODITI I, 1987, NATURE, V325, P272, DOI 10.1038/325272a0; Sambrook J., 2002, MOL CLONING LAB MANU; Silberstein S, 1996, FASEB J, V10, P849, DOI 10.1096/fasebj.10.8.8666161; TATE SS, 1974, J BIOL CHEM, V249, P7593; TATE SS, 1974, P NATL ACAD SCI USA, V71, P3329, DOI 10.1073/pnas.71.9.3329; UDENFRIEND S, 1995, ANNU REV BIOCHEM, V64, P563, DOI 10.1146/annurev.bi.64.070195.003023; VANIWAARDEN PR, 1992, BIOCHIM BIOPHYS ACTA, V1113, P161, DOI 10.1016/0304-4157(92)90037-B; VIDUGIRIENE J, 1995, EMBO J, V14, P4686, DOI 10.1002/j.1460-2075.1995.tb00150.x; Yu JL, 1997, P NATL ACAD SCI USA, V94, P12580, DOI 10.1073/pnas.94.23.12580	40	56	58	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16479	16486		10.1074/jbc.274.23.16479	http://dx.doi.org/10.1074/jbc.274.23.16479			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347210	hybrid			2022-12-25	WOS:000080668600070
J	Dmitriev, O; Jones, PC; Jiang, WP; Fillingame, RH				Dmitriev, O; Jones, PC; Jiang, WP; Fillingame, RH			Structure of the membrane domain of subunit b of the Escherichia coli F0F1 ATP synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLING H+ TRANSPORT; MOLECULAR MACHINE; CROSS-LINKING; ALPHA-SUBUNIT; GAMMA-SUBUNIT; F-0 SECTOR; 2ND STALK; F1-ATPASE; F1; PROTEINS	The structure of the N-terminal transmembrane domain (residues 1-34) of subunit b of the Escherichia coli F0F1-ATP synthase has been solved by two-dimensional H-1 NMR in a membrane mimetic solvent mixture of chloroform/methanol/H2O (4:4:1), Residues 4-22 form an cu-helix, which is likely to span the hydrophobic domain of the lipid bilayer to anchor the largely hydrophilic subunit b in the membrane. The helical structure is interrupted by a rigid bend in the region of residues 23-26 with cu-helical structure resuming at Pro-27 at an angle offset by 20 degrees from the transmembrane helix. In native subunit b, the hinge region and C-terminal alpha-helical segment would connect the transmembrane helix to the cytoplasmic domain. The transmembrane domains of the two subunit b in F-0 were shown to be close to each other by cross-linking experiments in which single Cys were substituted for residues 2-21 of the native subunit and b-b dimer formation tested after oxidation with Cu(II) (phenanthroline)(2). Cys residues that formed disulfide cross-links were found with a periodicity indicative of one face of an alpha-helix, over the span of residues 2-18, where Cys at positions 2, 6, and 10 formed dimers in highest yield. A model for the dimer is presented based upon the NMR structure and distance constraints from the cross-linking data. The transmembrane Lu-helices are positioned at a 23 degrees angle to each other with the side chains of Thr 6, Gln-10, Phe-14, and Phe-17 at the interface between subunits, The change in direction of helical packing at the hinge region may be important in the functional interaction of the cytoplasmic domains.	Univ Wisconsin, Sch Med, Dept Biomol Chem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Fillingame, RH (corresponding author), Univ Wisconsin, Sch Med, Dept Biomol Chem, Madison, WI 53706 USA.	filingam@macc.wisc.edu	Dmitriev, Oleg/AAB-7830-2019		NCRR NIH HHS [RR02301] Funding Source: Medline; NIGMS NIH HHS [GM23105] Funding Source: Medline; PHS HHS [R02301] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR002301] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023105, R37GM023105] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; BIRKENHAGER R, 1995, EUR J BIOCHEM, V230, P58, DOI 10.1111/j.1432-1033.1995.tb20534.x; Bottcher B, 1998, J MOL BIOL, V281, P757, DOI 10.1006/jmbi.1998.1957; Bowie JU, 1997, J MOL BIOL, V272, P780, DOI 10.1006/jmbi.1997.1279; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; Boyer PD, 1998, ANGEW CHEM INT EDIT, V37, P2297, DOI 10.1002/(SICI)1521-3773(19980918)37:17<2296::AID-ANIE2296>3.0.CO;2-W; BURLEY SK, 1985, SCIENCE, V229, P23, DOI 10.1126/science.3892686; DMITRIEV OY, 1995, EUR J BIOCHEM, V233, P478, DOI 10.1111/j.1432-1033.1995.478_2.x; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; DUNN SD, 1992, J BIOL CHEM, V267, P7630; Dunn SD, 1998, J BIOL CHEM, V273, P8646, DOI 10.1074/jbc.273.15.8646; Elston T, 1998, NATURE, V391, P510, DOI 10.1038/35185; Engelbrecht S, 1997, FEBS LETT, V414, P485, DOI 10.1016/S0014-5793(97)00997-6; Fillingame RH, 1997, J EXP BIOL, V200, P217; Fillingame RH, 1998, BBA-BIOENERGETICS, V1365, P135, DOI 10.1016/S0005-2728(98)00053-X; Girvin ME, 1998, BIOCHEMISTRY-US, V37, P8817, DOI 10.1021/bi980511m; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; HOPPE J, 1983, J BIOL CHEM, V258, P2882; HOPPE J, 1984, BIOCHEMISTRY-US, V23, P5610, DOI 10.1021/bi00318a035; HWANG TL, 1995, J MAGN RESON SER A, V112, P275, DOI 10.1006/jmra.1995.1047; JANS DA, 1984, J BACTERIOL, V160, P764, DOI 10.1128/JB.160.2.764-770.1984; Jiang WP, 1998, P NATL ACAD SCI USA, V95, P6607, DOI 10.1073/pnas.95.12.6607; Jones PC, 1998, J BIOL CHEM, V273, P29701, DOI 10.1074/jbc.273.45.29701; Jones PC, 1998, J BIOL CHEM, V273, P17178, DOI 10.1074/jbc.273.27.17178; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; PERLIN DS, 1985, ARCH BIOCHEM BIOPHYS, V236, P603, DOI 10.1016/0003-9861(85)90664-2; REITHMEIER RAF, 1995, CURR OPIN STRUC BIOL, V5, P491, DOI 10.1016/0959-440X(95)80034-4; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; Rodgers AJW, 1997, J BIOL CHEM, V272, P31058, DOI 10.1074/jbc.272.49.31058; Rodgers AJW, 1998, J BIOL CHEM, V273, P29406, DOI 10.1074/jbc.273.45.29406; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; SCHIFFER M, 1992, PROTEIN ENG, V5, P213, DOI 10.1093/protein/5.3.213; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; SHAKA AJ, 1988, J MAGN RESON, V77, P274, DOI 10.1016/0022-2364(88)90178-3; Singh S, 1996, FEBS LETT, V397, P30, DOI 10.1016/S0014-5793(96)01127-1; Sorgen PL, 1998, BIOCHEMISTRY-US, V37, P923, DOI 10.1021/bi972309+; STEFFENS K, 1987, J BIOL CHEM, V262, P5866; TAKEYAMA M, 1988, J BIOL CHEM, V263, P16106; Takeyasu K, 1996, FEBS LETT, V392, P110, DOI 10.1016/0014-5793(96)00796-X; TITMAN JJ, 1990, J MAGN RESON, V89, P640, DOI 10.1016/0022-2364(90)90351-9; VIK SB, 1994, J BIOL CHEM, V269, P30364; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X; Walker JE, 1998, ANGEW CHEM INT EDIT, V37, P2309, DOI 10.1002/(SICI)1521-3773(19980918)37:17<2308::AID-ANIE2308>3.0.CO;2-W; WALLINE, 1995, PROTEIN SCI, V6, P808; WARREN WS, 1993, SCIENCE, V262, P2005, DOI 10.1126/science.8266096; WATTS SD, 1995, FEBS LETT, V368, P235, DOI 10.1016/0014-5793(95)00658-V; Watts SD, 1996, J BIOL CHEM, V271, P28341, DOI 10.1074/jbc.271.45.28341; WIENER MC, 1992, BIOPHYS J, V61, P434, DOI 10.1016/S0006-3495(92)81849-0; Wilkens S, 1997, NAT STRUCT BIOL, V4, P198, DOI 10.1038/nsb0397-198; Wilkens S, 1998, NATURE, V393, P29, DOI 10.1038/29908; WILKENS S, 1995, NAT STRUCT BIOL, V2, P961, DOI 10.1038/nsb1195-961; WISHART DS, 1994, METHOD ENZYMOL, V239, P363; Wuthrich K, 1986, NMR PROTEIN NUCL ACI; Yau WM, 1998, BIOCHEMISTRY-US, V37, P14713, DOI 10.1021/bi980809c; ZHANG Y, 1995, J BIOL CHEM, V270, P24609, DOI 10.1074/jbc.270.41.24609	56	121	127	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15598	15604		10.1074/jbc.274.22.15598	http://dx.doi.org/10.1074/jbc.274.22.15598			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336456	hybrid			2022-12-25	WOS:000080560100045
J	Fasshauer, D; Antonin, W; Margittai, M; Pabst, S; Jahn, R				Fasshauer, D; Antonin, W; Margittai, M; Pabst, S; Jahn, R			Mixed and non-cognate SNARE complexes - Characterization of assembly and biophysical properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLE DOCKING; N-TERMINAL DOMAIN; MEMBRANE-FUSION; CLOSTRIDIAL NEUROTOXINS; PROTEIN INTERACTIONS; STRUCTURAL-CHANGES; LIGHT-SCATTERING; SYNTAXIN; SYNAPTOBREVIN; TRANSPORT	Assembly of soluble N-ethylmaleimide-sensitive fusion attachment protein receptor (SNARE) proteins between two opposing membranes is thought to be the key event that initiates membrane fusion. Many new SNARE proteins have recently been localized to distinct intracellular compartments, supporting the view that sets of specific SNAREs are specialized for distinct trafficking steps. We have now investigated whether other SNAREs can form complexes with components of the synaptic SNARE complex including synaptobrevin/VAMP 2, SNAP-25, and syntaxin 1, When the Q-SNAREs syntaxin 2, 3, and 4, and the R-SNARE endobrevin/VAMP 8 were used in various combinations, heat-resistant complexes were formed. Limited proteolysis revealed that these complexes contained a protease-resistant core similar to that of the synaptic complex. All complexes were disassembled by the ATPase N-ethylmaleimide-sensitive fusion protein and its cofactor alpha-SNAP. Circular dichroism spectroscopy showed that major conformational changes occur during assembly, which are associated with induction of structure from unstructured monomers, Furthermore, no preference for synaptobrevin was observed during the assembly of the synaptic complex when endobrevin/VAMP 8 was present in equal concentrations. We conclude that cognate and non-cognate SNARE complexes are very similar with respect to biophysical properties, assembly, and disassembly, suggesting that specificity of membrane fusion in intracellular membrane traffic is not due to intrinsic specificity of SNARE pairing.	Max Planck Inst Biophys Chem, Dept Neurobiol, D-37077 Gottingen, Germany	Max Planck Society	Jahn, R (corresponding author), Max Planck Inst Biophys Chem, Dept Neurobiol, Fassberg 11, D-37077 Gottingen, Germany.	rjahn@gwdg.de	Margittai, Martin/D-5039-2014; Fasshauer, Dirk/B-1563-2013; Antonin, Wolfram/A-8656-2014; Antonin, Wolfram/P-3648-2019	Margittai, Martin/0000-0003-1903-5927; Fasshauer, Dirk/0000-0002-1040-4282; Antonin, Wolfram/0000-0003-4669-379X; Antonin, Wolfram/0000-0003-4669-379X; Jahn, Reinhard/0000-0003-1542-3498				Advani RJ, 1998, J BIOL CHEM, V273, P10317, DOI 10.1074/jbc.273.17.10317; BARNSTABLE CJ, 1985, DEV BRAIN RES, V20, P286, DOI 10.1016/0165-3806(85)90116-6; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; EDELMANN L, 1995, EMBO J, V14, P224, DOI 10.1002/j.1460-2075.1995.tb06995.x; Fasshauer D, 1998, P NATL ACAD SCI USA, V95, P15781, DOI 10.1073/pnas.95.26.15781; Fasshauer D, 1998, BIOCHEMISTRY-US, V37, P10354, DOI 10.1021/bi980542h; Fasshauer D, 1997, J BIOL CHEM, V272, P28036, DOI 10.1074/jbc.272.44.28036; Fasshauer D, 1997, J BIOL CHEM, V272, P4582, DOI 10.1074/jbc.272.7.4582; Fernandez I, 1998, CELL, V94, P841, DOI 10.1016/S0092-8674(00)81742-0; Fiebig KM, 1999, NAT STRUCT BIOL, V6, P117; Gotte M, 1998, TRENDS CELL BIOL, V8, P215, DOI 10.1016/S0962-8924(98)01272-0; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; Hanson PI, 1997, CURR OPIN NEUROBIOL, V7, P310, DOI 10.1016/S0959-4388(97)80057-8; Hay JC, 1998, J CELL BIOL, V141, P1489, DOI 10.1083/jcb.141.7.1489; Hay JC, 1997, CURR OPIN CELL BIOL, V9, P505, DOI 10.1016/S0955-0674(97)80026-9; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; Katz L, 1998, EMBO J, V17, P6200, DOI 10.1093/emboj/17.21.6200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lin RC, 1997, NEURON, V19, P1087, DOI 10.1016/S0896-6273(00)80399-2; Nichols BJ, 1998, BBA-MOL CELL RES, V1404, P9, DOI 10.1016/S0167-4889(98)00044-5; Nicholson KL, 1998, NAT STRUCT BIOL, V5, P793, DOI 10.1038/1834; Otto H, 1997, P NATL ACAD SCI USA, V94, P6197, DOI 10.1073/pnas.94.12.6197; PELLEGRINI LL, 1994, FEBS LETT, V353, P319, DOI 10.1016/0014-5793(94)01070-6; PELLEGRINI LL, 1995, EMBO J, V14, P4705, DOI 10.1002/j.1460-2075.1995.tb00152.x; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; Poirier MA, 1998, NAT STRUCT BIOL, V5, P765, DOI 10.1038/1799; Rice LM, 1997, FEBS LETT, V415, P49, DOI 10.1016/S0014-5793(97)01091-0; Rizo J, 1998, NAT STRUCT BIOL, V5, P839, DOI 10.1038/2280; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Ungermann C, 1998, NATURE, V396, P543, DOI 10.1038/25069; vonMollard GF, 1997, J CELL BIOL, V137, P1511, DOI 10.1083/jcb.137.7.1511; WALCHSOLIMENA C, 1995, J CELL BIOL, V128, P637, DOI 10.1083/jcb.128.4.637; Weimbs T, 1998, TRENDS CELL BIOL, V8, P260, DOI 10.1016/S0962-8924(98)01285-9; Weis WI, 1998, NATURE, V395, P328, DOI 10.1038/26354; Wen J, 1996, ANAL BIOCHEM, V240, P155, DOI 10.1006/abio.1996.0345; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Wong SH, 1998, MOL BIOL CELL, V9, P1549, DOI 10.1091/mbc.9.6.1549; WYATT PJ, 1993, ANAL CHIM ACTA, V272, P1, DOI 10.1016/0003-2670(93)80373-S; Yang B, 1999, J BIOL CHEM, V274, P5649, DOI 10.1074/jbc.274.9.5649	47	243	260	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15440	15446		10.1074/jbc.274.22.15440	http://dx.doi.org/10.1074/jbc.274.22.15440			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336434	hybrid			2022-12-25	WOS:000080560100023
J	Nishida, CR; de Montellano, PRO				Nishida, CR; de Montellano, PRO			Autoinhibition of endothelial nitric-oxide synthase - Identification of an electron transfer control element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MOLECULAR-CLONING; REDUCTASE-ACTIVITY; HUMAN-LIVER; CALMODULIN; EXPRESSION; PURIFICATION; BINDING; CDNA; FLAVOPROTEIN	The primary sequences of the three mammalian nitric- oxide synthase (NOS) isoforms differ by the insertion of a 52-55-amino acid loop into the reductase domains of the endothelial (eNOS) and neuronal (nNOS), but not inducible (iNOS). On the basis of studies of peptide derivatives as inhibitors of (NO)-N-. formation and calmodulin (CaM) binding (Salerno, J. C., Harris, D. E., Irizarry, K., Patel, B., Morales, A. J., Smith, S. M., Martasek, P., Roman, L. J., Masters, B. S., Jones, C. L., Weissman, B. A., Lane, P., Liu, Q., and Gross, S. S. (1997) J. Biol, Chem. 272, 29769-29777), the insert has been proposed to be an autoinhibitory element. We have examined the role of the insert in its native protein context by deleting the insert from both wild-type eNOS and fi om chimeras obtained by swapping the reductase domains of the three NOS isoforms. The Ca2+ concentrations required to activate the enzymes decrease significantly when the insert is deleted, consistent with suppression of autoinhibition. Furthermore, removal of the insert greatly enhances the maximal activity of mild-type eNOS, the least active of the three isoform. Despite the correlation between reductase and overall enzymatic activity for the wild-type and chimeric NOS proteins, the loop-free eNOS still requires CaM to synthesize (NO)-N-.. However, the reductive activity of the CaM-free, loop-deleted eNOS is enhanced significantly over that of CaM-free wild-type eNOS and approaches the same level as that of CaM-bound wild-type eNOS. Thus, the inhibitory effect of the loop on both the eNOS reductase and (NO)-N-.-synthesizing activities may have an origin distinct from the loop's inhibitory effects on the binding of CaM and the concomitant activation of the reductase and (NO)-N-.-synthesizing activities. The eNOS insert not only inhibits activation of the enzyme by CaM but also contributes to the relatively low overall activity of this NOS isoform.	Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	de Montellano, PRO (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA.	ortiz@cgl.ucsf.edu			NIGMS NIH HHS [GM25515] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM025515, R01GM025515] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABUSOUD HM, 1994, J BIOL CHEM, V269, P32047; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BUSSE R, 1990, FEBS LETT, V265, P133, DOI 10.1016/0014-5793(90)80902-U; Chen PF, 1997, J BIOL CHEM, V272, P6114, DOI 10.1074/jbc.272.10.6114; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; FORSTERMANN U, 1994, HYPERTENSION, V23, P1121, DOI 10.1161/01.HYP.23.6.1121; Fossetta JD, 1996, FEBS LETT, V379, P135, DOI 10.1016/0014-5793(95)01496-9; Gachhui R, 1996, J BIOL CHEM, V271, P20594, DOI 10.1074/jbc.271.34.20594; Gerber NC, 1997, ARCH BIOCHEM BIOPHYS, V343, P249, DOI 10.1006/abbi.1997.0187; GERBER NC, 1995, J BIOL CHEM, V270, P17791, DOI 10.1074/jbc.270.30.17791; Grabowski PS, 1996, PORTL PR P, V10, P48; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; HANIU M, 1989, BIOCHEMISTRY-US, V28, P8639, DOI 10.1021/bi00447a054; HARTENECK C, 1994, BIOCHEM J, V304, P683, DOI 10.1042/bj3040683; HEVEL JM, 1991, J BIOL CHEM, V266, P22789; HEVEL JM, 1994, METHOD ENZYMOL, V233, P250; HORECKER BL, 1950, J BIOL CHEM, V183, P593; Huhmer AFR, 1997, CHEM RES TOXICOL, V10, P618, DOI 10.1021/tx960188t; JANSSENS SP, 1992, J BIOL CHEM, V267, P22694; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; KLATT P, 1992, J BIOL CHEM, V267, P11374; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; Lin AW, 1996, J BIOL CHEM, V271, P11911, DOI 10.1074/jbc.271.20.11911; List BM, 1997, BIOCHEM J, V323, P159, DOI 10.1042/bj3230159; Luckhart S, 1998, P NATL ACAD SCI USA, V95, P5700, DOI 10.1073/pnas.95.10.5700; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; Martasek P, 1996, BIOCHEM BIOPH RES CO, V219, P359, DOI 10.1006/bbrc.1996.0238; MASTERS BSS, 1994, ANNU REV NUTR, V14, P131, DOI 10.1146/annurev.nu.14.070194.001023; MURPHY ME, 1994, METHOD ENZYMOL, V233, P240; NAKANE M, 1993, FEBS LETT, V316, P175, DOI 10.1016/0014-5793(93)81210-Q; Nishida CR, 1998, J BIOL CHEM, V273, P5566, DOI 10.1074/jbc.273.10.5566; PHILLIPS AH, 1962, J BIOL CHEM, V237, P2652; POLLOCK JS, 1991, P NATL ACAD SCI USA, V88, P10480, DOI 10.1073/pnas.88.23.10480; Rafferty S, 1996, BIOCHEM BIOPH RES CO, V220, P1002, DOI 10.1006/bbrc.1996.0522; REGULSKI M, 1995, P NATL ACAD SCI USA, V92, P9072, DOI 10.1073/pnas.92.20.9072; RHYNER JA, 1992, BIOCHEMISTRY-US, V31, P12826, DOI 10.1021/bi00166a017; RIVEROSMORENO V, 1995, EUR J BIOCHEM, V230, P52; RodriguezCrespo I, 1996, ARCH BIOCHEM BIOPHYS, V336, P151, DOI 10.1006/abbi.1996.0543; RodriguezCrespo I, 1996, J BIOL CHEM, V271, P11462, DOI 10.1074/jbc.271.19.11462; ROMAN LJ, 1995, P NATL ACAD SCI USA, V92, P8428, DOI 10.1073/pnas.92.18.8428; Ruan J, 1996, J BIOL CHEM, V271, P22679, DOI 10.1074/jbc.271.37.22679; Salerno JC, 1997, J BIOL CHEM, V272, P29769, DOI 10.1074/jbc.272.47.29769; Schrammel A, 1998, BBA-PROTEIN STRUCT M, V1387, P257, DOI 10.1016/S0167-4838(98)00138-1; SESSA WC, 1994, J VASC RES, V31, P131, DOI 10.1159/000159039; SESSA WC, 1992, J BIOL CHEM, V267, P15274; SHERMAN PA, 1993, BIOCHEMISTRY-US, V32, P11600, DOI 10.1021/bi00094a017; Shirato M, 1998, BIOCHEM J, V333, P795, DOI 10.1042/bj3330795; Strobel Henry W., 1995, P225; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; Tao Bernard Y., 1994, P69; TSIEN R, 1989, METHOD ENZYMOL, V172, P230; VERMILION JL, 1974, BIOCHEM BIOPH RES CO, V60, P1315, DOI 10.1016/0006-291X(74)90341-6; WILLIAMS CH, 1962, J BIOL CHEM, V237, P587; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; Yuda M, 1996, EUR J BIOCHEM, V242, P807, DOI 10.1111/j.1432-1033.1996.0807r.x	59	94	97	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					14692	14698		10.1074/jbc.274.21.14692	http://dx.doi.org/10.1074/jbc.274.21.14692			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329664	hybrid			2022-12-25	WOS:000081965200029
J	Kirch, HC; Flaswinkel, S; Rumpf, H; Brockmann, D; Esche, H				Kirch, HC; Flaswinkel, S; Rumpf, H; Brockmann, D; Esche, H			Expression of human p53 requires synergistic activation of transcription from the p53 promoter by AP-1, NF-kappa B and Myc/Max	ONCOGENE			English	Article						p53; promoter; transcription; AP-1; NF-kappa B; Myc/Max	HUMAN HEPATOCELLULAR-CARCINOMA; INDUCIBLE ENHANCER ELEMENTS; CYCLE CHECKPOINT PATHWAY; TUMOR-SUPPRESSOR GENE; NECROSIS-FACTOR-ALPHA; HELIX-LOOP-HELIX; WILD-TYPE P53; BINDING PROTEIN; CANCER-CELLS; DNA-BINDING	Transcriptional control of p53 expression participates in the generation of appropriate le, els of active p53 in response to mitogenic stimulation, This prompted us to study the role of a putative AP-1 and a NF-kappa B motif in the human p53 promoter for transcriptional regulation, We show that mutation of the AP-1 or the NF-kappa B motif abolishes transcription from the human p53 promoter in HeLa, HepG2 and adenovirus type 5 E1-transformed 293 cells, In comparison, mutation of the previously characterized Myc/Max/USF binding site in the human p53 promoter reduces the transcription rate fivefold. The AP-1 motif in the human p53 promoter binds c-Fos and c-Jun and the NF-kappa-B motif binds p50(NF-kappa B1) and p65(RelA). The cooperative nature of transcriptional activation by these factors was documented by repression of c-fos or NF-kappa B1 translation: Pretreatment of the cells,vith a c-fos or p50(NF-kappa B1) antisense oligonucleotide suppresses transcription from the human p53 promoter completely. In addition, we show that (a) the level of endogenous p53 mRNA and (b) transcription from the strictly p53-dependent human mdm2 promoter are reduced in the presence of c-fos, c-jun, p50(NF-kappa B1), p65(RelA) or c-myc antisense oligonucleotides, underscoring the importance of these transcription factors for the expression of functional p53.	Univ Essen Gesamthsch, Sch Med, Inst Mol Biol Canc Res, D-45122 Essen, Germany	University of Duisburg Essen	Kirch, HC (corresponding author), Univ Essen Gesamthsch, Sch Med, Inst Mol Biol Canc Res, Hufelandstr 55, D-45122 Essen, Germany.							ALAM J, 1990, ANAL BIOCHEM, V188, P254; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Balint E, 1996, CANCER RES, V56, P1648; BIENZTADMOR B, 1985, EMBO J, V4, P3209, DOI 10.1002/j.1460-2075.1985.tb04067.x; BOHNLEIN E, 1988, CELL, V53, P827, DOI 10.1016/0092-8674(88)90099-2; BRACH MA, 1993, MOL CELL BIOL, V13, P4284, DOI 10.1128/MCB.13.7.4284; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; Brockmann D, 1996, ONCOGENE, V12, P1715; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; BUTZ K, 1995, ONCOGENE, V10, P927; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DEFFIE A, 1993, MOL CELL BIOL, V13, P3415, DOI 10.1128/MCB.13.6.3415; DU H, 1993, EMBO J, V12, P501, DOI 10.1002/j.1460-2075.1993.tb05682.x; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; FARSHID M, 1992, J MED VIROL, V38, P235, DOI 10.1002/jmv.1890380402; Foletta VC, 1996, IMMUNOL CELL BIOL, V74, P121, DOI 10.1038/icb.1996.17; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; Furlong EEM, 1996, MOL CELL BIOL, V16, P5933; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; GINSBERG D, 1990, ONCOGENE, V5, P1285; Hagmeyer BM, 1996, ONCOGENE, V12, P1025; HAGMEYER BM, 1993, EMBO J, V12, P3559, DOI 10.1002/j.1460-2075.1993.tb06030.x; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; HARELBELLAN A, 1988, J IMMUNOL, V140, P2431; Ho YS, 1996, MOL CARCINOGEN, V16, P20, DOI 10.1002/(SICI)1098-2744(199605)16:1<20::AID-MC4>3.3.CO;2-I; Jiang SS, 1996, CHINESE PHYS LETT, V13, P9, DOI 10.1088/0256-307X/13/1/003; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASZUBSKA W, 1993, MOL CELL BIOL, V13, P7180, DOI 10.1128/MCB.13.11.7180; KIRCH HC, 1993, CELL MOL BIOL RES, V39, P705; Kirch HC, 1997, EUR J BIOCHEM, V246, P736, DOI 10.1111/j.1432-1033.1997.00736.x; Kralova J, 1996, ONCOGENE, V12, P2595; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LANZA F, 1995, BRIT J HAEMATOL, V90, P8, DOI 10.1111/j.1365-2141.1995.tb03374.x; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MIYASHITA T, 1995, CELL, V80, P293; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; PUISIEUX A, 1993, FASEB J, V7, P1407, DOI 10.1096/fasebj.7.14.8224613; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; REISMAN D, 1993, NUCLEIC ACIDS RES, V21, P345, DOI 10.1093/nar/21.2.345; RONEN D, 1991, P NATL ACAD SCI USA, V88, P4128, DOI 10.1073/pnas.88.10.4128; Roy B, 1996, ONCOGENE, V13, P2359; ROY B, 1994, MOL CELL BIOL, V14, P7805, DOI 10.1128/MCB.14.12.7805; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SHEN YQ, 1995, CURR OPIN GENET DEV, V5, P105, DOI 10.1016/S0959-437X(95)90061-6; SOINI Y, 1992, VIRCHOWS ARCH A, V421, P415, DOI 10.1007/BF01606914; SOKOLOSKI JA, 1993, BLOOD, V82, P625; SONOBE MH, 1995, ONCOGENE, V10, P689; SOUSSI T, 1994, INT J CANCER, V57, P1, DOI 10.1002/ijc.2910570102; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; SUN XG, 1995, MOL CELL BIOL, V15, P4489; Teodoro JG, 1997, J VIROL, V71, P1739, DOI 10.1128/JVI.71.3.1739-1746.1997; TUCK SP, 1989, MOL CELL BIOL, V9, P2163, DOI 10.1128/MCB.9.5.2163; WU HY, 1994, J BIOL CHEM, V269, P20067; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YASUMOTO K, 1992, J BIOL CHEM, V267, P22506; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584; ZOIDL G, 1993, GENE, V131, P269, DOI 10.1016/0378-1119(93)90305-M	69	116	118	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 29	1999	18	17					2728	2738		10.1038/sj.onc.1202626	http://dx.doi.org/10.1038/sj.onc.1202626			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FH	10348347				2022-12-25	WOS:000080124900008
J	Jones, DR; Pettitt, TR; Sanjuan, MA; Merida, I; Wakelam, MJO				Jones, DR; Pettitt, TR; Sanjuan, MA; Merida, I; Wakelam, MJO			Interleukin-2 causes an increase in saturated monounsaturated phosphatidic acid derived from 1,2-diacylglycerol and 1-O-alkyl-2-acylglycerol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ETHER-LINKED DIGLYCERIDES; PHOSPHOLIPASE-D; LYMPHOCYTE-PROLIFERATION; MESANGIAL CELLS; T-CELLS; ACTIVATION; DIACYLGLYCEROL; GENERATION; ZETA	Phosphatidic acid generation through activation of diacylglycerol kinase cu has been implicated in interleukin-2-dependent T-lymphocyte proliferation. To investigate this lipid signaling in more detail, we characterized the molecular structures of the diradylglycerols and phosphatidic acids in the murine CTLL-2 T-cell line under both basal and stimulated conditions. In resting cells, 1,2-diacylglycerol and 1-O-alkyl-2-acylglycerol subtypes represented 44 and 55% of total diradylglycerol, respectively, and both showed a highly saturated profile containing primarily 16:0 and 18:1 fatty acids. 1-O-Alk-1'-enyl-2-acylglycerol represented 1-2% of total diradylglycerol, Interleukin-2 stimulation did not alter the molecular species profiles, however, it did selectively reduce total 1-O-alkyl-2-acylglycerol by over 50% at 15 min while only causing a 10% drop in 1,2-diacylglycerol, When radiolabeled CTLL-2 cells were challenged with interleukin-a, no change in the cellular content of phosphatidylcholine nor phosphatidylethanolamine was observed thereby ruling out phospholipase C activity as the source of diradylglycerol, In addition, interleukin-a failed to stimulate de novo synthesis of diradylglycerol, Structural analysis revealed approximately equal amounts of 1,2-diacyl phosphatidic acid and 1-O-alkyl-2-acyl phosphatidic acid under resting conditions, both containing only saturated and monounsaturated fatty acids. After acute (2 and 15 min) interleukin-a stimulation the total phosphatidic acid mass increased, almost entirely through the formation of 1-O-alkyl-2-acyl species. In vitro assays revealed that both 1,2-diacylglycerol and 1-O-alkyl-2-acylglycerol were substrates for 1,2-diacylglycerol kinase cu, the major isoform in CTLL-2 cells, and that the lipid kinase activity was almost totally inhibited by R59949, In conclusion, this investigation shows that, in CTLL-2 cells, 1,2-diacylglycerol kinase ct specifically phosphorylates a pre-existing pool of 1-O-alkyl-2-acylglycerol to form the intracellular messenger 1-O-alkyl-2-acyl phosphatidic acid.	CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, Madrid 28049, Spain; Univ Birmingham, CRC, Inst Canc Studies, Birmingham, W Midlands, England	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); University of Birmingham	Merida, I (corresponding author), CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, Madrid 28049, Spain.	imerida@cnb.uam.es	Sanjuán, Miguel Ángel/I-6896-2019; Merida, Isabel/A-9713-2014	Sanjuán, Miguel Ángel/0000-0001-6694-0634; Merida, Isabel/0000-0003-2762-6241; Wakelam, Michael/0000-0003-4059-9276				BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CABOT MC, 1984, BIOCHEM BIOPH RES CO, V125, P163, DOI 10.1016/S0006-291X(84)80349-6; Cross MJ, 1996, CURR BIOL, V6, P588, DOI 10.1016/S0960-9822(02)00545-6; DECOURCELLES DD, 1989, J BIOL CHEM, V264, P3274; English D, 1996, CHEM PHYS LIPIDS, V80, P117, DOI 10.1016/0009-3084(96)02549-2; Exton JH, 1997, PHYSIOL REV, V77, P303, DOI 10.1152/physrev.1997.77.2.303; FERGUSON MAJ, 1994, PRACTICAL APPROACH G, V125, P349; Flores I, 1996, J BIOL CHEM, V271, P10334, DOI 10.1074/jbc.271.17.10334; FORD DA, 1989, J BIOL CHEM, V264, P13818; FORD DA, 1990, AM J PHYSIOL, V25, pC30; Gomez J, 1997, J IMMUNOL, V158, P1516; Gomez J, 1998, CRIT REV IMMUNOL, V18, P185, DOI 10.1615/CritRevImmunol.v18.i3.20; Hermans SWG, 1996, EUR J BIOCHEM, V235, P73, DOI 10.1111/j.1432-1033.1996.00073.x; Hodgkin MN, 1998, TRENDS BIOCHEM SCI, V23, P200, DOI 10.1016/S0968-0004(98)01200-6; Jones DR, 1998, FEBS LETT, V433, P23, DOI 10.1016/S0014-5793(98)00875-8; KESTER M, 1989, J CLIN INVEST, V83, P718, DOI 10.1172/JCI113937; Limatola C, 1997, BIOCHEM J, V321, P497, DOI 10.1042/bj3210497; LIMATOLA C, 1994, BIOCHEM J, V304, P1001, DOI 10.1042/bj3041001; Mandal A, 1997, J BIOL CHEM, V272, P20306, DOI 10.1074/jbc.272.32.20306; Martin A, 1997, ONCOGENE, V14, P1571, DOI 10.1038/sj.onc.1200987; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; MERIDA I, 1993, DNA CELL BIOL, V12, P473, DOI 10.1089/dna.1993.12.473; MERIDA I, 1990, P NATL ACAD SCI USA, V87, P9421, DOI 10.1073/pnas.87.23.9421; Michell RH, 1997, ESSAYS BIOCHEM, V32, P31; MILLS GB, 1986, J IMMUNOL, V136, P3019; MILLS GB, 1988, CELL, V55, P91, DOI 10.1016/0092-8674(88)90012-8; MUSIAL A, 1995, J BIOL CHEM, V270, P21632, DOI 10.1074/jbc.270.37.21632; Pettitt TR, 1997, J BIOL CHEM, V272, P17354, DOI 10.1074/jbc.272.28.17354; PETTITT TR, 1994, BIOCHEM J, V298, P655, DOI 10.1042/bj2980655; Pettitt TR, 1998, FEBS LETT, V427, P371, DOI 10.1016/S0014-5793(98)00471-2; Sakane F, 1997, INT J BIOCHEM CELL B, V29, P1139, DOI 10.1016/S1357-2725(97)00037-X; SAWAMI H, 1992, J CELL PHYSIOL, V151, P367, DOI 10.1002/jcp.1041510218; TIGGES MA, 1989, SCIENCE, V243, P781, DOI 10.1126/science.2492678; VALGE VE, 1988, CELL, V55, P101, DOI 10.1016/0092-8674(88)90013-X	34	27	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16846	16852		10.1074/jbc.274.24.16846	http://dx.doi.org/10.1074/jbc.274.24.16846			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358029	hybrid			2022-12-25	WOS:000080780400028
J	Park, SG; Jung, KH; Lee, JS; Jo, YJ; Motegi, H; Kim, S; Shiba, K				Park, SG; Jung, KH; Lee, JS; Jo, YJ; Motegi, H; Kim, S; Shiba, K			Precursor of pro-apoptotic cytokine modulates aminoacylation activity of tRNA synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; ACTIVATING POLYPEPTIDE-II; PROTEIN-PROTEIN INTERACTIONS; ELONGATION-FACTOR 1-ALPHA; MULTISYNTHETASE COMPLEX; TERMINAL PEPTIDE; COMPONENT; MECHANISMS; EUKARYOTES; CLONING	Endothelial monocyte activating polypeptide II (EMAPII) is a cytokine that is specifically induced by apoptosis, Its precursor (pro-EMAPII) has been suggested to be identical to p43, which is associated with the multi-tRNA synthetase complex. Herein, we have demonstrated that the N-terminal domain of pro-EMAPII interacts with the N-terminal extension of human cytoplasmic arginyl-tRNA synthetase (RRS) using genetic and immunoprecipitation analyses. Aminoacylation activity of RRS was enhanced about 2.5-fold by the interaction with pro-EMAPII but not with its N- or C-terminal domains alone. The N-terminal extension of RRS was not required for enzyme activity but did mediate activity stimulation by pro-EMAPII. Pro-EMAPII reduced the apparent K-m of RRS to tRNA, whereas the k(cat) value remained unchanged. Therefore, the precursor of EMAPII is a multi-functional protein that assists aminoacylation in normal cells and releases the functional cytokine upon apoptosis.	Sungkyunkwan Univ, Dept Biol Sci, Natl Creat Res Initiat Ctr ARS Network, Suwon 440746, Kyunggido, South Korea; Japanese Fdn Canc Res, Inst Canc, Dept Cell Biol, Tokyo 1708455, Japan	Sungkyunkwan University (SKKU); Japanese Foundation for Cancer Research	Kim, S (corresponding author), Sungkyunkwan Univ, Dept Biol Sci, Natl Creat Res Initiat Ctr ARS Network, 300 Chunchundong, Suwon 440746, Kyunggido, South Korea.	shkim@yurim.skku.ac.kr	Shiba, Kiyotaka/I-9588-2014; Kim, Sunghoon/AAE-8314-2020	Shiba, Kiyotaka/0000-0001-6459-0204; 				FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; FILONENKO VV, 1994, J BIOL CHEM, V269, P17375; GIRJES AA, 1995, GENE, V164, P347, DOI 10.1016/0378-1119(95)00502-W; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; KAO J, 1992, J BIOL CHEM, V267, P20239; KAO J, 1994, J BIOL CHEM, V269, P25106; KAO J, 1994, J BIOL CHEM, V269, P9774; KIM S, 1993, BIOCHEMISTRY-US, V32, P13026, DOI 10.1021/bi00211a011; KISSELEV LL, 1994, PROG NUCLEIC ACID RE, V48, P83, DOI 10.1016/S0079-6603(08)60854-5; Knies UE, 1998, P NATL ACAD SCI USA, V95, P12322, DOI 10.1073/pnas.95.21.12322; LAZARD M, 1993, GENE, V132, P237, DOI 10.1016/0378-1119(93)90201-D; MIRANDE M, 1991, PROG NUCLEIC ACID RE, V40, P95; Negrutskii BS, 1999, J BIOL CHEM, V274, P4545, DOI 10.1074/jbc.274.8.4545; Norcum MT, 1998, PROTEIN SCI, V7, P79, DOI 10.1002/pro.5560070108; Quevillon S, 1996, FEBS LETT, V395, P63, DOI 10.1016/0014-5793(96)01005-8; Quevillon S, 1999, J MOL BIOL, V285, P183, DOI 10.1006/jmbi.1998.2316; Quevillon S, 1997, J BIOL CHEM, V272, P32573, DOI 10.1074/jbc.272.51.32573; REED VS, 1994, J BIOL CHEM, V269, P32932; REED VS, 1994, J BIOL CHEM, V269, P32937; Rho SB, 1999, P NATL ACAD SCI USA, V96, P4488, DOI 10.1073/pnas.96.8.4488; Shiba K, 1997, J BIOL CHEM, V272, P22809, DOI 10.1074/jbc.272.36.22809; Simos G, 1998, MOL CELL, V1, P235, DOI 10.1016/S1097-2765(00)80024-6; Tas MPR, 1996, INT J BIOCHEM CELL B, V28, P837, DOI 10.1016/1357-2725(96)00038-6; VELLEKAMP G, 1985, J BIOL CHEM, V260, P9843; Wakasugi K, 1999, SCIENCE, V284, P147, DOI 10.1126/science.284.5411.147; Whelihan EF, 1997, EMBO J, V16, P2968, DOI 10.1093/emboj/16.10.2968; Yang DCH, 1996, CURR TOP CELL REGUL, V34, P101, DOI 10.1016/S0070-2137(96)80004-5	28	83	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16673	16676		10.1074/jbc.274.24.16673	http://dx.doi.org/10.1074/jbc.274.24.16673			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358004	hybrid			2022-12-25	WOS:000080780400003
J	Perez-Mato, I; Castro, C; Ruiz, FA; Corrales, FJ; Mato, JM				Perez-Mato, I; Castro, C; Ruiz, FA; Corrales, FJ; Mato, JM			Methionine adenosyltransferase S-nitrosylation is regulated by the basic and acidic amino acids surrounding the target thiol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSYLMETHIONINE SYNTHETASE; RAT-LIVER; NITRIC-OXIDE; GENE-EXPRESSION; MESSENGER-RNA; INJURY; PEROXYNITRITE; CIRRHOSIS	S-Adenosylmethionine serves as the methyl donor for many biological methylation reactions and provides the propylamine group for the synthesis of polyamines. S-Adenosylmethionine is synthesized from methionine and ATP by the enzyme methionine adenosyltransferase. The cellular factors regulating S-adenosylmethionine synthesis have not been well defined. Here we show that in rat hepatocytes S-nitrosoglutathione monoethyl ester, a cell-permeable nitric oxide donor, markedly reduces cellular S-adenosylmethionine content via inactivation of methionine adenosyltransferase by S-nitrosylation. Removal of the nitric oxide donor from the incubation medium leads to the denitrosylation and reactivation of methionine adenosyltransferase and to the rapid recovery of cellular S-adenosylmethionine levels. Nitric oxide inactivates methionine adenosyltransferase via S-nitrosylation of cysteine 121. Replacement of the acidic (aspartate 355) or basic (arginine 357 and arginine 363) amino acids located in the vicinity of cysteine 121 by serine leads to a marked reduction in the ability of nitric oxide to S-nitrosylate and inactivate hepatic methionine adenosyltransferase. These results indicate that protein S-nitrosylation is regulated by the basic and acidic amino acids surrounding the target cysteine.	Univ Navarra, Dept Med, Div Hepatol & Gene Therapy, Pamplona 31008, Spain	University of Navarra	Mato, JM (corresponding author), Univ Navarra, Dept Med, Div Hepatol & Gene Therapy, Pamplona 31008, Spain.		MATO, JOSE/A-5187-2011; Carmen, Castro/C-7813-2009; Ruiz, Felix A./B-1032-2008	MATO, JOSE/0000-0003-1264-3153; Carmen, Castro/0000-0002-6802-0572; Ruiz, Felix A./0000-0003-0748-5015; Corrales, Fernando/0000-0002-0231-5159				ALVAREZ L, 1991, FEBS LETT, V290, P142, DOI 10.1016/0014-5793(91)81245-4; ALVAREZ L, 1993, BIOCHEM J, V293, P481, DOI 10.1042/bj2930481; Avila MA, 1998, GASTROENTEROLOGY, V114, P364, DOI 10.1016/S0016-5085(98)70489-5; Avila MA, 1997, HEPATOLOGY, V25, P391; BECKMAN JS, 1994, METHOD ENZYMOL, V233, P229; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CABRERO C, 1987, EUR J BIOCHEM, V170, P299, DOI 10.1111/j.1432-1033.1987.tb13699.x; CANTONI GL, 1975, ANNU REV BIOCHEM, V44, P435, DOI 10.1146/annurev.bi.44.070175.002251; CORRALES F, 1992, HEPATOLOGY, V16, P1022, DOI 10.1002/hep.1840160427; FELL D, 1985, J CHROMATOGR, V345, P150, DOI 10.1016/0378-4347(85)80146-8; FINKELSTEIN JD, 1990, J NUTR BIOCHEM, V1, P228, DOI 10.1016/0955-2863(90)90070-2; Freeswick Paul D., 1994, P1031; GUARNER C, 1993, HEPATOLOGY, V18, P1139; HORIKAWA S, 1989, EUR J BIOCHEM, V184, P497, DOI 10.1111/j.1432-1033.1989.tb15042.x; HOROWITZ JH, 1981, GASTROENTEROLOGY, V81, P668; KINSELL LW, 1947, SCIENCE, V106, P589, DOI 10.1126/science.106.2763.589; Kotb M, 1997, TRENDS GENET, V13, P51, DOI 10.1016/S0168-9525(97)01013-5; LIEBER CS, 1990, HEPATOLOGY, V11, P165, DOI 10.1002/hep.1840110203; MARTINDUCE A, 1998, HEPATOLOGY, V8, P65; Mato Jose M., 1994, P461; Mingorance J, 1996, BIOCHEM J, V315, P761, DOI 10.1042/bj3150761; MUDD SH, 1975, METABOLISM, V24, P721, DOI 10.1016/0026-0495(75)90040-2; Pannala A, 1997, BIOCHEM BIOPH RES CO, V232, P164, DOI 10.1006/bbrc.1997.6254; Ruiz F, 1998, HEPATOLOGY, V28, P1051, DOI 10.1002/hep.510280420; SanchezGongora E, 1997, FASEB J, V11, P1013, DOI 10.1096/fasebj.11.12.9337154; SAYLE R, 1993, RAS WIN MOL GRAPHICS; SERRANO L, 1990, BIOCHEMISTRY-US, V29, P9343, DOI 10.1021/bi00492a006; Stamler JS, 1997, NEURON, V18, P691, DOI 10.1016/S0896-6273(00)80310-4; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; Takusagawa F, 1996, J BIOL CHEM, V271, P136, DOI 10.1074/jbc.271.1.136; Takusagawa F, 1996, BIOCHEMISTRY-US, V35, P2586, DOI 10.1021/bi952604z; VARELAMOREIRAS G, 1995, HEPATOLOGY, V22, P1310, DOI 10.1016/0270-9139(95)90644-4	32	118	124	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17075	17079		10.1074/jbc.274.24.17075	http://dx.doi.org/10.1074/jbc.274.24.17075			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358060	Green Published, hybrid			2022-12-25	WOS:000080780400059
J	Bafico, A; Gazit, A; Pramila, T; Finch, PW; Yaniv, A; Aaronson, SA				Bafico, A; Gazit, A; Pramila, T; Finch, PW; Yaniv, A; Aaronson, SA			Interaction of frizzled related protein (FRP) with Wnt ligands and the frizzled receptor suggests alternative mechanisms for FRP inhibition of Wnt signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CATENIN; GROWTH-FACTOR; TRANSCRIPTIONAL ACTIVATION; SECRETED PROTEINS; CELL-LINES; FAMILY; TRANSFORMATION; EXPRESSION; MEMBER; GENE	Frizzled related proteins (FRPs) comprise a family of secreted molecules that contain an N-terminal cysteine-rich domain (CRD) highly similar to the CRDs of the frizzled family of membrane-anchored Wnt receptors. FRPs have been shown to interact with Wnt proteins and antagonize Wnt signaling in a Xenopus developmental model. Fire demonstrated that FRP antagonizes the Wnt-induced increase in uncomplexed beta-catenin in both transient cotransfection and stable transformation models, where Wnt-induced morphological alterations are inhibited as well. We showed further that FRP inhibits Wnt signaling in a paracrine mode using a T-cell factor luciferase reporter to measure Wnt function. Investigation of the mechanisms responsible for FRP inhibition revealed that FRP forms complexes with WNT-1 or WNT-2 through its CRD domain. Transfection analysis with FRPs containing different tags revealed that FRP itself forms complexes and that this ability is conferred by its CRD domain. Finally, we demonstrated by cotransfection that FRP forms complexes with a prototype frizzled. AU of these findings are consistent with a model by which FRP inhibits Wnt signaling through interactions with Wnt and/or formation of nonfunctional complexes with the frizzled receptor.	CUNY, Mt Sinai Med Ctr, David H Ruttenberg Canc Ctr, New York, NY 10029 USA; Tel Aviv Univ, Sackler Sch Med, Dept Human Microbiol, IL-69978 Tel Aviv, Israel	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Tel Aviv University; Sackler Faculty of Medicine	Aaronson, SA (corresponding author), CUNY, Mt Sinai Med Ctr, David H Ruttenberg Canc Ctr, 1 Gustave L Levy Pl,Box 1130, New York, NY 10029 USA.							ALIMANDI M, 1995, ONCOGENE, V10, P1813; Bafico A, 1998, ONCOGENE, V16, P2819, DOI 10.1038/sj.onc.1201797; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; BROWN AMC, 1986, CELL, V46, P1001, DOI 10.1016/0092-8674(86)90699-9; CHAN AML, 1994, P NATL ACAD SCI USA, V91, P7558, DOI 10.1073/pnas.91.16.7558; Dale TC, 1996, CANCER RES, V56, P4320; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Finch PW, 1997, P NATL ACAD SCI USA, V94, P6770, DOI 10.1073/pnas.94.13.6770; Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848; He X, 1997, SCIENCE, V275, P1652, DOI 10.1126/science.275.5306.1652; HEIDARAN MA, 1991, J BIOL CHEM, V266, P20232; HELDIN CH, 1986, NATURE, V319, P511, DOI 10.1038/319511a0; HUGUET EL, 1994, CANCER RES, V54, P2615; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; LAROCHELLE WJ, 1995, J CELL BIOL, V129, P357, DOI 10.1083/jcb.129.2.357; LAROCHELLE WJ, 1989, MOL CELL BIOL, V9, P3538, DOI 10.1128/MCB.9.8.3538; Leyns L, 1997, CELL, V88, P747, DOI 10.1016/S0092-8674(00)81921-2; Lin KM, 1997, P NATL ACAD SCI USA, V94, P11196, DOI 10.1073/pnas.94.21.11196; LIN TP, 1992, CANCER RES, V52, P4413; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; PAPKOFF J, 1990, MOL CELL BIOL, V10, P2723, DOI 10.1128/MCB.10.6.2723; Rattner A, 1997, P NATL ACAD SCI USA, V94, P2859, DOI 10.1073/pnas.94.7.2859; Reichsman F, 1996, J CELL BIOL, V135, P819, DOI 10.1083/jcb.135.3.819; ROBBINS KC, 1983, NATURE, V305, P605, DOI 10.1038/305605a0; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; Wang SW, 1997, CELL, V88, P757, DOI 10.1016/S0092-8674(00)81922-4; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WONG GT, 1994, MOL CELL BIOL, V14, P6278, DOI 10.1128/MCB.14.9.6278; Xu QH, 1998, DEVELOPMENT, V125, P4767; Young CS, 1998, MOL CELL BIOL, V18, P2474, DOI 10.1128/MCB.18.5.2474	34	286	319	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16180	16187		10.1074/jbc.274.23.16180	http://dx.doi.org/10.1074/jbc.274.23.16180			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347172	hybrid			2022-12-25	WOS:000080668600032
J	Orlov, SN; Thorin-Trescases, N; Kotelevtsev, SV; Tremblay, J; Hamet, P				Orlov, SN; Thorin-Trescases, N; Kotelevtsev, SV; Tremblay, J; Hamet, P			Inversion of the intracellular Na+/K+ ratio blocks apoptosis in vascular smooth muscle at a site upstream of caspase-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; DNA FRAGMENTATION; HUMAN-LYMPHOCYTES; CELL SHRINKAGE; ACTIVATION; FAS; PROLIFERATION; INHIBITION; MECHANISM; POTASSIUM	Long term elevation of the intracellular Na+/K+ ratio inhibits macromolecule synthesis and proliferation in the majority of cell types studied so far, including vascular smooth muscle cells (VSMC). We report here that inhibition of the Na+,K+ pump in VSMC by ouabain or a 1-h preincubation in K+-depleted medium attenuated apoptosis triggered by serum withdrawal, staurosporine, or okadaic acid. In the absence of ouabain, both DNA degradation and Caspase-3 activation in VSMC undergoing apoptosis were insensitive to modification of the extracellular Na+/K+ ratio as well as to hyperosmotic cell shrinkage. In contrast, protection of VSMC from apoptosis by ouabain was abolished under equimolar substitution of Na-o(+) with K-o(+), showing that the antiapoptotic action of Na+,K+ pump inhibition was caused by inversion of the intracellular Na+/K+ ratio. Unlike VSMC, the same level of increment of the [Na+](i)/ [K+](i) ratio caused by a 2-h preincubation of Jurkat cells with ouabain did not affect chromatin cleavage and Caspase-3 activity triggered by treatment with Fas ligand, staurosporine, or hyperosmotic shrinkage, Thus, our results show for the first time that similar to cell proliferation, maintenance of a physiologically low intracellular Na+/K+ ratio is required for progression of VSMC apoptosis.	Univ Montreal, CHU Montreal, Ctr Rech, Mol Med Lab, Montreal, PQ H2W 1T8, Canada; Moscow MV Lomonosov State Univ, Fac Biol, Lab Biomembranes, Moscow, Russia	Universite de Montreal; Lomonosov Moscow State University	Hamet, P (corresponding author), Univ Montreal, CHU Montreal, Ctr Rech, Mol Med Lab, Campus Hotel Dieu,3850 Rue St Urbain, Montreal, PQ H2W 1T8, Canada.	hamet@ere.umontreal.ca	ORLOV, SERGEI/I-4071-2013; Cossette, Suzanne/I-8008-2016					Adachi S, 1998, J BIOL CHEM, V273, P19892, DOI 10.1074/jbc.273.31.19892; BALASUBRAMANYAM M, 1994, J CLIN INVEST, V94, P2002, DOI 10.1172/JCI117553; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; BENNETT MR, 1995, CIRC RES, V77, P266, DOI 10.1161/01.RES.77.2.266; BENNETT MR, 1994, CIRC RES, V74, P525, DOI 10.1161/01.RES.74.3.525; BERTHE P, 1991, CELL SIGNAL, V3, P453, DOI 10.1016/0898-6568(91)90075-6; BERTRAND R, 1994, EXP CELL RES, V211, P314, DOI 10.1006/excr.1994.1093; BOBIK A, 1988, J HYPERTENS, V6, pS219, DOI 10.1097/00004872-198812040-00065; Bortner CD, 1996, AM J PHYSIOL-CELL PH, V271, pC950, DOI 10.1152/ajpcell.1996.271.3.C950; Bortner CD, 1997, J BIOL CHEM, V272, P32436, DOI 10.1074/jbc.272.51.32436; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; BRODIE C, 1995, J CELL PHYSIOL, V165, P246, DOI 10.1002/jcp.1041650205; Champagne MJ, 1999, HYPERTENSION, V33, P906, DOI 10.1161/01.HYP.33.3.906; COTTER TG, 1990, ANTICANCER RES, V10, P1153; FRANKS DJ, 1984, J CELL PHYSIOL, V119, P41, DOI 10.1002/jcp.1041190108; GARNER R, 1994, J IMMUNOL, V153, P5413; Geng YJ, 1997, ARTERIOSCL THROM VAS, V17, P2200, DOI 10.1161/01.ATV.17.10.2200; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; HAMET P, 1995, HYPERTENSION, V26, P642, DOI 10.1161/01.HYP.26.4.642; HENNINGSEN NC, 1984, SCAND J CLIN LAB INV, V44, P197, DOI 10.3109/00365518409083796; Hughes FM, 1997, J BIOL CHEM, V272, P30567, DOI 10.1074/jbc.272.48.30567; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; KAPLAN JG, 1978, ANNU REV PHYSIOL, V40, P19, DOI 10.1146/annurev.ph.40.030178.000315; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KLASSEN NV, 1993, INT J RADIAT BIOL, V64, P571, DOI 10.1080/09553009314551791; Lang F, 1998, PFLUG ARCH EUR J PHY, V436, P377, DOI 10.1007/s004240050646; Lang F, 1998, CONTRIB NEPHROL, V123, P158, DOI 10.1159/000059911; LUBIN M, 1980, BIOCHEM BIOPH RES CO, V97, P1060, DOI 10.1016/0006-291X(80)91483-7; LUBIN M, 1967, NATURE, V213, P451, DOI 10.1038/213451a0; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; McConkey DJ, 1997, BIOCHEM BIOPH RES CO, V239, P357, DOI 10.1006/bbrc.1997.7409; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OHYAMA H, 1981, RADIAT RES, V85, P333, DOI 10.2307/3575566; Olej B, 1998, BIOSCIENCE REP, V18, P1, DOI 10.1023/A:1022259832207; Orlov SN, 1996, BIOCHEM BIOPH RES CO, V221, P708, DOI 10.1006/bbrc.1996.0661; Orlov SN, 1996, J MEMBRANE BIOL, V153, P125, DOI 10.1007/s002329900116; ORLOV SN, 1999, IN PRESS CARDIOVASC; OSHIMI Y, 1995, J IMMUNOL, V154, P599; PRASAD KVS, 1987, CANCER RES, V47, P5397; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; WEBB GD, 1995, CLIN SCI, V88, P695, DOI 10.1042/cs0880695; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Wyllie A.H., 1981, CELL DEATH BIOL PATH, P9	45	106	115	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16545	16552		10.1074/jbc.274.23.16545	http://dx.doi.org/10.1074/jbc.274.23.16545			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347219	hybrid			2022-12-25	WOS:000080668600079
J	Adams, CM; Snyder, PM; Welsh, MJ				Adams, CM; Snyder, PM; Welsh, MJ			Paradoxical stimulation of a DEG ENaC channel by amiloride	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL SODIUM-CHANNEL; MUTATIONS CAUSING NEURODEGENERATION; SENSITIVE NA+ CHANNEL; ION CHANNELS; CAENORHABDITIS-ELEGANS; ALPHA-SUBUNIT; CATION CHANNELS; C-ELEGANS; FAMILY; EXPRESSION	Extracellular amiloride inhibits all known DEG/ENaC ion channels, including BNC1, a proton-activated human neuronal cation channel. Earlier studies showed that protons cause a conformational change that activates BNC1 and exposes residue 430 to the extracellular solution, Here we demonstrate that, in addition to blocking BNC1, amiloride also exposes residue 430, This result suggested that, like protons, amiloride might be capable of activating the channel. To test this hypothesis, we introduced a mutation in the BNC1 pore that reduces amiloride block, and found that amiloride stimulated these channels. Amiloride inhibition was voltage-dependent, suggesting block within the pore, whereas stimulation was not, suggesting binding to an extracellular site. These data show that amiloride can have two distinct effects on BNC1, and they suggest two different interaction sites. The results suggest that extracellular amiloride binding may have a stimulatory effect similar to that of protons in BNC1 or extracellular ligands in other DEG/ENaC channels.	Univ Iowa, Coll Med, Howard Hughes Med Inst, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA	Howard Hughes Medical Institute; University of Iowa; University of Iowa; University of Iowa	Welsh, MJ (corresponding author), Univ Iowa, Coll Med, Howard Hughes Med Inst, 500 EMRB, Iowa City, IA 52242 USA.	mjwelsh@blue.weeg.uiowa.edu		Welsh, Michael/0000-0002-1646-6206; Adams, Christopher/0000-0002-5795-7212				Adams CM, 1998, J BIOL CHEM, V273, P30204, DOI 10.1074/jbc.273.46.30204; Adams CM, 1998, J CELL BIOL, V140, P143, DOI 10.1083/jcb.140.1.143; Adams CM, 1999, BIOPHYS J, V76, P1377, DOI 10.1016/S0006-3495(99)77299-1; Champigny G, 1998, J BIOL CHEM, V273, P15418, DOI 10.1074/jbc.273.25.15418; DRISCOLL M, 1991, NATURE, V349, P588, DOI 10.1038/349588a0; Du HP, 1996, NEURON, V16, P183, DOI 10.1016/S0896-6273(00)80035-5; Fuller CM, 1997, BIOPHYS J, V72, P1622, DOI 10.1016/S0006-3495(97)78808-8; Fyfe GK, 1998, SEMIN NEPHROL, V18, P138; Garcia-Anoveros J, 1998, NEURON, V20, P1231, DOI 10.1016/S0896-6273(00)80503-6; GarciaAnoveros J, 1997, P NATL ACAD SCI USA, V94, P1459, DOI 10.1073/pnas.94.4.1459; HONG KS, 1994, NATURE, V367, P470, DOI 10.1038/367470a0; Ismailov II, 1997, J BIOL CHEM, V272, P21075, DOI 10.1074/jbc.272.34.21075; LI XJ, 1995, MOL PHARMACOL, V47, P1133; Lingueglia E, 1997, J BIOL CHEM, V272, P29778, DOI 10.1074/jbc.272.47.29778; LINGUEGLIA E, 1995, NATURE, V378, P730, DOI 10.1038/378730a0; Liu JD, 1996, SCIENCE, V273, P361, DOI 10.1126/science.273.5273.361; MCDONALD FJ, 1994, AM J PHYSIOL, V266, pL728, DOI 10.1152/ajplung.1994.266.6.L728; MCDONALD FJ, 1995, AM J PHYSIOL-CELL PH, V268, pC1157, DOI 10.1152/ajpcell.1995.268.5.C1157; McNicholas CM, 1997, J GEN PHYSIOL, V109, P681, DOI 10.1085/jgp.109.6.681; Price MP, 1996, J BIOL CHEM, V271, P7879, DOI 10.1074/jbc.271.14.7879; Schild L, 1997, J GEN PHYSIOL, V109, P15, DOI 10.1085/jgp.109.1.15; Snyder PM, 1998, J BIOL CHEM, V273, P681, DOI 10.1074/jbc.273.2.681; SWICK AG, 1992, P NATL ACAD SCI USA, V89, P1812, DOI 10.1073/pnas.89.5.1812; Ugawa S, 1998, NATURE, V395, P555, DOI 10.1038/26882; Waldmann R, 1996, J BIOL CHEM, V271, P10433, DOI 10.1074/jbc.271.18.10433; Waldmann R, 1998, CURR OPIN NEUROBIOL, V8, P418, DOI 10.1016/S0959-4388(98)80070-6; WALDMANN R, 1995, J BIOL CHEM, V270, P11735, DOI 10.1074/jbc.270.20.11735	27	48	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15500	15504		10.1074/jbc.274.22.15500	http://dx.doi.org/10.1074/jbc.274.22.15500			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336442	hybrid			2022-12-25	WOS:000080560100031
J	Hanakahi, LA; Sun, H; Maizels, N				Hanakahi, LA; Sun, H; Maizels, N			High affinity interactions of nucleolin with G-G-paired rDNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING DOMAINS; PRE-RIBOSOMAL-RNA; TELOMERIC DNA; CRYSTAL-STRUCTURE; PROTEIN-KINASE; CDNA SEQUENCE; CELLS; LOCALIZATION; ORGANIZATION; RECOGNITION	Nucleolin is a very abundant eukaryotic protein that localizes to the nucleolus, where the rDNA undergoes transcription, replication, and recombination and where rRNA processing occurs. The top (non-template) strand of the rDNA is very guanine-rich and has considerable potential to form structures stabilized by G-G pairing, We have assayed binding of endogenous and recombinant nucleolin to synthetic oligonucleotides in which G-rich regions have formed intermolecular G-G pairs to produce either two-stranded G2 or four-stranded G4 DNA. We report that nucleolin binds G-G-paired DNA with very high affinity; the dissociation constant for interaction with G4 DNA is K-D = 1 nM. TWO separate domains of nucleolin can interact with G-G-paired DNA, the four RNA binding domains and the C-terminal Arg-Gly-Gly repeats. Both domains bind G4 DNA with high specificity and recognize G4 DNA structure independent of sequence context. The high affinity of the nucleolin/G4 DNA interaction identifies G-G-paired structures as natural binding targets of nucleolin in the nucleolus, The ability of two independent domains of nucleolin to bind G-G-paired structures suggests that nucleolin can function as an architectural factor in rDNA transcription, replication, or recombination.	Yale Univ, Sch Med, Dept Mol Biophys & Biochem, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA	Yale University; Yale University	Maizels, N (corresponding author), Yale Univ, Sch Med, Dept Mol Biophys & Biochem, 333 Cedar St, New Haven, CT 06510 USA.	nancy.maizels@yale.edu			NATIONAL CANCER INSTITUTE [P01CA016038] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039799] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA16038] Funding Source: Medline; NIGMS NIH HHS [R01 GM39799, R01 GM039799] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELENGUER P, 1989, NUCLEIC ACIDS RES, V17, P6625; BELENGUER P, 1990, MOL CELL BIOL, V10, P3607, DOI 10.1128/MCB.10.7.3607; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; BOURBON HM, 1990, GENE, V88, P187, DOI 10.1016/0378-1119(90)90031-L; BOURBON HM, 1988, J MOL BIOL, V200, P627, DOI 10.1016/0022-2836(88)90476-7; Bouvet P, 1997, EMBO J, V16, P5235, DOI 10.1093/emboj/16.17.5235; Bouvet P, 1998, J BIOL CHEM, V273, P19025, DOI 10.1074/jbc.273.30.19025; CAIZERGUESFERRER M, 1987, BIOCHEMISTRY-US, V26, P7876, DOI 10.1021/bi00398a051; CREANCIER L, 1993, MOL BIOL CELL, V4, P1239, DOI 10.1091/mbc.4.12.1239; Dempsey LA, 1998, J BIOL CHEM, V273, P29224, DOI 10.1074/jbc.273.44.29224; Dempsey LA, 1999, J BIOL CHEM, V274, P1066, DOI 10.1074/jbc.274.2.1066; Fakan S, 1980, Int Rev Cytol, V65, P255; Gacy AM, 1998, MOL CELL, V1, P583, DOI 10.1016/S1097-2765(00)80058-1; GELLERT M, 1962, P NATL ACAD SCI USA, V48, P2013, DOI 10.1073/pnas.48.12.2013; Gerbi SA, 1995, BIOCHEM CELL BIOL, V73, P845, DOI 10.1139/o95-092; GhisolfiNieto L, 1996, J MOL BIOL, V260, P34, DOI 10.1006/jmbi.1996.0380; Ginisty H, 1998, EMBO J, V17, P1476, DOI 10.1093/emboj/17.5.1476; Gray MD, 1998, EXP CELL RES, V242, P487, DOI 10.1006/excr.1998.4124; Hanakahi LA, 1997, P NATL ACAD SCI USA, V94, P3605, DOI 10.1073/pnas.94.8.3605; HEINE MA, 1993, MOL BIOL CELL, V4, P1189, DOI 10.1091/mbc.4.11.1189; JORDAN G, 1987, NATURE, V329, P489, DOI 10.1038/329489a0; KANG C, 1992, NATURE, V356, P126, DOI 10.1038/356126a0; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KIM J, 1991, NATURE, V351, P331, DOI 10.1038/351331a0; LAPEYRE B, 1987, P NATL ACAD SCI USA, V84, P1472, DOI 10.1073/pnas.84.6.1472; LAPEYRE B, 1986, J BIOL CHEM, V261, P9167; LAUGHLAN G, 1994, SCIENCE, V265, P520, DOI 10.1126/science.8036494; LISCHWE MA, 1985, BIOCHEMISTRY-US, V24, P6025, DOI 10.1021/bi00343a001; Marciniak RA, 1998, P NATL ACAD SCI USA, V95, P6887, DOI 10.1073/pnas.95.12.6887; MARIDOR G, 1990, NUCLEIC ACIDS RES, V18, P1286, DOI 10.1093/nar/18.5.1286; Maxam A M, 1980, Methods Enzymol, V65, P499; Osheim YN, 1996, J CELL BIOL, V133, P943, DOI 10.1083/jcb.133.5.943; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PuvionDutilleul F, 1997, CHROMOSOMA, V105, P496, DOI 10.1007/s004120050211; PUVIONDUTILLEUL F, 1991, CHROMOSOMA, V100, P395, DOI 10.1007/BF00337518; RANKIN ML, 1993, NUCLEIC ACIDS RES, V21, P169, DOI 10.1093/nar/21.1.169; SCHMIDTZACHMANN MS, 1993, J CELL SCI, V105, P799; SEN D, 1992, BIOCHEMISTRY-US, V31, P65, DOI 10.1021/bi00116a011; SEN D, 1990, NATURE, V344, P410, DOI 10.1038/344410a0; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; Serin G, 1997, J BIOL CHEM, V272, P13109, DOI 10.1074/jbc.272.20.13109; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6; Sinclair DA, 1997, SCIENCE, V277, P1313, DOI 10.1126/science.277.5330.1313; SRIVASTAVA M, 1990, J BIOL CHEM, V265, P14922; SRIVASTAVA M, 1989, FEBS LETT, V250, P99, DOI 10.1016/0014-5793(89)80692-1; Sun H, 1998, J BIOL CHEM, V273, P27587, DOI 10.1074/jbc.273.42.27587; Sun H, 1999, NUCLEIC ACIDS RES, V27, P1978, DOI 10.1093/nar/27.9.1978; WANG Y, 1992, BIOCHEMISTRY-US, V31, P8112, DOI 10.1021/bi00150a002; WILLIAMSON JR, 1994, ANNU REV BIOPH BIOM, V23, P703, DOI 10.1146/annurev.bb.23.060194.003415; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7	50	190	201	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15908	15912		10.1074/jbc.274.22.15908	http://dx.doi.org/10.1074/jbc.274.22.15908			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336496	hybrid			2022-12-25	WOS:000080560100085
J	Hussain, NK; Yamabhai, M; Ramjaun, AR; Guy, AM; Baranes, D; O'Bryan, JP; Der, CJ; Kay, BK; McPherson, PS				Hussain, NK; Yamabhai, M; Ramjaun, AR; Guy, AM; Baranes, D; O'Bryan, JP; Der, CJ; Kay, BK; McPherson, PS			Splice variants of intersectin are components of the endocytic machinery in neurons and nonneuronal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLATHRIN-MEDIATED ENDOCYTOSIS; DOMAIN-CONTAINING PROTEIN; HIPPOCAMPAL MOSSY FIBER; KINASE SUBSTRATE EPS15; AMPHIPHYSIN SH3 DOMAIN; ACTIN CYTOSKELETON; EH-DOMAIN; BINDING-SITE; ARRESTIN/CLATHRIN INTERACTION; SACCHAROMYCES-CEREVISIAE	We recently identified and cloned intersectin, a protein containing two Eps15 homology (EH) domains and five Src homology 3 (SH3) domains. Using a newly developed intersectin antibody, we demonstrate that endogenous COS-7 cell intersectin localizes to clathrin-coated pits, and transfection studies suggest that the EH domains may direct this localization. Through alternative splicing in a stop codon, a long form of intersectin is generated with a C-terminal extension containing Dbl homology (DH), pleckstrin homology (PH), and C2 domains. Western blots reveal that the long form of intersectin is expressed specifically in neurons, whereas the short isoform is expressed at lower levels in glia and other nonneuronal cells. Immunofluorescence analysis of cultured hippocampal neurons reveals that intersectin is found at the plasma membrane where it is colocalized with clathrin. Ibp2, a protein identified based on its interactions with the EH domains of intersectin, binds to clathrin through the N terminus of the heavy chain, suggesting a mechanism for the localization of intersectin at clathrin-coated pits. Ibp2 also binds to the clathrin adaptor AP2, and antibodies against intersectin co-immunoprecipitate clathrin, AP2, and dynamin from brain extracts, These data suggest that the long and short forms of intersectin are components of the endocytic machinery in neurons and nonneuronal cells.	Univ Wisconsin, Dept Pharmacol, Madison, WI 53706 USA; McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, Montreal, PQ H3A 2B4, Canada; McGill Univ, Dept Anat & Cell Biol, Montreal, PQ H3A 2B4, Canada; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA	University of Wisconsin System; University of Wisconsin Madison; McGill University; McGill University; University of North Carolina; University of North Carolina Chapel Hill	Kay, BK (corresponding author), Univ Wisconsin, Dept Pharmacol, 3795 Med Sci Ctr,1300 Univ Ave, Madison, WI 53706 USA.			O'Bryan, John/0000-0001-5386-1080; Der, Channing/0000-0002-7751-2747	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES090091] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Baranes D, 1996, P NATL ACAD SCI USA, V93, P4706, DOI 10.1073/pnas.93.10.4706; Baranes D, 1998, NEURON, V21, P813, DOI 10.1016/S0896-6273(00)80597-8; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BENEDETTI H, 1994, MOL BIOL CELL, V5, P1023, DOI 10.1091/mbc.5.9.1023; Benmerah A, 1996, J BIOL CHEM, V271, P12111, DOI 10.1074/jbc.271.20.12111; Benmerah A, 1995, J CELL BIOL, V131, P1831, DOI 10.1083/jcb.131.6.1831; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; Cupers P, 1998, J BIOL CHEM, V273, P1847, DOI 10.1074/jbc.273.4.1847; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; Dell'Angelica EC, 1998, SCIENCE, V280, P431, DOI 10.1126/science.280.5362.431; Goodman OB, 1997, J BIOL CHEM, V272, P15017, DOI 10.1074/jbc.272.23.15017; GOSSLIN K, 1990, CULTURING NERVE CELL, P251; Guipponi M, 1998, GENOMICS, V53, P369, DOI 10.1006/geno.1998.5521; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HARLAN JE, 1995, BIOCHEMISTRY-US, V34, P9859, DOI 10.1021/bi00031a006; INNOLO G, 1997, CANCER RES, V57, P240; KIRCHHAUSEN T, 1981, CELL, V23, P755, DOI 10.1016/0092-8674(81)90439-6; Krupnick JG, 1997, J BIOL CHEM, V272, P15011, DOI 10.1074/jbc.272.23.15011; Leprince C, 1997, J BIOL CHEM, V272, P15101, DOI 10.1074/jbc.272.24.15101; MATTEOLI M, 1992, J CELL BIOL, V117, P849, DOI 10.1083/jcb.117.4.849; Mazzoni IE, 1996, BRAIN RES, V707, P88, DOI 10.1016/0006-8993(95)01225-7; McMahon HT, 1997, FEBS LETT, V413, P319, DOI 10.1016/S0014-5793(97)00928-9; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V91, P6486, DOI 10.1073/pnas.91.14.6486; MCPHERSON PS, 1994, J BIOL CHEM, V269, P30132; McPherson PS, 1999, CELL SIGNAL, V11, P229, DOI 10.1016/S0898-6568(98)00059-X; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; MOORE MS, 1987, SCIENCE, V236, P558, DOI 10.1126/science.2883727; Owen DJ, 1998, EMBO J, V17, P5273, DOI 10.1093/emboj/17.18.5273; Paoluzi S, 1998, EMBO J, V17, P6541, DOI 10.1093/emboj/17.22.6541; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Ramjaun AR, 1996, J BIOL CHEM, V271, P24856, DOI 10.1074/jbc.271.40.24856; Ramjaun AR, 1997, J BIOL CHEM, V272, P16700, DOI 10.1074/jbc.272.26.16700; Ramjaun AR, 1998, J NEUROCHEM, V70, P2369; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; ROBINSON MS, 1987, J CELL BIOL, V104, P887, DOI 10.1083/jcb.104.4.887; Roos J, 1998, J BIOL CHEM, V273, P19108, DOI 10.1074/jbc.273.30.19108; Salcini AE, 1997, GENE DEV, V11, P2239, DOI 10.1101/gad.11.17.2239; Sambrook J., 2002, MOL CLONING LAB MANU; Sengar AS, 1999, EMBO J, V18, P1159, DOI 10.1093/emboj/18.5.1159; SHARP AH, 1993, J NEUROSCI, V13, P3051; Shpetner HS, 1996, J BIOL CHEM, V271, P13, DOI 10.1074/jbc.271.1.13; Shupliakov O, 1997, SCIENCE, V276, P259, DOI 10.1126/science.276.5310.259; Simpson F, 1996, J CELL BIOL, V133, P749, DOI 10.1083/jcb.133.4.749; Slepnev VI, 1998, SCIENCE, V281, P821, DOI 10.1126/science.281.5378.821; Stukenberg PT, 1997, CURR BIOL, V7, P338, DOI 10.1016/S0960-9822(06)00157-6; Sweitzer SM, 1998, CELL, V93, P1021, DOI 10.1016/S0092-8674(00)81207-6; Takei K, 1998, CELL, V94, P131, DOI 10.1016/S0092-8674(00)81228-3; Tang HY, 1997, MOL CELL BIOL, V17, P4294, DOI 10.1128/MCB.17.8.4294; Tang HY, 1996, MOL CELL BIOL, V16, P4897; Tebar F, 1996, J BIOL CHEM, V271, P28727, DOI 10.1074/jbc.271.46.28727; vanDelft S, 1997, J CELL BIOL, V136, P811, DOI 10.1083/jcb.136.4.811; Volchuk A, 1998, J BIOL CHEM, V273, P8169, DOI 10.1074/jbc.273.14.8169; WANG LH, 1995, J BIOL CHEM, V270, P10079, DOI 10.1074/jbc.270.17.10079; Wendland B, 1998, J CELL BIOL, V141, P71, DOI 10.1083/jcb.141.1.71; Wendland B, 1996, J CELL BIOL, V135, P1485, DOI 10.1083/jcb.135.6.1485; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; Wigge P, 1997, MOL BIOL CELL, V8, P2003, DOI 10.1091/mbc.8.10.2003; Wigge P, 1997, CURR BIOL, V7, P554, DOI 10.1016/S0960-9822(06)00254-5; WONG WT, 1995, P NATL ACAD SCI USA, V92, P9530, DOI 10.1073/pnas.92.21.9530; Yamabhai M, 1998, J BIOL CHEM, V273, P31401, DOI 10.1074/jbc.273.47.31401	62	144	151	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15671	15677		10.1074/jbc.274.22.15671	http://dx.doi.org/10.1074/jbc.274.22.15671			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336464	hybrid			2022-12-25	WOS:000080560100053
J	Mera, A; Suga, M; Ando, M; Suda, T; Yamaguchi, N				Mera, A; Suga, M; Ando, M; Suda, T; Yamaguchi, N			Induction of cell shape changes through activation of the interleukin-3 common beta chain receptor by the RON receptor-type tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROPHAGE-STIMULATING PROTEIN; HEPATOCYTE GROWTH-FACTOR; SIGNAL-TRANSDUCTION; GM-CSF; GENE-PRODUCT; DOMAINS; SUBUNIT; FAMILY; STK; IDENTIFICATION	The RON receptor-type tyrosine kinase, a member of the hepatocyte growth factor receptor family, is a receptor for macrophage-stimulating protein (MSP), Recently, we observed that MSP induces morphological changes in interleukin (IL)-3-dependent Ba/F3 cells ectopically expressing RON. We show here that stimulation of those cells with either MSP or IL-3 increases tyrosine phosphorylation of proteins of 130, 110, 90, 62, and 58 kDa and induces similar morphological changes, accompanied by unique nuclear shape and redistribution of F-actin, A tyrosine kinase inhibitor, genistein, blocked both the increase in tyrosine phosphorylation and morphological changes. Upon stimulation with either MSP or IL-3, prominent tyrosine-phosphorylated pp90 was similarly co-immunoprecipitated with the common beta chain of IL-3 receptor (beta(c)). Unlike IL-3, stimulation with MSP increased tyrosine phosphorylation of beta(c) without activation of JAK2, resulting in morphological changes with modest cell growth. Confocal immunofluorescence analyses showed colocalization of RON, beta(c), and tyrosine-phosphorylated proteins. In vitro kinase assays revealed that autophosphorylated RON phosphorylated beta(c), These results suggest that the signaling pathway for morphological changes through beta(c) and its associated protein pp90 is distinct from the pathway for cell growth in the IL-3 signal transduction system.	Kumamoto Univ, Sch Med, Dept Internal Med 1, Kumamoto 8600811, Japan; Kumamoto Univ, Sch Med, Inst Mol Embryol & Genet, Dept Cell Differentiat, Kumamoto 8600811, Japan	Kumamoto University; Kumamoto University	Mera, A (corresponding author), Univ Shizuoka, Sch Pharmaceut Sci, Dept Radiobiochem, Yada 52-1, Shizuoka 4228526, Japan.		Suda, Toshio/H-6761-2013	Suda, Toshio/0000-0001-7540-1771				Bretscher MS, 1996, CELL, V87, P601, DOI 10.1016/S0092-8674(00)81380-X; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; GAUGINO G, 1994, EMBO J, V13, P3524; HAN S, 1991, BIOCHEMISTRY-US, V30, P9768, DOI 10.1021/bi00104a029; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hirao A, 1998, J BIOL CHEM, V273, P10004, DOI 10.1074/jbc.273.16.10004; Hirao A, 1997, EMBO J, V16, P2342, DOI 10.1093/emboj/16.9.2342; HUFF JL, 1993, P NATL ACAD SCI USA, V90, P6140, DOI 10.1073/pnas.90.13.6140; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Iwama A, 1996, EMBO J, V15, P5866, DOI 10.1002/j.1460-2075.1996.tb00973.x; IWAMA A, 1994, BLOOD, V83, P3160, DOI 10.1182/blood.V83.11.3160.bloodjournal83113160; IWAMA A, 1995, BLOOD, V86, P3394, DOI 10.1182/blood.V86.9.3394.bloodjournal8693394; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; Kurihara N, 1996, BLOOD, V87, P3704, DOI 10.1182/blood.V87.9.3704.bloodjournal8793704; LEONARD EJ, 1976, EXP CELL RES, V102, P434, DOI 10.1016/0014-4827(76)90065-3; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Qiu Y, 1998, NATURE, V393, P83, DOI 10.1038/30012; RONSIN C, 1993, ONCOGENE, V8, P1195; SABE H, 1991, INT IMMUNOL, V3, P1137, DOI 10.1093/intimm/3.11.1137; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; Sakamoto O, 1997, J CLIN INVEST, V99, P701, DOI 10.1172/JCI119214; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SHIMAMOTO A, 1993, FEBS LETT, V333, P61, DOI 10.1016/0014-5793(93)80375-5; SKEEL A, 1991, J EXP MED, V173, P1227, DOI 10.1084/jem.173.5.1227; SKEEL A, 1994, J IMMUNOL, V152, P4618; TADA J, 1999, IN PRESS BLOOD; TAKAKI S, 1991, EMBO J, V10, P2833, DOI 10.1002/j.1460-2075.1991.tb07832.x; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; Wang MH, 1996, EXP CELL RES, V226, P39, DOI 10.1006/excr.1996.0200; WANG MH, 1994, J BIOL CHEM, V269, P14027; WANG MH, 1995, P NATL ACAD SCI USA, V92, P3933, DOI 10.1073/pnas.92.9.3933; WANG MH, 1994, SCIENCE, V266, P117, DOI 10.1126/science.7939629; WARRINGA RAJ, 1991, BLOOD, V77, P2694; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5; WU H, 1995, NATURE, V377, P242, DOI 10.1038/377242a0; YAMAGUCHI N, 1995, J BIOL CHEM, V270, P12170, DOI 10.1074/jbc.270.20.12170; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YOSHIMURA T, 1993, J BIOL CHEM, V268, P15461	43	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15766	15774		10.1074/jbc.274.22.15766	http://dx.doi.org/10.1074/jbc.274.22.15766			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336478	hybrid			2022-12-25	WOS:000080560100067
J	Perletti, L; Dantonel, JC; Davidson, I				Perletti, L; Dantonel, JC; Davidson, I			The TATA-binding protein and its associated factors are differentially expressed in adult mouse tissues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; HISTONE-LIKE TAFS; TRANSCRIPTIONAL ACTIVATION; PROMOTER SELECTIVITY; ACETYLASE COMPLEX; TFIID COMPLEX; CYCLIN GENES; DISTINCT; YEAST; CELLS	We have investigated the expression levels of the TATA-binding protein (TBP) and several TBP-associated factors (TAF(II)s) in differentiated adult mouse tissues. Immunoblots performed using monoclonal antibodies show that there are considerable variations in the levels of TBP and many TAF(II) proteins present in various tissues. Consequently, the relative levels of TAF(II)s and TBP vary significantly from one tissue to another. TBP and several TAF(II)s are overexpressed in both testis and small intestine, while in marked contrast, many of these proteins, including TBP itself, were substantially down-regulated in nervous tissues and in the heart. These tissues do, however, show a high expression level of the TBP-like factor, which thus may represent an alternative factor for the specialized transcription program in some differentiated tissues. While there are significant variations in the levels of TAF(II)28 protein, reverse transcription-coupled polymerase chain reaction shows similar expression of the TAF(II)28 mRNA in different tissues. The variations in TAF(II)28 protein levels therefore result from post-transcriptional regulatory events.	ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Davidson, I (corresponding author), ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, BP 163-67404, Strasbourg, France.			Davidson, Irwin/0000-0001-5533-1171				Apone LM, 1998, MOL CELL, V2, P653, DOI 10.1016/S1097-2765(00)80163-X; Bell B, 1999, EXP CELL RES, V246, P11, DOI 10.1006/excr.1998.4294; Birck C, 1998, CELL, V94, P239, DOI 10.1016/S0092-8674(00)81423-3; CHOMCZYNSKI P, 1986, BIOCHEM BIOPH RES CO, V134, P812, DOI 10.1016/S0006-291X(86)80493-4; Dikstein R, 1996, CELL, V87, P137, DOI 10.1016/S0092-8674(00)81330-6; Dubrovskaya V, 1996, EMBO J, V15, P3702, DOI 10.1002/j.1460-2075.1996.tb00740.x; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Hahn S, 1998, CELL, V95, P579, DOI 10.1016/S0092-8674(00)81625-6; Hansen SK, 1997, CELL, V91, P71, DOI 10.1016/S0092-8674(01)80010-6; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; Lavigne AC, 1996, J BIOL CHEM, V271, P19774, DOI 10.1074/jbc.271.33.19774; LESCURE A, 1994, EMBO J, V13, P1166, DOI 10.1002/j.1460-2075.1994.tb06366.x; Martinez E, 1998, J BIOL CHEM, V273, P23781, DOI 10.1074/jbc.273.37.23781; May M, 1996, EMBO J, V15, P3093, DOI 10.1002/j.1460-2075.1996.tb00672.x; Mengus G, 1997, GENE DEV, V11, P1381, DOI 10.1101/gad.11.11.1381; MENGUS G, 1995, EMBO J, V14, P1520, DOI 10.1002/j.1460-2075.1995.tb07138.x; Michel B, 1998, MOL CELL, V2, P663, DOI 10.1016/S1097-2765(00)80164-1; Moqtaderi Z, 1998, MOL CELL, V2, P675, DOI 10.1016/S1097-2765(00)80165-3; Moqtaderi Z, 1996, NATURE, V383, P188, DOI 10.1038/383188a0; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Ohbayashi T, 1999, NUCLEIC ACIDS RES, V27, P750, DOI 10.1093/nar/27.3.750; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Purrello M, 1998, ONCOGENE, V16, P1633, DOI 10.1038/sj.onc.1201673; Saluja D, 1998, MOL CELL BIOL, V18, P5734, DOI 10.1128/MCB.18.10.5734; SCHMIDT EE, 1995, DEVELOPMENT, V121, P2373; SCHMIDT EE, 1995, J CELL BIOL, V128, P467, DOI 10.1083/jcb.128.4.467; Shen WC, 1997, CELL, V90, P615, DOI 10.1016/S0092-8674(00)80523-1; SuzukiYagawa Y, 1997, MOL CELL BIOL, V17, P3284, DOI 10.1128/MCB.17.6.3284; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X; Walker SS, 1996, NATURE, V383, P185, DOI 10.1038/383185a0; Walker SS, 1997, CELL, V90, P607, DOI 10.1016/S0092-8674(00)80522-X; Wang EH, 1997, GENE DEV, V11, P2658, DOI 10.1101/gad.11.20.2658; WANG EH, 1994, SCIENCE, V263, P811, DOI 10.1126/science.8303298; Wieczorek E, 1998, NATURE, V393, P187, DOI 10.1038/30283; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959	36	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15301	15304		10.1074/jbc.274.22.15301	http://dx.doi.org/10.1074/jbc.274.22.15301			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336414	hybrid			2022-12-25	WOS:000080560100003
J	Fadel, MP; Dziak, E; Lo, CM; Ferrier, J; Mesaeli, N; Michalak, M; Opas, M				Fadel, MP; Dziak, E; Lo, CM; Ferrier, J; Mesaeli, N; Michalak, M; Opas, M			Calreticulin affects focal contact-dependent but not close contact-dependent cell-substratum adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEIN; STRESS FIBER FORMATION; SWISS 3T3 FIBROBLASTS; TYROSINE PHOSPHORYLATION; GENE-EXPRESSION; INTERFERENCE-REFLECTION; SARCOPLASMIC-RETICULUM; SPHINGOSINE DERIVATIVES; INTRACELLULAR CALCIUM; CULTURED FIBROBLASTS	We used two cell lines expressing fast (RPEfast) and slow (RPEslow) attachment kinetics to investigate mechanisms of cell-substratum adhesion. We show that the abundance of a cytoskeletal protein, vinculin, is dramatically decreased in RPEfast cells. This coincides with the diminished expression level of an endoplasmic reticulum chaperone, calreticulin. Both protein and mRNA levels for calreticulin and vinculin were decreased in RPEfast cells. After RPEfast cells were transfected with cDNA encoding calreticulin, both the expression of endoplasmic reticulum-resident calreticulin and cytoplasmic vinculin increased. The abundance of other adhesion-related proteins was not affected. RPEfast cells underexpressing calreticulin displayed a dramatic increase in the abundance of total cellular phosphotyrosine suggesting that the effects of calreticulin on cell adhesiveness may involve modulation of the activities of protein tyrosine kinases or phosphatases which may affect the stability of focal contacts. The calreticulin and vinculin underexpressing RPEfast cells lacked extensive focal contacts and adhered weakly but attached fast to the substratum. In contrast, the RPEslow cells that expressed calreticulin and vinculin abundantly developed numerous and prominent focal contacts slowly, but adhered strongly, Thus, while the calreticulin overexpressing RPEslow cells "grip" the substratum with focal contacts, calreticulin underexpressing RPEfast cells use close contacts to "stick" to it.	Univ Toronto, Dept Cell Biol & Anat, Toronto, ON M5S 1A8, Canada; Univ Toronto, MRC, Periodontal Physiol Grp, Toronto, ON M5S 1A8, Canada; Univ Alberta, Dept Biochem, MRC, Grp Mol Biol Membranes, Edmonton, AB T6G 2H7, Canada	University of Toronto; University of Toronto; University of Alberta	Fadel, MP (corresponding author), Univ Toronto, Dept Cell Biol & Anat, Med Sci Bldg, Toronto, ON M5S 1A8, Canada.	m.opas@utoronto.ca		Mesaeli, Nasrin/0000-0003-1456-4643; Lo, Chun-Min/0000-0003-4382-4512				Andrin C, 1998, BIOCHEMISTRY-US, V37, P10386, DOI 10.1021/bi980595z; BADLEY RA, 1980, J CELL SCI, V43, P379; BASTIANUTTO C, 1995, J CELL BIOL, V130, P847, DOI 10.1083/jcb.130.4.847; BEREITERHAHN J, 1979, J CELL BIOL, V82, P767, DOI 10.1083/jcb.82.3.767; Bershadsky A, 1996, CURR BIOL, V6, P1279, DOI 10.1016/S0960-9822(02)70714-8; BURNS K, 1994, NATURE, V367, P476, DOI 10.1038/367476a0; Burridge K, 1997, TRENDS CELL BIOL, V7, P342, DOI 10.1016/S0962-8924(97)01127-6; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; CHEN WT, 1982, J CELL BIOL, V95, P205, DOI 10.1083/jcb.95.1.205; CHEN WT, 1985, J CELL BIOL, V100, P1103, DOI 10.1083/jcb.100.4.1103; COPPOLINO M, 1995, J BIOL CHEM, V270, P23132, DOI 10.1074/jbc.270.39.23132; Coppolino MG, 1997, NATURE, V386, P843, DOI 10.1038/386843a0; COTTLERFOX M, 1979, EXP CELL RES, V118, P414, DOI 10.1016/0014-4827(79)90169-1; COUCHMAN JR, 1979, CELL BIOL INT REP, V3, P431, DOI 10.1016/0309-1651(79)90004-3; COUCHMAN JR, 1979, J CELL SCI, V39, P149; COUTU MD, 1988, P NATL ACAD SCI USA, V85, P8535, DOI 10.1073/pnas.85.22.8535; Craig SW, 1996, CURR OPIN CELL BIOL, V8, P74, DOI 10.1016/S0955-0674(96)80051-2; CROWLEY E, 1995, J CELL BIOL, V131, P525, DOI 10.1083/jcb.131.2.525; CURTIS ASG, 1964, J CELL BIOL, V20, P199, DOI 10.1083/jcb.20.2.199; Daniel JM, 1997, BIOESSAYS, V19, P883, DOI 10.1002/bies.950191008; DANOWSKI BA, 1989, J CELL SCI, V93, P255; DEDHAR S, 1994, NATURE, V367, P480, DOI 10.1038/367480a0; Desai D, 1996, J BIOL CHEM, V271, P15153, DOI 10.1074/jbc.271.25.15153; DESAI NN, 1993, J CELL BIOL, V121, P1385, DOI 10.1083/jcb.121.6.1385; Enomoto T, 1996, CELL STRUCT FUNCT, V21, P317, DOI 10.1247/csf.21.317; Ezzell RM, 1997, EXP CELL RES, V231, P14, DOI 10.1006/excr.1996.3451; Fasolato C, 1998, MOL BIOL CELL, V9, P1513, DOI 10.1091/mbc.9.6.1513; FERNANDEZ JLR, 1992, CELL MOTIL CYTOSKEL, V22, P127, DOI 10.1002/cm.970220206; FLIEGEL L, 1989, J BIOL CHEM, V264, P21522; FLIEGEL L, 1989, BIOCHIM BIOPHYS ACTA, V982, P1, DOI 10.1016/0005-2736(89)90166-1; GEIGER B, 1983, BIOCHIM BIOPHYS ACTA, V737, P305, DOI 10.1016/0304-4157(83)90005-9; GEIGER B, 1979, CELL, V18, P193, DOI 10.1016/0092-8674(79)90368-4; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; GIAEVER I, 1993, NATURE, V366, P591, DOI 10.1038/366591a0; GIAEVER I, 1991, P NATL ACAD SCI USA, V88, P7896, DOI 10.1073/pnas.88.17.7896; GINGELL D, 1979, BIOPHYS J, V26, P507, DOI 10.1016/S0006-3495(79)85268-6; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; HEATH JP, 1978, J CELL SCI, V29, P197; Helenius A, 1997, TRENDS CELL BIOL, V7, P193; HERTL W, 1984, IN VITRO CELL DEV B, V20, P796; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Ilic D, 1997, J CELL SCI, V110, P401; IZZARD CS, 1976, J CELL SCI, V21, P129; Jockusch BM, 1995, ANNU REV CELL DEV BI, V11, P379, DOI 10.1146/annurev.cellbio.11.1.379; Katoh K, 1996, CELL STRUCT FUNCT, V21, P27, DOI 10.1247/csf.21.27; LEUNGHAGESTEIJN CY, 1994, J CELL SCI, V107, P589; Liu BP, 1998, CELL ADHES COMMUN, V5, P249, DOI 10.3109/15419069809040295; LIU NG, 1994, J BIOL CHEM, V269, P28635; Lo CM, 1998, EUR BIOPHYS J BIOPHY, V27, P9, DOI 10.1007/s002490050105; Lo CM, 1998, PHYS REV E, V57, P6982, DOI 10.1103/PhysRevE.57.6982; Lo CM, 1995, BIOPHYS J, V69, P2800, DOI 10.1016/S0006-3495(95)80153-0; LOTZ MM, 1989, J CELL BIOL, V109, P1795, DOI 10.1083/jcb.109.4.1795; MARRS JA, 1995, J CELL BIOL, V129, P507, DOI 10.1083/jcb.129.2.507; MASSIA SP, 1991, J CELL BIOL, V114, P1089, DOI 10.1083/jcb.114.5.1089; MATTIE M, 1994, J BIOL CHEM, V269, P3181; Mery L, 1996, J BIOL CHEM, V271, P9332, DOI 10.1074/jbc.271.16.9332; MICHALAK M, 1980, J BIOL CHEM, V255, P1327; Michalak M, 1996, J BIOL CHEM, V271, P29436, DOI 10.1074/jbc.271.46.29436; MITRA P, 1991, BIOTECHNIQUES, V11, P504; Moore DD, 1995, GLOB MOB SURV; Moy AB, 1996, J CLIN INVEST, V97, P1020, DOI 10.1172/JCI118493; NABI IR, 1993, J CELL SCI, V104, P37; NORTON EK, 1982, EXP CELL RES, V139, P463, DOI 10.1016/0014-4827(82)90282-8; Opas M, 1995, BIOCHEM CELL BIOL, V73, P311, DOI 10.1139/o95-039; OPAS M, 1986, INVEST OPHTH VIS SCI, V27, P1622; OPAS M, 1991, J CELL PHYSIOL, V149, P160, DOI 10.1002/jcp.1041490120; Opas M, 1996, J CELL BIOL, V135, P1913, DOI 10.1083/jcb.135.6.1913; OPAS M, 1984, EUR J CELL BIOL, V33, P60; Otey CA, 1996, INT REV CYTOL, V167, P161, DOI 10.1016/S0074-7696(08)61347-9; Pletjushkina OJ, 1998, CELL ADHES COMMUN, V5, P121, DOI 10.3109/15419069809040286; REES DA, 1977, NATURE, V267, P124, DOI 10.1038/267124a0; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P27610; Shago M, 1997, EXP CELL RES, V230, P50, DOI 10.1006/excr.1996.3408; Sjaastad MD, 1997, BIOESSAYS, V19, P47, DOI 10.1002/bies.950190109; TARTAKOFF AM, 1983, J CELL BIOL, V97, P1243, DOI 10.1083/jcb.97.4.1243; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TORNQUIST K, 1994, BIOCHEM J, V299, P213, DOI 10.1042/bj2990213; VIRTANEN I, 1980, J CELL BIOL, V85, P429, DOI 10.1083/jcb.85.2.429; Wang F, 1997, BIOCHEM J, V324, P481, DOI 10.1042/bj3240481; WARD MD, 1993, BIOPHYS J, V64, P936, DOI 10.1016/S0006-3495(93)81456-5; WARD MD, 1994, J MATH BIOL, V32, P677, DOI 10.1007/BF00163022; WARD MD, 1995, ANN BIOMED ENG, V23, P322, DOI 10.1007/BF02584432; WARD MD, 1994, BIOPHYS J, V67, P2522, DOI 10.1016/S0006-3495(94)80742-8; Waser M, 1997, J CELL BIOL, V138, P547, DOI 10.1083/jcb.138.3.547; Xu WM, 1998, DEVELOPMENT, V125, P327; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155	86	65	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					15085	15094		10.1074/jbc.274.21.15085	http://dx.doi.org/10.1074/jbc.274.21.15085			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329714	hybrid			2022-12-25	WOS:000081965200079
J	Mingot, JM; Penalva, MA; Fernandez-Canon, JM				Mingot, JM; Penalva, MA; Fernandez-Canon, JM			Disruption of phacA, an Aspergillus nidulans gene encoding a novel cytochrome P450 monooxygenase catalyzing phenylacetate 2-hydroxylation, results in penicillin overproduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-PUTIDA U; MOLECULAR CHARACTERIZATION; HOMOGENTISATE DIOXYGENASE; IDENTIFICATION; SUPERFAMILY; EXPRESSION; REDUCTASE	Aspergillus nidulans utilizes phenylacetate as a carbon source via homogentisate, which is degraded to fumarate and acetoacetate. Mutational evidence strongly suggested that phenylacetate is converted to homogentisate through two sequential hydroxylating reactions in positions 2 and 5 of the aromatic ring. Using cDNA substraction techniques, we have characterized a gene, denoted phacA, whose transcription is strongly induced by phenylacetate and which putatively encodes a cytochrome P450 protein. A disrupted phacA strain does not grow on phenylacetate but grows on 2-hydroxy- or 2,5-dihydroxyphenylacetate. Microsomal extracts of the disrupted strain are deficient in the NADPH-dependent conversion of phenylacetate to 2-hydroxyphenylacetate. We conclude that PhacA catalyzes the ortho-hydroxylation of phenylacetate, the first step of A. nidulans phenylacetate catabolism, The involvement of a P450 enzyme in the ortho-hydroxylation of a monoaromatic compound has no precedent, In addition, PhacA shows substantial sequence divergence with known cytochromes P450 and defines a new family of these enzymes, suggesting that saprophytic fungi may represent a source of novel cytochromes P450, Phenylacetate is a precursor for benzylpenicillin production, phacA disruption increases penicillin production 3-5-fold, indicating that catabolism competes with antibiotic biosynthesis for phenylacetate and strongly suggesting strategies for Penicillium chrysogenum strain improvement by reverse genetics.	CSIC, Ctr Invest Biol, Dept Mol Microbiol, E-28006 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Penalva, MA (corresponding author), CSIC, Ctr Invest Biol, Dept Mol Microbiol, Velazquez 144, E-28006 Madrid, Spain.		Fernandez-canon, Jose/ADI-4196-2022; Fernández-Cañón, José Manuel/AAO-6088-2020; Penalva, Miguel A/G-2295-2015; Fernández-Cañón, José Manuel/AAO-5607-2020	Fernández-Cañón, José Manuel/0000-0002-8092-2181; Penalva, Miguel A/0000-0002-3102-2806; 				ANDERSON JJ, 1980, J BACTERIOL, V141, P534, DOI 10.1128/JB.141.2.534-543.1980; APIRION D, 1965, GENET RES, V6, P317, DOI 10.1017/S0016672300004213; BENVENISTE I, 1989, BIOCHEM J, V259, P847, DOI 10.1042/bj2590847; Brown DW, 1996, P NATL ACAD SCI USA, V93, P1418, DOI 10.1073/pnas.93.4.1418; CLUTTERBUCK AJ, 1993, GENETIC MAPS LOCUS M; COVE DJ, 1966, BIOCHIM BIOPHYS ACTA, V113, P51, DOI 10.1016/S0926-6593(66)80120-0; ESPESO EA, 1992, MOL MICROBIOL, V6, P1457, DOI 10.1111/j.1365-2958.1992.tb00866.x; Fernandez-Canon JM, 1998, J BIOL CHEM, V273, P329, DOI 10.1074/jbc.273.1.329; FERNANDEZCANON JM, 1995, J BIOL CHEM, V270, P21199, DOI 10.1074/jbc.270.36.21199; FERNANDEZCANON JM, 1995, P NATL ACAD SCI USA, V92, P9132, DOI 10.1073/pnas.92.20.9132; FernandezCanon JM, 1997, ANAL BIOCHEM, V245, P218, DOI 10.1006/abio.1996.9957; HARAYAMA S, 1992, ANNU REV MICROBIOL, V46, P565, DOI 10.1146/annurev.micro.46.1.565; Harayama Shigeaki, 1992, V28, P99; HOCKENHULL DJD, 1951, BIOCHEMISTRY-US, V50, P605; Lein J., 1986, OVERPRODUCTION MICRO, P105; LUENGO JM, 1994, ASPERGILLUS 50 YEARS, P603; Minambres B, 1996, J BIOL CHEM, V271, P33531, DOI 10.1074/jbc.271.52.33531; NEBERT DW, 1987, ANNU REV BIOCHEM, V56, P945, DOI 10.1146/annurev.biochem.56.1.945; Nelson DR, 1996, PHARMACOGENETICS, V6, P1, DOI 10.1097/00008571-199602000-00002; Olivera ER, 1998, P NATL ACAD SCI USA, V95, P6419, DOI 10.1073/pnas.95.11.6419; SCHREUDER HA, 1989, J MOL BIOL, V208, P679, DOI 10.1016/0022-2836(89)90158-7; Strobel H W, 1978, Methods Enzymol, V52, P89; SUGUMARAN M, 1979, FEMS MICROBIOL LETT, V5, P427, DOI 10.1111/j.1574-6968.1979.tb03373.x; TILBURN J, 1983, GENE, V26, P205, DOI 10.1016/0378-1119(83)90191-9; van den Brink HJM, 1998, FUNGAL GENET BIOL, V23, P1, DOI 10.1006/fgbi.1997.1021; VANGORCOM RFM, 1990, MOL GEN GENET, V223, P192, DOI 10.1007/BF00265053; VERMILION JL, 1978, J BIOL CHEM, V253, P8812; WHITED GM, 1991, J BACTERIOL, V173, P3010, DOI 10.1128/JB.173.9.3010-3016.1991	28	59	65	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					14545	14550		10.1074/jbc.274.21.14545	http://dx.doi.org/10.1074/jbc.274.21.14545			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329644	Green Published, hybrid			2022-12-25	WOS:000081965200009
J	van de Poel, RHL; Meijers, JCM; Bouma, BN				van de Poel, RHL; Meijers, JCM; Bouma, BN			Interaction between protein S and complement C4b-binding protein (C4BP) - Affinity studies using chimeras containing C4BP beta-chain short consensus repeats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN C4-BINDING PROTEIN; COAGULATION FACTOR-XI; BINDING-SITE; COFACTOR ACTIVITY; CLASSICAL PATHWAY; ENDOTHELIAL-CELLS; ALPHA-CHAIN; PLASMA; PROTEOLYSIS; SYSTEM	Human C4b-binding protein (C4BP) is a regulator of the complement system and plays an important role in the regulation of the anticoagulant protein C pathway. C4BP can bind anticoagulant protein S, resulting in a decreased cofactor function of protein S for activated protein C, C4BP is a multimeric protein containing several identical alpha chains and a single beta-chain (C4BP beta), each chain being composed of short consensus repeats (SCRs), Previous studies have localized the protein S binding site to the NH2-terminal SCR (SCR-1) of C4BP beta. To further localize the protein S binding site, we constructed chimeras containing C4BP beta SCR-1, SCR-2, SCR-3, SCR-1+2, SCR-1+3, and SCR-2+3 fused to tissue-type plasminogen activator. Binding assays of protein S with these chimeras indicated that SCR-S contributes to the interaction of protein S with SCR-1, since the affinity of protein S for SCR-1+2 was up to B-fold higher compared with SCR-1 and SCR-1+3. Using an assay that measures protein S cofactor activity, we showed that cofactor activity was decreased due to binding to constructs that contain SCR-1. SCR-1+2 inhibited more potently than SCR-1 and SCR-1+3. SCR-3 had no additional effect on SCR-1, and therefore the effect of SCR-S was specific. In conclusion, beta-chain SCR-2 contributes to the interaction of C4BP with protein S.	Univ Utrecht, Med Ctr, Dept Haematol, Thrombosis & Haemostasis Lab, NL-3508 GA Utrecht, Netherlands; Univ Utrecht, Inst Biomembranes, NL-3584 CH Utrecht, Netherlands	Utrecht University; Utrecht University	van de Poel, RHL (corresponding author), Univ Utrecht, Med Ctr, Dept Haematol, Thrombosis & Haemostasis Lab, POB 85500, NL-3508 GA Utrecht, Netherlands.		Meijers, J.C.M./S-5981-2019	Meijers, J.C.M./0000-0002-4198-6780				BERTINA RM, 1985, THROMB HAEMOSTASIS, V53, P268; CHANG CTG, 1994, THROMB HAEMOSTASIS, V71, P461; CHUNG LP, 1985, BIOCHEM J, V230, P133, DOI 10.1042/bj2300133; COMP PC, 1984, NEW ENGL J MED, V311, P1525, DOI 10.1056/NEJM198412133112401; DAHA MR, 1980, J IMMUNOL, V125, P2051; DAHLBACK B, 1984, J BIOL CHEM, V259, P1631; DAHLBACK B, 1991, THROMB HAEMOSTASIS, V66, P49; DAHLBACK B, 1983, BIOCHEM J, V209, P847, DOI 10.1042/bj2090847; DAHLBACK B, 1986, J BIOL CHEM, V261, P2022; DAHLBACK B, 1983, P NATL ACAD SCI-BIOL, V80, P3461, DOI 10.1073/pnas.80.11.3461; DAHLBACK B, 1981, P NATL ACAD SCI-BIOL, V78, P2512, DOI 10.1073/pnas.78.4.2512; DAHLBACK B, 1990, J BIOL CHEM, V265, P16082; DE FRUTOS PG, 1994, BLOOD, V84, P815; FERNANDEZ JA, 1993, J BIOL CHEM, V268, P16788; FERNANDEZ JA, 1994, J BIOL CHEM, V269, P2535; FERNANDEZ JA, 1994, BIOCHEMISTRY-US, V33, P11073, DOI 10.1021/bi00203a003; FUJITA T, 1979, J EXP MED, V150, P267, DOI 10.1084/jem.150.2.267; FUJITA T, 1978, J EXP MED, V148, P1044, DOI 10.1084/jem.148.4.1044; FUJITA T, 1983, J EXP MED, V157, P1239, DOI 10.1084/jem.157.4.1239; GIGLI I, 1979, P NATL ACAD SCI USA, V76, P6596, DOI 10.1073/pnas.76.12.6596; GRIFFIN JH, 1992, BLOOD, V79, P3203; HACKENG TM, 1993, J BIOL CHEM, V268, P3993; HACKENG TM, 1994, J BIOL CHEM, V269, P21051; Hardig Y, 1996, J BIOL CHEM, V271, P20861, DOI 10.1074/jbc.271.34.20861; HARDIG Y, 1993, J BIOL CHEM, V268, P3033; Herwald H, 1996, J BIOL CHEM, V271, P13061, DOI 10.1074/jbc.271.22.13061; HESSING M, 1991, EUR J IMMUNOL, V21, P2077, DOI 10.1002/eji.1830210916; HESSING M, 1990, THROMB HAEMOSTASIS, V64, P245; HILLARP A, 1993, J BIOL CHEM, V268, P15017; HILLARP A, 1989, FEBS LETT, V259, P53, DOI 10.1016/0014-5793(89)81492-9; HILLARP A, 1990, P NATL ACAD SCI USA, V87, P1183, DOI 10.1073/pnas.87.3.1183; HILLARP A, 1988, J BIOL CHEM, V263, P12759; JOHANNESSEN M, 1990, THROMB HAEMOSTASIS, V63, P54; KOEDAM JA, 1988, J CLIN INVEST, V82, P1236, DOI 10.1172/JCI113721; Linse S, 1997, J BIOL CHEM, V272, P14658, DOI 10.1074/jbc.272.23.14658; MEIJERS JCM, 1992, BLOOD, V79, P1435; MEIJERS JCM, 1992, BIOCHEMISTRY-US, V31, P4680, DOI 10.1021/bi00134a021; NELSON RM, 1992, J BIOL CHEM, V267, P8140; NISHIOKA J, 1990, J BIOL CHEM, V265, P9072; NUSSENZWEIG V, 1981, METHOD ENZYMOL, V80, P124; REID KBM, 1986, IMMUNOL TODAY, V7, P230, DOI 10.1016/0167-5699(86)90110-6; REID KBM, 1989, IMMUNOL TODAY, V10, P177, DOI 10.1016/0167-5699(89)90317-4; SCHARFSTEIN J, 1978, J EXP MED, V148, P207, DOI 10.1084/jem.148.1.207; SUZUKI K, 1988, J BIOL CHEM, V263, P17034; Villoutreix BO, 1995, PROTEIN ENG, V8, P1253, DOI 10.1093/protein/8.12.1253; WALKER FJ, 1989, J BIOL CHEM, V264, P17645; Yegneswaran S, 1997, J BIOL CHEM, V272, P25013, DOI 10.1074/jbc.272.40.25013	47	24	24	5	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					15144	15150		10.1074/jbc.274.21.15144	http://dx.doi.org/10.1074/jbc.274.21.15144			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329721	hybrid			2022-12-25	WOS:000081965200086
J	Yan, SF; Lu, JS; Zou, YS; Soh-Won, J; Cohen, DM; Buttrick, PM; Cooper, DR; Steinberg, SF; Mackman, N; Pinsky, DJ; Stern, DM				Yan, SF; Lu, JS; Zou, YS; Soh-Won, J; Cohen, DM; Buttrick, PM; Cooper, DR; Steinberg, SF; Mackman, N; Pinsky, DJ; Stern, DM			Hypoxia-associated induction of early growth response-1 gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; NF-KAPPA-B; VASCULAR ENDOTHELIAL-CELLS; TYROSINE-HYDROXYLASE GENE; RAT VENTRICULAR MYOCYTES; TERNARY COMPLEX FACTORS; TISSUE FACTOR GENE; FIBRIN DEPOSITION; TRANSCRIPTIONAL REGULATION; OXYGEN DEPRIVATION	The paradigm for the response to hypoxia is erythropoietin gene expression; activation of hypoxia-inducible factor-1 (HIF-1) results in erythropoietin production. Previously, we found that oxygen deprivation induced tissue factor, especially in mononuclear phagocytes, by an early growth response (Egr-1)-dependent pathway without involvement of HIF-1 (Yan, S.-F., Zou, Y.-S., Gao, Y., Zhai, C., Mackman, N., Lee, S., Milbrandt, J., Pinsky, D., Kisiel, TY., and Stern, D. (1998) Proc. Natl. Acad Sci. U.S.A. 95, 8298-8303). Now, we show that cultured monocytes subjected to hypoxia (pO(2) approximate to 12 torr) displayed increased Egr-1 expression because of de novo biosynthesis, with a approximate to 10-fold increased rate of transcription. Transfection of monocytes with Egr-1 promoter-luciferase constructs localized elements responsible for hypoxia-enhanced expression to -424/-65, a region including EBS (ets binding site)-SRE (serum response element)-EBS and SRE-EBS-SRE sites. Further studies with each of these regions Ligated to the basal thymidine kinase promoter and luciferase demonstrated that EBS sites in the element spanning -424/-375 were critical for hypoxia-enhanceable gene expression. These data suggested that an activated ets factor, such as Elk-1, in complex with serum response factor, was the likely proximal trigger of Egr-1 transcription. Indeed, hypoxia induced activation of Elk-1, and suppression of Elk-1 blocked up-regulation of Egr-1 transcription. The signaling cascade preceding Elk-1 activation in response to oxygen deprivation was traced to activation of protein kinase C-beta II, Raf, mitogen-activated protein kinase/extracellular signal-regulated protein kinase kinase and mitogen-activated protein kinases. Comparable hypoxia-mediated Egr-1 induction and activation were observed in cultured hepatoma-derived cells deficient in HIF-1 beta and wild-type hepatoma cells, indicating that the HIF-1 and Egr-1 pathways are initiated independently in response to oxygen deprivation. me propose that activation of Egr-1 in response to hypoxia induces a different facet of the adaptive response than HIF-1, one component of which causes expression of tissue factor, resulting in fibrin deposition.	Columbia Univ Coll Phys & Surg, Dept Surg, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Physiol & Cellular Biophys, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Pharmacol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Oregon Hlth Sci Univ, Dept Med, Div Nephrol, Portland, OR 97201 USA; Univ Illinois, Dept Med, Cardiol Sect, Chicago, IL 60612 USA; Univ S Florida, James A Haley Vet Hosp, Tampa, FL 33711 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA	Columbia University; Columbia University; Columbia University; Columbia University; Columbia University; Oregon Health & Science University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; State University System of Florida; University of South Florida; US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital; Scripps Research Institute; Scripps Research Institute	Yan, SF (corresponding author), Columbia Univ Coll Phys & Surg, Dept Surg, 630 W 168th St,P&S 11-420, New York, NY 10032 USA.				NHLBI NIH HHS [HL42507, HL59488, HL55397] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059488, R01HL055397, R01HL042507] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bowman JC, 1997, J CLIN INVEST, V100, P2189, DOI 10.1172/JCI119755; BRAND T, 1992, CIRC RES, V71, P1351, DOI 10.1161/01.RES.71.6.1351; BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; CARDELL M, 1993, J NEUROCHEM, V61, P1308, DOI 10.1111/j.1471-4159.1993.tb13623.x; Chalfant CE, 1996, MOL ENDOCRINOL, V10, P1273, DOI 10.1210/me.10.10.1273; Cohen DM, 1996, J BIOL CHEM, V271, P12903, DOI 10.1074/jbc.271.22.12903; CONRAD R, 1994, J BIOL CHEM, V269, P32051; Contrino J, 1996, NAT MED, V2, P209, DOI 10.1038/nm0296-209; Cui MZ, 1996, J BIOL CHEM, V271, P2731, DOI 10.1074/jbc.271.5.2731; Danis RP, 1998, INVEST OPHTH VIS SCI, V39, P171; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; EBERT BL, 1995, J BIOL CHEM, V270, P29083, DOI 10.1074/jbc.270.49.29083; Folkman J, 1996, NAT MED, V2, P167, DOI 10.1038/nm0296-167; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; Goldberg M, 1997, J CLIN INVEST, V99, P55, DOI 10.1172/JCI119133; Gozal E, 1998, J APPL PHYSIOL, V85, P372, DOI 10.1152/jappl.1998.85.1.372; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Jiang TR, 1996, CIRC RES, V78, P553, DOI 10.1161/01.RES.78.4.553; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; KARAKURUM M, 1994, J CLIN INVEST, V93, P1564, DOI 10.1172/JCI117135; Khachigian LM, 1997, CIRC RES, V81, P457, DOI 10.1161/01.RES.81.4.457; KILEY SC, 1995, J CELL SCI, V108, P1003; KOONG AC, 1994, CANCER RES, V54, P1425; KORTENJANN M, 1995, ONCOGENE, V11, P2105; Koya D, 1998, DIABETES, V47, P859, DOI 10.2337/diabetes.47.6.859; Lawson CA, 1997, J CLIN INVEST, V99, P1729, DOI 10.1172/JCI119337; Lee SL, 1996, SCIENCE, V273, P1219, DOI 10.1126/science.273.5279.1219; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LI YW, 1995, AM J PHYSIOL-HEART C, V268, pH426, DOI 10.1152/ajpheart.1995.268.1.H426; Mackman N, 1997, THROMB HAEMOSTASIS, V78, P747; Maltepe E, 1997, NATURE, V386, P403, DOI 10.1038/386403a0; Mishra RR, 1998, MOL BRAIN RES, V59, P74, DOI 10.1016/S0169-328X(98)00139-9; MITCHELL FE, 1989, BIOCHEM J, V261, P131, DOI 10.1042/bj2610131; Muller JM, 1997, EUR J BIOCHEM, V244, P45, DOI 10.1111/j.1432-1033.1997.00045.x; Muller JN, 1997, J BIOL CHEM, V272, P23435, DOI 10.1074/jbc.272.37.23435; MURAMATSU MA, 1989, MOL CELL BIOL, V9, P831, DOI 10.1128/MCB.9.2.831; NORRIS ML, 1995, J BIOL CHEM, V270, P23774, DOI 10.1074/jbc.270.40.23774; OUELLETTE AJ, 1990, J CLIN INVEST, V85, P766, DOI 10.1172/JCI114502; Pinsky DJ, 1998, J CLIN INVEST, V102, P919, DOI 10.1172/JCI307; ROBERTSON M, 1998, MOL CELL BIOL, V15, P3531; Royds JA, 1998, J CLIN PATHOL-MOL PA, V51, P55; RUPEC RA, 1995, EUR J BIOCHEM, V234, P632, DOI 10.1111/j.1432-1033.1995.632_b.x; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Schmedtje JF, 1997, J BIOL CHEM, V272, P601; Schwachtgen JL, 1998, J CLIN INVEST, V101, P2540, DOI 10.1172/JCI1404; Semenza GL, 1996, TRENDS CARDIOVAS MED, V6, P151, DOI 10.1016/1050-1738(96)00039-4; Sieber FE, 1998, STROKE, V29, P1445, DOI 10.1161/01.STR.29.7.1445; Soh JW, 1999, MOL CELL BIOL, V19, P1313; SPEECHLYDICK ME, 1994, CIRC RES, V75, P586, DOI 10.1161/01.RES.75.3.586; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Watson DK, 1997, ONCOGENE, V14, P213, DOI 10.1038/sj.onc.1200839; Wood SM, 1996, J BIOL CHEM, V271, P15117, DOI 10.1074/jbc.271.25.15117; Yan SF, 1997, J BIOL CHEM, V272, P4287, DOI 10.1074/jbc.272.7.4287; Yan SF, 1998, P NATL ACAD SCI USA, V95, P8298, DOI 10.1073/pnas.95.14.8298; YAN SF, 1995, J BIOL CHEM, V270, P11463, DOI 10.1074/jbc.270.19.11463; YAO KS, 1994, MOL CELL BIOL, V14, P5997, DOI 10.1128/MCB.14.9.5997; Zhang YM, 1996, J CLIN INVEST, V97, P2213, DOI 10.1172/JCI118662	59	213	226	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					15030	15040		10.1074/jbc.274.21.15030	http://dx.doi.org/10.1074/jbc.274.21.15030			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329706	hybrid			2022-12-25	WOS:000081965200071
J	Plager, DA; Loegering, DA; Weiler, DA; Checkel, JL; Wagner, JM; Clarke, NJ; Naylor, S; Page, SM; Thomas, LL; Akerblom, I; Cocks, B; Stuart, S; Gleich, GJ				Plager, DA; Loegering, DA; Weiler, DA; Checkel, JL; Wagner, JM; Clarke, NJ; Naylor, S; Page, SM; Thomas, LL; Akerblom, I; Cocks, B; Stuart, S; Gleich, GJ			A novel and highly divergent homolog of human eosinophil granule major basic protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; SEQUENCE-ANALYSIS; CATIONIC PROTEIN; MESSENGER-RNA; AMINO-ACID; CELLS; RIBONUCLEASE; NEUROTOXIN; ACTIVATION; MECHANISM	Eosinophils are important effector cells in defense against helminth infection and in allergic diseases. To identify novel eosinophil proteins, large scale sequencing of a cDNA library prepared from interleukin-5-stimulated umbilical cord precursor cells was performed, and the major genes expressed by maturing eosinophils were determined. This resulted in the identification of a cDNA with 64% identity to human prepro-major basic protein (hprepro-MBP). This cDNA was designated hprepro-MBP homolog (hprepro-MBPH). Interestingly, the calculated pI values for hMBPH and hMBP differed by > 100-fold, with pI values of 8.7 and 11.4, respectively, Given this pronounced basicity difference, the homolog transcript's abundance (1.1%), and MBP's critical role in eosinophil biological activity, we further characterized the homolog. Reverse transcription-polymerase chain reaction detected transcription of hprepro-MBPH in bone marrow only, and this result was confirmed by analysis of a large cDNA data base (electronic Northern). hMBPH was isolated from human eosinophil granule lysates, and its identity was verified by amino acid sequencing and by mass spectrometry. Analyses of the biological activities showed that hMBPH had effects similar to hMBP in cell killing and neutrophil (superoxide anion production and interleukin-8 release) and basophil (histamine and leukotriene C-4 release) stimulation assays, but usually with reduced potency. Overall, this novel homolog's unique physical properties indicated that the high net positive charge of hMBP is important but not essential for biological activity.	Mayo Clin & Mayo Fdn, Dept Immunol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Internal Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biochem, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Mol Biol, Rochester, MN 55905 USA; Incyte Pharmaceut, Palo Alto, CA 94304 USA; Rush Presbyterian St Lukes Med Ctr, Dept Immunol Microbiol, Chicago, IL 60612 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Incyte; Rush University	Plager, DA (corresponding author), Mayo Clin & Mayo Fdn, Dept Immunol, 200 1st St SW, Rochester, MN 55905 USA.	plager.douglas@mayo.edu			NIAID NIH HHS [AI 34577, AI 32041, AI 09728] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI009728, R37AI009728, R01AI032041, U19AI034577, U01AI034577] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABUGHAZALEH RI, 1992, J MEMBRANE BIOL, V128, P153; ABUGHAZALEH RI, 1992, J LEUKOCYTE BIOL, V52, P611, DOI 10.1002/jlb.52.6.611; Anderson L, 1997, ELECTROPHORESIS, V18, P533, DOI 10.1002/elps.1150180333; AOKI I, 1991, FEBS LETT, V282, P56, DOI 10.1016/0014-5793(91)80443-7; Bains W, 1996, NAT BIOTECHNOL, V14, P711, DOI 10.1038/nbt0696-711; BARKER RL, 1990, GENE, V86, P285, DOI 10.1016/0378-1119(90)90292-Y; BONNO M, 1994, LAB INVEST, V70, P234; BOURDON MA, 1987, P NATL ACAD SCI USA, V84, P3194, DOI 10.1073/pnas.84.10.3194; Chen HX, 1998, J EXP MED, V188, P1657, DOI 10.1084/jem.188.9.1657; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; DURACK DT, 1981, P NATL ACAD SCI-BIOL, V78, P5165, DOI 10.1073/pnas.78.8.5165; Evans CM, 1997, J CLIN INVEST, V100, P2254, DOI 10.1172/JCI119763; Fasman G.D., 1989, PRACTICAL HDB BIOCH, P196; GLEICH GJ, 1986, ADV IMMUNOL, V39, P177; GLEICH GJ, 1988, J ALLERGY CLIN IMMUN, V81, P776, DOI 10.1016/0091-6749(88)90931-1; GLEICH GJ, 1986, P NATL ACAD SCI USA, V83, P3146, DOI 10.1073/pnas.83.10.3146; GLEICH GJ, 1976, J CLIN INVEST, V57, P633, DOI 10.1172/JCI108319; GLEICH GJ, 1992, INFLAMMATION BASIC P, P663; GRUART V, 1992, BLOOD, V79, P2592; GUNDEL RH, 1991, J CLIN INVEST, V87, P1470, DOI 10.1172/JCI115155; HAMANN KJ, 1990, J IMMUNOL, V144, P3166; HARLOW E, 1988, ANTIBODIES LABORATOR, P207; HASKELL MD, 1995, BLOOD, V86, P4627, DOI 10.1182/blood.V86.12.4627.bloodjournal86124627; HOFSTEENGE J, 1994, BIOCHEMISTRY-US, V33, P13524, DOI 10.1021/bi00250a003; KINGSTON RE, 1997, CURRENT PROTOCOLS MO, V1, pCH4; KITA H, 1995, J IMMUNOL, V154, P4749; KITA H, 1998, ALLERGY PRINCIPLES P, V1, P242; KROEGEL C, 1987, LANCET, V1, P1380; LARSON KA, 1995, J IMMUNOL, V155, P3002; LEIFERMAN KM, 1985, NEW ENGL J MED, V313, P282, DOI 10.1056/NEJM198508013130502; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LODISH H, 1995, MOL CELL BIOL, P694; LODISH H, 1995, MOL CELL BIOL, P1139; MACGLASHAN DW, 1986, J IMMUNOL, V136, P2231; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; MADDOX DE, 1984, J EXP MED, V160, P29, DOI 10.1084/jem.160.1.29; MCCONAHEY P, 1980, IMMUNOCHEMICAL TEC A, V70, P210; MCGROGAN M, 1988, J EXP MED, V168, P2295, DOI 10.1084/jem.168.6.2295; MOY JN, 1990, J IMMUNOL, V145, P2626; ODONNELL MC, 1983, J EXP MED, V157, P1981, DOI 10.1084/jem.157.6.1981; OKUBO K, 1992, NAT GENET, V2, P173, DOI 10.1038/ng1192-173; OXVIG C, 1994, FEBS LETT, V341, P213, DOI 10.1016/0014-5793(94)80459-1; OXVIG C, 1994, BIOCHEM MOL BIOL INT, V33, P329; OXVIG C, 1993, J BIOL CHEM, V268, P12243; Popken-Harris P, 1998, BLOOD, V92, P623, DOI 10.1182/blood.V92.2.623.414k32_623_631; POPKENHARRIS P, 1995, J IMMUNOL, V155, P1472; ROCHESTER CL, 1995, CHEST, V107, pS117, DOI 10.1378/chest.107.3_Supplement.117S; ROSENBERG HF, 1995, NAT GENET, V10, P219, DOI 10.1038/ng0695-219; SAITO H, 1988, P NATL ACAD SCI USA, V85, P2288, DOI 10.1073/pnas.85.7.2288; SARMIENTO EU, 1995, J IMMUNOL, V155, P2211; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Sivaraman T, 1997, J PROTEIN CHEM, V16, P291, DOI 10.1023/A:1026357009886; SLIFMAN NR, 1986, J IMMUNOL, V137, P2913; SPRY CJF, 1983, Q J MED, V52, P1; TAI PC, 1987, LANCET, V1, P643; TEN RM, 1991, CYTOKINE, V3, P350, DOI 10.1016/1043-4666(91)90505-8; TEN RM, 1989, J EXP MED, V169, P1757, DOI 10.1084/jem.169.5.1757; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; WAGNER JM, 1993, PLACENTA, V14, P671, DOI 10.1016/S0143-4004(05)80384-4; WASMOEN TL, 1988, J BIOL CHEM, V263, P12559; Yamaguchi Y, 1998, BLOOD, V91, P3447, DOI 10.1182/blood.V91.9.3447.3447_3447_3458; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	62	58	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					14464	14473		10.1074/jbc.274.20.14464	http://dx.doi.org/10.1074/jbc.274.20.14464			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318872	hybrid			2022-12-25	WOS:000080322200101
J	Haber, M; Bordow, SB; Gilbert, J; Madafiglio, J; Kavallaris, M; Marshall, GM; Mechetner, EB; Fruehauf, JP; Tee, L; Cohn, SL; Salwen, H; Schmidt, ML; Norris, MD				Haber, M; Bordow, SB; Gilbert, J; Madafiglio, J; Kavallaris, M; Marshall, GM; Mechetner, EB; Fruehauf, JP; Tee, L; Cohn, SL; Salwen, H; Schmidt, ML; Norris, MD			Altered expression of the MYCN oncogene modulates MRP gene expression and response to cytotoxic drugs in neuroblastoma cells	ONCOGENE			English	Article						neuroblastoma; MYCN oncogene; MRP gene; antisense; transfection; cytotoxicity	RESISTANCE-ASSOCIATED PROTEIN; NEURO-BLASTOMA CELLS; MULTIDRUG-RESISTANCE; N-MYC; P-GLYCOPROTEIN; TUMOR-CELLS; OVEREXPRESSION; SENSITIVITY	We have recently shown a close correlation between expression of the Multidrug Resistance-associated Protein (MRP) gene and the MYCN oncogene and provided evidence that high MRP expression is a powerful independent predictor of poor outcome in neuroblastoma (Norris ct al., New Engl. J, Med., 334, 231-238, 1996), The effect of MYCN down-regulation on MRP expression and response to cytotoxic drugs was investigated in NBL-S neuroblastoma cells transfected with MYCN antisense RNA constructs. Concomitant with,MYCN down-regulation, the level of MRP expression was decreased in the NBAS-4 and NBAS-5 antisense transfectants. These cells demonstrated significantly increased sensitivity to the high affinity MRP substrates vincristine, doxorubicin, sodium arsenate and potassium antimony tartrate, but not to the poor MRP substrates, taxol or cisplatin, Similarly, transfection of full-length MYCN cDNA into SH-EP neuroblastoma cells resulted in increased MRP expression and significantly increased resistance specifically to MRP substrates. The results provide evidence for the MYCN oncogene influencing cytotoxic drug response via regulation of MRP gene expression, Our data also provide a link between the malignant and chemoresistant phenotypes of this childhood malignancy.	Sydney Childrens Hosp, Childrens Canc Res Inst, Sydney, NSW, Australia; Oncotech Inc, Irvine, CA USA; Northwestern Univ, Dept Pediat, Chicago, IL 60611 USA; Univ Illinois, Dept Pediat, Chicago, IL USA	Children's Cancer Institute; University of Sydney; Northwestern University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Norris, MD (corresponding author), Sydney Childrens Hosp, Childrens Canc Res Inst, Sydney, NSW, Australia.		Cohn, Susan/AAB-6010-2021; Kavallaris, Maria/J-5240-2014	Gilbert, Jayne/0000-0001-5034-386X; Haber, Michelle/0000-0003-2036-8817; Cohn, Susan/0000-0001-5749-7650; Norris, Murray/0000-0002-0632-4589				BORDOW SB, 1994, CANCER RES, V54, P5036; BRODEUR GM, 1992, CANCER-AM CANCER SOC, V70, P1685, DOI 10.1002/1097-0142(19920915)70:4+<1685::AID-CNCR2820701607>3.0.CO;2-H; COLE SPC, 1994, CANCER RES, V54, P5902; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; FLENS MJ, 1994, CANCER RES, V54, P4557; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; GRANT CE, 1994, CANCER RES, V54, P357; HABER M, 1989, CANCER RES, V49, P5281; Lee JS, 1997, J CELL BIOCHEM, V65, P513, DOI 10.1002/(SICI)1097-4644(19970615)65:4<513::AID-JCB7>3.3.CO;2-W; Norris MD, 1996, NEW ENGL J MED, V334, P231, DOI 10.1056/NEJM199601253340405; Norris MD, 1997, EUR J CANCER, V33, P1911, DOI 10.1016/S0959-8049(97)00284-0; NORRIS MD, 1998, IN PRESS EUR J CANC; RASCHELLA G, 1994, CANCER RES, V54, P2251; ROSS RA, 1983, J NATL CANCER I, V71, P741; SCHMIDT ML, 1994, CELL GROWTH DIFFER, V5, P171; SCHNEIDER E, 1994, CANCER RES, V54, P152; SCHWAB M, 1985, NATURE, V316, P160, DOI 10.1038/316160a0; SPENGLER BA, 1986, CANCER TREAT REP, V70, P959; Stram DO, 1996, J CLIN ONCOL, V14, P2417, DOI 10.1200/JCO.1996.14.9.2417; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; WENZEL A, 1995, EUR J CANCER, V31A, P516, DOI 10.1016/0959-8049(95)00060-V; ZAMAN GJR, 1994, P NATL ACAD SCI USA, V91, P8822, DOI 10.1073/pnas.91.19.8822	22	62	64	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 29	1999	18	17					2777	2782		10.1038/sj.onc.1202859	http://dx.doi.org/10.1038/sj.onc.1202859			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FH	10348353				2022-12-25	WOS:000080124900014
J	Miyake, M; Adachi, M; Huang, CL; Higashiyama, M; Kodama, K; Taki, T				Miyake, M; Adachi, M; Huang, CL; Higashiyama, M; Kodama, K; Taki, T			A novel molecular staging protocol for non-small cell lung cancer	ONCOGENE			English	Article						MRP-1/CD9; KA11/CD82; K-ras; p53; lung cancer; metastasis; prognosis; TM4SF	K-RAS; POOR-PROGNOSIS; GENE-EXPRESSION; SUPPRESSOR GENE; P53 GENE; MUTATIONS; MOTILITY; MRP-1/CD9; METASTASIS; CARCINOMA	A molecular staging protocol using reliable markers is of importance in predicting the prognosis of patients with non-small cell lung cancer (NSCLC) and for instituting their appropriate post-surgical treatment. We analysed tumor tissues from 187 NSCLC patients. The DNA and mRNA mere extracted from frozen specimens, and then polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) and direct sequencing were performed to investigate mutations of p53 from exons 5-8, and mutations of K-ras at exon 1, To determine MRP-1/CD9 gene and KA11/CD82 gene expression, which have been postulated to be metastasis suppressor genes, we have applied quantitative RT-PCR, A Cox multivariate regression analysis showed that nodal status, MRP-1/CD9 and K-ras status were significant factors for prognosis (P<0.0001, P=0.0083 and P=0.0004, respectively). Based on these results, me classified the patients into three groups according to their MRP-1/CD9 and K-ras status. Patients with both MRP-1/CD9 positive and wild Ii-ras tumors were defined as group A, patients with either reduced MRP-1/CD9 or mutant Kr as tumors were defined as group B and patients with both reduced MRP-1/CD9 and mutant Ii-ras tumors were designated as group C, This new classification was significantly correlated with the tumor status and pathological stage (P=0.0098 and P=0.0017, respectively). The overall survival rate of the group A patients was significantly better than the group B patients (59.6% vs 27.9%, P=0.0001) and also that of group B patients mas better than the group C patients (27.9% vs 20.0%, P=0.0378), This tendency was also found in patients with 110 node-negative NSCLCs (A vs B vs C=75.8% vs 34.9%,fs 0.0%, P<0.0001), A Cox multivariate regression analysis in NSCLC patients demonstrated that an evaluation for both MRP-1/CD9 expression and K-ras mutations had a significant prognostic effect as well as nodal status (P<0.0001).	Kitano Hosp, Tazuke Kofukai Med Res Inst, Dept Thorac Surg, Osaka 530, Japan; Kitano Hosp, Tazuke Kofukai Med Res Inst, Dept Oncol 5, Osaka 530, Japan; Osaka Med Ctr Canc & Cardiovasc Dis, Dept Surg, Osaka 537, Japan	Kitano Hospital; Kitano Hospital; Osaka Medical Center for Cancer & Cardiovascular Diseases	Miyake, M (corresponding author), Kitano Hosp, Tazuke Kofukai Med Res Inst, Dept Thorac Surg, Osaka 530, Japan.							Adachi M, 1996, CANCER RES, V56, P1751; BAINS MS, 1991, CHEST, V100, P826, DOI 10.1378/chest.100.3.826; Cajot JF, 1997, CANCER RES, V57, P2593; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COX DR, 1972, J R STAT SOC B, V34, P187; Curiel DT, 1996, AM J RESP CELL MOL, V14, P1; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; Fukuyama Y, 1997, BRIT J CANCER, V75, P1125, DOI 10.1038/bjc.1997.194; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HIGASHIYAMA M, 1995, CANCER RES, V55, P6040; HONGYO T, 1995, CANCER RES, V55, P2665; Huang C, 1998, ONCOGENE, V16, P2469, DOI 10.1038/sj.onc.1201776; Huang CL, 1997, INT J ONCOL, V11, P1045; IKEYAMA S, 1993, J EXP MED, V177, P1231, DOI 10.1084/jem.177.5.1231; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LEE JS, 1995, J CLIN ONCOL, V13, P1893, DOI 10.1200/JCO.1995.13.8.1893; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MASTERS GA, 1996, ADV ONCOL, V12, P16; MITSUDOMI T, 1993, JNCI-J NATL CANCER I, V85, P2018, DOI 10.1093/jnci/85.24.2018; MIYAKE M, 1991, J EXP MED, V174, P1347, DOI 10.1084/jem.174.6.1347; MIYAKE M, 1992, NEW ENGL J MED, V327, P14, DOI 10.1056/NEJM199207023270103; Miyake M, 1996, CANCER RES, V56, P1244; Mountain CF, 1997, CHEST, V111, P1710, DOI 10.1378/chest.111.6.1710; NAKAJIMAIIJIMA S, 1985, P NATL ACAD SCI USA, V82, P6133, DOI 10.1073/pnas.82.18.6133; ROSELL R, 1993, ONCOGENE, V8, P2407; Roth JA, 1996, NAT MED, V2, P985, DOI 10.1038/nm0996-985; SAMBROOK J, 1989, LAB MANUAL, V3, pE3; SKLAR MD, 1988, SCIENCE, V239, P645, DOI 10.1126/science.3277276; SLEBOS RJC, 1990, NEW ENGL J MED, V323, P561, DOI 10.1056/NEJM199008303230902; SUNDARESAN V, 1995, ANN ONCOL, V6, P27, DOI 10.1093/annonc/6.suppl_1.S27; TAKAHASHI H, 1992, ELECTRON LETT, V28, P380, DOI 10.1049/el:19920238; ZHANG YJ, 1993, HUM GENE THER, V4, P451, DOI 10.1089/hum.1993.4.4-451	32	56	60	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	1999	18	14					2397	2404		10.1038/sj.onc.1202556	http://dx.doi.org/10.1038/sj.onc.1202556			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184DT	10327061				2022-12-25	WOS:000079595500013
J	Klefstrom, J; Kovanen, PE; Somersalo, K; Hueber, AO; Littlewood, T; Evan, GI; Greenberg, AH; Saksela, E; Timonen, T; Alitalo, K				Klefstrom, J; Kovanen, PE; Somersalo, K; Hueber, AO; Littlewood, T; Evan, GI; Greenberg, AH; Saksela, E; Timonen, T; Alitalo, K			c-Myc and E1A induced cellular sensitivity to activated NK cells involves cytotoxic granules as death effectors	ONCOGENE			English	Article						apoptosis; c-Myc; E1A; NK cells; cytotoxicity	NATURAL-KILLER-CELLS; TUMOR-NECROSIS-FACTOR; WILD-TYPE P53; GRANZYME-B; CYTOLYTIC SUSCEPTIBILITY; ONCOGENE EXPRESSION; DEPENDENT APOPTOSIS; MELANOMA-CELLS; CYTO-TOXICITY; TARGET-CELLS	The contact of natural killer (NK) cells with foreign cells and with certain virus-infected or tumor cells triggers the cytolytic machinery of NK cells. This triggering leads to exocytosis of the cytotoxic NK cell granules. The oncoproteins c-Myc and E1A render cells vulnerable to NK cell mediated cytolysis yet the mechanisms of sensitization are not well understood. In a model where foreign cells (rat fibroblasts) were cocultured with human IL-2 activated NK cells, we observed that NK cells were capable of efficiently killing their targets only if the cells overexpressed the oncogene c-Myc or E1A. Both the parental and the oncogene expressing fibroblasts similarly triggered phosphoinositide hydrolysis in the bound NK cells, demonstrating that NK cells were cytolytically activated in contact with both resistant parental and oncogene expressing sensitive target fibroblasts. The cell death was independent of mild-type p53 and was not inhibited by an anti-apoptotic protein E1B19K. These results provided evidence that c-Myc and E1A activated the NK cell induced cytolysis at a post-triggering stage of NK cell-target cell interaction. In consistence, the c-Myc and E1A overexpressing fibroblasts were more sensitive to the cytolytic effects of isolated NK cell-derived granules than parental cells. The data indicate that oncogenes activate the cytotoxicity of NK cell granules. This mechanism can have a role in directing the cytolytic action of NK cells towards the virus-infected and cancer cells.	Imperial Canc Res Fund, Biochem Cell Nucleus Lab, London WC2A 3PX, England; Univ Helsinki, Haartman Inst, Mol Canc Biol Lab, FIN-00014 Helsinki, Finland; Univ Helsinki, Haartman Inst, Dept Pathol, FIN-00014 Helsinki, Finland; Univ Manitoba, Manitoba Inst Cell Biol, Dept Pediat, Winnipeg, MB R3E 0V9, Canada; Univ Manitoba, Dept Immunol, Winnipeg, MB R3E 0V9, Canada	Cancer Research UK; University of Helsinki; University of Helsinki; University of Manitoba; University of Manitoba	Klefstrom, J (corresponding author), Imperial Canc Res Fund, Biochem Cell Nucleus Lab, POB 123,44 Lincolns Inn Fields, London WC2A 3PX, England.		Anne-Odile, Hueber/P-9860-2019; Alitalo, Kari K/J-5013-2014; Anne-Odile, Hueber/G-4352-2013	Anne-Odile, Hueber/0000-0003-3816-2446; Alitalo, Kari K/0000-0002-7331-0902; Anne-Odile, Hueber/0000-0003-3816-2446				ARASE H, 1995, J EXP MED, V181, P1235, DOI 10.1084/jem.181.3.1235; ATKINSON EA, 1990, J LEUKOCYTE BIOL, V47, P39, DOI 10.1002/jlb.47.1.39; AVERSA G, 1993, J EXP MED, V177, P1575, DOI 10.1084/jem.177.6.1575; BERKE G, 1994, ANNU REV IMMUNOL, V12, P735, DOI 10.1146/annurev.immunol.12.1.735; BRUTKIEWICZ RR, 1995, J VIROL, V69, P3967, DOI 10.1128/JVI.69.7.3967-3971.1995; CHEN MJ, 1987, NATURE, V330, P581, DOI 10.1038/330581a0; CHOW DA, 1990, CELL IMMUNOL, V127, P172, DOI 10.1016/0008-8749(90)90123-9; CHOW SC, 1990, IMMUNOLOGY, V70, P106; Cook JL, 1996, ONCOGENE, V13, P833; COOK JL, 1989, J IMMUNOL, V142, P4527; CUOMO L, 1993, INT J CANCER, V53, P1008; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Fearnhead HO, 1997, GENE DEV, V11, P1266, DOI 10.1101/gad.11.10.1266; GRIFFITHS GM, 1995, CURR OPIN IMMUNOL, V7, P343, DOI 10.1016/0952-7915(95)80108-1; GUMPERZ JE, 1995, NATURE, V378, P245, DOI 10.1038/378245a0; Helander TS, 1996, NATURE, V382, P265, DOI 10.1038/382265a0; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; IRMLER M, 1995, J EXP MED, V181, P1917, DOI 10.1084/jem.181.5.1917; Jans DA, 1996, J BIOL CHEM, V271, P30781, DOI 10.1074/jbc.271.48.30781; KHALIL N, 1990, J IMMUNOL, V145, P1286; Klefstrom J, 1997, EMBO J, V16, P7382, DOI 10.1093/emboj/16.24.7382; KLEFSTROM J, 1994, EMBO J, V13, P5442, DOI 10.1002/j.1460-2075.1994.tb06879.x; LACAVA A, 1994, INT J CANCER, V58, P123, DOI 10.1002/ijc.2910580120; Lanier LL, 1997, IMMUNITY, V6, P371, DOI 10.1016/S1074-7613(00)80280-0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LJUNGGREN HG, 1990, IMMUNOL TODAY, V11, P237, DOI 10.1016/0167-5699(90)90097-S; PELTENBURG LTC, 1992, EUR J IMMUNOL, V22, P2737, DOI 10.1002/eji.1830221040; RAULET DH, 1995, CELL, V82, P697, DOI 10.1016/0092-8674(95)90466-2; SHAULIAN E, 1995, ONCOGENE, V10, P671; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SHI LF, 1992, J EXP MED, V175, P553, DOI 10.1084/jem.175.2.553; Shi LF, 1996, P NATL ACAD SCI USA, V93, P11002, DOI 10.1073/pnas.93.20.11002; Shi LF, 1997, J EXP MED, V185, P855, DOI 10.1084/jem.185.5.855; STAHLS AK, 1989, SCAND J IMMUNOL, V29, P211, DOI 10.1111/j.1365-3083.1989.tb01118.x; Sutton VR, 1997, J IMMUNOL, V158, P5783; TIMONEN T, 1980, J IMMUNOL METHODS, V36, P285, DOI 10.1016/0022-1759(80)90133-7; VERSTEEG R, 1989, J IMMUNOL, V143, P4331; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WALKER TA, 1991, P NATL ACAD SCI USA, V88, P6491, DOI 10.1073/pnas.88.15.6491; WRIGHT SC, 1987, J IMMUNOL, V138, P1791	44	12	13	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 1	1999	18	13					2181	2188		10.1038/sj.onc.1202546	http://dx.doi.org/10.1038/sj.onc.1202546			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	182YE	10327064				2022-12-25	WOS:000079525100002
J	Zehbe, I; Ratsch, A; Alunni-Fabbroni, M; Burzlaff, A; Bakos, E; Durst, M; Wilander, E; Tommasino, M				Zehbe, I; Ratsch, A; Alunni-Fabbroni, M; Burzlaff, A; Bakos, E; Durst, M; Wilander, E; Tommasino, M			Overriding of cyclin-dependent kinase inhibitors by high and low risk human papillomavirus types: evidence for an in vivo role in cervical lesions	ONCOGENE			English	Article						cervical lesions; high and low risk HPV types; CDK inhibitors; cell cycle	CELL-CYCLE; E7 ONCOPROTEIN; GENE-EXPRESSION; DNA-REPLICATION; P21(WAF1/CIP1) EXPRESSION; POTENTIAL MEDIATOR; DIFFERENTIATION; P27(KIP1); P53; PROTEIN	High risk types of human papillomavirus (HPV) are agents in the aetiology of cervical carcinoma. The products of two early genes, E6 and E7, appear to be the principal transforming proteins. Studies of various monolayer cell culture systems have shown that the E7 oncoprotein of human papillomavirus type 16 is able to neutralize or bypass the inhibitory effect of the cell cycle-dependent kinase (CDK) inhibitors (CKIs) p21(WAF1/CIP1) and p27(KIP1). To understand whether the p21(WAF1/CIP1) Or p27(KIP1) neutralization also plays a role in vivo, we performed studies on clinical specimens. Forty-five cervical biopsies, including HPV-negative mucosa, HPV 16-positive preinvasive (low and high grade lesions) and invasive neoplasia as well as HPV 6-positive condyloma acuminatum were analysed by single and double immunohistology. We examined the positive cell cycle regulator cyclin A and the universal cell cycle marker Ki67 as well as the negative cell cycle regulators p21(WAF1/CIP1) and p(27KIP1). Here, we show that in a significant fraction of cells the G1 block can be overcome despite high levels of CKIs in HPV lesions. This phenomenon, which was more evident for p21(WAF/CIP1) than for p27(KIP1) was most marked in low grade lesions and in condylomata acuminata, in which a high viral productivity is expected. These results indicate that the overriding of CKI inactivation by viral oncoproteins appears to be a conserved property between low and high risk HPV types. We conclude that the CKI neutralization by HPVs is likely to be required for viral DNA replication rather than for malignant transformation of the host cell.	Deutsch Krebsforschungszentrum, D-69120 Heidelberg, Germany; Klin Frauenheilkunde & Geburtshilfe, D-07740 Jena, Germany; Univ Uppsala, Dept Genet & Pathol, S-75185 Uppsala, Sweden	Helmholtz Association; German Cancer Research Center (DKFZ); Uppsala University	Tommasino, M (corresponding author), Deutsch Krebsforschungszentrum, Neuenheimer Feld 242, D-69120 Heidelberg, Germany.							Beijersbergen RL, 1996, BBA-REV CANCER, V1287, P103, DOI 10.1016/0304-419X(96)00002-9; BLANTON RA, 1992, CELL GROWTH DIFFER, V3, P791; Byrne C, 1997, BIOESSAYS, V19, P691, DOI 10.1002/bies.950190809; CHENG S, 1995, GENE DEV, V9, P2335, DOI 10.1101/gad.9.19.2335; Chinery R, 1997, NAT MED, V3, P1233, DOI 10.1038/nm1197-1233; DAVIES R, 1993, J VIROL, V67, P2525; Demers GW, 1996, J VIROL, V70, P6862, DOI 10.1128/JVI.70.10.6862-6869.1996; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; DURST M, 1992, VIROLOGY, V189, P132, DOI 10.1016/0042-6822(92)90688-L; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Fredersdorf S, 1996, AM J PATHOL, V148, P825; Fredersdorf S, 1997, P NATL ACAD SCI USA, V94, P6380, DOI 10.1073/pnas.94.12.6380; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; GISSMANN L, 1982, INT J CANCER, V29, P143, DOI 10.1002/ijc.2910290205; Herwig S, 1997, EUR J BIOCHEM, V246, P581, DOI 10.1111/j.1432-1033.1997.t01-2-00581.x; HICKMAN ES, 1994, ONCOGENE, V9, P2177; Hiyama H, 1998, ONCOGENE, V16, P1513, DOI 10.1038/sj.onc.1201667; Howley Peter M., 1996, P947; HU TH, 1995, INT J ONCOL, V6, P167; Jones DL, 1997, GENE DEV, V11, P2101, DOI 10.1101/gad.11.16.2101; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Mandal M, 1998, ONCOGENE, V16, P217, DOI 10.1038/sj.onc.1201529; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PINES J, 1995, ADV CANCER RES, V66, P181, DOI 10.1016/S0065-230X(08)60254-7; PINES J, 1990, NATURE, V46, P60; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Ruesch MN, 1997, J VIROL, V71, P5570, DOI 10.1128/JVI.71.7.5570-5578.1997; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Schmidt-Grimminger DC, 1998, AM J PATHOL, V152, P1015; Schulze A, 1998, J VIROL, V72, P2323, DOI 10.1128/JVI.72.3.2323-2334.1998; TOMMASINO M, 1993, ONCOGENE, V8, P195; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Zehbe I, 1997, J PATHOL, V181, P270; Zehbe I, 1996, DIAGN MOL PATHOL, V5, P206, DOI 10.1097/00019606-199609000-00010; ZerfassThome K, 1997, MOL CELL BIOL, V17, P407, DOI 10.1128/MCB.17.1.407; ZerfassThome K, 1996, ONCOGENE, V13, P2323; ZURHAUSEN H, 1994, ANNU REV MICROBIOL, V48, P427, DOI 10.1146/annurev.micro.48.1.427; ZURHAUSEN H, 1986, LANCET, V2, P498	43	43	45	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 1	1999	18	13					2201	2211		10.1038/sj.onc.1202549	http://dx.doi.org/10.1038/sj.onc.1202549			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	182YE	10327066	Bronze			2022-12-25	WOS:000079525100004
J	Coccia, EM; Del Russo, N; Stellacci, E; Orsatti, R; Benedetti, E; Marziali, G; Hiscott, J; Battistini, A				Coccia, EM; Del Russo, N; Stellacci, E; Orsatti, R; Benedetti, E; Marziali, G; Hiscott, J; Battistini, A			Activation and repression of the 2-5A synthetase and p21 gene promoters by IRF-1 and IRF-2	ONCOGENE			English	Article						interferon regulatory factors; cell growth; p21 (WAF1/CP1); 2-5A synthetase	REGULATORY FACTOR-I; INTERFERON-INDUCIBLE GENES; TRANSCRIPTION FACTOR IRF-1; CELL-GROWTH INHIBITION; PROTEIN-KINASE; DNA-DAMAGE; P21(WAF1/CIP1) EXPRESSION; CONSTITUTIVE EXPRESSION; LEUKEMIA-CELLS; INDUCTION	The Interferon Regulatory Factors-1 and -2 (IRF-1 and IRF-2) were originally identified as transcriptional regulators of the interferon (IFN) and IFN-stimulated genes, These factors also modulate immune response and play a role in cell growth regulation, In this study we analysed the effect of the ectopic expression of IRF-1 and IRF-2 on the regulation of two potential IRF target genes involved in cell growth regulation, 2-5A synthetase and p21 (WAF/CP1), both of which contain consensus binding sites for IRF family members within their promoters. Following ectopic expression, IRF-1 transactivated 2-5A synthetase and p21 genes, an effect that was counterbalanced by concomitant ectopic expression of IRF-2, These effects were mediated by direct binding of IRF to the gene promoters. A construct expressing an IRF-2 antisense (FRI-2) was able to revert the inhibitory effect of IRF-2 on the IRF-1 transactivation, IRF-1 also induced expression of its homologous repressor IRF-2 as indicated by EMSA analysis using an IRF-E probe from the IRF-2 promoter; and by cotransfection of IRF-1 together with an IRF-2 promoter CAT construct, Therefore, the induction of IRF-1 by IFNs or other stimuli acts as a transactivator of genes involved in cell growth regulation, as web as of its own repressor IRF-2, thus providing autoinhibitory regulation of IRF-1 activated genes.	Ist Super Sanita, Virol Lab, I-00161 Rome, Italy; Ist Super Sanita, Immunol Lab, I-00161 Rome, Italy; Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Terry Fox Mol Oncol Grp, Montreal, PQ H3T 1E2, Canada	Istituto Superiore di Sanita (ISS); Istituto Superiore di Sanita (ISS); Lady Davis Institute; McGill University	Battistini, A (corresponding author), Ist Super Sanita, Virol Lab, Viale Regina Elena 299, I-00161 Rome, Italy.		Coccia, Eliana M/B-4752-2013; BATTISTINI, ANGELA/C-2944-2016; Marziali, Giovanna/J-9808-2016; stellacci, emilia/J-2747-2014	Coccia, Eliana M/0000-0002-1606-2949; Marziali, Giovanna/0000-0001-7450-1017; stellacci, emilia/0000-0003-0415-3285				BATTISTINI A, 1991, BLOOD, V78, P2098, DOI 10.1182/blood.V78.8.2098.bloodjournal7882098; BENECH P, 1987, MOL CELL BIOL, V7, P4498, DOI 10.1128/MCB.7.12.4498; CHIN IE, 1996, SCIENCE, V272, P729; CLEMENS MJ, 1978, CELL, V13, P565, DOI 10.1016/0092-8674(78)90329-X; COCCIA EM, 1995, VIROLOGY, V211, P113, DOI 10.1006/viro.1995.1384; COCCIA EM, 1991, J VIROL, V65, P2081, DOI 10.1128/JVI.65.4.2081-2087.1991; COCCIA EM, 1988, J INTERFERON RES, V7, P113; Demaeyer E., 1988, INTERFERONS OTHER RE; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1995, CANCER RES, V55, P2910; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARADA H, 1994, ONCOGENE, V9, P3313; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HARADA H, 1994, MOL CELL BIOL, V14, P1500, DOI 10.1128/MCB.14.2.1500; HASSEL BA, 1993, EMBO J, V12, P3297, DOI 10.1002/j.1460-2075.1993.tb05999.x; HIRAMA T, 1995, BLOOD, V86, P841; HISCOTT J, 1995, SEMIN VIROL, V6, P161, DOI 10.1006/smvy.1995.0021; HOVANESSIAN AG, 1991, J INTERFERON RES, V11, P199, DOI 10.1089/jir.1991.11.199; JACOBSEN H, 1983, P NATL ACAD SCI-BIOL, V80, P4954, DOI 10.1073/pnas.80.16.4954; JIANG HP, 1994, ONCOGENE, V9, P3397; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; KIMURA T, 1994, SCIENCE, V264, P1921, DOI 10.1126/science.8009222; KIRCHHOFF S, 1993, NUCLEIC ACIDS RES, V21, P2881, DOI 10.1093/nar/21.12.2881; KIRCHHOFF S, 1995, ONCOGENE, V11, P439; LENGYEL P, 1993, P NATL ACAD SCI USA, V90, P5893, DOI 10.1073/pnas.90.13.5893; LIN RT, 1994, J BIOL CHEM, V269, P17542; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MANIATIS T, 1992, TRANSCRIPTIONAL REGU, P1193; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; NGUYEN H, 1995, ONCOGENE, V11, P537; Nguyen H, 1997, ONCOGENE, V15, P1425, DOI 10.1038/sj.onc.1201318; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; OZAWA H, 1996, NATURE, V382, P816; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PINE R, 1992, J VIROL, V66, P4470, DOI 10.1128/JVI.66.7.4470-4478.1992; REIS LF, 1994, EMBO J, V11, P185; RUFFNER H, 1993, P NATL ACAD SCI USA, V90, P11503, DOI 10.1073/pnas.90.24.11503; RYSIECKI G, 1989, J INTERFERON RES, V9, P649, DOI 10.1089/jir.1989.9.649; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; STEINMAN RA, 1994, ONCOGENE, V9, P3389; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; TANAKA H, 1994, P NATL ACAD SCI USA, V91, P7995, DOI 10.1073/pnas.91.17.7995; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; TANIGUCHI T, 1995, J CANCER RES CLIN, V121, P516, DOI 10.1007/BF01197763; VILCEK J, 1994, FIELDS VIROLOGY, P717; WATANABE N, 1991, NUCLEIC ACIDS RES, V19, P4421, DOI 10.1093/nar/19.16.4421; WELLS V, 1985, EXP CELL RES, V159, P27, DOI 10.1016/S0014-4827(85)80034-3; WILLIAMS BRG, 1985, 2 5A SYSTEM; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; WRESCHNER DH, 1981, NATURE, V289, P414, DOI 10.1038/289414a0; YAMAMOTO H, 1994, ONCOGENE, V9, P1423; Zeng YX, 1996, ONCOGENE, V12, P1557; ZHANG W, 1995, CANCER RES, V55, P668	61	58	58	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 25	1999	18	12					2129	2137		10.1038/sj.onc.1202536	http://dx.doi.org/10.1038/sj.onc.1202536			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	179TX	10321737				2022-12-25	WOS:000079346200010
J	Ireton, K; Payrastre, B; Cossart, P				Ireton, K; Payrastre, B; Cossart, P			The Listeria monocytogenes protein InlB is an agonist of mammalian phosphoinositide 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; FOCAL ADHESION KINASE; ACTIN-BASED MOVEMENT; PHOSPHATIDYLINOSITOL 3-KINASE; EGF-RECEPTOR; SURFACE PROTEIN; CELLS; ENTRY; ACTIVATION; INTERNALIN	The Gram-positive pathogen Listeria monocytogenes induces its own internalization into some non-phagocytic mammalian cells by stimulating host tyrosine phosphorylation, phosphoinositide (PI) 3-kinase activity, and rearrangements in the actin cytoskeleton, Entry into many cultured cell lines is mediated by the bacterial protein In1B, Here we investigate the role of In1B in regulating mammalian signal transduction and cytoskeletal structure. Treatment of Vero cells with purified In1B caused rapid and transient increases in the lipid products of the PI 3-kinase p85-p110, tyrosine phosphorylation of the mammalian adaptor proteins Gab1, Chi, and Shc, and association of these proteins with p85. In1B also stimulated large scale changes in the actin cytoskeleton(membrane ruffling), which were PIS-kinase-dependent. These results identify In1B as the first reported non-mammalian agonist of PI 3-kinase and demonstrate similarities in the signal transduction events elicited by this bacterial protein and known agonists such as epidermal growth factor.	Unite Interact Bacteries Cellules, F-75724 Paris 15, France; Hop Purpan, INSERM U326, F-31059 Toulouse, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)	Cossart, P (corresponding author), Univ Toronto, Dept Med Genet & Microbiol, 100 Coll St, Toronto, ON M5S 1A8, Canada.			, Bernard/0000-0002-8693-0190				Bonfini L, 1996, TRENDS BIOCHEM SCI, V21, P257, DOI 10.1016/S0968-0004(96)10033-5; BOWTELL DDL, 1995, ONCOGENE, V11, P1561; Braun L, 1998, MOL MICROBIOL, V27, P1077, DOI 10.1046/j.1365-2958.1998.00750.x; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; Chen LM, 1996, SCIENCE, V274, P2115, DOI 10.1126/science.274.5295.2115; Cossart P, 1998, EMBO J, V17, P3797, DOI 10.1093/emboj/17.14.3797; Cox D, 1997, J EXP MED, V186, P1487, DOI 10.1084/jem.186.9.1487; DRAMSI S, 1995, MOL MICROBIOL, V16, P251, DOI 10.1111/j.1365-2958.1995.tb02297.x; DRAMSI S, 1997, INFECT IMMUN, V65, P1616; Finlay BB, 1997, MICROBIOL MOL BIOL R, V61, P136, DOI 10.1128/.61.2.136-169.1997; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GAILLARD JL, 1991, CELL, V65, P1127, DOI 10.1016/0092-8674(91)90009-N; Gaillard JL, 1996, J EXP MED, V183, P359, DOI 10.1084/jem.183.2.359; Galan JE, 1996, ANNU REV CELL DEV BI, V12, P221, DOI 10.1146/annurev.cellbio.12.1.221; GUINEBAULT C, 1995, J CELL BIOL, V129, P831, DOI 10.1083/jcb.129.3.831; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HARRISONFINDIK D, 1995, ONCOGENE, V10, P1385; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HERZOG M, 1994, CELL BIOL LAB HDB, P355; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HolgadoMadruga M, 1997, P NATL ACAD SCI USA, V94, P12419, DOI 10.1073/pnas.94.23.12419; Ireton K, 1997, ANNU REV GENET, V31, P113, DOI 10.1146/annurev.genet.31.1.113; Ireton K, 1996, SCIENCE, V274, P780, DOI 10.1126/science.274.5288.780; Kajava AV, 1998, J MOL BIOL, V277, P519, DOI 10.1006/jmbi.1998.1643; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KIM L, 1995, MOL CELL BIOL, V15, P4553; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LINGNAU A, 1995, INFECT IMMUN, V63, P3896, DOI 10.1128/IAI.63.10.3896-3903.1995; Mengaud J, 1996, CELL, V84, P923, DOI 10.1016/S0092-8674(00)81070-3; Missy K, 1998, J BIOL CHEM, V273, P30279, DOI 10.1074/jbc.273.46.30279; NOBES CD, 1995, J CELL SCI, V108, P225; Parida SK, 1998, MOL MICROBIOL, V28, P81, DOI 10.1046/j.1365-2958.1998.00776.x; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; SCHLECH WF, 1983, NEW ENGL J MED, V308, P203, DOI 10.1056/NEJM198301273080407; Sheehan B, 1996, MOL MICROBIOL, V20, P785, DOI 10.1111/j.1365-2958.1996.tb02517.x; Soltoff SP, 1996, J BIOL CHEM, V271, P563, DOI 10.1074/jbc.271.1.563; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7	38	143	152	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17025	17032		10.1074/jbc.274.24.17025	http://dx.doi.org/10.1074/jbc.274.24.17025			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358053	hybrid			2022-12-25	WOS:000080780400052
J	Brix, J; Rudiger, S; Bukau, B; Schneider-Mergener, J; Pfanner, N				Brix, J; Rudiger, S; Bukau, B; Schneider-Mergener, J; Pfanner, N			Distribution of binding sequences for the mitochondrial import receptors Tom20, Tom22, and Tom70 in a presequence-carrying preprotein and a non-cleavable preprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC DIHYDROFOLATE-REDUCTASE; OUTER-MEMBRANE PROTEIN; ADP-ATP CARRIER; 12 AMINO-ACIDS; INNER MEMBRANE; SACCHAROMYCES-CEREVISIAE; YEAST MITOCHONDRIA; PRECURSOR PROTEINS; TARGETING SIGNAL; ADP/ATP CARRIER	Preproteins destined for mitochondria either are synthesized with amino-terminal signal sequences, termed presequences, or possess internal targeting information within the protein. The preprotein translocase of the outer mitochondrial membrane (designated Tom) contains specific import receptors. The cytosolic domains of three import receptors, Tom20, Tom22, and Tom70, have been shown to interact with preproteins. Little is known about the internal targeting information in preproteins and the distribution of binding sequences for the three import receptors, We have studied the binding of the purified cytosolic domains of Tom20, Tom22, and Tom70 to cellulose-bound peptide scans derived from a presequence-carrying cleavable preprotein, cytochrome c oxidase subunit IV, and a non-cleavable preprotein with internal targeting information, the phosphate carrier. All three receptor domains are able to bind efficiently to linear 13-mer peptides, yet with different specificity. Tom20 preferentially binds to presequence segments of subunit IV. Tom22 binds to segments corresponding to the carboxyl-terminal part of the presequence and the amino-terminal part of the mature protein. Tom70 does not bind efficiently to any region of subunit IV. In contrast, Tom70 and Tom20 bind to multiple segments within the phosphate carrier, yet the amino-terminal region is excluded. Both charged and uncharged peptides derived from the phosphate carrier show specific binding properties for Tom70 and Tom20, indicating that charge is not a critical determinant of internal targeting sequences. This feature contrasts with the crucial role of positively charged amino acids in presequences. Our results demonstrate that linear peptide segments of preproteins can serve as binding sites for all three receptors with differential specificity and imply different mechanisms for translocation of cleavable and non-cleavable preproteins.	Univ Freiburg, Inst Biochem & Mol Biol, D-79104 Freiburg, Germany; Humboldt Univ, Univ Klinikum Charite, Inst Med Immunol, D-10098 Berlin, Germany	University of Freiburg; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Pfanner, N (corresponding author), Univ Freiburg, Inst Biochem & Mol Biol, Hermann Herder Str 7, D-79104 Freiburg, Germany.		Rüdiger, Stefan GD/G-4906-2012; Pfanner, Nikolaus/AAV-7878-2021	Rüdiger, Stefan GD/0000-0002-1807-2972; Bukau, Bernd/0000-0003-0521-7199				ADRIAN GS, 1986, MOL CELL BIOL, V6, P626, DOI 10.1128/MCB.6.2.626; ALLISON DS, 1986, P NATL ACAD SCI USA, V83, P9011, DOI 10.1073/pnas.83.23.9011; ARAKAWA H, 1990, J BIOCHEM-TOKYO, V107, P160, DOI 10.1093/oxfordjournals.jbchem.a123001; Arnold I, 1998, J BIOL CHEM, V273, P1469, DOI 10.1074/jbc.273.3.1469; BEDWELL DM, 1987, MOL CELL BIOL, V7, P4038, DOI 10.1128/MCB.7.11.4038; Brix J, 1997, J BIOL CHEM, V272, P20730, DOI 10.1074/jbc.272.33.20730; Davis AJ, 1998, MOL BIOL CELL, V9, P2577, DOI 10.1091/mbc.9.9.2577; Dekker PJT, 1998, MOL CELL BIOL, V18, P6515, DOI 10.1128/MCB.18.11.6515; Dietmeier K, 1997, NATURE, V388, P195, DOI 10.1038/40663; DIETMEIER K, 1993, J BIOL CHEM, V268, P25958; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; ELMOUALIJ B, 1997, YEAST, V13, P578; ENDO T, 1989, J BIOCHEM, V106, P396, DOI 10.1093/oxfordjournals.jbchem.a122864; Folsch H, 1996, EMBO J, V15, P479, DOI 10.1002/j.1460-2075.1996.tb00380.x; FRANK R, 1992, TETRAHEDRON, V48, P9217, DOI 10.1016/S0040-4020(01)85612-X; GLASER SM, 1990, J BIOL CHEM, V265, P8817; GLASER SM, 1990, J BIOL CHEM, V265, P8808; HAHNE K, 1994, CELL, V79, P829, DOI 10.1016/0092-8674(94)90072-8; Hammen PK, 1996, J BIOL CHEM, V271, P21041, DOI 10.1074/jbc.271.35.21041; HASE T, 1983, EMBO J, V2, P2169, DOI 10.1002/j.1460-2075.1983.tb01718.x; Hill K, 1998, NATURE, V395, P516, DOI 10.1038/26780; HONLINGER A, 1995, MOL CELL BIOL, V15, P3382; Horwich A, 1990, CURR OPIN CELL BIOL, V2, P625, DOI 10.1016/0955-0674(90)90103-L; HORWICH AL, 1986, CELL, V44, P451, DOI 10.1016/0092-8674(86)90466-6; HORWICH AL, 1985, EMBO J, V4, P1129, DOI 10.1002/j.1460-2075.1985.tb03750.x; HURT EC, 1985, EMBO J, V4, P3509, DOI 10.1002/j.1460-2075.1985.tb04110.x; HURT EC, 1985, EMBO J, V4, P2061, DOI 10.1002/j.1460-2075.1985.tb03892.x; HURT EC, 1986, TRENDS BIOCHEM SCI, V11, P204, DOI 10.1016/0968-0004(86)90007-1; HURT EC, 1984, FEBS LETT, V178, P306, DOI 10.1016/0014-5793(84)80622-5; JARVIS JA, 1995, J BIOL CHEM, V270, P1323, DOI 10.1074/jbc.270.3.1323; Kaldi K, 1998, EMBO J, V17, P1569, DOI 10.1093/emboj/17.6.1569; KIEBLER M, 1993, CELL, V74, P483, DOI 10.1016/0092-8674(93)80050-O; Komiya T, 1998, EMBO J, V17, P3886, DOI 10.1093/emboj/17.14.3886; Komiya T, 1997, EMBO J, V16, P4267, DOI 10.1093/emboj/16.14.4267; Kramer A, 1998, METH MOL B, V87, P25; Kramer Achim, 1994, Methods (Orlando), V6, P388, DOI 10.1006/meth.1994.1039; LITHGOW T, 1994, P NATL ACAD SCI USA, V91, P11973, DOI 10.1073/pnas.91.25.11973; LIU XQ, 1988, J CELL BIOL, V107, P503, DOI 10.1083/jcb.107.2.503; MAYER A, 1995, EMBO J, V14, P4204, DOI 10.1002/j.1460-2075.1995.tb00094.x; MOCZKO M, 1994, J BIOL CHEM, V269, P9045; NARGANG FE, 1995, EMBO J, V14, P1099, DOI 10.1002/j.1460-2075.1995.tb07093.x; Nelson DR, 1998, J MOL BIOL, V277, P285, DOI 10.1006/jmbi.1997.1594; PALMIERI F, 1994, FEBS LETT, V346, P48, DOI 10.1016/0014-5793(94)00329-7; PFANNER N, 1987, J BIOL CHEM, V262, P14851; PFANNER N, 1987, EMBO J, V6, P3449, DOI 10.1002/j.1460-2075.1987.tb02668.x; Pfanner N, 1997, ANNU REV CELL DEV BI, V13, P25, DOI 10.1146/annurev.cellbio.13.1.25; RAMAGE L, 1993, EMBO J, V12, P4115, DOI 10.1002/j.1460-2075.1993.tb06095.x; RASSOW J, 1990, FEBS LETT, V275, P190, DOI 10.1016/0014-5793(90)81469-5; Reineke U, 1996, MOL DIVERS, V1, P141, DOI 10.1007/BF01544952; ROISE D, 1992, P NATL ACAD SCI USA, V89, P608, DOI 10.1073/pnas.89.2.608; ROISE D, 1986, EMBO J, V5, P1327, DOI 10.1002/j.1460-2075.1986.tb04363.x; ROSPERT S, 1993, FEBS LETT, V335, P358, DOI 10.1016/0014-5793(93)80419-U; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; Ryan MT, 1998, BIOL CHEM, V379, P289; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; Schleiff E, 1998, BIOCHEMISTRY-US, V37, P13052, DOI 10.1021/bi980746y; Schleiff E, 1997, J BIOL CHEM, V272, P17784, DOI 10.1074/jbc.272.28.17784; SCHLEYER M, 1985, CELL, V43, P339, DOI 10.1016/0092-8674(85)90039-X; SCHLOSSMANN J, 1994, J BIOL CHEM, V269, P11893; SCHMID D, 1992, EUR J BIOCHEM, V208, P699, DOI 10.1111/j.1432-1033.1992.tb17237.x; SCHNEIDER H, 1991, SCIENCE, V254, P1659, DOI 10.1126/science.1661031; SMAGULA C, 1988, J BIOL CHEM, V263, P6783; SMAGULA CS, 1988, J CELL BIOCHEM, V36, P323, DOI 10.1002/jcb.240360402; SOLLNER T, 1989, CELL, V59, P1061, DOI 10.1016/0092-8674(89)90762-9; SOLLNER T, 1990, CELL, V62, P107, DOI 10.1016/0092-8674(90)90244-9; STEGER HF, 1990, J CELL BIOL, V111, P2353, DOI 10.1083/jcb.111.6.2353; TAMM LK, 1990, FEBS LETT, V272, P29, DOI 10.1016/0014-5793(90)80441-K; VANLOON APGM, 1987, EMBO J, V6, P2441, DOI 10.1002/j.1460-2075.1987.tb02523.x	68	187	191	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16522	16530		10.1074/jbc.274.23.16522	http://dx.doi.org/10.1074/jbc.274.23.16522			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347216	hybrid			2022-12-25	WOS:000080668600076
J	Xue, HH; Sakaguchi, T; Fujie, M; Ogawa, H; Ichiyama, A				Xue, HH; Sakaguchi, T; Fujie, M; Ogawa, H; Ichiyama, A			Flux of the L-serine metabolism in rabbit, human, and dog livers - Substantial contributions of both mitochondrial and peroxisomal serine : pyruvate/alanine : glyoxylate aminotransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBCELLULAR-DISTRIBUTION; HEPATIC ALANINE; RAT-LIVER; GLYCINE; COMPARTMENTATION; BINDING	L-Serine metabolism in rabbit, dog, and human livers was investigated, focusing on the relative contributions of the three pathways, one initiated by serine dehydratase, another by serine:pyruvate/alanine:glyoxylate aminotransferase (SPT/AGT), and the other involving serine hydroxymethyltransferase and the mitochondrial glycine cleavage enzyme system (GCS), Under quasi-physiological in vitro conditions (1 mM L-serine and 0.25 mar pyruvate), flux through serine dehydratase accounted for only traces, and that through SPT/AGT substantially contributed no matter whether the enzyme was located in peroxisomes (rabbit and human) or largely in mitochondria (dog), As for flux through serine hydroxymethyltransferase and GCS, the conversion of serine to glycine occurred fairly rapidly, followed by GCS-mediated slow decarboxylation of the accumulated glycine, The flux through GCS was relatively high in the dog and low in the rabbit, and only in the dog was it comparable with that through SPT/AGT, An in vivo experiment with L-[3-(3)H,(14)C]serine as the substrate indicated that in rabbit liver, gluconeogenesis from Lserine proceeds mainly via hydroxypyruvate, Because an important role in the conversion of glyoxylate to glycine has been assigned to peroxisomal SPT/AGT from the studies on primary hyperoxaluria type I, these results suggest that SPT/AGT in this organelle plays dual roles in the metabolism of glyoxylate and serine.	Hamamatsu Univ Sch Med, Dept Biochem 1, Shizuoka 4313192, Japan; Hamamatsu Univ Sch Med, Dept Surg 2, Shizuoka 4313192, Japan; Hamamatsu Univ Sch Med, Equipment Ctr, Shizuoka 4313192, Japan; Toyama Med & Pharmaceut Univ, Fac Med, Dept Biochem, Toyama 9300194, Japan	Hamamatsu University School of Medicine; Hamamatsu University School of Medicine; Hamamatsu University School of Medicine; University of Toyama	Ichiyama, A (corresponding author), Hamamatsu Univ Sch Med, Dept Biochem 1, 3600 Handa Cho, Shizuoka 4313192, Japan.			Xue, Hai-Hui/0000-0002-9163-7669				APPLING DR, 1991, FASEB J, V5, P2645, DOI 10.1096/fasebj.5.12.1916088; BELIVEAU GP, 1982, COMP BIOCHEM PHYS B, V71, P13, DOI 10.1016/0305-0491(82)90168-7; BLOXAM DL, 1972, BRIT J NUTR, V27, P233, DOI 10.1079/BJN19720090; DANPURE CJ, 1990, J CELL SCI, V97, P669; DANPURE CJ, 1995, METABOLIC MOL BASES, V2, P2385; FELIG P, 1969, J CLIN INVEST, V48, P584, DOI 10.1172/JCI106017; GELLER AM, 1989, ANAL BIOCHEM, V180, P120, DOI 10.1016/0003-2697(89)90098-5; HARRIS KS, 1980, INVEST UROL, V18, P106; ISHIKAWA E, 1965, J BIOCHEM, V57, P506, DOI 10.1093/oxfordjournals.jbchem.a128109; Ishikawa K, 1996, J BIOCHEM, V119, P970; JOIS M, 1990, J BIOL CHEM, V265, P1246; KEYS AJ, 1978, NATURE, V275, P741, DOI 10.1038/275741a0; KIKUCHI G, 1973, MOL CELL BIOCHEM, V1, P169, DOI 10.1007/BF01659328; MAITRA U, 1964, J BIOL CHEM, V237, P1485; NOGUCHI T, 1978, J BIOL CHEM, V253, P7593; ODA T, 1990, J BIOL CHEM, V265, P7513; PANDE SV, 1978, J BIOL CHEM, V253, P1565; ROWSELL EV, 1979, COMP BIOCHEM PHYS B, V63, P543, DOI 10.1016/0305-0491(79)90061-0; ROWSELL EV, 1972, BIOCHEM J, V127, P155, DOI 10.1042/bj1270155; RYAN WL, 1966, NATURE, V212, P292, DOI 10.1038/212292a0; SNELL K, 1984, ADV ENZYME REGUL, V22, P325, DOI 10.1016/0065-2571(84)90021-9; TAKADA Y, 1982, COMP BIOCHEM PHYS B, V72, P597, DOI 10.1016/0305-0491(82)90512-0; Wagner C, 1996, J NUTR, V126, pS1228, DOI 10.1093/jn/126.suppl_4.1228S; Xue HH, 1999, J BIOL CHEM, V274, P16020, DOI 10.1074/jbc.274.23.16020; YANAGISAWA M, 1983, BIOCH METABOLIC PROC, P413	25	49	49	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16028	16033		10.1074/jbc.274.23.16028	http://dx.doi.org/10.1074/jbc.274.23.16028			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347152	hybrid, Green Submitted			2022-12-25	WOS:000080668600012
J	Johnson, KJ; Sage, H; Briscoe, G; Erickson, HP				Johnson, KJ; Sage, H; Briscoe, G; Erickson, HP			The compact conformation of fibronectin is determined by intramolecular ionic interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLASMA FIBRONECTIN; RESONANCE SPIN-LABEL; CIRCULAR-DICHROISM; ELECTRON-MICROSCOPY; SELF-ASSOCIATION; HEPARIN-BINDING; CELLS; STABILITY; FRAGMENTS; STRENGTH	Fibronectin exists in a compact or extended conformation, depending upon environmental pH and salt concentration. Using recombinant fragments expressed in bacteria and baculovirus, we determined the domains responsible for producing fibronectin's compact conformation. Our velocity and equilibrium sedimentation data show that FN2-14 (a protein containing FN-III domains 2 through 14) forms dimers in low salt. Experiments with smaller fragments indicates that the compact conformation is produced by binding of FN12-14 of one subunit to FN2-3 of the other subunit in the dimer, The binding is weakened at higher salt concentrations, implying an electrostatic interaction. Furthermore, segment FN7-14+A, which contains the alternatively spliced A domain between FN11 and 12, forms dimers, whereas FN7-14 without A does not. Segment FN12-14+A also forms dimers, but the isolated A domain does not. These data imply an association of domain A with FN12-14, and the presence of A may favor an open conformation by competing with FN2-3 for binding to FN12-14.	Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University; Duke University	Erickson, HP (corresponding author), Duke Univ, Med Ctr, Dept Cell Biol, 365 Sands Bldg,Box 3011, Durham, NC 27710 USA.			Johnson, Kamin/0000-0003-4550-5566	NATIONAL CANCER INSTITUTE [R37CA047056, R01CA047056] Funding Source: NIH RePORTER; NCI NIH HHS [CA47056] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA SK, 1985, J BIOL CHEM, V260, P3256; ALEXANDER SS, 1979, J BIOL CHEM, V254, P1501; ANKEL EG, 1986, ARCH BIOCHEM BIOPHYS, V244, P50, DOI 10.1016/0003-9861(86)90093-7; AOTA S, 1994, J BIOL CHEM, V269, P24756; BOWDITCH RD, 1991, J BIOL CHEM, V266, P23323; BUSBY TF, 1995, J BIOL CHEM, V270, P18558, DOI 10.1074/jbc.270.31.18558; Carnemolla B, 1996, BIOCHEM CELL BIOL, V74, P745, DOI 10.1139/o96-081; CASTELLANI P, 1986, J CELL BIOL, V103, P1671, DOI 10.1083/jcb.103.5.1671; EHRISMANN R, 1982, J BIOL CHEM, V257, P7381; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; ERICKSON HP, 1989, J MOL BIOL, V206, P465, DOI 10.1016/0022-2836(89)90494-4; ERICKSON HP, 1983, J BIOL CHEM, V258, P4539; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; Grant RP, 1997, J BIOL CHEM, V272, P6159, DOI 10.1074/jbc.272.10.6159; HAYASHI M, 1983, J BIOL CHEM, V258, P3332; Hino K, 1996, ARTHRITIS RHEUM, V39, P1685, DOI 10.1002/art.1780391011; HOMANDBERG GA, 1986, BIOCHEMISTRY-US, V25, P6917, DOI 10.1021/bi00370a027; HORMANN H, 1982, KLIN WOCHENSCHR, V60, P1265, DOI 10.1007/BF01727483; Hynes RO, 1990, FIBRONECTINS; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; LAI CS, 1993, J MOL BIOL, V230, P625, DOI 10.1006/jmbi.1993.1174; LAI CS, 1984, BIOCHEMISTRY-US, V23, P6393, DOI 10.1021/bi00321a017; Leahy DJ, 1996, CELL, V84, P155, DOI 10.1016/S0092-8674(00)81002-8; Manabe R, 1997, J CELL BIOL, V139, P295, DOI 10.1083/jcb.139.1.295; MARKOVIC Z, 1983, H-S Z PHYSIOL CHEM, V364, P1795, DOI 10.1515/bchm2.1983.364.2.1795; ODERMATT E, 1982, J MOL BIOL, V159, P109, DOI 10.1016/0022-2836(82)90034-1; PETERSEN TE, 1983, P NATL ACAD SCI-BIOL, V80, P137, DOI 10.1073/pnas.80.1.137; ROCCO M, 1983, J BIOL CHEM, V258, P4545; ROCCO M, 1984, FEBS LETT, V178, P327, DOI 10.1016/0014-5793(84)80627-4; Sambrook J., 2002, MOL CLONING LAB MANU; SCHWARZBAUER JE, 1987, EMBO J, V6, P2673; SEKIGUCHI K, 1986, BIOCHEMISTRY-US, V25, P4936, DOI 10.1021/bi00365a032; WILLIAMS EC, 1982, J BIOL CHEM, V257, P4973; ZARDI L, 1987, EMBO J, V6, P2337, DOI 10.1002/j.1460-2075.1987.tb02509.x	34	155	156	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15473	15479		10.1074/jbc.274.22.15473	http://dx.doi.org/10.1074/jbc.274.22.15473			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336438	hybrid			2022-12-25	WOS:000080560100027
J	Oh, HJ; Easton, D; Murawski, M; Kaneko, Y; Subjeck, JR				Oh, HJ; Easton, D; Murawski, M; Kaneko, Y; Subjeck, JR			The chaperoning activity of hsp110 - Identification of functional domains by use of targeted deletions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; SECONDARY STRUCTURE PREDICTION; REGULATED STRESS PROTEIN; PEPTIDE-BINDING DOMAIN; AMINO-ACID-ANALOGS; ENDOPLASMIC-RETICULUM; MOLECULAR CHAPERONES; NONNATIVE PROTEIN; SUBSTRATE-BINDING; LARGE HSP70-LIKE	hsp110 is one of major heat shock proteins of eukaryotic cells and is a diverged relative of the hsp70 family. It has been previously shown that hsp110 maintains heat-denatured luciferase in a soluble, folding competent state and also confers cellular heat resistance in vivo. In the present study the functional domains of hsp110 that are responsible for its chaperoning activity are identified by targeted deletion mutagenesis using the DnaK structure as the model. The chaperoning activity of mutants is assessed based on their ability to solubilize heat-denatured luciferase as well as to refold luciferase in the presence of rabbit reticulocyte lysate. It is shown that these functions require only an internal region of hsp110 that includes the predicted peptide binding domain and two immediately adjacent C-terminal domains. It is also shown that although hsp110 binds ATP, binding can be blocked by its C-terminal region.	Roswell Pk Canc Inst, Dept Mol & Cellular Biophys, Buffalo, NY 14263 USA; SUNY Coll Buffalo, Dept Biol, Buffalo, NY 14222 USA	Roswell Park Cancer Institute; State University of New York (SUNY) System; Buffalo State College	Subjeck, JR (corresponding author), Roswell Pk Canc Inst, Dept Mol & Cellular Biophys, Buffalo, NY 14263 USA.		Easton, Douglas/A-9359-2009; Easton, Douglas/AAU-4216-2020	Easton, Douglas/0000-0003-4288-0774; Easton, Douglas/0000-0003-4288-0774; Oh, Kelly/0000-0001-8203-5247	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045994] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45994] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Boice JA, 1997, J BIOL CHEM, V272, P24825, DOI 10.1074/jbc.272.40.24825; BRODSKY JL, 1993, J CELL BIOL, V120, P95, DOI 10.1083/jcb.120.1.95; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Chen X, 1996, FEBS LETT, V380, P68, DOI 10.1016/0014-5793(96)00011-7; Chung KS, 1998, GENE, V210, P143, DOI 10.1016/S0378-1119(98)00061-4; CRAIG EA, 1985, MOL CELL BIOL, V5, P3517, DOI 10.1128/MCB.5.12.3517; Craven RA, 1997, TRENDS CELL BIOL, V7, P277, DOI 10.1016/S0962-8924(97)01079-9; Depiereux E, 1997, COMPUT APPL BIOSCI, V13, P249; Dierks T, 1996, EMBO J, V15, P6931, DOI 10.1002/j.1460-2075.1996.tb01085.x; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; FOLTZ KR, 1993, SCIENCE, V259, P1421, DOI 10.1126/science.8383878; FREEMAN BC, 1995, EMBO J, V14, P2281, DOI 10.1002/j.1460-2075.1995.tb07222.x; Freeman BC, 1996, EMBO J, V15, P2969, DOI 10.1002/j.1460-2075.1996.tb00660.x; GAO BC, 1991, J BIOL CHEM, V266, P19565; GLICK BS, 1995, CELL, V80, P11, DOI 10.1016/0092-8674(95)90444-1; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HIGHTOWER LE, 1980, J CELL PHYSIOL, V102, P407, DOI 10.1002/jcp.1041020315; Johnson JL, 1997, CELL, V90, P201, DOI 10.1016/S0092-8674(00)80327-X; Kaneko Y, 1997, J BIOL CHEM, V272, P2640, DOI 10.1074/jbc.272.5.2640; Kaneko Y, 1997, GENE, V189, P19, DOI 10.1016/S0378-1119(96)00807-4; Kojima R, 1996, J BIOL CHEM, V271, P12327, DOI 10.1074/jbc.271.21.12327; LANDRY J, 1982, CANCER RES, V42, P2457; Lee GJ, 1997, EMBO J, V16, P659, DOI 10.1093/emboj/16.3.659; LEEYOON D, 1995, J BIOL CHEM, V270, P15725, DOI 10.1074/jbc.270.26.15725; LEVINSON W, 1980, BIOCHIM BIOPHYS ACTA, V606, P170, DOI 10.1016/0005-2787(80)90108-2; LI GC, 1992, P NATL ACAD SCI USA, V89, P2036, DOI 10.1073/pnas.89.6.2036; LI GC, 1985, J CELL PHYSIOL, V122, P91, DOI 10.1002/jcp.1041220114; LIN HY, 1993, MOL BIOL CELL, V4, P1109, DOI 10.1091/mbc.4.11.1109; Mauk R, 1997, DEV BIOL, V184, P31, DOI 10.1006/dbio.1997.8512; MILARSKI KL, 1989, J CELL BIOL, V109, P1947, DOI 10.1083/jcb.109.5.1947; MOROZOV A, 1995, FEBS LETT, V371, P214, DOI 10.1016/0014-5793(95)00884-C; MUKAI H, 1993, GENE, V132, P57; Oh HJ, 1997, J BIOL CHEM, V272, P31636, DOI 10.1074/jbc.272.50.31636; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; RUTHERFORD SL, 1994, CELL, V79, P1129, DOI 10.1016/0092-8674(94)90003-5; Storozhenko S, 1996, FEBS LETT, V390, P113, DOI 10.1016/0014-5793(96)00640-0; SUBJECK JR, 1982, HEAT SHOCK BACTERIA, P405; TOMASOVIC SP, 1983, RADIAT RES, V95, P399, DOI 10.2307/3576265; TSAI MY, 1994, J BIOL CHEM, V269, P5958; WANG TF, 1993, J BIOL CHEM, V268, P26049; WELCH WJ, 1983, J BIOL CHEM, V258, P7102; YASUDA K, 1995, J BIOL CHEM, V270, P29718, DOI 10.1074/jbc.270.50.29718; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	44	112	115	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15712	15718		10.1074/jbc.274.22.15712	http://dx.doi.org/10.1074/jbc.274.22.15712			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336470	hybrid			2022-12-25	WOS:000080560100059
J	Hirohashi, T; Suzuki, H; Sugiyama, Y				Hirohashi, T; Suzuki, H; Sugiyama, Y			Characterization of the transport properties of cloned rat multidrug resistance-associated protein 3 (MRP3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORGANIC-ANION TRANSPORTER; CONJUGATE EXPORT PUMP; EISAI HYPERBILIRUBINEMIC RATS; PRIMARY ACTIVE-TRANSPORT; DUBIN-JOHNSON-SYNDROME; CANCER CELL-LINES; CANALICULAR MEMBRANE; DEPENDENT TRANSPORT; BILIARY-EXCRETION; LEUKOTRIENE C-4	We have previously cloned rat MRP3 as an inducible transporter in the liver (Hirohashi, T,, Suzuki, H., Ito, K,, Ogawa, K,, Kume, K,, Shimizu, T,, and Sugiyama, Y, (1998) Mol. Pharmacol, 53, 1068-1075), In the present study, the function of rat MRP3 was investigated using membrane vesicles isolated from LLC-PK1 and HeLa cell population transfected with corresponding cDNA, The ATP-dependent uptake of both 17 beta estradiol 17-beta-D-glucuronide ([H-3]E(2)17 beta G) and glucuronide of [C-14] 6-hydroxy-5,7- dimethyl-2-methylamino-4- (3-pyridylmethyl) benzothiazole (E3040), but not that of [H-3]leukotriene C-4 and [H-3]2,4-dinitrophenyl-S-glutathione, was markedly stimulated by MRP3 transfection in both cell lines. The K-m and V-max values for the uptake of [H-3]E(2)17 beta G were 67 +/- 14 mu M and 415 +/- 73 pmol/min/mg of protein, respectively, for MRP3-expressing membrane vesicles and 3.0 +/- 0.7 mu M and 3.4 +/- 0.4 pmol/min/mg of protein, respectively, for the endogenous transporter expressed on HeLa cells. [H-3]E(2)17 beta G had also a similar K-m value for MRP3 when LLC-PK1 cells were used as the host. All glucuronide conjugates examined (E3040 glucuronide, 4-methylumbelliferone glucuronide, and naphthyl glucuronide) and methotrexate inhibited MRP3-mediated [H-3]E(2)17 beta G transport in LLC-PK1 cells, Moreover, [H-3]methotrexate was transported via MRP3, The inhibitory effect of estrone sulfate, [H-3]2,4-dinitrophenyl-S-glutathione, and [H-3]leukotriene C-4 was moderate or minimal, whereas N-acetyl-2,4-dinitrophenylcysteine had no effect on the uptake of [H-3]E(2)17 beta G. The uptake of [H-3]E(2)17 beta G was enhanced by E3040 sulfate and 4-methylumbelliferone sulfate. Thus we were able to demonstrate that several kinds of organic anions are transported via MRP3, although the substrate specificity of MRP3 differs from that of MRP1 and cMOAT/MRP2 in that glutathione conjugates are poor substrates for MRP3.	Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo	Suzuki, H (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan.							Buchler M, 1996, J BIOL CHEM, V271, P15091; Deeley RG, 1997, SEMIN CANCER BIOL, V8, P193, DOI 10.1006/scbi.1997.0070; DEVRIES MH, 1989, N-S ARCH PHARMACOL, V340, P588, DOI 10.1007/BF00260615; DEVRIES MH, 1989, N-S ARCH PHARMACOL, V340, P239, DOI 10.1007/BF00168975; ELFERINK RPJO, 1995, BBA-REV BIOMEMBRANES, V1241, P215, DOI 10.1016/0304-4157(95)00006-D; Evers R, 1998, J CLIN INVEST, V101, P1310, DOI 10.1172/JCI119886; HINCHMAN CA, 1991, J BIOL CHEM, V266, P22179; Hirohashi T, 1998, MOL PHARMACOL, V53, P1068; Hirohashi Tomoko, 1997, Pharmaceutical Research (New York), V14, pS458; ISHIKAWA T, 1990, J BIOL CHEM, V265, P19279; Ishikawa T, 1997, BIOSCIENCE REP, V17, P189, DOI 10.1023/A:1027385513483; Ito K, 1997, AM J PHYSIOL-GASTR L, V272, pG16, DOI 10.1152/ajpgi.1997.272.1.G16; Ito K, 1998, J BIOL CHEM, V273, P1684, DOI 10.1074/jbc.273.3.1684; Jedlitschky G, 1996, CANCER RES, V56, P988; Keppler D, 1997, FASEB J, V11, P509, DOI 10.1096/fasebj.11.7.9212074; Kiuchi Y, 1998, FEBS LETT, V433, P149, DOI 10.1016/S0014-5793(98)00899-0; KOBAYASHI K, 1990, J BIOL CHEM, V265, P7737; Koike K, 1997, CANCER RES, V57, P5475; Kool M, 1997, CANCER RES, V57, P3537; LEIER I, 1994, J BIOL CHEM, V269, P27807; Loe DW, 1996, J BIOL CHEM, V271, P9683, DOI 10.1074/jbc.271.16.9683; Loe DW, 1996, J BIOL CHEM, V271, P9675, DOI 10.1074/jbc.271.16.9675; Madon J, 1997, FEBS LETT, V406, P75, DOI 10.1016/S0014-5793(97)00245-7; Masuda M, 1997, CANCER RES, V57, P3506; MULLER M, 1994, P NATL ACAD SCI USA, V91, P13033, DOI 10.1073/pnas.91.26.13033; Niinuma K, 1997, J PHARMACOL EXP THER, V282, P866; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Paulusma CC, 1997, HEPATOLOGY, V25, P1539, DOI 10.1002/hep.510250635; Paulusma CC, 1996, SCIENCE, V271, P1126, DOI 10.1126/science.271.5252.1126; Saxena M, 1996, BIOCHEM J, V320, P273, DOI 10.1042/bj3200273; SCHINKEL AH, 1994, CELL, V77, P491, DOI 10.1016/0092-8674(94)90212-7; SCHWENK M, 1982, ARCH PHARM, V321, P223; Stride BD, 1996, MOL PHARMACOL, V49, P962; TAKENAKA O, 1995, J PHARMACOL EXP THER, V274, P1362; Taniguchi K, 1996, CANCER RES, V56, P4124; van Aubel RAMH, 1998, MOL PHARMACOL, V53, P1062; Wada M, 1998, HUM MOL GENET, V7, P203, DOI 10.1093/hmg/7.2.203; Yamazaki M, 1996, PHARMACEUT RES, V13, P497, DOI 10.1023/A:1016077517241	38	298	306	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					15181	15185		10.1074/jbc.274.21.15181	http://dx.doi.org/10.1074/jbc.274.21.15181			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329726	hybrid			2022-12-25	WOS:000081965200091
J	Olsson, C; Riebeck, K; Dohlsten, M; Michaelsson, E				Olsson, C; Riebeck, K; Dohlsten, M; Michaelsson, E			CTLA-4 ligation suppresses CD28-induced NF-kappa B and AP-1 activity in mouse T cell blasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE PHOSPHATIDYLINOSITOL 3-KINASE; TRANSCRIPTION FACTORS; IN-VIVO; CD28; ACTIVATION; RECEPTOR; BINDING; COSTIMULATION; PROTEINS; ALPHA	The effects of cytotoxic lymphocyte antigen 4 (CTLA-4) on CD3/CD28 monoclonal antibody (mAb) activation of CD4(+)/CTLA-4(+) blastoid T cells were studied in an in vitro model system. As previously reported, coligation of CTLA-4 mAb results in suppression of T cell proliferation and cytokine production. The proliferation but not the interleukin 2 (IL-2) production could be restored by addition of exogenous IL-2, suggesting that the inhibitory effect occurred at the level of IL-2 production rather than at the regulation of the IL-2 receptor pathway. To study the effects on nuclear factors critical for T cell activation, we analyzed the levels of the transcription factors NF-kappa B and AP-1. These were potently induced in CD3/CD28 mAb-restimulated T cells. In contrast, CTLA-4 ligation strongly suppressed the induction of both transcription factors. The compositions of NF-kappa B and AP-1 family members were similar, irrespective of stimulation conditions. Analyses of the NF-kappa B regulator I kappa B-alpha revealed similar levels of I kappa B-alpha protein in the preparations. However, a reduced phosphorylation of I kappa B-alpha in CTLA-4 coengaged T cell blasts compared with T cells ligated with CD3/CD28 was-found. Previous studies have concluded that CTLA-4 ligation regulates T cell activation by inhibiting the T cell receptor-mediated signals, However, the present findings propose that the major impact of CTLA-4 ligation is inhibition of signals mediated by CD28.	Act Biotech Res AB, SE-22007 Lund, Sweden; Malmo Univ Hosp, Dept Med Microbiol, SE-22007 Lund, Sweden; Univ Lund, Dept Cell & Mol Biol, Sect Tumor Immunol, Wallenberg Lab, SE-22007 Lund, Sweden	Lund University; Skane University Hospital; Lund University	Olsson, C (corresponding author), Act Biotech Res AB, POB 724, SE-22007 Lund, Sweden.			Riesbeck, Kristian/0000-0001-6274-6965; Michaelsson, Erik/0000-0001-8643-2821				Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Calvo CR, 1997, J EXP MED, V186, P1645, DOI 10.1084/jem.186.10.1645; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; Cefai D, 1998, J IMMUNOL, V160, P2223; Fallarino F, 1998, J EXP MED, V188, P205, DOI 10.1084/jem.188.1.205; Finn PW, 1997, J IMMUNOL, V158, P4074; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Greene JAL, 1996, J BIOL CHEM, V271, P26762, DOI 10.1074/jbc.271.43.26762; Hutchcroft JE, 1996, J IMMUNOL, V156, P4071; HUTCHCROFT JE, 1995, P NATL ACAD SCI USA, V92, P8808, DOI 10.1073/pnas.92.19.8808; JAIN JN, 1993, J IMMUNOL, V151, P837; Kariv I, 1996, J IMMUNOL, V157, P29; Krummel MF, 1996, INT IMMUNOL, V8, P519, DOI 10.1093/intimm/8.4.519; Krummel MF, 1996, J EXP MED, V183, P2533, DOI 10.1084/jem.183.6.2533; KRUMMEL MF, 1995, J EXP MED, V182, P459, DOI 10.1084/jem.182.2.459; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Lenschow DJ, 1996, ANNU REV IMMUNOL, V14, P233, DOI 10.1146/annurev.immunol.14.1.233; LEUNG HT, 1995, J BIOL CHEM, V270, P25107, DOI 10.1074/jbc.270.42.25107; Lin H, 1998, J EXP MED, V188, P199, DOI 10.1084/jem.188.1.199; LINSLEY PS, 1992, J EXP MED, V176, P1595, DOI 10.1084/jem.176.6.1595; Marengere LEM, 1996, SCIENCE, V272, P1170, DOI 10.1126/science.272.5265.1170; Olsson C, 1998, INT IMMUNOL, V10, P499, DOI 10.1093/intimm/10.4.499; PAGES F, 1994, NATURE, V369, P327, DOI 10.1038/369327a0; Perkins D, 1996, J IMMUNOL, V156, P4154; PRASAD KVS, 1994, P NATL ACAD SCI USA, V91, P2834, DOI 10.1073/pnas.91.7.2834; RINCON M, 1994, EMBO J, V13, P4370, DOI 10.1002/j.1460-2075.1994.tb06757.x; SCHNEIDER H, 1995, J EXP MED, V181, P351, DOI 10.1084/jem.181.1.351; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SERFLING E, 1995, BBA-GENE STRUCT EXPR, V1263, P181, DOI 10.1016/0167-4781(95)00112-T; Sundstedt A, 1996, P NATL ACAD SCI USA, V93, P979, DOI 10.1073/pnas.93.3.979; TIVOL EA, 1995, IMMUNITY, V3, P541, DOI 10.1016/1074-7613(95)90125-6; Walunas TL, 1996, J EXP MED, V183, P2541, DOI 10.1084/jem.183.6.2541; WALUNAS TL, 1994, IMMUNITY, V1, P405, DOI 10.1016/1074-7613(94)90071-X; Ward SG, 1996, BIOCHEM J, V318, P361, DOI 10.1042/bj3180361; WATERHOUSE P, 1995, SCIENCE, V270, P985, DOI 10.1126/science.270.5238.985; Wu Y, 1997, J EXP MED, V185, P1327, DOI 10.1084/jem.185.7.1327	38	59	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					14400	14405		10.1074/jbc.274.20.14400	http://dx.doi.org/10.1074/jbc.274.20.14400			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318864	hybrid			2022-12-25	WOS:000080322200093
J	Corradin, S; Mauel, J; Ransijn, A; Sturzinger, C; Vergeres, G				Corradin, S; Mauel, J; Ransijn, A; Sturzinger, C; Vergeres, G			Down-regulation of MARCKS-related protein (MRP) in macrophages infected with Leishmania	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ABNORMAL BRAIN-DEVELOPMENT; NECROSIS-FACTOR-ALPHA; KINASE-C; DONOVANI LIPOPHOSPHOGLYCAN; TYROSINE PHOSPHORYLATION; INDEPENDENT PATHWAYS; INTERFERON-GAMMA; MAJOR SUBSTRATE; GROWTH-FACTOR; IFN-GAMMA	Leishmania, a protozoan parasite of macrophages, has been shown to interfere with host cell signal transduction pathways including protein kinase C (PKC)-dependent signaling. Myristoylated alanine-rich C kinase substrate (MARCKS) and MARCKS-related protein (MRP, MacMARCKS) are PKC substrates in diverse cell types, MARCKS and MRP are thought to regulate the actin network and thereby participate in cellular responses involving cytoskeletal rearrangement. Because MRP is a major PKC substrate in macrophages, we examined its expression in response to infection by Leishmania, Activation of murine macrophages by cytokines increased MRP expression as determined by Western blot analysis. Infection with Leishmania promastigotes at the time of activation or up to 48 h postactivation strongly decreased MRP levels. Leishmania-dependent MRP depletion was confirmed by [H-3]myristate labeling and by immunofluorescence microscopy. All species or strains of Leishmania parasites tested, including lipophosphoglycan-deficient Leishmania major L119, decreased MRP levels. MRP depletion was not obtained with other phagocytic stimuli including zymosan, latex beads, or heat-killed Streptococcus mitis, a Gram-positive bacterium. Experiments with [H-3]myristate labeled proteins revealed the appearance of lower molecular weight fragments in Leishmania-infected cells suggesting that MRP depletion may be due to proteolytic degradation.	Univ Lausanne, Inst Biochem, CH-1066 Epalinges, Switzerland; Univ Basel, Biozentrum, Dept Biophys Chem, CH-4056 Basel, Switzerland	University of Lausanne; University of Basel	Corradin, S (corresponding author), Univ Lausanne, Inst Biochem, Chemin Boveresses 155, CH-1066 Epalinges, Switzerland.							ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; Aderem A, 1992, Curr Top Microbiol Immunol, V181, P189; ADEREM AA, 1988, P NATL ACAD SCI USA, V85, P6310, DOI 10.1073/pnas.85.17.6310; ADEREM AA, 1988, NATURE, V332, P362, DOI 10.1038/332362a0; ADEREM AA, 1986, P NATL ACAD SCI USA, V83, P5817, DOI 10.1073/pnas.83.16.5817; ALLEN LAH, 1995, J EXP MED, V182, P829, DOI 10.1084/jem.182.3.829; BEHIN R, 1979, EXP PARASITOL, V48, P81, DOI 10.1016/0014-4894(79)90057-2; BERENS RL, 1978, J PARASITOL, V64, P160, DOI 10.2307/3279633; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BLACKSHEAR PJ, 1985, J BIOL CHEM, V260, P3304; Bogdan C, 1996, CURR OPIN IMMUNOL, V8, P517, DOI 10.1016/S0952-7915(96)80040-9; BROOKS SF, 1992, J BIOL CHEM, V267, P14212; CORRADIN SB, 1991, J IMMUNOL, V146, P279; CORRADIN SB, 1991, EUR J IMMUNOL, V21, P2553, DOI 10.1002/eji.1830211036; DESCOTEAUX A, 1992, J IMMUNOL, V149, P3008; DING AH, 1988, J IMMUNOL, V141, P2407; FRANKENBURG S, 1990, J IMMUNOL, V145, P4284; GREEN SJ, 1990, J IMMUNOL, V145, P4290; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; LAUMAS S, 1989, P NATL ACAD SCI USA, V86, P3021, DOI 10.1073/pnas.86.9.3021; Li JX, 1996, J BIOL CHEM, V271, P12985, DOI 10.1074/jbc.271.22.12985; LI JX, 1992, CELL, V70, P791, DOI 10.1016/0092-8674(92)90312-Z; MAUEL J, 1991, J LEUKOCYTE BIOL, V49, P73, DOI 10.1002/jlb.49.1.73; MCNEELY TB, 1987, BIOCHEM BIOPH RES CO, V148, P653, DOI 10.1016/0006-291X(87)90926-0; MEERPOHL HG, 1976, EUR J IMMUNOL, V6, P213, DOI 10.1002/eji.1830060313; MOORE KJ, 1993, J IMMUNOL, V150, P4457; MURRAY PJ, 1990, EXP PARASITOL, V71, P294, DOI 10.1016/0014-4894(90)90034-A; NANDAN D, 1995, INFECT IMMUN, V63, P4495, DOI 10.1128/IAI.63.11.4495-4500.1995; OLIVIER M, 1992, P NATL ACAD SCI USA, V89, P7481, DOI 10.1073/pnas.89.16.7481; OLIVIER M, 1992, J IMMUNOL, V148, P1188; REINER NE, 1994, IMMUNOL TODAY, V15, P374, DOI 10.1016/0167-5699(94)90176-7; Rittig MG, 1998, INFECT IMMUN, V66, P4331; Rose SD, 1996, J NEUROSCI RES, V44, P235; ROSEN A, 1990, J EXP MED, V172, P1211, DOI 10.1084/jem.172.4.1211; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P7244, DOI 10.1073/pnas.80.23.7244; Schleiff E, 1996, J BIOL CHEM, V271, P26794, DOI 10.1074/jbc.271.43.26794; Spizz G, 1997, J BIOL CHEM, V272, P23833, DOI 10.1074/jbc.272.38.23833; Spizz G, 1996, J BIOL CHEM, V271, P553, DOI 10.1074/jbc.271.1.553; STUMPO DJ, 1995, P NATL ACAD SCI USA, V92, P944, DOI 10.1073/pnas.92.4.944; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; Underhill DM, 1998, J BIOL CHEM, V273, P33619, DOI 10.1074/jbc.273.50.33619; VALMORI D, 1992, J IMMUNOL, V149, P717; VERGERES G, 1995, J BIOL CHEM, V270, P19879, DOI 10.1074/jbc.270.34.19879; WOLFMAN A, 1987, J BIOL CHEM, V262, P16546; Wu M, 1996, P NATL ACAD SCI USA, V93, P2110, DOI 10.1073/pnas.93.5.2110; ZHU ZX, 1995, J BIOL CHEM, V270, P17652, DOI 10.1074/jbc.270.30.17652	46	35	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16782	16787		10.1074/jbc.274.24.16782	http://dx.doi.org/10.1074/jbc.274.24.16782			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358020	hybrid			2022-12-25	WOS:000080780400019
J	Deltour, L; Foglio, MH; Duester, G				Deltour, L; Foglio, MH; Duester, G			Metabolic deficiencies in alcohol dehydrogenase Adh1, Adh3, and Adh4 null mutant mice - Overlapping roles of Adh1 and Adh4 in ethanol clearance and metabolism of retinol to retinoic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-III ALCOHOL; DEPENDENT FORMALDEHYDE DEHYDROGENASE; CLASS-I; ALCOHOL/RETINOL DEHYDROGENASES; MOLECULAR-PROPERTIES; EXPRESSION PATTERNS; NUCLEOTIDE-SEQUENCE; MOUSE; GENE; INHIBITION	Targeting of mouse alcohol dehydrogenase genes Adh1, Adh3, and Adh4 resulted in null mutant mice that all developed and reproduced apparently normally but differed markedly in clearance of ethanol and formaldehyde plus metabolism of retinol to the signaling molecule retinoic acid. Following administration of an intoxicating dose of ethanol, Adh1 -/- mice, and to a lesser extent Adh4 -/- mice, but not Adh3 -/- mice, displayed significant reductions in blood ethanol clearance. Ethanol-induced sleep was significantly longer only in Adh1 -/- mice. The incidence of embryonic resorption following ethanol administration was increased S-fold in Adh1 -/- mice and 1.5-fold in Adh4 -/- mice but was unchanged in Adh3 -/- mice. Formaldehyde toxicity studies revealed that only Adh3 -/- mice had a significantly reduced LD,, value. Retinoic acid production following retinol administration was reduced 4.8-fold in Adh1 -/- mice and 8.5-fold in Adh4 -/- mice. Thus, Adh1 and Adh4 demonstrate overlapping functions in ethanol and retinol metabolism in vivo, whereas Adh3 plays no role with these substrates but instead functions in formaldehyde metabolism. Redundant roles for Adh1 and Adh4 in retinoic acid production may explain the apparent normal development of mutant mice.	Burnham Inst, Gene Regulat Program, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Duester, G (corresponding author), Burnham Inst, Gene Regulat Program, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.			Duester, Gregg/0000-0003-4335-3650	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA009731] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA09731] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ALGAR EM, 1983, EUR J BIOCHEM, V137, P139, DOI 10.1111/j.1432-1033.1983.tb07807.x; Allali-Hassani A, 1998, FEBS LETT, V426, P362, DOI 10.1016/S0014-5793(98)00374-3; Ang HL, 1996, ALCOHOL CLIN EXP RES, V20, P1050, DOI 10.1111/j.1530-0277.1996.tb01946.x; Ang HL, 1996, J BIOL CHEM, V271, P9526, DOI 10.1074/jbc.271.16.9526; BURNETT KG, 1980, BIOCHEM PHARMACOL, V29, P125, DOI 10.1016/0006-2952(80)90318-4; CECI JD, 1987, GENE, V59, P171, DOI 10.1016/0378-1119(87)90325-8; CECI JD, 1986, GENE, V41, P217, DOI 10.1016/0378-1119(86)90101-0; CHAI XY, 1995, J BIOL CHEM, V270, P3900, DOI 10.1074/jbc.270.8.3900; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; COLLINS MD, 1992, ARCH TOXICOL, V66, P652, DOI 10.1007/BF01981505; CONNOR MJ, 1987, BIOCHEM J, V244, P489, DOI 10.1042/bj2440489; Deltour L, 1996, FASEB J, V10, P1050, DOI 10.1096/fasebj.10.9.8801166; Deltour L, 1997, BIOL REPROD, V56, P102, DOI 10.1095/biolreprod56.1.102; DELTOUR L, 1999, IN PRESS DEV GENET; Duester G, 1996, BIOCHEMISTRY-US, V35, P12221, DOI 10.1021/bi961176+; DUESTER G, 1991, ALCOHOL CLIN EXP RES, V15, P568, DOI 10.1111/j.1530-0277.1991.tb00562.x; DUESTER G, 1999, IN PRESS BIOCH PHARM; Ferguson RA, 1997, CLIN CHIM ACTA, V257, P199, DOI 10.1016/S0009-8981(96)06444-3; Foglio MH, 1996, EUR J BIOCHEM, V237, P496, DOI 10.1111/j.1432-1033.1996.0496k.x; Goate AM, 1998, CURR OPIN GENET DEV, V8, P282, DOI 10.1016/S0959-437X(98)80082-8; Gough WH, 1998, J BIOL CHEM, V273, P19778, DOI 10.1074/jbc.273.31.19778; Han CL, 1998, EUR J BIOCHEM, V254, P25, DOI 10.1046/j.1432-1327.1998.2540025.x; Haselbeck RJ, 1997, ALCOHOL CLIN EXP RES, V21, P1484; Haselbeck RJ, 1998, ALCOHOL CLIN EXP RES, V22, P1607, DOI 10.1111/j.1530-0277.1998.tb03955.x; Haselbeck RJ, 1997, ENDOCRINOLOGY, V138, P3035, DOI 10.1210/en.138.7.3035; Haselbeck RJ, 1997, DEV DYNAM, V208, P447, DOI 10.1002/(SICI)1097-0177(199704)208:4<447::AID-AJA1>3.0.CO;2-I; Haselbeck RJ, 1998, DEV DYNAM, V213, P114, DOI 10.1002/(SICI)1097-0177(199809)213:1<114::AID-AJA11>3.0.CO;2-2; Hogan B, 1994, MANIPULATING MOUSE E; HOLMES RS, 1981, J EXP ZOOL, V217, P151, DOI 10.1002/jez.1402170202; HOLMES RS, 1977, GENETICS, V87, P709; HOLMQUIST B, 1991, BIOCHEM BIOPH RES CO, V178, P1371, DOI 10.1016/0006-291X(91)91045-E; JORNVALL H, 1995, ADV EXP MED BIOL, V372, P281; Joyner AL, 1993, GENE TARGETING PRACT; Kaufman M.H., 1992, ATLAS MOUSE DEV; Kedishvili NY, 1998, BIOCHEM BIOPH RES CO, V249, P191, DOI 10.1006/bbrc.1998.9105; Martinez MC, 1996, EUR J BIOCHEM, V241, P849, DOI 10.1111/j.1432-1033.1996.00849.x; Mertz JR, 1997, J BIOL CHEM, V272, P11744, DOI 10.1074/jbc.272.18.11744; Miyakawa T, 1997, SCIENCE, V278, P698, DOI 10.1126/science.278.5338.698; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SIMON A, 1995, J BIOL CHEM, V270, P1107, DOI 10.1074/jbc.270.34.19979; VOELKER RA, 1980, P NATL ACAD SCI-BIOL, V77, P1091, DOI 10.1073/pnas.77.2.1091; WEHNER EP, 1993, MOL GEN GENET, V237, P351, DOI 10.1007/BF00279438; Yamamoto M, 1998, DEV BRAIN RES, V107, P103, DOI 10.1016/S0165-3806(98)00003-0; ZgombicKnight M, 1997, GENOMICS, V41, P105, DOI 10.1006/geno.1997.4637; ZGOMBICKNIGHT M, 1995, J BIOL CHEM, V270, P10868, DOI 10.1074/jbc.270.18.10868; ZHANG K, 1987, GENE, V57, P27, DOI 10.1016/0378-1119(87)90173-9	46	143	151	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16796	16801		10.1074/jbc.274.24.16796	http://dx.doi.org/10.1074/jbc.274.24.16796			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358022	hybrid			2022-12-25	WOS:000080780400021
J	Espinas, ML; Jimenez-Garcia, E; Vaquero, A; Canudas, S; Bernues, J; Azorin, F				Espinas, ML; Jimenez-Garcia, E; Vaquero, A; Canudas, S; Bernues, J; Azorin, F			The N-terminal POZ domain of GAGA mediates the formation of oligomers that bind DNA with high affinity and specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSOME REMODELING FACTOR; PROTEIN INTERACTION MOTIF; TRIPLE-STRANDED DNA; TRANSCRIPTION FACTOR; BTB DOMAIN; IN-VITRO; CELL-CYCLE; DROSOPHILA; CHROMATIN; GENE	The Drosophila GAGA factor self-oligomerizes both in vivo and in vitro. GAGA oligomerization depends on the presence of the N-terminal POZ domain and the formation of dimers, tetramers, and oligomers of high stoichiometry is observed in vitro. GAGA oligomers bind DNA with high affinity and specificity, As a consequence of its multimeric character, the interaction of GAGA with DNA fragments carrying several GAGA binding sites is multivalent and of higher affinity than its interaction with fragments containing single short sites. A single GAGA oligomer is capable of binding adjacent GAGA binding sites spaced by as many as 20 base pairs. GAGA oligomers are functionally active, being transcriptionally competent in vitro. GAG;A-dependent transcription activation depends strongly on the number of GAGA binding sites present in the promoter. The POZ domain is not necessary for in vitro transcription but, in its absence, no synergism is observed on increasing the number of binding sites contained within the promoter. These results are discussed in view of the distribution of GAGA binding sites that, most frequently, form clusters of relatively short sites spaced by small variable distances.	CSIC, Ctr Invest & Desenvolupament, Inst Biol Mol Barcelona, Dept Mol & Cellular Biol, ES-08034 Barcelona, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biologia Molecular de Barcelona (IBMB)	Azorin, F (corresponding author), CSIC, Ctr Invest & Desenvolupament, Inst Biol Mol Barcelona, Dept Mol & Cellular Biol, Jordi Girona Salgado 18-26, ES-08034 Barcelona, Spain.		Canudas, Silvia/K-4184-2014; Bernues, Jordi/ABE-8360-2021; Canudas, Silvia/AAC-3163-2022; Azorin, Fernando/N-4388-2014; Vaquero, Alejandro/ABG-8634-2020	Canudas, Silvia/0000-0002-5630-1588; Bernues, Jordi/0000-0001-6218-8254; Canudas, Silvia/0000-0002-5630-1588; Azorin, Fernando/0000-0002-8426-7858; Espinas, M Lluisa/0000-0003-3914-2228				Ahmad KF, 1998, P NATL ACAD SCI USA, V95, P12123, DOI 10.1073/pnas.95.21.12123; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Benyajati C, 1997, NUCLEIC ACIDS RES, V25, P3345, DOI 10.1093/nar/25.16.3345; Bernues J, 1996, NUCLEIC ACIDS RES, V24, P2950, DOI 10.1093/nar/24.15.2950; BERNUES J, 1993, EMBO J, V12, P3573, DOI 10.1002/j.1460-2075.1993.tb06031.x; BIGGIN MD, 1988, CELL, V53, P699, DOI 10.1016/0092-8674(88)90088-8; CHEN W, 1995, MOL CELL BIOL, V15, P3424; CROSTON GE, 1991, SCIENCE, V251, P643, DOI 10.1126/science.1899487; Dhordain P, 1995, ONCOGENE, V11, P2689; Dong S, 1996, P NATL ACAD SCI USA, V93, P3624, DOI 10.1073/pnas.93.8.3624; DORN R, 1993, P NATL ACAD SCI USA, V90, P11376, DOI 10.1073/pnas.90.23.11376; Espinas ML, 1996, J BIOL CHEM, V271, P31807, DOI 10.1074/jbc.271.50.31807; FARKAS G, 1994, NATURE, V371, P806, DOI 10.1038/371806a0; GILMOUR DS, 1989, SCIENCE, V245, P1487, DOI 10.1126/science.2781290; GODT D, 1993, DEVELOPMENT, V119, P799; GRANOK H, 1995, CURR BIOL, V5, P238, DOI 10.1016/S0960-9822(95)00048-0; Jimenez-Garcia E, 1998, J BIOL CHEM, V273, P24640, DOI 10.1074/jbc.273.38.24640; Katsani KR, 1999, EMBO J, V18, P698, DOI 10.1093/emboj/18.3.698; Lehmann M, 1998, J BIOL CHEM, V273, P28504, DOI 10.1074/jbc.273.43.28504; Mizuguchi G, 1997, MOL CELL, V1, P141, DOI 10.1016/S1097-2765(00)80015-5; Okada M, 1998, MOL CELL BIOL, V18, P2455, DOI 10.1128/MCB.18.5.2455; Pedone PV, 1996, P NATL ACAD SCI USA, V93, P2822, DOI 10.1073/pnas.93.7.2822; Platero JS, 1998, J CELL BIOL, V140, P1297; RAFF JW, 1994, EMBO J, V13, P5977, DOI 10.1002/j.1460-2075.1994.tb06943.x; READ D, 1990, MOL CELL BIOL, V10, P4334, DOI 10.1128/MCB.10.8.4334; Robinson DN, 1997, J CELL BIOL, V138, P799, DOI 10.1083/jcb.138.4.799; SOELLER WC, 1988, GENE DEV, V2, P68, DOI 10.1101/gad.2.1.68; SOELLER WC, 1993, MOL CELL BIOL, V13, P7961, DOI 10.1128/MCB.13.12.7961; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; WALL G, 1995, EMBO J, V14, P1727, DOI 10.1002/j.1460-2075.1995.tb07162.x; WEBER JA, 1995, NUCLEIC ACIDS RES, V23, P3327, DOI 10.1093/nar/23.16.3327; Wilkins RC, 1997, NUCLEIC ACIDS RES, V25, P3963, DOI 10.1093/nar/25.20.3963; ZOLLMAN S, 1994, P NATL ACAD SCI USA, V91, P10717, DOI 10.1073/pnas.91.22.10717	34	80	83	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16461	16469		10.1074/jbc.274.23.16461	http://dx.doi.org/10.1074/jbc.274.23.16461			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347208	hybrid			2022-12-25	WOS:000080668600068
J	Maki, CG				Maki, CG			Oligomerization is required for p53 to be efficiently ubiquitinated by MDM2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA DAMAGE; IN-VIVO; PROTEIN; DEGRADATION; GENE; EXPRESSION; E6; ACCUMULATION; LOCALIZATION; INHIBITION	Wild-type p53 is degraded in part through the ubiquitin proteolysis pathway. Recent studies indicate that MDM2 can bind p53 and promote its rapid degradation although the molecular basis for this degradation has not been clarified. This report demonstrates that MDM2 can promote the ubiquitination of wild-type p53 and cancer-derived p53 mutants in transiently transfected cells. Deletion mutants that disrupted the oligomerization domain of p53 displayed low binding affinity for MDM2 and were poor substrates for ubiquitination. However, efficient MDM2 binding and ubiquitination were restored when an olgomerization-deficient p53 mutant was fused to the dimerization domain from another protein. These results indicate that oligomerization is required for p53 to efficiently bind and be ubiquitinated by MDM2. p53 ubiquitination was inhibited in cells exposed to UV radiation, and this inhibition coincided with a decrease in MDM2 protein levels and p53 MDM2 complex formation. In contrast, p53 dimerization was unaffected following UV treatment. These results suggest that UV radiation may stabilize p53 by blocking the ubiquitination and degradation of p53 mediated by MDM2.	Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Maki, CG (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, 665 Huntington Ave, Boston, MA 02115 USA.							Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; Bottger V, 1996, ONCOGENE, V13, P2141; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1998, MOL CELL BIOL, V18, P5690, DOI 10.1128/MCB.18.10.5690; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Maki CG, 1996, CANCER RES, V56, P2649; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MARSTON NJ, 1995, ONCOGENE, V10, P1709; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Pariat M, 1997, MOL CELL BIOL, V17, P2806, DOI 10.1128/MCB.17.5.2806; PELLEGATA NS, 1995, ONCOGENE, V11, P337; Perego P, 1996, CANCER RES, V56, P556; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1988; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X	32	99	100	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16531	16535		10.1074/jbc.274.23.16531	http://dx.doi.org/10.1074/jbc.274.23.16531			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347217	hybrid			2022-12-25	WOS:000080668600077
J	Riley, JK; Takeda, K; Akira, S; Schreiber, RD				Riley, JK; Takeda, K; Akira, S; Schreiber, RD			Interleukin-10 receptor signaling through the JAK-STAT pathway - Requirement for two distinct receptor-derived signals for anti-inflammatory action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFERON-GAMMA RECEPTOR; MONOCLONAL-ANTIBODIES; TYROSINE PHOSPHORYLATION; CYTOPLASMIC DOMAIN; T-CELLS; CYTOKINE; IL-10; ACTIVATION; GROWTH; GENE	Interleukin-10 (IL-IO) is a cytokine that has pleiotropic effects on a variety of different cell types. Although many of the biologic responses induced by IL-10 are also induced by other cytokines, such as IL-6, IL-10 is relatively unique in its ability to potently inhibit production of pro-inflammatory cytokines in macrophages. In this study, we have used gain-of-function and loss-of-function genetic approaches to define the intracellular components involved in the different biologic actions of IL-10. Herein, we demonstrate that the ability of IL-10 to inhibit tumor necrosis factor alpha (TNF alpha) production in lipopolysaccharide stimulated macrophages requires the presence of Stat3, Jak1, and two distinct regions of the IL-10 receptor intracellular domain. Macrophages deficient in Stat3 or Jak1 were unable to inhibit lipopolysaccharide-induced TNF alpha production following treatment with murine IL-10. Structure-function analysis of the intracellular domain of the IL-10 receptor cu chain showed that whereas two redundant Stat3 recruitment sites ((427)YQKQ(430) and (477)YLKQ(480)) were required for all IL-10-dependent effects on either B cells or macrophages, expression of IL-10-dependent anti-inflammatory function required the presence on the intracellular domain of the IL-10 receptor of a carboxyl-terminal sequence containing at least one functionally critical serine, These results thus demonstrate that IL-10-induced inhibition of TNF alpha production requires two distinct regions of the IL-10 receptor intracellular domain and thereby establish a distinctive molecular basis for the developmental versus the anti-inflammatory actions of IL-10.	Washington Univ, Sch Med, Dept Pathol, Ctr Immunol, St Louis, MO 63110 USA; Hyogo Coll Med, Dept Biochem, Nishinomiya, Hyogo 6638501, Japan	Washington University (WUSTL); Hyogo College of Medicine	Schreiber, RD (corresponding author), Washington Univ, Sch Med, Dept Pathol, Ctr Immunol, 660 S Euclid Ave,Box 8118, St Louis, MO 63110 USA.	schreiber@immunology.wustl.edu	Takeda, Kiyoshi/C-9331-2009; Akira, Shizuo/C-3134-2009; Schreiber, Robert D/A-1276-2013; Schreiber, Robert/Q-7550-2019	Schreiber, Robert D/0000-0001-6311-0432; Schreiber, Robert/0000-0003-1590-2341				AGUET M, 1988, CELL, V55, P273, DOI 10.1016/0092-8674(88)90050-5; [Anonymous], 1989, Ann N Y Acad Sci, V557, P1; Bach EA, 1996, MOL CELL BIOL, V16, P3214; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FARRAR MA, 1991, J BIOL CHEM, V266, P19626; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; FARRAR MA, 1992, P NATL ACAD SCI USA, V89, P11706, DOI 10.1073/pnas.89.24.11706; FINBLOOM DS, 1995, J IMMUNOL, V155, P1079; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; HARPUR AG, 1992, ONCOGENE, V7, P1347; HIRANO T, 1994, CYTOKINE HDB, P145; HO ASY, 1993, P NATL ACAD SCI USA, V90, P11267, DOI 10.1073/pnas.90.23.11267; HO ASY, 1995, MOL CELL BIOL, V15, P5043; HOWARD M, 1992, IMMUNOL TODAY, V13, P198, DOI 10.1016/0167-5699(92)90153-X; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; Kotenko SV, 1997, EMBO J, V16, P5894, DOI 10.1093/emboj/16.19.5894; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; Lai CF, 1996, J BIOL CHEM, V271, P13968, DOI 10.1074/jbc.271.24.13968; LIU Y, 1994, J IMMUNOL, V152, P1821; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; MOORE KW, 1993, ANNU REV IMMUNOL, V11, P165, DOI 10.1146/annurev.immunol.11.1.165; MOORE KW, 1990, SCIENCE, V248, P1230, DOI 10.1126/science.2161559; MOSMANN TR, 1994, ADV IMMUNOL, V56, P1, DOI 10.1016/S0065-2776(08)60449-6; MOSMANN TR, 1991, INT ARCH ALLER A IMM, V94, P110, DOI 10.1159/000235340; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; O'Farrell AM, 1998, EMBO J, V17, P1006, DOI 10.1093/emboj/17.4.1006; OGARRA A, 1990, INT IMMUNOL, V2, P821, DOI 10.1093/intimm/2.9.821; OSWALD IP, 1992, P NATL ACAD SCI USA, V89, P8676, DOI 10.1073/pnas.89.18.8676; Rodig SJ, 1998, CELL, V93, P373, DOI 10.1016/S0092-8674(00)81166-6; ROUSSET F, 1992, P NATL ACAD SCI USA, V89, P1890, DOI 10.1073/pnas.89.5.1890; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHEEHAN KCF, 1988, J IMMUNOL, V140, P4231; SHEEHAN KCF, 1989, J IMMUNOL, V142, P3884; Spencer SD, 1998, J EXP MED, V187, P571, DOI 10.1084/jem.187.4.571; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; TAGA K, 1993, BLOOD, V81, P2964; Takeda K, 1999, IMMUNITY, V10, P39, DOI 10.1016/S1074-7613(00)80005-9; TRAVERSARI C, 1992, IMMUNOGENETICS, V35, P145, DOI 10.1007/BF00185107; VANSNICK J, 1990, ANNU REV IMMUNOL, V8, P253, DOI 10.1146/annurev.immunol.8.1.253; WEBERNORDT RM, 1994, J IMMUNOL, V153, P3734; WeberNordt RM, 1996, J BIOL CHEM, V271, P27954, DOI 10.1074/jbc.271.44.27954; Wehinger J, 1996, FEBS LETT, V394, P365, DOI 10.1016/0014-5793(96)00990-8	44	283	305	0	18	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16513	16521		10.1074/jbc.274.23.16513	http://dx.doi.org/10.1074/jbc.274.23.16513			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347215	hybrid			2022-12-25	WOS:000080668600075
J	Walmsley, AR; Zhou, TQ; Borges-Walmsley, MI; Rosen, BP				Walmsley, AR; Zhou, TQ; Borges-Walmsley, MI; Rosen, BP			The ATPase mechanism of ArsA, the catalytic subunit of the arsenite pump	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANION-TRANSLOCATING ATPASE; NUCLEOTIDE-BINDING SITE; MUTAGENESIS; RESISTANCE; DOMAIN	The ArsA ATPase is the catalytic subunit of a novel arsenite pump, with two nucleotide-binding consensus sequences in the N- and C-terminal halves of the protein. The single tryptophan-containing Trp(159) ArsA was used to elucidate the elementary steps of the ATPase mechanism by fluorescence stopped-flow experiments. The binding and hydrolysis of MgATP is a multistep process with a minimal kinetic mechanism (Mechanism 1). A notable feature of the reaction is that MgATP binding induces a slow transient increase in fluorescence of ArsA, which is independent of the ATP concentration, indicative of the build-up of a pre-steady state intermediate, This finding, coupled with a phosphate burst, implies that the steady-state intermediate builds up subsequent to product release. We propose that the rate-limiting step is an isomerization between different conformational forms of ArsA. k(cat) is faster than the phosphate burst, indicating that both nucleotide binding sites of ArsA are catalytic, Consistent with this interpretation, approximately 2 mol of phosphate are released per mole of ArsA during the phosphate burst. [GRAPHICS] ion is enhanced by the addition of ligand. Thus, ARA70 can function as a ligand-enhanced coactivator of PPAR gamma. Finally, we show that AR can squelch PPAR gamma-ARA70 transactivation, which suggests that cross-talk may occur between PPAR gamma- and AR-mediated responses in adipocytes.	Univ Glasgow, Inst Biomed & Life Sci, Div Infect & Immun, Glasgow G12 8QQ, Lanark, Scotland; Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA	University of Glasgow; Wayne State University	Walmsley, AR (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, Div Infect & Immun, Joseph Black Bldg, Glasgow G12 8QQ, Lanark, Scotland.	A.Walmsley@bio.gla.ac.uk	Zhou, Tongqing/A-6880-2010	Zhou, Tongqing/0000-0002-3935-4637; Rosen, Barry P./0000-0002-5230-4271	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM055425, R01GM055425] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM55425] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aitken Alastair, 1996, P3, DOI 10.1007/978-1-60327-259-9_1; CHEN CM, 1986, J BIOL CHEM, V261, P5030; DEY S, 1994, ARCH BIOCHEM BIOPHYS, V311, P418, DOI 10.1006/abbi.1994.1256; DEY S, 1995, DRUG TRANSPORT ANTIM, P103; KARKARIA CE, 1990, J BIOL CHEM, V265, P7832; KAUR P, 1993, J BACTERIOL, V175, P351, DOI 10.1128/JB.175.2.351-357.1993; KAUR P, 1992, J BIOL CHEM, V267, P19272; KAUR P, 1994, BIOCHEMISTRY-US, V33, P6456, DOI 10.1021/bi00187a010; KAUR P, 1998, ADV MOL CEL A&B, V23, P455; Li JX, 1996, J BIOL CHEM, V271, P25247, DOI 10.1074/jbc.271.41.25247; MA YZ, 1995, BIOCHEMISTRY-US, V34, P13233, DOI 10.1021/bi00040a039; Ramaswamy S, 1998, J BIOL CHEM, V273, P9243, DOI 10.1074/jbc.273.15.9243; Rosen BP, 1996, J BIOL INORG CHEM, V1, P273, DOI 10.1007/s007750050053; ROSEN BP, 1988, J BIOL CHEM, V263, P3067; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WEBB MR, 1992, P NATL ACAD SCI USA, V89, P4884, DOI 10.1073/pnas.89.11.4884; ZHOU TQ, 1995, BIOCHEMISTRY-US, V34, P13622, DOI 10.1021/bi00041a042; Zhou TQ, 1997, J BIOL CHEM, V272, P19731, DOI 10.1074/jbc.272.32.19731	18	23	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16153	16161		10.1074/jbc.274.23.16153	http://dx.doi.org/10.1074/jbc.274.23.16153			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347168	hybrid			2022-12-25	WOS:000080668600028
J	Yu, H; Olshevskaya, E; Duda, T; Seno, K; Hayashi, F; Sharma, RK; Dizhoor, AM; Yamazaki, A				Yu, H; Olshevskaya, E; Duda, T; Seno, K; Hayashi, F; Sharma, RK; Dizhoor, AM; Yamazaki, A			Activation of retinal guanylyl cyclase-1 by Ca2+-binding proteins involves its dimerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VERTEBRATE ROD PHOTORECEPTORS; GTP-BINDING PROTEIN; OUTER SEGMENTS; FUNCTIONAL-CHARACTERIZATION; CGMP-PHOSPHODIESTERASE; MOLECULAR-CLONING; CALCIUM; PURIFICATION; EXPRESSION; PHOTOTRANSDUCTION	Retinal guanylyl cyclase-1 (retGC-1), a key enzyme in phototransduction, is activated by guanylyl cyclase-activating proteins (GCAPs) if [Ca2+] is less than 300 nM. The activation is believed to be essential for the recovery of photoreceptors to the dark state; however, the molecular mechanism of the activation is unknown. Here, we report that dimerization of retGC-1 is involved in its activation by GCAPs, The GC activity and the formation of a 210-kDa cross-linked product of retGC-1 were monitored in bovine rod outer segment homogenates, GCAPs-free bovine rod outer segment membranes and recombinant bovine retGC-1 expressed in COS-7 cells. In addition to recombinant bovine GCAPs, constitutively active mutants of GCAPs that activate retGC-1 in a [Ca2+]-independent manner and bovine brain S100b that activates retGC-1 in the presence of similar to 10 mu M [Ca2+] were used to investigate whether these activations take place through a similar mechanism, and whether [Ca2+] is directly involved in the dimerization. We found that a monomeric form of retGC-1 (similar to 110 kDa) was mainly observed whenever GC activity was at basal or low levels. However, the 210-kDa product was increased whenever the GC activity was stimulated by any Ca2+-binding proteins used. We also found that [Ca2+] did not directly regulate the formation of the 210-kDa product. The 210-kDa product was detected in a purified GC preparation and did not contain GCAPs even when the formation of the 210-kDa product was stimulated by GCAPs, These data strongly suggest that the 210-kDa cross-linked product is a homodimer of retGC-1. We conclude that inactive retGC-1 is predominantly a monomeric form, and that dimerization of retGC-1 may be an essential step for its activation by active forms of GCAPs.	Wayne State Univ, Sch Med, Kresge Eye Inst, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Ophthalmol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA; Univ Med & Dent New Jersey, Unit Regulatory & Mol Biol, Dept Cell Biol, Stratford, NJ 08084 USA; Univ Med & Dent New Jersey, Unit Regulatory & Mol Biol, Dept Ophthalmol, Stratford, NJ 08084 USA; Kobe Univ, Fac Sci, Dept Biol, Kobe, Hyogo 657, Japan	Wayne State University; Wayne State University; Wayne State University; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Kobe University	Yamazaki, A (corresponding author), Wayne State Univ, Sch Med, Kresge Eye Inst, 4717 St Antoine St, Detroit, MI 48201 USA.	akio_yamazaki@wayne.edu		Dizhoor, Alexander/0000-0001-6770-9186	NEI NIH HHS [EY09631, EY11522, EY07546] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY011522, R01EY009631, R01EY007546] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Aparicio JG, 1996, J BIOL CHEM, V271, P27083, DOI 10.1074/jbc.271.43.27083; APARICIO JG, 1995, PROTEIN EXPRES PURIF, V6, P501, DOI 10.1006/prep.1995.1067; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cooper N, 1995, J MOL NEUROSCI, V6, P211, DOI 10.1007/BF02736766; Cuenca N, 1998, INVEST OPHTH VIS SCI, V39, P1243; Dizhoor AM, 1998, J BIOL CHEM, V273, P17311, DOI 10.1074/jbc.273.28.17311; DIZHOOR AM, 1995, J BIOL CHEM, V270, P25200, DOI 10.1074/jbc.270.42.25200; DIZHOOR AM, 1994, NEURON, V12, P1345, DOI 10.1016/0896-6273(94)90449-9; Dizhoor AM, 1996, J BIOL CHEM, V271, P19346, DOI 10.1074/jbc.271.32.19346; Duda T, 1996, BIOCHEMISTRY-US, V35, P8478, DOI 10.1021/bi960752z; Duda T, 1998, BIOCHEM BIOPH RES CO, V242, P118, DOI 10.1006/bbrc.1997.7921; GARBERS DL, 1989, J BIOL CHEM, V264, P9103; GARBERS DL, 1994, J BIOL CHEM, V269, P30741; Goraczniak R, 1997, BIOCHEM BIOPH RES CO, V234, P666, DOI 10.1006/bbrc.1997.6579; GORACZNIAK RM, 1994, BIOCHEM J, V302, P455, DOI 10.1042/bj3020455; Goraczniak RM, 1998, BIOCHEM BIOPH RES CO, V245, P447, DOI 10.1006/bbrc.1998.8455; GORCZYCA WA, 1994, BIOCHEMISTRY-US, V33, P3217, DOI 10.1021/bi00177a011; GORCZYCA WA, 1994, P NATL ACAD SCI USA, V91, P4014, DOI 10.1073/pnas.91.9.4014; GRAYKELLER MP, 1994, NEURON, V13, P849, DOI 10.1016/0896-6273(94)90251-8; HAKKI S, 1990, BIOCHEMISTRY-US, V29, P1088, DOI 10.1021/bi00456a035; Hallett MA, 1996, J CELL SCI, V109, P1803; HAYASHI F, 1991, P NATL ACAD SCI USA, V88, P4746, DOI 10.1073/pnas.88.11.4746; Howes K, 1998, INVEST OPHTH VIS SCI, V39, P867; HURLEY JB, 1987, ANNU REV PHYSIOL, V49, P793; IWATA T, 1991, J BIOCHEM-TOKYO, V110, P73; Kachi S, 1999, EXP EYE RES, V68, P465, DOI 10.1006/exer.1998.0629; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; KOCH KW, 1991, J BIOL CHEM, V266, P8634; Koutalos Y, 1996, TRENDS NEUROSCI, V19, P73; Laura RP, 1996, J BIOL CHEM, V271, P11646, DOI 10.1074/jbc.271.20.11646; Li N, 1998, EUR J BIOCHEM, V252, P591, DOI 10.1046/j.1432-1327.1998.2520591.x; LIU XR, 1994, EXP EYE RES, V59, P761, DOI 10.1006/exer.1994.1162; LOWE DG, 1992, BIOCHEMISTRY-US, V31, P10421, DOI 10.1021/bi00158a001; LOWE DG, 1995, P NATL ACAD SCI USA, V92, P5535, DOI 10.1073/pnas.92.12.5535; Margulis A, 1996, BIOCHEM BIOPH RES CO, V218, P243, DOI 10.1006/bbrc.1996.0043; Olshevskaya EV, 1997, J BIOL CHEM, V272, P14327, DOI 10.1074/jbc.272.22.14327; PALCZEWSKI K, 1994, NEURON, V13, P395, DOI 10.1016/0896-6273(94)90355-7; POZDNYAKOV N, 1995, BIOCHEMISTRY-US, V34, P14279, DOI 10.1021/bi00044a002; PUGH EN, 1993, BIOCHIM BIOPHYS ACTA, V1141, P111, DOI 10.1016/0005-2728(93)90038-H; Semple-Rowland SL, 1998, P NATL ACAD SCI USA, V95, P1271, DOI 10.1073/pnas.95.3.1271; Seno K, 1998, J BIOL CHEM, V273, P22169, DOI 10.1074/jbc.273.35.22169; SHYJAN AW, 1992, NEURON, V9, P727, DOI 10.1016/0896-6273(92)90035-C; SITARAMAYYA A, 1991, BIOCHEMISTRY-US, V30, P6742, DOI 10.1021/bi00241a016; Sunahara RK, 1998, J BIOL CHEM, V273, P16332, DOI 10.1074/jbc.273.26.16332; TANG WJ, 1991, J BIOL CHEM, V266, P8595; TSIEN R, 1989, METHOD ENZYMOL, V172, P230; Tucker CL, 1998, P NATL ACAD SCI USA, V95, P5993, DOI 10.1073/pnas.95.11.5993; Tucker CL, 1997, BIOCHEMISTRY-US, V36, P11995, DOI 10.1021/bi971212k; WILSON EM, 1995, BIOCHEMISTRY-US, V34, P4696, DOI 10.1021/bi00014a025; Wolbring G, 1996, BIOCHEMISTRY-US, V35, P11013, DOI 10.1021/bi960699e; YAMAZAKI A, 1988, METHOD ENZYMOL, V159, P702; YAMAZAKI A, 1987, J BIOL CHEM, V262, P9316; Yang RB, 1997, J BIOL CHEM, V272, P13738, DOI 10.1074/jbc.272.21.13738; YANG RB, 1995, P NATL ACAD SCI USA, V92, P602, DOI 10.1073/pnas.92.2.602; YAU KW, 1989, ANNU REV NEUROSCI, V12, P289, DOI 10.1146/annurev.ne.12.030189.001445	55	60	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15547	15555		10.1074/jbc.274.22.15547	http://dx.doi.org/10.1074/jbc.274.22.15547			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336449	hybrid			2022-12-25	WOS:000080560100038
J	Jaworowski, A; Wilson, NJ; Christy, E; Byrne, R; Hamilton, JA				Jaworowski, A; Wilson, NJ; Christy, E; Byrne, R; Hamilton, JA			Roles of the mitogen-activated protein kinase family in macrophage responses to colony stimulating factor-1 addition and withdrawal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-MYC EXPRESSION; GROWTH-FACTOR; CELL-CYCLE; FACTOR-I; ANTIPROLIFERATIVE AGENTS; MONONUCLEAR PHAGOCYTES; CYTOKINE BIOSYNTHESIS; SIGNALING PATHWAYS; APOPTOSIS; CSF-1	Colony stimulating factor-1 (CSF-1) (or macrophage CSF) is involved in the survival, proliferation, differentiation, and activation of cells of the monocyte/macrophage lineage. Because the mitogen-activated protein kinase family members extracellular signal-regulated kinases (ERKs), p38, and c-Jun N-terminal kinase are widely implicated in such cellular functions, we measured their activity in growing and growth-arrested cultures of bone marrow-derived macrophages (BMM), as well as their stimulation by saturating concentrations of CSF-1, ERK activity was approximately a-fold higher in cycling BMM compared with growth-arrested BMM; in addition, CSF-l-stimulated BMM DNA synthesis was partially inhibited by PD98059, a specific inhibitor of MEK activation, suggesting a role for a mitogen-activated protein-ERK kinase (MEK)/ERK pathway in the control of DNA synthesis but surprisingly not in the control of cyclin D1 mRNA or c-myc mRNA expression. The suppression of BMM apoptosis by CSF-1, i.e, enhanced survival, was not reversed by PD98059, suggesting that a MEK/ERK pathway is not involved in this process. Using a quantitative kinase assay, it was found that CSF-1 gave a slight increase in BMM p38 activity, supporting prior data that CSF-1 is a relatively weak stimulator of inflammatory cytokine production in monocytes/macrophages, Relatively high concentrations of the p38 inhibitor, SKB202190, suppressed CSF-l-stimulated BMM DNA synthesis. No evidence could be obtained for the involvement of p38 activity in BMM apoptosis following CSF-1 withdrawal. We were not able to show that CSF-1 enhanced BMM JNK-1 activity to a significant extent; again, no role could be found for JNK-1 activity in the BMM apoptosis occurring after CSF-1 removal.	Univ Melbourne, Royal Melbourne Hosp, Inflammat Res Ctr, Parkville, Vic 3050, Australia	Royal Melbourne Hospital; University of Melbourne	Jaworowski, A (corresponding author), Macfarlane Burnet Ctr Med Res, POB 254, Fairfield, Vic 3078, Australia.			jaworowski, anthony/0000-0002-3844-805X; Hamilton, John A/0000-0002-9493-9224				Aziz N, 1999, MOL CELL BIOL, V19, P1101; BUSCHER D, 1995, MOL CELL BIOL, V15, P466; COCKS BG, 1992, J BIOL CHEM, V267, P12307; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; Crawley JB, 1997, J BIOL CHEM, V272, P15023, DOI 10.1074/jbc.272.23.15023; Dello Sbarba P, 1991, Growth Factors, V5, P75; Ding AH, 1996, J EXP MED, V183, P1899, DOI 10.1084/jem.183.4.1899; EVANS R, 1989, J LEUKOCYTE BIOL, V46, P428, DOI 10.1002/jlb.46.5.428; Foltz IN, 1997, J BIOL CHEM, V272, P3296, DOI 10.1074/jbc.272.6.3296; Fowles LF, 1998, MOL CELL BIOL, V18, P5148, DOI 10.1128/MCB.18.9.5148; Hambleton J, 1996, P NATL ACAD SCI USA, V93, P2774, DOI 10.1073/pnas.93.7.2774; Hamilton JA, 1997, J LEUKOCYTE BIOL, V62, P145, DOI 10.1002/jlb.62.2.145; HAMILTON JA, 1993, IMMUNOL TODAY, V14, P18, DOI 10.1016/0167-5699(93)90319-G; HAMILTON JA, 1993, J LEUKOCYTE BIOL, V53, P707, DOI 10.1002/jlb.53.6.707; HART B, 1967, J MOL BIOL, V26, P365; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Jaworowski A, 1996, BIOCHEM J, V320, P1011, DOI 10.1042/bj3201011; Kummer JL, 1997, J BIOL CHEM, V272, P20490, DOI 10.1074/jbc.272.33.20490; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; L'Allemain Gilles, 1994, Progress in Growth Factor Research, V5, P291, DOI 10.1016/0955-2235(94)90011-6; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; LEE JC, 1993, ANN NY ACAD SCI, V696, P149; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; Messina A, 1996, J COMP NEUROL, V372, P544, DOI 10.1002/(SICI)1096-9861(19960902)372:4<544::AID-CNE4>3.0.CO;2-4; MOORE RN, 1980, J IMMUNOL, V125, P1302; Nagata Y, 1997, BLOOD, V90, P929, DOI 10.1182/blood.V90.3.929.929_929_934; Nemoto S, 1998, J BIOL CHEM, V273, P16415, DOI 10.1074/jbc.273.26.16415; OSTER W, 1992, BLOOD, V79, P1260; POLLARD JW, 1991, P NATL ACAD SCI USA, V88, P1474, DOI 10.1073/pnas.88.4.1474; ROCK CO, 1992, MOL CELL BIOL, V12, P2351, DOI 10.1128/MCB.12.5.2351; ROUSSEL MF, 1995, P NATL ACAD SCI USA, V92, P6837, DOI 10.1073/pnas.92.15.6837; ROUSSEL MF, 1991, NATURE, V353, P361, DOI 10.1038/353361a0; Salmon RA, 1997, J IMMUNOL, V159, P5309; TUSHINSKI RJ, 1983, J CELL PHYSIOL, V116, P67, DOI 10.1002/jcp.1041160111; TUSHINSKI RJ, 1982, CELL, V28, P71, DOI 10.1016/0092-8674(82)90376-2; Vadiveloo PK, 1996, ONCOGENE, V13, P599; VAIRO G, 1985, BIOCHEM BIOPH RES CO, V132, P430, DOI 10.1016/0006-291X(85)91040-X; VAIRO G, 1990, J BIOL CHEM, V265, P2692; VAIRO G, 1995, ONCOGENE, V10, P1969; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; Wilson NJ, 1998, BIOCHEM BIOPH RES CO, V244, P475, DOI 10.1006/bbrc.1998.8290; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Zornig M, 1996, CURR BIOL, V6, P1553, DOI 10.1016/S0960-9822(02)70769-0	45	53	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					15127	15133		10.1074/jbc.274.21.15127	http://dx.doi.org/10.1074/jbc.274.21.15127			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329719	hybrid			2022-12-25	WOS:000081965200084
J	Lin, JH; Makris, A; McMahon, C; Bear, SE; Patriotis, C; Prasad, VR; Brent, R; Golemis, EA; Tsichlis, PN				Lin, JH; Makris, A; McMahon, C; Bear, SE; Patriotis, C; Prasad, VR; Brent, R; Golemis, EA; Tsichlis, PN			The ankyrin repeat-containing adaptor protein Tvl-1 is a novel substrate and regulator of Raf-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; DISTINCT BINDING DOMAINS; KINASE-KINASE; IN-VITRO; PLASMA-MEMBRANE; ACTIVATES RAF-1; RAS; PHOSPHORYLATION; C-RAF-1; ACID	Tvl-1 is a 269-amino acid ankyrin repeat protein ex pressed primarily in thymus, lung, and testes that was identified by screening a murine T-cell two-hybrid cDNA library for proteins that associate with the serine-threonine kinase Raf-1. The interaction of Tvl-1 with Raf-1 was confirmed by co-immunoprecipitation of the two proteins from COS-1 cells transiently transfected with Tvl-1 and Raf-1 expression constructs as well as by co-immunoprecipitation of the endogenous proteins from CV-1 and NB2 cells. Tvl-1 interacts with Raf-1 via its carboxyl-terminal ankyrin repeat domain, The same domain also mediates Tvl-1 homodimerization, Tvl-1 was detected by immunofluorescence in both the cytoplasm and the nucleus suggesting that in addition to Raf-1 it may also interact with nuclear proteins. Activated Raf-1 phosphorylates Tvl-1 both in vitro and in vivo. In baculovirus-infected Sf9 insect cells, Tvl-1 potentiates the activation of Raf-1 by Src and Ras while in COS-1 cells it potentiates the activation of Raf-1 by EGF. These data suggest that Tvl-1 is both a target as well as a regulator of Raf-1. The human homologue of Tvl-1 maps to chromosome 19p12, upstream of MEF2B with the two genes in a head to head arrangement.	Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Fox Chase Canc Ctr, Philadelphia, PA 19111 USA; Albert Einstein Coll Med, New York, NY USA; Inst Mol Sci, Berkeley, CA 94704 USA	Jefferson University; Fox Chase Cancer Center; Yeshiva University; The Molecular Sciences Institute	Tsichlis, PN (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, 233 10th St, Philadelphia, PA 19107 USA.	P_Tsichlis@lac.jci.tju.edu	Prasad, Vinayaka R./A-1029-2011	Prasad, Vinayaka/0000-0002-9461-0189; Golemis, Erica/0000-0003-3618-3673	NATIONAL CANCER INSTITUTE [P30CA006927, T32CA009683] Funding Source: NIH RePORTER; NCI NIH HHS [CA06927, T32-CA09683, R01-CA38147] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; BUSCHER D, 1995, MOL CELL BIOL, V15, P466; CHAN W, 1993, J CELL BIOL, V123, P1463, DOI 10.1083/jcb.123.6.1463; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUANG E, 1994, MOL CELL BIOL, V14, P5318, DOI 10.1128/MCB.14.8.5318; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DENT P, 1995, MOL CELL BIOL, V15, P4125; Dent P, 1996, J BIOL CHEM, V271, P3119, DOI 10.1074/jbc.271.6.3119; Drugan JK, 1996, J BIOL CHEM, V271, P233, DOI 10.1074/jbc.271.1.233; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; FINLEY RL, 1994, P NATL ACAD SCI USA, V91, P12980, DOI 10.1073/pnas.91.26.12980; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; GARDNER AM, 1993, J BIOL CHEM, V268, P17896; GHOSH S, 1994, J BIOL CHEM, V269, P30785; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; Golemis E A, 1997, Methods Mol Biol, V63, P197; Grammatikakis N, 1999, MOL CELL BIOL, V19, P1661; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; HOBSON GM, 1995, GENOMICS, V29, P704, DOI 10.1006/geno.1995.9007; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KYRIAKIS JM, 1993, J BIOL CHEM, V268, P16009; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LUO ZJ, 1995, J BIOL CHEM, V270, P23681, DOI 10.1074/jbc.270.40.23681; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; Masternak K, 1998, NAT GENET, V20, P273, DOI 10.1038/3081; Matsuno K, 1997, DEVELOPMENT, V124, P4265; Michaely P, 1992, Trends Cell Biol, V2, P127, DOI 10.1016/0962-8924(92)90084-Z; MORRISON DK, 1995, METHOD ENZYMOL, V255, P301; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; Park RK, 1996, J BIOL CHEM, V271, P13342, DOI 10.1074/jbc.271.23.13342; PATRIOTIS C, 1994, P NATL ACAD SCI USA, V91, P9755, DOI 10.1073/pnas.91.21.9755; Popik W, 1996, MOL CELL BIOL, V16, P6532; RAPP UR, 1991, ONCOGENE, V6, P495; SCHULTE TW, 1995, J BIOL CHEM, V270, P24585, DOI 10.1074/jbc.270.41.24585; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Stokoe D, 1997, EMBO J, V16, P2384, DOI 10.1093/emboj/16.9.2384; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	58	32	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					14706	14715		10.1074/jbc.274.21.14706	http://dx.doi.org/10.1074/jbc.274.21.14706			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329666	hybrid			2022-12-25	WOS:000081965200031
J	Maamra, M; Finidori, J; Von Laue, S; Simon, S; Justice, S; Webster, J; Dower, S; Ross, R				Maamra, M; Finidori, J; Von Laue, S; Simon, S; Justice, S; Webster, J; Dower, S; Ross, R			Studies with a growth hormone antagonist and dual-fluorescent confocal microscopy demonstrate that the full-length human growth hormone receptor, but not the truncated isoform, is very rapidly internalized independent of Jak2-Stat5 signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GH-BINDING PROTEIN; DOWN-REGULATION; BETA(2)-ADRENERGIC RECEPTOR; MEDIATED INTERNALIZATION; LIVING CELLS; LIGAND; VISUALIZATION; TRANSLOCATION; TRAFFICKING; ACTIVATION	We have investigated trafficking of two negative regulators of growth hormone receptor (GHR) signaling: a human, truncated receptor, GHR1-279, and a GH antagonist, B2036, Fluorescent-labeled growth hormone (GH) was rapidly internalized by the full-length GHR, with >80% of the hormone internalized within 5 min of exposure to GH, In contrast, <5% of labeled GH was internalized by cells expressing truncated GHR1-279, Using another truncated receptor, GHR1-317 fused to enhanced green fluorescent protein (EGFP), we have exploited fluorescence energy transfer to monitor the trafficking of ligand-receptor complexes. The data confirmed that internalization of this truncated receptor is very inefficient, It was possible to visualize the truncated GHR1-317-EGFP packaged in the endoplasmic reticulum, its rapid movement in membrane bound vesicles to the Golgi apparatus, and subsequent transport to the cell membrane, The GH antagonist, B2036, blocked Jak2-Stat5-mediated GHR signaling but was internalized with a similar time course to native GH, The results: 1) demonstrate the rapid internalization of GH when studied under physiological conditions; 2) confirm the hypothesis that internalization of cytoplasmic domain truncated human GHRs is very inefficient, which explains their dominant negative action; and 3) show that the antagonist action of B2036 is independent of receptor internalization.	Univ Sheffield, Div Clin Sci, Sheffield S5 7AU, S Yorkshire, England; Univ Sheffield, Div Med & Mol Genet, Sheffield S5 7AU, S Yorkshire, England; Fac Med Necker, INSERM U344, F-75730 Paris, France	University of Sheffield; University of Sheffield; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Ross, R (corresponding author), No Gen Hosp, Sheffield S5 7AU, S Yorkshire, England.		Ross, Richard/B-2672-2012	Ross, Richard/0000-0001-9222-9678; dower, steve/0000-0002-4675-4225; von Laue, Sigward/0000-0002-5229-4712				ALLEVATO G, 1995, J BIOL CHEM, V270, P17210, DOI 10.1074/jbc.270.29.17210; Amit T, 1997, J CLIN ENDOCR METAB, V82, P3813, DOI 10.1210/jc.82.11.3813; Ayling RM, 1997, NAT GENET, V16, P13, DOI 10.1038/ng0597-13; Barak LS, 1997, MOL PHARMACOL, V51, P177, DOI 10.1124/mol.51.2.177; Dastot F, 1996, P NATL ACAD SCI USA, V93, P10723, DOI 10.1073/pnas.93.20.10723; FINIDORI J, 1995, J ENDOCRINOL, V147, P11, DOI 10.1677/joe.0.1470011; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; GOUJON L, 1994, P NATL ACAD SCI USA, V91, P957, DOI 10.1073/pnas.91.3.957; Govers P, 1998, J BIOL CHEM, V273, P16426, DOI 10.1074/jbc.273.26.16426; Govers R, 1997, EMBO J, V16, P4851, DOI 10.1093/emboj/16.16.4851; Harding PA, 1996, J BIOL CHEM, V271, P6708, DOI 10.1074/jbc.271.12.6708; Htun H, 1996, P NATL ACAD SCI USA, V93, P4845, DOI 10.1073/pnas.93.10.4845; Iida K, 1998, J CLIN ENDOCR METAB, V83, P531, DOI 10.1210/jc.83.2.531; ILONDO MM, 1991, ENDOCRINOLOGY, V128, P1597, DOI 10.1210/endo-128-3-1597; Kallal L, 1998, J BIOL CHEM, V273, P322, DOI 10.1074/jbc.273.1.322; Leung KC, 1997, P NATL ACAD SCI USA, V94, P11381, DOI 10.1073/pnas.94.21.11381; LOWMAN HB, 1993, J MOL BIOL, V234, P564, DOI 10.1006/jmbi.1993.1612; Mellado M, 1997, J BIOL CHEM, V272, P9189; Presley JF, 1997, NATURE, V389, P81, DOI 10.1038/38001; SILVA CM, 1993, ENDOCRINOLOGY, V132, P101, DOI 10.1210/en.132.1.101; Sotiropoulos A, 1996, MOL ENDOCRINOL, V10, P998, DOI 10.1210/me.10.8.998; Tarasova NI, 1997, J BIOL CHEM, V272, P14817, DOI 10.1074/jbc.272.23.14817; THORNER MO, 1998, ENDOCRINE SOC 1998, P57; VANDERLELY AJ, 1998, ENDOCRINE SOC 1998, P57; WANG YD, 1995, MOL ENDOCRINOL, V9, P303, DOI 10.1210/me.9.3.303; Wojcik R, 1998, J CLIN ENDOCR METAB, V83, P4481, DOI 10.1210/jc.83.12.4481	26	50	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					14791	14798		10.1074/jbc.274.21.14791	http://dx.doi.org/10.1074/jbc.274.21.14791			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329677	hybrid			2022-12-25	WOS:000081965200042
J	Ericsson, J; Usheva, A; Edwards, PA				Ericsson, J; Usheva, A; Edwards, PA			YY1 is a negative regulator of transcription of three sterol regulatory element-binding protein-responsive genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR FACTOR-Y; SYNTHASE GENE; DIFFERENTIATION FACTOR-1; ADIPOCYTE DETERMINATION; SYNERGISTIC ACTIVATION; PROMOTER ACTIVITY; NF-Y; REPRESSION; EXPRESSION; TRANSACTIVATION	Ying Yang 1 (YY1) is shown to bind to the proximal promoters of the genes encoding 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) synthase, farnesyl diphosphate (FPP) synthase, and the low density lipoprotein (LDL) receptor. To investigate the potential effect of YY1 on the expression of SREBP-responsive genes, HepG2 cells were transiently transfected with luciferase reporter constructs under the control of promoters derived from either HMG-CoA synthase, FPP synthase, or the LDL receptor genes, The luciferase activity of each construct increased when HepG2 cells were incubated in lipid-depleted media or when the cells were contransfected with a plasmid encoding mature sterol regulatory element-binding protein (SREBP)-1a. In each case, the increase in luciferase activity was attenuated by coexpression of wild-type YY1 but not by coexpression of mutant YY1 proteins that are known to be defective in either DNA binding or in modulating transcription of other known YY1-responsive genes. In contrast, incubation of cells in lipid-depleted media resulted in induction of an HMG-CoA reductase promoter-luciferase construct by a process that was unaffected by coexpression of wild-type YY1. Electromobility shift assays were used to demonstrate that the proximal promoters of the HMG-CoA synthase, FPP synthase, and the LDL receptor contain YY1 binding sites and that YY1 displaced nuclear factor Y from the promoter of the HMG-CoA synthase gene. We conclude that YY1 inhibits the transcription of specific SREBP-dependent genes and that, in the case of the HMG-CoA synthase gene, this involves displacement of nuclear factor Y from the promoter. We hypothesize that YY1 plays a regulatory role in the transcriptional regulation of specific SREBP-responsive genes.	Univ Calif Los Angeles, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Harvard University; Harvard Medical School	Edwards, PA (corresponding author), Univ Calif Los Angeles, Dept Biol Chem, CHS 33-257, Los Angeles, CA 90095 USA.		Ericsson, Johan/AAA-6664-2020	Ericsson, Johan/0000-0003-1186-6574	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030568] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 30568] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Austen M, 1997, J BIOL CHEM, V272, P1709, DOI 10.1074/jbc.272.3.1709; BENNETT MK, 1995, J BIOL CHEM, V270, P25578, DOI 10.1074/jbc.270.43.25578; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Chen CY, 1997, MOL ENDOCRINOL, V11, P812, DOI 10.1210/me.11.6.812; Dooley KA, 1998, J BIOL CHEM, V273, P1349, DOI 10.1074/jbc.273.3.1349; Edwards PA, 1998, CURR OPIN LIPIDOL, V9, P433, DOI 10.1097/00041433-199810000-00007; Ericsson J, 1998, J BIOL CHEM, V273, P17865, DOI 10.1074/jbc.273.28.17865; Ericsson J, 1996, P NATL ACAD SCI USA, V93, P945, DOI 10.1073/pnas.93.2.945; Ericsson J, 1997, J BIOL CHEM, V272, P7298, DOI 10.1074/jbc.272.11.7298; Ericsson J, 1996, J BIOL CHEM, V271, P24359, DOI 10.1074/jbc.271.40.24359; Furlong EEM, 1996, MOL CELL BIOL, V16, P5933; Galvin KM, 1997, MOL CELL BIOL, V17, P3723, DOI 10.1128/MCB.17.7.3723; Guan GM, 1997, J BIOL CHEM, V272, P10295; Guo B, 1997, P NATL ACAD SCI USA, V94, P121, DOI 10.1073/pnas.94.1.121; GUO B, 1995, P NATL ACAD SCI USA, V92, P10526, DOI 10.1073/pnas.92.23.10526; Horton JD, 1998, J CLIN INVEST, V101, P2331, DOI 10.1172/JCI2961; Jackson SM, 1998, J LIPID RES, V39, P767; JACKSON SM, 1995, J BIOL CHEM, V270, P21445, DOI 10.1074/jbc.270.37.21445; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; Kim JS, 1996, NUCLEIC ACIDS RES, V24, P4341, DOI 10.1093/nar/24.21.4341; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; LEE TC, 1992, P NATL ACAD SCI USA, V89, P9814, DOI 10.1073/pnas.89.20.9814; Lopez JM, 1996, P NATL ACAD SCI USA, V93, P1049, DOI 10.1073/pnas.93.3.1049; LU SY, 1994, MOL CELL BIOL, V14, P6253, DOI 10.1128/MCB.14.9.6253; Oliner JD, 1996, GENE DEV, V10, P2903, DOI 10.1101/gad.10.22.2903; Rawson RB, 1997, MOL CELL, V1, P47, DOI 10.1016/S1097-2765(00)80006-4; SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161; Sato R, 1996, J BIOL CHEM, V271, P26461, DOI 10.1074/jbc.271.43.26461; Seelan RS, 1997, J BIOL CHEM, V272, P10175, DOI 10.1074/jbc.272.15.10175; Shi Y, 1997, BBA-REV CANCER, V1332, pF49, DOI 10.1016/S0304-419X(96)00044-3; SHRIVASTAVA A, 1994, NUCLEIC ACIDS RES, V22, P5151, DOI 10.1093/nar/22.24.5151; Tabor DE, 1998, J BIOL CHEM, V273, P22052, DOI 10.1074/jbc.273.34.22052; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; Usheva A, 1996, P NATL ACAD SCI USA, V93, P13571, DOI 10.1073/pnas.93.24.13571; Vallett SM, 1996, J BIOL CHEM, V271, P12247, DOI 10.1074/jbc.271.21.12247; Walowitz JL, 1998, J BIOL CHEM, V273, P6656, DOI 10.1074/jbc.273.12.6656; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; YANT SR, 1995, NUCLEIC ACIDS RES, V23, P4353, DOI 10.1093/nar/23.21.4353; Ye JP, 1996, MOL CELL BIOL, V16, P157; YIEH L, 1995, P NATL ACAD SCI USA, V92, P6102, DOI 10.1073/pnas.92.13.6102	41	48	51	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					14508	14513		10.1074/jbc.274.20.14508	http://dx.doi.org/10.1074/jbc.274.20.14508			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318878	hybrid			2022-12-25	WOS:000080322200107
J	Soulez, M; Saurin, AJ; Freemont, PS; Knight, JC				Soulez, M; Saurin, AJ; Freemont, PS; Knight, JC			SSX and the synovial-sarcoma-specific chimaeric protein SYT-SSX co-localize with the human Polycomb group complex	ONCOGENE			English	Article						chromosome translocation; SSX; SYT; polycomb; chromatin; nucleus	MYC TRANSGENIC MICE; TRANSCRIPTIONAL REPRESSOR; NUCLEAR-BODIES; GROUP GENES; IDENTIFICATION; DROSOPHILA; TRANSLOCATION; CHROMATIN; HOMOLOG; FUSION	Chromosome translocation t(X;18)(p11.2;q11.2) is unique to synovial sarcomas and results in an 'in frame' fusion of the SYT gene with the SSX1 or closely-related SSX2 gene. Wild-type SYT and SSX proteins, and the SYT-SSX chimaeric proteins, can modulate transcription in gene reporter assays. To help elucidate the role of these proteins in cell function and neoplasia we have performed immunolabeliing experiments to determine their subcellular localization in three cell types. Transient expression of epitope-tagged proteins produced distinctive nuclear staining patterns, The punctate staining of SYT and SYT-SSX proteins showed some similarities. We immunolabelled a series of endogenous nuclear antigens and excluded the SYT and SYT-SSX focal staining from association with these domains (e.g. sites of active transcription, snRNPs), In further experiments we immunolabelled the Polycomb group (PcG) proteins RING1 or BMI-1 and showed that SSX and SYT-SSX proteins, but not SYT, co-localized with these markers. Consistent with this we show that SSX and SYT-SSX associate with chromatin, and also associate with condensed chromatin at metaphase, Noteably, SSX produced a dense signal over the surface of metaphase chromosomes whereas SYT-SSX produced discrete focal staining, Our data indicate that SSX and SYT-SSX proteins are recruited to nuclear domains occupied by PcG complexes, and this provides us with a new insight into the possible function of wild-type SSX and the mechanism by which the aberrant SYT-SSX protein might disrupt fundamental mechanisms controlling cell division and cell fate.	Univ London Imperial Coll Sci Technol & Med, Dept Canc Med, London W12 0NN, England; Univ London Imperial Coll Sci Technol & Med, Imperial Canc Res Fund Labs, London W12 0NN, England; Imperial Canc Res Fund, Mol Struct & Funct Lab, London WC2A 3PX, England	Imperial College London; Cancer Research UK; Imperial College London; Cancer Research UK	Freemont, PS (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Canc Med, Hammersmith Campus,Du Cane Rd, London W12 0NN, England.			Freemont, Paul/0000-0002-5658-8486; Saurin, Andrew/0000-0001-5162-003X				Alkema MJ, 1997, J MOL BIOL, V273, P993, DOI 10.1006/jmbi.1997.1372; Alkema MJ, 1997, GENE DEV, V11, P226, DOI 10.1101/gad.11.2.226; BIENZ L, 1995, BIOESSAYS, V17, P775, DOI 10.1002/bies.950170907; Brett D, 1997, HUM MOL GENET, V6, P1559, DOI 10.1093/hmg/6.9.1559; Bridge JA, 1994, CYTOGENETICS BONE SO; BUNKER CA, 1994, MOL CELL BIOL, V14, P1721, DOI 10.1128/MCB.14.3.1721; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; Core N, 1997, DEVELOPMENT, V124, P721; CREW AJ, 1995, EMBO J, V14, P2333, DOI 10.1002/j.1460-2075.1995.tb07228.x; deBruijn DRH, 1996, ONCOGENE, V13, P643; DELEEUW B, 1995, HUM MOL GENET, V4, P1097, DOI 10.1093/hmg/4.6.1097; dosSantos NR, 1997, HUM MOL GENET, V6, P1549, DOI 10.1093/hmg/6.9.1549; Enzinger FM, 1995, SOFT TISSUE TUMORS, V3rd; FISHER C, 1986, HUM PATHOL, V17, P996, DOI 10.1016/S0046-8177(86)80083-1; Gould A, 1997, CURR OPIN GENET DEV, V7, P488, DOI 10.1016/S0959-437X(97)80075-5; Gunster MJ, 1997, MOL CELL BIOL, V17, P2326, DOI 10.1128/MCB.17.4.2326; Gure AO, 1997, INT J CANCER, V72, P965, DOI 10.1002/(SICI)1097-0215(19970917)72:6<965::AID-IJC8>3.0.CO;2-N; Hashimoto N, 1998, BIOCHEM BIOPH RES CO, V245, P356, DOI 10.1006/bbrc.1998.8438; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; Huang S, 1997, J CELL BIOL, V137, P965, DOI 10.1083/jcb.137.5.965; LIM FL, 1998, IN PRESS ONCOGENE; MARTINEZBALBAS MA, 1995, CELL, V83, P29, DOI 10.1016/0092-8674(95)90231-7; PARO R, 1990, TRENDS GENET, V6, P416, DOI 10.1016/0168-9525(90)90303-N; Pirrotta V, 1998, CELL, V93, P333, DOI 10.1016/S0092-8674(00)81162-9; RENWICK PJ, 1995, CYTOGENET CELL GENET, V70, P58, DOI 10.1159/000133992; Satijn DPE, 1997, MOL CELL BIOL, V17, P4105, DOI 10.1128/MCB.17.7.4105; Saurin AJ, 1998, J CELL BIOL, V142, P887, DOI 10.1083/jcb.142.4.887; Schoorlemmer J, 1997, EMBO J, V16, P5930, DOI 10.1093/emboj/16.19.5930; Schumacher A, 1997, TRENDS GENET, V13, P167, DOI 10.1016/S0168-9525(97)01133-5; STUURMAN N, 1992, J CELL SCI, V101, P773; van Lohuizen M, 1998, CELL MOL LIFE SCI, V54, P71, DOI 10.1007/s000180050126; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; Wang G, 1997, CYTOGENET CELL GENET, V78, P50, DOI 10.1159/000134626; WANSINK DG, 1994, J CELL SCI, V107, P1449	34	84	87	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	1999	18	17					2739	2746		10.1038/sj.onc.1202613	http://dx.doi.org/10.1038/sj.onc.1202613			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FH	10348348				2022-12-25	WOS:000080124900009
J	Liang, SH; Clarke, MF				Liang, SH; Clarke, MF			The nuclear import of p53 is determined by the presence of a basic domain and its relative position to the nuclear localization signal	ONCOGENE			English	Article						p53; nuclear localization; tumor suppressor gene 5	STRUCTURAL ASPECTS; GENE EVOLUTION; CELL-CYCLE; PROTEIN; ACCUMULATION; TRAFFICKING; RECEPTOR; SEQUENCE; LOCATION; MYC	It has been reported that Lysine-305 is needed for the nuclear import of the p53 protein (Liang et al., 1998). In the present study, further mutagenesis analyses were carried out between Lys-305 and the major nuclear localization signal (NLS I) of p53. It was found that a single mutation of Arg-306 resulted in the defect of p53 nuclear import. This effect is the same as that of Lys-305 mutation. Other mutations between Arg-306 and NLS I have no effect on the nuclear import of p53. However, deletions of more than two amino acids between this region abolished the transport of p53 into the nucleus. These results indicate that a basic domain other than the well defined NLS is required for the nuclear import of p53. A spacer between this basic domain and NLS I is necessary for the entrance of p53 into the cell nucleus.	Univ Michigan, Med Ctr, Dept Internal Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Clarke, MF (corresponding author), Univ Michigan, Med Ctr, Dept Internal Med, 4310 CCGC,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.				NATIONAL CANCER INSTITUTE [R55CA067140, R01CA067140] Funding Source: NIH RePORTER; NCI NIH HHS [CA67140] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOSARI S, 1995, AM J PATHOL, V147, P790; Carey KL, 1996, J CELL BIOL, V133, P985, DOI 10.1083/jcb.133.5.985; DANG CV, 1989, J BIOL CHEM, V264, P18019; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; HOLSTEIN M, 1991, SCIENCE, V253, P49; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Koepp DM, 1996, CELL, V87, P1, DOI 10.1016/S0092-8674(00)81315-X; Liang SH, 1998, J BIOL CHEM, V273, P19817, DOI 10.1074/jbc.273.31.19817; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; ROBERTS BL, 1987, CELL, V50, P465, DOI 10.1016/0092-8674(87)90500-9; RYAN JJ, 1994, P NATL ACAD SCI USA, V91, P5878, DOI 10.1073/pnas.91.13.5878; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; SOUSSI T, 1990, ONCOGENE, V5, P945; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Ullman KS, 1997, CELL, V90, P967, DOI 10.1016/S0092-8674(00)80361-X	21	44	46	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 25	1999	18	12					2163	2166		10.1038/sj.onc.1202350	http://dx.doi.org/10.1038/sj.onc.1202350			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	179TX	10321742	Bronze			2022-12-25	WOS:000079346200015
J	Hosaka, M; Sudhof, TC				Hosaka, M; Sudhof, TC			Homo- and heterodimerization of synapsins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; PHOSPHORYLATION; FAMILY; PHOSPHOPROTEINS; ISOFORMS; SITE; CA2+; MICE	In vertebrates, synapsins constitute a family of synaptic vesicle proteins encoded by three genes. Synapsins contain a central ATP-binding domain, the C-domain, that is highly homologous between synapsins and evolutionarily conserved in invertebrates. The crystal structure of the C-domain from synapsin I revealed that it constitutes a large (>300 amino acids), independently folded domain that forms a tight dimer with or without bound ATP, We now show that the C-domains of all synapsins form homodimers, and that in addition, C-domains from different synapsins associate into heterodimers, This conclusion is based on four findings: 1) in yeast two-hybrid screens with full-length synapsin IIa as a bait, the most frequently isolated prey cDNAs encoded the C-domain of synapsins; 2) quantitative yeast two-hybrid protein-protein binding assays demonstrated pairwise strong interactions between all synapsins; 3) immunoprecipitations from transfected COS cells confirmed that synapsin II heteromultimerizes with synapsins I and III in intact cells, and similar results were obtained with bacterial expression systems; and 4) quantification of the synapsin III level in synapsin I/II double knockout mice showed that the level of synapsin III is decreased by 50%, indicating that heteromultimerization of synapsin III with synapsins I or II occurs in vivo and is required for protein stabilization. These data suggest that synapsins coat the surface of synaptic vesicles as homo- and heterodimers in which the C-domains of the various subunits have distinct regulatory properties and are flanked by variable C-terminal sequences. The data also imply that synapsin III does not compensate for the loss of synapsins I and II in the double knockout mice.	Univ Texas, SW Med Sch, Ctr Basic Neurosci, Dallas, TX 75235 USA; Univ Texas, SW Med Sch, Howard Hughes Med Inst, Dept Mol Genet, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Sudhof, TC (corresponding author), Univ Texas, SW Med Sch, Ctr Basic Neurosci, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.			Hosaka, Masahiro/0000-0002-1422-1774				Esser L, 1998, EMBO J, V17, P977, DOI 10.1093/emboj/17.4.977; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GREENGARD P, 1987, MOL NEUROBIOL, V1, P81, DOI 10.1007/BF02935265; HALL FL, 1990, J BIOL CHEM, V265, P6944; Hata Y, 1996, J NEUROSCI, V16, P2488; Hicks A, 1997, NEUROSCIENCE, V79, P329, DOI 10.1016/S0306-4522(96)00700-2; Hosaka M, 1998, J BIOL CHEM, V273, P13371, DOI 10.1074/jbc.273.22.13371; Hosaka M, 1998, J BIOL CHEM, V273, P1425, DOI 10.1074/jbc.273.3.1425; HUTTNER WB, 1981, J BIOL CHEM, V256, P1482; Jovanovic JN, 1996, P NATL ACAD SCI USA, V93, P3679, DOI 10.1073/pnas.93.8.3679; Kao HT, 1998, P NATL ACAD SCI USA, V95, P4667, DOI 10.1073/pnas.95.8.4667; Klagges BRE, 1996, J NEUROSCI, V16, P3154; Matsubara M, 1996, J BIOL CHEM, V271, P21108, DOI 10.1074/jbc.271.35.21108; MatusLeibovitch N, 1997, MOL BRAIN RES, V45, P301, DOI 10.1016/S0169-328X(96)00265-3; Missler M, 1998, J NEUROSCI, V18, P3630; Morimoto K, 1998, SEIZURE-EUR J EPILEP, V7, P229; Okamoto M, 1997, J BIOL CHEM, V272, P31459, DOI 10.1074/jbc.272.50.31459; ROSAHL TW, 1995, NATURE, V375, P488, DOI 10.1038/375488a0; ROSAHL TW, 1993, CELL, V75, P661, DOI 10.1016/0092-8674(93)90487-B; Rose MD., 1990, METHODS YEAST GENETI; Ryan TA, 1996, J CELL BIOL, V134, P1219, DOI 10.1083/jcb.134.5.1219; Staple JK, 1997, EUR J NEUROSCI, V9, P721, DOI 10.1111/j.1460-9568.1997.tb01420.x; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; SUDHOF TC, 1989, SCIENCE, V245, P1474, DOI 10.1126/science.2506642; SUDHOF TC, 1996, P UEH MEM FDT S, P3; SUDHOF TC, 1991, NEUROSCI YEAR, V2, P146; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WOODS CM, 1985, CELL, V40, P959, DOI 10.1016/0092-8674(85)90356-3	28	72	73	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16747	16753		10.1074/jbc.274.24.16747	http://dx.doi.org/10.1074/jbc.274.24.16747			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358015	hybrid			2022-12-25	WOS:000080780400014
J	Coulson, EJ; Reid, K; Barrett, GL; Bartlett, PF				Coulson, EJ; Reid, K; Barrett, GL; Bartlett, PF			p75 neurotrophin receptor-mediated neuronal death is promoted by Bcl-2 and prevented by Bcl-x(L)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; LEUKEMIA INHIBITORY FACTOR; CELL-DEATH; NMR STRUCTURE; PC12 CELLS; APOPTOSIS; DOMAIN; BAX; EXPRESSION; SURVIVAL	The p75 neurotrophin receptor (p75NTR) has been shown to mediate neuronal death through an unknown pathway. We microinjected p75NTR expression plasmids into sensory neurons in the presence of growth factors and assessed the effect of the expressed proteins on cell survival. We show that, unlike other members of the TNFR family, p75NTR signals death through a unique caspase-dependent death pathway that does not involve the "death domain" and is differentially regulated by Bcl-2 family members: the anti-apoptotic molecule Bcl-2 both promoted, and was required for, p75NTR killing, whereas killing was inhibited by its homologue BcI-x(L). These results demonstrate that Bcl-2, through distinct molecular mechanisms, either promotes or inhibits neuronal death depending on the nature of the death stimulus.	Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia; Univ Melbourne, Dept Physiol, Parkville, Vic 3052, Australia	Royal Melbourne Hospital; Walter & Eliza Hall Institute; University of Melbourne	Bartlett, PF (corresponding author), Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia.		Coulson, Elizabeth J./C-8766-2009; Bartlett, Perry/F-3813-2012	Coulson, Elizabeth J./0000-0003-3783-6197; 				ALLSOPP TE, 1995, EUR J NEUROSCI, V7, P1266, DOI 10.1111/j.1460-9568.1995.tb01116.x; ALLSOPP TE, 1993, CELL, V73, P295, DOI 10.1016/0092-8674(93)90230-N; Bamji SX, 1998, J CELL BIOL, V140, P911, DOI 10.1083/jcb.140.4.911; Barrett GL, 1996, J NEUROSCI RES, V45, P117, DOI 10.1002/(SICI)1097-4547(19960715)45:2<117::AID-JNR4>3.0.CO;2-D; BARRETT GL, 1994, P NATL ACAD SCI USA, V91, P6501, DOI 10.1073/pnas.91.14.6501; BERNARD O, 1996, FRONTIERS SPINAL COR; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; CasacciaBonnefil P, 1996, NATURE, V383, P716, DOI 10.1038/383716a0; CHAO MV, 1995, TRENDS NEUROSCI, V18, P321, DOI 10.1016/0166-2236(95)93922-K; Cheema SS, 1996, J NEUROSCI RES, V46, P239, DOI 10.1002/(SICI)1097-4547(19961015)46:2<239::AID-JNR12>3.0.CO;2-Y; Chen J, 1996, P NATL ACAD SCI USA, V93, P7042, DOI 10.1073/pnas.93.14.7042; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Coulpier M, 1996, J NEUROSCI, V16, P5897; Davey F, 1998, CURR BIOL, V8, P915, DOI 10.1016/S0960-9822(07)00371-5; Deckwerth TL, 1996, NEURON, V17, P401, DOI 10.1016/S0896-6273(00)80173-7; Ekert PG, 1999, EMBO J, V18, P330, DOI 10.1093/emboj/18.2.330; Erhardt P, 1996, J BIOL CHEM, V271, P17601, DOI 10.1074/jbc.271.30.17601; FARLIE PG, 1995, P NATL ACAD SCI USA, V92, P4397, DOI 10.1073/pnas.92.10.4397; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; Frade JM, 1998, NEURON, V20, P35, DOI 10.1016/S0896-6273(00)80432-8; Frade JM, 1996, NATURE, V383, P166; Huang DCS, 1998, EMBO J, V17, P1029, DOI 10.1093/emboj/17.4.1029; Huang DCS, 1997, ONCOGENE, V14, P405, DOI 10.1038/sj.onc.1200848; Ihara S, 1997, EMBO J, V16, P5345, DOI 10.1093/emboj/16.17.5345; KOTZBAUER PT, 1994, NEURON, V12, P763, DOI 10.1016/0896-6273(94)90329-8; Liepinsh E, 1997, EMBO J, V16, P4999, DOI 10.1093/emboj/16.16.4999; Majdan M, 1997, J NEUROSCI, V17, P6988; Merry DE, 1997, ANNU REV NEUROSCI, V20, P245, DOI 10.1146/annurev.neuro.20.1.245; MERRY DE, 1994, DEVELOPMENT, V120, P301; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; MURPHY M, 1993, DEVELOPMENT, V117, P1173; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Uhlmann EJ, 1998, J BIOL CHEM, V273, P17926, DOI 10.1074/jbc.273.28.17926; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0	42	52	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16387	16391		10.1074/jbc.274.23.16387	http://dx.doi.org/10.1074/jbc.274.23.16387			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347198	hybrid			2022-12-25	WOS:000080668600058
J	Jeong, EJ; Bang, S; Lee, TH; Park, YI; Sim, WS; Kim, KS				Jeong, EJ; Bang, S; Lee, TH; Park, YI; Sim, WS; Kim, KS			The solution structure of FADD death domain - Structural basis of death domain interactions of Fas and FADD	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-STRUCTURE DETERMINATION; SIGNALING COMPLEX DISC; NMR STRUCTURE; INDUCED APOPTOSIS; DIRECT REFINEMENT; RECEPTOR SIGNALS; EFFECTOR DOMAIN; CD95 FAS/APO-1; CELL-DEATH; RESONANCE	A signal of Pas-mediated apoptosis is transferred through an adaptor protein Pas-associated death domain protein (FADD) by interactions between the death domains of Pas and FADD. To understand the signal transduction mechanism of Pas-mediated apoptosis, we solved the solution structure of a murine FADD death domain. It consists of six helices arranged in a similar fold to the other death domains. The interactions between the death domains of Pas and FADD analyzed by site-directed mutagenesis indicate that charged residues in helices alpha 2 and alpha 3 are involved in death domain interactions, and the interacting helices appear to interact in anti-parallel pattern, alpha 2 of FADD with alpha 3 of Fas and vice versa.	KIST, Struct biol Ctr, Seoul 130650, South Korea; Korea Univ, Dept Biol, Seoul 136701, South Korea; Korea Univ, Grad Sch Biotechnol, Seoul 136701, South Korea; Yonsei Univ, Dept Biol, Seoul 120749, South Korea	Korea Institute of Science & Technology (KIST); Korea University; Korea University; Yonsei University	Kim, KS (corresponding author), KIST, Struct biol Ctr, Seoul 130650, South Korea.							Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Chou JJ, 1998, CELL, V94, P171, DOI 10.1016/S0092-8674(00)81417-8; CLORE G M, 1991, Journal of Biomolecular NMR, V1, P13, DOI 10.1007/BF01874566; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Eberstadt M, 1998, NATURE, V392, P941, DOI 10.1038/31972; Eberstadt M, 1997, NAT STRUCT BIOL, V4, P983, DOI 10.1038/nsb1297-983; GARRETT DS, 1994, J MAGN RESON SER B, V104, P99, DOI 10.1006/jmrb.1994.1061; Goltsev YV, 1997, J BIOL CHEM, V272, P19641, DOI 10.1074/jbc.272.32.19641; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hu SM, 1997, J BIOL CHEM, V272, P9621; Huang BH, 1996, NATURE, V384, P638, DOI 10.1038/384638a0; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KAY LE, 1993, J MAGN RESON SER B, V101, P333, DOI 10.1006/jmrb.1993.1053; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUBONIWA H, 1994, J BIOMOL NMR, V4, P871, DOI 10.1007/BF00398416; Kuszewski J, 1997, J MAGN RESON, V125, P171, DOI 10.1006/jmre.1997.1116; KUSZEWSKI J, 1995, J MAGN RESON SER B, V106, P92, DOI 10.1006/jmrb.1995.1017; Kuszewski J, 1996, PROTEIN SCI, V5, P1067; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Liepinsh E, 1997, EMBO J, V16, P4999, DOI 10.1093/emboj/16.16.4999; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MUHANDIRAM DR, 1994, J MAGN RESON SER B, V103, P203, DOI 10.1006/jmrb.1994.1032; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NICHOLSON D, 1991, CHARACTERIZATION POR, V2, P11; Park A, 1996, J BIOL CHEM, V271, P9858, DOI 10.1074/jbc.271.16.9858; PASCAL SM, 1994, J MAGN RESON SER B, V103, P197, DOI 10.1006/jmrb.1994.1031; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Wiegmann K, 1999, J BIOL CHEM, V274, P5267, DOI 10.1074/jbc.274.9.5267; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Zhang J, 1996, MOL CELL BIOL, V16, P2756; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413	43	95	97	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16337	16342		10.1074/jbc.274.23.16337	http://dx.doi.org/10.1074/jbc.274.23.16337			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347191	hybrid			2022-12-25	WOS:000080668600051
J	Mount, DB; Mercado, A; Song, LY; Xu, J; George, AL; Delpire, E; Gamba, G				Mount, DB; Mercado, A; Song, LY; Xu, J; George, AL; Delpire, E; Gamba, G			Cloning and characterization of KCC3 and KCC4, new members of the cation-chloride cotransporter gene family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K-CL COTRANSPORTER; BARTTERS-SYNDROME; HYPOKALEMIC ALKALOSIS; MOLECULAR-CLONING; CHROMOSOME 15Q; ION-TRANSPORT; RABBIT; EXPRESSION; MUTATIONS; EPILEPSY	The K+-Cl- cotransporters (KCCs) belong to the gene family of electroneutral cation-chloride cotransporters, which also includes two bumetanide-sensitive Na+-K+-2Cl(-) cotransporters and a thiazide sensitive Na+-Cl- cotransporter. We have cloned cDNAs encoding mouse KCC3, human KCC3, and human KCC4, three new members of this gene family. The KCC3 and KCC4 cDNAs predict proteins of 1083 and 1150 amino acids, respectively. The KCC3 and KCC4 proteins are 65-71% identical to the previously characterized transporters KCC1 and KCC2, with which they share a predicted membrane topology, The four KCC proteins differ at amino acid residues within key transmembrane domains and in the distribution of putative phosphorylation sites within the amino- and carboxyl-terminal cytoplasmic domains. The expression of mouse KCC3 in Xenopus laevis oocytes reveals the expected functional characteristics of a K+Cl- cotransporter: Cl--dependent uptake of Rb-86(+) which is strongly activated by cell swelling and weakly sensitive to furosemide, A direct functional comparison of mouse KCC3 to rabbit KCC1 indicates that KCC3 has a much greater volume sensitivity. The human KCC3 and KCC4 genes are located on chromosomes 5p15 and 15q14, respectively. Although widely expressed, KCC3 transcripts are the most abundant in heart and kidney, and KCC4 is expressed in muscle, brain, lung, heart, and kidney, The unexpected molecular heterogeneity of K+-Cl- cotransport has implications for the physiology and pathophysiology of a number of tissues.	Vanderbilt Univ, Med Ctr, Div Nephrol, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Anesthesiol, Nashville, TN 37232 USA; Univ Nacl Autonoma Mexico, Inst Invest Biomed, Mexico City, DF, Mexico; Univ Nacl Autonoma Mexico, Inst Nacl Nutr Salvador Zubiran, Mol Physiol Unit, Mexico City, DF, Mexico	Vanderbilt University; Vanderbilt University; Universidad Nacional Autonoma de Mexico; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran - Mexico; Universidad Nacional Autonoma de Mexico	Mount, DB (corresponding author), Vanderbilt Univ, Med Ctr, Div Nephrol, Dept Med, MCN S-3223, Nashville, TN 37232 USA.	david.mount@mcmail.vanderbilt.edu	Mercado, Adriana/AAR-6143-2021; Gamba, Gerardo/P-4873-2016	Mercado, Adriana/0000-0002-6881-0160; Gamba, Gerardo/0000-0002-4378-9043	NHLBI NIH HHS [R-29 HL-49251] Funding Source: Medline; NIDDK NIH HHS [K-11 DK02103] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL049251] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K11DK002103] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADRAGNA NC, 1994, J MEMBRANE BIOL, V142, P195; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; AMLAL H, 1994, AM J PHYSIOL-CELL PH, V267, pC1607, DOI 10.1152/ajpcell.1994.267.6.C1607; Andersen GO, 1998, AM J PHYSIOL-HEART C, V275, pH641, DOI 10.1152/ajpheart.1998.275.2.H641; Armour JAL, 1996, ANN HUM GENET, V60, P11, DOI 10.1111/j.1469-1809.1996.tb01167.x; AVISON MJ, 1988, J MEMBRANE BIOL, V105, P197, DOI 10.1007/BF01870997; Casaubon LK, 1996, AM J HUM GENET, V58, P28; Clayton GH, 1998, DEV BRAIN RES, V109, P281, DOI 10.1016/S0165-3806(98)00078-9; Cossins AR, 1997, J EXP BIOL, V200, P343; DRWINGA HL, 1993, GENOMICS, V16, P311, DOI 10.1006/geno.1993.1190; ELLISON DH, 1985, AM J PHYSIOL, V248, pF638, DOI 10.1152/ajprenal.1985.248.5.F638; Elmslie FV, 1997, HUM MOL GENET, V6, P1329, DOI 10.1093/hmg/6.8.1329; Flatman PW, 1996, AM J PHYSIOL-CELL PH, V271, pC255, DOI 10.1152/ajpcell.1996.271.1.C255; Freedman R, 1997, P NATL ACAD SCI USA, V94, P587, DOI 10.1073/pnas.94.2.587; GAMBA G, 1994, J BIOL CHEM, V269, P17713; Gillen CM, 1996, J BIOL CHEM, V271, P16237, DOI 10.1074/jbc.271.27.16237; GREGER R, 1985, PHYSIOL REV, V65, P760, DOI 10.1152/physrev.1985.65.3.760; Haas M, 1998, J BIOENERG BIOMEMBR, V30, P161, DOI 10.1023/A:1020521308985; Holtzman EJ, 1998, AM J PHYSIOL-RENAL, V275, pF550, DOI 10.1152/ajprenal.1998.275.4.F550; Isenring P, 1998, J GEN PHYSIOL, V112, P549, DOI 10.1085/jgp.112.5.549; Isenring P, 1998, P NATL ACAD SCI USA, V95, P7179, DOI 10.1073/pnas.95.12.7179; Lafreniere RG, 1997, NAT GENET, V15, P298, DOI 10.1038/ng0397-298; LARSEN F, 1993, HUM MOL GENET, V2, P1589, DOI 10.1093/hmg/2.10.1589; LAUF PK, 1992, AM J PHYSIOL, V63, pC917; Liapis H, 1998, AM J PHYSIOL-CELL PH, V275, pC1432, DOI 10.1152/ajpcell.1998.275.6.C1432; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; LING BN, 1995, KIDNEY INT, V48, P1158, DOI 10.1038/ki.1995.399; LU J, 1999, IN PRESS J NEUROBIOL; Makalowski W, 1998, P NATL ACAD SCI USA, V95, P9407, DOI 10.1073/pnas.95.16.9407; MISGELD U, 1986, SCIENCE, V232, P1413, DOI 10.1126/science.2424084; Mount DB, 1998, J EXP BIOL, V201, P2091; Neubauer BA, 1998, NEUROLOGY, V51, P1608, DOI 10.1212/WNL.51.6.1608; Payne JA, 1996, J BIOL CHEM, V271, P16245, DOI 10.1074/jbc.271.27.16245; Payne JA, 1997, AM J PHYSIOL-CELL PH, V273, pC1516, DOI 10.1152/ajpcell.1997.273.5.C1516; Pellegrino CM, 1998, BLOOD CELL MOL DIS, V24, P31, DOI 10.1006/bcmd.1998.0168; PIWNICAWORMS D, 1985, AM J PHYSIOL, V249, pC337, DOI 10.1152/ajpcell.1985.249.3.C337; Plotkin MD, 1997, AM J PHYSIOL-CELL PH, V272, pC173, DOI 10.1152/ajpcell.1997.272.1.C173; Randall J, 1997, AM J PHYSIOL-CELL PH, V273, pC1267, DOI 10.1152/ajpcell.1997.273.4.C1267; Rivera C, 1999, NATURE, V397, P251, DOI 10.1038/16697; SASAKI S, 1988, J CLIN INVEST, V81, P194, DOI 10.1172/JCI113294; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Simon DB, 1996, NAT GENET, V12, P24, DOI 10.1038/ng0196-24; Simon DB, 1996, NAT GENET, V13, P183, DOI 10.1038/ng0696-183; Simon DB, 1997, NAT GENET, V17, P171, DOI 10.1038/ng1097-171; WEILMASLANSKY E, 1994, AM J PHYSIOL-CELL PH, V267, pC932, DOI 10.1152/ajpcell.1994.267.4.C932; WINGO CS, 1989, AM J PHYSIOL, V256, pF697, DOI 10.1152/ajprenal.1989.256.4.F697; Yan GX, 1996, J PHYSIOL-LONDON, V490, P215, DOI 10.1113/jphysiol.1996.sp021137	47	239	247	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16355	16362		10.1074/jbc.274.23.16355	http://dx.doi.org/10.1074/jbc.274.23.16355			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347194	hybrid			2022-12-25	WOS:000080668600054
J	Pushkin, A; Abuladze, N; Lee, I; Newman, D; Hwang, J; Kurtz, I				Pushkin, A; Abuladze, N; Lee, I; Newman, D; Hwang, J; Kurtz, I			Cloning, tissue distribution, genomic organization, and functional characterization of NBCS, a new member of the sodium bicarbonate cotransporter family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR-PH REGULATION; VASCULAR SMOOTH-MUSCLE; HYDROGEN EXCHANGE; PROXIMAL TUBULE; INFARCT SIZE; RABBIT HEART; ETHYLISOPROPYL-AMILORIDE; RESISTANCE ARTERIES; NA+/H+ EXCHANGE; SKELETAL-MUSCLE	Previous functional studies have demonstrated that muscle intracellular pH regulation is mediated by sodium-coupled bicarbonate transport, Na+/H+ exchange, and Cl-/bicarbonate exchange. We report the cloning, sequence analysis, tissue distribution, genomic organization, and functional analysis of a new member of the sodium bicarbonate cotransporter (NBC) family, NBC3, from human skeletal muscle. mNBC3 encodes a 1214-residue polypeptide with 12 putative membrane-spanning domains. The similar to 7.8-kilobase transcript is expressed uniquely in skeletal muscle and heart. The NBCS gene (SLC4A7) spans similar to 80 kb and is composed of 25 coding exons and 24 introns that are flanked by typical splice donor and acceptor sequences. Expression of mNBC3 cRNA in Xenopus laevis oocytes demonstrated that the protein encodes a novel stilbene-insensitive 5-(N-ethyl-N-isopropyl)-amiloride-inhibitable sodium bicarbonate cotransporter.	Univ Calif Los Angeles, Div Nephrol, Ctr Hlth Sci, Sch Med, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Kurtz, I (corresponding author), Univ Calif Los Angeles, Div Nephrol, Ctr Hlth Sci, Sch Med, 10833 Le Conte Ave,Rm 7-155 Factor Bldg, Los Angeles, CA 90095 USA.	IKurtz@med1.medsch.ucla.edu			NIDDK NIH HHS [DK46976] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046976] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AALKJAER C, 1991, AM J PHYSIOL, V261, pC1010, DOI 10.1152/ajpcell.1991.261.6.C1010; AALKJAER C, 1991, J PHYSIOL-LONDON, V436, P57, DOI 10.1113/jphysiol.1991.sp018539; AALKJAER C, 1988, J PHYSIOL-LONDON, V402, P391, DOI 10.1113/jphysiol.1988.sp017211; Aalkjaer C, 1997, ACTA PHYSIOL SCAND, V161, P557, DOI 10.1046/j.1365-201X.1997.00263.x; Abuladze N, 1998, J BIOL CHEM, V273, P17689, DOI 10.1074/jbc.273.28.17689; ABULADZE N, 1998, AM J PHYSIOL, V43, pF628; AICKIN CC, 1977, J PHYSIOL-LONDON, V273, P295, DOI 10.1113/jphysiol.1977.sp012095; AICKIN CC, 1994, J PHYSIOL-LONDON, V479, P331, DOI 10.1113/jphysiol.1994.sp020299; AICKIN CC, 1994, J PHYSIOL-LONDON, V479, P317, DOI 10.1113/jphysiol.1994.sp020298; BLATTER LA, 1991, CIRC RES, V68, P150, DOI 10.1161/01.RES.68.1.150; BOBIK A, 1990, CLIN EXP PHARMACOL P, V17, P297, DOI 10.1111/j.1440-1681.1990.tb01324.x; BOBIK A, 1991, AM J PHYSIOL, V260, pC581, DOI 10.1152/ajpcell.1991.260.3.C581; BONANNO JA, 1992, INVEST OPHTH VIS SCI, V33, P3068; BORON WF, 1981, AM J PHYSIOL, V240, pC80, DOI 10.1152/ajpcell.1981.240.1.C80; BORON WF, 1983, J GEN PHYSIOL, V81, P53, DOI 10.1085/jgp.81.1.53; Boussouf A, 1997, GLIA, V19, P74, DOI 10.1002/(SICI)1098-1136(199701)19:1<74::AID-GLIA8>3.0.CO;2-A; BUGGE E, 1995, CARDIOVASC RES, V29, P269, DOI 10.1016/S0008-6363(96)88580-4; Bugge E, 1996, BASIC RES CARDIOL, V91, P203, DOI 10.1007/BF00788906; Burnham CE, 1998, AM J PHYSIOL-RENAL, V274, pF1119, DOI 10.1152/ajprenal.1998.274.6.F1119; Burnham CE, 1997, J BIOL CHEM, V272, P19111, DOI 10.1074/jbc.272.31.19111; CARR P, 1995, AM J PHYSIOL-CELL PH, V268, pC580, DOI 10.1152/ajpcell.1995.268.3.C580; DART C, 1992, J PHYSIOL-LONDON, V451, P365, DOI 10.1113/jphysiol.1992.sp019169; DASCAL N, 1984, J PHYSIOL-LONDON, V352, P551, DOI 10.1113/jphysiol.1984.sp015310; DEHURTADO MCC, 1995, J MOL CELL CARDIOL, V27, P231; GALLER S, 1986, J PHYSIOL-LONDON, V374, P137, DOI 10.1113/jphysiol.1986.sp016071; GERSTHEIMER FP, 1987, PFLUG ARCH EUR J PHY, V409, P60, DOI 10.1007/BF00584750; GRICHTCHENKO II, 1994, NEUROSCIENCE, V62, P1071, DOI 10.1016/0306-4522(94)90344-1; GROSSIE J, 1988, J MEMBRANE BIOL, V105, P265, DOI 10.1007/BF01871003; Henry P, 1996, CARDIOVASC RES, V32, P930; Ishibashi K, 1998, BIOCHEM BIOPH RES CO, V246, P535, DOI 10.1006/bbrc.1998.8658; Juel C, 1996, ACTA PHYSIOL SCAND, V156, P369, DOI 10.1046/j.1365-201X.1996.206000.x; KAHN AM, 1986, AM J PHYSIOL, V261, pC837; KETTENMANN H, 1988, J PHYSIOL-LONDON, V406, P147, DOI 10.1113/jphysiol.1988.sp017373; KLOCKNER U, 1994, J GEN PHYSIOL, V103, P647, DOI 10.1085/jgp.103.4.647; Komukai K, 1998, AM J PHYSIOL-HEART C, V274, pH147, DOI 10.1152/ajpheart.1998.274.1.H147; KURTZ I, 1987, J CLIN INVEST, V80, P928, DOI 10.1172/JCI113184; LAGADICGOSSMANN D, 1992, J PHYSIOL-LONDON, V458, P361, DOI 10.1113/jphysiol.1992.sp019422; LITTLE PJ, 1995, CARDIOVASC RES, V29, P239, DOI 10.1016/0008-6363(96)88576-2; LUCCHESI PA, 1995, CARDIOVASC RES, V29, P172, DOI 10.1016/0008-6363(96)88566-X; Munch-Ellingsen J, 1998, MOL CELL BIOCHEM, V186, P13, DOI 10.1023/A:1006820509480; NEYLON CB, 1990, CIRC RES, V67, P814, DOI 10.1161/01.RES.67.4.814; OKUBO K, 1994, J BIOL CHEM, V269, P1918; Olson TM, 1996, J CLIN INVEST, V97, P528, DOI 10.1172/JCI118445; PEREZ NG, 1995, CAN J CARDIOL, V11, P553; Pushkin A, 1999, GENOMICS, V57, P321, DOI 10.1006/geno.1999.5781; PUTNAM RW, 1990, AM J PHYSIOL, V258, pC470, DOI 10.1152/ajpcell.1990.258.3.C470; REUSCH HP, 1995, AM J PHYSIOL-CELL PH, V268, pC147, DOI 10.1152/ajpcell.1995.268.1.C147; Romero MF, 1997, NATURE, V387, P409, DOI 10.1038/387409a0; ROMERO MF, 1998, AM J PHYSIOL, V274, pF413; SASAKI S, 1992, BIOCHIM BIOPHYS ACTA, V1137, P45, DOI 10.1016/0167-4889(92)90098-V; Sato H, 1997, BASIC RES CARDIOL, V92, P339, DOI 10.1007/BF00788946; STAHL F, 1992, AM J PHYSIOL, V262, pC427, DOI 10.1152/ajpcell.1992.262.2.C427; WESTERBLAD H, 1992, J PHYSIOL-LONDON, V449, P49, DOI 10.1113/jphysiol.1992.sp019074; WOOD PG, 1992, J MEMBRANE BIOL, V127, P139; Wu C, 1998, J PHYSIOL-LONDON, V508, P131, DOI 10.1111/j.1469-7793.1998.131br.x	55	156	161	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16569	16575		10.1074/jbc.274.23.16569	http://dx.doi.org/10.1074/jbc.274.23.16569			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347222	hybrid			2022-12-25	WOS:000080668600082
J	Sallmann, FR; Baveye-Descamps, S; Pattus, F; Salmon, V; Branza, N; Spik, G; Legrand, D				Sallmann, FR; Baveye-Descamps, S; Pattus, F; Salmon, V; Branza, N; Spik, G; Legrand, D			Porins OmpC and PhoE of Escherichia coli as specific cell-surface targets of human lactoferrin - Binding characteristics and biological effects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; HUMAN LACTOTRANSFERRIN; OUTER-MEMBRANE; ANTIBACTERIAL ACTIVITY; BOVINE LACTOFERRIN; HUMAN TRANSFERRINS; LOOP REGION; PROTEIN; RECEPTOR; LIPOPOLYSACCHARIDE	The binding of lactoferrin, an iron-binding glycoprotein found in secretions and leukocytes, to the outer membrane of Gram-negative bacteria is a prerequisite to exert its bactericidal activity. It was proposed that porins, in addition to lipopolysaccharides, are responsible for this binding. We studied the interactions of human lactoferrin with the three major porins of Escherichia coli OmpC, OmpF, and PhoE. Binding experiments were performed on both purified porins and porin-deficient E. coli K12 isogenic mutants. We determined that lactoferrin binds to the purified native OmpC or PhoE trimer with molar ratios of 1.9 +/- 0.4 and 1.8 +/- 0.5 and K-d values of 39 +/- 18 and 103 +/- 15 mM, respectively, but not to OmpF, Furthermore, preferential binding of lactoferrin was observed on strains that express either OmpC or PhoE, It was also demonstrated that residues 1-5, 28-34, and 39-42 of lactoferrin interact with porins, Eased on sequence comparisons, the involvement of lactoferrin amino acid residues and porin loops in the interactions is discussed. The relationships between binding and antibacterial activity of the protein were studied using E. coli mutants and planar Lipid bilayers. Electrophysiological studies revealed that lactoferrin can act as a blocking agent for OmpC but not for PhoE or OmpF. However, a total inhibition of the growth was only observed for the PhoE-expressing strain (minimal inhibitory concentration of lactoferrin was 2.4 mg/ml). These data support the proposal that the antibacterial activity of lactoferrin may depend, at least in part, on its ability to bind to porins, thus modifying the stability and/or the permeability of the bacterial outer membrane.	Univ Sci & Technol Lille, Chim Biol Lab, F-59655 Villeneuve Dascq, France; Univ Sci & Technol Lille, CNRS, UMR 8576, F-59655 Villeneuve Dascq, France; Ecole Super Biotechnol Strasbourg, CNRS, Unite Propre Rech 9050, Dept Recepteurs & Prot Membranaires, F-67400 Illkirch, France	Universite de Lille - ISITE; Universite de Lille; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Lille - ISITE; Universite de Lille; Centre National de la Recherche Scientifique (CNRS)	Legrand, D (corresponding author), Univ Sci & Technol Lille, Chim Biol Lab, F-59655 Villeneuve Dascq, France.		Legrand, Dominique/AAT-5715-2021	LEGRAND, Dominique/0000-0002-0814-221X				APPELMELK BJ, 1994, INFECT IMMUN, V62, P2628, DOI 10.1128/IAI.62.6.2628-2632.1994; BELLAMY W, 1992, BIOCHIM BIOPHYS ACTA, V1121, P130, DOI 10.1016/0167-4838(92)90346-F; BELLAMY WR, 1993, J APPL BACTERIOL, V75, P478; BENZ R, 1988, ANNU REV MICROBIOL, V42, P359, DOI 10.1146/annurev.mi.42.100188.002043; Chapple DS, 1998, INFECT IMMUN, V66, P2434, DOI 10.1128/IAI.66.6.2434-2440.1998; DELAVEGA AL, 1995, EMBO J, V14, P6058, DOI 10.1002/j.1460-2075.1995.tb00294.x; Elass-Rochard E, 1998, INFECT IMMUN, V66, P486, DOI 10.1128/IAI.66.2.486-491.1998; ElassRochard E, 1995, BIOCHEM J, V312, P839, DOI 10.1042/bj3120839; ELLISON RT, 1990, J GEN MICROBIOL, V136, P1437, DOI 10.1099/00221287-136-7-1437; ERDEI J, 1994, INFECT IMMUN, V62, P1236, DOI 10.1128/IAI.62.4.1236-1240.1994; FOUREL D, 1993, J BACTERIOL, V175, P2754, DOI 10.1128/JB.175.9.2754-2757.1993; HUETTINGER M, 1992, J BIOL CHEM, V267, P18551; Hwang PM, 1998, BIOCHEMISTRY-US, V37, P4288, DOI 10.1021/bi972323m; JEANTEUR D, 1991, MOL MICROBIOL, V5, P2153, DOI 10.1111/j.1365-2958.1991.tb02145.x; Kang JH, 1996, INT J PEPT PROT RES, V48, P357; KORTELAND J, 1982, BIOCHIM BIOPHYS ACTA, V690, P282, DOI 10.1016/0005-2736(82)90332-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKEY JH, 1989, EUR J BIOCHEM, V186, P303, DOI 10.1111/j.1432-1033.1989.tb15209.x; LEAR JD, 1988, SCIENCE, V240, P1177, DOI 10.1126/science.2453923; LEGRAND D, 1984, BIOCHIM BIOPHYS ACTA, V787, P90, DOI 10.1016/0167-4838(84)90111-0; LEGRAND D, 1992, BIOCHEMISTRY-US, V31, P9243, DOI 10.1021/bi00153a018; Legrand D, 1997, BIOCHEM J, V327, P841, DOI 10.1042/bj3270841; LEGRAND D, 1995, FEBS LETT, V365, P57, DOI 10.1016/0014-5793(95)00441-B; LEVYTOLEDANO S, 1995, THROMB HAEMOSTASIS, V73, P857; MACGILLIVRAY RTA, 1982, P NATL ACAD SCI-BIOL, V79, P2504, DOI 10.1073/pnas.79.8.2504; MANN DM, 1994, J BIOL CHEM, V269, P23661; MASSON PL, 1969, J EXP MED, V130, P643, DOI 10.1084/jem.130.3.643; MAZURIER J, 1980, BIOCHIM BIOPHYS ACTA, V629, P399, DOI 10.1016/0304-4165(80)90112-9; MAZURIER J, 1983, BIOCHIM BIOPHYS ACTA, V745, P44, DOI 10.1016/0167-4838(83)90168-1; METZBOUTIGUE MH, 1984, EUR J BIOCHEM, V145, P659, DOI 10.1111/j.1432-1033.1984.tb08607.x; MONTREUIL J, 1960, BIOCHIM BIOPHYS ACTA, V45, P413, DOI 10.1016/0006-3002(60)91478-5; MORONA R, 1985, EUR J BIOCHEM, V150, P161, DOI 10.1111/j.1432-1033.1985.tb09002.x; MYERS EW, 1988, COMPUT APPL BIOSCI, V4, P11, DOI 10.1093/bioinformatics/4.1.11; NAIDU SS, 1993, ANTIMICROB AGENTS CH, V37, P240, DOI 10.1128/AAC.37.2.240; NIKAIDO H, 1985, MICROBIOL REV, V49, P1; Odell EW, 1996, FEBS LETT, V382, P175, DOI 10.1016/0014-5793(96)00168-8; ORAM JD, 1968, BIOCHIM BIOPHYS ACTA, V170, P351, DOI 10.1016/0304-4165(68)90015-9; PIERCE A, 1991, EUR J BIOCHEM, V196, P177, DOI 10.1111/j.1432-1033.1991.tb15801.x; PUGSLEY AP, 1984, MICROBIOL SCI, V1, P168; REY MW, 1990, NUCLEIC ACIDS RES, V18, P5288, DOI 10.1093/nar/18.17.5288; Salmon V, 1997, PROTEIN EXPRES PURIF, V9, P203, DOI 10.1006/prep.1996.0687; Sambrook J., 2002, MOL CLONING LAB MANU; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHINDLER H, 1978, P NATL ACAD SCI USA, V75, P3751, DOI 10.1073/pnas.75.8.3751; SCHINDLER H, 1980, FEBS LETT, V122, P77, DOI 10.1016/0014-5793(80)80405-4; SCHINDLER M, 1979, BIOCHEMISTRY-US, V18, P4425, DOI 10.1021/bi00587a024; Shimazaki K, 1998, J DAIRY SCI, V81, P2841, DOI 10.3168/jds.S0022-0302(98)75843-6; SPIK G, 1982, EUR J BIOCHEM, V121, P413, DOI 10.1111/j.1432-1033.1982.tb05803.x; STEPHENS S, 1980, IMMUNOLOGY, V41, P597; TIGYL Z, 1992, INFECT IMMUN, V60, P2619, DOI 10.1128/IAI.60.7.2619-2626.1992; TOMMASSEN J, 1985, EMBO J, V4, P1583, DOI 10.1002/j.1460-2075.1985.tb03820.x; TUCKER AD, 1991, J MOL BIOL, V222, P881, DOI 10.1016/0022-2836(91)90582-Q; vanBerkel PHC, 1997, BIOCHEM J, V328, P145, DOI 10.1042/bj3280145; VISCA P, 1990, MED MICROBIOL IMMUN, V179, P323; WU HF, 1995, ARCH BIOCHEM BIOPHYS, V317, P85, DOI 10.1006/abbi.1995.1139; YAMAUCHI K, 1993, INFECT IMMUN, V61, P719, DOI 10.1128/IAI.61.2.719-728.1993; Ziere GJ, 1996, BIOCHEM J, V313, P289, DOI 10.1042/bj3130289; ZIERE GJ, 1993, J BIOL CHEM, V268, P27069	58	48	51	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16107	16114		10.1074/jbc.274.23.16107	http://dx.doi.org/10.1074/jbc.274.23.16107			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347162	hybrid			2022-12-25	WOS:000080668600022
J	Chen, NY; Ma, WY; Huang, CS; Dong, ZG				Chen, NY; Ma, WY; Huang, CS; Dong, ZG			Translocation of protein kinase C epsilon and protein kinase C delta to membrane is required for ultraviolet B-induced activation of mitogen-activated protein kinases and apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED AP-1 ACTIVATION; GROWTH-FACTOR; UV IRRADIATION; PHORBOL ESTER; SIGNAL; INHIBITION; CELLS; P53; PHOSPHORYLATION; RECEPTOR	UV-induced signal transduction may be involved in tumor promotion and induction of apoptosis, The role of protein kinase C (PKC) in UVB-induced signal transduction is not well understood. This study showed that UVB markedly induced translocation of membrane-associated PKC epsilon and PKC delta, but not PKC alpha, from cytosol to membrane. Dominant negative mutant (DNM) PKC epsilon or PKC delta inhibited UVB-induced translocation of PKC epsilon and PKC delta, respectively, UVB-induced activation of extracellular signal-regulated protein kinases (Erks) and c-Jun NH2-terminal kinases (JNKs) was strongly inhibited by DNM PKC epsilon and PKC delta, whereas the DNM of PKC alpha was less effective on the UVB-induced phosphorylation of Erks and JNKs, Among the PKC inhibitors used only rottlerin, a selective inhibitor of PKC delta, markedly inhibited the UVB-induced activation of Erks and JNKs, but not p38 kinases, Safingol, a selective inhibitor for PKC alpha, did not show any inhibitory effect on UVB-induced mitogen-activated protein kinase activation. GF109203X is a stronger inhibitor of classical PKC than novel PKC, Lower concentrations of GF109203X (<10 mu M) had no effect on UVB-induced activation of Erks or JNKs, However, at higher concentrations (over 20 mu M), GF109203X inhibited UVB-induced activation of JNKs, Erks, and even p38 kinases. Meanwhile, rottlerin and GF109203X markedly inhibited UVB-induced apoptosis of JB6 cells, whereas safingol had little inhibitory effect. DNM-Erk2 cells and PD98059, a selective inhibitor for mitogen-activated protein kinase/extracellular signal-regulated kinase 1 that directly activates Erks, inhibited UVB-induced apoptosis. DNM-JNK1 cells also blocked UVB-induced apoptosis, whereas SB202190, a specific inhibitor for p38 kinases, did not produce the inhibitory effect. These data demonstrate that PKC delta and PKC epsilon, but not PKC alpha, mediate UVB-induced signal transduction and apoptosis in JB6 cells through activation of Erks and JNKs.	Univ Minnesota, Hormel Inst, Austin, MN 55912 USA	University of Minnesota System	Dong, ZG (corresponding author), Univ Minnesota, Hormel Inst, 801 16Th Ave NE, Austin, MN 55912 USA.			Huang, Chuanshu/0000-0003-4133-5096	NATIONAL CANCER INSTITUTE [R29CA074916] Funding Source: NIH RePORTER; NCI NIH HHS [CA74916] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER V, 1995, J BIOL CHEM, V270, P26071, DOI 10.1074/jbc.270.44.26071; Adler V, 1996, J BIOL CHEM, V271, P23304, DOI 10.1074/jbc.271.38.23304; ANGEL P, 1995, INDUCIBLE GENE EXPRE, P62; Berra E, 1998, J BIOL CHEM, V273, P10792, DOI 10.1074/jbc.273.17.10792; BLACKSHEAR PJ, 1988, FASEB J, V2, P2957, DOI 10.1096/fasebj.2.14.2972578; Boutwell R K, 1974, CRC Crit Rev Toxicol, V2, P419; CHAN TM, 1986, BIOCHEM BIOPH RES CO, V139, P439, DOI 10.1016/S0006-291X(86)80010-9; CUNNINGHAM M L, 1985, Journal of Free Radicals in Biology and Medicine, V1, P381, DOI 10.1016/0748-5514(85)90150-3; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; Dong ZG, 1997, J BIOL CHEM, V272, P9962; Dong ZG, 1998, ONCOGENE, V17, P1845, DOI 10.1038/sj.onc.1202084; EPSTEIN JH, 1983, J AM ACAD DERMATOL, V9, P487, DOI 10.1016/S0190-9622(83)70160-X; Findlay GM, 1928, LANCET, V2, P1070; FITZPATRICK TB, 1976, RES PHOTOBIOLOGY, P485; FORBES PD, 1976, RES PHOTOBIOLOGY, P469; Fry R J, 1989, Carcinog Compr Surv, V11, P321; GOPALAKRISHNA R, 1989, P NATL ACAD SCI USA, V86, P6758, DOI 10.1073/pnas.86.17.6758; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; HAYES GR, 1987, P NATL ACAD SCI USA, V84, P8115, DOI 10.1073/pnas.84.22.8115; Huang CS, 1998, CANCER RES, V58, P4102; Huang CS, 1998, CELL SIGNAL, V10, P185, DOI 10.1016/S0898-6568(97)00098-3; Huang CS, 1996, J BIOL CHEM, V271, P31262, DOI 10.1074/jbc.271.49.31262; Huang CS, 1997, P NATL ACAD SCI USA, V94, P11957, DOI 10.1073/pnas.94.22.11957; Huang CS, 1997, ONCOGENE, V14, P1945, DOI 10.1038/sj.onc.1201056; Huang CS, 1997, J BIOL CHEM, V272, P27753, DOI 10.1074/jbc.272.44.27753; Jimenez LA, 1997, AM J PHYSIOL-LUNG C, V273, pL1029, DOI 10.1152/ajplung.1997.273.5.L1029; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KRAFT AS, 1982, J BIOL CHEM, V257, P13193; LEHEL C, 1995, J BIOL CHEM, V270, P19651, DOI 10.1074/jbc.270.33.19651; LIU M, 1994, CARCINOGENESIS, V15, P1089, DOI 10.1093/carcin/15.6.1089; MATSUI MS, 1995, SKIN CANC MECH HUMAN, P21; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; NEWTON AC, 1995, CURR BIOL, V5, P973, DOI 10.1016/S0960-9822(95)00191-6; OLAH Z, 1994, ANAL BIOCHEM, V221, P94, DOI 10.1006/abio.1994.1384; OLIVIER AR, 1994, J BIOL CHEM, V269, P2758; PETERSEN M, 1995, PHOTOCHEM PHOTOBIOL, V62, P444, DOI 10.1111/j.1751-1097.1995.tb02366.x; PUNNONEN K, 1992, J INVEST DERMATOL, V99, P221, DOI 10.1111/1523-1747.ep12650445; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; RUNNEBAUM IB, 1994, ANTICANCER RES, V14, P1137; SACHS CW, 1995, J BIOL CHEM, V270, P26639, DOI 10.1074/jbc.270.44.26639; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; STRICKLAND PT, 1986, J INVEST DERMATOL, V86, P37, DOI 10.1111/1523-1747.ep12283779; Sun Y, 1997, ONCOGENE, V14, P385, DOI 10.1038/sj.onc.1200834; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; WILKINSON SE, 1993, BIOCHEM J, V294, P335, DOI 10.1042/bj2940335; WILLIS I, 1981, J INVEST DERMATOL, V76, P404, DOI 10.1111/1523-1747.ep12520945	49	124	126	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15389	15394		10.1074/jbc.274.22.15389	http://dx.doi.org/10.1074/jbc.274.22.15389			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336426	hybrid			2022-12-25	WOS:000080560100015
J	Faulkner, A; Chen, XM; Rush, J; Horazdovsky, B; Waechter, CJ; Carman, GM; Sternweis, PC				Faulkner, A; Chen, XM; Rush, J; Horazdovsky, B; Waechter, CJ; Carman, GM; Sternweis, PC			The LPP1 and DPP1 gene products account for most of the isoprenoid phosphate phosphatase activities in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIACYLGLYCEROL PYROPHOSPHATE PHOSPHATASE; RAT-LIVER MICROSOMES; DOLICHYL-PHOSPHATE; ESCHERICHIA-COLI; ACID PHOSPHATASE; PLASMA-MEMBRANES; YEAST; PROTEIN; PURIFICATION; PHOSPHOHYDROLASE	Two genes in Saccharomyces cerevisiae, LPP1 and DPP1, with homology to a mammalian phosphatidic acid (PA) phosphatase were identified and disrupted. Neither single nor combined deletions resulted in growth or secretion phenotypes. As observed previously (Toke, D. A., Bennett, W. L., Dillon, D. A., Wu, W.-I., Chen, X., Ostrander, D. B., Oshiro, J., Cremesti, A., Voelker, D. R., Fischl, A. S., and Carman, G. M. (1998) J. Biol. Chem. 273, 3278-3284; Toke, D. A., Bennett, W. L., Oshiro, J., Wu, W.-I., Voelker, D. R., and Carman, G. M. (1998) J. Biol. Chem. 273, 14331-14338), the disruption of DPP1 and LPP1 produced profound losses of Mg2+-independent PA phosphatase activity. The coincident attenuation of hydrolytic activity against diacylglycerol pyrophosphate prompted an examination of the effects of these disruptions on hydrolysis of isoprenoid pyrophosphates. Disruption of either LPP1 or DPP1 caused respective decreases of about 25 and 75% in Mg2+-independent hydrolysis of several isoprenoid phosphates by particulate fractions isolated from these cells. The particulate and cytosolic fractions from the double disruption (lpp1 Delta dpp1 Delta) showed essentially complete loss of Mg2+-independent hydrolytic activity toward dolichyl phosphate (dolichyl-P), dolichyl pyrophosphate (dolichyl-P-P), farnesyl pyrophosphate (farnesyl-P-P), and geranylgeranyl pyrophosphate (geranylgeranyl-P-P). However, a modest Mg2+-stimulated activity toward PA and dolichyl-P was retained in cytosol from lpp1 Delta dpp1 Delta cells. The action of Dpp1p on isoprenyl pyrophosphates was confirmed by characterization of the hydrolysis of geranylgeranyl-P-P by the purified protein. These results indicate that LPP1 and DPP1 account for most of the hydrolytic activities toward dolichyl-P-P, dolichyl-P, farnesyl-P-P, and geranylgeranyl-P-P but also suggest that yeast contain other enzymes capable of dephosphorylating these essential isoprenoid intermediates.	Univ Texas, SW Med Sch, Dept Pharmacol, Dallas, TX 75235 USA; Univ Texas, SW Med Sch, Dept Biochem, Dallas, TX 75235 USA; Rutgers State Univ, Cook Coll, Dept Food Sci, New Brunswick, NJ 08901 USA; Univ Kentucky, Albert B Chandler Med Ctr, Dept Biochem, Coll Med, Lexington, KY 40536 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Rutgers State University New Brunswick; University of Kentucky	Sternweis, PC (corresponding author), Univ Texas, SW Med Sch, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	sternwei@UTSW.swmed.edu	Lazar, Alexander J/A-3416-2008	Lazar, Alexander J/0000-0002-6395-4499	NIGMS NIH HHS [GM36065, GM31954, GM28140] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM028140, R01GM031954, R01GM028140, R01GM036065] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANSAL VS, 1994, ARCH BIOCHEM BIOPHYS, V315, P393, DOI 10.1006/abbi.1994.1516; BELOCOPITOW E, 1982, EUR J BIOCHEM, V125, P167, DOI 10.1111/j.1432-1033.1982.tb06664.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brindley DN, 1998, J BIOL CHEM, V273, P24281, DOI 10.1074/jbc.273.38.24281; Brindley DN, 1996, CHEM PHYS LIPIDS, V80, P45, DOI 10.1016/0009-3084(96)02545-5; BURTON WA, 1981, ARCH BIOCHEM BIOPHYS, V208, P409, DOI 10.1016/0003-9861(81)90526-9; CARMAN GM, 1991, METHOD ENZYMOL, V197, P548; Carman GM, 1996, J BIOL CHEM, V271, P13293, DOI 10.1074/jbc.271.23.13293; Carman GM, 1997, BBA-LIPID LIPID MET, V1348, P45, DOI 10.1016/S0005-2760(97)00095-7; CARMAN GM, 1992, METHOD ENZYMOL, V209, P219; CHOJNACKI T, 1988, BIOCHEM J, V251, P1; Crick DC, 1997, BIOCHEM BIOPH RES CO, V237, P483, DOI 10.1006/bbrc.1997.7145; Dillon DA, 1997, J BIOL CHEM, V272, P10361; Dillon DA, 1996, J BIOL CHEM, V271, P30548, DOI 10.1074/jbc.271.48.30548; Frank DW, 1998, J BIOL CHEM, V273, P11791, DOI 10.1074/jbc.273.19.11791; Guthrie C, 1991, METHOD ENZYMOL, V194, P3; HEMMING FW, 1992, BIOCHEM CELL BIOL, V70, P377, DOI 10.1139/o92-058; Hemrika W, 1997, P NATL ACAD SCI USA, V94, P2145, DOI 10.1073/pnas.94.6.2145; HERSCOVICS A, 1993, FASEB J, V7, P540, DOI 10.1096/fasebj.7.6.8472892; Hooks SB, 1998, FEBS LETT, V427, P188, DOI 10.1016/S0014-5793(98)00421-9; HOSAKA K, 1984, BIOCHIM BIOPHYS ACTA, V796, P102; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSON LM, 1987, CELL, V48, P875, DOI 10.1016/0092-8674(87)90084-5; Kai M, 1996, J BIOL CHEM, V271, P18931, DOI 10.1074/jbc.271.31.18931; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; MARTIN A, 1991, METHOD ENZYMOL, V197, P553; MORLOCK KR, 1991, J BIOL CHEM, V266, P3586; MORLOCK KR, 1988, J BACTERIOL, V170, P3561, DOI 10.1128/jb.170.8.3561-3566.1988; Neuwald AF, 1997, PROTEIN SCI, V6, P1764, DOI 10.1002/pro.5560060817; ORLEAN P, 1992, BIOCHEM CELL BIOL, V70, P438, DOI 10.1139/o92-067; RIP JW, 1981, J BIOL CHEM, V256, P1929; Roberts R, 1998, J BIOL CHEM, V273, P22059, DOI 10.1074/jbc.273.34.22059; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; ROSSIGNOL DP, 1983, J BIOL CHEM, V258, P9122; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHER MG, 1985, J BIOL CHEM, V260, P3742; SCHER MG, 1985, METHOD ENZYMOL, V111, P547; Sherman F, 1979, METHODS YEAST GENETI; STEINER S, 1972, J BACTERIOL, V109, P81, DOI 10.1128/JB.109.1.81-88.1972; Stukey J, 1997, PROTEIN SCI, V6, P469; SUMBILLA C, 1985, METHOD ENZYMOL, V111, P471; Szkopinska A, 1997, J LIPID RES, V38, P962; Toke DA, 1998, J BIOL CHEM, V273, P3278, DOI 10.1074/jbc.273.6.3278; Toke DA, 1998, J BIOL CHEM, V273, P14331, DOI 10.1074/jbc.273.23.14331; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WAECHTER CJ, 1981, RES METHODS NEUROCHE, P201; Waggoner DW, 1996, J BIOL CHEM, V271, P16506, DOI 10.1074/jbc.271.28.16506; WAGGONER DW, 1995, J BIOL CHEM, V270, P19422, DOI 10.1074/jbc.270.33.19422; Wu WI, 1996, J BIOL CHEM, V271, P1868, DOI 10.1074/jbc.271.4.1868; WU WI, 1994, J BIOL CHEM, V269, P29495; WU WI, 1993, J BIOL CHEM, V268, P13830; Zhang N, 1997, NATURE, V385, P64, DOI 10.1038/385064a0	52	106	113	2	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					14831	14837		10.1074/jbc.274.21.14831	http://dx.doi.org/10.1074/jbc.274.21.14831			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329682	hybrid			2022-12-25	WOS:000081965200047
J	Lee, L; Abe, A; Shayman, JA				Lee, L; Abe, A; Shayman, JA			Improved inhibitors of glucosylceramide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOCEREBROSIDE SYNTHETASE; CERAMIDE	Previous work has led to the identification of inhibitors of glucosylceramide synthase, the enzyme catalyzing the first glycosylation step in the synthesis of glucosylceramide-based glycosphingolipids. These inhibitors have two identified sites of action: the inhibition of glucosylceramide synthase, resulting in the depletion of cellular glycosphingolipids, and the inhibition of 1-O-acylceramide synthase, resulting in the elevation of cell ceramide levels. A new series of glucosylceramide synthase inhibitors based on substitutions in the phenyl ring of a parent compound, 1-phenyl-2-palmitoylamino3-pyrrolidino-1-propanol (P4), was made. For substitutions of single functional groups, the potency of these inhibitors in blocking glucosylceramide synthase was primarily dependent upon the hydrophobic and electronic properties of the substituents, An exponential relationship was found between the IC50 of each inhibitor and the sum of derived hydrophobic (pi) and electronic (sigma) parameters. This relationship demonstrated that substitutions that increased the electron-donating characteristics and decreased the lipophilic characteristics of the homologues enhanced the potency of these compounds in blocking glucosylceramide formation. A novel compound was subsequently designed and observed to be even more active in blocking glucosylceramide formation. This compound, D-threo-4'-hydroxy-P4, inhibited glucosylceramide synthase at an IC50 of 90 nM In addition, a series of dioxane substitutions was designed and tested. These included 3',4'-methylenedioxyphenyl-, 3',4'-ethylenedioxyphenyl-, and 3'4'-trimethylenedioxyphenyl substituted homologues. D-threo-3',4'-Ethylenedioxy-P4-inhibited glucosylceramide synthase was comparably active to the p-hydroxy homologue. 4'-Hydroxy-P4 and ethylenedioxy-P4 blocked glucosylceramide synthase activity at concentrations that had little effect on 1-O-acylceramide synthase activity. These novel inhibitors resulted in the inhibition of glycosphingolipid synthesis in cultured cells at concentrations that did not significantly raise intracellular ceramide levels or inhibit cell growth.	Univ Michigan, Med Ctr, Dept Internal Med, Div Nephrol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Shayman, JA (corresponding author), Univ Michigan, Med Ctr, Dept Internal Med, Div Nephrol, POB 0676,Rm 1560 MSRBII,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.				NIDDK NIH HHS [R01 DK41487] Funding Source: Medline; PHS HHS [R0139255] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041487] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABE A, 1992, EUR J BIOCHEM, V210, P765, DOI 10.1111/j.1432-1033.1992.tb17479.x; ABE A, 1995, J LIPID RES, V36, P611; Abe A, 1996, J BIOL CHEM, V271, P14383, DOI 10.1074/jbc.271.24.14383; Abe A, 1998, J BIOL CHEM, V273, P8467, DOI 10.1074/jbc.273.14.8467; ABE A, 1992, J BIOCHEM-TOKYO, V111, P191, DOI 10.1093/oxfordjournals.jbchem.a123736; ABE A, 1996, BIOCH BIOCH ACTA, V1299, P331; Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; HAKOMORI S, 1993, ADV LIPID RES, V23, P147; HAMMETT LP, 1940, PHYSICAL ORGANIC CHE; HOGBERG T, 1991, TXB DRUG DESIGN DEV, P55; INOKUCHI JI, 1987, J LIPID RES, V28, P565; Platt FM, 1997, SCIENCE, V276, P428, DOI 10.1126/science.276.5311.428; PREISS J, 1986, J BIOL CHEM, V261, P8597; RANI CSS, 1995, J BIOL CHEM, V270, P2859, DOI 10.1074/jbc.270.6.2859; SHAYMAN JA, 1990, J BIOL CHEM, V265, P12135; SHUKLA GS, 1991, BIOCHIM BIOPHYS ACTA, V1083, P101, DOI 10.1016/0005-2760(91)90130-A; TUTE MS, 1970, ADV DRUG RES, V6, P1; VUNNAM RR, 1980, CHEM PHYS LIPIDS, V26, P265	18	189	224	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					14662	14669		10.1074/jbc.274.21.14662	http://dx.doi.org/10.1074/jbc.274.21.14662			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329660	hybrid			2022-12-25	WOS:000081965200025
J	Sahni, A; Sporn, LA; Francis, CW				Sahni, A; Sporn, LA; Francis, CW			Potentiation of endothelial cell proliferation by fibrin(ogen)-bound fibroblast growth factor-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR PRODUCTION; DNA-SYNTHESIS; BETA-CHAIN; EXTRACELLULAR-MATRIX; VONWILLEBRAND-FACTOR; AFFINITY RECEPTORS; FIBRIN; EXPRESSION; HEPARIN; PROTEIN	Endothelial cell growth is stimulated by fibroblast growth factor-2 (FGF-2), and both adhesion and proliferation are modulated by interactions with fibrinogen and fibrin. Previous evidence indicates that FGF-2 binds specifically and with high affinity to fibrinogen and fibrin, suggesting that their effects on endothelial cells may be coordinated. In this study, we have, therefore, investigated the ability of FGF-2 bound to fibrinogen and fibrin to stimulate proliferation of endothelial cells. Human umbilical vein endothelial cells were cultured in the presence of FGF-2 with or without fibrinogen, and proliferation was assessed by microscopic examination of cultures, incorporation of [H-3]thymidine and by cell counting. Cells cultured in the presence of both FGF-2 and fibrinogen proliferated more rapidly than those with FGF-2 alone and exhibited a decreased population doubling time. At concentrations of FGF-2 up to 150 ng/ml, there was greater endothelial cell proliferation in the presence of fibrinogen than in its absence with the most pronounced effect below 1 ng/ml. The maximum effect of fibrinogen was observed at a molar ratio of fibrinogen to FGF-2 of 2:1, corresponding to the maximum molar binding ratio. Endothelial cells proliferated when plated on fibrin or surface-immobilized fibrinogen with FGF-2, indicating that FGF-2 bound to surface-associated fibrin(ogen) retained activity. We conclude that fibrinogen- or fibrin-bound FGF-2 is able to support endothelial cell proliferation and that fibrinogen potentiates the proliferative capacity of FGF-2.	Univ Rochester, Med Ctr, Dept Med, Vasc Med Unit,Sch Med & Dent, Rochester, NY 14642 USA	University of Rochester	Francis, CW (corresponding author), Univ Rochester, Med Ctr, Dept Med, Vasc Med Unit,Sch Med & Dent, Box 610,601 Elmwood Ave, Rochester, NY 14642 USA.	charles_francis@URMC.rochester.edu			NHLBI NIH HHS [HL-07152, HL-30616] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030616] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARAKI S, 1990, BIOCHEM BIOPH RES CO, V168, P1194, DOI 10.1016/0006-291X(90)91155-L; Bach TL, 1998, EXP CELL RES, V238, P324, DOI 10.1006/excr.1997.3844; BARBIERI B, 1981, P SOC EXP BIOL MED, V168, P204; BASHKIN P, 1989, BIOCHEMISTRY-US, V28, P1737, DOI 10.1021/bi00430a047; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BUNCE LA, 1992, J CLIN INVEST, V89, P842, DOI 10.1172/JCI115663; CASSCELLS W, 1992, P NATL ACAD SCI USA, V89, P7159, DOI 10.1073/pnas.89.15.7159; CHERESH DA, 1989, CELL, V58, P945, DOI 10.1016/0092-8674(89)90946-X; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; ERBAN JK, 1992, J BIOL CHEM, V267, P2451; FLAUMENHAFT R, 1989, J CELL PHYSIOL, V140, P75, DOI 10.1002/jcp.1041400110; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; FUKAO H, 1990, THROMB RES, P11; FUKAO H, 1995, LIFE SCI, V57, P1267, DOI 10.1016/0024-3205(95)02083-U; GORCZYCA W, 1993, CANCER RES, V53, P1945; GOSPODAROWICZ D, 1986, J CELL PHYSIOL, V128, P475, DOI 10.1002/jcp.1041280317; GUALANDRIS A, 1995, J CELL PHYSIOL, V162, P400, DOI 10.1002/jcp.1041620312; Hartung H, 1997, MECH DEVELOP, V64, P31, DOI 10.1016/S0925-4773(97)00042-7; HOBSON B, 1984, BRIT J CANCER, V49, P405, DOI 10.1038/bjc.1984.66; HUGHES SE, 1993, CARDIOVASC RES, V27, P1199, DOI 10.1093/cvr/27.7.1199; KAPLAN KL, 1989, ARTERIOSCLEROSIS, V9, P43, DOI 10.1161/01.ATV.9.1.43; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; KLEIN S, 1993, MOL BIOL CELL, V4, P973, DOI 10.1091/mbc.4.10.973; LANGUINO LR, 1993, CELL, V73, P1423, DOI 10.1016/0092-8674(93)90367-Y; MIGNATTI P, 1991, J CELL BIOL, V113, P1193, DOI 10.1083/jcb.113.5.1193; MOSCATELLI D, 1986, P NATL ACAD SCI USA, V83, P2091, DOI 10.1073/pnas.83.7.2091; Pepper MS, 1997, ARTERIOSCL THROM VAS, V17, P605, DOI 10.1161/01.ATV.17.4.605; PEPPER MS, 1990, J CELL BIOL, V111, P743, DOI 10.1083/jcb.111.2.743; PLOPPER GE, 1995, MOL BIOL CELL, V6, P1349, DOI 10.1091/mbc.6.10.1349; PRESTA M, 1986, MOL CELL BIOL, V6, P4060, DOI 10.1128/MCB.6.11.4060; QI JF, 1995, J IMMUNOL, V155, P867; RAMSBY ML, 1993, INVEST OPHTH VIS SCI, V34, P3207; RIBES JA, 1987, J CLIN INVEST, V79, P117, DOI 10.1172/JCI112771; RIBES JA, 1989, J CLIN INVEST, V84, P435, DOI 10.1172/JCI114184; ROSENGART TK, 1988, BIOCHEM BIOPH RES CO, V152, P432, DOI 10.1016/S0006-291X(88)80732-0; Rusnati M, 1997, MOL BIOL CELL, V8, P2449, DOI 10.1091/mbc.8.12.2449; Sahni A, 1998, J BIOL CHEM, V273, P7554, DOI 10.1074/jbc.273.13.7554; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SCHLEEF RR, 1982, TISSUE CELL, V14, P629, DOI 10.1016/0040-8166(82)90053-2; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; SPORN LA, 1995, BLOOD, V86, P1802, DOI 10.1182/blood.V86.5.1802.bloodjournal8651802; Suehiro K, 1997, J BIOL CHEM, V272, P5360, DOI 10.1074/jbc.272.8.5360; TERRANOVA VP, 1985, J CELL BIOL, V101, P2330, DOI 10.1083/jcb.101.6.2330; THORNTON SC, 1983, SCIENCE, V222, P623, DOI 10.1126/science.6635659; TSAI JC, 1995, J NEUROSURG, V82, P864, DOI 10.3171/jns.1995.82.5.0864; WAGNER DD, 1982, J CELL BIOL, V95, P355, DOI 10.1083/jcb.95.1.355	49	70	84	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					14936	14941		10.1074/jbc.274.21.14936	http://dx.doi.org/10.1074/jbc.274.21.14936			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329694	hybrid			2022-12-25	WOS:000081965200059
J	Schullery, DS; Ostrowski, J; Denisenko, ON; Stempka, L; Shnyreva, M; Suzuki, H; Gschwendt, M; Bomsztyk, K				Schullery, DS; Ostrowski, J; Denisenko, ON; Stempka, L; Shnyreva, M; Suzuki, H; Gschwendt, M; Bomsztyk, K			Regulated interaction of protein kinase C delta with the heterogeneous nuclear ribonucleoprotein K protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VAV PROTOONCOGENE PRODUCT; HNRNP-K; TYROSINE PHOSPHORYLATION; RNA-BINDING; TRANSCRIPTIONAL REPRESSOR; IN-VITRO; DNA; PURIFICATION; DOMAIN; IDENTIFICATION	The heterogeneous nuclear ribonucleoprotein (hnRNP) K protein recruits a diversity of molecular partners that are involved in signal transduction, transcription, RNA processing, and translation. K protein is phosphorylated in vivo and in vitro by inducible kinase(s) and contains several potential sites for protein kinase C (PKC) phosphorylation, In this study we show that K protein is phosphorylated in vitro by PKC delta and by other PKCs, Deletion analysis and site-directed mutagenesis revealed that Ser(302) is a major K protein site phosphorylated by PKC delta in vitro, This residue is located in the middle of a short amino acid fragment that divides the two clusters of SH3-binding domains. Mutation of Ser(302) decreased the level of phosphorylation of exogenously expressed K protein in phorbol la-myristate 13-acetate-treated COS cells, suggesting that Ser(302) is also a site for PKC-mediated phosphorylation in vivo. In vitro, PKC delta binds K protein via the highly interactive KI domain, an interaction that is blocked by poly(C) RNA. Mutation of Ser(302) did not alter the K protein-PKG delta interaction in vitro, suggesting that phosphorylation of this residue alone is not sufficient to alter this interaction. Instead, binding of PKC delta to K protein in vitro and in vivo was greatly increased by K protein phosphorylation on tyrosine residues. The ability of PKC delta to bind and phosphorylate K protein may serve not only to alter the activity of K protein itself, but K protein may also bridge PKC delta to other K protein molecular partners and thus facilitate molecular cross-talk. The regulated nature of the PKC delta-K protein interaction may serve to meet cellular needs at sites of active transcription, RNA processing and translation in response to changing extracellular environment.	Univ Washington, Dept Med, Seattle, WA 98195 USA; German Canc Res Ctr, D-69120 Heidelberg, Germany; Maria Sklodowska Curie Mem Canc Ctr, Dept Gastroenterol, PL-02781 Warsaw, Poland; Inst Oncol, PL-02781 Warsaw, Poland	University of Washington; University of Washington Seattle; Helmholtz Association; German Cancer Research Center (DKFZ); Maria Sklodowska-Curie National Research Institute of Oncology; Maria Sklodowska-Curie National Research Institute of Oncology	Bomsztyk, K (corresponding author), Univ Washington, Dept Med, Box 356521, Seattle, WA 98195 USA.				NIDDK NIH HHS [DK45978] Funding Source: Medline; NIGMS NIH HHS [GM45134] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045978, R37DK045978] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045134] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bomsztyk K, 1997, FEBS LETT, V403, P113, DOI 10.1016/S0014-5793(97)00041-0; BUSTELO XR, 1995, MOL CELL BIOL, V15, P1324; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; Collier B, 1998, J BIOL CHEM, V273, P22648, DOI 10.1074/jbc.273.35.22648; DEJGAARD K, 1994, J MOL BIOL, V236, P33, DOI 10.1006/jmbi.1994.1116; Denisenko ON, 1997, MOL CELL BIOL, V17, P4707, DOI 10.1128/MCB.17.8.4707; Denisenko ON, 1996, J BIOL CHEM, V271, P27701, DOI 10.1074/jbc.271.44.27701; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Du Q, 1998, J BIOL CHEM, V273, P19877, DOI 10.1074/jbc.273.31.19877; HOBERT O, 1994, J BIOL CHEM, V269, P20225; Hsieh TY, 1998, J BIOL CHEM, V273, P17651, DOI 10.1074/jbc.273.28.17651; ITO K, 1994, NUCLEIC ACIDS RES, V22, P53, DOI 10.1093/nar/22.1.53; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; KIELBASSA K, 1995, J BIOL CHEM, V270, P6156, DOI 10.1074/jbc.270.11.6156; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee MH, 1996, J BIOL CHEM, V271, P3420; LEIBERSPERGER H, 1990, J BIOL CHEM, V265, P16108; LOWENTHAL JW, 1986, J EXP MED, V164, P1060, DOI 10.1084/jem.164.4.1060; MANAK JR, 1990, GENE DEV, V4, P955, DOI 10.1101/gad.4.6.955; Mangus DA, 1998, MOL CELL BIOL, V18, P7383, DOI 10.1128/MCB.18.12.7383; MATUNIS MJ, 1994, NUCLEIC ACIDS RES, V22, P1059, DOI 10.1093/nar/22.6.1059; MATUNIS MJ, 1992, MOL CELL BIOL, V12, P164, DOI 10.1128/MCB.12.1.164; Miau LH, 1998, J BIOL CHEM, V273, P10784, DOI 10.1074/jbc.273.17.10784; Michael WM, 1997, EMBO J, V16, P3587, DOI 10.1093/emboj/16.12.3587; Michelotti EF, 1996, MOL CELL BIOL, V16, P2350, DOI 10.1128/mcb.16.5.2350; MICHELOTTI EF, 1995, J BIOL CHEM, V270, P9494, DOI 10.1074/jbc.270.16.9494; MUNICIO MM, 1995, J BIOL CHEM, V270, P15884, DOI 10.1074/jbc.270.26.15884; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; Ostareck DH, 1997, CELL, V89, P597, DOI 10.1016/S0092-8674(00)80241-X; OSTROWSKI J, 1994, J BIOL CHEM, V269, P17626; OSTROWSKI J, 1991, J BIOL CHEM, V266, P12722; OSTROWSKI J, 1993, NUCLEIC ACIDS RES, V21, P1045, DOI 10.1093/nar/21.4.1045; ROSENBERGER U, 1995, BIOCHEM J, V305, P269, DOI 10.1042/bj3050269; ROSENBERGER U, 1996, EUR J CELL BIOL S42, V69, P288; SIOMI H, 1994, CELL, V77, P33, DOI 10.1016/0092-8674(94)90232-1; SIOMI H, 1993, NUCLEIC ACIDS RES, V21, P1193, DOI 10.1093/nar/21.5.1193; Stempka L, 1997, J BIOL CHEM, V272, P6805, DOI 10.1074/jbc.272.10.6805; VANSEUNINGEN I, 1995, BIOCHEMISTRY-US, V34, P5644, DOI 10.1021/bi00016a040; VANSEUNINGEN I, 1995, J BIOL CHEM, V270, P26976, DOI 10.1074/jbc.270.45.26976; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; Zang Q, 1997, J BIOL CHEM, V272, P13275, DOI 10.1074/jbc.272.20.13275; ZANG R, 1994, BIOCHEM J, V304, P641, DOI 10.1042/bj3040641; ZICK Y, 1990, BIOCHEMISTRY-US, V29, P10240, DOI 10.1021/bi00496a013	44	87	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					15101	15109		10.1074/jbc.274.21.15101	http://dx.doi.org/10.1074/jbc.274.21.15101			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329716	hybrid			2022-12-25	WOS:000081965200081
J	Kaspar, P; Dvorakova, M; Kralova, J; Pajer, P; Kozmik, Z; Dvorak, M				Kaspar, P; Dvorakova, M; Kralova, J; Pajer, P; Kozmik, Z; Dvorak, M			Myb-interacting protein, ATBF1, represses transcriptional activity of Myb oncoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-MYB; V-MYB; LEUCINE-ZIPPER; NUCLEOTIDE-SEQUENCE; CELLULAR PROGENITOR; MAMMALIAN-CELLS; GENE-EXPRESSION; BINDING PROTEIN; ONCOGENE; TRANSACTIVATION	Using the yeast two-hybrid system, the transcription factor ATBF1 was identified as v-Myb- and c-Myb-binding protein. Deletion mutagenesis revealed amino acids 2484-2520 in human ATBF1 and 279-300 in v-Myb as regions required for in vitro binding of both proteins. Further experiments identified leucines Leu(325) and Leu(332) of the Myb leucine zipper motif as additional amino acid residues important for efficient ATBF1-Myb interaction in vitro, In co-transfection experiments, the full-length ATBF1 was found to form in vivo complexes with v-Myb and inhibit v-Myb transcriptional activity. Both ATBF1 2484-2520 and Myb 279-300 regions were required for the inhibitory effect. Finally, the chicken ATBF1 was identified, showing high degree of amino acid sequence homology with human and murine proteins. Our data reveal Myb proteins as the first ATBF1 partners detected so far and identify amino acids 279-300 in v-Myb as a novel protein-protein interaction interface through which Myb transcriptional activity can he regulated.	Acad Sci Czech Republ, Inst Mol Genet, Prague 16637 6, Czech Republic	Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences	Dvorak, M (corresponding author), Acad Sci Czech Republ, Inst Mol Genet, Flemingovo 2, Prague 16637 6, Czech Republic.	mdvorak@img.cas.cz	Kozmik, Zbynek/I-8807-2014; Kozmik, Zbynek/G-3581-2014; Kralova, Jarmila/G-3834-2014; Kaspar, Petr/G-5864-2014; Pajer, Petr/G-5869-2014; Kaspar, Petr/J-1705-2014; Dvořák, Michal/I-9939-2014; Dvorak, Michal/G-5861-2014	Kralova, Jarmila/0000-0002-4735-8857; Kozmik, Zbynek/0000-0002-5850-2105				ARSURA M, 1995, MOL CELL BIOL, V15, P6702; Bartunek P, 1997, ONCOGENE, V15, P2939, DOI 10.1038/sj.onc.1201457; BARTUNEK P, 1992, VIROLOGY, V190, P882, DOI 10.1016/0042-6822(92)90930-N; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; Dash AB, 1996, GENE DEV, V10, P1858, DOI 10.1101/gad.10.15.1858; DVORAK M, 1989, NUCLEIC ACIDS RES, V17, P5651; FAVIER D, 1994, ONCOGENE, V9, P305; Gonda TJ, 1996, CURR TOP MICROBIOL, V211, P99; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; Hegde SP, 1998, MOL CELL BIOL, V18, P2729, DOI 10.1128/MCB.18.5.2729; INTRONA M, 1994, SEMIN CANCER BIOL, V5, P113; KALKBRENNER F, 1990, ONCOGENE, V5, P657; KaneiIshii C, 1997, SCIENCE, V277, P246, DOI 10.1126/science.277.5323.246; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; Leverson JD, 1998, MOL CELL, V1, P203, DOI 10.1016/S1097-2765(00)80021-0; Lipsick JS, 1996, ONCOGENE, V13, P223; LIPSICK JS, 1986, J VIROL, V59, P267, DOI 10.1128/JVI.59.2.267-275.1986; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MAHESWARAN S, 1994, MOL CELL BIOL, V14, P1147, DOI 10.1128/MCB.14.2.1147; Mink S, 1996, MOL CELL BIOL, V16, P1316; MIURA Y, 1995, J BIOL CHEM, V270, P26840, DOI 10.1074/jbc.270.45.26840; MORINAGA T, 1991, MOL CELL BIOL, V11, P6041, DOI 10.1128/MCB.11.12.6041; Ness SA, 1996, BBA-REV CANCER, V1288, pF123, DOI 10.1016/S0304-419X(96)00027-3; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; Pfitzner E, 1998, P NATL ACAD SCI USA, V95, P5539, DOI 10.1073/pnas.95.10.5539; Postigo AA, 1997, EMBO J, V16, P3924, DOI 10.1093/emboj/16.13.3924; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SENECA S, 1993, ONCOGENE, V8, P2335; VRANOVSKY K, 1992, GENE, V117, P233; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; YASUDA H, 1994, MOL CELL BIOL, V14, P1395, DOI 10.1128/MCB.14.2.1395	38	51	57	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					14422	14428		10.1074/jbc.274.20.14422	http://dx.doi.org/10.1074/jbc.274.20.14422			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318867	hybrid			2022-12-25	WOS:000080322200096
J	Vilk, G; Saulnier, RB; St Pierre, R; Litchfield, DW				Vilk, G; Saulnier, RB; St Pierre, R; Litchfield, DW			Inducible expression of protein kinase CK2 in mammalian cells - Evidence for functional specialization of CK2 isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SUBUNIT; SACCHAROMYCES-CEREVISIAE; CASEIN KINASE-2; DNA-BINDING; II-ALPHA; CELLULAR-REGULATION; CYCLE PROGRESSION; BETA-SUBUNIT; GENE CSNK2A1; PHOSPHORYLATION	Protein kinase CK2 (formerly casein kinase II) exhibits elevated expression in a variety of cancers, induces lymphocyte transformation in transgenic mice, and collaborates with Ha-Ras in fibroblast transformation. To systematically examine the cellular functions of CK2, human osteosarcoma U2-OS cells constitutively expressing a tetracycline-regulated transactivator were stably transfected with a bidirectional plasmid encoding either catalytic isoform. of CK2 (i.e, CK2 alpha or CK2 alpha') together with the regulatory CK2 beta subunit in order to increase the cellular levels of either CK2 isoform. To interfere with either CK2 isoform, cells were also transfected with kinase-inactive CK2 alpha or CK2 alpha' (i.e. GK2 alpha (K68M) or CK2 alpha' (K69M)) together with CK2 beta. In these cells, removal of tetracycline from the growth medium stimulated coordinate expression of catalytic and regulatory CK2 subunits. Increased expression of active forms of CK2 alpha or CK2 alpha' resulted in modest decreases in cell proliferation, suggesting that optimal levels of CK2 are required for optimal proliferation. By comparison, the effects of induced expression of kinase-inactive CK2 alpha differed significantly from the effects of induced expression of kinase-inactive CK2 alpha'. Of particular interest is the dramatic attenuation of proliferation that is observed following induction of CK2 alpha'(K69M), but not following induction of CK2 alpha(K68M). These results provide evidence for functional specialization of CK2 isoforms in mammalian cells. Moreover, cell lines exhibiting regulatable expression of CK2 will facilitate efforts to systematically elucidate its cellular functions.	Univ Western Ontario, Hlth Sci Ctr, Dept Biochem, London, ON N6A 5C1, Canada	London Health Sciences Centre; University of Manitoba; Children's Hospital Research Institute of Manitoba; Western University (University of Western Ontario)	Litchfield, DW (corresponding author), Univ Western Ontario, Hlth Sci Ctr, Dept Biochem, London, ON N6A 5C1, Canada.	litchfi@julian.uwo.ca	Litchfield, David/E-4636-2015	Litchfield, David/0000-0002-2425-6620				ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; BARON U, 1995, NUCLEIC ACIDS RES, V23, P3605, DOI 10.1093/nar/23.17.3605; BOSC DG, 1995, J BIOL CHEM, V270, P25872, DOI 10.1074/jbc.270.43.25872; Bosc DG, 1999, MOL CELL BIOCHEM, V191, P213, DOI 10.1023/A:1006840329973; CARDENAS ME, 1992, EMBO J, V11, P1785, DOI 10.1002/j.1460-2075.1992.tb05230.x; CHENWU JLP, 1988, MOL CELL BIOL, V8, P4981, DOI 10.1128/MCB.8.11.4981; Cosmelli D, 1997, FEBS LETT, V410, P391, DOI 10.1016/S0014-5793(97)00625-X; DAYAMAKIN M, 1994, CANCER RES, V54, P2262; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Faust RA, 1996, CANCER LETT, V101, P31, DOI 10.1016/0304-3835(96)04110-9; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FRIEDRICH TD, 1989, BIOCHIM BIOPHYS ACTA, V992, P41, DOI 10.1016/0304-4165(89)90048-2; Ghavidel A, 1997, GENE DEV, V11, P2780, DOI 10.1101/gad.11.21.2780; Glover CVC, 1998, PROG NUCLEIC ACID RE, V59, P95; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HANNA DE, 1995, J BIOL CHEM, V270, P25905, DOI 10.1074/jbc.270.43.25905; Heriche JK, 1997, SCIENCE, V276, P952, DOI 10.1126/science.276.5314.952; ISSINGER OG, 1993, PHARMACOL THERAPEUT, V59, P1, DOI 10.1016/0163-7258(93)90039-G; Kelliher MA, 1996, EMBO J, V15, P5160, DOI 10.1002/j.1460-2075.1996.tb00900.x; KIKKAWA U, 1992, MOL CELL BIOL, V12, P5711, DOI 10.1128/MCB.12.12.5711; KREK W, 1992, J CELL BIOL, V116, P43, DOI 10.1083/jcb.116.1.43; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; LITCHFIELD DW, 1992, J BIOL CHEM, V267, P13943; LITCHFIELD DW, 1990, J BIOL CHEM, V265, P7638; LITCHFIELD DW, 1994, CELL MOL BIOL RES, V40, P373; LITCHFIELD DW, 1993, MOL CELL BIOCHEM, V128, P187, DOI 10.1007/BF01076770; LITCHFIELD DW, 1991, J BIOL CHEM, V266, P20380; LORENZ P, 1993, J BIOL CHEM, V268, P2733; LOZEMAN FJ, 1990, BIOCHEMISTRY-US, V29, P8436, DOI 10.1021/bi00488a034; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; LUSCHER B, 1994, EUR J BIOCHEM, V220, P521, DOI 10.1111/j.1432-1033.1994.tb18651.x; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MARIDOR G, 1991, J BIOL CHEM, V266, P2362; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MUNSTERMANN U, 1990, EUR J BIOCHEM, V189, P251, DOI 10.1111/j.1432-1033.1990.tb15484.x; OELGESCHLAGER M, 1995, MOL CELL BIOL, V15, P5966; OLEMOIYOI OK, 1993, EMBO J, V12, P1621, DOI 10.1002/j.1460-2075.1993.tb05807.x; Orlandini M, 1998, J BIOL CHEM, V273, P21291, DOI 10.1074/jbc.273.33.21291; PADMANABHA R, 1990, MOL CELL BIOL, V10, P4089, DOI 10.1128/MCB.10.8.4089; Penner CG, 1997, J CELL BIOCHEM, V64, P525; PEPPERKOK R, 1991, EXP CELL RES, V197, P245, DOI 10.1016/0014-4827(91)90429-X; PEPPERKOK R, 1994, J BIOL CHEM, V269, P6986; Pinna L A, 1997, Prog Cell Cycle Res, V3, P77; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; Resnitzky D, 1997, MOL CELL BIOL, V17, P5640, DOI 10.1128/MCB.17.9.5640; Rethinaswamy A, 1998, J BIOL CHEM, V273, P5869, DOI 10.1074/jbc.273.10.5869; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEITZ G, 1989, BIOCHEM BIOPH RES CO, V163, P635, DOI 10.1016/0006-291X(89)92184-0; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; STALTER G, 1994, BIOCHEM BIOPH RES CO, V202, P141, DOI 10.1006/bbrc.1994.1904; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WIRKNER U, 1994, GENOMICS, V19, P257, DOI 10.1006/geno.1994.1056; YANGFENG TL, 1994, GENOMICS, V19, P173, DOI 10.1006/geno.1994.1032; YENICE S, 1994, PROSTATE, V24, P11, DOI 10.1002/pros.2990240105; YU IJ, 1991, J CELL BIOL, V114, P1217, DOI 10.1083/jcb.114.6.1217	60	87	90	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					14406	14414		10.1074/jbc.274.20.14406	http://dx.doi.org/10.1074/jbc.274.20.14406			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318865	hybrid			2022-12-25	WOS:000080322200094
J	Gondran, P; Dautry, D				Gondran, P; Dautry, D			Regulation of mRNA splicing and transport by the tyrosine kinase activity of src	ONCOGENE			English	Article						src; tyrosine phosphorylation; SH2 and SH3 domain; splicing; mRNA transport	C-SRC; RNA-BINDING; CELL-TRANSFORMATION; SH3 DOMAINS; PHOSPHORYLATION; ACTIVATION; EXPRESSION; PROTEINS; MITOSIS; SITES	The regulation of transcription by signal transduction pathways is well documented. In addition, me have previously shown that src can regulate pre-mRNA processing. To investigate which functional domains of src are involved in the regulation of splicing and transport of Lymphotoxin alpha (LT alpha) transcripts, we have used SPC mutants in the catalytic, SH2 and SH3 domains in association with the Y527F or the E378G activating mutation. Our results establish that the regulation of pre-mRNA processing and transcription can occur independently of each other. The splicing and transport phenotypes require an intact tyrosine kinase domain and both are insensitive to the deletion of the SH3 domain, Therefore these phenotypes do not depend upon the recruitment through the SH3 domain of src of RNA binding proteins (Sam 68, hnRNP K), By contrast, deletions in the SH2 domain have no effect on splicing but either abolish or exacerbate the transport phenotype depending upon the activating mutation (Y527F or E378G), These divergent responses are associated with specific changes in the pattern of tyrosine phosphorylated proteins. Thus, the regulation of transcription, splicing and mRNA transport implicate different effector pathways of src, Furthermore, analysis of the transport phenotype reveals the interplay between the SH2 and catalytic domain of the protein.	Inst Rech Sci Canc, CNRS, UPR 9044, F-94801 Villejuif, France	Centre National de la Recherche Scientifique (CNRS)	Dautry, D (corresponding author), Inst Rech Sci Canc, CNRS, UPR 9044, 7 Rue Guy Moquet, F-94801 Villejuif, France.							BEUG H, 1978, CELL, V14, P843, DOI 10.1016/0092-8674(78)90340-9; BLOBEL GA, 1991, P NATL ACAD SCI USA, V88, P1162, DOI 10.1073/pnas.88.4.1162; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Cabannes E, 1997, ONCOGENE, V15, P29, DOI 10.1038/sj.onc.1201162; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; Goodison S, 1998, FRONT BIOSCI, V3, P89; HIRAI H, 1990, GENE DEV, V4, P2342, DOI 10.1101/gad.4.12b.2342; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; LEVY JB, 1986, P NATL ACAD SCI USA, V83, P4228, DOI 10.1073/pnas.83.12.4228; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; Murakami M, 1997, ONCOGENE, V14, P2435, DOI 10.1038/sj.onc.1201077; NEEL H, 1995, CURR BIOL, V5, P413, DOI 10.1016/S0960-9822(95)00082-0; NEEL H, 1993, GENE DEV, V7, P2194, DOI 10.1101/gad.7.11.2194; Pellicena P, 1998, J BIOL CHEM, V273, P15325, DOI 10.1074/jbc.273.25.15325; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; PYPE S, 1994, J BIOL CHEM, V269, P31457; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SupertiFurga G, 1997, BIOESSAYS, V19, P447, DOI 10.1002/bies.950190602; Taylor SJ, 1996, BIOESSAYS, V18, P9, DOI 10.1002/bies.950180105; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; WEIL D, 1990, MOL CELL BIOL, V10, P5865, DOI 10.1128/MCB.10.11.5865; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0	28	8	8	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	1999	18	16					2547	2555		10.1038/sj.onc.1202598	http://dx.doi.org/10.1038/sj.onc.1202598			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	189LU	10353598				2022-12-25	WOS:000079907100002
J	Oki, E; Oda, S; Maehara, Y; Sugimachi, K				Oki, E; Oda, S; Maehara, Y; Sugimachi, K			Mutated gene-specific phenotypes of dinucleotide repeat instability in human colorectal carcinoma cell lines deficient in DNA mismatch repair	ONCOGENE			English	Article						hMSH2; hMSH6 (GTBP); hMLH1; microsatellite instability; RER	NONPOLYPOSIS COLON-CANCER; MICROSATELLITE INSTABILITY; REPEATED SEQUENCES; HMSH2 MUTATIONS; TUMOR-CELLS; HOMOLOG; MSH2; DEFECTS; HMLH1; ASSOCIATION	Mutations in DNA mismatch repair (MMR) genes in hereditary non-polyposis colon cancer (HNPCC) patients revealed the importance of MMR deficiency as a risk for carcinogenesis. Since diverse mutations occur in several MMR genes, the instability of repeat sequences dispersed in the genome, which are also governed by the MMR system, is a well used marker. However, the relationship between repeat sequence instability and MMR gene mutation in human cells has not been well defined mainly because precise systems to analyse repeat sequences have not been available. Using our newly developed system, we analysed alteration of dinucleotide repeats in human cell lines which harbour mutations in MMR genes. Among 24 subclones of DLD-1 cells (hMSH6(-)) only one had a dinucleotide repeat alteration in only one microsatellite locus, while LoVo cells (hMSH2(-)/hMSH6(-)) exhibited marked dinucleotide repeat instability (DRI). HCT116 cells, a hMLH1-mutant, showed an ultimate DRI phenotype. Interestingly, SW48 cells lacking hMLH1 expression also demonstrated DRI, albeit the extent of diversity being significantly lower than HCT116. These data suggest that the DRI phenotype in human cells is highly dependent on mutated MMR genes and on forms of mutation. The results of DRI analyses used to detect MMR-deficiency should be interpreted with caution.	Kyushu Univ Hosp, Ctr Canc, Fukuoka 8128582, Japan; Kyushu Univ, Fac Med, Dept Surg 2, Fukuoka 8128582, Japan	Kyushu University; Kyushu University	Oda, S (corresponding author), Kyushu Univ Hosp, Ctr Canc, Fukuoka 8128582, Japan.		Maehara, Yoshihiko/A-4867-2010					Ahuja N, 1997, CANCER RES, V57, P3370; Akiyama Y, 1997, CANCER RES, V57, P3920; Beck NE, 1997, HUM GENET, V99, P219, DOI 10.1007/s004390050343; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BOYER JC, 1995, CANCER RES, V55, P6063; BRANCH P, 1995, CANCER RES, V55, P2304; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Herfarth KKF, 1997, GENE CHROMOSOME CANC, V18, P42, DOI 10.1002/(SICI)1098-2264(199701)18:1<42::AID-GCC5>3.0.CO;2-1; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Kowalski LD, 1997, GENE CHROMOSOME CANC, V18, P219, DOI 10.1002/(SICI)1098-2264(199703)18:3<219::AID-GCC8>3.0.CO;2-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; LIU B, 1994, CANCER RES, V54, P4590; NAKABEPPU Y, 1993, MOL CELL BIOL, V13, P4157, DOI 10.1128/MCB.13.7.4157; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; NystromLahti M, 1996, HUM MOL GENET, V5, P763, DOI 10.1093/hmg/5.6.763; Oda S, 1997, NUCLEIC ACIDS RES, V25, P3415, DOI 10.1093/nar/25.17.3415; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; Schug MD, 1997, NAT GENET, V15, P99, DOI 10.1038/ng0197-99; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Thibodeau SN, 1996, CANCER RES, V56, P4836; Weber TK, 1997, CANCER RES, V57, P3798; Wu MS, 1997, CANCER LETT, V112, P161, DOI 10.1016/S0304-3835(96)04565-X; Wu Y, 1997, GENE CHROMOSOME CANC, V18, P269, DOI 10.1002/(SICI)1098-2264(199704)18:4<269::AID-GCC4>3.0.CO;2-Z	32	59	61	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 25	1999	18	12					2143	2147		10.1038/sj.onc.1202583	http://dx.doi.org/10.1038/sj.onc.1202583			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	179TX	10321739				2022-12-25	WOS:000079346200012
J	Coleman, DE; Sprang, SR				Coleman, DE; Sprang, SR			Structure of G(i alpha 1)center dot GppNHp, autoinhibition in a G(alpha) protein-substrate complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; ELONGATION-FACTOR TU; X-RAY-DIFFRACTION; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; ADENYLYL-CYCLASE; TRANSITION-STATE; STEREOCHEMICAL COURSE; BINDING PROTEINS; RGS PROTEINS	The structure of the G protein G(i alpha 1) complexed with the nonhydrolyzable GTP analog guanosine-5'-(beta gamma-imino)triphosphate (GppNHp) has been determined at a resolution of 1.5 Angstrom. In the active site of G(i alpha 1). GppNHp, a water molecule is hydrogen bonded to the side chain of Glu(43) and to an oxygen atom of the gamma-phosphate group. The side chain of the essential catalytic residue Gln(204) assumes a conformation which is distinctly different from that observed in complexes with either guanosine 5'-O-3-thiotriphosphate or the transition state analog GDP . AIF(4)(-). Hydrogen bonding and steric interactions position Gln(204) such that it interacts with a presumptive nucleophilic water molecule, but cannot interact with the pentacoordinate transition state. Gln(204) must be released from this auto-inhibited state to participate in catalysis, RGS proteins may accelerate the rate of GTP hydrolysis by G protein alpha subunits, in part, by inserting an amino acid side chain into the site occupied by Gln(204), thereby destabilizing the auto-inhibited state of G alpha.	Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Sprang, SR (corresponding author), Univ Texas, SW Med Ctr, Howard Hughes Med Inst, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.							BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1992, XPLOR VERSION 3 1; COLEMAN DE, 1994, J MOL BIOL, V238, P630, DOI 10.1006/jmbi.1994.1320; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; ECCLESTON JF, 1982, J BIOL CHEM, V257, P5046; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FEUERSTEIN J, 1989, J BIOL CHEM, V264, P6188; FREISSMUTH M, 1989, J BIOL CHEM, V264, P21907; GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475; Hirshberg M, 1997, NAT STRUCT BIOL, V4, P147, DOI 10.1038/nsb0297-147; HODEL A, 1992, ACTA CRYSTALLOGR A, V48, P851, DOI 10.1107/S0108767392006044; JIANG JS, 1994, J MOL BIOL, V243, P100, DOI 10.1006/jmbi.1994.1633; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KRENGEL U, 1990, CELL, V62, P539, DOI 10.1016/0092-8674(90)90018-A; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE E, 1994, METHOD ENZYMOL, V237, P146; LINDER ME, 1990, J BIOL CHEM, V265, P8243; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MIXON MB, 1995, SCIENCE, V270, P954, DOI 10.1126/science.270.5238.954; Nassar N, 1998, NAT STRUCT BIOL, V5, P1047, DOI 10.1038/4156; Natochin M, 1998, J BIOL CHEM, V273, P6731, DOI 10.1074/jbc.273.12.6731; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; POSNER BA, 1999, IN PRESS BIOLCHEMIST; PRIVE GG, 1992, P NATL ACAD SCI USA, V89, P3649, DOI 10.1073/pnas.89.8.3649; Raw AS, 1997, BIOCHEMISTRY-US, V36, P15660, DOI 10.1021/bi971912p; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Rittinger K, 1997, NATURE, V389, P758, DOI 10.1038/39651; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Schweins T, 1996, BIOCHEMISTRY-US, V35, P14225, DOI 10.1021/bi961118o; SCHWEINS T, 1995, NAT STRUCT BIOL, V2, P36, DOI 10.1038/nsb0195-36; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Sunahara RK, 1997, SCIENCE, V278, P1943, DOI 10.1126/science.278.5345.1943; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WEBB MR, 1981, J BIOL CHEM, V256, P7734; Zor T, 1998, FEBS LETT, V433, P326, DOI 10.1016/S0014-5793(98)00930-2	47	47	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16669	16672		10.1074/jbc.274.24.16669	http://dx.doi.org/10.1074/jbc.274.24.16669			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358003	hybrid			2022-12-25	WOS:000080780400002
J	Goretzki, L; Burg, MA; Grako, KA; Stallcup, WB				Goretzki, L; Burg, MA; Grako, KA; Stallcup, WB			High-affinity binding of basic fibroblast growth factor and platelet-derived growth factor-AA to the core protein of the NG2 proteoglycan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; MEMBRANE-SPANNING PROTEOGLYCAN; O2A PROGENITOR CELLS; PDGF ALPHA-RECEPTOR; RAT OPTIC-NERVE; HEPARAN-SULFATE; ENDOTHELIAL-CELLS; EXPRESSION; SURFACE; GENE	NG2 is a transmembrane chondroitin sulfate proteoglycan that is expressed by immature progenitor cells in several developmental lineages and by some types of malignant cells. In vitro studies have suggested that NG2 participates in growth factor activation of the platelet-derived growth factor-alpha receptor. In this study the ability of recombinant NG2 core protein to interact with several different growth factors (epidermal growth factor (EGF), basic fibroblast growth factor (bFGF), platelet-derived growth factor (PDGF)-AA, PDGF-BB, vascular endothelial growth factor (VEGF)(165) and transforming growth factor (TGF)-beta 1) was investigated using two different assay systems: enzyme-linked immunosorbent assay-type solid-phase binding and an optical biosensor (BIAcore) system. High-affinity binding of bFGF and PDGF-AA to the core protein of NG2 could be demonstrated with both types of assays. Using both the BIAcore software analysis program and nonlinear regression analysis of the solid phase binding data, K-D values in the low nanomolar range were obtained for binding of each of these growth factors to NG2. The results further indicate that NG2 contains at least two binding sites for each of these two growth factors. PDGF-BB, TGF-beta 1, VEGF, and EGF exhibited little or no binding to NG2 in either type of assay. These data suggest that NG2 can have an important role in organizing and presenting some types of mitogenic growth factors at the cell surface.	Burnham Inst, Ctr Canc Res, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Goretzki, L (corresponding author), Burnham Inst, Ctr Canc Res, La Jolla, CA 92037 USA.				NATIONAL CANCER INSTITUTE [F32CA072220] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL009541] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021990] Funding Source: NIH RePORTER; NCI NIH HHS [F32 CA72220] Funding Source: Medline; NHLBI NIH HHS [F32 HL09541] Funding Source: Medline; NINDS NIH HHS [R01 NS21990] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABRAHAM JA, 1986, EMBO J, V5, P2523, DOI 10.1002/j.1460-2075.1986.tb04530.x; AVIEZER D, 1994, J BIOL CHEM, V269, P114; AVIEZER D, 1994, CELL, V79, P1005, DOI 10.1016/0092-8674(94)90031-0; Behm FG, 1996, BLOOD, V87, P1134, DOI 10.1182/blood.V87.3.1134.bloodjournal8731134; BERTSHOLTZ C, 1986, NATURE, V320, P695; BOGLER O, 1990, P NATL ACAD SCI USA, V76, P514; BONTHRON DT, 1988, P NATL ACAD SCI USA, V85, P1492, DOI 10.1073/pnas.85.5.1492; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; CUNNINGHAM BC, 1993, J MOL BIOL, V234, P554, DOI 10.1006/jmbi.1993.1611; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; FAGER G, 1992, IN VITRO CELL DEV-AN, V28A, P176; GARD AL, 1990, NEURON, V5, P615, DOI 10.1016/0896-6273(90)90216-3; Gohring W, 1998, EUR J BIOCHEM, V255, P60, DOI 10.1046/j.1432-1327.1998.2550060.x; GOSPODAROWICZ D, 1986, J CELL PHYSIOL, V128, P475, DOI 10.1002/jcp.1041280317; Grako KA, 1999, J CELL SCI, V112, P905; GRAKO KA, 1995, EXP CELL RES, V221, P231, DOI 10.1006/excr.1995.1371; Hocking AM, 1998, MATRIX BIOL, V17, P1; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; JOSEPHS SF, 1984, SCIENCE, V225, P636, DOI 10.1126/science.6740330; Kaname S, 1996, BIOCHEM J, V315, P815, DOI 10.1042/bj3150815; LEGER O, 1994, INT J CANCER, V58, P700, DOI 10.1002/ijc.2910580514; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MCKINNON RD, 1990, NEURON, V5, P603, DOI 10.1016/0896-6273(90)90215-2; Milev P, 1998, J BIOL CHEM, V273, P21439, DOI 10.1074/jbc.273.34.21439; NISHIYAMA A, 1995, MOL BIOL CELL, V6, P1819, DOI 10.1091/mbc.6.12.1819; NISHIYAMA A, 1991, J CELL BIOL, V114, P359, DOI 10.1083/jcb.114.2.359; NISHIYAMA A, 1991, DEVELOPMENT, V111, P933; Nishiyama A, 1996, J NEUROSCI RES, V43, P315, DOI 10.1002/(SICI)1097-4547(19960201)43:3<315::AID-JNR6>3.3.CO;2-3; Nishiyama A, 1996, J NEUROSCI RES, V43, P299, DOI 10.1002/(SICI)1097-4547(19960201)43:3<299::AID-JNR5>3.0.CO;2-E; NOBLE M, 1988, NATURE, V333, P560, DOI 10.1038/333560a0; NURCOMBE V, 1993, SCIENCE, V260, P103, DOI 10.1126/science.7682010; PRINGLE N, 1989, EMBO J, V8, P1049, DOI 10.1002/j.1460-2075.1989.tb03472.x; RAFF MC, 1984, EMBO J, V3, P1857, DOI 10.1002/j.1460-2075.1984.tb02059.x; RAFF MC, 1989, SCIENCE, V243, P1450, DOI 10.1126/science.2648568; RAPRAEGER AC, 1994, METHOD ENZYMOL, V245, P219; REAL FX, 1985, CANCER RES, V45, P4401; RORSMAN F, 1988, MOL CELL BIOL, V8, P571, DOI 10.1128/MCB.8.2.571; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; SAKSELA O, 1990, J CELL BIOL, V110, P767, DOI 10.1083/jcb.110.3.767; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; SCHRAPPE M, 1991, CANCER RES, V51, P4986; STALLCUP WB, 1987, J NEUROSCI, V7, P2737; Tillet E, 1997, J BIOL CHEM, V272, P10769; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	47	173	181	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16831	16837		10.1074/jbc.274.24.16831	http://dx.doi.org/10.1074/jbc.274.24.16831			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358027	hybrid			2022-12-25	WOS:000080780400026
J	Ahmad, A; Takami, Y; Nakayama, T				Ahmad, A; Takami, Y; Nakayama, T			WD repeats of the p48 subunit of chicken chromatin assembly factor-1 required for in vitro interaction with chicken histone deacetylase-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-CELL LINE; DNA-REPLICATION INVITRO; VARIANT CAUSES CHANGES; TARGETED DISRUPTION; CRYSTAL-STRUCTURE; PROTEIN-PATTERNS; GENE-EXPRESSION; IDENTIFICATION; PROLIFERATION; ACETYLATION	Chromatin assembly factor-1 (CAF-1) is essential for chromatin assembly in eukaryotes, and comprises three subunits of 150 kDa (p150), 60 kDa (p60), and 48 kDa (p48). We cloned and sequenced cDNA encoding the small subunit of the chicken CAF-1, chCAF-1p48. It consists of 425 amino acid residues including a putative initiation Met, possesses seven WD repeat motifs, and contains only one amino acid change relative to the human and mouse CAF-1p48s. The immunoprecipitation experiment followed by Western blotting revealed that chCAF-1p48 interacts with chicken histone deacetylases (chHDAC-1 and -2) in vivo. The glutathione S-transferase pulldown affinity assay revealed the in vitro interaction of chCAF-1p48 with chHDAC-1, -2, and -3. We showed that the p48 subunit tightly binds to two regions of chHDAC-2, located between amino acid residues 82-180 and 245-314, respectively. We also established that two N-terminal, two C-terminal, or one N-terminal and one C-terminal WD repeat motif of chCAF-1p48 are required for this interaction, using deletion mutants of the respective regions. These results suggest that chCAF-1p48 is involved in many aspects of DNA-utilizing processes, through alterations in the chromatin structure based on both the acetylation and deacetylation of core histones.	Miyazaki Med Coll, Dept Biochem, Miyazaki 8891692, Japan	University of Miyazaki	Nakayama, T (corresponding author), Miyazaki Med Coll, Dept Biochem, Miyazaki 8891692, Japan.							ANNUNZIATO AT, 1995, NUCLEOSOME, P31; Bartl S, 1997, MOL CELL BIOL, V17, P5033, DOI 10.1128/MCB.17.9.5033; BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; Denisenko O, 1998, MOL CELL BIOL, V18, P5634, DOI 10.1128/MCB.18.10.5634; DURONIO RJ, 1992, PROTEINS, V13, P41, DOI 10.1002/prot.340130105; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Ito T, 1997, GENES CELLS, V2, P593, DOI 10.1046/j.1365-2443.1997.1500348.x; Ito T, 1996, MOL CELL BIOL, V16, P3112; Kaufman PD, 1996, CURR OPIN CELL BIOL, V8, P369, DOI 10.1016/S0955-0674(96)80012-3; KAUFMAN PD, 1995, CELL, V81, P1105, DOI 10.1016/S0092-8674(05)80015-7; Komachi K, 1997, MOL CELL BIOL, V17, P6023, DOI 10.1128/MCB.17.10.6023; KRUDE T, 1995, EXP CELL RES, V220, P304, DOI 10.1006/excr.1995.1320; KRUDE T, 1995, CURR BIOL, V5, P1232, DOI 10.1016/S0960-9822(95)00245-4; Ladomery M, 1997, GENE, V198, P275, DOI 10.1016/S0378-1119(97)00325-9; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Leipe DD, 1997, NUCLEIC ACIDS RES, V25, P3693, DOI 10.1093/nar/25.18.3693; Lusser A, 1997, SCIENCE, V277, P88, DOI 10.1126/science.277.5322.88; Martinez-Balbas MA, 1998, P NATL ACAD SCI USA, V95, P132, DOI 10.1073/pnas.95.1.132; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Neer EJ, 1996, CELL, V84, P175, DOI 10.1016/S0092-8674(00)80969-1; Roth SY, 1996, CELL, V87, P5, DOI 10.1016/S0092-8674(00)81316-1; Sambrook J., 2002, MOL CLONING LAB MANU; SEGUCHI K, 1995, J MOL BIOL, V254, P869, DOI 10.1006/jmbi.1995.0662; SMITH S, 1991, EMBO J, V10, P971, DOI 10.1002/j.1460-2075.1991.tb08031.x; SMITH S, 1989, CELL, V58, P15, DOI 10.1016/0092-8674(89)90398-X; SOGO JM, 1995, CHROMATIN STRUCTURE, P49; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; STILLMAN B, 1986, CELL, V45, P555, DOI 10.1016/0092-8674(86)90287-4; SVAREN J, 1990, TRENDS GENET, V6, P52, DOI 10.1016/0168-9525(90)90074-G; Takami Y, 1997, J MOL BIOL, V265, P394, DOI 10.1006/jmbi.1996.0733; Takami Y, 1997, GENES CELLS, V2, P711, DOI 10.1046/j.1365-2443.1997.1550353.x; Takami Y, 1995, J BIOL CHEM, V270, P30664, DOI 10.1074/jbc.270.51.30664; TAKAMI Y, 1995, J MOL BIOL, V250, P420, DOI 10.1006/jmbi.1995.0387; Takami Y, 1997, BBA-GENE STRUCT EXPR, V1354, P105, DOI 10.1016/S0167-4781(97)00077-8; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Tyler JK, 1996, MOL CELL BIOL, V16, P6149; VANDERVOORN L, 1992, FEBS LETT, V307, P131, DOI 10.1016/0014-5793(92)80751-2; Verreault A, 1996, CELL, V87, P95, DOI 10.1016/S0092-8674(00)81326-4; Wolffe A., 1995, CHROMATIN STRUCTURE	40	33	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16646	16653		10.1074/jbc.274.23.16646	http://dx.doi.org/10.1074/jbc.274.23.16646			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347232	hybrid			2022-12-25	WOS:000080668600092
J	Eliopoulos, AG; Gallagher, NJ; Blake, SMS; Dawson, CW; Young, LS				Eliopoulos, AG; Gallagher, NJ; Blake, SMS; Dawson, CW; Young, LS			Activation of the p38 mitogen-activated protein kinase pathway by Epstein-Barr virus-encoded latent membrane protein 1 coregulates interleukin-6 and interleukin-8 production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; C-JUN; TERMINAL KINASE; FACTOR-ALPHA; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; TNF RECEPTOR-1; CELL-DEATH; LYMPHOCYTE TRANSFORMATION	The Epstein-Barr virus-encoded latent membrane protein 1 (LMP1) is a pleiotropic protein the activities of which include effects on gene expression and cell transformation, growth, and death. LMP1 has been shown to induce nuclear factor (NF)-kappa B and c-Jun NH2-terminal kinase/AP-1 activities in target cells, and in this study we demonstrate that LMP1 also engages the p38 mitogen-activated protein kinase cascade, leading to activation of the transcription factor ATF2. Mutational analysis of the LMP1 cytoplasmic COOH terminus revealed that p38 activation occurs from both the tumor necrosis factor receptor-associated factor (TRAF)-interacting, membrane proximal COOH-terminal activating region (CTAR)1 domain (amino acids 186-231) and the extreme tumor necrosis factor receptor-associated death domain (TRADD) binding CTAR2 region (amino acids 351-386), Because LMP1 also engages signaling on the NF-kappa B axis through CTAR1 and CTAR2, we have examined whether these two pathways are overlapping or independent. We have found that inhibition of p58 by the highly specific inhibitor SB203580 did not affect NF-kappa B binding activity. Conversely, although the metabolic inhibitor D609 Mocked NF-kappa B activation, it did not impair the ability of LMP1 to signal on the p38 axis, suggesting that these two LMP1-mediated pathways are primarily independent. Divergence of signals must, however, occur downstream of TRAF2 as a dominant negative TRAF2 mutant that blocks LMP1-induced NF-kappa B activation also inhibited p38 signaling, In addition, we have found that p38 inhibition significantly impaired LMP1-mediated interleukin-g and -8 expression. Thus, p38 may play a significant cooperative role in regulating at least some of the pleiotropic activities of LMP1.	Univ Birmingham, Canc Res Campaign, Inst Canc Studies, Sch Med, Birmingham B15 2TA, W Midlands, England	University of Birmingham	Young, LS (corresponding author), Univ Birmingham, Canc Res Campaign, Inst Canc Studies, Sch Med, Birmingham B15 2TA, W Midlands, England.	L.S.Young@bham.ac.uk	Young, Lawrence S/B-7213-2009; ELIOPOULOS, ARISTIDES/R-9449-2018; ELIOPOULOS, ARISTIDES/ABI-6632-2020	Young, Lawrence S/0000-0003-3919-4298; ELIOPOULOS, ARISTIDES/0000-0002-6403-6761; ELIOPOULOS, ARISTIDES/0000-0002-6403-6761				BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BAICHWAL VR, 1988, ONCOGENE, V2, P461; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Craxton A, 1998, J IMMUNOL, V161, P3225; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; De Cesaris P, 1998, J BIOL CHEM, V273, P7566, DOI 10.1074/jbc.273.13.7566; DECESARE D, 1995, ONCOGENE, V11, P365; Devergne O, 1996, MOL CELL BIOL, V16, P7098; Eliopoulos AG, 1999, J VIROL, V73, P1023, DOI 10.1128/JVI.73.2.1023-1035.1999; Eliopoulos AG, 1998, CURR BIOL, V8, pR196, DOI 10.1016/S0960-9822(98)70123-X; Eliopoulos AG, 1997, ONCOGENE, V14, P2899, DOI 10.1038/sj.onc.1201258; Eliopoulos AG, 1998, ONCOGENE, V16, P1731, DOI 10.1038/sj.onc.1201694; FAHRAEUS R, 1990, NATURE, V345, P447, DOI 10.1038/345447a0; Floettmann JE, 1997, ONCOGENE, V15, P1851, DOI 10.1038/sj.onc.1201359; Fries KL, 1996, J VIROL, V70, P8653, DOI 10.1128/JVI.70.12.8653-8659.1996; Gires O, 1997, EMBO J, V16, P6131, DOI 10.1093/emboj/16.20.6131; Hatzivassiliou E, 1998, J IMMUNOL, V160, P1116; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; HUEN DS, 1995, ONCOGENE, V10, P549; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P12592, DOI 10.1073/pnas.94.23.12592; KAYE KM, 1995, J VIROL, V69, P675, DOI 10.1128/JVI.69.2.675-683.1995; Kaye KM, 1996, P NATL ACAD SCI USA, V93, P11085, DOI 10.1073/pnas.93.20.11085; Kieff E., 1996, FIELDS VIROLOGY, V2, P2343; Kieser A, 1997, EMBO J, V16, P6478, DOI 10.1093/emboj/16.21.6478; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MITCHELL T, 1995, J VIROL, V69, P2968, DOI 10.1128/JVI.69.5.2968-2976.1995; MOORTHY RK, 1993, J VIROL, V67, P1638, DOI 10.1128/JVI.67.3.1638-1646.1993; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; NAKAGOMI H, 1994, INT J CANCER, V57, P240, DOI 10.1002/ijc.2910570218; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Read MA, 1997, J BIOL CHEM, V272, P2753, DOI 10.1074/jbc.272.5.2753; Reinhard C, 1997, EMBO J, V16, P1080, DOI 10.1093/emboj/16.5.1080; Roberts ML, 1998, VIROLOGY, V240, P93, DOI 10.1006/viro.1997.8901; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; Roulston A, 1998, J BIOL CHEM, V273, P10232, DOI 10.1074/jbc.273.17.10232; ROWE M, 1987, J GEN VIROL, V68, P1575, DOI 10.1099/0022-1317-68-6-1575; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; Schwenger P, 1998, MOL CELL BIOL, V18, P78, DOI 10.1128/MCB.18.1.78; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; Wesselborg S, 1997, J BIOL CHEM, V272, P12422, DOI 10.1074/jbc.272.19.12422; Wu GD, 1997, J BIOL CHEM, V272, P2396; Yoshizaki T, 1998, P NATL ACAD SCI USA, V95, P3621, DOI 10.1073/pnas.95.7.3621; Young LS, 1997, BRIT MED BULL, V53, P509; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116; ZERVOS AS, 1995, P NATL ACAD SCI USA, V92, P10531, DOI 10.1073/pnas.92.23.10531	57	285	291	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16085	16096		10.1074/jbc.274.23.16085	http://dx.doi.org/10.1074/jbc.274.23.16085			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347160	hybrid			2022-12-25	WOS:000080668600020
J	Gloe, T; Riedmayr, S; Sohn, HY; Pohl, U				Gloe, T; Riedmayr, S; Sohn, HY; Pohl, U			The 67-kDa laminin-binding protein is involved in shear stress-dependent endothelial nitric-oxide synthase expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; GENE-EXPRESSION; IN-VITRO; SIGNAL-TRANSDUCTION; CELL-ADHESION; FLOW; RECEPTOR; FORCES; MODEL; DIFFERENTIATION	It has been suggested that the mechanical forces acting on endothelial cells may be sensed in part by cell-matrix connections. We therefore studied the role of different matrix proteins, in particular laminin I, on a shear stress-dependent endothelial response, namely nitric-oxide synthase (eNOS) expression. Primary porcine aortic endothelial cells were seeded onto glass plates either noncoated (NC cells) or precoated with fibronectin (FN cells), laminin (LN cells), or collagen I (CN cells). Western blots were used to detect differences in the final matrix composition of these cells. A shear stress of 16 dyn/cm(2) was applied for 6 h, Only LN cells showed detectable amounts of laminin I in their underlying matrix when they reached confluence. They reacted with a a-fold increase of eNOS expression (n = 16, p < 0.001) to the exposure of shear stress, which went along with enhanced eNOS protein and NO release. In contrast, neither FN cells (n = 9) nor NC cells (n = 13) showed a significant increase of eNOS expression under shear stress, The increase in CN cells was borderline (1.4-fold; n = 9, p < 0.05) and was not associated with an increase of eNOS protein. The shear-induced increase in eNOS expression of LN cells was abolished by the peptide YIGSR, which blocks the cellular binding to laminin I via a 67-kDa laminin-binding protein, whereas a control peptide (YIGSK) had no effect. The induction of eNOS expression by shear stress is stimulated by an interaction of endothelial cells with laminin which is, at least in part, mediated by a 67-kDa laminin-binding protein.	Univ Munich, Inst Physiol, D-80336 Munich, Germany	University of Munich	Gloe, T (corresponding author), Univ Munich, Inst Physiol, Schillerstr 44, D-80336 Munich, Germany.							ADAMS JC, 1993, DEVELOPMENT, V117, P1183; Ardini E, 1997, J BIOL CHEM, V272, P2342; Aumailley M, 1998, J MOL MED-JMM, V76, P253, DOI 10.1007/s001090050215; Babaei S, 1998, CIRC RES, V82, P1007, DOI 10.1161/01.RES.82.9.1007; BALLERMANN BJ, 1995, BLOOD PURIFICAT, V13, P125, DOI 10.1159/000170195; Black SM, 1997, J CLIN INVEST, V100, P1448, DOI 10.1172/JCI119665; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519; DAVIES PF, 1994, J CLIN INVEST, V93, P2031, DOI 10.1172/JCI117197; Golledge J, 1997, J CLIN INVEST, V99, P2719, DOI 10.1172/JCI119461; GRAF J, 1987, BIOCHEMISTRY-US, V26, P6896, DOI 10.1021/bi00396a004; GUPTE A, 1990, IN VITRO CELL DEV B, V26, P57; Halatsch ME, 1997, CANCER LETT, V118, P7, DOI 10.1016/S0304-3835(97)00217-6; IWAMOTO Y, 1987, SCIENCE, V238, P1132, DOI 10.1126/science.2961059; JIANG B, 1994, J CELL SCI, V107, P2499; KOLPAKOV V, 1995, CIRC RES, V77, P823, DOI 10.1161/01.RES.77.4.823; KOSLOW AR, 1986, J BIOMECH ENG-T ASME, V108, P338, DOI 10.1115/1.3138625; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; MALEK AM, 1994, J HYPERTENS, V12, P989; MASSIA SP, 1993, J BIOL CHEM, V268, P8053; MECHAM RP, 1991, FASEB J, V5, P2538, DOI 10.1096/fasebj.5.11.1651264; Menard S, 1997, J CELL BIOCHEM, V67, P155, DOI 10.1002/(SICI)1097-4644(19971101)67:2<155::AID-JCB1>3.3.CO;2-O; Muller JM, 1997, CIRC RES, V80, P320, DOI 10.1161/01.RES.80.3.320; Nadaud S, 1996, CIRC RES, V79, P857, DOI 10.1161/01.RES.79.4.857; NISHIDA K, 1992, J CLIN INVEST, V90, P2092, DOI 10.1172/JCI116092; NORIS M, 1995, CIRC RES, V76, P536, DOI 10.1161/01.RES.76.4.536; Ott MJ, 1995, ENDOTHELIUM, V3, P21; RANJAN V, 1995, AM J PHYSIOL-HEART C, V269, pH550, DOI 10.1152/ajpheart.1995.269.2.H550; REDMOND EM, 1995, IN VITRO CELL DEV-AN, V31, P601; RESNICK N, 1995, FASEB J, V9, P874, DOI 10.1096/fasebj.9.10.7615157; Rosenthal AM, 1990, CELL CULTURE TECHNIQ, P117; SESSA WC, 1994, CIRC RES, V74, P349, DOI 10.1161/01.RES.74.2.349; Sorokin LM, 1997, DEV DYNAM, V210, P446, DOI 10.1002/(SICI)1097-0177(199712)210:4<446::AID-AJA8>3.0.CO;2-G; THOUMINE O, 1995, LAB INVEST, V73, P565; Topper JN, 1996, P NATL ACAD SCI USA, V93, P10417, DOI 10.1073/pnas.93.19.10417; Uematsu M, 1995, AM J PHYSIOL-CELL PH, V269, pC1371, DOI 10.1152/ajpcell.1995.269.6.C1371; Xiao ZS, 1997, J CELL PHYSIOL, V171, P205, DOI 10.1002/(SICI)1097-4652(199705)171:2<205::AID-JCP11>3.3.CO;2-3; ZAMAN Z, 1979, ANAL BIOCHEM, V100, P64, DOI 10.1016/0003-2697(79)90110-6	38	59	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					15996	16002		10.1074/jbc.274.23.15996	http://dx.doi.org/10.1074/jbc.274.23.15996			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347148	hybrid			2022-12-25	WOS:000080668600008
J	Jiang, HL; Kruger, N; Lahiri, DR; Wang, DR; Vatele, JM; Balazy, M				Jiang, HL; Kruger, N; Lahiri, DR; Wang, DR; Vatele, JM; Balazy, M			Nitrogen dioxide induces cis-trans-isomerization of arachidonic acid within cellular phospholipids - Detection of trans-arachidonic acids in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACIDS; LIPID-PEROXIDATION; MASS-SPECTROMETRY; NITRIC-OXIDE; DERIVATIVES; METABOLISM; OXIDATION; PLATELET; PRODUCTS; RISK	Oxygen free radicals oxidize arachidonic acid to a complex mixture of metabolites termed isoeicosanoids that share structural similarity to enzymatically derived eicosanoids. However, little is known about oxidations of arachidonic acid mediated by reactive radical nitrogen oxides. We have studied the reaction of arachidonic acid with NO2, a free radical generated by nitric oxide and nitrite oxidations, A major group of products appeared to be a mixture of arachidonic acid isomers having one trans-bond and three cis-double bonds, We have termed these new products trans-arachidonic acids, These isomers were chromatographically distinct from arachidonic acid and produced mass spectra that were nearly identical with mass spectra of arachidonic acid. The lack of ultraviolet absorbance above 205 nm and the similarity of mass spectra of dimethyloxazoline derivatives suggested that the trans-bond was not conjugated with any of the cis-bonds, and the C=C bonds were located at carbons 5, 8, 11, and 14, Further identification was based on comparison of chromatographic properties with synthetic standards and revealed that NO2 generated 14-trans-eicosatetraenoic acid and a mixture containing 11-trans-, 8-trans, and 5-trans-eieosatetraenoic acids. Exposure of human platelets to submicromolar levels of NO2 resulted in a dose-dependent formation of 14-trans-eicosatetraenoic acid and other isomers within platelet glycerophospholipids. Using a sensitive isotopic dilution assay we detected trans-arachidonic acids in human plasma (50.3 +/- 10 ng/ml) and urine (122 +/- 50 pg/ml), We proposed a mechanism of arachidonic acid isomerization that involves a reversible attachment of NO2 to a double bond with formation of a nitroarachidonyl radical. Thus, free radical processes mediated by NO2 lead to generation of trans-arachidonic acid isomers, including biologically active 14-trans-eicosatetraenoic acid, within membrane phospholipids from which they can be released and excreted into urine.	New York Med Coll, Dept Pharmacol, Valhalla, NY 10595 USA; Univ Lyon 1, Lab Chim Organ 1, F-69622 Villeurbanne, France	New York Medical College; UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Balazy, M (corresponding author), New York Med Coll, Dept Pharmacol, Valhalla, NY 10595 USA.	michael_balazy@nymc.edu		Balazy, Ph.D., Michael/0000-0003-0218-8820	NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR012993] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034300] Funding Source: NIH RePORTER; NCRR NIH HHS [SO1 RR 12993] Funding Source: Medline; NHLBI NIH HHS [P01 HL034300, HL 34300] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALAZY M, 1989, BIOMED ENVIRON MASS, V18, P328, DOI 10.1002/bms.1200180508; BALAZY M, 1991, J BIOL CHEM, V266, P23561; BALAZY M, 1986, ANAL CHEM, V58, P1098, DOI 10.1021/ac00297a026; Berdeaux O, 1996, J LIPID RES, V37, P2244; BERDEAUX O, 1995, CHEM PHYS LIPIDS, V78, P71, DOI 10.1016/0009-3084(95)02486-3; Feldman EB, 1996, AM J CLIN NUTR, V63, P663; GALLON AA, 1994, LIPIDS, V29, P171, DOI 10.1007/BF02536725; GIBSON TW, 1976, J ORG CHEM, V41, P791, DOI 10.1021/jo00867a009; HARRISON KA, 1995, J BIOL CHEM, V270, P17273, DOI 10.1074/jbc.270.29.17273; Jiang HL, 1998, NITRIC OXIDE-BIOL CH, V2, P350, DOI 10.1006/niox.1998.0196; KICE JL, 1962, J AM CHEM SOC, V84, P605, DOI 10.1021/ja00863a021; Kritchevsky D, 1997, PROSTAG LEUKOTR ESS, V57, P399, DOI 10.1016/S0952-3278(97)90418-X; LI YD, 1994, TOXICOL APPL PHARM, V129, P114, DOI 10.1006/taap.1994.1234; Liu XP, 1998, P NATL ACAD SCI USA, V95, P2175, DOI 10.1073/pnas.95.5.2175; Morrow JD, 1997, PROG LIPID RES, V36, P1, DOI 10.1016/S0163-7827(97)00001-5; Nelson GJ, 1998, NUTR REV, V56, P250, DOI 10.1111/j.1753-4887.1998.tb01758.x; PATEL JM, 1986, AM REV RESPIR DIS, V134, P1196; PRUTZ WA, 1985, ARCH BIOCHEM BIOPHYS, V243, P125, DOI 10.1016/0003-9861(85)90780-5; PRYOR WA, 1981, SCIENCE, V214, P435, DOI 10.1126/science.214.4519.435; RATNAYAKE WMN, 1994, LIPIDS, V29, P707, DOI 10.1007/BF02538915; Reilly MP, 1998, J NUTR, V128, p434S, DOI 10.1093/jn/128.2.434S; RUBBO H, 1994, J BIOL CHEM, V269, P26066; SAMUELSSON B, 1991, Z RHEUMATOL, V50, P3; SNYDER JM, 1982, J AM OIL CHEM SOC, V59, P469, DOI 10.1007/BF02636144; vanderVliet A, 1997, J BIOL CHEM, V272, P7617, DOI 10.1074/jbc.272.12.7617; WITTIG G, 1955, CHEM BER-RECL, V88, P1654, DOI 10.1002/cber.19550881110; World Health Organization (WHO), 1997, ENV HLTH CRIT, V188; ZHANG JY, 1988, BIOMED ENVIRON MASS, V15, P33, DOI 10.1002/bms.1200150106	28	91	93	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16235	16241		10.1074/jbc.274.23.16235	http://dx.doi.org/10.1074/jbc.274.23.16235			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347179	hybrid			2022-12-25	WOS:000080668600039
J	Nakae, J; Park, BC; Accili, D				Nakae, J; Park, BC; Accili, D			Insulin stimulates phosphorylation of the forkhead transcription factor FKHR on serine 253 through wortmannin-sensitive pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; INDUCED GLUCOSE-TRANSPORT; CAENORHABDITIS-ELEGANS; PHOSPHATIDYLINOSITOL 3-KINASE; 3T3-L1 ADIPOCYTES; SER/THR KINASE; RAT ADIPOCYTES; POTENTIAL ROLE; FAMILY MEMBER; LONGEVITY	In the nematode Caenorhabditis elegans, mutations of the insulin/insulin-like growth factor-1 receptor homologue Daf-a gene cause developmental arrest at the dauer stage. The effect of Daf-2 mutations is counteracted by mutations in the Daf-16 gene, suggesting that Daf-16 is required for signaling by Daf-2. Daf-16 encodes a forkhead transcription factor. Based on sequence similarity, the FKHR genes are the likeliest mammalian Daf-16 homologues, FKHR proteins contain potential sites for phosphorylation by the serine/threonine kinase Akt. Because Akt is phosphorylated in response to insulin and has been implicated in a variety of insulin effects, we investigated whether insulin affects phosphorylation of FKHR. Insulin stimulated phosphorylation of endogenous FKHR and of a recombinant c-Myc/FKHR fusion protein transiently expressed in murine SV40-transformed hepatocytes. The effect of insulin was inhibited by wortmannin treatment, suggesting that PI S-kinase activity is required for FKHR phosphorylation. Mutation of serine 253, located in a consensus Akt phosphorylation site at the carboxyl-terminal end of the forkhead domain, abolished the effect of insulin on FKHR phosphorylation. In contrast, mutation of two additional Akt phosphorylation sites, at amino acids threonine 24 or serine 316, did not abolish insulin-induced phosphorylation. These data indicate that FKHR may represent a distal effector of insulin action.	NICHD, Dev Endocrinol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Accili, D (corresponding author), NICHD, Dev Endocrinol Branch, NIH, Bldg 10,Rm 10D18, Bethesda, MD 20892 USA.		Nakae, Jun/Q-6141-2019					Abraham RT, 1996, ANNU REV IMMUNOL, V14, P483, DOI 10.1146/annurev.immunol.14.1.483; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Anderson MJ, 1998, GENOMICS, V47, P187, DOI 10.1006/geno.1997.5122; Barr FG, 1997, CURR TOP MICROBIOL, V220, P113; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; FREDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522; KADOWAKI H, 1989, GENE, V76, P161, DOI 10.1016/0378-1119(89)90018-8; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; Kotani K, 1998, MOL CELL BIOL, V18, P6971, DOI 10.1128/MCB.18.12.6971; Liao JF, 1998, J BIOL CHEM, V273, P27320, DOI 10.1074/jbc.273.42.27320; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Morris JZ, 1996, NATURE, V382, P536, DOI 10.1038/382536a0; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; OKADA T, 1994, J BIOL CHEM, V269, P3568; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; Rother KI, 1998, J BIOL CHEM, V273, P17491, DOI 10.1074/jbc.273.28.17491; Salvatore P, 1998, J BIOL CHEM, V273, P6989, DOI 10.1074/jbc.273.12.6989; SHIMIZU Y, 1994, BIOCHEM BIOPH RES CO, V202, P660, DOI 10.1006/bbrc.1994.1981; Standaert ML, 1997, J BIOL CHEM, V272, P30075, DOI 10.1074/jbc.272.48.30075; Tissenbaum HA, 1998, GENETICS, V148, P703; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; TOMIZAWA M, 1999, IN PRESS DIABETES, V48; Ueki K, 1998, J BIOL CHEM, V273, P5315, DOI 10.1074/jbc.273.9.5315; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619	28	391	400	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					15982	15985		10.1074/jbc.274.23.15982	http://dx.doi.org/10.1074/jbc.274.23.15982			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347145	hybrid			2022-12-25	WOS:000080668600005
J	Zeng, FY; Hopp, A; Soldner, A; Wess, J				Zeng, FY; Hopp, A; Soldner, A; Wess, J			Use of a disulfide cross-linking strategy to study muscarinic receptor structure and mechanisms of activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; 3RD CYTOPLASMIC LOOP; SITE-DIRECTED MUTAGENESIS; ACETYLCHOLINE-RECEPTOR; LIGAND-BINDING; HORMONE RECEPTOR; BOVINE RHODOPSIN; CONFORMATIONAL-CHANGES; TRANSMEMBRANE HELICES; CHOLINERGIC RECEPTOR	To gain insight into the molecular architecture of the cytoplasmic surface of G protein-coupled receptors, we have developed a disulfide cross-linking strategy using the m3 muscarinic receptor as a model system. To facilitate the interpretation of disulfide cross-linking data, we initially generated a mutant m3 muscarinic receptor (referred to as m3'(3C)-Xa) in which most native Cys residues had been deleted or substituted with Ala or Ser (remaining Cys residues Cys-140, Cys-220, and Cys-532) and in which the central portion of the third intracellular loop had been replaced with a factor Xa cleavage site. Radioligand binding and second messenger assays showed that the m3'(3C)-Xa mutant receptor was fully functional. In the next step, pairs of Cys residues were reintroduced into the m3'(3C)-Xa construct, thus generating 10 double Cys mutant receptors, All 10 mutant receptors contained a Cys residue at position 169 at the beginning of the second intracellular loop and a second Cys within the C-terminal portion of the third intracellular loop, at positions 484-493, Radioligand binding studies and phosphatidylinositol assays indicated that all double Cys mutant receptors were properly folded. Membrane lysates prepared from COS-7 cells transfected with the different mutant receptor constructs were incubated with factor Xa protease and the oxidizing agent Cu(II)-(1,10-phenanthroline)(3), and the formation of intramolecular disulfide bonds between juxtaposed Cys residues was monitored by using a combined immunoprecipitation/immunoblotting strategy. To our surprise, efficient disulfide cross-linking was observed with 8 of the 10 double Cys mutant receptors studied (Cys-169/Cys-484 to Cys-491), suggesting that the intracellular m3 receptor surface is characterized by pronounced backbone fluctuations. Moreover, [S-35]guanosine 5'-3-O-(thio)triphosphate binding assays indicated that the formation of intramolecular disulfide cross-links prevented or strongly inhibited receptor-mediated G protein activation, suggesting that the highly dynamic character of the cytoplasmic receptor surface is a prerequisite for efficient receptor-G protein interactions. This is the first study using a disulfide mapping strategy to examine the three-dimensional structure of a hormone-activated G protein-coupled receptor.	NIDDK, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Wess, J (corresponding author), NIDDK, Bioorgan Chem Lab, NIH, Bldg 8A,Rm B1A-05, Bethesda, MD 20892 USA.							Altenbach C, 1996, BIOCHEMISTRY-US, V35, P12470, DOI 10.1021/bi960849l; Bai M, 1998, J BIOL CHEM, V273, P23605, DOI 10.1074/jbc.273.36.23605; Baldwin JM, 1997, J MOL BIOL, V272, P144, DOI 10.1006/jmbi.1997.1240; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; Cai KW, 1997, P NATL ACAD SCI USA, V94, P14267, DOI 10.1073/pnas.94.26.14267; CAREAGA CL, 1992, J MOL BIOL, V226, P1219, DOI 10.1016/0022-2836(92)91063-U; Cook JVF, 1996, ENDOCRINOLOGY, V137, P2851, DOI 10.1210/en.137.7.2851; CURTIS CAM, 1989, J BIOL CHEM, V264, P489; Danielson MA, 1997, J BIOL CHEM, V272, P32878, DOI 10.1074/jbc.272.52.32878; DIXON RAF, 1987, EMBO J, V6, P3269, DOI 10.1002/j.1460-2075.1987.tb02645.x; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DOHLMAN HG, 1990, BIOCHEMISTRY-US, V29, P2335, DOI 10.1021/bi00461a018; DORJE F, 1991, J PHARMACOL EXP THER, V256, P727; FALKE JJ, 1987, SCIENCE, V237, P1596, DOI 10.1126/science.2820061; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P8812, DOI 10.1021/bi00027a033; FARAHBAKHSH ZT, 1993, SCIENCE, V262, P1416, DOI 10.1126/science.8248781; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Gether U, 1997, EMBO J, V16, P6737, DOI 10.1093/emboj/16.22.6737; Grosse R, 1997, MOL ENDOCRINOL, V11, P1305, DOI 10.1210/me.11.9.1305; Higuchi R., 1989, PCR TECHNOLOGY, P61; Javitch JA, 1997, J BIOL CHEM, V272, P18546, DOI 10.1074/jbc.272.30.18546; JUNG H, 1995, FEBS LETT, V358, P133, DOI 10.1016/0014-5793(94)01409-T; Jung H, 1996, BIOCHEMISTRY-US, V35, P6399, DOI 10.1021/bi952575s; KARNIK SS, 1988, P NATL ACAD SCI USA, V85, P8459, DOI 10.1073/pnas.85.22.8459; KOBILKA B, 1992, ANNU REV NEUROSCI, V15, P97; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KUNKEL MT, 1993, EMBO J, V12, P3809, DOI 10.1002/j.1460-2075.1993.tb06059.x; KURTENBACH E, 1990, J BIOL CHEM, V265, P13702; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMEH J, 1992, J BIOL CHEM, V267, P13406; LAZARENO S, 1993, LIFE SCI, V52, P449, DOI 10.1016/0024-3205(93)90301-I; LEE GF, 1994, J BIOL CHEM, V269, P29920; LYNCH BA, 1991, P NATL ACAD SCI USA, V88, P10402, DOI 10.1073/pnas.88.23.10402; MAEDA S, 1990, FEBS LETT, V269, P386, DOI 10.1016/0014-5793(90)81199-X; Maggio R, 1996, J BIOL CHEM, V271, P31055, DOI 10.1074/jbc.271.49.31055; MAGGIO R, 1993, FEBS LETT, V319, P195, DOI 10.1016/0014-5793(93)80066-4; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Nielsen SM, 1998, EUR J BIOCHEM, V251, P217, DOI 10.1046/j.1432-1327.1998.2510217.x; PAKULA AA, 1992, P NATL ACAD SCI USA, V89, P4144, DOI 10.1073/pnas.89.9.4144; PERLMAN JH, 1995, J BIOL CHEM, V270, P24682, DOI 10.1074/jbc.270.42.24682; RIDGE KD, 1995, P NATL ACAD SCI USA, V92, P3204, DOI 10.1073/pnas.92.8.3204; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; SAVARESE TM, 1992, BIOCHEM J, V283, P1; SAVARESE TM, 1992, J BIOL CHEM, V267, P11439; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; SCHONEBERG T, 1995, J BIOL CHEM, V270, P18000; Schoneberg T, 1996, EMBO J, V15, P1283, DOI 10.1002/j.1460-2075.1996.tb00470.x; SHAPIRO RA, 1989, BIOCHEMISTRY-US, V28, P8946, DOI 10.1021/bi00448a039; Sheikh SP, 1996, NATURE, V383, P347, DOI 10.1038/383347a0; SRINIVASAN N, 1990, INT J PEPT PROT RES, V36, P147; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; Unger VM, 1997, NATURE, V389, P203, DOI 10.1038/38316; VANKOPPEN CJ, 1990, J BIOL CHEM, V265, P20887; Ward DT, 1998, J BIOL CHEM, V273, P14476, DOI 10.1074/jbc.273.23.14476; WATSON S, 1994, G PROTEIN LINKED REC, P1; Wess J, 1996, CRIT REV NEUROBIOL, V10, P69, DOI 10.1615/CritRevNeurobiol.v10.i1.40; Wess J, 1998, PHARMACOL THERAPEUT, V80, P231, DOI 10.1016/S0163-7258(98)00030-8; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; Yang K, 1996, BIOCHEMISTRY-US, V35, P12464, DOI 10.1021/bi960848t; Yang K, 1996, BIOCHEMISTRY-US, V35, P14040, DOI 10.1021/bi962113u; YEAGLE PL, 1995, BIOCHEMISTRY-US, V34, P14621, DOI 10.1021/bi00045a002; YEAGLE PL, 1995, NAT STRUCT BIOL, V2, P832, DOI 10.1038/nsb1095-832; Yeagle PL, 1997, BIOCHEMISTRY-US, V36, P3864, DOI 10.1021/bi962403a; YU HB, 1995, BIOCHEMISTRY-US, V34, P14963, DOI 10.1021/bi00046a002	68	55	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16629	16640		10.1074/jbc.274.23.16629	http://dx.doi.org/10.1074/jbc.274.23.16629			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347230	hybrid			2022-12-25	WOS:000080668600090
J	Esteve, JM; Mompo, J; De La Asuncion, JG; Sastre, J; Asensi, M; Boix, J; Vina, JR; Vina, J; Pallardo, FV				Esteve, JM; Mompo, J; De La Asuncion, JG; Sastre, J; Asensi, M; Boix, J; Vina, JR; Vina, J; Pallardo, FV			Oxidative damage to mitochondrial DNA and glutathione oxidation in apoptosis: studies in vivo and in vitro	FASEB JOURNAL			English	Article						oxidative stress; mtDNA; mammary gland; glutathione	PERFORMANCE LIQUID-CHROMATOGRAPHY; PROGRAMMED CELL-DEATH; FLOW-CYTOMETRY; OXIDIZED GLUTATHIONE; ASCORBIC-ACID; CYTOCHROME-C; HEPATOCYTES; GENERATION; OXYGEN; BLOOD	Free radicals may be involved in apoptosis although this is the subject of some controversy. Furthermore, the source of free radicals in apoptotic cells is not certain. The aim of this study was to elucidate the role of oxidative stress in the induction of apoptosis in serum-deprived fibroblast cultures and in weaned lactating mammary glands as in vitro and in vivo experimental models, respectively. Oxidative damage to mtDNA is higher in apoptotic cells than in controls. Oxidized glutathione (GSSG) levels in mitochondria from lactating mammary gland are also higher in apoptosis, There is a direct relationship between mtDNA damage and the GSSG/reduced glutathione (GSH) ratio, Furthermore, whole cell GSH is decreased and GSSG is increased in both models of apoptosis, Glutathione oxidation precedes nuclear DNA fragmentation. These signs of oxidative stress are caused, at least in part, by an increase in peroxide production by mitochondria from apoptotic cells. We report a direct relationship between glutathione oxidation and mtDNA damage in apoptosis, Our results support the role of mitochondrial oxidative stress in the induction of apoptosis.	Univ Valencia, Fac Med, Dept Fisiol, Valencia 46010, Spain; Univ Valencia, Dept Patol, Valencia 46010, Spain; Univ Valencia, Dept Bioquim & Biol Mol, Valencia 46010, Spain	University of Valencia; University of Valencia; University of Valencia	Pallardo, FV (corresponding author), Univ Valencia, Fac Med, Dept Fisiol, Ave Blasco Ibanez 17, Valencia 46010, Spain.		Vina, Jose/AAB-3069-2021; Viña, Juan R/ABE-5698-2021; Miralles, Miguel A Asensi/I-2756-2015; Pallardo, Federico V./T-1156-2017	Vina, Jose/0000-0001-9709-0089; Viña, Juan R/0000-0002-4035-3615; Miralles, Miguel A Asensi/0000-0003-1922-7777; Pallardo, Federico V./0000-0003-3715-1980				ANDERSON ME, 1989, ANAL BIOCHEM, V183, P16, DOI 10.1016/0003-2697(89)90164-4; ASENSI M, 1994, METHOD ENZYMOL, V234, P367; ASENSI M, 1994, ANAL BIOCHEM, V217, P323, DOI 10.1006/abio.1994.1126; BRIGELIUS R, 1983, BIOCHEM PHARMACOL, V32, P2326; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; DeLaAsuncion JG, 1996, FASEB J, V10, P333, DOI 10.1096/fasebj.10.2.8641567; FRAGA CG, 1991, P NATL ACAD SCI USA, V88, P11003, DOI 10.1073/pnas.88.24.11003; GHIBELLI L, 1995, BIOCHEM BIOPH RES CO, V216, P313, DOI 10.1006/bbrc.1995.2626; GILBERT HF, 1982, J BIOL CHEM, V257, P2086; GONG JP, 1994, ANAL BIOCHEM, V218, P314, DOI 10.1006/abio.1994.1184; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; JUAN G, 1994, CYTOMETRY, V15, P335, DOI 10.1002/cyto.990150409; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KASAI H, 1984, NUCLEIC ACIDS RES, V12, P2137, DOI 10.1093/nar/12.4.2137; KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017; LATORRE A, 1986, P NATL ACAD SCI USA, V83, P8649, DOI 10.1073/pnas.83.22.8649; MILLS BJ, 1990, ANAL BIOCHEM, V184, P263, DOI 10.1016/0003-2697(90)90678-3; MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; REED DJ, 1980, ANAL BIOCHEM, V106, P55, DOI 10.1016/0003-2697(80)90118-9; RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465; RICKWOOD DW, 1987, MITOCHONDRIA PRACTIC, P4; ROTHE G, 1990, J LEUKOCYTE BIOL, V47, P440, DOI 10.1002/jlb.47.5.440; Sastre J, 1996, HEPATOLOGY, V24, P1199, DOI 10.1002/hep.510240536; SHIGENAGA MK, 1990, METHOD ENZYMOL, V186, P521; vandenDobbelsteen DJ, 1996, J BIOL CHEM, V271, P15420, DOI 10.1074/jbc.271.26.15420; Vina J., 1990, GLUTATHIONE METABOLI; Yang JC, 1998, FREE RADICAL BIO MED, V24, P624, DOI 10.1016/S0891-5849(97)00367-5; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533	31	146	148	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	1999	13	9					1055	1064		10.1096/fasebj.13.9.1055	http://dx.doi.org/10.1096/fasebj.13.9.1055			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	200NZ	10336888	Bronze			2022-12-25	WOS:000080547700010
J	de Saro, FJL; Yoshikawa, N; Helmann, JD				de Saro, FJL; Yoshikawa, N; Helmann, JD			Expression, abundance, and RNA polymerase binding properties of the delta factor of Bacillus subtilis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGMA-FACTOR; STAPHYLOCOCCUS-AUREUS; GENE-EXPRESSION; PROMOTER; DNA; INITIATION; SUBUNIT; PURIFICATION; CORE; TRANSCRIPTION	The delta protein is a dispensable subunit of Bacillus subtilis RNA polymerase (RNAP) that has major effects on the biochemical properties of the purified enzyme. In the presence of delta, RNAP displays an increased specificity of transcription, a decreased affinity for nucleic acids, and an increased efficiency of RNA synthesis because of enhanced recycling. Despite these profound effects, a strain containing a deletion of the delta gene (rpoE) is viable and shows no major alterations in gene expression, Quantitative immunoblotting experiments demonstrate that delta is present in molar excess relative to RNAP in both vegetative cells and spores. Expression of rpoE initiates from a single, sigma(A)-dependent promoter and is maximal in transition phase. A rpoE mutant strain has an altered morphology and is delayed in the exit from stationary phase. For biochemical analyses we have created derivatives of delta and sigma(A) that can be radiolabeled with protein kinase A. Using electrophoretic mobility shift assays, we demonstrate that delta binds core RNAP with an apparent affinity of 2.5 x 10(6) M-1, but we are unable to demonstrate the formation of a ternary complex containing core enzyme, delta, and sigma(A).	Cornell Univ, Microbiol Sect, Ithaca, NY 14853 USA	Cornell University	Helmann, JD (corresponding author), Cornell Univ, Microbiol Sect, Ithaca, NY 14853 USA.			Helmann, John/0000-0002-3832-3249	NIGMS NIH HHS [GM-47446] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047446] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACHBERGER EC, 1982, J BACTERIOL, V150, P977, DOI 10.1128/JB.150.2.977-980.1982; ACHBERGER EC, 1982, NUCLEIC ACIDS RES, V10, P2893, DOI 10.1093/nar/10.9.2893; ACHBERGER EC, 1981, J BIOL CHEM, V256, P7424; ALTMANN CR, 1994, P NATL ACAD SCI USA, V91, P3784, DOI 10.1073/pnas.91.9.3784; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; CHANG BY, 1990, J BACTERIOL, V172, P3257, DOI 10.1128/jb.172.6.3257-3263.1990; CHEN L, 1993, J BACTERIOL, V175, P5428, DOI 10.1128/JB.175.17.5428-5437.1993; Chen YF, 1997, J MOL BIOL, V267, P47, DOI 10.1006/jmbi.1996.0853; DEORA R, 1995, BIOCHEM BIOPH RES CO, V208, P610, DOI 10.1006/bbrc.1995.1382; DESARO FJL, 1995, J MOL BIOL, V252, P189, DOI 10.1006/jmbi.1995.0487; DICKEL CD, 1980, BIOCHEM BIOPH RES CO, V95, P1789, DOI 10.1016/S0006-291X(80)80106-9; DOBINSON KF, 1987, BIOCHEMISTRY-US, V26, P8206, DOI 10.1021/bi00399a028; GILL SC, 1991, J MOL BIOL, V220, P307, DOI 10.1016/0022-2836(91)90015-X; HANSEN UM, 1980, J BIOL CHEM, V255, P9564; HELMANN JD, 1995, NUCLEIC ACIDS RES, V23, P2351, DOI 10.1093/nar/23.13.2351; HYDE EI, 1986, J BIOL CHEM, V261, P6565; JUANG YL, 1995, BIOCHEMISTRY-US, V34, P8465, DOI 10.1021/bi00026a030; JUANG YL, 1994, J MOL BIOL, V235, P1470, DOI 10.1006/jmbi.1994.1102; JUANG YL, 1994, J MOL BIOL, V239, P1, DOI 10.1006/jmbi.1994.1346; Kelman Z, 1995, METHOD ENZYMOL, V262, P430; KENNEY TJ, 1991, J BACTERIOL, V173, P3282, DOI 10.1128/jb.173.11.3282-3290.1991; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; LAMPE M, 1988, GENE, V67, P13, DOI 10.1016/0378-1119(88)90003-0; Mendelson NH, 1996, J BACTERIOL, V178, P1980, DOI 10.1128/jb.178.7.1980-1989.1996; Nicholson WL., 1990, MOL BIOL METHODS BAC, P391, DOI DOI 10.1111/J.1751-1097.1991.TB02087.X; PERO J, 1975, P NATL ACAD SCI USA, V72, P1589, DOI 10.1073/pnas.72.4.1589; Rudner R, 1998, MOL MICROBIOL, V27, P687, DOI 10.1046/j.1365-2958.1998.00717.x; Sambrook J., 1990, MOL CLONING LAB MANU, V2nd; SLACK FJ, 1993, J BACTERIOL, V175, P4605, DOI 10.1128/JB.175.15.4605-4614.1993; SPIEGELMAN GB, 1978, J BIOL CHEM, V253, P1756; STRAGIER P, 1988, CELL, V52, P697, DOI 10.1016/0092-8674(88)90407-2; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; WALTER AE, 1994, P NATL ACAD SCI USA, V91, P9218, DOI 10.1073/pnas.91.20.9218; Watson SP, 1998, MICROBIOL-UK, V144, P3159, DOI 10.1099/00221287-144-11-3159; WIGGS JL, 1981, P NATL ACAD SCI-BIOL, V78, P2762, DOI 10.1073/pnas.78.5.2762; ZUBER P, 1987, J BACTERIOL, V169, P2223, DOI 10.1128/jb.169.5.2223-2230.1987	37	38	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15953	15958		10.1074/jbc.274.22.15953	http://dx.doi.org/10.1074/jbc.274.22.15953			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336502	hybrid			2022-12-25	WOS:000080560100091
J	Ito, T; Yang, ML; May, WS				Ito, T; Yang, ML; May, WS			RAX, a cellular activator for double-stranded RNA-dependent protein kinase during stress signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN; TRANSLATIONAL CONTROL; INTERFERON; PKR; PHOSPHORYLATION; INITIATION; IDENTIFICATION; INTERLEUKIN-3; EXPRESSION; APOPTOSIS	The double-stranded (ds) RNA-dependent protein kinase (PKR) regulates protein synthesis by phosphorylating the alpha subunit of eukaryotic initiation factor-2, PKR is activated by viral induced dsRNA and thought to be involved in the host antiviral defense mechanism. PKR is also activated by various nonviral stresses such as growth factor deprivation, although the mechanism is unknown. By screening a mouse cDNA expression library, we have identified an ubiquitously expressed PKR-associated protein, RAX, RAX has a high sequence homology to human PACT, which activates PKR in the absence of dsRNA. Although RAX also can directly activate PKR in vitro, overexpression of RAX does not induce PKR activation or inhibit growth of interleukin-3 (IL-3)-dependent cells in the presence of IL-3. However, IL-3 deprivation as well as diverse cell stress treatments including arsenite, thapsigargin, and H2O2, which are known to inhibit protein synthesis, induce the rapid phosphorylation of RAX followed by RAX-PKR association and activation of PKR, Therefore, cellular RAX may be a stress-activated, physiologic activator of PKR that couples transmembrane stress signals and protein synthesis.	Univ Texas, Med Branch, Dept Internal Med, Sealy Ctr Oncol & Hematol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Ito, T (corresponding author), Univ Texas, Med Branch, Dept Internal Med, Sealy Ctr Oncol & Hematol, Galveston, TX 77555 USA.	tito@utmb.edu		Yang, Mingli/0000-0002-4781-690X	NATIONAL CANCER INSTITUTE [R01CA044649] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054083] Funding Source: NIH RePORTER; NCI NIH HHS [CA44649] Funding Source: Medline; NHLBI NIH HHS [HL54083] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOSWELL HS, 1990, EXP HEMATOL, V18, P794; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Brostrom CO, 1998, PROG NUCLEIC ACID RE, V58, P79; Brostrom CO, 1996, J BIOL CHEM, V271, P24995, DOI 10.1074/jbc.271.40.24995; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; Clemens MJ, 1996, TRANSLATIONAL CONTRO, P139; DUNCAN RF, 1987, ARCH BIOCHEM BIOPHYS, V256, P651, DOI 10.1016/0003-9861(87)90622-9; Eckmann CR, 1997, J CELL BIOL, V138, P239, DOI 10.1083/jcb.138.2.239; FARRELL PJ, 1977, CELL, V11, P187, DOI 10.1016/0092-8674(77)90330-0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GATIGNOL A, 1991, SCIENCE, V251, P1597, DOI 10.1126/science.2011739; Goldman LA, 1996, BIOTECHNIQUES, V21, P1013; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harlow E., 1988, ANTIBODIES LAB MANUA; ICELY PL, 1991, J BIOL CHEM, V266, P16073; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; ITO T, 1994, P NATL ACAD SCI USA, V91, P7455, DOI 10.1073/pnas.91.16.7455; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Lee K, 1996, MOL CELL BIOL, V16, P3023; LEE SB, 1994, VIROLOGY, V199, P491, DOI 10.1006/viro.1994.1151; LEE TG, 1994, MOL CELL BIOL, V14, P2331, DOI 10.1128/MCB.14.4.2331; MATHEWS MB, 1996, TRANSLATIONAL CONTRO, P505; MAURIDES PA, 1989, ANAL BIOCHEM, V183, P144, DOI 10.1016/0003-2697(89)90182-6; Merrick WC., 1996, TRANSLATION CONTROL, P31; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; PARK HS, 1994, P NATL ACAD SCI USA, V91, P4713, DOI 10.1073/pnas.91.11.4713; Patel RC, 1998, EMBO J, V17, P4379, DOI 10.1093/emboj/17.15.4379; PROSTKO CR, 1995, J BIOL CHEM, V270, P6211, DOI 10.1074/jbc.270.11.6211; PROUD CG, 1995, TRENDS BIOCHEM SCI, V20, P241, DOI 10.1016/S0968-0004(00)89025-8; PROUD CG, 1992, CURR TOP CELL REGUL, V32, P243; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Shi YG, 1998, MOL CELL BIOL, V18, P7499, DOI 10.1128/MCB.18.12.7499; SRIVASTAVA SP, 1995, J BIOL CHEM, V270, P16619, DOI 10.1074/jbc.270.28.16619; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; Wu SY, 1998, BIOCHEMISTRY-US, V37, P13816, DOI 10.1021/bi981472h; Zhu SH, 1997, J BIOL CHEM, V272, P14434, DOI 10.1074/jbc.272.22.14434; ZINN K, 1988, SCIENCE, V240, P210, DOI 10.1126/science.3281258	37	186	189	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15427	15432		10.1074/jbc.274.22.15427	http://dx.doi.org/10.1074/jbc.274.22.15427			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336432	hybrid			2022-12-25	WOS:000080560100021
J	Osterlund, T; Beussman, DJ; Julenius, K; Poon, PH; Linse, S; Shabanowitz, J; Hunt, DF; Schotz, MC; Derewenda, ZS; Holm, C				Osterlund, T; Beussman, DJ; Julenius, K; Poon, PH; Linse, S; Shabanowitz, J; Hunt, DF; Schotz, MC; Derewenda, ZS; Holm, C			Domain identification of hormone-sensitive lipase by circular dichroism and fluorescence spectroscopy, limited proteolysis, and mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTROPHORESIS; SEPARATION; CHARACTER; PROTEIN	Structure-function relationship analyses of hormone-sensitive lipase (HSL) have suggested that this metabolically important enzyme consists of several functional and at least two structural domains (Osterlund, T., Danielsson, B., Degerman, E., Contreras, J. A., Edgren, G., Davis, R. C., Schotz, M. C., and Helm, C. (1996) Bio-chem. J. 319, 411-420; Contreras, J. A., Karlsson, M., Osterlund, T., Laurell, H., Svensson, A, and Helm, C. (1996) J. Biol. Chem. 271, 31426-31430). To analyze the structural domain composition of HSL in more detail, we applied biophysical methods. Denaturation of HSL was followed by circular dichroism measurements and fluorescence spectroscopy, revealing that the unfolding of HSL is a two-step event. Using limited proteolysis in combination with mass spectrometry, several proteolytic fragments of HSL were identified, including one corresponding exactly to the proposed N-terminal domain. Major cleavage sites were found in the predicted hinge region between the two domains and in the regulatory module of the C-terminal, catalytic domain. Analyses of a hinge region cleavage mutant and calculations of the hydropathic pattern of HSL further suggest that the hinge region and regulatory module are exposed parts of HSL. Together, these data support our previous hypothesis that HSL consists of two major structural domains, encoded by exons 1-4 and 5-9, respectively, of which the latter contains an exposed regulatory module outside the catalytic alpha/beta-hydrolase fold core.	Univ Lund, Dept Cell & Mol Biol, Sect Mol Signalling, S-22100 Lund, Sweden; Univ Lund, Dept Phys Chem 2, S-22100 Lund, Sweden; Univ Virginia, Dept Chem, Charlottesville, VA 22906 USA; Univ Virginia, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22906 USA; Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90024 USA; W Los Angeles Vet Affairs Med Ctr, Lipid Res Lab, Los Angeles, CA 90073 USA	Lund University; Lund University; University of Virginia; University of Virginia; University of California System; University of California Los Angeles; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; West Los Angeles VA Medical Center	Holm, C (corresponding author), Univ Lund, Dept Cell & Mol Biol, Sect Mol Signalling, S-22100 Lund, Sweden.		Hunt, Donald F/I-6936-2012	Hunt, Donald F/0000-0003-2815-6368; Linse, Sara/0000-0001-9629-7109; Osterlund, Torben/0000-0002-2047-767X				Anthonsen MW, 1998, J BIOL CHEM, V273, P215, DOI 10.1074/jbc.273.1.215; Contreras JA, 1996, J BIOL CHEM, V271, P31426, DOI 10.1074/jbc.271.49.31426; Degerman E, 1997, J BIOL CHEM, V272, P6823, DOI 10.1074/jbc.272.11.6823; DEREWENDA ZS, 1994, ADV PROTEIN CHEM, V45, P1; GARTON AJ, 1989, EUR J BIOCHEM, V179, P249, DOI 10.1111/j.1432-1033.1989.tb14548.x; HOLM C, 1986, J BIOL CHEM, V261, P5659; Holm C, 1997, METHOD ENZYMOL, V286, P45; HOLM C, 1994, FEBS LETT, V344, P234, DOI 10.1016/0014-5793(94)00403-X; HOLM C, 1990, LIPIDS, V25, P254, DOI 10.1007/BF02544384; Holm C, 1997, METHOD ENZYMOL, V284, P272; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Osterlund T, 1997, FEBS LETT, V403, P259, DOI 10.1016/S0014-5793(97)00063-X; Osterlund T, 1996, BIOCHEM J, V319, P411, DOI 10.1042/bj3190411; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Smith GM, 1996, FEBS LETT, V396, P90, DOI 10.1016/0014-5793(96)01076-9; STRALFORS P, 1987, ENZYMES B, V18, P147; SULLIVAN JE, 1994, FEBS LETT, V353, P33, DOI 10.1016/0014-5793(94)01006-4	19	29	31	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15382	15388		10.1074/jbc.274.22.15382	http://dx.doi.org/10.1074/jbc.274.22.15382			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336425	hybrid			2022-12-25	WOS:000080560100014
J	Qi, C; Zhu, YJ; Pan, J; Usuda, N; Maeda, N; Yeldandi, AV; Rao, MS; Hashimoto, T; Reddy, JK				Qi, C; Zhu, YJ; Pan, J; Usuda, N; Maeda, N; Yeldandi, AV; Rao, MS; Hashimoto, T; Reddy, JK			Absence of spontaneous peroxisome proliferation in Enoyl-CoA hydratase/L-3-Hydroxyacyl-CoA dehydrogenase-deficient mouse liver - Further support for the role of fatty acyl CoA oxidase in PPAR alpha ligand metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED RECEPTOR-ALPHA; STEROL CARRIER PROTEIN-2; MICE LACKING; RAT-LIVER; GENE; CLOFIBRATE; CLONING	Peroxisomes contain a classical L-hydroxy-specific peroxisome proliferator-inducible beta-oxidation system and also a second noninducible D-hydroxy-specific beta-oxidation system. We previously generated mice lacking fatty acyl-CoA oxidase (AOX), the first enzyme of the L-hydroxy-specific classical beta-oxidation system; these AOX(-/-) mice exhibited sustained activation of peroxisome proliferator-activated receptor alpha (PPAR alpha), resulting in profound spontaneous peroxisome proliferation liver cells. These observations implied that AOX is responsible for the metabolic degradation of PPAR alpha ligands, In this study, the function of enoyl-CoA hydratase/L-3-hydroxyacyl-CoA dehydrogenase (L-PBE), the second enzyme of this peroxisomal beta-oxidation system, was investigated by disrupting its gene. Mutant mice (L-PBE-/-) were viable and fertile and exhibited no detectable gross phenotypic defects. L-PBE-/- mice showed no hepatic steatosis and manifested no spontaneous peroxisome proliferation, unlike that encountered in livers of mice deficient in AOX. These results indicate that disruption of classical peroxisomal fatty acid beta-oxidation system distal to AOX step does not interfere with the inactivation of endogenous ligands of PPAR alpha, further confirming that the AOX gene is indispensable for the physiological regulation of this receptor. The absence of appreciable changes in lipid metabolism also indicates that enoyl-CoAs, generated in the classical system in L-PBE-/- mice are diverted to D-hydroxy-specific system for metabolism by D-PBE, When challenged with a peroxisome proliferator, L-PBE-/- mice showed increases in the levels of hepatic mRNAs and proteins that are regulated by PPAR alpha except for appreciable blunting of peroxisome proliferative response as compared with that observed in hepatocytes of wild type mice similarly treated. This blunting of peroxisome proliferative response is attributed to the absence of L-PBE protein in L-PBE-/- mouse liver, because all other proteins are induced essentially to the same extent in both wild type and L-PBE-/- mice.	Northwestern Univ, Sch Med, Dept Pathol, Chicago, IL 60611 USA; Univ N Carolina, Dept Pathol, Chapel Hill, NC 27599 USA	Northwestern University; University of North Carolina; University of North Carolina Chapel Hill	Reddy, JK (corresponding author), Northwestern Univ, Sch Med, Dept Pathol, 303 E Chicago Ave, Chicago, IL 60611 USA.				NIGMS NIH HHS [GM 23750] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023750, R01GM023750] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aoyama T, 1998, J BIOL CHEM, V273, P5678, DOI 10.1074/jbc.273.10.5678; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; Baumgart E, 1996, P NATL ACAD SCI USA, V93, P13748, DOI 10.1073/pnas.93.24.13748; Faergeman NJ, 1997, BIOCHEM J, V323, P1; Fan CY, 1998, J BIOL CHEM, V273, P15639, DOI 10.1074/jbc.273.25.15639; FORMAN BM, 1997, P NATL ACAD SCI USA, V89, P4653; Gonzalez FJ, 1998, J NATL CANCER I, V90, P1702, DOI 10.1093/jnci/90.22.1702; HASHIMOTO T, 1999, IN PRESS NEUROCHEM R; ISHII N, 1987, J BIOL CHEM, V262, P8144; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; Jiang LL, 1997, J BIOCHEM-TOKYO, V121, P506; Kurtz DM, 1998, P NATL ACAD SCI USA, V95, P15592, DOI 10.1073/pnas.95.26.15592; LAZAROW PB, 1976, P NATL ACAD SCI USA, V73, P2043, DOI 10.1073/pnas.73.6.2043; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Lu JF, 1997, P NATL ACAD SCI USA, V94, P9366, DOI 10.1073/pnas.94.17.9366; MORI T, 1991, P NATL ACAD SCI USA, V88, P4338, DOI 10.1073/pnas.88.10.4338; RAO MS, 1987, CARCINOGENESIS, V8, P631; REDDY JK, 1975, SCIENCE, V190, P787, DOI 10.1126/science.1198095; REDDY JK, 1977, BIOCHEM BIOPH RES CO, V77, P824, DOI 10.1016/S0006-291X(77)80052-1; REDDY JK, 1994, ANNU REV NUTR, V14, P343, DOI 10.1146/annurev.nu.14.070194.002015; Seedorf U, 1998, GENE DEV, V12, P1189, DOI 10.1101/gad.12.8.1189; Usuda N, 1996, ANN NY ACAD SCI, V804, P297, DOI 10.1111/j.1749-6632.1996.tb18624.x	22	81	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15775	15780		10.1074/jbc.274.22.15775	http://dx.doi.org/10.1074/jbc.274.22.15775			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336479	hybrid			2022-12-25	WOS:000080560100068
J	Sugawara, H; Yamamoto, H; Shihata, N; Inoue, T; Okada, S; Miyake, C; Yokota, A; Kai, Y				Sugawara, H; Yamamoto, H; Shihata, N; Inoue, T; Okada, S; Miyake, C; Yokota, A; Kai, Y			Crystal structure of carboxylase reaction-oriented ribulose 1,5-bisphosphate carboxylase oxygenase from a thermophilic red alga, Galdieria partita	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; SPINACH RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE/OXYGENASE; SUBSTRATE-SPECIFICITY FACTOR; RIBULOSEBISPHOSPHATE CARBOXYLASE; ACTIVE-SITE; PYLAIELLA-LITTORALIS; PYROCOCCUS-FURIOSUS; CARBON-DIOXIDE; SMALL SUBUNITS; BISPHOSPHATE	Ribulose 1,5-bisphosphate carboxylase/oxygenase (Rubisco, EC 4.1.1.39) obtained from a thermophilic red alga Galdieria partita has the highest specificity factor of 238 among the Rubiscos hitherto reported. Crystal structure of activated Rubisco from G. partita complexed with the reaction intermediate analogue, 2-carboxyarabinitol 1,5-bisphosphate (P-CABP) has been determined at 2.4-Angstrom resolution. Compared with other Rubiscos, different amino residues bring the structural differences in active site, which are marked around the binding sites of P-2 phosphate of 2-CABP. Especially, side chains of His-327 and Arg-295 show the significant differences from those of spinach Rubisco. Moreover, the side chains of Asn-123 and His-294 which are reported to bind the substrate, ribulose 1,5-bisphosphate, form hydrogen bonds characteristic of Galdieria Rubisco. Small subunits of Galdieria Rubisco have more than 30 extra amino acid residues on the C terminus, which make up a hairpin-loop structure to form many interactions with the neighboring small subunits. When the structures of Galdieria and spinach Rubiscos are superimposed, the hairpin region of the neighboring small subunit in Galdieria enzyme and apical portion of insertion residues 52-63 characteristic of small subunits in higher plant enzymes are almost overlapped to each other.	Osaka Univ, Grad Sch Engn, Dept Chem Mat, Suita, Osaka 5650871, Japan; Nara Inst Sci & Technol, Grad Sch Biol Sci, Nara 6300101, Japan	Osaka University; Nara Institute of Science & Technology	Kai, Y (corresponding author), Osaka Univ, Grad Sch Engn, Dept Chem Mat, 2-1 Yamada Oka, Suita, Osaka 5650871, Japan.		Shibata, Naoki/AFK-9971-2022	Shibata, Naoki/0000-0002-5096-1104				Andersson I, 1996, J MOL BIOL, V259, P160, DOI 10.1006/jmbi.1996.0310; Andrews T.J., 1987, BIOCH PLANTS, P131, DOI 10.1016/B978-0-12-675410-0.50009-9; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; ASSALI NE, 1990, PLANT MOL BIOL, V15, P307, DOI 10.1007/BF00036916; ASSALI NE, 1991, PLANT MOL BIOL, V17, P853, DOI 10.1007/BF00037066; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Brunger AT, 1997, METHOD ENZYMOL, V277, P366, DOI 10.1016/S0076-6879(97)77021-6; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Cleland WW, 1998, CHEM REV, V98, P549, DOI 10.1021/cr970010r; CURMI PMG, 1992, J BIOL CHEM, V267, P16980; DAY MW, 1992, PROTEIN SCI, V1, P1494, DOI 10.1002/pro.5560011111; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; HAINING RL, 1990, J BIOL CHEM, V265, P5434; Harpel MR, 1996, BIOCHEMISTRY-US, V35, P13865, DOI 10.1021/bi962184t; HARPEL MR, 1991, J BIOL CHEM, V266, P24734; HARTMAN FC, 1985, J BIOL CHEM, V260, P3968; HARTMAN FC, 1987, J BIOL CHEM, V262, P3496; Hennig M, 1995, STRUCTURE, V3, P1295, DOI 10.1016/S0969-2126(01)00267-2; HUANG CC, 1991, J MOL GRAPHICS, V9, P230, DOI 10.1016/0263-7855(91)80016-S; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KNIGHT S, 1990, J MOL BIOL, V215, P113, DOI 10.1016/S0022-2836(05)80100-7; KORNDORFER I, 1995, J MOL BIOL, V246, P511, DOI 10.1006/jmbi.1994.0103; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRECKL W, 1989, J BIOL CHEM, V264, P10982; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE EH, 1993, J BIOL CHEM, V268, P26583; LEE GJ, 1992, BIOCHEMISTRY-US, V31, P2304, DOI 10.1021/bi00123a014; LIANG WA, 1974, PLANT PHYSIOL, V54, P678; LORIMER GH, 1981, BIOCHEMISTRY-US, V20, P1236, DOI 10.1021/bi00508a028; LUNDQVIST T, 1991, J BIOL CHEM, V266, P12604; LUNDQVIST T, 1989, J BIOL CHEM, V264, P7078; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MCPHERSON A, 1982, PREPARATION ANAL PRO, P96; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MORDEN CW, 1991, J MOL EVOL, V32, P379, DOI 10.1007/BF02101278; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NEWMAN J, 1993, J BIOL CHEM, V268, P25876; NIYOGI SK, 1986, J BIOL CHEM, V261, P87; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; PIERCE J, 1980, BIOCHEMISTRY-US, V19, P934, DOI 10.1021/bi00546a018; PORTIS AR, 1990, BIOCHIM BIOPHYS ACTA, V1015, P15, DOI 10.1016/0005-2728(90)90211-L; READ BA, 1992, BIOCHEMISTRY-US, V31, P5553, DOI 10.1021/bi00139a018; READ BA, 1994, ARCH BIOCHEM BIOPHYS, V312, P210, DOI 10.1006/abbi.1994.1301; READ BA, 1992, BIOCHEMISTRY-US, V31, P519, DOI 10.1021/bi00117a031; SAKABE N, 1991, NUCL INSTRUM METH A, V303, P448, DOI 10.1016/0168-9002(91)90282-U; SAVER BG, 1982, BIOCHEMISTRY-US, V21, P5398, DOI 10.1021/bi00265a003; SCHREUDER HA, 1993, PROTEIN SCI, V2, P1136, DOI 10.1002/pro.5560020708; Shibata N, 1996, J BIOL CHEM, V271, P26449, DOI 10.1074/jbc.271.43.26449; Shibata N, 1996, J BIOCHEM-TOKYO, V120, P1064; TABITA FR, 1988, MICROBIOL REV, V52, P155, DOI 10.1128/MMBR.52.2.155-189.1988; TAPIA O, 1995, THEOCHEM-J MOL STRUC, V342, P131; Taylor TC, 1997, BIOCHEMISTRY-US, V36, P4041, DOI 10.1021/bi962818w; Taylor TC, 1996, NAT STRUCT BIOL, V3, P95, DOI 10.1038/nsb0196-95; Taylor TC, 1997, J MOL BIOL, V265, P432, DOI 10.1006/jmbi.1996.0738; Uemura K, 1996, PLANT CELL PHYSIOL, V37, P325, DOI 10.1093/oxfordjournals.pcp.a028949; VONCAEMMERER S, 1991, J PLANT PHYSL, V18, P287; YIP KSP, 1995, STRUCTURE, V3, P1147, DOI 10.1016/S0969-2126(01)00251-9; ZELITCH I, 1975, SCIENCE, V188, P626, DOI 10.1126/science.188.4188.626	59	50	53	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15655	15661		10.1074/jbc.274.22.15655	http://dx.doi.org/10.1074/jbc.274.22.15655			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336462	hybrid			2022-12-25	WOS:000080560100051
J	Uehara, T; Matsuno, J; Kaneko, M; Nishiya, T; Fujimuro, M; Yokosawa, H; Nomura, Y				Uehara, T; Matsuno, J; Kaneko, M; Nishiya, T; Fujimuro, M; Yokosawa, H; Nomura, Y			Transient nuclear factor kappa B (NF-kappa B) activation stimulated by interleukin-1 beta may be partly dependent on proteasome activity, but not phosphorylation and ubiquitination of the I kappa B alpha molecule, in C6 glioma cells - Regulation of NF-kappa B linked to chemokine production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTICATALYTIC PROTEINASE COMPLEX; CASEIN KINASE-II; MEDIATED PROTEOLYSIS; 26-S PROTEASOME; DEGRADATION; SUFFICIENT; COMPONENT; INDUCTION; REQUIRES; PATHWAY	We previously reported that several stresses can induce cytokine-induced neutrophil chemoattractant expression in a nuclear factor kappa B (NF-kappa B)-dependent manner. In this study, we focused further on the regulation of NF-kappa B, The activation of NF-kappa B and the subsequent cytokine-induced neutrophil chemoattractant induction in response to interleukin-1 beta (IL-1 beta) were inhibited by proteasome inhibitors, MG132 and proteasome inhibitor I. Translocation of NF-kappa B into nuclei occurs by the phosphorylation, multi-ubiquitination, and degradation of I kappa B alpha, a regulatory protein of NF-kappa B, Nascent I kappa B alpha began to degrade 5 min after treatment with IL-1 beta and disappeared completely after 15 min. However, I kappa B alpha returned to basal levels after 45-60 min. Interestingly, resynthesized I kappa B alpha was already phosphorylated at Ser-32, These results suggest that 1) the upstream signals are still activated, although the translocation of NF-kappa B peaks at 15 min; and 2) the regulated protein(s) acts downstream of I kappa B alpha phosphorylation, Western blotting showed that the resynthesized and phosphorylated I kappa B molecules were also upward-shifted by multi-ubiquitination in response to IL-1 beta treatment. On the other hand, ATP-dependent Leu-Leu-Val-Tyr cleaving activity transiently increased, peaked at 15 min, and then decreased to basal levels at 60 min. Furthermore, the cytosolic fraction that was stimulated by IL-1 beta for 15 min, but not for 0 and 60 min, could degrade phosphorylated and multi-ubiquitinated I kappa B alpha, These results indicate that the transient translocation of NF-kappa B in response to IL-1 beta may be partly dependent on transient proteasome activation.	Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Pharmacol, Sapporo, Hokkaido 0600812, Japan; Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Biochem, Sapporo, Hokkaido 0600812, Japan	Hokkaido University; Hokkaido University	Nomura, Y (corresponding author), Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Pharmacol, Sapporo, Hokkaido 0600812, Japan.	nomura@pharm.hokudai.ac.jp	Kaneko, Masayuki/F-9302-2011; Fujimuro, Masahiro/AAC-4727-2020	Kaneko, Masayuki/0000-0002-0477-0171; Fujimuro, Masahiro/0000-0002-5165-0789; Uehara, Takashi/0000-0002-8545-4006				Aizawa H, 1996, BIOCHEM BIOPH RES CO, V218, P224, DOI 10.1006/bbrc.1996.0039; ALKALAY I, 1995, MOL CELL BIOL, V15, P1294; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldi L, 1996, J BIOL CHEM, V271, P376, DOI 10.1074/jbc.271.1.376; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Castano JG, 1996, BIOCHEMISTRY-US, V35, P3782, DOI 10.1021/bi952540s; Chen F, 1997, ARCH BIOCHEM BIOPHYS, V342, P383, DOI 10.1006/abbi.1997.0132; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Ciechanover A, 1996, NAT MED, V2, P1188, DOI 10.1038/nm1196-1188; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; DONALD R, 1995, J BIOL CHEM, V270, P9, DOI 10.1074/jbc.270.1.9; DRISCOLL J, 1990, J BIOL CHEM, V265, P4789; ETLINGER JD, 1993, ENZYME PROTEIN, V47, P325, DOI 10.1159/000468690; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; GILMORE TD, 1993, TRENDS GENET, V9, P427, DOI 10.1016/0168-9525(93)90106-R; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOFFMAN L, 1992, J BIOL CHEM, V267, P22362; JENTSCH S, 1995, CELL, V82, P881, DOI 10.1016/0092-8674(95)90021-7; KAWAHARA H, 1992, FEBS LETT, V310, P119, DOI 10.1016/0014-5793(92)81310-I; KENNETH NL, 1996, BIOCHEM BIOPH RES CO, V225, P855; LUDEMANN R, 1993, J BIOL CHEM, V268, P17413; MA CP, 1994, J BIOL CHEM, V269, P3539; MATTHEWS W, 1989, P NATL ACAD SCI USA, V86, P2597, DOI 10.1073/pnas.86.8.2597; NISHIYA T, 1995, FEBS LETT, V371, P333, DOI 10.1016/0014-5793(95)00933-Z; ORINO E, 1991, FEBS LETT, V284, P206, DOI 10.1016/0014-5793(91)80686-W; PETERS JM, 1994, J BIOL CHEM, V269, P7709; RODRIGUEZ MS, 1995, MOL CELL BIOL, V15, P2413; SAWADA H, 1993, FEBS LETT, V335, P207, DOI 10.1016/0014-5793(93)80731-9; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; UDVARDY A, 1993, J BIOL CHEM, V268, P9055; Uehara T, 1999, J NEUROCHEM, V72, P196, DOI 10.1046/j.1471-4159.1999.0720196.x; Uehara T, 1998, BRAIN RES, V790, P284, DOI 10.1016/S0006-8993(98)00080-8; WEITMAN D, 1992, J BIOL CHEM, V267, P6977; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339; YOSHIMURA T, 1993, J STRUCT BIOL, V111, P200, DOI 10.1006/jsbi.1993.1050	44	40	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15875	15882		10.1074/jbc.274.22.15875	http://dx.doi.org/10.1074/jbc.274.22.15875			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336492	hybrid			2022-12-25	WOS:000080560100081
J	Yang, YJ; Keeney, D; Tang, XJ; Canfield, N; Rasmussen, BA				Yang, YJ; Keeney, D; Tang, XJ; Canfield, N; Rasmussen, BA			Kinetic properties and metal content of the metallo-beta-lactamase CcrA harboring selective amino acid substitutions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IONIZATION MASS-SPECTROMETRY; BACTEROIDES-FRAGILIS; ESCHERICHIA-COLI; AEROMONAS-HYDROPHILA; SERRATIA-MARCESCENS; GENE; PURIFICATION; SPECIFICITY; EXPRESSION; RESISTANCE	The crystal structure of the metallo-beta-lactamase CcrA3 indicates that the active site of this enzyme contains a binuclear zinc center. To aid in assessing the involvement of specific residues in beta-lactam hydrolysis and susceptibility to inhibitors, individual substitutions of selected amino acids were generated. Substitution of the zinc-ligating residue Cys(181) with Ser (C181S) resulted in a significant reduction in hydrolytic activity; k(cat) values decreased 2-4 orders of magnitude for all substrates. Replacement of His(99) with Asn (H99N) significantly reduced the hydrolytic activity for penicillin and imipenem, Replacement of Asp(103) with Asn (D103N) showed reduced hydrolytic activity for cephaloridine and imipenem, Deletion of amino acids 46-51 dramatically reduced both the hydrolytic activity and affinity for all beta-lactams, The metal binding capacity of each mutant enzyme was examined using nondenaturing electrospray ionization mass spectrometry, Two zinc ions were observed for the wild-type enzyme and most of the mutant enzymes. However, for the H99N, C181S, and D103N enzymes, three different zinc content patterns were observed. These enzymes contained two zinc molecules, one zinc molecule, and a mixture of one or two zinc molecules/enzyme molecule, respectively. Two enzymes with substitutions of Cys(104) Or Cys(104) and Cys(155) were also composed of mixed enzyme populations.	Wyeth Ayerst Res, Pearl River, NY 10965 USA	Pfizer	Rasmussen, BA (corresponding author), Wyeth Ayerst Res, 401 N Middletown Rd, Pearl River, NY 10965 USA.							Alksne LE, 1996, J BACTERIOL, V178, P4306; BANDOH K, 1991, ANTIMICROB AGENTS CH, V35, P371, DOI 10.1128/AAC.35.2.371; Bounaga S, 1998, BIOCHEM J, V331, P703, DOI 10.1042/bj3310703; BUSH K, 1993, ANTIMICROB AGENTS CH, V37, P851, DOI 10.1128/AAC.37.4.851; BUSH K, 1995, ANTIMICROB AGENTS CH, V39, P1211, DOI 10.1128/AAC.39.6.1211; Concha NO, 1996, STRUCTURE, V4, P823, DOI 10.1016/S0969-2126(96)00089-5; Crowder MW, 1996, BIOCHEMISTRY-US, V35, P12126, DOI 10.1021/bi960976h; DAVIES RB, 1974, BIOCHEM J, V143, P129, DOI 10.1042/bj1430129; FELICI A, 1995, ANTIMICROB AGENTS CH, V39, P192, DOI 10.1128/AAC.39.1.192; FELICI A, 1993, BIOCHEM J, V291, P151, DOI 10.1042/bj2910151; GANEM B, 1991, J AM CHEM SOC, V113, P6294, DOI 10.1021/ja00016a069; HUSSAIN M, 1985, J BACTERIOL, V164, P223, DOI 10.1128/JB.164.1.223-229.1985; Li Z, 1999, PROTEIN SCI, V8, P249; MARUMO K, 1995, MICROBIOL IMMUNOL, V39, P27, DOI 10.1111/j.1348-0421.1995.tb02164.x; OSANO E, 1994, ANTIMICROB AGENTS CH, V38, P71, DOI 10.1128/AAC.38.1.71; RASMUSSEN BA, 1991, MOL MICROBIOL, V5, P1211, DOI 10.1111/j.1365-2958.1991.tb01895.x; Rasmussen BA, 1997, ANTIMICROB AGENTS CH, V41, P223, DOI 10.1128/AAC.41.2.223; RASMUSSEN BA, 1994, ANTIMICROB AGENTS CH, V38, P2116, DOI 10.1128/AAC.38.9.2116; Sambrook J., 2002, MOL CLONING LAB MANU; SEGATORE B, 1993, ANTIMICROB AGENTS CH, V37, P1324, DOI 10.1128/AAC.37.6.1324; SMITH RD, 1993, BIOL MASS SPECTROM, V22, P493, DOI 10.1002/bms.1200220902; Wang F, 1996, BIOCHEMISTRY-US, V35, P4069, DOI 10.1021/bi9521304; YANG YJ, 1992, ANTIMICROB AGENTS CH, V36, P1155, DOI 10.1128/AAC.36.5.1155	23	59	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15706	15711		10.1074/jbc.274.22.15706	http://dx.doi.org/10.1074/jbc.274.22.15706			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336469	hybrid			2022-12-25	WOS:000080560100058
J	Hoffmann, C; Moro, S; Nicholas, RA; Harden, TK; Jacobson, KA				Hoffmann, C; Moro, S; Nicholas, RA; Harden, TK; Jacobson, KA			The role of amino acids in extracellular loops of the human P2Y(1) receptor in surface expression and activation processes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROTROPIN-RELEASING-HORMONE; PROTEIN-COUPLED RECEPTORS; SITE-DIRECTED MUTAGENESIS; ANGIOTENSIN-II; ANTAGONIST BINDING; PEPTIDE BINDING; LIGAND-BINDING; P-2Y-PURINOCEPTOR AGONISTS; MUTATIONAL ANALYSIS; RESIDUES	The P2Y(1) receptor is a membrane-bound G protein-coupled receptor stimulated by adenine nucleotides, Using alanine scanning mutagenesis, the role in receptor activation of charged amino acids (Asp, Glu, Lys, and Arg) and cysteines in the extracellular loops (EL) of the human P2Y(1) receptor has been investigated. The mutant receptors were expressed in COS-7 cells and measured for stimulation of phospholipase C induced by the potent agonist 2-methylthioadenosine-5'-diphosphate (2-MeSADP), In addition to single point mutations, all receptors carried the hemagglutinin epitope at the N-terminus for detection of cell-surface expression. The C124A and C202A mutations, located near the exofacial end of transmembrane helix 3 and in EL2, respectively, ablated phospholipase C stimulation by less than or equal to 100 mu M 2-MeSADP, Surface enzyme-linked immunosorbent assay detection of both mutant receptors showed <10% expression, suggesting that a critical disulfide bridge between EL2 and the upper part of transmembrane 3, as found in many other G protein coupled receptors, is required for proper trafficking of the P2Y(1) receptor to the cell surface. In contrast, the C42A and C296A mutant receptors (located in the N-terminal domain and EL3) were activated by 2-MeSADP, but the EC50 values were > 1000-fold greater than for the wild-type receptor. The double mutant receptor C42A/C296A exhibited no additive shift in the concentration-response curve for 2-MeSADP, These data suggest that Cys(42) and Cys(296) form another disulfide bridge in the extracellular region, which is critical for activation. Replacement of charged amino acids produced only minor changes in receptor activation, with two remarkable exceptions. The E209A mutant receptor (EL2) exhibited a >1000-fold shift in EC,,, However, if Glu(209) were substituted with amino acids capable of hydrogen bonding (Asp, Gin, or Arg), the mutant receptors responded like the wild-type receptor. Arg(287) in EL3 was impaired similarly to Glu(209) when substituted by alanine. Substitution of Arg287 by lysine, another positively charged residue, failed to fully restore wild-type activity.	NIDDK, Bioorgan Chem Lab, Mol Recognit Sect, NIH, Bethesda, MD 20892 USA; Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Jacobson, KA (corresponding author), NIDDK, Bioorgan Chem Lab, Mol Recognit Sect, NIH, Bldg 8A,Rm B1A-17, Bethesda, MD 20892 USA.		Jacobson, Kenneth Alan/A-1530-2009; Moro, Stefano/A-2979-2012	Jacobson, Kenneth Alan/0000-0001-8104-1493; Moro, Stefano/0000-0002-7514-3802	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK031116, Z01DK031117, Z01DK031115] Funding Source: NIH RePORTER; Intramural NIH HHS [Z99 DK999999, Z01 DK031116-20] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		ABBRACCHIO MP, 1994, PHARMACOL THERAPEUT, V64, P445, DOI 10.1016/0163-7258(94)00048-4; AKENSON M, 1997, J BIOL CHEM, V272, P17405; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; Berthold M, 1997, NEUROCHEM RES, V22, P1023, DOI 10.1023/A:1022483027858; Boyd ND, 1996, P NATL ACAD SCI USA, V93, P433, DOI 10.1073/pnas.93.1.433; Boyer JL, 1996, BRIT J PHARMACOL, V118, P1959, DOI 10.1111/j.1476-5381.1996.tb15630.x; Burnstock G, 1996, DRUG DEVELOP RES, V38, P67, DOI 10.1002/(SICI)1098-2299(199605)38:1<67::AID-DDR9>3.0.CO;2-J; Camaioni E, 1998, J MED CHEM, V41, P183, DOI 10.1021/jm970433l; Cook JVF, 1996, ENDOCRINOLOGY, V137, P2851, DOI 10.1210/en.137.7.2851; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; ERB L, 1995, J BIOL CHEM, V270, P4185, DOI 10.1074/jbc.270.9.4185; FENG YH, 1995, J BIOL CHEM, V270, P12846, DOI 10.1074/jbc.270.21.12846; Filtz Theresa M., 1997, P39; FISCHER B, 1993, J MED CHEM, V36, P3937, DOI 10.1021/jm00076a023; FREDHOLM BB, 1994, PHARMACOL REV, V46, P143; HAN BM, 1995, MOL ENDOCRINOL, V9, P1708, DOI 10.1210/me.9.12.1708; HARDEN TK, 1988, BIOCHEM J, V252, P583, DOI 10.1042/bj2520583; Heerding JN, 1997, REGUL PEPTIDES, V72, P97, DOI 10.1016/S0167-0115(97)01042-2; Higuchi R., 1989, PCR TECHNOLOGY, P61; HJORTH SA, 1994, J BIOL CHEM, V269, P30953; HUANG RRC, 1994, MOL PHARMACOL, V45, P690; Inoue Y, 1997, J HYPERTENS, V15, P703, DOI 10.1097/00004872-199715070-00001; Jakubik J, 1999, J BIOL CHEM, V274, P1349, DOI 10.1074/jbc.274.3.1349; Jiang QL, 1997, MOL PHARMACOL, V52, P499, DOI 10.1124/mol.52.3.499; Jin JG, 1998, P NATL ACAD SCI USA, V95, P8070, DOI 10.1073/pnas.95.14.8070; Kim JH, 1996, MOL PHARMACOL, V49, P683; LeGouill C, 1997, FEBS LETT, V402, P203, DOI 10.1016/S0014-5793(96)01531-1; LEONG SR, 1994, J BIOL CHEM, V269, P19343; LUI J, 1995, P NATL ACAD SCI USA, V92, P11642; Moro S, 1998, J MED CHEM, V41, P1456, DOI 10.1021/jm970684u; Moro S, 1999, BIOCHEMISTRY-US, V38, P3498, DOI 10.1021/bi982369v; NANEVICZ T, 1995, J BIOL CHEM, V270, P21619, DOI 10.1074/jbc.270.37.21619; Nanevicz T, 1996, J BIOL CHEM, V271, P702, DOI 10.1074/jbc.271.2.702; NOVOTNY EA, 1994, BIOCHEM BIOPH RES CO, V201, P523, DOI 10.1006/bbrc.1994.1733; OHYAMA K, 1995, REGUL PEPTIDES, V57, P141, DOI 10.1016/0167-0115(95)00030-F; OLAH ME, 1994, J BIOL CHEM, V269, P24692; Perlman JH, 1997, BIOCHEMISTRY-US, V36, P15670, DOI 10.1021/bi9713310; Robeva AS, 1996, BIOCHEM PHARMACOL, V51, P545, DOI 10.1016/0006-2952(95)02235-X; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schachter JB, 1997, BRIT J PHARMACOL, V121, P338, DOI 10.1038/sj.bjp.0701136; Silvente-Poirot S, 1998, MOL PHARMACOL, V54, P364, DOI 10.1124/mol.54.2.364; Van Rhee A M, 1995, Drug Des Discov, V13, P133; vanRhee AM, 1996, DRUG DEVELOP RES, V37, P1, DOI 10.1002/(SICI)1098-2299(199601)37:1<1::AID-DDR1>3.0.CO;2-S; WALKER P, 1994, J BIOL CHEM, V269, P2863; Zhao MM, 1996, MOL PHARMACOL, V50, P1118	45	120	122	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					14639	14647		10.1074/jbc.274.21.14639	http://dx.doi.org/10.1074/jbc.274.21.14639			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329657	Green Submitted, hybrid, Green Accepted			2022-12-25	WOS:000081965200022
J	Wang, HP; Huang, W; Fei, YJ; Xia, H; Yang-Feng, TL; Leibach, FH; Devoe, LD; Ganapathy, V; Prasad, PD				Wang, HP; Huang, W; Fei, YJ; Xia, H; Yang-Feng, TL; Leibach, FH; Devoe, LD; Ganapathy, V; Prasad, PD			Human placental Na+-dependent multivitamin transporter - Cloning, functional expression, gene structure, and chromosomal localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER MEMBRANE; PROTEIN-KINASE-C; MULTIPLE CARBOXYLASE DEFICIENCY; CHORIOCARCINOMA CELL-LINE; BIOTIN TRANSPORT; INTESTINAL-ABSORPTION; TAURINE TRANSPORTER; PANTOTHENIC-ACID; KIDNEY CORTEX; RAT-KIDNEY	We have cloned the human Na+-dependent multivitamin transporter (SMVT), which transports the water-soluble vitamins pantothenate, biotin, and lipoate, from a placental choriocarcinoma cell line (JAR), The cDNA codes for a protein of 635 amino acids with 12 transmembrane domains and 4 putative sites for N-linked glycosylation, The human SMVT exhibits a high degree of homology (84% identity and 89% similarity) to the rat counterpart. When expressed in HRPE cells, the cDNA-induced transport process is obligatorily dependent on Na+ and accepts pantothenate, biotin, and lipoate as substrates, The relationship between the cDNA-specific uptake rate of pantothenate or biotin and Naf concentration is sigmoidal with a Na+:vitamin stoichiometry of 2:1, The human SMVT, when expressed in Xenopus laevis oocytes, induces inward currents in the presence of pantothenate, biotin, and lipoate in a Na+-, concentration-, and potential dependent manner. We also report here on the structural organization and chromosomal localization of the human SMVT gene. The SMVT gene is similar to 14 kilobase pairs in length and consists of 17 exons, The SMVT gene is located on chromosome 2p23 as evidenced by somatic cell hybrid analysis and fluorescence in situ hybridization.	Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA; Med Coll Georgia, Dept Obstet & Gynecol, Augusta, GA 30912 USA; Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University; Yale University	Prasad, PD (corresponding author), Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA.				NICHD NIH HHS [HD 33347] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD033347] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BARBARAT B, 1986, J BIOL CHEM, V261, P4455; BARBARAT B, 1991, J PHYSIOL-LONDON, V443, P79, DOI 10.1113/jphysiol.1991.sp018823; BAUMGARTNER R, 1982, HELV PAEDIATR ACTA, V37, P499; BAUR B, 1993, PFLUG ARCH EUR J PHY, V422, P499, DOI 10.1007/BF00375078; BAUR B, 1990, AM J PHYSIOL, V258, pF840, DOI 10.1152/ajprenal.1990.258.4.F840; BLAKELY RD, 1991, ANAL BIOCHEM, V194, P302, DOI 10.1016/0003-2697(91)90233-J; FENSTERMACHER DK, 1986, AM J PHYSIOL, V250, pG155, DOI 10.1152/ajpgi.1986.250.2.G155; GANAPATHY V, 1995, CURR EYE RES, V14, P843, DOI 10.3109/02713689508995807; GRASSL SM, 1992, J BIOL CHEM, V267, P22902; GRASSL SM, 1992, J BIOL CHEM, V267, P17760; KARNITZ LM, 1984, BIOCHIM BIOPHYS ACTA, V769, P486, DOI 10.1016/0005-2736(84)90334-1; Kekuda R, 1998, J BIOL CHEM, V273, P15971, DOI 10.1074/jbc.273.26.15971; Kekuda R, 1996, J BIOL CHEM, V271, P18657, DOI 10.1074/jbc.271.31.18657; KISHIMOTO A, 1985, J BIOL CHEM, V260, P2492; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KULANTHAIVEL P, 1991, BIOCHEM J, V277, P53, DOI 10.1042/bj2770053; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LOO DDF, 1993, P NATL ACAD SCI USA, V90, P5767, DOI 10.1073/pnas.90.12.5767; Mackenzie B, 1996, J BIOL CHEM, V271, P5430, DOI 10.1074/jbc.271.10.5430; Mackenzie B, 1996, BBA-BIOMEMBRANES, V1284, P125, DOI 10.1016/S0005-2736(96)00170-8; MUNNICH A, 1981, LANCET, V2, P263; PARENT L, 1992, J MEMBRANE BIOL, V125, P49; PODEVIN RA, 1986, BIOCHIM BIOPHYS ACTA, V856, P471, DOI 10.1016/0005-2736(86)90138-0; Prasad PD, 1997, PLACENTA, V18, P527, DOI 10.1016/0143-4004(77)90006-6; Prasad PD, 1998, J NEUROCHEM, V70, P443; Prasad PD, 1998, J BIOL CHEM, V273, P7501, DOI 10.1074/jbc.273.13.7501; RAMAMOORTHY S, 1994, CURR EYE RES, V13, P523, DOI 10.3109/02713689408999884; SAID HM, 1987, AM J PHYSIOL, V253, pG631, DOI 10.1152/ajpgi.1987.253.5.G631; SAID HM, 1987, AM J PHYSIOL, V252, pG52, DOI 10.1152/ajpgi.1987.252.1.G52; SAID HM, 1992, BIOCHIM BIOPHYS ACTA, V1107, P238, DOI 10.1016/0005-2736(92)90410-N; SHAPER NL, 1992, GENOMICS, V12, P613, DOI 10.1016/0888-7543(92)90458-5; Smanik PA, 1996, BIOCHEM BIOPH RES CO, V226, P339, DOI 10.1006/bbrc.1996.1358; THOENE JG, 1983, NEW ENGL J MED, V308, P639, DOI 10.1056/NEJM198303173081107; THOENE JG, 1983, NEW ENGL J MED, V304, P817; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x; Wu X, 1998, J BIOL CHEM, V273, P32776, DOI 10.1074/jbc.273.49.32776	37	115	119	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					14875	14883		10.1074/jbc.274.21.14875	http://dx.doi.org/10.1074/jbc.274.21.14875			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329687	hybrid			2022-12-25	WOS:000081965200052
J	Yamashita, H; Avraham, S; Jiang, SX; Dikic, I; Avraham, H				Yamashita, H; Avraham, S; Jiang, SX; Dikic, I; Avraham, H			The Csk homologous kinase associates with TrkA receptors and is involved in neurite outgrowth of PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; SIGNAL-TRANSDUCTION PATHWAYS; FAMILY TYROSINE KINASES; BREAST-CANCER CELLS; NEURONAL DIFFERENTIATION; PROTOONCOGENE PRODUCT; MOLECULAR-CLONING; BINDING-SITES; C-KIT; IDENTIFICATION	Csk homologous kinase (CHK), a member of the Csk regulatory tyrosine kinase family, is expressed primarily in brain and hematopoietic cells. The role of CHK in the nervous system is as yet unknown. Using PC12 cells as a model system of neuronal cells, we show that CHK participates in signaling mediated by TrkA receptors, CHK was found to be associated with tyrosine phosphorylated TrkA receptors in PC12 cells upon stimulation with NGF. Binding assays and far Western blotting analysis, using glutathione S-transferase fusion proteins containing the Src homology 2 (SH2) and SH3 domains of CHK, demonstrate that the SH2 domain of CHK binds directly to the tyrosine-phosphorylated TrkA receptors. Site-directed mutagenesis of TrkA cDNA, as well as phosphopeptide inhibition of the in vitro interaction of the CHK-SH2 domain or native CHK with TrkA receptors, indicated that the residue Tyr-785 on TrkA is required for its binding to the CHK-SH2 domain upon NGF stimulation. In addition, overexpression of CHK resulted in enhanced activation of the mitogen-activated protein kinase pathway upon NGF stimulation, and microinjection of anti-CHK antibodies, but not anti-Csk antibodies, inhibited neurite outgrowth of PC12 cells in response to NGF. Thus, CHK is a novel signaling molecule that participates in TrkA signaling, associates directly with TrkA receptors upon NGF stimulation, and is involved in neurite outgrowth of PC12 cells in response to NGF.	Beth Israel Deaconess Med Ctr, Div Expt Med, Harvard Inst Med, Harvard Med Sch, Boston, MA 02115 USA; Biomed Ctr, Ludwig Inst Canc Res, S-75124 Uppsala, Sweden	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Ludwig Institute for Cancer Research	Avraham, H (corresponding author), Beth Israel Deaconess Med Ctr, Div Expt Med, Harvard Inst Med, Harvard Med Sch, 4 Blackfan Circle, Boston, MA 02115 USA.		Dikic, Ivan/O-4650-2015	Dikic, Ivan/0000-0001-8156-9511; Avraham, Hava/0000-0002-7545-3640	NCI NIH HHS [CA 76226] Funding Source: Medline; NHLBI NIH HHS [HL51456-02, HL55445] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076226] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055445, R01HL051456] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALONSO G, 1995, J BIOL CHEM, V270, P9840, DOI 10.1074/jbc.270.17.9840; AVRAHAM S, 1995, J BIOL CHEM, V270, P1833, DOI 10.1074/jbc.270.4.1833; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BENNETT BD, 1994, J BIOL CHEM, V269, P1068; BRINKLEY PM, 1995, GENE, V163, P179, DOI 10.1016/0378-1119(95)00352-7; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHOW LML, 1994, P NATL ACAD SCI USA, V91, P4975, DOI 10.1073/pnas.91.11.4975; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HALEGOUA S, 1991, CURR TOP MICROBIOL, V165, P119; HEMPSTEAD BL, 1992, NEURON, V9, P883, DOI 10.1016/0896-6273(92)90241-5; JHUN BH, 1995, J BIOL CHEM, V270, P9661, DOI 10.1074/jbc.270.16.9661; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KAPLAN DR, 1994, J NEUROBIOL, V25, P1404, DOI 10.1002/neu.480251108; Keegan K, 1993, Curr Opin Neurobiol, V3, P14, DOI 10.1016/0959-4388(93)90029-X; Kita Y, 1998, J CELL SCI, V111, P907; KLAGES S, 1994, P NATL ACAD SCI USA, V91, P2597, DOI 10.1073/pnas.91.7.2597; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; Kuo SS, 1997, EUR J NEUROSCI, V9, P2383, DOI 10.1111/j.1460-9568.1997.tb01655.x; KUO SS, 1994, J NEUROSCI RES, V38, P705, DOI 10.1002/jnr.490380613; LOEB DM, 1994, J BIOL CHEM, V269, P8901; MAHER PA, 1988, P NATL ACAD SCI USA, V85, P6788, DOI 10.1073/pnas.85.18.6788; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MCVICAR DW, 1994, ONCOGENE, V9, P2037; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; OBERMEIER A, 1993, EMBO J, V12, P933, DOI 10.1002/j.1460-2075.1993.tb05734.x; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; Price DJ, 1997, J BIOL CHEM, V272, P5915, DOI 10.1074/jbc.272.9.5915; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; Riccio A, 1997, SCIENCE, V277, P1097, DOI 10.1126/science.277.5329.1097; SAKANO S, 1994, ONCOGENE, V9, P1155; SCHUBERT D, 1977, P NATL ACAD SCI USA, V74, P4055, DOI 10.1073/pnas.74.9.4055; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zrihan-Licht S, 1998, J BIOL CHEM, V273, P4065, DOI 10.1074/jbc.273.7.4065; ZrihanLicht S, 1997, J BIOL CHEM, V272, P1856, DOI 10.1074/jbc.272.3.1856	41	44	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					15059	15065		10.1074/jbc.274.21.15059	http://dx.doi.org/10.1074/jbc.274.21.15059			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329710	hybrid			2022-12-25	WOS:000081965200075
J	Dejong, V; Degeorges, A; Filleur, S; Ait-Si-Ali, S; Mettouchi, A; Bornstein, P; Binetruy, B; Cabon, F				Dejong, V; Degeorges, A; Filleur, S; Ait-Si-Ali, S; Mettouchi, A; Bornstein, P; Binetruy, B; Cabon, F			The Wilms' tumor gene product represses the transcription of thrombospondin 1 in response to overexpression of c-Jun	ONCOGENE			English	Article						angiogenesis; c-Jun; EGR1; thrombospondin 1; transcription factors; transformation; WT1	NEOPLASTIC HUMAN BREAST; ZINC-FINGER PROTEINS; DNA-BINDING; ENDOTHELIAL-CELLS; SUBNUCLEAR LOCALIZATION; MOUSE THROMBOSPONDIN-1; SUPPRESSOR GENE; SPLICE VARIANTS; IN-VITRO; WT1	Thrombospondin 1 (TSP1) is known for its significant anti-angiogenic properties. In a previous study, we have shown that transient or stable overexpression of the transcription factor c-Jun, in rat fibroblasts, leads to repression of TSP1, We now demonstrate that the c-Jun-induced repression of TSP1 does not occur directly and does not require binding of c-Jun to the TSP1 promoter. Instead, repression involves a factor secreted by c-Jun-overexpressing cells. This secreted factor triggers a signal transduction pathway from the membrane to the nucleus, and these signals lead to the binding of the product of the Wilms' tumor suppressor gene, WT1, to the -210 region of the TSP1 promoter, This region binds WT1 and SP1, but not EGR1, although its sequence fits the consensus binding site for this transcription factor. WT1 overexpression in transfected cells inhibits endogenous TSP1 gene expression and TSP1 transcription in experiments using TSP1 promoter-reporter constructs. The WT1-KTS isoform is more active in repressing TSP1 transcription than WT1+KTS, while EGR1 is inactive, Enhancement of WT1 binding to DNA in response to c-Jun does not require de novo protein synthesis. The above mechanism for TSP1 repression could apply to other genes, thus coordinating their regulation in the vicinity of a c-Jun-overexpressing cell. We conclude that WT1, which was discovered as a result of its tumor suppressor properties, may also possess oncogenic characteristics in the c-Jun transformation process, and thus repress the antiangiogenic protein, TSP1.	CNRS, UPR 9079, F-94801 Villejuif, France; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA	Centre National de la Recherche Scientifique (CNRS); University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Cabon, F (corresponding author), CNRS, UPR 9079, 7 Rue Moquet,BP8, F-94801 Villejuif, France.		Binetruy, Bernard/AAG-7139-2022; Binetruy, Bernard/AFL-7188-2022; Cabon, Florence/B-3284-2013; Binetruy, Bernard/S-2062-2019; Binetruy, Bernard/A-6465-2009	Cabon, Florence/0000-0002-6149-082X; Binetruy, Bernard/0000-0001-8012-7092; Filleur, Stephanie/0000-0002-3420-5536; METTOUCHI, Amel/0000-0003-1453-6482	NHLBI NIH HHS [HL 18645] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018645] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bertin N, 1997, CANCER RES, V57, P396; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BORNSTEIN P, 1995, J CELL BIOL, V130, P503, DOI 10.1083/jcb.130.3.503; BORNSTEIN P, 1990, J BIOL CHEM, V265, P16691; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; CAO XM, 1993, J BIOL CHEM, V268, P16949; Caricasole A, 1996, P NATL ACAD SCI USA, V93, P7562, DOI 10.1073/pnas.93.15.7562; CASTLE VP, 1993, J BIOL CHEM, V268, P2899; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEZARDIN P, 1993, CANCER RES, V53, P1421; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DESBOIS C, 1991, CELL, V67, P731, DOI 10.1016/0092-8674(91)90068-A; DIPIETRO LA, 1994, J VASC RES, V31, P178, DOI 10.1159/000319585; Duarte A, 1998, BRIT J CANCER, V77, P253, DOI 10.1038/bjc.1998.41; Englert C, 1995, P NATL ACAD SCI USA, V92, P11960, DOI 10.1073/pnas.92.26.11960; Gao AG, 1996, J CELL BIOL, V135, P533, DOI 10.1083/jcb.135.2.533; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; Hamilton TB, 1998, BIOCHEMISTRY-US, V37, P2051, DOI 10.1021/bi9717993; HAMILTON TB, 1995, NUCLEIC ACIDS RES, V23, P277, DOI 10.1093/nar/23.2.277; Hewitt SM, 1996, J BIOL CHEM, V271, P8588, DOI 10.1074/jbc.271.15.8588; Kleymenova EV, 1998, ONCOGENE, V16, P713, DOI 10.1038/sj.onc.1201583; KRAMER B, 1994, BBA-GENE STRUCT EXPR, V1219, P413, DOI 10.1016/0167-4781(94)90066-3; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; MAHESWARAN S, 1995, GENE DEV, V9, P2143, DOI 10.1101/gad.9.17.2143; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MAJACK RA, 1987, J BIOL CHEM, V262, P8821; Menke AL, 1996, ONCOGENE, V12, P537; METTOUCHI A, 1994, EMBO J, V13, P5668, DOI 10.1002/j.1460-2075.1994.tb06905.x; Mettouchi A, 1997, MOL CELL BIOL, V17, P3202, DOI 10.1128/MCB.17.6.3202; NAKAGAMA H, 1995, MOL CELL BIOL, V15, P1489; Qian XH, 1996, P SOC EXP BIOL MED, V212, P199; Qian XH, 1997, EXP CELL RES, V235, P403, DOI 10.1006/excr.1997.3681; Reddy JC, 1996, BBA-REV CANCER, V1287, P1, DOI 10.1016/0304-419X(95)00014-7; RODECK U, 1994, INT J CANCER, V59, P78, DOI 10.1002/ijc.2910590116; Sakamoto Y, 1997, ONCOGENE, V15, P2001, DOI 10.1038/sj.onc.1201391; SALNIKOW K, 1994, MOL CELL BIOL, V14, P851, DOI 10.1128/MCB.14.1.851; SCHUG J, 1997, U PENNSYLVANIA; SHEIBANI N, 1995, P NATL ACAD SCI USA, V92, P6788, DOI 10.1073/pnas.92.15.6788; Sheibani N, 1996, CANCER LETT, V107, P45, DOI 10.1016/0304-3835(96)04341-8; SHINGU T, 1994, J BIOL CHEM, V269, P32551; SLACK JL, 1994, CELL GROWTH DIFFER, V5, P1373; STRUHL K, 1987, CELL, V50, P841, DOI 10.1016/0092-8674(87)90511-3; Svedberg H, 1998, ONCOGENE, V16, P925, DOI 10.1038/sj.onc.1201613; Tikhonenko AT, 1996, J BIOL CHEM, V271, P30741, DOI 10.1074/jbc.271.48.30741; Tolsma SS, 1997, MICROVASC RES, V54, P13, DOI 10.1006/mvre.1997.2015; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; VINCENT S, 1993, NUCLEIC ACIDS RES, V21, P1498, DOI 10.1093/nar/21.6.1498; Volpert OV, 1998, P NATL ACAD SCI USA, V95, P6343, DOI 10.1073/pnas.95.11.6343; Webster NJG, 1997, BIOCHEM MOL MED, V62, P139, DOI 10.1006/bmme.1997.2648; WEINSTATSASLOW DL, 1994, CANCER RES, V54, P6504; Ye Y, 1996, EMBO J, V15, P5606, DOI 10.1002/j.1460-2075.1996.tb00945.x	52	56	57	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 20	1999	18	20					3143	3151		10.1038/sj.onc.1202654	http://dx.doi.org/10.1038/sj.onc.1202654			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	197WB	10340386				2022-12-25	WOS:000080388000010
J	van der Geer, P; Wiley, S; Pawson, T				van der Geer, P; Wiley, S; Pawson, T			Re-engineering the target specificity of the insulin receptor by modification of a PTB domain binding site	ONCOGENE			English	Article						Shc; IRS-1; PTB domain specificity; protein modules	AMYLOID PRECURSOR PROTEIN; JUXTAMEMBRANE REGION; SIGNAL-TRANSDUCTION; SH2 DOMAIN; DISTINCT; IRS-1; MOTIF; SUBSTRATE-1; RECOGNITION; RESIDUES	Shc and IRS-1 (and their relatives) are cytoplasmic docking proteins that possess phosphotyrosine-binding (PTB) domains, through which they bind specific activated receptor tyrosine kinases (RTK), The subsequent phosphorylation of Shc or IRS-1 creates binding sites for the SH2 domains of multiple signaling proteins, leading to the activation of intracellular biochemical pathways, The PTB domains of Shc and IRS-1 both recognize autophosphorylation sites in RTKs with the consensus sequence NPXpY, but show distinct abilities to bind stably to RTKs such as the TrkA nerve growth factor receptor and the insulin receptor. In vitro analysis has suggested that residues N-terminal to the NPXpY motif may determine the affinity with which phosphopeptide ligands are recognized by the Shc and IRS-1 PTB domains, Unlike IRS-1, the Shc PTB domain binds poorly to the insulin-receptor (IR) beta subunit in vitro, owing to its low affinity for the NPXpY autophosphorylation site at Tyr 960 of the IR, As a consequence, Shc does not bind stably to the activated IR in cells. We show that substitution of Ser 955, five residues N-terminal to the Tyr 960 autophosphorylation site (the -5 position), with Ile alters the target specificity of the IR such that it stably associates with Shc in insulin-stimulated cells. A triple substitution of the -5, -8 and -9 residues relative to Tyr 960 of the IR to the corresponding amino acids found in the Shc PTB domain binding site of TrkA results in even stronger binding of the IR to Shc in vivo, The variant IRs with enhanced ability to bind Shc showed an increased ability Ito activate the MAPK pathway in response to insulin stimulation. These results demonstrate that subtle differences in residues N-terminal to NPXpY autophosphorylation sites determine the ability of RTKs tea bind specific PTB domain proteins in vivo, and thus modify the signaling properties of activated receptors.	Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Programme Mol Biol & Canc, Toronto, ON M5G 1X5, Canada; Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of California System; University of California San Diego; University of Toronto	Pawson, T (corresponding author), Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Programme Mol Biol & Canc, 600 Univ Ave, Toronto, ON M5G 1X5, Canada.		Pawson, Tony J/E-4578-2013	Wiley, Sandra/0000-0003-3979-2474				BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; Borg JP, 1996, MOL CELL BIOL, V16, P6229; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; FEENER EP, 1993, J BIOL CHEM, V268, P11256; Fiore F, 1995, J BIOL CHEM, V270, P30853, DOI 10.1074/jbc.270.52.30853; HE WM, 1995, J BIOL CHEM, V270, P23258, DOI 10.1074/jbc.270.40.23258; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; Kuriyan J, 1997, ANNU REV BIOPH BIOM, V26, P259, DOI 10.1146/annurev.biophys.26.1.259; Li SC, 1997, P NATL ACAD SCI USA, V94, P7204, DOI 10.1073/pnas.94.14.7204; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; SONGYANG Z, 1995, J BIOL CHEM, V270, P14863, DOI 10.1074/jbc.270.25.14863; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; vanderGeer P, 1996, P NATL ACAD SCI USA, V93, P963, DOI 10.1073/pnas.93.3.963; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0	22	11	11	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 20	1999	18	20					3071	3075		10.1038/sj.onc.1202879	http://dx.doi.org/10.1038/sj.onc.1202879			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	197WB	10340378				2022-12-25	WOS:000080388000002
J	Wolff, B; Naumann, M				Wolff, B; Naumann, M			INK4 cell cycle inhibitors direct transcriptional inactivation of NF-kappa B	ONCOGENE			English	Article						NF-kappa B; ankyrin; INK4 cell cycle inhibitors; p27	DEPENDENT KINASES; PRECURSOR P105; DNA-BINDING; PROTEIN; BCL-3; IDENTIFICATION; ONCOGENESIS; COACTIVATOR; TRANSITION; P16(INK4A)	The nuclear factor kappa B, a transcription factor regulating the expression of multiple genes including genes essential for cell cycle control, is found in most cells in a dormant state in the cytoplasm bound to the inhibitory family I kappa B via an ankyrin repeat domain. Stimulation of cells with a variety of inducers inactivates I kappa B proteins. The active dimeric NF-kappa B complex, often composed of 50- and 65-kilodalton subunits of the Rel family, translocates into the nucleus, where the NF-kappa Bp65 subunit stimulates transcription. Here me report that a family of proteins containing ankyrin repeats, the inhibitors of Cdk4 (INK4) is able to bind NF-kappa Bp65, The association of p161NK4 with NF-kappa Bp65 is considerable in HeLa- or 293 cells, if the NF-kappa B inhibitor I kappa B alpha is degraded in response to TNF alpha stimulation. Overexpression of INK4 molecules suppresses the transactivational ability of NF-kappa B significantly, In contrast to INK4 proteins, the cell cycle inhibitor p27 enhances NF-kappa B transactivation activity. Thus, the effect of INK4 proteins on NF-kappa B function possibly modifies NF-kappa B mediated transcriptional activation of cell cycle associated factors.	Max Planck Inst Infekt Biol, Mol Biol Abt, D-10117 Berlin, Germany	Max Planck Society	Naumann, M (corresponding author), Max Planck Inst Infekt Biol, Mol Biol Abt, Monbijoustr 2, D-10117 Berlin, Germany.		Naumann, Michael/B-5285-2011	Naumann, Michael/0000-0002-8060-2313				Baeuerle PA, 1997, ADV IMMUNOL, V65, P111, DOI 10.1016/S0065-2776(08)60742-7; BALDWIN AS, 1991, MOL CELL BIOL, V11, P4943, DOI 10.1128/MCB.11.10.4943; Bash J, 1997, MOL CELL BIOL, V17, P6526, DOI 10.1128/MCB.17.11.6526; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; DellaRagione F, 1996, J BIOL CHEM, V271, P15942, DOI 10.1074/jbc.271.27.15942; DUYAO MP, 1990, P NATL ACAD SCI USA, V87, P4727, DOI 10.1073/pnas.87.12.4727; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; HATADA EN, 1993, EMBO J, V12, P2781, DOI 10.1002/j.1460-2075.1993.tb05939.x; HIRST K, 1994, EMBO J, V13, P5410, DOI 10.1002/j.1460-2075.1994.tb06876.x; KAMB A, 1994, SCIENCE, V264, P440; Low KG, 1997, J VIROL, V71, P1956, DOI 10.1128/JVI.71.3.1956-1962.1997; Luh FY, 1997, NATURE, V389, P999, DOI 10.1038/40202; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Luque I, 1997, SEMIN CANCER BIOL, V8, P103, DOI 10.1006/scbi.1997.0061; Mosialos G, 1997, SEMIN CANCER BIOL, V8, P121, DOI 10.1006/scbi.1997.0063; NAUMANN M, 1993, EMBO J, V12, P213, DOI 10.1002/j.1460-2075.1993.tb05647.x; Naumann M, 1996, GASTROENTEROLOGY, V110, P1215, DOI 10.1053/gast.1996.v110.pm8613012; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; Paal K, 1997, NUCLEIC ACIDS RES, V25, P1050, DOI 10.1093/nar/25.5.1050; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; Schmitz ML, 1996, MOL CELL BIOL, V16, P4052; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; WULCZYN FG, 1992, NATURE, V358, P597, DOI 10.1038/358597a0; Wulczyn FG, 1996, J MOL MED, V74, P749, DOI 10.1007/s001090050078	30	65	65	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 22	1999	18	16					2663	2666		10.1038/sj.onc.1202617	http://dx.doi.org/10.1038/sj.onc.1202617			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	189LU	10353611				2022-12-25	WOS:000079907100015
J	Daviet, L; Lehtonen, JYA; Tamura, K; Griese, DP; Horiuchi, M; Dzau, VJ				Daviet, L; Lehtonen, JYA; Tamura, K; Griese, DP; Horiuchi, M; Dzau, VJ			Cloning and characterization of ATRAP, a novel protein that interacts with the angiotensin II type 1 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGONIST-INDUCED INTERNALIZATION; SIGNAL-TRANSDUCTION; COUPLED RECEPTORS; ADRENERGIC-RECEPTORS; KINASES; EXPRESSION; DOMAIN; AT(1); TAIL; IDENTIFICATION	The carboxyl-terminal cytoplasmic domain of the angiotensin II type 1 (AT(1)) receptor has recently been shown to interact with several classes of cytoplasmic proteins that regulate different aspects of AT(1) receptor physiology. Employing yeast two-hybrid screening of a mouse kidney cDNA library with the carboxyl-terminal cytoplasmic domain of the murine AT(1a) receptor as a bait, we have isolated a novel protein with a predicted molecular mass of 18 kDa, which we have named ATRAP (for AT(1) receptor-associated protein). ATRAP interacts specifically with the carboxyl-terminal domain of the AT(1a) receptor but not with those of ansotensin II type 2 (AT(2)), m(3) muscarinic acetylcholine, bradykinin B-2, endothelin B, and beta(2)-adrenergic receptors, The mRNA of ATRAP was abundantly expressed in kidney, heart, and testis but was poorly expressed in lung, liver, spleen, and brain. The ATRAP-AT(1a) receptor association was confirmed by affinity chromatography, by specific co-immunoprecipitation of the two proteins, and by fluorescence microscopy, showing co-localization of these proteins in intact cells. Overexpression of ATRAP in COS-7 cells caused a marked inhibition of AT(1a) receptor-mediated activation of phospholipase C without affecting m(3) receptor-mediated activation. In conclusion, we have isolated a novel protein that interacts specifically with the carboxyl-terminal cytoplasmic domain of the AT(1a) receptor and affects AT(1a) receptor signaling.	Harvard Univ, Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital	Dzau, VJ (corresponding author), Harvard Univ, Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035610, R37HL035610, R01HL046631, R01HL035252] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL35610, HL35252, HL46631] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ali MS, 1997, J BIOL CHEM, V272, P23382, DOI 10.1074/jbc.272.37.23382; BENICHOU S, 1994, J BIOL CHEM, V269, P30073; Berk BC, 1997, CIRC RES, V80, P607, DOI 10.1161/01.RES.80.5.607; BLIN N, 1995, J BIOL CHEM, V270, P17741, DOI 10.1074/jbc.270.30.17741; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; Conchon S, 1997, J BIOL CHEM, V272, P25566, DOI 10.1074/jbc.272.41.25566; Conchon S, 1998, AM J PHYSIOL-ENDOC M, V274, pE336, DOI 10.1152/ajpendo.1998.274.2.E336; Eason MG, 1996, J BIOL CHEM, V271, P12826, DOI 10.1074/jbc.271.22.12826; GUIRAMAND J, 1995, J BIOL CHEM, V270, P7354, DOI 10.1074/jbc.270.13.7354; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; HAUSDORFF WP, 1990, J BIOL CHEM, V265, P1388; HEIN L, 1995, NEUROPHARMACOLOGY, V34, P357, DOI 10.1016/0028-3908(95)00018-2; Hein L, 1997, MOL ENDOCRINOL, V11, P1266, DOI 10.1210/me.11.9.1266; HUNYADY L, 1994, J BIOL CHEM, V269, P31378; IWABUCHI K, 1993, ONCOGENE, V8, P1693; Ju H, 1998, J BIOL CHEM, V273, P24025, DOI 10.1074/jbc.273.37.24025; Klein U, 1997, J BIOL CHEM, V272, P19099, DOI 10.1074/jbc.272.31.19099; KOBILKA B, 1992, ANNU REV NEUROSCI, V15, P87, DOI 10.1146/annurev.ne.15.030192.000511; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; MUKOYAMA M, 1993, J BIOL CHEM, V268, P24539; Oppermann M, 1996, J BIOL CHEM, V271, P13266, DOI 10.1074/jbc.271.22.13266; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; SADOSHIMA J, 1993, CIRC RES, V73, P424, DOI 10.1161/01.RES.73.3.424; Sano T, 1997, J BIOL CHEM, V272, P23631, DOI 10.1074/jbc.272.38.23631; SterneMarr R, 1995, VITAM HORM, V51, P193, DOI 10.1016/S0083-6729(08)61039-0; Tang H, 1998, CIRC RES, V82, P523, DOI 10.1161/01.RES.82.5.523; THOMAS WG, 1995, J BIOL CHEM, V270, P207, DOI 10.1074/jbc.270.1.207; TSENG MJ, 1995, J BIOL CHEM, V270, P17884, DOI 10.1074/jbc.270.30.17884; Venema RC, 1998, J BIOL CHEM, V273, P7703, DOI 10.1074/jbc.273.13.7703; WANG CL, 1995, J BIOL CHEM, V270, P16677, DOI 10.1074/jbc.270.28.16677	30	135	141	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17058	17062		10.1074/jbc.274.24.17058	http://dx.doi.org/10.1074/jbc.274.24.17058			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358057	hybrid			2022-12-25	WOS:000080780400056
J	Hoshino, S; Imai, M; Kobayashi, T; Uchida, N; Katada, T				Hoshino, S; Imai, M; Kobayashi, T; Uchida, N; Katada, T			The eukaryotic polypeptide chain releasing factor (eRF3/GSPT) carrying the translation termination signal to the 3 '-poly(A) tail of mRNA - Direct association of eRF3/GSPT with polyadenylate-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; SACCHAROMYCES-CEREVISIAE; POLY(A); YEAST; ERF1; COMPLEX; GENE	The mammalian GTP-binding protein GSPT, whose carboxyl-terminal sequence is homologous to the eukaryotic elongation factor EF1 alpha, binds to the polypeptide chain releasing factor eRF1 to function as eRF3 in the translation termination. The amino-terminal domain of GSPT was, however, not required for the binding. Search for other GSPT-binding proteins in yeast two-hybrid screening system resulted in the identification of a cDNA encoding polyadenylate-binding protein (PABP), whose amino terminus is associating with the poly(A) tail of mRNAs presumably for their stabilization. The interaction appeared to be mediated through the carboxyl-terminal domain of PABP and the aminoterminal region of GSPT, Interestingly, multimerization of PABP with poly(A), which is ascribed to the action of its carboxyl-terminal domain, was completely inhibited by the interaction with the amino-terminal domain of GSPT. These results indicate that GSPT/eRF3 may play important roles not only in the termination of protein synthesis but also in the regulation of mRNA stability. Thus, the present study is the first report showing that GSPT/eRF3 carries the translation termination signal to 3'-poly(A) tail ubiquitously present in eukaryotic mRNAs.	Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Physiol Chem, Tokyo 1130033, Japan	University of Tokyo	Hoshino, S (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Physiol Chem, Tokyo 1130033, Japan.			Uchida, Naoyuki/0000-0002-4123-6154; Hoshino, Shinichi/0000-0001-6135-7896				BERNSTEIN P, 1989, MOL CELL BIOL, V9, P659, DOI 10.1128/MCB.9.2.659; BERNSTEIN P, 1989, TRENDS BIOCHEM SCI, V14, P373, DOI 10.1016/0968-0004(89)90011-X; Czaplinski K, 1998, GENE DEV, V12, P1665, DOI 10.1101/gad.12.11.1665; EUSTICE DC, 1986, J MOL BIOL, V188, P207, DOI 10.1016/0022-2836(86)90305-0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FINKELSTEIN DB, 1983, MOL CELL BIOL, V3, P1625, DOI 10.1128/MCB.3.9.1625; Hoshino S, 1998, J BIOL CHEM, V273, P22254, DOI 10.1074/jbc.273.35.22254; HOSHINO S, 1989, EMBO J, V8, P3807, DOI 10.1002/j.1460-2075.1989.tb08558.x; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; KIKUCHI Y, 1988, EMBO J, V7, P1175, DOI 10.1002/j.1460-2075.1988.tb02928.x; Kuhn U, 1996, J MOL BIOL, V256, P20, DOI 10.1006/jmbi.1996.0065; KUSHNIROV VV, 1988, GENE, V66, P45, DOI 10.1016/0378-1119(88)90223-5; Sachs AB, 1997, TRENDS BIOCHEM SCI, V22, P189, DOI 10.1016/S0968-0004(97)01051-7; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; SACHS AB, 1986, CELL, V45, P812; STANSFIELD I, 1995, EMBO J, V14, P4365, DOI 10.1002/j.1460-2075.1995.tb00111.x; SURGUCHOV AP, 1980, FEBS LETT, V111, P175, DOI 10.1016/0014-5793(80)80786-1; SURGUCHOV AP, 1988, TRENDS BIOCHEM SCI, V13, P120, DOI 10.1016/0968-0004(88)90062-X; Wormington M, 1996, EMBO J, V15, P900, DOI 10.1002/j.1460-2075.1996.tb00424.x; ZHOURAVLEVA G, 1995, EMBO J, V14, P4065, DOI 10.1002/j.1460-2075.1995.tb00078.x	20	220	226	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16677	16680		10.1074/jbc.274.24.16677	http://dx.doi.org/10.1074/jbc.274.24.16677			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358005	hybrid			2022-12-25	WOS:000080780400004
J	Krugmann, S; Hawkins, PT; Pryer, N; Braselmann, S				Krugmann, S; Hawkins, PT; Pryer, N; Braselmann, S			Characterizing the interactions between the two subunits of the p101/p110 gamma phosphoinositide 3-kinase and their role in the activation of this enzyme by G(beta gamma) subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; REGULATORY SUBUNIT; KINASE; P85; DOMAINS; CLONING; PI3K	Recently, we have reported the purification and cloning of a novel G protein beta gamma subunit-activated phosphoinositide S-kinase from pig neutrophils. The enzyme comprises a p110 gamma catalytic subunit and a p101 regulatory subunit. Now we have cloned the human ortholog of p101 and generated panels of p101 and p110 gamma truncations and deletions and used these in in vitro and in vivo assays to determine the protein domains responsible for subunit interaction and activation by beta gamma subunits. Our results suggest large areas of p101 including both N- and C-terminal portions interact with the N-terminal half of p110 gamma, While modifications of the N terminus of p110 gamma could modulate its intrinsic catalytic activity, binding to the N-terminal region of p101 was found to be indispensable for activation of heterodimers with G(beta gamma).	Babraham Inst, Signalling Programme, Cambridge CB2 4AT, England; Onyx Pharmaceut, Richmond, CA 94806 USA	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	Krugmann, S (corresponding author), Babraham Inst, Signalling Programme, Cambridge CB2 4AT, England.		Vermeren, Sonja/AAK-7442-2020	Vermeren, Sonja/0000-0002-8460-0884; Hawkins, Phillip/0000-0002-6979-0464				CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; Domin J, 1997, FEBS LETT, V410, P91, DOI 10.1016/S0014-5793(97)00617-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; HU P, 1993, MOL CELL BIOL, V13, P7677, DOI 10.1128/MCB.13.12.7677; HU P, 1994, MOL CELL BIOL, V14, P2577, DOI 10.1128/MCB.14.4.2577; Inukai K, 1996, J BIOL CHEM, V271, P5317, DOI 10.1074/jbc.271.10.5317; Leopoldt D, 1998, J BIOL CHEM, V273, P7024, DOI 10.1074/jbc.273.12.7024; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PONS S, 1995, MOL CELL BIOL, V15, P4453; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; STERNWEIS PC, 1990, RECEPTOR EFFECTOR CO, P1; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Yu JH, 1998, MOL CELL BIOL, V18, P1379, DOI 10.1128/MCB.18.3.1379	18	72	94	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17152	17158		10.1074/jbc.274.24.17152	http://dx.doi.org/10.1074/jbc.274.24.17152			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358071	hybrid			2022-12-25	WOS:000080780400070
J	Huete-Perez, JA; Engel, JC; Brinen, LS; Mottram, JC; McKerrow, JH				Huete-Perez, JA; Engel, JC; Brinen, LS; Mottram, JC; McKerrow, JH			Protease trafficking in two primitive eukaryotes is mediated by a prodomain protein motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPANOSOMA-CRUZI; CYSTEINE PROTEINASE; PROCATHEPSIN-L; LEISHMANIA-MEXICANA; AMINO-ACID; CATHEPSIN-L; GENES; SEQUENCE; PROPEPTIDE; EXPRESSION	Trypanosome protozoa, an early lineage of eukaryotic cells, have proteases homologous to mammalian lysosomal cathepsins, but the precursor proteins lack mannose 6-phosphate. Utilizing green fluorescent protein as a reporter, we demonstrate that the carbohydrate-free prodomain of a trypanosome cathepsin L is necessary and sufficient for directing green fluorescent protein to the lysosome/endosome compartment. A proper prodomain/catalytic domain processing site sequence is also required to free the mature protease for delivery to the lysosome/endosome compartment. A nine-amino acid prodomain loop motif, implicated in prodomain-receptor interactions in mammalian cells, is conserved in the protozoa, Site-directed mutagenesis now confirms the importance of this loop to protease trafficking and suggests that a protein motif targeting signal for lysosomal proteases arose early in eukaryotic cell evolution.	Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94121 USA; Univ Glasgow, Anderson Coll, Wellcome Unit Mol Parasitol, Glasgow G11 6NU, Lanark, Scotland	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Glasgow	McKerrow, JH (corresponding author), Univ Calif San Francisco, Dept Pathol, VAMC-113B,4150 Clement St, San Francisco, CA 94121 USA.		Huete-Perez, Jorge/AAJ-9840-2021	Huete-Perez, Jorge A./0000-0001-5259-8428; Mottram, Jeremy/0000-0001-5574-3766	NIAID NIH HHS [AI35707] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI035707] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BART G, 1995, MOL BIOCHEM PARASIT, V73, P271, DOI 10.1016/0166-6851(95)00113-F; CAZZULO JJ, 1990, MOL BIOCHEM PARASIT, V38, P41, DOI 10.1016/0166-6851(90)90203-X; CAZZULO JJ, 1989, MOL BIOCHEM PARASIT, V33, P33, DOI 10.1016/0166-6851(89)90039-X; Cazzulo JJ, 1996, CELL MOL BIOL, V42, P691; CONNER GE, 1992, J BIOL CHEM, V267, P21738; Coombs GH, 1997, PARASITOLOGY, V114, pS61, DOI 10.1017/S003118209700111X; Coulombe R, 1996, EMBO J, V15, P5492, DOI 10.1002/j.1460-2075.1996.tb00934.x; DelNery E, 1997, J BIOL CHEM, V272, P25713, DOI 10.1074/jbc.272.41.25713; DESOUZA W, 1984, INT REV CYTOL, V86, P197, DOI 10.1016/S0074-7696(08)60180-1; Drenth J, 1971, Adv Protein Chem, V25, P79, DOI 10.1016/S0065-3233(08)60279-X; DUBOISE SM, 1994, MOL BIOCHEM PARASIT, V68, P119, DOI 10.1016/0166-6851(94)00157-X; EAKIN AE, 1992, J BIOL CHEM, V267, P7411; Engel JC, 1998, J CELL SCI, V111, P597; Ha DS, 1996, MOL BIOCHEM PARASIT, V77, P57, DOI 10.1016/0166-6851(96)02580-7; HARIHARAN S, 1993, MOL BIOCHEM PARASIT, V57, P15, DOI 10.1016/0166-6851(93)90240-X; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; KELLY JM, 1992, NUCLEIC ACIDS RES, V20, P3963, DOI 10.1093/nar/20.15.3963; KENDALL G, 1990, EMBO J, V9, P2751, DOI 10.1002/j.1460-2075.1990.tb07462.x; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MACH L, 1994, J BIOL CHEM, V269, P13030; MCINTYRE GF, 1991, J BIOL CHEM, V266, P15438; MCINTYRE GF, 1994, J BIOL CHEM, V269, P567; MCINTYRE GF, 1993, P NATL ACAD SCI USA, V90, P10588, DOI 10.1073/pnas.90.22.10588; MIERENDORF RC, 1985, J CELL BIOL, V100, P1777, DOI 10.1083/jcb.100.5.1777; Mottram JC, 1997, J BIOL CHEM, V272, P14285, DOI 10.1074/jbc.272.22.14285; OWADA M, 1982, BIOCHEM BIOPH RES CO, V105, P814, DOI 10.1016/0006-291X(82)91042-7; PIPER J, 1995, CYTOMETRY, V19, P10, DOI 10.1002/cyto.990190104; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; Sack J. S., 1988, J MOL GRAPHICS, V6, P244; Sakanari JA, 1997, EXP PARASITOL, V85, P63, DOI 10.1006/expr.1996.4116; SOUZA AE, 1992, FEBS LETT, V311, P124, DOI 10.1016/0014-5793(92)81382-V; TAO K, 1994, ARCH BIOCHEM BIOPHYS, V311, P19, DOI 10.1006/abbi.1994.1203; TRAUBCSEKO YM, 1993, MOL BIOCHEM PARASIT, V57, P101, DOI 10.1016/0166-6851(93)90248-V	34	78	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16249	16256		10.1074/jbc.274.23.16249	http://dx.doi.org/10.1074/jbc.274.23.16249			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347181	hybrid			2022-12-25	WOS:000080668600041
J	Lee, YF; Young, WJ; Lin, WJ; Shyr, CR; Chang, CS				Lee, YF; Young, WJ; Lin, WJ; Shyr, CR; Chang, CS			Differential regulation of direct repeat 3 vitamin D-3 and direct repeat 4 thyroid hormone signaling pathways by the human TR4 orphan receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOIC ACID RECEPTORS; D-RESPONSIVE ELEMENTS; MAJOR LATE PROMOTER; STEROID-RECEPTOR; GENE-EXPRESSION; 1,25-DIHYDROXYVITAMIN D-3; 24-HYDROXYLASE GENE; X-RECEPTOR; MOLECULAR MECHANISMS; COUP-TF	In situ hybridization analysis demonstrated that abundant testicular orphan receptor (TR4) transcripts were detected in kidney, intestine, and bone, which are vitamin D-3 target organs. Cell transfection studies also demonstrated that the expression of the vitamin D-3 target gene, 25-hydroxyvitamin D-3 24-hydroxylase, can be repressed by TR4 through high affinity binding (K-d = 1.32 nM) to the direct repeat 3 vitamin D-3 receptor response element (DR3VDRE). This TR4-mediated repression of DR3VDRE is in contrast to our earlier report that TR4 could induce thyroid hormone target genes containing a direct repeat 4 thyroid hormone response element (DR4T(3)RE). Electrophoretic mobility shift assay using several TR4 monoclonal antibodies when combined with either TR4-DR3VDRE or TR4-DR4T(3)RE showed a distinct supershifted pattern, and proteolytic analysis further demonstrated distinct digested peptides with either TR4-DR3VDRE or TR4-DR4T(3)RE, These results may therefore suggest that TR4 can adapt to different conformations once bound to DR3VDRE or DR4T(3)RE. The consequence of these different conformations of TR4-DR3VDRE and TR4-DR4T(3)RE may allow each of them to recruit different coregulators. The differential repression of TR4-mediated DR3VDRE and DR4T(3)RE transactivation by the receptor interacting protein 140, a TR4 coregulator, further strengthens our hypothesis that the specificity of gene regulation by TR4 can be modulated by protein-DNA and protein-protein interactions.	Univ Rochester, Med Ctr, Dept Pathol Urol Radiat Oncol, George Whipple Lab Canc Res, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Ctr Canc, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Chang, CS (corresponding author), Univ Rochester, Med Ctr, Dept Pathol Urol Radiat Oncol, George Whipple Lab Canc Res, Rochester, NY 14642 USA.	chang@pathology.rochester.edu	Lin, Wen-Jye/D-1028-2016		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047258] Funding Source: NIH RePORTER; NCI NIH HHS [CA68568, CA71570] Funding Source: Medline; NIDDK NIH HHS [DK47258] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BROMMAGE R, 1985, ENDOCR REV, V6, P491, DOI 10.1210/edrv-6-4-491; CHANG C, 1988, BIOCHEM BIOPH RES CO, V155, P971, DOI 10.1016/S0006-291X(88)80591-6; CHANG C, 1989, BIOCHEM BIOPH RES CO, V165, P735, DOI 10.1016/S0006-291X(89)80028-2; CHANG CS, 1994, P NATL ACAD SCI USA, V91, P6040, DOI 10.1073/pnas.91.13.6040; CHEN KS, 1995, BBA-GENE STRUCT EXPR, V1263, P1, DOI 10.1016/0167-4781(95)00060-T; CHESKIS B, 1994, MOL CELL BIOL, V14, P3329, DOI 10.1128/MCB.14.5.3329; Collingwood TN, 1997, P NATL ACAD SCI USA, V94, P248, DOI 10.1073/pnas.94.1.248; COONEY AJ, 1992, MOL CELL BIOL, V12, P4153, DOI 10.1128/MCB.12.9.4153; COONEY AJ, 1993, J BIOL CHEM, V268, P4152; Davideau JL, 1996, ENDOCRINOLOGY, V137, P3577, DOI 10.1210/en.137.8.3577; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; HAUSSLER MR, 1998, RECENT PROG HORM RES, V44, P263; Johnson JA, 1996, J BONE MINER RES, V11, P56; Kerry DM, 1996, J BIOL CHEM, V271, P29715, DOI 10.1074/jbc.271.47.29715; KUMAR R, 1994, AM J PHYSIOL, V266, pF477, DOI 10.1152/ajprenal.1994.266.3.F477; LEE HJ, 1995, J BIOL CHEM, V270, P5434, DOI 10.1074/jbc.270.10.5434; LEE HJ, 1995, J BIOL CHEM, V270, P30129; Lee YF, 1998, J BIOL CHEM, V273, P13437, DOI 10.1074/jbc.273.22.13437; Lee YF, 1997, J BIOL CHEM, V272, P12215, DOI 10.1074/jbc.272.18.12215; Leng X, 1996, MOL CELL BIOL, V16, P2332; LIN TM, 1995, J BIOL CHEM, V270, P30121; LIU LT, 1994, J AM SOC NEPHROL, V5, P1251; Masuyama H, 1997, MOL ENDOCRINOL, V11, P1507, DOI 10.1210/me.11.10.1507; MINGHETTI PP, 1988, FASEB J, V2, P3043, DOI 10.1096/fasebj.2.15.2847948; Ohyama Y, 1996, J BIOL CHEM, V271, P30381, DOI 10.1074/jbc.271.48.30381; OHYAMA Y, 1994, J BIOL CHEM, V269, P10545; OHYAMA Y, 1991, J BIOL CHEM, V266, P8690; OMALLEY BW, 1992, MOL ENDOCRINOL, V6, P1359, DOI 10.1210/me.6.9.1359; Parker MG, 1993, CURR OPIN CELL BIOL, V5, P499, DOI 10.1016/0955-0674(93)90016-J; PIKE JW, 1989, ANNU REV NUTR, V11, P189; REICHRATH J, 1994, BRIT J DERMATOL, V131, P477; ROSEN ED, 1993, J BIOL CHEM, V268, P11534; Roy S, 1996, ENDOCRINOLOGY, V137, P2938, DOI 10.1210/en.137.7.2938; SAATCIOGLU F, 1993, CELL, V75, P1095, DOI 10.1016/0092-8674(93)90319-L; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WALTERS MR, 1992, ENDOCR REV, V13, P719, DOI 10.1210/er.13.4.719; Yan ZH, 1998, J BIOL CHEM, V273, P10948, DOI 10.1074/jbc.273.18.10948; Young WJ, 1998, J BIOL CHEM, V273, P20877, DOI 10.1074/jbc.273.33.20877; Young WJ, 1997, J BIOL CHEM, V272, P3109, DOI 10.1074/jbc.272.5.3109; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0; ZHONG K, 1994, AM J RESP CELL MOL, V11, P480, DOI 10.1165/ajrcmb.11.4.7917316	43	38	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16198	16205		10.1074/jbc.274.23.16198	http://dx.doi.org/10.1074/jbc.274.23.16198			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347174	hybrid			2022-12-25	WOS:000080668600034
J	Sheikh, MS; Fernandez-Salas, E; Yu, MH; Hussain, A; Dinman, JD; Peltz, SW; Huang, Y; Fornace, AJ				Sheikh, MS; Fernandez-Salas, E; Yu, MH; Hussain, A; Dinman, JD; Peltz, SW; Huang, Y; Fornace, AJ			Cloning and characterization of a human genotoxic and endoplasmic reticulum stress-inducible cDNA that encodes translation initiation factor 1 (eIF(1A121/SUI1))	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ TRANSPORT ATPASE; SACCHAROMYCES-CEREVISIAE; GENE; DNA; PROTEIN; GROWTH; YEAST; SUI1; THAPSIGARGIN; TRANSCRIPTS	We report the cloning and characterization of a DNA damage-inducible (DDI) transcript DDI A121. The full-length human DDI A121 cDNA contains an open reading frame of 113 amino acids, corresponding to a protein of 12.7 kDa. The deduced amino acid sequence of A121 shows high homology to the yeast translation initiation factor (eIF) sui1 and also exhibits perfect identity to the partial sequence of recently purified human eIF1. Expression of human A121 corrected the mutant suil phenotype in yeast, demonstrating that human A121 encodes a bona fide translation initiation factor that is equivalent to yeast sui1p. The mammalian A121/SUI1 gene exhibits two transcripts (1.35 kilobases and 0.65 kilobases) containing a common coding region but differing in their 3'-untranslated region. The long and short A121/SUI1 mRNAs are differentially regulated by genotoxic and endoplasmic reticulum stress. The genotoxic stress induction of A121/SUI1 mRNA is conserved in both humans and rodents and occurs in a p53-independent manner. Our identification of a stress-inducible cDNA that encodes eIF1 suggests that modulation of translation initiation appears to occur during cellular stress and may represent an important adaptive response to genotoxic as well as endoplasmic reticulum stress.	NCI, Div Basic Sci, NIH, Bethesda, MD 20892 USA; NCI, Cellular Carcinogenesis & Tumor Promot Lab, NIH, Bethesda, MD 20892 USA; Univ Maryland, Greenbaum Canc Ctr, Baltimore, MD 21201 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet & Microbiol, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Grad Programs Mol Biosci Rutgers, Piscataway, NJ 08854 USA; NIA, Biol Chem Lab, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University System of Maryland; University of Maryland Baltimore; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Sheikh, MS (corresponding author), NCI, Div Basic Sci, NIH, Bldg 37,Rm 5C09, Bethesda, MD 20892 USA.		Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X; Dinman, Jonathan/0000-0002-2402-9698	DIVISION OF BASIC SCIENCES - NCI [Z01BC007184] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BESANSKY NJ, 1994, GENE, V141, P299, DOI 10.1016/0378-1119(94)90589-4; CASTILHOVALAVICIUS B, 1990, GENETICS, V124, P483; CIGAN AM, 1989, P NATL ACAD SCI USA, V86, P2784, DOI 10.1073/pnas.86.8.2784; Cui Y, 1996, EMBO J, V15, P5726, DOI 10.1002/j.1460-2075.1996.tb00956.x; Cui Y, 1998, MOL CELL BIOL, V18, P1506, DOI 10.1128/MCB.18.3.1506; DINMAN JD, 1994, GENETICS, V136, P75; FARGNOLI J, 1990, ANAL BIOCHEM, V187, P364, DOI 10.1016/0003-2697(90)90471-K; FIELDS C, 1994, BIOCHEM BIOPH RES CO, V198, P288, DOI 10.1006/bbrc.1994.1040; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; GILL DL, 1992, ADV 2 MESSENGER PHOS, P265; HOLLANDER MC, 1996, NUCLEIC ACIDS RES, V12, P387; HOLLANDER MC, 1994, DNA REPAIR MECH IMPA, P221; HUSSAIN A, 1995, J BIOL CHEM, V270, P12140, DOI 10.1074/jbc.270.20.12140; LUETHY JD, 1990, J BIOL CHEM, V265, P16521; Naranda T, 1996, MOL CELL BIOL, V16, P2307; Pestova TV, 1998, NATURE, V394, P854, DOI 10.1038/29703; SCHENA M, 1988, SCIENCE, V241, P965, DOI 10.1126/science.3043665; Sheikh MS, 1997, J BIOL CHEM, V272, P26720, DOI 10.1074/jbc.272.42.26720; Sheikh MS, 1998, CANCER RES, V58, P1593; WU SV, 1995, EUR J BIOCHEM, V230, P439, DOI 10.1111/j.1432-1033.1995.0439h.x; YOON HJ, 1992, MOL CELL BIOL, V12, P248, DOI 10.1128/MCB.12.1.248; Yu MH, 1998, J BIOL CHEM, V273, P3542, DOI 10.1074/jbc.273.6.3542; YUSPA SH, 1985, METHODS SKIN RES, P213; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361	26	26	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16487	16493		10.1074/jbc.274.23.16487	http://dx.doi.org/10.1074/jbc.274.23.16487			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347211	hybrid			2022-12-25	WOS:000080668600071
J	Bhattacharyya, J; Das, KP				Bhattacharyya, J; Das, KP			Molecular chaperone-like properties of an unfolded protein, alpha(s)-casein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE ALPHA-CRYSTALLIN; BETA-LACTOGLOBULIN; 1,1'-BI(4-ANILINO)NAPHTHALENE-5,5'-DISULFONIC ACID; FUNCTIONAL-PROPERTIES; ESCHERICHIA-COLI; WHEY PROTEINS; RIBOSOMAL-RNA; GROEL; LACTALBUMIN; CASEIN	All molecular chaperones known to date are well organized, folded protein molecules whose three-dimensional structure are believed to play a key role in the mechanism of substrate recognition and subsequent assistance to folding. A common feature of all protein and nonprotein molecular chaperones is the propensity to form aggregates very similar to the micellar aggregates. In this paper we show that alpha(s)-casein, abundant in mammalian milk, which has no well defined secondary and tertiary structure but exits in nature as a micellar aggregate, can prevent a variety of unrelated proteins/enzymes against thermal-, chemical-, or light-induced aggregation. It also prevents aggregation of its natural substrates, the whey proteins. alpha(s)-Casein interacts with partially unfolded proteins through its solvent-exposed hydrophobic surfaces. The absence of disulfide bridge or free thiol groups in its sequence plays important role in preventing thermal aggregation of whey proteins caused by thiol-disulfide interchange reactions. Our results indicate that alpha(s)-casein not only prevents the formation of huge insoluble aggregates but it can also inhibit accumulation of soluble aggregates of appreciable size. Unlike other molecular chaperones, this protein can solubilize hydrophobically aggregated proteins. This protein seems to have some characteristics of cold shock protein, and its chaperone-like activity increases with decrease of temperature.	Bose Inst, Dept Chem, Prot Chem Lab, Calcutta 700009, W Bengal, India	Department of Science & Technology (India); Bose Institute	Das, KP (corresponding author), Bose Inst, Dept Chem, Prot Chem Lab, Main Campus,93-1 APC Rd, Calcutta 700009, W Bengal, India.			Das, Kali/0000-0001-7686-9077				Bhattacharyya J, 1998, BIOCHEM MOL BIOL INT, V46, P249; BIGELOW CC, 1967, J THEOR BIOL, V16, P187, DOI 10.1016/0022-5193(67)90004-5; Bogdanov M, 1996, J BIOL CHEM, V271, P11615, DOI 10.1074/jbc.271.20.11615; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; CREAMER LK, 1981, ARCH BIOCHEM BIOPHYS, V211, P689, DOI 10.1016/0003-9861(81)90505-1; Dalgleish DG, 1997, J AGR FOOD CHEM, V45, P4806, DOI 10.1021/jf970524r; Dalgleish DG, 1997, J AGR FOOD CHEM, V45, P3459, DOI 10.1021/jf970113a; Das B, 1996, EUR J BIOCHEM, V235, P613, DOI 10.1111/j.1432-1033.1996.00613.x; DAS KP, 1995, BIOCHEM J, V311, P367, DOI 10.1042/bj3110367; DAS KP, 1995, FEBS LETT, V369, P321, DOI 10.1016/0014-5793(95)00775-5; Das KP, 1996, J BIOL CHEM, V271, P10449, DOI 10.1074/jbc.271.18.10449; DEWIT JN, 1983, NETH MILK DAIRY J, V37, P37; Doi N, 1998, FEBS LETT, V430, P150, DOI 10.1016/S0014-5793(98)00674-7; Ellis RJ, 1996, SCIENCE, V272, P1448; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P509, DOI 10.1021/bi00002a015; Frydman J, 1997, TRENDS BIOCHEM SCI, V22, P87, DOI 10.1016/S0968-0004(97)01005-0; GETHING MJ, 1997, GUIDEBOOK MOL CHAPAR; Gezimati J, 1996, ACS SYM SER, V650, P113; Graumann P, 1996, ARCH MICROBIOL, V166, P293, DOI 10.1007/s002030050386; Guha S, 1998, J BIOL CHEM, V273, P30077, DOI 10.1074/jbc.273.46.30077; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HERSCHLAG D, 1995, J BIOL CHEM, V270, P20871, DOI 10.1074/jbc.270.36.20871; JENNESS R, 1970, MILK PROTEINS CHEMIS, V1, P17; JONES PG, 1994, MOL MICROBIOL, V11, P811, DOI 10.1111/j.1365-2958.1994.tb00359.x; KENKARE DB, 1964, J DAIRY SCI, V47, P947, DOI 10.3168/jds.S0022-0302(64)88817-2; KINSELLA JE, 1984, CRC CR REV FOOD SCI, V21, P197, DOI 10.1080/10408398409527401; Kudlicki W, 1997, FOLD DES, V2, P101, DOI 10.1016/S1359-0278(97)00014-X; LALIGANT A, 1991, J AGR FOOD CHEM, V39, P2147, DOI 10.1021/jf00012a009; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MCMEEKIN TL, 1949, ADV PROTEIN CHEM, V5, P201, DOI 10.1016/S0065-3233(08)60586-0; MERCIER JC, 1971, EUR J BIOCHEM, V23, P41, DOI 10.1111/j.1432-1033.1971.tb01590.x; MERCK KB, 1993, J BIOL CHEM, V268, P1046; MORR CV, 1968, J DAIRY SCI, V51, P1349, DOI 10.3168/jds.S0022-0302(68)87193-0; Netzer WJ, 1998, TRENDS BIOCHEM SCI, V23, P68, DOI 10.1016/S0968-0004(97)01171-7; RAMAN B, 1994, J BIOL CHEM, V269, P27264; Reid KL, 1998, PROTEIN SCI, V7, P470; ROMMELAERE H, 1993, P NATL ACAD SCI USA, V90, P11975, DOI 10.1073/pnas.90.24.11975; Ruddon RW, 1997, J BIOL CHEM, V272, P3125, DOI 10.1074/jbc.272.6.3125; RUEGG M, 1977, J DAIRY RES, V44, P509, DOI 10.1017/S002202990002046X; Sharma KK, 1998, J BIOL CHEM, V273, P15474, DOI 10.1074/jbc.273.25.15474; Sharma KK, 1998, J BIOL CHEM, V273, P8965, DOI 10.1074/jbc.273.15.8965; Sigler PB, 1998, ANNU REV BIOCHEM, V67, P581, DOI 10.1146/annurev.biochem.67.1.581; Smulders RHPH, 1998, INT J BIOL MACROMOL, V22, P187, DOI 10.1016/S0141-8130(98)00016-6; SUSI H, 1967, J BIOL CHEM, V242, P5460; WALSH MT, 1991, J BIOL CHEM, V266, P20079; Wang JD, 1998, P NATL ACAD SCI USA, V95, P12163, DOI 10.1073/pnas.95.21.12163; WANG KY, 1994, J BIOL CHEM, V269, P13601; Waugh D. F., 1971, MILK PROTEINS CHEM B, V2, P3; XIANG YL, 1992, J AGR FOOD CHEM, V40, P380	49	154	157	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15505	15509		10.1074/jbc.274.22.15505	http://dx.doi.org/10.1074/jbc.274.22.15505			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336443	hybrid			2022-12-25	WOS:000080560100032
J	Efrati, E; Tocco, G; Eritja, R; Wilson, SH; Goodman, MF				Efrati, E; Tocco, G; Eritja, R; Wilson, SH; Goodman, MF			"Action-at-a-distance" mutagenesis - 8-oxo-7,8-dihydro-2 '-deoxyguanosine causes base substitution errors at neighboring template sites when copied by DNA polymerase beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; 8-HYDROXYGUANINE 7,8-DIHYDRO-8-OXOGUANINE; NUCLEOSIDE TRIPHOSPHATASE; MUTT PROTEIN; REPLICATION; INSERTION; FIDELITY; EXCISION; LESION; REPAIR	8-Oxo-7,8-dihydro-2'-deoxyguanosine (8-oxo-dG), a common oxidative DNA lesion, favors a syn-conformation in DNA, enabling formation of stable 8-oxo-dG A base mispairs resulting in G.C --> T.A transversion mutations. When human DNA polymerase (pol) beta was used to copy a short single-stranded gap containing a site-directed 8-oxo-dG lesion, incorporation of dAMP opposite 8-oxo-dG was slightly favored over dCMP depending on "downstream" sequence context. Unexpectedly, however, a significant increase in dCMP A and dGMP A mispairs was also observed at the "upstream" 3'-template site adjacent to the lesion. Errors at these undamaged template sites occurred in four sequence contexts with both gapped and primed single-stranded DNA templates, but not when pol alpha replaced pol beta. Error rates at sites adjacent to 8-oxo-dG were roughly 1% of the values opposite 8-oxo-dG:, potentially generating tandem mutations during in vivo short-gap repair synthesis by pol beta, When 8-oxo-dG was replaced with 8-bromo-2'-deoxyguanosine, incorporation of dCMP was strongly favored by both enzymes, with no detectable misincorporation occurring at neighboring template sites.	Univ So Calif, Dept Biol Sci, Los Angeles, CA 90089 USA; Univ So Calif, Dept Chem, Hedco Mol Biol Labs, Los Angeles, CA 90089 USA; European Mol Biol Org, D-69012 Heidelberg, Germany; NIEHS, Res Triangle Pk, NC 27709 USA	University of Southern California; University of Southern California; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Goodman, MF (corresponding author), Univ So Calif, Dept Biol Sci, Los Angeles, CA 90089 USA.		Eritja, Ramon/B-5613-2008; Wilson, Samuel H/E-6644-2019	Eritja, Ramon/0000-0001-5383-9334; Wilson, Samuel H/0000-0002-1702-5293	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES050158] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM021422, R01GM021422] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM21422] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABBOTTS J, 1988, BIOCHEMISTRY-US, V27, P901, DOI 10.1021/bi00403a010; AKIYAMA M, 1989, P NATL ACAD SCI USA, V86, P3949, DOI 10.1073/pnas.86.11.3949; Bessman MJ, 1996, J BIOL CHEM, V271, P25059, DOI 10.1074/jbc.271.41.25059; BHATNAGAR SK, 1991, J BIOL CHEM, V266, P9050; BHATNAGAR SK, 1988, J BIOL CHEM, V263, P8953; BOOSALIS MS, 1987, J BIOL CHEM, V262, P14689; Chagovetz AM, 1997, J BIOL CHEM, V272, P27501, DOI 10.1074/jbc.272.44.27501; COPELAND WC, 1991, J BIOL CHEM, V266, P22739; Efrati E, 1997, J BIOL CHEM, V272, P2559; FEIG DI, 1994, J MOL BIOL, V235, P33, DOI 10.1016/S0022-2836(05)80009-9; GROLLMAN AP, 1993, TRENDS GENET, V9, P246, DOI 10.1016/0168-9525(93)90089-Z; Hashim MF, 1997, J BIOL CHEM, V272, P20205, DOI 10.1074/jbc.272.32.20205; Hatahet Z, 1998, P NATL ACAD SCI USA, V95, P8556, DOI 10.1073/pnas.95.15.8556; KASAI H, 1984, NUCLEIC ACIDS RES, V12, P2137, DOI 10.1093/nar/12.4.2137; KOIZUME S, 1994, NUCLEOS NUCLEOT, V13, P1517, DOI 10.1080/15257779408012168; KOUCHAKDJIAN M, 1991, BIOCHEMISTRY-US, V30, P1403, DOI 10.1021/bi00219a034; KUCHINO Y, 1987, NATURE, V327, P77, DOI 10.1038/327077a0; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; MICHAELS ML, 1992, P NATL ACAD SCI USA, V89, P7022, DOI 10.1073/pnas.89.15.7022; MICHAELS ML, 1992, J BACTERIOL, V174, P6321, DOI 10.1128/JB.174.20.6321-6325.1992; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; ODA Y, 1991, NUCLEIC ACIDS RES, V19, P1407, DOI 10.1093/nar/19.7.1407; Piersen CE, 1996, J BIOL CHEM, V271, P17811, DOI 10.1074/jbc.271.30.17811; RANDALL SK, 1987, J BIOL CHEM, V262, P6864; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; SHIGENAGA MK, 1989, P NATL ACAD SCI USA, V86, P9697, DOI 10.1073/pnas.86.24.9697; SINGHAL RK, 1993, J BIOL CHEM, V268, P15906; SOBEL RW, 1996, NATURE, V379, P183; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; Wilson SH, 1998, MUTAT RES-DNA REPAIR, V407, P203, DOI 10.1016/S0921-8777(98)00002-0	31	60	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15920	15926		10.1074/jbc.274.22.15920	http://dx.doi.org/10.1074/jbc.274.22.15920			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336498	hybrid			2022-12-25	WOS:000080560100087
J	Enghild, JJ; Thogersen, IB; Oury, TD; Valnickova, Z; Hojrup, P; Crapo, JD				Enghild, JJ; Thogersen, IB; Oury, TD; Valnickova, Z; Hojrup, P; Crapo, JD			The heparin-binding domain of extracellular superoxide dismutase is proteolytically processed intracellularly during biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-SITU HYBRIDIZATION; HUMAN LUNG; IMMUNOCYTOCHEMICAL LOCALIZATION; PRECURSOR PROTEINS; HEPATOCYTES; AFFINITY	Extracellular superoxide dismutase (EC-SOD) is the only known extracellular enzyme designed to scavenge the superoxide anion. The purified enzyme exists in two forms when visualized by reduced SDS-polyacrylamide gel electrophoresis: (i) intact EC-SOD (Trp(1)-Ala(222)) containing the C-terminal heparin-binding domain and (ii) cleaved EC-SOD (Trp(1)-Glu(209)) without the C-terminal heparin-binding domain. The proteolytic event(s) leading to proteolysis at Glu(209)-Arg(210) and removal of the heparin-binding domain are not known, but may represent an important regulatory mechanism. Removal of the heparin-binding domain affects both the affinity of EC-SOD for and its distribution to the extracellular matrix, in which it is secreted. During the purification of human EC-SOD, the intact/cleaved ratio remains constant, suggesting that proteolytic removal of the heparin-binding domain does not occur during purification (Oury, T. D., Crape, J. D., Valnickova, Z., and Enghild, J. J. (1996) Biochem. J. 317, 51-57). This was supported by the finding that fresh mouse tissue contains both intact and cleaved EC-SOD. To study other possible mechanisms leading to the formation of cleaved EC-SOD, we examined biosynthesis in cultured rat L2 epithelial-like cells using a pulse-chase protocol. The results of these studies suggest that the heparin-binding domain is removed intracellularly just prior to secretion. In addition, the intact/cleaved EC-SOD ratio appears to be tissue-dependent, implying that the intracellular processing event is regulated in a tissue-specific manner. The existence of this intracellular processing pathway may thus represent a novel regulatory pathway for affecting the distribution and effect of EC-SOD.	Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA; Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15213 USA; Odense Univ, DK-5230 Odense, Denmark; Natl Jewish Med & Res Ctr, Denver, CO 80206 USA	Duke University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Southern Denmark; National Jewish Health	Enghild, JJ (corresponding author), Duke Univ, Med Ctr, Dept Pathol, POB 3712, Durham, NC 27710 USA.	enghi001@mc.duke.edu	Højrup, Peter/ABG-8477-2020	Enghild, Jan Johannes/0000-0001-9292-9172; Hojrup, Peter/0000-0002-7838-6180	NHLBI NIH HHS [HL31992, HL49542, HL42444] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL031992, P01HL042444, R01HL049542] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADACHI T, 1989, J BIOL CHEM, V264, P8537; BRATT T, 1993, BIOCHIM BIOPHYS ACTA, V1157, P147, DOI 10.1016/0304-4165(93)90058-G; BURY AF, 1981, J CHROMATOGR, V213, P491, DOI 10.1016/S0021-9673(00)80500-2; Folz RJ, 1997, AM J RESP CELL MOL, V17, P393, DOI 10.1165/ajrcmb.17.4.2826; FORMAN HJ, 1973, ARCH BIOCHEM BIOPHYS, V158, P396, DOI 10.1016/0003-9861(73)90636-X; KARLSSON K, 1993, BIOCHEM J, V290, P623, DOI 10.1042/bj2900623; MARKLUND SL, 1982, P NATL ACAD SCI-BIOL, V79, P7634, DOI 10.1073/pnas.79.24.7634; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; OURY TD, 1994, LAB INVEST, V70, P889; Oury TD, 1996, BIOCHEM J, V317, P51, DOI 10.1042/bj3170051; Oury TD, 1996, FREE RADICAL BIO MED, V20, P957, DOI 10.1016/0891-5849(95)02222-8; OURY TD, 1993, AM REV RESPIR DIS, V147, pA444; OZOLS J, 1990, METHOD ENZYMOL, V182, P587; SALVESEN G, 1990, BIOCHEMISTRY-US, V29, P5304, DOI 10.1021/bi00474a013; Salvesen G, 1989, PROTEOLYTIC ENZYMES, P83; SANDSTROM J, 1992, J BIOL CHEM, V267, P18205; Seidah NG, 1997, CURR OPIN BIOTECH, V8, P602, DOI 10.1016/S0958-1669(97)80036-5; SJOBERG EM, 1992, ARCH BIOCHEM BIOPHYS, V295, P217, DOI 10.1016/0003-9861(92)90509-U; STRALIN P, 1995, ARTERIOSCL THROM VAS, V15, P2032, DOI 10.1161/01.ATV.15.11.2032; Su WY, 1997, AM J RESP CELL MOL, V16, P162, DOI 10.1165/ajrcmb.16.2.9032123; THOGERSEN IB, 1995, J BIOL CHEM, V270, P18700	22	84	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					14818	14822		10.1074/jbc.274.21.14818	http://dx.doi.org/10.1074/jbc.274.21.14818			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329680	hybrid			2022-12-25	WOS:000081965200045
J	Kraichely, DM; Collins, JJ; DeLisle, RK; MacDonald, PN				Kraichely, DM; Collins, JJ; DeLisle, RK; MacDonald, PN			The autonomous transactivation domain in helix H3 of the vitamin D receptor is required for transactivation and coactivator interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ESTROGEN-RECEPTOR; LIGAND-BINDING DOMAIN; THYROID-HORMONE RECEPTOR; D-MEDIATED TRANSCRIPTION; NUCLEAR RECEPTORS; RETINOIC ACID; CRYSTAL-STRUCTURE; CONSERVED REGION; DNA-BINDING; FACTOR IIB	A ligand-inducible transactivation function (AF-2) exists in the extreme carboxyl terminus of the vitamin D receptor (VDR) that is essential for 1 alpha,25-dihydroxyvitamin D-3 (1,25-(OH)(2)D-3)-activated transcription and p160 coactivator interaction. Crystallographic data of related nuclear receptors suggest that binding of 1,26-(OH)(2)D-3 by VDR induces conformational changes in the ligand-binding domain (LBD), the most striking of which is a packing of the AF-2 helix onto the LED adjacent to helices H3 and H4. In this study, a panel of VDR helix H3 mutants was generated, and residues in helix H3 that are important for ligand-activated transcription by the full-length VDR were identified. In particular, one mutant (VDR (Y236A)) exhibited normal ligand binding and heterodimerization with the retinoid X receptor (RXR) but was transcriptionally inactive. Yeast two-hybrid studies and in vitro protein interaction assays demonstrated that VDR (Y236A) was selectively impaired in interaction with AF-2-interacting coactivator proteins such as SRC-1 and GRIP-1. These data indicate an importance of helix H3 in the mechanism of VDR-mediated transcription, and they support the concept that helix HS functions in concert with the AF-2 domain to form a transactivation surface for binding the p160 class of nuclear receptor coactivators.	St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, Hlth Sci Ctr, St Louis, MO 63104 USA	Saint Louis University	MacDonald, PN (corresponding author), St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, Hlth Sci Ctr, 1402 S Grand Blvd, St Louis, MO 63104 USA.	macdonal@slu.edu			NIDDK NIH HHS [R01DK50348] Funding Source: Medline; NIGMS NIH HHS [T32-GM08306] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050348] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008306] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; Baudino TA, 1998, J BIOL CHEM, V273, P16434, DOI 10.1074/jbc.273.26.16434; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Collingwood TN, 1998, EMBO J, V17, P4760, DOI 10.1093/emboj/17.16.4760; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FAGAN R, 1994, CELL, V78, P799, DOI 10.1016/S0092-8674(94)90522-3; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; FOLKERS GE, 1993, MOL ENDOCRINOL, V7, P616, DOI 10.1210/me.7.4.616; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Henttu PMA, 1997, MOL CELL BIOL, V17, P1832, DOI 10.1128/MCB.17.4.1832; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; HSIEH JC, 1991, P NATL ACAD SCI USA, V88, P9315, DOI 10.1073/pnas.88.20.9315; Jeyakumar M, 1997, MOL ENDOCRINOL, V11, P755, DOI 10.1210/me.11.6.755; Jurutka PW, 1997, J BIOL CHEM, V272, P14592, DOI 10.1074/jbc.272.23.14592; Kraichely Dennis M., 1998, Frontiers in Bioscience, V3, pD821; MACDONALD PN, 1994, SEMIN NEPHROL, V14, P101; MACDONALD PN, 1993, MOL CELL BIOL, V13, P5907, DOI 10.1128/MCB.13.9.5907; Masuyama H, 1997, MOL ENDOCRINOL, V11, P218, DOI 10.1210/me.11.2.218; Masuyama H, 1997, MOL ENDOCRINOL, V11, P1507, DOI 10.1210/me.11.10.1507; METZGER D, 1995, J BIOL CHEM, V270, P9535, DOI 10.1074/jbc.270.16.9535; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; NAKAJIMA S, 1993, BIOCHEM BIOPH RES CO, V197, P478, DOI 10.1006/bbrc.1993.2504; Norris JD, 1997, MOL ENDOCRINOL, V11, P747, DOI 10.1210/me.11.6.747; ONATE SA, 1995, SCIENCE, V270, P1354; PHAM TA, 1992, MOL ENDOCRINOL, V6, P1043, DOI 10.1210/me.6.7.1043; PIERRAT B, 1994, GENE, V143, P193, DOI 10.1016/0378-1119(94)90096-5; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; Seol W, 1996, SCIENCE, V272, P1336, DOI 10.1126/science.272.5266.1336; Shibata H, 1997, RECENT PROG HORM RES, V52, P141; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; Williams SP, 1998, NATURE, V393, P392, DOI 10.1038/30775; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; WURTZ JM, 1997, VITAMIN D CHEM BIOL, P165	39	35	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					14352	14358		10.1074/jbc.274.20.14352	http://dx.doi.org/10.1074/jbc.274.20.14352			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318858	hybrid			2022-12-25	WOS:000080322200087
J	Duyndam, MCA; van Dam, H; Smits, PHM; Verlaan, M; van der Eb, AJ; Zantema, A				Duyndam, MCA; van Dam, H; Smits, PHM; Verlaan, M; van der Eb, AJ; Zantema, A			The N-terminal transactivation domain of ATF2 is a target for the co-operative activation of the c-jun promoter by p300 and 12S E1A	ONCOGENE			English	Article						ATF; Jun; SAPK; CBP; transcription; coactivator	TRANSCRIPTION FACTOR FAMILY; CBP-INDUCED STIMULATION; NUCLEAR-PROTEIN CBP; ADENOVIRUS E1A; HETERODIMER FORMATION; GENE-TRANSCRIPTION; COACTIVATOR P300; RETINOIC ACID; UV RESPONSE; CYCLIC-AMP	The adenovirus EIA proteins activate the c-jun promoter through two Jun/ATF-binding sites, jun1 and jun2. P300, a transcriptional coactivator of several AP1 and ATF transcription factors has been postulated to play a role in this activation, Here,,ve present evidence that p300 can control c-jun transcription by acting as a cofactor for ATF2: (1) Over-expression of p300 mas found to stimulate c-jun transcription both in the presence and absence of EIA. (2) Like E1A, p300 activates the c-jun promoter through the jun1 and jun2 elements and preferentially activates the N-terminal domain of ATF2. (3) Co-immunoprecipitation assays of crude cell extracts indicate that endogenous p300/CBP(-like) proteins and ATF2 proteins are present in a multiprotein complex that can bind specifically to the jun2 element, We further demonstrate that the Stress-Activated-Protein-Kinase (SAPK) target sites of ATF2, Thr69 and Thr71 are not required for the formation of the p300/CBP-ATF2 multiprotein complex. These data indicate that E1A does not inhibit all transcription activation functions of p300, and, in fact, cooperates with p300 in the activation of the ATF2 N-terminus.	Leiden Univ, Med Ctr, Mol Carcinogenesis Lab, NL-2333 AL Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Zantema, A (corresponding author), Leiden Univ, Med Ctr, Mol Carcinogenesis Lab, Wassenaarseweg 72, NL-2333 AL Leiden, Netherlands.			van Dam, Hans/0000-0002-8307-4325				ABDELHAFIZ HAM, 1993, ONCOGENE, V8, P1161; ABRAHAM SE, 1993, ONCOGENE, V8, P1639; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARIAS J, 1994, NATURE, V351, P494; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; Bannister AJ, 1995, ONCOGENE, V11, P2509; BENBROOK DM, 1990, ONCOGENE, V5, P295; Billon N, 1996, ONCOGENE, V13, P2047; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DORSMAN JC, 1995, J VIROL, V69, P2962, DOI 10.1128/JVI.69.5.2962-2967.1995; Duyndam MCA, 1996, J VIROL, V70, P5852, DOI 10.1128/JVI.70.9.5852-5859.1996; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; FLINT KJ, 1991, ONCOGENE, V6, P2019; FRANKLIN CC, 1992, P NATL ACAD SCI USA, V89, P7247, DOI 10.1073/pnas.89.15.7247; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Hagmeyer BM, 1996, ONCOGENE, V12, P1025; HAGMEYER BM, 1993, EMBO J, V12, P3559, DOI 10.1002/j.1460-2075.1993.tb06030.x; HAGMEYER BM, 1995, BIOESSAYS, V17, P621, DOI 10.1002/bies.950170708; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; Hasegawa K, 1997, J BIOL CHEM, V272, P20049, DOI 10.1074/jbc.272.32.20049; HERR I, 1994, CARCINOGENESIS, V15, P1105, DOI 10.1093/carcin/15.6.1105; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; Kawasaki H, 1998, GENE DEV, V12, P233, DOI 10.1101/gad.12.2.233; Kawasaki H, 1996, EUR J BIOCHEM, V241, P315, DOI 10.1111/j.1432-1033.1996.00315.x; Kee BL, 1996, J BIOL CHEM, V271, P2373, DOI 10.1074/jbc.271.5.2373; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KITABAYASHI I, 1995, EMBO J, V14, P3496, DOI 10.1002/j.1460-2075.1995.tb07356.x; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lee JS, 1996, MOL CELL BIOL, V16, P4312; Lee JS, 1996, J BIOL CHEM, V271, P17666, DOI 10.1074/jbc.271.30.17666; Li XY, 1996, GENE DEV, V10, P517, DOI 10.1101/gad.10.5.517; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; Liu YS, 1996, FREE RADICAL BIO MED, V21, P771, DOI 10.1016/0891-5849(96)00176-1; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; LOW KG, 1994, MOL CELL BIOL, V14, P4958, DOI 10.1128/MCB.14.7.4958; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Merika M, 1998, MOL CELL, V1, P277, DOI 10.1016/S1097-2765(00)80028-3; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; Nakajima T, 1997, GENE DEV, V11, P738, DOI 10.1101/gad.11.6.738; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; ROZEK D, 1993, MOL CELL BIOL, V13, P5490, DOI 10.1128/MCB.13.9.5490; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; Smits PHM, 1996, ONCOGENE, V12, P1529; STEIN B, 1992, PHOTOCHEM PHOTOBIOL, V55, P409, DOI 10.1111/j.1751-1097.1992.tb04255.x; VANDAM H, 1990, MOL CELL BIOL, V10, P5857, DOI 10.1128/MCB.10.11.5857; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VANDAM H, 1989, ONCOGENE, V4, P1207; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; VIEIRA J, 1991, GENE, V100, P189, DOI 10.1016/0378-1119(91)90365-I; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009	71	27	28	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 8	1999	18	14					2311	2321		10.1038/sj.onc.1202584	http://dx.doi.org/10.1038/sj.onc.1202584			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184DT	10327051				2022-12-25	WOS:000079595500003
J	Fuchs, SY; Chen, A; Xiong, Y; Pan, ZQ; Ronai, Z				Fuchs, SY; Chen, A; Xiong, Y; Pan, ZQ; Ronai, Z			HOS, a human homolog of Slimb, forms an SCF complex with Skp1 and Cullin1 and targets the phosphorylation-dependent degradation of I kappa B and beta-catenin	ONCOGENE			English	Article						ubiquitination; SCF E2 ligase; I kappa B; beta-catenin; phosphorylation; degradation	UBIQUITIN-PROTEASOME PATHWAY; F-BOX; PROTEINS; ACTIVATION; FAMILY; KINASE; ALPHA; CDC4P; APC	SCF E3 ubiquitin ligases mediate ubiquitination and proteasome-dependent degradation of phosphorylated substrates. We identified a human F-box/WD40 repeats protein (HOS), which is homologous to Slimb/h beta TrCP. Being a part of SCF complex with Skp1 and Cullin1, HOS specifically interacted with the phosphorylated I kappa B and beta-catenin, targeting these proteins for proteasome-dependent degradation in vivo, This targeting required Cullin1 as expression of a mutant Cullin1 abrogated the degradation of I kappa B and of beta-catenin. Mutant HOS which lacks the F-box blocked TNF alpha-induced degradation of I kappa B as well as GSK3 beta-mediated degradation of beta-catenin. This mutant also inhibited NF-kappa B transactivation and increased the beta-catenine-dependent transcription activity of Tcf. These results demonstrate that SCFHOS E3 ubiquitin ligase regulate both NF-kappa B and beta-catenin signaling pathways.	CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA; Univ N Carolina, Sch Med, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Fuchs, SY (corresponding author), CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, 1 Gustave L Levy Pl, New York, NY 10029 USA.			RONAI, ZEEV/0000-0002-3859-0400	NATIONAL CANCER INSTITUTE [R01CA078419] Funding Source: NIH RePORTER; NCI NIH HHS [CA 78419] Funding Source: Medline; NIGMS NIH HHS [GM 55059] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; EldarFinkelman H, 1997, P NATL ACAD SCI USA, V94, P9660, DOI 10.1073/pnas.94.18.9660; Elledge SJ, 1998, BBA-REV CANCER, V1377, pM61, DOI 10.1016/S0304-419X(98)00005-5; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; Ishikawa K, 1998, DNA Res, V5, P169, DOI 10.1093/dnares/5.3.169; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; KOBE B, 1995, CURR OPIN STRUC BIOL, V5, P409, DOI 10.1016/0959-440X(95)80105-7; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Krek W, 1998, CURR OPIN GENET DEV, V8, P36, DOI 10.1016/S0959-437X(98)80059-2; Lisztwan J, 1998, EMBO J, V17, P368, DOI 10.1093/emboj/17.2.368; Lyapina SA, 1998, P NATL ACAD SCI USA, V95, P7451, DOI 10.1073/pnas.95.13.7451; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; Mathias N, 1996, MOL CELL BIOL, V16, P6634; Michel JJ, 1998, CELL GROWTH DIFFER, V9, P435; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Patton EE, 1998, GENE DEV, V12, P692, DOI 10.1101/gad.12.5.692; Patton EE, 1998, TRENDS GENET, V14, P236, DOI 10.1016/S0168-9525(98)01473-5; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhou PB, 1998, MOL CELL, V2, P571, DOI 10.1016/S1097-2765(00)80156-2	37	158	164	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	1999	18	12					2039	2046		10.1038/sj.onc.1202760	http://dx.doi.org/10.1038/sj.onc.1202760			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	179TX	10321728				2022-12-25	WOS:000079346200001
J	Cheng, HH; Xu, LW; Kumagai, H; Simoni, RD				Cheng, HH; Xu, LW; Kumagai, H; Simoni, RD			Oligomerization state influences the degradation rate of 3-hydroxy-3-methylglutaryl-CoA reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; TRANSCOBALAMIN-II RECEPTOR; ENDOPLASMIC-RETICULUM; ESCHERICHIA-COLI; REGULATED DEGRADATION; CHOLESTEROL HOMEOSTASIS; BETA-GALACTOSIDASE; MEMBRANE DOMAIN; UDP-GLCNAC; PROTEIN	The steady-state level of the resident endoplasmic reticulum protein, 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGR), is regulated, in part, by accelerated degradation in response to excess sterols or mevalonate, Previous studies of a chimeric protein (HM-Gal) composed of the membrane domain of HMGR fused to Escherichia coli beta-galactosidase, as a replacement of the normal HMGR cytosolic domain, have shown that the regulated degradation of this chimeric protein, HM-Gal, is identical to that of HMGR (Chun, K. T., Bar-Nun, S., and Simoni, R. D. (1990) J. Biol. Chem. 265, 22004-22010; Skalnik, D. G., Narita, H., Kent, C., and Simoni, R. D. (1988) J. Biol. Chem. 263, 6836-6841), Since the cytosolic domain can be replaced with beta-galactosidase without effect on regulated degradation, it has been assumed that the cytosolic domain was not important to this process and also that the membrane domain of HMGR was both necessary and sufficient for regulated degradation. In contrast to our previous results with HM-Gal, we observed in this study that replacement of the cytosolic domain of HMGR with various heterologous proteins can have an effect on the regulated degradation, and the effect correlates with the oligomeric state of the replacement cytosolic protein. Chimeric proteins that are oligomeric in structure are relatively stable, and those that are monomeric are unstable. To test the hypothesis that the oligomeric state of the cytosolic domain of HMGR influences degradation, we use an "inducible" system for altering the oligomeric state of a protein in vivo, Using a chimeric protein that contains the membrane domain of HMGR fused to three copies of FK506-binding protein 12, we were able to induce oligomerization by addition of a "double-headed" FK506-like "dimerizer" drug (AP1510) and to monitor the degradation rate of both the monomeric form and the drug-induced oligomeric form of the protein. We show that this chimeric protein, HM-3FKBP, is unstable in the monomeric state and is stabilized by AP1510-induced oligomerization, We also examined the degradation rate of HMGR as a function of concentrations within the cell. HMGR is a functional dimer; therefore, its oligomeric state and, we predict, its degradation rate should be concentration-dependent. We observed that it is degraded more rapidly at lower concentrations.	Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA	Stanford University	Simoni, RD (corresponding author), Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA.				NHLBI NIH HHS [HL 26502] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL026502] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amara JF, 1997, P NATL ACAD SCI USA, V94, P10618, DOI 10.1073/pnas.94.20.10618; BOSE S, 1995, BIOCHEM J, V310, P923, DOI 10.1042/bj3100923; BOSE S, 1995, J BIOL CHEM, V270, P8152, DOI 10.1074/jbc.270.14.8152; Bose S, 1996, J BIOL CHEM, V271, P11718, DOI 10.1074/jbc.271.20.11718; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; CHANDRA NC, 1991, ARCH BIOCHEM BIOPHYS, V290, P345, DOI 10.1016/0003-9861(91)90550-3; CHIN DJ, 1985, MOL CELL BIOL, V5, P634, DOI 10.1128/MCB.5.4.634; CHUN KT, 1990, J BIOL CHEM, V265, P22004; CHUN KT, 1992, J BIOL CHEM, V267, P4236; Dan N, 1997, J BIOL CHEM, V272, P14214, DOI 10.1074/jbc.272.22.14214; EDWARDS PA, 1983, J BIOL CHEM, V258, P219; EDWARDS PA, 1985, J BIOL CHEM, V260, P278; FAUST JR, 1982, P NATL ACAD SCI-BIOL, V79, P5205, DOI 10.1073/pnas.79.17.5205; FOWLER AV, 1966, SCIENCE, V154, P1027, DOI 10.1126/science.154.3752.1027; FRUMAN DA, 1994, FASEB J, V8, P391, DOI 10.1096/fasebj.8.6.7513288; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GRITZ L, 1983, GENE, V25, P179, DOI 10.1016/0378-1119(83)90223-8; HARDEMAN EC, 1984, ARCH BIOCHEM BIOPHYS, V232, P549, DOI 10.1016/0003-9861(84)90572-1; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; Jin LQ, 1998, BLOOD, V91, P890, DOI 10.1182/blood.V91.3.890.890_890_897; JINGAMI H, 1987, J CELL BIOL, V104, P1693, DOI 10.1083/jcb.104.6.1693; LAWRENCE CM, 1995, SCIENCE, V268, P1758, DOI 10.1126/science.7792601; LEHRMAN M A, 1991, Glycobiology, V1, P553, DOI 10.1093/glycob/1.6.553; LISCUM L, 1985, J BIOL CHEM, V260, P522; LIU SW, 1983, J BIOL CHEM, V258, P7469; Loftus SK, 1997, SCIENCE, V277, P232, DOI 10.1126/science.277.5323.232; LOWRY OH, 1951, J BIOL CHEM, V193, P265; McGee TP, 1996, J BIOL CHEM, V271, P25630, DOI 10.1074/jbc.271.41.25630; NESS GC, 1988, BIOCHIM BIOPHYS ACTA, V953, P361, DOI 10.1016/0167-4838(88)90046-5; OLENDER EH, 1992, J BIOL CHEM, V267, P4223; PRATT D, 1983, NUCLEIC ACIDS RES, V11, P8817, DOI 10.1093/nar/11.24.8817; ROTHBLAT GH, 1976, IN VITRO CELL DEV B, V12, P554; SKALNIK DG, 1988, J BIOL CHEM, V263, P6836; SPENCER DM, 1993, SCIENCE, V262, P1019, DOI 10.1126/science.7694365; TSUNEOKA M, 1992, J BIOL CHEM, V267, P9107	35	30	30	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17171	17178		10.1074/jbc.274.24.17171	http://dx.doi.org/10.1074/jbc.274.24.17171			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358074	hybrid			2022-12-25	WOS:000080780400073
J	Diamond, DA; Parsian, A; Hunt, CR; Lofgren, S; Spitz, DR; Goswami, PC; Gius, D				Diamond, DA; Parsian, A; Hunt, CR; Lofgren, S; Spitz, DR; Goswami, PC; Gius, D			Redox factor-1 (Ref-1) mediates the activation of AP-1 in HeLa and NIH 3T3 cells in response to heat shock	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; CHINESE-HAMSTER FIBROBLASTS; GLUTATHIONE LEVELS; OXIDATIVE STRESS; GENE-EXPRESSION; NUCLEAR-PROTEIN; MESSENGER-RNA; REPAIR ENZYME; FREE-RADICALS; FOS	The early response genes, c-Fos and c-Jun, are induced by environmental stress and are thought to modulate injury processes via the induction of AP-l-dependent target genes. AP-I activation is thought to be regulated by changes in intracellular oxidation/reduction reactions involving the redox factor-1 (Ref-l) protein. In this study, NIH 3T3 and HeLa cells were used to determine whether heat shock induces the AP-1 transcription factor via signaling pathways involving Ref-l, Reverse transcriptase-polymerase chain reaction analysis and immunoblotting demonstrated that c-Fos and c-Jun were induced 2-10 h following heat shock, and this induction was accompanied by an increase in AP-1 DNA binding. Electrophoretic mobility shift assay extracts immunodepleted of Ref-l protein demonstrated that the increase in AP-1 DNA-binding activity following heating was dependent upon the presence of Ref-l and that Ref-l regulates inducible, but not basal, AP-1 DNA-binding activity. This was confirmed by the restoration of heat-inducible DNA binding upon addition of Ref-l to immunodepleted extracts. The ability of Ref-l from heated cells to stimulate AP-1 DNA binding was abolished by chemical oxidation and restored by chemical reduction. These results indicate that heat shock activates c-Fos/c-Jun gene expression and AP-1 DNA binding and suggests that redox-sensitive signal transduction pathways involving Ref-l may mediate heat-induced alterations in AP-1 activation.	Washington Univ, Sch Med, Radiat Oncol Ctr, Sect Canc Biol, St Louis, MO 63108 USA; Edward Mallinckrodt Inst Radiol, Radiat Oncol Ctr, Sect Canc Biol, St Louis, MO 63108 USA	Washington University (WUSTL); Washington University (WUSTL)	Gius, D (corresponding author), Washington Univ, Sch Med, Radiat Oncol Ctr, Sect Canc Biol, 4511 Forest Pk Blvd,Suite 411, St Louis, MO 63108 USA.			Goswami, Prabhat/0000-0002-5700-2096; Spitz, Douglas/0000-0002-1254-8765	NCI NIH HHS [K08CA72602, CA69593, P01 CA75556] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA069593, P01CA075556, K08CA072602] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ADLER V, 1995, J BIOL CHEM, V270, P26071, DOI 10.1074/jbc.270.44.26071; ANDREWS GK, 1994, MOL CELL BIOL, V10, P3452; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ASHBURNER M, 1979, CELL, V17, P241, DOI 10.1016/0092-8674(79)90150-8; BERGELSON S, 1994, CANCER RES, V54, P36; Cotto JJ, 1996, J BIOL CHEM, V271, P3355; Davidson JF, 1996, P NATL ACAD SCI USA, V93, P5116, DOI 10.1073/pnas.93.10.5116; DUBOIS MF, 1993, FEBS LETT, V324, P191, DOI 10.1016/0014-5793(93)81391-C; Elbirt KK, 1998, J BIOL CHEM, V273, P8922, DOI 10.1074/jbc.273.15.8922; ERDOS G, 1995, J CELL PHYSIOL, V164, P404, DOI 10.1002/jcp.1041640221; Flanagan SW, 1998, FEBS LETT, V431, P285, DOI 10.1016/S0014-5793(98)00779-0; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; FREEMAN ML, 1990, RADIAT RES, V124, P288, DOI 10.2307/3577841; FREEMAN ML, 1988, RADIAT RES, V115, P461, DOI 10.2307/3577295; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; Goswami PC, 1997, CELL PROLIFERAT, V30, P271, DOI 10.1111/j.1365-2184.1997.tb00940.x; Guyton KZ, 1996, FREE RADICAL BIO MED, V20, P735, DOI 10.1016/0891-5849(95)02151-5; HALL DM, 1994, J APPL PHYSIOL, V77, P548, DOI 10.1152/jappl.1994.77.2.548; HALLIWELL B, 1992, J LAB CLIN MED, V119, P598; JURIVICH DA, 1991, J CELL PHYSIOL, V148, P252, DOI 10.1002/jcp.1041480210; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; KERPPOLA T, 1995, NATURE, V373, P199, DOI 10.1038/373199a0; KERR L D, 1992, Current Opinion in Cell Biology, V4, P496, DOI 10.1016/0955-0674(92)90017-7; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; Maity A, 1997, INT J RADIAT ONCOL, V37, P639, DOI 10.1016/S0360-3016(96)00598-6; MITCHELL JB, 1983, RADIAT RES, V95, P471, DOI 10.2307/3576094; Morimoto RI, 1997, ESSAYS BIOCHEM, V32, P17; Mulcahy RT, 1997, J BIOL CHEM, V272, P7445, DOI 10.1074/jbc.272.11.7445; OKUNO H, 1993, ONCOGENE, V8, P695; Polla BS, 1996, P NATL ACAD SCI USA, V93, P6458, DOI 10.1073/pnas.93.13.6458; PRIVALLE CT, 1987, P NATL ACAD SCI USA, V84, P2723, DOI 10.1073/pnas.84.9.2723; RITZ MF, 1993, RECEPTOR, V3, P311; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Sekhar KR, 1997, BIOCHEM BIOPH RES CO, V234, P588, DOI 10.1006/bbrc.1997.6697; SKIBBA JL, 1989, J BIOCHEM TOXICOL, V4, P119, DOI 10.1002/jbt.2570040208; SKIBBA JL, 1986, CANCER RES, V46, P6000; SPITZ DR, 1987, J CELL PHYSIOL, V131, P364, DOI 10.1002/jcp.1041310308; SPITZ DR, 1990, J CELL PHYSIOL, V142, P255, DOI 10.1002/jcp.1041420206; STEVENSON MA, 1994, CANCER RES, V54, P12; WALKER LJ, 1994, NUCLEIC ACIDS RES, V22, P4884, DOI 10.1093/nar/22.23.4884; WOOTEN MW, 1991, EXP CELL RES, V193, P274, DOI 10.1016/0014-4827(91)90096-D; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x; YAO KS, 1994, MOL CELL BIOL, V14, P5997, DOI 10.1128/MCB.14.9.5997	45	59	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16959	16964		10.1074/jbc.274.24.16959	http://dx.doi.org/10.1074/jbc.274.24.16959			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358044	hybrid			2022-12-25	WOS:000080780400043
J	Rodriguez, A; Martinez, I; Chung, A; Berlot, CH; Andrews, NW				Rodriguez, A; Martinez, I; Chung, A; Berlot, CH; Andrews, NW			cAMP regulates Ca2+-dependent exocytosis of lysosomes and lysosome-mediated cell invasion by trypanosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-A; PERMEABILIZED CHROMAFFIN CELLS; CYCLIC-AMP; ADENYLATE-CYCLASE; EPITHELIAL-CELLS; DEPENDENT REGULATION; ACTIN-FILAMENTS; RAT-LIVER; CALCIUM; RELEASE	Ca2+-regulated exocytosis, previously believed to be restricted to specialized cells, was recently recognized as a ubiquitous process. In mammalian fibroblasts and epithelial cells, exocytic vesicles mobilized by Ca2+ were identified as lysosomes, Here we show that elevation in intracellular cAMP potentiates Ca2+-dependent exocytosis of lysosomes in normal rat kidney fibroblasts. The process can be modulated by the heterotrimeric Gr proteins G(s) and G(i), consistent with activation or inhibition of adenylyl cyclase, Normal rat kidney cell stimulation with isoproterenol, a beta-adrenergic agonist that activates adenylyl cyclase, enhances Ca2+-dependent lysosome exocytosis and cell invasion by Trypanosoma cruzi, a process that involves parasite-induced [Ca2+](i) transients and fusion of host cell lysosomes with the plasma membrane. Similarly to what is observed for T, cruzi invasion, the actin cytoskeleton acts as a barrier for Ca2+-induced lysosomal exocytosis, In addition, infective stages of T, cruzi trigger elevation in host cell cAMP levels, whereas no effect is observed with noninfective forms of the parasite, These findings demonstrate that cAMP regulates lysosomal exocytosis triggered by Ca2+ and a parasite/host cell interaction known to involve Ca2+-dependent lysosomal fusion.	Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Mol & Cellular Pharmacol, New Haven, CT 06520 USA	Yale University; Yale University	Andrews, NW (corresponding author), Yale Univ, Sch Med, Dept Cell Biol, 333 Cedar St, New Haven, CT 06520 USA.			Martinez, Inigo/0000-0001-5408-9088; Andrews, Norma/0000-0002-0611-2412	NIAID NIH HHS [R01AI34867] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034867] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMMALA C, 1993, NATURE, V363, P356, DOI 10.1038/363356a0; Bi GQ, 1995, J CELL BIOL, V131, P1747, DOI 10.1083/jcb.131.6.1747; Bi GQ, 1997, J CELL BIOL, V138, P999, DOI 10.1083/jcb.138.5.999; Caler EV, 1998, EMBO J, V17, P4975, DOI 10.1093/emboj/17.17.4975; Coorssen JR, 1996, EMBO J, V15, P3787, DOI 10.1002/j.1460-2075.1996.tb00752.x; DOWNEY GP, 1991, J CELL BIOL, V114, P1179, DOI 10.1083/jcb.114.6.1179; Eddleman CS, 1997, P NATL ACAD SCI USA, V94, P4745, DOI 10.1073/pnas.94.9.4745; Epple HJ, 1997, PFLUG ARCH EUR J PHY, V433, P638, DOI 10.1007/s004240050325; FORSCHER P, 1987, J NEUROSCI, V7, P3600; Fushimi K, 1997, J BIOL CHEM, V272, P14800, DOI 10.1074/jbc.272.23.14800; GIROD R, 1995, J NEUROSCI, V15, P2826; GOLDMAN JE, 1990, BRAIN RES, V528, P189, DOI 10.1016/0006-8993(90)91657-3; GUELLAEN G, 1977, BIOCHIM BIOPHYS ACTA, V484, P465, DOI 10.1016/0005-2744(77)90102-4; HANSEN SH, 1994, J CELL BIOL, V126, P677, DOI 10.1083/jcb.126.3.677; HAYAKAWA T, 1990, AM J PHYSIOL, V259, pG727, DOI 10.1152/ajpgi.1990.259.5.G727; HEUSER J, 1989, J CELL BIOL, V108, P855, DOI 10.1083/jcb.108.3.855; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; Huang CC, 1998, J NEUROSCI, V18, P2276; Jilling T, 1996, J BIOL CHEM, V271, P4381; KEHLENBACH RH, 1994, NATURE, V372, P804; KOFFER A, 1990, J CELL BIOL, V111, P919, DOI 10.1083/jcb.111.3.919; KOTZ KJ, 1994, J CELL BIOL, V124, P463, DOI 10.1083/jcb.124.4.463; LANG J, 1995, EMBO J, V14, P3535; LELKES PI, 1986, FEBS LETT, V208, P357, DOI 10.1016/0014-5793(86)81049-3; MATTER K, 1989, J NEUROCHEM, V52, P370, DOI 10.1111/j.1471-4159.1989.tb09131.x; McNeil PL, 1997, J CELL BIOL, V137, P1, DOI 10.1083/jcb.137.1.1; Miyake K, 1995, J CELL BIOL, V131, P1737, DOI 10.1083/jcb.131.6.1737; MORGAN A, 1993, EMBO J, V12, P3747, DOI 10.1002/j.1460-2075.1993.tb06052.x; Morgan A, 1995, ESSAYS BIOCHEM, V30, P77; MUALLEM S, 1995, J CELL BIOL, V128, P589, DOI 10.1083/jcb.128.4.589; NEER EJ, 1995, CELL, V80, P248; Ninomiya Y, 1996, J BIOL CHEM, V271, P17751, DOI 10.1074/jbc.271.30.17751; OSULLIVAN AJ, 1992, BIOCHEM J, V287, P403, DOI 10.1042/bj2870403; PIMPLIKAR SW, 1994, J BIOL CHEM, V269, P19054; PIMPLIKAR SW, 1993, NATURE, V362, P456, DOI 10.1038/362456a0; Rodriguez A, 1996, J CELL BIOL, V134, P349, DOI 10.1083/jcb.134.2.349; RODRIGUEZ A, 1995, J CELL BIOL, V129, P1263, DOI 10.1083/jcb.129.5.1263; Rodriguez A, 1997, J CELL BIOL, V137, P93, DOI 10.1083/jcb.137.1.93; Rovere P, 1996, J IMMUNOL, V156, P2273; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SONTAG JM, 1988, EUR J CELL BIOL, V46, P316; SPERELAKIS N, 1994, MOL CELL BIOCHEM, V140, P103, DOI 10.1007/BF00926749; SPIEGEL AM, 1981, ENDOCR REV, V2, P275, DOI 10.1210/edrv-2-3-275; STEINHARDT RA, 1994, SCIENCE, V263, P390, DOI 10.1126/science.7904084; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; TARDIEUX I, 1994, J EXP MED, V179, P1017, DOI 10.1084/jem.179.3.1017; TARDIEUX I, 1992, CELL, V71, P1117, DOI 10.1016/S0092-8674(05)80061-3; Tousson A, 1996, J CELL SCI, V109, P1325; TRIFARO JM, 1992, MOL NEUROBIOL, V6, P339, DOI 10.1007/BF02757940; Verhey KJ, 1998, J CELL BIOL, V143, P1053, DOI 10.1083/jcb.143.4.1053; VITALE ML, 1995, NEURON, V14, P353, DOI 10.1016/0896-6273(95)90291-0; VITALE N, 1996, EUR J NEUROSCI, V8, P1274; Zhang C, 1996, AM J PHYSIOL-RENAL, V270, pF131, DOI 10.1152/ajprenal.1996.270.1.F131	53	98	100	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16754	16759		10.1074/jbc.274.24.16754	http://dx.doi.org/10.1074/jbc.274.24.16754			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358016	hybrid			2022-12-25	WOS:000080780400015
J	Banks, GC; Mohr, B; Reeves, R				Banks, GC; Mohr, B; Reeves, R			The HMG-I(Y) A center dot T-hook peptide motif confers DNA-binding specificity to a structured chimeric protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOBILITY-GROUP PROTEINS; 4-WAY JUNCTION DNA; HMG-I; MINOR-GROOVE; CHROMOSOMAL TRANSLOCATIONS; DROSOPHILA-TRITHORAX; ACUTE LEUKEMIAS; SATELLITE DNA; GENE; SEQUENCE	Chromosomal translocations involving genes coding for members of the HMG-I(Y) family of "high mobility group" non-histone chromatin proteins (HMG-I, HMG-Y, and HMG-IC) have been observed in numerous types of human tumors. Many of these gene rearrangements result in the creation of chimeric proteins in which the DNA-binding domains of the HMG-I(Y) proteins, the so-called A.T-hook motifs, have been fused to heterologous peptide sequences. Although little is known about either the structure or biophysical properties of these naturally occurring fusion proteins, the suggestion has been made that such chimeras have probably assumed an altered in vivo DNA-binding specificity due to the presence of the A.T-hook motifs. To investigate this possibility, we performed in vitro "domain-swap" experiments using a model protein fusion system in which a single A.T-hook peptide was exchanged for a corresponding length peptide in the well characterized "B-box" DNA-binding domain of the HMG-1 non-histone chromatin protein. Here we report that chimeric A.T-hook/B box hybrids exhibit in vitro DNA-binding characteristics resembling those of wild type HMG-I(Y) protein, rather than the HMG-1 protein. These results strongly suggest that the chimeric fusion proteins produced in human tumors as a result of HMG-I(Y) gene chromosomal translocations also retain A.T-hook-imparted DNA-binding properties in vivo.	Washington State Univ, Dept Biochem Biophys, Pullman, WA 99164 USA; Washington State Univ, Dept Genet & Cell Biol, Pullman, WA 99164 USA	Washington State University; Washington State University	Reeves, R (corresponding author), Washington State Univ, Dept Biochem Biophys, Pullman, WA 99164 USA.	reevesr@mail.wsu.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046352] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-46352] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHAR HR, 1995, CELL, V82, P57; BRENOWITZ M, 1995, CURRENT PROTOCOLS MO; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; CHAU KY, 1995, NUCLEIC ACIDS RES, V23, P4262, DOI 10.1093/nar/23.21.4262; COMPTON LA, 1986, ANAL BIOCHEM, V155, P155, DOI 10.1016/0003-2697(86)90241-1; DOMER PH, 1993, P NATL ACAD SCI USA, V90, P7884, DOI 10.1073/pnas.90.16.7884; ELTON TS, 1987, BIOCHEM BIOPH RES CO, V143, P260, DOI 10.1016/0006-291X(87)90659-0; EVANS JNS, 1995, INT J PEPT PROT RES, V45, P554; FRIEDMANN M, 1993, NUCLEIC ACIDS RES, V21, P4259, DOI 10.1093/nar/21.18.4259; GEIERSTANGER BH, 1994, BIOCHEMISTRY-US, V33, P5347, DOI 10.1021/bi00183a043; Geurts JMW, 1997, CANCER RES, V57, P13; Geurts JMW, 1998, ONCOGENE, V16, P865, DOI 10.1038/sj.onc.1201609; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Hess JL, 1998, AM J CLIN PATHOL, V109, P251, DOI 10.1093/ajcp/109.3.251; Hill DA, 1997, NUCLEIC ACIDS RES, V25, P3523, DOI 10.1093/nar/25.17.3523; Huth JR, 1997, NAT STRUCT BIOL, V4, P657, DOI 10.1038/nsb0897-657; JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114; JOHNSON KR, 1988, J BIOL CHEM, V263, P18338; Kazmierczak B, 1998, AM J PATHOL, V152, P431; KAZMIERCZAK B, 1995, CANCER RES, V55, P6038; Kools PFJ, 1996, CANCER GENET CYTOGEN, V91, P1, DOI 10.1016/S0165-4608(96)00109-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; LAUDET V, 1993, NUCLEIC ACIDS RES, V21, P2493, DOI 10.1093/nar/21.10.2493; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; NAGAI K, 1987, METHOD ENZYMOL, V153, P461; Nicolas FJ, 1996, P NATL ACAD SCI USA, V93, P6881, DOI 10.1073/pnas.93.14.6881; NISSEN MS, 1991, J BIOL CHEM, V266, P19945; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RADIC MZ, 1992, CHROMOSOMA, V101, P602, DOI 10.1007/BF00360537; READ CM, 1994, EMBO J, V13, P5639, DOI 10.1002/j.1460-2075.1994.tb06902.x; READ CM, 1993, NUCLEIC ACIDS RES, V21, P3427, DOI 10.1093/nar/21.15.3427; REEVES R, 1993, J BIOL CHEM, V268, P21137; Reeves R, 1996, BIOCHEMISTRY-US, V35, P5063, DOI 10.1021/bi952424p; REEVES R, 1990, J BIOL CHEM, V265, P8573; REEVES R, 1987, P NATL ACAD SCI USA, V84, P6531, DOI 10.1073/pnas.84.18.6531; Reeves R, 1995, PROG CELL CYCLE RES, V1, P337; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Sobulo OM, 1997, P NATL ACAD SCI USA, V94, P8732, DOI 10.1073/pnas.94.16.8732; SOLOMON MJ, 1986, P NATL ACAD SCI USA, V83, P1276, DOI 10.1073/pnas.83.5.1276; STRAUSS F, 1984, CELL, V37, P889, DOI 10.1016/0092-8674(84)90424-0; TEO SH, 1995, EMBO J, V14, P3844, DOI 10.1002/j.1460-2075.1995.tb00054.x; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; WEIR HM, 1993, EMBO J, V12, P1311, DOI 10.1002/j.1460-2075.1993.tb05776.x; WEN L, 1989, NUCLEIC ACIDS RES, V17, P1197, DOI 10.1093/nar/17.3.1197; WERNER MH, 1995, CELL, V81, P705, DOI 10.1016/0092-8674(95)90532-4; Xiao S, 1997, AM J PATHOL, V150, P901; ZELEZNIKLE NJ, 1994, P NATL ACAD SCI USA, V91, P10610, DOI 10.1073/pnas.91.22.10610; ZHOU XJ, 1995, NATURE, V376, P771, DOI 10.1038/376771a0	50	25	34	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16536	16544		10.1074/jbc.274.23.16536	http://dx.doi.org/10.1074/jbc.274.23.16536			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347218	hybrid			2022-12-25	WOS:000080668600078
J	Chen, SH; Xu, M; Lin, F; Lee, D; Riek, P; Graham, RM				Chen, SH; Xu, M; Lin, F; Lee, D; Riek, P; Graham, RM			Phe(310) in transmembrane VI of the alpha(1B)-adrenergic receptor is a key switch residue involved in activation and catecholamine ring aromatic bonding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA(2) ADRENERGIC-RECEPTOR; MEMBRANE-SPANNING SEGMENT; BINDING-SITE CREVICE; DOPAMINE D2 RECEPTOR; CONSTITUTIVE ACTIVATION; ALPHA-1B-ADRENERGIC RECEPTOR; CONFORMATIONAL-CHANGES; AGONIST BINDING; ACTIVE STATE; SALT BRIDGE	Pharmacophore mapping of adrenergic receptors indicates that the phenyl ring of catecholamine agonists is involved in receptor binding and activation. Here we evaluated Phe(310), Phe(311), and Phe(303) in transmembrane VI (TMVI), as well as Tyr(348) in TMVII of the alpha(IB)-adrenergic receptor (alpha(1B)-AR), which have been implicated in a catechol-ring interaction. Neither catecholamine docking studies nor mutagenesis studies of Phe311, Phe303, or Tyr348 supported a role for these residues in catecholring binding. By contrast, docking studies indicated that the Phe310 side chain is well positioned to interact with the catechol-ring, and substituted cysteine accessibility method studies revealed that the side chain of the 310, but not 311 residue, is both solvent accessible and directed into the agonist-binding pocket. Also, saturation mutagenesis of both Phe310 and Phe311 revealed for the former, but not for the latter, a direct relationship between side chain volume and agonist affinity, and that aromaticity is essential for wild-type agonist binding, and for both wild-type agonist potency and efficacy. Moreover, studies of Phe310 mutants combined with a previously described constitutively active alpha(1B)-AR mutant, A293E, indicated that although not required for spontaneous receptor isomerization from the basal state, R, to a partially activated conformation R', interaction of Phe(310) with catecholamine agonists is essential for isomerization from R' to the fully activated state, R*.	St Vincents Hosp, Victor Chang Cardiac Res Inst, Mol Cardiol Unit, Sydney, NSW 2010, Australia; Univ New S Wales, Sch Biochem & Mol Genet, Kensington, NSW 2033, Australia	St Vincents Hospital Sydney; Victor Chang Cardiac Research Institute; University of New South Wales Sydney	Graham, RM (corresponding author), Victor Chang Cardiac Res Inst, 384 Victoria St, Darlinghurst, NSW 2010, Australia.			Lin, Fang/0000-0003-2179-7031; chen, songhai/0000-0001-7316-7125				AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen SH, 1996, J BIOL CHEM, V271, P32385, DOI 10.1074/jbc.271.50.32385; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; FRANKE RR, 1992, J BIOL CHEM, V267, P14767; GETHER U, 1995, J BIOL CHEM, V270, P28268; Graham RM, 1996, CIRC RES, V78, P737, DOI 10.1161/01.RES.78.5.737; Hwa J, 1996, J BIOL CHEM, V271, P7956, DOI 10.1074/jbc.271.14.7956; Hwa J, 1996, J BIOL CHEM, V271, P6322, DOI 10.1074/jbc.271.11.6322; HWA J, 1995, J BIOL CHEM, V270, P23189, DOI 10.1074/jbc.270.39.23189; JAVITCH JA, 1995, NEURON, V14, P825, DOI 10.1016/0896-6273(95)90226-0; Javitch JA, 1997, J BIOL CHEM, V272, P18546, DOI 10.1074/jbc.272.30.18546; Javitch JA, 1998, BIOCHEMISTRY-US, V37, P998, DOI 10.1021/bi972241y; JORGENSEN WL, 1990, J AM CHEM SOC, V112, P4768, DOI 10.1021/ja00168a022; Kenakin T, 1997, TRENDS PHARMACOL SCI, V18, P416, DOI 10.1016/S0165-6147(97)01127-9; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; Noda K, 1996, BIOCHEMISTRY-US, V35, P16435, DOI 10.1021/bi961593m; PARINI A, 1987, CIRC RES, V61, P100; Perez DM, 1996, MOL PHARMACOL, V49, P112; PEREZ DM, 1991, MOL PHARMACOL, V40, P876; Porter JE, 1996, J BIOL CHEM, V271, P28318, DOI 10.1074/jbc.271.45.28318; Porter JE, 1998, MOL PHARMACOL, V53, P766, DOI 10.1124/mol.53.4.766; RIEK RP, 1995, J THEOR BIOL, V172, P245; ROBINSON PR, 1992, NEURON, V9, P719, DOI 10.1016/0896-6273(92)90034-B; ROTHSCHILD KJ, 1983, SCIENCE, V219, P1333, DOI 10.1126/science.6828860; SALAMON Z, 1994, BIOCHEMISTRY-US, V33, P13706, DOI 10.1021/bi00250a022; Shieh T, 1997, J MOL BIOL, V269, P373, DOI 10.1006/jmbi.1997.1035; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; STRADER CD, 1989, J BIOL CHEM, V264, P13572; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; STRADER CD, 1987, P NATL ACAD SCI USA, V83, P917; SUNG SS, 1991, FASEB J, V5, pA804; Wieland K, 1996, P NATL ACAD SCI USA, V93, P9276, DOI 10.1073/pnas.93.17.9276; WU DQ, 1992, J BIOL CHEM, V267, P25798	38	48	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16320	16330		10.1074/jbc.274.23.16320	http://dx.doi.org/10.1074/jbc.274.23.16320			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347189	hybrid			2022-12-25	WOS:000080668600049
J	Sakahira, H; Enari, M; Nagata, S				Sakahira, H; Enari, M; Nagata, S			Functional differences of two forms of the inhibitor of caspase-activated DNase, ICAD-L, and ICAD-S	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; MOLECULAR CHAPERONES; PROLYL 4-HYDROXYLASE; APOPTOSIS; PROTEIN; FRAGMENTATION; SPECIFICITIES; RECEPTOR; SUBUNIT; FAMILY	Caspase-activated DNase (CAD) is responsible for the DNA fragmentation that occurs during apoptosis. CAD is complexed with an inhibitor of CAD (ICAD) in non-apoptotic, growing cells. Here, we report that mouse WR19L and human Jurkat T lymphoma cells express two alternative forms of ICAD, ICAD-L and ICAD-S, at similar levels. CAD was predominantly associated with ICAD-L in these cell lines. When CAD was expressed alone in Sf9 cells, it was found in insoluble fractions. However, when CAD was co-expressed with ICAD-L and ICAD-S, it was recovered as a soluble protein complexed predominantly with ICAD-L. In vitro transcription and translation of CAD cDNA did not produce a functional protein. Addition of ICAD-L but not ICAD-S to the assay mixture resulted in the synthesis of functional CAD. These results indicated that ICAD-L but not ICAD-S works as a specific chaperone for CAD, facilitating its correct folding during synthesis. Recombinant CAD, as a complex with ICAD-L, was then produced in Sf9 cells. The complex was treated with caspase 3, and CAD was purified to homogeneity. The purified CAD had DNase activity with a high specific activity.	Osaka Univ, Sch Med, Dept Genet, Suita, Osaka 5650871, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Suita, Osaka 5650871, Japan	Osaka University; Japan Science & Technology Agency (JST)	Nagata, S (corresponding author), Osaka Univ, Sch Med, Dept Genet, B-3,2-2 Yamada Oka, Suita, Osaka 5650871, Japan.	nagata@genetic.med.osaka-u.ac.jp	Nagata, Shigekazu/AAG-3203-2019; Enari, Masato/E-5507-2014	Nagata, Shigekazu/0000-0001-9758-8426; Enari, Masato/0000-0003-4293-3848				Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; EARNSHAW WC, 1995, CURR OPIN CELL BIOL, V7, P337, DOI 10.1016/0955-0674(95)80088-3; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HARTL FU, 1994, TRENDS BIOCHEM SCI, V19, P20, DOI 10.1016/0968-0004(94)90169-4; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; JAKOB U, 1993, J BIOL CHEM, V268, P1517; JOHN DCA, 1993, EMBO J, V12, P1587, DOI 10.1002/j.1460-2075.1993.tb05803.x; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KIVIRIKKO KI, 1989, FASEB J, V3, P1609, DOI 10.1096/fasebj.3.5.2537773; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Mukae N, 1998, P NATL ACAD SCI USA, V95, P9123, DOI 10.1073/pnas.95.16.9123; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Raff M, 1998, NATURE, V396, P119, DOI 10.1038/24055; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Shaham S, 1996, GENE DEV, V10, P578, DOI 10.1101/gad.10.5.578; SMULDERS RHPH, 1995, J BIOL CHEM, V270, P13916, DOI 10.1074/jbc.270.23.13916; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; VUORI K, 1992, EMBO J, V11, P4213, DOI 10.1002/j.1460-2075.1992.tb05515.x; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YOSHIKAWA A, 1995, EMBO J, V14, P5288, DOI 10.1002/j.1460-2075.1995.tb00213.x; Zhang JH, 1998, P NATL ACAD SCI USA, V95, P12480, DOI 10.1073/pnas.95.21.12480	30	89	92	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15740	15744		10.1074/jbc.274.22.15740	http://dx.doi.org/10.1074/jbc.274.22.15740			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336474	hybrid			2022-12-25	WOS:000080560100063
J	Xin, HB; Rogers, K; Qi, Y; Kanematsu, T; Fleischer, S				Xin, HB; Rogers, K; Qi, Y; Kanematsu, T; Fleischer, S			Three amino acid residues determine selective binding of FK506-binding protein 12.6 to the cardiac ryanodine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE CHANNEL; SKELETAL-MUSCLE; SARCOPLASMIC-RETICULUM; FK-506-BINDING PROTEIN; FK506; CALCINEURIN; COMPLEX; FKBP; TRANSPLANTATION; FKBP-FK506	FK506-binding protein (FKBP12) has been found to be associated with the skeletal muscle ryanodine receptor (RyR1) (calcium release channel), whereas FKBP12.6, a novel isoform of FKBP, is selectively associated with the cardiac ryanodine receptor (RyR2), For both RyRs, the stoichiometry is 4 FKBP/RyR. Although FKBP12.6 differs from FKBP12 by only 18 of 108 amino acids, FKBP12.6 selectively binds to RyR2 and exchanges with bound FKBP12.6 of RyR2, whereas both FKBP isoforms bind to RyR1 and exchange with bound FKBP12 of RyR1. To assess the amino acid residues of FKBP12.6 that are critical for selective binding to RyR2, the residues of FKBP12.6 that differ with FKBP12 were mutated to the respective residues of FKBP12. RyR2 of cardiac sarcoplasmic reticulum, prelabeled by exchange with [S-35]FKBP12.6, was used as assay system for binding/ exchange with the mutants. The triple mutant (Q31E/ N32D/F59W) of FKBP12.6 was found to lack selective binding to the cardiac RyR2, comparable with that of FKBP12.0. In complementary studies, mutations of FKBP12 to the three critical amino acids of FKBP12.6, conferred selective binding to RyR2, Each of the FKBP12.6 and FKBP12 mutants retained binding to the skeletal muscle RyR1, We conclude that three amino acid residues (Gln(31), Asn(32), and Phe(59)) of human FKBP12.6 account for the selective binding to cardiac RyR2.	Vanderbilt Univ, Dept Mol Biol, Nashville, TN 37235 USA	Vanderbilt University	Fleischer, S (corresponding author), Vanderbilt Univ, Dept Mol Biol, Nashville, TN 37235 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032711] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL32711] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBERS MW, 1990, J ORG CHEM, V55, P4984, DOI 10.1021/jo00304a003; Barg S, 1997, AM J PHYSIOL-CELL PH, V272, pC1726, DOI 10.1152/ajpcell.1997.272.5.C1726; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; Cameron AM, 1997, J BIOL CHEM, V272, P27582, DOI 10.1074/jbc.272.44.27582; CHAMBERLAIN BK, 1983, J BIOL CHEM, V258, P6602; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAM E, 1995, J BIOL CHEM, V270, P26511, DOI 10.1074/jbc.270.44.26511; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCPHERSON PS, 1993, J BIOL CHEM, V268, P13765; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; MICHNICK SW, 1991, SCIENCE, V252, P836, DOI 10.1126/science.1709301; MOORE JM, 1991, NATURE, V351, P248, DOI 10.1038/351248a0; Noguchi N, 1997, J BIOL CHEM, V272, P3133, DOI 10.1074/jbc.272.6.3133; OCHIAI T, 1987, TRANSPLANTATION, V44, P734, DOI 10.1097/00007890-198712000-00002; SAITO A, 1984, J CELL BIOL, V99, P875, DOI 10.1083/jcb.99.3.875; SEWELL TJ, 1994, J BIOL CHEM, V269, P21094; STANDAERT RF, 1990, NATURE, V346, P671, DOI 10.1038/346671a0; STERZL TE, 1995, LANCET, V346, P1346; TIMERMAN AP, 1995, J BIOL CHEM, V270, P2451, DOI 10.1074/jbc.270.6.2451; TIMERMAN AP, 1994, BIOCHEM BIOPH RES CO, V198, P701, DOI 10.1006/bbrc.1994.1101; Timerman AP, 1996, J BIOL CHEM, V271, P20385, DOI 10.1074/jbc.271.34.20385; TIMERMAN AP, 1993, J BIOL CHEM, V268, P22992; TODO S, 1989, SURGERY, V106, P444; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302; Wagenknecht T, 1997, J BIOL CHEM, V272, P32463, DOI 10.1074/jbc.272.51.32463; Wagenknecht T, 1996, BIOPHYS J, V70, P1709, DOI 10.1016/S0006-3495(96)79733-3; WINKLER M, 1995, DRUG SAFETY, V12, P348, DOI 10.2165/00002018-199512050-00006; XIN HB, 1995, BIOCHEM BIOPH RES CO, V214, P263, DOI 10.1006/bbrc.1995.2283	34	62	65	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15315	15319		10.1074/jbc.274.22.15315	http://dx.doi.org/10.1074/jbc.274.22.15315			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336416	hybrid			2022-12-25	WOS:000080560100005
J	Benachour, A; Sipos, G; Flury, I; Reggiori, F; Canivenc-Gansel, E; Vionnet, C; Conzelmann, A; Benghezal, M				Benachour, A; Sipos, G; Flury, I; Reggiori, F; Canivenc-Gansel, E; Vionnet, C; Conzelmann, A; Benghezal, M			Deletion of GPI7, a yeast gene required for addition of a side chain to the glycosylphosphatidylinositol (GPI) core structure, affects GPI protein transport, remodeling, and cell wall integrity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOSYL-PHOSPHATIDYLINOSITOL ANCHOR; HUMAN-ERYTHROCYTE ACETYLCHOLINESTERASE; GLYCOINOSITOL PHOSPHOLIPID ANCHOR; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; MEMBRANE ANCHOR; INOSITOL-ACYLATION; PLASMA-MEMBRANE; FIRST STEP; CLASS-H	Gpi7 was isolated by screening for mutants defective in the surface expression of glycosylphosphatidylinositol (GPI) proteins. Gpi7 mutants are deficient in YJL062w, herein named GP17. GPI7 is not essential, but its deletion renders cells hypersensitive to Calcofluor White, indicating cell wall fragility. Several aspects of GPI biosynthesis are disturbed in Delta gpi7. The extent of anchor remodeling, i.e. replacement of the primary lipid moiety of GPI anchors by ceramide, is significantly reduced, and the transport of GPI proteins to the Golgi is delayed, Gpi7p is a highly glycosylated integral membrane protein with 9-11 predicted transmembrane domains in the C-terminal part and a large, hydrophilic N-terminal ectodomain. The bulk of Gpi7p is located at the plasma membrane, but a small amount is found in the endoplasmic reticulum. GP17 has homologues in Saccharomyces cerevisiae, Caenorhabditis elegans, and man, but the precise biochemical function of this protein family is unknown. Based on the analysis of M4, an abnormal GPI lipid accumulating in gpi7, we propose that Gpi7p adds a side chain onto the GPI core structure. Indeed, when compared with complete GPI lipids, M4 lacks a previously unrecognized phosphodiester-linked side chain, possibly an ethanolamine phosphate. Gpi7p contains significant homology with phosphodiesterases suggesting that Gpi7p itself is the transferase adding a side chain to the alpha 1,6-linked mannose of the GPI core structure.	Univ Fribourg, Inst Biochem, CH-1700 Fribourg, Switzerland	University of Fribourg	Conzelmann, A (corresponding author), Univ Fribourg, Inst Biochem, Chemin Musee 5, CH-1700 Fribourg, Switzerland.	andreas.conzelmann@unifr.ch	Reggiori, Fulvio/U-8327-2019; Sipos, György/AAC-8267-2019; Sipos, Gyorgy/D-9287-2011	Reggiori, Fulvio/0000-0003-2652-2686; Sipos, György/0000-0002-6666-1384; 				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; AZZOUZ N, 1995, EMBO J, V14, P4422, DOI 10.1002/j.1460-2075.1995.tb00121.x; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; Baxter BK, 1996, MOL CELL BIOL, V16, P6444; BENGHEZAL M, 1995, J CELL BIOL, V130, P1333, DOI 10.1083/jcb.130.6.1333; Benghezal M, 1996, EMBO J, V15, P6575, DOI 10.1002/j.1460-2075.1996.tb01048.x; BREWIS IA, 1995, J BIOL CHEM, V270, P22946, DOI 10.1074/jbc.270.39.22946; Canivenc-Gansel E, 1998, GLYCOBIOLOGY, V8, P761, DOI 10.1093/glycob/8.8.761; Caro LHP, 1997, YEAST, V13, P1477, DOI 10.1002/(SICI)1097-0061(199712)13:15<1477::AID-YEA184>3.0.CO;2-L; CARRINGTON DM, 1985, NATURE, V313, P64, DOI 10.1038/313064a0; Chen R, 1996, P NATL ACAD SCI USA, V93, P2280, DOI 10.1073/pnas.93.6.2280; CONZELMANN A, 1992, EMBO J, V11, P457, DOI 10.1002/j.1460-2075.1992.tb05075.x; COSTELLO LC, 1992, J BIOL CHEM, V267, P8599; De Nobel Hans, 1994, Trends in Cell Biology, V4, P42, DOI 10.1016/0962-8924(94)90003-5; DEEG MA, 1992, J BIOL CHEM, V267, P18573; FANKHAUSER C, 1991, EUR J BIOCHEM, V195, P439, DOI 10.1111/j.1432-1033.1991.tb15723.x; FANKHAUSER C, 1993, J BIOL CHEM, V268, P26365; FELDHEIM D, 1994, J CELL BIOL, V126, P935, DOI 10.1083/jcb.126.4.935; FRANZUSOFF A, 1991, METHOD ENZYMOL, V194, P662; Gaynor EC, 1997, J CELL BIOL, V136, P789, DOI 10.1083/jcb.136.4.789; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GUTHER MLS, 1994, J BIOL CHEM, V269, P18694; HAMBURGER D, 1995, J CELL BIOL, V129, P629, DOI 10.1083/jcb.129.3.629; HARLOW E, 1988, ANTIBODIES LAB MANUA, P541; HEESEN ST, 1991, EUR J CELL BIOL, V56, P8; HILL JE, 1993, YEAST, V2, p1Y63; HIROSE S, 1992, J BIOL CHEM, V267, P16968; HOMANS SW, 1988, NATURE, V333, P269, DOI 10.1038/333269a0; INOUE N, 1993, J BIOL CHEM, V268, P6882; KAMITANI T, 1993, J BIOL CHEM, V268, P20733; Kollar R, 1997, J BIOL CHEM, V272, P17762, DOI 10.1074/jbc.272.28.17762; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIDICH SD, 1994, J BIOL CHEM, V269, P10193; LEIDICH SD, 1995, J BIOL CHEM, V270, P13029, DOI 10.1074/jbc.270.22.13029; Leidich SD, 1996, J BIOL CHEM, V271, P27829, DOI 10.1074/jbc.271.44.27829; LU CF, 1995, J CELL BIOL, V128, P333, DOI 10.1083/jcb.128.3.333; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; MENON AK, 1993, EMBO J, V12, P1907, DOI 10.1002/j.1460-2075.1993.tb05839.x; MIYATA T, 1993, SCIENCE, V259, P1318, DOI 10.1126/science.7680492; Mondesert G, 1997, GENETICS, V147, P421; Nelissen B, 1997, FEMS MICROBIOL REV, V21, P113, DOI 10.1111/j.1574-6976.1997.tb00347.x; NUOFFER C, 1991, MOL CELL BIOL, V11, P27, DOI 10.1128/MCB.11.1.27; PUOTI A, 1993, J BIOL CHEM, V268, P7215; PUOTI A, 1991, J CELL BIOL, V113, P515, DOI 10.1083/jcb.113.3.515; PUOTI A, 1992, J BIOL CHEM, V267, P22673; RALTON JE, 1993, J BIOL CHEM, V268, P24183; Ramalingam S, 1996, P NATL ACAD SCI USA, V93, P7528, DOI 10.1073/pnas.93.15.7528; REDMAN CA, 1994, BIOCHEM J, V302, P861, DOI 10.1042/bj3020861; Reggiori F, 1997, EMBO J, V16, P3506, DOI 10.1093/emboj/16.12.3506; ROBERTS WL, 1988, J BIOL CHEM, V263, P18766; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER P, 1990, J BIOL CHEM, V265, P16955; SIPOS G, 1994, EMBO J, V13, P2789, DOI 10.1002/j.1460-2075.1994.tb06572.x; Sipos G, 1997, EMBO J, V16, P3494, DOI 10.1093/emboj/16.12.3494; STAHL N, 1992, BIOCHEMISTRY-US, V31, P5043, DOI 10.1021/bi00136a600; TAGUCHI R, 1994, BIOCHEMISTRY-US, V33, P1017, DOI 10.1021/bi00170a021; Takahashi M, 1996, EMBO J, V15, P4254, DOI 10.1002/j.1460-2075.1996.tb00800.x; TAKEDA J, 1995, TRENDS BIOCHEM SCI, V20, P367, DOI 10.1016/S0968-0004(00)89078-7; TAKEDA J, 1993, CELL, V73, P703, DOI 10.1016/0092-8674(93)90250-T; TREUMANN A, 1995, J BIOL CHEM, V270, P6088, DOI 10.1074/jbc.270.11.6088; UEDA E, 1993, J BIOL CHEM, V268, P9998; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Yu JL, 1997, P NATL ACAD SCI USA, V94, P12580, DOI 10.1073/pnas.94.23.12580	64	101	105	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					15251	15261		10.1074/jbc.274.21.15251	http://dx.doi.org/10.1074/jbc.274.21.15251			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329735	Green Published, hybrid			2022-12-25	WOS:000081965200100
J	Longland, CL; Mezna, M; Michelangeli, F				Longland, CL; Mezna, M; Michelangeli, F			The mechanism of inhibition of the Ca2+-ATPase by mastoparan - Mastoparan abolishes cooperative Ca2+ binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA-2+-ATPASE; GASTRIC (H+; ADENOSINE 5'-TRIPHOSPHATE; BOUND CONFORMATION; ATPASE; MELITTIN; CALCIUM; PEPTIDE; (CA2+-MG2+)-ATPASE; VESICLES	The amphiphilic peptide mastoparan, isolated from wasp venom, is a potent inhibitor of the sarcoplasmic reticulum Ca2+-ATPase. At pH 7.2, ATPase activity is inhibited with an inhibitory constant (K-i) of 1 +/- 0.13 mu M. Mastoparan shifts the E2-E1 equilibrium toward El and may affect the regulatory ATP binding site. The peptide also decreases the affinity of the ATPase for Ca2+ and abolishes the cooperativity of Ca2+ binding. In the presence of mastoparan, the two Ca2+ ions bind independently of one another. Our results appear to support the model that describes the relationship between the two Ca2+ binding sites as "side-by-side," because this model allows the possibility of independent Ca2+ entry to the two sites. Mastoparan shifts the steady-state equilibrium between E1'Ca-2 and E1'Ca-2. P toward E1'Ca-2. P, by possibly affecting the conformational change that follows ATP binding. The peptide also causes a reduction in the levels of phosphoenzyme formed from [P-32]P-i. Some analogues of mastoparan were also tested and were found to cause inhibition of the Ca2+-ATPase in the range of 2-4 mu M. The inhibitory action of mastoparan and its analogues appears dependent on their ability to form alpha-helices in membranes.	Univ Birmingham, Sch Biochem, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Michelangeli, F (corresponding author), Univ Birmingham, Sch Biochem, POB 363, Birmingham B15 2TT, W Midlands, England.							BAKER KJ, 1995, BIOCHEMISTRY-US, V34, P3596, DOI 10.1021/bi00011a014; BAKER KJ, 1995, BIOCHEM J, V307, P571, DOI 10.1042/bj3070571; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; COLL RJ, 1986, BIOCHEM BIOPH RES CO, V138, P652, DOI 10.1016/S0006-291X(86)80546-0; CUPPOLETTI J, 1990, ARCH BIOCHEM BIOPHYS, V283, P249, DOI 10.1016/0003-9861(90)90639-G; CUPPOLETTI J, 1989, ARCH BIOCHEM BIOPHYS, V275, P263, DOI 10.1016/0003-9861(89)90372-X; CUPPOLETTI J, 1992, MOL CELL BIOCHEM, V114, P57; CUPPOLETTI J, 1990, ARCH BIOCHEM BIOPHYS, V278, P409, DOI 10.1016/0003-9861(90)90278-7; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; DUPONT Y, 1985, J BIOL CHEM, V260, P7241; DUPONT Y, 1982, BIOCHEM BIOPH RES CO, V106, P1272, DOI 10.1016/0006-291X(82)91250-5; FERNANDEZBELDA F, 1984, J BIOL CHEM, V259, P9687; FROUD RJ, 1986, BIOCHEM J, V237, P197, DOI 10.1042/bj2370197; HENDERSON IMJ, 1994, BIOCHEM J, V297, P615, DOI 10.1042/bj2970615; HENDERSON IMJ, 1994, BIOCHEM J, V297, P625, DOI 10.1042/bj2970625; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; HIRAI Y, 1980, BIOMED RES-TOKYO, V1, P185, DOI 10.2220/biomedres.1.185; HIRAI Y, 1979, CHEM PHARM BULL, V27, P1942; INESI G, 1980, J BIOL CHEM, V255, P3025; KOSKKOSICKA D, 1983, BIOCHEMISTRY-US, V22, P2559, DOI 10.1021/bi00279a037; Langel U, 1996, REGUL PEPTIDES, V62, P47, DOI 10.1016/0167-0115(96)00002-X; Longland CL, 1998, CELL CALCIUM, V24, P27, DOI 10.1016/S0143-4160(98)90086-0; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; MAHANEY JE, 1991, BIOCHEMISTRY-US, V30, P7171, DOI 10.1021/bi00243a019; MICHELANGELI F, 1991, ANAL BIOCHEM, V194, P231, DOI 10.1016/0003-2697(91)90223-G; MICHELANGELI F, 1990, BIOCHEMISTRY-US, V29, P8307, DOI 10.1021/bi00488a015; MICHELANGELI F, 1990, BIOCHEMISTRY-US, V29, P3090; PETITHORY JR, 1986, BIOCHEMISTRY-US, V25, P4493, DOI 10.1021/bi00364a006; Rice WJ, 1996, J BIOL CHEM, V271, P31412, DOI 10.1074/jbc.271.49.31412; SUKUMAR M, 1992, J BIOL CHEM, V267, P21421; WAKABAYASHI S, 1990, J BIOCHEM-TOKYO, V107, P563, DOI 10.1093/oxfordjournals.jbchem.a123087; WAKAMATSU K, 1992, BIOCHEMISTRY-US, V31, P5654, DOI 10.1021/bi00139a032; WATANABE T, 1982, J BIOL CHEM, V257, P1510; WICTOME M, 1992, FEBS LETT, V304, P109, DOI 10.1016/0014-5793(92)80599-C	35	29	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					14799	14805		10.1074/jbc.274.21.14799	http://dx.doi.org/10.1074/jbc.274.21.14799			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329678	hybrid			2022-12-25	WOS:000081965200043
J	Nurizzo, D; Cutruzzola, F; Arese, M; Bourgeois, D; Brunori, M; Cambillau, C; Tegoni, M				Nurizzo, D; Cutruzzola, F; Arese, M; Bourgeois, D; Brunori, M; Cambillau, C; Tegoni, M			Does the reduction of c heme trigger the conformational change of crystalline nitrite reductase?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERM WHALE MYOGLOBIN; PSEUDOMONAS-AERUGINOSA; CYTOCHROME-OXIDASE; ARM EXCHANGE; MUTAGENESIS; CATALYSIS; DOMAIN; ENZYME; CD(1)	The structures of nitrite reductase from Paracoccus denitrificans GB17 (NiR-Pd) and Pseudomonas aeruginosa (NiR-Pa) have been described for the oxidized and reduced state (Fulop, V., Moir, J. W. B., Ferguson, S. J., and Hajdu, J. (1995) Cell 81, 369-377; Nurizzo, D., Silvestrini, M. C., Mathieu, M., Cutruzzola, F., Bourgeois, D., Fulop, V., Hajdu, J., Brunori, M., Tegoni, M., and Cambillau, C. (1997) Structure 5, 1157-1171; Nurizzo, D., Cutruzzola F., Arese, M., Bourgeois, D., Brunori, M., Cambillau, C., and Tegoni, M. (1998) Biochemistry 37, 13987-13996). Major conformational rearrangements are observed in the extreme states although they are more substantial in NiR-Pd. The four structures differ significantly in the c heme domains. Upon reduction, a His(17)/ Met(106) heme-ligand switch is observed in NiR-Pd together with concerted movements of the Tyr in the distal site of the d(1) heme (Tyr(10) in NiR-Pa, Tyr(25) in NiR-Pd) and of a loop of the c heme domain (56-62 in NiR-Pa, 99-116 in NiR-Pd). Whether the reduction of the c heme, which undergoes the major rearrangements, is the trigger of these movements is the question addressed by our study. This conformational reorganization is not observed in the partially reduced species, in which the c heme is partially or largely (15-90%) reduced but the d(1) heme is still oxidized. These results suggest that the d(1) heme reduction is likely to be responsible of the movements. We speculate about the mechanistic explanation as to why the opening of the d(1) heme distal pocket only occurs upon electron transfer to the d(1) heme itself, to allow binding of the physiological substrate NO2- exclusively to the reduced metal center.	IBSM, UPR9039, CNRS, Marseille 20, France; Univ Rome La Sapienza, CNR, Dipartimento Sci Biochim, I-00185 Rome, Italy; Univ Rome La Sapienza, CNR, Ctr Biol Mol, I-00185 Rome, Italy; European Synchrotron Radiat Facil, F-38043 Grenoble, France	Centre National de la Recherche Scientifique (CNRS); Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome; European Synchrotron Radiation Facility (ESRF)	Cambillau, C (corresponding author), IBSM, UPR9039, CNRS, 31 Ch Joseph Aiguier, Marseille 20, France.		Cutruzzola', Francesca/G-4052-2011; , Bourgeois/AAI-2337-2020	Cutruzzola', Francesca/0000-0002-4621-2135; ARESE, Marzia/0000-0002-6140-2287; Brunori, Maurizio/0000-0002-7795-1635				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; Averill BA, 1996, CHEM REV, V96, P2951, DOI 10.1021/cr950056p; BENNETT MJ, 1995, PROTEIN SCI, V4, P2455, DOI 10.1002/pro.5560041202; Bergdoll M, 1997, STRUCTURE, V5, P391, DOI 10.1016/S0969-2126(97)00196-2; BLATT Y, 1979, BIOCHEMISTRY-US, V18, P2917, DOI 10.1021/bi00580a037; Bourgeois D, 1998, J APPL CRYSTALLOGR, V31, P22, DOI 10.1107/S0021889897006730; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNGER AT, 1996, X PLOR MANUAL; Cutruzzola F, 1997, FEBS LETT, V412, P365, DOI 10.1016/S0014-5793(97)00583-8; EGEBERG KD, 1990, BIOCHEMISTRY-US, V29, P9783, DOI 10.1021/bi00494a004; FULOP V, 1995, CELL, V81, P369, DOI 10.1016/0092-8674(95)90390-9; GREENWOOD C, 1978, BIOCHEM J, V173, P11, DOI 10.1042/bj1730011; HOLMES MA, 1991, J MOL BIOL, V218, P583, DOI 10.1016/0022-2836(91)90703-9; Kleywegt GJ, 1997, METHOD ENZYMOL, V277, P525, DOI 10.1016/S0076-6879(97)77029-0; Kobayashi K, 1997, BIOCHEMISTRY-US, V36, P13611, DOI 10.1021/bi971045o; Nurizzo D, 1997, STRUCTURE, V5, P1157, DOI 10.1016/S0969-2126(97)00267-0; Nurizzo D, 1998, BIOCHEMISTRY-US, V37, P13987, DOI 10.1021/bi981348y; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PARR SR, 1977, BIOCHEM J, V167, P447, DOI 10.1042/bj1670447; PARR SR, 1976, BIOCHEM J, V157, P423, DOI 10.1042/bj1570423; PIN S, 1994, BIOCHEMISTRY-US, V33, P11618, DOI 10.1021/bi00204a024; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Roussel A, 1991, SILICON GRAPHICS GEO, P86; SCHICHMAN SA, 1981, J AM CHEM SOC, V103, P7794, DOI 10.1021/ja00416a020; SHIMADA H, 1976, J BIOCHEM-TOKYO, V80, P135, DOI 10.1093/oxfordjournals.jbchem.a131245; SILVESTRINI MC, 1979, BIOCHEM J, V183, P701, DOI 10.1042/bj1830701; SILVESTRINI MC, 1990, J BIOL CHEM, V265, P11783; Williams PA, 1997, NATURE, V389, P406, DOI 10.1038/38775; Yoshikawa S, 1998, SCIENCE, V280, P1723, DOI 10.1126/science.280.5370.1723; Zumft WG, 1997, MICROBIOL MOL BIOL R, V61, P533, DOI 10.1128/.61.4.533-616.1997	30	24	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					14997	15004		10.1074/jbc.274.21.14997	http://dx.doi.org/10.1074/jbc.274.21.14997			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329702	hybrid			2022-12-25	WOS:000081965200067
J	Smirnova, E; Shurland, DL; Newman-Smith, ED; Pishvaee, B; van der Bliek, AM				Smirnova, E; Shurland, DL; Newman-Smith, ED; Pishvaee, B; van der Bliek, AM			A model for dynamin self-assembly based on binding between three different protein domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT CONFORMATIONAL CHANGE; PLECKSTRIN HOMOLOGY DOMAINS; COATED VESICLE FORMATION; GTPASE ACTIVITY; SH3 DOMAINS; DROSOPHILA; ENDOCYTOSIS; SHIBIRE; OLIGOMERIZATION; MICROTUBULES	Dynamin is a 100-kDa GTPase that assembles into multimeric spirals at the necks of budding clathrin-coated vesicles. We describe three different intramolecular binding interactions that may account for the process of dynamin self-assembly. The first binding interaction is the dimerization of a 100-amino acid segment in the C-terminal half of dynamin. We call this segment the assembly domain, because it appears to be critical for multimerization. The second binding interaction occurs between the assembly domain and the N-terminal GTPase domain The strength of this interaction is controlled by the nucleotide-bound state of the GTPase domain, as shown with mutations in GTP binding motifs and in vitro binding experiments. The third binding interaction occurs between the assembly domain and a segment that we call the middle domain. This is the segment between the N-terminal GTPase domain and the pleckstrin homology domain The three different binding interactions suggest a model in which dynamin molecules first dimerize. The dimers are then linked into a chain by a second binding reaction. The third binding interaction might connect adjacent rungs of the spiral.	Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	van der Bliek, AM (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Biol Chem, POB 951737, Los Angeles, CA 90095 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051866] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51866] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Artalejo CR, 1997, EMBO J, V16, P1565, DOI 10.1093/emboj/16.7.1565; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; Baba T, 1995, COLD SPRING HARB SYM, V60, P235, DOI 10.1101/SQB.1995.060.01.027; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Fancy DA, 1996, CHEM BIOL, V3, P551, DOI 10.1016/S1074-5521(96)90146-5; Field CM, 1996, J CELL BIOL, V133, P605, DOI 10.1083/jcb.133.3.605; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; Grant D, 1998, GENETICS, V149, P1019; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; Klein DE, 1998, J BIOL CHEM, V273, P27725, DOI 10.1074/jbc.273.42.27725; KOSAKA T, 1983, J NEUROBIOL, V14, P207, DOI 10.1002/neu.480140305; LAI CC, 1993, MOL CELL BIOL, V13, P1345, DOI 10.1128/MCB.13.3.1345; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MELEN K, 1992, J BIOL CHEM, V267, P25898; Muhlberg AB, 1997, EMBO J, V16, P6676, DOI 10.1093/emboj/16.22.6676; NAKAYAMA M, 1993, J BIOL CHEM, V268, P15033; Okamoto PM, 1997, J BIOL CHEM, V272, P11629; POULLET P, 1995, EUR J BIOCHEM, V227, P537, DOI 10.1111/j.1432-1033.1995.tb20421.x; Roos J, 1997, TRENDS CELL BIOL, V7, P257, DOI 10.1016/S0962-8924(97)01068-4; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; Schnitzer MJ, 1997, NATURE, V388, P386, DOI 10.1038/41111; Schumacher B, 1998, J BIOL CHEM, V273, P28365, DOI 10.1074/jbc.273.43.28365; SCHWEMMLE M, 1995, J BIOL CHEM, V270, P13518, DOI 10.1074/jbc.270.22.13518; SHPETNER HS, 1992, NATURE, V355, P733, DOI 10.1038/355733a0; SHPETNER HS, 1989, CELL, V59, P421, DOI 10.1016/0092-8674(89)90027-5; Shpetner HS, 1996, J BIOL CHEM, V271, P13, DOI 10.1074/jbc.271.1.13; Sweitzer SM, 1998, CELL, V93, P1021, DOI 10.1016/S0092-8674(00)81207-6; Takei K, 1998, CELL, V94, P131, DOI 10.1016/S0092-8674(00)81228-3; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; Vale RD, 1996, J CELL BIOL, V135, P291, DOI 10.1083/jcb.135.2.291; van der Bliek AM, 1999, TRENDS CELL BIOL, V9, P96, DOI 10.1016/S0962-8924(98)01490-1; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; Warnock DE, 1996, J BIOL CHEM, V271, P22310, DOI 10.1074/jbc.271.37.22310	36	114	116	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					14942	14947		10.1074/jbc.274.21.14942	http://dx.doi.org/10.1074/jbc.274.21.14942			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329695	hybrid			2022-12-25	WOS:000081965200060
J	Su, KH; Roos, MD; Yang, XY; Han, I; Paterson, AJ; Kudlow, JE				Su, KH; Roos, MD; Yang, XY; Han, I; Paterson, AJ; Kudlow, JE			An N-terminal region of Sp1 targets its proteasome-dependent degradation in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR SP1; LACTACYSTIN BETA-LACTONE; EPIDERMAL GROWTH-FACTOR; 67-KDA POLYPEPTIDE P67; DNA-BINDING ACTIVITY; KAPPA-B-ALPHA; PROTEIN-DEGRADATION; O-GLYCOSYLATION; END RULE; C-JUN	The transcription factor Spl is important for the expression of many cellular genes. Previously, it was shown that reduced O-glycosylation of Spl is associated with increased proteasome susceptibility. Spl undergoes proteasome-dependent degradation in cells stressed with glucose deprivation and adenylate cyclase activation, and this process is blocked in cells treated with glucosamine. In this study, using a reconstituted in vitro system, we identified the principal structural determinant in Spl that targets Spl for proteasome-dependent degradation. We found by using deletion analysis that the N-terminal 54 amino acids of Spl is required for Spl degradation. This element can act as an independent processing signal by directing degradation of an unrelated protein Recognition of this Spl element by the proteasome-dependent system is saturable, and ubiquitination of this element is not required for recognition. Time course experiments revealed that Spl degradation is a two-step process. First, a discrete endoproteolytic cleavage occurs downstream of the target region immediately C-terminal to Leu(56). The Spl sequence C-terminal to the cleavage site is subsequently degraded, whereas the N-terminal peptide remains intact. The identification of this Spl degradation-targeting signal will facilitate the identification of the critical proteins involved in the control of Spl proteasome-dependent degradation and the role of O-GlcNAc in this process.	Univ Alabama, Dept Med, Div Endocrinol & Metab, Birmingham, AL 35294 USA; Univ Alabama, Dept Cell Biol, Div Endocrinol & Metab, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Kudlow, JE (corresponding author), Univ Alabama, Dept Med, Div Endocrinol & Metab, Birmingham, AL 35294 USA.							Ammanamanchi S, 1998, J BIOL CHEM, V273, P16527, DOI 10.1074/jbc.273.26.16527; Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CIECHANOVER A, 1978, BIOCHEM BIOPH RES CO, V81, P1100, DOI 10.1016/0006-291X(78)91249-4; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Coleman CS, 1997, J BIOL CHEM, V272, P12164, DOI 10.1074/jbc.272.18.12164; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Craiu A, 1997, J BIOL CHEM, V272, P13437, DOI 10.1074/jbc.272.20.13437; Daniel S, 1996, J BIOL CHEM, V271, P14692, DOI 10.1074/jbc.271.25.14692; DATTA B, 1989, J BIOL CHEM, V264, P20620; DATTA B, 1988, P NATL ACAD SCI USA, V85, P3324, DOI 10.1073/pnas.85.10.3324; DELARCO JE, 1978, J CELL PHYSIOL, V94, P335, DOI 10.1002/jcp.1040940311; Dick LR, 1997, J BIOL CHEM, V272, P182; Dick LR, 1996, J BIOL CHEM, V271, P7273, DOI 10.1074/jbc.271.13.7273; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRISCOLL J, 1990, J BIOL CHEM, V265, P4789; DYNAN WS, 1985, P NATL ACAD SCI USA, V82, P4915, DOI 10.1073/pnas.82.15.4915; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; Fenteany G, 1998, J BIOL CHEM, V273, P8545, DOI 10.1074/jbc.273.15.8545; FENTEANY G, 1994, P NATL ACAD SCI USA, V91, P3358, DOI 10.1073/pnas.91.8.3358; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; GHODA L, 1989, SCIENCE, V243, P1493, DOI 10.1126/science.2928784; GHODA L, 1992, MOL CELL BIOL, V12, P2178, DOI 10.1128/MCB.12.5.2178; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; Han I, 1997, MOL CELL BIOL, V17, P2550, DOI 10.1128/MCB.17.5.2550; Hart GW, 1997, ANNU REV BIOCHEM, V66, P315, DOI 10.1146/annurev.biochem.66.1.315; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Hochstrasser M, 1996, CELL, V84, P813, DOI 10.1016/S0092-8674(00)81058-2; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JANE SM, 1993, MOL CELL BIOL, V13, P3272, DOI 10.1128/MCB.13.6.3272; JARIELENCONTRE I, 1995, J BIOL CHEM, V270, P11623, DOI 10.1074/jbc.270.19.11623; JENTSCH S, 1995, CELL, V82, P881, DOI 10.1016/0092-8674(95)90021-7; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P200; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; LEGGETT RW, 1995, J BIOL CHEM, V270, P25879, DOI 10.1074/jbc.270.43.25879; Li XQ, 1996, J BIOL CHEM, V271, P4447; Lin L, 1996, MOL CELL BIOL, V16, P2248; Lin RT, 1996, MOL CELL BIOL, V16, P1401; LUCA FC, 1991, EMBO J, V10, P4311, DOI 10.1002/j.1460-2075.1991.tb05009.x; Moriyama T, 1998, J BIOL CHEM, V273, P22037, DOI 10.1074/jbc.273.34.22037; Mortensen ER, 1997, J BIOL CHEM, V272, P16540, DOI 10.1074/jbc.272.26.16540; MOSS B, 1991, SCIENCE, V252, P1662, DOI 10.1126/science.2047875; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; MURATA Y, 1994, J BIOL CHEM, V269, P20674; OMURA S, 1991, J ANTIBIOT, V44, P113, DOI 10.7164/antibiotics.44.113; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PARTHUN MR, 1992, MOL CELL BIOL, V12, P4981, DOI 10.1128/MCB.12.11.4981; Piedrafita FJ, 1997, MOL CELL BIOL, V17, P6348, DOI 10.1128/MCB.17.11.6348; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; RAY MK, 1992, P NATL ACAD SCI USA, V89, P539, DOI 10.1073/pnas.89.2.539; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Rohlff C, 1997, J BIOL CHEM, V272, P21137, DOI 10.1074/jbc.272.34.21137; Roos MD, 1997, MOL CELL BIOL, V17, P6472, DOI 10.1128/MCB.17.11.6472; SAFFER JD, 1990, GENE DEV, V4, P659, DOI 10.1101/gad.4.4.659; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; Sasaki T, 1990, J Enzyme Inhib, V3, P195, DOI 10.3109/14756369009035837; SHIN TH, 1992, MOL CELL BIOL, V12, P3998, DOI 10.1128/MCB.12.9.3998; Sijts AJAM, 1997, J BIOL CHEM, V272, P19261, DOI 10.1074/jbc.272.31.19261; Solomon V, 1998, J BIOL CHEM, V273, P25216, DOI 10.1074/jbc.273.39.25216; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; TSURUMI C, 1995, MOL CELL BIOL, V15, P5682; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; Vinals F, 1997, J BIOL CHEM, V272, P12913, DOI 10.1074/jbc.272.20.12913; Weil R, 1997, J BIOL CHEM, V272, P9942; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; Yurochko AD, 1997, J VIROL, V71, P4638, DOI 10.1128/JVI.71.6.4638-4648.1997	75	92	93	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					15194	15202		10.1074/jbc.274.21.15194	http://dx.doi.org/10.1074/jbc.274.21.15194			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329728	hybrid			2022-12-25	WOS:000081965200093
J	Plass, C; Yu, F; Yu, L; Strout, MP; El-Rifai, W; Elonen, E; Knuutila, S; Marcucci, G; Young, DC; Held, WA; Bloomfield, CD; Caligiuri, MA				Plass, C; Yu, F; Yu, L; Strout, MP; El-Rifai, W; Elonen, E; Knuutila, S; Marcucci, G; Young, DC; Held, WA; Bloomfield, CD; Caligiuri, MA			Restriction landmark genome scanning for aberrant methylation in primary refractory and relapsed acute myeloid leukemia; involvement of the WIT-1 gene	ONCOGENE			English	Article						RLGS; DNA methylation; WIT-1; acute myeloid leukemia	MOUSE-LIVER TUMORS; DNA METHYLATION; WILMS-TUMOR; HEMATOPOIETIC NEOPLASMS; CALCITONIN-GENE; CELL-LINE; WT1; HYPERMETHYLATION; IDENTIFICATION; PATTERNS	There is substantial evidence to suggest that aberrant DNA methylation in the regulatory regions of expressed genes may play a role in hematologic malignancy, In the current report, the Restriction Landmark Genomic Scanning (RLGS) method was used to detect aberrant DNA methylation (M) in acute myeloid leukemia (AML), RLGS-M profiles were initially performed using DNA from diagnostic, remission, and relapse samples from a patient with AML, Rp18, one of the eight spots found that was absent in the relapse sample, was cloned. Sequence analysis showed that the spot represented a portion of the WIT-1 gene on human chromosome 11p13, Rp18 was missing in the relapse sample due to a distinct DNA methylation pattern of the WIT-I gene. Twenty-seven AML patients that entered CR after therapy (i.e., chemosensitive) were studied and only 10 (37%) of the diagnostic bone marrow (BM) samples showed methylation of WIT-I, However, seven of eight (87.5%) diagnostic BM samples from primary refractory AML (chemosensitive) showed methylation of WIT-I. The incidence of WIT-I methylation in primary refractory AML was significantly higher than that noted in chemosensitive AML (P=0.018), Together, these results indicate that RLGS-M can be used to find novel epigenetic alterations in human cancer that are undetectable by standard methods, In addition, these results underline the potential importance of WIT-I methylation in chemoresistant AML.	Ohio State Univ, Ctr Comprehens Canc, Div Human Canc Genet, Dept Microbiol & Immunol, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Div Hematol Oncol, Dept Internal Med, Columbus, OH 43210 USA; Ohio State Univ, Biostat Unit, Columbus, OH 43210 USA; Univ Helsinki, Cent Hosp, Med Genet Lab, FIN-00290 Helsinki, Finland; Roswell Pk Canc Inst, Div Med, Buffalo, NY 14263 USA; Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University of Helsinki; Helsinki University Central Hospital; Roswell Park Cancer Institute; Roswell Park Cancer Institute	Plass, C (corresponding author), Ohio State Univ, Ctr Comprehens Canc, Div Human Canc Genet, Dept Microbiol & Immunol, 420 W 12th St, Columbus, OH 43210 USA.		Plass, Christoph/H-7192-2014		NCI NIH HHS [2RO1CA68612, P30 CA16058] Funding Source: Medline; NIGMS NIH HHS [1RO1GM58269] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016058, R01CA068612] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058269] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akama TO, 1997, CANCER RES, V57, P3294; BAYLIN SB, 1986, CANCER RES, V46, P2917; Baylin SB, 1998, ADV CANCER RES, V72, P141; BENNETT JM, 1985, ANN INTERN MED, V103, P620, DOI 10.7326/0003-4819-103-4-620; BERGMANN L, 1997, BLOOD, V90, pA5611; Caligiuri MA, 1997, SEMIN ONCOL, V24, P32; CHESON BD, 1990, J CLIN ONCOL, V8, P813, DOI 10.1200/JCO.1990.8.5.813; Costello JF, 1997, CANCER RES, V57, P1250; DEBUSTROS A, 1988, P NATL ACAD SCI USA, V85, P5693; GESSLER M, 1993, GENOMICS, V17, P499, DOI 10.1006/geno.1993.1355; Gonzalgo ML, 1997, CANCER RES, V57, P594; Herman JG, 1997, CANCER RES, V57, P837; Hiltunen MO, 1997, BRIT J CANCER, V76, P1124, DOI 10.1038/bjc.1997.522; HUANG A, 1990, SCIENCE, V250, P991, DOI 10.1126/science.2173145; Inoue K, 1997, BLOOD, V89, P1405, DOI 10.1182/blood.V89.4.1405; Issa JPJ, 1997, LEUKEMIA, V11, pS7; Issa JPJ, 1996, CANCER RES, V56, P973; Issa JPJ, 1997, CANCER RES, V57, P1678; JINNO Y, 1994, NAT GENET, V6, P305, DOI 10.1038/ng0394-305; NEUMANN B, 1995, NAT GENET, V9, P12, DOI 10.1038/ng0195-12; OKAZAKI Y, 1995, ELECTROPHORESIS, V16, P197, DOI 10.1002/elps.1150160134; PALUMBO A, 1984, BLOOD, V64, P1059; Plass C, 1997, DNA Res, V4, P253, DOI 10.1093/dnares/4.3.253; Plass C, 1996, NAT GENET, V14, P106, DOI 10.1038/ng0996-106; Sambrook J., 2002, MOL CLONING LAB MANU; TAOKA T, 1992, BLOOD, V80, P46; TYCKO B, 1994, AM J PATHOL, V144, P431; Ushijima T, 1997, P NATL ACAD SCI USA, V94, P2284, DOI 10.1073/pnas.94.6.2284; Yamagami T, 1996, BLOOD, V87, P2878, DOI 10.1182/blood.V87.7.2878.bloodjournal8772878	29	45	51	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 20	1999	18	20					3159	3165		10.1038/sj.onc.1202651	http://dx.doi.org/10.1038/sj.onc.1202651			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	197WB	10340388				2022-12-25	WOS:000080388000012
J	Qi, JH; Ito, N; Claesson-Welsh, L				Qi, JH; Ito, N; Claesson-Welsh, L			Tyrosine phosphatase SHP-2 is involved in regulation of platelet-derived growth factor-induced migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; FACTOR RECEPTOR-BETA; SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; PDGF RECEPTOR; CDNA CLONING; BINDING-SITE; PROTEIN; PHOSPHORYLATION; ACTIVATION; CHEMOTAXIS	SHP-2 is a ubiquitously expressed Src homology-2-containing cytosolic tyrosine phosphatase that binds to and becomes tyrosine-phosphorylated by the activated platelet-derived growth factor receptor-beta (PDGFR-beta). Removal of the binding site on the receptor, by mutation of Tyr(1009) to Phe(1009) (denoted Y1009F), led to loss of PDGF-stimulated phosphatase activity in cells expressing the mutated receptor, and these cells failed to form membrane edge ruffles and to migrate toward PDGF. Furthermore, treatment with phosphatase inhibitors phenylarsine oxide (PAO) and orthovanadate led to loss of PDGF-stimulated phosphatase activity and attenuated PDGF-stimulated migration of wild type PDGFR-beta cells. Treatment of wild type PDGFR-beta cells with combinations of PAO or orthovanadate and phosphatidylinositol 3-kinase inhibitors wortmannin or LY294002 resulted in a synergistic inhibition of PDGFR-beta-mediated cell migration. PDGF stimulation of wild type PDGFR-beta cells led to induction of p125 focal adhesion kinase (FAK) activity at low concentrations of the growth factor and a decrease at higher concentrations. In the mutant Y1009F cells and in wild type PDGFR-beta cells treated with PAO and orthovanadate, FAK activity was not increased in response to PDGF. These results suggest that SHP-2 activity is involved in regulation of FAK activity and thereby of cell migration through PDGFR-beta, independently of phosphatidylinositol 3-kinase.	Univ Uppsala, Dept Med Biochem & Microbiol, Ctr Biomed, S-75123 Uppsala, Sweden	Uppsala University	Claesson-Welsh, L (corresponding author), Univ Uppsala, Dept Med Biochem & Microbiol, Ctr Biomed, Box 575, S-75123 Uppsala, Sweden.							AUERBACH R, 1991, PHARMACOL THERAPEUT, V51, P1, DOI 10.1016/0163-7258(91)90038-N; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BRISCOE CP, 1995, BIOCHEM J, V306, P115, DOI 10.1042/bj3060115; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; DEFILIPPI P, 1995, EXP CELL RES, V221, P141, DOI 10.1006/excr.1995.1361; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; Hansen K, 1996, EMBO J, V15, P5299, DOI 10.1002/j.1460-2075.1996.tb00915.x; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KLINGHOFFER RA, 1995, J BIOL CHEM, V270, P22208, DOI 10.1074/jbc.270.38.22208; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MELLSTROM K, 1988, EXP CELL RES, V177, P347, DOI 10.1016/0014-4827(88)90468-5; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; Ouwens DM, 1996, BIOCHEM J, V318, P609, DOI 10.1042/bj3180609; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; RANKIN S, 1994, J BIOL CHEM, V269, P704; Rankin S, 1996, J BIOL CHEM, V271, P7829, DOI 10.1074/jbc.271.13.7829; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; Stokes C L, 1992, EXS, V61, P118; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WENNSTROM S, 1994, ONCOGENE, V9, P651; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125	37	53	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					14455	14463		10.1074/jbc.274.20.14455	http://dx.doi.org/10.1074/jbc.274.20.14455			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318871	hybrid			2022-12-25	WOS:000080322200100
J	Chen, YQ; Hsieh, JT; Yao, FY; Fang, BL; Pong, RC; Cipriano, SC; Krepulat, F				Chen, YQ; Hsieh, JT; Yao, FY; Fang, BL; Pong, RC; Cipriano, SC; Krepulat, F			Induction of apoptosis and G2/M cell cycle arrest by DCC	ONCOGENE			English	Article						DCC; apoptosis; caspase; tumor suppressor gene; cell cycle; Cdk1	POLY(ADP-RIBOSE) POLYMERASE; COLORECTAL-CANCER; GENE; DEATH; IDENTIFICATION; CARCINOMAS; ADENOVIRUS; CLEAVAGE; PROTEASE; HOMOLOG	The Deleted in Colorectal Cancer gene (DCC) encodes a cell surface receptor that belongs to the Ig superfamily, Inactivation of the DCC gene has been implicated in human tumor progression. Howe, er, little is known about the biological function of the DCC protein. In the present study, we demonstrated that expression of DCC activated caspase-3 and programmed cell death, or induced G2/M cell cycle arrest in tumor cells, In some cell lines, apoptosis was evident within 24 h of DCC expression. Timing of the appearance of apoptotic cells coincided with that of the cleavage of poly (ADP-ribose) polymerase, a substrate of caspase-3, Expression of the apoptosis inhibitory gene Bcl-2 was not able to abrogate the DCC-induced apoptosis, In the G2/M cycle arrest cells, cdk1 activity was inhibited. Our results suggest that the DCC protein may transduce signals resulting in activation of caspases ok inhibition of Cdk1, These data provide a possible mechanism by which DCC suppresses tumorigenesis.	Wayne State Univ, Dept Pathol, Detroit, MI 48201 USA; Univ Texas, SW Med Ctr, Dept Urol, Dallas, TX 75235 USA; MD Anderson Canc Ctr, Dept Thorac Surg, Houston, TX 77030 USA	Wayne State University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; UTMD Anderson Cancer Center	Chen, YQ (corresponding author), Wayne State Univ, Dept Pathol, Detroit, MI 48201 USA.		Chen, Yong Q/AAI-9864-2021	Chen, Yong Q/0000-0003-4747-4708	NCI NIH HHS [R01CA73017, R21CA69845] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA069845, R01CA073017] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Chan SSY, 1996, CELL, V87, P187, DOI 10.1016/S0092-8674(00)81337-9; CHEN YQ, 1995, CANCER RES, V55, P4536; CHEN YQ, 1994, CANCER MOL BIOL, V1, P357; CHO KR, 1994, GENOMICS, V19, P525, DOI 10.1006/geno.1994.1102; Cipriano SC, 1998, ONCOGENE, V17, P1549, DOI 10.1038/sj.onc.1202069; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Dunphy William G., 1994, Trends in Cell Biology, V4, P202; Fazeli A, 1997, NATURE, V386, P796, DOI 10.1038/386796a0; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1996, BIOCHIM BIOPHYS ACTA, V1288, P17; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; GAO X, 1993, CANCER RES, V53, P2723; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Haldar S, 1996, CANCER RES, V56, P1253; HEDRICK L, 1992, COLD SPRING HARB SYM, V57, P345, DOI 10.1101/SQB.1992.057.01.039; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KLEINERMAN DI, 1995, CANCER RES, V55, P2831; Kolodziej PA, 1996, CELL, V87, P197, DOI 10.1016/S0092-8674(00)81338-0; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1	33	52	54	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	1999	18	17					2747	2754		10.1038/sj.onc.1202629	http://dx.doi.org/10.1038/sj.onc.1202629			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FH	10348349				2022-12-25	WOS:000080124900010
J	Picon, A; Bertagna, X; de Keyzer, Y				Picon, A; Bertagna, X; de Keyzer, Y			Analysis of the human proopiomelanocortin gene promoter in a small cell lung carcinoma cell line reveals an unusual role for E2F transcription factors	ONCOGENE			English	Article						ectopic ACTH syndrome; SCLC; proopiomelanocortin; gene expression regulation; E2F; DNA binding proteins	RETINOBLASTOMA GENE; TRANSGENIC MICE; EXPRESSION; RECEPTOR; PROTEIN; ABNORMALITIES; CANCER; NUR77; SITE; DP	The small cell lung carcinoma (SCLC) cell line DMS-79 has been used as a model for studying the molecular mechanism underlying the ectopic ACTH syndrome, We previously showed that two domains of the human Proopiomelanocortin (POMC) gene promoter were specifically active in DMS-79 cells. The present study focuses on the more distal one, Domain IV (-376/-417), DNaseI footprinting experiments identified a single binding site for DMS-79 cell proteins in this domain, Gel-shift and sequence analysis indicated that E2F proteins might bind this site. Indeed, proteins from DMS-79 cells which bind this site (i) have in vitro DNA binding properties indistinguishable from those of E2F proteins (ii) form, like E2F proteins, multiprotein complexes which can be dissociated by sodium deoxycholate and (iii) are recognized by antibodies directed against E2F proteins. Further, we show that the rat POMC distal promoter domain contains a homologous sequence which constitutes a natural mutant of the human POMC E2F binding site, since it does not bind E2F. We show by transient transfection that this natural mutant, in the context of the rat POMC promoter, is not active in DMS-79 cells by contrast to the human POMC E2F binding site. We conclude that E2F binding is required for the activity of Domain IV in DMS-79 cells and contributes to the expression of the POMC gene in SCLC, Further studies are required to elucidate the role of E2F factors in POMC gene transcription in SCLC cells, but our results have identified mechanisms different from those in pituitary corticotroph cells that are used by these SCLC tumor cells.	CHU Cochin Port Royal, Inst Cochin Genet Mol, CNRS, F-75014 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	de Keyzer, Y (corresponding author), CHU Cochin Port Royal, Inst Cochin Genet Mol, CNRS, UPR 1524,3eme Etage,24 Rue Faubourg St Jacques, F-75014 Paris, France.							ABE K, 1984, ENDOCRINE LUNG HLTH, P549; Baylin S B, 1980, Endocr Rev, V1, P45; BECKER KL, 1984, ENDOCRINE LUNG HLTH; BERTAGNA XY, 1978, P NATL ACAD SCI USA, V75, P5160, DOI 10.1073/pnas.75.10.5160; DEKEYZER Y, 1985, J CLIN INVEST, V76, P1892, DOI 10.1172/JCI112184; deKeyzer Y, 1996, ENDOCR-RELAT CANCER, V3, P99, DOI 10.1677/erc.0.0030099; GAITAN D, 1995, MOL ENDOCRINOL, V9, P1193, DOI 10.1210/me.9.9.1193; Gould VE, 1984, ENDOCRINE LUNG HLTH, P406; HAMMER GD, 1990, MOL ENDOCRINOL, V4, P1689, DOI 10.1210/mend-4-11-1689; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HEDVAT CV, 1995, MOL ENDOCRINOL, V9, P1692, DOI 10.1210/me.9.12.1692; Helin K, 1997, P NATL ACAD SCI USA, V94, P6933, DOI 10.1073/pnas.94.13.6933; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; JEANNOTTE L, 1987, MOL CELL BIOL, V7, P4058, DOI 10.1128/MCB.7.11.4058; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; Lamonerie T, 1996, GENE DEV, V10, P1284, DOI 10.1101/gad.10.10.1284; Loiseau L, 1997, GENE EXPRESSION, V6, P259; Maxam A M, 1980, Methods Enzymol, V65, P499; Murphy EP, 1997, MOL ENDOCRINOL, V11, P39, DOI 10.1210/me.11.1.39; Okabe T, 1998, J ENDOCRINOL, V156, P169, DOI 10.1677/joe.0.1560169; ORTH DN, 1995, NEW ENGL J MED, V332, P791, DOI 10.1056/NEJM199503233321207; Phillips A, 1997, MOL CELL BIOL, V17, P5946, DOI 10.1128/MCB.17.10.5946; PICON A, 1995, J MOL ENDOCRINOL, V15, P187, DOI 10.1677/jme.0.0150187; Poulin G, 1997, MOL CELL BIOL, V17, P6673, DOI 10.1128/MCB.17.11.6673; RAYMONDJEAN M, 1988, P NATL ACAD SCI USA, V85, P757, DOI 10.1073/pnas.85.3.757; RYGAARD K, 1990, CANCER RES, V50, P5312; Sambrook J., 2002, MOL CLONING LAB MANU; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; SORENSON GD, 1981, CANCER, V47, P1289, DOI 10.1002/1097-0142(19810315)47:6<1289::AID-CNCR2820470610>3.0.CO;2-B; THERRIEN M, 1991, MOL CELL BIOL, V11, P3492, DOI 10.1128/MCB.11.7.3492; THERRIEN M, 1993, MOL CELL BIOL, V13, P2342, DOI 10.1128/MCB.13.4.2342; TREMBLAY Y, 1988, P NATL ACAD SCI USA, V85, P8890, DOI 10.1073/pnas.85.23.8890; WAJCHENBERG BL, 1994, ENDOCR REV, V15, P752, DOI 10.1210/er.15.6.752; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; WONG KK, 1995, MOL CELL BIOL, V15, P6535; YEE AS, 1987, EMBO J, V6, P2061, DOI 10.1002/j.1460-2075.1987.tb02471.x	37	17	17	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 22	1999	18	16					2627	2633		10.1038/sj.onc.1202635	http://dx.doi.org/10.1038/sj.onc.1202635			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	189LU	10353606				2022-12-25	WOS:000079907100010
J	Tash, JS; Bracho, GE				Tash, JS; Bracho, GE			Microgravity alters protein phosphorylation changes during initiation of sea urchin sperm motility	FASEB JOURNAL			English	Article; Proceedings Paper	Symposium of the European-Space-Agency/National-Aeronautics-and-Space-Administration Workshop on Cell and Molecular biology Research in Space	JUN, 1998	BELGIUM NATL ACAD SCI, LEUVEN, BELGIUM	European Space Agency, NASA	BELGIUM NATL ACAD SCI	space flight; phosphoamino acids; Western immunoblot	INNER-ARM DYNEIN; HUMAN-SPERMATOZOA; ACTIVATION; CALCIUM; HYPERACTIVATION; IDENTIFICATION; PHOSPHATASES; GRAVITROPISM; COMPONENTS; MUTANTS	European Space Agency (ESA) studies demonstrated that bull sperm swim with higher velocity in microgravity (mu G) than at 1 G, Coupling between protein phosphorylation and sperm motility during activation in mu G and at 1 G was examined in the ESA Biorack on two space shuttle missions. Immotile sperm were activated to swim (86-90% motility) at launch +20 h by dilution into artificial seawater (ASW), Parallel ground controls were performed 2 h after the flight experiment. Activation after 0, 30, and 60 s was terminated with electrophoresis sample buffer and samples analyzed for phosphoamino acids by Western blotting. Phosphorylation of a 130-kDa phosphothreonine-containing protein (FP130) occurred three to four times faster in mu C than at 1 G, A 32-kDa phosphoserine-containing protein was significantly stimulated at 30 s but returned to 1 G control levels at 60 s, The rate of FP130 phosphorylation in mu G was attenuated by D2O, suggesting that changes in water properties participate in altering signal transduction, Changes in FP130 phosphorylation triggered by the egg peptide speract were delayed in mu G. These results demonstrate that previously observed effects of mu G on sperm motility are coupled to changes in phosphorylation of specific flagellar proteins and that early events of sperm activation and fertilization are altered in mu G.	Univ Kansas, Med Ctr, Dept Mol & Integrat Physiol, Kansas City, KS 66160 USA	University of Kansas; University of Kansas Medical Center	Tash, JS (corresponding author), Univ Kansas, Med Ctr, Dept Mol & Integrat Physiol, 3901 Rainbow Blvd, Kansas City, KS 66160 USA.				NICHD NIH HHS [HD-33994] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AHMAD K, 1995, ARCH ANDROLOGY, V35, P187, DOI 10.3109/01485019508987871; BENTLEY JK, 1987, J BIOL CHEM, V262, P15708; BENTLEY JK, 1986, J BIOL CHEM, V261, P4859; Bracho GE, 1998, BIOCHEM BIOPH RES CO, V242, P231, DOI 10.1006/bbrc.1997.7937; Bracho GE, 1997, BIOCHEM BIOPH RES CO, V237, P59, DOI 10.1006/bbrc.1997.7074; BROOKS DE, 1970, J REPROD FERTIL, V23, P525, DOI 10.1530/jrf.0.0230525; COGOLI A, 1996, J BIOTECHNOL, P1; De Maziere A, 1996, Adv Space Res, V17, P219, DOI 10.1016/0273-1177(95)00638-U; ENGELMANN U, 1992, J ANDROL, V13, P433; Habermacher G, 1997, J CELL BIOL, V136, P167, DOI 10.1083/jcb.136.1.167; Jennings R T, 1990, Obstet Gynecol Surv, V45, P7, DOI 10.1097/00006254-199001000-00006; KAMIYA R, 1991, J CELL BIOL, V112, P441, DOI 10.1083/jcb.112.3.441; Kiss JZ, 1997, PLANT CELL PHYSIOL, V38, P518, DOI 10.1093/oxfordjournals.pcp.a029199; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDEMANN CB, 1990, MOL REPROD DEV, V26, P69, DOI 10.1002/mrd.1080260111; LONGDON N, 1987, BIORACK SPACEHAB D1; Lu YT, 1996, PLANTA, V199, P18; Lu YT, 1997, PLANTA, V203, pS91, DOI 10.1007/PL00008121; MAKLER A, 1993, INT J ANDROL, V16, P251, DOI 10.1111/j.1365-2605.1993.tb01188.x; Mann T, 1981, MALE REPROD FUNCTION; MATTOK C, 1995, BIORACK SPACEHAB IML; Merkys A, 1997, Adv Space Biol Med, V6, P213, DOI 10.1016/S1569-2574(08)60084-2; SAPP WJ, 1990, FASEB J, V4, P101, DOI 10.1096/fasebj.4.1.2295370; SCHWUCHOW J, 1994, CELL MOTIL CYTOSKEL, V29, P366, DOI 10.1002/cm.970290409; Serova L V, 1989, Physiologist, V32, pS29; SUAREZ SS, 1993, P NATL ACAD SCI USA, V90, P4660, DOI 10.1073/pnas.90.10.4660; Sullivan R, 1996, ACTA OBSTET GYN SCAN, V75, P372, DOI 10.3109/00016349609033334; Tash JS, 1998, BIOCHEM BIOPH RES CO, V251, P557, DOI 10.1006/bbrc.1998.9516; TASH JS, 1973, PROC R SOC SER B-BIO, V184, P109, DOI 10.1098/rspb.1973.0036; TASH JS, 1994, J ANDROL, V15, P505; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Vijayaraghavan S, 1997, J BIOL CHEM, V272, P4747, DOI 10.1074/jbc.272.8.4747; WHITE DR, 1989, GAMETE RES, V22, P163, DOI 10.1002/mrd.1120220205; WINET H, 1984, J REPROD FERTIL, V70, P511	34	25	29	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.		1999	13			S			S43	S54						12	Biochemistry & Molecular Biology; Biology; Cell Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	198CF	10352144				2022-12-25	WOS:000080403800006
J	Liu, Q; Jin, CW; Liao, XB; Shen, ZY; Chen, DJ; Chen, Y				Liu, Q; Jin, CW; Liao, XB; Shen, ZY; Chen, DJ; Chen, Y			The binding interface between an E2 (UBC9) and a ubiquitin homologue (UBL1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONJUGATING ENZYME; CRYSTAL-STRUCTURE; SACCHAROMYCES-CEREVISIAE; ANGSTROM RESOLUTION; PROTEIN; SYSTEM; GENE; IDENTIFICATION; DEGRADATION; MODIFIER	Human UBC9 is a member of the E2 (ubiquitin conjugation enzyme) family of proteins. Instead of conjugating to ubiquitin, it conjugates with a ubiquitin homologue UBL1 (also known as SUMO-1, GMP1, SMTP3, PIC1, and sentrin). UBC9 has been shown to be involved in cell cycle regulation, DNA repair, and p53-dependent processes. The binding interfaces of the UBC9 and UBL1 complex have been determined by chemical shift perturbation using nuclear magnetic resonance spectroscopy. The binding site of UBL1 resides on the ubiquitin domain, and the binding site of UBC9 is located on a structurally conserved region of E2, Because the UBC9-UBL1 system shares many similarities with the ubiquitin system in structures and in conjugation with each other and with target proteins, the observed binding interfaces may be conserved in Ea-ubiquitin interactions in general.	City Hope Natl Med Ctr, Beckman Res Inst, Div Immunol, Duarte, CA 91010 USA; Univ Illinois, Dept Biochem & Mol Biol, Chicago, IL 60612 USA; Univ Illinois, Ctr Canc, Chicago, IL 60607 USA; Univ Calif Los Alamos Natl Lab, Div Life Sci, DNA Damage & Repair Grp, Los Alamos, NM 87545 USA	City of Hope; Beckman Research Institute of City of Hope; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; United States Department of Energy (DOE); Los Alamos National Laboratory	Chen, Y (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Div Immunol, 1450 E Duarte Rd, Duarte, CA 91010 USA.			Shen, Zhiyuan/0000-0003-2834-0309	NIGMS NIH HHS [GM54190] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM054190] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALKHODAIRY F, 1995, J CELL SCI, V108, P475; Bailly V, 1997, MOL CELL BIOL, V17, P4536, DOI 10.1128/MCB.17.8.4536; Bayer P, 1998, J MOL BIOL, V280, P275, DOI 10.1006/jmbi.1998.1839; CHEN Y, 1993, BIOCHEMISTRY-US, V32, P32, DOI 10.1021/bi00052a006; COOK WJ, 1992, J BIOL CHEM, V267, P15116; COOK WJ, 1993, BIOCHEMISTRY-US, V32, P13809, DOI 10.1021/bi00213a009; Cook WJ, 1997, BIOCHEMISTRY-US, V36, P1621, DOI 10.1021/bi962639e; Desterro JMP, 1997, FEBS LETT, V417, P297, DOI 10.1016/S0014-5793(97)01305-7; Gong LM, 1997, J BIOL CHEM, V272, P28198, DOI 10.1074/jbc.272.45.28198; Gottlicher M, 1996, STEROIDS, V61, P257, DOI 10.1016/0039-128X(96)00032-3; Haas AL, 1997, FASEB J, V11, P1257; Hateboer G, 1996, J BIOL CHEM, V271, P25906, DOI 10.1074/jbc.271.42.25906; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; Liu Q, 1999, BIOCHEMISTRY-US, V38, P1415, DOI 10.1021/bi981840h; Liu Q, 1999, J BIOMOL NMR, V13, P89, DOI 10.1023/A:1008364314328; Loveys DA, 1997, GENE, V201, P169, DOI 10.1016/S0378-1119(97)00444-7; Pahl HL, 1996, CURR OPIN CELL BIOL, V8, P340, DOI 10.1016/S0955-0674(96)80007-X; Saitoh H, 1997, TRENDS BIOCHEM SCI, V22, P374, DOI 10.1016/S0968-0004(97)01102-X; SCHNEIDER DM, 1992, BIOCHEMISTRY-US, V31, P3645, DOI 10.1021/bi00129a013; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; Shen ZY, 1996, GENOMICS, V37, P183, DOI 10.1006/geno.1996.0540; SULLIVAN ML, 1991, J BIOL CHEM, V266, P23878; Tong H, 1997, J BIOL CHEM, V272, P21381, DOI 10.1074/jbc.272.34.21381; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; VIJAYKUMAR S, 1987, J MOL BIOL, V194, P531, DOI 10.1016/0022-2836(87)90679-6; Wang ZY, 1996, J BIOL CHEM, V271, P24811, DOI 10.1074/jbc.271.40.24811; Worthylake DR, 1998, J BIOL CHEM, V273, P6271, DOI 10.1074/jbc.273.11.6271; Yasugi T, 1996, NUCLEIC ACIDS RES, V24, P2005, DOI 10.1093/nar/24.11.2005	31	72	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16979	16987		10.1074/jbc.274.24.16979	http://dx.doi.org/10.1074/jbc.274.24.16979			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358047	hybrid			2022-12-25	WOS:000080780400046
J	McConalogue, K; Dery, O; Lovett, M; Wong, H; Walsh, JH; Grady, EF; Bunnett, NW				McConalogue, K; Dery, O; Lovett, M; Wong, H; Walsh, JH; Grady, EF; Bunnett, NW			Substance P-induced trafficking of beta-arrestins - The role of beta-arrestins in endocytosis of the neutrokinin-1 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; GREEN FLUORESCENT PROTEIN; MUSCARINIC ACETYLCHOLINE-RECEPTOR; AGONIST-INDUCED DESENSITIZATION; ADRENERGIC-RECEPTOR; BETA(2)-ADRENERGIC RECEPTOR; NEUROKININ-1 RECEPTOR; ARRESTIN/CLATHRIN INTERACTION; CHOLECYSTOKININ RECEPTOR; INDUCED INTERNALIZATION	Agonist-induced redistribution of G-protein-coupled receptors (GPCRs) and beta-arrestins determines the subsequent cellular responsiveness to agonists and is important for signal transduction. We examined substance P (SP)-induced trafficking of beta-arrestin1 and the neurokinin-1 receptor (NK1R) in KNRK cells in real time using green fluorescent protein. Green fluorescent protein did not alter function or localization of the NK1R or beta-arrestin1, SP induced (a) striking and rapid (<1 min) translocation of beta-arrestin1 from the cytosol to the plasma membrane, which preceded NK1R endocytosis; (b) redistribution of the NK1R and beta-arrestin1 into the same endosomes containing SP and the transferrin receptor (2-10 min); (c) prolonged colocalization of the NK1R and beta-arrestin1 in endosomes (>60 min); (d) gradual resumption of the steady state distribution of the NK1R at the plasma membrane and beta-arrestin1 in the cytosol (4-6 h), SP stimulated a similar redistribution of immunoreactive beta-arrestin1 and beta-arrestin2. In contrast, SP did not affect G alpha(q/11) distribution, which remained at the plasma membrane. Expression of the dominant negative beta-arrestin(319-418) inhibited SP-induced endocytosis of the NK1R, Thus, SP induces rapid translocation of beta-arrestins to the plasma membrane, where they participate in NK1R endocytosis. beta-Arrestins colocalize with the NK1R in endosomes until the NK1R recycles and beta-arrestins return to the cytosol.	Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif Los Angeles, Sch Med, W Los Angeles Vet Affairs Med Ctr, CURE Digest Dis Res Ctr, Los Angeles, CA 90073 USA; Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90073 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; West Los Angeles VA Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Bunnett, NW (corresponding author), Univ Calif San Francisco, Dept Surg, 521 Parnassus Ave, San Francisco, CA 94143 USA.		McConalogue, Karen/AAE-6778-2019	Bunnett, Nigel W./0000-0003-3367-0644	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK039957, R01DK039957, R01DK043207, R56DK043207] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021710] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43207, DK39957] Funding Source: Medline; NINDS NIH HHS [NS21710] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; Barak LS, 1997, MOL PHARMACOL, V51, P177, DOI 10.1124/mol.51.2.177; BARAK LS, 1994, J BIOL CHEM, V269, P2790; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; BENOVIC JL, 1991, J BIOL CHEM, V266, P14939; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; Bohm SK, 1997, BIOCHEM J, V322, P1; Bohm SK, 1997, J BIOL CHEM, V272, P2363; BOWDEN JJ, 1994, P NATL ACAD SCI USA, V91, P8964, DOI 10.1073/pnas.91.19.8964; Bunnett NW, 1996, HISTOCHEM J, V28, P811, DOI 10.1007/BF02272154; CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728; Daaka Y, 1997, P NATL ACAD SCI USA, V94, P2180, DOI 10.1073/pnas.94.6.2180; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Garland AM, 1996, MOL PHARMACOL, V49, P438; GARLAND AM, 1994, BIOCHEM J, V303, P177, DOI 10.1042/bj3030177; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Goodman OB, 1997, J BIOL CHEM, V272, P15017, DOI 10.1074/jbc.272.23.15017; Grady EF, 1996, J NEUROSCI, V16, P6975, DOI 10.1523/jneurosci.16-21-06975.1996; GRADY EF, 1995, MOL BIOL CELL, V6, P509, DOI 10.1091/mbc.6.5.509; GRADY EF, 1996, NEUROSCIENCE, V16, P1239; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; Kallal L, 1998, J BIOL CHEM, V273, P322, DOI 10.1074/jbc.273.1.322; Kramer MS, 1998, SCIENCE, V281, P1640, DOI 10.1126/science.281.5383.1640; Krueger KM, 1997, J BIOL CHEM, V272, P5; Krupnick JG, 1997, J BIOL CHEM, V272, P32507, DOI 10.1074/jbc.272.51.32507; Krupnick JG, 1997, J BIOL CHEM, V272, P15011, DOI 10.1074/jbc.272.23.15011; KWATRA MM, 1993, J BIOL CHEM, V268, P9161; Li HZ, 1997, P NATL ACAD SCI USA, V94, P9475, DOI 10.1073/pnas.94.17.9475; Lin FT, 1997, J BIOL CHEM, V272, P31051, DOI 10.1074/jbc.272.49.31051; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; Macdonald SG, 1996, BIOCHEMISTRY-US, V35, P2909, DOI 10.1021/bi952351+; MANTYH PW, 1995, P NATL ACAD SCI USA, V92, P2622, DOI 10.1073/pnas.92.7.2622; McConalogue K, 1998, MOL BIOL CELL, V9, P2305, DOI 10.1091/mbc.9.8.2305; Nishimura K, 1998, BIOCHEMISTRY-US, V37, P1192, DOI 10.1021/bi972302s; OTSUKA M, 1993, PHYSIOL REV, V73, P229, DOI 10.1152/physrev.1993.73.2.229; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P23682, DOI 10.1074/jbc.272.38.23682; PIPPIG S, 1993, J BIOL CHEM, V268, P3201; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; PITCHER JA, 1995, P NATL ACAD SCI USA, V92, P8343, DOI 10.1073/pnas.92.18.8343; RICHARDSON RM, 1993, J BIOL CHEM, V268, P13650; ROETTGER BF, 1995, J CELL BIOL, V128, P1029, DOI 10.1083/jcb.128.6.1029; SASAKAWA N, 1994, MOL PHARMACOL, V46, P380; SASAKAWA N, 1994, FEBS LETT, V347, P181, DOI 10.1016/0014-5793(94)00532-X; Schlador ML, 1997, J BIOL CHEM, V272, P18882, DOI 10.1074/jbc.272.30.18882; SOHLEMANN P, 1995, EUR J BIOCHEM, V232, P464, DOI 10.1111/j.1432-1033.1995.tb20832.x; Tarasova NI, 1997, J BIOL CHEM, V272, P14817, DOI 10.1074/jbc.272.23.14817; TSUGA H, 1994, J BIOL CHEM, V269, P32522; VIGNA SR, 1994, J NEUROSCI, V14, P834; Wedegaertner PB, 1996, MOL BIOL CELL, V7, P1225, DOI 10.1091/mbc.7.8.1225; YU SS, 1993, J BIOL CHEM, V268, P337; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	55	84	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16257	16268		10.1074/jbc.274.23.16257	http://dx.doi.org/10.1074/jbc.274.23.16257			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347182	hybrid			2022-12-25	WOS:000080668600042
J	Wang, CC; Schimmel, P				Wang, CC; Schimmel, P			Species barrier to RNA recognition overcome with nonspecific RNA binding domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; PROTEIN; SYNTHETASE; DNA; COELECTROPHORESIS; FEATURES	We show here that nonspecific RNA-protein interactions can significantly enhance the biological activity of an essential RNA protein complex. Bacterial glutaminyl-tRNA synthetase poorly aminoacylates yeast tRNA and, as a consequence, cannot rescue a knockout allele of the gene for the yeast homologue. In contrast to the bacterial protein, the yeast enzyme has an extra appended domain at the N terminus. Previously, we showed that fusion of this yeast-specific domain to the bacterial protein enabled it to function as a yeast enzyme in vivo and in vitro. We suggested that the novel yeast-specific domain contributed to RNA interactions in a way that compensated for the poor fit between the yeast tRNA and bacterial enzyme. Here we establish that the novel appended domain by itself binds nonspecifically to different RNA structures. In addition, we show that fusion of an unrelated yeast protein, Arc1p, to the bacterial enzyme also converts it into a functional yeast enzyme in vivo and in vitro. A small C-terminal segment of Arc1p is necessary and sufficient for this conversion. This segment was shown by others to have nonspecific tRNA binding properties. Thus, nonspecific RNA binding interactions in general can compensate for barriers to formation of a specific and essential RNA protein complex.	Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Schimmel, P (corresponding author), Scripps Res Inst, Skaggs Inst Chem Biol, 10550 N Torrey Pines Rd,Mail Code BCC-379, La Jolla, CA 92037 USA.	schimmel@scripps.edu			NIGMS NIH HHS [GM23532] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALZHANOVA AT, 1980, FEBS LETT, V120, P225, DOI 10.1016/0014-5793(80)80303-6; BEDOUELLE H, 1990, J BACTERIOL, V172, P3940, DOI 10.1128/jb.172.7.3940-3945.1990; CHURCHILL MEA, 1991, TRENDS BIOCHEM SCI, V16, P92, DOI 10.1016/0968-0004(91)90040-3; Cilley CD, 1997, RNA, V3, P57; CIRAKOGLU B, 1985, EUR J BIOCHEM, V149, P353; DRAPER DE, 1995, ANNU REV BIOCHEM, V64, P593, DOI 10.1146/annurev.bi.64.070195.003113; FRANKEL AD, 1992, PROTEIN SCI, V1, P1539, DOI 10.1002/pro.5560011202; GALE AJ, 1995, BIOCHEMISTRY-US, V34, P8896, DOI 10.1021/bi00027a042; GARCIA A, 1993, NUCLEIC ACIDS RES, V21, P401, DOI 10.1093/nar/21.3.401; GIEGE R, 1993, PROG NUCLEIC ACID RE, V45, P129, DOI 10.1016/S0079-6603(08)60869-7; INOKUCHI H, 1984, P NATL ACAD SCI-BIOL, V81, P5076, DOI 10.1073/pnas.81.16.5076; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LIM WA, 1991, METHOD ENZYMOL, V208, P196; LUDMERER SW, 1987, J BIOL CHEM, V262, P10807; MIRANDE M, 1991, PROG NUCLEIC ACID RE, V40, P95; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHIMMEL PR, 1979, ANNU REV BIOCHEM, V48, P601, DOI 10.1146/annurev.bi.48.070179.003125; SHEN WC, 1993, J BIOL CHEM, V268, P19436; Simos G, 1996, EMBO J, V15, P5437, DOI 10.1002/j.1460-2075.1996.tb00927.x; Simos G, 1998, MOL CELL, V1, P235, DOI 10.1016/S1097-2765(00)80024-6; VIDALCROS A, 1992, J MOL BIOL, V223, P801, DOI 10.1016/0022-2836(92)90991-R; Whelihan EF, 1997, EMBO J, V16, P2968, DOI 10.1093/emboj/16.10.2968; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4	24	49	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16508	16512		10.1074/jbc.274.23.16508	http://dx.doi.org/10.1074/jbc.274.23.16508			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347214	hybrid			2022-12-25	WOS:000080668600074
J	Xue, HH; Fujie, M; Sakaguchi, T; Oda, T; Ogawa, H; Kneer, NM; Lardy, HA; Ichiyama, A				Xue, HH; Fujie, M; Sakaguchi, T; Oda, T; Ogawa, H; Kneer, NM; Lardy, HA; Ichiyama, A			Flux of the L-serine metabolism in rat liver - The predominant contribution of serine dehydratase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE AMINOTRANSFERASE; GLYOXYLATE AMINOTRANSFERASE; SUBCELLULAR-DISTRIBUTION; GLYCINE CATABOLISM; HEPATIC ALANINE; MITOCHONDRIA; GENE; GLUCONEOGENESIS; LOCALIZATION; EXPRESSION	L-Serine metabolism in rat liver was investigated, focusing on the relative contributions of the three pathways, one initiated by L-serine dehydratase (SDR), another by serine: pyruvate/alanine:glyoxylate aminotransferase (SPT/AGT), and the other involving serine hydroxymethyltransferase and the mitochondrial glycine cleavage enzyme system (GCS). Because serine hydroxymethyltransferase is responsible for the interconversion between serine and glycine, SDH, SPT/AGT, and GCS were considered to be the metabolic exits of the serine-glycine pool. In vitro, flux through SDH was predominant in both 24-h starved and glucagon-treated rats. Flux through SPT/AGT was enhanced by glucagon administration, but even after the induction, its contribution under quasi-physiological conditions (1 mM L-serine and 0.25 mM pyruvate) was about 1/10 of that through SDH. Flux through GCS accounted for only several percent of the amount of L-serine metabolized. Relative contributions of SDH and SPT/AGT to gluconeogenesis from L-serine were evaluated in vivo based on the principle that H-3 at the 3 position of L-serine is mostly removed in the SDH pathway, whereas it is largely retained in the SPT/AGT pathway. The results showed that SPT/AGT contributed only 10-20% even after the enhancement of its activity by glucagon. These results suggested that SDH is the major metabolic exit of L-serine in rat liver.	Hamamatsu Univ Sch Med, Dept Biochem 1, Shizuoka 4313192, Japan; Hamamatsu Univ Sch Med, Equipment Ctr, Shizuoka 4313192, Japan; Hamamatsu Univ Sch Med, Dept Surg 2, Shizuoka 4313192, Japan; Toyama Med & Pharmaceut Univ, Fac Med, Dept Biochem, Toyama 9300194, Japan; Univ Wisconsin, Inst Enzyme Res, Madison, WI 53706 USA; Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	Hamamatsu University School of Medicine; Hamamatsu University School of Medicine; Hamamatsu University School of Medicine; University of Toyama; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Ichiyama, A (corresponding author), Hamamatsu Univ Sch Med, Dept Biochem 1, 3600 Handa Cho, Shizuoka 4313192, Japan.			Xue, Hai-Hui/0000-0002-9163-7669				AIKAWA T, 1972, BIOCHIM BIOPHYS ACTA, V279, P234, DOI 10.1016/0304-4165(72)90139-0; AIKAWA T, 1973, J BIOCHEM, V74, P1003; BELIVEAU GP, 1982, J NUTR, V112, P686, DOI 10.1093/jn/112.4.686; Bergmeyer HU, 1974, METHODS ENZYMATIC AN; BHATIA SC, 1975, LIFE SCI, V17, P267, DOI 10.1016/0024-3205(75)90514-7; CHAN TM, 1971, BIOCHIM BIOPHYS ACTA, V237, P99, DOI 10.1016/0304-4165(71)90034-1; Cowin GJ, 1996, BBA-MOL CELL RES, V1310, P41, DOI 10.1016/0167-4889(95)00141-7; CYBULSKI RL, 1976, BIOCHEMISTRY-US, V15, P3183, DOI 10.1021/bi00660a004; DANPURE CJ, 1990, J CELL SCI, V97, P669; DANPURE CJ, 1995, METABOLIC MOL BASES, V2, P2385; DUVE CD, 1955, BIOCHEM J, V60, P604, DOI 10.1042/bj0600604; EXON JH, 1970, RECENT PROG HORM RES, V26, P411; FREEDLAND RA, 1964, J BIOL CHEM, V239, P3357; GELLER AM, 1989, ANAL BIOCHEM, V180, P120, DOI 10.1016/0003-2697(89)90098-5; HEDRICK JL, 1961, J BIOL CHEM, V236, P1867; HEDRICK JL, 1964, ARCH BIOCHEM BIOPHYS, V105, P261, DOI 10.1016/0003-9861(64)90007-4; HORNE DW, 1989, ARCH BIOCHEM BIOPHYS, V270, P729, DOI 10.1016/0003-9861(89)90556-0; ICHIYAMA A, 1970, J BIOL CHEM, V245, P1699; ICHIYAMA A, 1985, J BIOCHEM-TOKYO, V98, P1375, DOI 10.1093/oxfordjournals.jbchem.a135405; JOIS M, 1992, BIOCHEM J, V283, P435, DOI 10.1042/bj2830435; JOIS M, 1990, J BIOL CHEM, V265, P1246; KIKUCHI G, 1973, MOL CELL BIOCHEM, V1, P169, DOI 10.1007/BF01659328; KITAGAWA Y, 1979, BIOCHIM BIOPHYS ACTA, V582, P276, DOI 10.1016/0304-4165(79)90390-8; LARDY HA, 1965, P NATL ACAD SCI USA, V53, P1410, DOI 10.1073/pnas.53.6.1410; LARDY HA, 1969, FEBS S, V19, P55; MALLETTE LE, 1969, J BIOL CHEM, V244, P5713; MENDESMOURAO J, 1975, FEBS LETT, V53, P29, DOI 10.1016/0014-5793(75)80674-0; METZ T, 1972, H-S Z PHYSIOL CHEM, V353, P1496; NAKAGAWA H, 1967, BIOCHEM BIOPH RES CO, V28, P359, DOI 10.1016/0006-291X(67)90318-X; NOGUCHI T, 1978, J BIOL CHEM, V253, P7598; NORDLIE RC, 1963, J BIOL CHEM, V238, P2259; ODA T, 1989, J BIOCHEM-TOKYO, V106, P460, DOI 10.1093/oxfordjournals.jbchem.a122874; ODA T, 1982, J BIOCHEM, V91, P219, DOI 10.1093/oxfordjournals.jbchem.a133679; ODA T, 1990, J BIOL CHEM, V265, P7513; OGAWA H, 1995, HISTOCHEM J, V27, P380, DOI 10.1007/BF02389024; PANDE SV, 1978, J BIOL CHEM, V253, P1565; REMESY C, 1983, J NUTR, V113, P28, DOI 10.1093/jn/113.1.28; ROWSELL EV, 1979, COMP BIOCHEM PHYS B, V63, P543, DOI 10.1016/0305-0491(79)90061-0; RYAN WL, 1966, NATURE, V212, P292, DOI 10.1038/212292a0; SALLACH HJ, 1972, ENDOCRINOLOGY, V91, P1054, DOI 10.1210/endo-91-4-1054; SANDOVAL IV, 1974, EUR J BIOCHEM, V43, P609, DOI 10.1111/j.1432-1033.1974.tb03448.x; SNELL K, 1984, ADV ENZYME REGUL, V22, P325, DOI 10.1016/0065-2571(84)90021-9; SNELL K, 1974, BIOCHEM J, V142, P433, DOI 10.1042/bj1420433; TAKADA Y, 1982, COMP BIOCHEM PHYS B, V72, P597, DOI 10.1016/0305-0491(82)90512-0; UCHIDA C, 1994, J BIOL CHEM, V269, P8849; VARNER JE, 1957, METHOD ENZYMOL, V3, P397, DOI 10.1016/S0076-6879(57)03404-7; VENEZIAL.CM, 1967, BIOCHEMISTRY-US, V6, P2129, DOI 10.1021/bi00859a034; YOSHIDA T, 1969, BIOCHEM BIOPH RES CO, V35, P577, DOI 10.1016/0006-291X(69)90387-8; YOSHIDA T, 1970, ARCH BIOCHEM BIOPHYS, V139, P380, DOI 10.1016/0003-9861(70)90490-X; YOSHIDA T, 1972, J BIOCHEM, V72, P1503, DOI 10.1093/oxfordjournals.jbchem.a130042	50	37	39	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16020	16027		10.1074/jbc.274.23.16020	http://dx.doi.org/10.1074/jbc.274.23.16020			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347151	hybrid			2022-12-25	WOS:000080668600011
J	Dowell, P; Ishmael, JE; Avram, D; Peterson, VJ; Nevrivy, DJ; Leid, M				Dowell, P; Ishmael, JE; Avram, D; Peterson, VJ; Nevrivy, DJ; Leid, M			Identification of nuclear receptor corepressor as a peroxisome proliferator-activated receptor alpha interacting protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOID-X-RECEPTOR; LIGAND-BINDING DOMAIN; HORMONE RECEPTORS; PPAR-GAMMA; HISTONE ACETYLTRANSFERASE; DIFFERENTIAL EXPRESSION; FUNCTIONAL-ANALYSIS; ESTROGEN-RECEPTOR; RESPONSE ELEMENT; CO-REPRESSOR	Nuclear receptor corepressor (NCoR) was demonstrated to interact strongly with peroxisome proliferator-activated receptor alpha (PPAR alpha), and PPAR alpha ligands suppressed this interaction. In contrast to the interaction of PPAR alpha with the coactivator protein, p300, association of the receptor with NCoR did not require any part of the PPAR alpha ligand binding domain. NCoR was found to suppress PPAR alpha-dependent transcriptional activation in the context of a PPAR alpha.retinoid X receptor alpha (RXR alpha) heterodimeric complex bound to a peroxisome proliferator-responsive element in human embryonic kidney 293 cells. This repression was reversed agonists of either receptor demonstrating a functional interaction between NCoR and PPAR alpha.RXR alpha heterodimeric complexes in mammalian cells. NCoR appears to influence PPARa signaling pathways and, therefore, may modulate tissue responsiveness to peroxisome proliferators.	Oregon State Univ, Coll Pharm, Mol Pharmacol Lab, Corvallis, OR 97331 USA; Oregon State Univ, Coll Pharm, Mol & Cellular Biol Program, Corvallis, OR 97331 USA	Oregon State University; Oregon State University	Leid, M (corresponding author), Oregon State Univ, Coll Pharm, Mol Pharmacol Lab, Corvallis, OR 97331 USA.				NIEHS NIH HHS [ES00040] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES000040] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Avram D, 1999, J BIOL CHEM, V274, P14331, DOI 10.1074/jbc.274.20.14331; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BARDOT O, 1993, BIOCHEM BIOPH RES CO, V192, P37, DOI 10.1006/bbrc.1993.1378; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; Dowell P, 1997, J BIOL CHEM, V272, P2013, DOI 10.1074/jbc.272.3.2013; Dowell P, 1997, J BIOL CHEM, V272, P33435, DOI 10.1074/jbc.272.52.33435; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; GEARING KL, 1993, P NATL ACAD SCI USA, V90, P1440, DOI 10.1073/pnas.90.4.1440; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; Green S, 1995, MUTAT RES-FUND MOL M, V333, P101, DOI 10.1016/0027-5107(95)00136-0; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; ISSEMANN I, 1993, BIOCHIMIE, V75, P251, DOI 10.1016/0300-9084(93)90084-6; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LAKE BG, 1995, ANNU REV PHARMACOL, V35, P483, DOI 10.1146/annurev.pa.35.040195.002411; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; LEDOUARIN B, 1995, NUCLEIC ACIDS RES, V23, P876, DOI 10.1093/nar/23.5.876; LEID M, 1994, J BIOL CHEM, V269, P14175; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; Lemberger T, 1996, ANNU REV CELL DEV BI, V12, P335, DOI 10.1146/annurev.cellbio.12.1.335; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; OMALLEY BW, 1992, BIOL REPROD, V46, P163, DOI 10.1095/biolreprod46.2.163; ONATE SA, 1995, SCIENCE, V270, P1354; PIERRAT B, 1992, GENE, V119, P237, DOI 10.1016/0378-1119(92)90277-V; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Schoonjans K, 1996, BBA-LIPID LIPID MET, V1302, P93, DOI 10.1016/0005-2760(96)00066-5; Schulman IG, 1998, MOL CELL BIOL, V18, P3483, DOI 10.1128/MCB.18.6.3483; Seol W, 1996, MOL ENDOCRINOL, V10, P1646, DOI 10.1210/me.10.12.1646; SEOL WG, 1995, MOL ENDOCRINOL, V9, P72, DOI 10.1210/me.9.1.72; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; TONTONOZ P, 1994, NUCLEIC ACIDS RES, V22, P5628, DOI 10.1093/nar/22.25.5628; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; Varanasi U, 1996, J BIOL CHEM, V271, P2147, DOI 10.1074/jbc.271.4.2147; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; Zamir I, 1997, GENE DEV, V11, P835, DOI 10.1101/gad.11.7.835; Zhu YJ, 1996, GENE EXPRESSION, V6, P185; Zhu YJ, 1997, J BIOL CHEM, V272, P25500, DOI 10.1074/jbc.272.41.25500	57	108	112	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15901	15907		10.1074/jbc.274.22.15901	http://dx.doi.org/10.1074/jbc.274.22.15901			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336495	hybrid			2022-12-25	WOS:000080560100084
J	Lievremont, JP; Sciorati, C; Morandi, E; Paolucci, C; Bunone, G; Della Valle, G; Meldolesi, J; Clementi, E				Lievremont, JP; Sciorati, C; Morandi, E; Paolucci, C; Bunone, G; Della Valle, G; Meldolesi, J; Clementi, E			The p75(NTR)-induced apoptotic program develops through a ceramide-caspase pathway negatively regulated by nitric oxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P75 NEUROTROPHIN RECEPTOR; NERVE GROWTH-FACTOR; AFFINITY NGF RECEPTOR; NF-KAPPA-B; CELL-DEATH; INTRACELLULAR DOMAIN; NEURONAL APOPTOSIS; FAMILY PROTEASES; T-LYMPHOCYTES; SYSTEM	SK-N-BE neuroblastoma cell clones transfected with p75(NTR) and lacking Trk neurotrophin receptors, previously reported to undergo extensive spontaneous apoptosis and to be protected by nerve growth factor (NGF) (Bunone, G., Mariotti, A., Compagni, A., Morandi, E., and Della Valle, G:. (1997) Oncogene 14, 1463-1470), are shown to exhibit (i) increased levels of the pro-apoptotic lipid metabolite ceramide and (ii) high activity of caspases, the proteases of the cell death cascade. In the p75(NTR) expressing cells, these parameters were partially normalized by prolonged NGF treatment, which, in addition, decreased apoptosis, similar to caspase blockers. Conversely, exogenous ceramide increased caspase activity and apoptosis in both wild-type and p75(NTR)-expressing cells. A new p75(NTR)-expressing clone characterized by low spontaneous apoptosis exhibited high endogenous ceramide and low caspase levels. A marked difference between the apoptotic and resistant clones concerned the very low and high activities of nitric-oxide (NO) synthase, respectively. Protection from apoptosis by NO was confirmed by results with the NO donor S-nitrosoacetylpenicillamine and the NO-trapping agent hemoglobin, We conclude that the p75NTR receptor, while free of NGF, triggers a cascade leading to apoptosis; the cascade includes generation of ceramide and increased caspase activity; and the protective role of NO occurs at step(s) in between the latter events.	San Raffaele Sci Inst, Dept Neurosci, DIBIT, I-20132 Milan, Italy; Univ Milan, Consiglio Nazl Ric, Ctr Mol & Cellular Pharmacol, Dept Pharmacol, I-20132 Milan, Italy; Univ Milan, Consiglio Nazl Ric, Ctr Mol & Cellular Pharmacol, Bruno Ceccarelli Ctr, I-20132 Milan, Italy; Univ Pavia, Dept Genet & Microbiol, I-27100 Pavia, Italy; Natl Canc Inst, I-20129 Milan, Italy; Univ Bologna, Dept Biol, I-40126 Bologna, Italy; Univ Calabria, Sch Pharm, Dept Pharmacol, I-87036 Arcavacata, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Milan; Consiglio Nazionale delle Ricerche (CNR); University of Milan; University of Pavia; Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Bologna; University of Calabria	Meldolesi, J (corresponding author), San Raffaele Sci Inst, Dept Neurosci, DIBIT, Via Olgettina 58, I-20132 Milan, Italy.		sciorati, clara/K-4823-2016	sciorati, clara/0000-0003-2030-9366				Aloyz RS, 1998, J CELL BIOL, V143, P1691, DOI 10.1083/jcb.143.6.1691; BARRETT GL, 1994, P NATL ACAD SCI USA, V91, P6501, DOI 10.1073/pnas.91.14.6501; Bredesen DE, 1997, TRENDS NEUROSCI, V20, P287, DOI 10.1016/S0166-2236(96)01049-1; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; Bunone G, 1997, ONCOGENE, V14, P1463, DOI 10.1038/sj.onc.1200972; CasacciaBonnefil P, 1996, NATURE, V383, P716, DOI 10.1038/383716a0; CHAO MV, 1995, TRENDS NEUROSCI, V18, P321, DOI 10.1016/0166-2236(95)93922-K; CIFONE MG, 1995, EMBO J, V14, P5859, DOI 10.1002/j.1460-2075.1995.tb00274.x; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; Farschon DM, 1997, J CELL BIOL, V137, P1117, DOI 10.1083/jcb.137.5.1117; FERRARINI M, 1995, J IMMUNOL, V154, P3704; Frade JM, 1996, NATURE, V383, P166; GREENE LA, 1995, CURR OPIN NEUROBIOL, V5, P579, DOI 10.1016/0959-4388(95)80062-X; Hebestreit H, 1998, J EXP MED, V187, P415, DOI 10.1084/jem.187.3.415; Hehner SP, 1998, J BIOL CHEM, V273, P18117, DOI 10.1074/jbc.273.29.18117; Henderson Z, 1996, PROG NEUROBIOL, V48, P219, DOI 10.1016/0301-0082(95)00041-0; Heumann Rolf, 1994, Current Opinion in Neurobiology, V4, P668, DOI 10.1016/0959-4388(94)90008-6; Ladiwala U, 1998, J NEUROSCI, V18, P1297; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; LIPTON SA, 1993, NATURE, V364, P577; MacPhee IJ, 1997, J BIOL CHEM, V272, P23547, DOI 10.1074/jbc.272.38.23547; Majdan M, 1997, J NEUROSCI, V17, P6988; Maliartchouk S, 1997, J NEUROSCI, V17, P6031; Mannick JB, 1997, J BIOL CHEM, V272, P24125, DOI 10.1074/jbc.272.39.24125; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Miller FD, 1998, CELL DEATH DIFFER, V5, P343, DOI 10.1038/sj.cdd.4400385; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nicotera P, 1997, TRENDS PHARMACOL SCI, V18, P189, DOI 10.1016/S0165-6147(97)90619-2; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; Rooney E, 1996, J BIOL CHEM, V271, P29304, DOI 10.1074/jbc.271.46.29304; ROSKAMS AJ, 1994, NEURON, V13, P289; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Samdani AF, 1997, J NEUROSCI, V17, P4633; Schwandner R, 1998, J BIOL CHEM, V273, P5916, DOI 10.1074/jbc.273.10.5916; Sciorati C, 1997, J BIOL CHEM, V272, P23211, DOI 10.1074/jbc.272.37.23211; Srinivasan A, 1996, J NEUROSCI, V16, P5654; Stefanis L, 1997, CURR OPIN NEUROL, V10, P299, DOI 10.1097/00019052-199708000-00004; Tenneti L, 1997, NEUROSCI LETT, V236, P139, DOI 10.1016/S0304-3940(97)00780-5; VERDI JM, 1994, NEURON, V12, P733, DOI 10.1016/0896-6273(94)90327-1; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; WILLIAMS CV, 1994, J NEUROSCI, V14, P1746, DOI 10.1523/JNEUROSCI.14-03-01746.1994; WU HH, 1994, SCIENCE, V265, P1593, DOI 10.1126/science.7521541; Yun HY, 1996, CRIT REV NEUROBIOL, V10, P291, DOI 10.1615/CritRevNeurobiol.v10.i3-4.20; ZHANG J, 1995, ANNU REV PHARMACOL, V35, P213	46	46	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15466	15472		10.1074/jbc.274.22.15466	http://dx.doi.org/10.1074/jbc.274.22.15466			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336437	hybrid			2022-12-25	WOS:000080560100026
J	Webb, BL; Cox, MM; Inman, RB				Webb, BL; Cox, MM; Inman, RB			ATP hydrolysis and DNA binding by the Escherichia coli RecF protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; GENETIC-RECOMBINATION; POSTREPLICATION REPAIR; EXCISION REPAIR; PURIFICATION; MUTATIONS; FILAMENTS; PATHWAY; K-12; TRIPHOSPHATE	The Escherichia coli RecF protein possesses a weak ATP hydrolytic activity. ATP hydrolysis leads to RecF dissociation from double-stranded (ds)DNA, The RecF protein is subject to precipitation and an accompanying inactivation in vitro when not bound to DNA. A mutant RecF protein that can bind but cannot hydrolyze ATP (RecF K36R) does not readily dissociate from dsDNA in the presence of ATP. This is in contrast to the limited dsDNA binding observed for wild-type RecF protein in the presence of ATP but is similar to dsDNA binding by wild-type RecF binding in the presence of the nonhydrolyzable ATP analog, adenosine 5'-O-(3-thio)triphosphate (ATPyS). In addition, wild-type RecF protein binds tightly to dsDNA in the presence of ATP at low pH where its ATPase activity is blocked. A transfer of RecF protein from labeled to unlabeled dsDNA is observed in the presence of ATP but not ATP gamma S. The transfer is slowed considerably when the RecR protein is also present. In competition experiments, RecF protein appears to bind at random locations on dsDNA and exhibits no special affinity for single strand/double strand junctions when bound to gapped DNA. Possible roles for the ATPase activity of RecF in the regulation of recombinational DNA repair are discussed.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Cox, MM (corresponding author), Univ Wisconsin, Dept Biochem, 420 Henry Mall, Madison, WI 53706 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM014711, R01GM052725] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52725, GM14711] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ayora S, 1997, NUCLEIC ACIDS RES, V25, P2766, DOI 10.1093/nar/25.14.2766; Bjornson KP, 1996, J MOL BIOL, V263, P411, DOI 10.1006/jmbi.1996.0585; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLARK AJ, 1994, CRIT REV MICROBIOL, V20, P125, DOI 10.3109/10408419409113552; COHEN A, 1983, MOL GEN GENET, V189, P471, DOI 10.1007/BF00325911; Courcelle J, 1997, P NATL ACAD SCI USA, V94, P3714, DOI 10.1073/pnas.94.8.3714; Cox MM, 1998, GENES CELLS, V3, P65, DOI 10.1046/j.1365-2443.1998.00175.x; GRIFFIN TJ, 1990, J BACTERIOL, V172, P6291, DOI 10.1128/jb.172.11.6291-6299.1990; HEGDE S, 1995, MOL GEN GENET, V246, P254, DOI 10.1007/BF00294689; Hegde SP, 1996, J BACTERIOL, V178, P184, DOI 10.1128/jb.178.1.184-190.1996; HORII ZI, 1973, J MOL BIOL, V80, P327, DOI 10.1016/0022-2836(73)90176-9; Huang LC, 1997, J BACTERIOL, V179, P6076, DOI 10.1128/jb.179.19.6076-6083.1997; LINDSLEY JE, 1989, J MOL BIOL, V205, P695, DOI 10.1016/0022-2836(89)90315-X; LINDSLEY JE, 1990, J BIOL CHEM, V265, P10164; LOHMAN TM, 1989, J BIOL CHEM, V264, P10139; MADIRAJU MVVS, 1992, J BACTERIOL, V174, P7705, DOI 10.1128/JB.174.23.7705-7710.1992; MADIRAJU MVVS, 1991, NUCLEIC ACIDS RES, V19, P6295, DOI 10.1093/nar/19.22.6295; MARRIONE PE, 1995, BIOCHEMISTRY-US, V34, P9809, DOI 10.1021/bi00030a019; REHRAUER WM, 1993, J BIOL CHEM, V268, P1292; ROTHMAN RH, 1977, MOL GEN GENET, V155, P279, DOI 10.1007/BF00272806; Sandler SJ, 1996, MOL MICROBIOL, V19, P871, DOI 10.1046/j.1365-2958.1996.429959.x; SANDLER SJ, 1993, GENETICS, V135, P643; SANDLER SJ, 1992, NUCLEIC ACIDS RES, V20, P839, DOI 10.1093/nar/20.4.839; SEELEY TW, 1989, P NATL ACAD SCI USA, V86, P6577, DOI 10.1073/pnas.86.17.6577; Shan Q, 1997, J MOL BIOL, V265, P519, DOI 10.1006/jmbi.1996.0748; Shan Q, 1996, J BIOL CHEM, V271, P5712, DOI 10.1074/jbc.271.10.5712; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; THIAGALINGAM S, 1991, J BIOL CHEM, V266, P11395; TSENG YC, 1994, MUTAT RES, V315, P1; UMEZU K, 1994, J BIOL CHEM, V269, P30005; Webb BL, 1997, CELL, V91, P347, DOI 10.1016/S0092-8674(00)80418-3; Webb BL, 1995, J BIOL CHEM, V270, P31397, DOI 10.1074/jbc.270.52.31397; WHITBY MC, 1995, MOL GEN GENET, V246, P174, DOI 10.1007/BF00294680	34	33	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15367	15374		10.1074/jbc.274.22.15367	http://dx.doi.org/10.1074/jbc.274.22.15367			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336423	hybrid			2022-12-25	WOS:000080560100012
J	Bakker, BM; Michels, PAM; Opperdoes, FR; Westerhoff, HV				Bakker, BM; Michels, PAM; Opperdoes, FR; Westerhoff, HV			What controls glycolysis in bloodstream form Trypanosoma brucei?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-STREAM FORM; GLYCOSOMAL GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; PYRUVATE-KINASE; FRUCTOSE 2,6-BISPHOSPHATE; SACCHAROMYCES-CEREVISIAE; KINETIC CHARACTERIZATION; CARBOHYDRATE-METABOLISM; GLUCOSE TRANSPORTERS; ENZYMES; PHOSPHOFRUCTOKINASE	On the basis of the experimentally determined kinetic properties of the trypanosomal enzymes, the question is addressed of which step limits the glycolytic flux in bloodstream form Trypanosoma brucei. There appeared to be no single answer; in the physiological range, control shifted between the glucose transporter on the one hand and aldolase (ALD), glyceraldehyde-3-phosphate dehydrogenase (GAPBH), phosphoglycerate kinase (PGK), and glycerol-3-phosphate dehydrogenase (GDH) on the other hand. The other kinases, which are often thought to control glycolysis, exerted little control; so did the utilization of ATP. We identified potential targets for anti-trypanosomal drugs by calculating which steps need the least inhibition to achieve a certain inhibition of the glycolytic flux in these parasites. The glucose transporter appeared to be the most promising target, followed by ALD, GDH, GAPDH, and PGK, By contrast, in erythrocytes more than 95% deficiencies of PGK, GAPDH, or ALD did not cause any clinical symptoms (Schuster, R. and Holzhutter, H.-G. (1995) fur. J. Biochem. 229, 403-418), Therefore, the selectivity of drugs inhibiting these enzymes may be much higher than expected from their molecular effects alone, Quite unexpectedly trypanosomes seem to possess a substantial overcapacity of hexokinase, phosphofructokinase, and pyruvate kinase, making these "irreversible" enzymes mediocre drug targets.	Free Univ Amsterdam, BioCtr Amsterdam, NL-1081 HV Amsterdam, Netherlands; Univ Amsterdam, EC Slater Inst Biochem Res, BioCtr Amsterdam, NL-1018 TV Amsterdam, Netherlands; Catholic Univ Louvain, Christian de Duve Inst Cellular Pathol, Trop Dis Res Unit, B-1200 Brussels, Belgium; Catholic Univ Louvain, Biochem Lab, B-1200 Brussels, Belgium	University of Amsterdam; Vrije Universiteit Amsterdam; University of Amsterdam; Universite Catholique Louvain; Universite Catholique Louvain	Westerhoff, HV (corresponding author), Free Univ Amsterdam, BioCtr Amsterdam, De Boelelaan 1087, NL-1081 HV Amsterdam, Netherlands.	hw@bio.vu.nl	Opperdoes, Frederik R/C-8897-2018; Westerhoff, Hans V/I-5762-2012; Michels, Paul A/A-5637-2009; Opperdoes, Fred/N-9922-2019	Opperdoes, Frederik R/0000-0003-1984-3764; Westerhoff, Hans V/0000-0002-0443-6114; Michels, Paul A/0000-0003-3726-6104; Opperdoes, Fred/0000-0003-1984-3764; Bakker, Barbara/0000-0001-6274-3633				Bakker BM, 1995, J BIOENERG BIOMEMBR, V27, P513, DOI 10.1007/BF02110191; Bakker BM, 1997, J BIOL CHEM, V272, P3207, DOI 10.1074/jbc.272.6.3207; Bakker BM, 1996, BIOTHERMOKINETICS LI, P136; BARNARD JP, 1988, MOL BIOCHEM PARASIT, V31, P141, DOI 10.1016/0166-6851(88)90165-X; Bergmeyer HU, 1974, METHODS ENZYMATIC AN; Bernstein BE, 1997, NATURE, V385, P275, DOI 10.1038/385275a0; BURNS JA, 1985, TRENDS BIOCHEM SCI, V10, P16, DOI 10.1016/0968-0004(85)90008-8; CALLENS M, 1991, MOL BIOCHEM PARASIT, V47, P19, DOI 10.1016/0166-6851(91)90144-U; CALLENS M, 1992, MOL BIOCHEM PARASIT, V50, P235, DOI 10.1016/0166-6851(92)90220-E; Colowick SP., 1973, ENZYMES, V9, P1, DOI DOI 10.1016/S1874-6047(08)60113-4; CRONIN CN, 1985, BIOCHEM J, V227, P113, DOI 10.1042/bj2270113; CRONIN CN, 1987, BIOCHEM J, V245, P13, DOI 10.1042/bj2450013; DAVIES SEC, 1992, BIOCHEMISTRY-US, V31, P4729, DOI 10.1021/bi00134a028; EISENTHAL R, 1985, FEBS LETT, V181, P23, DOI 10.1016/0014-5793(85)81106-6; EISENTHAL R, 1989, BIOCHIM BIOPHYS ACTA, V985, P81, DOI 10.1016/0005-2736(89)90107-7; FAIRLAMB AH, 1977, NATURE, V265, P270, DOI 10.1038/265270a0; Fell D., 1997, UNDERSTANDING CONTRO; FRANKEL S, 1963, GRADWOHLS CLIN LAB M, V1; GIFFIN BF, 1989, AM J TROP MED HYG, V40, P487, DOI 10.4269/ajtmh.1989.40.487; GOULD GW, 1991, BIOCHEMISTRY-US, V30, P5139, DOI 10.1021/bi00235a004; GROEN AK, 1982, J BIOL CHEM, V257, P2754; GRUENBERG J, 1978, EUR J BIOCHEM, V89, P461, DOI 10.1111/j.1432-1033.1978.tb12549.x; HAMMOND DJ, 1980, MOL BIOCHEM PARASIT, V2, P77, DOI 10.1016/0166-6851(80)90033-X; HAMMOND DJ, 1985, J BIOL CHEM, V260, P5646; HAMMOND DJ, 1980, MOL BIOCHEM PARASIT, V2, P63, DOI 10.1016/0166-6851(80)90032-8; HANNAERT V, 1994, J BIOENERG BIOMEMBR, V26, P205, DOI 10.1007/BF00763069; HENRY RJ, 1974, CLIN CHEM PRINCIPLES; HOFMEYR JHS, 1991, EUR J BIOCHEM, V200, P223, DOI 10.1111/j.1432-1033.1991.tb21071.x; JENSEN PR, 1993, EMBO J, V12, P1277, DOI 10.1002/j.1460-2075.1993.tb05772.x; Kacser H, 1973, Symp Soc Exp Biol, V27, P65; KASHIWAYA Y, 1994, J BIOL CHEM, V269, P25502; KHOLODENKO BN, 1995, BIOPHYS CHEM, V56, P215, DOI 10.1016/0301-4622(95)00039-Z; Kholodenko BN, 1996, BIOCHEM J, V314, P753, DOI 10.1042/bj3140753; KIAIRA JK, 1994, BIOTECHNOL APPL BIOC, V20, P347, DOI 10.1111/j.1470-8744.1994.tb00322.x; KIM HD, 1995, BIOCHEMISTRY-US, V34, P14975, DOI 10.1021/bi00046a004; Kruckeberg AL, 1996, ARCH MICROBIOL, V166, P283, DOI 10.1007/s002030050385; KRUPKA RM, 1980, BIOCHIM BIOPHYS ACTA, V598, P134, DOI 10.1016/0005-2736(80)90271-0; LANHAM SM, 1968, NATURE, V218, P1273, DOI 10.1038/2181273a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MICHELS PAM, 1994, J BIOENERG BIOMEMBR, V26, P213, DOI 10.1007/BF00763070; MICHELS PAM, 1988, BIOL CELL, V64, P157, DOI 10.1016/0248-4900(88)90075-5; MISSET O, 1986, EUR J BIOCHEM, V157, P441, DOI 10.1111/j.1432-1033.1986.tb09687.x; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; NWAGWU M, 1982, ACTA TROP, V39, P61; OPPERDOES FR, 1977, FEBS LETT, V80, P360, DOI 10.1016/0014-5793(77)80476-6; OPPERDOES FR, 1987, ANNU REV MICROBIOL, V41, P127, DOI 10.1146/annurev.mi.41.100187.001015; PERIE J, 1993, PHARMACOL THERAPEUT, V60, P347, DOI 10.1016/0163-7258(93)90016-7; POOLMAN B, 1987, J BACTERIOL, V169, P5887, DOI 10.1128/jb.169.12.5887-5890.1987; RAPOPORT TA, 1974, EUR J BIOCHEM, V42, P107, DOI 10.1111/j.1432-1033.1974.tb03320.x; Rohwer JM, 1996, J THEOR BIOL, V179, P213, DOI 10.1006/jtbi.1996.0062; RUIJTER GJG, 1991, J BACTERIOL, V173, P6184; SAURO HM, 1991, MATH COMPUT MODEL, V15, P15, DOI 10.1016/0895-7177(91)90038-9; SCHAAFF I, 1989, YEAST, V5, P285, DOI 10.1002/yea.320050408; SCHUSTER R, 1995, EUR J BIOCHEM, V229, P403, DOI 10.1111/j.1432-1033.1995.0403k.x; SCHUSTER S, 1993, BIOPHYS CHEM, V48, P1, DOI 10.1016/0301-4622(93)80037-J; SEYFANG A, 1991, EUR J BIOCHEM, V202, P191, DOI 10.1111/j.1432-1033.1991.tb16362.x; SHULMAN RG, 1995, P NATL ACAD SCI USA, V92, P8535, DOI 10.1073/pnas.92.19.8535; Snoep JL, 1996, BIOTECHNOL BIOENG, V51, P190, DOI 10.1002/(SICI)1097-0290(19960720)51:2<190::AID-BIT8>3.0.CO;2-E; STANBURY JB, 1993, METABOLIC BASIS INHE; TERKUILE BH, 1991, J BIOL CHEM, V266, P857; VANCALENBERGH S, 1995, J MED CHEM, V38, P3838, DOI 10.1021/jm00019a014; VANSCHAFTINGEN E, 1985, EUR J BIOCHEM, V153, P403, DOI 10.1111/j.1432-1033.1985.tb09316.x; VANSCHAFTINGEN E, 1987, EUR J BIOCHEM, V166, P653; VELLIEUX FMD, 1993, P NATL ACAD SCI USA, V90, P2355, DOI 10.1073/pnas.90.6.2355; VERLINDE CLMJ, 1994, J MED CHEM, V37, P3605, DOI 10.1021/jm00047a017; VISSER N, 1981, EUR J BIOCHEM, V118, P521, DOI 10.1111/j.1432-1033.1981.tb05550.x; VISSER N, 1980, EUR J BIOCHEM, V103, P623, DOI 10.1111/j.1432-1033.1980.tb05988.x; Westerhoff H., 1987, THERMODYNAMICS CONTR; WILLSON M, 1994, BIOCHEMISTRY-US, V33, P214, DOI 10.1021/bi00167a028	69	145	150	2	22	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					14551	14559		10.1074/jbc.274.21.14551	http://dx.doi.org/10.1074/jbc.274.21.14551			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329645	hybrid, Green Published			2022-12-25	WOS:000081965200010
J	Manthey, D; Bukauskas, F; Lee, CG; Kozak, CA; Willecke, K				Manthey, D; Bukauskas, F; Lee, CG; Kozak, CA; Willecke, K			Molecular cloning and functional expression of the mouse gap junction gene connexin-57 in human HeLa cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOSOMAL ASSIGNMENTS; CHANNELS; PROTEINS; FAMILY; PH; HYBRIDIZATION; SEQUENCE; PAIRS; BRAIN; CDNA	A new mouse connexin gene has been isolated that codes for a connexin protein of 505 amino acid residues. Based on the predicted molecular mass of 57.115 kDa, it has been designated connexin-57. Similar to most other mouse connexin genes, the coding region of connexin-57 is not interrupted by introns and exists in the mouse genome as a single-copy gene. Within the connexin family, this new gene shows highest sequence identity to porcine connexin-60 in the Lu group of connexins. The connexin-57 gene was mapped to a position on mouse chromosome 4, 30 centimorgans proximal to a cluster of previously mapped connexin genes. Low levels of connexin-57 mRNA were detected in skin, heart, kidney, testis, ovary, intestine, and in the mouse embryo after 8 days post coitum, but expression was not detected in brain, sciatic nerve or liver. In order to analyze gene function, the connexin-57 coding region was expressed by transfection in human HeLa cells, where it restored homotypic intercellular transfer of microinjected neurobiotin. Heterotypic transfer was observed between HeLa connexin-57 transfectants and HeLa cells, expressing murine connexin-83, -37, or -30.3. Double whole-cell voltage clamp analyses revealed that HeLa-connexin-57 transfectants expressed about 10 times more channels than parental HeLa cells. Voltage gating by transjunctional and transmembrane voltages as well as unitary conductance (similar to 27 picosiemens) were different from intrinsic connexin channels in parental HeLa cells.	Univ Bonn, Genet Inst, D-53117 Bonn, Germany; Yeshiva Univ Albert Einstein Coll Med, Dept Neurosci, Bronx, NY 10461 USA; Kaunas Med Univ, Lab Excitable Struct, Kaunas, Lithuania; NIAID, Mol Microbiol Lab, NIH, Bethesda, MD 20892 USA	University of Bonn; Yeshiva University; Albert Einstein College of Medicine; Lithuanian University of Health Sciences; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Willecke, K (corresponding author), Univ Bonn, Genet Inst, Romerstr 164, D-53117 Bonn, Germany.	genetik@uni-bonn.de			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000301] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMSON MC, 1991, VIROLOGY, V183, P778, DOI 10.1016/0042-6822(91)91010-E; Barrio LC, 1997, BIOPHYS J, V73, P757, DOI 10.1016/S0006-3495(97)78108-6; Bevans CG, 1998, J BIOL CHEM, V273, P2808, DOI 10.1074/jbc.273.5.2808; BEYER EC, 1988, INT REV CYTOL C, V137, P231; Bruzzone R, 1996, EUR J BIOCHEM, V238, P1, DOI 10.1111/j.1432-1033.1996.0001q.x; BUKAUSKAS F, 1992, J PHYSIOL-LONDON, V448, P321, DOI 10.1113/jphysiol.1992.sp019044; BUKAUSKAS FF, 1995, BIOPHYS J, V68, P2289, DOI 10.1016/S0006-3495(95)80411-X; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Condorelli DF, 1998, EUR J NEUROSCI, V10, P1202, DOI 10.1046/j.1460-9568.1998.00163.x; Dahl E, 1996, J BIOL CHEM, V271, P17903, DOI 10.1074/jbc.271.30.17903; Delmar M, 1998, GAP JUNCTIONS, P8; ECKERT R, 1993, PFLUG ARCH EUR J PHY, V424, P335, DOI 10.1007/BF00384361; EK JF, 1994, CIRC RES, V74, P1058, DOI 10.1161/01.RES.74.6.1058; ELFGANG C, 1995, J CELL BIOL, V129, P805, DOI 10.1083/jcb.129.3.805; Fusenig N E, 1985, Carcinog Compr Surv, V9, P293; FUSENIG NE, 1983, J INVEST DERMATOL, V81, pS168, DOI 10.1111/1523-1747.ep12541032; GIMLICH RL, 1990, J CELL BIOL, V110, P597, DOI 10.1083/jcb.110.3.597; GOLDBERG GS, 1995, BIOTECHNIQUES, V18, P490; HAEFLIGER JA, 1992, J BIOL CHEM, V267, P2057; HANAUER A, 1984, EMBO J, V3, P2627, DOI 10.1002/j.1460-2075.1984.tb02185.x; HENNEMANN H, 1992, EUR J CELL BIOL, V57, P51; HENNEMANN H, 1992, EUR J CELL BIOL, V58, P81; HENNEMANN H, 1992, J CELL BIOL, V117, P1299, DOI 10.1083/jcb.117.6.1299; HORST M, 1991, J BIOL CHEM, V266, P13914; Itahana K, 1998, ENDOCRINOLOGY, V139, P320, DOI 10.1210/en.139.1.320; Itahana K, 1996, ENDOCRINOLOGY, V137, P5036, DOI 10.1210/en.137.11.5036; Jiang JX, 1996, P NATL ACAD SCI USA, V93, P1287, DOI 10.1073/pnas.93.3.1287; KOZAK CA, 1990, GENOMICS, V8, P519, DOI 10.1016/0888-7543(90)90039-W; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAIRD DW, 1990, J CELL SCI, V97, P109; MILKS LC, 1988, EMBO J, V7, P2967, DOI 10.1002/j.1460-2075.1988.tb03159.x; Morley GE, 1996, BIOPHYS J, V70, P1294, DOI 10.1016/S0006-3495(96)79686-8; NEYTON J, 1985, NATURE, V317, P331, DOI 10.1038/317331a0; O'Brien J, 1998, J NEUROSCI, V18, P7625; OBAID AL, 1983, J MEMBRANE BIOL, V73, P69, DOI 10.1007/BF01870342; PAUL DL, 1995, CURR OPIN CELL BIOL, V7, P665, DOI 10.1016/0955-0674(95)80108-1; Peracchia C, 1997, BRAZ J MED BIOL RES, V30, P577, DOI 10.1590/S0100-879X1997000500003; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHWARZ HJ, 1994, SOMAT CELL MOLEC GEN, V20, P243, DOI 10.1007/BF02254763; SCHWARZ HJ, 1992, SOMAT CELL MOLEC GEN, V18, P351, DOI 10.1007/BF01235758; SHAPER NL, 1990, CYTOGENET CELL GENET, V54, P172, DOI 10.1159/000132987; Simon AM, 1997, NATURE, V385, P525, DOI 10.1038/385525a0; SOHL G, 1998, EUR J CELL BIOL, V69, P27; STAUFFER KA, 1995, J BIOL CHEM, V270, P6768; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829; VERSELIS VK, 1991, BIOPHYS J, V59, P114, DOI 10.1016/S0006-3495(91)82204-4; WEINGART R, 1986, J PHYSIOL-LONDON, V370, P267, DOI 10.1113/jphysiol.1986.sp015934; WHITE TW, 1995, MOL BIOL CELL, V6, P459, DOI 10.1091/mbc.6.4.459; Willecke K, 1999, NOVART FDN SYMP, V219, P76; WILLECKE K, 1991, J CELL BIOL, V114, P1049, DOI 10.1083/jcb.114.5.1049; Willecke K, 1996, J BIOENERG BIOMEMBR, V28, P319, DOI 10.1007/BF02110108; ZHANG JT, 1994, J MEMBRANE BIOL, V139, P15	53	82	85	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					14716	14723		10.1074/jbc.274.21.14716	http://dx.doi.org/10.1074/jbc.274.21.14716			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329667	hybrid			2022-12-25	WOS:000081965200032
J	Rhee, CH; Hess, K; Jabbur, J; Ruiz, M; Yang, Y; Chen, S; Chenchik, A; Fuller, GN; Zhang, W				Rhee, CH; Hess, K; Jabbur, J; Ruiz, M; Yang, Y; Chen, S; Chenchik, A; Fuller, GN; Zhang, W			cDNA expression array reveals heterogeneous gene expression profiles in three glioblastoma cell lines	ONCOGENE			English	Article						gene expression; glioblastoma; cDNA array	TUMOR-SUPPRESSOR GENE; P53; GROWTH; INHIBITION; INDUCTION; CANDIDATE; DPC4	Tumor cell lines are an indispensable tool for cancer research. However, among cell lines of the same pathological group, heterogeneity has been detected in gene expression, gene mutation, and cellular response to various treatments. In this study, we systematically investigated the extent of heterogeneity of gene expression in three glioblastoma cell lines using cDNA array technology in which the expression of 588 cellular genes is studied simultaneously. Comparison of the expression profiles revealed substantial qualitative and quantitative heterogeneity, Among the 588 genes, 197 genes were expressed in all three lines and 56 genes were not expressed in any of the three lines; total of 222 genes were expressed in only two of the three cell lines, acid 113 genes were expressed in only one of the three cell lines. These results provide molecular evidence that cell lines of the same pathological origin can be highly heterogeneous.	Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biomath, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Clontech Labs Inc, Palo Alto, CA 94303 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Zhang, W (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA.		Hess, Kenneth/K-6546-2019	Hess, Kenneth/0000-0003-1377-6070; Fuller, Gregory/0000-0001-9447-2647	NATIONAL CANCER INSTITUTE [R29CA067987, P01CA055164] Funding Source: NIH RePORTER; NCI NIH HHS [CA67987, CA55164] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		DIMERY IW, 1983, EXP HEMATOL, V11, P601; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Grau AM, 1997, CANCER RES, V57, P3929; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HOLLIDAY R, 1989, TRENDS GENET, V5, P42, DOI 10.1016/0168-9525(89)90020-6; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JUNG JM, 1995, CELL GROWTH DIFFER, V6, P909; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KASTAN MB, 1991, CANCER RES, V51, P6304; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; NOWELL PC, 1986, CANCER RES, V46, P2203; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; VAN MEIR EG, 1994, CANCER RES, V54, P649; WEINBERG RA, 1989, CANCER RES, V49, P3713; ZHANG W, 1995, CANCER RES, V55, P668	16	55	59	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 29	1999	18	17					2711	2717		10.1038/sj.onc.1202623	http://dx.doi.org/10.1038/sj.onc.1202623			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FH	10348345				2022-12-25	WOS:000080124900006
J	Chi, SJ; Kitanaka, C; Noguchi, K; Mochizuki, T; Nagashima, Y; Shirouzu, M; Fujita, H; Yoshida, M; Chen, WB; Asai, A; Himeno, M; Yokoyama, S; Kuchino, Y				Chi, SJ; Kitanaka, C; Noguchi, K; Mochizuki, T; Nagashima, Y; Shirouzu, M; Fujita, H; Yoshida, M; Chen, WB; Asai, A; Himeno, M; Yokoyama, S; Kuchino, Y			Oncogenic Ras triggers cell suicide through the activation of a caspase-independent cell death program in human cancer cells	ONCOGENE			English	Article						Bcl-2; caspase; oncogenic Ras; human glioma	WILD-TYPE P53; S-MYC; MEDIATED APOPTOSIS; GLIOMA-CELLS; GENE; TRANSFORMATION; INDUCTION; PROTEASES; DISEASE; FIBROBLASTS	To prevent neoplasia, cells of multicellular organisms activate cellular disposal programs such as apoptosis in response to deregulated oncogene expression, making the suppression of such programs an essential step for potentially neoplastic cells to become established as clinically relevant tumors. Since the mutation of ras proto-oncogenes, the most frequently mutated protooncogenes in human tumors, is very rare in some tumor types such as glioblastomas and gastric cancers, we hypothesized that mutated ras genes might activate a cell death program that cannot be overcome by these tumor types. Here we show that the expression of oncogenically mutated ras gene induces cellular degeneration accompanied by cytoplasmic vacuoles in human glioma and gastric cancer cell lines. Cells dying as a result of oncogenic Ras expression had relatively well-preserved nuclei that were negative for TUNEL staining. An immunocytochemical analysis demonstrated that the cytoplasmic vacuoles are derived mainly from lysosomes, This oncogenic Ras-induced cell death occurred in the absence of caspase activation, and was not inhibited by the overexpression of anti-apoptotic Bcl-2 protein. These observations suggested that oncogenic Ras-induced cell death is most consistent with a type of programmed cell death designated 'type 2 physiological cell death' or 'autophagic degeneration', and that this cell death is regulated by a molecular mechanism distinct from that of apoptosis, Our findings suggest a possible role for this non-apoptotic cell death in the prevention of neoplasia, and the activation of the non-apoptotic cell death program may become a potential cancer therapy complementing apoptosis-based therapies. In addition, the approach used in this study may be a valuable way to find genetically-regulated cell suicide programs that cannot be overcome by particular tumor types.	Natl Canc Ctr Res Inst, Div Biophys, Chuo Ku, Tokyo 1040045, Japan; Yokohama City Univ, Sch Med, Dept Pathol, Yokohama, Kanagawa 236004, Japan; Inst Phys & Chem Res, RIKEN, Cellular Signaling Lab, Wako, Saitama 3510198, Japan; Kyushu Univ, Fac Pharmaceut Sci, Div Physiol Chem, Higashi Ku, Fukuoka 8120082, Japan; Sasaki Inst, Dept Pathol, Chiyoda Ku, Tokyo 1010062, Japan; Univ Tokyo, Fac Med, Dept Neurosurg, Bunkyo Ku, Tokyo 1138655, Japan; Univ Tokyo, Grad Sch Sci, Dept Biochem & Biophys, Bunkyo Ku, Tokyo 1138655, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi, Saitama 3320012, Japan	National Cancer Center - Japan; Yokohama City University; RIKEN; Kyushu University; University of Tokyo; University of Tokyo; Japan Science & Technology Agency (JST)	Kitanaka, C (corresponding author), Natl Canc Ctr Res Inst, Div Biophys, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.		Yokoyama, Shigeyuki/N-6911-2015; Shirouzu, Mikako/A-6521-2016	Yokoyama, Shigeyuki/0000-0003-3133-7338; Fujita, Hideaki/0000-0002-4105-4430				Adachi J, 1996, CELL GROWTH DIFFER, V7, P879; Anglade P, 1997, HISTOL HISTOPATHOL, V12, P25; ASAI A, 1994, J NEURO-ONCOL, V19, P259, DOI 10.1007/BF01053280; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; BOS JL, 1989, CANCER RES, V49, P4682; CATALDO AM, 1994, BRAIN RES, V640, P68, DOI 10.1016/0006-8993(94)91858-9; CATALDO AM, 1995, NEURON, V14, P671, DOI 10.1016/0896-6273(95)90324-0; CHEN JW, 1985, J CELL BIOL, V101, P85, DOI 10.1083/jcb.101.1.85; CLARKE EF, 1990, MUSIC PERCEPT, V7, P213; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; Faleiro L, 1997, EMBO J, V16, P2271, DOI 10.1093/emboj/16.9.2271; FENG Y, 1995, J CELL BIOL, V131, P1435, DOI 10.1083/jcb.131.6.1435; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; HOYVIK H, 1991, J CELL BIOL, V113, P1305, DOI 10.1083/jcb.113.6.1305; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Kagaya S, 1997, MOL CELL BIOL, V17, P6736, DOI 10.1128/MCB.17.11.6736; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kitanaka C, 1997, ONCOGENE, V15, P1763, DOI 10.1038/sj.onc.1201349; KITANAKA C, 1995, CELL DEATH DIFFER, V2, P123; Kumar S, 1996, CELL DEATH DIFFER, V3, P255; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LOVEC H, 1994, ONCOGENE, V9, P323; MAHER J, 1995, ONCOGENE, V11, P1639; MATTAR R, 1992, ONCOLOGY LIFE SCI AD, V11, P7; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SCHWEICHEL JU, 1973, TERATOLOGY, V7, P253, DOI 10.1002/tera.1420070306; SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Shimizu S, 1996, ONCOGENE, V12, P2045; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; TAPAROWSKY E, 1982, NATURE, V300, P762, DOI 10.1038/300762a0; ZAKERI Z, 1995, CELL DEATH DIFFER, V2, P87	39	203	213	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 1	1999	18	13					2281	2290		10.1038/sj.onc.1202538	http://dx.doi.org/10.1038/sj.onc.1202538			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	182YE	10327074	Bronze			2022-12-25	WOS:000079525100012
J	Bracher, A; Fischer, M; Eisenreich, W; Ritz, H; Schramek, N; Boyle, P; Gentili, P; Huber, R; Nar, H; Auerbach, G; Bacher, A				Bracher, A; Fischer, M; Eisenreich, W; Ritz, H; Schramek, N; Boyle, P; Gentili, P; Huber, R; Nar, H; Auerbach, G; Bacher, A			Histidine 179 mutants of GTP cyclohydrolase I catalyze the formation of 2-amino-5-formylamino-8-ribofuranosylamino-4(3H)-pyrimidinone triphosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOSYNTHESIS; GENE; TETRAHYDROBIOPTERIN; MOLYBDOPTERIN; MUTATIONS; SYNTHASE; COFACTOR	GTP cyclohydrolase I catalyzes the conversion of GTP to dihydroneopterin triphosphate. The replacement of histidine 179 by other amino acids affords mutant enzymes that do not catalyze the formation of dihydroneopterin triphosphate. However, some of these mutant proteins catalyze the conversion of GTP to 2-amino-5-formylamino-6-ribofuranosylamino-4(3H) -pyrimidinone 5'-triphosphate as shown by multinuclear NMR analysis. The equilibrium constant for the reversible conversion of GTP to the ring-opened derivative is approximately 0.1, The wild-type enzyme converts the formylamino pyrimidine derivative to dihydroneopterin triphosphate; the rate is similar to that observed with GTP as substrate. The data support the conclusion that the formylamino pyrimidine derivative is an intermediate in the overall reaction catalyzed by GTP cyclohydrolase I.	Tech Univ Munich, Lehrstuhl Organ Chem & Biochem, D-85747 Garching, Germany; Univ Dublin Trinity Coll, Chem Lab, Dublin 2, Ireland; Max Planck Inst Biochem, D-82152 Martinsried, Germany	Technical University of Munich; Trinity College Dublin; Max Planck Society	Bacher, A (corresponding author), Tech Univ Munich, Lehrstuhl Organ Chem & Biochem, Lichtenbergstr 4, D-85747 Garching, Germany.	adelbert.bacher@ch.tum.de	Fischer, Markus J./G-9477-2012; Eisenreich, Wolfgang/A-1258-2013; Fischer, Markus/AFT-1856-2022	Eisenreich, Wolfgang/0000-0002-9832-8279; Fischer, Markus/0000-0001-7243-4199; Nar, Herbert/0000-0002-3878-6964				Bandmann O, 1996, HUM MOL GENET, V5, P403, DOI 10.1093/hmg/5.3.403; Bandmann O, 1996, J NEUROL SCI, V141, P27, DOI 10.1016/0022-510X(96)00098-6; Bracher A, 1998, J BIOL CHEM, V273, P28132, DOI 10.1074/jbc.273.43.28132; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREITMAIER E, 1987, CARBON 13 NMR SPECTR, P229; Brown G. M., 1987, ESCHERICHIA COLI SAL, V1, P521; BURG AW, 1968, J BIOL CHEM, V243, P2349; FISCHER M, 1997, THESIS TU MUNCHEN MU; KENNE L, 1988, J CHEM SOC P1, V4, P1183; KWON NS, 1989, J BIOL CHEM, V264, P20496; LUDWIG J, 1981, ACTA BIOCHIM BIOPHYS, V16, P131; Nagatsu T, 1997, J NEURAL TRANSM-SUPP, P203; Nar H, 1995, P NATL ACAD SCI USA, V92, P12120, DOI 10.1073/pnas.92.26.12120; NAR H, 1995, STRUCTURE, V3, P459, DOI 10.1016/S0969-2126(01)00179-4; NEUMAN RC, 1971, BIOCHEM BIOPH RES CO, V44, P1156, DOI 10.1016/S0006-291X(71)80207-3; NICHOL CA, 1985, ANNU REV BIOCHEM, V54, P729, DOI 10.1146/annurev.biochem.54.1.729; PERRICAUDET M, 1973, INT J PEPT PROT RES, V5, P99; PFLEIDERER W, 1957, CHEM BER-RECL, V90, P2272, DOI 10.1002/cber.19570901022; RADOM L, 1972, AUST J CHEM, V25, P1601, DOI 10.1071/CH9721601; READ SM, 1981, ANAL BIOCHEM, V116, P53, DOI 10.1016/0003-2697(81)90321-3; RICHTER G, 1993, J BACTERIOL, V175, P4045, DOI 10.1128/JB.175.13.4045-4051.1993; Rieder C, 1998, EUR J BIOCHEM, V255, P24, DOI 10.1046/j.1432-1327.1998.2550024.x; SCHMID C, 1993, ADV EXP MED BIOL, V338, P157; SHIOTA T, 1969, BIOCHIM BIOPHYS ACTA, V192, P205, DOI 10.1016/0304-4165(69)90357-2; SHIOTA T, 1967, J BIOL CHEM, V242, P1961; TAYEH MA, 1989, J BIOL CHEM, V264, P19654; Thony B, 1997, HUM MUTAT, V10, P11; YOSHIKAWA M, 1967, TETRAHEDRON LETT, P5065; ZOU R, 1987, CAN J CHEM, V65, P1436, DOI 10.1139/v87-243	29	38	40	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16727	16735		10.1074/jbc.274.24.16727	http://dx.doi.org/10.1074/jbc.274.24.16727			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358012	hybrid			2022-12-25	WOS:000080780400011
J	Oh, SK; Kang, H; Shin, DH; Yang, J; Chow, KS; Yeang, HY; Wagner, B; Breiteneder, H; Han, KH				Oh, SK; Kang, H; Shin, DH; Yang, J; Chow, KS; Yeang, HY; Wagner, B; Breiteneder, H; Han, KH			Isolation, characterization, and functional analysis of a novel cDNA clone encoding a small rubber particle protein from Hevea brasiliensis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; ELONGATION-FACTOR; PARTHENIUM-ARGENTATUM; LATEX; TREE; IDENTIFICATION; EXPRESSION; ALLERGEN; BIOSYNTHESIS; LATICIFERS	Biochemical evidence reported so far suggests that rubber synthesis takes place on the surface of rubber particles suspended in the latex of Hevea brasiliensis. We have isolated and characterized a cDNA clone that encodes a protein tightly bound on a small rubber particle. We named this protein small rubber particle protein (SRPP), Prior to this study, this protein was known as a latex allergen, and only its partial amino acid sequence was reported. Sequence analysis revealed that this protein is highly homologous to the rubber elongation factor and the Phaseolus vulgaris stress-related protein. Southern and Northern analyses indicate that the protein is encoded by a single gene and highly expressed in latex. An allergenicity test using the recombinant protein confirmed that the cloned cDNA encodes the known 24-kDa latex allergen. Neither ethylene stimulation nor wounding changed the transcript level of the SRPP gene in H. brasiliensis. An in vitro rubber assay showed that the protein plays a positive role in rubber biosynthesis. Therefore, it is likely that SRPP is a part of the rubber biosynthesis machinery, if not the rubber polymerase, along with the rubber elongation factor.	Kumho Life & Environm Sci Lab, Puk Gu, Kwangju 500480, South Korea; Rubber Res Inst Malaysia, Biotechnol & Strateg Res Unit, Kuala Lumpur 50908, Malaysia; Univ Vienna, Inst Gen & Expt Pathol, AKH EBO 3Q, A-1090 Vienna, Austria	Institute Penyelidikan Getah Malaysia; University of Vienna	Han, KH (corresponding author), Michigan State Univ, Dept Forestry, 126 Nat Resources Bldg, E Lansing, MI 48824 USA.		Han, Kyung-Hwan/G-6141-2012; Moussa, Luciana/M-2257-2013	Han, Kyung-Hwan/0000-0001-9481-4643; 				Abeles F, 1992, ETHYLENE PLANT BIOL; Adiwilaga K, 1996, PLANT MOL BIOL, V30, P935, DOI 10.1007/BF00020805; Akasawa A, 1996, J BIOL CHEM, V271, P25389, DOI 10.1074/jbc.271.41.25389; ARCHER BL, 1963, BIOCHEM J, V89, P565, DOI 10.1042/bj0890565; Arokiaraj P, 1998, PLANT CELL REP, V17, P621, DOI 10.1007/s002990050454; BACKHAUS RA, 1985, ISRAEL J BOT, V34, P283; BROEKAERT W, 1990, P NATL ACAD SCI USA, V87, P7633, DOI 10.1073/pnas.87.19.7633; CHYE ML, 1995, PLANT MOL BIOL, V29, P397, DOI 10.1007/BF00043663; CHYE ML, 1992, PLANT MOL BIOL, V19, P473, DOI 10.1007/BF00023395; CORNISH K, 1990, PHYTOCHEMISTRY, V29, P3809, DOI 10.1016/0031-9422(90)85337-F; CORNISH K, 1993, EUR J BIOCHEM, V218, P267, DOI 10.1111/j.1432-1033.1993.tb18374.x; DENNIS MS, 1989, J BIOL CHEM, V264, P18618; DENNIS MS, 1989, J BIOL CHEM, V264, P18608; FUJII H, 1982, BIOCHIM BIOPHYS ACTA, V712, P716; GOYVAERTS E, 1991, PLANT PHYSIOL, V97, P317, DOI 10.1104/pp.97.1.317; Han KH, 1997, CAN J FOREST RES, V27, P464, DOI 10.1139/cjfr-27-4-464; John P., 1993, BIOSYNTHESIS MAJOR C, P114; KUSH A, 1990, P NATL ACAD SCI USA, V87, P1787, DOI 10.1073/pnas.87.5.1787; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIGHT DR, 1989, J BIOL CHEM, V264, P18598; LYNEN F., 1969, Journal of the Rubber Research Institute, V21, P389; MADHAVAN S, 1989, PLANT PHYSIOL, V89, P506, DOI 10.1104/pp.89.2.506; MARTIN MN, 1991, PLANT PHYSIOL, V95, P469, DOI 10.1104/pp.95.2.469; PAN ZQ, 1995, J BIOL CHEM, V270, P8487, DOI 10.1074/jbc.270.15.8487; Posch A, 1997, J ALLERGY CLIN IMMUN, V99, P385, DOI 10.1016/S0091-6749(97)70057-5; Sambrook J., 1989, MOL CLONING, pA1; Siler DJ, 1997, PLANT PHYSIOL BIOCH, V35, P881; SILER DJ, 1993, PHYTOCHEMISTRY, V32, P1097, DOI 10.1016/S0031-9422(00)95072-6; SIVASUBRAMANIAM S, 1995, PLANT MOL BIOL, V29, P173, DOI 10.1007/BF00019129; Slater JE, 1996, J BIOL CHEM, V271, P25394, DOI 10.1074/jbc.271.41.25394; Sowka S, 1998, EUR J BIOCHEM, V255, P213, DOI 10.1046/j.1432-1327.1998.2550213.x; Yeang H., 1995, J NAT RUBBER RES, V10, P108; Yeang HY, 1998, ALLERGY, V53, P513, DOI 10.1111/j.1398-9995.1998.tb04089.x; Yeang HY, 1996, J ALLERGY CLIN IMMUN, V98, P628, DOI 10.1016/S0091-6749(96)70097-0	35	142	189	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17132	17138		10.1074/jbc.274.24.17132	http://dx.doi.org/10.1074/jbc.274.24.17132			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358068	hybrid			2022-12-25	WOS:000080780400067
J	Cummins, PM; Pabon, A; Margulies, EH; Glucksman, MJ				Cummins, PM; Pabon, A; Margulies, EH; Glucksman, MJ			Zinc coordination and substrate catalysis within the neuropeptide processing enzyme endopeptidase EC 3.4.24.15 - Identification of active site histidine and glutamate residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-RELEASING HORMONE; ENKEPHALIN-CONTAINING PEPTIDES; ANGIOTENSIN-CONVERTING ENZYME; LUTEINIZING-HORMONE; RAT-BRAIN; SOLUBLE METALLOENDOPEPTIDASE; PSEUDOMONAS-AERUGINOSA; DIRECTED MUTAGENESIS; MOLECULAR-CLONING; NATURAL PEPTIDES	Endopeptidase EC 5.4.24.15 (EP24.15) is a zinc metalloendopeptidase that is broadly distributed within the brain, pituitary, and gonads. Its substrate specificity includes a number of physiologically important neuropeptides such as neurotensin, bradykinin, and gonadotropin-releasing hormone, the principal regulatory peptide for reproduction. In studying the structure and function of EP24.15, we have employed in. vitro mutagenesis and subsequent protein expression to genetically dissect the enzyme and allow us to glean insight into the mechanism of substrate binding and catalysis, Comparison of the sequence of EP24.15 with bacterial homologues previously solved by x-ray crystallography and used as models for mammalian metalloendopeptidases, indicates conserved residues. The active site of EP24.15 exhibits an HEXXH motif, a common feature of zinc metalloenzymes, Mutations have confirmed the importance, for binding and catalysis, of the residues (His(473), Glu(474), and His(477)) within this motif, A third putative metal ligand, presumed to coordinate directly to the active site zinc ion in concert with His(473) and His(477), has been identified as Glu(502). Conservative alterations to these residues drastically reduces enzymatic activity against both a putative physiological substrate and a synthetic quenched fluorescent substrate as well as binding of the specific active site-directed inhibitor, N-[1-(RS) -carboxy-3-phenylpropyl] -Ala-Ala-Tyr-p-aminobenzoate, the binding of which we have shown to be dependent upon the presence, and possibly coordination, of the active site zinc ion. These studies contribute to a more complete understanding of the catalytic mechanism of EP24.15 and will aid in rational design of inhibitors and pharmacological agents for this class of enzymes.	CUNY Mt Sinai Sch Med, Fishberg Res Ctr Neurobiol, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Glucksman, MJ (corresponding author), CUNY Mt Sinai Sch Med, Fishberg Res Ctr Neurobiol, Box 1065,1425 Madison Ave, New York, NY 10029 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK045493] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [T32DA007135] Funding Source: NIH RePORTER; NIDA NIH HHS [2T32-DA7135-16] Funding Source: Medline; NIDDK NIH HHS [DK45493] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACKER GR, 1987, J NEUROCHEM, V48, P284, DOI 10.1111/j.1471-4159.1987.tb13160.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN NL, 1988, EUR J PHARMACOL, V148, P79, DOI 10.1016/0014-2999(88)90456-6; BULL HG, 1985, J BIOL CHEM, V260, P2952; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; CHU TG, 1985, ENDOCRINOLOGY, V116, P1418, DOI 10.1210/endo-116-4-1418; Creighton T. E., 1993, PROTEINS STRUCTURES; DAUCH P, 1995, J BIOL CHEM, V270, P27266, DOI 10.1074/jbc.270.45.27266; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; Davis JP, 1997, BIOCHEM PHARMACOL, V54, P459, DOI 10.1016/S0006-2952(97)00197-4; DEVAULT A, 1988, J BIOL CHEM, V263, P4033; DEVAULT A, 1988, FEBS LETT, V231, P54, DOI 10.1016/0014-5793(88)80701-4; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ELMOUJAHED A, 1990, FEBS LETT, V265, P137, DOI 10.1016/0014-5793(90)80903-V; GLUCKSMAN MJ, 1992, BIOPHYS J, V62, P119, DOI 10.1016/S0006-3495(92)81798-8; GLUCKSMAN MJ, 1995, METH NEUROSCI, V23, P296; HANGAUER DG, 1984, BIOCHEMISTRY-US, V23, P5730, DOI 10.1021/bi00319a011; HEALY DP, 1992, BRAIN RES, V571, P121, DOI 10.1016/0006-8993(92)90517-D; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; HOLMES MA, 1982, J MOL BIOL, V160, P623, DOI 10.1016/0022-2836(82)90319-9; JOHNSON WC, 1988, ANNU REV BIOPHYS BIO, V17, P145, DOI 10.1146/annurev.bb.17.060188.001045; KAWAMOTO S, 1993, INFECT IMMUN, V61, P1400, DOI 10.1128/IAI.61.4.1400-1405.1993; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUNUGI S, 1982, EUR J BIOCHEM, V124, P157, DOI 10.1111/j.1432-1033.1982.tb05919.x; LASDUN A, 1989, J PHARMACOL EXP THER, V251, P439; LASDUN A, 1990, J PHARMACOL EXP THER, V253, P1265; LEMOUAL H, 1991, J BIOL CHEM, V266, P15670; Lesburg CA, 1997, BIOCHEMISTRY-US, V36, P15780, DOI 10.1021/bi971296x; LEVY PL, 1975, P NATL ACAD SCI USA, V72, P4341, DOI 10.1073/pnas.72.11.4341; LEW RA, 1994, J BIOL CHEM, V269, P12626; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; MAO D, 1982, BIOCHEMISTRY-US, V21, P4960, DOI 10.1021/bi00263a020; MATTHEWS BW, 1988, ACCOUNTS CHEM RES, V21, P333, DOI 10.1021/ar00153a003; MATTHEWS BW, 1972, NATURE-NEW BIOL, V249, P8030; MCDERMOTT JR, 1992, BIOCHEM BIOPH RES CO, V185, P746, DOI 10.1016/0006-291X(92)91689-N; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MOLINEAUX CJ, 1988, J NEUROCHEM, V51, P624, DOI 10.1111/j.1471-4159.1988.tb01084.x; MOLINEAUX CJ, 1990, J NEUROCHEM, V55, P611, DOI 10.1111/j.1471-4159.1990.tb04177.x; Montiel JL, 1997, J NEUROCHEM, V68, P354; ORLOWSKI M, 1983, EUR J BIOCHEM, V135, P81, DOI 10.1111/j.1432-1033.1983.tb07620.x; ORLOWSKI M, 1988, BIOCHEMISTRY-US, V27, P597, DOI 10.1021/bi00402a015; ORLOWSKI M, 1989, BIOCHEM J, V261, P951, DOI 10.1042/bj2610951; Oyama K., 1981, J CHEM SOC P2, P356; PAPASTOITSIS G, 1994, BIOCHEMISTRY-US, V33, P192, DOI 10.1021/bi00167a025; PAUPTIT RA, 1988, J MOL BIOL, V199, P525, DOI 10.1016/0022-2836(88)90623-7; PIEROTTI A, 1990, BIOCHEMISTRY-US, V29, P10323, DOI 10.1021/bi00497a006; Ripellino James A., 1998, Society for Neuroscience Abstracts, V24, P1006; SALACINSKI PRP, 1981, ANAL BIOCHEM, V117, P136, DOI 10.1016/0003-2697(81)90703-X; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Shrimpton CN, 1997, J BIOL CHEM, V272, P17395, DOI 10.1074/jbc.272.28.17395; SMITH AI, 1994, BIOCHIMIE, V76, P288, DOI 10.1016/0300-9084(94)90160-0; STARK W, 1992, EUR J BIOCHEM, V207, P781, DOI 10.1111/j.1432-1033.1992.tb17109.x; THAYER MM, 1991, J BIOL CHEM, V266, P2864; TIPTON K F, 1992, P1; TISLJAR U, 1993, BIOL CHEM H-S, V374, P91; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; VALLEE BL, 1990, P NATL ACAD SCI USA, V87, P220, DOI 10.1073/pnas.87.1.220; WEI L, 1992, J BIOL CHEM, V267, P13398; WILLIAMS TA, 1994, J BIOL CHEM, V269, P29430; Wu TJ, 1997, J NEUROENDOCRINOL, V9, P813, DOI 10.1046/j.1365-2826.1997.00637.x	62	34	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16003	16009		10.1074/jbc.274.23.16003	http://dx.doi.org/10.1074/jbc.274.23.16003			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347149	hybrid			2022-12-25	WOS:000080668600009
J	Gavigan, SA; Nguyen, T; Nguyen, N; Senear, DF				Gavigan, SA; Nguyen, T; Nguyen, N; Senear, DF			Role of multiple CytR binding sites on cooperativity, competition, and induction at the Escherichia coli udp promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAMP RECEPTOR PROTEIN; CRP ACTIVATOR PROTEIN; LAMBDA-CI REPRESSOR; DNA-BINDING; DEOP2 PROMOTER; TRANSCRIPTION ACTIVATION; PARAMETER-ESTIMATION; CRYSTAL-STRUCTURE; PURINE REPRESSOR; GENE-EXPRESSION	The CytR repressor fulfills dual roles as both a repressor of transcription from promoters of the Escherichia coli CytR regulon and a co-activator in some circumstances. Transcription is repressed by a three-protein complex (cAMP receptor protein (CRP)-CytR-CRP) that is stabilized by cooperative interactions between CRP and CytR, However, cooperativity also means that CytR can recruit CRP and, by doing so, can act as a co-activator, The central role of cooperativity in regulation is highlighted by the fact that binding of the inducer, cytidine, to CytR is coupled to CytR-CRP cooperativity; this underlies the mechanism for induction. Similar interactions at the different promoters of the CytR regulon coordinate expression of the transport proteins and enzymes required for nucleoside catabolism but also provide differential expression of these genes. A fundamental question in both prokaryotic and eukaryotic gene regulation is how combinatorial mechanisms of this sort regulate differential expression. Recently, we showed that CytR binds specifically to multiple sites in the E, coli deoP promoter, thereby providing competition for CRP binding to CRP operator site 1 (CRP1) and CRP2 as well as cooperativity, The effect of the competition at this promoter is to negate the role of CytR in recruiting CRP, Here, we have used quantitative footprint and mobility shift analysis to investigate CRP and CytR binding to the E, coli udp promoter. Here too, we find that CytR both cooperates and competes for CRP binding. However, consistent with both the distribution of CytR recognition motifs in the sequence of the promoter and the regulation of the promoter, the competition is limited to CRP2, When cytidine binds to CytR, the effect on cooperativity is very different at the udp promoter than at the deoP2 promoter. Cooperativity with CRP at CRP1 is nearly eliminated, but the effect on CytR-CRP2 cooperativity is negligible. These results are discussed in relation to the current structural model of CytR in which the core, inducer-binding domain is tethered to the helix-turn-helix, DNA-binding domain via flexible peptide linkers.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA	University of California System; University of California Irvine	Senear, DF (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA.							ACKERS GK, 1983, J MOL BIOL, V170, P223, DOI 10.1016/S0022-2836(83)80234-4; Barbier CS, 1997, J BIOL CHEM, V272, P16962, DOI 10.1074/jbc.272.27.16962; BARBIER CS, 1992, J BACTERIOL, V174, P2881, DOI 10.1128/JB.174.9.2881-2890.1992; Belyaeva TA, 1998, J MOL BIOL, V277, P789, DOI 10.1006/jmbi.1998.1666; BRENOWITZ M, 1986, METHOD ENZYMOL, V130, P132; BRENOWITZ M, 1989, CURRENT PROTOCOLS MO, V2; CHOI KY, 1992, J BACTERIOL, V174, P6207, DOI 10.1128/JB.174.19.6207-6214.1992; EBRIGHT RH, 1993, MOL MICROBIOL, V8, P797, DOI 10.1111/j.1365-2958.1993.tb01626.x; FILES JG, 1976, J BIOL CHEM, V251, P3386; GRONENBORN AM, 1986, BIOCHEM J, V236, P643, DOI 10.1042/bj2360643; JOHNSON ML, 1992, METHOD ENZYMOL, V210, P1; Jorgensen CI, 1998, MOL MICROBIOL, V27, P41, DOI 10.1046/j.1365-2958.1998.00655.x; Kallipolitis BH, 1997, CELL, V89, P1101, DOI 10.1016/S0092-8674(00)80297-4; Kristensen HH, 1997, J MOL BIOL, V266, P866, DOI 10.1006/jmbi.1996.0852; Kristensen HH, 1996, J MOL BIOL, V260, P113, DOI 10.1006/jmbi.1996.0385; Lewis M, 1996, SCIENCE, V271, P1247, DOI 10.1126/science.271.5253.1247; Maniatas T., 1989, MOL CLONING LAB MANU; MARTINUSSEN J, 1989, DNA PROTEIN INTERACT, P31; PEDERSEN H, 1991, J BIOL CHEM, V266, P17804; PEDERSEN H, 1995, MOL MICROBIOL, V17, P843, DOI 10.1111/j.1365-2958.1995.mmi_17050843.x; Pedersen H, 1997, EMBO J, V16, P2108, DOI 10.1093/emboj/16.8.2108; Perini LT, 1996, J BIOL CHEM, V271, P33242, DOI 10.1074/jbc.271.52.33242; RASMUSSEN PB, 1993, NUCLEIC ACIDS RES, V21, P879, DOI 10.1093/nar/21.4.879; Rasmussen PB, 1996, P NATL ACAD SCI USA, V93, P10151, DOI 10.1073/pnas.93.19.10151; SCHUMACHER MA, 1995, CELL, V83, P147, DOI 10.1016/0092-8674(95)90243-0; SCHUMACHER MA, 1994, SCIENCE, V266, P763, DOI 10.1126/science.7973627; SENEAR DF, 1990, BIOCHEMISTRY-US, V29, P6568, DOI 10.1021/bi00480a004; SENEAR DF, 1992, METHOD ENZYMOL, V210, P463; Senear DF, 1998, METHOD ENZYMOL, V295, P403; SENEAR DF, 1991, BIOCHEMISTRY-US, V30, P6677, DOI 10.1021/bi00241a007; TAKAHASHI M, 1989, J MOL BIOL, V207, P783, DOI 10.1016/0022-2836(89)90244-1; USHIDA C, 1990, NUCLEIC ACIDS RES, V18, P6325, DOI 10.1093/nar/18.21.6325; ValentinHansen P, 1996, MOL MICROBIOL, V20, P461, DOI 10.1046/j.1365-2958.1996.5341056.x; WAXMAN E, 1993, ANAL BIOCHEM, V210, P425, DOI 10.1006/abio.1993.1220; WEICKERT MJ, 1992, J BIOL CHEM, V267, P15869; WETLAUFER DB, 1962, ADV PROTEIN CHEM, V17, P303	36	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16010	16019		10.1074/jbc.274.23.16010	http://dx.doi.org/10.1074/jbc.274.23.16010			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347150	hybrid			2022-12-25	WOS:000080668600010
J	Hang, Q; Woods, L; Feiss, M; Catalano, CE				Hang, Q; Woods, L; Feiss, M; Catalano, CE			Cloning, expression, and biochemical characterization of hexahistidine-tagged terminase proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-LAMBDA TERMINASE; DNA PACKAGING ENZYME; INTEGRATION HOST FACTOR; GENE-PRODUCT-A; LARGE SUBUNIT; PHAGE-LAMBDA; ENDONUCLEASE ACTIVITY; PROHEAD BINDING; KINETIC CHARACTERIZATION; DOMAIN	The terminase enzyme from bacteriophage lambda is composed of two viral proteins (gpA, 73.2 kDa; gpNu1, 20.4 kDa) and is responsible for packaging viral DNA into the confines of an empty procapsid, We are interested in the genetic, biochemical, and biophysical properties of DNA packaging in phage lambda and, in particular, the nucleoprotein complexes involved in these processes. These studies require the routine purification of large quantities of wild-type and mutant proteins in order to probe the molecular mechanism of DNA packaging. Toward this end, we have constructed a hexahistidine (hexa-His)tagged terminase holoenzyme as well as hexa-His-tagged gpNu1 and gpA subunits. We present a simple, one-step purification scheme for the purification of large quantities of the holoenzyme and the individual subunits directly from the crude cell lysate, Importantly, we have developed a method to purify the highly insoluble gpNu1 subunit from inclusion bodies in a single step. Hexa-His terminase holoenzyme is functional in vise and possesses steady-state and single-turnover ATPase activity that is indistinguishable from wild-type enzyme. The nuclease activity of the modified holoenzyme is near wild type, but the reaction exhibits a greater dependence on Escherichia coli integration host factor, a result that is mirrored in vivo, These results suggest that the hexa-His-tagged holoenzyme possesses a mild DNA-binding defect that is masked, at least in part, by integration host factor. The mild defect in hexa-His terminase holoenzyme is more significant in the isolated gpA-hexa-His subunit that does not appear to bind DNA Moreover, whereas the hexa-His-tagged gpNul subunit may be reconstituted into a holoenzyme complex with wild-type catalytic activities, gpa-hexa-His is impaired in its interactions with the gpNu1 subunit of the enzyme. The results reported here underscore that a complete biochemical characterization of the effects of purification tags on enzyme function must be performed prior to their use in mechanistic studies.	Univ Colorado, Hlth Sci Ctr, Program Mol Biol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmaceut Sci, Denver, CO 80262 USA; Univ Iowa, Dept Microbiol, Iowa City, IA 52242 USA; Univ Iowa, Program Mol Biol, Iowa City, IA 52242 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Iowa; University of Iowa	Catalano, CE (corresponding author), Univ Colorado, Hlth Sci Ctr, Program Mol Biol, 4200 E 9th Ave, Denver, CO 80262 USA.	carlos.catalano@uchsc.edu		Catalano, Carlos E./0000-0003-2349-5758	NIGMS NIH HHS [GM51611, GM50328-03] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050328, R01GM051611] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECKER A, 1990, J BACTERIOL, V172, P2819, DOI 10.1128/jb.172.6.2819-2824.1990; BLACK LW, 1989, ANNU REV MICROBIOL, V43, P267, DOI 10.1146/annurev.micro.43.1.267; Cai ZH, 1997, J BACTERIOL, V179, P2479, DOI 10.1128/jb.179.8.2479-2485.1997; CATALANO CE, 1995, MOL MICROBIOL, V16, P1075, DOI 10.1111/j.1365-2958.1995.tb02333.x; CHOW S, 1987, GENE, V60, P277, DOI 10.1016/0378-1119(87)90236-8; CUE D, 1992, J MOL BIOL, V228, P58, DOI 10.1016/0022-2836(92)90491-2; DANIELS DL, 1983, LAMBDA, V2, P522; DAVIDSON AR, 1992, VIROLOGY, V189, P21, DOI 10.1016/0042-6822(92)90677-H; FEISS M, 1986, TRENDS GENET, V2, P100, DOI 10.1016/0168-9525(86)90193-9; FEISS M, 1983, P NATL ACAD SCI-BIOL, V80, P955, DOI 10.1073/pnas.80.4.955; FEISS M, 1982, GENE, V17, P123, DOI 10.1016/0378-1119(82)90064-6; FEISS M, 1983, LAMBDA, V2, P305; FRACKMAN S, 1984, J MOL BIOL, V180, P283, DOI 10.1016/S0022-2836(84)80005-4; FRACKMAN S, 1985, J MOL BIOL, V183, P225, DOI 10.1016/0022-2836(85)90215-3; GOLD M, 1983, J BIOL CHEM, V258, P4619; Hanagan A, 1998, INT J BIOL MACROMOL, V23, P37, DOI 10.1016/S0141-8130(98)00010-5; HOHN B, 1983, P NATL ACAD SCI-BIOL, V80, P7456, DOI 10.1073/pnas.80.24.7456; HOHN B, 1975, J MOL BIOL, V98, P93, DOI 10.1016/S0022-2836(75)80103-3; Hwang Y, 1996, BIOCHEMISTRY-US, V35, P2796, DOI 10.1021/bi952322z; HWANG Y, 1995, VIROLOGY, V211, P367, DOI 10.1006/viro.1995.1419; KYPR J, 1986, J MOL BIOL, V191, P139, DOI 10.1016/0022-2836(86)90430-4; MANIATIS T, 1982, MOL CLONING LABORATO, P440; Meyer JD, 1998, INT J BIOL MACROMOL, V23, P27, DOI 10.1016/S0141-8130(98)00009-9; MIWA T, 1983, GENE, V24, P199; MURIALDO H, 1991, ANNU REV BIOCHEM, V60, P125; NASH HA, 1987, J BACTERIOL, V169, P4124, DOI 10.1128/jb.169.9.4124-4127.1987; PAL SK, 1988, J BACTERIOL, V172, P2819; PARRIS W, 1988, J BIOL CHEM, V263, P8413; PARRIS W, 1994, J BIOL CHEM, V269, P13564; RUBINCHIK S, 1994, J BIOL CHEM, V269, P13586; RUBINCHIK S, 1994, J BIOL CHEM, V269, P13575; SIPPY J, 1992, J BACTERIOL, V174, P850, DOI 10.1128/jb.174.3.850-856.1992; SIX EW, 1973, VIROLOGY, V51, P327, DOI 10.1016/0042-6822(73)90432-7; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TOMKA MA, 1993, BIOCHEMISTRY-US, V32, P11992, DOI 10.1021/bi00096a008; TOMKA MA, 1993, J BIOL CHEM, V268, P3056; Woods L, 1997, BIOCHEMISTRY-US, V36, P5777, DOI 10.1021/bi963044m; WU WF, 1988, GENETICS, V119, P477; XIN W, 1988, NUCLEIC ACIDS RES, V16, P2015, DOI 10.1093/nar/16.5.2015; XIN W, 1993, J MOL BIOL, V230, P492, DOI 10.1006/jmbi.1993.1166; Yang Q, 1999, BIOCHEMISTRY-US, V38, P465, DOI 10.1021/bi981271d; YEO A, 1995, J MOL BIOL, V245, P126; [No title captured]	43	32	35	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15305	15314		10.1074/jbc.274.22.15305	http://dx.doi.org/10.1074/jbc.274.22.15305			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336415	hybrid			2022-12-25	WOS:000080560100004
J	Liu, MS; Lee, BH; Mathews, MB				Liu, MS; Lee, BH; Mathews, MB			Involvement of RFX1 protein in the regulation of the human proliferating cell nuclear antigen promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOVIRUS E1A ONCOPROTEIN; DNA-BINDING PROTEINS; B VIRUS ENHANCER; TRANSCRIPTIONAL ACTIVATION; FUNCTIONAL DOMAINS; MOLECULAR-CLONING; AUXILIARY PROTEIN; POLYMERASE-DELTA; GENE; CYCLIN	The proliferating cell nuclear antigen (PCNA) is an essential eukaryotic DNA replication factor that is transcriptionally regulated by the adenovirus oncoprotein E1A 243B. Inducibility of the human PCNA promoter by E1A 243R is conferred by the cis-acting PCNA E1A-responsive element (PERE), which associates with the ATF-1, cAMP response element-binding protein (CREB), and RFX1 transcription factors and is modulated by cellular proteins such as the coactivator CREB-binding protein (CBP) and tumor suppressor p107 (Labrie, C., Lee, B. R, and Mathews, M. B. (1995) Nucleic Acids Res. 23, 3732-3741; Lee, B, H., and Mathews, M, B, (1997) Proc. Natl. Acad Sci. U.S, R 94, 4481-4486; Lee, B. H., Liu, M, and Mathews, M. B, (1998) J. ViroL 72, 1138-1145). RFX1 also forms a complex with sequences in the PCNA promoter of mouse and rat that share homology with the RFX1 consensus site. To explore the role of RFX1 in regulating the PCNA promoter, we examined the effects of mutations in the human PERE on RFX1 binding and gene expression. Mutations within the RFX1 consensus binding site reduced RFX1 binding, whereas mutations up-stream of the site, or on its border, increased RFX1 binding. These mutations also affected the transcriptional activity of PCNA-chloramphenicol acetyltransferase reporter constructs in transient expression assays. The relative transcriptional activity of mutant PCNA promoters, both in the presence and absence of E1A 243R, was inversely related to their ability to complex with RFX1. These findings suggest that the binding of RFX1 is influenced by sequences outside its consensus binding site and that this transcription factor plays an inhibitory role in the regulation of PCNA gene expression.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ 07103 USA; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11790 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Cold Spring Harbor Laboratory; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Liu, MS (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, 185 S Orange Ave, Newark, NJ 07103 USA.	mathews@umdnj.edu			NATIONAL CANCER INSTITUTE [P01CA013106] Funding Source: NIH RePORTER; NCI NIH HHS [CA 13106] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALMENDRAL JM, 1987, P NATL ACAD SCI USA, V84, P1575, DOI 10.1073/pnas.84.6.1575; BAUER GA, 1990, NUCLEIC ACIDS RES, V18, P261, DOI 10.1093/nar/18.2.261; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Emery P, 1996, MOL CELL BIOL, V16, P4486; Emery P, 1996, NUCLEIC ACIDS RES, V24, P803, DOI 10.1093/nar/24.5.803; JASKULSKI D, 1988, J BIOL CHEM, V263, P10175; Katan Y, 1997, NUCLEIC ACIDS RES, V25, P3621, DOI 10.1093/nar/25.18.3621; LABRIE C, 1993, MOL CELL BIOL, V13, P1697, DOI 10.1128/MCB.13.3.1697; LABRIE C, 1995, NUCLEIC ACIDS RES, V23, P3732, DOI 10.1093/nar/23.18.3732; Lee BH, 1997, P NATL ACAD SCI USA, V94, P4481, DOI 10.1073/pnas.94.9.4481; Lee BH, 1998, J VIROL, V72, P1138, DOI 10.1128/JVI.72.2.1138-1145.1998; MOORE KS, 1987, J BIOL CHEM, V262, P8447; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MORRIS GF, 1990, J BIOL CHEM, V265, P16116; MORRIS GF, 1994, MOL CELL BIOL, V14, P543, DOI 10.1128/MCB.14.1.543; Morris GF, 1996, P NATL ACAD SCI USA, V93, P895, DOI 10.1073/pnas.93.2.895; MORRIS GF, 1991, J VIROL, V65, P6397, DOI 10.1128/JVI.65.12.6397-6406.1991; NEVINS JR, 1989, ADV VIRUS RES, V37, P35; OHASHI Y, 1992, BIOCHIM BIOPHYS ACTA, V1130, P175, DOI 10.1016/0167-4781(92)90525-5; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; REINHOLD W, 1995, MOL CELL BIOL, V15, P3041; REITH W, 1990, GENE DEV, V4, P1528, DOI 10.1101/gad.4.9.1528; SHENK T, 1991, ADV CANCER RES, V57, P47; SHIVAKUMAR CV, 1995, MOL CELL BIOL, V15, P6785; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SIEGRIST CA, 1993, MOL CELL BIOL, V13, P6375, DOI 10.1128/MCB.13.10.6375; TAN CK, 1986, J BIOL CHEM, V261, P2310; TRAVALI S, 1989, J BIOL CHEM, V264, P7466; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; WOLD MS, 1987, CANCER CELL, P133; YAMAGUCHI M, 1991, NUCLEIC ACIDS RES, V19, P2403, DOI 10.1093/nar/19.9.2403; ZAJAC-KAYE M, 1988, SCIENCE, V240, P1776, DOI 10.1126/science.2454510; ZERLER B, 1987, MOL CELL BIOL, V7, P821, DOI 10.1128/MCB.7.2.821	36	41	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15433	15439		10.1074/jbc.274.22.15433	http://dx.doi.org/10.1074/jbc.274.22.15433			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336433	hybrid			2022-12-25	WOS:000080560100022
J	Yang, JP; Hori, M; Sanda, T; Okamoto, T				Yang, JP; Hori, M; Sanda, T; Okamoto, T			Identification of a novel inhibitor of nuclear factor-kappa B RelA-associated inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; IN-VITRO; ACTIVATION; ALPHA; SEQUENCES; PROTEINS; TRANSCRIPTION; ANKYRIN; KINASE; 53BP2	Here we report the identification and characterization of a novel protein, RelA-associated inhibitor (RAI), that binds to the NF-kappa B subunit p65 (RelA) and inhibits its transcriptional activity. RAI gene was isolated in a yeast two-hybrid screen using the central region of p65 as bait. We confirmed the physical interaction in vitro using recombinant proteins as well as in vivo by immunoprecipitation/Western blot assay. RAI gene encodes a protein with homology to the C-terminal region of 53BP2 containing four consecutive ankyrin repeats and an Src homology 3 domain. RAI mRNA was preferentially expressed in human heart, placenta, and prostate. Despite its similarity to 53BP2, RAI did not interact with p53 in a yeast two-hybrid assay. RAI inhibited the action of NF-kappa B p65 but not that of p53 in transient luciferase gene expression assays. Similarly, RAI inhibited the endogenous NF-kappa B activity induced by tumor necrosis factor-alpha. RAI specifically inhibited the DNA binding activity of p65 when co-transfected in 293 cells. RAI protein appeared to be located in the nucleus and colocalized with NF-kappa B p65 that was activated by TNF-alpha. These observations indicate that RAI is another inhibitor of NF-kappa B in addition to I kappa B proteins and may confer an alternative mechanism of regulation.	Nagoya City Univ, Sch Med, Dept Mol Genet, Mizuho Ku, Nagoya, Aichi 4678601, Japan	Nagoya City University	Okamoto, T (corresponding author), Nagoya City Univ, Sch Med, Dept Mol Genet, Mizuho Ku, 1 Kawasumi,Mizuho Cho, Nagoya, Aichi 4678601, Japan.							Baeuerle PA, 1997, ADV IMMUNOL, V65, P111, DOI 10.1016/S0065-2776(08)60742-7; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; Brown K, 1997, MOL CELL BIOL, V17, P3021, DOI 10.1128/MCB.17.6.3021; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; HAYASHI T, 1993, J BIOL CHEM, V268, P11380; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Lamerdin JE, 1996, GENOMICS, V34, P399, DOI 10.1006/geno.1996.0303; Liu ZQ, 1996, FEBS LETT, V385, P109, DOI 10.1016/0014-5793(96)00360-2; Malek S, 1998, J BIOL CHEM, V273, P25427, DOI 10.1074/jbc.273.39.25427; Min W, 1996, MOL CELL BIOL, V16, P359; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; Naumovski L, 1996, MOL CELL BIOL, V16, P3884; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OKAMOTO T, 1990, VIROLOGY, V177, P606, DOI 10.1016/0042-6822(90)90526-W; Okamoto T, 1997, CURR TOP CELL REGUL, V35, P149, DOI 10.1016/S0070-2137(97)80006-4; Okamoto T, 1998, CYTOGENET CELL GENET, V82, P105, DOI 10.1159/000015077; OKAMOTO T, 1989, AIDS RES HUM RETROV, V5, P131, DOI 10.1089/aid.1989.5.131; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; Sachdev S, 1998, MOL CELL BIOL, V18, P2524, DOI 10.1128/MCB.18.5.2524; Sakurada S, 1996, INT IMMUNOL, V8, P1483, DOI 10.1093/intimm/8.10.1483; Sambrook J., 2002, MOL CLONING LAB MANU; Sato T, 1998, AIDS RES HUM RETROV, V14, P293, DOI 10.1089/aid.1998.14.293; Shen CH, 1998, MOL CELL BIOL, V18, P3395, DOI 10.1128/MCB.18.6.3395; SIEBENLIST U, 1995, NF KAPPAB MEDIATOR P, V1, P93; SUN SC, 1994, P NATL ACAD SCI USA, V91, P1346, DOI 10.1073/pnas.91.4.1346; Suyang H, 1996, MOL CELL BIOL, V16, P5444; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; THUKRAL SK, 1994, MOL CELL BIOL, V14, P8315, DOI 10.1128/MCB.14.12.8315; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yamit-Hezi A, 1998, EMBO J, V17, P5161, DOI 10.1093/emboj/17.17.5161; YANG JP, 1995, FEBS LETT, V361, P89, DOI 10.1016/0014-5793(95)00157-5	40	137	151	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15662	15670		10.1074/jbc.274.22.15662	http://dx.doi.org/10.1074/jbc.274.22.15662			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336463	hybrid			2022-12-25	WOS:000080560100052
J	Lee, MG; Choi, JY; Luo, X; Strickland, E; Thomas, PJ; Muallem, S				Lee, MG; Choi, JY; Luo, X; Strickland, E; Thomas, PJ; Muallem, S			Cystic fibrosis transmembrane conductance regulator regulates luminal Cl-/HCO3- exchange in mouse submandibular and pancreatic ducts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUINEA-PIG PANCREAS; BICARBONATE SECRETION; INTERLOBULAR DUCTS; AIRWAY EPITHELIA; MEMBRANE LOCALIZATION; CHLORIDE CHANNELS; SALIVARY DUCTS; ION CHANNELS; CFTR; TRANSPORT	We have demonstrated previously the regulation of Cl-/HCO3- exchange activity by the cystic fibrosis transmembrane conductance regulator (CFTR) in model systems of cells stably or transiently transfected with CFTR (Lee, M. G., Wigley, W. C., Zeng, W., Noel, L. E., Marino, C, R,, Thomas, P. J., and Muallem, S, (1999) J. Biol. Chem. 274, 3414-3421), In the present work we examine the significance of this regulation in cells naturally expressing CFTR. These include the human colonic T84 cell line and the mouse submandibular gland and pancreatic ducts, tissues that express high levels of CFTR in the luminal membrane. As in heterologous expression systems, stimulation of T84 cells with forskolin increased the Cl-/HCO3- exchange activity independently of CFTR Cl- channel activity. Freshly isolated submandibular gland ducts from wild type mice showed variable Cl-/HCO3- exchange activity. Measurement of [Cl-](i) revealed that this was largely the result of variable steady-state [Cl-](i). Membrane depolarization with 5 mM Ba2+ or 100 mM K+ increased and stabilized [Cl-](i). Under depolarized conditions wild type and Delta F/Delta F mice had comparable basal Cl-/HCO3- exchange activity. Notably, stimulation with forskolin increased Cl-/HCO3- exchange activity in submandibular gland ducts from wild type but not Delta F/Delta F mice. Microperfusion of the main pancreatic duct showed Cl-/HCO3- exchange activity in both the basolateral and luminal membranes. Stimulation of ducts from wild type animals with forskolin had no effect on basolateral but markedly stimulated luminal Cl-/HCO3- exchange activity. By contrast, forskolin had no effect on either basolateral or luminal Cl-/HCO3- exchange activity of ducts from Delta F/Delta F animals. We conclude that CFTR regulates luminal Cl-/HCO3- exchange activity in CFTR-expressing cells, and we discuss the possible physiological significance of these findings regarding cystic fibrosis.	Yonsei Univ, Coll Med, Dept Pharmacol, Seoul 120752, South Korea; Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Program Mol Biophys, Dallas, TX 75235 USA	Yonsei University; Yonsei University Health System; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Lee, MG (corresponding author), Yonsei Univ, Coll Med, Dept Pharmacol, 134 Sinchon Dong, Seoul 120752, South Korea.	mlee@yumc.yonsei.ac.kr	Thomas, Philip J/F-7115-2012; Lee, Min Goo/D-5635-2012; Lee, Min Goo/AAS-4636-2020	Lee, Min Goo/0000-0001-7436-012X; Lee, Min Goo/0000-0001-7436-012X	NIDCR NIH HHS [DE12309] Funding Source: Medline; NIDDK NIH HHS [DK49835, DK38938] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012309] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038938, R01DK049835, R37DK049835] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AlAwqati Q, 1996, AM J PHYSIOL-CELL PH, V270, pC1571, DOI 10.1152/ajpcell.1996.270.6.C1571; ALLEN A, 1993, PHYSIOL REV, V73, P823, DOI 10.1152/physrev.1993.73.4.823; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; ARGENT BE, 1994, PHYSL GASTROINTESTIN, P1478; BARRETT KE, 1993, AM J PHYSIOL, V265, pC859; Barrett KE, 1997, AM J PHYSIOL-CELL PH, V272, pC1069, DOI 10.1152/ajpcell.1997.272.4.C1069; BOUCHER RC, 1994, AM J RESP CRIT CARE, V150, P581, DOI 10.1164/ajrccm.150.2.8049852; Chaturapanich G, 1997, J PHYSIOL-LONDON, V503, P583, DOI 10.1111/j.1469-7793.1997.583bg.x; Cheng HS, 1998, J MEMBRANE BIOL, V164, P155, DOI 10.1007/s002329900401; Cook D. I., 1994, P1061; CRAWFORD I, 1991, P NATL ACAD SCI USA, V88, P9262, DOI 10.1073/pnas.88.20.9262; GRAY MA, 1989, AM J PHYSIOL, V257, pC240, DOI 10.1152/ajpcell.1989.257.2.C240; Gray MA, 1995, BIOSCIENCE REP, V15, P531, DOI 10.1007/BF01204355; Greger R, 1996, J MOL MED-JMM, V74, P527; GRUBB BR, 1995, AM J PHYSIOL-GASTR L, V268, pG505, DOI 10.1152/ajpgi.1995.268.3.G505; He XJ, 1997, PFLUG ARCH EUR J PHY, V433, P260; Hogan DL, 1997, GASTROENTEROLOGY, V113, P533, DOI 10.1053/gast.1997.v113.pm9247473; Illek B, 1997, AM J PHYSIOL-LUNG C, V272, pL752, DOI 10.1152/ajplung.1997.272.4.L752; Illek B, 1996, AM J PHYSIOL-CELL PH, V270, pC265, DOI 10.1152/ajpcell.1996.270.1.C265; Ishiguro H, 1998, J PHYSIOL-LONDON, V511, P407, DOI 10.1111/j.1469-7793.1998.407bh.x; Ishiguro H, 1996, J PHYSIOL-LONDON, V495, P169, DOI 10.1113/jphysiol.1996.sp021582; Ishiguro H, 1996, J PHYSIOL-LONDON, V495, P179, DOI 10.1113/jphysiol.1996.sp021583; LAU KR, 1994, PFLUG ARCH EUR J PHY, V427, P24, DOI 10.1007/BF00585938; Lee MC, 1998, AM J PHYSIOL-LUNG C, V274, pL450, DOI 10.1152/ajplung.1998.274.3.L450; Lee MG, 1999, J BIOL CHEM, V274, P3414, DOI 10.1074/jbc.274.6.3414; Lee MG, 1998, J PHYSIOL-LONDON, V513, P341, DOI 10.1111/j.1469-7793.1998.341bb.x; MARINO CR, 1991, J CLIN INVEST, V88, P712, DOI 10.1172/JCI115358; Matsui H, 1998, CELL, V95, P1005, DOI 10.1016/S0092-8674(00)81724-9; McNicholas CM, 1996, P NATL ACAD SCI USA, V93, P8083, DOI 10.1073/pnas.93.15.8083; PETERSEN OH, 1992, J PHYSIOL-LONDON, V448, P1; POULSEN JH, 1994, P NATL ACAD SCI USA, V91, P5340, DOI 10.1073/pnas.91.12.5340; Quinton PM, 1999, CYSTIC FIBROSIS IN ADULTS, P419, DOI 10.1111/b.9780631213284.1999.00056.x; REDDY MM, 1993, PEDIATR PULM S, V9, P208; SCHULTZ SG, 1972, GASTROENTEROLOGY, V63, P161; Seidler U, 1997, J PHYSIOL-LONDON, V505, P411, DOI 10.1111/j.1469-7793.1997.411bb.x; SMITH JJ, 1992, J CLIN INVEST, V89, P1148, DOI 10.1172/JCI115696; STUTTS MJ, 1995, SCIENCE, V269, P847, DOI 10.1126/science.7543698; TABAK LA, 1995, ANNU REV PHYSIOL, V57, P547, DOI 10.1146/annurev.ph.57.030195.002555; WELSH MJ, 1987, PHYSIOL REV, V67, P1143, DOI 10.1152/physrev.1987.67.4.1143; WELSH MJ, 1995, SCI AM, V273, P52, DOI 10.1038/scientificamerican1295-52; XU X, 1995, J BIOL CHEM, V270, P19606, DOI 10.1074/jbc.270.33.19606; Zabner J, 1998, MOL CELL, V2, P397, DOI 10.1016/S1097-2765(00)80284-1; ZEIHER BG, 1995, J CLIN INVEST, V96, P2051, DOI 10.1172/JCI118253; Zeng WZ, 1997, J BIOL CHEM, V272, P32956, DOI 10.1074/jbc.272.52.32956; Zeng WZ, 1997, AM J PHYSIOL-CELL PH, V273, pC442, DOI 10.1152/ajpcell.1997.273.2.C442; ZHAO H, 1994, J GEN PHYSIOL, V104, P57, DOI 10.1085/jgp.104.1.57; ZHAO H, 1995, J BIOL CHEM, V270, P19599, DOI 10.1074/jbc.270.33.19599	47	143	147	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					14670	14677		10.1074/jbc.274.21.14670	http://dx.doi.org/10.1074/jbc.274.21.14670			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329661	Green Published, hybrid			2022-12-25	WOS:000081965200026
J	Nueda, A; Hudson, F; Mivechi, NF; Dynan, WS				Nueda, A; Hudson, F; Mivechi, NF; Dynan, WS			DNA-dependent protein kinase protects against heat-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND-BREAK-REPAIR; SHOCK TRANSCRIPTION FACTOR-1; STRESS-INDUCED APOPTOSIS; RNA-POLYMERASE-II; MOUSE-CELL LINES; CATALYTIC SUBUNIT; KU AUTOANTIGEN; CHO CELLS; HYPERTHERMIC RADIOSENSITIZATION; NONSENSE MUTATION	Purified heat shock transcription factor 1 (HSF1) binds to both the regulatory and catalytic components of the DNA-dependent protein kinase (DNA-PK). This observation suggests that DNA-PK may have a physiological role in the heat shock response. To investigate this possibility, we performed a comparison of cell lines that were deficient in either the Ku protein or the DNA-PK catalytic subunit versus the same cell lines that had been rescued by the introduction of a functional gene. DNA-PK-negative cell lines were up to 10-fold more sensitive to heat-induced apoptosis than matched DNA-PK-positive cell lines. There may be a regulatory interaction between DNA-PK and HSF1 in vivo, because constitutive overexpression of HSF1 sensitized the DNA-PK-positive cells to heat but had no effect in DNA-PK-negative cells. The initial burst of hsp70 mRNA expression was similar in DNA-PK-negative and -positive cell lines, but the DNA-PK-negative cells showed an attenuated rate of mRNA synthesis at later times and, in some cases, lower heat shock protein expression. These findings provide evidence for an antiapoptotic function of DNA-PK that is experimentally separable from its mechanical role in DNA double strand break repair.	Med Coll Georgia, Inst Mol Med & Genet, Program Gene Regulat, Augusta, GA 30912 USA	University System of Georgia; Augusta University	Dynan, WS (corresponding author), Med Coll Georgia, Inst Mol Med & Genet, Program Gene Regulat, 1120 15th St, Augusta, GA 30912 USA.			Dynan, William/0000-0002-4045-5662; Nueda, Arsenio/0000-0001-8373-500X	NCI NIH HHS [CA 62130] Funding Source: Medline; NIGMS NIH HHS [GM 35866] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA062130] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035866] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLAN DJ, 1986, SCAN ELECTRON MICROS, V1986, P1121; Araki R, 1997, P NATL ACAD SCI USA, V94, P2438, DOI 10.1073/pnas.94.6.2438; Barnes G, 1997, P NATL ACAD SCI USA, V94, P867, DOI 10.1073/pnas.94.3.867; BELLON T, 1994, EUR J IMMUNOL, V24, P41, DOI 10.1002/eji.1830240107; BENHUR E, 1974, RADIAT RES, V58, P38, DOI 10.2307/3573947; Blunt T, 1996, P NATL ACAD SCI USA, V93, P10285, DOI 10.1073/pnas.93.19.10285; BROWN T, 1997, CURRENT PROTOCOLS MO, V1; BURGMAN P, 1997, CANCER RES, V57, P2874; Chan DW, 1996, J BIOL CHEM, V271, P8936, DOI 10.1074/jbc.271.15.8936; Chang Y, 1995, P NATL ACAD SCI USA, V92, P12275, DOI 10.1073/pnas.92.26.12275; Chen FQ, 1996, MUTAT RES-DNA REPAIR, V362, P9, DOI 10.1016/0921-8777(95)00026-7; Chu BY, 1996, J BIOL CHEM, V271, P30847, DOI 10.1074/jbc.271.48.30847; Chu G, 1997, J BIOL CHEM, V272, P24097, DOI 10.1074/jbc.272.39.24097; Danska JS, 1996, MOL CELL BIOL, V16, P5507; DUKE RC, 1986, J IMMUNOL, V137, P1442; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; Dynan WS, 1998, NUCLEIC ACIDS RES, V26, P1551, DOI 10.1093/nar/26.7.1551; DYSON JED, 1986, CELL TISSUE KINET, V19, P311, DOI 10.1111/j.1365-2184.1986.tb00683.x; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Giffin W, 1997, J BIOL CHEM, V272, P5647, DOI 10.1074/jbc.272.9.5647; GORZOWSKI JJ, 1995, J BIOL CHEM, V270, P26940, DOI 10.1074/jbc.270.45.26940; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; GREENBERG ME, 1997, CURRENT PROTOCOLS MO, V1; HARMON BV, 1991, INT J RADIAT BIOL, V59, P489, DOI 10.1080/09553009114550441; HARMON BV, 1990, INT J RADIAT BIOL, V58, P845, DOI 10.1080/09553009014552221; He B, 1998, MOL CELL BIOL, V18, P6624, DOI 10.1128/MCB.18.11.6624; HENLE KJ, 1976, RADIAT RES, V66, P505, DOI 10.2307/3574455; HENSOLD JO, 1990, MOL CELL BIOL, V10, P1600, DOI 10.1128/MCB.10.4.1600; HICKEY E, 1986, NUCLEIC ACIDS RES, V14, P4127, DOI 10.1093/nar/14.10.4127; Huang JR, 1997, J BIOL CHEM, V272, P26009, DOI 10.1074/jbc.272.41.26009; HUNT C, 1990, GENE, V87, P199, DOI 10.1016/0378-1119(90)90302-8; ILIAKIS G, 1990, INT J HYPERTHER, V6, P801, DOI 10.3109/02656739009140827; JEGGO PA, 1983, MUTAT RES, V112, P313, DOI 10.1016/0167-8817(83)90026-3; JORRITSMA JBM, 1986, RADIAT RES, V106, P89, DOI 10.2307/3576564; JORRITSMA JBM, 1984, RADIAT RES, V98, P198, DOI 10.2307/3576063; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; KIM D, 1995, J BIOL CHEM, V270, P15277, DOI 10.1074/jbc.270.25.15277; Kim Y, 1997, J CELL BIOCHEM, V67, P43, DOI 10.1002/(SICI)1097-4644(19971001)67:1<43::AID-JCB5>3.0.CO;2-W; Kline MP, 1997, MOL CELL BIOL, V17, P2107, DOI 10.1128/MCB.17.4.2107; Knauf U, 1996, GENE DEV, V10, P2782, DOI 10.1101/gad.10.21.2782; KURIMASA A, 1994, HUM GENET, V93, P21; LASZLO, 1992, CELL PROLIFERATION, V25, P59; LI GC, 1995, P NATL ACAD SCI USA, V92, P4512, DOI 10.1073/pnas.92.10.4512; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; Liu L, 1998, MOL CELL BIOL, V18, P4221, DOI 10.1128/MCB.18.7.4221; Matsumoto Y, 1997, BIOCHEM BIOPH RES CO, V234, P568, DOI 10.1006/bbrc.1997.6689; MIMORI T, 1986, J BIOL CHEM, V261, P2274; MIVECHI NF, 1995, J CELL BIOCHEM, V59, P266, DOI 10.1002/jcb.240590215; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; OHARA MD, 1995, INT J RADIAT ONCOL, V31, P905, DOI 10.1016/0360-3016(94)00435-8; PETERSON SR, 1995, P NATL ACAD SCI USA, V92, P3171, DOI 10.1073/pnas.92.8.3171; PETERSON SR, 1995, J BIOL CHEM, V270, P1449, DOI 10.1074/jbc.270.3.1449; ROBINSON JE, 1974, ACTA RADIOL THER PHY, V13, P241, DOI 10.3109/02841867409129880; Romero F, 1996, MOL CELL BIOL, V16, P37; Ruscetti T, 1998, J BIOL CHEM, V273, P14461, DOI 10.1074/jbc.273.23.14461; SAKAGUCHI Y, 1995, CANCER RES, V55, P5459; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; SELLINS KS, 1991, RADIAT RES, V126, P88, DOI 10.2307/3578175; Singleton BK, 1997, MOL CELL BIOL, V17, P1264, DOI 10.1128/MCB.17.3.1264; SUWA A, 1994, P NATL ACAD SCI USA, V91, P6904, DOI 10.1073/pnas.91.15.6904; Tsukamoto Y, 1998, GENES CELLS, V3, P135, DOI 10.1046/j.1365-2443.1998.00180.x; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WARTERS RL, 1985, J CELL PHYSIOL, V124, P481, DOI 10.1002/jcp.1041240318; WONG RSL, 1995, INT J RADIAT BIOL, V68, P141, DOI 10.1080/09553009514551041; Yang SH, 1996, MOL CELL BIOL, V16, P3799, DOI 10.1128/mcb.16.7.3799; Yang SH, 1998, EMBO J, V17, P1740, DOI 10.1093/emboj/17.6.1740; Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710; ZIMARINO V, 1987, NATURE, V327, P727, DOI 10.1038/327727a0	69	34	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					14988	14996		10.1074/jbc.274.21.14988	http://dx.doi.org/10.1074/jbc.274.21.14988			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329701	hybrid			2022-12-25	WOS:000081965200066
J	Schwartz, BS; Espana, F				Schwartz, BS; Espana, F			Two distinct urokinase-serpin interactions regulate the initiation of cell surface-associated plasminogen activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-CHAIN UROKINASE; PROTEIN-C INHIBITOR; ENZYMATIC-ACTIVITY; PLASMA; RECEPTOR; MONOCYTES; COMPLEXES; PURIFICATION; TYPE-1	Single-chain urokinase-type plasminogen activator (scu-PA) possesses enzymatic activity that increases by 2-3 orders of magnitude upon binding to its cellular cofactor, the u-PA receptor (u-PAR), hence activating an enzymatic cascade initially composed of zymogens. The present study demonstrates that plasminogen activator inhibitor type 3 (PAI-3) reversibly inhibits scu-PA in solution, maintaining the system "off." Because the scu-PA/PAT-3 interaction is reversible, cellular expression of u-PAR allows partitioning of scu-PA from PAI-3 to u-PAR with resultant expression of full enzymatic activity. PAI-3 that was originally complexed to scu-PA remains in solution, retaining its functional activity. Importantly, the scu-PA on cell surface u-PAR is protected from PAI-3 inhibition, remaining an effective activator in a PAI-rich environment. Plasmin formed as a result of scu-PA activity then cleaves scu-PA to the mature protease, two-chain u-PA (tcu-PA), which is efficiently and irreversibly inhibited by PAI-3 via the standard serpin mechanism, even on u-PAR. This data generates a new hypothesis which in contrast to the previous paradigm, holds that receptor bound scu-PA is the initiating enzyme and that tcu-PA is generated not to augment enzymatic activity but rather to allow for inhibition and therefore appropriate regulation of the process.	Univ Wisconsin, Dept Med, Madison, WI 53706 USA; Univ Wisconsin, Dept Biomol Chem, Madison, WI 53706 USA; Hosp La Fe, Ctr Invest, E-46009 Valencia, Spain	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Hospital Universitari i Politecnic La Fe	Schwartz, BS (corresponding author), Univ Wisconsin, Dept Med, Madison, WI 53706 USA.		España, Francisco/A-7286-2008		NHLBI NIH HHS [HL43506] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043506] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; BACHMAN F, 1994, HEMOSTASIS THROMBOSI, P1605; Bachmann F., 1994, HEMOSTASIS THROMBOSI, V3rd, P1592; BRUCH M, 1988, J BIOL CHEM, V263, P16626; CUBELLIS MV, 1989, P NATL ACAD SCI USA, V86, P4828, DOI 10.1073/pnas.86.13.4828; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; ESPANA F, 1989, THROMB RES, V55, P369, DOI 10.1016/0049-3848(89)90069-8; ESPANA F, 1993, THROMB HAEMOSTASIS, V70, P989; ESTREICHER A, 1990, J CELL BIOL, V111, P783, DOI 10.1083/jcb.111.2.783; HEEB MJ, 1987, J BIOL CHEM, V262, P15813; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; HIGAZI AA, 1995, J BIOL CHEM, V270, P17375, DOI 10.1074/jbc.270.29.17375; Koshland DE, 1998, SCIENCE, V280, P852, DOI 10.1126/science.280.5365.852; LAWRENCE DA, 1995, J BIOL CHEM, V270, P25309, DOI 10.1074/jbc.270.43.25309; MADISON EL, 1989, NATURE, V339, P721, DOI 10.1038/339721a0; MANCHANDA N, 1995, J BIOL CHEM, V270, P20032, DOI 10.1074/jbc.270.34.20032; MANCHANDA N, 1991, J BIOL CHEM, V266, P14580; MANCHANDA N, 1990, J IMMUNOL, V145, P4174; MUSSONI L, 1984, THROMB RES, V34, P241, DOI 10.1016/0049-3848(84)90008-2; NYKIAER A, 1992, J BIOL CHEM, V267, P14543; PANNELL R, 1987, BLOOD, V69, P22; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; RABBANI SA, 1992, J BIOL CHEM, V267, P14151; Stratikos E, 1997, P NATL ACAD SCI USA, V94, P453, DOI 10.1073/pnas.94.2.453; Tachias K, 1997, J BIOL CHEM, V272, P28; VASSALLI JD, 1984, J EXP MED, V159, P1653, DOI 10.1084/jem.159.6.1653; WILCZYNSKA M, 1995, J BIOL CHEM, V270, P29652; WUN TC, 1982, J BIOL CHEM, V257, P7262	28	28	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					15278	15283		10.1074/jbc.274.21.15278	http://dx.doi.org/10.1074/jbc.274.21.15278			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329738	hybrid			2022-12-25	WOS:000081965200103
J	van Endert, PM				van Endert, PM			Role of nucleotides and peptide substrate for stability and functional state of the human ABC family transporters associated with antigen processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; BINDING CASSETTE TRANSPORTER; RECONSTITUTED P-GLYCOPROTEIN; ATPASE ACTIVITY; ENCODED TRANSPORTER; ESCHERICHIA-COLI; TAP; PROTEIN; CFTR; DOMAINS	The transporters associated with antigen processing (TAP) belong to the family of ATP-binding cassette (ABC) transporters which share structural organization and use energy provided by ATP to translocate a large variety of solutes across cellular membranes. TAP is thought to hydrolyze ATP in order to deliver peptides to the endoplasmic reticulum where they can assemble with major histocompatibility complex class I molecules. However, initial binding of peptide substrates to TAP has been suggested to be ATP-independent. In this study, the effect of temperature, energetic nucleotides, and peptide on conformation and functional capacity of TAP proteins was examined. Incubation of insect cell microsomes overexpressing human TAP complexes or of human B cell microsomes at 37 degrees C induced a rapid and irreversible structural change that reduced dramatically TAP reactivity with antibodies to transmembrane and nucleotide-binding domains and abolished peptide binding and transport by TAP. These alterations were inhibited almost completely by di- or trinucleotides, and partially by high affinity peptides, suggesting that complete nucleotide dissociation inactivates TAP complexes. Experiments with isolated TAP subunits and fragments suggested that TAP complex stabilization by nucleotides may depend on their binding to the TAP1 subunit. Thus, the cellular level of functional TAP complexes may be regulated by nucleotide concentrations. It is speculated that this regulation may serve to prevent induction of autoimmunity by stressed cells with low energy levels.	Hop Necker Enfants Malad, INSERM, U25, F-75743 Paris 15, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	van Endert, PM (corresponding author), INSERM, U25, 161 Rue Sevres, F-75743 Paris 15, France.		van Endert, Peter/R-4606-2017	van Endert, Peter/0000-0003-3782-0750				Ahn K, 1996, EMBO J, V15, P3247, DOI 10.1002/j.1460-2075.1996.tb00689.x; ANDERSON MP, 1992, SCIENCE, V257, P1701, DOI 10.1126/science.1382316; ANDROLEWICZ MJ, 1994, IMMUNITY, V1, P7, DOI 10.1016/1074-7613(94)90004-3; Bakos E, 1997, BIOCHEM J, V323, P777, DOI 10.1042/bj3230777; Bliss JM, 1996, GLYCOBIOLOGY, V6, P445, DOI 10.1093/glycob/6.4.445; CARSON MR, 1995, J BIOL CHEM, V270, P1711, DOI 10.1074/jbc.270.4.1711; Chang XB, 1998, J BIOL CHEM, V273, P23844, DOI 10.1074/jbc.273.37.23844; Elliott T, 1997, ADV IMMUNOL, V65, P47, DOI 10.1016/S0065-2776(08)60741-5; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; KORONAKIS V, 1993, MOL MICROBIOL, V8, P1163, DOI 10.1111/j.1365-2958.1993.tb01661.x; Lacaille VG, 1998, J BIOL CHEM, V273, P17386, DOI 10.1074/jbc.273.28.17386; Li CH, 1996, J BIOL CHEM, V271, P28463, DOI 10.1074/jbc.271.45.28463; Mechetner EB, 1997, P NATL ACAD SCI USA, V94, P12908, DOI 10.1073/pnas.94.24.12908; MULLER KM, 1994, J BIOL CHEM, V269, P14032; NEEFJES JJ, 1993, SCIENCE, V261, P769, DOI 10.1126/science.8342042; Nijenhuis M, 1996, J IMMUNOL, V157, P5467; Nijenhuis M, 1996, J IMMUNOL, V156, P2186; Pamer E, 1998, ANNU REV IMMUNOL, V16, P323, DOI 10.1146/annurev.immunol.16.1.323; PANAGIOTIDIS CH, 1993, J BIOL CHEM, V268, P23685; QUINTON PM, 1992, NATURE, V360, P79, DOI 10.1038/360079a0; RUSS G, 1995, J BIOL CHEM, V270, P21312, DOI 10.1074/jbc.270.36.21312; SCHNEIDER E, 1994, J BIOL CHEM, V269, P20456; Schneider E, 1998, FEMS MICROBIOL REV, V22, P1; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; Senior AE, 1997, SEMIN CANCER BIOL, V8, P143, DOI 10.1006/scbi.1997.0065; SHAPIRO AB, 1994, J BIOL CHEM, V269, P3745; Sonveaux N, 1996, J BIOL CHEM, V271, P24617, DOI 10.1074/jbc.271.40.24617; Stephens DB, 1997, FEBS LETT, V416, P353, DOI 10.1016/S0014-5793(97)01221-0; Tomazin R, 1996, EMBO J, V15, P3256, DOI 10.1002/j.1460-2075.1996.tb00690.x; Uebel S, 1997, FEBS LETT, V416, P359, DOI 10.1016/S0014-5793(97)01222-2; VANENDERT PM, 1995, J EXP MED, V182, P1883, DOI 10.1084/jem.182.6.1883; VANENDERT PM, 1994, IMMUNITY, V1, P491, DOI 10.1016/1074-7613(94)90091-4; WANG K, 1994, FEBS LETT, V350, P337, DOI 10.1016/0014-5793(94)00806-X	33	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					14632	14638		10.1074/jbc.274.21.14632	http://dx.doi.org/10.1074/jbc.274.21.14632			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329656	hybrid			2022-12-25	WOS:000081965200021
J	Djellas, Y; Manganello, JM; Antonakis, K; Le Breton, GC				Djellas, Y; Manganello, JM; Antonakis, K; Le Breton, GC			Identification of G alpha(13) as one of the G-proteins that couple to human platelet thromboxane A(2) receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE BINDING-PROTEIN; STIMULATE PHOSPHOLIPASE-C; HUMAN-BLOOD PLATELETS; PORTAL-VEIN MYOCYTES; ALPHA-SUBUNITS; ADENYLYL-CYCLASE; G13 PROTEINS; P115 RHOGEF; EXCHANGE; PURIFICATION	Previous studies have shown that ligand or immunoaffinity chromatography can be used to purify the human platelet thromboxane A(2) (TXA(2)) receptor-G alpha(q) complex. The same principle of co-elution was used to identify another G-protein associated with platelet TXA(2) receptors, It was found that in addition to G alpha(q), purification of TXA(2) receptors by ligand (SQ31,491)-affinity chromatography resulted in the co-purification of a member of the G(12) family, Using an antipeptide antibody specific for the human G(13) alpha-subunit, this G-protein was identified as G alpha(13). In separate experiments, it was found that the TXA(2) receptor agonist U46619 stimulated [S-35]guanosine 5'-O-(3-thiotriphosphate) incorporation into G(13) alpha-subunit. Further evidence for functional coupling of G(13) to TXA(2) receptors was provided in studies where solubilized platelet membranes were subjected to immunoaffinity chromatography using an antibody raised against native TXA(2) receptor protein. It was found that U46619 induced a significant decrease in G alpha(q) and G alpha(13) association with the receptor protein. These results indicate that both G alpha(q) and G alpha(13) are functionally coupled to TXA(2) receptors and dissociate upon agonist activation. Furthermore, this agonist effect was specifically blocked by pretreatment with the TXA(2) receptor antagonist, BM13.505. Taken collectively, these data provide direct evidence that endogenous G alpha(13) is a TXA(2) receptor-coupled G-protein, as: 1) its alpha-subunit can be co-purified with the receptor protein using both ligand and immunoaffinity chromatography, 2) TXA(2) receptor activation stimulates GTP gamma S binding to G alpha(13), and 3) G alpha(13) affinity for the TXA(2) receptor can be modulated by agonist-receptor activation.	Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA; CNRS, Inst Rech Sci Canc, Chim Organ Biol & Spect UMR 133, F-94802 Villejuif, France	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Centre National de la Recherche Scientifique (CNRS)	Le Breton, GC (corresponding author), Univ Illinois, Coll Med, Dept Pharmacol, 835 S Wolcott Ave,M-C 868, Chicago, IL 60612 USA.				NHLBI NIH HHS [HL-24530, T32 HL07692] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024530, T32HL007692] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Allan CJ, 1996, J PHARMACOL EXP THER, V277, P1132; Althoefer H, 1997, J BIOL CHEM, V272, P24380, DOI 10.1074/jbc.272.39.24380; ARAGAY AM, 1995, J BIOL CHEM, V270, P20073, DOI 10.1074/jbc.270.34.20073; BALDASSARE JJ, 1993, BIOCHEM J, V291, P235, DOI 10.1042/bj2910235; Berestetskaya YV, 1998, J BIOL CHEM, V273, P27816, DOI 10.1074/jbc.273.43.27816; BORG C, 1993, BIOCHEM PHARMACOL, V45, P2071, DOI 10.1016/0006-2952(93)90018-R; BORG C, 1994, J BIOL CHEM, V269, P6109; BRACE LD, 1985, AM J PHYSIOL, V249, pH1, DOI 10.1152/ajpheart.1985.249.1.H1; BRASS LF, 1988, J BIOL CHEM, V263, P5348; BRASS LF, 1987, J CLIN INVEST, V79, P1269, DOI 10.1172/JCI112947; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; COLEMAN RA, 1979, BRIT J PHARMACOL, V68, pP127; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; Djellas Y, 1998, P NATL ACAD SCI USA, V95, P10944, DOI 10.1073/pnas.95.18.10944; DORN GW, 1990, CIRCULATION, V81, P212, DOI 10.1161/01.CIR.81.1.212; FITZGERALD DJ, 1986, NEW ENGL J MED, V315, P983, DOI 10.1056/NEJM198610163151602; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; Gohla A, 1998, J BIOL CHEM, V273, P4653, DOI 10.1074/jbc.273.8.4653; HAMBERG M, 1975, P NATL ACAD SCI USA, V72, P2994, DOI 10.1073/pnas.72.8.2994; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; KABOURIDIS PS, 1995, MOL CELL BIOCHEM, V144, P45, DOI 10.1007/BF00926739; KIM SO, 1992, BIOCHEM PHARMACOL, V43, P313; Kitamura K, 1996, J BIOL CHEM, V271, P7412, DOI 10.1074/jbc.271.13.7412; KITAMURA K, 1995, AM J PHYSIOL-CELL PH, V268, pC101, DOI 10.1152/ajpcell.1995.268.1.C101; KNEZEVIC I, 1993, J BIOL CHEM, V268, P26011; KNEZEVIC I, 1992, J PHARMACOL EXP THER, V260, P947; Kozasa T, 1996, J BIOL CHEM, V271, P12562, DOI 10.1074/jbc.271.21.12562; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lin X, 1996, J BIOL CHEM, V271, P22604, DOI 10.1074/jbc.271.37.22604; Macrez N, 1997, J BIOL CHEM, V272, P23180, DOI 10.1074/jbc.272.37.23180; MacrezLepretre N, 1997, J BIOL CHEM, V272, P10095; MILLIGAN G, 1992, FEBS LETT, V297, P186, DOI 10.1016/0014-5793(92)80357-M; NEEDLEMAN P, 1976, SCIENCE, V193, P163, DOI 10.1126/science.945611; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; PATSCHEKE H, 1987, THROMB HAEMOSTASIS, V58, P182; PATSCHEKE H, 1984, THROMB RES, V33, P277, DOI 10.1016/0049-3848(84)90163-4; PATSCHEKE H, 1984, BIOMED BIOCHIM ACTA, V43, P312; Plonk SG, 1998, J BIOL CHEM, V273, P4823, DOI 10.1074/jbc.273.9.4823; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SIESS W, 1985, BLOOD, V65, P1141; SIFFERT W, 1990, J BIOL CHEM, V265, P719; SPICHER K, 1994, BIOCHEM BIOPH RES CO, V198, P906, DOI 10.1006/bbrc.1994.1129; STRATHMANN M, 1989, P NATL ACAD SCI USA, V86, P7407, DOI 10.1073/pnas.86.19.7407; STRATHMANN M, 1989, P NATL ACAD SCI USA, V88, P5582; STRYER L, 1985, BIOPOLYMERS, V24, P29, DOI 10.1002/bip.360240105; SWEATT JD, 1986, J BIOL CHEM, V261, P8667; SWEATT JD, 1986, J BIOL CHEM, V261, P8660; Tosun M, 1998, J PHARMACOL EXP THER, V284, P921; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; USHIKUBI F, 1989, J BIOL CHEM, V264, P16496; USHIKUBI F, 1987, THROMB HAEMOSTASIS, V57, P158; VOYNOYASENETSKAYA T, 1994, J BIOL CHEM, V269, P4721; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; WU KK, 1981, J CLIN INVEST, V67, P1801, DOI 10.1172/JCI110221; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; XU NZ, 1994, BIOCHEM BIOPH RES CO, V201, P603, DOI 10.1006/bbrc.1994.1744	62	60	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					14325	14330		10.1074/jbc.274.20.14325	http://dx.doi.org/10.1074/jbc.274.20.14325			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318854	hybrid			2022-12-25	WOS:000080322200083
J	Pelkmans, L; Helenius, A				Pelkmans, L; Helenius, A			Expression of antibody interferes with disulfide bond formation and intracellular transport of antigen in the secretory pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLUENZA-VIRUS HEMAGGLUTININ; ENDOPLASMIC-RETICULUM; MEMBRANE-FUSION; PROTEIN; CALNEXIN; CELL; IMMUNIZATION; NETWORK	To determine whether antibodies would interfere with the folding of glycoprotein antigens in the endoplasmic reticulum lumen of living cells, hybridoma cells producing monoclonal anti-hemagglutinin (HA) antibodies were infected with influenza virus. The fate of the newly synthesized HA was determined using an established pulse-chase approach. When the monoclonal antibodies were against epitopes present on early folding intermediates, folding and intracellular transport of HA to the Golgi complex were severely disturbed. On the other hand, when the antibodies were specific for the native HA trimers, immune complexes were formed, but folding or transport of HA was not affected. The use of antibodies in this way provided in situ information about the protein folding process inside the endoplasmic reticulum lumen of cells without external perturbation of the folding chains or the folding compartment.	ETH Zurich, Biochem Lab, Swiss Fed Inst Technol, CH-8092 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Helenius, A (corresponding author), ETH Zurich, Biochem Lab, Swiss Fed Inst Technol, Univ Str 16, CH-8092 Zurich, Switzerland.			Pelkmans, Lucas/0000-0002-6754-9730				Anfinsen C B, 1975, Adv Protein Chem, V29, P205, DOI 10.1016/S0065-3233(08)60413-1; BIOCCA S, 1995, TRENDS CELL BIOL, V5, P248, DOI 10.1016/S0962-8924(00)89019-4; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; BURKE B, 1984, CELL, V36, P847, DOI 10.1016/0092-8674(84)90034-5; CHEN W, 1995, P NATL ACAD SCI USA, V92, P6229, DOI 10.1073/pnas.92.14.6229; COPELAND CS, 1986, J CELL BIOL, V103, P1179, DOI 10.1083/jcb.103.4.1179; COPELAND CS, 1988, CELL, V53, P197, DOI 10.1016/0092-8674(88)90381-9; DOMS RW, 1985, J BIOL CHEM, V260, P2973; Ellis RJ, 1996, FASEB J, V10, P20, DOI 10.1096/fasebj.10.1.8566542; Fedorov AN, 1997, J BIOL CHEM, V272, P32715, DOI 10.1074/jbc.272.52.32715; GETHING MJ, 1986, J CELL BIOL, V102, P11, DOI 10.1083/jcb.102.1.11; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GREBER UF, 1992, J CELL BIOL, V116, P15, DOI 10.1083/jcb.116.1.15; Hebert DN, 1997, J CELL BIOL, V139, P613, DOI 10.1083/jcb.139.3.613; Helenius Ari, 1992, Trends in Cell Biology, V2, P227, DOI 10.1016/0962-8924(92)90309-B; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; LODISH HF, 1993, J BIOL CHEM, V268, P20598; MCCAFFERTY J, 1990, NATURE, V348, P552, DOI 10.1038/348552a0; Persic L, 1997, GENE, V187, P1, DOI 10.1016/S0378-1119(96)00627-0; TATU U, 1995, EMBO J, V14, P1340, DOI 10.1002/j.1460-2075.1995.tb07120.x; Tatu U, 1997, J CELL BIOL, V136, P555, DOI 10.1083/jcb.136.3.555; TSOU CL, 1988, BIOCHEMISTRY-US, V27, P1809, DOI 10.1021/bi00406a001; Zhou P, 1998, J IMMUNOL, V160, P1489	24	2	3	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					14495	14499		10.1074/jbc.274.20.14495	http://dx.doi.org/10.1074/jbc.274.20.14495			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318876	hybrid, Green Published			2022-12-25	WOS:000080322200105
J	Liu, PCC; Thiele, DJ				Liu, PCC; Thiele, DJ			Modulation of human heat shock factor trimerization by the linker domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING DOMAIN; ZN(2)CYS(6) BINUCLEAR CLUSTER; TRANSCRIPTION FACTOR CONTAINS; COILED-COIL; NUCLEAR-LOCALIZATION; CRYSTAL-STRUCTURE; ACTIVATION DOMAIN; FACTOR-II; YEAST; PROTEIN	Heat shock transcription factors (HSFs) are stress-responsive proteins that activate the expression of heat shock genes and are highly conserved from bakers' yeast to humans. Under basal conditions, the human HSF1 protein is maintained as an inactive monomer through intramolecular interactions between two coiled-coil domains and interactions with heat shock proteins; upon environmental, pharmacological, or physiological stress, HSF1 is converted to a homotrimer that binds to its cognate DNA binding site with high affinity. To dissect regions of HSF1 that make important contributions to the stability of the monomer under unstressed conditions, we have used functional complementation in bakers' yeast as a facile assay system. Whereas wild-type human HSF1 is restrained as an inactive monomer in yeast that is unable to substitute for the essential yeast HSF protein, mutations in the linker region between the DNA binding domain and the first coiled-coil allow HSF1 to homotrimerize and rescue the viability defect of a hsf Delta strain. Fine mapping by functional analysis of HSF1-HSF2 chimeras and point mutagenesis revealed that a small region in the aminoterminal portion of the HSF1 linker is required for maintenance of HSF1 in the monomeric state in both yeast and in transfected human 293 cells. Although linker regions in transcription factors are known to modulate DNA binding specificity, our studies suggest that the human HSF1 linker plays no role in determining HSF1 binding preferences in vivo but is a critical determinant in regulating the HSF1 monomer-trimer equilibrium.	Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Thiele, DJ (corresponding author), Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA.	dthiele@umich.edu			NIGMS NIH HHS [GM18858] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAVAYA K, 1992, GENE DEV, V6, P1153, DOI 10.1101/gad.6.7.1153; Ali A, 1998, MOL CELL BIOL, V18, P4949, DOI 10.1128/MCB.18.9.4949; BALER R, 1993, MOL CELL BIOL, V13, P2486, DOI 10.1128/MCB.13.4.2486; Farkas T, 1998, MOL CELL BIOL, V18, P906, DOI 10.1128/MCB.18.2.906; FLICK KE, 1994, J BIOL CHEM, V269, P12475; GALLO GJ, 1993, MOL CELL BIOL, V13, P749, DOI 10.1128/MCB.13.2.749; GIARDINA C, 1995, MOL CELL BIOL, V15, P2737; GREEN M, 1995, MOL CELL BIOL, V15, P3354; HARRISON CJ, 1994, SCIENCE, V263, P224, DOI 10.1126/science.8284672; JAKOBSEN BK, 1988, MOL CELL BIOL, V8, P5040, DOI 10.1128/MCB.8.11.5040; Jedlicka P, 1997, EMBO J, V16, P2452, DOI 10.1093/emboj/16.9.2452; JURIVICH DA, 1992, SCIENCE, V255, P1243, DOI 10.1126/science.1546322; KRAULIS PJ, 1992, NATURE, V356, P448, DOI 10.1038/356448a0; KROEGER PE, 1994, MOL CELL BIOL, V14, P7592, DOI 10.1128/MCB.14.11.7592; KROEGER PE, 1993, MOL CELL BIOL, V13, P3370, DOI 10.1128/MCB.13.6.3370; LIS J, 1993, CELL, V74, P1, DOI 10.1016/0092-8674(93)90286-Y; Liu XD, 1997, EMBO J, V16, P6466, DOI 10.1093/emboj/16.21.6466; MARMORSTEIN R, 1992, NATURE, V356, P408, DOI 10.1038/356408a0; MARMORSTEIN R, 1994, GENE DEV, V8, P2504, DOI 10.1101/gad.8.20.2504; McMillan DR, 1998, J BIOL CHEM, V273, P7523, DOI 10.1074/jbc.273.13.7523; Morimoto R. I., 1994, COLD SPRING HARBOR M, V26; NIETOSOTELO J, 1990, CELL, V62, P807, DOI 10.1016/0092-8674(90)90124-W; Nover L, 1997, CELL MOL LIFE SCI, V53, P80, DOI 10.1007/PL00000583; Orosz A, 1996, MOL CELL BIOL, V16, P7018; PERISIC O, 1989, CELL, V59, P797, DOI 10.1016/0092-8674(89)90603-X; PETERANDERL R, 1992, BIOCHEMISTRY-US, V31, P12272, DOI 10.1021/bi00163a042; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; REECE RJ, 1993, SCIENCE, V261, P909, DOI 10.1126/science.8346441; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; Satyal SH, 1998, GENE DEV, V12, P1962, DOI 10.1101/gad.12.13.1962; Schwabe JWR, 1997, NAT STRUCT BIOL, V4, P680, DOI 10.1038/nsb0997-680; SHELDON LA, 1993, GENE DEV, V7, P1549, DOI 10.1101/gad.7.8.1549; Shi YH, 1998, GENE DEV, V12, P654, DOI 10.1101/gad.12.5.654; SHI YH, 1995, MOL CELL BIOL, V15, P4309; SILAR P, 1991, MOL CELL BIOL, V11, P1232, DOI 10.1128/MCB.11.3.1232; SORGER PK, 1991, CELL, V65, P363, DOI 10.1016/0092-8674(91)90452-5; SORGER PK, 1987, NATURE, V329, P81, DOI 10.1038/329081a0; SORGER PK, 1989, CELL, V59, P807, DOI 10.1016/0092-8674(89)90604-1; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; Swaminathan K, 1997, NAT STRUCT BIOL, V4, P751, DOI 10.1038/nsb0997-751; VUISTER GW, 1994, NAT STRUCT BIOL, V1, P605, DOI 10.1038/nsb0994-605; Walters KJ, 1997, NAT STRUCT BIOL, V4, P744, DOI 10.1038/nsb0997-744; WESTWOOD JT, 1993, MOL CELL BIOL, V13, P3481, DOI 10.1128/MCB.13.6.3481; WESTWOOD JT, 1991, NATURE, V353, P822, DOI 10.1038/353822a0; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; Zandi E, 1997, GENE DEV, V11, P1299, DOI 10.1101/gad.11.10.1299; Zhong M, 1999, J BIOL CHEM, V274, P3135, DOI 10.1074/jbc.274.5.3135; Zhong M, 1998, MOL CELL, V2, P101, DOI 10.1016/S1097-2765(00)80118-5; Zou JY, 1998, CELL, V94, P471, DOI 10.1016/S0092-8674(00)81588-3; ZUO JR, 1994, MOL CELL BIOL, V14, P7557, DOI 10.1128/MCB.14.11.7557; ZUO JR, 1995, MOL CELL BIOL, V15, P4319	51	49	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17219	17225		10.1074/jbc.274.24.17219	http://dx.doi.org/10.1074/jbc.274.24.17219			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358080	hybrid			2022-12-25	WOS:000080780400079
J	Zimmermann, S; Baumann, A; Jaekel, K; Marbach, I; Engelberg, D; Frohnmeyer, H				Zimmermann, S; Baumann, A; Jaekel, K; Marbach, I; Engelberg, D; Frohnmeyer, H			UV-responsive genes of Arabidopsis revealed by similarity to the Gcn4-mediated UV response in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSIDE DIPHOSPHATE KINASE; AMINO-ACID TRANSPORTER; NF-KAPPA-B; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTOR; CHALCONE SYNTHASE; PROTEIN-KINASE; DNA-DAMAGE; SIGNALING PATHWAY; TYROSINE KINASES	A UV response that involves the Ras proteins and AP-1 transcription factors has recently been described in mammals and yeast. To test whether an equivalent response exists in plants, we monitored the expression of Arabidopsis histidinol dehydrogenase gene (HDH), a homologue of the yeast HIS4 gene, which is strongly induced by UV light and is a target of the transcriptional activator Gcn4. We show that HDH mRNA levels increase specifically in response to UV-B light. Only small increases were detected upon exposure to other wavelengths. To isolate plant genes involved in this UV response, a gcn4 mutant was transfected with an Arabidopsis thaliana cDNA library. A new type of nucleotide diphosphate kinase (NDPK Ia) with a significant homology to the human tumor suppressor protein Nm23 rescued the gcn4 phenotype. NDPK Ia specifically binds to the HIS4 promoter in vitro and induces HIS4 transcription in yeast. In Arabidopsis, the NDPK Ia protein is located in the nucleus and cytosol, Expression studies in seedlings revealed that the level of NDPK la mRNA, like that of HDH, increases in response to UV-B light. It appears that NDPK Ia and HDH are components of a novel W-responsive pathway in A. thaliana.	Univ Freiburg, Inst Biol Bot 2, D-79104 Freiburg, Germany; Hebrew Univ Jerusalem, Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel	University of Freiburg; Hebrew University of Jerusalem	Frohnmeyer, H (corresponding author), Univ Freiburg, Inst Biol Bot 2, Schanzlestr 1, D-79104 Freiburg, Germany.							ARNDT K, 1986, P NATL ACAD SCI USA, V83, P8516, DOI 10.1073/pnas.83.22.8516; Bender K, 1998, EMBO J, V17, P5170, DOI 10.1093/emboj/17.17.5170; Bonk M, 1997, EUR J BIOCHEM, V247, P942, DOI 10.1111/j.1432-1033.1997.00942.x; BREWS T, 1991, GENETIC ENG, P221; Britt AB, 1996, ANNU REV PLANT PHYS, V47, P75, DOI 10.1146/annurev.arplant.47.1.75; Chen LS, 1997, PLANT PHYSIOL, V115, P1127, DOI 10.1104/pp.115.3.1127; Christie JM, 1996, PLANT CELL, V8, P1555, DOI 10.1105/tpc.8.9.1555; Conconi A, 1996, NATURE, V383, P826, DOI 10.1038/383826a0; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; ENGELBERG D, 1994, CELL, V77, P381, DOI 10.1016/0092-8674(94)90153-8; FROHNMEYER H, 1992, PLANT J, V2, P899, DOI 10.1111/j.1365-313X.1992.00899.x; Frohnmeyer H, 1997, J EXP BOT, V48, P739, DOI 10.1093/jxb/48.3.739; Frohnmeyer H, 1998, PLANT J, V13, P763, DOI 10.1046/j.1365-313X.1998.00074.x; FROMMER WB, 1993, P NATL ACAD SCI USA, V90, P5944, DOI 10.1073/pnas.90.13.5944; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GUYER D, 1995, P NATL ACAD SCI USA, V92, P4997, DOI 10.1073/pnas.92.11.4997; HAHLBROCK K, 1989, ANNU REV PLANT PHYS, V40, P347, DOI 10.1146/annurev.pp.40.060189.002023; Haseloff J, 1997, P NATL ACAD SCI USA, V94, P2122, DOI 10.1073/pnas.94.6.2122; Herrlich P, 1997, BIOL CHEM, V378, P1217; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILDEBRANDT M, 1995, NUCLEIC ACIDS RES, V23, P3858, DOI 10.1093/nar/23.19.3858; HINNEBUSCH AG, 1988, MICROBIOL REV, V52, P248, DOI 10.1128/MMBR.52.2.248-273.1988; Holdsworth MJ, 1995, PLANT MOL BIOL, V29, P711, DOI 10.1007/BF00041162; HOPE IA, 1985, CELL, V43, P177, DOI 10.1016/0092-8674(85)90022-4; HSU LC, 1993, P NATL ACAD SCI USA, V90, P7441, DOI 10.1073/pnas.90.16.7441; JORDAN BR, 1996, ADV BOT RES, V22, P98; KANAZAWA S, 1988, MOL CELL BIOL, V8, P664, DOI 10.1128/MCB.8.2.664; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kircher S, 1998, MOL GEN GENET, V257, P595, DOI 10.1007/s004380050687; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; Kraeft SK, 1996, EXP CELL RES, V227, P63, DOI 10.1006/excr.1996.0250; Lee H, 1997, INT J ONCOL, V11, P965; LIEBECK J, 1995, PLANTA, V196, P668; LITTLE JW, 1982, CELL, V29, P11, DOI 10.1016/0092-8674(82)90085-X; LUCCHINI G, 1984, MOL CELL BIOL, V4, P1326, DOI 10.1128/MCB.4.7.1326; MAURI I, 1993, MOL GEN GENET, V241, P319, DOI 10.1007/BF00284684; Michelotti EF, 1997, J BIOL CHEM, V272, P22526, DOI 10.1074/jbc.272.36.22526; MINET M, 1992, PLANT J, V2, P417; NAGAI A, 1991, P NATL ACAD SCI USA, V88, P4133, DOI 10.1073/pnas.88.10.4133; Navas TA, 1996, GENE DEV, V10, P2632, DOI 10.1101/gad.10.20.2632; NIYOGI KK, 1992, PLANT CELL, V4, P721, DOI 10.1105/tpc.4.6.721; NOMURA T, 1991, BIOCHIM BIOPHYS ACTA, V1077, P47, DOI 10.1016/0167-4838(91)90524-4; Ouatas T, 1998, INT J DEV BIOL, V42, P43; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; Postel EH, 1996, P NATL ACAD SCI USA, V93, P6892, DOI 10.1073/pnas.93.14.6892; ROLFES RJ, 1993, MOL CELL BIOL, V13, P5099, DOI 10.1128/MCB.13.8.5099; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SCHAFER E, 1977, OPTISCHE STRAHLUNGSQ, P249; SCHINDLER U, 1992, EMBO J, V11, P1261, DOI 10.1002/j.1460-2075.1992.tb05170.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STRUHL K, 1988, NATURE, V332, P649, DOI 10.1038/332649a0; TADA S, 1994, PLANT PHYSIOL, V105, P79; TICEBALDWIN K, 1989, SCIENCE, V246, P931, DOI 10.1126/science.2683089; WALKER GC, 1985, ANNU REV BIOCHEM, V54, P425, DOI 10.1146/annurev.bi.54.070185.002233; WEISSHAAR B, 1991, EMBO J, V10, P1777, DOI 10.1002/j.1460-2075.1991.tb07702.x	58	69	78	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17017	17024		10.1074/jbc.274.24.17017	http://dx.doi.org/10.1074/jbc.274.24.17017			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358052	hybrid			2022-12-25	WOS:000080780400051
J	Agata, Y; Matsuda, E; Shimizu, A				Agata, Y; Matsuda, E; Shimizu, A			Two novel Kruppel-associated box-containing zinc-finger proteins, KRAZ1 and KRAZ2, repress transcription through functional interaction with the corepressor KAP-1 (TIF1 beta/KRIP-1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; NUCLEAR RECEPTORS; RING FINGER; DOMAIN; DROSOPHILA; FAMILY; BROMODOMAIN; EXPRESSION; TIF1-ALPHA; ACTIVATION	We have isolated two novel Kruppel-like zinc finger proteins containing the evolutionarily conserved Kruppel-associated box (KRAB), KRAZ1 and KRAZ2, and demonstrated that they repress transcription when heterologously targeted to DNA. Their repression activity appeared to be mediated by the putative corepressor RAP-1 (KRAB-associated protein-1), because KRAZ1/2 bind to KAP-1, but KRAB mutants of KRAZ1/2 that are unable to interact with KAP-1 lack repression activity, and KAP-1 has intrinsic repressor activity and potentiates KRAZ1/2-mediated repression. We dissected the KAP-1 protein into a KRAB-interacting domain and a region necessary for repression. Using a mammalian two-hybrid assay, we further demonstrated that KAP-1 deletions lacking repression activity fused to the VP16 transactivation domain strongly activated transcription when coexpressed with KRAZ1. In contrast, VP16-KAP-1 fusions retaining repression activity resulted in repression. These results provide the first evidence that KAP-1 functionally interacts with KRAB in mammalian cells and seems to exert repressor activity in the DNA-bound KRAB-KAP-1 complex, and they further support the hypothesis that KAP-1 functions as a corepressor for the large class of KRAB-containing zinc finger proteins.	Kyoto Univ, Ctr Mol Biol & Genet, Sakyo Ku, Kyoto 6068501, Japan	Kyoto University	Shimizu, A (corresponding author), Kyoto Univ, Ctr Mol Biol & Genet, Sakyo Ku, Kyoto 6068501, Japan.	shimizu@virus.kyoto-u.ac.jp		Agata, Yasutoshi/0000-0001-9642-6994				AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; Agata Y, 1998, GENE, V213, P55, DOI 10.1016/S0378-1119(98)00213-3; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BELLEFROID EJ, 1991, P NATL ACAD SCI USA, V88, P3608, DOI 10.1073/pnas.88.9.3608; BELLEFROID EJ, 1989, DNA-J MOLEC CELL BIO, V8, P377, DOI 10.1089/dna.1.1989.8.377; Chang CJ, 1998, MOL CELL BIOL, V18, P5880, DOI 10.1128/MCB.18.10.5880; CHOWDHURY K, 1987, CELL, V48, P771, DOI 10.1016/0092-8674(87)90074-2; Fraser RA, 1998, J BIOL CHEM, V273, P16199, DOI 10.1074/jbc.273.26.16199; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067; HAYNES SR, 1992, NUCLEIC ACIDS RES, V20, P2603, DOI 10.1093/nar/20.10.2603; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Jeanmougin F, 1997, TRENDS BIOCHEM SCI, V22, P151, DOI 10.1016/S0968-0004(97)01042-6; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Kim SS, 1996, P NATL ACAD SCI USA, V93, P15299, DOI 10.1073/pnas.93.26.15299; KLUG A, 1995, FASEB J, V9, P597, DOI 10.1096/fasebj.9.8.7768350; KOPAN R, 1994, DEVELOPMENT, V120, P2385; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; Kurooka H, 1998, NUCLEIC ACIDS RES, V26, P5448, DOI 10.1093/nar/26.23.5448; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MARGOLIN JF, 1994, P NATL ACAD SCI USA, V91, P4509, DOI 10.1073/pnas.91.10.4509; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Moosmann P, 1996, NUCLEIC ACIDS RES, V24, P4859, DOI 10.1093/nar/24.24.4859; Moosmann P, 1997, BIOL CHEM, V378, P669, DOI 10.1515/bchm.1997.378.7.669; Nakamura M, 1996, INT IMMUNOL, V8, P193, DOI 10.1093/intimm/8.2.193; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PENGUE G, 1994, NUCLEIC ACIDS RES, V22, P2908, DOI 10.1093/nar/22.15.2908; Pengue G, 1996, P NATL ACAD SCI USA, V93, P1015, DOI 10.1073/pnas.93.3.1015; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; SCHUH R, 1986, CELL, V47, P1025, DOI 10.1016/0092-8674(86)90817-2; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; VISSING H, 1995, FEBS LETT, V369, P153, DOI 10.1016/0014-5793(95)00728-R; WITZGALL R, 1994, P NATL ACAD SCI USA, V91, P4514, DOI 10.1073/pnas.91.10.4514	38	72	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16412	16422		10.1074/jbc.274.23.16412	http://dx.doi.org/10.1074/jbc.274.23.16412			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347202	hybrid			2022-12-25	WOS:000080668600062
J	Bohrmann, B; Tjernberg, L; Kuner, P; Poli, S; Levet-Trafit, B; Naslund, J; Richards, G; Huber, W; Dobeli, H; Nordstedt, C				Bohrmann, B; Tjernberg, L; Kuner, P; Poli, S; Levet-Trafit, B; Naslund, J; Richards, G; Huber, W; Dobeli, H; Nordstedt, C			Endogenous proteins controlling amyloid beta-peptide polymerization - Possible implications for beta-amyloid formation in the central nervous system and in peripheral tissues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; CEREBROSPINAL-FLUID; PRECURSOR PROTEIN; FIBRIL FORMATION; HUMAN PLASMA; P COMPONENT; ALPHA-2-MACROGLOBULIN; DEPOSITION; TERMINUS; INVITRO	We report that certain plasma proteins, at physiological concentrations, are potent inhibitors of amyloid beta-peptide (A beta) polymerization. These proteins are also present in cerebrospinal fluid, but at low concentrations having little or no effect on A beta. Thirteen proteins representing more than 90% of the protein content in plasma and cerebrospinal fluid were studied. Quantitatively, albumin was the most important protein, representing 60% of the total amyloid inhibitory activity, followed by alpha(1)-antitrypsin and immunoglobulins A and G, Albumin suppressed amyloid formation by binding to the oligomeric or polymeric A beta, blocking a further addition of peptide. This effect was also observed when the incorporation of labeled A beta into genuine beta-amyloid in tissue section was studied. The A beta and the anti-diabetic drug tolbutamide apparently bind to the same site on albumin. Tolbutamide displaces A beta from albumin, increasing its free concentration and enhancing amyloid formation. The present results suggest that several endogenous proteins are negative regulators of amyloid formation. Plasma contains at least 300 times more amyloid inhibitory activity than cerebrospinal fluid. These findings may provide one explanation as to why beta-amyloid deposits are not found in peripheral tissues but are only found in the central nervous system. Moreover, the data suggest that some drugs that display an affinity for albumin may enhance beta-amyloid formation and promote the development of Alzheimer's disease.	F Hoffmann La Roche AG, Div Pharma, Preclin Res, CH-4070 Basel, Switzerland; Karolinska Hosp, Lab Biochem & Mol Pharmacol, Sect Drug Dependence Res, Dept Clin Neurosci, S-17177 Stockholm, Sweden; Karolinska Inst, Dept Clin Neurosci Occupat Therapy & Elderly Care, S-14186 Huddinge, Sweden	Roche Holding; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet	Nordstedt, C (corresponding author), F Hoffmann La Roche AG, Div Pharma, Preclin Res, CH-4070 Basel, Switzerland.			Kuner, Pascal/0000-0001-6513-5414				Biere AL, 1996, J BIOL CHEM, V271, P32916, DOI 10.1074/jbc.271.51.32916; Blacker D, 1998, NAT GENET, V19, P357, DOI 10.1038/1243; Breitner JCS, 1996, NEUROBIOL AGING, V17, P789; Burtis C.A., 1994, TXB CLIN CHEM, V2nd, P1715; DOOLITTLE DF, 1994, MOL BASIS BLOOD DIS, P701; ERIKSSON S, 1995, P NATL ACAD SCI USA, V92, P2313, DOI 10.1073/pnas.92.6.2313; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V122, P1131, DOI 10.1016/0006-291X(84)91209-9; Goodman Gilman G, 1996, GOODMAN GILMANS PHAR, V9th, P3; HAASS C, 1993, ANN NY ACAD SCI, V695, P109, DOI 10.1111/j.1749-6632.1993.tb23037.x; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; Hardman J. G., 1996, GOODMAN GILMANS PHAR; HAWKINS PN, 1994, BIOCHEM BIOPH RES CO, V201, P722, DOI 10.1006/bbrc.1994.1760; JANCIAUSKIENE S, 1995, J BIOL CHEM, V270, P26041, DOI 10.1074/jbc.270.44.26041; JARRETT JT, 1993, ANN NY ACAD SCI, V695, P144, DOI 10.1111/j.1749-6632.1993.tb23043.x; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; KISILEVSKY R, 1988, PATHOLOGY, P1178; KOUDINOV A, 1994, BIOCHEM BIOPH RES CO, V205, P1164, DOI 10.1006/bbrc.1994.2788; LANNFELT L, 1995, NEUROSCI LETT, V199, P203, DOI 10.1016/0304-3940(95)12059-D; LANNFELT L, 1995, NAT MED, V1, P829, DOI 10.1038/nm0895-829; MAGGIO JE, 1992, P NATL ACAD SCI USA, V89, P5462, DOI 10.1073/pnas.89.12.5462; NASLUND J, 1994, P NATL ACAD SCI USA, V91, P8378, DOI 10.1073/pnas.91.18.8378; Orgel LE, 1996, CHEM BIOL, V3, P413, DOI 10.1016/S1074-5521(96)90087-3; PIKE CJ, 1993, J NEUROSCI, V13, P1676; Pitschke M, 1998, NAT MED, V4, P832, DOI 10.1038/nm0798-832; Podlisny MB, 1998, BIOCHEMISTRY-US, V37, P3602, DOI 10.1021/bi972029u; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; SELKOE DJ, 1989, ANN MED, V21, P73, DOI 10.3109/07853898909149187; SMITH MD, 1976, J IMMUNOL METHODS, V9, P373, DOI 10.1016/0022-1759(76)90212-X; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; VASILEVA TG, 1989, VOP MED KHIM, V35, P48; VATASSERY GT, 1991, CLIN CHIM ACTA, V197, P19, DOI 10.1016/0009-8981(91)90344-C; WALLUM BJ, 1987, J CLIN ENDOCR METAB, V64, P190, DOI 10.1210/jcem-64-1-190; WISNIEWSKI T, 1993, ANN NEUROL, V34, P631, DOI 10.1002/ana.410340422; WRIGLEY NG, 1968, J ULTRA MOL STRUCT R, V24, P454, DOI 10.1016/S0022-5320(68)80048-6	41	131	138	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					15990	15995		10.1074/jbc.274.23.15990	http://dx.doi.org/10.1074/jbc.274.23.15990			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347147	hybrid			2022-12-25	WOS:000080668600007
J	Feinmesser, RL; Wicks, SJ; Taverner, CJ; Chantry, A				Feinmesser, RL; Wicks, SJ; Taverner, CJ; Chantry, A			Ca2+/calmodulin-dependent kinase II phosphorylates the epidermal growth factor receptor on multiple sites in the cytoplasmic tail and serine 744 within the kinase domain to regulate signal generation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; TYROSINE KINASE; EGF RECEPTOR; SELF-PHOSPHORYLATION; V-ERBB; ACTIVATION; THREONINE; CELLS; TRANSFORMATION; TRANSDUCTION	Down-regulation of receptor tyrosine kinase activity plays an essential role in coordinating and controlling cellular growth/differentiation. Ca2+/calmodulin-dependent kinase II (CaM kinase II)-mediated phosphorylation of threonine 1172 in the cytoplasmic tail of HER2/c-erbB2 can modulate tyrosine kinase activity and consensus phosphorylation sites are also found at serines 1046/1047 in the structurally related epidermal growth factor receptor (EGFR). We show that serines 1046/1047 are sites for CaM kinase II phosphorylation, although there is a preference for serine 1047, which resides within the consensus -R-X-X-S-, In addition, we have identified major phosphorylation sites at serine 1142 and serine 1057, which lie within a novel -S-X-D-consensus. Mutation of serines 1046/1047 in full-length EGFR enhanced both fibroblast transformation and tyrosine autokinase activity that was significantly potentiated by additional mutation of serines 1057 and 1142. A single CaM kinase II site was also identified at serine 744 within sub-kinase domain III, and autokinase activity was significantly affected by mutation of this serine to an aspartic acid making this site appear constitutively phosphorylated, We have addressed the mechanism by which CaM kinase II phosphorylation of the EGFR might regulate receptor autokinase activity and show that this modification can hinder association of the cytoplasmic tail with the kinase domain to prevent an enzyme-substrate interaction. We postulate that the location and greater number of CaM kinase II phosphorylation sites in the EGFR compared with HER-2/c-erbB2, leading to differential regulation of autokinase activity, contributes to differences in the strength of downstream signaling events and may explain the higher relative transforming potential of HER-2/c-erbB2.	Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Canc Med, London W6 8RP, England	Imperial College London	Chantry, A (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Canc Med, Charing Cross Campus,Fulham Palace Rd, London W6 8RP, England.							ADAM MA, 1991, J VIROL, V65, P4985, DOI 10.1128/JVI.65.9.4985-4990.1991; ANDO S, 1991, BIOCHEM BIOPH RES CO, V175, P955, DOI 10.1016/0006-291X(91)91658-Y; CHANTRY A, 1995, J BIOL CHEM, V270, P3068; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COUNTAWAY JL, 1992, J BIOL CHEM, V267, P1129; COUNTAWAY JL, 1990, J BIOL CHEM, V265, P3407; DAVIS RJ, 1988, J BIOL CHEM, V263, P9462; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; Feinmesser RL, 1996, ONCOGENE, V12, P2725; FRIEDMAN B, 1989, P NATL ACAD SCI USA, V86, P812, DOI 10.1073/pnas.86.3.812; Groenen LC, 1997, BIOCHEMISTRY-US, V36, P3826, DOI 10.1021/bi9614141; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HEISERMANN GJ, 1988, J BIOL CHEM, V263, P13152; HILL SC, 1996, CELL, V80, P199; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; KHAZAIE K, 1988, EMBO J, V7, P3061, DOI 10.1002/j.1460-2075.1988.tb03171.x; Kornilova E, 1996, J BIOL CHEM, V271, P30340, DOI 10.1074/jbc.271.48.30340; LEE EB, 1993, ONCOGENE, V8, P1317; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MASSOGLIA S, 1990, MOL CELL BIOL, V10, P3048, DOI 10.1128/MCB.10.6.3048; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; MORRISON P, 1993, J BIOL CHEM, V268, P15536; NORTHWOOD IC, 1989, J BIOL CHEM, V264, P5746; NORTHWOOD IC, 1991, J BIOL CHEM, V266, P15266; PANAYOTOU G, 1993, BIOESSAYS, V15, P171, DOI 10.1002/bies.950150305; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; Scharenberg AM, 1998, CELL, V94, P5, DOI 10.1016/S0092-8674(00)81214-3; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SHU HKG, 1991, J VIROL, V65, P6173, DOI 10.1128/JVI.65.11.6173-6180.1991; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; TAKISHIMA K, 1991, P NATL ACAD SCI USA, V88, P2520, DOI 10.1073/pnas.88.6.2520; THEROUX SJ, 1992, J BIOL CHEM, V267, P7967; Tinhofer I, 1996, J BIOL CHEM, V271, P30505, DOI 10.1074/jbc.271.48.30505; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WALTON GM, 1990, J BIOL CHEM, V265, P1750; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034	44	62	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16168	16173		10.1074/jbc.274.23.16168	http://dx.doi.org/10.1074/jbc.274.23.16168			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347170	hybrid			2022-12-25	WOS:000080668600030
J	Galigniana, MD; Housley, PR; DeFranco, DB; Pratt, WB				Galigniana, MD; Housley, PR; DeFranco, DB; Pratt, WB			Inhibition of glucocorticoid receptor nucleocytoplasmic shuttling by okadaic acid requires intact cytoskeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; PROGESTERONE-RECEPTOR; STEROID-RECEPTORS; IN-VIVO; NUCLEUS; BINDING; CELLS; PHOSPHORYLATION; GELDANAMYCIN; CYTOPLASM	It has been shown previously that glucocorticoid receptors (GRs) that have undergone hormone-dependent translocation to the nucleus and have subsequently exited the nucleus upon hormone withdrawal are unable to recycle into the nucleus if cells are treated during hormone withdrawal with okadaic acid, a cell-permeable inhibitor of certain serine/threonine protein phosphatases. Using a green fluorescent protein (GFP) GR chimera (GFP-GR), we report here that okadaic acid inhibition of steroid-dependent receptor recycling to the nucleus is abrogated in cells treated for 1 h with colcemid to eliminate microtubule networks prior to steroid addition. After withdrawal of colcemid, normal cytoskeletal architecture is restored and okadaic acid inhibition of steroid-dependent GFP-GR nuclear recycling is restored. When okadaic acid is present during hormone withdrawal, GR that is recycled to the cytoplasm becomes complexed with hsp90 and binds steroid, but it does not undergo the normal agonist-dependent dissociation from hsp90 upon retreatment with steroid. However, when the cytoskeleton is disrupted by colcemid, the GR in okadaic acid-treated cells recycles from the cytoplasm to the nucleus in an agonist-dependent manner without dissociating from hsp90, This suggests that under physiological conditions where the cytoskeleton is intact, a dephosphorylation event is required for loss of high affinity binding to hsp90 that is required for receptor translocation through the cytoplasm to the nucleus along cytoskeletal tracts.	Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA; Univ S Carolina, Sch Med, Dept Pharmacol, Columbia, SC 29208 USA; Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA	University of Michigan System; University of Michigan; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Pratt, WB (corresponding author), Univ Michigan, Sch Med, Dept Pharmacol, 1301 Med Sci Res Bldg 3, Ann Arbor, MI 48109 USA.			GALIGNIANA, MARIO/0000-0002-9130-8574	NCI NIH HHS [CA43037, CA28010] Funding Source: Medline; NIDDK NIH HHS [DK47951] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA028010, R01CA043037] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047951] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BODWELL JE, 1991, J BIOL CHEM, V266, P7549; CHANDRAN UR, 1992, MOL ENDOCRINOL, V6, P837, DOI 10.1210/me.6.5.837; Czar MJ, 1997, BIOCHEMISTRY-US, V36, P7776, DOI 10.1021/bi970648x; CZAR MJ, 1995, MOL ENDOCRINOL, V9, P1549, DOI 10.1210/me.9.11.1549; DAUVOIS S, 1993, J CELL SCI, V106, P1377; DeFranco DB, 1995, VITAM HORM, V51, P315, DOI 10.1016/S0083-6729(08)61043-2; DEFRANCO DB, 1991, MOL ENDOCRINOL, V5, P1215, DOI 10.1210/mend-5-9-1215; Galigniana MD, 1998, MOL ENDOCRINOL, V12, P1903, DOI 10.1210/me.12.12.1903; GUICHONMANTEL A, 1991, EMBO J, V10, P3851; HOECK W, 1989, J BIOL CHEM, V264, P14396; KANG KI, 1994, P NATL ACAD SCI USA, V91, P340, DOI 10.1073/pnas.91.1.340; MADAN AP, 1993, P NATL ACAD SCI USA, V90, P3588, DOI 10.1073/pnas.90.8.3588; ORTI E, 1992, ENDOCR REV, V13, P105, DOI 10.1210/er.13.1.105; ORTI E, 1989, J BIOL CHEM, V264, P9728; PERROTAPPLANAT M, 1992, J CELL BIOL, V119, P337, DOI 10.1083/jcb.119.2.337; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; QI M, 1990, MOL ENDOCRINOL, V4, P455, DOI 10.1210/mend-4-3-455; QI M, 1989, MOL ENDOCRINOL, V3, P1279, DOI 10.1210/mend-3-8-1279; RAAKA BM, 1985, J BIOL CHEM, V260, P4009; SCHERRER LC, 1993, BIOCHEMISTRY-US, V32, P5381, DOI 10.1021/bi00071a013; SMITH DF, 1993, MOL ENDOCRINOL, V7, P1418, DOI 10.1210/me.7.11.1418; SMITH DF, 1995, MOL CELL BIOL, V15, P6804; SZAPARY D, 1994, J STEROID BIOCHEM, V51, P143, DOI 10.1016/0960-0760(94)90087-6; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; WILSON L, 1970, BIOCHEMISTRY-US, V9, P4999, DOI 10.1021/bi00827a026; Yang J, 1996, MOL ENDOCRINOL, V10, P3, DOI 10.1210/me.10.1.3	28	73	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16222	16227		10.1074/jbc.274.23.16222	http://dx.doi.org/10.1074/jbc.274.23.16222			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347177	hybrid			2022-12-25	WOS:000080668600037
J	Sellers, LA; Feniuk, W; Humphrey, PPA; Lauder, H				Sellers, LA; Feniuk, W; Humphrey, PPA; Lauder, H			Activated g protein-coupled receptor induces tyrosine phosphorylation of STAT3 and agonist-selective serine phosphorylation via sustained stimulation of mitogen-activated protein kinase - Resultant effects on cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II AT(1) RECEPTOR; SOMATOSTATIN RECEPTOR; MAP KINASE; NEURONAL DIFFERENTIATION; PC12 CELLS; GROWTH; CANCER; ANALOG; INHIBITION; PHOSPHATASE	The peptide hormone somatostatin exhibits antipro liferative activity by interacting with the G protein-coupled sst, or sst, receptor types. We show here that somatostatin at the human recombinant sst, receptor induced a concentration-dependent increase in proliferation (EC50 20 nM) with a maximal response 5-fold greater than that produced by its synthetic analog, L-362,855. Analysis of the phosphorylation status of extracellular signal-regulated kinase (ERK)1 and ERK2 showed temporal differences in the changes evoked by the agonists, Phosphorylation induced by somatostatin (100 nM) peaked 10 min after the application and produced a response that continued for at least 4 h. In contrast, L-362,855 (1 mu M) showed transient phosphorylation that had declined to basal levels by I h, However, both agonists induced rapid and sustained tyrosine phosphorylation of signal transducer and activator of transcription 3 (STAT3) which was pertussis toxin-insensitive. Serine phosphorylation of STAT3 was only apparent after somatostatin treatment and was abolished by pertussis toxin or PD 98059, together with the associated increases in proliferation. Mitogen-activated protein/ERK kinase-1 inhibition also decreased the time interval over which somatostatin-induced ERK phosphorylation was observed (<2 h), We conclude that the difference in the magnitude of the proliferative response evoked by the two agonists at the sst(4) receptor can be accounted for by their differential ability to phosphorylate STAT3 on serine residues and supports the concept that selective signaling can be achieved through pharmacological diversity.	Univ Cambridge, Dept Pharmacol, Glaxo Inst Appl Pharmacol, Cambridge CB2 1QJ, England	University of Cambridge	Sellers, LA (corresponding author), Univ Cambridge, Dept Pharmacol, Glaxo Inst Appl Pharmacol, Tennis Court Rd, Cambridge CB2 1QJ, England.							AKBAR M, 1994, FEBS LETT, V348, P192, DOI 10.1016/0014-5793(94)00603-2; Alderton F, 1998, BRIT J PHARMACOL, V124, P323, DOI 10.1038/sj.bjp.0701843; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Ali MS, 1997, J BIOL CHEM, V272, P23382, DOI 10.1074/jbc.272.37.23382; BITO H, 1994, J BIOL CHEM, V269, P12722; BREVINI TAL, 1993, J CLIN ENDOCR METAB, V77, P626, DOI 10.1210/jc.77.3.626; BUSCAIL L, 1995, P NATL ACAD SCI USA, V92, P1580, DOI 10.1073/pnas.92.5.1580; Cao XM, 1996, MOL CELL BIOL, V16, P1595; CHANG JH, 1995, J CELL BIOL, V130, P355, DOI 10.1083/jcb.130.2.355; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; DY DY, 1992, CANCER RES, V52, P917; EVERS BM, 1991, ANN SURG, V213, P190, DOI 10.1097/00000658-199103000-00002; GERICH JE, 1981, AM J MED, V70, P619, DOI 10.1016/0002-9343(81)90584-2; Hofland LJ, 1996, BAILLIERE CLIN ENDOC, V10, P163, DOI 10.1016/S0950-351X(96)80362-4; HOYER D, 1995, TRENDS PHARMACOL SCI, V16, P86, DOI 10.1016/S0165-6147(00)88988-9; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; ISHIZUKA J, 1992, BIOCHEM BIOPH RES CO, V185, P577, DOI 10.1016/0006-291X(92)91663-B; KAMIYA Y, 1993, BIOCHEM BIOPH RES CO, V191, P302, DOI 10.1006/bbrc.1993.1217; Kerkhoff E, 1998, CANCER RES, V58, P1636; Lauder H, 1998, Angiogenesis, V2, P67, DOI 10.1023/A:1009006527462; Lauder H, 1997, BRIT J PHARMACOL, V122, P663, DOI 10.1038/sj.bjp.0701443; LAUDER H, 1998, BRIT J PHARMACOL, V123, P126; Leaman DW, 1996, FASEB J, V10, P1578, DOI 10.1096/fasebj.10.14.9002549; LIEBOW C, 1989, P NATL ACAD SCI USA, V86, P2003, DOI 10.1073/pnas.86.6.2003; Lopez F, 1997, J BIOL CHEM, V272, P24448, DOI 10.1074/jbc.272.39.24448; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; MACAULAY VM, 1991, BRIT J CANCER, V64, P451, DOI 10.1038/bjc.1991.330; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; PAGLIACCI MC, 1991, ENDOCRINOLOGY, V129, P2555, DOI 10.1210/endo-129-5-2555; PAN MG, 1992, SCIENCE, V256, P1215, DOI 10.1126/science.256.5060.1215; PATEL YC, 1994, BIOCHEM BIOPH RES CO, V198, P605, DOI 10.1006/bbrc.1994.1088; REUBI JC, 1994, CANCER RES, V54, P3455; RUIZTORRES P, 1993, BIOCHEM BIOPH RES CO, V195, P1057, DOI 10.1006/bbrc.1993.2151; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; Smalley KSM, 1998, BRIT J PHARMACOL, V125, P833, DOI 10.1038/sj.bjp.0702133; Tombes RM, 1998, BIOCHEM J, V330, P1451; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	46	50	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16423	16430		10.1074/jbc.274.23.16423	http://dx.doi.org/10.1074/jbc.274.23.16423			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347203	hybrid			2022-12-25	WOS:000080668600063
J	Bolhuis, A; Tjalsma, H; Stephenson, K; Harwood, CR; Venema, G; Bron, S; van Dijl, JM				Bolhuis, A; Tjalsma, H; Stephenson, K; Harwood, CR; Venema, G; Bron, S; van Dijl, JM			Different mechanisms for thermal inactivation of Bacillus subtilis signal peptidase mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TEMPORALLY CONTROLLED EXPRESSION; WALL-ASSOCIATED PROTEASE; ESCHERICHIA-COLI; MEMBRANE-PROTEIN; DEGRADATION; IDENTIFICATION; SIPS; GENE; SITE	The type I signal peptidase SipS of Bacillus subtilis is of major importance for the processing of secretory precursor proteins. In the present studies, we have investigated possible mechanisms of thermal inactivation of five temperature-sensitive SipS mutants. The results demonstrate that two of these mutants, L74A and Y81A, are structurally stable but strongly impaired in catalytic activity at 48 degrees C, showing the (unprecedented) involvement of the conserved leucine 74 and tyrosine 81 residues in the catalytic reaction of type I signal peptidases. This conclusion is supported by the crystal structure of the homologous signal peptidase of Escherichia coli (Paetzel, M., Dalbey, R. E., and Strynadka, N, C, J, (1998) Nature 396, 188-190), In contrast, the SipS mutant proteins R84A, R84H, and D146A were inactivated by proteolytic degradation, indicating that the conserved arginine 84 and aspartic acid 146 residues are required to obtain a protease-resistant conformation. The cell wall-bound protease WprA was shown to be involved in the degradation of SipS D146A, which is in accord with the fact that SipS has a large extracytoplasmic domain. As WprA was not involved in the degradation of the SipS mutant proteins R84A and R84H, we conclude that multiple proteases are responsible for the thermal inactivation of temperature-sensitive SipS mutants.	Groningen Biomol Sci & Biotechnol Inst, Dept Genet, NL-9751 NN Haren, Netherlands; Univ Newcastle Upon Tyne, Sch Med, Sch Microbiol Immunol & Virol Sci, Newcastle Upon Tyne NE4 4HH, Tyne & Wear, England	University of Groningen; Newcastle University - UK	van Dijl, JM (corresponding author), Univ Groningen, Dept Pharmaceut Biol, Antonius Deusinglaan 1, NL-9713 AV Groningen, Netherlands.		Harwood, Colin/AGF-0120-2022; Tjalsma, Harold/I-7146-2012; van Dijl, Jan Maarten/G-1205-2013; Bolhuis, Albert/E-9932-2010	Bolhuis, Albert/0000-0001-9307-0515; Harwood, Colin/0000-0002-3624-0001				Biederer T, 1997, SCIENCE, V278, P1806, DOI 10.1126/science.278.5344.1806; Bolhuis A, 1996, MOL MICROBIOL, V22, P605, DOI 10.1046/j.1365-2958.1996.d01-4676.x; DALBEY RE, 1997, PROTEIN SCI, V17, P474; Gottesman S, 1996, ANNU REV GENET, V30, P465, DOI 10.1146/annurev.genet.30.1.465; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; KUNST F, 1995, J BACTERIOL, V177, P2403, DOI 10.1128/jb.177.9.2403-2407.1995; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LITTLE JW, 1993, J BACTERIOL, V175, P4943, DOI 10.1128/JB.175.16.4943-4950.1993; Margot P, 1996, MICROBIOL-UK, V142, P3437, DOI 10.1099/13500872-142-12-3437; MULLINS C, 1995, J BIOL CHEM, V270, P17139, DOI 10.1074/jbc.270.29.17139; Paetzel M, 1997, J BIOL CHEM, V272, P9994; Paetzel M, 1998, NATURE, V396, P186, DOI 10.1038/24196; Paetzel M, 1997, TRENDS BIOCHEM SCI, V22, P28, DOI 10.1016/S0968-0004(96)10065-7; Peat TS, 1996, NATURE, V380, P727, DOI 10.1038/380727a0; Plemper RK, 1997, NATURE, V388, P891, DOI 10.1038/42276; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; ROLAND KL, 1990, J BIOL CHEM, V265, P12828; Stephenson K, 1998, APPL ENVIRON MICROB, V64, P2875; Tjalsma H, 1997, J BIOL CHEM, V272, P25983, DOI 10.1074/jbc.272.41.25983; Tjalsma H, 1998, GENE DEV, V12, P2318, DOI 10.1101/gad.12.15.2318; VANDIJL JM, 1992, EMBO J, V11, P2819, DOI 10.1002/j.1460-2075.1992.tb05349.x; VANDIJL JM, 1995, J BIOL CHEM, V270, P3611, DOI 10.1074/jbc.270.8.3611; VANDIJL JM, 1991, J GEN MICROBIOL, V137, P2073, DOI 10.1099/00221287-137-9-2073; VANDIJL JM, 1998, HDB PROTEOLITIC ENZY, P451; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0	25	38	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15865	15868		10.1074/jbc.274.22.15865	http://dx.doi.org/10.1074/jbc.274.22.15865			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336490	hybrid			2022-12-25	WOS:000080560100079
J	Li, Y; Hashimoto, Y; Agadir, A; Kagechika, H; Zhang, XK				Li, Y; Hashimoto, Y; Agadir, A; Kagechika, H; Zhang, XK			Identification of a novel class of retinoic acid receptor beta-selective retinoid antagonists and their inhibitory effects on AP-1 activity and retinoic acid-induced apoptosis in human breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN LUNG-CANCER; ESTROGEN RESPONSE ELEMENT; LIGAND-BINDING DOMAIN; X-RECEPTOR; NUCLEAR RECEPTORS; TRANSCRIPTIONAL ACTIVATION; RETINOBENZOIC ACIDS; CRYSTAL-STRUCTURE; THYROID-HORMONE; RAR	Four candidate retinoid antagonists (LE135, LE511, LE540, and LE550) were designed on the basis of the ligand superfamily concept and synthesized. Analysis of these related retinoids by transient transfection assay demonstrated that LE135, LE540, and LE550 are effective retinoic acid receptor (RAR) antagonists, whereas LE511 selectively induced RAR beta transcriptional activity. Both LE135 and LE540 inhibited retinoic acid (RA)induced transcriptional activation of RAR beta, but not RAR alpha, RAR gamma or retinoid X receptor alpha (RXR alpha), on a variety of RA response elements. The retinoid antagonists also inhibited all-trans-RA-induced transcriptional activation of RAR beta/RXR alpha heterodimers, although they did not show any effect on transactivation activity of RXR/ RXR homodimers, In ZR-75-1 human breast cancer cells, cotreatment of LE135 and LE540 with all-trans-RA inhibited all-trans-RA-induced apoptosis of the cells, further demonstrating that RAR beta plays a role in RA-induced apoptosis of breast cancer cells. We also evaluated the effect of these retinoids on AP-1 activity. Our data showed that LE135 and LE540 strongly repressed 12-O-tetradecanoylphorbol-13-acetate-induced AP-1 activity in the presence of RAR beta and RXR alpha, Interestingly, LE550 induced AP-1 activity when RAR beta and RXR alpha were expressed in HeLa cells but not in breast cancer cells. These results demonstrate that LE135 and LE540 were a novel class of RAR beta-selective antagonists and anti-AP-1 retinoids and should be useful tools for studying the role of retinoids and their receptors.	La Jolla Canc Res Fdn, Canc Res Ctr, Burnham Inst, La Jolla, CA 92037 USA; Univ Tokyo, Inst Mol & Cellular Biosci, Tokyo 113, Japan; Univ Tokyo, Fac Pharmaceut Sci, Tokyo 113, Japan	Sanford Burnham Prebys Medical Discovery Institute; University of Tokyo; University of Tokyo	Zhang, XK (corresponding author), La Jolla Canc Res Fdn, Canc Res Ctr, Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.			Kagechika, Hiroyuki/0000-0002-6747-1013				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; APFEL C, 1992, P NATL ACAD SCI USA, V89, P7129, DOI 10.1073/pnas.89.15.7129; BENBROOK D, 1998, NATURE, V333, P624; BERNARD BA, 1992, BIOCHEM BIOPH RES CO, V186, P977, DOI 10.1016/0006-291X(92)90842-9; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x; DEJEAN A, 1986, NATURE, V322, P70, DOI 10.1038/322070a0; DELESCLUSE C, 1991, MOL PHARMACOL, V40, P556; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; EYROLLES L, 1994, J MED CHEM, V37, P1508, DOI 10.1021/jm00036a017; Eyrolles L., 1992, MED CHEM RES, V2, P361; FANJUL A, 1994, NATURE, V372, P107, DOI 10.1038/372107a0; Fanjul AN, 1996, CANCER RES, V56, P1571; GEBERT JF, 1991, ONCOGENE, V6, P1859; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GUDAS LJ, 1996, RETINOIDS, P443; HAMADA K, 1989, P NATL ACAD SCI USA, V86, P8289, DOI 10.1073/pnas.86.21.8289; HOFFMANN B, 1990, MOL ENDOCRINOL, V4, P1734; HOULE B, 1991, EXP CELL RES, V195, P163; JONG L, 1993, J MED CHEM, V36, P2605, DOI 10.1021/jm00070a003; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KANEKO S, 1991, MED CHEM RES, V1, P220; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LEE MO, 1995, MOL CELL BIOL, V15, P4194; LEHMANN JM, 1991, CANCER RES, V51, P4804; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; Li JJ, 1996, CANCER RES, V56, P483; Li Y, 1998, INT J CANCER, V75, P88, DOI 10.1002/(SICI)1097-0215(19980105)75:1<88::AID-IJC14>3.0.CO;2-9; Liu Y, 1996, MOL CELL BIOL, V16, P1138; LOTAN R, 1980, BIOCHIM BIOPHYS ACTA, V605, P33, DOI 10.1016/0304-419X(80)90021-9; LOTAN R, 1987, CANC TREAT REP, V71, P493; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; NAGPAL S, 1995, J BIOL CHEM, V270, P923, DOI 10.1074/jbc.270.2.923; NERVI C, 1991, EXP CELL RES, V195, P163, DOI 10.1016/0014-4827(91)90512-S; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; ROBERTS AB, 1984, RETINOIDS, V2, P209; SHEMSHEDINI L, 1991, EMBO J, V10, P3839, DOI 10.1002/j.1460-2075.1991.tb04953.x; TRAN P, 1992, MOL CELL BIOL, V12, P4666, DOI 10.1128/MCB.12.10.4666; Umemiya H, 1997, J MED CHEM, V40, P4222, DOI 10.1021/jm9704309; VANDERLEEDE BJM, 1993, MOL CARCINOGEN, V8, P112, DOI 10.1002/mc.2940080208; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; YANGYEN HF, 1991, NEW BIOL, V3, P1206; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1994, CANCER RES, V54, P5663; ZHANG XK, 1994, MOL CELL BIOL, V14, P4311, DOI 10.1128/MCB.14.6.4311; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	53	93	95	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15360	15366		10.1074/jbc.274.22.15360	http://dx.doi.org/10.1074/jbc.274.22.15360			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336422	hybrid			2022-12-25	WOS:000080560100011
J	Nishimura, N; Bannykh, S; Slabough, S; Matteson, J; Altschuler, Y; Hahn, K; Balch, WE				Nishimura, N; Bannykh, S; Slabough, S; Matteson, J; Altschuler, Y; Hahn, K; Balch, WE			A di-acidic (DXE) code directs concentration of cargo during export from the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICULAR STOMATITIS-VIRUS; COATED VESICLE FORMATION; SEMI-INTACT CELLS; GOLGI TRANSPORT; INTRACELLULAR-TRANSPORT; SUBUNIT INTERACTIONS; PROTEIN-TRANSPORT; SECRETORY PATHWAY; COPII VESICLES; PRE-GOLGI	Efficient export of vesicular stomatitis virus glycoprotein (Vm-G), a type I transmembrane protein, from the endoplasmic reticulum requires a di-acidic code (DXE) located in the cytosolic carboxyl-terminal tail (Nishimura, N,, and Balch, W, E, (1997) Science 277, 558-558), Mutation of the DXE code by mutation to AXA did not prevent VSV-G recruitment to pre-budding complexes formed in the presence of the activated form of the Sari and the Sec23/24 complex, components of the COPII budding machinery. However, the signal was required at a subsequent concentration step preceding vesicle fission. By using green fluorescence protein-tagged VSV-G to image movement in a single cell, we found that VSV-G lacking the DXE code fails to be concentrated into COPII vesicles. As a result, the normal 5-10-fold increase in the steady-state concentration of VSV-G in downstream pre-Golgi intermediates and Golgi compartments was lost. These results demonstrate for the first time that inactivation of the DXE signal uncouples early cargo selection steps from concentration into COPII. vesicles. We propose that two sequential steps are required for efficient export from the endoplasmic reticulum.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Biol Mol, La Jolla, CA 92037 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA	Scripps Research Institute; Scripps Research Institute; University of California System; University of California San Francisco	Balch, WE (corresponding author), Scripps Res Inst, Dept Cell Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.			Hahn, Klaus/0000-0002-1970-7562	NCI NIH HHS [CA 58689] Funding Source: Medline; NIGMS NIH HHS [GM 42336] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA058689] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042336] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschuler Y, 1998, J CELL BIOL, V143, P1871, DOI 10.1083/jcb.143.7.1871; Aridor M, 1996, TRENDS CELL BIOL, V6, P315, DOI 10.1016/0962-8924(96)10027-1; Aridor M, 1999, J BIOL CHEM, V274, P4389, DOI 10.1074/jbc.274.7.4389; ARIDOR M, 1995, J CELL BIOL, V131, P875, DOI 10.1083/jcb.131.4.875; Aridor M, 1998, J CELL BIOL, V141, P61, DOI 10.1083/jcb.141.1.61; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; Bannykh SI, 1996, J CELL BIOL, V135, P19, DOI 10.1083/jcb.135.1.19; Bannykh SI, 1998, TRENDS CELL BIOL, V8, P21, DOI 10.1016/S0962-8924(97)01184-7; BECKERS CJM, 1987, CELL, V50, P523, DOI 10.1016/0092-8674(87)90025-0; Bonifacino JS, 1996, P ASSOC AM PHYSICIAN, V108, P285; Bu GJ, 1998, TRENDS CELL BIOL, V8, P272, DOI 10.1016/S0962-8924(98)01283-5; Campbell JL, 1997, P NATL ACAD SCI USA, V94, P837, DOI 10.1073/pnas.94.3.837; COLLEY NJ, 1991, CELL, V67, P255, DOI 10.1016/0092-8674(91)90177-Z; COLLEY NJ, 1995, P NATL ACAD SCI USA, V92, P3070, DOI 10.1073/pnas.92.7.3070; Cosson P, 1997, CURR OPIN CELL BIOL, V9, P484, DOI 10.1016/S0955-0674(97)80023-3; Dascher C, 1996, J BIOL CHEM, V271, P15866, DOI 10.1074/jbc.271.27.15866; Dominguez M, 1998, J CELL BIOL, V140, P751, DOI 10.1083/jcb.140.4.751; ESPENSHADE P, 1995, J CELL BIOL, V131, P311, DOI 10.1083/jcb.131.2.311; Fiedler K, 1996, SCIENCE, V273, P1396, DOI 10.1126/science.273.5280.1396; Gimeno RE, 1996, MOL BIOL CELL, V7, P1815, DOI 10.1091/mbc.7.11.1815; GRIFFITHS G, 1989, J CELL BIOL, V108, P277, DOI 10.1083/jcb.108.2.277; Harter C, 1998, P NATL ACAD SCI USA, V95, P11649, DOI 10.1073/pnas.95.20.11649; HELM R, 1995, NATURE, V373, P663; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; Kappeler F, 1997, J BIOL CHEM, V272, P31801, DOI 10.1074/jbc.272.50.31801; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; Kuehn MJ, 1996, J CELL BIOL, V135, P585, DOI 10.1083/jcb.135.3.585; Kuehn MJ, 1998, NATURE, V391, P187, DOI 10.1038/34438; KUGE O, 1994, J CELL BIOL, V125, P51, DOI 10.1083/jcb.125.1.51; LAFAY F, 1974, J VIROL, V14, P1220, DOI 10.1128/JVI.14.5.1220-1228.1974; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Matsuoka K, 1998, CELL, V93, P263, DOI 10.1016/S0092-8674(00)81577-9; Nakamura N, 1998, MOL BIOL CELL, V9, P3493, DOI 10.1091/mbc.9.12.3493; Nichols WC, 1998, CELL, V93, P61, DOI 10.1016/S0092-8674(00)81146-0; Nishimura N, 1997, SCIENCE, V277, P556, DOI 10.1126/science.277.5325.556; PLUTNER H, 1992, J CELL BIOL, V119, P1097, DOI 10.1083/jcb.119.5.1097; Presley JF, 1997, NATURE, V389, P81, DOI 10.1038/38001; Rowe T, 1996, J CELL BIOL, V135, P895, DOI 10.1083/jcb.135.4.895; Rowe T, 1998, SCIENCE, V279, P696, DOI 10.1126/science.279.5351.696; SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7; SARASTE J, 1991, J CELL SCI, V100, P415; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SCHIMMOLLER F, 1995, EMBO J, V14, P1329, DOI 10.1002/j.1460-2075.1995.tb07119.x; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; SCHWANINGER R, 1991, J BIOL CHEM, V266, P13055; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; Shaywitz DA, 1997, J BIOL CHEM, V272, P25413, DOI 10.1074/jbc.272.41.25413; Springer S, 1998, SCIENCE, V281, P698, DOI 10.1126/science.281.5377.698; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39; Vollenweider F, 1998, J CELL BIOL, V142, P377, DOI 10.1083/jcb.142.2.377	52	132	133	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15937	15946		10.1074/jbc.274.22.15937	http://dx.doi.org/10.1074/jbc.274.22.15937			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336500	hybrid			2022-12-25	WOS:000080560100089
J	Sakai, T; de la Pena, JM; Mosher, DF				Sakai, T; de la Pena, JM; Mosher, DF			Synergism among lysophosphatidic acid, beta(1)A integrins, and epidermal growth factor or platelet-derived growth factor in mediation of cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; SMOOTH-MUSCLE CELLS; ACTIN STRESS FIBERS; SPHINGOSINE 1-PHOSPHATE; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; EGF RECEPTOR; DEPENDENT MECHANISM; RHO; FIBRONECTIN	GD25 cells lacking the beta(1) integrin subunit or expressing beta(1)A with certain cytoplasmic mutations have poor directed cell migration to platelet derived growth factor (PDGF) or epidermal growth factor (EGF), ligands of receptor tyrosine kinases, or to lysophosphatidic acid (LPA), a ligand of G-protein-coupled receptors (Sakai, T., Zhang, Q., Fassler, R., and Mosher, D. F. (1998) J. Cell Biol, 141, 527-538 and Sakai, T,, Peyruchaud, O,, Fassler, R,, and Mosher, D, F, (1998) J, Biol, Chem, 273, 19378-19382), We demonstrate here that LPA synergizes with signals induced by beta(1)A integrins and ligated EGF or PDGF receptors to modulate migration. When LPA was mixed with EGF or PDGF, migration was greater than with EGF or PDGF alone. The enhancement was greater for beta(1)A-expressing cells than for beta(1)-null cells. Cells expressing beta(1)A with mutations of prolines or tyrosines in conserved cytoplasmic NPXY motifs had blunted migratory responses to mixtures of LPA and EG:F or PDGF, The major effects on beta(1)A-expressing cells of LPA when combined with EC:F or PDGF were to sensitize cells so that maximal responses were obtained with >10-fold lower concentrations of growth factor and increase the chemokinetic component of migration. Sensitization by LPA was lost when cells were preincubated with pertussis toxin or C3 exotransferase. There was no evidence for transactivation or sensitization of receptors for EGF or PDGF by LPA. EGF or PDGF and LPA caused activation of mitogen-activated protein kinase by pertussis toxin-insensitive and -sensitive pathways respectively, but activation was not additive. These findings indicate that signaling pathways initiated by the cytoplasmic domains of ligated beta(1)A integrins and tyrosine kinase receptors interact with signaling pathways initiated by LPA to facilitate directed cell migration.	Univ Wisconsin, Dept Med, Madison, WI 53706 USA; Univ Wisconsin, Dept Biomol Chem, Madison, WI 53706 USA; Univ Lund, Dept Expt Pathol, S-22185 Lund, Sweden	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Lund University	Mosher, DF (corresponding author), Univ Wisconsin, Dept Med, 1300 Univ Ave, Madison, WI 53706 USA.				NHLBI NIH HHS [HL56396, HL21644] Funding Source: Medline; NIGMS NIH HHS [T32 GM07215] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056396, R01HL021644] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007215] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		An SZ, 1997, FEBS LETT, V417, P279, DOI 10.1016/S0014-5793(97)01301-X; An SZ, 1998, J BIOL CHEM, V273, P7906, DOI 10.1074/jbc.273.14.7906; An SZ, 1997, BIOCHEM BIOPH RES CO, V231, P619, DOI 10.1006/bbrc.1997.6150; Anand-Apte B, 1997, J BIOL CHEM, V272, P30688, DOI 10.1074/jbc.272.49.30688; AnandApte B, 1997, STEM CELLS, V15, P259, DOI 10.1002/stem.150259; BORNFELDT KE, 1995, J CELL BIOL, V130, P193, DOI 10.1083/jcb.130.1.193; Bretscher MS, 1996, CELL, V85, P465, DOI 10.1016/S0092-8674(00)81246-5; BRETSCHER MS, 1989, EMBO J, V8, P1341, DOI 10.1002/j.1460-2075.1989.tb03514.x; CHECOVICH WJ, 1993, ARTERIOSCLER THROMB, V13, P1662, DOI 10.1161/01.ATV.13.11.1662; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; FASSLER R, 1995, J CELL BIOL, V128, P979, DOI 10.1083/jcb.128.5.979; Giancotti FG, 1997, CURR OPIN CELL BIOL, V9, P691, DOI 10.1016/S0955-0674(97)80123-8; Goetzl EJ, 1998, FASEB J, V12, P1589, DOI 10.1096/fasebj.12.15.1589; Gohla A, 1998, J BIOL CHEM, V273, P4653, DOI 10.1074/jbc.273.8.4653; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; Herrlich A, 1998, P NATL ACAD SCI USA, V95, P8985, DOI 10.1073/pnas.95.15.8985; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; HUTTENLOCHER A, 1995, CURR OPIN CELL BIOL, V7, P697, DOI 10.1016/0955-0674(95)80112-X; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Imamura F, 1996, INT J CANCER, V65, P627, DOI 10.1002/(SICI)1097-0215(19960301)65:5<627::AID-IJC12>3.0.CO;2-4; IMAMURA F, 1993, BIOCHEM BIOPH RES CO, V193, P497, DOI 10.1006/bbrc.1993.1651; Kiss Z, 1997, FEBS LETT, V412, P197, DOI 10.1016/S0014-5793(97)00776-X; KUNDRA V, 1995, J CELL BIOL, V130, P725, DOI 10.1083/jcb.130.3.725; LaFlamme SE, 1997, MATRIX BIOL, V16, P153, DOI 10.1016/S0945-053X(97)90003-2; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lee MJ, 1998, J BIOL CHEM, V273, P22105, DOI 10.1074/jbc.273.34.22105; Li J, 1999, J BIOL CHEM, V274, P11209, DOI 10.1074/jbc.274.16.11209; LINSEMAN DA, 1995, J BIOL CHEM, V270, P12563, DOI 10.1074/jbc.270.21.12563; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Moolenaar WH, 1997, CURR OPIN CELL BIOL, V9, P168, DOI 10.1016/S0955-0674(97)80059-2; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; Panetti TS, 1997, J LAB CLIN MED, V129, P208, DOI 10.1016/S0022-2143(97)90141-4; Pietruck F, 1997, N-S ARCH PHARMACOL, V355, P1; Postma FR, 1996, EMBO J, V15, P2388, DOI 10.1002/j.1460-2075.1996.tb00595.x; Renshaw MW, 1996, J BIOL CHEM, V271, P21691, DOI 10.1074/jbc.271.36.21691; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SADAHIRA Y, 1992, P NATL ACAD SCI USA, V89, P9686, DOI 10.1073/pnas.89.20.9686; SAKAI T, 1995, INT J CANCER, V63, P720, DOI 10.1002/ijc.2910630519; Sakai T, 1998, J CELL BIOL, V141, P527, DOI 10.1083/jcb.141.2.527; Sakai T, 1998, J BIOL CHEM, V273, P19378, DOI 10.1074/jbc.273.31.19378; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; STOKES CL, 1991, J THEOR BIOL, V152, P377, DOI 10.1016/S0022-5193(05)80201-2; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; Sundberg C, 1996, J CELL BIOL, V132, P741, DOI 10.1083/jcb.132.4.741; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; Wang F, 1997, BIOCHEM J, V324, P481, DOI 10.1042/bj3240481; Ware MF, 1998, J CELL SCI, V111, P2423; Wennerberg K, 1996, J CELL BIOL, V132, P227, DOI 10.1083/jcb.132.1.227; Woodard AS, 1998, J CELL SCI, V111, P469; WU J, 1995, J BIOL CHEM, V270, P11484, DOI 10.1074/jbc.270.19.11484; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; ZETTER BR, 1990, NEW ENGL J MED, V322, P605; Zhang QH, 1997, MOL BIOL CELL, V8, P1415, DOI 10.1091/mbc.8.8.1415; ZHANG QH, 1994, J CELL BIOL, V127, P1447, DOI 10.1083/jcb.127.5.1447; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X; Zondag GCM, 1998, BIOCHEM J, V330, P605, DOI 10.1042/bj3300605	60	48	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15480	15486		10.1074/jbc.274.22.15480	http://dx.doi.org/10.1074/jbc.274.22.15480			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336439	hybrid			2022-12-25	WOS:000080560100028
J	Strobeck, MW; Okuda, M; Yamaguchi, H; Schwartz, A; Fukasawa, K				Strobeck, MW; Okuda, M; Yamaguchi, H; Schwartz, A; Fukasawa, K			Morphological transformation induced by activation of the mitogen-activated protein kinase pathway requires suppression of the T-type Ca2+ channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-BINDING PROTEINS; NUCLEOTIDE DISSOCIATION STIMULATOR; MAP KINASE; CALCIUM CHANNELS; PHOSPHATIDYLINOSITOL 3-KINASE; MOLECULAR CHARACTERIZATION; INCREASING COMPLEXITY; SIGNAL-TRANSDUCTION; CELL MORPHOLOGY; RAS INTERACTS	Transformation of fibroblasts by various oncogenes, including ras, mos, and src accompanies with characteristic morphological changes from flat to round (or spindle) shapes, Such morphological change is believed to play an important role in establishing malignant characteristics of cancer cells. Activation of the mitogen-activated protein kinase (MAPR) pathway is a converging downstream event of transforming activities of many oncogene products commonly found in human cancers. Intracellular calcium is known to regulate cellular morphology, In fibroblasts, Ca2+ influx is primarily controlled by two types of Ca2+ channels (T- and L-types), Here, we report that the T-type current was specifically inhibited in cells expressing oncogenically activated Ras as well as gain-of-function mutant MEK (MAPK/extracellular signal-regulated kinase (ERK) kinase, a direct activator of MAPK), whereas treatment of ras-transformed cells with a MEK-specific inhibitor restored T-type Ca2+ channel activity. Using a T-type Ca2+ channel antagonist, we further found that suppression of the T-type Ca2+ channel by the activated MAPK pathway is a prerequisite event for the induction and/or maintenance of transformation-associated morphological changes.	Univ Cincinnati, Coll Med, Dept Cell Biol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Inst Mol Pharmacol & Cell Biophys, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Fukasawa, K (corresponding author), Univ Cincinnati, Coll Med, Dept Cell Biol, POB 670521, Cincinnati, OH 45267 USA.			Okuda, Masaru/0000-0003-4690-8244	NHLBI NIH HHS [P01 HL22619-19] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL022619] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHLIJANIAN MK, 1991, J BIOL CHEM, V266, P20192; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Andersson P, 1980, Adv Cancer Res, V33, P109, DOI 10.1016/S0065-230X(08)60670-3; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Bean BP, 1998, NEURON, V20, P825, DOI 10.1016/S0896-6273(00)80463-8; BEAN BP, 1989, ANNU REV PHYSIOL, V51, P367, DOI 10.1146/annurev.physiol.51.1.367; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BURRIDGE K, 1981, NATURE, V294, P565, DOI 10.1038/294565a0; CANTOR SB, 1995, MOL CELL BIOL, V15, P4578; CATTERALL WA, 1995, ANNU REV BIOCHEM, V64, P493, DOI 10.1146/annurev.biochem.64.1.493; CHEN CF, 1988, SCIENCE, V239, P1024, DOI 10.1126/science.2449730; Chik CL, 1996, FASEB J, V10, P1310, DOI 10.1096/fasebj.10.11.8836045; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; Cribbs LL, 1998, CIRC RES, V83, P103, DOI 10.1161/01.RES.83.1.103; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FRANCK Z, 1990, J CELL BIOL, V111, P2475, DOI 10.1083/jcb.111.6.2475; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Fukasawa K, 1997, MOL CELL BIOL, V17, P506, DOI 10.1128/MCB.17.1.506; GALIZZI JP, 1987, J BIOL CHEM, V262, P6947; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HELL JW, 1995, EMBO J, V14, P3036, DOI 10.1002/j.1460-2075.1995.tb07306.x; HELL JW, 1994, J BIOL CHEM, V269, P7390; HICKS GG, 1991, MOL CELL BIOL, V11, P1344, DOI 10.1128/MCB.11.3.1344; Hille B., 1992, IONIC CHANNELS EXCIT; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; Jones SW, 1998, J BIOENERG BIOMEMBR, V30, P299, DOI 10.1023/A:1021977304001; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KhosraviFar R, 1998, ADV CANCER RES, V72, P57; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; Klippel A, 1996, MOL CELL BIOL, V16, P4117; KODAKI T, 1994, CURR BIOL, V4, P798, DOI 10.1016/S0960-9822(00)00177-9; KRETSINGER RH, 1980, CRC CR REV BIOCH MOL, V8, P119, DOI 10.3109/10409238009105467; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Louvard D, 1989, CURR OPIN CELL BIOL, V1, P51, DOI 10.1016/S0955-0674(89)80036-5; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; MEHRKE G, 1994, J PHARMACOL EXP THER, V271, P1483; MISHRA SK, 1994, CIRC RES, V75, P144, DOI 10.1161/01.RES.75.1.144; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MOODIE SA, 1994, TRENDS GENET, V10, P14; MOOSEKER MS, 1985, ANNU REV CELL BIOL, V1, P209, DOI 10.1146/annurev.cellbio.1.1.209; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; OKADA Y, 1977, J MEMBRANE BIOL, V35, P319, DOI 10.1007/BF01869957; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PERES A, 1988, PFLUG ARCH EUR J PHY, V411, P554, DOI 10.1007/BF00582377; Perez-Reyes E, 1998, J BIOENERG BIOMEMBR, V30, P313, DOI 10.1023/A:1021981420839; Perez-Reyes E, 1998, NATURE, V391, P896, DOI 10.1038/36110; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; RASMUSSEN CD, 1992, CELL MOTIL CYTOSKEL, V21, P45, DOI 10.1002/cm.970210106; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; STOSSEL TP, 1985, ANNU REV CELL BIOL, V1, P353, DOI 10.1146/annurev.cb.01.110185.002033; TSIEN RW, 1991, TRENDS PHARMACOL SCI, V12, P349, DOI 10.1016/0165-6147(91)90595-J; UEDA S, 1986, J MEMBRANE BIOL, V91, P65, DOI 10.1007/BF01870215; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VARADI G, 1995, TRENDS PHARMACOL SCI, V16, P43, DOI 10.1016/S0165-6147(00)88977-4; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WEEDS A, 1982, NATURE, V296, P811, DOI 10.1038/296811a0; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Yamaguchi H, 1998, J BIOL CHEM, V273, P19348, DOI 10.1074/jbc.273.30.19348; YIN HL, 1980, J BIOL CHEM, V255, P9494; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	76	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15694	15700		10.1074/jbc.274.22.15694	http://dx.doi.org/10.1074/jbc.274.22.15694			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336467	hybrid			2022-12-25	WOS:000080560100056
J	Bhattacharya, SK; Dubey, AK				Bhattacharya, SK; Dubey, AK			Kinetic mechanism of cytosine DNA ethyltransferase MspI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC PROPERTIES; ESCHERICHIA-COLI; METHYLTRANSFERASE; SUBSTRATE; METHYLATION; BINDING	A kinetic analysis of MspI DNA methyltransferase (M.MspI) is presented. The enzyme catalyzes methylation of A-DNA, a 50-kilobase pair linear molecule with multiple M.MspI-specific sites, with a specificity constant (k(cat)/K-M) of 0.9 x 10(8) M-1 s(-1). But the values of the specificity constants for the smaller DNA substrates (121 and 1459 base pairs (bp)) with single methylation target or with multiple targets (sonicated A-DNA) were less by an order of magnitude. Product inhibition of the M.MspI-catalyzed methylation reaction by methylated DNA is competitive with respect to DNA and noncompetitive with respect to S-adenosylmethionine (AdoMet). The S-adenosylhomocysteine inhibition of the methylation reaction is competitive with respect to AdoMet and uncompetitive with respect to DNA. The presteady state kinetic analysis showed a burst of product formation when AdoMet was added to the enzyme preincubated with the substrate DNA. The burst is followed by a constant rate of product formation (0.06 mol per mol of enzyme s(-1)) which is similar to catalytic constants (k(cat) = similar to 0.056 s(-1)) measured under steady state conditions. The isotope exchange in chasing the labeled methyltransferase-DNA complex with unlabeled DNA and AdoMet leads to a reduced burst as compared with the one involving chase with labeled DNA and AdoMet. The enzyme is capable of exchanging tritium at C-5 of target cytosine in the substrate DNA in the absence of cofactor AdoMet. The kinetic data are consistent with an ordered Bi Bi mechanism for the M.MspI-catalyzed DNA methylation where DNA binds first.	Indian Inst Technol, Dept Biochem Engn & Biotechnol, New Delhi 110016, India	Indian Institute of Technology System (IIT System); Indian Institute of Technology (IIT) - Delhi	Bhattacharya, SK (corresponding author), Cleveland Clin Fdn, Dept Mol Cardiol NB20, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.		Bhattacharya, Sanjoy K/B-2001-2008					BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cleland W W, 1979, Methods Enzymol, V63, P103; CLELAND WW, 1967, ADV ENZYMOL RAMB, V29, P1; DUBEY AK, 1992, NUCLEIC ACIDS RES, V20, P3167, DOI 10.1093/nar/20.12.3167; Dubey AK, 1997, NUCLEIC ACIDS RES, V25, P2025, DOI 10.1093/nar/25.10.2025; DUBEY AK, 1992, NUCLEIC ACIDS RES, V20, P1579, DOI 10.1093/nar/20.7.1579; ENGLER P, 1993, MOL CELL BIOL, V13, P571, DOI 10.1128/MCB.13.1.571; FEDOROFF NV, 1989, CELL, V77, P473; GARTLER SM, 1983, ANNU REV GENET, V17, P155, DOI 10.1146/annurev.ge.17.120183.001103; GUNTHERT U, 1981, J BIOL CHEM, V256, P9346; HANCK T, 1993, NUCLEIC ACIDS RES, V21, P303, DOI 10.1093/nar/21.2.303; Hiromi K., 1979, KINETICS FAST ENZYME; IVANETICH KM, 1992, PROG NUCLEIC ACID RE, V42, P127, DOI 10.1016/S0079-6603(08)60575-9; KUMAR S, 1994, NUCLEIC ACIDS RES, V22, P1, DOI 10.1093/nar/22.1.1; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MATSUO K, 1994, NUCLEIC ACIDS RES, V22, P5354, DOI 10.1093/nar/22.24.5354; MI S, 1992, NUCLEIC ACIDS RES, V20, P4811, DOI 10.1093/nar/20.18.4811; NARDONE G, 1986, J BIOL CHEM, V261, P2128; Orsi B A, 1979, Methods Enzymol, V63, P159; POSFAI J, 1989, NUCLEIC ACIDS RES, V17, P2421, DOI 10.1093/nar/17.7.2421; REICH NO, 1991, BIOCHEMISTRY-US, V30, P2933, DOI 10.1021/bi00225a029; RUBIN RA, 1977, J BIOL CHEM, V252, P7265; Sambrook J., 2002, MOL CLONING LAB MANU; SANTI DV, 1987, BIOCHEMISTRY-US, V26, P8599, DOI 10.1021/bi00400a016; SZILAK L, 1994, NUCLEIC ACIDS RES, V22, P2876, DOI 10.1093/nar/22.15.2876; TAYLOR C, 1993, BIOCHEM J, V291, P493, DOI 10.1042/bj2910493; TIMINSKAS A, 1995, GENE, V157, P3, DOI 10.1016/0378-1119(94)00783-O; VONHIPPE PH, 1972, ANNU REV BIOCHEM, V41, P231, DOI 10.1146/annurev.bi.41.070172.001311; WU JC, 1987, J BIOL CHEM, V262, P4778; ZWIEB C, 1991, LAB GUIDE IN VITRO S, P245	30	39	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					14743	14749		10.1074/jbc.274.21.14743	http://dx.doi.org/10.1074/jbc.274.21.14743			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329670	hybrid			2022-12-25	WOS:000081965200035
J	Giet, R; Uzbekov, R; Cubizolles, F; Le Guellec, K; Prigent, C				Giet, R; Uzbekov, R; Cubizolles, F; Le Guellec, K; Prigent, C			The Xenopus laevis aurora-related protein kinase pEg2 associates with and phosphorylates the kinesin-related protein XlEg5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOSOME SEGREGATION REGULATORS; CYCLE-DEPENDENT EXPRESSION; MITOTIC SPINDLE; CENTROSOME SEPARATION; MICROTUBULE DYNAMICS; CYTOPLASMIC DYNEIN; DROSOPHILA-AURORA; BIPOLAR SPINDLE; FISSION YEAST; EGG EXTRACTS	We have previously reported on the cloning of XlEg5, a Xenopus laevis kinesin-related protein from the bimC family (Le Guellec, R., Paris, J., Couturier, A., Roghi, C., and Philippe, M. (1991) Mol. Cell. Biol. 11, 3395-3408) as well as pEg2, an Aurora-related serine/threonine kinase (Roghi, C., Giet, R., Uzbekov, R., Morin, N., Chartrain, I., Le Guellec, R., Couturier, A., Doree, M., Philippe, M., and Prigent, C. (1998) J. Cell Sci. 111, 557-572). Inhibition of either XlEg5 or pEg2 activity during mitosis in Xenopus egg extract led to monopolar spindle formation. Here, we report that in Xenopus XL2 cells, pEg2 and XlEg5 are both confined to separated centrosomes in prophase, and then to the microtubule spindle poles. We also show that pEg2 co-immunoprecipitates with XlEg5 from egg extracts and XL2 cell lysates. Both proteins can directly interact in vitro, but also through the two-hybrid system. Furthermore immunoprecipitated pEg2 were found to remain active when bound to the beads and phosphorylate XlEg5 present in the precipitate. Two-dimensional mapping of XlEg5 tryptic peptides phosphorylated in vivo first confirmed that XlEg5 was phosphorylated by p34(cdc2) and next revealed that in vitro pEg2 kinase phosphorylated XlEg5 on the same stalk domain serine residue that was phosphorylated in metabolically labeled XL2 cells. The kinesin-related XlEg5 is to our knowledge the first in vivo substrate ever reported for an Aurora-related kinase.	CNRS, UPR 41, Biol & Genet Dev Lab, Fac Med,Grp Cycle Cellulaire, F-35043 Rennes, France; CNRS, UPR 41, Biol & Genet Dev Lab, Fac Med,Grp Struct Dynam Chromatine, F-35043 Rennes, France	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS)	Prigent, C (corresponding author), CNRS, UPR 41, Biol & Genet Dev Lab, Fac Med,Grp Cycle Cellulaire, F-35043 Rennes, France.	claude.prigent@univ-rennes1.fr	Uzbekov, Rustem/J-8922-2012	Cubizolles, Fabien/0000-0002-9822-4074				AIZAWA H, 1991, BIOCHEM BIOPH RES CO, V179, P1620, DOI 10.1016/0006-291X(91)91760-A; Andresson T, 1998, EMBO J, V17, P5627, DOI 10.1093/emboj/17.19.5627; ANIZET MP, 1981, IN VITRO CELL DEV B, V17, P267; BALCZON R, 1995, J CELL BIOL, V130, P105, DOI 10.1083/jcb.130.1.105; Bartel P. L., 1993, CELLULAR INTERACTION, P153; BARTON NR, 1995, MOL BIOL CELL, V6, P1563, DOI 10.1091/mbc.6.11.1563; Bernard M, 1998, GENOMICS, V53, P406, DOI 10.1006/geno.1998.5522; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Blangy A, 1997, J BIOL CHEM, V272, P19418, DOI 10.1074/jbc.272.31.19418; Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; Boleti H, 1996, CELL, V84, P49, DOI 10.1016/S0092-8674(00)80992-7; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; COLE DG, 1994, J BIOL CHEM, V269, P22913; Drummond DR, 1998, J CELL SCI, V111, P853; ENOS AP, 1990, CELL, V60, P1019, DOI 10.1016/0092-8674(90)90350-N; FRANCISCO L, 1994, MOL CELL BIOL, V14, P4731, DOI 10.1128/MCB.14.7.4731; Frolova L, 1996, RNA, V2, P334; Gaglio T, 1997, J CELL BIOL, V138, P1055, DOI 10.1083/jcb.138.5.1055; Giet R, 1998, EXP CELL RES, V244, P470, DOI 10.1006/excr.1998.4218; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; Gopalan G, 1997, J CELL BIOL, V138, P643, DOI 10.1083/jcb.138.3.643; HAGAN I, 1992, NATURE, V356, P74, DOI 10.1038/356074a0; HAGAN I, 1990, NATURE, V347, P563, DOI 10.1038/347563a0; HECK MMS, 1993, J CELL BIOL, V123, P665, DOI 10.1083/jcb.123.3.665; HOYT MA, 1992, J CELL BIOL, V118, P109, DOI 10.1083/jcb.118.1.109; Hyman AA, 1996, CELL, V84, P401, DOI 10.1016/S0092-8674(00)81285-4; Kashina AS, 1996, NATURE, V379, P270, DOI 10.1038/379270a0; Kimura M, 1997, J BIOL CHEM, V272, P13766, DOI 10.1074/jbc.272.21.13766; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE KS, 1995, MOL CELL BIOL, V15, P7143; LEGUELLEC R, 1991, MOL CELL BIOL, V11, P3395, DOI 10.1128/MCB.11.6.3395; LOHKA MJ, 1988, EXP CELL RES, V179, P303, DOI 10.1016/0014-4827(88)90370-9; Merdes A, 1996, CELL, V87, P447, DOI 10.1016/S0092-8674(00)81365-3; Niwa H, 1996, GENE, V169, P197, DOI 10.1016/0378-1119(95)00809-8; OHKURA H, 1995, GENE DEV, V9, P1059, DOI 10.1101/gad.9.9.1059; PARIS J, 1990, DEV BIOL, V140, P221, DOI 10.1016/0012-1606(90)90070-Y; PARIS J, 1988, GENE, V72, P169, DOI 10.1016/0378-1119(88)90139-4; PRIGENT C, 1998, SILICO BIOL; Roghi C, 1998, J CELL SCI, V111, P557; ROOF DM, 1992, J CELL BIOL, V118, P95, DOI 10.1083/jcb.118.1.95; SAWIN KE, 1995, P NATL ACAD SCI USA, V92, P4289, DOI 10.1073/pnas.92.10.4289; SAWIN KE, 1992, NATURE, V359, P540, DOI 10.1038/359540a0; Sen S, 1997, ONCOGENE, V14, P2195, DOI 10.1038/sj.onc.1201065; Shindo M, 1998, BIOCHEM BIOPH RES CO, V244, P285, DOI 10.1006/bbrc.1998.8250; Tatsuka M, 1998, CANCER RES, V58, P4811; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; Tournebize R, 1997, EMBO J, V16, P5537, DOI 10.1093/emboj/16.18.5537; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tseng TC, 1998, DNA CELL BIOL, V17, P823, DOI 10.1089/dna.1998.17.823; Uzbekov R, 1998, EXP CELL RES, V242, P60, DOI 10.1006/excr.1998.4097; VAISBERG EA, 1993, J CELL BIOL, V123, P849, DOI 10.1083/jcb.123.4.849; VERDE F, 1991, J CELL BIOL, V112, P1177, DOI 10.1083/jcb.112.6.1177; VERDE F, 1990, NATURE, V343, P233, DOI 10.1038/343233a0; VERNOS I, 1995, CELL, V81, P117, DOI 10.1016/0092-8674(95)90376-3; Walczak CE, 1996, CELL, V84, P37, DOI 10.1016/S0092-8674(00)80991-5; Walczak CE, 1997, J CELL BIOL, V136, P859, DOI 10.1083/jcb.136.4.859; Wood KW, 1997, CELL, V91, P357, DOI 10.1016/S0092-8674(00)80419-5; Yanai A, 1997, ONCOGENE, V14, P2943, DOI 10.1038/sj.onc.1201144; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	61	180	192	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					15005	15013		10.1074/jbc.274.21.15005	http://dx.doi.org/10.1074/jbc.274.21.15005			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329703	hybrid			2022-12-25	WOS:000081965200068
J	Zenser, TV; Lakshmi, VM; Hsu, FF; Davis, BB				Zenser, TV; Lakshmi, VM; Hsu, FF; Davis, BB			Peroxygenase metabolism of N-acetylbenzidine by prostaglandin H synthase - Formation of an N-hydroxylamine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARCINOGEN 2-AMINO-4-(5-NITRO-2-FURYL)-THIAZOLE ANFT; DNA-ADDUCTS; HORSERADISH-PEROXIDASE; ENDOPEROXIDE SYNTHETASE; EXPOSED WORKERS; OXYGEN-TRANSFER; BENZIDINE; OXIDATION; MECHANISM; ACTIVATION	Synthesis of prostaglandin H-2 by prostaglandin H synthase (PHS) results in a two electron oxidation of the enzyme. An active reduced enzyme is regenerated by reducing cofactors, which become oxidized. This report examines the mechanism by which PHS from ram seminal vesicle microsomes catalyzes the oxidation of the reducing cofactor N-acetylbenzidine (ABZ). During the conversion of 0.06 mM ABZ to its final end product, 4'-nitro-4-acetylaminobiphenyl, a new metabolite was observed when 1 mM ascorbic acid was present. Similar results were observed whether 0.2 mM arachidonic acid or 0.5 mM H2O2 was used as the substrate. This metabolite co-eluted with synthetic N'-hydroxy-N-acetylbenzidine (N'HA), but not with N-hydroxy-N-acetylbenzidine. The new metabolite was identified as N'HA by electrospray ionization/MS/MS. N'HA represented as much as 10% of the total radioactivity recovered by high pressure liquid chromatography. When N'HA was substituted for ABZ, PHS metabolized N'HA to 4'-nitro-4-acetylaminobiphenyl. Inhibitor studies demonstrated that metabolism was due to PHS, not cytochrome P-450. The lack of effect of 5,5-dimethyl-1-pyrroline N-oxide, mannitol, and superoxide dismutase suggests the lack of involvement of one-electron transfer reactions and suggests that hydroxyl radicals and superoxide are not sources of oxygen or oxidants. Oxygen uptake studies did not demonstrate a requirement for molecular oxygen. When [O-18]H2O2 was used as the substrate, O-18 enrichment was observed for 4'-nitro-4-acetylaminobiphenyl, but not for N'HA. A 97% enrichment was observed for one atom of O-18, and a 17 +/- 7% enrichment was observed for two O-18 atoms. The rapid exchange of O-18-N'HA with water was suggested to explain the lack of enrichment of N'HA and the low enrichment of two O-18 atoms into 4'-nitro-4-acetylaminobiphenyl. Results demonstrate a peroxygenase oxidation of ABZ and N'HA by PHS and suggest a stepwise oxidation of ABZ to N'-hydroxy, 4'-nitroso, and 4'-nitro products.	Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Div Geriatr Med, St Louis, MO 63125 USA; St Louis Univ, Sch Med, Dept Biochem, St Louis, MO 63125 USA; Washington Univ, Dept Med, St Louis, MO 63125 USA	Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Saint Louis University; Washington University (WUSTL)	Zenser, TV (corresponding author), Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Div Geriatr Med, 11G-JB, St Louis, MO 63125 USA.			Hsu, Fong-Fu/0000-0001-5368-0183	NCI NIH HHS [CA72613] Funding Source: Medline; NCRR NIH HHS [RR-00954] Funding Source: Medline; NIADDK NIH HHS [AM-20579] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [P60AM020579] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA072613] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000954] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ATOR MA, 1987, J BIOL CHEM, V262, P1542; Babu SR, 1995, CARCINOGENESIS, V16, P3069, DOI 10.1093/carcin/16.12.3069; BELAND FA, 1983, ENVIRON HEALTH PERSP, V49, P125, DOI 10.2307/3429589; BOYD JA, 1983, J BIOL CHEM, V258, P8246; CORBETT MD, 1985, BIOCHEM ARCH, V1, P115; CORBETT MD, 1980, BIOCHEM J, V187, P893, DOI 10.1042/bj1870893; Correia MA, 1995, CYTOCHROME P450 STRU, P607; DANON A, 1986, CANCER RES, V46, P5676; DEMONTELLANO PRO, 1985, J BIOL CHEM, V260, P9265; DOERGE DR, 1991, BIOCHEMISTRY-US, V30, P8960, DOI 10.1021/bi00101a007; DOERGE DR, 1991, CHEM RES TOXICOL, V4, P556, DOI 10.1021/tx00023a011; EGAN RW, 1980, J BIOL CHEM, V255, P323; ELING TE, 1990, ANNU REV PHARMACOL, V30, P1, DOI 10.1146/annurev.pa.30.040190.000245; FLAMMANG TJ, 1989, CANCER RES, V49, P1977; FOX TR, 1990, CANCER RES, V50, P4014; FREDERICK CB, 1985, CARCINOGENESIS, V6, P959, DOI 10.1093/carcin/6.7.959; HARRIS RZ, 1993, J BIOL CHEM, V268, P1637; HATCHER JF, 1995, CARCINOGENESIS, V16, P2149, DOI 10.1093/carcin/16.9.2149; HEFLICH RH, 1986, MUTAGENESIS, V1, P201, DOI 10.1093/mutage/1.3.201; Hsu FF, 1996, ANAL BIOCHEM, V234, P183, DOI 10.1006/abio.1996.0070; JOSEPHY PD, 1982, J BIOL CHEM, V257, P3669; JOSEPHY PD, 1983, MOL PHARMACOL, V23, P766; KRAEMER SA, 1992, ARCH BIOCHEM BIOPHYS, V293, P391, DOI 10.1016/0003-9861(92)90411-O; KUJUBU DA, 1992, J BIOL CHEM, V267, P7991; Lakshmi VM, 1997, DRUG METAB DISPOS, V25, P481; LAKSHMI VM, 1994, TOXICOL APPL PHARM, V125, P256, DOI 10.1006/taap.1994.1071; LAKSHMI VM, 1990, CARCINOGENESIS, V11, P139, DOI 10.1093/carcin/11.1.139; LAKSHMI VM, 1992, CARCINOGENESIS, V13, P2087, DOI 10.1093/carcin/13.11.2087; LAKSHMI VM, 1993, J PHARMACOL EXP THER, V266, P81; LAKSHMI VM, 1990, CARCINOGENESIS, V11, P1965, DOI 10.1093/carcin/11.11.1965; Lakshmi VM, 1998, CARCINOGENESIS, V19, P911, DOI 10.1093/carcin/19.5.911; LAMBEIR AM, 1985, J BIOL CHEM, V260, P4894; LASKER JM, 1981, J BIOL CHEM, V256, P7764; MARKEY CM, 1987, J BIOL CHEM, V262, P6266; MARNETT LJ, 1977, BIOCHEM BIOPH RES CO, V79, P569, DOI 10.1016/0006-291X(77)90195-4; MARNETT LJ, 1979, FEBS LETT, V106, P13, DOI 10.1016/0014-5793(79)80684-5; MARNETT LJ, 1980, ADV PROSTAGLANDIN TH, P149; MARTIN CN, 1982, CANCER RES, V42, P2678; MELCHIOR WB, 1994, CARCINOGENESIS, V15, P889, DOI 10.1093/carcin/15.5.889; MORRISON LD, 1993, MUTAT RES, V302, P45, DOI 10.1016/0165-7992(93)90089-E; MOTTLEY C, 1989, BIOL MAGN RESON, V8, P489; MULDER GJ, 1982, CHEM-BIOL INTERACT, V39, P111, DOI 10.1016/0009-2797(82)90010-2; NOVAK M, 1993, J AM CHEM SOC, V115, P9453, DOI 10.1021/ja00074a010; OHKI S, 1979, J BIOL CHEM, V254, P829; OLDFIELD LF, 1951, J PHYS COLLOID CHEM, V55, P1255, DOI 10.1021/j150490a016; PAGELS WR, 1983, J BIOL CHEM, V258, P6517; PLE P, 1989, J BIOL CHEM, V264, P13983; RIFI MR, 1969, TETRAHEDRON LETT, V58, P5089; Rothman N, 1997, CANCER EPIDEM BIOMAR, V6, P1039; Rothman N, 1996, P NATL ACAD SCI USA, V93, P5084, DOI 10.1073/pnas.93.10.5084; Schulte PA, 1988, CARCINOGENIC MUTAGEN, P23; SESARDIC D, 1990, BRIT J CLIN PHARMACO, V29, P651, DOI 10.1111/j.1365-2125.1990.tb03686.x; SMITH BJ, 1992, CHEM RES TOXICOL, V5, P431, DOI 10.1021/tx00027a018; WISE RW, 1985, CARCINOGENESIS, V6, P579, DOI 10.1093/carcin/6.4.579; WISE RW, 1983, CARCINOGENESIS, V4, P285, DOI 10.1093/carcin/4.3.285; WISE RW, 1984, CANCER RES, V44, P1893; ZENSER TV, 1978, J PHARMACOL EXP THER, V207, P719; ZENSER TV, 1983, J PHARMACOL EXP THER, V227, P545	58	15	15	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					14850	14856		10.1074/jbc.274.21.14850	http://dx.doi.org/10.1074/jbc.274.21.14850			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329684	hybrid			2022-12-25	WOS:000081965200049
J	Ichiba, T; Hashimoto, Y; Nakaya, M; Kuraishi, Y; Tanaka, S; Kurata, T; Mochizuki, N; Matsuda, M				Ichiba, T; Hashimoto, Y; Nakaya, M; Kuraishi, Y; Tanaka, S; Kurata, T; Mochizuki, N; Matsuda, M			Activation of C3G guanine nucleotide exchange factor for Rap1 by phosphorylation of tyrosine 504	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; DEPENDENT ACTIVATION; GDP/GTP EXCHANGE; PROTEIN C3G; SH3 DOMAIN; MAP KINASE; CRK; BINDING; ONCOGENE; PRODUCT	C3G is a guanine nucleotide exchange factor fbr Rap1 and is activated by the expression of Crk adaptor proteins, We found that expression of CrkI in COS cells induced significant tyrosine phosphorylation of C3G. To understand the mechanism by which C3G is phosphorylated and activated by Crk, we constructed a series of deletion mutants. Deletion of the amino terminus of C3G to amino acid 61 did not remarkably affect either tyrosine phosphorylation or Crk-dependent activation of C3G. When C3G was truncated to amino acid 390, C3G was still phosphorylated on tyrosine but was not effectively activated by CrkI, Deletion of the amino terminus of C3G to amino acid 579 significantly reduced the Crk-dependent tyrosine phosphorylation of C3G and increased GTP-bound Rap1 irrespective of the presence of CrkI. We substituted all seven tyrosine residues in this region, amino acids 391-579, for phenylalanine for identification of the phosphorylation site. Among the substitution mutants, the C3G-Y504F mutant, in which tyrosine 504 was substituted by phenylalanine, was remarkably less activated and phosphorylated than the wild type, All the other substitution mutants were activated and tyrosyl-phosphorylated by the expression of CrkI. Thus, CrkI activates C3G by the phosphorylation of tyrosine 504, which represses the cis-acting negative regulatory domain outside the catalytic region.	Int Med Ctr Japan, Res Inst, Dept Pathol, Shinjuku Ku, Tokyo 1628655, Japan; Natl Inst Infect Dis, Dept Pathol, Shinjuku Ku, Tokyo 1628640, Japan; Jikei Univ, Sch Med, Dept Internal Med 3, Minato Ku, Tokyo 1058461, Japan; Hokkaido Univ, Sch Med, Dept Pathol, Kita Ku, Sapporo, Hokkaido 0608638, Japan	National Center for Global Health & Medicine - Japan; National Institute of Infectious Diseases (NIID); Jikei University; Hokkaido University	Matsuda, M (corresponding author), Int Med Ctr Japan, Res Inst, Dept Pathol, Shinjuku Ku, 1-21-1 Toyama, Tokyo 1628655, Japan.		Tanaka, Shinya/D-3586-2011	Matsuda, Michiyuki/0000-0002-5876-9969				Baouz S, 1997, J BIOL CHEM, V272, P6671, DOI 10.1074/jbc.272.10.6671; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; Corbalan-Garcia S, 1998, MOL CELL BIOL, V18, P880, DOI 10.1128/MCB.18.2.880; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FRANKE B, 1997, AMBO J, V15, P252; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; HAMAGUCHI M, 1990, MOL CELL BIOL, V10, P830, DOI 10.1128/MCB.10.2.830; Hashimoto Y, 1998, J BIOL CHEM, V273, P17186, DOI 10.1074/jbc.273.27.17186; Ichiba T, 1997, J BIOL CHEM, V272, P22215, DOI 10.1074/jbc.272.35.22215; Ishimaru S, 1999, EMBO J, V18, P145, DOI 10.1093/emboj/18.1.145; Kawasaki H, 1998, P NATL ACAD SCI USA, V95, P13278, DOI 10.1073/pnas.95.22.13278; Kirsch KH, 1998, J BIOL CHEM, V273, P25673, DOI 10.1074/jbc.273.40.25673; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Kiyokawa E, 1997, CRIT REV ONCOGENESIS, V8, P329, DOI 10.1615/CritRevOncog.v8.i4.30; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; Matsuda M, 1996, J BIOL CHEM, V271, P14468, DOI 10.1074/jbc.271.24.14468; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; Mattingly RR, 1996, NATURE, V382, P268, DOI 10.1038/382268a0; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MUROYA K, 1992, ONCOGENE, V7, P277; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; Ohtsuka T, 1996, J BIOL CHEM, V271, P1258, DOI 10.1074/jbc.271.3.1258; Olayioye MA, 1998, MOL CELL BIOL, V18, P5042, DOI 10.1128/MCB.18.9.5042; Qian XL, 1998, MOL CELL BIOL, V18, P771, DOI 10.1128/MCB.18.2.771; Tanaka S, 1998, J BIOL CHEM, V273, P1281, DOI 10.1074/jbc.273.3.1281; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451	33	94	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					14376	14381		10.1074/jbc.274.20.14376	http://dx.doi.org/10.1074/jbc.274.20.14376			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318861	hybrid			2022-12-25	WOS:000080322200090
J	Quinn, JM; Nakamoto, SS; Merchant, S				Quinn, JM; Nakamoto, SS; Merchant, S			Induction of coproporphyrinogen oxidase in Chlamydomonas chloroplasts occurs via transcriptional regulation of Cpx1 mediated by copper response elements and increased translation from a copper-deficiency-specific form of the transcript	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLOROPHYLL BIOSYNTHETIC ENZYME; PLASTIDIC CYTOCHROME-C; MESSENGER-RNA; GENE-EXPRESSION; CARBOXYLASE-OXYGENASE; COMPLEMENTARY-DNA; HEME ATTACHMENT; 2 GENES; REINHARDTII; PLASTOCYANIN	Coproporphyrinogen III oxidase, encoded by a single nuclear gene in Chlamydomonas reinhardtii, produces three distinct transcripts. One of these transcripts is greatly induced in copper-deficient cells by transcriptional activation, whereas the other forms are copper-insensitive. The induced form of the transcript was expressed coordinately with the cytochrome c(6)-encoding (Cyc6) gene, which is known to be transcriptionally regulated in copper-deficient cells. The sequence GTAC, which forms the care of a copper response element associated with the Cyc6 gene, is also essential for induction of the Cpx1 gene, suggesting that both are targets of the same signal transduction pathway. The constitutive and induced Cpx1 transcripts have the same half-lives in vivo and all encode the same polypeptide with a chloroplast-targeting transit sequence, but the shortest one representing the induced form is a 2-4-fold better template for translation than are either of the constitutive forms. The enzyme remains localized to a soluble compartment in the chloroplast even in induced cells, and its abundance is not affected when the tetrapyrrole pathway is manipulated either genetically or by gabaculine treatment.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Merchant, S (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, POB 951569, Los Angeles, CA 90095 USA.	merchant@chem.ucla.edu			NIGMS NIH HHS [GM07185, GM42143] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM042143, R01GM042143, R37GM042143] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], MOL BIOL CHLOROPLAST; BCALE SI, 1993, MOL BIOL CYANOBACTER, P519; CHATTON B, 1988, J BIOL CHEM, V263, P52; Chow KS, 1997, J BIOL CHEM, V272, P27565, DOI 10.1074/jbc.272.44.27565; Chow KS, 1998, PLANT J, V15, P531, DOI 10.1046/j.1365-313X.1998.00235.x; DAVIES JP, 1992, NUCLEIC ACIDS RES, V20, P2959, DOI 10.1093/nar/20.12.2959; DAVIES JP, 1994, MOL CELL BIOL, V14, P5165, DOI 10.1128/MCB.14.8.5165; DEHOSTOS EL, 1989, MOL GEN GENET, V218, P229, DOI 10.1007/BF00331273; DROPPA M, 1990, CRIT REV PLANT SCI, V9, P111, DOI 10.1080/07352689009382284; ERIKSSON M, 1995, PLANT PHYSIOL, V107, P479, DOI 10.1104/pp.107.2.479; FALVEY E, 1995, EMBO J, V14, P4307, DOI 10.1002/j.1460-2075.1995.tb00105.x; FISCHMAN K, 1990, MOL CELL BIOL, V10, P146, DOI 10.1128/MCB.10.1.146; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GOLDSCHMIDTCLERMONT M, 1986, PLANT MOL BIOL, V6, P13, DOI 10.1007/BF00021302; GOLDSCHMIDTCLERMONT M, 1986, J MOL BIOL, V191, P421, DOI 10.1016/0022-2836(86)90137-3; HE ZH, 1994, PLANT PHYSIOL, V106, P537, DOI 10.1104/pp.106.2.537; HILL KL, 1991, J BIOL CHEM, V266, P15060; Hill KL, 1996, PLANT PHYSIOL, V112, P697, DOI 10.1104/pp.112.2.697; HILL KL, 1995, EMBO J, V14, P857, DOI 10.1002/j.1460-2075.1995.tb07067.x; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOWE G, 1994, J BIOL CHEM, V269, P5824; HOWE G, 1995, MOL GEN GENET, V246, P156, DOI 10.1007/BF00294678; Ishikawa N, 1997, J BIOL CHEM, V272, P3289, DOI 10.1074/jbc.272.6.3289; Kerfeld CA, 1998, ANNU REV PLANT PHYS, V49, P397, DOI 10.1146/annurev.arplant.49.1.397; KINDLE KL, 1989, J CELL BIOL, V109, P2589, DOI 10.1083/jcb.109.6.2589; KOHNO H, 1993, J BIOL CHEM, V268, P21359; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lermontova I, 1997, P NATL ACAD SCI USA, V94, P8895, DOI 10.1073/pnas.94.16.8895; LI HH, 1995, J BIOL CHEM, V270, P23504, DOI 10.1074/jbc.270.40.23504; Li HH, 1996, J BIOL CHEM, V271, P31283, DOI 10.1074/jbc.271.49.31283; LI HH, 1992, J BIOL CHEM, V267, P9368; LUMBRERAS V, 1995, PLANT J, V8, P541, DOI 10.1046/j.1365-313X.1995.8040541.x; Luo MZ, 1997, PLANT MOL BIOL, V33, P709, DOI 10.1023/A:1005798207693; MADSEN O, 1993, PLANT MOL BIOL, V23, P35, DOI 10.1007/BF00021417; MARCK C, 1988, NUCLEIC ACIDS RES, V16, P1829, DOI 10.1093/nar/16.5.1829; Marston F. A. O., 1987, DNA CLONING, P59; MATTERS GL, 1994, PLANT MOL BIOL, V24, P617, DOI 10.1007/BF00023558; MATTERS GL, 1995, PLANT MOL BIOL, V27, P607, DOI 10.1007/BF00019326; MAYER M, 1997, PLANT PHYSL S, V114, P180; MCCARTHY JEG, 1995, TRENDS BIOCHEM SCI, V20, P191, DOI 10.1016/S0968-0004(00)89006-4; MERCHANT S, 1987, EMBO J, V6, P2531, DOI 10.1002/j.1460-2075.1987.tb02540.x; Merchant S, 1997, CH MICROBIOL SER, P450; MERCHANT S, 1991, EMBO J, V10, P1383, DOI 10.1002/j.1460-2075.1991.tb07658.x; MERCHANT S, 1990, J BIOL CHEM, V265, P12372; MERCHANT S, 1987, J BIOL CHEM, V262, P9062; MERCHANT S, 1986, J BIOL CHEM, V261, P5850; MERCHANT S, 1998, MOL BIOL CHLAMYDOMON, V7, P597; MORAND LZ, 1994, MOL BIOL CYANOBACTER, P243; Owen CA., 1981, COPPER DEFICIENCY TO, V1st; Peck SC, 1998, PLANT J, V14, P573, DOI 10.1046/j.1365-313X.1998.00156.x; Quinn JM, 1998, METHOD ENZYMOL, V297, P263; QUINN JM, 1995, PLANT CELL, V7, P623, DOI 10.1105/tpc.7.5.623; Randolph-Anderson BL, 1998, PLANT MOL BIOL, V38, P839, DOI 10.1023/A:1006085026294; REDINBO MR, 1994, J BIOENERG BIOMEMBR, V26, P49, DOI 10.1007/BF00763219; SANDMANN G, 1986, ARCH MICROBIOL, V145, P76, DOI 10.1007/BF00413030; SANDMANN G, 1983, ARCH MICROBIOL, V134, P23, DOI 10.1007/BF00429401; SANDMANN G, 1987, PHOTOSYNTH RES, V11, P37, DOI 10.1007/BF00117672; Sharp P A, 1980, Methods Enzymol, V65, P750; Sigfridsson K, 1998, PHOTOSYNTH RES, V57, P1, DOI 10.1023/A:1006067631076; SMITH AG, 1993, BIOCHEM J, V292, P503, DOI 10.1042/bj2920503; TAMAOKI M, 1995, PLANT J, V7, P927, DOI 10.1046/j.1365-313X.1995.07060927.x; WOOD PM, 1978, EUR J BIOCHEM, V87, P9, DOI 10.1111/j.1432-1033.1978.tb12346.x; Xie ZY, 1996, J BIOL CHEM, V271, P4632; ZAGOREC M, 1986, J BIOL CHEM, V261, P2506; ZAGOREC M, 1988, J BIOL CHEM, V263, P9718	65	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					14444	14454		10.1074/jbc.274.20.14444	http://dx.doi.org/10.1074/jbc.274.20.14444			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318870	hybrid			2022-12-25	WOS:000080322200099
J	Sohm, F; Gaiddon, C; Antoine, M; Boutillier, AL; Loeffler, JP				Sohm, F; Gaiddon, C; Antoine, M; Boutillier, AL; Loeffler, JP			The retinoblastoma susceptibility gene product/Sp1 signalling pathway is modulated by Ca2+/calmodulin kinases II and IV activity	ONCOGENE			English	Article						Ca2+ signalling pathway; cell cycle; differentiation; retinoblastoma; SP1	DEPENDENT PROTEIN-KINASE; DNA-BINDING ACTIVITY; C-FOS TRANSCRIPTION; CELL-CYCLE; SP1-MEDIATED TRANSCRIPTION; RB PROTEIN; EXPRESSION; PHOSPHORYLATION; CALCIUM; PROMOTER	To investigate the possible link between Ca2+ signalling and cell cycle control we analysed Ca2+/calmodulin kinases (CamK) interaction with the retinoblastoma susceptibility gene product/SP1 pathway, CamK II and IV activate c-fos transcription through a short promoter region (-99 to -53) containing the retinoblastoma control element (RCE) and a cAMP response element (CRE) related sequences. Deletion analysis revealed that the RCE is a major CamK responsive element and is sufficient to confer CamK and Ca2+ regulation to a minimal promoter, Direct interactions between SP1 and RCE were confirmed by gel shift experiments. Using transient transfection experiments, we show that CamK-dependent transcription is regulated by the retinoblastoma (Rb) susceptibility gene product and the p107 Rb related protein. However, the stimulatory effects of CamKs and Rb on c-fos are blocked by overexpression of both proteins, These effects appear to be directly mediated by SP1 as shown by the use of a Gal4/SP1 fusion proteins. In conclusion, CamK II and IV, two major Ca2+-dependent intracellular effecters, may represent a molecular link between this second messenger transduction pathway and effecters that control cell cycle progression through Rb/SP1 signalling pathway.	IPCB, CNRS, UMR 7519, F-67084 Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Loeffler, JP (corresponding author), IPCB, CNRS, UMR 7519, 21 Rene Descartes, F-67084 Strasbourg, France.		LOEFFLER, Jean-Philippe/AAS-4401-2020; Gaiddon, Christian/F-7321-2012	Gaiddon, Christian/0000-0003-4315-3851				ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Antoine M, 1996, MOL CELL ENDOCRINOL, V120, P1, DOI 10.1016/0303-7207(96)03806-3; Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; BARTON LL, 1995, ANAEROBE, V1, P1, DOI 10.1016/S1075-9964(95)80327-0; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GHOSH A, 1994, J NEUROBIOL, V25, P294, DOI 10.1002/neu.480250309; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; Hardingham GE, 1998, CELL CALCIUM, V23, P131, DOI 10.1016/S0143-4160(98)90111-7; Hollingsworth RE, 1993, CURR OPIN CELL BIOL, V5, P194, DOI 10.1016/0955-0674(93)90102-V; HOROWITZ JM, 1993, GENE CHROMOSOME CANC, V6, P124, DOI 10.1002/gcc.2870060211; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; Johnson CM, 1997, J NEUROSCI, V17, P6189; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LOEFFLER JP, 1993, METHOD ENZYMOL, V217, P599; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MISRA RP, 1994, J BIOL CHEM, V269, P25483; NEVINS JR, 1992, SCIENCE, V258, P424; Nishinaka T, 1997, BBA-GENE STRUCT EXPR, V1351, P274, DOI 10.1016/S0167-4781(96)00210-2; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; Rubin Lee L., 1994, Current Opinion in Neurobiology, V4, P696, DOI 10.1016/0959-4388(94)90012-4; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SIF S, 1993, ONCOGENE, V8, P2501; SPITZER NC, 1994, TRENDS NEUROSCI, V17, P115, DOI 10.1016/0166-2236(94)90120-1; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; TAKUWA N, 1995, CELL SIGNAL, V7, P93, DOI 10.1016/0898-6568(94)00074-L; TAKUWA N, 1993, J BIOL CHEM, V268, P138; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; UDVADIA AJ, 1992, CELL GROWTH DIFFER, V3, P597; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; Wang Y, 1996, MOL CELL BIOL, V16, P5915; XU HJ, 1989, ONCOGENE, V4, P807; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	50	26	26	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 29	1999	18	17					2762	2769		10.1038/sj.onc.1202634	http://dx.doi.org/10.1038/sj.onc.1202634			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FH	10348351				2022-12-25	WOS:000080124900012
J	Weis, B; Giehl, K; Gana-Weisz, M; Egozi, Y; Ben-Baruch, G; Marciano, D; Gierschik, P; Kloog, Y				Weis, B; Giehl, K; Gana-Weisz, M; Egozi, Y; Ben-Baruch, G; Marciano, D; Gierschik, P; Kloog, Y			A new functional Ras antagonist inhibits human pancreatic tumor growth in nude mice	ONCOGENE			English	Article						Ras oncogenes; Ras antagonists; human pancreatic tumor; FTS; Panc-1; EGF; MAPK	DEPENDENT CELL-GROWTH; K-RAS; FARNESYLTRANSFERASE INHIBITORS; TRANSFORMED-CELLS; FACTOR RECEPTOR; FARNESYLTHIOSALICYLIC ACID; STRUCTURAL REQUIREMENTS; TRANSFERASE INHIBITORS; SIGNAL-TRANSDUCTION; HUMAN CANCER	Constitutively active Pas proteins, their regulatory components, and overexpressed tyrosine kinase receptors that activate Pas, are frequently associated with cell transformation in human tumors. This suggests that functional Pas antagonists may have anti-tumor activity. Studies in rodent fibroblasts have shown that S-trans, transfarnesylthiosalicylic acid (FTS) acts as a rather specific nontoxic Pas antagonist, dislodging Pas from its membrane anchorage domains and accelerating its degradation. FTS is not a farnesyltransferase inhibitor, and does not affect Pas maturation. Here we demonstrate that FTS also acts as a functional Pas antagonist in human pancreatic cell lines that express activated K-Ras (Panc-1 and MiaPaCa-2). In Panc-1 cells, FTS at a concentration of 25-100 mu M reduced the amount of Pas in a dose-dependent manner and interfered with serum-dependent and epidermal growth factor-stimulated ERK activation, thus inhibiting both anchorage-dependent and anchorage-independent growth of Panc-1 cells in vitro. FTS also inhibited tumor growth in Panc-1 xenografted nude mice, apparently without systemic toxicity. Daily FTS treatment (5 mg/kg intraperitoneallly) in mice with tumors (mean volume 0.07 cm(3)) markedly decreased tumor growth (after treatment for 18 days, tumor volume had increased by only 23+/-30-fold in the FTS-treated group and by 127+/-66-fold in controls). These findings suggest that FTS represents a new class of functional Pas antagonists with potential therapeutic value.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel; Univ Ulm, Dept Pharmacol & Toxicol, D-89069 Ulm, Germany; Chaim Sheba Med Ctr, Dept Obstet & Gynecol, IL-52621 Tel Hashomer, Israel; Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel; Israel Inst Biol Res, IL-70450 Ness Ziona, Israel	Tel Aviv University; Ulm University; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine	Kloog, Y (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel.							Aharonson Z, 1998, BBA-MOL BASIS DIS, V1406, P40, DOI 10.1016/S0925-4439(97)00077-X; ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BERROZPE G, 1994, INT J CANCER, V58, P185, DOI 10.1002/ijc.2910580207; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Bos JL, 1997, BBA-REV CANCER, V1333, pM19, DOI 10.1016/S0304-419X(97)00015-2; BOS JL, 1995, EUR J CANCER, V31A, P1051, DOI 10.1016/0959-8049(95)00168-I; BOS JL, 1989, CANCER RES, V49, P4682; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CHEN YF, 1990, PANCREAS, V5, P278, DOI 10.1097/00006676-199005000-00006; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Cox AD, 1997, BBA-REV CANCER, V1333, pF51, DOI 10.1016/S0304-419X(97)00011-5; Cox Adrienne D., 1992, Current Opinion in Cell Biology, V4, P1008, DOI 10.1016/0955-0674(92)90133-W; Dhanasekaran N., 1995, Endocrine Reviews, V16, P259; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; Fearon ER, 1997, SCIENCE, V278, P1043, DOI 10.1126/science.278.5340.1043; GanaWeisz ML, 1997, BIOCHEM BIOPH RES CO, V239, P900, DOI 10.1006/bbrc.1997.7582; Gibbs JB, 1997, ANNU REV PHARMACOL, V37, P143, DOI 10.1146/annurev.pharmtox.37.1.143; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; Haklai R, 1998, BIOCHEMISTRY-US, V37, P1306, DOI 10.1021/bi972032d; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; HUBRAN RH, 1993, AM J PATHOL, V143, P545; James G, 1996, P NATL ACAD SCI USA, V93, P4454, DOI 10.1073/pnas.93.9.4454; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; KhosraviFar R, 1998, ADV CANCER RES, V72, P57; KINOSHITA T, 1995, ONCOGENE, V10, P2207; KOHL NE, 1994, P NATL ACAD SCI USA, V91, P9141, DOI 10.1073/pnas.91.19.9141; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; Kolibaba KS, 1997, BBA-REV CANCER, V1333, pF217, DOI 10.1016/S0304-419X(97)00022-X; KORC M, 1986, P NATL ACAD SCI USA, V83, P5141, DOI 10.1073/pnas.83.14.5141; KUNDRA V, 1995, J CELL BIOL, V130, P725, DOI 10.1083/jcb.130.3.725; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; Lebowitz PF, 1997, CANCER RES, V57, P708; LEMOINE NR, 1992, J PATHOL, V166, P7, DOI 10.1002/path.1711660103; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; LOWRY DR, 1993, ANNU REV BIOCHEM, V62, P851; MANNE V, 1995, ONCOGENE, V10, P1763; MARCIANO D, 1995, J MED CHEM, V38, P1267, DOI 10.1021/jm00008a004; Marciano D, 1997, BIOORG MED CHEM LETT, V7, P1709, DOI 10.1016/S0960-894X(97)00294-1; MAROM M, 1995, J BIOL CHEM, V270, P22263, DOI 10.1074/jbc.270.38.22263; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MEIMBROOK DC, 1998, CURR OPIN CELL BIOL, V10, P284; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; NAGASU Y, 1995, CANCER RES, V55, P3510; PELLEGATA NS, 1994, CANCER RES, V54, P1556; Rall CJN, 1996, PANCREAS, V12, P10, DOI 10.1097/00006676-199601000-00002; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Rowell CA, 1997, J BIOL CHEM, V272, P14093, DOI 10.1074/jbc.272.22.14093; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; SEPPLORENZINO L, 1995, CANCER RES, V55, P5302; Siddiqui AA, 1998, J BIOL CHEM, V273, P3712, DOI 10.1074/jbc.273.6.3712; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SMITH JJ, 1987, P NATL ACAD SCI USA, V84, P7567, DOI 10.1073/pnas.84.21.7567; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; SUN JZ, 1995, CANCER RES, V55, P4243; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; Trent JC, 1996, EMBO J, V15, P4497, DOI 10.1002/j.1460-2075.1996.tb00827.x; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459	65	98	100	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	1999	18	16					2579	2588		10.1038/sj.onc.1202602	http://dx.doi.org/10.1038/sj.onc.1202602			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	189LU	10353601				2022-12-25	WOS:000079907100005
J	Schmidt, L; Junker, K; Nakaigawa, N; Kinjerski, T; Weirich, G; Miller, M; Lubensky, I; Neumann, HPH; Brauch, H; Decker, J; Vocke, C; Brown, JA; Jenkins, R; Richard, S; Bergerheim, U; Gerrard, B; Dean, M; Linehan, WM; Zbar, B				Schmidt, L; Junker, K; Nakaigawa, N; Kinjerski, T; Weirich, G; Miller, M; Lubensky, I; Neumann, HPH; Brauch, H; Decker, J; Vocke, C; Brown, JA; Jenkins, R; Richard, S; Bergerheim, U; Gerrard, B; Dean, M; Linehan, WM; Zbar, B			Novel mutations of the MET proto-oncogene in papillary renal carcinomas	ONCOGENE			English	Article						papillary renal carcinoma; MET protooncogene mutations; receptor tyrosine kinase	TYROSINE KINASE DOMAIN; TUMOR-SUPPRESSOR GENE; GROWTH-FACTOR RECEPTORS; ACTIVATING MUTATIONS; CRYSTAL-STRUCTURE; INSULIN-RECEPTOR; POINT MUTATIONS; CELL CARCINOMA; PROTOONCOGENE; ERBB	Hereditary papillary renal carcinoma (HPRC) is characterized by multiple, bilateral papillary renal carcinomas. Previously, we demonstrated missense mutations in the tyrosine kinase domain of the MET proto-oncogene in HPRC and a subset of sporadic papillary renal carcinoma In this study, me screened a large panel of sporadic papillary renal carcinomas and various solid tumors for mutations in the MET protooncogene, Summarizing these and previous results, mutations of the MET proto-oncogene were detected in 17/129 sporadic papillary renal carcinomas but not in other solid tumors. We detected five novel: missense mutations; three of five mutations were located in the ATP-binding region of the tyrosine kinase domain of MET. One novel mutation in MET, V1110I, was located at a codon homologous to an activating mutation in the c-erbB proto-oncogene, These mutations caused constitutive phosphorylation of MET when transfected into NIH3T3 cells. Molecular modeling studies suggest that these activating mutations interfere with the intrasteric mechanism of tyrosine kinase autoinhibition and facilitate transition to the active form of the MET kinase, The low frequency of MET mutations in noninherited papillary renal carcinomas (PRC) suggests that noninherited PRC may develop by a different mechanism than hereditary papillary renal carcinoma.	NCI, Frederick Canc Res & Dev Ctr, Immunobiol Lab, Frederick, MD 21702 USA; NCI, Frederick Canc Res & Dev Ctr, SAIC Frederick, Intramural Res Support Program, Frederick, MD 21702 USA; NCI, Frederick Canc Res & Dev Ctr, ABL Basic Res Program, Macromol Struct Lab, Frederick, MD 21702 USA; NCI, Frederick Canc Res & Dev Ctr, Lab Genom Divers, Frederick, MD 21702 USA; NIH, Urol Oncol Branch, Bethesda, MD 20892 USA; NIH, Pathol Lab, Bethesda, MD 20892 USA; Univ Freiburg, D-79106 Freiburg, Germany; Univ Hamburg, Womens Clin, Hamburg Eppendorf UKE, D-20246 Hamburg, Germany; Johannes Gutenberg Univ Mainz, D-55131 Mainz, Germany; Mayo Clin & Mayo Fdn, Div Lab Genet, Rochester, MN 55905 USA; Karolinska Inst, Stockholm, Sweden; Hop Bicetre, Dept Urol, Paris, France; EPHE, Lab Neuoroncol, F-75006 Paris, France; Univ Jena, Dept Urol, D-07743 Jena, Germany; David Grant Med Ctr, Travis AFB, CA 94535 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; University of Freiburg; University of Hamburg; University Medical Center Hamburg-Eppendorf; Johannes Gutenberg University of Mainz; Mayo Clinic; Karolinska Institutet; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; PSL Research University Paris; Ecole Pratique des Hautes Etudes (EPHE); Friedrich Schiller University of Jena	Schmidt, L (corresponding author), NCI, Frederick Canc Res & Dev Ctr, Immunobiol Lab, Bldg 560 Rm 12-29, Frederick, MD 21702 USA.		Dean, Michael/R-7501-2019; Dean, Michael C/G-8172-2012; Miller, Maria/I-1636-2013; RICHARD, Stéphane/O-1005-2017	Dean, Michael C/0000-0003-2234-0631; Miller, Maria/0000-0003-0252-5348; RICHARD, Stéphane/0000-0002-9859-9773; Brauch, Hiltrud/0000-0001-7531-2736; Brown, James/0000-0002-6065-1716	NATIONAL CANCER INSTITUTE [Z01BC008579, Z01BC005652] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO056000] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-56000] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Berndt I, 1998, J CLIN ENDOCR METAB, V83, P770, DOI 10.1210/jc.83.3.770; BORDEN EC, 1982, CANCER RES, V42, P4948; Brown JA, 1997, J UROLOGY, V158, P370, DOI 10.1016/S0022-5347(01)64482-3; DIRENZO MF, 1995, J ENDOCRINOL INVEST, V18, P134, DOI 10.1007/BF03349722; Duh FM, 1997, ONCOGENE, V15, P1583, DOI 10.1038/sj.onc.1201338; ERMIS A, 1995, HUM GENET, V96, P651, DOI 10.1007/BF00210293; Fattoruso O, 1998, HUM MUTAT, pS167; Fischer Joachim, 1998, Proceedings of the American Association for Cancer Research Annual Meeting, V39, P130; Grignon DJ, 1998, SEMIN DIAGN PATHOL, V15, P41; Hanafusa H., 1986, ONCOGENES GROWTH CON, P100; Huang HJ, 1998, GENE CHROMOSOME CANC, V21, P152, DOI 10.1002/(SICI)1098-2264(199802)21:2<152::AID-GCC11>3.0.CO;2-T; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976; KOVACS G, 1993, ADV CANCER RES, V62, P89, DOI 10.1016/S0065-230X(08)60316-4; LEVY JB, 1986, P NATL ACAD SCI USA, V83, P4228, DOI 10.1073/pnas.83.12.4228; Lin JC, 1996, ONCOGENE, V13, P2001; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; Pignon JM, 1997, HEMATOL CELL THER, V39, P114, DOI 10.1007/s00282-997-0114-4; Santoro MM, 1998, ONCOGENE, V17, P741, DOI 10.1038/sj.onc.1201994; Schmidt L, 1995, Cancer J Sci Am, V1, P191; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Schmidt L, 1998, CANCER RES, V58, P1719; SCHMIDT L, 1993, HUM MOL GENET, V2, P817, DOI 10.1093/hmg/2.6.817; SHU HKG, 1991, J VIROL, V65, P6173, DOI 10.1128/JVI.65.11.6173-6180.1991; SHU HKG, 1994, MOL CELL BIOL, V14, P6868, DOI 10.1128/MCB.14.10.6868; SHU HKG, 1990, P NATL ACAD SCI USA, V87, P9103, DOI 10.1073/pnas.87.23.9103; Sidhar SK, 1996, HUM MOL GENET, V5, P1333, DOI 10.1093/hmg/5.9.1333; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Underhill PA, 1996, P NATL ACAD SCI USA, V93, P196, DOI 10.1073/pnas.93.1.196; Weterman MAJ, 1996, P NATL ACAD SCI USA, V93, P15294, DOI 10.1073/pnas.93.26.15294; ZBAR B, 1994, J UROLOGY, V151, P561, DOI 10.1016/S0022-5347(17)35015-2; Zbar B, 1998, ADV CANCER RES, V75, P163, DOI 10.1016/S0065-230X(08)60742-3; ZENKLUSEN JC, 1995, ONCOGENE, V11, P359; ZENKLUSEN JC, 1994, CANCER RES, V54, P6370; Zhuang ZP, 1998, NAT GENET, V20, P66, DOI 10.1038/1727	37	386	423	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	1999	18	14					2343	2350		10.1038/sj.onc.1202547	http://dx.doi.org/10.1038/sj.onc.1202547			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184DT	10327054				2022-12-25	WOS:000079595500006
J	Leone, PE; Bello, MJ; de Campos, JM; Vaquero, J; Sarasa, JL; Pestana, A; Rey, JA				Leone, PE; Bello, MJ; de Campos, JM; Vaquero, J; Sarasa, JL; Pestana, A; Rey, JA			NF2 gene mutations and allelic status of 1p, 14q and 22q in sporadic meningiomas	ONCOGENE			English	Article						meningiomas; NF2; allelic losses; tumor progression; 1p and 14q deletion mapping	TUMOR-SUPPRESSOR GENE; NEUROFIBROMATOSIS TYPE-2; HISTOPATHOLOGICAL FINDINGS; OLIGODENDROGLIAL TUMORS; MALIGNANT MENINGIOMA; CYTOGENETIC ANALYSIS; SOMATIC MUTATIONS; FREQUENT LOSS; BRAIN-TUMORS; PROGRESSION	Formation of meningiomas and their progression to malignancy may be a multi-step process, implying accumulation of genetic mutations at specific loci. To determine the relationship between early NF2 gene inactivation and the molecular mechanisms that may contribute to meningioma tumor progression, we have performed deletion mapping analysis at chromosomes 1, 14 and 22 in a series of 81 sporadic meningiomas (54 grade I(typical), 25 grade LI (atypical) and two grade III (anaplastic)), which were also studied for NF2 gene mutations. Single-strand conformational polymorphism analysis was used to identify 11 mutations in five of the eight exons of the NF2 gene studied. All 11 tumors displayed loss of heterozygosity (LOH) for chromosome 22 markers; this anomaly was also detected in 33 additional tumors. Twenty-nine and 23 cases were characterized by LOH at 1p and 14q, respectively, mostly corresponding to aggressive tumors that also generally displayed LOH 22. All three alterations were detected in association in seven grade II and two grade III meningiomas, corroborating the hypothesis that the formation of aggressive meningiomas follows a multi-step tumor progression model.	CSIC, Inst Invest Biomed, E-28029 Madrid, Spain; Hosp Rio Hortega, Dept Neurosurg, Valladolid, Spain; Clin Puerta Hierro, Dept Neurosurg, Madrid, Spain; Fdn Jimenez Diaz, Dept Pathol Anat, E-28040 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Hospital del Rio Hortega; Clinica Veterinaria Puerta de Hierro; Hospital Puerta de Hierro-Majadahonda	Rey, JA (corresponding author), CSIC, Inst Invest Biomed, Arturo Duperier 4, E-28029 Madrid, Spain.		Rey, Juan A/H-5026-2013					ALSAADI A, 1987, CANCER GENET CYTOGEN, V26, P127, DOI 10.1016/0165-4608(87)90140-3; Bandera CA, 1997, CANCER RES, V57, P513; BATTERSBY RDE, 1986, J NEUROL NEUROSUR PS, V49, P362, DOI 10.1136/jnnp.49.4.362; BELLO MJ, 1995, INT J CANCER, V64, P207; BELLO MJ, 1994, GENE CHROMOSOME CANC, V9, P296, DOI 10.1002/gcc.2870090411; BENDER B, 1994, BIOTECHNIQUES, V16, P204; BIECHE I, 1994, CANCER RES, V54, P4274; BUTTI G, 1989, SURG NEUROL, V31, P225; CASALONE R, 1990, CANCER GENET CYTOGEN, V45, P237, DOI 10.1016/0165-4608(90)90088-R; CASARTELLI C, 1989, CANCER GENET CYTOGEN, V40, P33, DOI 10.1016/0165-4608(89)90143-X; CHANG WYH, 1995, CANCER RES, V55, P3246; DEPREZ RHL, 1994, AM J HUM GENET, V54, P1022; DEPREZ RHL, 1995, ONCOGENE, V10, P1521; DEPREZ RHL, 1995, J NEUROPATH EXP NEUR, V54, P224, DOI 10.1097/00005072-199503000-00009; DeVitis LR, 1996, HUM GENET, V97, P632; DOMENICUCCI M, 1989, J NEUROSURG, V70, P41, DOI 10.3171/jns.1989.70.1.0041; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FUJINO T, 1994, CANCER RES, V54, P4294; Harada T, 1996, J NEUROSURG, V84, P847, DOI 10.3171/jns.1996.84.5.0847; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KLEIHUES P, 1993, BRAIN PATHOL, V3, P255, DOI 10.1111/j.1750-3639.1993.tb00752.x; KOVACS G, 1993, HISTOPATHOLOGY, V22, P1, DOI 10.1111/j.1365-2559.1993.tb00061.x; KRAUS JA, 1995, J NEUROPATH EXP NEUR, V54, P91, DOI 10.1097/00005072-199501000-00011; LINDBLOM A, 1994, INT J CANCER, V56, P354, DOI 10.1002/ijc.2910560310; LopezGines C, 1995, CANCER GENET CYTOGEN, V85, P113, DOI 10.1016/0165-4608(95)00148-4; MALTBY EL, 1988, CANCER GENET CYTOGEN, V31, P199, DOI 10.1016/0165-4608(88)90218-X; MARTUZA RL, 1988, NEW ENGL J MED, V318, P684, DOI 10.1056/NEJM198803173181106; MEMON MY, 1980, NEUROSURGERY, V7, P262, DOI 10.1227/00006123-198009000-00010; Menon AG, 1997, ONCOGENE, V14, P611, DOI 10.1038/sj.onc.1200853; MEREL P, 1995, GENE CHROMOSOME CANC, V13, P211, DOI 10.1002/gcc.2870130311; Mertens F, 1997, CANCER RES, V57, P2765; PAPI L, 1995, HUM GENET, V95, P347, DOI 10.1007/BF00225206; Perry A, 1996, CANCER, V77, P2567, DOI 10.1002/(SICI)1097-0142(19960615)77:12<2567::AID-CNCR21>3.0.CO;2-P; PEYRARD M, 1994, HUM MOL GENET, V3, P1393, DOI 10.1093/hmg/3.8.1393; Poulsgard Lars, 1993, P249; Rasio D, 1997, CANCER RES, V57, P2378; REIFENBERGER J, 1994, AM J PATHOL, V145, P1175; REMPEL SA, 1993, CANCER RES, V53, P2386; REY JA, 1988, CANCER GENET CYTOGEN, V33, P275, DOI 10.1016/0165-4608(88)90036-2; REY JA, 1992, INT J CANCER, V51, P703, DOI 10.1002/ijc.2910510507; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; RUTTLEDGE MH, 1994, NAT GENET, V6, P180, DOI 10.1038/ng0294-180; Schneider BF, 1995, CANCER GENET CYTOGEN, V85, P101, DOI 10.1016/0165-4608(95)00154-9; Schwab M, 1996, GENE CHROMOSOME CANC, V16, P211, DOI 10.1002/(SICI)1098-2264(199608)16:4<211::AID-GCC1>3.0.CO;2-0; SIMON M, 1995, CANCER RES, V55, P4696; TAKAYAMA H, 1992, ONCOGENE, V7, P1185; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; VAGNERCAPODANO AM, 1993, NEUROSURGERY, V32, P892, DOI 10.1227/00006123-199306000-00002; WELLENREUTHER R, 1995, AM J PATHOL, V146, P827; YOUNG J, 1993, ONCOGENE, V8, P671; ZANG KD, 1982, CANCER GENET CYTOGEN, V6, P249, DOI 10.1016/0165-4608(82)90063-2	54	120	123	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	1999	18	13					2231	2239		10.1038/sj.onc.1202531	http://dx.doi.org/10.1038/sj.onc.1202531			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	182YE	10327069				2022-12-25	WOS:000079525100007
J	Dobbelstein, M; Wienzek, S; Konig, C; Roth, J				Dobbelstein, M; Wienzek, S; Konig, C; Roth, J			Inactivation of the p53-homologue p73 by the mdm2-oncoprotein	ONCOGENE			English	Article						p53; p73; mdm2; transcription; protein stability	TUMOR-SUPPRESSOR; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; P53 BINDING; MDM2; PROTEIN; DOMAIN; TRANSACTIVATION; GROWTH; ACTIVATION	The p73 beta protein shares structural and functional similarities with the tumor suppressor gene product p53, Both proteins activate transcription from p53-responsive promoters. p53's activity is antagonized by the mdm2 protein (also termed hdma in human cells). Complex formation between p53 and mdm2 results in p53's transcriptional inactivation and destabilization, Here we show that overexpression of mdm2 reduces p73 beta's ability to activate transcription, too. The mdm2 protein forms a specific complex with p73 beta in vitro with an efficiency comparable to p53-binding. Further, both p73 beta and p53 relocalize a transport-defective mutant of mdm2 from the cytoplasm to the nucleus, arguing that complex formation occurs in vivo as well. Mutational analysis suggests that the interaction between p73 beta and mdm2 follows structural principles analogous to the p53-mdm2-complex, Whereas p53 is destabilized in the presence of mdm2, the amount of intracellular p73 beta was not detectably reduced by mdm2, The carboxyterminal RING finger domain of mdm2 was found to be required to reduce the intracellular abundance of p53, but it was dispensable for transcriptionally inactivating either p53 or p73 beta, Our results suggest that the autoregulatory feedback loop between p53 and mdm2 also controls p73's activity, but that mdm2-mediated protein degradation is unique to p53.	Univ Marburg, Fachbereich Med, Abt Gastroenterol & Stoffwechsel, Zentrum Innere Med, D-35045 Marburg, Germany; Univ Marburg, Zentrum Mikrobiol & Hyg, Inst Virol, D-35037 Marburg, Germany	Philipps University Marburg; Philipps University Marburg	Roth, J (corresponding author), Univ Marburg, Fachbereich Med, Abt Gastroenterol & Stoffwechsel, Zentrum Innere Med, Baldingerstr, D-35045 Marburg, Germany.			Dobbelstein, Matthias/0000-0001-5052-3967				Bian JH, 1997, P NATL ACAD SCI USA, V94, P14753, DOI 10.1073/pnas.94.26.14753; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Dickman S, 1997, SCIENCE, V277, P1605, DOI 10.1126/science.277.5332.1605; DOBBELSTEIN M, 1992, ONCOGENE, V7, P837; DOBBLESTEIN M, 1997, IN PRESS J GEN VIROL; Elenbaas B, 1996, MOL MED, V2, P439, DOI 10.1007/BF03401903; Freedman DA, 1997, MOL MED, V3, P248, DOI 10.1007/BF03401678; HAINES DS, 1994, MOL CELL BIOL, V14, P1171, DOI 10.1128/MCB.14.2.1171; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Jones SN, 1996, P NATL ACAD SCI USA, V93, P14106, DOI 10.1073/pnas.93.24.14106; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Leveillard T, 1996, EMBO J, V15, P1615, DOI 10.1002/j.1460-2075.1996.tb00506.x; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LUNA RMD, 1995, NATURE, V378, P203; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; Mai M, 1998, CANCER RES, V58, P2347; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Nomoto S, 1998, CANCER RES, V58, P1380; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Oren M, 1997, CELL, V90, P829, DOI 10.1016/S0092-8674(00)80347-5; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Prabhu NS, 1998, INT J ONCOL, V13, P5; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Roth J, 1998, J VIROL, V72, P8510, DOI 10.1128/JVI.72.11.8510-8516.1998; Schmale H, 1997, ONCOGENE, V15, P1363, DOI 10.1038/sj.onc.1201500; Sunahara M, 1998, INT J ONCOL, V13, P319; Takahashi H, 1998, CANCER RES, V58, P2076; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; Zeng XY, 1998, P NATL ACAD SCI USA, V95, P6681, DOI 10.1073/pnas.95.12.6681; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	43	142	145	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 25	1999	18	12					2101	2106		10.1038/sj.onc.1202512	http://dx.doi.org/10.1038/sj.onc.1202512			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	179TX	10321734				2022-12-25	WOS:000079346200007
J	Lai, A; Marcellus, RC; Corbeil, HB; Branton, PE				Lai, A; Marcellus, RC; Corbeil, HB; Branton, PE			RBP1 induces growth arrest by repression of E2F-dependent transcription	ONCOGENE			English	Article						growth arrest; transcriptional repression; E2F; retinoblastoma protein; pocket binding protein; cell cycle	RETINOBLASTOMA GENE-PRODUCT; HUMAN ADENOVIRUS TYPE-5; CELL-CYCLE; BINDING PROTEIN; FACTOR E2F; E1B PROTEIN; DNA; PHOSPHORYLATION; COMPLEX; FAMILY	Growth arrest and cell cycle progression are regulated by the retinoblastoma tumour suppressor pRB and related proteins p130 and p107 that bind to and inhibit the E2F family of transcription factors. Although the precise mechanism of this inhibition remains to be established, previous studies indicated the presence of transcriptional repression activity in the 'pocket' of RE family members. We show here that RBP1, a known pRB pocket-binding protein, possesses transcriptional repression activity and associates with p130-E2F and pRB-E2F complexes specifically during growth arrest. Overexpression of RBP1 both inhibited E2F-dependent gene expression and suppressed cell growth. Thus repression of E2F-dependent transcription by RBP1 via RE family members may play a central role in inducing growth arrest.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada	McGill University	Branton, PE (corresponding author), McGill Univ, Dept Biochem, McIntyre Med Bldg,3655 Drummond St, Montreal, PQ H3G 1Y6, Canada.							Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; BUYSE IM, 1995, P NATL ACAD SCI USA, V92, P4467, DOI 10.1073/pnas.92.10.4467; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; Chow KNB, 1996, MOL CELL BIOL, V16, P4862; Chow KNB, 1996, MOL CELL BIOL, V16, P7173; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; CORBEIL HB, 1995, ONCOGENE, V11, P909; Corbeil HB, 1997, ONCOGENE, V15, P657, DOI 10.1038/sj.onc.1201224; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; FATTAEY AR, 1993, ONCOGENE, V8, P3149; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Gregory SL, 1996, MOL CELL BIOL, V16, P792; Herrscher RF, 1995, GENE DEV, V9, P3067, DOI 10.1101/gad.9.24.3067; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; Huang TH, 1996, NUCLEIC ACIDS RES, V24, P1695, DOI 10.1093/nar/24.9.1695; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1995, ONCOGENE, V11, P1685; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KIM YW, 1994, MOL CELL BIOL, V14, P7256, DOI 10.1128/MCB.14.11.7256; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MITSUDOMI T, 1992, ONCOGENE, V7, P171; NEVINS JR, 1992, NATURE, V358, P375, DOI 10.1038/358375a0; OTTERSON GA, 1993, ONCOGENE, V8, P949; POPPERL H, 1992, EMBO J, V11, P3673, DOI 10.1002/j.1460-2075.1992.tb05452.x; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; Starostik P, 1996, MOL CELL BIOL, V16, P3606; Strober BE, 1996, MOL CELL BIOL, V16, P1576; Teodoro JG, 1997, J VIROL, V71, P3620, DOI 10.1128/JVI.71.5.3620-3627.1997; TEODORO JG, 1994, J VIROL, V68, P776, DOI 10.1128/JVI.68.2.776-786.1994; Tevosian SG, 1997, GENE DEV, V11, P383, DOI 10.1101/gad.11.3.383; WEINTRAUB SJ, 1992, MOL CELL BIOL, V12, P512, DOI 10.1128/MCB.12.2.512; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190	49	58	66	2	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 25	1999	18	12					2091	2100		10.1038/sj.onc.1202520	http://dx.doi.org/10.1038/sj.onc.1202520			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	179TX	10321733				2022-12-25	WOS:000079346200006
J	Bakhtiari, N; Jie, LZ; Yao, BY; Mueller, DM				Bakhtiari, N; Jie, LZ; Yao, BY; Mueller, DM			Structure function of the beta-barrel domain of F-1-ATPase in the yeast Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE HEART-MITOCHONDRIA; ESCHERICHIA-COLI F1-ATPASE; SITE-DIRECTED MUTAGENESIS; ATP SYNTHASE; ALPHA-SUBUNIT; CROSS-LINKING; TERMINAL REGION; DELTA-SUBUNITS; 2ND STALK; F1	The first 90 amino acids of the alpha- and beta-subunits of mitochondrial F-1-ATPase are folded into beta-barrel dor mains and were postulated to be important for stabilizing the enzyme (Abrahams, J. P., Leslie, A. G., Lutter, R., and Walker, J. E. (1994) Nature 370, 621-628), The role of the domains was studied by making chimeric enzymes, replacing the domains from the yeast Saccharomyces cerevisiae enzyme with the corresponding domains from the enzyme of the thermophilic bacterium Bacillus PS3, The enzymes containing the chimeric alpha-, beta-, or alpha- and beta-subunits were not functional. However, gain-of-function mutations were obtained from the strain containing the enzyme with the chimeric PS3/yeast beta-subunit, The gain-of-function mutations were all in codons encoding the beta-barrel domain of the beta-subunit, and the residues appear to map out a region of subunit-subunit interactions. Gain-of-function mutations were also obtained that provided functional expression of the chimeric PS3/ yeast alpha- and beta-subunits together. Biochemical analysis of this active chimeric enzyme indicated that it was not significantly more thermostable or labile than the wild type. The results of this study indicate that the beta-barrel domains form critical contacts (distinct from those between the alpha- and beta-subunits) that are important for the assembly of the ATP synthase.	Finch Univ Hlth Sci Chicago Med Sch, Dept Biochem & Mol Biol, N Chicago, IL 60064 USA	Chicago Medical School	Mueller, DM (corresponding author), Finch Univ Hlth Sci Chicago Med Sch, Dept Biochem & Mol Biol, 3333 Greenbay Rd, N Chicago, IL 60064 USA.	muellerd@mis.finchcms.edu			NIGMS NIH HHS [GM44412] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044412] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ACKERMAN SH, 1990, P NATL ACAD SCI USA, V87, P4986, DOI 10.1073/pnas.87.13.4986; Arnold I, 1999, J BIOL CHEM, V274, P36, DOI 10.1074/jbc.274.1.36; Arselin G, 1996, J BIOL CHEM, V271, P20284, DOI 10.1074/jbc.271.34.20284; Bianchet MA, 1998, P NATL ACAD SCI USA, V95, P11065, DOI 10.1073/pnas.95.19.11065; Bottcher B, 1998, J MOL BIOL, V281, P757, DOI 10.1006/jmbi.1998.1957; BRAGG PD, 1986, BIOCHIM BIOPHYS ACTA, V851, P385, DOI 10.1016/0005-2728(86)90075-7; BURKOVSKI A, 1994, BBA-BIOENERGETICS, V1186, P243, DOI 10.1016/0005-2728(94)90184-8; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; Collinson IR, 1996, BIOCHEMISTRY-US, V35, P12640, DOI 10.1021/bi960969t; DUNN SD, 1980, J BIOL CHEM, V255, P6891; Gietz RD, 1995, METHOD MOL CELL BIOL, V5, P255; Groth G, 1996, BIOCHEM J, V318, P351, DOI 10.1042/bj3180351; Hase B, 1996, FEBS LETT, V382, P171, DOI 10.1016/0014-5793(96)00167-6; Lill H, 1996, J BIOL CHEM, V271, P32737, DOI 10.1074/jbc.271.51.32737; MA H, 1987, GENE, V58, P201, DOI 10.1016/0378-1119(87)90376-3; MAGGIO MB, 1988, J BIOL CHEM, V263, P4619; MATTEN SR, 1995, J BIOL CHEM, V270, P1489, DOI 10.1074/jbc.270.4.1489; MIKI J, 1994, ARCH BIOCHEM BIOPHYS, V312, P317, DOI 10.1006/abbi.1994.1315; MUELLER DM, 1989, BIOCHEM BIOPH RES CO, V164, P381, DOI 10.1016/0006-291X(89)91730-0; MUELLER DM, 1988, J BIOL CHEM, V263, P5634; MUKHOPADHYAY A, 1994, FEBS LETT, V343, P160, DOI 10.1016/0014-5793(94)80310-2; NORAIS N, 1991, J BIOL CHEM, V266, P16541; Ogilvie I, 1997, J BIOL CHEM, V272, P16652, DOI 10.1074/jbc.272.26.16652; Rodgers AJW, 1998, J BIOL CHEM, V273, P29406, DOI 10.1074/jbc.273.45.29406; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Shirakihara Y, 1997, STRUCTURE, V5, P825, DOI 10.1016/S0969-2126(97)00236-0; SIKORSKI RS, 1989, GENETICS, V122, P19; Sorgen PL, 1998, J BIOL CHEM, V273, P27873, DOI 10.1074/jbc.273.43.27873; Spannagel C, 1997, EUR J BIOCHEM, V247, P1111, DOI 10.1111/j.1432-1033.1997.01111.x; STOSCHECK CM, 1990, METHOD ENZYMOL, V182, P50; TAKEDA M, 1986, J BIOL CHEM, V261, P5126; TOZER RG, 1986, EUR J BIOCHEM, V161, P513, DOI 10.1111/j.1432-1033.1986.tb10472.x; UH M, 1990, J BIOL CHEM, V265, P19047; Vaillier J, 1999, J BIOL CHEM, V274, P543, DOI 10.1074/jbc.274.1.543; VASSAROTTI A, 1987, J BIOL CHEM, V262, P411; WALKER JE, 1991, BIOCHEMISTRY-US, V30, P5369, DOI 10.1021/bi00236a007; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4; Walker JE, 1995, METHOD ENZYMOL, V260, P163, DOI 10.1016/0076-6879(95)60136-8; Xu T, 1998, EUR J BIOCHEM, V252, P155, DOI 10.1046/j.1432-1327.1998.2520155.x	41	13	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16363	16369		10.1074/jbc.274.23.16363	http://dx.doi.org/10.1074/jbc.274.23.16363			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347195	hybrid			2022-12-25	WOS:000080668600055
J	Floer, M; Blobel, G				Floer, M; Blobel, G			Putative reaction intermediates in Crm1-mediated nuclear protein export	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; VIRAL MESSENGER-RNA; RAN-BINDING-PROTEIN; GUANINE-NUCLEOTIDE EXCHANGE; ORDER CHROMOSOME STRUCTURE; VIRUS TYPE-1 AFFECTS; REV TRANS-ACTIVATOR; PORE COMPLEX; KARYOPHERIN-BETA; IMPORTIN-ALPHA	We discovered several novel interactions between proteins involved in Crm1-mediated nuclear export of the nuclear export signal containing human immunodeficiency virus type 1 protein Rev. First, a Rev/Crm1/ RanGTP complex (where Ran is Ras-related nuclear protein) reacts with some nucleoporins (Nup42 and Nup159) but not others (NSP1, Nup116, and Nup1), forming a Nup/Crm1/RanGTP complex and concomitantly releasing Rev. Second, RanBP1 (or homologous proteins) can displace Nup and form a ternary RanBP1/RanGTP/ Crm1 complex that can be disassembled by RanGAP via GTP hydrolysis. Third, and most surprisingly, RanBP1/ RanGTP/Crm1 can be disassembled without GTP hydrolysis by the nucleotide exchange factor RanGEF. Recycling of a Ran/RanGEF complex by GTP and Mg2+ is stimulated by both Crm1 and Rev, allowing reformation of a Rev/Crm1/RanGTP complex. Based on these reactions we propose a model for Crm1-mediated export.	Rockefeller Univ, Howard Hughes Med Inst, Cell Biol Lab, New York, NY 10021 USA	Howard Hughes Medical Institute; Rockefeller University	Blobel, G (corresponding author), Rockefeller Univ, Howard Hughes Med Inst, Cell Biol Lab, New York, NY 10021 USA.							ADACHI Y, 1989, J CELL BIOL, V108, P1195, DOI 10.1083/jcb.108.4.1195; AMBERG DC, 1993, EMBO J, V12, P233, DOI 10.1002/j.1460-2075.1993.tb05649.x; ArenzanaSeisdedos F, 1997, J CELL SCI, V110, P369; Askjaer P, 1998, J BIOL CHEM, V273, P33414, DOI 10.1074/jbc.273.50.33414; BISCHOFF FR, 1991, P NATL ACAD SCI USA, V88, P10830, DOI 10.1073/pnas.88.23.10830; BISCHOFF FR, 1990, P NATL ACAD SCI USA, V87, P8617, DOI 10.1073/pnas.87.21.8617; BISCHOFF FR, 1995, EMBO J, V14, P705, DOI 10.1002/j.1460-2075.1995.tb07049.x; Bischoff FR, 1997, FEBS LETT, V419, P249, DOI 10.1016/S0014-5793(97)01467-1; Bogerd HP, 1998, J VIROL, V72, P8627, DOI 10.1128/JVI.72.11.8627-8635.1998; BOGERD HP, 1995, CELL, V82, P485, DOI 10.1016/0092-8674(95)90437-9; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; CHENG Y, 1995, SCIENCE, V267, P1807, DOI 10.1126/science.7534442; Chi NC, 1996, J CELL BIOL, V135, P559, DOI 10.1083/jcb.135.3.559; Corbett AH, 1996, J BIOL CHEM, V271, P18477, DOI 10.1074/jbc.271.31.18477; COUTAVAS E, 1993, NATURE, V366, P585, DOI 10.1038/366585a0; Delphin C, 1997, MOL BIOL CELL, V8, P2379, DOI 10.1091/mbc.8.12.2379; DINGWALL C, 1995, P NATL ACAD SCI USA, V92, P7525, DOI 10.1073/pnas.92.16.7525; Doye V, 1997, CURR OPIN CELL BIOL, V9, P401, DOI 10.1016/S0955-0674(97)80014-2; FELBER BK, 1989, P NATL ACAD SCI USA, V86, P1495, DOI 10.1073/pnas.86.5.1495; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; FISCHER U, 1994, EMBO J, V13, P4105, DOI 10.1002/j.1460-2075.1994.tb06728.x; Floer M, 1997, J BIOL CHEM, V272, P19538, DOI 10.1074/jbc.272.31.19538; Floer M, 1996, J BIOL CHEM, V271, P5313, DOI 10.1074/jbc.271.10.5313; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fornerod M, 1997, EMBO J, V16, P807, DOI 10.1093/emboj/16.4.807; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Goldberg J, 1998, CELL, V95, P237, DOI 10.1016/S0092-8674(00)81754-7; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; HADZOPOULOUCLADARAS M, 1989, J VIROL, V63, P1265, DOI 10.1128/JVI.63.3.1265-1274.1989; HARTMANN E, 1995, TRENDS CELL BIOL, V5, P192, DOI 10.1016/S0962-8924(00)88992-8; Hellmuth K, 1998, MOL CELL BIOL, V18, P6374, DOI 10.1128/MCB.18.11.6374; HOPPER AK, 1990, J CELL BIOL, V111, P309, DOI 10.1083/jcb.111.2.309; Hu TH, 1996, J CELL BIOL, V134, P589, DOI 10.1083/jcb.134.3.589; Izaurralde E, 1997, EMBO J, V16, P6535, DOI 10.1093/emboj/16.21.6535; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P639, DOI 10.1021/bi00002a031; KORNBLUTH S, 1994, J CELL BIOL, V125, P705, DOI 10.1083/jcb.125.4.705; KRAEMER DM, 1995, J BIOL CHEM, V270, P19017, DOI 10.1074/jbc.270.32.19017; Kuhlmann J, 1997, BIOCHEMISTRY-US, V36, P12027, DOI 10.1021/bi970524k; Kunzler M, 1998, FEBS LETT, V433, P185, DOI 10.1016/S0014-5793(98)00892-8; Kutay U, 1998, MOL CELL, V1, P359, DOI 10.1016/S1097-2765(00)80036-2; Kutay U, 1997, CELL, V90, P1061, DOI 10.1016/S0092-8674(00)80372-4; LOUNSBURY KM, 1994, J BIOL CHEM, V269, P11285; Lounsbury KM, 1997, J BIOL CHEM, V272, P551; MALIM MH, 1991, J VIROL, V65, P4248, DOI 10.1128/JVI.65.8.4248-4254.1991; MALIM MH, 1993, MOL CELL BIOL, V13, P6180, DOI 10.1128/MCB.13.10.6180; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; Nehrbass U, 1996, SCIENCE, V272, P120, DOI 10.1126/science.272.5258.120; Neville M, 1997, CURR BIOL, V7, P767, DOI 10.1016/S0960-9822(06)00335-6; NISHI K, 1994, J BIOL CHEM, V269, P6320; Noguchi E, 1997, MOL CELL BIOL, V17, P2235, DOI 10.1128/MCB.17.4.2235; Ohno M, 1998, CELL, V92, P327, DOI 10.1016/S0092-8674(00)80926-5; OHTSUBO M, 1989, J CELL BIOL, V109, P1389, DOI 10.1083/jcb.109.4.1389; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Paschal BM, 1996, P NATL ACAD SCI USA, V93, P7679, DOI 10.1073/pnas.93.15.7679; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; Pemberton LF, 1998, CURR OPIN CELL BIOL, V10, P392, DOI 10.1016/S0955-0674(98)80016-1; Percipalle P, 1997, J MOL BIOL, V266, P722, DOI 10.1006/jmbi.1996.0801; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Richards SA, 1997, SCIENCE, V276, P1842, DOI 10.1126/science.276.5320.1842; Richards SA, 1996, J CELL BIOL, V134, P1157, DOI 10.1083/jcb.134.5.1157; Rout Michael P., 1994, Trends in Cell Biology, V4, P357, DOI 10.1016/0962-8924(94)90085-X; Sarkar S, 1998, MOL BIOL CELL, V9, P3041, DOI 10.1091/mbc.9.11.3041; SCHLENSTEDT G, 1995, P NATL ACAD SCI USA, V92, P225, DOI 10.1073/pnas.92.1.225; SCHLENSTEDT G, 1995, EMBO J, V14, P5367, DOI 10.1002/j.1460-2075.1995.tb00221.x; Solsbacher J, 1998, MOL CELL BIOL, V18, P6805, DOI 10.1128/MCB.18.11.6805; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Stewart M, 1998, J MOL BIOL, V277, P635, DOI 10.1006/jmbi.1997.1602; Stutz F, 1996, MOL CELL BIOL, V16, P7144; STUTZ F, 1995, CELL, V82, P495, DOI 10.1016/0092-8674(95)90438-7; Taura T, 1997, J BIOL CHEM, V272, P31877, DOI 10.1074/jbc.272.50.31877; Taura T, 1998, P NATL ACAD SCI USA, V95, P7427, DOI 10.1073/pnas.95.13.7427; Traglia HM, 1996, P NATL ACAD SCI USA, V93, P7667, DOI 10.1073/pnas.93.15.7667; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; Wozniak RW, 1998, TRENDS CELL BIOL, V8, P184, DOI 10.1016/S0962-8924(98)01248-3	79	48	49	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16279	16286		10.1074/jbc.274.23.16279	http://dx.doi.org/10.1074/jbc.274.23.16279			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347184	hybrid			2022-12-25	WOS:000080668600044
J	Nakajima, K; Kato, H; Oda, J; Yamada, Y; Hashimoto, T				Nakajima, K; Kato, H; Oda, J; Yamada, Y; Hashimoto, T			Site-directed mutagenesis of putative substrate-binding residues reveals a mechanism controlling the different stereospecificities of two tropinone reductases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TROPANE ALKALOIDS; HYOSCYAMUS-NIGER; CALYSTEGINES; SOLANACEAE	Two tropinone reductases (TRs) constitute a key branch point in the biosynthetic pathway of tropane alkaloids, which are mainly produced in several solanaceous plants, The two TRs share 64% identical amino acid residues and reduce the 3-carbonyl group of a common substrate, tropinone, but they produce distinct alcohol products with different stereospecific configurations. Previous x-ray crystallographic analysis has revealed their highly conserved overall folding, and the modeling of tropinone within the putative substrate-binding sites has suggested that the different stereospecificities may be determined solely by the different binding orientations of tropinone to the enzymes, In this study, we have constructed various mutant TRs, in which putative substrate-binding residues from one TR were substituted with those found in the corresponding positions of the other TR, Substitution of five amino acid residues resulted in an almost complete reversal of stereospecificity, indicating that the different stereospecificities are indeed determined by the binding orientation of tropinone, Detailed kinetic analysis of the mutant enzymes has shown that TR stereospecificity is determined by varying the contributions from electrostatic and hydrophobic interactions and that the present TR structures represent highly evolved forms, in which strict stereospecificities and rapid turnover are accomplished together.	Nara Inst Sci & Technol, Grad Sch Biol Sci, Nara 6300101, Japan; Kyoto Univ, Chem Res Inst, Kyoto 6110011, Japan; Fukui Prefectural Univ, Fac Biotechnol, Matsuoka, Fukui 9101195, Japan	Nara Institute of Science & Technology; Kyoto University; Fukui Prefectural University	Nakajima, K (corresponding author), Nara Inst Sci & Technol, Grad Sch Biol Sci, Nara 6300101, Japan.			Nakajima, Keiji/0000-0002-1580-3354; Kato, Hiroaki/0000-0002-5993-4532				Asano N, 1997, GLYCOBIOLOGY, V7, P1085, DOI 10.1093/glycob/7.8.1085; Clackson T., 1991, PCR PRACTICAL APPROA, P207; Drager B, 1995, PLANTA MED, V61, P577, DOI 10.1055/s-2006-959381; DRAGER B, 1994, PLANT CELL TISS ORG, V38, P235, DOI 10.1007/BF00033882; Fersht A. R., 1985, ENZYME STRUCTURE MEC, P155; HASHIMOTO T, 1992, PLANT PHYSIOL, V100, P836, DOI 10.1104/pp.100.2.836; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; LEETE E, 1990, PLANTA MED, V56, P339, DOI 10.1055/s-2006-960979; MOLYNEUX RJ, 1993, ARCH BIOCHEM BIOPHYS, V304, P81, DOI 10.1006/abbi.1993.1324; Nakajima K, 1998, P NATL ACAD SCI USA, V95, P4876, DOI 10.1073/pnas.95.9.4876; NAKAJIMA K, 1993, P NATL ACAD SCI USA, V90, P9591, DOI 10.1073/pnas.90.20.9591; NAKAJIMA K, 1993, PLANT PHYSIOL, V103, P1465, DOI 10.1104/pp.103.4.1465; NAKAJIMA K, 1994, J BIOL CHEM, V269, P11695; PORTSTEFFEN A, 1994, PHYTOCHEMISTRY, V37, P391, DOI 10.1016/0031-9422(94)85066-6; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TEPFER D, 1988, J BACTERIOL, V170, P1153, DOI 10.1128/jb.170.3.1153-1161.1988; Yamada Y., 1990, SECONDARY PRODUCTS P, P227	17	56	57	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16563	16568		10.1074/jbc.274.23.16563	http://dx.doi.org/10.1074/jbc.274.23.16563			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347221	hybrid			2022-12-25	WOS:000080668600081
J	Jourdan, KB; Evans, TW; Goldstraw, P; Mitchell, JA				Jourdan, KB; Evans, TW; Goldstraw, P; Mitchell, JA			Isoprostanes and PGE(2) production in human isolated pulmonary artery smooth muscle cells: concomitant and differential release	FASEB JOURNAL			English	Article						8-iso PGF(2 alpha a); indomethacin; L-745,337; sepsis; lung vasculature	PROSTAGLANDIN ENDOPEROXIDE SYNTHASE-2; CYCLOOXYGENASE-DEPENDENT FORMATION; STRESS IN-VIVO; 8-EPI PROSTAGLANDIN-F2-ALPHA; LIPID-PEROXIDATION; 8-EPI-PROSTAGLANDIN F2-ALPHA; PROSTANOIDS F2-ISOPROSTANES; OXIDATIVE STRESS; HUMAN MONOCYTES; HUMAN PLATELETS	The isoprostanes are a group of biologically active arachidonic acid metabolites initially thought to be formed under conditions of oxidative stress and independently of cyclooxygenase, However, recent studies have demonstrated isoprostane production under conditions in which cyclooxygenase is intentionally activated/induced. Here we describe for the first time formation of isoprostanes by human vascular cells via independent pathways of oxidative stress and cyclooxygenase induction. We compared the release of the isoprostane with that of the traditional prostaglandin, prostaglandin E-2. Cyclooxygenase-2 induction was confirmed by Western blot. When cells were stimulated with cytokines, the release of isoprostanes was inhibited by the cyclooxygenase-l and -2 inhibitor indomethacin as well by as the cyclooxygenase-2 selective inhibitor L-745,337, However, treatment of cells with the superoxide-producing enzyme xanthine oxidase also resulted in isoprostane release, which was not affected by cyclooxygenase inhibition, unlike PGE(2) release under the same condition, Thus, two independent pathways relating to oxidative stress and cyclooxygenase-2 induction form isoprostanes, These findings may have particular importance in diseases such as sepsis and ARDS in which oxidant stress occurs and cyclooxygenase is induced.	Univ London Imperial Coll Sci Technol & Med, Royal Brompton Hosp, Natl Heart & Lung Inst, Crit Care Unit, London SW3 6NP, England	Imperial College London; Royal Brompton Hospital	Mitchell, JA (corresponding author), Univ London Imperial Coll Sci Technol & Med, Royal Brompton Hosp, Natl Heart & Lung Inst, Crit Care Unit, Sydney St, London SW3 6NP, England.		Mitchell, Jane A/A-1991-2009		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AWAD JA, 1994, J PHARMACOL EXP THER, V270, P858; AWAD JA, 1994, J NUTR, V124, P810, DOI 10.1093/jn/124.6.810; BANERJEE M, 1992, AM J PHYSIOL, V263, pH660, DOI 10.1152/ajpheart.1992.263.3.H660; BishopBailey D, 1997, BRIT J PHARMACOL, V121, P125, DOI 10.1038/sj.bjp.0701100; CHAN CC, 1995, J PHARMACOL EXP THER, V274, P1531; CRANKSHAW D, 1995, EUR J PHARMACOL, V285, P151, DOI 10.1016/0014-2999(95)00398-5; DABBAGH AJ, 1994, BIOCHEM J, V300, P799, DOI 10.1042/bj3000799; Delanty N, 1997, CIRCULATION, V95, P2492, DOI 10.1161/01.CIR.95.11.2492; FUKUMOTO S, 1993, MATER SCI TECH SER, V9, P264, DOI 10.1179/026708393790171962; FUKUNAGA M, 1995, J CARDIOVASC PHARM, V26, pS51; GOPAUL NK, 1995, FEBS LETT, V368, P225, DOI 10.1016/0014-5793(95)00649-T; GOPAUL NK, 1994, FEBS LETT, V348, P297, DOI 10.1016/0014-5793(94)00628-8; HAZBUN ME, 1993, AM J RESP CELL MOL, V9, P568, DOI 10.1165/ajrcmb/9.5.568; Jourdan KB, 1997, BRIT J PHARMACOL, V120, P1280, DOI 10.1038/sj.bjp.0701052; Jourdan KB, 1997, BIOCHEM BIOPH RES CO, V233, P668, DOI 10.1006/bbrc.1997.6523; KANG KH, 1993, J APPL PHYSIOL, V74, P460, DOI 10.1152/jappl.1993.74.1.460; Kawikova I, 1996, AM J RESP CRIT CARE, V153, P590, DOI 10.1164/ajrccm.153.2.8564103; Klein T, 1997, J PHARMACOL EXP THER, V282, P1658; Kromer BM, 1996, BRIT J PHARMACOL, V119, P1276, DOI 10.1111/j.1476-5381.1996.tb16033.x; Lynch SM, 1996, CIRCULATION, V94, P4133; MITCHELL JA, 1995, BIOCHEM PHARMACOL, V50, P1535, DOI 10.1016/0006-2952(95)00212-X; MITCHELL JA, 1993, P NATL ACAD SCI USA, V90, P11693, DOI 10.1073/pnas.90.24.11693; Morrow JD, 1998, ARCH BIOCHEM BIOPHYS, V353, P160, DOI 10.1006/abbi.1998.0645; MORROW JD, 1995, NEW ENGL J MED, V332, P1198, DOI 10.1056/NEJM199505043321804; MORROW JD, 1992, P NATL ACAD SCI USA, V89, P10721, DOI 10.1073/pnas.89.22.10721; MORROW JD, 1990, P NATL ACAD SCI USA, V87, P9383, DOI 10.1073/pnas.87.23.9383; MORROW JD, 1991, FREE RADICAL BIO MED, V10, P195, DOI 10.1016/0891-5849(91)90076-F; MORROW JD, 1992, PROSTAGLANDINS, V44, P155, DOI 10.1016/0090-6980(92)90077-7; MORROW JD, 1992, J CLIN INVEST, V90, P2502, DOI 10.1172/JCI116143; MORROW JD, 1990, ANAL BIOCHEM, V184, P1, DOI 10.1016/0003-2697(90)90002-Q; Natarajan R, 1996, AM J PHYSIOL-HEART C, V271, pH159, DOI 10.1152/ajpheart.1996.271.1.H159; Patrignani P, 1996, BRIT J PHARMACOL, V118, P1285, DOI 10.1111/j.1476-5381.1996.tb15535.x; PRATICO D, 1995, ADV PROSTAG THROMB L, V23, P229; PRATICO D, 1995, J BIOL CHEM, V270, P9800, DOI 10.1074/jbc.270.17.9800; Pratico D, 1996, J BIOL CHEM, V271, P14916, DOI 10.1074/jbc.271.25.14916; Pratico D, 1996, J BIOL CHEM, V271, P8919, DOI 10.1074/jbc.271.15.8919; PRATICO D, 1994, ANN NY ACAD SCI, V744, P139, DOI 10.1111/j.1749-6632.1994.tb52730.x; REILLY M, 1996, CIRCULATION, V94, P9; Reilly MP, 1996, CIRCULATION, V94, P3727; Siegle I, 1998, ARTHRITIS RHEUM-US, V41, P122, DOI 10.1002/1529-0131(199801)41:1<122::AID-ART15>3.3.CO;2-#; SWIERKOSZ TA, 1994, POL J PHARMACOL, V46, P7; TAKAHASHI K, 1992, J CLIN INVEST, V90, P136, DOI 10.1172/JCI115826; VACCHIANO CA, 1994, J APPL PHYSIOL, V77, P2912, DOI 10.1152/jappl.1994.77.6.2912; YIN K, 1994, J PHARMACOL EXP THER, V270, P1192	44	37	38	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	1999	13	9					1025	1030		10.1096/fasebj.13.9.1025	http://dx.doi.org/10.1096/fasebj.13.9.1025			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	200NZ	10336884	Bronze			2022-12-25	WOS:000080547700006
J	Communi, D; Dewaste, V; Erneux, C				Communi, D; Dewaste, V; Erneux, C			Calcium-calmodulin-dependent protein kinase II and protein kinase C-mediated phosphorylation and activation of D-myo-inositol 1,4,5-trisphosphate 3-kinase B in astrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBELLAR PURKINJE-CELLS; RAT-BRAIN; MOLECULAR-CLONING; CULTURED ASTROCYTES; DENDRITIC SPINES; EXPRESSION; RECEPTOR; PURIFICATION; LOCALIZATION; MESSENGER	D-myo-Inositol 1,4,5-trisphosphate (Ins(1,4,5)P-3) 3-kinase catalyzes the production of D-myo-inositol 1,3,4,5-tetrakisphosphate from the second messenger Ins (1,4,5)P-3. Transient and okadaic acid-sensitive activation of Ins(1,4,5)P-3 3-kinase by 8-10-fold is observed in homogenates prepared from rat cortical astrocytes after incubation with either carbachol or UTP. 12-O-Tetradecanoylphorbol-13-acetate provokes the activation of Ins(1,4,5)P-3 3-kinase by a-fold in both cell systems. The kinase was purified by calmodulin-Sepharose from the two cell systems. Enzyme activity corresponding to the silver-stained 88-kDa protein could be regenerated after SDS-polyacrylamide gel electrophoresis. Antibodies to two distinct peptides chosen in the primary structure of human Ins(1,4,5)P-3 3-kinase B recognized the astrocytic native isoform. In [P-32]orthophosphate-preincubated cells, a major phosphorylated 88-kDa enzyme could be purified and identified in cells in response to receptor activation or 12-O-tetradecanoylphorbol-13-acetate treatment. Calmodulin kinase II inhibitors (i.e. KN-93 and KN-62) and a protein kinase C inhibitor (i.e. calphostin C) prevented the phosphorylation of the 88-kDa isoenzyme. In addition to enzyme activation, a redistribution of Ins(1,4,5)P-3 3-kinase from soluble to particulate fraction of astrocytes was observed. In vitro phosphorylation of the purified enzyme by calmodulin kinase II and protein kinase C added together resulted in a maximal 60-70-fold activation.	Free Univ Brussels, Inst Interdisciplinary Res, B-1070 Brussels, Belgium	Universite Libre de Bruxelles; Vrije Universiteit Brussel	Communi, D (corresponding author), Free Univ Brussels, Inst Interdisciplinary Res, 808 Route Lennik,Campus Erasme,Bldg C, B-1070 Brussels, Belgium.	dcommuni@ulb.ac.be						BABA H, 1995, J NEUROSCI RES, V41, P846, DOI 10.1002/jnr.490410615; BABCOCKATKINSON E, 1989, GLIA, V2, P112, DOI 10.1002/glia.440020207; BARNES GN, 1995, J NEUROCHEM, V64, P340; BATTY IR, 1985, BIOCHEM J, V232, P211, DOI 10.1042/bj2320211; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BRONSTEIN J, 1988, J NEUROCHEM, V50, P45, DOI 10.1111/j.1471-4159.1988.tb13227.x; CHALLISS RAJ, 1990, J NEUROCHEM, V54, P2138, DOI 10.1111/j.1471-4159.1990.tb04920.x; CHOI KY, 1990, SCIENCE, V248, P64, DOI 10.1126/science.2157285; Collin T, 1998, NEUROSCI LETT, V255, P67, DOI 10.1016/S0304-3940(98)00699-5; COMMUNI D, 1994, BIOCHEM J, V298, P669, DOI 10.1042/bj2980669; Communi D, 1997, EMBO J, V16, P1943, DOI 10.1093/emboj/16.8.1943; CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; Dupont G, 1997, CELL CALCIUM, V22, P321, DOI 10.1016/S0143-4160(97)90017-8; Easom RA, 1998, BIOCHEM J, V329, P283; GO M, 1993, NEUROSCI LETT, V158, P135, DOI 10.1016/0304-3940(93)90247-I; Inagaki N, 1997, J BIOL CHEM, V272, P25195, DOI 10.1074/jbc.272.40.25195; IRVINE RF, 1991, BIOESSAYS, V13, P419, DOI 10.1002/bies.950130810; Ismailov II, 1996, P NATL ACAD SCI USA, V93, P10505, DOI 10.1073/pnas.93.19.10505; King BF, 1996, NEUROSCIENCE, V74, P1187, DOI 10.1016/0306-4522(96)00209-6; Loomis-Husselbee JW, 1998, BIOCHEM J, V331, P947, DOI 10.1042/bj3310947; LU CY, 1989, J MEMBRANE BIOL, V109, P85, DOI 10.1007/BF01870793; MAILLEUX P, 1992, NEUROSCI LETT, V137, P69, DOI 10.1016/0304-3940(92)90300-V; MAILLEUX P, 1991, BRAIN RES, V539, P203, DOI 10.1016/0006-8993(91)91622-8; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MURPHY JA, 1993, NEUROCHEM INT, V23, P87, DOI 10.1016/0197-0186(93)90147-W; NAKAHATA N, 1987, BIOCHEM J, V241, P337, DOI 10.1042/bj2410337; NEARY JT, 1988, J NEUROCHEM, V50, P1179, DOI 10.1111/j.1471-4159.1988.tb10590.x; Oliva AM, 1997, BIOCHEM PHARMACOL, V54, P1243, DOI 10.1016/S0006-2952(97)00329-8; PARR CE, 1994, P NATL ACAD SCI USA, V91, P3275, DOI 10.1073/pnas.91.8.3275; ROISIN MP, 1995, BRAIN RES, V701, P297, DOI 10.1016/0006-8993(95)01126-7; ROSKOSKI R, 1979, METHOD ENZYMOL, V99, P3; Sheppard CA, 1997, J NEUROCHEM, V68, P2317; SIM SS, 1990, J BIOL CHEM, V265, P10367; SMITH PM, 1998, J PHYSL P, V509, pP145; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; Soriano S, 1997, BIOCHEM J, V324, P579, DOI 10.1042/bj3240579; TAKAZAWA K, 1990, BIOCHEM J, V268, P213, DOI 10.1042/bj2680213; TAKAZAWA K, 1990, BIOCHEM J, V272, P107, DOI 10.1042/bj2720107; TAKAZAWA K, 1991, BIOCHEM J, V278, P883, DOI 10.1042/bj2780883; TAKAZAWA K, 1991, BIOCHEM BIOPH RES CO, V174, P529, DOI 10.1016/0006-291X(91)91449-M; TAKAZAWA K, 1988, BIOPHYS RES COMMUN, V158, P632; THOMAS S, 1994, BBA-MOL CELL RES, V1220, P219, DOI 10.1016/0167-4889(94)90139-2; Tsubokawa H, 1996, J PHYSIOL-LONDON, V497, P67, DOI 10.1113/jphysiol.1996.sp021750; VAJANAPHANICH M, 1994, NATURE, V371, P711, DOI 10.1038/371711a0; VANWEYENBERG V, 1995, BIOCHEM J, V306, P429, DOI 10.1042/bj3060429; Woodring PJ, 1997, J BIOL CHEM, V272, P30447, DOI 10.1074/jbc.272.48.30447; Xie WW, 1998, J PHYSIOL-LONDON, V510, P661, DOI 10.1111/j.1469-7793.1998.661bj.x; YAMADA M, 1993, BRAIN RES, V606, P335, DOI 10.1016/0006-8993(93)91004-C; YAMAMOTOHINO M, 1995, NEUROREPORT, V6, P273, DOI 10.1097/00001756-199501000-00012	49	29	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					14734	14742		10.1074/jbc.274.21.14734	http://dx.doi.org/10.1074/jbc.274.21.14734			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329669	hybrid			2022-12-25	WOS:000081965200034
J	Dhar, G; Bhaduri, A				Dhar, G; Bhaduri, A			Synthesis and characterization of stacked and quenched uridine nucleotide fluorophores	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AROMATIC-AROMATIC INTERACTIONS; MOLECULAR RECOGNITION; BENZENE DIMER; FLUORESCENCE; SYSTEMS; 1,8-DIARYLNAPHTHALENES; MECHANISM; POLAR/PI; SITES; BOND	Intramolecular aromatic interactions in aqueous solution often lead to stacked conformation for model organic molecules. This designing principle was used to develop stacked and folded uridine nucleotide analogs that showed highly quenched fluoroscence in aqueous solution by attaching the fluorophore 1-aminonaphthalene-5-sulfonate (AmNS) to the terminal phosphate via a phosphoramidate bond. Severalfold enhancement of fluorescence could be observed by destacking the molecules in organic solvents, such as isopropanol and dimethylsulfoxide or by enzymatic cleavage of the pyrophosphate bond. Stacking and destacking were confirmed by H1- NMR spectroscopy. The extent of quenching of the uridine derivatives correlated very well with the extent of stacking. Taking 5-H as the monitor, temperature-variable NMR studies demonstrated the presence of a rapid interconversionary equilibrium between the stacked and open forms for uridine-5'-diphosphoro-beta-1-(5-sulfonic acid) naphthylamidate (UDPAmNS) in aqueous solution. Delta H was calculated to be -2.3 Kcal/mol, with 43-50% of the population in stacked conformation. Fluorescence lifetime for UDPAmNS in water was determined to be 2.5 ns as against 11 ns in dimethyl sulfoxide or 15 ns for the pyrophosphate adduct of AmNS in water. Such a greatly reduced lifetime for UDPAmNS in water suggests collisional interaction between the pyrimidine and the fluorophore moieties to be responsible for quenching. The potential usefulness of such stacked and quenched nucleotide fluorophores as probes for protein-ligand interaction studies has been briefly discussed.	Indian Inst Chem Biol, Calcutta 700032, W Bengal, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Biology (IICB)	Bhaduri, A (corresponding author), Indian Inst Chem Biol, 4 Raja Sc Mullick Rd, Calcutta 700032, W Bengal, India.							AMABILINO DB, 1995, J AM CHEM SOC, V117, P1271, DOI 10.1021/ja00109a011; BARRIO JR, 1973, FEBS LETT, V29, P215, DOI 10.1016/0014-5793(73)80022-5; Bhattacharyya U, 1999, J BIOL CHEM, V274, P14573, DOI 10.1074/jbc.274.21.14573; BORNSEN KO, 1986, J CHEM PHYS, V85, P1726, DOI 10.1063/1.451173; BRENNAN JS, 1974, J CHEM SOC FARAD T 1, V70, P1965, DOI 10.1039/f19747001965; BURLEY SK, 1985, SCIENCE, V229, P23, DOI 10.1126/science.3892686; Chatterji D, 1996, METHOD ENZYMOL, V274, P456; CONSTANT JF, 1988, BIOCHEMISTRY-US, V27, P3997, DOI 10.1021/bi00411a016; COZZI F, 1992, J AM CHEM SOC, V114, P5729, DOI 10.1021/ja00040a036; COZZI F, 1993, J AM CHEM SOC, V115, P5330, DOI 10.1021/ja00065a069; COZZI F, 1995, ANGEW CHEM INT EDIT, V34, P1019, DOI 10.1002/anie.199510191; EVANS DA, 1987, ANGEW CHEM INT EDIT, V26, P1184, DOI 10.1002/anie.198711841; GROVER JR, 1987, J PHYS CHEM-US, V91, P3233, DOI 10.1021/j100296a026; GRUBER BA, 1975, P NATL ACAD SCI USA, V72, P3966, DOI 10.1073/pnas.72.10.3966; HENIS YI, 1980, P NATL ACAD SCI-BIOL, V77, P5055, DOI 10.1073/pnas.77.9.5055; JARDETZK.O, 1966, J BIOL CHEM, V241, P85; JORGENSEN WL, 1990, J AM CHEM SOC, V112, P4768, DOI 10.1021/ja00168a022; KELLY TR, 1990, J AM CHEM SOC, V112, P8024, DOI 10.1021/ja00178a027; LAATIKAINEN R, 1995, J AM CHEM SOC, V117, P11006, DOI 10.1021/ja00149a025; Lakowicz J. R., 1982, PRINCIPLES FLUORESCE; LEHN JM, 1990, ANGEW CHEM INT EDIT, V29, P1304, DOI 10.1002/anie.199013041; LEONARD NJ, 1984, CRC CR REV BIOCH MOL, V15, P125, DOI 10.3109/10409238409102299; Liljas A., 1974, ANNU REV BIOCHEM, V43, P475; MILES DW, 1968, J BIOL CHEM, V243, P4181; MURAKAMI Y, 1982, J AM CHEM SOC, V104, P5189, DOI 10.1021/ja00383a033; NEWCOMB LF, 1994, J AM CHEM SOC, V116, P4993, DOI 10.1021/ja00090a057; Saenger W., 1984, PRINCIPLES NUCL ACID; SCHLAGECK JG, 1979, J BIOL CHEM, V254, P2074; SECRIST JA, 1972, SCIENCE, V175, P646, DOI 10.1126/science.175.4022.646; SIJBESMA RP, 1992, J AM CHEM SOC, V114, P9807, DOI 10.1021/ja00051a013; Spencer R. D., 1972, STRUCTURE FUNCTION O, P393; TSO P, 1974, BASIC PRINCIPLES NUC, V1; UEDA H, 1988, BIOCHEM BIOPH RES CO, V154, P199, DOI 10.1016/0006-291X(88)90670-5; WEBER G, 1954, BIOCHEM J, V56, pP31; WINTNER EA, 1994, J AM CHEM SOC, V116, P8877, DOI 10.1021/ja00099a003; YARBROUGH LR, 1978, BIOCHEM BIOPH RES CO, V81, P35, DOI 10.1016/0006-291X(78)91627-3; YARBROUGH LR, 1979, J BIOL CHEM, V254, P2069	37	9	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					14568	14572		10.1074/jbc.274.21.14568	http://dx.doi.org/10.1074/jbc.274.21.14568			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329647	hybrid			2022-12-25	WOS:000081965200012
J	Grover, A; Houlden, H; Baker, M; Adamson, J; Lewis, J; Prihar, G; Pickering-Brown, S; Duff, K; Hutton, M				Grover, A; Houlden, H; Baker, M; Adamson, J; Lewis, J; Prihar, G; Pickering-Brown, S; Duff, K; Hutton, M			5 ' splice site mutations in tau associated with the inherited dementia FTDP-17 affect a stem-loop structure that regulates alternative splicing of exon 10	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA SECONDARY STRUCTURE; PROTEIN-TAU; NEUROFIBRILLARY TANGLES; FRONTOTEMPORAL DEMENTIA; ALZHEIMERS-DISEASE; GENE; CHROMOSOME-17; LOCALIZATION; SEQUENCES; IDENTIFICATION	Missense and splice site mutations in the microtubule-associated protein tau gene were recently found associated with fronto-temporal dementia and parkinsonism linked to chromosome 17 (Poorkaj et al. (1998) Ann. Neurol. 43, 815-825; Hutton et al. (1998) Nature 393, 702-705; Spillantini et al. (1998) Proc. Natl Acad Sci. U.S.A 95, 7737-7741). The mutations in the 5' splice site of exon 10 were shown to increase the ratio of tau mRNAs containing exon 10 and thus the proportion of Tau protein isoforms with 4 microtubule binding repeat domains, although how this increase leads to neurodegeneration is presently unclear. The mechanism by which these mutations increase tau exon 10 splicing was not determined, although the mutations were predicted to disrupt a potential stem-loop structure that was likely involved in the regulation of exon 10 alternative splicing. Here we describe in vitro splicing assays and RNA structural analysis that demonstrate that the mutations do indeed act through disruption of the stem-loop structure and that the stability of this secondary structure feature at least partially determines the ratio of tau exon 10+/- transcripts. In addition, we provide evidence that the stability of the stem-loop structure underlies the alternative splicing of this exon in other species.	Mayo Clin Jacksonville, Jacksonville, FL 32224 USA; Univ Manchester, Sch Biol Sci, Div Neurosci, Manchester M13 9PT, Lancs, England; Nathan S Kline Inst Psychiat Res, Orangeburg, NY 10962 USA	Mayo Clinic; University of Manchester; Nathan Kline Institute for Psychiatric Research	Hutton, M (corresponding author), Mayo Clin Jacksonville, 4500 San Pablo Rd, Jacksonville, FL 32224 USA.		Pickering-Brown, Stuart/D-4008-2009; Houlden, Henry J/C-1532-2008	Pickering-Brown, Stuart/0000-0003-1561-6054; Houlden, Henry J/0000-0002-2866-7777; Duff, Karen/0000-0002-6177-868X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037143] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS37143-01] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDREADIS A, 1992, BIOCHEMISTRY-US, V31, P10626, DOI 10.1021/bi00158a027; ANIELLO F, 1991, P NATL ACAD SCI USA, V88, P4035, DOI 10.1073/pnas.88.9.4035; CHEBLI K, 1989, MOL CELL BIOL, V9, P4852, DOI 10.1128/MCB.9.11.4852; CHURCH DM, 1994, NAT GENET, V6, P98, DOI 10.1038/ng0194-98; Clark LN, 1998, P NATL ACAD SCI USA, V95, P13103, DOI 10.1073/pnas.95.22.13103; Delacourte A, 1997, INT REV CYTOL, V171, P167; Dickson DW, 1997, ANN NEUROL, V42, P541, DOI 10.1002/ana.410420403; DOMENJOUD L, 1991, MOL CELL BIOL, V11, P4581, DOI 10.1128/MCB.11.9.4581; DORVAL BC, 1991, SCIENCE, V252, P1823, DOI 10.1126/science.2063195; Foster NL, 1997, ANN NEUROL, V41, P706, DOI 10.1002/ana.410410606; GOEDERT M, 1989, EMBO J, V8, P393, DOI 10.1002/j.1460-2075.1989.tb03390.x; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; GOGUEL V, 1993, MOL CELL BIOL, V13, P6841, DOI 10.1128/MCB.13.11.6841; Hardy J, 1998, NAT NEUROSCI, V1, P355, DOI 10.1038/1565; Hasegawa M, 1998, FEBS LETT, V437, P207, DOI 10.1016/S0014-5793(98)01217-4; Hong M, 1998, SCIENCE, V282, P1914, DOI 10.1126/science.282.5395.1914; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; KOSIK KS, 1989, NEURON, V2, P1389, DOI 10.1016/0896-6273(89)90077-9; KUO HC, 1991, SCIENCE, V251, P1045, DOI 10.1126/science.1825520; LEE G, 1989, NEURON, V2, P1615, DOI 10.1016/0896-6273(89)90050-0; LIBRI D, 1991, SCIENCE, V252, P1842, DOI 10.1126/science.2063196; NEVE RL, 1986, MOL BRAIN RES, V1, P271, DOI 10.1016/0169-328X(86)90033-1; Poorkaj P, 1998, ANN NEUROL, V43, P815, DOI 10.1002/ana.410430617; Reed LA, 1997, ANN NEUROL, V42, P564, DOI 10.1002/ana.410420406; Spillantini MG, 1998, BRAIN PATHOL, V8, P387; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P7737, DOI 10.1073/pnas.95.13.7737; WILHELMSEN KC, 1994, AM J HUM GENET, V55, P1159; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	28	239	251	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					15134	15143		10.1074/jbc.274.21.15134	http://dx.doi.org/10.1074/jbc.274.21.15134			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329720	hybrid			2022-12-25	WOS:000081965200085
J	Lin, HJ; Wing, SS				Lin, HJ; Wing, SS			Identification of rabbit reticulocyte E2(17K) as a UBC7 homologue and functional characterization of its core domain loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-CONJUGATING ENZYME; CELL-CYCLE; CARRIER PROTEIN; DNA-REPAIR; DEPENDENT PROTEOLYSIS; MOLECULAR-CLONING; CDC34 UBC3; IN-VIVO; DEGRADATION; SYSTEM	The structural basis by which ubiquitin (Ub)-conjugating enzymes (E2s) determine substrate specificity remains unclear. We cloned rabbit reticulocyte E2(17K) because unlike the similarly sized class I E2s, E2(14K) and UBC4, it is unable to support ubiquitin-protein ligase (E3)-dependent conjugation to endogenous proteins. RNA analysis revealed that this E2 was expressed in all tissues tested, with higher levels in the testis, Analysis of testis RNA from rats of different ages showed that E2(17K) mRNA was induced from days 15 to 30, The predicted amino acid sequence indicates that E2(17K) is a 19.5-kDa class I E2 but differs from other class I enzymes in possessing an insertion of 13 amino acids distal to the active site cysteine, E2(17K) shows 74% amino acid identity with Saccharomyces cerevisiae UBC7, and therefore, we rename it mammalian UBC7, Yeast UBC7 crystal structure indicates that this insertion forms a loop out of the otherwise conserved folding structure. Sequence analysis of E2s had previously suggested that this loop is a hypervariable region and may play a role in substrate specificity. We created mutant UBC7 lacking the loop (ubc7 Delta loop) and a mutant E2(17K) with an inserted loop (E2(14k)+loop) and characterized their biochemical functions. Ubc7 Delta loop had higher affinity for the E1-Ub thiol ester than native UBC7 and permitted conjugation of Ub to selected proteins in the testis but did not permit the broad spectrum E3-dependent conjugation to endogenous reticulocyte proteins. Surprisingly, E2(14k)+loop was unable to accept Ub from ubiquitin-activating enzyme (E1) but was able to accept NEDDS from E1. E2(14k)+loop was able to support conjugation of NEDD8 to endogenous reticulocyte proteins but with much lower efficiency than E2(14k). Thus, the loop can influence interactions of the E2 with charged El as well as with E3s or substrates, but the exact nature of these interactions depends on divergent sequences in the remaining conserved core domain.	McGill Univ, Polypeptide Lab, Dept Med, Montreal, PQ H3A 2B2, Canada	McGill University	Wing, SS (corresponding author), McGill Univ, Polypeptide Lab, Dept Med, 3640 Univ St,Strathcona Anat & Dent Bldg,Rm W-315, Montreal, PQ H3A 2B2, Canada.			Lin, Haijiang/0000-0003-2931-468X				Ausabel FM, 1993, CURRENT PROTOCOLS MO; Biederer T, 1997, SCIENCE, V278, P1806, DOI 10.1126/science.278.5344.1806; CHARBONNEAU H, 1989, PRACTICAL GUIDE PROT, P17; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; COOK W, 1997, BIOCHEMISTRY-US, V36, P1521; COOK WJ, 1992, J BIOL CHEM, V267, P15116; COOK WJ, 1993, BIOCHEMISTRY-US, V32, P13809, DOI 10.1021/bi00213a009; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; GIROD PA, 1993, J BIOL CHEM, V268, P955; HAAS AL, 1982, J BIOL CHEM, V257, P2543; HAAS AL, 1988, J BIOL CHEM, V263, P13268; HAAS AL, 1988, J BIOL CHEM, V263, P13258; Haldeman MT, 1997, BIOCHEMISTRY-US, V36, P10526, DOI 10.1021/bi970750u; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; Hershko A, 1997, CURR OPIN CELL BIOL, V9, P788, DOI 10.1016/S0955-0674(97)80079-8; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 1997, FASEB J, V11, P1215, DOI 10.1096/fasebj.11.14.9409540; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; JUNGMANN J, 1993, NATURE, V361, P369, DOI 10.1038/361369a0; Kamitani T, 1997, J BIOL CHEM, V272, P28557, DOI 10.1074/jbc.272.45.28557; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; KOLMAN CJ, 1992, EMBO J, V11, P3081, DOI 10.1002/j.1460-2075.1992.tb05380.x; MORI S, 1992, J BIOL CHEM, V267, P6429; Oughtred R, 1998, J BIOL CHEM, V273, P18435, DOI 10.1074/jbc.273.29.18435; PICKART CM, 1985, J BIOL CHEM, V260, P1573; REISS Y, 1989, J BIOL CHEM, V264, P10378; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Schauber C, 1998, NATURE, V391, P715, DOI 10.1038/35661; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SILVER ET, 1992, EMBO J, V11, P3091, DOI 10.1002/j.1460-2075.1992.tb05381.x; Townsley FM, 1998, TRENDS CELL BIOL, V8, P238, DOI 10.1016/S0962-8924(98)01268-9; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Watanabe TK, 1996, CYTOGENET CELL GENET, V74, P146, DOI 10.1159/000134403; Wing SS, 1996, MOL CELL BIOL, V16, P4064; WING SS, 1995, BIOCHEM J, V305, P125, DOI 10.1042/bj3050125; WING SS, 1992, J BIOL CHEM, V267, P6495; Yang M, 1997, J BIOL CHEM, V272, P1970, DOI 10.1074/jbc.272.3.1970	43	10	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					14685	14691		10.1074/jbc.274.21.14685	http://dx.doi.org/10.1074/jbc.274.21.14685			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329663	hybrid			2022-12-25	WOS:000081965200028
J	Miller, RT; Martasek, P; Raman, CS; Masters, BSS				Miller, RT; Martasek, P; Raman, CS; Masters, BSS			Zinc content of Escherichia coli-expressed constitutive isoforms of nitric-oxide synthase - Enzymatic activity and effect of pterin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RELAXING FACTOR; BRAIN; HEME; PURIFICATION; HEMOPROTEIN; STABILITY; CATALYSIS; PROTEIN; RELEASE; SUBUNIT	Recently, we obtained x-ray crystallographic data showing the presence of a ZnS4 center in the structure of Escherichia coli-expressed bovine endothelial nitric-oxide synthase (eNOS) and rat neuronal nitric oxide synthase (nNOS), The zinc atom is coordinated by two CXXXXC motifs, one motif being contributed by each NOS monomer (cysteine 326 through cysteine 331 in rat nNOS), Mutation of the nNOS cysteine 331 to alanine (C331A) results in the loss of NO. synthetic activity and also results in an inability to bind zinc efficiently. Although prolonged incubation of the C331A mutant of nNOS with high concentrations of L-arginine results in a catalytically active enzyme, zinc binding is not restored. In this study, we investigate the zinc stoichiometry in wild-type nNOS and eNOS, as well as in the C331A-mutated nNOS, using a chelation assay and electrothermal vaporization-inductively coupled plasma-mass spectrometry. The data reveal an approximate 2:1 stoichiometry of heme to zinc in (6R)-5,6,7,8-tetrahydro-L-biopterin-replete, wild-type nNOS and eNOS and show that the reactivated C331A mutant of nNOS has a limited ability to bind zinc. The present study substantiates that the zinc in NOS is structural rather than catalytic and is important for maintaining optimally functional, enzymatically active, constitutive NOSs.	Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78284 USA; Univ Calif Irvine, Dept Biochem & Mol Biol, Irvine, CA 92697 USA	University of Texas System; University of Texas Health San Antonio; University of California System; University of California Irvine	Masters, BSS (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78284 USA.		; Martasek, Pavel/G-6622-2017	Raman, C. S./0000-0002-1036-3193; Martasek, Pavel/0000-0001-6165-4444	NHLBI NIH HHS [HL07350-19] Funding Source: Medline; NIGMS NIH HHS [GM52419] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052419] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLAKE PR, 1992, PROTEIN SCI, V1, P1522, DOI 10.1002/pro.5560011113; CHEN PF, 1995, BIOCHEM BIOPH RES CO, V215, P1119, DOI 10.1006/bbrc.1995.2579; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; Crow JP, 1997, J NEUROCHEM, V69, P1936; EIDNESS MK, 1992, PROTEIN ENG, V5, P367; FISCHMANN TO, 1999, NAT STRUCT BIOL, V5, P602; FURCHGOTT R F, 1988, P401; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; Ghosh DK, 1997, BIOCHEMISTRY-US, V36, P10609, DOI 10.1021/bi9702290; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; KLATT P, 1992, BIOCHEM J, V288, P15, DOI 10.1042/bj2880015; MANN GJ, 1991, BIOCHEMISTRY-US, V30, P1939, DOI 10.1021/bi00221a030; Martasek P, 1998, J BIOL CHEM, V273, P34799, DOI 10.1074/jbc.273.52.34799; Martasek P, 1996, BIOCHEM BIOPH RES CO, V219, P359, DOI 10.1006/bbrc.1996.0238; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; Miller RT, 1997, BIOCHEMISTRY-US, V36, P15277, DOI 10.1021/bi972022c; NAR H, 1992, EUR J BIOCHEM, V205, P1123, DOI 10.1111/j.1432-1033.1992.tb16881.x; NISHIMURA JS, 1995, BIOCHEM BIOPH RES CO, V210, P288, DOI 10.1006/bbrc.1995.1659; Olsson MHM, 1998, J BIOL INORG CHEM, V3, P109, DOI 10.1007/s007750050212; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; Perry JM, 1998, P NATL ACAD SCI USA, V95, P11101, DOI 10.1073/pnas.95.19.11101; PERSECHINI A, 1995, BIOCHEMISTRY-US, V34, P15091, DOI 10.1021/bi00046a015; POLLOCK JS, 1991, P NATL ACAD SCI USA, V88, P10480, DOI 10.1073/pnas.88.23.10480; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; RodriguezCrespo I, 1997, BIOCHEMISTRY-US, V36, P8530, DOI 10.1021/bi970192j; ROMAN LJ, 1995, P NATL ACAD SCI USA, V92, P8428, DOI 10.1073/pnas.92.18.8428; SHETA EA, 1994, J BIOL CHEM, V269, P15147; SONO M, 1995, J BIOL CHEM, V270, P19943, DOI 10.1074/jbc.270.34.19943; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001	30	31	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					14537	14540		10.1074/jbc.274.21.14537	http://dx.doi.org/10.1074/jbc.274.21.14537			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329642	hybrid			2022-12-25	WOS:000081965200007
J	Ortiz, L; Aza-Blanc, P; Zannini, M; Cato, ACB; Santisteban, P				Ortiz, L; Aza-Blanc, P; Zannini, M; Cato, ACB; Santisteban, P			The interaction between the forkhead thyroid transcription factor TTF-2 and the constitutive factor CTF/NF-1 is required for efficient hormonal regulation of the thyroperoxidase gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR FACTOR-I; MAMMARY-TUMOR VIRUS; GROWTH-FACTOR-I; ADENOVIRUS DNA-REPLICATION; MAMMALIAN-CELLS; BINDING PROTEIN; THYROGLOBULIN PROMOTER; DOWN-REGULATION; RAT-LIVER; EXPRESSION	The forkhead thyroid-specific transcription factor TTF-2 is the main mediator of thyrotropin and insulin regulation of thyroperoxidase (TPO) gene expression. This function depends on multimerization and specific orientation of its DNA-binding site, suggesting that TTF-S is part of a complex interaction network within the TPO promoter, This was confirmed by transfection experiments and by protein-DNA interaction studies, which demonstrated that CTF/NF1 proteins bind 10 base pairs upstream of the TTF-a-binding site to enhance its action in hormone-induced expression of the TPO gene. GST pull-down assays showed that TTF-S physically interacts with CTF/NF1 proteins. In addition, we demonstrate that increasing the distance between both transcription factors binding sites by base pair insertion results in loss of promoter activity and in a drastic decrease on the ability of the promoter to respond to the hormones. CTF/NF1 is a family of transcription factors that contributes to constitutive and cell-type specific gene expression. Originally identified as factors implicated in the replication of adenovirus, this group of proteins (CTF/NF1-A, -B, -C, and -X) is now known to be involved in the regulation of several genes. In contrast to other reports regarding the involvement of these proteins in inducible gene expression, we show here that members of this family of transcription factors are regulated by hormones. With the use of specific CTF/NF1 DNA probes and antibodies we demonstrate that CTF/NF1-C is a thyrotropin-, cAMP-, and insulin-inducible protein. Thus CTF/NF1 proteins do not only mediate hormone-induced gene expression cooperating with TTF-2, but are themselves hormonally regulated. All these findings are clearly of important value in understanding the mechanisms governing the transcription regulation of RNA polymerase II promoters, which often contain binding sites for multiple transcription factors.	Univ Autonoma Madrid, Fac Med, CSIC, Inst Invest Biomed, E-28029 Madrid, Spain; Univ Autonoma Madrid, Fac Med, CSIC, Inst Invest Biomed Alberto Sols, E-28029 Madrid, Spain; Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; Forschungszentrum Karlsruhe, Inst Genet, D-76021 Karlsruhe, Germany	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); University of Naples Federico II; Helmholtz Association; Karlsruhe Institute of Technology	Santisteban, P (corresponding author), Univ Autonoma Madrid, Fac Med, CSIC, Inst Invest Biomed, Arturo Duperier 4, E-28029 Madrid, Spain.		Zannini, Mariastella/I-1735-2012; Cato, Andrew C. B./H-2071-2013; Santisteban, Pilar/E-7829-2016	Cato, Andrew C. B./0000-0001-8508-3834; Santisteban, Pilar/0000-0002-2758-796X; Ortiz Hernandez, Lourdes/0000-0001-6084-3411				AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; AMEMIYA K, 1992, J BIOL CHEM, V267, P14204; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ANNWEILER A, 1991, NUCLEIC ACIDS RES, V19, P3750, DOI 10.1093/nar/19.13.3750; AZABLANC P, 1993, MOL ENDOCRINOL, V7, P1297, DOI 10.1210/me.7.10.1297; Bachurski CJ, 1997, J BIOL CHEM, V272, P32759, DOI 10.1074/jbc.272.52.32759; BRUGGEMEIER U, 1990, EMBO J, V9, P2233, DOI 10.1002/j.1460-2075.1990.tb07393.x; CARDINAUX JR, 1994, J BIOL CHEM, V269, P32947; Chaudhry AZ, 1997, DEV DYNAM, V208, P313; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHU HM, 1991, NUCLEIC ACIDS RES, V19, P2721, DOI 10.1093/nar/19.10.2721; CIVITAREALE D, 1989, EMBO J, V8, P2537, DOI 10.1002/j.1460-2075.1989.tb08391.x; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; DAMANTE G, 1994, BBA-GENE STRUCT EXPR, V1218, P255, DOI 10.1016/0167-4781(94)90176-7; DEGROOT LJ, 1977, METABOLISM, V26, P665, DOI 10.1016/0026-0495(77)90088-9; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P576, DOI 10.1128/MCB.12.2.576; Gao B, 1996, MOL CELL BIOL, V16, P5997; GIL G, 1988, P NATL ACAD SCI USA, V85, P8963, DOI 10.1073/pnas.85.23.8963; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GOUNARI F, 1990, EMBO J, V9, P559, DOI 10.1002/j.1460-2075.1990.tb08143.x; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAVES RA, 1991, GENE DEV, V5, P428, DOI 10.1101/gad.5.3.428; GREWAL T, 1992, MOL CELL BIOL, V12, P2339, DOI 10.1128/MCB.12.5.2339; Gupta MP, 1997, MOL CELL BIOL, V17, P3924, DOI 10.1128/MCB.17.7.3924; ISOZAKI O, 1989, MOL ENDOCRINOL, V3, P1681, DOI 10.1210/mend-3-11-1681; JACKSON DA, 1993, MOL CELL BIOL, V13, P2401, DOI 10.1128/MCB.13.4.2401; JACKSON PD, 1989, GENE DEV, V3, P1860, DOI 10.1101/gad.3.12a.1860; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KRUSE U, 1994, FEBS LETT, V348, P46, DOI 10.1016/0014-5793(94)00585-0; LAZZARO D, 1991, DEVELOPMENT, V113, P1093; Liu YC, 1997, J BIOL CHEM, V272, P10739; LU GH, 1992, INT J BIOCHEM, V24, P455, DOI 10.1016/0020-711X(92)90039-4; MEISTERERNST M, 1989, BIOCHEMISTRY-US, V28, P8191, DOI 10.1021/bi00446a034; MIKSICEK R, 1987, EMBO J, V6, P1355, DOI 10.1002/j.1460-2075.1987.tb02375.x; MINTY AJ, 1981, J BIOL CHEM, V256, P1008; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NAGATA K, 1982, P NATL ACAD SCI-BIOL, V79, P6438, DOI 10.1073/pnas.79.21.6438; NEBL G, 1994, J BIOL CHEM, V269, P7371; NEBL G, 1995, CELL MOL BIOL RES, V41, P85; NOWOCK J, 1985, NUCLEIC ACIDS RES, V13, P2045, DOI 10.1093/nar/13.6.2045; Ortiz L, 1997, J BIOL CHEM, V272, P23334, DOI 10.1074/jbc.272.37.23334; PAONESSA G, 1988, EMBO J, V7, P3115, DOI 10.1002/j.1460-2075.1988.tb03178.x; PIERROU S, 1994, EMBO J, V13, P5002, DOI 10.1002/j.1460-2075.1994.tb06827.x; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; PLACHOV D, 1990, DEVELOPMENT, V110, P643; Pugh BF, 1996, CURR OPIN CELL BIOL, V8, P303, DOI 10.1016/S0955-0674(96)80002-0; Puzianowska-Kuznicka M, 1996, J BIOL CHEM, V271, P6273, DOI 10.1074/jbc.271.11.6273; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; RUPP RAW, 1990, NUCLEIC ACIDS RES, V18, P2607, DOI 10.1093/nar/18.9.2607; SALMINEN M, 1995, J MOL BIOL, V253, P17, DOI 10.1006/jmbi.1995.0532; SALVATORE G, 1980, THYROID GLAND, P443; SANTISTEBAN P, 1992, MOL ENDOCRINOL, V6, P1310, DOI 10.1210/me.6.8.1310; SANTISTEBAN P, 1987, J BIOL CHEM, V262, P4048; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; Sato K, 1996, BIOCHEM BIOPH RES CO, V220, P86, DOI 10.1006/bbrc.1996.0361; SCHILD C, 1993, EMBO J, V12, P423, DOI 10.1002/j.1460-2075.1993.tb05674.x; Schneikert J, 1996, J BIOL CHEM, V271, P23907, DOI 10.1074/jbc.271.39.23907; Taurog A., 1996, WERNER INGBARS THYRO, V7th, P47; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; Zannini M, 1997, EMBO J, V16, P3185, DOI 10.1093/emboj/16.11.3185; ZANNINI M, 1992, MOL CELL BIOL, V12, P4230, DOI 10.1128/MCB.12.9.4230; ZEINER M, 1995, P NATL ACAD SCI USA, V92, P11465, DOI 10.1073/pnas.92.25.11465	64	42	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					15213	15221		10.1074/jbc.274.21.15213	http://dx.doi.org/10.1074/jbc.274.21.15213			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329730	hybrid			2022-12-25	WOS:000081965200095
J	Agapova, LS; Ivanov, AV; Sablina, AA; Kopnin, PB; Sokova, OI; Chumakov, PM; Kopnin, BP				Agapova, LS; Ivanov, AV; Sablina, AA; Kopnin, PB; Sokova, OI; Chumakov, PM; Kopnin, BP			p53-dependent effects of RAS oncogene on chromosome stability and cell cycle checkpoints	ONCOGENE			English	Article						ras; p53; genome stability; chromosome breaks; polyploidy; endoreduplication	P-GLYCOPROTEIN FUNCTION; WILD-TYPE P53; GROWTH ARREST; GENE AMPLIFICATION; DEPENDENT KINASES; HUMAN FIBROBLASTS; DNA-REPLICATION; NORMAL P21N-RAS; TUMOR-ANTIGEN; ACTIVATED RAS	Mutations activating the function of ras proto-oncogenes are often observed in human tumors. Their oncogenic potential is mainly due to permanent stimulation of cellular proliferation and dramatic changes in morphogenic reactions of the cell. To learn more on the role of ras activation in cancerogenesis we studied its effects on chromosome stability and cell cycle checkpoints. Since the ability of ras oncogenes to cause cell transformation may be dependent on activity of the p53 tumor-suppressor the cells with different p53 state were analysed. Ectopic expression of N-ras(asp12) caused in p53-deficient MDAH041 cell line an augmentation in the number of chromosome breaks in mitogenic cells, significant increase in the frequency of metaphases showing chromosome endoreduplication and accumulation of polyploid cells. Similar effects were induced by different exogenous ras genes (N-ras(asp12), H-ras(leu12), N-ras proto-oncogene) in Rat1 and Rat2 cells which have a defect in p53-upstream pathways. In contrast, in REF52 and human LIM1215 cells showing ras-induced p53 upregulation, ras expression caused only slight increase in the number of chromosome breaks and did not enhance the frequency of endoreduplication and polyploidy. Inactivation in these cells of p53 function by transduction of dominant-negative C-terminal p53 fragment (genetic suppressor element #22, GSE22) or mutant p53s significantly increased the frequency of both spontaneous and uas-induced karyotypic changes. In concordance with these observations we have found that expression of uns oncogene caused in p53-defective cells further mitigation of ethyl-metansulphonate-induced G1 and G2 cell cycle arrest, but did not abrogate G1 and G2 cell cycle checkpoints in cells with normal p53 function. These data indicate that along with stimulation of cell proliferation and morphological transformation uas activation can contribute to cancerogenesis by increasing genetic instability.	Moscow Med Ctr, Engelhardt Inst Mol Biol, Moscow, Russia; Moscow Med Ctr, Inst Carcinogenesis, Canc Res Ctr, Moscow, Russia; Univ Oslo, Moscow Med Ctr, Moscow, Russia	Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS	Chumakov, PM (corresponding author), Moscow Med Ctr, Engelhardt Inst Mol Biol, Moscow, Russia.		Kopnin, Pavel/R-8213-2019; Chumakov, Peter M/E-7731-2014; Sablina, Anna/P-2818-2019; Sokova, Olga/R-7544-2019; Sablina, Anna/B-2217-2017; Ivanov, Alexey/I-9445-2012; Kopnin, Boris/R-8240-2019; Ivanov, Andrey/M-7039-2013	Kopnin, Pavel/0000-0002-2078-4274; Sablina, Anna/0000-0001-9526-4014; Sokova, Olga/0000-0001-7159-5302; Sablina, Anna/0000-0001-9526-4014; Kopnin, Boris/0000-0003-3100-2212; Ivanov, Andrey/0000-0001-7245-1108; Ivanov, Alexey/0000-0002-8617-4604; Chumakov, Peter/0000-0002-8078-2908				Agapova LS, 1996, MUTAT RES-FUND MOL M, V354, P129, DOI 10.1016/0027-5107(96)00062-0; AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; ALEXANDROVA AY, 1993, CELL MOTIL CYTOSKEL, V25, P254, DOI 10.1002/cm.970250306; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARBACID M, 1990, EUR J CLIN INVEST, V20, P225, DOI 10.1111/j.1365-2362.1990.tb01848.x; CARDER P, 1993, ONCOGENE, V8, P1397; Chen J, 1996, ONCOGENE, V13, P1395; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DENKO NC, 1994, P NATL ACAD SCI USA, V91, P5124, DOI 10.1073/pnas.91.11.5124; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; Fan JG, 1997, ONCOGENE, V14, P2595, DOI 10.1038/sj.onc.1201105; FILMUS J, 1994, ONCOGENE, V9, P3627; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HARVEY M, 1993, ONCOGENE, V8, P2456; HICKS GG, 1991, MOL CELL BIOL, V11, P1344, DOI 10.1128/MCB.11.3.1344; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V85, P1519, DOI 10.1073/pnas.85.5.1519; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; JENKINS JR, 1984, NATURE, V312, P851; Kawada M, 1997, ONCOGENE, V15, P629, DOI 10.1038/sj.onc.1201228; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; KONDRATOV RV, 1996, MOL BIOL, V30, P636; KOPNIN BP, 1995, ONCOL RES, V7, P299; Levine AJ, 1995, ANN NY ACAD SCI, V768, P111, DOI 10.1111/j.1749-6632.1995.tb12115.x; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MCKAY IA, 1986, EMBO J, V5, P2617, DOI 10.1002/j.1460-2075.1986.tb04542.x; Medema RH, 1998, ONCOGENE, V16, P431, DOI 10.1038/sj.onc.1201558; Mumberg D, 1996, ONCOGENE, V13, P2493; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; PRASOLOV V S, 1988, Molekulyarnaya Biologiya (Moscow), V22, P1371; Rodenhuis S, 1992, Semin Cancer Biol, V3, P241; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SOUYRI M, 1987, VIROLOGY, V158, P69, DOI 10.1016/0042-6822(87)90239-X; STEWART N, 1995, ONCOGENE, V10, P109; STROMSKAYA TP, 1995, FEBS LETT, V368, P373, DOI 10.1016/0014-5793(95)00662-S; Thompson DA, 1997, ONCOGENE, V15, P3025, DOI 10.1038/sj.onc.1201495; TSUKADA T, 1993, ONCOGENE, V8, P3313; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; WHITEHEAD RH, 1985, JNCI-J NATL CANCER I, V74, P759; Winston JT, 1996, ONCOGENE, V12, P127; WYLLIE FS, 1995, ONCOGENE, V10, P49; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZAICHUK TA, 1993, P RUSSIAN ACAD SCI, V330, P386	56	43	47	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 20	1999	18	20					3135	3142		10.1038/sj.onc.1202386	http://dx.doi.org/10.1038/sj.onc.1202386			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	197WB	10340385				2022-12-25	WOS:000080388000009
J	Li, YW; Upadhyay, S; Bhuiyan, M; Sarkar, FH				Li, YW; Upadhyay, S; Bhuiyan, M; Sarkar, FH			Induction of apoptosis in breast cancer cells MDA-MB-231 by genistein	ONCOGENE			English	Article						genistein; apoptosis; breast cancer cells	POLY(ADP-RIBOSE) POLYMERASE; PROTEIN-KINASES; LEUKEMIA-CELLS; IN-VITRO; CYCLE; SUPPRESSION; INHIBITOR; GROWTH; ARREST; DIET	Breast cancer is the most common cancer among American women, whereas Asian women, who consume a traditional diet high in soy products, have a relatively low incidence, Genistein is a prominent isoflavonoid in soy products and has been proposed as the agent responsible for lowering the rate of breast cancer in Asian women. We investigated the effects of genistein on cell growth and apoptosis-related gene expression in breast cancer cells MDA-MB-231. We found upregulation of Bar and p21(WAF1) expressions and downregulation of Bcl-2 and p53 expression in genistein-treated cells. Furthermore, DNA ladder formation, CPP32 activation, and PARP cleavage were observed after treatment with genistein, indicating apoptotic cell deaths. Flow cytometry with 7-amino actinomycin D staining showed that the number of apoptotic cells increased with longer treatment of genistein. From these results, we conclude that genistein inhibits the growth of MDA-MB-231 breast cancer cells, regulates the expression of apoptosis-related genes, and induces apoptosis through a p53-independent pathway. The up-regulation of Bar and p21(WAF1) may be the molecular mechanisms by which genistein induces apoptosis, however, further definitive studies are needed. These results suggest that genistein may be a potentially effective chemopreventive or therapeutic agent against breast cancer.	Wayne State Univ, Dept Pathol, Sch Med, Karmanos Canc Inst, Detroit, MI 48201 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University	Sarkar, FH (corresponding author), Wayne State Univ, Dept Pathol, Sch Med, Karmanos Canc Inst, 9374 Scott Hall,540 E Canfield, Detroit, MI 48201 USA.							ADLERCREUTZ H, 1991, AM J CLIN NUTR, V54, P1093, DOI 10.1093/ajcn/54.6.1093; AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; BARNES S, 1995, J NUTR, V125, pS777, DOI 10.1093/jn/125.3_Suppl.777S; BUCKLEY AR, 1993, MOL CELL ENDOCRINOL, V98, P17, DOI 10.1016/0303-7207(93)90231-8; CHIARUGI V, 1994, CELL MOL BIOL RES, V40, P603; CONSTANTINOU A, 1990, CANCER RES, V50, P2618; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Findley HW, 1997, BLOOD, V89, P2986, DOI 10.1182/blood.V89.8.2986; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; FOTSIS T, 1995, J NUTR, V125, pS790, DOI 10.1093/jn/125.suppl_3.790S; Gescher A, 1998, BRIT J CLIN PHARMACO, V45, P1, DOI 10.1046/j.1365-2125.1998.00640.x; HARPER JW, 1993, CELL, V75, P241; Huang P, 1997, CANCER RES, V57, P3407; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; Kyle E, 1997, MOL PHARMACOL, V51, P193, DOI 10.1124/mol.51.2.193; LAMARTINIERE CA, 1995, P SOC EXP BIOL MED, V208, P120; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LEE HP, 1991, LANCET, V337, P1197, DOI 10.1016/0140-6736(91)92867-2; LIAN F, 1998, IN PRESS NUTR CANC; MATSUKAWA Y, 1993, CANCER RES, V53, P1328; MESSINA M, 1991, JNCI-J NATL CANCER I, V83, P541, DOI 10.1093/jnci/83.8.541; MESSINA MJ, 1994, NUTR CANCER, V21, P113, DOI 10.1080/01635589409514310; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; Parker S. L., 1996, CA CANC J CLIN, V65, P5; PETERSON G, 1993, PROSTATE, V22, P335, DOI 10.1002/pros.2990220408; PETERSON G, 1991, BIOCHEM BIOPH RES CO, V179, P661, DOI 10.1016/0006-291X(91)91423-A; Philpott NJ, 1996, BLOOD, V87, P2244, DOI 10.1182/blood.V87.6.2244.bloodjournal8762244; Salomons GS, 1997, INT J CANCER, V71, P959, DOI 10.1002/(SICI)1097-0215(19970611)71:6<959::AID-IJC9>3.0.CO;2-X; SANO H, 1995, CANCER RES, V55, P3785; SEDLAK ML, 1995, P NATL ACAD SCI USA, V92, P7934; Shao ZM, 1998, J CELL BIOCHEM, V69, P44, DOI 10.1002/(SICI)1097-4644(19980401)69:1<44::AID-JCB5>3.3.CO;2-B; SPINOZZI F, 1994, LEUKEMIA RES, V18, P431, DOI 10.1016/0145-2126(94)90079-5; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; UCKUN FM, 1995, SCIENCE, V267, P886, DOI 10.1126/science.7531365; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Wang CF, 1997, NUTR CANCER, V28, P236, DOI 10.1080/01635589709514582; WANG TT, 1996, CARCINOGEN, V17, P272; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YUAN JM, 1995, BRIT J CANCER, V71, P1353, DOI 10.1038/bjc.1995.263; Zhou YH, 1998, J NATL CANCER I, V90, P381, DOI 10.1093/jnci/90.5.381	45	256	265	0	23	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 20	1999	18	20					3166	3172		10.1038/sj.onc.1202650	http://dx.doi.org/10.1038/sj.onc.1202650			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	197WB	10340389				2022-12-25	WOS:000080388000013
J	Morley, GM; Uden, M; Gullick, WJ; Dibb, NJ				Morley, GM; Uden, M; Gullick, WJ; Dibb, NJ			Cell specific transformation by c-fms activating loop mutations is attributable to constitutive receptor degradation	ONCOGENE			English	Article						c-fms; M-CSF; CSF-1; oncogene; transformation	COLONY-STIMULATING FACTOR; FACTOR-INDEPENDENT GROWTH; PROTO-ONCOGENE PRODUCT; HUMAN CSF-1 RECEPTOR; FACTOR-I RECEPTOR; TYROSINE KINASE; SURFACE EXPRESSION; FDC-P1 CELLS; MURINE; GENE	Expression of a receptor for human macrophage-colony stimulating factor (M-CSF or CSF-1), containing a point mutation which changes an aspartate to a valine at position 802 of the activating loop of the kinase domain, potently transforms the haemopoietic cell line FDC-P1 Set prevents Rat-2 fibroblast transformation, In order to understand this apparent paradox, aspartate 802 was changed by cassette mutagenesis to each of the other 19 amino acids, AU hydrophobic amino acid substitutions were transforming when tested in FDC-P1 cells yet inactivating when tested in Rat-2 fibroblasts. These same amino acid substitutions also activated receptor degradation, strongly suggesting a causal relationship between receptor degradation and inactivation in fibroblasts, Point mutations or small deletions of Y708 within the kinase insert region of the mutant D802V receptor partly inhibited receptor degradation, The more stable D802V receptor derivatives were able to transform both FDC-P1 cells and Rat-2 fibroblasts, so establishing that the cell specific effect of the c-fmsD802V activating loop mutation is attributable to receptor degradation which accompanies kinase activation and prevents the transformation of Rat-2 hut not of FDC-P1 cells.	Hammersmith Hosp, Imperial Coll, Sch Med, Cell Signalling Unit,Div Paediat Obstet & Gynaeco, London W12 0NN, England; Hammersmith Hosp, Imperial Coll, Sch Med, ICRF Mol Oncol Unit, London W12 0NN, England	Imperial College London; Imperial College London	Dibb, NJ (corresponding author), Hammersmith Hosp, Imperial Coll, Sch Med, Cell Signalling Unit,Div Paediat Obstet & Gynaeco, Du Cane Rd, London W12 0NN, England.							BAKER DA, 1994, LEUKEMIA, V8, P1970; CARLBERG K, 1991, EMBO J, V10, P877, DOI 10.1002/j.1460-2075.1991.tb08020.x; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; Dibb NJ, 1990, GROWTH FACTORS, V2, P301, DOI 10.3109/08977199009078018; DUBREUIL P, 1988, BLOOD, V72, P1081; GLOVER HR, 1995, ONCOGENE, V11, P1347; HADWIGER A, 1986, EMBO J, V5, P689, DOI 10.1002/j.1460-2075.1986.tb04268.x; HALENBECK R, 1989, BIO-TECHNOL, V7, P710, DOI 10.1038/nbt0789-710; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; Hubbard S. R., 1997, EMBO J, V16, P5573; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Kacinski BM, 1997, MOL REPROD DEV, V46, P71, DOI 10.1002/(SICI)1098-2795(199701)46:1<71::AID-MRD11>3.0.CO;2-6; KITAYAMA H, 1995, BLOOD, V85, P790, DOI 10.1182/blood.V85.3.790.bloodjournal853790; LADNER MB, 1987, EMBO J, V6, P2693, DOI 10.1002/j.1460-2075.1987.tb02561.x; LI W, 1991, EMBO J, V10, P277, DOI 10.1002/j.1460-2075.1991.tb07948.x; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MEIER T, 1992, ANAL BIOCHEM, V204, P220, DOI 10.1016/0003-2697(92)90165-4; MINOR DL, 1994, NATURE, V371, P264, DOI 10.1038/371264a0; NICHOLS EJ, 1985, MOL CELL BIOL, V5, P3467, DOI 10.1128/MCB.5.12.3467; Novak U, 1996, ONCOGENE, V13, P2607; Piao XH, 1996, P NATL ACAD SCI USA, V93, P14665, DOI 10.1073/pnas.93.25.14665; RAMBALDI A, 1988, J CLIN INVEST, V81, P1030, DOI 10.1172/JCI113413; REEDIJK M, 1990, MOL CELL BIOL, V10, P5601, DOI 10.1128/MCB.10.11.5601; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; RETTENMIER CW, 1987, MOL CELL BIOL, V7, P2378, DOI 10.1128/MCB.7.7.2378; ROHRSCHNEIDER LR, 1989, MOL CELL BIOL, V9, P5081, DOI 10.1128/MCB.9.11.5081; Roth P, 1992, Curr Top Microbiol Immunol, V181, P141; ROUSSEL MF, 1988, CELL, V55, P979, DOI 10.1016/0092-8674(88)90243-7; ROUSSEL MF, 1984, MOL CELL BIOL, V4, P1999, DOI 10.1128/MCB.4.10.1999; Sambrook J., 2002, MOL CLONING LAB MANU; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SMITH CK, 1994, BIOCHEMISTRY-US, V33, P5510, DOI 10.1021/bi00184a020; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; Stanley ER, 1997, MOL REPROD DEV, V46, P4, DOI 10.1002/(SICI)1098-2795(199701)46:1<4::AID-MRD2>3.0.CO;2-V; TAVORMINA PL, 1995, NAT GENET, V9, P321, DOI 10.1038/ng0395-321; TROULIARIS S, 1995, ARCH VIROL, V140, P179, DOI 10.1007/BF01309733; TSUJIMURA T, 1995, INT ARCH ALLERGY IMM, V106, P377, DOI 10.1159/000236870; VANDERGEER P, 1991, MOL CELL BIOL, V11, P4698, DOI 10.1128/MCB.11.9.4698; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; VERON M, 1993, P NATL ACAD SCI USA, V90, P10618, DOI 10.1073/pnas.90.22.10618; WHEELER EF, 1987, MOL CELL BIOL, V7, P1673, DOI 10.1128/MCB.7.5.1673	43	21	22	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 20	1999	18	20					3076	3084		10.1038/sj.onc.1202646	http://dx.doi.org/10.1038/sj.onc.1202646			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	197WB	10340379				2022-12-25	WOS:000080388000003
J	Dorkin, TJ; Robinson, MC; Marsh, C; Bjartell, A; Neal, DE; Leung, HY				Dorkin, TJ; Robinson, MC; Marsh, C; Bjartell, A; Neal, DE; Leung, HY			FGF8 over-expression in prostate cancer is associated with decreased patient survival and persists in androgen independent disease	ONCOGENE			English	Article						FGF8; prostate cancer; patient survival; androgen independent	FIBROBLAST GROWTH-FACTORS; MOLECULAR-CLONING; CARCINOMA-CELLS; FACTOR-VIII; TISSUES; INDUCTION; FORMS	Identification of prostate cancers at high risk of progression is difficult and a better understanding of how peptide growth factors influence cellular function might be useful. Fibroblast growth factors (FGFs) have been implicated in prostate cancer development. FGF8 was identified in the Shionogi mouse mammary carcinoma SC-3 cell line as an androgen-induced mitogen. We tested if FGF8 was over-expressed in human prostate cancer and if its expression correlated with clinical data and outcome. One hundred and six cases of prostate cancer and ten cases of BPH were examined. In situ hybridization was employed to detect FGF8 mRNA expression, which,vas identified within the malignant prostatic epithelium in 85/106 (80.2%) cases, Increased expression of FGF8 correlated significantly with higher Gleason scores (P=0.0004) and advanced tumour stage (P=0.0016), Using immunohistochemistry, me confirmed over-expression of the FGF8b isoform, Men with tumours which expressed high levels of FGF8 had worse survival (P=0.034), although FGF8 mRNA was not able to provide additional prognostic information in a multivariate analysis. Additionally, FGF8 expression was shown to persist in androgen independent prostate cancer. Using a range of normal adult tissues, FGF8 expression was restricted to neurones and the germinal epithelium in addition to the prostate, in vitro studies demonstrated that in the presence of neutralizing antibody to FGF8b there was significant inhibition of prostate cancer cell growth, confirming the biological significance of FGF8 in prostate carcinogenesis.	Newcastle Univ, Sch Med, Sch Surg Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Freeman Rd Hosp, Dept Pathol, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England; Univ Hosp, Dept Urol, S-20502 Malmo, Sweden	Newcastle University - UK; Newcastle Freeman Hospital; Newcastle University - UK; Lund University; Skane University Hospital	Leung, HY (corresponding author), Newcastle Univ, Sch Med, Sch Surg Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.			Neal, David/0000-0002-6033-5086; Leung, Hing Y./0000-0002-3933-3975				Crossley PH, 1996, CELL, V84, P127, DOI 10.1016/S0092-8674(00)80999-X; Gemel J, 1996, GENOMICS, V35, P253, DOI 10.1006/geno.1996.0349; Ghosh AK, 1996, CELL GROWTH DIFFER, V7, P1425; Ittman M, 1997, J UROLOGY, V157, P351, DOI 10.1016/S0022-5347(01)65376-X; Lee SMK, 1997, DEVELOPMENT, V124, P959; Leung HY, 1997, ONCOGENE, V15, P1115, DOI 10.1038/sj.onc.1201256; Leung HY, 1996, ONCOGENE, V12, P1833; MACARTHUR CA, 1995, DEVELOPMENT, V121, P3603; MACARTHUR CA, 1995, CELL GROWTH DIFFER, V6, P817; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; MYERS RL, 1995, ONCOGENE, V11, P785; *OFF NAT STAT, 1996, DH2962 OFF NAT STAT; Payson RA, 1996, ONCOGENE, V13, P47; Rudra-Ganguly N, 1998, ONCOGENE, V16, P1487, DOI 10.1038/sj.onc.1201652; Schmitt JF, 1996, J STEROID BIOCHEM, V57, P173, DOI 10.1016/0960-0760(95)00259-6; Smallwood PM, 1996, P NATL ACAD SCI USA, V93, P9850, DOI 10.1073/pnas.93.18.9850; Suzuki H, 1998, CANCER RES, V58, P204; Tanaka A, 1998, CANCER RES, V58, P2053; TANAKA A, 1995, FEBS LETT, V363, P226, DOI 10.1016/0014-5793(95)00324-3; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; YAZIDI IE, 1995, ANTICANCER, V15, P783	21	118	123	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	1999	18	17					2755	2761		10.1038/sj.onc.1202624	http://dx.doi.org/10.1038/sj.onc.1202624			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FH	10348350				2022-12-25	WOS:000080124900011
J	Hornigold, N; Devlin, J; Davies, AM; Aveyard, JS; Habuchi, T; Knowles, MA				Hornigold, N; Devlin, J; Davies, AM; Aveyard, JS; Habuchi, T; Knowles, MA			Mutation of the 9q34 gene TSC1 in sporadic bladder cancer	ONCOGENE			English	Article						TSC1; bladder cancer; loss of heterozygosity; 9q34	TUMOR-SUPPRESSOR LOCI; TUBEROUS SCLEROSIS; CANDIDATE REGION; CHROMOSOME-9; CARCINOMA; FREQUENT; DELETION; HETEROZYGOSITY; IDENTIFICATION; NEOPLASIA	Deletions involving chromosome 9 occur in more than 50% of human bladder cancers of all grades and stages. Most involve loss of the whole chromosome or of an entire chromosome arm but some small deletions are found which can be used to define critical regions which may contain tumour suppressor genes. We have localized such a critical region of deletion at 9q34 between the markers D9S149 and D9S66, an interval which contains the Tuberous Sclerosis gene TSC1. Single strand conformation polymorphism (SSCP) and sequence analysis of TSC1 in bladder tumours and cell lines with 9q34 loss of heterozygosity (LOH) has identified five mutations in retained TSC1 alleles. Our results support the hypothesis that TSC1 can act as a bladder tumour suppressor gene.	St James Univ Hosp, ICRF Canc Med Res Unit, Leeds LS9 7TF, W Yorkshire, England; Kyoto Univ, Grad Sch Med, Dept Urol, Sakyo Ku, Kyoto 606, Japan	Saint James's University Hospital; Kyoto University	Knowles, MA (corresponding author), St James Univ Hosp, ICRF Canc Med Res Unit, Beckett St, Leeds LS9 7TF, W Yorkshire, England.			Knowles, Margaret/0000-0002-9363-8657				Baylin SB, 1998, ADV CANCER RES, V72, P141; Bjornsson J, 1996, AM J PATHOL, V149, P1201; CAIRNS P, 1994, CANCER RES, V54, P1422; CAIRNS P, 1991, ONCOGENE, V6, P2305; CARBONARA C, 1994, HUM MOL GENET, V3, P1829, DOI 10.1093/hmg/3.10.1829; DEVLIN J, 1994, ONCOGENE, V9, P2757; HABUCHI T, 1995, ONCOGENE, V11, P1671; Habuchi T, 1997, HUM MOL GENET, V6, P913, DOI 10.1093/hmg/6.6.913; Henry KW, 1998, J BIOL CHEM, V273, P20535, DOI 10.1074/jbc.273.32.20535; Henske EP, 1996, AM J HUM GENET, V59, P400; Hornigold N, 1997, GENOMICS, V41, P385, DOI 10.1006/geno.1997.4681; ISHIBASHI Y, 1991, ANN NY ACAD SCI, V615, P228; Jones AC, 1997, HUM MOL GENET, V6, P2155, DOI 10.1093/hmg/6.12.2155; KEEN AJ, 1994, ONCOGENE, V9, P2083; Knowles MA, 1998, CANCER SURV, V31, P49; ORLOW I, 1994, CANCER RES, V54, P2848; Pajak L, 1997, AM J PHYSIOL-HEART C, V273, pH1619, DOI 10.1152/ajpheart.1997.273.3.H1619; Pea M, 1998, AM J SURG PATHOL, V22, P180, DOI 10.1097/00000478-199802000-00005; POVEY S, 1994, ANN HUM GENET, V58, P177, DOI 10.1111/j.1469-1809.1994.tb01887.x; SCAPPATICCI S, 1988, HUM GENET, V79, P151, DOI 10.1007/BF00280555; SCHULTZ DC, 1995, CANCER RES, V55, P2150; Simoneau AR, 1996, CANCER RES, V56, P5039; Soucek T, 1997, J BIOL CHEM, V272, P29301, DOI 10.1074/jbc.272.46.29301; van Slegtenhorst M, 1998, HUM MOL GENET, V7, P1053, DOI 10.1093/hmg/7.6.1053; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; Wolfe J, 1997, ANN HUM GENET, V61, P401; YOUNG JM, 1998, IN PRESS ANN HUM GEN	27	95	99	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	1999	18	16					2657	2661		10.1038/sj.onc.1202854	http://dx.doi.org/10.1038/sj.onc.1202854			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	189LU	10353610				2022-12-25	WOS:000079907100014
J	Joester, A; Faissner, A				Joester, A; Faissner, A			Evidence for combinatorial variability of tenascin-C isoforms and developmental regulation in the mouse central nervous system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; INSITU LOCALIZATION; EMBRYONIC-TISSUES; SPLICE VARIANTS; CELL-ADHESION; GROWTH-FACTOR; ADULT-MOUSE; III REPEAT; EXPRESSION; PROTEIN	The extracellular matrix glycoprotein tenascin-C (TN-C) displays a restricted and developmentally regulated distribution in the mouse central nervous system. Defined modules of the molecule have been shown to mediate specific functions, such as neuron migration, neurite outgrowth, cell adhesion, and cell proliferation. The smallest TN-C form contains a stretch of eight fibronectin type III (FNIII) domains, which are common to all TN-C isoforms, Unrestricted and independent alternative splicing of six consecutive FNIII cassettes between the fifth and sixth constitutive FNIII domain bears the potential to generate 64 different combinations that might code for TN-C proteins with subtly different functions. To explore TN-C isoform variability in mouse brain, the alternatively spliced region of TN-C mRNAs was examined by the reverse transcription-polymerase chain reaction technique. Polymerase chain reaction products of uniform size were subcloned and analyzed using domain-specific probes to reveal the expression of particular combinations of alternatively spliced FNIII domains. 27 TN-C isoforms were identified to be expressed in mouse central nervous system, of which 22 are novel. Furthermore, during development, specific TN-C isoforms were found to occur in distinct relative frequencies, as demonstrated for isoforms containing two alternatively spliced FNIII domains. We conclude that TN-C is expressed in a complex and regulated pattern in mouse central nervous system. These findings highlight the potential role of TN-C in mediating specific neuron glia interactions.	Univ Heidelberg, Dept Neurobiol, D-69120 Heidelberg, Germany; CNRS, Ctr Neurochim, UPR 1352, Lab Neurobiol Dev & Regenerat, F-67084 Strasbourg, France; Univ Strasbourg 1, F-67084 Strasbourg, France	Ruprecht Karls University Heidelberg; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Faissner, A (corresponding author), Univ Heidelberg, Dept Neurobiol, Neuenheimer Feld 364, D-69120 Heidelberg, Germany.		Faissner, Andreas/A-5314-2008	Faissner, Andreas/0000-0002-2211-8259				Altman J., 1982, CEREBELLUM NEW VISTA, V47, P8; BARTSCH S, 1992, J NEUROSCI, V12, P736; BARTSCH U, 1994, J NEUROSCI, V14, P4756; BARTSCH U, 1992, EUR J NEUROSCI, V4, P338, DOI 10.1111/j.1460-9568.1992.tb00881.x; Borsi L, 1996, INT J CANCER, V66, P632, DOI 10.1002/(SICI)1097-0215(19960529)66:5<632::AID-IJC9>3.0.CO;2-U; CHIQUETEHRISMANN R, 1995, BIOESSAYS, V17, P873, DOI 10.1002/bies.950171009; Derr LB, 1997, DIFFERENTIATION, V62, P71, DOI 10.1046/j.1432-0436.1997.6220071.x; DORRIES U, 1994, J NEUROSCI RES, V37, P336, DOI 10.1002/jnr.490370306; Dorries U, 1996, J NEUROSCI RES, V43, P420; Engel J, 1991, CURR OPIN CELL BIOL, V3, P779, DOI 10.1016/0955-0674(91)90050-9; ERICKSON HP, 1984, NATURE, V311, P267, DOI 10.1038/311267a0; ERICKSON HP, 1989, ANNU REV CELL BIOL, V5, P71, DOI 10.1146/annurev.cb.05.110189.000443; Faissner A, 1997, CELL TISSUE RES, V290, P331, DOI 10.1007/s004410050938; FAISSNER A, 1990, NEURON, V5, P627, DOI 10.1016/0896-6273(90)90217-4; FAISSNER A, 1996, TENASCIN COUNTERADHE, P47; Gotz B, 1996, J CELL BIOL, V132, P681, DOI 10.1083/jcb.132.4.681; Gotz M, 1997, EUR J NEUROSCI, V9, P496, DOI 10.1111/j.1460-9568.1997.tb01627.x; GULCHER JR, 1989, P NATL ACAD SCI USA, V86, P1588, DOI 10.1073/pnas.86.5.1588; KAPLONY A, 1991, DEVELOPMENT, V112, P605; MEINERS S, 1993, DEV BIOL, V160, P480, DOI 10.1006/dbio.1993.1322; Mighell AJ, 1997, INT J CANCER, V72, P236, DOI 10.1002/(SICI)1097-0215(19970717)72:2<236::AID-IJC6>3.0.CO;2-S; MIRAGALL F, 1992, MICROSC RES TECHNIQ, V23, P157, DOI 10.1002/jemt.1070230206; MITROVIC N, 1994, J NEUROCYTOL, V23, P364, DOI 10.1007/BF01666526; MURPHYULLRICH JE, 1991, J CELL BIOL, V115, P1127, DOI 10.1083/jcb.115.4.1127; NIES DE, 1991, J BIOL CHEM, V266, P2818; PEARSON CA, 1988, EMBO J, V7, P2977, DOI 10.1002/j.1460-2075.1988.tb03160.x; PRIETO AL, 1992, J CELL BIOL, V119, P663, DOI 10.1083/jcb.119.3.663; RETTIG WJ, 1992, BRAIN RES, V590, P219, DOI 10.1016/0006-8993(92)91099-Z; SAGA Y, 1991, GENE, V104, P177, DOI 10.1016/0378-1119(91)90248-A; SIRI A, 1991, NUCLEIC ACIDS RES, V19, P525, DOI 10.1093/nar/19.3.525; SPRING J, 1989, CELL, V59, P325, DOI 10.1016/0092-8674(89)90294-8; SRIRAMARAO P, 1993, NUCLEIC ACIDS RES, V21, P163, DOI 10.1093/nar/21.1.163; TUCKER RP, 1993, DEVELOPMENT, V117, P347; TUCKER RP, 1993, J CELL SCI, V104, P69; VRUCINICFILIPI N, 1993, SYM SOC EXP BIOL, V47, P155; WELLER A, 1991, J CELL BIOL, V112, P355, DOI 10.1083/jcb.112.2.355; ZHAO Y, 1995, AM J PHYSIOL-LUNG C, V268, pL173, DOI 10.1152/ajplung.1995.268.2.L173	37	72	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17144	17151		10.1074/jbc.274.24.17144	http://dx.doi.org/10.1074/jbc.274.24.17144			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358070	hybrid			2022-12-25	WOS:000080780400069
J	Wang, HX; Lawrence, CW; Li, GM; Hays, JB				Wang, HX; Lawrence, CW; Li, GM; Hays, JB			Specific binding of human MSH2 center dot MSH6 mismatch-repair protein heterodimers to DNA incorporating thymine- or uracil-containing UV light photoproducts opposite mismatched bases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONREPLICATING PHAGE DNA; ESCHERICHIA-COLI; MUTS-ALPHA; SACCHAROMYCES-CEREVISIAE; TRANSLOCATION MECHANISM; TUMOR-CELLS; CIS-SYN; RECOMBINATION; SYSTEM; GENES	Previous studies have demonstrated recognition of DNA-containing UV light photoproducts by bacterial (Feng, W,-Y., Lee, E., and Hays, J.B. (1991) Genetics 129, 1007-1020) and human (Mu, D., Tursun, M., Duckett, D, R., Drummond, J.T., Modrich, P., and Sancar, A. (1997) Mol. Cell. Biol. 17, 760-769) long-patch mismatch-repair systems. Mismatch repair directed specifically against incorrect bases inserted during semi-conservative DNA replication might efficiently antagonize UV mutagenesis. To test this hypothesis, DNA 51-mers containing site-specific T-T cis-syn-cyclobutane pyrimidine-dimers or T-T pyrimidine-(6-4')pyrimidinone photoproducts, with all four possible bases opposite the respective 3'-thymines in the photoproducts, were analyzed for the ability to compete with radiolabeled (T/G)-mismatched DNA for binding by highly purified human MSH2 . MSHG heterodimer protein (hMutS alpha). Both (cyclobutane-dimer)/AG and ((6-4)photoproduct)/AG mismatches competed about as well as non-photoproduct T/T mismatches. The two respective pairs of photoproduct/(A(T or C)) mismatches also showed higher hMutS alpha affinity than photoproduct/AA "matches"; the apparent affinity of hMutS alpha for the ((6 - 4)photoproduct)/AA"matched" substrate was actually less than that for TT/AA homoduplexes. Surprisingly, although hMutS alpha affinities for both non-photoproduct UU/GG double mismatches and for (uracil-cyclobutane-dimer)/AG single mismatches were high, affinity for the (uracil-cyclobutane-dimer)/GG mismatch was quite low. Equilibrium binding of hMutS alpha to DNA containing (photoproduct/base) mismatches and to (T/G)-mismatched DNA was reduced similarly by ATP (in the absence of magnesium).	Oregon State Univ, Dept Environm & Mol Toxicol, Corvallis, OR 97331 USA; Univ Rochester, Med Ctr, Dept Biophys & Biochem, Rochester, NY 14642 USA; Univ Kentucky, Med Ctr, Dept Pathol, Lexington, KY 40536 USA	Oregon State University; University of Rochester; University of Kentucky	Hays, JB (corresponding author), Oregon State Univ, Dept Environm & Mol Toxicol, Corvallis, OR 97331 USA.		Li, Guo-Min/I-5016-2014	Li, Guo-Min/0000-0002-9842-4578	NATIONAL CANCER INSTITUTE [R29CA072956] Funding Source: NIH RePORTER; NCI NIH HHS [CA 72956] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; Allen DJ, 1997, EMBO J, V16, P4467, DOI 10.1093/emboj/16.14.4467; Blackwell LJ, 1998, J BIOL CHEM, V273, P32055, DOI 10.1074/jbc.273.48.32055; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN TC, 1988, CELL, V54, P705, DOI 10.1016/S0092-8674(88)80015-1; D'Atri S, 1998, MOL PHARMACOL, V54, P334, DOI 10.1124/mol.54.2.334; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Drummond JT, 1996, J BIOL CHEM, V271, P19645, DOI 10.1074/jbc.271.33.19645; Duckett DR, 1996, P NATL ACAD SCI USA, V93, P6443, DOI 10.1073/pnas.93.13.6443; ELLINGTON A, 1994, CURRENT PROTOCOL MOL; FANG WH, 1993, J BIOL CHEM, V268, P11838; FENG WY, 1995, GENETICS, V140, P1175; FENG WY, 1991, GENETICS, V129, P1007; FISHEL R, 1995, CURR OPIN GENET DEV, V5, P382, DOI 10.1016/0959-437X(95)80055-7; FREIDBERG EC, 1995, DNA REPAIR MUTAGENES, P545; Genschel J, 1998, J BIOL CHEM, V273, P19895, DOI 10.1074/jbc.273.31.19895; Gentil A, 1996, NUCLEIC ACIDS RES, V24, P1837, DOI 10.1093/nar/24.10.1837; Gradia S, 1997, CELL, V91, P995, DOI 10.1016/S0092-8674(00)80490-0; GRILLEY M, 1993, J BIOL CHEM, V268, P11830; HOLLINGSWORTH NM, 1995, GENE DEV, V9, P1728, DOI 10.1101/gad.9.14.1728; HUGHES MJ, 1992, J BIOL CHEM, V267, P23876; Johnson RE, 1996, J BIOL CHEM, V271, P7285, DOI 10.1074/jbc.271.13.7285; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; KEMMINK J, 1987, NUCLEIC ACIDS RES, V15, P4645, DOI 10.1093/nar/15.11.4645; KIM JK, 1995, PHOTOCHEM PHOTOBIOL, V62, P44, DOI 10.1111/j.1751-1097.1995.tb05236.x; KORNBERG A, 1992, DNA REPLICATION, P497; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; LAWRENCE CW, 1990, MOL GEN GENET, V222, P166, DOI 10.1007/BF00283040; LECLERC JE, 1991, P NATL ACAD SCI USA, V88, P9685, DOI 10.1073/pnas.88.21.9685; Li GM, 1996, J BIOL CHEM, V271, P24084, DOI 10.1074/jbc.271.39.24084; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; Marsischky GT, 1996, GENE DEV, V10, P407, DOI 10.1101/gad.10.4.407; Mellon I, 1996, SCIENCE, V272, P557, DOI 10.1126/science.272.5261.557; Mellon I, 1996, P NATL ACAD SCI USA, V93, P1292, DOI 10.1073/pnas.93.3.1292; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Mu D, 1997, MOL CELL BIOL, V17, P760, DOI 10.1128/MCB.17.2.760; Peng W, 1996, BIOCHEMISTRY-US, V35, P10172, DOI 10.1021/bi960001x; REENAN A, 1992, GENETICS, V148, P1667; Richardson C.C., 1981, ENZYMES A, V14, P299, DOI DOI 10.1016/S1874-6047(08)60342-X; ROSSMACDONALD P, 1994, CELL, V79, P1069, DOI 10.1016/0092-8674(94)90037-X; Swann PF, 1996, SCIENCE, V273, P1109, DOI 10.1126/science.273.5278.1109; TAYLOR JS, 1990, BIOCHEMISTRY-US, V29, P8858, DOI 10.1021/bi00489a049; Umar A, 1998, GENETICS, V148, P1637	44	91	91	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16894	16900		10.1074/jbc.274.24.16894	http://dx.doi.org/10.1074/jbc.274.24.16894			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358035	hybrid			2022-12-25	WOS:000080780400034
J	Yang, W; Freedman, LP				Yang, W; Freedman, LP			20-epi analogues of 1,25-dihydroxyvitamin D-3 are highly potent inducers of DRIP coactivator complex binding to the vitamin D-3 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELOID-LEUKEMIA CELLS; NUCLEAR RECEPTOR; TRANSCRIPTIONAL ACTIVATION; LIGAND-BINDING; DIFFERENTIATION; 1-ALPHA,25-DIHYDROXYVITAMIN-D3; TRANSACTIVATION; INHIBITION; INTERACTS; INDUCTION	1,25-Dihydroxyvitamin D-3 (1,25(OH)(2)D-3) plays a major role in the stimulation of bone growth, mineralization, and intestinal calcium and phosphate absorption; it also acts as a general inhibitor of cellular proliferation. Several new, clinically relevant compounds dissociate antiproliferative and calcemic activities of 1,25(OH)(2)D-3, but the molecular basis for this has not been clearly elucidated. Here, we tested whether the potency of one class of compounds, 20-epi analogues, to induce myeloid cell differentiation, is because of direct molecular effects on vitamin D receptor (VDR). We report that two 20-epi analogues, MC1627 and MC1288, induced differentiation and transcription of p21(WAf1,Cip1), a key VDR target gene involved in growth inhibition, at a concentration 100-fold lower than that of 1,25(OH)(2)D-3. We compared this sensitivity to analogue effects on VDR interacting proteins: RXR, GRIP-I, and DRIP205, a subunit of the DRIP coactivator complex. Compared with the interaction of VDR with RXR or GRIP-1, the differentiation dose-response most closely correlated to the ligand dependent recruitment of the DRIP coactivator complex to VDR and to the ability of the receptor to activate transcription in a cell-free system. These results provide compelling links between the efficiency of the 20-epi analogue in inducing VDR/DRIP interactions, transactivation in vitro, and its enhanced ability to induce cellular differentiation.	Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Freedman, LP (corresponding author), Mem Sloan Kettering Canc Ctr, Cell Biol Program, 1275 York Ave, New York, NY 10021 USA.				NCI NIH HHS [CA08748] Funding Source: Medline; NIDDK NIH HHS [DK07313, DK45460] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045460, R37DK045460] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABE E, 1981, P NATL ACAD SCI-BIOL, V78, P4990, DOI 10.1073/pnas.78.8.4990; BINDERUP L, 1991, BIOCHEM PHARMACOL, V42, P1569, DOI 10.1016/0006-2952(91)90426-6; BLANCO JCG, 1995, P NATL ACAD SCI USA, V92, P1535, DOI 10.1073/pnas.92.5.1535; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; CHESKIS B, 1995, MOL ENDOCRINOL, V9, P1814, DOI 10.1210/me.9.12.1814; COLSTON K, 1981, ENDOCRINOLOGY, V108, P1083, DOI 10.1210/endo-108-3-1083; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DELUCA HF, 1981, HARVEY LECT, V75, P333; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DILWORTH FJ, 1994, BIOCHEM PHARMACOL, V47, P987; Freedman LP, 1999, CELL, V97, P5, DOI 10.1016/S0092-8674(00)80708-4; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; HAUSSLER MR, 1969, P NATL ACAD SCI USA, V62, P155, DOI 10.1073/pnas.62.1.155; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HONMA Y, 1983, P NATL ACAD SCI-BIOL, V80, P201, DOI 10.1073/pnas.80.1.201; Lemon BD, 1997, MOL CELL BIOL, V17, P1923, DOI 10.1128/MCB.17.4.1923; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; MACDONALD PN, 1995, J BIOL CHEM, V270, P4748, DOI 10.1074/jbc.270.9.4748; MCDONNELL DP, 1989, MOL ENDOCRINOL, V3, P635, DOI 10.1210/mend-3-4-635; MELLANY E, 1919, LANCET, V2, P407; NISHII Y, 1991, VITAMIN D, P289; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; OLSSON I, 1983, CANCER RES, V43, P5862; PELEG S, 1995, J BIOL CHEM, V270, P10551, DOI 10.1074/jbc.270.18.10551; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787; Ryhanen S, 1998, J CELL BIOCHEM, V70, P414, DOI 10.1002/(SICI)1097-4644(19980901)70:3<414::AID-JCB14>3.0.CO;2-K; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Shibata H, 1997, RECENT PROG HORM RES, V52, P141; Takeyama KI, 1999, MOL CELL BIOL, V19, P1049; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0	33	73	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16838	16845		10.1074/jbc.274.24.16838	http://dx.doi.org/10.1074/jbc.274.24.16838			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358028	hybrid			2022-12-25	WOS:000080780400027
J	Easwaran, V; Song, V; Polakis, P; Byers, S				Easwaran, V; Song, V; Polakis, P; Byers, S			The ubiquitin-proteasome pathway and serine kinase activity modulate adenomatous polyposis coli protein-mediated regulation of beta-catenin-lymphocyte enhancer-binding factor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; GLYCOGEN-SYNTHASE KINASE-3; APC GENE-PRODUCT; NEGATIVE REGULATOR; MOLECULAR MECHANISM; COLORECTAL TUMORS; SOMATIC MUTATIONS; XENOPUS EMBRYOS; AXIS FORMATION; INTACT-CELLS	The tumor suppressor function of the adenomatous polyposis coli protein (APC) depends, in part, on its ability to bind and regulate the multifunctional protein, beta-catenin. beta-Catenin binds the high mobility group box transcription factors, lymphocyte enhancer-binding factor (LEF) and T-cell factor, to directly regulate gene transcription. Using LEF reporter assays we find that APC-mediated down-regulation of beta-catenin-LEF signaling is reversed by proteasomal inhibitors in a dose-dependent manner. APC down-regulates signaling induced by wild type beta-catenin but not by the non-ubiquitinatable S37A mutant, beta-catenin, Bisindoylmaleimide type protein kinase C inhibitors, which prevent beta-catenin ubiquitination, decrease the ability of APC to down-regulate beta-catenin-LEF signaling. All these effects on LEF signaling are paralleled by changes in beta-catenin protein levels, Lithium, an inhibitor of glycogen synthase kinase-3 beta, does not alter the ability of APC to down-regulate beta-catenin protein and beta-catenin-LEF signaling in the colon cancer cells that were tested. These results point to a role for beta-catenin ubiquitination, proteasomal degradation, and potentially a serine kinase other than glycogen synthase kinase-3 beta in the tumor-suppressive actions of APC.	Georgetown Univ, Sch Med, Dept Cell Biol, Washington, DC 20007 USA; Vincent T Lombardi Canc Res Ctr, Washington, DC 20007 USA; Onyx Pharmaceut, Richmond, CA 94806 USA	Georgetown University	Byers, S (corresponding author), E415 Res Bldg,GUMC,8970 Reservoir Rd NW, Washington, DC 20007 USA.							Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Bullions Linda C., 1998, Current Opinion in Oncology, V10, P81, DOI 10.1097/00001622-199801000-00013; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Clevers H, 1997, TRENDS GENET, V13, P485, DOI 10.1016/S0168-9525(97)01305-X; Cook D, 1996, EMBO J, V15, P4526, DOI 10.1002/j.1460-2075.1996.tb00830.x; Fukuchi T, 1998, CANCER RES, V58, P3526; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Gumbiner B, 1997, CURR OPIN CELL BIOL, V7, P634; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hedgepeth CM, 1997, DEV BIOL, V185, P82, DOI 10.1006/dbio.1997.8552; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Ilyas M, 1997, P NATL ACAD SCI USA, V94, P10330, DOI 10.1073/pnas.94.19.10330; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; Kao KR, 1998, BIOL CELL, V90, P585, DOI 10.1016/S0248-4900(99)80016-1; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Li C, 1998, AM J PATHOL, V153, P709, DOI 10.1016/S0002-9440(10)65614-3; Marikawa Y, 1998, MECH DEVELOP, V77, P75, DOI 10.1016/S0925-4773(98)00134-8; MIKI Y, 1991, JPN J CANCER RES, V82, P1003, DOI 10.1111/j.1349-7006.1991.tb01935.x; MIYAKI M, 1994, CANCER RES, V54, P3011; Miyoshi Y, 1998, CANCER RES, V58, P2524; MIYOSHI Y, 1992, P NATL ACAD SCI USA, V89, P4452, DOI 10.1073/pnas.89.10.4452; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MUNEMITSU S, 1994, CANCER RES, V54, P3676; Munemitsu S, 1996, MOL CELL BIOL, V16, P4088; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Nakamura T, 1998, GENES CELLS, V3, P395, DOI 10.1046/j.1365-2443.1998.00198.x; NIKOLAKAKI E, 1993, ONCOGENE, V8, P833; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Palacios J, 1998, CANCER RES, V58, P1344; Papkoff J, 1996, MOL CELL BIOL, V16, P2128; PEIFER M, 1994, DEVELOPMENT, V120, P369; POLAKIS P, 1995, CURR OPIN GENET DEV, V5, P66, DOI 10.1016/S0959-437X(95)90055-1; Polakis P, 1997, BBA-REV CANCER, V1332, pF127, DOI 10.1016/S0304-419X(97)00008-5; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Rubinfeld B, 1997, CANCER RES, V57, P4624; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; SMITH KJ, 1993, P NATL ACAD SCI USA, V90, P2846, DOI 10.1073/pnas.90.7.2846; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Voeller HJ, 1998, CANCER RES, V58, P2520; Yamamoto H, 1998, MOL CELL BIOL, V18, P2867, DOI 10.1128/MCB.18.5.2867; Yang LM, 1997, CANCER RES, V57, P4652; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159	57	59	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16641	16645		10.1074/jbc.274.23.16641	http://dx.doi.org/10.1074/jbc.274.23.16641			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347231	hybrid			2022-12-25	WOS:000080668600091
J	Greene, B; King, J				Greene, B; King, J			Folding and stability of mutant scaffolding proteins defective in P22 capsid assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TAIL-SPIKE PROTEIN; TEMPERATURE-SENSITIVE MUTATIONS; PHAGE-P22 COAT PROTEIN; POLYPEPTIDE-CHAINS; BACTERIOPHAGE P22; TAILSPIKE PROTEIN; INCLUSION; VIRUS; PURIFICATION; SUBUNITS	Bacteriophage P22 scaffolding subunits are elongated molecules that interact through their C termini with coat subunits to direct icosahedral capsid assembly. The soluble state of the subunit exhibits a partially folded intermediate during equilibrium unfolding experiments, whose C-terminal domain is unfolded (Greene, B., and King, J. (1999) J. Biol. Chem. 274, 16135-16140). Four mutant scaffolding proteins exhibiting temperature-sensitive defects in different stages of particle assembly were purified. The purified mutant proteins adopted a similar conformation to wild type, but all were destabilized with respect to wild type. Analysis of the thermal melting transitions showed that the mutants S242F and Y214W further destabilized the C-terminal domain, whereas substitutions near the N terminus either destabilized a different domain or affected interactions between domains, Two mutant proteins carried an additional cysteine residue, which formed disulfide cross-links but did not affect the denaturation transition. These mutants differed both from temperature-sensitive folding mutants found in other P22 structural proteins and from the thermolabile temperature-sensitive mutants described for T4 lysozyme, The results suggest that the defects in these mutants are due to destabilization of domains affecting the weak subunit-subunit interactions important in the assembly and function of the virus precursor shell.	MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Greene, B (corresponding author), Univ Calif San Francisco, George Williams Hooper Fdn, San Francisco, CA 94143 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM017980, R37GM017980] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM17980] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBER T, 1987, BIOCHEMISTRY-US, V26, P3754, DOI 10.1021/bi00387a002; BAZINET C, 1988, BIOCHEMISTRY-US, V27, P1849, DOI 10.1021/bi00406a009; BAZINET C, 1988, J MOL BIOL, V202, P77, DOI 10.1016/0022-2836(88)90520-7; CASJENS S, 1991, GENETICS, V127, P637; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; Desai P, 1996, VIROLOGY, V220, P516, DOI 10.1006/viro.1996.0341; FULLER MT, 1981, VIROLOGY, V112, P529, DOI 10.1016/0042-6822(81)90300-7; GALISTEO ML, 1995, J BIOL CHEM, V270, P16595, DOI 10.1074/jbc.270.28.16595; GOLDENBERG DP, 1981, J MOL BIOL, V145, P633, DOI 10.1016/0022-2836(81)90307-7; GOLDENBERG DP, 1983, P NATL ACAD SCI-BIOL, V80, P7060, DOI 10.1073/pnas.80.23.7060; GORDON CL, 1993, J BIOL CHEM, V268, P9358; Greene B, 1996, VIROLOGY, V225, P82, DOI 10.1006/viro.1996.0577; Greene B, 1999, J BIOL CHEM, V274, P16135, DOI 10.1074/jbc.274.23.16135; HaasePettingell C, 1997, J MOL BIOL, V267, P88, DOI 10.1006/jmbi.1996.0841; KING J, 1978, CELL, V15, P551, DOI 10.1016/0092-8674(78)90023-5; King J, 1996, FASEB J, V10, P57, DOI 10.1096/fasebj.10.1.8566549; KING J, 1974, NATURE, V251, P112, DOI 10.1038/251112a0; LAKOWICZ JR, 1983, PRINCIPLES FLUORESCE, P279; MITRAKI A, 1991, SCIENCE, V253, P54, DOI 10.1126/science.1648264; Parker MH, 1997, PROTEIN SCI, V6, P1583, DOI 10.1002/pro.5560060722; Parker MH, 1997, J MOL BIOL, V268, P655, DOI 10.1006/jmbi.1997.0995; Pelletier A, 1997, J VIROL, V71, P5197, DOI 10.1128/JVI.71.7.5197-5208.1997; PREVELIGE PE, 1988, J MOL BIOL, V202, P743, DOI 10.1016/0022-2836(88)90555-4; PTITSYN OB, 1987, J PROTEIN CHEM, V6, P273; SMITH DH, 1980, GENETICS, V96, P331; Speed MA, 1996, NAT BIOTECHNOL, V14, P1283, DOI 10.1038/nbt1096-1283; SPEED MA, 1995, PROTEIN SCI, V4, P900; STEINBACHER S, 1994, SCIENCE, V265, P383, DOI 10.1126/science.8023158; STURTEVANT JM, 1989, J BIOL CHEM, V264, P10693; TESCHKE CM, 1993, BIOCHEMISTRY-US, V32, P10658, DOI 10.1021/bi00091a016; TESCHKE CM, 1993, BIOCHEMISTRY-US, V32, P10839, DOI 10.1021/bi00091a040; THOMAS GJ, 1990, BIOCHEMISTRY-US, V29, P4181, DOI 10.1021/bi00469a022; ThumanCommike PA, 1996, J MOL BIOL, V260, P85, DOI 10.1006/jmbi.1996.0383; Tuma R, 1998, J MOL BIOL, V281, P81, DOI 10.1006/jmbi.1998.1916; Tuma R, 1996, BIOCHEMISTRY-US, V35, P4619, DOI 10.1021/bi952793l; Wood LJ, 1997, J VIROL, V71, P179, DOI 10.1128/JVI.71.1.179-190.1997; ZHOU NE, 1992, J BIOL CHEM, V267, P2664	37	8	8	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16141	16146		10.1074/jbc.274.23.16141	http://dx.doi.org/10.1074/jbc.274.23.16141			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347166	hybrid			2022-12-25	WOS:000080668600026
J	Hughes, TA; La Boissiere, S; O'Hare, P				Hughes, TA; La Boissiere, S; O'Hare, P			Analysis of functional domains of the host cell factor involved in VP16 complex formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERPES-SIMPLEX VIRUS; OCTAMER-BINDING PROTEINS; IMMEDIATE EARLY GENE; POU-DOMAIN; TRANSCRIPTION FACTORS; CONFORMATIONAL ALTERATION; VP16-INDUCED COMPLEX; THYMIDINE KINASE; DNA-SEQUENCES; OCT-1	We present biochemical analyses of the regions of the host cell factor (HCF) involved in VP16 complex formation and in the association between the N- and C-terminal domains of HCF itself. We show that the kelch repeat region of HCF (residues 1-380) is sufficient for VP16 complex formation, but that residues C-terminal to the repeats (positions 381-450) interfere with this activity. However, these latter residues are required for the interaction between the N- and C-terminal regions of HCF. The extreme C-terminal region of HCF, corresponding to an area of strong conservation with a Caenorhabditis elegans homologue, is sufficient for interaction with the N-terminal region. These results are discussed with respect to possible differences in the roles of HCF in VP16 activity versus its normal cellular function.	The Chart, Marie Curie Res Inst, Surrey RH8 0TL, England		O'Hare, P (corresponding author), The Chart, Marie Curie Res Inst, Surrey RH8 0TL, England.		Hughes, Thomas A/O-8031-2015; Hughes, Thomas/M-7063-2019	Hughes, Thomas A/0000-0003-1169-3386; 				APRHYS CMJ, 1989, J VIROL, V63, P2798, DOI 10.1128/JVI.63.6.2798-2812.1989; CAMPBELL MEM, 1984, J MOL BIOL, V180, P1, DOI 10.1016/0022-2836(84)90427-3; Ford E, 1997, J BIOL CHEM, V272, P16048, DOI 10.1074/jbc.272.25.16048; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; Goto H, 1997, GENE DEV, V11, P726, DOI 10.1101/gad.11.6.726; Gstaiger M, 1996, EMBO J, V15, P2781, DOI 10.1002/j.1460-2075.1996.tb00638.x; HAYES S, 1993, J VIROL, V67, P852, DOI 10.1128/JVI.67.2.852-862.1993; HE X, 1991, MOL CELL BIOL, V11, P1739, DOI 10.1128/MCB.11.3.1739; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; HINKLEY CS, 1992, MOL CELL BIOL, V12, P638, DOI 10.1128/MCB.12.2.638; Huang CC, 1996, MOL CELL BIOL, V16, P2967; JOHNSON WA, 1990, NATURE, V343, P467, DOI 10.1038/343467a0; KATAN M, 1990, NUCLEIC ACIDS RES, V18, P6871, DOI 10.1093/nar/18.23.6871; KEMLER I, 1991, NUCLEIC ACIDS RES, V19, P237, DOI 10.1093/nar/19.2.237; KRISTIE TM, 1993, J BIOL CHEM, V268, P6525; KRISTIE TM, 1989, EMBO J, V8, P4229, DOI 10.1002/j.1460-2075.1989.tb08608.x; KRISTIE TM, 1995, J BIOL CHEM, V270, P4387, DOI 10.1074/jbc.270.9.4387; LaBoissiere S, 1997, MOL CELL BIOL, V17, P7108, DOI 10.1128/MCB.17.12.7108; LUO Y, 1995, MOL CELL BIOL, V15, P4115; MACKEM S, 1982, J VIROL, V44, P939, DOI 10.1128/JVI.44.3.939-949.1982; Misra V, 1996, MOL CELL BIOL, V16, P4404; MONUKI ES, 1993, MECH DEVELOP, V42, P15, DOI 10.1016/0925-4773(93)90095-F; MORRIS PJ, 1994, MOL CELL BIOL, V14, P6907, DOI 10.1128/MCB.14.10.6907; OHARE P, 1993, SEMIN VIROL, V4, P145, DOI 10.1006/smvy.1993.1010; OHARE P, 1988, CELL, V52, P435, DOI 10.1016/S0092-8674(88)80036-9; POST LE, 1981, CELL, V24, P555, DOI 10.1016/0092-8674(81)90346-9; PRESTON CM, 1984, J VIROL, V50, P708, DOI 10.1128/JVI.50.3.708-716.1984; PRESTON CM, 1988, CELL, V52, P425, DOI 10.1016/S0092-8674(88)80035-7; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; RUVKUN G, 1991, CELL, V64, P475, DOI 10.1016/0092-8674(91)90227-P; Simmen KA, 1997, J VIROL, V71, P3886, DOI 10.1128/JVI.71.5.3886-3894.1997; STERN S, 1991, GENE DEV, V5, P2555, DOI 10.1101/gad.5.12b.2555; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; THOMPSON CC, 1992, TRENDS GENET, V8, P232, DOI 10.1016/0168-9525(92)90121-J; VERRIJZER CP, 1993, BIOCHIM BIOPHYS ACTA, V1173, P1, DOI 10.1016/0167-4781(93)90237-8; WALKER S, 1994, CELL, V79, P841, DOI 10.1016/0092-8674(94)90073-6; Wegner M, 1993, CURR OPIN CELL BIOL, V5, P488, DOI 10.1016/0955-0674(93)90015-I; WILSON AC, 1993, COLD SPRING HARB SYM, V58, P167, DOI 10.1101/SQB.1993.058.01.021; Wilson AC, 1997, MOL CELL BIOL, V17, P6139, DOI 10.1128/MCB.17.10.6139; WILSON AC, 1993, CELL, V74, P115, DOI 10.1016/0092-8674(93)90299-6; XIAO P, 1990, MOL CELL BIOL, V10, P4974, DOI 10.1128/MCB.10.9.4974; XUE FY, 1993, CELL, V72, P681, DOI 10.1016/0092-8674(93)90397-9	42	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16437	16443		10.1074/jbc.274.23.16437	http://dx.doi.org/10.1074/jbc.274.23.16437			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347205	hybrid			2022-12-25	WOS:000080668600065
J	Park, HY; Perez, JM; Laursen, R; Hara, M; Gilchrest, BA				Park, HY; Perez, JM; Laursen, R; Hara, M; Gilchrest, BA			Protein kinase C-beta activates tyrosinase by phosphorylating serine residues in its cytoplasmic domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MELANOCYTE-STIMULATING HORMONE; PLATINUM C(P) MUTATION; CYCLIC-AMP; DIFFERENTIAL EXPRESSION; MAMMALIAN TYROSINASE; INDUCED PIGMENTATION; HUMAN MELANOGENESIS; CELLS; DIACYLGLYCEROL; PURIFICATION	We have previously shown that protein kinase C-beta (PKC-beta) is required for activation of tyrosinase (Park, H. Y,, Russakovsky, V., Ohno, S., and Gilchrest, B. A. (1993) J. Biol. Chem. 268, 11742-11749), the rate-limiting enzyme in melanogenesis, We now examine its mechanism of activation in human melanocytes. lit vivo phosphorylation experiments revealed that tyrosinase is phosphorylated through the PKC-dependent pathway and that introduction of PKC-beta into nonpigmented human melanoma cells lacking PKC-beta lead to the phosphorylation and activation of tyrosinase. Preincubation of intact melanosomes with purified active PKC-beta in vitro increased tyrosinase activity S-fold. By immunoelectron microscopy, PKC-beta but not PRC-alpha was closely associated with tyrosinase on the outer surface of melanosomes. Western blot analysis confirmed the association of PKC-beta with melanosomes. Only the cytoplasmic (extra-melanosomal) domain of tyrosinase, which contains two serines but no threonines, was phosphorylated by the serine/threonine kinase PKC-beta. These two serines at positions 505 and 509 both are present in the C-terminal peptide generated by trypsin digestion of tyrosinase. Go-migration experiments comparing synthetic peptide standards of all three possible phosphorylated tryptic peptides, a diphosphopeptide and two monophosphopeptides, to tyrosinase-phosphorylated in intact melanocytes by PKC-beta and then subjected to trypsin digestion revealed that both serine residues are phosphorylated by PKC-beta. We conclude that PKC-beta activates tyrosinase directly by phosphorylating serine residues at positions 505 and 509 in the cytoplasmic domain of this melanosome-associated protein.	Boston Univ, Sch Med, Dept Dermatol, Boston, MA 02118 USA; Boston Univ, Dept Chem, Boston, MA 02118 USA	Boston University; Boston University	Park, HY (corresponding author), Boston Univ, Sch Med, Dept Dermatol, J206,80 E Concord St, Boston, MA 02118 USA.	hypark@acs.bu.edu			NCI NIH HHS [R01 CA 72763] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072763] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDELMALEK Z, 1995, P NATL ACAD SCI USA, V92, P1789, DOI 10.1073/pnas.92.5.1789; ALLAN AE, 1995, J INVEST DERMATOL, V105, P687, DOI 10.1111/1523-1747.ep12324466; Ao Y, 1998, EXP CELL RES, V244, P117, DOI 10.1006/excr.1998.4086; Atherton E., 1990, SOLID PHASE PEPTIDE; BEERMANN F, 1995, EXP EYE RES, V61, P599, DOI 10.1016/S0014-4835(05)80053-3; Bertolotto C, 1998, MOL CELL BIOL, V18, P694, DOI 10.1128/MCB.18.2.694; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CAMBIER JC, 1987, NATURE, V327, P629, DOI 10.1038/327629a0; GORDON PR, 1989, J INVEST DERMATOL, V93, P700, DOI 10.1111/1523-1747.ep12319900; HALABAN R, 1984, ARCH BIOCHEM BIOPHYS, V230, P383, DOI 10.1016/0003-9861(84)90121-8; HEARING VJ, 1987, METHOD ENZYMOL, V142, P154; HEARING VJ, 1987, INT J BIOCHEM, V19, P1141, DOI 10.1016/0020-711X(87)90095-4; HEARING VJ, 1993, PIGMENTATION PIGMENT, P3; HOGANSON GE, 1989, SOMAT CELL MOLEC GEN, V15, P255, DOI 10.1007/BF01534876; Hopfer U., 1992, TXB BIOCH CLIN CORRE, P1059; IMOKAWA G, 1982, CANCER RES, V42, P1994; ITO S, 1998, PIGMENTARY SYSTEM PH, P33; JIMENEZ M, 1988, P NATL ACAD SCI USA, V85, P3830, DOI 10.1073/pnas.85.11.3830; JIMENEZ M, 1991, J BIOL CHEM, V266, P1147; JOHNSON R, 1992, NAT GENET, V1, P226, DOI 10.1038/ng0692-226; KING RA, 1993, PIGMENTATION PIGMENT, P297; KORNER A, 1977, NATURE, V267, P444, DOI 10.1038/267444a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUI MS, 1990, CARCINOGENESIS, V11, P229, DOI 10.1093/carcin/11.2.229; MCLEOD SD, 1995, J ENDOCRINOL, V146, P439, DOI 10.1677/joe.0.1460439; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; NAEYAERT JM, 1991, BRIT J DERMATOL, V125, P297, DOI 10.1111/j.1365-2133.1991.tb14161.x; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OETTING WS, 1998, PIGMENTARY SYSTEM PH, P231; OHNO S, 1987, NATURE, V325, P161, DOI 10.1038/325161a0; ORLOW SJ, 1993, J INVEST DERMATOL, V101, P137, DOI 10.1111/1523-1747.ep12363621; ORLOW SJ, 1994, J INVEST DERMATOL, V103, P196, DOI 10.1111/1523-1747.ep12392743; ORLOW SJ, 1995, J INVEST DERMATOL, V105, P3, DOI 10.1111/1523-1747.ep12312291; PARK HY, 1993, J BIOL CHEM, V268, P11742; Park HY, 1999, J INVEST DERMATOL, V112, P540; Park HY, 1996, EXP CELL RES, V227, P70, DOI 10.1006/excr.1996.0251; PARK HY, 1994, J INVEST DERMATOL, V102, P440; PARK HY, 1996, J CUTAN MED SURG, V1, P4; PAWELEK J, 1975, P NATL ACAD SCI USA, V72, P951, DOI 10.1073/pnas.72.3.951; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PUNNONEN K, 1992, J INVEST DERMATOL, V99, P221, DOI 10.1111/1523-1747.ep12650445; Salopek TG, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 2, APRIL 1996, P195; SEIJI M, 1961, J INVEST DERMATOL, V36, P243, DOI 10.1038/jid.1961.42; SHIBAHARA S, 1988, TOHOKU J EXP MED, V156, P403, DOI 10.1620/tjem.156.403; SIMEK SL, 1989, P NATL ACAD SCI USA, V86, P7410, DOI 10.1073/pnas.86.19.7410; UENO Y, 1995, INT J PEPT PROT RES, V46, P106; VIJAYAN E, 1982, ARCH BIOCHEM BIOPHYS, V217, P738, DOI 10.1016/0003-9861(82)90555-0; VIJAYASARADHI S, 1995, J CELL BIOL, V130, P807, DOI 10.1083/jcb.130.4.807; WOLF M, 1984, BIOCHEM BIOPH RES CO, V122, P1268, DOI 10.1016/0006-291X(84)91229-4; WONG G, 1975, NATURE, V255, P644, DOI 10.1038/255644a0; YAAR M, 1991, J INVEST DERMATOL, V97, P611, DOI 10.1111/1523-1747.ep12482985; YAMANISHI DT, 1991, CARCINOGENESIS, V12, P105, DOI 10.1093/carcin/12.1.105	54	117	130	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16470	16478		10.1074/jbc.274.23.16470	http://dx.doi.org/10.1074/jbc.274.23.16470			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347209	hybrid			2022-12-25	WOS:000080668600069
J	Fry, CJ; Pearson, A; Malinowski, E; Bartley, SM; Greenblatt, J; Farnham, PJ				Fry, CJ; Pearson, A; Malinowski, E; Bartley, SM; Greenblatt, J; Farnham, PJ			Activation of the murine dihydrofolate reductase promoter by E2F1 - A requirement for CBP recruitment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TATA-BINDING PROTEIN; TRANSCRIPTIONAL COACTIVATORS P300; HYDROPHOBIC AMINO-ACIDS; HISTONE DEACETYLASE; TRANSACTIVATION DOMAIN; COMPLEX-FORMATION; GROWTH-REGULATION; TERMINAL DOMAIN; FACTOR-TFIIB	The E2F family of heterodimeric transcription factors plays an important role in the regulation of gene expression at the G(1)/S phase transition of the mammalian cell cycle. Previously, we have demonstrated that cell cycle regulation of murine dihydrofolate reductase (dhfr) expression requires E2F-mediated activation of the dhfr promoter in S phase. To investigate the mechanism by which E2F activates an authentic E2F-regulated promoter, we precisely replaced the E2F binding site in the dhfr promoter with a Gal4 binding site. Using Gal4-E2F1 derivatives, we found that E2F1 amino acids 409-437 contain a potent core transactivation domain. Functional analysis of the E2F1 core domain demonstrated that replacement of phenylalanine residues 413, 425, and 429 with alanine reduces both transcriptional activation of the dhfr promoter and protein-protein interactions with CBP, transcription factor (TF) IIH, and TATA-binding protein (TBP), However, additional amino acid substitutions for phenylalanine 429 demonstrated a strong correlation between activation of the dhfr promoter and binding of CBP, but not TFIIH or TBP, Finally, transactivator bypass experiments indicated that direct recruitment of CBP is sufficient for activation of the dhfr promoter. Therefore, we suggest that recruitment of CBP is one mechanism by which E2F activates the dhfr promoter.	Univ Wisconsin, Sch Med, Mcardle Lab Canc Res, Madison, WI 53706 USA; Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada	University of Wisconsin System; University of Wisconsin Madison; University of Toronto	Farnham, PJ (corresponding author), Univ Wisconsin, Sch Med, Mcardle Lab Canc Res, 1400 Univ Ave, Madison, WI 53706 USA.			Pearson, Angela/0000-0002-5997-2846; Farnham, Peggy/0000-0003-4469-7914	NCI NIH HHS [CA07175, CA45240, CA09135] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009135, R29CA045240, R01CA045240, P30CA007175] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; BARLEV NA, 1995, J BIOL CHEM, V270, P19337, DOI 10.1074/jbc.270.33.19337; BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; Blau J, 1996, MOL CELL BIOL, V16, P2044; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Chiang YC, 1996, J BIOL CHEM, V271, P32359, DOI 10.1074/jbc.271.50.32359; Cho H, 1998, MOL CELL BIOL, V18, P5355, DOI 10.1128/MCB.18.9.5355; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DAS G, 1995, NATURE, V374, P657, DOI 10.1038/374657a0; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; EMAMI KH, 1995, MOL CELL BIOL, V15, P5906; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; FISCHER L, 1992, SCIENCE, V257, P1392, DOI 10.1126/science.1529339; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067; Fry CJ, 1997, MOL CELL BIOL, V17, P1966, DOI 10.1128/MCB.17.4.1966; FUJII H, 1992, FEBS LETT, V314, P33, DOI 10.1016/0014-5793(92)81455-U; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; Goldman PS, 1997, RECENT PROG HORM RES, V52, P103; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; HAGEMEIER C, 1993, NUCLEIC ACIDS RES, V21, P4998, DOI 10.1093/nar/21.22.4998; Hampsey M, 1998, MICROBIOL MOL BIOL R, V62, P465, DOI 10.1128/MMBR.62.2.465-503.1998; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; Ichinose H, 1997, GENE, V188, P95, DOI 10.1016/S0378-1119(96)00785-8; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; JEONG SW, 1994, NUCLEIC ACIDS RES, V22, P370, DOI 10.1093/nar/22.3.370; Johnson DG, 1998, FRONT BIOSCI, V3, pd447; Kobayashi N, 1998, MOL CELL BIOL, V18, P4023, DOI 10.1128/MCB.18.7.4023; KOLLMAR R, 1994, J BIOL CHEM, V269, P2252; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LI Y, 1994, MOL CELL BIOL, V14, P1861, DOI 10.1128/MCB.14.3.1861; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Majello B, 1998, J BIOL CHEM, V273, P16509, DOI 10.1074/jbc.273.26.16509; Maniatis T., 1982, MOL CLONING LAB MANU; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; Martinez-Balbas MA, 1998, EMBO J, V17, P2886, DOI 10.1093/emboj/17.10.2886; McEwan IJ, 1996, BIOCHEMISTRY-US, V35, P9584, DOI 10.1021/bi960793v; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; MEANS AL, 1990, MOL CELL BIOL, V10, P653, DOI 10.1128/MCB.10.2.653; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; Morkel M, 1997, NATURE, V390, P567, DOI 10.1038/37507; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; OZER J, 1994, GENE DEV, V8, P2324, DOI 10.1101/gad.8.19.2324; Parker D, 1996, MOL CELL BIOL, V16, P694; Pearson A, 1997, ONCOGENE, V15, P2643, DOI 10.1038/sj.onc.1201451; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; Radhakrishnan I, 1997, CELL, V91, P741, DOI 10.1016/S0092-8674(00)80463-8; REGIER JL, 1993, P NATL ACAD SCI USA, V90, P883, DOI 10.1073/pnas.90.3.883; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SCHILLING LJ, 1995, CELL GROWTH DIFFER, V6, P541; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SILVERMAN N, 1994, P NATL ACAD SCI USA, V91, P11665, DOI 10.1073/pnas.91.24.11665; SLANSKY J, 1995, THESIS U WISCONSIN M; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; Snowden AW, 1998, BIOCHEM PHARMACOL, V55, P1947, DOI 10.1016/S0006-2952(98)00020-3; SRUHL K, 1998, GENE DEV, V12, P599; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; Tanese N, 1996, P NATL ACAD SCI USA, V93, P13611, DOI 10.1073/pnas.93.24.13611; Trimarchi JM, 1998, P NATL ACAD SCI USA, V95, P2850, DOI 10.1073/pnas.95.6.2850; Trouche D, 1996, NUCLEIC ACIDS RES, V24, P4139, DOI 10.1093/nar/24.21.4139; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; Wells J, 1996, MOL CELL BIOL, V16, P634; Wu DY, 1996, J VIROL, V70, P6020, DOI 10.1128/JVI.70.9.6020-6028.1996; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; Xiao H, 1997, MOL CELL BIOL, V17, P6898, DOI 10.1128/MCB.17.12.6898; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; ZHU H, 1994, J BIOL CHEM, V269, P3489	81	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15883	15891		10.1074/jbc.274.22.15883	http://dx.doi.org/10.1074/jbc.274.22.15883			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336493	hybrid			2022-12-25	WOS:000080560100082
J	Lo Surdo, P; Bottomley, MJ; Arcaro, A; Siegal, G; Panayotou, G; Sankar, A; Gaffney, PRJ; Riley, AM; Potter, BVL; Waterfield, MD; Driscoll, PC				Lo Surdo, P; Bottomley, MJ; Arcaro, A; Siegal, G; Panayotou, G; Sankar, A; Gaffney, PRJ; Riley, AM; Potter, BVL; Waterfield, MD; Driscoll, PC			Structural and biochemical evaluation of the interaction of the phosphatidylinositol 3-kinase p85 alpha src homology 2 domains with phosphoinositides and inositol polyphosphates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL SH2 DOMAIN; PROTEIN-KINASE-B; RECEPTOR TYROSINE KINASES; PHOSPHOLIPASE C-GAMMA; ESCHERICHIA-COLI; NMR TECHNIQUES; BINDING; ACTIVATION; 3,4,5-TRISPHOSPHATE; SPECIFICITY	Src homology 2 (SH2) domains exist in many intracellular proteins and have well characterized roles in signal transduction. SH2 domains bind to phosphotyrosine (Tyr(P))-containing proteins. Although tyrosine phosphorylation is essential for protein-SHE domain interactions, the binding specificity also derives from sequences C-terminal to the Tyr(P) residue. The high affinity and specificity of this interaction is critical for precluding aberrant cross-talk between signaling pathways. The p85 alpha subunit of phosphoinositide S-kinase (PI 3-kinase) contains two SH2 domains, and it has been proposed that in competition with Tyr(P) binding they may also mediate membrane attachment via interactions with phosphoinositide products of PI 3-kinase. We used nuclear magnetic resonance spectroscopy and biosensor experiments to investigate interactions between the p85 alpha SH2 domains and phosphoinositides or inositol polyphosphates. We reported previously a similar approach when demonstrating that some pleckstrin homology domains show binding specificity for distinct phosphoinositides (Salim, K., Bottomley, M. J., Querfurth, E., Zvelebil, M. J., Gout, I., Scaife, R., Margolis, R. L., Gigg, R., Smith, C. I., Driscoll, P. C., Waterfield, M. D., and Panayotou, G. (1996) EMBO J. 15, 6241-6250). However, neither SH2 domain exhibited binding specificity for phosphoinositides in phospholipid bilayers. We show that the p85 alpha SH2 domain Tyr(P) binding pockets indiscriminately accommodate phosphoinositides and inositol polyphosphates. Binding of the SH2 domains to Tyr(P) peptides was only poorly competed for by phosphoinositides or inositol polyphosphates. We conclude that these ligands do not bind p85 alpha SH2 domains with high affinity or specificity. Moreover, we observed that although wortmannin blocks PI S-kinase activity in vivo, it does not affect the ability of tyrosine-phosphorylated proteins to bind to p85 alpha. Consequently phosphoinositide prodcts of PI 3 kinase are unlikely to regulate signaling through p85 alpha SH2 domains.	UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England; Univ London Univ Coll, Dept Chem, London WC1H 0AJ, England; Univ Bath, Dept Pharm & Pharmacol, Bath BA2 7AY, Avon, England; Ludwig Inst Canc Res, London W1P 8BT, England	University of London; University College London; University of London; University College London; University of Bath; Ludwig Institute for Cancer Research	Driscoll, PC (corresponding author), UCL, Dept Biochem & Mol Biol, Gower St, London WC1E 6BT, England.	driscoll@biochem.ucl.ac.uk	Driscoll, Paul C/B-8007-2010; Riley, Andrew M/F-3526-2013; Arcaro, Alexandre/G-1711-2010; Potter, Barry/AAX-4781-2020; Potter, Barry VL/A-1845-2012	Driscoll, Paul C/0000-0002-4124-6950; Riley, Andrew M/0000-0001-9003-3540; Arcaro, Alexandre/0000-0001-9107-2947; Siegal, Gregg/0000-0003-3806-4811				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; Bae YS, 1998, J BIOL CHEM, V273, P4465, DOI 10.1074/jbc.273.8.4465; Billeter M, 1995, J BIOMOL NMR, V5, P1; BOOKER GW, 1992, NATURE, V358, P684, DOI 10.1038/358684a0; Bottomley MJ, 1998, BBA-MOL CELL BIOL L, V1436, P165, DOI 10.1016/S0005-2760(98)00141-6; Breeze AL, 1996, EMBO J, V15, P3579, DOI 10.1002/j.1460-2075.1996.tb00727.x; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DESAI T, 1996, SYNTHESIS LIPID CHEM, P67; Downward J, 1998, SCIENCE, V279, P673, DOI 10.1126/science.279.5351.673; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; Fukuda M, 1996, J BIOL CHEM, V271, P30303, DOI 10.1074/jbc.271.48.30303; Gaffney PRJ, 1997, BIOORG MED CHEM LETT, V7, P3171, DOI 10.1016/S0960-894X(97)10166-4; Gunther UL, 1996, BIOCHEMISTRY-US, V35, P15570, DOI 10.1021/bi961783x; HENSMANN M, 1994, PROTEIN SCI, V3, P1020, DOI 10.1002/pro.5560030704; Isakoff SJ, 1998, EMBO J, V17, P5374, DOI 10.1093/emboj/17.18.5374; James SR, 1996, BIOCHEM J, V315, P709, DOI 10.1042/bj3150709; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; Kavran JM, 1998, J BIOL CHEM, V273, P30497, DOI 10.1074/jbc.273.46.30497; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nolte RT, 1996, NAT STRUCT BIOL, V3, P364, DOI 10.1038/nsb0496-364; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; OTTING G, 1993, CURR OPIN STRUC BIOL, V3, P760, DOI 10.1016/0959-440X(93)90061-O; PANAYOTOU G, 1993, MOL CELL BIOL, V13, P3567, DOI 10.1128/MCB.13.6.3567; PANAYOTOU G, 1993, BIOESSAYS, V15, P171, DOI 10.1002/bies.950150305; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PICCIONE E, 1993, BIOCHEMISTRY-US, V32, P3197, DOI 10.1021/bi00064a001; POTTER BVL, 1995, ANGEW CHEM INT EDIT, V34, P1933, DOI 10.1002/anie.199519331; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; Riley AM, 1997, ANGEW CHEM INT EDIT, V36, P1472, DOI 10.1002/anie.199714721; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; Siegal G, 1998, J MOL BIOL, V276, P461, DOI 10.1006/jmbi.1997.1562; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; VANNULAND NAJ, 1993, FEBS LETT, V315, P11, DOI 10.1016/0014-5793(93)81122-G; Wang DS, 1998, J ORG CHEM, V63, P5430, DOI 10.1021/jo980356h; WYMANN M, 1994, BIOCHEM J, V298, P517, DOI 10.1042/bj2980517; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413	49	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15678	15685		10.1074/jbc.274.22.15678	http://dx.doi.org/10.1074/jbc.274.22.15678			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336465	Green Published, hybrid			2022-12-25	WOS:000080560100054
J	Makino, Y; Kanemaki, M; Kurokawa, Y; Koji, T; Tamura, TA				Makino, Y; Kanemaki, M; Kurokawa, Y; Koji, T; Tamura, TA			A rat RuvB-like protein, TIP49a, is a germ cell-enriched novel DNA helicase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-II HOLOENZYME; RNA-POLYMERASE; MEIOTIC CHROMOSOMES; STRAND EXCHANGE; MOUSE TESTIS; RECOMBINATION; REPAIR; RECA; EXPRESSION; COMPLEX	We have isolated a novel nuclear protein with a molecular mass of 49 kDa (TIP49a) from rat liver. The rat TIP49a showed structural resemblance to several bacterial RuvBs and also displayed Walker A and B motifs, We overproduced the recombinant TIP49a in Escherichia coli and purified it to near homogeneity. Biochemical investigations demonstrated that TIP49a possessed ATPase activity that was stimulated by single-stranded DNA but neither by double-stranded DNA nor by any forms of RNA polymers tested. Moreover, a UV cross-linking assay indicated TIP49a specifically interacted with ATP, Interestingly, we found that DNA duplex was unwound by the recombinant TIP49a in the presence of ATP or dATP. Optimal concentrations of ATP and Mg2+ for the helicase activity were 1-2 mM and 0.25-1 mM, respectively. Displacement of the DNA strand occurred in the 3' to 5' direction with respect to the single-stranded DNA flanking the duplex. Western blot analysis revealed that TIP49a was abundantly expressed in testes and moderately in spleen, thymus, and lung. In mouse seminiferous tubules, the protein was restrictively observed in germ lineages from late pachytene spermatocytes to round spermatids. From these observations, we propose that TIP49a is a novel DNA helicase and may play a role in nuclear processes such as recombination and transcription.	Chiba Univ, Fac Sci, Dept Biol, Inage Ku, Chiba 2638522, Japan; Nagasaki Univ, Sch Med, Dept Histol & Cell Biol, Nagasaki 8528523, Japan; CREST Japan Sci & Technol Corp, Kawaguchi 3320012, Japan	Chiba University; Nagasaki University; Japan Science & Technology Agency (JST)	Tamura, TA (corresponding author), Chiba Univ, Fac Sci, Dept Biol, Inage Ku, 1-33 Yayoi Cho, Chiba 2638522, Japan.	btamura@nature.s.chiba-u.ac.jp						Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; ARMON T, 1990, J BIOL CHEM, V265, P20723; Baker SM, 1996, NAT GENET, V13, P336, DOI 10.1038/ng0796-336; Ellis NA, 1997, CURR OPIN GENET DEV, V7, P354, DOI 10.1016/S0959-437X(97)80149-9; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GOTO M, 1990, EXP CELL RES, V186, P273, DOI 10.1016/0014-4827(90)90306-U; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; Holzmann K, 1998, BIOCHEM BIOPH RES CO, V252, P39, DOI 10.1006/bbrc.1998.9604; Ikeya T, 1996, GENES CELLS, V1, P379, DOI 10.1046/j.1365-2443.1996.d01-249.x; Kanemaki M, 1997, BIOCHEM BIOPH RES CO, V235, P64, DOI 10.1006/bbrc.1997.6729; KOJI T, 1992, CELL BIOCHEM FUNCT, V10, P273, DOI 10.1002/cbf.290100411; Kurokawa Y, 1999, DNA SEQUENCE, V10, P37, DOI 10.3109/10425179909033934; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; Makino Y, 1998, BIOCHEM BIOPH RES CO, V245, P819, DOI 10.1006/bbrc.1998.8504; Makino Y, 1997, J BIOL CHEM, V272, P23201, DOI 10.1074/jbc.272.37.23201; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; MATSON SW, 1994, BIOESSAYS, V16, P13, DOI 10.1002/bies.950160103; PAUSE A, 1992, EMBO J, V11, P2643, DOI 10.1002/j.1460-2075.1992.tb05330.x; Qiu XB, 1998, J BIOL CHEM, V273, P27786, DOI 10.1074/jbc.273.43.27786; Roeder GS, 1997, GENE DEV, V11, P2600, DOI 10.1101/gad.11.20.2600; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Seitz EM, 1998, GENE DEV, V12, P1248, DOI 10.1101/gad.12.9.1248; Shinagawa H, 1996, TRENDS BIOCHEM SCI, V21, P107, DOI 10.1016/0968-0004(96)10014-1; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; Svejstrup JQ, 1996, TRENDS BIOCHEM SCI, V21, P346, DOI 10.1016/0968-0004(96)10046-3; TSANEVA IR, 1993, P NATL ACAD SCI USA, V90, P1315, DOI 10.1073/pnas.90.4.1315; TUTEJA N, 1991, NUCLEIC ACIDS RES, V19, P3613, DOI 10.1093/nar/19.13.3613; West SC, 1996, CELL, V86, P177, DOI 10.1016/S0092-8674(00)80088-4; WORLEY KC, 1995, GENOME RES, V5, P173, DOI 10.1101/gr.5.2.173	33	70	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15329	15335		10.1074/jbc.274.22.15329	http://dx.doi.org/10.1074/jbc.274.22.15329			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336418	hybrid			2022-12-25	WOS:000080560100007
J	Treuner, K; Findeisen, M; Strausfeld, U; Knippers, R				Treuner, K; Findeisen, M; Strausfeld, U; Knippers, R			Phosphorylation of replication protein a middle subunit (RPA32) leads to a disassembly of the RPA heterotrimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING-PROTEIN; NUCLEOTIDE EXCISION-REPAIR; A PHOSPHORYLATION; CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; P34 SUBUNIT; IN-VITRO; S-PHASE; KINASE; CDC2	Replication protein A (RPA), the major eukaryotic single-strand specific DNA binding protein, consists of three subunits, RPA70, RPA32, and RPA14. The middle subunit, RPA32, is phosphorylated in a cell cycle-dependent manner. RPA occurs in two nuclear compartments, bound to chromatin or free in the nucleosol, We show here that the chromatin-associated fraction of RPA contains the phosphorylated forms of RPA32, Treatment of chromatin with 0.4 hr NaCl releases bound RPA and causes a separation of the large and the phosphorylated middle RPA subunit, Unmodified RPA in the nucleosolic fraction remains perfectly stable under identical conditions. Phosphorylation is most likely an important determinant of RPA desintegration because dialysis from 0.4 to 0.1 NaCl causes the reformation of trimeric RPA only under dephosphorylating conditions, Biochemical studies with isolated Cyclin-dependent protein kinases showed that cyclin A/CDK1 and cyclin B/CDK1, but not cyclin E/CDK2, can phosphorylate human recombinant RPA in vitro, However, only a small fraction of in vitro phosphorylated RPA desintegrated, suggesting that phosphorylation may be one, but probably not the only, determinant affecting subunit interaction. We speculate that phosphorylation and changes in subunit interaction are required for the proposed role of RPA during the polymerase switch at replication forks.	Univ Konstanz, Dept Biol, D-78457 Constance, Germany	University of Konstanz	Knippers, R (corresponding author), Univ Konstanz, Dept Biol, D-78457 Constance, Germany.	rolf.knippers@uni-konstanz.de						ADAM SA, 1992, METHOD ENZYMOL, V219, P97; Blackwell LJ, 1996, MOL CELL BIOL, V16, P4798; Bochkarev A, 1997, NATURE, V385, P176, DOI 10.1038/385176a0; BOUBNOV NV, 1995, MOL CELL BIOL, V15, P5700; Brill SJ, 1998, MOL CELL BIOL, V18, P7225, DOI 10.1128/MCB.18.12.7225; Brush GS, 1996, P NATL ACAD SCI USA, V93, P15075, DOI 10.1073/pnas.93.26.15075; CARDOSO MC, 1993, CELL, V74, P979, DOI 10.1016/0092-8674(93)90721-2; CARTY MP, 1994, EMBO J, V13, P2114, DOI 10.1002/j.1460-2075.1994.tb06487.x; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; COVERLEY D, 1992, NUCLEIC ACIDS RES, V20, P3873, DOI 10.1093/nar/20.15.3873; de Laat WL, 1998, GENE DEV, V12, P2598, DOI 10.1101/gad.12.16.2598; DUTTA A, 1992, EMBO J, V11, P2189, DOI 10.1002/j.1460-2075.1992.tb05278.x; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; FANG F, 1993, J CELL SCI, V106, P983; Fried LM, 1996, P NATL ACAD SCI USA, V93, P13825, DOI 10.1073/pnas.93.24.13825; HANCOCK R, 1974, J MOL BIOL, V86, P649, DOI 10.1016/0022-2836(74)90187-9; Harlow E., 1988, ANTIBODIES LAB MANUA; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P24203; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; Henricksen LA, 1996, NUCLEIC ACIDS RES, V24, P3107, DOI 10.1093/nar/24.15.3107; HEYER WD, 1990, EMBO J, V9, P2321, DOI 10.1002/j.1460-2075.1990.tb07404.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEE SH, 1995, J BIOL CHEM, V270, P12801, DOI 10.1074/jbc.270.21.12801; LIU VF, 1993, MOL CELL BIOL, V13, P7222, DOI 10.1128/MCB.13.12.7222; Mass G, 1998, MOL CELL BIOL, V18, P6399, DOI 10.1128/MCB.18.11.6399; MOORE SP, 1991, P NATL ACAD SCI USA, V88, P9067, DOI 10.1073/pnas.88.20.9067; Murti KG, 1996, EXP CELL RES, V223, P279, DOI 10.1006/excr.1996.0083; Niu HW, 1997, J BIOL CHEM, V272, P12634, DOI 10.1074/jbc.272.19.12634; PAN ZQ, 1994, P NATL ACAD SCI USA, V91, P8343, DOI 10.1073/pnas.91.18.8343; PAULOVICH AG, 1995, CELL, V82, P841, DOI 10.1016/0092-8674(95)90481-6; Philipova D, 1996, GENE DEV, V10, P2222, DOI 10.1101/gad.10.17.2222; Ritzi M, 1998, J BIOL CHEM, V273, P24543, DOI 10.1074/jbc.273.38.24543; SALAHUDDIN, 1990, GENE DEV, V4, P968, DOI 10.1101/gad.4.6.968; Schwab BL, 1998, EXP CELL RES, V238, P415, DOI 10.1006/excr.1997.3850; SEROUSSI E, 1993, J BIOL CHEM, V268, P7147; SINGH KK, 1995, P NATL ACAD SCI USA, V92, P4907, DOI 10.1073/pnas.92.11.4907; Strausfeld UP, 1996, J CELL SCI, V109, P1555; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Treuner K, 1999, NUCLEIC ACIDS RES, V27, P1499, DOI 10.1093/nar/27.6.1499; Treuner K, 1998, J BIOL CHEM, V273, P31744, DOI 10.1074/jbc.273.48.31744; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; WOLD MS, 1987, P NATL ACAD SCI USA, V84, P3643, DOI 10.1073/pnas.84.11.3643; Yuzhakov A, 1999, CELL, V96, P153, DOI 10.1016/S0092-8674(00)80968-X	46	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15556	15561		10.1074/jbc.274.22.15556	http://dx.doi.org/10.1074/jbc.274.22.15556			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336450	hybrid			2022-12-25	WOS:000080560100039
J	Hama, H; Tall, GG; Horazdovsky, BF				Hama, H; Tall, GG; Horazdovsky, BF			Vps9p is a guanine nucleotide exchange factor involved in vesicle-mediated vacuolar protein transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; GDP-DISSOCIATION INHIBITOR; LYSOSOME-LIKE VACUOLE; SACCHAROMYCES-CEREVISIAE; SECRETORY PATHWAY; RAB-GTPASES; GDP/GTP EXCHANGE; MEMBRANE ASSOCIATION; ACTIVATING PROTEIN; SORTING RECEPTOR	Vacuolar protein sorting (vps) mutants of Saccharomyces cerevisiae missort and secrete vacuolar hydrolases, The gene affected in one of these mutants, VPS21, encodes a member of the Sec4/Ypt/Rab family of small GTPases. Rab proteins play an essential role in vesicle-mediated protein transport. Using both yeast two-hybrid assays and chemical cross-linking, we have identified another VPS gene product, Vps9p, that preferentially interacts with a mutant form of Vps21p-S21N that binds GDP but not GTP. In vitro purified Vps9p was found to stimulate GDP release hom Vps21p in a dose-dependent manner, Vps9p also stimulated GTP association as a result of facilitated GDP release. How ever Vps9p did not stimulate guanine nucleotide exchange of GTP-bound Vps21p or GTP hydrolysis. me tested the ability of Vps9p to stimulate the intrinsic guanine nucleotide exchange activity of Rab5, which is a mammalian sequence homologue of Vps21p, and Ypt7p, which is another yeast Rab protein involved in vacuolar protein transport, Rab5, but not Ypt7p was responsive to Vps9p, which indicates that Vps9p recognizes sequence variation among Rab proteins. We conclude that Vps9p is a novel guanine nucleotide exchange factor that is specific for Vps21p/Rab5. Since there are no obvious Vps9p sequence homologues in yeast, Vps9p may also possess unique regulatory functions required for vacuolar protein transport.	Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Horazdovsky, BF (corresponding author), Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA.				NIGMS NIH HHS [GM-55301] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXANDROV K, 1994, EMBO J, V13, P5262, DOI 10.1002/j.1460-2075.1994.tb06860.x; BANKAITIS VA, 1986, P NATL ACAD SCI USA, V83, P9075, DOI 10.1073/pnas.83.23.9075; BANROQUES J, 1986, CELL, V46, P837, DOI 10.1016/0092-8674(86)90065-6; Becherer KA, 1996, MOL BIOL CELL, V7, P579, DOI 10.1091/mbc.7.4.579; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BISCHOFF FR, 1991, P NATL ACAD SCI USA, V88, P10830, DOI 10.1073/pnas.88.23.10830; Burd CG, 1996, MOL CELL BIOL, V16, P2369; Burd CG, 1997, MOL BIOL CELL, V8, P1089, DOI 10.1091/mbc.8.6.1089; BURTON JL, 1994, EMBO J, V13, P5547, DOI 10.1002/j.1460-2075.1994.tb06892.x; CASADABAN MJ, 1983, METHOD ENZYMOL, V100, P293; Chen YJ, 1996, EUR J CELL BIOL, V70, P289; Collins RN, 1997, J BIOL CHEM, V272, P18281, DOI 10.1074/jbc.272.29.18281; COWLES CR, 1994, J CELL SCI, V107, P3449; DiracSvejstrup AB, 1997, EMBO J, V16, P465, DOI 10.1093/emboj/16.3.465; DUNN SD, 1986, ANAL BIOCHEM, V157, P144, DOI 10.1016/0003-2697(86)90207-1; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; Horazdovsky BF, 1996, J BIOL CHEM, V271, P33607, DOI 10.1074/jbc.271.52.33607; HORAZDOVSKY BF, 1995, CURR OPIN CELL BIOL, V7, P544, DOI 10.1016/0955-0674(95)80012-3; HORAZDOVSKY BF, 1994, EMBO J, V13, P1297, DOI 10.1002/j.1460-2075.1994.tb06382.x; HORAZDOVSKY BF, 1989, J BACTERIOL, V171, P3053, DOI 10.1128/jb.171.6.3053-3059.1989; Horazdovsky BF, 1997, MOL BIOL CELL, V8, P1529, DOI 10.1091/mbc.8.8.1529; Horiuchi H, 1997, CELL, V90, P1149, DOI 10.1016/S0092-8674(00)80380-3; JULLIENFLORES V, 1995, J BIOL CHEM, V270, P22473, DOI 10.1074/jbc.270.38.22473; LAI CC, 1993, MOL CELL BIOL, V13, P1345, DOI 10.1128/MCB.13.3.1345; Miller J.H., 1972, EXPT MOL GENETICS; MOYA M, 1993, NATURE, V361, P460, DOI 10.1038/361460a0; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PFEFFER SR, 1995, J BIOL CHEM, V270, P17057, DOI 10.1074/jbc.270.29.17057; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; PIPER RC, 1994, EUR J CELL BIOL, V65, P305; RAYMOND CK, 1992, MOL BIOL CELL, V3, P1389, DOI 10.1091/mbc.3.12.1389; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; ROMERO G, 1985, J BIOL CHEM, V260, P6167; Rosa JL, 1996, EMBO J, V15, P4262, DOI 10.1002/j.1460-2075.1996.tb00801.x; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; ROTHMAN JH, 1989, EMBO J, V8, P2057, DOI 10.1002/j.1460-2075.1989.tb03614.x; ROTHMAN JH, 1986, CELL, V47, P1041, DOI 10.1016/0092-8674(86)90819-6; SASAKI T, 1990, J BIOL CHEM, V265, P2333; Sherman F, 1979, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; SINGERKRUGER B, 1994, J CELL BIOL, V125, P283, DOI 10.1083/jcb.125.2.283; Sprang SR, 1998, CELL, V95, P155, DOI 10.1016/S0092-8674(00)81746-8; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Stack JH, 1995, ANNU REV CELL DEV BI, V11, P1; STACK JH, 1993, EMBO J, V12, P2195, DOI 10.1002/j.1460-2075.1993.tb05867.x; STROM M, 1993, NATURE, V361, P736, DOI 10.1038/361736a0; ULLRICH O, 1994, NATURE, V368, P157, DOI 10.1038/368157a0; ULLRICH O, 1993, J BIOL CHEM, V268, P18143; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Wada M, 1997, J BIOL CHEM, V272, P3875, DOI 10.1074/jbc.272.7.3875; WalchSolimena C, 1997, J CELL BIOL, V137, P1495, DOI 10.1083/jcb.137.7.1495; WICHMANN H, 1992, CELL, V71, P1131, DOI 10.1016/S0092-8674(05)80062-5	58	110	114	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					15284	15291		10.1074/jbc.274.21.15284	http://dx.doi.org/10.1074/jbc.274.21.15284			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329739	hybrid			2022-12-25	WOS:000081965200104
J	Holz, B; Dank, N; Eickhoff, JE; Lipps, G; Krauss, G; Weinhold, E				Holz, B; Dank, N; Eickhoff, JE; Lipps, G; Krauss, G; Weinhold, E			Identification of the binding site for the extrahelical target base in N-6-adenine DNA methyltransferases by photo-cross-linking with duplex oligodeoxyribonucleotides containing 5-iodouracil at the target position	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL-RNA METHYLTRANSFERASE; CRYSTAL-STRUCTURE; ANTIBIOTIC-RESISTANCE; S-ADENOSYLMETHIONINE; TAQ-I; PROTEINS; COMPLEX; DOMAIN; RESTRICTION; MISMATCHES	DNA methyltransferases flip their target bases out of the DNA double helix for catalysis. Base flipping of C-5-cytosine DNA methyltransferases was directly observed in the protein-DNA cocrystal structures of M.HhaI and M.HaeIII. Indirect structural evidence for base flipping of N-6-adenine and N-4-cytosine DNA methyltransferases was obtained by modeling DNA into the three-dimensional structures of M.TaqI and M.PvuII in complex with the cofactor. In addition, biochemical evidence of base flipping was reported for different N-6-adenine DNA methyltransferases. As no protein-DNA cocrystal structure for the related N-6-adenine and N-4-cytosine DNA methyltransferases is available, we used light-induced photochemical cross-linking to identify the binding site of the extrahelical target bases, The N-6-adenine DNA methyltransferases M.TaqI and M.CviBIII, which both methylate adenine within the double-stranded 5'-TCGA-3' DNA sequence, were photo cross-linked to duplex oligodeoxyribonucleotides containing 5-iodouracil at the target position in 50-60% and almost quantitative yield, respectively. Proteolytic fragmentation of the M.CviBIII-DNA complex followed by Edman degradation and electrospray ionization mass spectrometry indicates photo-cross-linking to tyrosine 122. In addition, the mutant methyltransferases M.TaqI/Y108A and MTaqI/F196A were photo-cross-linked with 6-fold and 2-fold reduced efficiency, respectively, which suggests that tyrosine 108 is the primary site of modification in M.TaqI. Our results indicate a close proximity between the extrahelical target base and tyrosine 122 in M.CviBIII or tyrosine 108 in M.TaqI. As both residues belong to the conserved motif IV ((N/D/S)(P/I)P(Y/F/W)) found in all N-6-adenine and N-4-cytosine DNA as well as in N-6-adenine RNA methyltransferases, a similar spatial relationship between the target bases and the aromatic amino acid residue within motif IV is expected for all these methyltransferases.	Max Planck Inst Mol Physiol, Phys Biochem Abt, D-44227 Dortmund, Germany; Univ Bayreuth, Biochem Lab, D-95440 Bayreuth, Germany	Max Planck Society; University of Bayreuth	Weinhold, E (corresponding author), Max Planck Inst Mol Physiol, Phys Biochem Abt, Otto Hahn Str 11, D-44227 Dortmund, Germany.							ABAGYAN R, 1994, J COMPUT CHEM, V15, P488, DOI 10.1002/jcc.540150503; ADAMS RLP, 1985, MOL BIOL DNA METHYLA, P3; Allan BW, 1998, J BIOL CHEM, V273, P2368, DOI 10.1074/jbc.273.4.2368; Allan BW, 1996, BIOCHEMISTRY-US, V35, P14757, DOI 10.1021/bi9615708; BARANY F, 1992, GENE, V112, P91, DOI 10.1016/0378-1119(92)90307-B; BARRAS F, 1989, TRENDS GENET, V5, P139, DOI 10.1016/0168-9525(89)90054-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bussiere DE, 1998, BIOCHEMISTRY-US, V37, P7103, DOI 10.1021/bi973113c; Cal S, 1997, J BIOL CHEM, V272, P490; Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779; CHENG XD, 1995, ANNU REV BIOPH BIOM, V24, P293, DOI 10.1146/annurev.bb.24.060195.001453; Ferrer E, 1997, BIOCONJUGATE CHEM, V8, P757, DOI 10.1021/bc970042l; Gong WM, 1997, NUCLEIC ACIDS RES, V25, P2702, DOI 10.1093/nar/25.14.2702; Heitman J, 1993, Genet Eng (N Y), V15, P57; Holz B, 1998, NUCLEIC ACIDS RES, V26, P1076, DOI 10.1093/nar/26.4.1076; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JOST JP, 1993, DNA METHYLATION MOL; KLIMASAUSKAS S, 1995, NUCLEIC ACIDS RES, V23, P1388, DOI 10.1093/nar/23.8.1388; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; LABAHN J, 1994, P NATL ACAD SCI USA, V91, P10957, DOI 10.1073/pnas.91.23.10957; LeCuyer KA, 1996, EMBO J, V15, P6847, DOI 10.1002/j.1460-2075.1996.tb01076.x; MALONE T, 1995, J MOL BIOL, V253, P618, DOI 10.1006/jmbi.1995.0577; Meisenheimer KM, 1997, CRIT REV BIOCHEM MOL, V32, P101, DOI 10.3109/10409239709108550; NARVA KE, 1987, NUCLEIC ACIDS RES, V15, P9807, DOI 10.1093/nar/15.23.9807; NARVA KE, 1988, GENE, V74, P253, DOI 10.1016/0378-1119(88)90298-3; Norris CL, 1996, J AM CHEM SOC, V118, P5796, DOI 10.1021/ja9607852; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; Pues H, 1999, BIOCHEMISTRY-US, V38, P1426, DOI 10.1021/bi9818016; REINISCH KM, 1995, CELL, V82, P143, DOI 10.1016/0092-8674(95)90060-8; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHLUCKEBIER G, 1995, GENE, V157, P131, DOI 10.1016/0378-1119(94)00690-T; Schluckebier G, 1997, J MOL BIOL, V265, P56, DOI 10.1006/jmbi.1996.0711; SCHLUCKEBIER G, 1995, J MOL BIOL, V247, P16, DOI 10.1006/jmbi.1994.0117; Serva S, 1998, NUCLEIC ACIDS RES, V26, P3473, DOI 10.1093/nar/26.15.3473; SLATKO BE, 1987, NUCLEIC ACIDS RES, V15, P9781, DOI 10.1093/nar/15.23.9781; STUMP WT, 1995, RNA, V1, P55; VALEGARD K, 1994, NATURE, V371, P623, DOI 10.1038/371623a0; WILLIAMS KR, 1991, METHOD ENZYMOL, V208, P516; WILLIS MC, 1993, SCIENCE, V262, P1255, DOI 10.1126/science.7694369; Wong DL, 1998, NUCLEIC ACIDS RES, V26, P645, DOI 10.1093/nar/26.2.645; YANG AS, 1995, NUCLEIC ACIDS RES, V23, P1380, DOI 10.1093/nar/23.8.1380; Yu LP, 1997, NAT STRUCT BIOL, V4, P483, DOI 10.1038/nsb0697-483	42	32	33	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					15066	15072		10.1074/jbc.274.21.15066	http://dx.doi.org/10.1074/jbc.274.21.15066			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329711	hybrid			2022-12-25	WOS:000081965200076
J	Khanna, R; Chang, MC; Joiner, WJ; Kaczmarek, LK; Schlichter, LC				Khanna, R; Chang, MC; Joiner, WJ; Kaczmarek, LK; Schlichter, LC			hSK4/hIK1, a calmodulin-binding K-Ca channel in human T lymphocytes - Roles in proliferation and volume regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED POTASSIUM CHANNELS; SMALL-CONDUCTANCE; PROTEIN-KINASE; KV1.3 CHANNELS; CELL-VOLUME; CALCIUM; ANTAGONISTS; INHIBITION; EXPRESSION; MECHANISMS	Human T lymphocytes express a Ca2+-activated K+ current (IK), whose roles and regulation are poorly understood. We amplified hSK4 cDNA hom human T lymphoblasts, and we showed that its biophysical and pharmacological properties when stably expressed in Chinese hamster ovary cells were essentially identical to the native IK current. In activated lymphoblasts, hSK4 mRNA increased 14.6-fold (Kv1.3 mRNA increased 1.3-fold), with functional consequences. Proliferation was inhibited when Kv1.3 and IK were blocked in naive T cells, but IK block alone inhibited re-stimulated lymphoblasts. IK and Kv1.3 were involved in volume regulation, but IK was more important, particularly in lymphoblasts. hSK4 lacks known Ca2+-binding sites; however, we mapped a Ca2+-dependent calmodulin (CaM)-binding site to the proximal C terminus (Ct1) of hSK4. Full-length hSK4 produced a highly negative membrane potential (V-m) in Chinese hamster ovary cells, whereas the channels did not function when either Ctl or the distal C terminus was deleted (V-m similar to 0 mV). Native IK (but not expressed hSK4) current was inhibited by CaM and CaM kinase antagonists at physiological V-m values, suggesting modulation by an accessory molecule in native cells. Our results provide evidence for increased roles for IK/hSK4 in activated T cell functions; thus hSK4 may be a promising therapeutic target for disorders involving the secondary immune response.	Toronto Western Hosp, Univ Hlth Network, Playfair Neurosci Unit, Toronto, ON M5T 2S8, Canada; Toronto Western Hosp, Dept Physiol, Toronto, ON M5T 2S8, Canada; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Yale University; Yale University	Schlichter, LC (corresponding author), Toronto Western Hosp, Univ Hlth Network, Playfair Neurosci Unit, MC 11-417,399 Bathurst St, Toronto, ON M5T 2S8, Canada.	schlicht@playfair.utoronto.ca	Chang, Martin/J-2329-2016	Khanna, Rajesh/0000-0002-9066-2969	NIDCD NIH HHS [DC01919] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC001919] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		ALVAREZ J, 1992, J BIOL CHEM, V267, P11789; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; Chang M. C., 1996, Society for Neuroscience Abstracts, V22, P1444; Chapin SJ, 1996, J BIOL CHEM, V271, P1336, DOI 10.1074/jbc.271.3.1336; CHEUNG RK, 1983, J IMMUNOL, V131, P2291; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chung I, 1997, J MEMBRANE BIOL, V156, P73, DOI 10.1007/s002329900189; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.biochem.63.1.1045; DEUTSCH C, 1993, P NATL ACAD SCI USA, V90, P10036, DOI 10.1073/pnas.90.21.10036; GIETZEN K, 1981, BIOCHEM BIOPH RES CO, V101, P418, DOI 10.1016/0006-291X(81)91276-6; GRINSTEIN S, 1982, J GEN PHYSIOL, V79, P849, DOI 10.1085/jgp.79.5.849; GRINSTEIN S, 1990, ANNU REV PHYSIOL, V52, P399; GRISSMER S, 1992, J GEN PHYSIOL, V99, P63, DOI 10.1085/jgp.99.1.63; GRISSMER S, 1993, J GEN PHYSIOL, V102, P601, DOI 10.1085/jgp.102.4.601; Grunwald ME, 1998, J BIOL CHEM, V273, P9148, DOI 10.1074/jbc.273.15.9148; HAIT WN, 1986, J CLIN ONCOL, V4, P994, DOI 10.1200/JCO.1986.4.6.994; HANISSIAN SH, 1993, J BIOL CHEM, V268, P20055; Ishii TM, 1997, J BIOL CHEM, V272, P23195, DOI 10.1074/jbc.272.37.23195; Ishii TM, 1997, P NATL ACAD SCI USA, V94, P11651, DOI 10.1073/pnas.94.21.11651; Joiner WJ, 1997, P NATL ACAD SCI USA, V94, P11013, DOI 10.1073/pnas.94.20.11013; Khanna R, 1998, BIOPHYS J, V74, pA35; KIHIRA M, 1990, BRIT J PHARMACOL, V100, P353, DOI 10.1111/j.1476-5381.1990.tb15808.x; KLOCKNER U, 1987, AM J PHYSIOL, V253, pH1601, DOI 10.1152/ajpheart.1987.253.6.H1601; Kohler M, 1996, SCIENCE, V273, P1709, DOI 10.1126/science.273.5282.1709; Koo GC, 1997, J IMMUNOL, V158, P5120; Lang F, 1998, CELL PHYSIOL BIOCHEM, V8, P1, DOI 10.1159/000016269; LEWIS RS, 1995, ANNU REV IMMUNOL, V13, P623, DOI 10.1146/annurev.iy.13.040195.003203; LIN CS, 1993, J EXP MED, V177, P637, DOI 10.1084/jem.177.3.637; LINSE S, 1991, J BIOL CHEM, V266, P8050; Logsdon NJ, 1997, J BIOL CHEM, V272, P32723, DOI 10.1074/jbc.272.52.32723; MAHAUT-SMITH M P, 1989, Pfluegers Archiv European Journal of Physiology, V414, pS164, DOI 10.1007/BF00582284; MAHAUTSMITH MP, 1989, J PHYSIOL-LONDON, V415, P69, DOI 10.1113/jphysiol.1989.sp017712; MCCANN JD, 1987, J GEN PHYSIOL, V89, P339, DOI 10.1085/jgp.89.2.339; MCGANN LE, 1988, CYTOMETRY, V9, P33, DOI 10.1002/cyto.990090106; NAKABAYASHI H, 1992, BIOL CELL, V75, P55, DOI 10.1016/0248-4900(92)90124-J; PAHAPILL PA, 1990, J PHYSIOL-LONDON, V422, P103, DOI 10.1113/jphysiol.1990.sp017975; PRICE M, 1989, P NATL ACAD SCI USA, V86, P10171, DOI 10.1073/pnas.86.24.10171; REES RC, 1987, BIOSCIENCE REP, V7, P771, DOI 10.1007/BF01116749; SARKADI B, 1991, BIOCHIM BIOPHYS ACTA, V1071, P407, DOI 10.1016/0304-4157(91)90005-H; SCHLICHTER LC, 1993, RECEPTOR CHANNEL, V1, P201; SCHLICHTER LC, 1994, EXP CELL RES, V215, P211, DOI 10.1006/excr.1994.1334; Schlichter LC, 1997, CELL PHYSIOL BIOCHEM, V7, P159, DOI 10.1159/000154871; SCHLICHTER LC, 1992, PFLUG ARCH EUR J PHY, V421, P400, DOI 10.1007/BF00374232; Schreiber M, 1997, BIOPHYS J, V73, P1355, DOI 10.1016/S0006-3495(97)78168-2; SCHUMACHER PA, 1995, J MEMBRANE BIOL, V145, P217; Shao XG, 1996, SCIENCE, V273, P248, DOI 10.1126/science.273.5272.248; TANAKA T, 1982, MOL PHARMACOL, V22, P408; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315; Verheugen JAH, 1997, CELL PHYSIOL BIOCHEM, V7, P188, DOI 10.1159/000154874; VERHEUGEN JAH, 1995, CELL CALCIUM, V17, P287, DOI 10.1016/0143-4160(95)90075-6; Wadsworth JDF, 1997, ARCH BIOCHEM BIOPHYS, V346, P151, DOI 10.1006/abbi.1997.0280; WALSH M P, 1985, Reviews in Clinical and Basic Pharmacology, V5, P35; WEINSTEIN H, 1994, ANNU REV PHYSIOL, V56, P213, DOI 10.1146/annurev.ph.56.030194.001241; Weiss B, 1980, Ann N Y Acad Sci, V356, P319, DOI 10.1111/j.1749-6632.1980.tb29621.x; Xia XM, 1998, NATURE, V395, P503, DOI 10.1038/26758	56	199	209	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					14838	14849		10.1074/jbc.274.21.14838	http://dx.doi.org/10.1074/jbc.274.21.14838			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329683	hybrid			2022-12-25	WOS:000081965200048
J	Koppaka, V; Silvestro, L; Engler, JA; Brouillette, CG; Axelsen, PH				Koppaka, V; Silvestro, L; Engler, JA; Brouillette, CG; Axelsen, PH			The structure of human lipoprotein A-I - Evidence for the "belt" model"	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; CORONARY HEART-DISEASE; LIPID-FREE STRUCTURE; INFRARED-SPECTROSCOPY; TERMINAL DELETIONS; CONFORMATION; FLUORESCENCE; MEMBRANES; RECEPTOR; GENE	The two main competing models for the structure of discoidal lipoprotein A-I complexes both presume that the protein component is helical and situated around the perimeter of a lipid bilayer disc. However, the more popular "picket fence" model orients the protein helices perpendicular to the surface of the lipid bilayer, while the alternative "belt" model orients them parallel to the bilayer surface. To distinguish between these models, we have investigated the structure of human lipoprotein A-I using a novel form of polarized internal reflection infrared spectroscopy that can characterize the relative orientation of protein and lipid components in the lipoprotein complexes under native conditions. Our results verify lipid bilayer structure in the complexes and point unambiguously to the belt model.	Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med, Infect Dis Sect, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Johnson Fdn Mol Biophys, Philadelphia, PA 19104 USA; Univ Alabama, Med Ctr, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA; Univ Alabama, Med Ctr, Dept Physiol Opt, Ctr Macromol Crystallog, Birmingham, AL 35294 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Axelsen, PH (corresponding author), Univ Penn, Sch Med, Dept Pharmacol, 3620 Hamilton Walk, Philadelphia, PA 19104 USA.							Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ANDREWS AL, 1976, EUR J BIOCHEM, V64, P549, DOI 10.1111/j.1432-1033.1976.tb10335.x; AXELSEN PH, 1995, APPL SPECTROSC, V49, P526, DOI 10.1366/0003702953964273; Axelsen PH, 1995, BIOPHYS J, V69, P2770, DOI 10.1016/S0006-3495(95)80150-5; AXELSEN PH, 1997, PROG BIOPHYS MOL BIO, V66, P227; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; Borhani DW, 1997, P NATL ACAD SCI USA, V94, P12291, DOI 10.1073/pnas.94.23.12291; BRASSEUR R, 1990, BIOCHIM BIOPHYS ACTA, V1043, P245, DOI 10.1016/0005-2760(90)90023-Q; BROUILLETTE CG, 1984, BIOCHEMISTRY-US, V23, P359, DOI 10.1021/bi00297a027; BROUILLETTE CG, 1995, BBA-LIPID LIPID MET, V1256, P103, DOI 10.1016/0005-2760(95)00018-8; CHEUNG P, 1983, NUCLEIC ACIDS RES, V11, P3703, DOI 10.1093/nar/11.11.3703; Citra MJ, 1996, BIOPHYS J, V71, P1796, DOI 10.1016/S0006-3495(96)79380-3; FIELDING CJ, 1995, J LIPID RES, V36, P211; GLOMSET JA, 1968, J LIPID RES, V9, P155; GORDON T, 1977, AM J MED, V62, P707, DOI 10.1016/0002-9343(77)90874-9; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HOEKSTRA D, 1982, BIOCHEMISTRY-US, V21, P1055, DOI 10.1021/bi00534a036; HUGHES TA, 1988, J LIPID RES, V29, P363; JONAS A, 1987, PLASMA LIPOPROTEINS; MILLER NE, 1989, HIGH DENSITY LIPOPRO; Picard F, 1999, BIOPHYS J, V76, P539, DOI 10.1016/S0006-3495(99)77222-X; RHOADS GG, 1976, NEW ENGL J MED, V294, P293, DOI 10.1056/NEJM197602052940601; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; Rogers DP, 1998, BIOCHEMISTRY-US, V37, P945, DOI 10.1021/bi9713512; Rogers DP, 1998, BIOCHEMISTRY-US, V37, P11714, DOI 10.1021/bi973112k; Rogers DP, 1997, BIOCHEMISTRY-US, V36, P288, DOI 10.1021/bi961876e; SEGREST JP, 1992, J LIPID RES, V33, P141; Silvestro L, 1999, BIOCHEMISTRY-US, V38, P113, DOI 10.1021/bi981289o; Silvestro L, 1998, CHEM PHYS LIPIDS, V96, P69, DOI 10.1016/S0009-3084(98)00081-4; VANLOO B, 1995, J LIPID RES, V36, P1686; WALD JH, 1990, J BIOL CHEM, V265, P20044; White S. H., 1995, PERMEABILITY STABILI, P1; Wimley WC, 1998, J MOL BIOL, V277, P1091, DOI 10.1006/jmbi.1998.1640	33	124	129	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					14541	14544		10.1074/jbc.274.21.14541	http://dx.doi.org/10.1074/jbc.274.21.14541			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329643	hybrid			2022-12-25	WOS:000081965200008
J	Russo, N; Shapiro, R				Russo, N; Shapiro, R			Potent inhibition of mammalian ribonucleases by 3 ',5 '-pyrophosphate-linked nucleotides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EOSINOPHIL-DERIVED NEUROTOXIN; SITE-DIRECTED MUTAGENESIS; AMINO-ACID-SEQUENCE; HUMAN ANGIOGENIN; 5'-DIPHOSPHOADENOSINE 3'-PHOSPHATE; RIBONUCLEOLYTIC ACTIVITY; PANCREATIC-TYPE; HUMAN-URINE; HUMAN-LIVER; URIDINE	Molecular modeling based on the crystal structure of the complex of bovine pancreatic RNase A with the inhibitor 5'-diphosphoadenosine 3'-phosphate (ppAp) (Leonidas, D. D., Shapiro, R., Irons, L. I., Russo, N., and Acharya, K. R. (1997) Biochemistry 36, 5578-5588) was used to design new inhibitors that extend into unoccupied regions of the enzyme active site. These compounds are dinucleotides that contain an unusual 3',5'-pyrophosphate Linkage and were synthesized in solution by a combined chemical and enzymatic procedure. The most potent of them, 5'-phospho-2'-deoxyuridine S'-pyrophosphate, P' --> 5'-ester with adenosine 3'-phosphate (pdUppAp), binds to RNase A with K-i values of 27 and 220 nM at pH 5.9 and 7, respectively. These values are 6-9-fold lower than those for ppAp and 50-fold lower than that for the transition state analogue, uridine vanadate. pdUppAp has broad specificity; it is an effective inhibitor of at least two other members of the pancreatic RNase superfamily, human RNase-a (eosinophil-derived neurotoxin) and RNase-4, which share only 36-44% sequence identity with the pancreatic enzyme. The potency of pdUppAp and the other inhibitors described here depends critically on the extended internucleotide linkage; the pyrophosphate group enhances dinucleotide binding to the three RNases by 2.1-2.9 orders of magnitude, as compared with a monophosphate. These data give further insight into the organization of the catalytic centers of the various RNases. Moreover, the new class of inhibitors provides a useful means by which to probe the biological actions of these and other related enzymes.	Harvard Univ, Sch Med, Ctr Biochem & Biophys Sci & Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Shapiro, R (corresponding author), Harvard Univ, Sch Med, Ctr Biochem & Biophys Sci & Med, Seeley G Mudd Bldg,250 Longwood Ave, Boston, MA 02115 USA.	shapiro@ferret.med.harvard.edu		Russo, Aniello/0000-0001-5421-3552				ANDERSON DG, 1968, BIOCHEMISTRY-US, V7, P1637, DOI 10.1021/bi00845a004; Beaven G.H., 1955, NUCL ACIDS, V1, P493, DOI DOI 10.1002/JPS.3030440720; BEINTEMA JJ, 1988, BIOCHEMISTRY-US, V27, P4530, DOI 10.1021/bi00412a046; BEINTEMA JJ, 1986, MOL BIOL EVOL, V3, P262; BEINTEMA JJ, 1989, FEBS LETT, V254, P1, DOI 10.1016/0014-5793(89)80996-2; BORAH B, 1985, BIOCHEMISTRY-US, V24, P2058, DOI 10.1021/bi00329a038; BORKAKOTI N, 1982, ACTA CRYSTALLOGR B, V38, P2210, DOI 10.1107/S0567740882008346; D'Alessio Giuseppe, 1993, Trends in Cell Biology, V3, P106, DOI 10.1016/0962-8924(93)90166-X; DALESSIO G, 1991, TRENDS BIOCHEM SCI, V16, P104, DOI 10.1016/0968-0004(91)90042-T; DELROSAR.EJ, 1969, BIOCHEMISTRY-US, V8, P1884, DOI 10.1021/bi00833a017; FETT JW, 1985, BIOCHEMISTRY-US, V24, P5480, DOI 10.1021/bi00341a030; Fisher BM, 1998, BIOCHEMISTRY-US, V37, P12121, DOI 10.1021/bi980743l; FONTECILLACAMPS JC, 1994, J BIOL CHEM, V269, P21526; GLEICH GJ, 1986, P NATL ACAD SCI USA, V83, P3146, DOI 10.1073/pnas.83.10.3146; HOFSTEENGE J, 1989, BIOCHEMISTRY-US, V28, P9806, DOI 10.1021/bi00451a040; Hofsteenge J, 1998, BIOCHEMISTRY-US, V37, P9250, DOI 10.1021/bi9803832; HOSOYA K, 1990, J BIOCHEM-TOKYO, V107, P613, DOI 10.1093/oxfordjournals.jbchem.a123095; IRIE M, 1984, J BIOCHEM-TOKYO, V95, P751, DOI 10.1093/oxfordjournals.jbchem.a134666; IWAHASHI K, 1981, J BIOCHEM-TOKYO, V90, P1685, DOI 10.1093/oxfordjournals.jbchem.a133644; IWAMA M, 1981, J BIOCHEM-TOKYO, V89, P1005; KING TV, 1991, J BONE JOINT SURG BR, V73, P587, DOI 10.1302/0301-620X.73B4.1712788; Leonidas DD, 1997, BIOCHEMISTRY-US, V36, P5578, DOI 10.1021/bi9700330; LINDQUIST RN, 1973, J AM CHEM SOC, V95, P8762, DOI 10.1021/ja00807a043; MOFFATT JG, 1961, J AM CHEM SOC, V83, P663, DOI 10.1021/ja01464a036; Mosimann SC, 1996, J MOL BIOL, V260, P540, DOI 10.1006/jmbi.1996.0420; NOGUES MV, 1995, BBA-PROTEIN STRUCT M, V1253, P16, DOI 10.1016/0167-4838(95)00138-K; OLSON KA, 1995, P NATL ACAD SCI USA, V92, P442, DOI 10.1073/pnas.92.2.442; RICHARDS FM, 1971, ENZYMES, V4, P647; RUSSO N, 1994, P NATL ACAD SCI USA, V91, P2920, DOI 10.1073/pnas.91.8.2920; Russo N, 1997, BIOCHEM BIOPH RES CO, V231, P671, DOI 10.1006/bbrc.1997.6167; SATO S, 1966, ARCH BIOCHEM BIOPHYS, V115, P48, DOI 10.1016/S0003-9861(66)81036-6; SELA M, 1957, BIOCHIM BIOPHYS ACTA, V24, P229, DOI 10.1016/0006-3002(57)90186-5; SHAPIRO R, 1991, BIOCHEMISTRY-US, V30, P2246, DOI 10.1021/bi00222a030; SHAPIRO R, 1989, BIOCHEMISTRY-US, V28, P7401, DOI 10.1021/bi00444a038; SHAPIRO R, 1989, BIOCHEMISTRY-US, V28, P1726, DOI 10.1021/bi00430a045; SHAPIRO R, 1986, BIOCHEMISTRY-US, V25, P3527, DOI 10.1021/bi00360a008; SHAPIRO R, 1987, BIOCHEMISTRY-US, V26, P5141, DOI 10.1021/bi00390a037; SHAPIRO R, 1986, BIOCHEMISTRY-US, V25, P7255, DOI 10.1021/bi00371a002; SORRENTINO S, 1988, J BIOL CHEM, V263, P16125; SORRENTINO S, 1992, J BIOL CHEM, V267, P14859; SORRENTINO S, 1994, ARCH BIOCHEM BIOPHYS, V312, P340, DOI 10.1006/abbi.1994.1318; Vicentini AM, 1996, BIOCHEMISTRY-US, V35, P9128, DOI 10.1021/bi960457e; WITZEL H, 1962, BIOCHEM BIOPH RES CO, V7, P295, DOI 10.1016/0006-291X(62)90194-8; ZHOU HM, 1993, EUR J BIOCHEM, V217, P401, DOI 10.1111/j.1432-1033.1993.tb18259.x	44	47	51	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					14902	14908		10.1074/jbc.274.21.14902	http://dx.doi.org/10.1074/jbc.274.21.14902			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329690	hybrid			2022-12-25	WOS:000081965200055
J	Balmanno, K; Cook, SJ				Balmanno, K; Cook, SJ			Sustained MAP kinase activation is required for the expression of cyclin D1, p21(Cip1) and a subset of AP-1 proteins in CCL39 cells	ONCOGENE			English	Article						thrombin; Fos; Jun; AP-1; cyclin D1	SIGNAL-REGULATED KINASE; NIH 3T3 CELLS; C-FOS; GROWTH-FACTORS; TRANSCRIPTIONAL ACTIVATION; NEURONAL DIFFERENTIATION; TRANSFORMING ACTIVITY; G0-TO-G1 TRANSITION; THROMBIN-RECEPTOR; MOUSE FIBROBLASTS	In CCL39 cells thrombin is a potent growth factor which requires sustained activation of mitogen activated protein kinases (MAPKs) to promote DNA synthesis. Some of the effects of thrombin can be mimicked by peptides based on the new amino terminus of the cleaved receptor; however, these thrombin receptor peptides (TRPs) fail to induce sustained activation of MAPK or DNA synthesis, We have used thrombin, TRP-7 and other agonists which elicit sustained or transient MAPK activation to identify immediate-early and delayed-early genes which are only expressed under conditions of sustained MAPK activation focusing on cyclin D1, p21(Cip1) and the AP-1 transcription factor, Of the stimuli tested only FBS and thrombin were able to stimulate a sustained activation of MAPK, expression of cyclin D1, p21(Cip1) and cell cycle re-entry, The expression of cyclin D1 was strongly, though not completely, inhibited by the MEK1 inhibitor PD098059. Thrombin stimulated a rapid but transient accumulation of c-Fos whereas the expression of Fra-1, Fra-2, c-Jun and JunB was sustained throughout the G1 phase of the cell cycle. We focussed our analysis on c-Fos (typical of AP-1 genes which are expressed rapidly and transiently) and Fra-1 and JunB (typical of AP-1 genes expressed after a delay but in a sustained manner). The expression of c-Fos, Fra-1 and JunB was dependent upon the activation of MAPK since these responses were inhibited by PD098059, However, a comparison of responses to FBS, thrombin, TRPs, LPA and EGF revealed that Fra-1 and JunB expression required sustained activation of MAPK whereas c-Fos expression was strongly induced even by non-mitogenic stimuli which elicited only transient MAPK activation, The expression of c-Fos (in response to thrombin; TRP or LPA) or Fra-1, JunB and cyclin D1 (thrombin only) was also inhibited by pertussis toxin, This suggests that both early and late AP-1 gene expression is regulated by the same Gi-mediated, MEK-dependent MAPK signalling pathway but that expression of late AP-1 genes and cyclin D1 requires that this pathway be persistently activated. The results suggest that the duration of receptor signalling and therefore MAPK activation is a key determinant of qualitative changes in gene expression during cell cycle re-entry.	Babraham Inst, Signalling Programme, Cambridge CB2 4AT, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	Cook, SJ (corresponding author), Babraham Inst, Signalling Programme, Babraham Hall, Cambridge CB2 4AT, England.			Balmanno, Kathryn/0000-0002-6417-3889				AGARWAL S, 1995, ONCOGENE, V11, P427; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; BERGERS G, 1995, MOL CELL BIOL, V15, P3748; BRUSSELBACH S, 1995, ONCOGENE, V10, P79; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Chen RH, 1996, ONCOGENE, V12, P1493; COBB MH, 1994, SEMIN CANCER BIOL, V5, P261; Cook SJ, 1997, J BIOL CHEM, V272, P13309, DOI 10.1074/jbc.272.20.13309; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; Cook SJ, 1996, BIOCHEM J, V320, P237, DOI 10.1042/bj3200237; COOK SJ, 1999, IN PRESS MOL CELL BI, V19; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DECESARE D, 1995, ONCOGENE, V11, P365; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; Fuchs SY, 1998, ONCOGENE, V17, P1483, DOI 10.1038/sj.onc.1202184; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GRUDA MC, 1994, ONCOGENE, V9, P2537; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; Hawker KL, 1996, ONCOGENE, V13, P283; HERBER B, 1994, ONCOGENE, V9, P1295; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HU ED, 1994, EMBO J, V13, P3094, DOI 10.1002/j.1460-2075.1994.tb06608.x; HUNG DT, 1992, J CELL BIOL, V116, P827, DOI 10.1083/jcb.116.3.827; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; KAHAN C, 1992, J BIOL CHEM, V267, P13369; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lallemand D, 1997, ONCOGENE, V14, P819, DOI 10.1038/sj.onc.1200901; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; Lloyd AC, 1998, CURR OPIN GENET DEV, V8, P43, DOI 10.1016/S0959-437X(98)80060-9; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; MIAO GG, 1994, MOL CELL BIOL, V14, P4295, DOI 10.1128/MCB.14.6.4295; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; MORGAN JI, 1989, TRENDS NEUROSCI, V12, P459, DOI 10.1016/0166-2236(89)90096-9; Murakami M, 1997, ONCOGENE, V14, P2435, DOI 10.1038/sj.onc.1201077; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; OKAZAKI K, 1995, EMBO J, V14, P5048, DOI 10.1002/j.1460-2075.1995.tb00187.x; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; POUYSSEGUR J, 1992, ANNU REV PHYSIOL, V54, P195, DOI 10.1146/annurev.ph.54.030192.001211; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; SONNENBERG JL, 1989, NEURON, V3, P359, DOI 10.1016/0896-6273(89)90260-2; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; TREINIES I, 1999, IN PRESS MOL CELL BI, V19; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Vallone D, 1997, EMBO J, V16, P5310, DOI 10.1093/emboj/16.17.5310; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VOURETCRAVIARI V, 1993, BIOCHEM J, V289, P209, DOI 10.1042/bj2890209; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; YAN GZ, 1995, J NEUROSCI, V15, P6200	69	204	207	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 20	1999	18	20					3085	3097		10.1038/sj.onc.1202647	http://dx.doi.org/10.1038/sj.onc.1202647			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	197WB	10340380				2022-12-25	WOS:000080388000004
J	Avram, D; Ishmael, JE; Nevrivy, DJ; Peterson, VJ; Lee, SH; Dowell, P; Leid, M				Avram, D; Ishmael, JE; Nevrivy, DJ; Peterson, VJ; Lee, SH; Dowell, P; Leid, M			Heterodimeric interactions between chicken ovalbumin upstream promoter-transcription factor family members ARP1 and Ear2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR ORPHAN RECEPTORS; RETINOIC ACID RECEPTORS; OXYTOCIN GENE PROMOTER; COUP-TF; RESPONSE ELEMENTS; ESTROGEN-RECEPTOR; THYROID-HORMONE; EXPRESSION PATTERNS; MOLECULAR-CLONING; BINDING-SITES	Members of the chicken ovalbumin upstream promoter-transcription factor (COUP-TF) subfamily of orphan nuclear receptors, which minimally includes COUP-TFI and ARP1, are highly expressed in brain and are generally considered to be constitutive repressors of transcription. We have used a yeast two-hybrid system to isolate proteins expressed in brain that interact with ARP1. One of the proteins isolated in this screen was Ear2, another orphan receptor that has been suggested to be a member of the COUP-TF subfamily. Here we demonstrate that ARP1 and Ear2 form heterodimers in solution and on directly repeated response elements with high efficiency and a specificity differing from that of homodimeric complexes composed of either receptor. ARP1 and Ear2 were observed to interact in mammalian cells, and the tissue distribution of Ear2 transcripts was found to overlap precisely with the expression pattern of ARP1 in several mouse tissues and embryonal carcinoma cell lines. Heterodimeric interactions between ARP1 and Ear2 may define a distinct pathway of orphan receptor signaling.	Oregon State Univ, Coll Pharm, Mol Pharmacol Lab, Corvallis, OR 97331 USA; Oregon State Univ, Mol & Cellular Biol Program, Corvallis, OR 97331 USA	Oregon State University; Oregon State University	Leid, M (corresponding author), Oregon State Univ, Coll Pharm, Mol Pharmacol Lab, Corvallis, OR 97331 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000210] Funding Source: NIH RePORTER; NIEHS NIH HHS [P30 ES000210, P30 ES000210-35] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Avram D, 1996, GENETICS, V144, P511; Bailey PJ, 1997, J STEROID BIOCHEM, V63, P165, DOI 10.1016/S0960-0760(97)00079-4; Chu K, 1998, MOL CELL ENDOCRINOL, V137, P145, DOI 10.1016/S0303-7207(97)00241-4; Chu K, 1997, J MOL ENDOCRINOL, V19, P163, DOI 10.1677/jme.0.0190163; COONEY AJ, 1992, MOL CELL BIOL, V12, P4153, DOI 10.1128/MCB.12.9.4153; COONEY AJ, 1993, J BIOL CHEM, V268, P4152; DASILVA SL, 1995, MOL BRAIN RES, V30, P131, DOI 10.1016/0169-328X(94)00289-Q; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; Dowell P, 1997, J BIOL CHEM, V272, P2013, DOI 10.1074/jbc.272.3.2013; Dowell P, 1997, J BIOL CHEM, V272, P33435, DOI 10.1074/jbc.272.52.33435; Escriva H, 1997, P NATL ACAD SCI USA, V94, P6803, DOI 10.1073/pnas.94.13.6803; FJOSE A, 1993, EMBO J, V12, P1403, DOI 10.1002/j.1460-2075.1993.tb05784.x; HWUNG YP, 1988, J BIOL CHEM, V263, P13470; ISLAM TC, 1994, BIOCHEM BIOPH RES CO, V203, P545, DOI 10.1006/bbrc.1994.2217; JONK LJC, 1994, MECH DEVELOP, V47, P81, DOI 10.1016/0925-4773(94)90098-1; KIMURA A, 1993, J BIOL CHEM, V268, P11125; KIPPERT F, 1995, FEMS MICROBIOL LETT, V128, P201, DOI 10.1016/0378-1097(95)00113-J; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; Klinge CM, 1997, J BIOL CHEM, V272, P31465, DOI 10.1074/jbc.272.50.31465; Krishnan V, 1997, SCIENCE, V278, P1947, DOI 10.1126/science.278.5345.1947; KRONCZYNSKA AM, 1989, NUCLEIC ACIDS RES, V17, P6408; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; LEDOUARIN B, 1995, NUCLEIC ACIDS RES, V23, P876, DOI 10.1093/nar/23.5.876; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; Leng X, 1996, MOL CELL BIOL, V16, P2332; LU XP, 1994, MOL ENDOCRINOL, V8, P1774, DOI 10.1210/me.8.12.1774; MALIK S, 1995, NUCLEIC ACIDS RES, V23, P1536, DOI 10.1093/nar/23.9.1536; MIETUSSNYDER M, 1992, MOL CELL BIOL, V12, P1798; MIYAJIMA N, 1988, NUCLEIC ACIDS RES, V16, P11057, DOI 10.1093/nar/16.23.11057; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; NAKSHATRI H, 1994, J BIOL CHEM, V269, P890; PALMER CNA, 1995, J BIOL CHEM, V270, P16114, DOI 10.1074/jbc.270.27.16114; PASTORCIC M, 1989, NUCLEIC ACIDS RES, V17, P6693, DOI 10.1093/nar/17.16.6693; PASTORCIC M, 1986, MOL CELL BIOL, V6, P2784, DOI 10.1128/MCB.6.8.2784; PIERRAT B, 1992, GENE, V119, P237, DOI 10.1016/0378-1119(92)90277-V; POWER RF, 1991, SCIENCE, V252, P1546, DOI 10.1126/science.2047861; Qiu YH, 1997, GENE DEV, V11, P1925, DOI 10.1101/gad.11.15.1925; QIU YH, 1994, P NATL ACAD SCI USA, V91, P4451, DOI 10.1073/pnas.91.10.4451; SAGAMI I, 1986, MOL CELL BIOL, V6, P4259, DOI 10.1128/MCB.6.12.4259; Schrader M, 1996, J BIOL CHEM, V271, P19732, DOI 10.1074/jbc.271.33.19732; Shibata H, 1997, MOL ENDOCRINOL, V11, P714, DOI 10.1210/me.11.6.714; Shigeta H, 1996, MOL REPROD DEV, V45, P21, DOI 10.1002/(SICI)1098-2795(199609)45:1&lt;21::AID-MRD3&gt;3.0.CO;2-U; TRAN P, 1992, MOL CELL BIOL, V12, P4666, DOI 10.1128/MCB.12.10.4666; Tsai SY, 1997, ENDOCR REV, V18, P229, DOI 10.1210/er.18.2.229; vanderWees J, 1996, MECH DEVELOP, V54, P173, DOI 10.1016/0925-4773(95)00471-8; Wang Lee-Ho, 1991, Gene Expression, V1, P207; WANG LH, 1987, J BIOL CHEM, V262, P16080; Wu Q, 1997, EMBO J, V16, P1656, DOI 10.1093/emboj/16.7.1656	50	25	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					14331	14336		10.1074/jbc.274.20.14331	http://dx.doi.org/10.1074/jbc.274.20.14331			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318855	Green Accepted, hybrid			2022-12-25	WOS:000080322200084
J	Gazit, E; Sauer, RT				Gazit, E; Sauer, RT			The Doc toxin and Phd antidote proteins of the bacteriophage P1 plasmid addiction system form a heterotrimeric complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CELL-DEATH; PROTEASE; CLPXP; MAINTENANCE; SPECIFICITY; SUBSTRATE; PROPHAGE; OPERON; MODEL	The toxin (Doc) and antidote (Phd) proteins of the plasmid addiction system of bacteriophage P1 were purified as a complex. Cocrystals of the complex contained a 2:1 molar ratio of Phd:Doc as assayed by dye binding following SDS-polyacrylamide gel electrophoresis and as determined by amino acid analysis. Gel filtration and analytical ultracentrifugation revealed that the two addiction proteins interact in solution to form a P2D trimer composed of one Doc and two Phd molecules, These results support a model in which Phd inhibits the toxic activity of Doc by direct binding, Circular dichroism experiments showed that changes in secondary structure accompany formation of the heterotrimeric complex, raising the possibility that Phd may act by an allosteric mechanism. Studies of Phd and Doc molecules labeled with fluorescent energy donor and acceptor groups gave an equilibrium dissociation constant of about 0.8 mu M-2 and a very short, sub second half-life of complex dissociation. As a consequence, low concentrations of free Doc toxin are likely to be present both transiently and in the steady state in cells containing the Phd antidote, making mechanisms of single-hit Doe toxicity improbable.	MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Sauer, RT (corresponding author), MIT, Dept Biol, 68-571, Cambridge, MA 02139 USA.		Gazit, Ehud/M-8026-2019; Gazit, Ehud/C-3715-2011; Gazit, Ehud/AHE-9332-2022	Gazit, Ehud/0000-0001-5764-1720; Gazit, Ehud/0000-0001-5764-1720; Sauer, Robert/0000-0002-1719-5399	NIAID NIH HHS [AI-16892, AI-15706] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI015706, R01AI015706, R01AI016892] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aizenman E, 1996, P NATL ACAD SCI USA, V93, P6059, DOI 10.1073/pnas.93.12.6059; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Engelberg-Kulka H, 1998, P NATL ACAD SCI USA, V95, P15481, DOI 10.1073/pnas.95.26.15481; Gazit E, 1997, BIOCHEMISTRY-US, V36, P15546, DOI 10.1021/bi9707584; Gazit E, 1999, J BIOL CHEM, V274, P2652, DOI 10.1074/jbc.274.5.2652; GERDES K, 1986, P NATL ACAD SCI USA, V83, P3116, DOI 10.1073/pnas.83.10.3116; Gottesman S, 1998, GENE DEV, V12, P1338, DOI 10.1101/gad.12.9.1338; Grimaud R, 1998, J BIOL CHEM, V273, P12476, DOI 10.1074/jbc.273.20.12476; Holcik M, 1997, MICROBIOL-SGM, V143, P3403, DOI 10.1099/00221287-143-11-3403; JENSEN RB, 1995, MOL MICROBIOL, V17, P205, DOI 10.1111/j.1365-2958.1995.mmi_17020205.x; LEHNHERR H, 1995, P NATL ACAD SCI USA, V92, P3274, DOI 10.1073/pnas.92.8.3274; LEHNHERR H, 1993, J MOL BIOL, V233, P414, DOI 10.1006/jmbi.1993.1521; Levchenko I, 1997, CELL, V91, P939, DOI 10.1016/S0092-8674(00)80485-7; Levchenko I, 1997, GENE DEV, V11, P1561, DOI 10.1101/gad.11.12.1561; LOH SM, 1988, GENE, V66, P259, DOI 10.1016/0378-1119(88)90362-9; Magnuson P, 1996, J BIOL CHEM, V271, P18705, DOI 10.1074/jbc.271.31.18705; Magnuson R, 1998, J BACTERIOL, V180, P6342; ROSNER JL, 1972, VIROLOGY, V49, P679; VanMelderen L, 1996, J BIOL CHEM, V271, P27730, DOI 10.1074/jbc.271.44.27730; WAWRZYNOW A, 1995, EMBO J, V14, P1867, DOI 10.1002/j.1460-2075.1995.tb07179.x; YOUNG C, 1985, P NATL ACAD SCI USA, V82, P7374, DOI 10.1073/pnas.82.21.7374	22	48	51	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16813	16818		10.1074/jbc.274.24.16813	http://dx.doi.org/10.1074/jbc.274.24.16813			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358024	hybrid			2022-12-25	WOS:000080780400023
J	Santagata, S; Bhattacharyya, D; Wang, FH; Singha, N; Hodtsev, A; Spanopoulou, E				Santagata, S; Bhattacharyya, D; Wang, FH; Singha, N; Hodtsev, A; Spanopoulou, E			Molecular cloning and characterization of a mouse homolog of bacterial ClpX, a novel mammalian class II member of the Hsp100/Clp chaperone family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; ATP-DEPENDENT PROTEASE; ESCHERICHIA-COLI; BACTERIOPHAGE-MU; SACCHAROMYCES-CEREVISIAE; SPECIFICITY COMPONENT; V(D)J RECOMBINATION; BACILLUS-SUBTILIS; ACTIVATED ATPASE; SERINE-PROTEASE	In this paper, we present the molecular cloning and characterization of a murine homolog of the Escherichia coli chaperone ClpX, Murine ClpX shares 38% amino acid sequence identity with the E, coli homolog and is a novel member of the Hsp100/Clp family of molecular chaperones. ClpX localizes to human chromosome 15q22.2-22.3 and in mouse is expressed tissue-specifically as one transcript of similar to 2.9 kilobases (kb) predominantly within the liver and as two isoforms of similar to 2.6 and similar to 2.9 kb within the testes. Purified recombinant ClpX displays intrinsic ATPase activity, with a K-m of similar to 25 mu M and a V-max of similar to 660 pmol min(-1) mu g(-1), which is active over a broad range of pH, temperature, ethanol, and salt parameters. Substitution of lysine 300 with alanine in the ATPase domain P-loop abolishes both ATP hydrolysis and binding. Recombinant ClpX can also interact with its putative partner protease subunit ClpP in overexpression experiments in 293T cells. Subcellular studies by confocal laser scanning microscopy localized murine ClpX green fluorescent protein fusions to the mitochondria. Deletion of the N-terminal mitochondrial targeting sequence abolished mitochondrial compartmentalization, Our results thus suggest that murine ClpX acts as a tissue-specific mammalian mitochondrial chaperone that may play a role in mitochondrial protein homeostasis.	CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Howard Hughes Med Inst, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Howard Hughes Medical Institute; Icahn School of Medicine at Mount Sinai	Santagata, S (corresponding author), CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, 1425 Madison Ave,E Bldg,Box 1130, New York, NY 10029 USA.		Santagata, Sandro/A-7714-2009	Santagata, Sandro/0000-0002-7528-9668	NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR009145] Funding Source: NIH RePORTER; NCRR NIH HHS [1 S10 RR0 9145-01] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; Beuron F, 1998, J STRUCT BIOL, V123, P248, DOI 10.1006/jsbi.1998.4039; Bross P, 1995, FEBS LETT, V377, P249, DOI 10.1016/0014-5793(95)01353-9; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; Corydon TJ, 1998, BIOCHEM J, V331, P309, DOI 10.1042/bj3310309; Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; Domian IJ, 1997, CELL, V90, P415, DOI 10.1016/S0092-8674(00)80502-4; GAVEL Y, 1990, PROTEIN ENG, V4, P33, DOI 10.1093/protein/4.1.33; Gerth U, 1996, GENE, V181, P77, DOI 10.1016/S0378-1119(96)00467-2; Gerth U, 1998, MOL MICROBIOL, V28, P787, DOI 10.1046/j.1365-2958.1998.00840.x; GEUSKENS V, 1992, EMBO J, V11, P5121, DOI 10.1002/j.1460-2075.1992.tb05619.x; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; GOFFEAU A, 1996, SCIENCE, V274, P563, DOI DOI 10.1126/SCIENCE.274.5287.546; Gottesman S, 1998, GENE DEV, V12, P1338, DOI 10.1101/gad.12.9.1338; GOTTESMAN S, 1993, J BIOL CHEM, V268, P22618; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; Hodges PE, 1998, NUCLEIC ACIDS RES, V26, P68, DOI 10.1093/nar/26.1.68; HWANG BJ, 1988, J BIOL CHEM, V263, P8727; Jenal U, 1998, EMBO J, V17, P5658, DOI 10.1093/emboj/17.19.5658; KATAYAMAFUJIMURA Y, 1987, J BIOL CHEM, V262, P4477; KESSEL M, 1995, J MOL BIOL, V250, P587, DOI 10.1006/jmbi.1995.0400; Kruklitis R, 1996, EMBO J, V15, P935, DOI 10.1002/j.1460-2075.1996.tb00428.x; Laachouch JE, 1996, EMBO J, V15, P437, DOI 10.1002/j.1460-2075.1996.tb00374.x; Land T, 1998, MOL CELL, V2, P807, DOI 10.1016/S1097-2765(00)80295-6; LEHNHERR H, 1995, P NATL ACAD SCI USA, V92, P3274, DOI 10.1073/pnas.92.8.3274; LEONHARDT SA, 1993, MOL CELL BIOL, V13, P6304, DOI 10.1128/MCB.13.10.6304; LEVCHENKO I, 1995, GENE DEV, V9, P2399, DOI 10.1101/gad.9.19.2399; Levchenko I, 1997, CELL, V91, P939, DOI 10.1016/S0092-8674(00)80485-7; Levchenko I, 1997, GENE DEV, V11, P1561, DOI 10.1101/gad.11.12.1561; Martin J, 1997, J BIOENERG BIOMEMBR, V29, P35, DOI 10.1023/A:1022407705182; Martin J, 1997, CURR OPIN STRUC BIOL, V7, P41, DOI 10.1016/S0959-440X(97)80006-1; MHAMMEDIALAOUI A, 1994, MOL MICROBIOL, V11, P1109, DOI 10.1111/j.1365-2958.1994.tb00387.x; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; Raynes DA, 1998, J BIOL CHEM, V273, P32883, DOI 10.1074/jbc.273.49.32883; ROISE D, 1988, J BIOL CHEM, V263, P4509; SANCHEZ Y, 1992, EMBO J, V11, P2357, DOI 10.1002/j.1460-2075.1992.tb05295.x; SANCHEZ Y, 1990, SCIENCE, V248, P1112, DOI 10.1126/science.2188365; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; Schirmer EC, 1998, J BIOL CHEM, V273, P15546, DOI 10.1074/jbc.273.25.15546; Schmitt M, 1996, J CELL BIOL, V134, P1375, DOI 10.1083/jcb.134.6.1375; SCHMITT M, 1995, EMBO J, V14, P3434, DOI 10.1002/j.1460-2075.1995.tb07349.x; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; SCHWARTZ RM, 1978, SCIENCE, V199, P395, DOI 10.1126/science.202030; Schweder T, 1996, J BACTERIOL, V178, P470, DOI 10.1128/jb.178.2.470-476.1996; Spanopoulou E, 1995, IMMUNITY, V3, P715, DOI 10.1016/1074-7613(95)90061-6; Spanopoulou E, 1996, CELL, V87, P263, DOI 10.1016/S0092-8674(00)81344-6; Szabo A, 1996, EMBO J, V15, P408, DOI 10.1002/j.1460-2075.1996.tb00371.x; van Dyck L, 1998, FEBS LETT, V438, P250, DOI 10.1016/S0014-5793(98)01310-6; WALKER JE, 1982, NATURE, V298, P867, DOI 10.1038/298867a0; WAWRZYNOW A, 1995, EMBO J, V14, P1867, DOI 10.1002/j.1460-2075.1995.tb07179.x; WOO KM, 1992, J BIOL CHEM, V267, P20429	56	25	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16311	16319		10.1074/jbc.274.23.16311	http://dx.doi.org/10.1074/jbc.274.23.16311			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347188	hybrid			2022-12-25	WOS:000080668600048
J	Costa, MCR; Mani, F; Santoro, W; Espreafico, EM; Larson, RE				Costa, MCR; Mani, F; Santoro, W; Espreafico, EM; Larson, RE			Brain myosin-V, a calmodulin-carrying myosin, binds to calmodulin-dependent protein kinase II and activates its kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSTSYNAPTIC DENSITY PROTEIN; UNCONVENTIONAL MYOSIN; SACCHAROMYCES-CEREVISIAE; LIGHT-CHAINS; GROWTH CONES; CELL-GROWTH; SYNAPSIN-I; RAT-BRAIN; LOCALIZATION; COMPLEX	Myosin-V, an unconventional myosin, has two notable structural features: (i) a regulatory neck domain having six IQ motifs that bind calmodulin and light chains, and (ii) a structurally distinct tail domain likely responsible for its specific intracellular interactions. Myosin-V copurifies with synaptic vesicles via its tail domain, which also is a substrate for calmodulin-dependent protein kinase II, We demonstrate here that myosin-V coimmunoprecipitates with CaM-kinase II from a Triton X-100-solubilized fraction of isolated nerve terminals, The purified proteins also coimmunoprecipitate from dilute solutions and bind in overlay experiments on Western blots. The binding region on myosin-V was mapped to its proximal and medial tail domains. Autophosphorylated CaM-kinase II binds to the tail domain of myosin-V with an apparent K-d of 7.7 nM. Surprisingly, myosin-V activates CaM-kinase II activity in a Ca2+-dependent manner, without the need for additional CaM, The apparent activation constants for the autophosphorylation of CaM-kinase II were 10 and 26 nM, respectively, for myo sin-V versus CaM. The maximum incorporation of P-32 into CaM-kinase II activated by myosin-V was twice that for CaM, suggesting that myosin-V binding to CaM-kinase II entails alterations in kinetic and/or phosphorylation site parameters. These data suggest that myosin-V, a calmodulin-carrying myosin, binds to and delivers CaM to CaM-kinase II, a calmodulin-dependent enzyme.	Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Biochem, BR-14049900 Sao Paulo, Brazil; Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Morphol, BR-14049900 Sao Paulo, Brazil	Universidade de Sao Paulo; Universidade de Sao Paulo	Larson, RE (corresponding author), Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Biochem, Av Bandeirantes 3900, BR-14049900 Sao Paulo, Brazil.	relarson@fmrp.usp.br	Espreafico, Enilza/O-3053-2016; Espreafico, Enilza/AAW-4658-2021	Espreafico, Enilza/0000-0002-7552-4234; Espreafico, Enilza/0000-0002-7552-4234				ALEXANDER KA, 1988, J BIOL CHEM, V263, P7544; Benfenati F, 1996, MOL BRAIN RES, V40, P297, DOI 10.1016/0169-328X(96)00053-8; BENFENATI F, 1992, NATURE, V359, P417, DOI 10.1038/359417a0; BENNETT MK, 1992, J CELL BIOL, V116, P761, DOI 10.1083/jcb.116.3.761; BENNETT MK, 1994, ANNU REV BIOCHEM, V63, P63, DOI 10.1146/annurev.bi.63.070194.000431; Bi GQ, 1997, J CELL BIOL, V138, P999, DOI 10.1083/jcb.138.5.999; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; BROCKERHOFF SE, 1992, J CELL BIOL, V118, P619, DOI 10.1083/jcb.118.3.619; BROCKERHOFF SE, 1994, J CELL BIOL, V124, P315, DOI 10.1083/jcb.124.3.315; Cameron LC, 1998, ARCH BIOCHEM BIOPHYS, V355, P35, DOI 10.1006/abbi.1998.0700; CECCALDI PE, 1995, J CELL BIOL, V128, P905, DOI 10.1083/jcb.128.5.905; CHAPMAN ER, 1995, J BIOL CHEM, V270, P23667, DOI 10.1074/jbc.270.40.23667; CHENEY R E, 1992, Current Opinion in Cell Biology, V4, P27, DOI 10.1016/0955-0674(92)90055-H; Cheney RE, 1998, METHOD ENZYMOL, V298, P3, DOI 10.1016/S0076-6879(98)98003-X; CHENEY RE, 1993, CELL, V75, P13, DOI 10.1016/0092-8674(93)90675-G; COELHO MV, 1993, BRAZ J MED BIOL RES, V26, P465; EDELMANN L, 1995, EMBO J, V14, P224, DOI 10.1002/j.1460-2075.1995.tb06995.x; ESPREAFICO EM, 1992, J CELL BIOL, V119, P1541, DOI 10.1083/jcb.119.6.1541; Evans LL, 1997, J CELL SCI, V110, P439; Evans LL, 1998, J CELL SCI, V111, P2055; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; GOLDENRING JR, 1983, J BIOL CHEM, V258, P2632; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; Grab D J, 1980, Ann N Y Acad Sci, V356, P55, DOI 10.1111/j.1749-6632.1980.tb29599.x; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HOSKINS B, 1986, J NEUROCHEM, V46, P303, DOI 10.1111/j.1471-4159.1986.tb12964.x; Kennedy M B, 1993, Curr Opin Neurobiol, V3, P732, DOI 10.1016/0959-4388(93)90145-O; KENNEDY MB, 1983, P NATL ACAD SCI-BIOL, V80, P7357, DOI 10.1073/pnas.80.23.7357; Kennedy MB, 1997, TRENDS NEUROSCI, V20, P264, DOI 10.1016/S0166-2236(96)01033-8; KLEE CB, 1977, BIOCHEMISTRY-US, V16, P1017, DOI 10.1021/bi00624a033; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LARSON RE, 1986, J NEUROSCI METH, V16, P47, DOI 10.1016/0165-0270(86)90007-5; Larson RE, 1996, BRAZ J MED BIOL RES, V29, P309; MANI F, 1994, BRAZ J MED BIOL RES, V27, P2639; MCNEILL RB, 1995, J BIOL CHEM, V270, P10043, DOI 10.1074/jbc.270.17.10043; Mermall V, 1998, SCIENCE, V279, P527, DOI 10.1126/science.279.5350.527; MONTELL C, 1988, CELL, V52, P757, DOI 10.1016/0092-8674(88)90413-8; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; NAGY A, 1984, J NEUROCHEM, V43, P1114, DOI 10.1111/j.1471-4159.1984.tb12851.x; Nascimento AAC, 1996, J BIOL CHEM, V271, P17561, DOI 10.1074/jbc.271.29.17561; OHTA Y, 1986, FEBS LETT, V208, P423, DOI 10.1016/0014-5793(86)81061-4; PORTER JA, 1993, SCIENCE, V262, P1038, DOI 10.1126/science.8235618; Prekeris R, 1997, J CELL BIOL, V137, P1589, DOI 10.1083/jcb.137.7.1589; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schlamp CL, 1996, EXP EYE RES, V63, P613, DOI 10.1006/exer.1996.0155; SCHULMAN H, 1988, ADV SEC MESS PHOSPH, V22, P39; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Titus MA, 1997, CURR BIOL, V7, pR301, DOI 10.1016/S0960-9822(06)00143-6; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Wang FS, 1996, SCIENCE, V273, P660, DOI 10.1126/science.273.5275.660; WELSH MJ, 1978, P NATL ACAD SCI USA, V75, P1867, DOI 10.1073/pnas.75.4.1867; Yoshimura Y, 1997, J BIOL CHEM, V272, P26354, DOI 10.1074/jbc.272.42.26354; ZHU QL, 1992, J CELL BIOL, V118, P347, DOI 10.1083/jcb.118.2.347	54	70	70	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15811	15819		10.1074/jbc.274.22.15811	http://dx.doi.org/10.1074/jbc.274.22.15811			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336484	hybrid			2022-12-25	WOS:000080560100073
J	Kan, M; Wu, XC; Wang, F; McKeehan, WL				Kan, M; Wu, XC; Wang, F; McKeehan, WL			Specificity for fibroblast growth factors determined by heparan sulfate in a binary complex with the receptor kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-AFFINITY BINDING; FACTOR FAMILY; CELL; IDENTIFICATION; ECTODOMAIN; EXPRESSION; SEQUENCE; FGF-2	A divalent cation-dependent association between heparin or heparan sulfate and the ectodomain of the FGF receptor kinase (FGFR) restricts FGF-independent trans-phosphorylation and supports the binding of activating FGF to self-associated FGFR, Here we show that in contrast to heparin, cellular heparan sulfate forms a binary complex with FGFR that discriminates between FGF-I and FGF-2. FGFR type 4 (FGFR4) in liver parenchymal cells binds only FGF-1, whereas FGFR1 binds FGF-I and FGF-2 equally. cell-free complexes of heparin and recombinant FGFR4 bound FGF-1 and FGF-2 equally. However, in contrast to FGFR1, when recombinant FGFR4 was expressed back in epithelial cells by transfection, it failed to bind FGF-2 unless heparan sulfate was depressed by chlorate or heparinase treatment, Isolated heparan sulfate proteoglycan (HSPG) from liver cells in cell-free complexes with FGFR4 restored the specificity for FGF-1 and supported the binding of both FGF-1 and FGF-S when complexed with FGFR1. In contrast, FGF-2 bound equally well to complexes of both FGFR1 and FGFR4 formed with endothelial cell-derived HSPG, but the endothelial HSPG was deficient for the binding of FGF-1 to both FGFR complexes. These data suggest that a heparan sulfate subunit is a cell type- and FGFR-specific determinant of the selectivity of the FGFR signaling complex for FGF. In a physiological context, the heparan sulfate subunit may limit the redundancy among the current 18 FGF polypeptides for the 4 known FGFR.	Texas A&M Univ, Hlth Sci Ctr, Inst Biosci & Technol, Ctr Canc Biol & Nutr, Houston, TX 77030 USA; Texas A&M Univ, Dept Biochem & Biophys, Houston, TX 77030 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; University of Texas Health Science Center Houston; Texas A&M University System	McKeehan, WL (corresponding author), Texas A&M Univ, Hlth Sci Ctr, Inst Biosci & Technol, Ctr Canc Biol & Nutr, 2121 W Holcombe Blvd, Houston, TX 77030 USA.	wmckeeha@ibt.tamu.edu			NATIONAL CANCER INSTITUTE [R01CA059971] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040739, R01DK035310] Funding Source: NIH RePORTER; NCI NIH HHS [CA59971] Funding Source: Medline; NIDDK NIH HHS [DK35310, DK40739] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BonnehBarkay D, 1997, J BIOL CHEM, V272, P12415, DOI 10.1074/jbc.272.19.12415; Brickman YG, 1998, J BIOL CHEM, V273, P4350, DOI 10.1074/jbc.273.8.4350; DiGabriele AD, 1998, NATURE, V393, P812, DOI 10.1038/31741; Feng SJ, 1996, BBA-MOL CELL RES, V1310, P67, DOI 10.1016/0167-4889(95)00146-8; Friedl A, 1997, AM J PATHOL, V150, P1443; Herr AB, 1997, J BIOL CHEM, V272, P16382, DOI 10.1074/jbc.272.26.16382; HOSHI H, 1988, IN VITRO CELL DEV B, V24, P309; Jang JH, 1997, IN VITRO CELL DEV-AN, V33, P819; KAN M, 1989, P NATL ACAD SCI USA, V86, P7432, DOI 10.1073/pnas.86.19.7432; Kan M, 1996, J BIOL CHEM, V271, P26143, DOI 10.1074/jbc.271.42.26143; KAN M, 1988, J BIOL CHEM, V263, P11306; KAN M, 1992, IN VITRO CELL DEV-AN, V28A, P515; KAN M, 1991, METHOD ENZYMOL, V198, P158; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; Kato M, 1998, NAT MED, V4, P691, DOI 10.1038/nm0698-691; Luo YD, 1996, J BIOL CHEM, V271, P26876, DOI 10.1074/jbc.271.43.26876; McKeehan WL, 1998, PROG NUCLEIC ACID RE, V59, P135; McKeehan WL, 1997, IN VITRO CELL DEV-AN, V33, P727, DOI 10.1007/s11626-997-0146-7; Moy FJ, 1997, BIOCHEMISTRY-US, V36, P4782, DOI 10.1021/bi9625455; NURCOMBE V, 1993, SCIENCE, V260, P103, DOI 10.1126/science.7682010; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; PANTOLIANO MW, 1994, BIOCHEMISTRY-US, V33, P10229, DOI 10.1021/bi00200a003; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; Pye DA, 1998, BIOCHEM BIOPH RES CO, V248, P889, DOI 10.1006/bbrc.1998.9081; Rahmoune H, 1998, J BIOL CHEM, V273, P7303, DOI 10.1074/jbc.273.13.7303; REICHSLOTKY R, 1994, J BIOL CHEM, V269, P32279; RON D, 1993, J BIOL CHEM, V268, P5388; VAINIKKA S, 1992, EMBO J, V11, P4273, DOI 10.1002/j.1460-2075.1992.tb05526.x; Wang F, 1997, J BIOL CHEM, V272, P23887, DOI 10.1074/jbc.272.38.23887; XU JM, 1992, J BIOL CHEM, V267, P17792	30	125	132	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15947	15952		10.1074/jbc.274.22.15947	http://dx.doi.org/10.1074/jbc.274.22.15947			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336501	hybrid			2022-12-25	WOS:000080560100090
J	Ollmann, MM; Barsh, GS				Ollmann, MM; Barsh, GS			Down-regulation of melanocortin receptor signaling mediated by the amino terminus of Agouti protein in Xenopus melanophores	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MELANOCYTE-STIMULATING-HORMONE; PROOPIOMELANOCORTIN MESSENGER-RNA; IN-VITRO; ALPHA-MELANOTROPIN; PROCESSING ENZYME; MOLECULAR-CLONING; TRANSGENIC MICE; KEX2 PROTEASE; INSECT CELLS; YELLOW MICE	Agouti protein and Agouti-related protein (Agrp) regulate pigmentation and body weight, respectively, by antagonizing melanocortin receptor signaling. A carboxyl-terminal fragment of Agouti protein, Ser(73)-Cys(131) is sufficient for melanocortin receptor antagonism, but Western blot analysis of skin extracts reveals that the electrophoretic mobility of native Agouti protein corresponds to the mature full-length form, His(23)-Cys(131), TO investigate the potential role of the amino-terminal residues, we compared the function of full-length and carboxyl-terminal fragments of Agrp and Agouti protein in a sensitive bioassay based on pigment dispersion in Xenopus melanophores. We find that carboxyl-terminal Agouti protein, and all forms of Agrp tested, act solely by competitive antagonism of melanocortin action. However, full-length Agouti protein acts by an additional mechanism that is time- and temperature-dependent, depresses maximal levels of pigment dispersion, and is therefore likely to be mediated by receptor down-regulation. Apparent down-regulation is not observed for a mixture of amino-terminal and carboxyl-terminal fragments. We propose that the phenotypic effects of Agouti in vivo represent a bipartite mechanism: competitive antagonism of agonist binding by the carboxyl-terminal portion of Agouti protein and down-regulation of melanocortin receptor signaling by an unknown mechanism that requires residues in the amino terminus of the Agouti protein.	Stanford Univ, Beckman Ctr, Sch Med, Dept Pediat, Stanford, CA 94305 USA; Stanford Univ, Dept Genet, Sch Med, Stanford, CA 94305 USA; Stanford Univ, Howard Hughes Med Inst, Sch Med, Stanford, CA 94305 USA	Stanford University; Stanford University; Howard Hughes Medical Institute; Stanford University	Ollmann, MM (corresponding author), Stanford Univ, Beckman Ctr, Sch Med, Dept Pediat, B271A, Stanford, CA 94305 USA.				NIDDK NIH HHS [DK28506] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ausubel FM, 1998, CURRENT PROTOCOLS MO; BLANCHARD SG, 1995, BIOCHEMISTRY-US, V34, P10406, DOI 10.1021/bi00033a012; BRENNER C, 1992, P NATL ACAD SCI USA, V89, P922, DOI 10.1073/pnas.89.3.922; BRENNER C, 1994, METHOD ENZYMOL, V244, P152; BULTMAN SJ, 1992, CELL, V71, P1195, DOI 10.1016/S0092-8674(05)80067-4; Cone RD, 1996, RECENT PROG HORM RES, V51, P287; DUHL DMJ, 1994, NAT GENET, V8, P59, DOI 10.1038/ng0994-59; EBERLE AN, 1988, MELANTROPINS CHEM PH; GANTZ I, 1993, J BIOL CHEM, V268, P15174; GANTZ I, 1993, J BIOL CHEM, V268, P8246; Graham M, 1997, NAT GENET, V17, P273, DOI 10.1038/ng1197-273; HUNT G, 1995, J ENDOCRINOL, V147, pR1, DOI 10.1677/joe.0.147R001; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; JAYAWICKREME CK, 1994, J BIOL CHEM, V269, P29846; Jones BH, 1996, AM J PHYSIOL-ENDOC M, V270, pE192, DOI 10.1152/ajpendo.1996.270.1.E192; KENAKIN T, 1995, BIOCHEM PHARMACOL, V50, P17, DOI 10.1016/0006-2952(95)00137-O; KENAKIN TP, 1982, CAN J PHYSIOL PHARM, V60, P249, DOI 10.1139/y82-036; Kiefer LL, 1998, BIOCHEMISTRY-US, V37, P991, DOI 10.1021/bi971913h; Kiefer LL, 1997, BIOCHEMISTRY-US, V36, P2084, DOI 10.1021/bi962647v; Kijas J M, 1998, Chromosome Res, V6, P243, DOI 10.1023/A:1009248432412; Kim JH, 1996, FASEB J, V10, P1646, DOI 10.1096/fasebj.10.14.9002558; KLEBIG ML, 1995, P NATL ACAD SCI USA, V92, P4728, DOI 10.1073/pnas.92.11.4728; KOBAYASHI T, 1995, J CELL SCI, V108, P2301; LEFKOWITZ RJ, 1993, ADV SEC MESS PHOSPH, V28, P1; LU DS, 1994, NATURE, V371, P799, DOI 10.1038/371799a0; MICHAUD EJ, 1994, GENE DEV, V8, P1463, DOI 10.1101/gad.8.12.1463; MILLAR SE, 1995, DEVELOPMENT, V121, P3223; MILLER MW, 1993, GENE DEV, V7, P454, DOI 10.1101/gad.7.3.454; MISRAHI M, 1994, EUR J BIOCHEM, V222, P711, DOI 10.1111/j.1432-1033.1994.tb18916.x; Mizuno TM, 1998, DIABETES, V47, P294, DOI 10.2337/diabetes.47.2.294; Mynatt RL, 1997, P NATL ACAD SCI USA, V94, P919, DOI 10.1073/pnas.94.3.919; OLIVERA BM, 1991, J BIOL CHEM, V266, P22067; Ollmann MM, 1997, SCIENCE, V278, P135, DOI 10.1126/science.278.5335.135; Ollmann MM, 1998, GENE DEV, V12, P316, DOI 10.1101/gad.12.3.316; OLSON MF, 1991, ENDOCR RES, V17, P19, DOI 10.1080/07435809109027187; Perry WL, 1996, GENETICS, V144, P255; PERRY WL, 1994, BIOESSAYS, V16, P705, DOI 10.1002/bies.950161002; POTENZA MN, 1992, PIGM CELL RES, V5, P372, DOI 10.1111/j.1600-0749.1992.tb00565.x; QUISTAD GB, 1994, J BIOL CHEM, V269, P11098; ROBBINS LS, 1993, CELL, V72, P827, DOI 10.1016/0092-8674(93)90572-8; ROSELLIREHFUSS L, 1993, P NATL ACAD SCI USA, V90, P8856, DOI 10.1073/pnas.90.19.8856; Sakai C, 1997, EMBO J, V16, P3544, DOI 10.1093/emboj/16.12.3544; Searle A.G., 1968, COMP GENETICS COAT C; Shutter JR, 1997, GENE DEV, V11, P593, DOI 10.1101/gad.11.5.593; Siegrist W, 1996, BIOCHEM BIOPH RES CO, V218, P171, DOI 10.1006/bbrc.1996.0030; Siegrist W, 1997, J RECEPT SIGNAL TR R, V17, P75, DOI 10.3109/10799899709036595; SIRACUSA LD, 1994, TRENDS GENET, V10, P423, DOI 10.1016/0168-9525(94)90112-0; Suzuki I, 1997, J INVEST DERMATOL, V108, P838, DOI 10.1111/1523-1747.ep12292572; Thornton JE, 1997, ENDOCRINOLOGY, V138, P5063, DOI 10.1210/en.138.11.5063; Vage DI, 1997, NAT GENET, V15, P311, DOI 10.1038/ng0397-311; VRIELING H, 1994, P NATL ACAD SCI USA, V91, P5667, DOI 10.1073/pnas.91.12.5667; Wang W, 1997, PEPTIDES, V18, P1295, DOI 10.1016/S0196-9781(97)00206-4; WILLARD DH, 1995, BIOCHEMISTRY-US, V34, P12341, DOI 10.1021/bi00038a030; Yang YK, 1997, MOL ENDOCRINOL, V11, P274, DOI 10.1210/me.11.3.274; ZEMEL MB, 1995, P NATL ACAD SCI USA, V92, P4733, DOI 10.1073/pnas.92.11.4733	55	29	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15837	15846		10.1074/jbc.274.22.15837	http://dx.doi.org/10.1074/jbc.274.22.15837			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336487	hybrid			2022-12-25	WOS:000080560100076
J	Rasmussen, M; Muller, HP; Bjorck, L				Rasmussen, M; Muller, HP; Bjorck, L			Protein GRAB of Streptococcus pyogenes regulates proteolysis at the bacterial surface by binding alpha(2)-macroglobulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR CYSTEINE PROTEASE; GROUP-A STREPTOCOCCI; NATIVE ALPHA(2)-MACROGLOBULIN; IGG-BINDING; FC-RECEPTOR; ALPHA-2-MACROGLOBULIN; ACTIVATION; DYSGALACTIAE; MODULATION; COMPLEXES	In the molecular interplay between pathogenic microorganisms and their host, proteolytic mechanisms are believed to play a crucial role. Here we find that the important human pathogen Streptococcus pyogenes (group A Streptococcus) expresses a surface protein with high affinity (K-alpha = 2.0 x 10(8) M-1) for alpha(2)-macroglobulin (alpha(2)M), the dominating proteinase inhibitor of human plasma. The immunoglobulin-binding protein G of group C and G streptococci also contains an alpha(2)M-binding domain and a gene encoding protein GRAB (protein G-related alpha(2)M-binding protein) was identified in the S. pyogenes Genome Sequencing data base. The grab gene is present in most S, pyogenes strains and is well conserved. Protein GRAB has typical features of a surface-attached protein of Gram-positive bacteria. It also contains a region homologous to parts of the alpha(2)M-binding domain of protein G and a variable number of a unique 28-amino acid-long repeat. Using Escherichia coli-produced protein GRAB and synthetic GRAB peptides, the alpha(2)M-binding region was mapped to the NH2-terminal part of protein GRAB, which is the region with homology to protein G, An isogenic S. pyogenes mutant lacking surface-associated protein GRAB showed no alpha(2)M-binding activity and was attenuated in virulence when injected intraperitoneally in mice. Finally, alpha(2)M bound to the bacterial surface via protein GRAB was found to entrap and inhibit the activity of both S. pyogenes and host proteinases, thereby protecting important virulence determinants from proteolytic degradation. This regulation of proteolytic activity at the bacterial surface should affect the host-microbe relation during S. pyogenes infections.	Univ Lund, Dept Cell & Mol Biol, Sect Mol Pathogenesis, S-22100 Lund, Sweden; Univ Greifswald, Dept Immunol & Transfus Med, D-17487 Greifswald, Germany	Lund University; Ernst Moritz Arndt Universitat Greifswald	Bjorck, L (corresponding author), Univ Lund, Dept Cell & Mol Biol, Sect Mol Pathogenesis, POB 94, S-22100 Lund, Sweden.			Rasmussen, Magnus/0000-0003-1588-5473				AKERSTROM B, 1987, J BIOL CHEM, V262, P13388; AKESSON P, 1990, MOL IMMUNOL, V27, P523, DOI 10.1016/0161-5890(90)90071-7; BENNASR A, 1995, BIOCHEM J, V305, P173, DOI 10.1042/bj3050173; Berge A, 1997, J BIOL CHEM, V272, P20774, DOI 10.1074/jbc.272.33.20774; BERGE A, 1995, J BIOL CHEM, V270, P9862, DOI 10.1074/jbc.270.17.9862; BJORCK L, 1987, MOL IMMUNOL, V24, P1113, DOI 10.1016/0161-5890(87)90080-0; BJORCK L, 1984, J IMMUNOL, V133, P969; BORTH W, 1992, FASEB J, V6, P3345, DOI 10.1096/fasebj.6.15.1281457; Burns EH, 1996, INFECT IMMUN, V64, P4744, DOI 10.1128/IAI.64.11.4744-4750.1996; CHEUNG AL, 1994, ANAL BIOCHEM, V222, P511, DOI 10.1006/abio.1994.1528; CHHATWAL GS, 1987, J BACTERIOL, V169, P3691, DOI 10.1128/jb.169.8.3691-3695.1987; CHU CT, 1994, ANN NY ACAD SCI, V737, P291, DOI 10.1111/j.1749-6632.1994.tb44319.x; ELLIOTT SD, 1945, J EXP MED, V81, P573, DOI 10.1084/jem.81.6.573; FEINMAN RD, 1994, ANN NY ACAD SCI, V737, P245, DOI 10.1111/j.1749-6632.1994.tb44316.x; FISCHETTI VA, 1989, CLIN MICROBIOL REV, V2, P285, DOI 10.1128/CMR.2.3.285-314.1989; GUSS B, 1986, EMBO J, V5, P1657; HANSKI E, 1995, METHOD ENZYMOL, V253, P269; HEATH DG, 1989, P NATL ACAD SCI USA, V86, P4741, DOI 10.1073/pnas.86.12.4741; Herwald H, 1996, J EXP MED, V184, P665, DOI 10.1084/jem.184.2.665; HOFFMAN MR, 1987, J IMMUNOL, V139, P1885; HOLM SE, 1992, J INFECT DIS, V166, P31, DOI 10.1093/infdis/166.1.31; HORSTMANN RD, 1988, P NATL ACAD SCI USA, V85, P1657, DOI 10.1073/pnas.85.5.1657; IKAI A, 1994, ANN NY ACAD SCI, V737, P339, DOI 10.1111/j.1749-6632.1994.tb44322.x; JONSSON H, 1994, EUR J BIOCHEM, V220, P819, DOI 10.1111/j.1432-1033.1994.tb18684.x; JONSSON H, 1994, GENE, V143, P85, DOI 10.1016/0378-1119(94)90609-2; JONSSON H, 1995, INFECT IMMUN, V63, P2968, DOI 10.1128/IAI.63.8.2968-2975.1995; KANTOR FS, 1965, J EXP MED, V121, P849, DOI 10.1084/jem.121.5.849; KAPUR V, 1993, P NATL ACAD SCI USA, V90, P7676, DOI 10.1073/pnas.90.16.7676; KAPUR V, 1993, MICROB PATHOGENESIS, V15, P327, DOI 10.1006/mpat.1993.1083; Lancefield RC, 1928, J EXP MED, V47, P91, DOI 10.1084/jem.47.1.91; LAPENTA D, 1994, P NATL ACAD SCI USA, V91, P12115, DOI 10.1073/pnas.91.25.12115; Lukomski S, 1997, J CLIN INVEST, V99, P2574, DOI 10.1172/JCI119445; MULLER HP, 1995, INFECT IMMUN, V63, P2833; MULLER HP, 1985, RECENT ADV STREPTOCO, P96; NEVILLE DM, 1971, J BIOL CHEM, V246, P6328; NILSON BHK, 1992, J BIOL CHEM, V267, P2234; PITCHER DG, 1989, LETT APPL MICROBIOL, V8, P151, DOI 10.1111/j.1472-765X.1989.tb00262.x; REIS KJ, 1984, J IMMUNOL, V132, P3091; SAMBROOK J, 1989, MOL CLONING LAB MANA; SCOTT BJ, 1983, CLIN CHEM, V29, P629; SJOBRING U, 1989, J IMMUNOL, V143, P2948; SOTTRUPJENSEN L, 1994, BIOL ALPHA2 MACROGLO, V737, P173; STOOPS JK, 1994, ANN NY ACAD SCI, V737, P212, DOI 10.1111/j.1749-6632.1994.tb44314.x; Suvorov AN, 1996, J BACTERIOL, V178, P5546, DOI 10.1128/jb.178.18.5546-5549.1996; THERN A, 1995, J IMMUNOL, V154, P375; VANLEUVEN F, 1982, TRENDS BIOCHEM SCI, V7, P185, DOI 10.1016/0968-0004(82)90135-9; WHITNACK E, 1985, J BACTERIOL, V164, P350, DOI 10.1128/JB.164.1.350-358.1985; WILLIAMS SE, 1994, ANN NY ACAD SCI, V737, P1, DOI 10.1111/j.1749-6632.1994.tb44297.x	48	104	109	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15336	15344		10.1074/jbc.274.22.15336	http://dx.doi.org/10.1074/jbc.274.22.15336			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336419	hybrid			2022-12-25	WOS:000080560100008
J	Yamaguchi, T; Mukasa, T; Uchida, E; Kanayasu-Toyoda, T; Hayakawa, T				Yamaguchi, T; Mukasa, T; Uchida, E; Kanayasu-Toyoda, T; Hayakawa, T			The role of STAT3 in granulocyte colony-stimulating factor-induced enhancement of neutrophilic differentiation of Me2SO-treated HL-60 cells - GM-CSF inhibits the nuclear translocation of tyrosine-phosphorylated STAT3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOKINE RECEPTOR SUPERFAMILY; PROMYELOCYTIC LEUKEMIA-CELLS; TERMINAL DIFFERENTIATION; SERINE PHOSPHORYLATION; RAPID ACTIVATION; RETINOIC ACID; INDUCTION; PATHWAYS; TRANSCRIPTION; INTERLEUKIN-3	The role of granulocyte colony-stimulating factor (G-CSF) on neutrophilic differentiation of Me2SO-treated HL-60 cells was studied. G-CSF augmented the functional maturation of Me2SO-treated HL-60 cells in terms of both O-2(radical anion)-generating ability and expression of the formyl-methionyl-leucyl-phenylalanine receptor. G-CSF induced enhancement of cell growth in Me2SO-treated HL-60 cells. These results indicate that G-CSF is a potent enhancer for the differentiation and proliferation of Me2SO-treated HL-60 cells. G-CSF caused the activation of p70 S6 kinase but not mitogen-activated protein (MAP) kinase. On the other hand, G-CSF rapidly induced tyrosine phosphorylation of signal transducers and activators of transcription-3 (STAT3), but did not induce serine727 phosphorylation, From the analysis of confocal laser scanning fluorescence microscopy and differential centrifugation, it was clearly demonstrated that G-CSF induced nuclear translocation of tyrosine-phosphorylated STATE. The G-CSF-dependent enhancement of neutrophilic differentiation in Me2SO-HL-60 cells was reversely inhibited by granulocyte-macrophage colony-stimulating factor (GMCSF), Notably, in the presence of GM-CSF, G-CSF induced the tyrosine phosphorylation of STATE but failed to induce the nuclear translocation of tyrosine-phosphorylated STATE, GM-CSF induced activation of not only p70 S6 kinase, but also of MAP kinase, Furthermore, GM-CSF caused the rapid serine727 phosphorylation of STAT3, both in the presence and absence of G-CSF, PD98059, an MEK1 inhibitor, inhibited the G-CSF-dependent serine727 phosphorylation of STAT3 and blocked the inhibitory effect of GM-CSF on G-CSF-dependent nuclear translocation of STAT3, These results suggest that G-CSF-dependent nuclear translocation of STAT3 coordinates with the promotion of neutrophilic differentiation in Me2SO-treated HL-60 cells.	Natl Inst Hlth Sci, Dept Biol Chem & Biol, Setagaya Ku, Tokyo 158, Japan	National Institute of Health Sciences - Japan	Yamaguchi, T (corresponding author), Natl Inst Hlth Sci, Dept Biol Chem & Biol, Setagaya Ku, 1-18-1 Kamiyoga, Tokyo 158, Japan.							Avalos BR, 1996, BLOOD, V88, P761, DOI 10.1182/blood.V88.3.761.bloodjournal883761; BARSHAVIT Z, 1983, P NATL ACAD SCI-BIOL, V80, P5907, DOI 10.1073/pnas.80.19.5907; BASHEY A, 1994, BLOOD, V83, P949, DOI 10.1182/blood.V83.4.949.bloodjournal834949; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BOLLAG W, 1991, BRIT J HAEMATOL, V79, P87, DOI 10.1111/j.1365-2141.1991.tb08129.x; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; deKoning JP, 1996, BLOOD, V87, P1335, DOI 10.1182/blood.V87.4.1335.bloodjournal8741335; DEMETRI GD, 1991, BLOOD, V78, P2791; FUKUNAGA R, 1990, P NATL ACAD SCI USA, V87, P8702, DOI 10.1073/pnas.87.22.8702; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; KAKINUMA K, 1978, BIOCHIM BIOPHYS ACTA, V538, P50, DOI 10.1016/0304-4165(78)90251-9; KAKINUMA K, 1979, J BIOCHEM-TOKYO, V86, P87; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LEONARD EJ, 1990, J IMMUNOL, V144, P1323; LIESCHKE GJ, 1994, BLOOD, V84, P1737; LORD KA, 1991, MOL CELL BIOL, V11, P4371, DOI 10.1128/MCB.11.9.4371; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; NICHOLSON SE, 1995, BLOOD, V86, P3698, DOI 10.1182/blood.V86.10.3698.bloodjournal86103698; NICOLA NA, 1987, INT J CELL CLONING, V5, P1, DOI 10.1002/stem.5530050102; OKUDA K, 1992, BLOOD, V79, P2880; Pullen N, 1997, FEBS LETT, V410, P78, DOI 10.1016/S0014-5793(97)00323-2; SAKAMAKI K, 1994, FEBS LETT, V353, P133, DOI 10.1016/0014-5793(94)01024-2; SAKAMAKI T, 1992, ANTICANCER RES, V12, P1331; SAKASHITA A, 1991, LEUKEMIA, V5, P26; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SCHWARTZ EL, 1988, CANCER RES, V48, P2683; Sengupta TK, 1996, P NATL ACAD SCI USA, V93, P9499, DOI 10.1073/pnas.93.18.9499; SONADA Y, 1988, P NATL ACAD SCI USA, V85, P4360; TIAN SS, 1994, BLOOD, V84, P1760; VALTIERI M, 1987, J IMMUNOL, V138, P3829; VAN EDE, 1990, J IMMUNOL, V144, P1062; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Yamaguchi T, 1997, BIOL PHARM BULL, V20, P943; Yamaguchi T, 1998, ARCH BIOCHEM BIOPHYS, V353, P93, DOI 10.1006/abbi.1998.0622; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	41	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15575	15581		10.1074/jbc.274.22.15575	http://dx.doi.org/10.1074/jbc.274.22.15575			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336453	hybrid			2022-12-25	WOS:000080560100042
J	Patrick, SM; Turchi, JJ				Patrick, SM; Turchi, JJ			Replication protein A (RPA) binding to duplex cisplatin-damaged DNA is mediated through the generation of single-stranded DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; ANTITUMOR DRUG CIS-DIAMMINEDICHLOROPLATINUM(II); MOBILITY GROUP-1 PROTEIN; MAJOR ADDUCT; CROSS-LINKS; RECOGNITION; RECONSTITUTION; CHEMOTHERAPY; XPF-ERCC1; NUCLEASES	Replication protein A (RPA) is a heterotrimeric protein composed of 70-, 34-, and 14-kDa subunits that has been shown to be required for DNA replication, repair, and homologous recombination. We have previously shown preferential binding of recombinant human RPA (rhRPA) to duplex cisplatin-damaged DNA compared with the control undamaged DNA (Patrick, S. M., and Turchi, J. J. (1998) Biochemistry 37, 8808-8815), Here we assess the binding of rhRPA to DNA containing site-specific cisplatin-DNA adducts. rhRPA is shown to bind 1.5-2-fold better to a duplex 30-base pair substrate containing a single 1,3d(GpXpG) compared with a 1,2d(GpG) cisplatin-DNA intrastrand adduct, consistent with the difference in thermal stability of DNA containing each adduct. Consistent with these data, a 21-base pair DNA substrate containing a centrally located single interstrand cisplatin cross-link resulted in less binding than to the undamaged control DNA. A series of experiments measuring rhRPA binding and concurrent DNA denaturation revealed that rhRPA binds duplex cisplatin-damaged DNA via the generation of single-stranded DNA. Single-strand DNA binding experiments show that rhRPA binds 3-4-fold better to an undamaged 24-base DNA compared with the same substrate containing a single 1,2d(GpG) cisplatin-DNA adduct. These data are consistent with a low affinity interaction of rhRPA with duplex-damaged DNA followed by the generation of single-stranded DNA and then high affinity binding to the undamaged DNA strand.	Wright State Univ, Dept Biochem & Mol Biol, Sch Med, Dayton, OH 45435 USA	University System of Ohio; Wright State University Dayton	Turchi, JJ (corresponding author), Wright State Univ, Dept Biochem & Mol Biol, Sch Med, 3640 Colonel Glenn Highway, Dayton, OH 45435 USA.		Turchi, John J/B-5807-2015	Turchi, John J/0000-0001-5375-2992	NATIONAL CANCER INSTITUTE [R29CA064374] Funding Source: NIH RePORTER; NCI NIH HHS [CA64374] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; ANIN MF, 1990, NUCLEIC ACIDS RES, V18, P4395, DOI 10.1093/nar/18.15.4395; BELLON SF, 1991, BIOCHEMISTRY-US, V30, P8026, DOI 10.1021/bi00246a021; Bessho T, 1997, J BIOL CHEM, V272, P3833, DOI 10.1074/jbc.272.6.3833; Bochkarev A, 1997, NATURE, V385, P176, DOI 10.1038/385176a0; BRABEC V, 1990, BIOPHYS CHEM, V35, P129, DOI 10.1016/0301-4622(90)80003-P; Burns JL, 1996, J BIOL CHEM, V271, P11607, DOI 10.1074/jbc.271.20.11607; CHU G, 1994, J BIOL CHEM, V269, P787; de Laat WL, 1998, GENE DEV, V12, P2598, DOI 10.1101/gad.12.16.2598; Eastman A, 1991, Cancer Treat Res, V57, P233; Evans E, 1997, EMBO J, V16, P625, DOI 10.1093/emboj/16.3.625; GEORGAKI A, 1992, FEBS LETT, V308, P240, DOI 10.1016/0014-5793(92)81283-R; Gunz D, 1996, J BIOL CHEM, V271, P25089, DOI 10.1074/jbc.271.41.25089; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P24203; Iftode C, 1997, MOL CELL BIOL, V17, P3876, DOI 10.1128/MCB.17.7.3876; JONES CJ, 1993, BIOCHEMISTRY-US, V32, P12096, DOI 10.1021/bi00096a021; KASPARKOVA J, 1995, BIOCHEMISTRY-US, V34, P12379, DOI 10.1021/bi00038a035; LI L, 1995, MOL CELL BIOL, V15, P5396; MATSUDA T, 1995, J BIOL CHEM, V270, P4152, DOI 10.1074/jbc.270.8.4152; Matsunaga T, 1996, J BIOL CHEM, V271, P11047, DOI 10.1074/jbc.271.19.11047; Moggs JG, 1997, NUCLEIC ACIDS RES, V25, P480, DOI 10.1093/nar/25.3.480; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; Patrick SM, 1997, BBA-GENE STRUCT EXPR, V1354, P279, DOI 10.1016/S0167-4781(97)00136-X; Patrick SM, 1998, BIOCHEMISTRY-US, V37, P8808, DOI 10.1021/bi9730590; PEREZ RP, 1993, CANCER, V71, P1571, DOI 10.1002/cncr.2820710424; PIL PM, 1993, P NATL ACAD SCI USA, V90, P9465, DOI 10.1073/pnas.90.20.9465; PIL PM, 1992, SCIENCE, V256, P234, DOI 10.1126/science.1566071; RICE JA, 1988, P NATL ACAD SCI USA, V85, P4158, DOI 10.1073/pnas.85.12.4158; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; Stigger E, 1998, J BIOL CHEM, V273, P9337, DOI 10.1074/jbc.273.15.9337; TAKAHARA PM, 1995, NATURE, V377, P649, DOI 10.1038/377649a0; Treuner K, 1996, J MOL BIOL, V259, P104, DOI 10.1006/jmbi.1996.0305; TURCHI JJ, 1993, J BIOL CHEM, V268, P15136; Turchi JJ, 1997, BIOCHEMISTRY-US, V36, P7586, DOI 10.1021/bi963124q; Turchi JJ, 1996, BIOCHEMISTRY-US, V35, P2992, DOI 10.1021/bi951843j; VANGARDEREN CJ, 1994, EUR J BIOCHEM, V225, P1169; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6; Xu YC, 1997, NUCLEIC ACIDS RES, V25, P4067, DOI 10.1093/nar/25.20.4067; ZAMBLE DB, 1995, TRENDS BIOCHEM SCI, V20, P435, DOI 10.1016/S0968-0004(00)89095-7	41	85	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					14972	14978		10.1074/jbc.274.21.14972	http://dx.doi.org/10.1074/jbc.274.21.14972			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329699	hybrid			2022-12-25	WOS:000081965200064
J	Quitterer, U; Zaki, E; AbdAlla, S				Quitterer, U; Zaki, E; AbdAlla, S			Investigation of the extracellular accessibility of the connecting loop between membrane domains I and II of the bradykinin B-2 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE TOPOLOGY; ODORANT RECEPTORS; AGONIST BINDING; PROTEINS; CLONING; EXPRESSION; ADJACENT; AFFINITY; RESIDUES; SITE	In analogy to the structure of rhodopsin, the seven hydrophobic segments of G-protein-coupled receptors are supposed to form seven membrane spanning alpha-helices. To analyze the topology of the bradykinin B-2 receptor, we raised site-directed antibodies to peptides corresponding to the loop regions and the amino and carboxyl terminus of this receptor. We found that a segment with predicted intracellular orientation according to the rhodopsin model, the connecting loop between membrane domains I and II of the bradykinin B-2 receptor, was accessible to site-directed antibodies on intact fibroblasts, A431 cells, or COS cells expressing human B-2 receptors, Extracellular orientation of this loop was further confirmed by the substituted cysteine accessibility method which showed that exchange of cysteine 94 for serine on this loop by point mutagenesis suppressed the effect of thiol modification by a membrane impermeant maleimide, In addition, this segment seemed to be involved in B-2 receptor activation, since (i) thiol modification of cysteine 94 partially suppressed B-2 receptor activation, and (ii) site-directed antibodies to the connecting loop between membrane domains I and II were agonists, The agonistic activity of the antibodies was suppressed by the B-2 antagonist HOE140 confirming the B-2 specificity of the antibody-generated signal. The extracellular orientation of the connecting loop between membrane domains I and II suggests a topology of the B-2 receptor different from rhodopsin, consisting of five (instead of seven) transmembrane domains and two hydrophobic segments with both ends facing the extracellular side.	Univ Wurzburg, Inst Pharmakol & Toxikol, D-97078 Wurzburg, Germany; Genet Engn & Biotechnol Res Inst, GEBRI, Alexandria, Egypt	University of Wurzburg	Quitterer, U (corresponding author), Univ Wurzburg, Inst Pharmakol & Toxikol, Versbacher Str 9, D-97078 Wurzburg, Germany.		Zaki, Essam/K-8456-2015	Zaki, Essam/0000-0002-3906-623X				Abd Alla S., 1996, J BIOL CHEM, V271, P1748; AbdAlla S, 1996, BIOCHEMISTRY-US, V35, P7514, DOI 10.1021/bi9601060; AbdAlla S, 1996, J BIOL CHEM, V271, P27382, DOI 10.1074/jbc.271.44.27382; ABDALLA S, 1993, J BIOL CHEM, V268, P17277; AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; BENNETT JA, 1995, NEURON, V14, P373, DOI 10.1016/0896-6273(95)90293-7; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; HENN DK, 1995, P NATL ACAD SCI USA, V92, P7425, DOI 10.1073/pnas.92.16.7425; HERZIG MCS, 1995, J BIOL CHEM, V270, P20591, DOI 10.1074/jbc.270.35.20591; HESS JF, 1992, BIOCHEM BIOPH RES CO, V184, P260, DOI 10.1016/0006-291X(92)91187-U; Kuner T, 1996, NEURON, V17, P343, DOI 10.1016/S0896-6273(00)80165-8; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LACATENA RM, 1994, P NATL ACAD SCI USA, V91, P10521, DOI 10.1073/pnas.91.22.10521; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; MCEACHERN AE, 1991, P NATL ACAD SCI USA, V88, P7724, DOI 10.1073/pnas.88.17.7724; NARDONE J, 1994, P NATL ACAD SCI USA, V91, P4417, DOI 10.1073/pnas.91.10.4417; NOVOTNY EA, 1994, BIOCHEM BIOPH RES CO, V201, P523, DOI 10.1006/bbrc.1994.1733; PebayPeyroula E, 1997, SCIENCE, V277, P1676, DOI 10.1126/science.277.5332.1676; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; QUITTERER U, 1995, J BIOL CHEM, V270, P1992, DOI 10.1074/jbc.270.5.1992; Quitterer U, 1996, BIOCHEMISTRY-US, V35, P13368, DOI 10.1021/bi961163w; RAMING K, 1993, NATURE, V361, P353, DOI 10.1038/361353a0; ROSCHER AA, 1983, J CLIN INVEST, V72, P626, DOI 10.1172/JCI111012; Schulein R, 1996, J BIOL CHEM, V271, P28844, DOI 10.1074/jbc.271.46.28844; Unger VM, 1997, NATURE, V389, P203, DOI 10.1038/38316; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; VONHEIJNE G, 1986, J MOL BIOL, V192, P287, DOI 10.1016/0022-2836(86)90365-7; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; WANG HY, 1989, J BIOL CHEM, V264, P14424	30	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					14773	14778		10.1074/jbc.274.21.14773	http://dx.doi.org/10.1074/jbc.274.21.14773			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329674	hybrid			2022-12-25	WOS:000081965200039
J	Wadhwa, R; Sugihara, T; Yoshida, A; Duncan, EL; Hardeman, EC; Nomura, H; Reddel, RR; Kaul, SC				Wadhwa, R; Sugihara, T; Yoshida, A; Duncan, EL; Hardeman, EC; Nomura, H; Reddel, RR; Kaul, SC			Cloning and characterization of a novel gene, striamin, that interacts with the tumor suppressor protein p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; MYOGENIC DIFFERENTIATION; TERMINAL DIFFERENTIATION; MYOBLAST DIFFERENTIATION; MOUSE MYOBLASTS; ALPHA-SKELETAL; EXPRESSION; CELLS; MYOD; ACTIN	Expression analysis of a novel cDNA isolated from immortal murine fibroblasts revealed a single transcript of 3.0 kilobase pairs that was highly expressed in mouse and human striated muscle and in mouse heart. The gene has therefore been named striamin. Its expression was confined to skeletal muscle types with a fast glycolytic (2B) contractile phenotype. It was also detected in C2C12 mouse myoblasts and was down-regulated during in vitro myogenesis. The cDNA has a single open reading frame encoding a predicted 16.8-kDa protein of 149 amino acids with no homology to known proteins. Microinjection and transfection of green fluorescence protein-tagged striamin demonstrated that it localizes to the nucleus. Coimmunoprecipitations revealed that it can interact with p53 (a positive marker for myoblast differentiation) in vivo and in vitro. Furthermore, it repressed p53 activity in p53-mediated reporter assays. Fluorescence in situ hybridization with a mouse P1 genomic clone localized the gene to chromosome 12C3, which is syntenic to human chromosome 14q21-22.	Chugai Res Inst Mol Med, Niihari, Ibaraki 30041, Japan; Childrens Med Res Inst, Westmead, NSW 2145, Australia; Natl Inst Biosci & Human Technol, Agcy Ind Sci & Technol, Tsukuba, Ibaraki 3058566, Japan	Children's Medical Research Institute - Australia; National Institute of Advanced Industrial Science & Technology (AIST)	Wadhwa, R (corresponding author), Chugai Res Inst Mol Med, 153-2 Nagai, Niihari, Ibaraki 30041, Japan.	renu@cimmed.com	Reddel, Roger R/A-6635-2014; Hardeman, Edna C/F-8872-2012; Wadhwa, Renu/L-8898-2018; Duncan, Emma L/L-1224-2013; Kaul, Sunil C/L-8671-2018	Reddel, Roger R/0000-0002-6302-6107; Wadhwa, Renu/0000-0001-8248-5192; Duncan, Emma L/0000-0002-8143-4403; Kaul, Sunil C/0000-0002-0046-3916; Hardeman, Edna/0000-0003-1649-7712				ALONIGRINSTEIN R, 1995, EMBO J, V14, P1392, DOI 10.1002/j.1460-2075.1995.tb07125.x; ANTONIO J, 1993, MED SCI SPORT EXER, V25, P1333; BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8; BOHELER KR, 1991, J CLIN INVEST, V88, P323, DOI 10.1172/JCI115295; COLBERT MC, 1992, DEV BIOL, V149, P66, DOI 10.1016/0012-1606(92)90264-H; DICKSON G, 1990, NATURE, V344, P348, DOI 10.1038/344348a0; Emerson CP, 1993, CURR OPIN CELL BIOL, V5, P1057, DOI 10.1016/0955-0674(93)90092-5; EPSTEIN JA, 1995, J BIOL CHEM, V270, P11719, DOI 10.1074/jbc.270.20.11719; FILVAROFF EH, 1994, DEVELOPMENT, V120, P1085; GOBLET C, 1995, DEV BIOL, V170, P262, DOI 10.1006/dbio.1995.1213; Grounds M D, 1993, Mol Cell Biol Hum Dis Ser, V3, P210; GUNNING P, 1983, MOL CELL BIOL, V3, P1985, DOI 10.1128/MCB.3.11.1985; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; GUO K, 1995, MOL CELL BIOL, V15, P3823; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HAMALAINEN N, 1993, J HISTOCHEM CYTOCHEM, V41, P733, DOI 10.1177/41.5.8468455; HEWETT TE, 1994, CIRC RES, V74, P740, DOI 10.1161/01.RES.74.4.740; Hughes SM, 1997, MECH DEVELOP, V61, P151, DOI 10.1016/S0925-4773(96)00631-4; HUGHES SM, 1993, DEVELOPMENT, V118, P1137; Inada M, 1996, BIOCHEM BIOPH RES CO, V222, P317, DOI 10.1006/bbrc.1996.0742; KIESS M, 1995, ONCOGENE, V10, P159; KNUDSEN KA, 1990, DEV BIOL, V138, P159, DOI 10.1016/0012-1606(90)90185-L; KOSTROMINOVA TY, 1995, J CELL BIOCHEM, V58, P527, DOI 10.1002/jcb.240580416; Lechner C, 1996, P NATL ACAD SCI USA, V93, P4355, DOI 10.1073/pnas.93.9.4355; LEFEROVICH JM, 1995, J NEUROSCI, V15, P596; LEWIS DM, 1982, J PHYSIOL-LONDON, V325, P393, DOI 10.1113/jphysiol.1982.sp014157; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; Pette D, 1990, Rev Physiol Biochem Pharmacol, V116, P1; PROKOCIMER M, 1994, BLOOD, V84, P2391; RAO SS, 1995, J BIOL CHEM, V270, P4093, DOI 10.1074/jbc.270.8.4093; ROSEN GD, 1992, CELL, V69, P1107, DOI 10.1016/0092-8674(92)90633-N; Schiaffino S, 1996, PHYSIOL REV, V76, P371, DOI 10.1152/physrev.1996.76.2.371; Shiio Y, 1996, ONCOGENE, V12, P1837; Soddu S, 1996, J CELL BIOL, V134, P193, DOI 10.1083/jcb.134.1.193; SODDU S, 1994, BLOOD, V83, P2230, DOI 10.1182/blood.V83.8.2230.bloodjournal8382230; Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160; TAKAGI H, 1995, EUR J BIOCHEM, V231, P282, DOI 10.1111/j.1432-1033.1995.tb20698.x; WADHWA R, 1991, MUTAT RES, V256, P243, DOI 10.1016/0921-8734(91)90015-4; WADHWA R, 1993, J BIOL CHEM, V268, P6615; Wang J, 1997, CANCER RES, V57, P351; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; YABLONKAREUVENI Z, 1994, DEV BIOL, V164, P588, DOI 10.1006/dbio.1994.1226; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0; ZARDINI DM, 1994, MUSCLE NERVE, V17, P1308, DOI 10.1002/mus.880171110	45	5	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					14948	14955		10.1074/jbc.274.21.14948	http://dx.doi.org/10.1074/jbc.274.21.14948			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329696	hybrid			2022-12-25	WOS:000081965200061
J	Yan, W; Sheng, N; Seto, M; Morser, J; Wu, QY				Yan, W; Sheng, N; Seto, M; Morser, J; Wu, QY			Corin, a mosaic transmembrane serine protease encoded by a novel cDNA from human heart	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASES; MACROPHAGE SCAVENGER RECEPTORS; AMINO-ACID SEQUENCE; 4 TANDEM REPEATS; DROSOPHILA-MELANOGASTER; PLASMA PREKALLIKREIN; INDIAN HEDGEHOG; GENE ENCODES; CRD DOMAIN; POLARITY	A novel cDNA has been identified from human heart that encodes an unusual mosaic serine protease, designated corin. Corin has a predicted structure of a type II transmembrane protein and contains two frizzled-like cysteine-rich motifs, seven low density Lipoprotein receptor repeats, a macrophage scavenger receptor-like domain, and a trypsin-like protease domain in the extracellular region. Northern analysis showed that corin mRNA was highly expressed in the human heart. In mice, corin mRNA was detected by in situ hybridization in the cardiac myocytes of the embryonic heart as early as embryonic day (E) 9.5. By E11.5-13.5, corin mRNA was most abundant in the primary atrial septum and the trabecular ventricular compartment. Expression in the heart was maintained through the adult. In addition, mouse corin mRNA was also detected in the prehypertrophic chrondrocytes in developing bones. By fluorescent in situ hybridization analysis, the human corin gene was mapped to 4p12-13 where a congenital heart disease locus, total anomalous pulmonary venous return, had been previously localized. The unique domain structure and specific embryonic expression pattern suggest that corin may have a function in cell differentiation during development. The chromosomal localization of the human corin gene makes it an attractive candidate gene for total anomalous pulmonary venous return.	Berlex Biosci, Dept Cardiovasc Res, Richmond, CA 94804 USA; Berlex Biosci, Dept Biophys, Richmond, CA 94804 USA		Wu, QY (corresponding author), Berlex Biosci, Dept Cardiovasc Res, 15049 San Pablo Ave, Richmond, CA 94804 USA.			Wu, Qingyu/0000-0003-0561-9315				ANDERSON KV, 1992, COLD SPRING HARB SYM, V57, P409, DOI 10.1101/SQB.1992.057.01.046; APPEL LF, 1993, P NATL ACAD SCI USA, V90, P4937, DOI 10.1073/pnas.90.11.4937; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; BLEYL S, 1995, AM J HUM GENET, V56, P408; Bodmer R, 1998, DEV GENET, V22, P181, DOI 10.1002/(SICI)1520-6408(1998)22:3<181::AID-DVG1>3.0.CO;2-2; Brown MS, 1997, NATURE, V388, P629, DOI 10.1038/41672; CATTERALL CF, 1987, BIOCHEM J, V242, P849, DOI 10.1042/bj2420849; CHAN SDH, 1992, J BIOL CHEM, V267, P25202; CHUNG DW, 1986, BIOCHEMISTRY-US, V25, P2410, DOI 10.1021/bi00357a017; DANGOTT LJ, 1989, P NATL ACAD SCI USA, V86, P2128, DOI 10.1073/pnas.86.7.2128; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; FUJIKAWA K, 1986, BIOCHEMISTRY-US, V25, P2417, DOI 10.1021/bi00357a018; GILBERT SF, 1994, DEV BIOL; GUBB D, 1982, J EMBRYOL EXP MORPH, V68, P37; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HONG CC, 1995, CELL, V82, P785, DOI 10.1016/0092-8674(95)90475-1; HUBER R, 1978, ACCOUNTS CHEM RES, V11, P114, DOI 10.1021/ar50123a006; Jen Y, 1997, DEV DYNAM, V208, P92, DOI 10.1002/(SICI)1097-0177(199701)208:1<92::AID-AJA9>3.0.CO;2-X; KITAMOTO Y, 1994, P NATL ACAD SCI USA, V91, P7588, DOI 10.1073/pnas.91.16.7588; Konrad KD, 1998, P NATL ACAD SCI USA, V95, P6819, DOI 10.1073/pnas.95.12.6819; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P14176; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lanske B, 1996, SCIENCE, V273, P663, DOI 10.1126/science.273.5275.663; LeMosy EK, 1998, DEVELOPMENT, V125, P4045; Leyns L, 1997, CELL, V88, P747, DOI 10.1016/S0092-8674(00)81921-2; LEYTUS SP, 1988, BIOCHEMISTRY-US, V27, P1067, DOI 10.1021/bi00403a032; Lin KM, 1997, P NATL ACAD SCI USA, V94, P11196, DOI 10.1073/pnas.94.21.11196; Masiakowski P, 1998, CURR BIOL, V8, pR407, DOI 10.1016/S0960-9822(98)70263-5; MATSUMOTO A, 1990, P NATL ACAD SCI USA, V87, P9133, DOI 10.1073/pnas.87.23.9133; Morisato D, 1995, ANNU REV GENET, V29, P371, DOI 10.1146/annurev.genet.29.1.371; NEURATH H, 1984, SCIENCE, V224, P350, DOI 10.1126/science.6369538; PaoloniGiacobino A, 1997, GENOMICS, V44, P309, DOI 10.1006/geno.1997.4845; Park MY, 1996, DEV BIOL, V177, P104, DOI 10.1006/dbio.1996.0149; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; REHN M, 1995, J BIOL CHEM, V270, P4705, DOI 10.1074/jbc.270.9.4705; Saldanha J, 1998, PROTEIN SCI, V7, P1632, DOI 10.1002/pro.5560070718; Sawa H, 1996, GENE DEV, V10, P2189, DOI 10.1101/gad.10.17.2189; SCHONBAUM CP, 1995, P NATL ACAD SCI USA, V92, P1485, DOI 10.1073/pnas.92.5.1485; Shulman JM, 1998, TRENDS GENET, V14, P452, DOI 10.1016/S0168-9525(98)01584-4; Song LX, 1997, J BIOL CHEM, V272, P10543; STORM EE, 1994, NATURE, V368, P639, DOI 10.1038/368639a0; THORPE DS, 1989, J BIOL CHEM, V264, P6545; TORRESROSADO A, 1993, P NATL ACAD SCI USA, V90, P7181, DOI 10.1073/pnas.90.15.7181; TSUJI A, 1991, J BIOL CHEM, V266, P16948; VINSON CR, 1989, NATURE, V338, P263, DOI 10.1038/338263a0; Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613; WANG DC, 1985, J MOL BIOL, V185, P595, DOI 10.1016/0022-2836(85)90074-9; Wang SW, 1997, CELL, V88, P757, DOI 10.1016/S0092-8674(00)81922-4; Wu QY, 1998, J CLIN INVEST, V101, P321, DOI 10.1172/JCI1617; WU XS, 1995, DEV BIOL, V169, P619, DOI 10.1006/dbio.1995.1174; Xu YK, 1998, CURR BIOL, V8, pR405, DOI 10.1016/S0960-9822(98)70262-3; Yamaoka K, 1998, J BIOL CHEM, V273, P11895, DOI 10.1074/jbc.273.19.11895; Zou HY, 1997, GENE DEV, V11, P2191, DOI 10.1101/gad.11.17.2191	55	213	240	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					14926	14935		10.1074/jbc.274.21.14926	http://dx.doi.org/10.1074/jbc.274.21.14926			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329693	hybrid			2022-12-25	WOS:000081965200058
J	Moll, U; Lau, R; Sypes, MA; Gupta, MM; Anderson, CW				Moll, U; Lau, R; Sypes, MA; Gupta, MM; Anderson, CW			DNA-PK, the DNA-activated protein kinase, is differentially expressed in normal and malignant human tissues	ONCOGENE			English	Article						cancer; DNA repair; DNA double-strand breaks; Brca2; Ku autoantigen; tissue-specific gene expression	STRAND-BREAK REPAIR; HUMAN AUTOANTIGEN KU; RNA-POLYMERASE-II; V(D)J RECOMBINATION; IONIZING-RADIATION; BINDING PROTEIN; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; CATALYTIC SUBUNIT; GENE-PRODUCT; HUMAN MRE11	DNA-PK is a nuclear, serine/threonine protein kinase required for repairing DNA double-sh and breaks and for V(D)J recombination. To determine the distribution of DNA-PK in human tissues, we assayed paraffin-embedded sections of normal and cancerous tissues for DNA-PKcs and Ku80 by immunohistochemistry. We also assayed for Brca2, a human tumor suppressor gene that is implicated in the repair of DNA strand-breaks. Brca2 was strongly expressed in epithelial cells of the breast, endometrium, and thymus, in tingible body macrophages of follicular germinal centers of lymphoid tissue, and in reticuloendothelial cells in the spleen. DNA-PKcs and Ku80 expression was usually parallel, but both were expressed in a highly cell- and tissue-specific manner. The highest levels were observed in spermatogenic cells (but not in spermatozoa), and in neurons and glial cells of the central and autonomic nervous system. Neither protein was consistently expressed in liver nor in resting mammary epithelium, but lactating breast epithelium was strongly positive for DNA-PKcs and Ku80. In contrast to established human cell cultures, expression between cells in the same tissue was highly selective in the epidermis, exocrine pancreas, renal glomeruli, the red pulp of the spleen, and within cellular compartments of tonsils, lymph nodes, and thymus. Most cancerous tissues were consistently positive for DNA-PKcs and Ku80, except invasive carcinoma of the breast. DNA-PKcs, Ku80, and Ku70 mRNAs were expressed in all normal tissues with relatively little variation in levels. Our results suggest that the apparent absence of DNA-PKcs and Ku80 from some cells or tissues is a consequence of posttranscriptional mechanisms that regulate protein levels.	Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA; SUNY Stony Brook, Dept Pathol, Stony Brook, NY 11794 USA	United States Department of Energy (DOE); Brookhaven National Laboratory; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Anderson, CW (corresponding author), Brookhaven Natl Lab, Dept Biol, 50 Bell Ave, Upton, NY 11973 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052825] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52825] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abbott DW, 1998, J NATL CANCER I, V90, P978, DOI 10.1093/jnci/90.13.978; AJMANI AK, 1995, J EXP MED, V181, P2049, DOI 10.1084/jem.181.6.2049; ALLALUNISTURNER MJ, 1993, RADIAT RES, V134, P349, DOI 10.2307/3578196; Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; Anderson CW, 1996, CURR TOP MICROBIOL, V217, P91; ARCARI P, 1984, NUCLEIC ACIDS RES, V12, P9179, DOI 10.1093/nar/12.23.9179; Barlev NA, 1998, MOL CELL BIOL, V18, P1349, DOI 10.1128/MCB.18.3.1349; Bernstein C., 1991, AGING SEX DNA REPAIR; Bertwistle D, 1998, CURR OPIN GENET DEV, V8, P14, DOI 10.1016/S0959-437X(98)80056-7; BLIER PR, 1993, J BIOL CHEM, V268, P7594; BRUSH GS, 1994, P NATL ACAD SCI USA, V91, P12520, DOI 10.1073/pnas.91.26.12520; CAI QQ, 1994, CYTOGENET CELL GENET, V65, P221, DOI 10.1159/000133635; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; Casey Graham, 1997, Current Opinion in Oncology, V9, P88; CHAN JYC, 1989, J BIOL CHEM, V264, P3651; Chibazakura T, 1997, EUR J BIOCHEM, V247, P1166, DOI 10.1111/j.1432-1033.1997.01166.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chu G, 1997, J BIOL CHEM, V272, P24097, DOI 10.1074/jbc.272.39.24097; Connelly MA, 1998, GENOMICS, V47, P71, DOI 10.1006/geno.1997.5076; Connelly MA, 1996, GENE, V175, P271, DOI 10.1016/0378-1119(96)00135-7; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Critchlow SE, 1997, CURR BIOL, V7, P588, DOI 10.1016/S0960-9822(06)00258-2; Dolganov GM, 1996, MOL CELL BIOL, V16, P4832; DVIR A, 1993, J BIOL CHEM, V268, P10440; Dynan WS, 1998, NUCLEIC ACIDS RES, V26, P1551, DOI 10.1093/nar/26.7.1551; EASTMAN A, 1992, CANCER INVEST, V10, P229, DOI 10.3109/07357909209032765; Essers J, 1997, CELL, V89, P195, DOI 10.1016/S0092-8674(00)80199-3; FALZON M, 1993, J BIOL CHEM, V268, P10546; FINNIE NJ, 1995, P NATL ACAD SCI USA, V92, P320, DOI 10.1073/pnas.92.1.320; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; GALLOWAY AM, 1998, IN PRESS ONCOGENE; Gellert M, 1994, Semin Immunol, V6, P125, DOI 10.1006/smim.1994.1018; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Grawunder U, 1996, EUR J BIOCHEM, V241, P931, DOI 10.1111/j.1432-1033.1996.00931.x; Gu YS, 1997, P NATL ACAD SCI USA, V94, P8076, DOI 10.1073/pnas.94.15.8076; HANAUER A, 1984, EMBO J, V3, P2627, DOI 10.1002/j.1460-2075.1984.tb02185.x; Hendrickson EA, 1997, AM J HUM GENET, V61, P795, DOI 10.1086/514895; HUNTER T, 1995, CELL, V83, P1, DOI 10.1016/0092-8674(95)90225-2; ILIAKIS G, 1991, BIOESSAYS, V13, P641; JACKSON SP, 1995, TRENDS BIOCHEM SCI, V20, P412, DOI 10.1016/S0968-0004(00)89090-8; Jhappan C, 1997, NAT GENET, V17, P483, DOI 10.1038/ng1297-483; Kanaar R, 1996, CURR BIOL, V6, P828, DOI 10.1016/S0960-9822(02)00606-1; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; KUHN A, 1995, GENE DEV, V9, P193, DOI 10.1101/gad.9.2.193; LABHART P, 1995, P NATL ACAD SCI USA, V92, P2934, DOI 10.1073/pnas.92.7.2934; Leber R, 1998, J BIOL CHEM, V273, P1794, DOI 10.1074/jbc.273.3.1794; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LEESMILLER SP, 1989, J BIOL CHEM, V264, P2431; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; Li GC, 1998, MOL CELL, V2, P1, DOI 10.1016/S1097-2765(00)80108-2; LI LL, 1992, EXP CELL RES, V199, P262, DOI 10.1016/0014-4827(92)90433-9; Li ZY, 1995, CELL, V83, P1079, DOI 10.1016/0092-8674(95)90135-3; MIMORI T, 1990, P NATL ACAD SCI USA, V87, P1777, DOI 10.1073/pnas.87.5.1777; MIMORI T, 1986, J BIOL CHEM, V261, P2274; MOROZOV VE, 1994, J BIOL CHEM, V269, P16684; Muller C, 1998, BLOOD, V92, P2213, DOI 10.1182/blood.V92.7.2213.2213_2213_2219; MURIS DFR, 1994, MUTAT RES-DNA REPAIR, V315, P295, DOI 10.1016/0921-8777(94)90040-X; Nagasawa M, 1997, CELL STRUCT FUNCT, V22, P585, DOI 10.1247/csf.22.585; PARK MS, 1995, J BIOL CHEM, V270, P15467, DOI 10.1074/jbc.270.26.15467; Petrini J H, 1997, Semin Immunol, V9, P181, DOI 10.1006/smim.1997.0067; PETRINI JHJ, 1995, GENOMICS, V29, P80, DOI 10.1006/geno.1995.1217; Pfeiffer P, 1996, MUTAT RES-REV GENET, V366, P69, DOI 10.1016/S0165-1110(96)90029-9; Rajan JV, 1996, P NATL ACAD SCI USA, V93, P13078, DOI 10.1073/pnas.93.23.13078; Rolink A, 1996, IMMUNITY, V5, P319, DOI 10.1016/S1074-7613(00)80258-7; Salminen A, 1997, BIOCHEM BIOPH RES CO, V238, P712, DOI 10.1006/bbrc.1997.7371; SATOH M, 1995, EUR J CELL BIOL, V66, P127; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Shin EK, 1997, J IMMUNOL, V158, P3565; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; Smider V, 1997, Semin Immunol, V9, P189, DOI 10.1006/smim.1997.0070; SUWA A, 1994, P NATL ACAD SCI USA, V91, P6904, DOI 10.1073/pnas.91.15.6904; Suzuki A, 1997, GENE DEV, V11, P1242, DOI 10.1101/gad.11.10.1242; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; THOMPSON LH, 1995, MUTAT RES-DNA REPAIR, V337, P131, DOI 10.1016/0921-8777(95)00018-F; WALKER AI, 1985, EMBO J, V4, P139, DOI 10.1002/j.1460-2075.1985.tb02328.x; Weaver D, 1995, ANN NY ACAD SCI, V764, P99; WILER R, 1995, P NATL ACAD SCI USA, V92, P11485, DOI 10.1073/pnas.92.25.11485; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343; Yamamoto A, 1996, MOL GEN GENET, V251, P1; YANEVA M, 1991, BIOCHIM BIOPHYS ACTA, V1090, P181, DOI 10.1016/0167-4781(91)90099-8; ZernikKobak M, 1997, J BIOL CHEM, V272, P23896, DOI 10.1074/jbc.272.38.23896	84	78	92	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 20	1999	18	20					3114	3126		10.1038/sj.onc.1202640	http://dx.doi.org/10.1038/sj.onc.1202640			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	197WB	10340383				2022-12-25	WOS:000080388000007
J	Diverse-Pierluissi, MA; Fischer, T; Jordan, JD; Schiff, M; Ortiz, DF; Farquhar, MG; De Vries, L				Diverse-Pierluissi, MA; Fischer, T; Jordan, JD; Schiff, M; Ortiz, DF; Farquhar, MG; De Vries, L			Regulators of G protein signaling proteins as determinants of the rate of desensitization of presynaptic calcium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEINS; GTPASE-ACTIVATING PROTEINS; RGS PROTEINS; MAMMALIAN-CELLS; ALPHA-SUBUNITS; CURRENTS; FAMILY; GAIP; LOCALIZATION; MECHANISMS	Norepinephrine inhibits omega-conotoxin GVIA-sensitive presynaptic Ca2+ channels in chick dorsal root ganglion neurons through two pathways, one mediated by G(o) and the other by G(i). These pathways desensitize at different rates. We have found that recombinant G alpha interacting protein (GAIP) and regulators of G protein signaling (RGS)4 selectively accelerate the rate of desensitization of G(o)- and G(i)-mediated pathways, respectively. Blockade of endogenous RGS proteins using antibodies raised against G alpha interacting protein and RGS4 slows the rate of desensitization of these pathways in a selective manner. These results demonstrate that different RGS proteins may interact with G(i) and G(o) selectively, giving rise to distinct time courses of transmitter-mediated effects.	CUNY Mt Sinai Sch Med, Dept Pharmacol, New York, NY 10029 USA; Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA; Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA; Univ Calif San Diego, Div Cellular & Mol Med, La Jolla, CA 92093 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Tufts University; University of California System; University of California San Diego; University of California System; University of California San Diego	Diverse-Pierluissi, MA (corresponding author), CUNY Mt Sinai Sch Med, Dept Pharmacol, 1 Gustave Levy Pl, New York, NY 10029 USA.			Jordan, Dedrick/0000-0002-0706-9583; Fischer, Thierry/0000-0002-9542-322X	NIDA NIH HHS [DA05798] Funding Source: Medline; NIDDK NIH HHS [DK17780] Funding Source: Medline; NINDS NIH HHS [NS37443] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK017780, R01DK017780] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037443] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [F30DA005798] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Arshavsky VY, 1998, NEURON, V20, P11, DOI 10.1016/S0896-6273(00)80430-4; BEECH DJ, 1992, NEURON, V8, P97, DOI 10.1016/0896-6273(92)90111-P; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; De Vries L, 1998, MOL BIOL CELL, V9, P1123, DOI 10.1091/mbc.9.5.1123; De Vries L, 1998, P NATL ACAD SCI USA, V95, P12340, DOI 10.1073/pnas.95.21.12340; DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916; DiversePierluissi M, 1996, NEURON, V16, P579, DOI 10.1016/S0896-6273(00)80077-X; DIVERSEPIERLUISSI M, 1995, NEURON, V14, P191, DOI 10.1016/0896-6273(95)90254-6; DIVERSEPIERLUISSI M, 1993, NEURON, V10, P753, DOI 10.1016/0896-6273(93)90175-Q; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; He W, 1998, NEURON, V20, P95, DOI 10.1016/S0896-6273(00)80437-7; HILLE B, 1992, NEURON, V9, P187, DOI 10.1016/0896-6273(92)90158-A; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; Huang CF, 1997, P NATL ACAD SCI USA, V94, P6159, DOI 10.1073/pnas.94.12.6159; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; LUEBKE JI, 1994, PFLUG ARCH EUR J PHY, V428, P499, DOI 10.1007/BF00374571; Saitoh O, 1997, NATURE, V390, P525, DOI 10.1038/37385; Saugstad JA, 1998, J NEUROSCI, V18, P905; Shuey DJ, 1998, J NEUROCHEM, V70, P1964; Siderovski DP, 1996, CURR BIOL, V6, P211, DOI 10.1016/S0960-9822(02)00454-2; Snow BE, 1998, GENE, V206, P247, DOI 10.1016/S0378-1119(97)00593-3; Snow BE, 1997, BIOCHEM BIOPH RES CO, V233, P770, DOI 10.1006/bbrc.1997.6537; Snow BE, 1998, J BIOL CHEM, V273, P17749, DOI 10.1074/jbc.273.28.17749; Srinivasa SP, 1998, P NATL ACAD SCI USA, V95, P5584, DOI 10.1073/pnas.95.10.5584; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; Zeng WZ, 1998, J BIOL CHEM, V273, P34687, DOI 10.1074/jbc.273.52.34687	28	59	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					14490	14494		10.1074/jbc.274.20.14490	http://dx.doi.org/10.1074/jbc.274.20.14490			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318875	hybrid			2022-12-25	WOS:000080322200104
J	Taupin, JL; Miossec, V; Pitard, V; Blanchard, F; Daburon, S; Raher, S; Jacques, Y; Godard, A; Moreau, JF				Taupin, JL; Miossec, V; Pitard, V; Blanchard, F; Daburon, S; Raher, S; Jacques, Y; Godard, A; Moreau, JF			Binding of leukemia inhibitory factor (LIF) to mutants of its low affinity receptor, gp190, reveals a LIF binding site outside and interactions between the two cytokine binding domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; IL-6 SIGNAL TRANSDUCER; IMMUNOGLOBULIN-LIKE DOMAIN; GROWTH-HORMONE RECEPTOR; AMINO-ACID-RESIDUES; FACTOR GM-CSF; MONOCLONAL-ANTIBODIES; EXPRESSION CLONING; LIGAND-BINDING; MUTATIONAL ANALYSIS	The gp190 transmembrane protein,the low affinity receptor for the leukemia inhibitory factor (LIF), belongs to the hematopoietin family of receptors characterized by the cytokine binding domain (CBD). gp190 is one of the very few members of this family to contain two such domains. The membrane-proximal CBD (herein called D2) is separated from the membrane-distal one (called D1) by an immunoglobulin-like (Ig) domain and is followed by three fibronectin type III repeats. We used truncated gp190 mutants and a blocking anti-gp190 monoclonal antibody to study the role of these repeats in low affinity receptor function. Our results showed that the D1Ig region was involved in LIF binding, while D2 appeared to be crucial for the proper folding of D1, suggesting functionally important interactions between the two CBDs in the wild-type protein. In addition, point mutation in the carboxyl terminus of the Ig region strongly impaired ligand binding. These findings suggest that at least two distinct sites, both located within the D1Ig region, are involved in LIF binding to gp190, and more generally, that Ligand binding sites on these receptors may well be located outside the canonical CBDs.	Univ Bordeaux 2, CNRS, UMR 5540, F-33076 Bordeaux, France; INSERM, U463, Inst Biol, F-44035 Nantes, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; Institut National de la Sante et de la Recherche Medicale (Inserm)	Taupin, JL (corresponding author), Univ Bordeaux 2, CNRS, UMR 5540, Batiment 1B,146 Rue Leo Saignat, F-33076 Bordeaux, France.		Blanchard, Frederic/AAS-1930-2021; Blanchard, Frederic/K-8018-2015	Blanchard, Frederic/0000-0003-1055-2573; Blanchard, Frederic/0000-0003-1055-2573				Bagley CJ, 1997, BLOOD, V89, P1471, DOI 10.1182/blood.V89.5.1471.1471_1471_1482; BASS SH, 1991, P NATL ACAD SCI USA, V88, P4498, DOI 10.1073/pnas.88.10.4498; BAUMGARTNER JW, 1994, J BIOL CHEM, V269, P29094; CHUA AO, 1994, J IMMUNOL, V153, P128; DAndrea RJ, 1996, BLOOD, V87, P2641, DOI 10.1182/blood.V87.7.2641.bloodjournal8772641; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; GEARING DP, 1992, NEW BIOL, V4, P61; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GODARD A, 1992, J BIOL CHEM, V267, P3214; GORMAN DM, 1990, P NATL ACAD SCI USA, V87, P5459, DOI 10.1073/pnas.87.14.5459; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; Hilton DJ, 1996, J BIOL CHEM, V271, P4699; HILTON DJ, 1992, J BIOL CHEM, V267, P10238; HIRAOKA O, 1994, J BIOL CHEM, V269, P22412; HIRAOKA O, 1995, J BIOL CHEM, V270, P25928, DOI 10.1074/jbc.270.43.25928; HORSTEN U, 1995, FEBS LETT, V360, P43, DOI 10.1016/0014-5793(95)00053-C; Hudson KR, 1996, J BIOL CHEM, V271, P11971, DOI 10.1074/jbc.271.20.11971; IMLER JL, 1992, EMBO J, V11, P2047, DOI 10.1002/j.1460-2075.1992.tb05262.x; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; KAUFMAN RJ, 1991, NUCLEIC ACIDS RES, V19, P4485, DOI 10.1093/nar/19.16.4485; LARSEN A, 1990, J EXP MED, V172, P1559, DOI 10.1084/jem.172.6.1559; LAYTON MJ, 1994, J BIOL CHEM, V269, P29891; LAYTON MJ, 1994, J BIOL CHEM, V269, P17048; Liautard J, 1997, CYTOKINE, V9, P233, DOI 10.1006/cyto.1996.0159; MIYAZAKI T, 1991, EMBO J, V10, P3191, DOI 10.1002/j.1460-2075.1991.tb04881.x; Mosley B, 1996, J BIOL CHEM, V271, P32635, DOI 10.1074/jbc.271.51.32635; Owczarek CM, 1997, J BIOL CHEM, V272, P23976, DOI 10.1074/jbc.272.38.23976; Pennica D, 1996, NEURON, V17, P63, DOI 10.1016/S0896-6273(00)80281-0; PENNICA D, 1995, J BIOL CHEM, V270, P10915, DOI 10.1074/jbc.270.18.10915; Pitard V, 1997, J IMMUNOL METHODS, V205, P177, DOI 10.1016/S0022-1759(97)00074-4; Pitard V, 1998, EUR CYTOKINE NETW, V9, P599; ROBINSON RC, 1994, CELL, V77, P1101, DOI 10.1016/0092-8674(94)90449-9; ROZAKISADCOCK M, 1991, J BIOL CHEM, V266, P16472; Simpson RJ, 1997, PROTEIN SCI, V6, P929, DOI 10.1002/pro.5560060501; Starr R, 1997, J BIOL CHEM, V272, P19982, DOI 10.1074/jbc.272.32.19982; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; TAUPIN JL, 1993, SCAND J IMMUNOL, V38, P293, DOI 10.1111/j.1365-3083.1993.tb01728.x; Taupin JL, 1997, CYTOKINE, V9, P112, DOI 10.1006/cyto.1996.0144; Tomida M, 1996, J BIOCHEM-TOKYO, V120, P201; Vignon I, 1992, P NATL ACAD SCI USA, V89, P5640; WOODCOCK JM, 1994, EMBO J, V13, P5176, DOI 10.1002/j.1460-2075.1994.tb06848.x; YAWATA H, 1993, EMBO J, V12, P1705, DOI 10.1002/j.1460-2075.1993.tb05815.x	48	22	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					14482	14489		10.1074/jbc.274.20.14482	http://dx.doi.org/10.1074/jbc.274.20.14482			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318874	hybrid			2022-12-25	WOS:000080322200103
J	Ohtani, K; Iwanaga, R; Nakamura, M; Ikeda, M; Yabuta, N; Tsuruga, H; Nojima, H				Ohtani, K; Iwanaga, R; Nakamura, M; Ikeda, M; Yabuta, N; Tsuruga, H; Nojima, H			Cell growth-regulated expression of mammalian MCM5 and MCM6 genes mediated by the transcription factor E2F	ONCOGENE			English	Article						mammalian MCM; E2F; promoter; cell cycle; DNA replication	S-PHASE ENTRY; REPLICATION LICENSING SYSTEM; DNA-REPLICATION; MCM/P1 PROTEINS; BUDDING YEAST; HUMAN HOMOLOG; CYCLE; COMPONENT; APOPTOSIS; FAMILY	Initiation of DNA replication requires the function of MCM gene products, which participate in ensuring that DNA replication occurs only once in the cell cycle, Expression of all mammalian genes of the MCM family is induced by growth stimulation, unlike yeast, and the mRNA levels peak at G1/S boundary, In this study, we examined the transcriptional activities of isolated human MCM gene promoters. Human MCMS and MCM6 promoters with mutation in the E2F sites failed in promoter regulation following serum stimulation and exogenous E2F expression. In addition, me identified a novel E2F-Like sequence in human MCM6 promoter which cooperates with the authentic E2F sites in E2F-dependent regulation. Forced expression of E2F1 could induce expression of all members of the endogenous MCM genes in rat embryonal fibroblast REF52 cells. Our results demonstrated that the growth-regulated expression of mammalian MCM5 and MCM6 genes, and presumably other MCM members, is primarily regulated by E2F through binding to multiple E2F sites in the promoters.	Tokyo Med & Dent Univ, Human Gene Sci Ctr, Tokyo 1138510, Japan; Tokyo Med & Dent Univ, Grad Sch Dent, Dept Dev Biol, Tokyo 1138549, Japan; Osaka Univ, Microbial Dis Res Inst, Dept Mol Genet, Suita, Osaka 5650871, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Osaka University	Nakamura, M (corresponding author), Tokyo Med & Dent Univ, Human Gene Sci Ctr, Tokyo 1138510, Japan.							BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; CHONG JPJ, 1995, NATURE, V375, P418, DOI 10.1038/375418a0; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Donovan S, 1997, P NATL ACAD SCI USA, V94, P5611, DOI 10.1073/pnas.94.11.5611; Fujita M, 1996, BIOCHEM BIOPH RES CO, V219, P604, DOI 10.1006/bbrc.1996.0280; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KIMURA H, 1994, EMBO J, V13, P4311, DOI 10.1002/j.1460-2075.1994.tb06751.x; Kiyono T, 1996, BBA-GENE STRUCT EXPR, V1307, P31, DOI 10.1016/0167-4781(96)00057-7; KUBOTA Y, 1995, CELL, V81, P601, DOI 10.1016/0092-8674(95)90081-0; Kubota Y, 1997, EMBO J, V16, P3320, DOI 10.1093/emboj/16.11.3320; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LATHANGUE NB, 1990, NUCLEIC ACIDS RES, V18, P2929, DOI 10.1093/nar/18.10.2929; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; MADINE MA, 1995, NATURE, V375, P421, DOI 10.1038/375421a0; NEVINS JR, 1992, SCIENCE, V258, P424; Ohtani K, 1998, ONCOGENE, V17, P1777, DOI 10.1038/sj.onc.1202105; Ohtani K, 1996, MOL CELL BIOL, V16, P6977; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; ROSE M, 1983, METHOD ENZYMOL, V101, P167; Sato N, 1997, EMBO J, V16, P4340, DOI 10.1093/emboj/16.14.4340; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; Thommes P, 1997, EMBO J, V16, P3312, DOI 10.1093/emboj/16.11.3312; Tsuruga H, 1997, GENES CELLS, V2, P381, DOI 10.1046/j.1365-2443.1997.1290327.x; Tsuruga H, 1997, BIOCHEM BIOPH RES CO, V236, P118, DOI 10.1006/bbrc.1997.6865; Yan Z, 1998, P NATL ACAD SCI USA, V95, P3603, DOI 10.1073/pnas.95.7.3603; YEE AS, 1989, MOL CELL BIOL, V9, P578, DOI 10.1128/MCB.9.2.578	31	110	114	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 8	1999	18	14					2299	2309		10.1038/sj.onc.1202544	http://dx.doi.org/10.1038/sj.onc.1202544			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184DT	10327050				2022-12-25	WOS:000079595500002
J	Zhu, JH; Jiang, JY; Zhou, WJ; Zhu, KC; Chen, XB				Zhu, JH; Jiang, JY; Zhou, WJ; Zhu, KC; Chen, XB			Differential regulation of cellular target genes by p53 devoid of the PXXP motifs with impaired apoptotic activity	ONCOGENE			English	Article						p53; p21(wafl/cipl); apoptosis; cell cycle arrest	WILD-TYPE P53; TRANSCRIPTIONAL ACTIVATION; GROWTH ARREST; TUMOR-CELLS; IN-VIVO; PATHWAY; P21(WAF1/CIP1); IDENTIFICATION; SUPPRESSION; INHIBITOR	Activation of the p53 tumor suppressor protein can lead to either cell cycle arrest or apoptosis. Several functional domains necessary for mediating cell cycle arrest and apoptosis in p53 have been mapped, e.g., the proline-rich domain. The proline-rich domain is located within residues 60-90, which comprise five PXXP motifs (where P represents proline and X any amino acid). To further delineate the function of the proline-rich domain and its potential role in transactivation, we generated several groups of cell lines that inducibly express various p53 mutants using a tetracycline-regulated expression system. We found that p53(Delta 62-91), which lacks all five PXXP motifs in human p53, is capable of inducing cell cycle arrest but not apoptosis, while p53(gln22-ser23/Delta 62-91), which contains a double point mutation in the activation domain as well as deletion of the proline-rich domain, completely loses its activity. However, p53(Delta 74-91), which contains only one PXXP motif at its N-terminus, is not only capable of inducing cell cycle arrest but also retains a partial apoptotic activity. Furthermore, we found that deletion of the proline-rich region has no or very mild effects on activation of several transiently transfected p53 target gene promoters, i.e., the p21, MDM2, BAX, and GADD45 promoters. However, such deletion differentially affects p53 induction of endogenous target genes, i.e., induction of p21, MDM2, BTG2, p85, PIG3, PIG6 and PIG11 was reduced or abrogated but induction of BAX, KILLER/DR5, PIG2, PIG7 and PIGS was not substantially affected. Interestingly, induction of GADD45 was enhanced. These results suggest that the proline-rich region may play a role in chromatin remodeling, which counteracts chromatin-mediated repression for some of the endogenous p53 target genes.	Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA	University System of Georgia; Augusta University	Chen, XB (corresponding author), Med Coll Georgia, Inst Mol Med & Genet, CB-2803, Augusta, GA 30912 USA.			Zhu, Kuichun/0000-0002-3594-5616	NCI NIH HHS [CA76069] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076069, R29CA076069] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gerber AN, 1997, GENE DEV, V11, P436, DOI 10.1101/gad.11.4.436; GOTTLIEB TM, 1996, IOCH BIOPHYS ACTA, V1287, P77; HARPER JW, 1993, CELL, V75, P805; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; Ruaro EM, 1997, P NATL ACAD SCI USA, V94, P4675, DOI 10.1073/pnas.94.9.4675; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; Smith CL, 1997, J BIOL CHEM, V272, P27493, DOI 10.1074/jbc.272.44.27493; Sugrue MM, 1997, P NATL ACAD SCI USA, V94, P9648, DOI 10.1073/pnas.94.18.9648; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yin YX, 1998, NATURE, V391, P707, DOI 10.1038/35648; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030	30	100	102	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 25	1999	18	12					2149	2155		10.1038/sj.onc.1202533	http://dx.doi.org/10.1038/sj.onc.1202533			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	179TX	10321740				2022-12-25	WOS:000079346200013
J	Eppenberger, HM; Zuppinger, C				Eppenberger, HM; Zuppinger, C			In vitro reestablishment of cell-cell contacts in adult rat cardiomyocytes. Functional role of transmembrane components in the formation of new intercalated disk-like cell contacts	FASEB JOURNAL			English	Article; Proceedings Paper	Symposium of the European-Space-Agency/National-Aeronautics-and-Space-Administration Workshop on Cell and Molecular biology Research in Space	JUN, 1998	BELGIUM NATL ACAD SCI, LEUVEN, BELGIUM	European Space Agency, NASA	BELGIUM NATL ACAD SCI	cardiomyocytes; N-cadherin; gap junction; GFP	ATRIAL-NATRIURETIC-FACTOR; GENE-EXPRESSION; CARDIAC MYOCYTE; MUSCLE-CELLS; N-CADHERIN; IGF-I; CULTURE; MICROGRAVITY; PROTEIN; ALPHA	Primary adult rat cardiomyocytes (ARC) in culture are shown to be a model system for cardiac cell hypertrophy in vitro, ARC undergo a process of morphological transformation and grow only by increase in cell size, however, without loss of the cardiac phenotype, The isolated cells spread and establish new cell-cell contacts, eventually forming a two-dimensional heart tissue-like synchronously beating cell, sheet. The reformation of specific cell contacts (intercalated disks) is shown also between ventricular and atrial cardiomyocytes by using antibodies against the gap junction protein connexin-43 and after microinjection into ARC of N-cadherin cDNA fused to reporter green fluorescent protein (GFP) cDNA. The expressed fusion protein allowed the study of live cell cultures and of the dynamics of the adherens junction protein N-cadherin during the formation of new cell-cell contacts. The possible use of the formed ARC cell-sheet cells under microgravity conditions as a test system for the reformation of the cytoskeleton of heart muscle cells is proposed.	ETH Honggerberg, Inst Cell Biol, Dept Biol, CH-8093 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Eppenberger, HM (corresponding author), ETH Honggerberg, Inst Cell Biol, Dept Biol, CH-8093 Zurich, Switzerland.		Zuppinger, Christian/H-4452-2019	Zuppinger, Christian/0000-0003-1786-0800				Akins RE, 1997, IN VITRO CELL DEV-AN, V33, P337; BOHELER KR, 1992, TRENDS CARDIOVAS MED, V2, P176, DOI 10.1016/1050-1738(92)90046-U; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CLAYCOMB WC, 1983, DEV BIOL, V99, P331, DOI 10.1016/0012-1606(83)90283-X; Connold AL, 1997, J MUSCLE RES CELL M, V18, P63, DOI 10.1023/A:1018680900305; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; EPPENBERGER ME, 1988, DEV BIOL, V130, P1, DOI 10.1016/0012-1606(88)90408-3; EPPENBERGEREBERHARDT M, 1990, DEV BIOL, V139, P269, DOI 10.1016/0012-1606(90)90296-U; EppenbergerEberhardt M, 1997, J MOL CELL CARDIOL, V29, P2027, DOI 10.1006/jmcc.1997.0408; Freed LE, 1997, IN VITRO CELL DEV-AN, V33, P381; GEIGER B, 1992, ANNU REV CELL BIOL, V8, P307, DOI 10.1146/annurev.cb.08.110192.001515; Gerdes A M, 1992, J Fla Med Assoc, V79, P253; GROVE BK, 1984, J CELL BIOL, V98, P518, DOI 10.1083/jcb.98.2.518; Harder BA, 1996, J MOL CELL CARDIOL, V28, P19, DOI 10.1006/jmcc.1996.0003; HATTA K, 1988, J CELL BIOL, V106, P873, DOI 10.1083/jcb.106.3.873; Hefti MA, 1997, J MOL CELL CARDIOL, V29, P2873, DOI 10.1006/jmcc.1997.0523; Hertig CM, 1996, J CELL SCI, V109, P1; Hertig CM, 1996, J CELL SCI, V109, P11; HughesFulford M, 1996, EXP CELL RES, V224, P103, DOI 10.1006/excr.1996.0116; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; KOH GY, 1993, J CLIN INVEST, V92, P1548, DOI 10.1172/JCI116734; Ludin B, 1998, TRENDS CELL BIOL, V8, P72, DOI 10.1016/S0962-8924(97)01169-0; MESSERLI JM, 1993, HISTOCHEMISTRY, V100, P193, DOI 10.1007/BF00269092; MOSES RL, 1982, J ULTRA MOL STRUCT R, V81, P358, DOI 10.1016/S0022-5320(82)90064-8; Scorsin M, 1996, CIRCULATION, V94, P337; SEVERS NJ, 1989, CIRC RES, V65, P22, DOI 10.1161/01.RES.65.1.22; SEVERS NJ, 1990, J MUSCLE RES CELL M, V11, P154, DOI 10.1007/BF01766494; Vandenburgh HH, 1996, AM J PHYSIOL-CELL PH, V270, pC1284, DOI 10.1152/ajpcell.1996.270.5.C1284	28	22	23	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.		1999	13			S			S83	S89						7	Biochemistry & Molecular Biology; Biology; Cell Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	198CF	10352149				2022-12-25	WOS:000080403800011
J	Pedram, M; Donelson, JE				Pedram, M; Donelson, JE			The anatomy and transcription of a monocistronic expression site for a metacyclic variant surface glycoprotein gene in Trypanosoma brucei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-GLUCOSYL-HYDROXYMETHYLURACIL; AFRICAN TRYPANOSOMES; VSG GENE; ANTIGENIC VARIATION; DNA MODIFICATION; POINT MUTATIONS; LIFE-CYCLE; RHODESIENSE; PROMOTER; BASE	African trypanosomes evade the immune response of their mammalian hosts by switching the expression of their variant surface glycoprotein genes (vsg). The bloodstream trypanosome clone MVAT4 of Trypanosoma brucei rhodesiense expresses a metacyclic vsg as a monocistronic RNA from a promoter located 2 kilobases (kb) upstream of its start codon. Determination of 23 kb of sequence at the metacyclic variant antigen type 4 (MVAT) vsg expression site (ES) revealed an ES-associated gene (esag) 1 preceded by an ingi retroposon and an inverted region containing an unrelated vsg, short stretches of 70-bp repeats and a pseudo esag 3. Nuclear run-on experiments indicate that the 18-kb region upstream of the MVAT4 vsg promoter is transcriptionally silent. However, multiple members of different esag families are expressed from elsewhere in the genome. The MVAT4 vsg promoter is highly repressed in the procyclic stage, in contrast to the known polycistronic vsg ESs which undergo abortive transcription. Activation of the MVAT4 vsg ES occurs in situ without nucleotide sequence changes, although this monocistronic ES undergoes a pattern of base J modifications similar to that reported for the polycistronic ESs. The relative simplicity of the MVAT4 vsg ES and the uncoupled expression of the vsg and esags provide a unique opportunity for investigating the molecular mechanisms responsible for antigenic variation in African trypanosomes.	Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA	University of Iowa	Donelson, JE (corresponding author), Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA.		Donelson, John E/F-5795-2010; Pedram, Mehrdad/L-4072-2016	Pedram, Mehrdad/0000-0002-7348-3475	NIAID NIH HHS [AI32135, AI40591] Funding Source: Medline; NIDDK NIH HHS [DK25295] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI032135, R01AI040591, R01AI032135] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALARCON CM, 1994, MOL CELL BIOL, V14, P5579, DOI 10.1128/MCB.14.8.5579; ALEXANDRE S, 1988, MOL CELL BIOL, V8, P2367, DOI 10.1128/MCB.8.6.2367; Barry JD, 1998, MOL BIOCHEM PARASIT, V91, P93, DOI 10.1016/S0166-6851(97)00193-X; BERNARDS A, 1984, NUCLEIC ACIDS RES, V12, P4153, DOI 10.1093/nar/12.10.4153; Bitter W, 1998, NATURE, V391, P499, DOI 10.1038/35166; Borst P, 1997, Behring Inst Mitt, P1; Borst P, 1997, MOL BIOCHEM PARASIT, V90, P1, DOI 10.1016/S0166-6851(97)00170-9; Borst P, 1998, MOL BIOCHEM PARASIT, V91, P67, DOI 10.1016/S0166-6851(97)00184-9; Borst Piet, 1997, P109; CAMPBELL DA, 1984, NUCLEIC ACIDS RES, V12, P2759, DOI 10.1093/nar/12.6.2759; CAMPBELL GH, 1979, AM J TROP MED HYG, V28, P974, DOI 10.4269/ajtmh.1979.28.974; CARRINGTON M, 1991, J MOL BIOL, V221, P823, DOI 10.1016/0022-2836(91)80178-W; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COQUELET H, 1989, MOL CELL BIOL, V9, P4022, DOI 10.1128/MCB.9.9.4022; COQUELET H, 1991, MOL BIOCHEM PARASIT, V44, P33, DOI 10.1016/0166-6851(91)90218-U; Cross GAM, 1998, MOL BIOCHEM PARASIT, V91, P77, DOI 10.1016/S0166-6851(97)00186-2; Cross GAM, 1996, BIOESSAYS, V18, P283, DOI 10.1002/bies.950180406; CULLY DF, 1985, CELL, V42, P173, DOI 10.1016/S0092-8674(85)80113-6; DONELSON JE, 1995, J BIOL CHEM, V270, P7783, DOI 10.1074/jbc.270.14.7783; Donelson JE, 1998, MOL BIOCHEM PARASIT, V91, P51, DOI 10.1016/S0166-6851(97)00209-0; ELSAYED NMA, 1995, MOL BIOCHEM PARASIT, V73, P75, DOI 10.1016/0166-6851(95)00098-L; GERRITS H, 1998, WOODS HOLE MOL PARAS, V9, P84; GOMMERSAMPT J, 1991, NUCLEIC ACIDS RES, V19, P1745, DOI 10.1093/nar/19.8.1745; GOMMERSAMPT JH, 1993, CELL, V75, P1129, DOI 10.1016/0092-8674(93)90322-H; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; GRAHAM SV, 1995, MOL CELL BIOL, V15, P5945; JOHNSON PJ, 1987, CELL, V51, P273, DOI 10.1016/0092-8674(87)90154-1; Kim KS, 1997, J BIOL CHEM, V272, P24637, DOI 10.1074/jbc.272.39.24637; KIMMEL BE, 1987, MOL CELL BIOL, V7, P1465, DOI 10.1128/MCB.7.4.1465; LENARDO MJ, 1986, MOL CELL BIOL, V6, P1991, DOI 10.1128/MCB.6.6.1991; LIPS S, 1993, MOL BIOCHEM PARASIT, V62, P135, DOI 10.1016/0166-6851(93)90189-5; LODES MJ, 1993, MOL CELL BIOL, V13, P7036, DOI 10.1128/MCB.13.11.7036; LU Y, 1994, MOL CELL BIOL, V14, P3971, DOI 10.1128/MCB.14.6.3971; LU Y, 1993, CELL, V72, P397, DOI 10.1016/0092-8674(93)90116-8; McCulloch R, 1997, MOL CELL BIOL, V17, P833, DOI 10.1128/MCB.17.2.833; Morgan RW, 1996, J BIOL CHEM, V271, P9771, DOI 10.1074/jbc.271.16.9771; MURPHY NB, 1987, J MOL BIOL, V195, P855, DOI 10.1016/0022-2836(87)90490-6; NAGOSHI YL, 1995, MOL BIOCHEM PARASIT, V72, P33, DOI 10.1016/0166-6851(95)00062-6; Navarro M, 1996, MOL CELL BIOL, V16, P3615; PAYS E, 1990, EMBO J, V9, P3145, DOI 10.1002/j.1460-2075.1990.tb07512.x; Pays E, 1998, MOL BIOCHEM PARASIT, V91, P3, DOI 10.1016/S0166-6851(97)00183-7; PAYS E, 1994, ANNU REV MICROBIOL, V48, P25, DOI 10.1146/annurev.mi.48.100194.000325; PAYS E, 1984, NUCLEIC ACIDS RES, V12, P5235, DOI 10.1093/nar/12.13.5235; PAYS E, 1989, MOL CELL BIOL, V9, P4018, DOI 10.1128/MCB.9.9.4018; RENAULD H, 1993, GENE DEV, V7, P1133, DOI 10.1101/gad.7.7a.1133; Roditi I, 1998, MOL BIOCHEM PARASIT, V91, P117, DOI 10.1016/S0166-6851(97)00195-3; ROGERS JH, 1985, INT REV CYTOL, V93, P187, DOI 10.1016/S0074-7696(08)61375-3; Rudenko G, 1998, MOL BIOCHEM PARASIT, V95, P97, DOI 10.1016/S0166-6851(98)00099-1; Rudenko G, 1996, MOL BIOCHEM PARASIT, V80, P65, DOI 10.1016/0166-6851(96)02669-2; RUDENKO G, 1994, EMBO J, V13, P5470, DOI 10.1002/j.1460-2075.1994.tb06882.x; SALMON D, 1994, CELL, V78, P75, DOI 10.1016/0092-8674(94)90574-6; Sambrook J., 2002, MOL CLONING LAB MANU; SMILEY BL, 1990, MOL CELL BIOL, V10, P6436, DOI 10.1128/MCB.10.12.6436; STEVERDING D, 1994, EUR J CELL BIOL, V64, P78; TETLEY L, 1987, J CELL SCI, V87, P363; THOMPSON JS, 1994, MOL CELL BIOL, V14, P446, DOI 10.1128/MCB.14.1.446; TURNER CMR, 1988, PARASITOLOGY, V97, P269, DOI 10.1017/S0031182000058479; van Leeuwen F, 1998, MOL CELL BIOL, V18, P5643, DOI 10.1128/MCB.18.10.5643; van Leeuwen F, 1998, P NATL ACAD SCI USA, V95, P2366, DOI 10.1073/pnas.95.5.2366; VANDERPLOEG LHT, 1982, NUCLEIC ACIDS RES, V10, P5905, DOI 10.1093/nar/10.19.5905; Vanhamme L, 1998, MOL BIOCHEM PARASIT, V91, P107, DOI 10.1016/S0166-6851(97)00194-1; VANHAMME L, 1995, MICROBIOL REV, V59, P223, DOI 10.1128/MMBR.59.2.223-240.1995; vanLeeuwen F, 1996, NUCLEIC ACIDS RES, V24, P2476, DOI 10.1093/nar/24.13.2476; Vassella E, 1996, MOL BIOCHEM PARASIT, V82, P131, DOI 10.1016/0166-6851(96)02726-0; VICKERMAN K, 1985, BRIT MED BULL, V41, P105, DOI 10.1093/oxfordjournals.bmb.a072036; VICKERMAN K, 1988, BIOL CELL, V64, P109, DOI 10.1016/0248-4900(88)90070-6; ZOMERDIJK JCBM, 1990, EMBO J, V9, P2791, DOI 10.1002/j.1460-2075.1990.tb07467.x	68	15	15	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16876	16883		10.1074/jbc.274.24.16876	http://dx.doi.org/10.1074/jbc.274.24.16876			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358033	hybrid			2022-12-25	WOS:000080780400032
J	Richman, TJ; Sawyer, MM; Johnson, DI				Richman, TJ; Sawyer, MM; Johnson, DI			The Cdc42p GTPase is involved in a G(2)/M morphogenetic checkpoint regulating the apical-isotropic switch and nuclear division in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE GENE; PHEROMONE-RESPONSE PATHWAY; GUANINE-NUCLEOTIDE EXCHANGE; STE20P PROTEIN-KINASE; ACTIN CYTOSKELETON; CELL POLARITY; BUDDING YEAST; BINDING PROTEIN; MOLECULAR CHARACTERIZATION; ACTIVATING PROTEIN	The Cdc42p GTPase is involved in the signal transduction cascades controlling bud emergence and polarized cell growth in S. cerevisiae. Cells expressing the cdc42(V44A) effector domain mutant allele displayed morphological defects of highly elongated and multielongated budded cells indicative of a defect in the apicalisotropic switch in bud growth. In addition, these cells contained one, two, or multiple nuclei indicative of a G(2)/M delay in nuclear division and also a defect in cytokinesis and/or cell separation. Actin and chitin were delocalized, and septin ring structure was aberrant and partially delocalized to the tips of elongated Cdc42(V44A) cells; however, Cdc42(V44A)p localization was normal. Two-hybrid protein analyses showed that the V44A mutation interfered with Cdc42p's interactions with Cla4p, a p21(Cdc42/Rac)-activated kinase (PAK)-like kinase, and the novel effecters Gic1p and Gic2p, but not with the Ste20p or Skm1p PAK-like kinases, the Bni1p formin, or the Iqg1p IQGAP homolog. Furthermore, the CdC42V44A morphological defects were suppressed by deletion of the Swe1p cyclin-dependent kinase inhibitory kinase and by overexpression of Cla ip, Ste20p, the Cdc12 septin protein, or the guanine nucleotide exchange factor Cdc24p, In sum, these results suggest that proper Cdc42p function is essential for timely progression through the apical-isotropic switch and G(2)/M transition and that Cdc42(V44A)p differentially interacts with a number of effecters and regulators.	Univ Vermont, Dept Microbiol & Mol Genet, Burlington, VT 05405 USA; Univ Vermont, Markey Ctr Mol Genet, Burlington, VT 05405 USA	University of Vermont; University of Vermont	Johnson, DI (corresponding author), Univ Vermont, Dept Microbiol & Mol Genet, 202 Stafford Hall, Burlington, VT 05405 USA.				NCI NIH HHS [T32-CA09286-19] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009286] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS AEM, 1984, J CELL BIOL, V98, P934, DOI 10.1083/jcb.98.3.934; ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; Akada R, 1996, GENETICS, V143, P103; Altman R, 1997, J CELL BIOL, V138, P119, DOI 10.1083/jcb.138.1.119; Barral Y, 1999, GENE DEV, V13, P176, DOI 10.1101/gad.13.2.176; BENDER A, 1991, MOL CELL BIOL, V11, P1295, DOI 10.1128/MCB.11.3.1295; Benton BK, 1997, MOL CELL BIOL, V17, P5067, DOI 10.1128/MCB.17.9.5067; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BOOHER RN, 1993, EMBO J, V12, P3417, DOI 10.1002/j.1460-2075.1993.tb06016.x; Brown JL, 1997, GENE DEV, V11, P2972, DOI 10.1101/gad.11.22.2972; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Carroll CW, 1998, J CELL BIOL, V143, P709, DOI 10.1083/jcb.143.3.709; Chen GC, 1997, GENE DEV, V11, P2958, DOI 10.1101/gad.11.22.2958; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; Cross FR, 1997, YEAST, V13, P647, DOI 10.1002/(SICI)1097-0061(19970615)13:7<647::AID-YEA115>3.0.CO;2-#; CVRCKOVA F, 1995, GENE DEV, V9, P1817, DOI 10.1101/gad.9.15.1817; Davis CR, 1998, J BIOL CHEM, V273, P849, DOI 10.1074/jbc.273.2.849; DeMarini DJ, 1997, J CELL BIOL, V139, P75, DOI 10.1083/jcb.139.1.75; Eby JJ, 1998, CURR BIOL, V8, P967, DOI 10.1016/S0960-9822(98)00398-4; Epp JA, 1997, CURR BIOL, V7, P921, DOI 10.1016/S0960-9822(06)00411-8; Evangelista M, 1997, SCIENCE, V276, P118, DOI 10.1126/science.276.5309.118; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HAARER BK, 1987, MOL CELL BIOL, V7, P3678, DOI 10.1128/MCB.7.10.3678; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HARTWELL LH, 1973, GENETICS, V74, P267; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; Imamura H, 1997, EMBO J, V16, P2745, DOI 10.1093/emboj/16.10.2745; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; Johnson DI, 1999, MICROBIOL MOL BIOL R, V63, P54, DOI 10.1128/MMBR.63.1.54-105.1999; KIM HB, 1991, J CELL BIOL, V112, P535, DOI 10.1083/jcb.112.4.535; Kohno H, 1996, EMBO J, V15, P6060, DOI 10.1002/j.1460-2075.1996.tb00994.x; Leberer E, 1997, EMBO J, V16, P83, DOI 10.1093/emboj/16.1.83; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; Lee L, 1999, J CELL BIOL, V144, P947, DOI 10.1083/jcb.144.5.947; LEW DJ, 1993, J CELL BIOL, V120, P1305, DOI 10.1083/jcb.120.6.1305; LEW DJ, 1995, J CELL BIOL, V129, P739, DOI 10.1083/jcb.129.3.739; Li R, 1997, J CELL BIOL, V136, P649, DOI 10.1083/jcb.136.3.649; Lippincott J, 1998, J CELL BIOL, V140, P355, DOI 10.1083/jcb.140.2.355; Longtine MS, 1996, CURR OPIN CELL BIOL, V8, P106, DOI 10.1016/S0955-0674(96)80054-8; Longtine MS, 1998, J CELL BIOL, V143, P719, DOI 10.1083/jcb.143.3.719; Martin H, 1997, MOL MICROBIOL, V23, P431, DOI 10.1046/j.1365-2958.1997.d01-1870.x; McMillan JN, 1998, J CELL BIOL, V142, P1487, DOI 10.1083/jcb.142.6.1487; Miller PJ, 1997, YEAST, V13, P561; Osman MA, 1998, J CELL BIOL, V142, P443, DOI 10.1083/jcb.142.2.443; Peter M, 1996, EMBO J, V15, P7046, DOI 10.1002/j.1460-2075.1996.tb01096.x; PRINGLE JR, 1989, METHOD CELL BIOL, V31, P357; REYNOLDS A, 1989, CURRENT PROTOCOLS MO, V2; RUSSELL P, 1989, CELL, V57, P295, DOI 10.1016/0092-8674(89)90967-7; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sherman F., 1986, METHODS YEAST GENETI; Sia RAL, 1998, EMBO J, V17, P6678, DOI 10.1093/emboj/17.22.6678; Sia RAL, 1996, MOL BIOL CELL, V7, P1657, DOI 10.1091/mbc.7.11.1657; SLOAT BF, 1978, SCIENCE, V200, P1171, DOI 10.1126/science.349694; SLOAT BF, 1981, J CELL BIOL, V89, P395, DOI 10.1083/jcb.89.3.395; STEVENSON BJ, 1995, GENE DEV, V9, P2949, DOI 10.1101/gad.9.23.2949; STEVENSON BJ, 1992, GENE DEV, V6, P1293, DOI 10.1101/gad.6.7.1293; Tjandra H, 1998, CURR BIOL, V8, P991, DOI 10.1016/S0960-9822(07)00419-8; WILKINSON LE, 1974, EXP CELL RES, V89, P175, DOI 10.1016/0014-4827(74)90200-6; Wu CL, 1998, J BIOL CHEM, V273, P28107, DOI 10.1074/jbc.273.43.28107; WU CL, 1995, J BIOL CHEM, V270, P15984, DOI 10.1074/jbc.270.27.15984; ZHENG Y, 1994, J BIOL CHEM, V269, P2369; ZHENG Y, 1993, J BIOL CHEM, V268, P24629; ZIMAN M, 1994, YEAST, V10, P463, DOI 10.1002/yea.320100405; ZIMAN M, 1993, MOL BIOL CELL, V4, P1307, DOI 10.1091/mbc.4.12.1307; ZIMAN M, 1991, MOL CELL BIOL, V11, P3537, DOI 10.1128/MCB.11.7.3537	65	79	81	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16861	16870		10.1074/jbc.274.24.16861	http://dx.doi.org/10.1074/jbc.274.24.16861			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358031	hybrid			2022-12-25	WOS:000080780400030
J	Fujio, Y; Walsh, K				Fujio, Y; Walsh, K			Akt mediates cytoprotection of endothelial cells by vascular endothelial growth factor in an anchorage-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; PHOSPHATIDYLINOSITOL 3-KINASE; INTEGRIN ALPHA(V)BETA(3); VESSEL DEVELOPMENT; SURVIVAL FACTOR; APOPTOSIS; ACTIVATION; EXPRESSION; ANGIOGENESIS; INSULIN	Regulation of endothelial cell apoptosis is a critical modulator of normal and pathological angiogenesis. In this study, we examined the role of the protein kinase Akt/PKB in endothelial cell survival in response to growth factor and matrix attachment signals. Vascular endothelial growth factor(VEGF)-induced cytoprotection of endothelial cell monolayers correlated with the wortmannin-sensitive induction of Akt activity. Transfection of an adenovirus expressing a dominant-negative Akt mutant decreased endothelial cell viability in the presence of VEGF. Conversely, adenoviral transduction of wild-type Akt facilitated the cell survival effects of VEGF, whereas transduction of constitutively active Akt conferred endothelial cell survival in the absence of VEGF. Constitutively active Akt also conferred survival to endothelial cells in suspension culture, whereas stimulation with VEGF did not. In suspension cultures, VEGF stimulation was unable to activate Akt, and Akt protein levels were repressed in cells undergoing anoikis. These data suggest that cross-talk between growth factor- and anchorage-dependent signaling pathways are essential for Akt activation and endothelial cell survival.	Tufts Univ, Sch Med, St Elizabeths Med Ctr, Div Cardiovasc Res, Boston, MA 02135 USA; Tufts Univ, Sch Med, Sackler Sch Biomed Studies, Program Cell Mol & Dev Biol, Boston, MA 02135 USA	St. Elizabeth's Medical Center; Tufts University; Tufts University	Walsh, K (corresponding author), Tufts Univ, Sch Med, St Elizabeths Med Ctr, Div Cardiovasc Res, 736 Cambridge St, Boston, MA 02135 USA.		Fujio, Yasushi/H-3421-2017	Fujio, Yasushi/0000-0003-0828-2930; Walsh, Kenneth/0000-0001-7580-2276	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG015052, R01AG015052] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR040197, AR40197] Funding Source: Medline; NIA NIH HHS [R37 AG015052, AG15052, R01 AG015052] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024; BANAI S, 1994, CIRCULATION, V89, P2183, DOI 10.1161/01.CIR.89.5.2183; Baumgartner I, 1998, CIRCULATION, V97, P1114, DOI 10.1161/01.CIR.97.12.1114; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; Benjamin LE, 1997, P NATL ACAD SCI USA, V94, P8761, DOI 10.1073/pnas.94.16.8761; Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; BROWN LF, 1992, J EXP MED, V176, P1375, DOI 10.1084/jem.176.5.1375; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Claesson-Welsh L, 1998, P NATL ACAD SCI USA, V95, P5579, DOI 10.1073/pnas.95.10.5579; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Gasparini G, 1998, CLIN CANCER RES, V4, P2625; Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KENNEDY SG, 1997, GENE DEV, V11, P710; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MESNER PW, 1992, J CELL BIOL, V119, P1669, DOI 10.1083/jcb.119.6.1669; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; Nicolaou KC, 1998, BIOORGAN MED CHEM, V6, P1185, DOI 10.1016/S0968-0896(98)00090-X; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Scatena M, 1998, J CELL BIOL, V141, P1083, DOI 10.1083/jcb.141.4.1083; Smith RC, 1997, GENE DEV, V11, P1674, DOI 10.1101/gad.11.13.1674; Spyridopoulos I, 1997, J MOL CELL CARDIOL, V29, P1321, DOI 10.1006/jmcc.1996.0365; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Tanaka M, 1996, NAT MED, V2, P317, DOI 10.1038/nm0396-317; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Xia P, 1996, J CLIN INVEST, V98, P2018, DOI 10.1172/JCI119006; Yuan F, 1996, P NATL ACAD SCI USA, V93, P14765, DOI 10.1073/pnas.93.25.14765; Zheng B, 1998, P NATL ACAD SCI USA, V95, P11217, DOI 10.1073/pnas.95.19.11217; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345	44	472	503	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16349	16354		10.1074/jbc.274.23.16349	http://dx.doi.org/10.1074/jbc.274.23.16349			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347193	Green Accepted, hybrid			2022-12-25	WOS:000080668600053
J	Lin, FT; Miller, WE; Luttrell, LM; Lefkowitz, RJ				Lin, FT; Miller, WE; Luttrell, LM; Lefkowitz, RJ			Feedback regulation of beta-arrestin1 function by extracellular signal-regulated kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; CLATHRIN-MEDIATED ENDOCYTOSIS; BETA-ADRENERGIC-RECEPTOR; FACTOR-I RECEPTOR; COUPLED RECEPTORS; BETA(2)-ADRENERGIC RECEPTOR; TYROSINE PHOSPHORYLATION; INSULIN; ARRESTIN; INTERNALIZATION	The functions of beta-arrestin1 to facilitate clathrin-mediated endocytosis of the beta(2)-adrenergic receptor and to promote agonist-induced activation of extracellular signal-regulated kinases (ERK) are regulated by its phosphorylation/dephosphorylation at Ser-412. Cytoplasmic beta-arrestin1 is almost stoichiometrically phosphorylated at Ser-412. Dephosphorylation of beta-arrestin1 at the plasma membrane is required for targeting a signaling complex that includes the agonist-occupied receptors to the clathrin-coated pits. Here we demonstrate that beta-arrestin1 phosphorylation and function are modulated by an ERK-dependent negative feedback mechanism, ERK1 and ERK2 phosphorylate beta-arrestin1 at Ser-412 in vitro. Inhibition of ERK activity by a dominant-negative MEK1 mutant significantly attenuates beta-arrestin1 phosphorylation, thereby increasing the concentration of dephosphorylated beta-arrestin1. Under such conditions, beta-arrestin1-mediated beta(2)-adrenergic receptor internalization is enhanced as is its ability to bind clathrin. In contrast, if ERK-mediated phosphorylation is increased by transfection of a constitutively active MEK1 mutant, receptor internalization is inhibited. Our results suggest that dephosphorylated beta-arrestin1 mediates endocytosis-dependent ERK activation. Following activation, ERKs phosphorylate beta-arrestin1, thereby exerting an inhibitory feedback control of its function.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Biochem, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute	Lefkowitz, RJ (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med, Box 3821, Durham, NC 27710 USA.	lefko001@mc.duke.edu	Lefkowitz, Robert/AAW-2649-2021	Luttrell, Louis/0000-0003-2805-6949	NHLBI NIH HHS [HL16037] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016037, R01HL016037] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; BARAK LS, 1994, J BIOL CHEM, V269, P2790; BRUNET A, 1994, FEBS LETT, V346, P299, DOI 10.1016/0014-5793(94)00475-7; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; Chow JC, 1998, J BIOL CHEM, V273, P4672, DOI 10.1074/jbc.273.8.4672; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; DeFea K, 1997, J BIOL CHEM, V272, P31400, DOI 10.1074/jbc.272.50.31400; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Foschi M, 1997, EMBO J, V16, P6439, DOI 10.1093/emboj/16.21.6439; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; HUANG WD, 1995, MOL BIOL CELL, V6, P237, DOI 10.1091/mbc.6.3.237; HUGANIR RL, 1984, P NATL ACAD SCI-BIOL, V81, P6968, DOI 10.1073/pnas.81.22.6968; LEE RM, 1992, J BIOL CHEM, V267, P1088; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Lin FT, 1997, J BIOL CHEM, V272, P31051, DOI 10.1074/jbc.272.49.31051; Lin FT, 1998, J BIOL CHEM, V273, P31640, DOI 10.1074/jbc.273.48.31640; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; LUO KX, 1991, METHOD ENZYMOL, V201, P149; Luttrell LM, 1997, J BIOL CHEM, V272, P31648, DOI 10.1074/jbc.272.50.31648; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Porfiri E, 1996, J BIOL CHEM, V271, P5871, DOI 10.1074/jbc.271.10.5871; Riccio A, 1997, SCIENCE, V277, P1097, DOI 10.1126/science.277.5329.1097; SEGER R, 1994, J BIOL CHEM, V269, P25699; UEKI K, 1994, J BIOL CHEM, V269, P15756; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086	27	115	119	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					15971	15974		10.1074/jbc.274.23.15971	http://dx.doi.org/10.1074/jbc.274.23.15971			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347142	hybrid			2022-12-25	WOS:000080668600002
J	Scalia, R; Booth, G; Lefer, DJ				Scalia, R; Booth, G; Lefer, DJ			Vascular endothelial growth factor attenuates leukocyte-endothelium interaction during acute endothelial dysfunction: essential role of endothelium-derived nitric oxide	FASEB JOURNAL			English	Article						intravital microscopy; inflammation; neutrophil; microcirculation; mesentery	MYOCARDIAL ISCHEMIA-REPERFUSION; GENE-TRANSFER; P-SELECTIN; ANGIOGENESIS; EXPRESSION; ADHESION; RELEASE; MICROCIRCULATION; ADHERENCE; PROTECTS	Vascular endothelial growth factor (VEGF) is an endothelium-specific secreted protein that induces vasodilation and increases endothelial release of nitric oxide (NO). NO is also reported to modulate leukocyte-endothelium interaction. Therefore, we hypothesized that VEGF might inhibit leukocyte-endothelium interaction via increased release of NO from the vascular endothelium. We used intravital microscopy of the rat mesenteric microcirculation to measure leukocyte-endothelium interactions 2, 4, and 24 h after systemic administration of VEGF to the rat (120 mu g/kg, i.v., bolus). Superfusion of the rat mesentery with either 0.5 U/ml thrombin or 50 mu M L-NAME consistently increased the number of rolling, adhering, and transmigrated leukocytes (P<0.01 vs, control mesenteries superfused with Krebs-Henseleit buffer). At 4 and 24 h posttreatment, VEGF significantly attenuated thrombin-induced and L-NAME-induced leukocyte rolling, adherence, and transmigration in rat mesenteric venules. In addition, adherence of isolated rat PMNs to thrombin-stimulated mesenteric artery segments in vitro was significantly reduced in mesenteric arteries isolated from VEGF-treated rats (P<0.001 vs. control rats). Direct measurement of NO demonstrated a threefold increase in basal NO release from aortic tissue of rats injected with VEGF, at 4 and 24 h posttreatment (P<0.01 vs, aortic tissue from control rats). Finally, systemic administration of VEGF to ecNOS-deficient mice failed to inhibit leukocyte-endothelium interactions observed in peri-intestinal venules. We concluded that VEGF is a potent inhibitor of leukocyte-endothelium interaction, and this effect is specifically correlated to augmentation of NO release from the vascular endothelium.	Thomas Jefferson Univ, Jefferson Med Coll, Dept Physiol, Philadelphia, PA 19107 USA; Louisiana State Univ, Med Ctr, Dept Mol & Cellular Physiol, Shreveport, LA 71130 USA	Jefferson University; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Scalia, R (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Physiol, 1020 Locust St, Philadelphia, PA 19107 USA.		Lefer, David/A-6372-2012	Lefer, David/0000-0003-2293-7278; Scalia, Rosario/0000-0002-1829-943X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045434] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-45434] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AOKI N, 1990, AM J PHYSIOL, V258, pG275, DOI 10.1152/ajpgi.1990.258.2.G275; Asahara T, 1996, CIRCULATION, V94, P3291, DOI 10.1161/01.CIR.94.12.3291; BAUTERS C, 1995, CIRCULATION, V91, P2802, DOI 10.1161/01.CIR.91.11.2802; BORDERS JL, 1984, MICROVASC RES, V27, P117, DOI 10.1016/0026-2862(84)90047-5; BROCK TA, 1991, AM J PATHOL, V138, P213; DAVENPECK KL, 1994, GASTROENTEROLOGY, V107, P1050, DOI 10.1016/0016-5085(94)90229-1; DECATERINA R, 1995, J CLIN INVEST, V96, P60, DOI 10.1172/JCI118074; ENTMAN ML, 1990, J CLIN INVEST, V85, P1497, DOI 10.1172/JCI114596; GAUTHIER TW, 1994, AM J PHYSIOL-GASTR L, V267, pG562, DOI 10.1152/ajpgi.1994.267.4.G562; GAUTHIER TW, 1995, ARTERIOSCL THROM VAS, V15, P1652, DOI 10.1161/01.ATV.15.10.1652; GRANGER DN, 1994, J LEUKOCYTE BIOL, V55, P662, DOI 10.1002/jlb.55.5.662; GRANGER DN, 1989, AM J PHYSIOL, V257, pG685; Guo JP, 1996, J APPL PHYSIOL, V81, P774, DOI 10.1152/jappl.1996.81.2.774; Hood JD, 1998, AM J PHYSIOL, V274, P1054; JOHNSON G, 1991, CRIT CARE MED, V19, P244, DOI 10.1097/00003246-199102000-00021; KU DD, 1993, AM J PHYSIOL, V265, pH586, DOI 10.1152/ajpheart.1993.265.2.H586; KUBES P, 1991, P NATL ACAD SCI USA, V88, P4651, DOI 10.1073/pnas.88.11.4651; KUROSE I, 1993, HEPATOLOGY, V18, P380, DOI 10.1002/hep.1840180223; Laitinen M, 1997, HUM GENE THER, V8, P1737, DOI 10.1089/hum.1997.8.15-1737; Luo ZY, 1997, ANN THORAC SURG, V64, P993, DOI 10.1016/S0003-4975(97)00715-7; MA XL, 1993, CIRCULATION, V88, P649, DOI 10.1161/01.CIR.88.2.649; MONACCI WT, 1993, AM J PHYSIOL, V264, pC995, DOI 10.1152/ajpcell.1993.264.4.C995; MONCADA S, 1991, EUR J CLIN INVEST, V21, P361, DOI 10.1111/j.1365-2362.1991.tb01383.x; Morbidelli L, 1996, AM J PHYSIOL-HEART C, V270, pH411, DOI 10.1152/ajpheart.1996.270.1.H411; Murohara T, 1998, J CLIN INVEST, V101, P2567, DOI 10.1172/JCI1560; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Scalia R, 1997, P NATL ACAD SCI USA, V94, P9967, DOI 10.1073/pnas.94.18.9967; Scalia R, 1997, CARDIOVASC PATHOBIOL, V1, P160; SIEGFRIED MR, 1992, J PHARMACOL EXP THER, V260, P668; Thompson RC, 1996, J AM COLL CARDIOL, V27, P8, DOI 10.1016/0735-1097(95)00436-X; vanderZee R, 1997, CIRCULATION, V95, P1030; WEYRICH AS, 1992, CIRCULATION, V86, P279, DOI 10.1161/01.CIR.86.1.279; WILLIAMS JH, 1987, J LEUKOCYTE BIOL, V42, P455, DOI 10.1002/jlb.42.5.455; Wu HM, 1996, AM J PHYSIOL-HEART C, V271, pH2735, DOI 10.1152/ajpheart.1996.271.6.H2735; Yang RH, 1998, J PHARMACOL EXP THER, V284, P103; YUAN Y, 1990, MICROVASC RES, V40, P218, DOI 10.1016/0026-2862(90)90021-I; Ziche M, 1997, J CLIN INVEST, V99, P2625, DOI 10.1172/JCI119451	37	58	59	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	1999	13	9					1039	1046		10.1096/fasebj.13.9.1039	http://dx.doi.org/10.1096/fasebj.13.9.1039			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	200NZ	10336886				2022-12-25	WOS:000080547700008
J	Herrmann, A; Davies, JR; Lindell, G; Martensson, S; Packer, NH; Swallow, DM; Carlstedt, I				Herrmann, A; Davies, JR; Lindell, G; Martensson, S; Packer, NH; Swallow, DM; Carlstedt, I			Studies on the "insoluble" glycoprotein complex from human colon - Identification of reduction-insensitive MUC2 oligomers and C-terminal cleavage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SMALL-INTESTINE; MOLECULAR-CLONING; 6M-GUANIDINIUM CHLORIDE; MUCINS; REGION; GENE; CDNA; GLYCOSYLATION; BIOSYNTHESIS; POLYMORPHISM	The "insoluble" glycoprotein complex was isolated from human colonic tissue and mucin subunits were prepared following reduction, Antibodies raised against peptide sequences within MUC2 revealed that virtually all of this mucin occurs in the insoluble glycoprotein complex. In addition, reduction released a 120-kDa C-terminal MUC2 fragment, showing that proteolytic cleavage in this domain may occur and leave the fragment attached to the complex via disulfide bonds. The variable number tandem repeat region and the irregular repeat domain were isolated after trypsin digestion and shown to have molecular weights of 930,000 and 180,000, respectively, suggesting a molecular weight for the entire MUC2 monomer of approximately 1.5 million. Gel chromatography and agarose gel electrophoresis revealed several populations of MUGS subunits, and analytical ultracentrifugation showed that these have molecular weights on the order of 2 million, 4 million, and 5 million, corresponding to monomers, dimers, and trimers, respectively, Agarose gel electrophoresis of subunits from individuals expressing both a "long" and a "short" MUC2 allele revealed a larger number of populations, consistent with the presence of short and long monomers and oligomers arising from permutations of the two types of monomers. In addition to disulfide bonds, MUGS monomers are apparently joined by a "novel," reduction-insensitive bond.	Lund Univ, Dept Cell & Mol Biol, Mucosal Biol Grp, Sect Mol Pathogenesis, S-22100 Lund, Sweden; Univ Lund Hosp, Dept Surg, S-22185 Lund, Sweden; Univ Lund Hosp, Dept Urol, S-22185 Lund, Sweden; Macquarie Univ, Ctr Analyt Biotechnol, Sydney, NSW 2019, Australia; UCL, Human Biochem Genet Unit, London NW1 2HE, England	Lund University; Lund University; Skane University Hospital; Lund University; Skane University Hospital; Macquarie University; University of London; University College London	Carlstedt, I (corresponding author), Lund Univ, Dept Cell & Mol Biol, Mucosal Biol Grp, Sect Mol Pathogenesis, POB 94, S-22100 Lund, Sweden.	Ingemar.Carlstedt@medkem.lu.se	Packer, Nicolle/Q-8929-2019; Davies, Julia R/H-4194-2011	Davies, Julia R/0000-0001-5888-664X; Packer, Nicolle/0000-0002-7532-4021				Asker N, 1998, J BIOL CHEM, V273, P18857, DOI 10.1074/jbc.273.30.18857; ASKER N, 1995, BIOCHEM J, V308, P873, DOI 10.1042/bj3080873; Axelsson MAB, 1998, J BIOL CHEM, V273, P18864, DOI 10.1074/jbc.273.30.18864; CARLSTEDT I, 1984, CIBA F SYMP, V109, P157, DOI 10.1002/9780470720905.ch11; CARLSTEDT I, 1993, J BIOL CHEM, V268, P18771; Carlstedt I, 1995, BIOCHEM SOC T, V23, P845, DOI 10.1042/bst0230845; CREETH JM, 1982, J BIOCHEM BIOPH METH, V7, P25, DOI 10.1016/0165-022X(82)90033-1; Davies JR, 1996, BIOCHEM J, V313, P431, DOI 10.1042/bj3130431; DEVINE PL, 1992, BIOTECHNIQUES, V12, P160; FAHIM REF, 1983, BIOCHEM J, V209, P117, DOI 10.1042/bj2090117; GENDLER SJ, 1995, ANNU REV PHYSIOL, V57, P607, DOI 10.1146/annurev.ph.57.030195.003135; GUM JR, 1990, BIOCHEM BIOPH RES CO, V171, P407, DOI 10.1016/0006-291X(90)91408-K; GUM JR, 1992, J BIOL CHEM, V267, P21375; GUM JR, 1994, J BIOL CHEM, V269, P2440; HANSSON GC, 1994, BIOCHEM BIOPH RES CO, V198, P181, DOI 10.1006/bbrc.1994.1026; Herrmann A, 1995, BIOCHEM SOC T, V23, pS535, DOI 10.1042/bst023535s; HERRMANN A, 1996, 4 INT WORKSH CARC AS, P133; Khatri IA, 1998, BIOCHEM J, V331, P323, DOI 10.1042/bj3310323; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANSSON W, 1990, J UROLOGY, V144, P1359, DOI 10.1016/S0022-5347(17)39740-9; MANTLE M, 1984, BIOCHEM J, V224, P345, DOI 10.1042/bj2240345; MARTENSSON S, 1988, SCAND J CLIN LAB INV, V48, P633, DOI 10.3109/00365518809085783; OHMORI H, 1994, J BIOL CHEM, V269, P17833; Ou KL, 1996, J CHROMATOGR A, V723, P219, DOI 10.1016/0021-9673(95)00879-9; PORCHET N, 1991, BIOCHEM BIOPH RES CO, V175, P414, DOI 10.1016/0006-291X(91)91580-6; SHEEHAN JK, 1986, BIOCHEM J, V239, P147, DOI 10.1042/bj2390147; Sheehan JK, 1996, BIOCHEM J, V315, P1055, DOI 10.1042/bj3151055; SHEEHAN JK, 1984, BIOCHEM J, V221, P499, DOI 10.1042/bj2210499; SHEEHAN JK, 1984, BIOCHEM J, V217, P93, DOI 10.1042/bj2170093; THORNTON DJ, 1989, ANAL BIOCHEM, V182, P160, DOI 10.1016/0003-2697(89)90735-5; THORNTON DJ, 1995, ANAL BIOCHEM, V227, P162, DOI 10.1006/abio.1995.1266; TORIBARA NW, 1991, J CLIN INVEST, V88, P1005, DOI 10.1172/JCI115360; van Klinken BJW, 1998, AM J PHYSIOL-GASTR L, V274, pG871, DOI 10.1152/ajpgi.1998.274.5.G871; van Klinken BJW, 1998, GLYCOBIOLOGY, V8, P67, DOI 10.1093/glycob/8.1.67; Vinall LE, 1998, HUM GENET, V102, P357, DOI 10.1007/s004390050705; XU G, 1992, BIOCHEM BIOPH RES CO, V183, P821, DOI 10.1016/0006-291X(92)90557-2; XU GQ, 1992, J BIOL CHEM, V267, P5401; ZIMM BH, 1948, J CHEM PHYS, V16, P1099, DOI 10.1063/1.1746740	38	121	123	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15828	15836		10.1074/jbc.274.22.15828	http://dx.doi.org/10.1074/jbc.274.22.15828			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336486	hybrid			2022-12-25	WOS:000080560100075
J	Liu, J; Razani, B; Tang, SQ; Terman, BI; Ware, JA; Lisanti, MP				Liu, J; Razani, B; Tang, SQ; Terman, BI; Ware, JA; Lisanti, MP			Angiogenesis activators and inhibitors differentially regulate caveolin-1 expression and caveolae formation in vascular endothelial cells - Angiogenesis inhibitors block vascular endothelial growth factor-induced down-regulation of caveolin-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE CASCADE; PROTEIN-KINASE; TUMOR-GROWTH; IN-VIVO; SIGNAL-TRANSDUCTION; TYROSINE KINASE; MEMBRANE; CANCER; ANGIOSTATIN; METASTASIS	Angiogenesis is the process by which new blood vessels are formed via proliferation of vascular endothelial cells. A variety of angiogenesis inhibitors that antagonize the effects of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) have recently been identified. However, the mechanism by which these diverse angiogenesis inhibitors exert their common effects remains largely unknown. Caveolin-1 and -2 are known to be highly expressed in vascular endothelial cells both in vitro and in vivo, Here, we examine the potential role of caveolins in the angiogenic response, For this purpose, we used the well established human umbilical vein endothelial cell line, ECV 304, Treatment of ECV 304 cells with known angiogenic growth factors (VEGF, bFGF, or hepatocyte growth factor/scatter factor), resulted in a dramatic reduction in the expression of caveolin-1, This down-regulation event was selective for caveolin-1, as caveolin-2 levels remained constant under these conditions of growth factor stimulation. VEGF-induced down-regulation of caveolin-1 expression also resulted in the morphological loss of cell surface caveolae organelles as seen by trans mission electron microscopy, A variety of well characterized angiogenesis inhibitors (including angiostatin, fumagillin, 2-methoxy estradiol, transforming growth factor-A and thalidomide) effectively blocked VEGF-induced down-regulation of caveolin-1 as seen by immunoblotting and immunofluorescence microscopy, However, treatment with angiogenesis inhibitors alone did not significantly affect the expression of caveolin-1. PD98059, a specific inhibitor of mitogen-activated protein kinase and a known angiogenesis inhibitor, also blocked the observed VEGF-induced down-regulation of caveolin-1. Furthermore, we show that caveoliln-1 can function as a negative regulator of VEGF-R (KDR) signal transduction in vivo, Thus, down-regulation of caveolin-1 may be an important step along the pathway toward endothelial cell proliferation.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; Albert Einstein Canc Ctr, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University	Lisanti, MP (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	lisanti@aecom.yu.edu	Lisanti, Michael P/C-6866-2013; Ware, Joseph/AAC-2843-2022; Lisanti, Michael/B-6131-2018	Lisanti, Michael/0000-0003-2034-1382; Razani, Babak/0000-0002-7172-9240	NATIONAL CANCER INSTITUTE [R01CA080250] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007288] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA-80250] Funding Source: Medline; NIGMS NIH HHS [T32-GM07288] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAIRD A, 1986, BIOCHEM BIOPH RES CO, V138, P476, DOI 10.1016/0006-291X(86)90305-0; BATTEGAY EJ, 1995, J MOL MED, V73, P333; BICKNELL R, 1994, ANN ONCOL, V5, pS45, DOI 10.1093/annonc/5.suppl_4.S45; Bicknell Roy, 1996, Current Opinion in Oncology, V8, P60, DOI 10.1097/00001622-199601000-00011; Bussolino F, 1997, TRENDS BIOCHEM SCI, V22, P251, DOI 10.1016/S0968-0004(97)01074-8; Claesson-Welsh L, 1998, P NATL ACAD SCI USA, V95, P5579, DOI 10.1073/pnas.95.10.5579; DAMATO RJ, 1994, P NATL ACAD SCI USA, V91, P4082, DOI 10.1073/pnas.91.9.4082; Eliceiri BP, 1998, J CELL BIOL, V140, P1255, DOI 10.1083/jcb.140.5.1255; Engelman JA, 1998, FEBS LETT, V428, P205, DOI 10.1016/S0014-5793(98)00470-0; Engelman JA, 1998, J BIOL CHEM, V273, P20448, DOI 10.1074/jbc.273.32.20448; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FOTIS T, 1994, NATURE, V368, P237; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; Gately S, 1997, P NATL ACAD SCI USA, V94, P10868, DOI 10.1073/pnas.94.20.10868; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; GUERIN C, 1992, BIOCHEM BIOPH RES CO, V188, P740, DOI 10.1016/0006-291X(92)91118-A; INGBER D, 1990, NATURE, V348, P555, DOI 10.1038/348555a0; IRUELAARISPE ML, 1991, P NATL ACAD SCI USA, V88, P5026, DOI 10.1073/pnas.88.11.5026; Jones MK, 1998, BIOCHEM BIOPH RES CO, V249, P118, DOI 10.1006/bbrc.1998.9095; Kalebic T, 1996, INT J CANCER, V68, P596; Kenyon BM, 1997, EXP EYE RES, V64, P971, DOI 10.1006/exer.1997.0292; Kevil CG, 1998, J BIOL CHEM, V273, P15099, DOI 10.1074/jbc.273.24.15099; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Liu J, 1997, J BIOL CHEM, V272, P7211, DOI 10.1074/jbc.272.11.7211; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; Liu PS, 1997, P NATL ACAD SCI USA, V94, P13666, DOI 10.1073/pnas.94.25.13666; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; MULLER G, 1987, P NATL ACAD SCI USA, V84, P5600, DOI 10.1073/pnas.84.16.5600; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Rosen EM, 1997, CIBA F SYMP, V212, P215; Saphir A, 1997, J NATL CANCER I, V89, P1658; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Sasaki T, 1998, EMBO J, V17, P4249, DOI 10.1093/emboj/17.15.4249; Scherer PE, 1997, J BIOL CHEM, V272, P29337, DOI 10.1074/jbc.272.46.29337; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160; Standker L, 1997, FEBS LETT, V420, P129, DOI 10.1016/S0014-5793(97)01503-2; Stathakis P, 1997, J BIOL CHEM, V272, P20641, DOI 10.1074/jbc.272.33.20641; TAKAHASHI H, 1992, ELECTRON LETT, V28, P380, DOI 10.1049/el:19920238; TAKAHASHI K, 1990, IN VITRO CELL DEV B, V26, P265; TAKAHASHI K, 1991, IN VITRO CELL DEV B, V27, P766; TAMARGO RJ, 1991, CANCER RES, V51, P672; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; TERMAN BI, 1991, ONCOGENE, V6, P1677; WAY M, 1995, FEBS LETT, V376, P108, DOI 10.1016/0014-5793(95)01256-7; YAMAOKA M, 1993, CANCER RES, V53, P4262; Yue TL, 1997, MOL PHARMACOL, V51, P951, DOI 10.1124/mol.51.6.951; Zetter BR, 1998, ANNU REV MED, V49, P407, DOI 10.1146/annurev.med.49.1.407	54	148	169	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15781	15785		10.1074/jbc.274.22.15781	http://dx.doi.org/10.1074/jbc.274.22.15781			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336480	hybrid			2022-12-25	WOS:000080560100069
J	Farr, CL; Wang, YX; Kaguni, LS				Farr, CL; Wang, YX; Kaguni, LS			Functional interactions of mitochondrial DNA polymerase and single-stranded DNA-binding protein - Template-primer DNA binding and initiation and elongation of DNA strand synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEOXYRIBONUCLEIC-ACID SYNTHESIS; ESCHERICHIA-COLI; DROSOPHILA-MELANOGASTER; REPLICATION; SSB; HOLOENZYME; EMBRYOS; BACTERIOPHAGE-T7; PURIFICATION; PROCESSIVITY	Functional interactions between mitochondrial DNA polymerase (pol gamma) and mitochondrial single stranded DNA-binding protein (mtSSB) from Drosophila embryos have been evaluated with regard to the overall activity of poli gamma and in partial reactions involving template-primer binding and initiation and idling in DNA strand synthesis. Both the 5' --> 3' DNA polymerase and 3' --> 5' exonuclease in pol gamma are stimulated 15-20-fold on oligonucleotide-primed single-stranded DNA by native and recombinant forms of mtSSB. That the extent of stimulation is similar for both enzyme activities over a broad range of KCI concentrations suggests their functional coordination and a similar mechanism of stimulation by mtSSB. At the same time, the high mispair specificity of pol gamma in exonucleolytic hydrolysis is maintained, indicating that enhancement of pol gamma catalytic efficiency is likely not accompanied by increased nucleotide turnover. DNase I footprinting of pol gamma DNA complexes and initial rate measurements show that mtSSB enhances primer recognition and binding and stimulates 30-fold the rate of initiation of DNA strands. Dissociation studies show that productive complexes of the native pol gamma heterodimer with template-primer DNA are formed and remain stable in the absence of replication accessory proteins.	Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA	Michigan State University	Kaguni, LS (corresponding author), Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045295] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45295] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER TA, 1986, CELL, V45, P53, DOI 10.1016/0092-8674(86)90537-4; CHA TA, 1988, CANCER CELL, V6, P1; CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6; CURTH U, 1994, EUR J BIOCHEM, V221, P435, DOI 10.1111/j.1432-1033.1994.tb18756.x; FORMOSA T, 1983, P NATL ACAD SCI-BIOL, V80, P2442, DOI 10.1073/pnas.80.9.2442; GHRIR R, 1991, ARCH BIOCHEM BIOPHYS, V291, P395, DOI 10.1016/0003-9861(91)90152-9; Glover BP, 1998, J BIOL CHEM, V273, P23476, DOI 10.1074/jbc.273.36.23476; HACKENBR.CR, 1968, P NATL ACAD SCI USA, V61, P598, DOI 10.1073/pnas.61.2.598; HACKER KJ, 1994, J BIOL CHEM, V269, P24209; Kelman Z, 1998, EMBO J, V17, P2436, DOI 10.1093/emboj/17.8.2436; KIM YT, 1992, J BIOL CHEM, V267, P15032; Kong DC, 1998, J BIOL CHEM, V273, P6556, DOI 10.1074/jbc.273.11.6556; Kornberg A., 1992, DNA REPLICATION; KUNKEL TA, 1979, P NATL ACAD SCI USA, V76, P6331, DOI 10.1073/pnas.76.12.6331; KUNKEL TA, 1983, BIOCHEMISTRY-US, V22, P2378, DOI 10.1021/bi00279a012; LADUCA RJ, 1983, BIOCHEMISTRY-US, V22, P5177, DOI 10.1021/bi00291a018; LOHMAN TM, 1994, ANNU REV BIOCHEM, V63, P527, DOI 10.1146/annurev.biochem.63.1.527; MIGNOTTE B, 1985, NUCLEIC ACIDS RES, V13, P1703, DOI 10.1093/nar/13.5.1703; Mikhailov VS, 1996, J BIOL CHEM, V271, P18939, DOI 10.1074/jbc.271.31.18939; PAVCO PA, 1985, J CELL BIOL, V100, P258, DOI 10.1083/jcb.100.1.258; REEMS JA, 1994, J BIOL CHEM, V269, P33091; REUBEN RC, 1974, J BIOL CHEM, V249, P3843; RIGLER MN, 1995, J BIOL CHEM, V270, P8910, DOI 10.1074/jbc.270.15.8910; SHERMAN LA, 1976, J MOL BIOL, V103, P61, DOI 10.1016/0022-2836(76)90052-8; SRERE PA, 1980, TRENDS BIOCHEM SCI, V5, P120, DOI 10.1016/0968-0004(80)90051-1; STROUMBAKIS ND, 1994, GENE, V143, P171, DOI 10.1016/0378-1119(94)90093-0; TABOR S, 1987, J BIOL CHEM, V262, P16212; THOMMES P, 1995, J BIOL CHEM, V270, P21137, DOI 10.1074/jbc.270.36.21137; TIRANTI V, 1993, GENE, V126, P219, DOI 10.1016/0378-1119(93)90370-I; VANDYCK E, 1992, EMBO J, V11, P3421, DOI 10.1002/j.1460-2075.1992.tb05421.x; VANTUYLE GC, 1985, J CELL BIOL, V100, P251, DOI 10.1083/jcb.100.1.251; WERNETTE CM, 1988, BIOCHEMISTRY-US, V27, P6046, DOI 10.1021/bi00416a033; WERNETTE CM, 1986, J BIOL CHEM, V261, P4764; WILLIAMS AJ, 1993, J BIOL CHEM, V268, P24855; WILLIAMS AJ, 1995, J BIOL CHEM, V270, P860, DOI 10.1074/jbc.270.2.860; Yang C, 1997, NAT STRUCT BIOL, V4, P153, DOI 10.1038/nsb0297-153	36	80	81	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					14779	14785		10.1074/jbc.274.21.14779	http://dx.doi.org/10.1074/jbc.274.21.14779			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329675	hybrid			2022-12-25	WOS:000081965200040
J	Herold, J; Siddell, SG; Gorbalenya, AE				Herold, J; Siddell, SG; Gorbalenya, AE			A human RNA viral cysteine proteinase that depends upon a unique Zn2+-binding finger connecting the two domains of a papain-like fold	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; HEPATITIS-C VIRUS; INFECTIOUS-BRONCHITIS VIRUS; ZINC-CONTAINING ENZYME; P-28 CLEAVAGE SITE; CRYSTAL-STRUCTURE; MURINE CORONAVIRUS; BLEOMYCIN HYDROLASE; SECONDARY STRUCTURE; BINDING SITE	A cysteine proteinase, papain-like proteinase (PL1pro), of the human coronavirus 229E (HCoV) regulates the expression of the replicase polyproteins, pp1a and ppa1ab, by cleavage between Gly(111) and Asn(112), far upstream of its own catalytic residue Cys(1054). In this report, using bioinformatics tools, we predict that, unlike its distant cellular homologues, HCoV PL1pro and its coronaviral relatives have a poorly conserved Zn2+ finger connecting the left and right hand domains of a papain-like fold. Optical emission spectrometry has been used to confirm the presence of Zn2+ in a purified and proteolytically active form of the HCoV PL1pro fused with the Escherichia coli maltose-binding protein. In denaturation/renaturation experiments using the recombinant protein, its activity was shown to be strongly dependent upon Zn2+, which could be partly substituted by Co2+ during renaturation, The reconstituted, Zn2+-containing PL1pro was not sensitive to 1,10-phenanthroline, and the Zn2+-depleted protein was not reactivated by adding Zn2+ after renaturation. Consistent with the proposed essential structural role of Zn2+, PL1pro was selectively inactivated by mutations in the Zn2+ finger including replacements of any of four conserved Cys residues predicted to co-ordinate Zn2+. The unique domain organization of HCoV PL1pro provides a potential framework for regulatory processes and may be indicative of a nonproteolytic activity of this enzyme.	NCI, Frederick Canc Res & Dev Ctr, Adv Biomed Comp Ctr, SAIC,NIH, Frederick, MD 21702 USA; Univ Wurzburg, Inst Immunol & Virol, D-97078 Wurzburg, Germany; Leiden Univ, Ctr Med, NL-2300 RC Leiden, Netherlands; Russian Acad Med Sci, Inst Poliomyelitis & Viral Encephalitis, Moscow 142782, Russia	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of Wurzburg; Leiden University; Leiden University - Excl LUMC; Russian Academy of Medical Sciences	Gorbalenya, AE (corresponding author), NCI, Frederick Canc Res & Dev Ctr, Adv Biomed Comp Ctr, SAIC,NIH, 430 Miller Dr,Rm 235, Frederick, MD 21702 USA.		Gorbalenya, Alexander E/J-4818-2012	Gorbalenya, Alexander E/0000-0002-4967-7341	NCI NIH HHS [N01-CO-56000] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO056000] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexandrov N N, 1996, Pac Symp Biocomput, P53; Alexandrov NN, 1996, PROTEINS, V25, P354, DOI 10.1002/(SICI)1097-0134(199607)25:3<354::AID-PROT7>3.3.CO;2-W; ALLAIRE M, 1994, NATURE, V369, P72, DOI 10.1038/369072a0; ALTMAN RB, 1995, J MOL GRAPH MODEL, V13, P142, DOI 10.1016/0263-7855(95)00002-N; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ANDINO R, 1990, CELL, V63, P369, DOI 10.1016/0092-8674(90)90170-J; Aurora R, 1998, P NATL ACAD SCI USA, V95, P2818, DOI 10.1073/pnas.95.6.2818; BAKER EN, 1980, J MOL BIOL, V141, P441, DOI 10.1016/0022-2836(80)90255-7; BAKER SC, 1993, J VIROL, V67, P6056, DOI 10.1128/JVI.67.10.6056-6063.1993; BAZAN JF, 1988, P NATL ACAD SCI USA, V85, P7872, DOI 10.1073/pnas.85.21.7872; Berg JM, 1996, SCIENCE, V271, P1081, DOI 10.1126/science.271.5252.1081; BONILLA PJ, 1995, VIROLOGY, V209, P489, DOI 10.1006/viro.1995.1281; BONILLA PJ, 1994, VIROLOGY, V198, P736, DOI 10.1006/viro.1994.1088; Bonilla PJ, 1997, J VIROL, V71, P900, DOI 10.1128/JVI.71.2.900-909.1997; BOURSNELL MEG, 1987, J GEN VIROL, V68, P57, DOI 10.1099/0022-1317-68-1-57; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; BRIERLEY I, 1995, J GEN VIROL, V76, P1885, DOI 10.1099/0022-1317-76-8-1885; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; CHOI HK, 1991, NATURE, V354, P37, DOI 10.1038/354037a0; Coulombe R, 1996, EMBO J, V15, P5492, DOI 10.1002/j.1460-2075.1996.tb00934.x; DeFrancesco R, 1996, BIOCHEMISTRY-US, V35, P13282, DOI 10.1021/bi9616458; DONG SH, 1994, VIROLOGY, V204, P541, DOI 10.1006/viro.1994.1567; DOUGHERTY WG, 1993, MICROBIOL REV, V57, P781, DOI 10.1128/MMBR.57.4.781-822.1993; Eddy SR, 1996, CURR OPIN STRUC BIOL, V6, P361, DOI 10.1016/S0959-440X(96)80056-X; ELEOUET JF, 1995, VIROLOGY, V206, P817, DOI 10.1006/viro.1995.1004; Gerstein M, 1995, COMPUT APPL BIOSCI, V11, P633; Gorbalenya A.E., 1993, SOV SCI REV D, V11, P1; GORBALENYA AE, 1991, FEBS LETT, V288, P201, DOI 10.1016/0014-5793(91)81034-6; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4847, DOI 10.1093/nar/17.12.4847; GORBALENYA AE, 1989, FEBS LETT, V243, P103, DOI 10.1016/0014-5793(89)80109-7; Gorbalenya AE, 1996, PERSPECT DRUG DISCOV, V6, P64, DOI 10.1007/BF02174046; GORBALENYA AE, 1986, FEBS LETT, V194, P253, DOI 10.1016/0014-5793(86)80095-3; Guarne A, 1998, EMBO J, V17, P7469, DOI 10.1093/emboj/17.24.7469; HARDY WR, 1989, J VIROL, V63, P4653, DOI 10.1128/JVI.63.11.4653-4664.1989; HARRIS GW, 1992, ACTA CRYSTALLOGR B, V48, P67, DOI 10.1107/S0108768191006663; HARTLEY BS, 1960, ANNU REV BIOCHEM, V29, P45, DOI 10.1146/annurev.bi.29.070160.000401; Henikoff S, 1998, NUCLEIC ACIDS RES, V26, P309, DOI 10.1093/nar/26.1.309; Herold J, 1996, METHOD ENZYMOL, V275, P68; Herold J, 1998, J VIROL, V72, P910, DOI 10.1128/JVI.72.2.910-918.1998; HEROLD J, 1993, VIROLOGY, V195, P680, DOI 10.1006/viro.1993.1419; Holland J, 1998, VIRUS GENES, V16, P13, DOI 10.1023/A:1007989407305; Hubbard TJP, 1997, NUCLEIC ACIDS RES, V25, P236, DOI 10.1093/nar/25.1.236; HUGHES SA, 1995, J VIROL, V69, P809, DOI 10.1128/JVI.69.2.809-813.1995; JIA ZC, 1995, J BIOL CHEM, V270, P5527, DOI 10.1074/jbc.270.10.5527; JOSHUATOR L, 1995, SCIENCE, V269, P945, DOI 10.1126/science.7638617; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KAMPHUIS IG, 1985, J MOL BIOL, V182, P317, DOI 10.1016/0022-2836(85)90348-1; Kim JL, 1996, CELL, V87, P343, DOI 10.1016/S0092-8674(00)81351-3; King RD, 1997, COMPUT APPL BIOSCI, V13, P473; KRAUSSLICH HG, 1988, ANNU REV BIOCHEM, V57, P701, DOI 10.1146/annurev.bi.57.070188.003413; Lai MMC, 1997, ADV VIRUS RES, V48, P1, DOI 10.1016/S0065-3527(08)60286-9; LEE HJ, 1991, VIROLOGY, V180, P567, DOI 10.1016/0042-6822(91)90071-I; Lim KP, 1998, VIROLOGY, V245, P303, DOI 10.1006/viro.1998.9164; Liu X, 1998, J VIROL, V72, P4463, DOI 10.1128/JVI.72.5.4463-4466.1998; Love RA, 1996, CELL, V87, P331, DOI 10.1016/S0092-8674(00)81350-1; Maes D, 1996, BIOCHEMISTRY-US, V35, P16292, DOI 10.1021/bi961491w; Mangel WF, 1997, TRENDS BIOCHEM SCI, V22, P393, DOI 10.1016/S0968-0004(97)01123-7; MATTHEWS DA, 1994, CELL, V77, P761, DOI 10.1016/0092-8674(94)90059-0; MCGRATH ME, 1995, J MOL BIOL, V247, P251, DOI 10.1006/jmbi.1994.0137; McGrath ME, 1997, NAT STRUCT BIOL, V4, P105, DOI 10.1038/nsb0297-105; NEURATH H, 1984, SCIENCE, V224, P350, DOI 10.1126/science.6369538; OH CS, 1989, VIROLOGY, V173, P692, DOI 10.1016/0042-6822(89)90582-5; OHARA BP, 1995, BIOCHEMISTRY-US, V34, P13190, DOI 10.1021/bi00040a034; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; PICKERSGILL RW, 1991, ACTA CRYSTALLOGR B, V47, P766, DOI 10.1107/S0108768191003191; QIAN XQ, 1993, BIOCHEMISTRY-US, V32, P9944, DOI 10.1021/bi00089a010; RAWLINGS ND, 1993, BIOCHEM J, V290, P205, DOI 10.1042/bj2900205; RITONJA A, 1989, FEBS LETT, V247, P419, DOI 10.1016/0014-5793(89)81383-3; Rost B, 1996, METHOD ENZYMOL, V266, P525; Ryan MD, 1997, J GEN VIROL, V78, P699, DOI 10.1099/0022-1317-78-4-699; Sanchez R, 1997, CURR OPIN STRUC BIOL, V7, P206, DOI 10.1016/S0959-440X(97)80027-9; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SCHWABE JWR, 1994, NAT STRUCT BIOL, V1, P345, DOI 10.1038/nsb0694-345; Skern T, 1998, J GEN VIROL, V79, P301, DOI 10.1099/0022-1317-79-2-301; SOMMERGRUBER W, 1994, VIROLOGY, V204, P815, DOI 10.1006/viro.1994.1599; Sommergruber W, 1997, VIROLOGY, V234, P203, DOI 10.1006/viro.1997.8595; Stempniak M, 1997, J VIROL, V71, P2881, DOI 10.1128/JVI.71.4.2881-2886.1997; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VERNET T, 1995, J BIOL CHEM, V270, P16645, DOI 10.1074/jbc.270.28.16645; VRIEND G, 1993, J APPL CRYSTALLOGR, V26, P47, DOI 10.1107/S0021889892008240; Wang B, 1998, STRUCTURE, V6, P555, DOI 10.1016/S0969-2126(98)00058-6; WILKINSON KD, 1995, ANNU REV NUTR, V15, P161, DOI 10.1146/annurev.nu.15.070195.001113; XU HE, 1994, J BIOL CHEM, V269, P21177; YU SYF, 1992, VIROLOGY, V186, P725, DOI 10.1016/0042-6822(92)90039-R; Zhu WL, 1996, NAT STRUCT BIOL, V3, P122, DOI 10.1038/nsb0296-122	86	55	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					14918	14925		10.1074/jbc.274.21.14918	http://dx.doi.org/10.1074/jbc.274.21.14918			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329692	hybrid, Green Published			2022-12-25	WOS:000081965200057
J	Wang, KL; Roufogalis, BD				Wang, KL; Roufogalis, BD			Ca2+/calmodulin stimulates GTP binding to the Ras-related protein Ral-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISSOCIATION STIMULATOR; SYNAPTIC VESICLES; EXCHANGE FACTOR; HUMAN-PLATELETS; KINASE-II; CALMODULIN; ACTIVATION; GROWTH; CELLS; IDENTIFICATION	Ral-A is a Ras-related GTP-binding protein that has been suggested to be the downstream target of Ras proteins and is involved in the tyrosine kinase-mediated, Ras-dependent activation of phospholipase D. We reported recently that Ral-A purified from human erythrocyte membrane binds to calmodulin in a Ca2+-dependent manner at a calmodulin binding domain identified near its C-terminal region (Wang, K. L., Khan, M. T., and Roufogalis, B. D. (1997) J. Biol. Chem. 272, 16002-16009). In this study we show the enhancement of GTP binding to Ral-A by Ca2+/calmodulin. The stimulation up to 3-fold by calmodulin was Ca2+-dependent, with half-maximum activation occurring at 180 nM calmodulin and 80 nM free Ca2+ concentration. The present work supports a regulatory role of Ca2+/calnodulin for the activation of Ral-A and suggests a possible direct link between signal transduction pathways of Ca2+/calmodulin and Ral-A proteins.	Univ Sydney, Dept Pharm, Sydney, NSW 2006, Australia	University of Sydney	Roufogalis, BD (corresponding author), Univ Sydney, Dept Pharm, A15, Sydney, NSW 2006, Australia.	basilr@pharm.usyd.edu.au		Roufogalis, Basil/0000-0001-9123-5478				Bhullar RP, 1996, BBA-MOL CELL RES, V1311, P181, DOI 10.1016/0167-4889(96)00002-X; BIELINSKI DF, 1993, BIOCHIM BIOPHYS ACTA, V1151, P246, DOI 10.1016/0005-2736(93)90109-D; BOKOCH GM, 1993, FASEB J, V7, P750, DOI 10.1096/fasebj.7.9.8330683; Cohen P, 1988, CALMODULIN; De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; Fischer R, 1996, J BIOL CHEM, V271, P25067, DOI 10.1074/jbc.271.41.25067; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3450; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; Hinoi T, 1996, J BIOL CHEM, V271, P19710, DOI 10.1074/jbc.271.33.19710; Hofer F, 1998, CURR BIOL, V8, P839, DOI 10.1016/S0960-9822(98)70327-6; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; Joyal JL, 1997, J BIOL CHEM, V272, P15419, DOI 10.1074/jbc.272.24.15419; Lee CHJ, 1996, J NEUROSCI, V16, P6784; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; Moyers JS, 1997, J BIOL CHEM, V272, P11832, DOI 10.1074/jbc.272.18.11832; Park JB, 1997, J BIOL CHEM, V272, P20857, DOI 10.1074/jbc.272.33.20857; Peppelenbosch MP, 1996, J BIOL CHEM, V271, P7883, DOI 10.1074/jbc.271.14.7883; POLAKIS PG, 1989, J BIOL CHEM, V264, P16383; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Romoser VA, 1997, J BIOL CHEM, V272, P13270, DOI 10.1074/jbc.272.20.13270; Rosen LB, 1996, P NATL ACAD SCI USA, V93, P1113, DOI 10.1073/pnas.93.3.1113; Rusanescu G, 1995, NEURON, V15, P1415, DOI 10.1016/0896-6273(95)90019-5; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; TANSEY MG, 1994, J BIOL CHEM, V269, P9912; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; VOGEL HJ, 1995, MOL CELL BIOCHEM, V149, P3, DOI 10.1007/BF01076558; VOGEL HJ, 1994, BIOCHEM CELL BIOL, V72, P357, DOI 10.1139/o94-049; VOLKNANDT W, 1993, FEBS LETT, V317, P53, DOI 10.1016/0014-5793(93)81490-Q; WALSH MP, 1994, MOL CELL BIOCHEM, V135, P21, DOI 10.1007/BF00925958; WANG KKW, 1988, ARCH BIOCHEM BIOPHYS, V267, P317, DOI 10.1016/0003-9861(88)90037-9; Wang KL, 1997, J BIOL CHEM, V272, P16002, DOI 10.1074/jbc.272.25.16002; Wes PD, 1996, EMBO J, V15, P5839, DOI 10.1002/j.1460-2075.1996.tb00971.x; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; Wolthuis RMF, 1998, CURR BIOL, V8, P471, DOI 10.1016/S0960-9822(98)70183-6; Wolthuis RMF, 1998, MOL CELL BIOL, V18, P2486, DOI 10.1128/MCB.18.5.2486	38	39	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					14525	14528		10.1074/jbc.274.21.14525	http://dx.doi.org/10.1074/jbc.274.21.14525			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329639	hybrid			2022-12-25	WOS:000081965200004
J	Yarwood, SJ; Steele, MR; Scotland, G; Houslay, MD; Bolger, GB				Yarwood, SJ; Steele, MR; Scotland, G; Houslay, MD; Bolger, GB			The RACK1 signaling scaffold protein selectively interacts with the cAMP-specific phosphodiesterase PDE4D5 isoform	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMP-SPECIFIC PHOSPHODIESTERASE; N-TERMINAL DOMAIN; KINASE-C; BETA-SUBUNIT; INTRACELLULAR RECEPTOR; MEMBRANE ASSOCIATION; MOLECULAR-CLONING; RPDE-6 RNPDE4A5; COS7 CELLS; GENE	The WD-repeat protein receptor for activated C-kinase (RACK1) was identified by its interaction with the cyclic AMP-specific phosphodiesterase (PDE4) isoform PDE4D5 in a yeast two-hybrid screen. The interaction was confirmed by co-immunoprecipitation of native RACK1 and PDE4D5 from COS7, HEK293, 3T3-F442A, and SK-N-SH cell lines. The interaction was unaffected by stimulation of the cells with the phorbol ester phorbol S-myristate S-acetate. PDE4D5 did not interact with two other WD-repeat proteins, beta'-coatomer protein and G(s)beta, in two-hybrid tests. RACK1 did not interact with other PDE4D isoforms or with known PDE4A, PDE4B, and PDE4C isoforms, PDE4D5 and RACK1 interacted with high affinity (K-a approximately 7 pM) when they were expressed and purified from Escherichia coli, demonstrating that the interaction does not require intermediate proteins, The binding of the E. coli-expressed proteins did not alter the kinetics of cAMP hydrolysis by PDE4D5 but caused a 3-4-fold change in its sensitivity to inhibition by the PDE4 selective inhibitor rolipram. The subcellular distributions of RACK1 and PDE4D5 were extremely similar, with the major amount of both proteins (70%) in the high speed supernatant (S2) fraction. Analysis of constructs with specific deletions or single amino acid mutations in PDE4D5 demonstrated that a small cluster of amino acids in the unique amino terminal region of PDE4D5 was necessary for its interaction with RACK1. We suggest that RACK1 may act as a scaffold protein to recruit PDE4D5 and other proteins into a signaling complex.	Univ Utah, Dept Med Hematol Oncol, Vet Affairs Med Ctr, Salt Lake City, UT 84148 USA; Univ Utah, Dept Oncol Sci, Vet Affairs Med Ctr, Salt Lake City, UT 84148 USA; Univ Glasgow, Mol Pharmacol Grp, Div Biochem & Mol Biol, Inst Biol & Life Sci, Glasgow G12 8QQ, Lanark, Scotland	US Department of Veterans Affairs; Veterans Health Administration (VHA); Utah System of Higher Education; University of Utah; US Department of Veterans Affairs; Veterans Health Administration (VHA); Utah System of Higher Education; University of Utah; University of Glasgow	Bolger, GB (corresponding author), Univ Utah, Dept Med Hematol Oncol, Vet Affairs Med Ctr, 500 Foothills Blvd, Salt Lake City, UT 84148 USA.	Graeme.Bolger@m.cc.utah.edu	Houslay, Miles/AAM-5281-2020; Houslay, Miles D/A-6825-2011	Yarwood, Stephen/0000-0001-9489-9253; Houslay, Miles/0000-0002-3826-8091				ALVAREZ R, 1995, MOL PHARMACOL, V48, P616; BARTEL PL, 1995, METHOD ENZYMOL, V254, P241; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; BOLGER G, 1993, MOL CELL BIOL, V13, P6558, DOI 10.1128/MCB.13.10.6558; Bolger GB, 1997, BIOCHEM J, V328, P539; Bolger GB, 1996, J BIOL CHEM, V271, P1065, DOI 10.1074/jbc.271.2.1065; Bolger GB, 1998, METH MOL B, V88, P101; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chang BY, 1998, MOL CELL BIOL, V18, P3245, DOI 10.1128/MCB.18.6.3245; Csukai M, 1997, J BIOL CHEM, V272, P29200, DOI 10.1074/jbc.272.46.29200; Faulstich D, 1996, J CELL BIOL, V135, P53, DOI 10.1083/jcb.135.1.53; GarciaHiguera I, 1996, BIOCHEMISTRY-US, V35, P13985, DOI 10.1021/bi9612879; GUAN C, 1988, GENE, V67, P21; GUILLEMOT F, 1989, P NATL ACAD SCI USA, V86, P4594, DOI 10.1073/pnas.86.12.4594; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HARLOW E, 1990, ANTIBODIES LAB MANUA, P474; Hoffmann R, 1998, BIOCHEM J, V333, P139, DOI 10.1042/bj3330139; Houslay MD, 1998, ADV PHARMACOL, V44, P225, DOI 10.1016/S1054-3589(08)60128-3; Huston E, 1997, BIOCHEM J, V328, P549, DOI 10.1042/bj3280549; Huston E, 1996, J BIOL CHEM, V271, P31334, DOI 10.1074/jbc.271.49.31334; Jin SLC, 1998, J BIOL CHEM, V273, P19672, DOI 10.1074/jbc.273.31.19672; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Liliental J, 1998, J BIOL CHEM, V273, P2379, DOI 10.1074/jbc.273.4.2379; MARCHMONT RJ, 1980, BIOCHEM J, V187, P381, DOI 10.1042/bj1870381; MCPHEE I, 1995, BIOCHEM J, V310, P965, DOI 10.1042/bj3100965; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Nemoz G, 1996, FEBS LETT, V384, P97, DOI 10.1016/0014-5793(96)00300-6; OConnell JC, 1996, BIOCHEM J, V318, P255, DOI 10.1042/bj3180255; Owens RJ, 1997, CELL SIGNAL, V9, P575, DOI 10.1016/S0898-6568(97)00072-7; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; RON D, 1995, P NATL ACAD SCI USA, V92, P492, DOI 10.1073/pnas.92.2.492; RON D, 1995, J BIOL CHEM, V270, P24180, DOI 10.1074/jbc.270.41.24180; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; SCOTLAND G, 1995, BIOCHEM J, V308, P673, DOI 10.1042/bj3080673; Sette C, 1996, J BIOL CHEM, V271, P16526, DOI 10.1074/jbc.271.28.16526; SETTE C, 1994, J BIOL CHEM, V269, P9245; SETTE C, 1994, J BIOL CHEM, V269, P18271; SHAKUR Y, 1993, BIOCHEM J, V292, P677, DOI 10.1042/bj2920677; SHAKUR Y, 1995, BIOCHEM J, V306, P801, DOI 10.1042/bj3060801; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Souness JE, 1997, CELL SIGNAL, V9, P227, DOI 10.1016/S0898-6568(96)00173-8; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1	49	249	257	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					14909	14917		10.1074/jbc.274.21.14909	http://dx.doi.org/10.1074/jbc.274.21.14909			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329691	hybrid			2022-12-25	WOS:000081965200056
J	Zhao, T; Eissenberg, JC				Zhao, T; Eissenberg, JC			Phosphorylation of heterochromatin protein 1 by casein kinase II is required for efficient heterochromatin binding in Drosophila	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSITION-EFFECT VARIEGATION; ORIGIN RECOGNITION COMPLEX; DNA-BINDING; CHROMOSOMAL PROTEIN; CHROMATIN STRUCTURE; GENE-EXPRESSION; HP1; MELANOGASTER; DOMAIN; TRANSCRIPTION	Heterochromatin-associated protein 1 (HP1) is a nonhistone chromosomal protein with a dose-dependent effect on heterochromatin mediated position-effect silencing. It is multiply phosphorylated in vivo. Hyperphosphorylation of HP1 is correlated with heterochromatin assembly. We report here that HP1 is phosphorylated by casein kinase II in vivo at three serine residues located at the N and C termini of the protein. Alanine substitution mutations in the casein kinase II target phosphorylation sites dramatically reduce the heterochromatin binding activity of HP1, whereas glutamate substitution mutations, which mimic the charge contributions of phosphorylated serine, have apparently wild-type binding activity. We propose that phosphorylation of HP1 promotes protein-protein interaction between HP1 and target binding proteins in heterochromatin.	St Louis Univ, Hlth Sci Ctr, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA	Saint Louis University	Eissenberg, JC (corresponding author), St Louis Univ, Hlth Sci Ctr, Edward A Doisy Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.							ACKERMAN P, 1988, J BIOL CHEM, V263, P12653; ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; Ball LJ, 1997, EMBO J, V16, P2473, DOI 10.1093/emboj/16.9.2473; BIRNBAUM MJ, 1992, PROTEIN EXPRES PURIF, V3, P142, DOI 10.1016/S1046-5928(05)80098-1; BLUMENFELD M, 1978, P NATL ACAD SCI USA, V75, P866, DOI 10.1073/pnas.75.2.866; BOURBON HM, 1995, J BIOL CHEM, V270, P11130, DOI 10.1074/jbc.270.19.11130; Coqueret O, 1998, J BIOL CHEM, V273, P2561, DOI 10.1074/jbc.273.5.2561; DADD CA, 1993, BIOTECHNIQUES, V14, P266; EISSENBERG JC, 1992, GENETICS, V131, P345; EISSENBERG JC, 1994, J BIOL CHEM, V269, P21315; EISSENBERG JC, 1990, P NATL ACAD SCI USA, V87, P9923, DOI 10.1073/pnas.87.24.9923; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; FRIDELL YWC, 1991, NUCLEIC ACIDS RES, V19, P5082, DOI 10.1093/nar/19.18.5082; GLOVER CVC, 1983, J BIOL CHEM, V258, P3258; HARLOW E, 1988, ANTIBODIES LABORATOR, P505; Heitz E., 1928, JB WISS BOT, V69, P728; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HOLMQUIST GP, 1987, AM J HUM GENET, V40, P151; Huang DW, 1998, J CELL BIOL, V142, P307, DOI 10.1083/jcb.142.2.307; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Jaffe L, 1997, GENE DEV, V11, P1327, DOI 10.1101/gad.11.10.1327; JAMES TC, 1989, EUR J CELL BIOL, V50, P170; John B, 1979, Int Rev Cytol, V58, P1, DOI 10.1016/S0074-7696(08)61473-4; KARESS RE, 1984, CELL, V38, P135, DOI 10.1016/0092-8674(84)90534-8; KELLUM R, 1995, J CELL SCI, V108, P1407; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; Leroy D, 1997, BIOCHEMISTRY-US, V36, P1242, DOI 10.1021/bi961949u; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; Liu ZP, 1997, GENE DEV, V11, P3413, DOI 10.1101/gad.11.24.3413; LOCKE J, 1988, GENETICS, V120, P181; MARTIN P, 1986, DEV BIOL, V117, P574, DOI 10.1016/0012-1606(86)90326-X; Massimi P, 1996, ONCOGENE, V12, P2325; MEEK DW, 1992, BIOCHEM J, V287, P1; ODA Y, 1993, J BIOL CHEM, V268, P27318; OReilly D, 1997, EMBO J, V16, P2420, DOI 10.1093/emboj/16.9.2420; Pak DTS, 1997, CELL, V91, P311, DOI 10.1016/S0092-8674(00)80415-8; PIMPINELLI S, 1986, TRENDS GENET, V2, P17, DOI 10.1016/0168-9525(86)90163-0; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; PLATERO JS, 1995, EMBO J, V14, P3977, DOI 10.1002/j.1460-2075.1995.tb00069.x; POWERS JA, 1993, J CELL BIOL, V120, P291, DOI 10.1083/jcb.120.2.291; ROTH SY, 1992, TRENDS BIOCHEM SCI, V17, P93, DOI 10.1016/0968-0004(92)90243-3; SHORE EM, 1987, GENE DEV, V1, P829, DOI 10.1101/gad.1.8.829; SIMON JA, 1985, CELL, V40, P805, DOI 10.1016/0092-8674(85)90340-X; SPOFFORD JB, 1976, GENETICS BIOL DROS C, V1, P955; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; SWEENEY HL, 1994, P NATL ACAD SCI USA, V91, P1490, DOI 10.1073/pnas.91.4.1490; Sweet MT, 1997, J BIOL CHEM, V272, P916, DOI 10.1074/jbc.272.2.916; WALLRATH LL, 1995, GENE DEV, V9, P1263, DOI 10.1101/gad.9.10.1263; WEST MHP, 1984, ELECTROPHORESIS, V5, P133, DOI 10.1002/elps.1150050302; WU C, 1979, CELL, V16, P797, DOI 10.1016/0092-8674(79)90095-3; WUSTMANN G, 1989, MOL GEN GENET, V217, P520, DOI 10.1007/BF02464926; Ye Q, 1996, J BIOL CHEM, V271, P14653, DOI 10.1074/jbc.271.25.14653	53	64	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					15095	15100		10.1074/jbc.274.21.15095	http://dx.doi.org/10.1074/jbc.274.21.15095			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329715	hybrid			2022-12-25	WOS:000081965200080
J	Pineau, P; Nagai, H; Prigent, S; Wei, Y; Gyapay, G; Weissenbach, J; Tiollais, P; Buendia, MA; Dejean, A				Pineau, P; Nagai, H; Prigent, S; Wei, Y; Gyapay, G; Weissenbach, J; Tiollais, P; Buendia, MA; Dejean, A			Identification of three distinct regions of allelic deletions on the short arm of chromosome 8 in hepatocellular carcinoma	ONCOGENE			English	Article						hepatocellular carcinoma; chromosome 8p; loss of heterozygosity; tumor suppressor gene; microsatellite marker	COMPARATIVE GENOMIC HYBRIDIZATION; TUMOR-SUPPRESSOR GENES; COLORECTAL-CANCER; BREAST-CANCER; REPEAT POLYMORPHISMS; SQUAMOUS CARCINOMA; CELL CARCINOMAS; LONG ARM; IN-SITU; MAP	The chromosome 8p is associated with a large number of allelic imbalances in epithelial tumors including hepatocellular carcinoma (HCC), However, no tumor suppressor gene has been identified so far in this particular region of the genome. To further clarify the pattern of allelic deletions on chromosome 8p in HCC, we have undertaken high-density polymorphic marker analysis of 109 paired normal and primary tumor samples using 40 microsatellites positioned every 2 cm in average throughout 8p, We found that 60% of the tumors exhibited loss of heterozygosity (LOH) at one or more loci at 8p with three distinct minimal deleted areas : a 13 cm region in the distal part of 8p21, a 9 cm area in the more proximal portion of 8p22 and a 5 cm area in 8p23, These data strongly suggest the presence of at least three novel tumor suppressor loci on 8p in hepatocellular carcinoma.	Inst Pasteur, INSERM, Unite Recombinaison & Express Genet, U163, F-75724 Paris 15, France; Genethon, CNRS, URA 1922, F-91000 Evry, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS)	Dejean, A (corresponding author), Inst Pasteur, INSERM, Unite Recombinaison & Express Genet, U163, 28 Rue Docteur Roux, F-75724 Paris 15, France.		Pineau, Pascal/AAP-5614-2020; Wei, Yu/A-7289-2016; Dejean, Anne/L-5145-2018	Pineau, Pascal/0000-0002-9407-1592; 				ADAMSON D, 1995, AM J HUM GENET, V57, P619; Adelaide J, 1998, GENE CHROMOSOME CANC, V22, P186, DOI 10.1002/(SICI)1098-2264(199807)22:3<186::AID-GCC4>3.0.CO;2-S; Anbazhagan R, 1998, AM J PATHOL, V152, P815; Becker SA, 1996, CANCER RES, V56, P5092; Boige V, 1997, CANCER RES, V57, P1986; Brat DJ, 1997, AM J PATHOL, V150, P383; CHER ML, 1994, GENE CHROMOSOME CANC, V11, P153, DOI 10.1002/gcc.2870110304; CHUAQUI RF, 1995, CANCER RES, V55, P4995; CLIBY W, 1993, CANCER RES, V53, P2393; Courjal F, 1997, CANCER RES, V57, P4360; CUNNINGHAM C, 1993, ONCOGENE, V8, P1391; DESOUZA AT, 1995, NAT GENET, V11, P447, DOI 10.1038/ng1295-447; DEVILEE P, 1994, BBA-REV CANCER, V1198, P113, DOI 10.1016/0304-419X(94)90009-4; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; El-Naggar AK, 1998, ONCOGENE, V16, P2983, DOI 10.1038/sj.onc.1201808; ELNAGGAR AK, 1995, CANCER RES, V55, P2656; EMI M, 1993, GENE CHROMOSOME CANC, V7, P152, DOI 10.1002/gcc.2870070307; EMMERTBUCK MR, 1995, CANCER RES, V55, P2959; Farrington SM, 1996, ONCOGENE, V12, P1803; FUJIWARA Y, 1993, CANCER RES, V53, P857; FUJIWARA Y, 1994, GENE CHROMOSOME CANC, V10, P7, DOI 10.1002/gcc.2870100103; FUJIWARA Y, 1993, CANCER RES, V53, P1172; Gronwald J, 1997, CANCER RES, V57, P481; Gustafson CE, 1996, CANCER RES, V56, P5238; Gyapay G, 1996, HUM MOL GENET, V5, P339, DOI 10.1093/hmg/5.3.339; Hammoud ZT, 1996, CANCER RES, V56, P4499; Hecker KH, 1996, BIOTECHNIQUES, V20, P478; *J HOPK U SCH MED, 1997, GEN DAT BAS; James LA, 1997, ONCOGENE, V14, P1059, DOI 10.1038/sj.onc.1200923; Johansson B, 1996, GENE CHROMOSOME CANC, V16, P155, DOI 10.1002/(SICI)1098-2264(199607)16:3<155::AID-GCC1>3.0.CO;2-Y; KNOWLES MA, 1993, ONCOGENE, V8, P1357; LITT M, 1993, BIOTECHNIQUES, V15, P280; Marchio A, 1997, GENE CHROMOSOME CANC, V18, P59, DOI 10.1002/(SICI)1098-2264(199701)18:1<59::AID-GCC7>3.0.CO;2-0; MURRAY JC, 1994, SCIENCE, V265, P2049, DOI 10.1126/science.8091227; Nagai H, 1997, ONCOGENE, V14, P2927, DOI 10.1038/sj.onc.1201136; NORDER H, 1993, ARCH VIROL, P189; Pineau P, 1998, J GEN VIROL, V79, P591, DOI 10.1099/0022-1317-79-3-591; Ried T, 1996, GENE CHROMOSOME CANC, V15, P234, DOI 10.1002/(SICI)1098-2264(199604)15:4<234::AID-GCC5>3.0.CO;2-2; ROSIN MP, 1995, CANC RES, V55; Roylance R, 1997, SEMIN CANCER BIOL, V8, P37, DOI 10.1006/scbi.1997.0051; Seitz S, 1997, ONCOGENE, V14, P741, DOI 10.1038/sj.onc.1200881; SHEFFIELD VC, 1995, HUM MOL GENET, V4, P1837, DOI 10.1093/hmg/4.10.1837; Simonic I, 1996, HUM GENET, V97, P524; Sunwoo JB, 1996, GENE CHROMOSOME CANC, V16, P164, DOI 10.1002/(SICI)1098-2264(199607)16:3<164::AID-GCC2>3.0.CO;2-X; Tishkoff SA, 1996, HUM GENET, V97, P759; TOMFOHRDE J, 1992, GENOMICS, V14, P144, DOI 10.1016/S0888-7543(05)80297-6; Van Hul W, 1998, GENOMICS, V47, P230, DOI 10.1006/geno.1997.5101; Vocke CD, 1996, CANCER RES, V56, P2411; VOORTER C, 1995, AM J PATHOL, V146, P1341; WOOD S, 1991, CYTOGENET CELL GENET, V58, P1932; Wu CL, 1997, GENE CHROMOSOME CANC, V20, P347, DOI 10.1002/(SICI)1098-2264(199712)20:4<347::AID-GCC5>3.0.CO;2-1	51	100	103	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	1999	18	20					3127	3134		10.1038/sj.onc.1202648	http://dx.doi.org/10.1038/sj.onc.1202648			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	197WB	10340384	hybrid			2022-12-25	WOS:000080388000008
J	Heidenreich, O; Neininger, A; Schratt, G; Zinck, R; Cahill, MA; Engel, K; Kotlyarov, A; Kraft, R; Kostka, S; Gaestel, M; Nordheim, A				Heidenreich, O; Neininger, A; Schratt, G; Zinck, R; Cahill, MA; Engel, K; Kotlyarov, A; Kraft, R; Kostka, S; Gaestel, M; Nordheim, A			MAPKAP kinase 2 phosphorylates serum response factor in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; C-FOS PROMOTER; TERNARY COMPLEX-FORMATION; GROWTH-FACTOR; TRANSCRIPTION FACTOR; TERMINAL PHOSPHORYLATION; CELLULAR STRESSES; NUCLEAR EXPORT; SAP KINASES; ELEMENT	Several growth factor- and calcium-regulated kinases such as pp90(rsk) or CaM kinase TV can phosphorylate the transcription factor serum response factor (SRF) at serine 103 (Ser-103). However, it is unknown whether stress-regulated kinases can also phosphorylate SRF. We show that treatment of cells with anisomycin, arsenite, sodium fluoride, or tetrafluoroaluminate induces phosphorylation of SRF at Ser-103 in both HeLa and NIH3T3 cells. This phosphorylation is dependent on the kinase p38/SAPK2 and correlates with the activation of MAPKAP kinase 2 (MK2). MK2 phosphorylates SRF in vitro at Ser-103 with similar efficiency as the small heat shock protein Hsp25 and significantly better than CREB, Comparison of wild type murine fibroblasts with those derived from MK2-deficient mice (Mk(-/-)) reveals MK2 as the major SRF kinase induced by arsenite. These results demonstrate that SRF is targeted by several signal transduction pathways within cells and establishes SRF as a nuclear target for MAPKAP kinase 2.	Univ Tubingen, Inst Zellbiol, Mol Biol Abt, D-72076 Tubingen, Germany; Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany; Med Hsch Hannover, Inst Klin Chem, D-30623 Hannover, Germany; Univ Halle Wittenberg, Innovationskolleg Zellspezialisierung, D-06120 Halle, Germany	Eberhard Karls University of Tubingen; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Hannover Medical School; Martin Luther University Halle Wittenberg	Nordheim, A (corresponding author), Univ Tubingen, Inst Zellbiol, Mol Biol Abt, Morgenstelle 15, D-72076 Tubingen, Germany.		Heidenreich, Olaf/AAP-5045-2021; Gaestel, Matthias/A-6560-2013; CAHILL, Michael/J-8035-2012	Heidenreich, Olaf/0000-0001-5404-6483; Gaestel, Matthias/0000-0002-4944-4652; CAHILL, Michael/0000-0002-8593-8844				Alberts AS, 1998, EMBO J, V17, P4075, DOI 10.1093/emboj/17.14.4075; Alberts AS, 1998, CELL, V92, P475, DOI 10.1016/S0092-8674(00)80941-1; Arsenian S, 1998, EMBO J, V17, P6289, DOI 10.1093/emboj/17.21.6289; Ben-Levy R, 1998, CURR BIOL, V8, P1049, DOI 10.1016/S0960-9822(98)70442-7; Cano E, 1996, ONCOGENE, V12, P805; Carnac G, 1998, MOL BIOL CELL, V9, P1891, DOI 10.1091/mbc.9.7.1891; Cavigelli M, 1996, EMBO J, V15, P6269, DOI 10.1002/j.1460-2075.1996.tb01017.x; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Engel K, 1998, EMBO J, V17, P3363, DOI 10.1093/emboj/17.12.3363; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; GAUTHIERROUVIERE C, 1995, MOL CELL BIOL, V15, P433, DOI 10.1128/MCB.15.1.433; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; GUTMAN A, 1991, MOL CELL BIOL, V11, P5381, DOI 10.1128/MCB.11.10.5381; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Iordanov M, 1997, EMBO J, V16, P1009, DOI 10.1093/emboj/16.5.1009; JANKNECHT R, 1995, CARCINOGENESIS, V16, P443, DOI 10.1093/carcin/16.3.443; JANKNECHT R, 1992, EMBO J, V11, P1045, DOI 10.1002/j.1460-2075.1992.tb05143.x; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JANKNECHT R, 1993, EUR J BIOCHEM, V216, P469, DOI 10.1111/j.1432-1033.1993.tb18165.x; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; KRACHT M, 1994, J EXP MED, V180, P2017, DOI 10.1084/jem.180.6.2017; Ludwig S, 1996, MOL CELL BIOL, V16, P6687; Ludwig S, 1998, J BIOL CHEM, V273, P1917, DOI 10.1074/jbc.273.4.1917; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARAIS RM, 1992, EMBO J, V11, P97, DOI 10.1002/j.1460-2075.1992.tb05032.x; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Minden A, 1997, BBA-REV CANCER, V1333, pF85, DOI 10.1016/S0304-419X(97)00018-8; MIRANTI CK, 1995, MOL CELL BIOL, V15, P3672; MISRA RP, 1991, MOL CELL BIOL, V11, P4545, DOI 10.1128/MCB.11.9.4545; New L, 1998, EMBO J, V17, P3372, DOI 10.1093/emboj/17.12.3372; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Ramirez S, 1997, J BIOL CHEM, V272, P31016, DOI 10.1074/jbc.272.49.31016; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SCHAUDER B, 1987, GENE, V52, P279, DOI 10.1016/0378-1119(87)90054-0; Schultz H, 1997, J CELL PHYSIOL, V173, P310, DOI 10.1002/(SICI)1097-4652(199712)173:3<310::AID-JCP2>3.0.CO;2-Q; Sealy L, 1997, MOL CELL BIOL, V17, P1744, DOI 10.1128/MCB.17.3.1744; Soulez M, 1996, MOL CELL BIOL, V16, P6065; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Thuerauf DJ, 1998, J BIOL CHEM, V273, P20636, DOI 10.1074/jbc.273.32.20636; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; VELCICH A, 1990, MOL CELL BIOL, V10, P6273, DOI 10.1128/MCB.10.12.6273; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; Zhu C, 1997, MOL CELL BIOL, V17, P4957, DOI 10.1128/MCB.17.9.4957; ZINCK R, 1995, MOL CELL BIOL, V15, P4930	58	144	150	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					14434	14443		10.1074/jbc.274.20.14434	http://dx.doi.org/10.1074/jbc.274.20.14434			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318869	hybrid			2022-12-25	WOS:000080322200098
J	Ogris, E; Du, XX; Nelson, KC; Mak, EK; Yu, XX; Lane, WS; Pallas, DC				Ogris, E; Du, XX; Nelson, KC; Mak, EK; Yu, XX; Lane, WS; Pallas, DC			A protein phosphatase methylesterase (PME-1) is one of several novel proteins stably associating with two inactive mutants of protein phosphatase 2A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYOMAVIRUS MIDDLE-T; BACTERIAL CHEMOTAXIS; CATALYTIC SUBUNIT; BOVINE BRAIN; TYROSINE PHOSPHORYLATION; METHYL ESTERIFICATION; POLYACRYLAMIDE GELS; MUTATIONAL ANALYSIS; CELLULAR PROTEINS; OKADAIC ACID	Carboxymethylation of proteins is a highly conserved means of regulation in eukaryotic: cells. The protein phosphatase 2A (PP2A) catalytic (C) subunit is reversibly methylated at its carboxyl terminus by specific methyltransferase and methylesterase enzymes which have been purified, but not cloned. Carboxymethylation affects PP2A activity and varies during the cell cycle. Here, we report that substitution of glutamine for either of two putative active site histidines in the PP2A C subunit results in inactivation of PP2A and formation of stable complexes between PP2A and several cellular proteins. One of these cellular proteins, herein named protein phosphatase methylesterase-1 (PME-1), was purified and microsequenced, and its cDNA was cloned. PME-1 is conserved from yeast to human and contains a motif found in lipases having a catalytic triad-activated serine as their active site nucleophile. Bacterially expressed PME-1 demethylated PP2A C subunit in vitro, and okadaic acid, a known inhibitor of the PP2A methylesterase, inhibited this reaction. To our knowledge, PME-1 represents the first mammalian protein methylesterase to be cloned. Several lines of evidence indicate that, although there appears to be a role for C subunit carboxyl-terminal amino acids in PME-1 binding, amino acids other than those at the extreme carboxyl terminus of the C subunit also play an important role in PME-1 binding to a catalytically inactive mutant.	Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Winship Canc Ctr, Atlanta, GA 30322 USA; Harvard Univ, Biol Labs, Harvard Microchem Facil, Cambridge, MA 02138 USA; Univ Vienna, Inst Mol Biol, A-1030 Vienna, Austria; Dana Farber Canc Inst, Div Cellular & Mol Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Emory University; Emory University; Harvard University; University of Vienna; Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA); Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Pallas, DC (corresponding author), Emory Univ, Sch Med, Dept Biochem, 1510 Clifton Rd, Atlanta, GA 30322 USA.			Ogris, Egon/0000-0001-5950-9264	NATIONAL CANCER INSTITUTE [R01CA057327] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA057327, CA57327] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Ansai T, 1996, J BIOL CHEM, V271, P24401, DOI 10.1074/jbc.271.40.24401; BLISKA JB, 1992, J EXP MED, V176, P1625, DOI 10.1084/jem.176.6.1625; CAMPBELL KS, 1995, J VIROL, V69, P3721, DOI 10.1128/JVI.69.6.3721-3728.1995; CAYLA X, 1990, BIOCHEMISTRY-US, V29, P658, DOI 10.1021/bi00455a010; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; CHERINGTON V, 1986, P NATL ACAD SCI USA, V83, P4307, DOI 10.1073/pnas.83.12.4307; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; FAVRE B, 1994, J BIOL CHEM, V269, P16311; FERNANDEZ J, 1994, ANAL BIOCHEM, V218, P112, DOI 10.1006/abio.1994.1148; FLOER M, 1994, BIOCHEM BIOPH RES CO, V198, P372, DOI 10.1006/bbrc.1994.1052; Gelderloos JA, 1996, ONCOGENE, V13, P2367; GLENN GM, 1995, J VIROL, V69, P3729, DOI 10.1128/JVI.69.6.3729-3736.1995; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; GRUSSENMEYER T, 1987, J VIROL, V61, P3902, DOI 10.1128/JVI.61.12.3902-3909.1987; Harlow E., 1988, ANTIBODIES LAB MANUA; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; JAKES S, 1986, BIOCHIM BIOPHYS ACTA, V888, P135, DOI 10.1016/0167-4889(86)90079-0; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; Kitakawa M, 1997, EUR J BIOCHEM, V245, P449, DOI 10.1111/j.1432-1033.1997.t01-2-00449.x; KRUEGER JK, 1992, BIOCHIM BIOPHYS ACTA, V1119, P322, DOI 10.1016/0167-4838(92)90220-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; LEE J, 1993, J BIOL CHEM, V268, P19192; Lee J, 1996, P NATL ACAD SCI USA, V93, P6043, DOI 10.1073/pnas.93.12.6043; LI M, 1995, BIOCHEMISTRY-US, V34, P1988, DOI 10.1021/bi00006a020; LI M, 1994, BIOCHEM BIOPH RES CO, V202, P1023, DOI 10.1006/bbrc.1994.2031; MADER S, 1993, P NATL ACAD SCI USA, V90, P5603, DOI 10.1073/pnas.90.12.5603; MAYERJAEKEL RE, 1994, J CELL SCI, V107, P2609; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; Ogris E, 1997, ONCOGENE, V15, P911, DOI 10.1038/sj.onc.1201259; PALLAS D, 1982, CELL, V30, P407, DOI 10.1016/0092-8674(82)90238-0; PALLAS DC, 1986, J VIROL, V60, P1075, DOI 10.1128/JVI.60.3.1075-1084.1986; PALLAS DC, 1988, J VIROL, V62, P3934, DOI 10.1128/JVI.62.11.3934-3940.1988; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; RUNDELL K, 1987, J VIROL, V61, P1240, DOI 10.1128/JVI.61.4.1240-1243.1987; Sambrook J., 2002, MOL CLONING LAB MANU; SIM ATR, 1994, J NEUROCHEM, V62, P1552; SIMMS SA, 1987, J BIOL CHEM, V262, P29; SNYDER MA, 1984, METHOD ENZYMOL, V106, P321; SONTAG E, 1995, J CELL BIOL, V128, P1131, DOI 10.1083/jcb.128.6.1131; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TUROWSKI P, 1995, J CELL BIOL, V129, P397, DOI 10.1083/jcb.129.2.397; ULUG ET, 1992, J VIROL, V66, P1458, DOI 10.1128/JVI.66.3.1458-1467.1992; USUI H, 1988, J BIOL CHEM, V263, P3752; WEST AH, 1995, J MOL BIOL, V250, P276, DOI 10.1006/jmbi.1995.0376; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; WYLIE D, 1988, BIOCHEM BIOPH RES CO, V151, P891, DOI 10.1016/S0006-291X(88)80365-6; XIE HY, 1994, BIOCHEM BIOPH RES CO, V203, P1710, DOI 10.1006/bbrc.1994.2383; XIE HY, 1994, J BIOL CHEM, V269, P1981; Zhang J, 1996, BIOCHEMISTRY-US, V35, P6276, DOI 10.1021/bi952954l; ZHUO SQ, 1994, J BIOL CHEM, V269, P26234	54	147	159	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					14382	14391		10.1074/jbc.274.20.14382	http://dx.doi.org/10.1074/jbc.274.20.14382			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318862	Green Accepted, hybrid			2022-12-25	WOS:000080322200091
J	Kosako, H; Goto, H; Yanagida, M; Matsuzawa, K; Fujita, M; Tomono, Y; Okigaki, T; Odai, H; Kaibuchi, K; Inagaki, M				Kosako, H; Goto, H; Yanagida, M; Matsuzawa, K; Fujita, M; Tomono, Y; Okigaki, T; Odai, H; Kaibuchi, K; Inagaki, M			Specific accumulation of Rho-associated kinase at the cleavage furrow during cytokinesis: cleavage furrow-specific phosphorylation of intermediate filaments	ONCOGENE			English	Article						cell cycle; cytokinesis; cleavage furrow; Rho-associated kinase (Rho-kinase); intermediate filament	BINDING PROTEIN-RHO; MYOSIN PHOSPHATASE; PLASMA-MEMBRANE; ERM PROTEINS; VIMENTIN; MITOSIS; SITES; TRANSITION; ADHESION; GTPASES	The small GTPase Rho and one of its targets, Rho-associated kinase (Rho-kinase), are implicated in a wide spectrum of cellular functions, including cytoskeletal rearrangements, transcriptional activation and smooth muscle contraction, Since Rho also plays an essential role in cytokinesis, Rho-kinase may possibly mediate some biological aspects of cytokinesis. Here, using a series of monoclonal antibodies that can specifically recognize distinct phosphorylated sites on glial fibrillary acidic protein (GFAP) and vimentin, phosphorylation sites by Rho-kinase in vitro were revealed to be identical to in vivo phosphorylation sites on these intermediate filament (IF) proteins at the cleavage furrow in dividing cells, We then found, by preparing two types of anti-Rho-kinase antibodies, that Rho-kinase accumulated highly and circumferentially at the cleavage furrow in various cell lines, This subcellular distribution during cytokinesis was very similar to that of ezrin/radixin/moesin (ERM) proteins and Ser(19)-phosphorylated myosin light chain, These results raise the possibility that Rho-kinase might be involved in the formation of the contractile ring by modulating these F-actin-binding proteins during cytokinesis and in the phosphorylation and regulation of if proteins at the cleavage furrow.	Aichi Canc Ctr, Res Inst, Biochem Lab, Aichi 4648681, Japan; Mie Univ, Sch Med, Dept Pediat, Tsu, Mie 5148507, Japan; Hokkaido Univ, Inst Immunol Sci, Sapporo, Hokkaido 0600815, Japan; Aichi Canc Ctr, Res Inst, Lab Viral Oncol, Aichi 4648681, Japan; Kirin Brewery Co Ltd, Cent Labs Key Technol, Yokohama, Kanagawa 2360004, Japan; Nara Inst Sci & Technol, Div Signal Transduct, Ikoma 6300101, Japan	Aichi Cancer Center; Mie University; Hokkaido University; Aichi Cancer Center; Kirin Brewery Company Limited; Nara Institute of Science & Technology	Inagaki, M (corresponding author), Aichi Canc Ctr, Res Inst, Biochem Lab, Aichi 4648681, Japan.		Inagaki, Masaki/B-9920-2016	Goto, Hidemasa/0000-0002-6796-4467; Fujita, Masatoshi/0000-0001-6617-2452				Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Drechsel DN, 1997, CURR BIOL, V7, P12, DOI 10.1016/S0960-9822(06)00023-6; Fukata Y, 1998, J CELL BIOL, V141, P409, DOI 10.1083/jcb.141.2.409; GEORGATOS SD, 1987, J CELL BIOL, V105, P105, DOI 10.1083/jcb.105.1.105; Goto H, 1998, J BIOL CHEM, V273, P11728, DOI 10.1074/jbc.273.19.11728; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Ho CL, 1998, J CELL SCI, V111, P1767; Hunt T, 1991, Semin Cell Biol, V2, P213; HUTTENLOCHER A, 1995, CURR OPIN CELL BIOL, V7, P697, DOI 10.1016/0955-0674(95)80112-X; Inagaki M, 1997, J BIOCHEM, V121, P407; Inagaki N, 1997, J BIOL CHEM, V272, P25195, DOI 10.1074/jbc.272.40.25195; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Kimura K, 1998, J BIOL CHEM, V273, P5542, DOI 10.1074/jbc.273.10.5542; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; Kosako H, 1997, J BIOL CHEM, V272, P10333; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Mabuchi I, 1993, ZYGOTE, V1, P325, DOI 10.1017/S0967199400001659; Madaule P, 1998, NATURE, V394, P491, DOI 10.1038/28873; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; Matsumura F, 1998, J CELL BIOL, V140, P119, DOI 10.1083/jcb.140.1.119; MATSUOKA Y, 1992, EMBO J, V11, P2895, DOI 10.1002/j.1460-2075.1992.tb05358.x; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; OGAWARA M, 1995, J CELL BIOL, V131, P1055, DOI 10.1083/jcb.131.4.1055; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; SATO N, 1991, J CELL BIOL, V113, P321, DOI 10.1083/jcb.113.2.321; Sekimata M, 1996, J CELL BIOL, V132, P635, DOI 10.1083/jcb.132.4.635; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Takai Y, 1996, J CELL BIOL, V133, P141, DOI 10.1083/jcb.133.1.141; TAKAISHI K, 1995, ONCOGENE, V11, P39; TSUJIMURA K, 1994, J BIOL CHEM, V269, P31097; Tsukita S, 1997, TRENDS BIOCHEM SCI, V22, P53, DOI 10.1016/S0968-0004(96)10071-2; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Yasui Y, 1998, J CELL BIOL, V143, P1249, DOI 10.1083/jcb.143.5.1249	38	101	103	1	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 29	1999	18	17					2783	2788		10.1038/sj.onc.1202633	http://dx.doi.org/10.1038/sj.onc.1202633			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FH	10348354				2022-12-25	WOS:000080124900015
J	Shinobu, N; Maeda, T; Aso, T; Ito, T; Kondo, T; Koike, K; Hatakeyama, M				Shinobu, N; Maeda, T; Aso, T; Ito, T; Kondo, T; Koike, K; Hatakeyama, M			Physical interaction and functional antagonism between the RNA polymerase II elongation factor ELL and p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; TUMOR-SUPPRESSOR PROTEIN; C-TERMINAL DOMAIN; BOX-BINDING PROTEIN; CELL-CYCLE CONTROL; TRANSCRIPTIONAL ACTIVATION; DNA-BINDING; OLIGOMERIZATION DOMAIN; RETINOBLASTOMA PROTEIN; REPRESSION FUNCTIONS	ELL was originally identified as a gene that undergoes translocation with the trithorax-like MLL gene in acute myeloid leukemia. Recent studies have shown that the gene product, ELL, functions as an RNA polymerase II elongation factor that increases the rate of transcription by RNA polymerase II by suppressing transient pausing. Using yeast two-hybrid screening with ELL as bait, we isolated the p53 tumor suppressor protein as a specific interactor of ELL. The interaction involves respectively the transcription elongation activation domain of ELL and the C-terminal tail of p53, Through this interaction, ELL inhibits both sequence-specific transactivation and sequence-independent transrepression by p53, Thus, ELL acts as a negative regulator of p53 in transcription. Conversely, p53 inhibits the transcription elongation activity of ELL, suggesting that p53 is capable of regulating general transcription by RNA polymerase II through controlling the ELL activity. Elevated levels of ELL in cells resulted in the inhibition of p53-dependent induction of endogenous p21 and substantially protected cells from p53-mediated apoptosis that is induced by genotoxic stress. Our observations indicate the existence of a mutually inhibitory interaction between p53 and a general transcription elongation factor ELL and raise the possibility that an aberrant interaction between p53 and ELL may play a role in the genesis of leukemias carrying MLL-ELL gene translocations.	Japanese Fdn Canc Res, Inst Canc, Dept Viral Oncol, Toshima Ku, Tokyo 1708455, Japan; Japanese Fdn Canc Res, Inst Canc, Dept Gene Res, Toshima Ku, Tokyo 1708455, Japan	Japanese Foundation for Cancer Research; Japanese Foundation for Cancer Research	Hatakeyama, M (corresponding author), Japanese Fdn Canc Res, Inst Canc, Dept Viral Oncol, Toshima Ku, 1-37-1 Kami Ikebukuro, Tokyo 1708455, Japan.	mhatakeyama@jfcr.or.jp	Maeda, Tatsuya/L-5540-2019					ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BALKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413; BALKALKIN G, 1995, NUCLEIC ACIDS RES, V23, P362; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BAYLE JH, 1995, P NATL ACAD SCI USA, V92, P5729, DOI 10.1073/pnas.92.12.5729; BRAIN R, 1994, ONCOGENE, V9, P1775; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Canman CE, 1998, ONCOGENE, V16, P957, DOI 10.1038/sj.onc.1201612; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CLORE GM, 1995, NAT STRUCT BIOL, V2, P321, DOI 10.1038/nsb0495-321; COLLINS MKL, 1992, J EXP MED, V176, P1043, DOI 10.1084/jem.176.4.1043; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Farmer G, 1996, NUCLEIC ACIDS RES, V24, P4281, DOI 10.1093/nar/24.21.4281; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HARPER JW, 1993, CELL, V75, P805; HARVEY M, 1993, ONCOGENE, V8, P2457; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Hoshikawa Y, 1998, ANAL BIOCHEM, V261, P211, DOI 10.1006/abio.1998.2742; Hoshikawa Y, 1998, P NATL ACAD SCI USA, V95, P8574, DOI 10.1073/pnas.95.15.8574; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; Kanda Y, 1998, J BIOL CHEM, V273, P5248, DOI 10.1074/jbc.273.9.5248; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LEE WT, 1994, NAT STRUCT BIOL, V1, P877, DOI 10.1038/nsb1294-877; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; Megonigal MD, 1998, ONCOGENE, V16, P1351, DOI 10.1038/sj.onc.1201637; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MITANI K, 1995, BLOOD, V85, P2017, DOI 10.1182/blood.V85.8.2017.bloodjournal8582017; MIYASHITA T, 1995, CELL, V80, P293; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; RAGIMOV N, 1993, ONCOGENE, V8, P1183; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; REED M, 1995, P NATL ACAD SCI USA, V92, P9455, DOI 10.1073/pnas.92.21.9455; SANG BC, 1994, ONCOGENE, V9, P853; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULIAN E, 1995, ONCOGENE, V10, P671; SHAULIAN E, 1993, EMBO J, V12, P2789, DOI 10.1002/j.1460-2075.1993.tb05940.x; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; Shilatifard A, 1998, J BIOL CHEM, V273, P11212, DOI 10.1074/jbc.273.18.11212; Shilatifard A, 1996, SCIENCE, V271, P1873, DOI 10.1126/science.271.5257.1873; Shilatifard A, 1997, J BIOL CHEM, V272, P22355, DOI 10.1074/jbc.272.35.22355; SUBLER MA, 1994, ONCOGENE, V9, P1351; Thirman MJ, 1997, P NATL ACAD SCI USA, V94, P1408, DOI 10.1073/pnas.94.4.1408; THIRMAN MJ, 1994, P NATL ACAD SCI USA, V91, P12110, DOI 10.1073/pnas.91.25.12110; TRUANT R, 1993, J BIOL CHEM, V268, P2284; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; WU L, 1995, MOL CELL BIOL, V15, P497, DOI 10.1128/MCB.15.1.497; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZHAN QM, 1994, ONCOGENE, V9, P3743	80	42	44	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17003	17010		10.1074/jbc.274.24.17003	http://dx.doi.org/10.1074/jbc.274.24.17003			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358050	hybrid			2022-12-25	WOS:000080780400049
J	Johnston, H; Kneer, J; Chackalaparampil, I; Yaciuk, P; Chrivia, J				Johnston, H; Kneer, J; Chackalaparampil, I; Yaciuk, P; Chrivia, J			Identification of a novel SNF2/SWI2 protein family member, SRCAP, which interacts with CREB-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TRANSCRIPTIONAL ACTIVATION; HISTONE ACETYLTRANSFERASE; DNA; CBP; COACTIVATOR; RECEPTOR; COMPLEX; P300; ONCOPROTEIN	The ability of cAMP response-element binding protein (CREB)-binding protein (CBP) to function as a co-activator for a number of transcription factors appears to be mediated by its ability to act as a histone acetyltransferase and through its interaction with a number of other proteins (general transcription factors, histone acetyltransferases, and other co-activators). Here we report that CBP also interacts with a novelATPase termed Snf2-Related CBP Activator Protein (SRCAP). Consistent with this activity, SRCAP contains the conserved ATPase domain found within members of the Snf2 family. Transfection experiments demonstrate that SRCAP is able to activate transcription when expressed as a Gal-SRCAP chimera and that SRCAP also enhances the ability of CBP to activate transcription. The adenoviral protein E1A was found to disrupt interaction between SRCAP and CBP possibly representing a mechanism for E1A-mediated transcriptional repression.	St Louis Univ, Dept Pharmacol & Physiol Sci, St Louis, MO 63104 USA; St Louis Univ, Dept Mol Microbiol & Immunol, St Louis, MO 63104 USA	Saint Louis University; Saint Louis University	Chrivia, J (corresponding author), St Louis Univ, Dept Pharmacol & Physiol Sci, St Louis, MO 63104 USA.							ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ASHLEY CT, 1989, J BIOL CHEM, V264, P8394; Auble DT, 1997, MOL CELL BIOL, V17, P4842, DOI 10.1128/MCB.17.8.4842; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHARKRAVARTI D, 1996, NATURE, V383, P99; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHIBA H, 1994, NUCLEIC ACIDS RES, V22, P1815, DOI 10.1093/nar/22.10.1815; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CHURCHILL MEA, 1991, TRENDS BIOCHEM SCI, V16, P92, DOI 10.1016/0968-0004(91)90040-3; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; Dallas PB, 1997, J VIROL, V71, P1726, DOI 10.1128/JVI.71.2.1726-1731.1997; DALRYMPLE MA, 1985, NUCLEIC ACIDS RES, V13, P7865, DOI 10.1093/nar/13.21.7865; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; Fields Stanley, 1993, Methods (Orlando), V5, P116, DOI 10.1006/meth.1993.1016; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LAURENT BC, 1993, GENE DEV, V7, P583, DOI 10.1101/gad.7.4.583; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MORAN E, 1994, SEMIN VIROL, V5, P237; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; PETERSON CL, 1995, TRENDS BIOCHEM SCI, V20, P143, DOI 10.1016/S0968-0004(00)88990-2; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; STOKES DG, 1995, MOL CELL BIOL, V15, P2745; Swope DL, 1996, J BIOL CHEM, V271, P28138, DOI 10.1074/jbc.271.45.28138; YACIUK P, 1991, MOL CELL BIOL, V11, P5389, DOI 10.1128/MCB.11.11.5389; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092; Zhang Q, 1997, GENE, V202, P31, DOI 10.1016/S0378-1119(97)00446-0	33	62	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16370	16376		10.1074/jbc.274.23.16370	http://dx.doi.org/10.1074/jbc.274.23.16370			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347196	hybrid			2022-12-25	WOS:000080668600056
J	Kambara, T; Rhodes, TE; Ikebe, R; Yamada, M; White, HD; Ikebe, M				Kambara, T; Rhodes, TE; Ikebe, R; Yamada, M; White, HD; Ikebe, M			Functional significance of the conserved residues in the flexible hinge region of the myosin motor domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE MYOSIN; PHOSPHORYLATION-DEPENDENT REGULATION; ACTOMYOSIN ADENOSINE-TRIPHOSPHATASE; 3-DIMENSIONAL STRUCTURE; ENZYMATIC-PROPERTIES; 2-HEADED STRUCTURE; MOLECULAR MOTOR; LIGHT-CHAIN; HYDROLYSIS; SUBFRAGMENT-1	Analysis of the three-dimensional crystal structure of the Dictyosteliun myosin motor domain revealed that the myosin head is required to bend at residues Il-455 and Gly-457 to produce the conformation changes observed in the ternary complexes that resemble the pre- and post-hydrolysis states (Fisher, A. J., Smith, C. A., Thoden, J. B., Smith, R., Sutoh, K., Holden, H. M., and Rayment, I. (1995) Biochemistry 34, 8960-8972). Asp-454, Il-455, and Gly-457 of smooth muscle myosin were substituted by Ala, Met, and Ala, respectively, and the mechano-enzymatic activities were determined to study the role of these residues in myosin motor function. Whereas the basal steady-state Mg2+-ATPase activity of D454A was higher than that of the wild type, the rate of the hydrolytic step is reduced similar to 2,000-fold and becomes rate-limiting. M-ATP rather than M-ADP-P is the predominant steady-state intermediate, and the initial P-i burst and the ATP-induced enhancement of intrinsic tryptophan fluorescence are absent in D454A. D454A binds actin in the absence of ATP but is not dissociated from actin by ATP. Moreover, actin inhibits rather than activates the ATPase activity; consequently, D454A does not support actin translocating activity. I455M has normal actin-activated ATPase activity, P-i burst, and ATP-induced enhancement of intrinsic tryptophan fluorescence, suggesting that the enzymatic properties are normal. However, the actin translocating activity was completely inhibited. This suggests that the side chain at Ile-455 is critical for myosin motor activity but not for relatively normal enzymatic function, which indicates an apparent uncoupling between enzymatic activity and motile function. Although G457A has normal ATP-dependent actin dissociation, ATP hydrolytic step is reduced by similar to 10(5)-fold in the presence or absence of actin; consequently, G457A does not have actin translocating activity. These results indicate the importance of these conserved residues at the hinge region for normal myosin motor function.	Univ Massachusetts, Med Ctr, Dept Physiol, Worcester, MA 01655 USA; Eastern Virginia Med Sch, Dept Biochem, Norfolk, VA 23507 USA	University of Massachusetts System; University of Massachusetts Worcester; Eastern Virginia Medical School	Ikebe, M (corresponding author), Univ Massachusetts, Med Ctr, Dept Physiol, 55 Lake Ave N, Worcester, MA 01655 USA.				NHLBI NIH HHS [HL56218, HL41776] Funding Source: Medline; NIAMS NIH HHS [AR41653] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041776, R01HL056218] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041653] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		CHENEY R E, 1992, Current Opinion in Cell Biology, V4, P27, DOI 10.1016/0955-0674(92)90055-H; CHIEN YH, 1984, MOL CELL BIOL, V4, P507, DOI 10.1128/MCB.4.3.507; DYSON RD, 1971, BIOCHEMISTRY-US, V15, P5818; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; GEEVES MA, 1992, PHILOS T ROY SOC B, V336, P63, DOI 10.1098/rstb.1992.0045; GOODSON HV, 1993, P NATL ACAD SCI USA, V90, P659, DOI 10.1073/pnas.90.2.659; HIGASHIHARA M, 1990, FEBS LETT, V263, P241, DOI 10.1016/0014-5793(90)81383-Y; HIRATSUKA T, 1992, J BIOL CHEM, V267, P14941; IKEBE M, 1985, J BIOL CHEM, V260, P3146; Ikebe M, 1998, J BIOL CHEM, V273, P17702, DOI 10.1074/jbc.273.28.17702; IKEBE M, 1987, J BIOL CHEM, V262, P13828; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li XD, 1998, J BIOL CHEM, V273, P27404, DOI 10.1074/jbc.273.42.27404; MARUTA H, 1981, J BIOL CHEM, V256, P499; MATSUURA M, 1995, FEBS LETT, V363, P246, DOI 10.1016/0014-5793(95)00326-5; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; Onishi H, 1997, BIOCHEMISTRY-US, V36, P3767, DOI 10.1021/bi9630772; ORIELLY DR, 1992, BACULOVIRUS EXPRESSI; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; RAYMENT I, 1994, TRENDS BIOCHEM SCI, V19, P129, DOI 10.1016/0968-0004(94)90206-2; Sata M, 1996, BIOCHEMISTRY-US, V35, P11113, DOI 10.1021/bi960435s; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STEIN LA, 1979, BIOCHEMISTRY-US, V18, P3895, DOI 10.1021/bi00585a009; TAYLOR EW, 1977, BIOCHEMISTRY-US, V16, P732, DOI 10.1021/bi00623a027; Titus MA, 1993, CURR OPIN CELL BIOL, V5, P77, DOI 10.1016/S0955-0674(05)80011-0; TRENTHAM DR, 1976, Q REV BIOPHYS, V9, P217, DOI 10.1017/S0033583500002419; WAKABAYASHI K, 1992, SCIENCE, V258, P443, DOI 10.1126/science.1411537; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WHITE HD, 1993, BIOCHEMISTRY-US, V32, P9859, DOI 10.1021/bi00088a042; WHITE HD, 1976, BIOCHEMISTRY-US, V15, P5818, DOI 10.1021/bi00671a020; WHITE HD, 1993, J BIOL CHEM, V268, P10039; White HD, 1997, BIOCHEMISTRY-US, V36, P11828, DOI 10.1021/bi970540h; YOUNT RG, 1995, BIOPHYS J, V68, pS44	36	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16400	16406		10.1074/jbc.274.23.16400	http://dx.doi.org/10.1074/jbc.274.23.16400			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347200	hybrid			2022-12-25	WOS:000080668600060
J	Mukhopadhyay, A; Ni, J; Zhai, YF; Yu, GL; Aggarwal, BB				Mukhopadhyay, A; Ni, J; Zhai, YF; Yu, GL; Aggarwal, BB			Identification and characterization of a novel cytokine, THANK, a (T)under-barNF (H)under-baromologue that activates (A)under-barpoptosis, nuclear factor-kappa B, and c-Jun NH2-terminal (K)under-barinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; TNF RECEPTOR; CELL-GROWTH; HUMAN LYMPHOTOXIN; FACTOR FAMILY; LIGAND; APOPTOSIS; DEATH; PURIFICATION; SUPERFAMILY	By using the amino acid sequence motif of tumor necrosis factor (TNF), we searched the expressed sequence tag data base and identified a novel full-length cDNA encoding 285 amino acid residues and named it THANK. THANK is a type II transmembrane protein with 15-20% overall amino acid sequence homology to TNF, LT-alpha, Fast, and LIGHT, all members of the TNF family. The mRNA for THANK was expressed at high levels by peripheral blood leukocytes, lymph node, spleen, and thymus and at low levels by small intestine, pancreas, placenta, and lungs. THANK was also prominently expressed in hematopoietic cell lines. The recombinant purified protein expressed in the baculovirus system had an approximate molecular size 20 kDa with amino-terminal sequence of AVQGP. Treatment of human myeloid U937 cells with purified THANK activated nuclear transcription factor-kappa B (NF-kappa B) consisting of p50 and p65. Activation was time- and dose-dependent, beginning with as little as a 1 pM amount of the cytokines and as early as 15 min. Under the same conditions, THANK also activated c-jun NH2-terminal kinase (JNK) in U937 cells. THANK also strongly suppressed the growth of tumor cell lines and activated caspase-3. Although THANK had all the activities and potency of TNF, it did not bind to the TNF receptors. Thus our results indicate that THANK is a novel cytokine that belongs to the TNF family and activates apoptosis, NF-kappa B, and JNK through a distinct receptor.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Oncol, Cytokine Res Lab, Houston, TX 77030 USA; Human Genome Sci Inc, Rockville, MD 20850 USA	University of Texas System; UTMD Anderson Cancer Center; GlaxoSmithKline; Human Genome Sciences Inc	Aggarwal, BB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Oncol, Cytokine Res Lab, 1515 Holcombe Blvd, Houston, TX 77030 USA.	aggarwal@utmdacc.mda.uth.tmc.edu	Aggarwal, Bharat B/G-3388-2013					AGGARWAL BB, 1985, J BIOL CHEM, V260, P2345; AGGARWAL BB, 1984, J BIOL CHEM, V259, P686; Aggarwal BB, 1996, EUR CYTOKINE NETW, V7, P93; AGGARWAL BB, 1985, NATURE, V318, P665, DOI 10.1038/318665a0; Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; CHATURVEDI MM, 1994, J BIOL CHEM, V269, P14575; Chicheportiche Y, 1997, J BIOL CHEM, V272, P32401, DOI 10.1074/jbc.272.51.32401; GRAY PW, 1984, NATURE, V312, P721, DOI 10.1038/312721a0; Hahne M, 1998, J EXP MED, V188, P1185, DOI 10.1084/jem.188.6.1185; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Haridas V, 1998, J IMMUNOL, V160, P3152; HIGUCHI M, 1992, ANAL BIOCHEM, V204, P53, DOI 10.1016/0003-2697(92)90138-W; Kumar A, 1999, METHOD ENZYMOL, V300, P339; Mauri DN, 1998, IMMUNITY, V8, P21, DOI 10.1016/S1074-7613(00)80455-0; Ni J, 1997, J BIOL CHEM, V272, P10853; PENNICA D, 1984, NATURE, V312, P724, DOI 10.1038/312724a0; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Singh A, 1998, J INTERF CYTOK RES, V18, P439, DOI 10.1089/jir.1998.18.439; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190; Zhai YF, 1999, FASEB J, V13, P181, DOI 10.1096/fasebj.13.1.181	25	276	379	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					15978	15981		10.1074/jbc.274.23.15978	http://dx.doi.org/10.1074/jbc.274.23.15978			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347144	hybrid			2022-12-25	WOS:000080668600004
J	Noah, JW; Dolan, MA; Babin, P; Wollenzien, P				Noah, JW; Dolan, MA; Babin, P; Wollenzien, P			Effects of tetracycline and spectinomycin on the tertiary structure of ribosomal RNA in the Escherichia coli 30 S ribosomal subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-SITE; PROTEIN-SYNTHESIS; P-SITE; ELONGATION; BINDING; ANTIBIOTICS; MODEL; PHOTOINCORPORATION; NUCLEOTIDES	Structural analysis of the 16 S rRNA in the 30 S subunit and 70 S ribosome in the presence of ribosome-specific antibiotics was performed to determine whether they produced rRNA structural changes that might provide further insight to their action. An UV cross-linking procedure that determines the pattern and frequency of intramolecular 16 S RNA cross-links was used to detect differences reflecting structural changes. Tetracycline and spectinomycin have specific effects detected by this assay. The presence of tetracycline inhibits the cross-link C967 x C1400 completely, increases the frequency of cross-link C1402 x 1501 twofold, and decreases the cross-link G894 x U244 by one-half without affecting other cross-links. Spectinomycin reduces the frequency of the cross-link C934 x U1345 by 60% without affecting cross-linking at other sites. The structural changes occur at concentrations at which the antibiotics exert their inhibitory effects. For spectinomycin, the apparent binding site and the affected crosslinking site are distant in the secondary structure but are close in tertiary structure in several recent models, indicating a localized effect. For tetracycline, the apparent binding sites are significantly separated in both the secondary and the three-dimensional structures, suggesting a more regional effect.	N Carolina State Univ, Dept Biochem, Raleigh, NC 27695 USA	University of North Carolina; North Carolina State University	Wollenzien, P (corresponding author), N Carolina State Univ, Dept Biochem, Box 7622, Raleigh, NC 27695 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043237] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43237] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUDOWSKY EI, 1989, EUR J BIOCHEM, V159, P95; COOPERMAN BS, 1980, RIBOSOMES STRUCTURE, P531; Dragon F, 1996, J MOL BIOL, V259, P207, DOI 10.1006/jmbi.1996.0313; EPE B, 1987, FEBS LETT, V213, P443, DOI 10.1016/0014-5793(87)81539-9; Fink DL, 1996, RNA, V2, P851; Gale E.F., 1981, MOL BASIS ANTIBIOTIC, Vsecond; GEIGENMULLER U, 1986, EUR J BIOCHEM, V161, P723, DOI 10.1111/j.1432-1033.1986.tb10499.x; GOLDMAN RA, 1983, BIOCHEMISTRY-US, V22, P359, DOI 10.1021/bi00271a020; MAKHNO VI, 1988, MOL BIOL+, V22, P528; MALHOTRA A, 1994, J MOL BIOL, V240, P308, DOI 10.1006/jmbi.1994.1448; MOAZED D, 1990, J MOL BIOL, V211, P135, DOI 10.1016/0022-2836(90)90016-F; MOAZED D, 1987, NATURE, V327, P389, DOI 10.1038/327389a0; Mueller F, 1997, J MOL BIOL, V271, P524, DOI 10.1006/jmbi.1997.1210; Mundus D, 1998, RNA, V4, P1373, DOI 10.1017/S1355838298981134; Noah JW, 1998, BIOCHEMISTRY-US, V37, P15442, DOI 10.1021/bi981148m; Oehler R, 1997, NUCLEIC ACIDS RES, V25, P1219, DOI 10.1093/nar/25.6.1219; POWERS T, 1995, RNA, V1, P194; PUROHIT P, 1994, NATURE, V370, P659, DOI 10.1038/370659a0; Recht MI, 1996, J MOL BIOL, V262, P421, DOI 10.1006/jmbi.1996.0526; RODNINA MV, 1994, BIOCHEMISTRY-US, V33, P12267, DOI 10.1021/bi00206a033; Ross JI, 1998, ANTIMICROB AGENTS CH, V42, P1702, DOI 10.1128/AAC.42.7.1702; SARKAR S, 1968, P NATL ACAD SCI USA, V60, P1479, DOI 10.1073/pnas.60.4.1479; Spahn CMT, 1996, J MOL MED, V74, P423, DOI 10.1007/s001090050044; Spickler C, 1997, J MOL BIOL, V273, P586, DOI 10.1006/jmbi.1997.1323; Triman KL, 1995, ADV GENET, V33, P1, DOI 10.1016/S0065-2660(08)60329-6; WILMS C, 1994, ANAL BIOCHEM, V221, P204, DOI 10.1006/abio.1994.1399; Wilms C, 1997, RNA, V3, P602; Wilson KS, 1998, CELL, V92, P131, DOI 10.1016/S0092-8674(00)80905-8; WURMBACH P, 1983, EUR J BIOCHEM, V130, P9	29	39	40	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16576	16581		10.1074/jbc.274.23.16576	http://dx.doi.org/10.1074/jbc.274.23.16576			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347223	hybrid			2022-12-25	WOS:000080668600083
J	Allen, RM; Roll, JT; Rangaraj, P; Shah, VK; Roberts, GP; Ludden, PW				Allen, RM; Roll, JT; Rangaraj, P; Shah, VK; Roberts, GP; Ludden, PW			Incorporation of molybdenum into the iron-molybdenum cofactor of nitrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AZOTOBACTER-VINELANDII STRAINS; IN-VITRO SYNTHESIS; KLEBSIELLA-PNEUMONIAE; GENE-PRODUCT; DINITROGENASE REDUCTASE; NUCLEOTIDE-SEQUENCE; INVITRO SYNTHESIS; NIFB COFACTOR; PROTEIN; PURIFICATION	The biosynthesis of the iron-molybdenum cofactor (FeMo-co) of dinitrogenase was investigated using Mo-99 to follow the incorporation of Mo into precursors. Mo-99 label accumulates on dinitrogenase only when all known components of the FeMo-co synthesis system, NfH, NifNE, NifB-cofactor, homocitrate, MgATP, and reductant, are present. Furthermore, Mo-99 label accumulates only on the gamma protein, which has been shown to serve as a chaperone/insertase for the maturation of apodinitrogenase when all known components are present, It appears that only completed FeMo-co can accumulate on the gamma protein. Very little FeMo-co synthesis was observed when all known components are used in purified forms, indicating that additional factors are required for optimal FeMo-co synthesis. Mo-99 did not accumulate on NifNE under any conditions tested, suggesting that Mo enters the pathway at some other step, although it remains possible that a MO-containing precursor of FeMo-co that is not sufficiently stable to persist during gel electrophoresis occurs but is not observed. Mo-99 accumulates on several unidentified species, which may be the additional components required for FeMo-co synthesis. The molybdenum storage protein was observed and the accumulation of Mo-99 on this protein required nucleotide.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA; Univ Wisconsin, Ctr Study Nitrogen Fixat, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Ludden, PW (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.	ludden@biochem.wisc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM035332, R01GM035332] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 35332] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN RM, 1993, J BIOL CHEM, V268, P23670; Allen RM, 1996, J BIOL CHEM, V271, P4256; ALLEN RM, 1995, J BIOL CHEM, V270, P26890, DOI 10.1074/jbc.270.45.26890; BISHOP PE, 1986, SCIENCE, V232, P92, DOI 10.1126/science.232.4746.92; BRIGLE KE, 1987, J BACTERIOL, V169, P1547, DOI 10.1128/jb.169.4.1547-1553.1987; BRIGLE KE, 1985, GENE, V37, P37, DOI 10.1016/0378-1119(85)90255-0; CARRELL CJ, 1988, J AM CHEM SOC, V110, P8651, DOI 10.1021/ja00234a011; CHAN MK, 1993, SCIENCE, V260, P792, DOI 10.1126/science.8484118; Chatterjee R, 1997, J BIOL CHEM, V272, P21604, DOI 10.1074/jbc.272.34.21604; EMERICH DW, 1978, BIOCHIM BIOPHYS ACTA, V527, P359, DOI 10.1016/0005-2744(78)90350-9; FILLER WA, 1986, EUR J BIOCHEM, V160, P371, DOI 10.1111/j.1432-1033.1986.tb09981.x; GLUSKER JP, 1980, ACCOUNTS CHEM RES, V13, P345, DOI 10.1021/ar50154a002; HAWKES TR, 1983, BIOCHEM J, V209, P43, DOI 10.1042/bj2090043; HAWKES TR, 1984, BIOCHEM J, V217, P317, DOI 10.1042/bj2170317; HOMER MJ, 1995, J BIOL CHEM, V270, P24745, DOI 10.1074/jbc.270.42.24745; HOOVER TR, 1988, BIOCHEMISTRY-US, V27, P3647, DOI 10.1021/bi00410a019; HOOVER TR, 1989, BIOCHEMISTRY-US, V28, P2768, DOI 10.1021/bi00433a004; IMPERIAL J, 1989, BIOCHEMISTRY-US, V28, P7796, DOI 10.1021/bi00445a040; IMPERIAL J, 1984, J BACTERIOL, V158, P187, DOI 10.1128/JB.158.1.187-194.1984; JACOBSON MR, 1989, MOL GEN GENET, V219, P49, DOI 10.1007/BF00261156; JOERGER RD, 1988, J BACTERIOL, V170, P1475, DOI 10.1128/jb.170.4.1475-1487.1988; KIM JS, 1992, NATURE, V360, P553, DOI 10.1038/360553a0; MCLEAN PA, 1983, BIOCHEM J, V211, P589, DOI 10.1042/bj2110589; Mouncey NJ, 1996, MICROBIOL-SGM, V142, P1997, DOI 10.1099/13500872-142-8-1997; PAUSTIAN TD, 1990, BIOCHEMISTRY-US, V29, P3515, DOI 10.1021/bi00466a014; PIENKOS PT, 1981, J BACTERIOL, V145, P743, DOI 10.1128/JB.145.2.743-751.1981; ROBERTS GP, 1980, J BACTERIOL, V144, P210, DOI 10.1128/JB.144.1.210-216.1980; ROBINSON AC, 1987, J BIOL CHEM, V262, P14327; ROLL JT, 1995, J BIOL CHEM, V270, P4432, DOI 10.1074/jbc.270.9.4432; ROSENTEL JK, 1995, J BACTERIOL, V177, P4857, DOI 10.1128/jb.177.17.4857-4864.1995; SHAH VK, 1972, BIOCHIM BIOPHYS ACTA, V256, P498, DOI 10.1016/0005-2728(72)90078-3; SHAH VK, 1994, J BIOL CHEM, V269, P1154; SHAH VK, 1973, BIOCHIM BIOPHYS ACTA, V305, P445, DOI 10.1016/0005-2728(73)90190-4; SHAH VK, 1986, P NATL ACAD SCI USA, V83, P1636, DOI 10.1073/pnas.83.6.1636; SHAH VK, 1977, P NATL ACAD SCI USA, V74, P3249, DOI 10.1073/pnas.74.8.3249; STEWART WDP, 1967, P NATL ACAD SCI USA, V58, P2071, DOI 10.1073/pnas.58.5.2071; UGALDE RA, 1984, J BACTERIOL, V159, P888, DOI 10.1128/JB.159.3.888-893.1984; WAUGH SI, 1995, J BACTERIOL, V177, P1505, DOI 10.1128/jb.177.6.1505-1510.1995; Wright DW, 1996, J BIOL INORG CHEM, V1, P143, DOI 10.1007/s007750050033	39	21	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15869	15874		10.1074/jbc.274.22.15869	http://dx.doi.org/10.1074/jbc.274.22.15869			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336491	hybrid			2022-12-25	WOS:000080560100080
J	Baranski, TJ; Herzmark, P; Lichtarge, O; Gerber, BO; Trueheart, J; Meng, EC; Iiri, T; Sheikh, SP; Bourne, HR				Baranski, TJ; Herzmark, P; Lichtarge, O; Gerber, BO; Trueheart, J; Meng, EC; Iiri, T; Sheikh, SP; Bourne, HR			C5a receptor activation - Genetic identification of critical residues in four transmembrane helices	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; PHEROMONE RESPONSE PATHWAY; MEMBRANE-SPANNING SEGMENT; SITE-DIRECTED MUTAGENESIS; SCHIFF-BASE COUNTERION; DOPAMINE D2 RECEPTOR; ACID SIDE-CHAINS; BOVINE RHODOPSIN; LIGAND-BINDING; CONFORMATIONAL-CHANGES	Hormones and sensory stimuli activate serpentine receptors, transmembrane switches that relay signals to heterotrimeric guanine nucleotide-binding proteins (G proteins). To understand the switch mechanism, we subjected 93 amino acids in transmembrane helices III, V, VI, and VII of the human chemoattractant C5a receptor to random saturation mutagenesis. A yeast selection identified 121 functioning mutant receptors, containing a total of 523 amino acid substitutions. Conserved hydrophobic residues are located on helix surfaces that face other helices in a modeled seven-helix bundle (Baldwin, J. M., Schertler, G. F., and Unger, V. M. (1997) J. Mol. Biol. 272, 144-164), whereas surfaces predicted to contact the surrounding lipid tolerate many substitutions. Our analysis identified 25 amino acid positions resistant to nonconservative substitutions. These appear to comprise two distinct components of the receptor switch, a surface at or near the extracellular membrane interface and a core cluster in the cytoplasmic half of the bundle. Twenty-one of the 121 mutant receptors exhibit constitutive activity, Amino acids substitutions in these activated receptors predominate in helices III and VI; other activating mutations truncate the receptor near the extracellular end of helix VI. These results identify key elements of a general mechanism for the serpentine receptor switch.	Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Cadus Pharmaceut Corp, Tarrytown, NY 10591 USA	University of California System; University of California San Francisco	Bourne, HR (corresponding author), Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, Box 0450,513 Parnassus Ave, San Francisco, CA 94143 USA.				NIGMS NIH HHS [GM-27800] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM027800, R01GM027800] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altenbach C, 1996, BIOCHEMISTRY-US, V35, P12470, DOI 10.1021/bi960849l; Baldwin JM, 1997, J MOL BIOL, V272, P144, DOI 10.1006/jmbi.1997.1240; BALDWIN JM, 1994, CURR OPIN CELL BIOL, V6, P180, DOI 10.1016/0955-0674(94)90134-1; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; Bower MJ, 1997, J MOL BIOL, V267, P1268, DOI 10.1006/jmbi.1997.0926; Chen ZG, 1998, J BIOL CHEM, V273, P10411, DOI 10.1074/jbc.273.17.10411; CHOTHIA C, 1984, ANNU REV BIOCHEM, V53, P537; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; COTECCHIA S, 1992, J BIOL CHEM, V267, P1633; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; Erickson JP, 1998, J BIOL CHEM, V273, P1506, DOI 10.1074/jbc.273.3.1506; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P8812, DOI 10.1021/bi00027a033; FARAHBAKHSH ZT, 1993, SCIENCE, V262, P1416, DOI 10.1126/science.8248781; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; FAUCHERE JL, 1983, EUR J MED CHEM, V18, P369; FONG TM, 1992, J BIOL CHEM, V267, P25668; Fu DY, 1996, BIOCHEMISTRY-US, V35, P11278, DOI 10.1021/bi960928x; GERARD C, 1985, J BIOL CHEM, V260, P2613; GERARD C, 1994, ANNU REV IMMUNOL, V12, P775, DOI 10.1146/annurev.iy.12.040194.004015; Gether U, 1997, EMBO J, V16, P6737, DOI 10.1093/emboj/16.22.6737; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; HASHIMOTO K, 1995, J CLIN ENDOCR METAB, V80, P2933, DOI 10.1210/jc.80.10.2933; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HILL DE, 1987, METHOD ENZYMOL, V155, P558; HillEubanks D, 1996, J BIOL CHEM, V271, P3058, DOI 10.1074/jbc.271.6.3058; HO BY, 1992, FEBS LETT, V312, P259, DOI 10.1016/0014-5793(92)80948-G; Horn F, 1998, NUCLEIC ACIDS RES, V26, P275, DOI 10.1093/nar/26.1.275; JAVITCH JA, 1995, NEURON, V14, P825, DOI 10.1016/0896-6273(95)90226-0; Javitch JA, 1997, J BIOL CHEM, V272, P18546, DOI 10.1074/jbc.272.30.18546; Javitch JA, 1995, BIOCHEMISTRY-US, V34, P16433, DOI 10.1021/bi00050a026; JIANG MS, 1995, EXP EYE RES, V60, P401, DOI 10.1016/S0014-4835(05)80096-X; Leberer E, 1997, CURR OPIN GENET DEV, V7, P59, DOI 10.1016/S0959-437X(97)80110-4; Lichtarge O, 1996, J MOL BIOL, V257, P342, DOI 10.1006/jmbi.1996.0167; Lichtarge O, 1996, P NATL ACAD SCI USA, V93, P7507, DOI 10.1073/pnas.93.15.7507; Lin ZL, 1997, PROTEIN ENG, V10, P501, DOI 10.1093/protein/10.5.501; LIU J, 1995, P NATL ACAD SCI USA, V92, P11642, DOI 10.1073/pnas.92.25.11642; MacKenzie KR, 1997, SCIENCE, V276, P131, DOI 10.1126/science.276.5309.131; MATTEUCCI MD, 1983, NUCLEIC ACIDS RES, V11, P3113, DOI 10.1093/nar/11.10.3113; MERY L, 1994, J BIOL CHEM, V269, P3457; NAMBA T, 1993, NATURE, V365, P166, DOI 10.1038/365166a0; NATHANS J, 1990, BIOCHEMISTRY-US, V29, P9746, DOI 10.1021/bi00493a034; Paschke R, 1997, NEW ENGL J MED, V337, P1675, DOI 10.1056/NEJM199712043372307; PHILLIPS WJ, 1992, J BIOL CHEM, V267, P17032; PHILLIPS WJ, 1994, BIOCHEM J, V299, P351, DOI 10.1042/bj2990351; Price LA, 1996, MOL PHARMACOL, V50, P829; PRICE LA, 1995, MOL CELL BIOL, V15, P6188; Raffetseder U, 1996, EUR J BIOCHEM, V235, P82, DOI 10.1111/j.1432-1033.1996.00082.x; ROBINSON PR, 1992, NEURON, V9, P719, DOI 10.1016/0896-6273(92)90034-B; SAKMAR TP, 1989, P NATL ACAD SCI USA, V86, P8309, DOI 10.1073/pnas.86.21.8309; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Scheer A, 1997, J RECEPT SIGNAL TR R, V17, P57, DOI 10.3109/10799899709036594; Sheikh SP, 1996, NATURE, V383, P347, DOI 10.1038/383347a0; Shyu JF, 1996, J BIOL CHEM, V271, P31127, DOI 10.1074/jbc.271.49.31127; SICILIANO SJ, 1994, P NATL ACAD SCI USA, V91, P1214, DOI 10.1073/pnas.91.4.1214; Silversides DW, 1997, J MOL ENDOCRINOL, V18, P101, DOI 10.1677/jme.0.0180101; Spalding TA, 1998, J BIOL CHEM, V273, P21563, DOI 10.1074/jbc.273.34.21563; STEVENSON BJ, 1992, GENE DEV, V6, P1293, DOI 10.1101/gad.6.7.1293; STRADER CD, 1995, FASEB J, V9, P745, DOI 10.1096/fasebj.9.9.7601339; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; Unger VM, 1997, NATURE, V389, P203, DOI 10.1038/38316; vanRhee AM, 1996, DRUG DEVELOP RES, V37, P1, DOI 10.1002/(SICI)1098-2299(199601)37:1<1::AID-DDR1>3.0.CO;2-S; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Wen JA, 1996, NAT STRUCT BIOL, V3, P141, DOI 10.1038/nsb0296-141; WESS J, 1991, EMBO J, V10, P3729, DOI 10.1002/j.1460-2075.1991.tb04941.x; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; Wittenberg C, 1996, CURR OPIN CELL BIOL, V8, P223, DOI 10.1016/S0955-0674(96)80069-X; WONG SKF, 1990, J BIOL CHEM, V265, P6219; Zhang XL, 1997, PROTEINS, V28, P261, DOI 10.1002/(SICI)1097-0134(199706)28:2<261::AID-PROT13>3.0.CO;2-G; ZHUKOVSKY EA, 1989, SCIENCE, V246, P928, DOI 10.1126/science.2573154	71	118	121	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15757	15765		10.1074/jbc.274.22.15757	http://dx.doi.org/10.1074/jbc.274.22.15757			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336477	hybrid			2022-12-25	WOS:000080560100066
J	Szameit, C; Miech, C; Balleininger, M; Schmidt, B; von Figura, K; Dierks, T				Szameit, C; Miech, C; Balleininger, M; Schmidt, B; von Figura, K; Dierks, T			The iron sulfur protein AtsB is required for posttranslational formation of formylglycine in the Klebsiella sulfatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-AERUGINOSA; ENDOPLASMIC-RETICULUM; MONOAMINE REGULON; GENE-CLUSTER; ARYLSULFATASE; CYSTEINE; BIOSYNTHESIS; CONVERSION; AEROGENES; REGULATOR	The catalytic residue of eukaryotic and prokaryotic sulfatases is a alpha-formylglycine. In the sulfatase of Klebsiella pneumoniae the formylglycine is generated by posttranslational oxidation of serine 72, We cloned the atsBA operon of K. pneumoniae and found that the sulfatase was expressed in inactive form in Escherichia coli transformed with the structural gene (atsA), Coexpression of the atsB gene, however, led to production of high sulfatase activity, indicating that the atsB gene product plays a posttranslational role that is essential for the sulfatase to gain its catalytic activity. This was verified after purification of the sulfatase from the periplasm of the cells. Peptide analysis of the protein expressed in the presence of AtsB revealed that half of the polypeptides carried the formylglycine at position 72, while the remaining polypeptides carried the encoded serine. The inactive sulfatase expressed in the absence of AtsB carried exclusively serine 72, demonstrating that the atsB gene is required for formylglycine modification. This gene encodes a 395-amino acid residue iron sulfur protein that has a cytosolic localization and is supposed to directly or indirectly catalyze the oxidation of the serine to formylglycine.	Univ Gottingen, Inst Biochem & Mol Zellbiol, Abt Biochem 2, D-37073 Gottingen, Germany	University of Gottingen	Dierks, T (corresponding author), Univ Gottingen, Inst Biochem & Mol Zellbiol, Abt Biochem 2, Gosslerstr 12D, D-37073 Gottingen, Germany.	dierks@ukb2-00.uni-be.gwdg.de	Dierks, Thomas/A-3596-2012	Dierks, Thomas/0000-0001-6426-1339				Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; AZAKAMI H, 1993, J BACTERIOL, V175, P6287, DOI 10.1128/JB.175.19.6287-6292.1993; AZAKAMI H, 1995, GENE, V164, P89, DOI 10.1016/0378-1119(95)00400-Z; BEIL S, 1995, EUR J BIOCHEM, V229, P385, DOI 10.1111/j.1432-1033.1995.0385k.x; Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653; Bond CS, 1997, STRUCTURE, V5, P277, DOI 10.1016/S0969-2126(97)00185-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURLAND V, 1993, GENOMICS, V16, P551, DOI 10.1006/geno.1993.1230; CHENG Q, 1992, J BACTERIOL, V174, P7185, DOI 10.1128/jb.174.22.7185-7193.1992; Dierks T, 1998, FEBS LETT, V423, P61, DOI 10.1016/S0014-5793(98)00065-9; Dierks T, 1997, P NATL ACAD SCI USA, V94, P11963, DOI 10.1073/pnas.94.22.11963; Dierks T, 1998, J BIOL CHEM, V273, P25560, DOI 10.1074/jbc.273.40.25560; Dierks T, 1999, EMBO J, V18, P2084, DOI 10.1093/emboj/18.8.2084; Dodgson K.S., 1982, SULFATASES MICROBIAL; FRANCO B, 1995, CELL, V81, P15, DOI 10.1016/0092-8674(95)90367-4; GOOSEN N, 1989, J BACTERIOL, V171, P447, DOI 10.1128/jb.171.1.447-455.1989; Kawasaki S, 1997, J BACTERIOL, V179, P235, DOI 10.1128/jb.179.1.235-242.1997; KLETZIN A, 1995, J BACTERIOL, V177, P4817, DOI 10.1128/jb.177.16.4817-4819.1995; Kolodny E.H., 1995, METABOLIC MOL BASES, V7th, P2693; KOVACH ME, 1994, BIOTECHNIQUES, V16, P800; Lovry O.H., 1951, J BIOL CHEM, V193, P265; Lukatela G, 1998, BIOCHEMISTRY-US, V37, P3654, DOI 10.1021/bi9714924; Miech C, 1998, J BIOL CHEM, V273, P4835, DOI 10.1074/jbc.273.9.4835; MULLIGAN ME, 1989, J BIOL CHEM, V264, P19200; MUROOKA Y, 1990, J BACTERIOL, V172, P2131, DOI 10.1128/jb.172.4.2131-2140.1990; Neubauer H, 1998, FEMS MICROBIOL LETT, V164, P55, DOI 10.1016/S0378-1097(98)00196-7; Parenti G, 1997, CURR OPIN GENET DEV, V7, P386, DOI 10.1016/S0959-437X(97)80153-0; Recksiek R, 1998, J BIOL CHEM, V273, P6096, DOI 10.1074/jbc.273.11.6096; Schirmer A, 1998, CHEM BIOL, V5, pR181, DOI 10.1016/S1074-5521(98)90154-5; SCHMIDT B, 1995, CELL, V82, P271, DOI 10.1016/0092-8674(95)90314-3; Selmer T, 1996, EUR J BIOCHEM, V238, P341, DOI 10.1111/j.1432-1033.1996.0341z.x; von Figura K, 1998, BIOESSAYS, V20, P505, DOI 10.1002/(SICI)1521-1878(199806)20:6<505::AID-BIES9>3.0.CO;2-K; Waldow A, 1999, J BIOL CHEM, V274, P12284, DOI 10.1074/jbc.274.18.12284	33	62	79	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15375	15381		10.1074/jbc.274.22.15375	http://dx.doi.org/10.1074/jbc.274.22.15375			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336424	hybrid			2022-12-25	WOS:000080560100013
J	Tian, JM; Karin, M				Tian, JM; Karin, M			Stimulation of Elk1 transcriptional activity by mitogen-activated protein kinases is negatively regulated by protein phosphatase 2B (calcineurin)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; C-FOS PROMOTER; JUN NH2-TERMINAL KINASE; SERUM RESPONSE ELEMENT; MAP KINASE; T-LYMPHOCYTES; DEPENDENT TRANSCRIPTION; SELECTIVE ACTIVATION; MOLECULAR-CLONING; GENE-EXPRESSION	Cellular calcium (Ca2+) and the Ca2+-binding protein calmodulin (CaM) regulate the activities of Ca2+/CaM-dependent protein kinases and protein phosphatase 2B (calcineurin). Functional interactions between CaM kinases and mitogen-activated protein (MAP) kinases were described. In this report, we describe crosstalk, between calcineurin and mitogen-activated protein kinase signaling. Calcineurin was found to specifically down-regulate the transcriptional activity of transcription factor Elk1, following stimulation of this activity by the ERK, Jun N-terminal kinase, or p38 MAP kinase pathways. Expression of constitutively activated calcineurin or activation of endogenous calcineurin by Ca2+ ionophore decreased the phosphorylation of Elk1 at sites that positively regulate its transcriptional activity. Calcineurin specifically dephosphorylates Elk1 at phosphoserine 383, a site whose phosphorylation by MAP kinases makes a critical contribution to the enhanced transcriptional activity of Elk1. The cross-talk between calcineurin and MAP kinases is of physiological significance as low doses of Ca2+ ionophore which by themselves are insufficient for c-fos induction can actually inhibit induction of c-fos expression by activators of MAP kinases. Thus through the effect of calcineurin on Elk1 phosphorylation, Ca2+ can have a negative effect on expression of Elk1 target genes. This mechanism explains why different levels of intracellular Ca2+ can result in very different effects on gene expression.	Univ Calif San Diego, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Karin, M (corresponding author), Univ Calif San Diego, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, 9500 Gilman Dr, La Jolla, CA 92093 USA.							ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Bading H, 1997, BIOCHEM BIOPH RES CO, V236, P541, DOI 10.1006/bbrc.1997.7037; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; Cantrell DA, 1996, CANCER SURV, V27, P165; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; CLIPSTONE NA, 1993, ANN NY ACAD SCI, V696, P20; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.biochem.63.1.1045; CRUZALEGUI FH, 1993, J BIOL CHEM, V268, P26171; DAERIJARD B, 1995, SCIENCE, V267, P682; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; ENSLEN H, 1994, J BIOL CHEM, V269, P20872; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Enslen H, 1996, P NATL ACAD SCI USA, V93, P10803, DOI 10.1073/pnas.93.20.10803; Finch A, 1997, FEBS LETT, V418, P144, DOI 10.1016/S0014-5793(97)01364-1; FREODIN M, 1995, J BIOL CHEM, V270, P7882; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; GJERTSEN BT, 1994, J CELL SCI, V107, P3363; GonzalezCuadrado S, 1996, CLIN EXP IMMUNOL, V106, P518, DOI 10.1046/j.1365-2249.1996.d01-864.x; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; Guerini D, 1997, BIOCHEM BIOPH RES CO, V235, P271, DOI 10.1006/bbrc.1997.6802; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JANKNECHT R, 1995, CARCINOGENESIS, V16, P443, DOI 10.1093/carcin/16.3.443; JANKNECHT R, 1995, IMMUNOBIOLOGY, V193, P137, DOI 10.1016/S0171-2985(11)80536-X; Jiang HS, 1997, MOL IMMUNOL, V34, P663, DOI 10.1016/S0161-5890(97)00054-0; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; KLEE CB, 1991, NEUROCHEM RES, V16, P1059, DOI 10.1007/BF00965851; LALLI E, 1994, J BIOL CHEM, V269, P17359; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LOHSE DL, 1995, STRUCTURE, V3, P987, DOI 10.1016/S0969-2126(01)00234-9; Luo C, 1996, P NATL ACAD SCI USA, V93, P8907, DOI 10.1073/pnas.93.17.8907; Malviya AN, 1998, CELL, V92, P17, DOI 10.1016/S0092-8674(00)80895-8; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MARUMO T, 1995, HYPERTENSION, V25, P764, DOI 10.1161/01.HYP.25.4.764; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; McCarthy SA, 1997, MOL CELL BIOL, V17, P2401, DOI 10.1128/MCB.17.5.2401; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MIRANTI CK, 1995, MOL CELL BIOL, V15, P3672; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; Pende M, 1997, J NEUROSCI, V17, P1291; Resing KA, 1998, BIOCHEMISTRY-US, V37, P463, DOI 10.1021/bi971750x; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Shapiro PS, 1998, J BIOL CHEM, V273, P1788, DOI 10.1074/jbc.273.3.1788; Sharrocks AD, 1997, INT J BIOCHEM CELL B, V29, P1371, DOI 10.1016/S1357-2725(97)00086-1; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Stein B, 1996, J BIOL CHEM, V271, P11427, DOI 10.1074/jbc.271.19.11427; Stoddard BL, 1996, CURR OPIN STRUC BIOL, V6, P770, DOI 10.1016/S0959-440X(96)80006-6; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Sugimoto T, 1997, J BIOL CHEM, V272, P29415, DOI 10.1074/jbc.272.47.29415; Sugiura R, 1998, EMBO J, V17, P140, DOI 10.1093/emboj/17.1.140; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; Tokumitsu H, 1996, J BIOL CHEM, V271, P5617, DOI 10.1074/jbc.271.10.5617; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; Villafranca JE, 1996, CURR OPIN BIOTECH, V7, P397; VOGEL HJ, 1995, MOL CELL BIOCHEM, V149, P3, DOI 10.1007/BF01076558; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; Wayman GA, 1997, J BIOL CHEM, V272, P16073, DOI 10.1074/jbc.272.26.16073; Werlen G, 1998, EMBO J, V17, P3101, DOI 10.1093/emboj/17.11.3101; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; Winder DG, 1998, CELL, V92, P25, DOI 10.1016/S0092-8674(00)80896-X; Wu ZG, 1997, MOL CELL BIOL, V17, P7407, DOI 10.1128/MCB.17.12.7407; Xia Y, 1998, GENE DEV, V12, P3369, DOI 10.1101/gad.12.21.3369; XIE HJ, 1995, J IMMUNOL, V154, P1717; ZINCK R, 1993, EMBO J, V12, P2377, DOI 10.1002/j.1460-2075.1993.tb05892.x	82	88	89	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					15173	15180		10.1074/jbc.274.21.15173	http://dx.doi.org/10.1074/jbc.274.21.15173			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329725	hybrid			2022-12-25	WOS:000081965200090
J	Yamashita, H; Xu, J; Erwin, RA; Larner, AC; Rui, H				Yamashita, H; Xu, J; Erwin, RA; Larner, AC; Rui, H			A lymphoma growth inhibitor blocks some but not all prolactin-stimulated signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; HUMAN BREAST-CANCER; TYROSINE PHOSPHORYLATION; EXTRACELLULAR-MATRIX; NB2 LYMPHOMA; MAP KINASE; CELL-LINES; C-FOS; RECEPTOR; STAT5	Cytokines and hormones activate a network of intracellular signaling pathways to regulate cell division, survival and differentiation. In parallel, a series of growth inhibitory mechanisms critically restrict cell population sizes. For example, mitogens can be opposed in crowded cell cultures through contact-inhibition or by autocrine release of antiproliferative substances. Here, we characterize a small, heat-stable growth inhibitor secreted by a rat T lymphoma line when cultured at high cell density. Short term incubation (<60 min) of prolactin-responsive Nb2 lymphoma cells at high density selectively blocked prolactin stimulation of p42/p44 mitogen-activated protein kinases and transcription factors Stat1 and Stat3 but not prolactin activation of Stat5 or the tyrosine kinase Jak2. The selective effects of cell density on prolactin signaling were reversible. Furthermore, exposure of cells at low density to conditioned media from cells incubated at high density had the same inhibitory effects on prolactin signaling. This selective inhibition of discrete prolactin signals was mimicked by short term preincubation of cells at low density with staurosporine or genistein but not with bis-indoleyl maleimide, cyclic nucleotide analogs, calcium ionophore A23187, or phorbol 12-myristate 13-acetate. A heat-stable, proteinase K-resistant, low molecular weight factor with these characteristics was recovered from high density culture medium, The partially purified inhibitor suppressed Nb2 cell growth with a sigmoidal concentration response consistent with a saturable, receptor-mediated process.	Uniformed Serv Univ Hlth Sci, Dept Pathol, Sch Med, Bethesda, MD 20814 USA; Univ Texas, Dept Integrat Biol Pharmacol & Physiol, Houston, TX 77030 USA; Cleveland Clin Fdn, Dept Immunol, Lerner Res Inst, Cleveland, OH 44195 USA	Uniformed Services University of the Health Sciences - USA; University of Texas System; Cleveland Clinic Foundation	Rui, H (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Pathol, Sch Med, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	hrui@usuhs.mil	Yamashita, Hiroko/D-5102-2012	Yamashita, Hiroko/0000-0003-4281-8727	NIDDK NIH HHS [R01 DK52013-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052013] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALI S, 1991, J BIOL CHEM, V266, P20110; Barahmand-Pour F, 1998, J BIOL CHEM, V273, P12567, DOI 10.1074/jbc.273.20.12567; Berlanga JJ, 1997, J BIOL CHEM, V272, P2050; BERTRAND R, 1994, EXP CELL RES, V211, P314, DOI 10.1006/excr.1994.1093; BUCKLEY AR, 1994, BIOCHEM BIOPH RES CO, V204, P1158, DOI 10.1006/bbrc.1994.2584; CAREY GB, 1995, ARCH BIOCHEM BIOPHYS, V316, P179, DOI 10.1006/abbi.1995.1026; CLEVENGER CV, 1994, MOL ENDOCRINOL, V8, P674, DOI 10.1210/me.8.6.674; CLEVENGER CV, 1994, J BIOL CHEM, V269, P5559; COULDWELL WT, 1992, J NEUROL SCI, V110, P178, DOI 10.1016/0022-510X(92)90026-H; DASILVA L, 1994, J BIOL CHEM, V269, P18267; DaSilva L, 1996, MOL CELL ENDOCRINOL, V117, P131, DOI 10.1016/0303-7207(95)03738-1; DAVID M, 1994, P NATL ACAD SCI USA, V91, P7174, DOI 10.1073/pnas.91.15.7174; Edwards GM, 1998, J BIOL CHEM, V273, P9495, DOI 10.1074/jbc.273.16.9495; EINHORN S, 1993, MED ONCOL TUMOR PHAR, V10, P25; ERWIN RA, 1995, ENDOCRINOLOGY, V136, P3512, DOI 10.1210/en.136.8.3512; Fagotto F, 1996, DEV BIOL, V180, P445, DOI 10.1006/dbio.1996.0318; FORSCHUNG B, 1974, EUR J BIOCHEM, V47, P91; FYNAN TM, 1993, CRIT REV ONCOGENESIS, V4, P493; Gong TWL, 1998, ENDOCRINOLOGY, V139, P1863, DOI 10.1210/en.139.4.1863; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; GOUT PW, 1980, CANCER RES, V40, P2433; HAREL L, 1984, J CELL PHYSIOL, V119, P101, DOI 10.1002/jcp.1041190117; JOHNSON TC, 1994, PHARMACOL THERAPEUT, V62, P247, DOI 10.1016/0163-7258(94)90013-2; Kirken RA, 1997, J BIOL CHEM, V272, P14098, DOI 10.1074/jbc.272.22.14098; LIN CQ, 1993, FASEB J, V7, P737, DOI 10.1096/fasebj.7.9.8330681; Liu XW, 1996, MOL ENDOCRINOL, V10, P1496, DOI 10.1210/me.10.12.1496; MARNETT LJ, 1992, CANCER RES, V52, P5575; RAO YP, 1995, J CELL PHYSIOL, V163, P266, DOI 10.1002/jcp.1041630207; RAO YP, 1995, CELL GROWTH DIFFER, V6, P1235; RUEGG UT, 1989, TRENDS PHARMACOL SCI, V10, P218, DOI 10.1016/0165-6147(89)90263-0; RUI H, 1994, J BIOL CHEM, V269, P5364; RUI H, 1994, ENDOCRINOLOGY, V135, P1299, DOI 10.1210/en.135.4.1299; Rui H, 1998, J BIOL CHEM, V273, P28, DOI 10.1074/jbc.273.1.28; Schaber JD, 1998, CANCER RES, V58, P1914; Shao RG, 1997, CANCER RES, V57, P4029; SIDIS Y, 1994, ENDOCRINOLOGY, V134, P1979, DOI 10.1210/en.134.4.1979; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; Smith WL, 1997, ADV EXP MED BIOL, V400, P989; STREULI CH, 1995, J BIOL CHEM, V270, P21639, DOI 10.1074/jbc.270.37.21639; TAMAOKI T, 1991, METHOD ENZYMOL, V201, P340; VANGIJN R, 1995, J CHROMATOGR B, V667, P269, DOI 10.1016/0378-4347(95)00037-J; Yamashita H, 1998, J BIOL CHEM, V273, P30218, DOI 10.1074/jbc.273.46.30218; YuLee LY, 1997, P SOC EXP BIOL MED, V215, P35, DOI 10.3181/00379727-215-44111	43	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					14699	14705		10.1074/jbc.274.21.14699	http://dx.doi.org/10.1074/jbc.274.21.14699			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329665	hybrid			2022-12-25	WOS:000081965200030
J	Schwarte-Waldhoff, I; Klein, S; Blass-Kampmann, S; Hintelmann, A; Eilert, C; Dreschers, S; Kalthoff, H; Hahn, SA; Schmiegel, W				Schwarte-Waldhoff, I; Klein, S; Blass-Kampmann, S; Hintelmann, A; Eilert, C; Dreschers, S; Kalthoff, H; Hahn, SA; Schmiegel, W			DPC4/SMAD4 mediated tumor suppression of colon carcinoma cells is associated with reduced urokinase expression	ONCOGENE			English	Article						DPC4/Smad4; tumor suppressor gene; TGF-beta; urokinase; colon carcinoma; SW480	GROWTH-FACTOR-BETA; COLORECTAL-CANCER; GENE; LINES; MUTATIONS; TGF-BETA-1; INHIBITION; MICE; DPC4; APC	We recently identified DPC4/Smad4 as a candidate tumor suppressor gene mutated or lost in one half of pancreatic carcinomas and in a subset of colon and biliary tract carcinomas. DPC4 plays a key role in signal transduction of the TGF-beta superfamily of molecules and inactivation of TGF-beta mediated growth inhibition is supposed to be the driving force for DPC4 inactivation in human tumors. However, DPC4 mediated tumor suppression by reconstitution of defective cells has not yet been reported. Here we show suppression of tumorigenicity in nude mice by stable reexpression of DPC4 in SW480 colon carcinoma cells. In vitro growth of DPC4-transfected cells was not affected and resistance towards TGF-beta mediated growth inhibition was retained. Instead, cells exhibited morphological alterations and adhesion and spreading were accelerated. These phenotypic changes were associated with reduced expression levels of the endogenous urokinase-type plasminogen activator (uPA) and plasminogen-activator-inhibitor-1 (PAI-I) genes, the products of which are implicated in the control of cell adhesion and invasion. Ln patients, high expression levels of uPA and PAI-1 correlate with poor prognosis. Thus, reduced expression of uPA and PAL-I is consistent with suppression of tumorigenicity in DPC4 reconstituted cells. These results demonstrate DPC4's tumor suppressive function and suggest a potential role for DPC4 as a modulator of cell adhesion and invasion.	Ruhr Univ Bochum, Knappschaftskrankenhaus, Med Klin, D-44892 Bochum, Germany; Univ Essen Gesamthsch Klin, Inst Zellbiol Tumorforsch, D-45122 Essen, Germany; CAU Kiel, Klin Allgemeine & Thoraxchirurg, D-24105 Kiel, Germany	Ruhr University Bochum; University of Duisburg Essen; University of Kiel	Schwarte-Waldhoff, I (corresponding author), Ruhr Univ Bochum, Knappschaftskrankenhaus, Med Klin, Schornau 23-25, D-44892 Bochum, Germany.		Kalthoff, Holger/B-1618-2010; Hahn, Stephan/E-3880-2010; Hahn, Stephan A./AAV-6062-2021	Hahn, Stephan/0000-0003-0855-9741; Hahn, Stephan A./0000-0003-0855-9741				Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BLAYDES JP, 1995, ONCOGENE, V10, P307; Candia AF, 1997, DEVELOPMENT, V124, P4467; CAPON DJ, 1983, NATURE, V304, P507, DOI 10.1038/304507a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COFFEY RJ, 1987, CANCER RES, V47, P4590; COFFEY RJ, 1986, CANCER RES, V46, P1164; Derynck R, 1997, BBA-REV CANCER, V1333, pF105, DOI 10.1016/S0304-419X(97)00017-6; Duffy MJ, 1996, CLIN CANCER RES, V2, P613; Fazeli A, 1997, NATURE, V386, P796, DOI 10.1038/386796a0; FILMUS J, 1992, ONCOGENE, V7, P521; GERWIN BI, 1992, P NATL ACAD SCI USA, V89, P2759, DOI 10.1073/pnas.89.7.2759; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; GRODEN J, 1995, CANCER RES, V55, P1531; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hahn SA, 1998, CANCER RES, V58, P1124; Hahn SA, 1996, CANCER RES, V56, P490; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; Kinzler KW, 1998, SCIENCE, V280, P1036, DOI 10.1126/science.280.5366.1036; KUROKAWA M, 1989, BIOCHEM BIOPH RES CO, V142, P775; LAIHO M, 1986, J CELL BIOL, V103, P2403, DOI 10.1083/jcb.103.6.2403; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; Moskaluk CA, 1996, BBA-REV CANCER, V1288, pM31, DOI 10.1016/S0304-419X(96)00033-9; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; OSHIMA M, 1995, P NATL ACAD SCI USA, V92, P4482, DOI 10.1073/pnas.92.10.4482; Polyak K, 1996, BBA-REV CANCER, V1242, P185, DOI 10.1016/0304-419X(95)00009-5; REISS M, 1993, CANCER RES, V53, P899; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; Schutte M, 1996, CANCER RES, V56, P2527; SCHWARTEWALDHOFF I, 1994, ONCOGENE, V9, P899; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; THIAGALINGAM S, 1996, NAT GENET, V13, P342; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Winesett MP, 1996, CARCINOGENESIS, V17, P989, DOI 10.1093/carcin/17.5.989; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019	40	75	81	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 20	1999	18	20					3152	3158		10.1038/sj.onc.1202641	http://dx.doi.org/10.1038/sj.onc.1202641			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	197WB	10340387				2022-12-25	WOS:000080388000011
J	Hawkes, NA; Roberts, SGE				Hawkes, NA; Roberts, SGE			The role of human TFIIB in transcription start site selection in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TATA-BINDING PROTEIN; N-TERMINAL REGION; SACCHAROMYCES-CEREVISIAE; FUNCTIONAL DOMAINS; LARGEST SUBUNIT; DNA-BINDING; YEAST; MUTATIONS; ACTIVATOR	The general transcription factor TFIIB plays a crucial role in selecting the transcription initiation site in yeast. We have analyzed the human homologs of TFIIB mutants that have previously been shown to affect transcription start site selection in the yeast Saccharomyces cerevisiae. Despite the distinct mechanisms of transcription start site selection observed in S. cerevisiae and humans, the role of TFIIB in this process is similar. However, unlike their yeast counterparts, the human mutants do not show a severe defect in supporting either basal transcription or transcription stimulated by an acidic activator in vitro. Transient transfection analysis revealed that, in addition to a role in transcription start site selection, human TFIIB residue Arg-66 performs a critical function in vivo that is bypassed in vitro. Furthermore, although correct transcription start site selection is dependent upon an arginine residue at position 66 in human TFIIB, innate function in vivo is determined by the charge of the residue alone. Our observations raise questions as to the evolutionary conservation of TFIIB and uncover an additional function for TFIIB that is required in vivo but can be bypassed in vitro.	Univ Dundee, Dept Biochem, Div Gene Express, Dundee DD1 5EH, Scotland	University of Dundee	Roberts, SGE (corresponding author), Univ Dundee, Dept Biochem, Div Gene Express, Wellcome Trust Bldg, Dundee DD1 5EH, Scotland.	sgeroberts@bad.dundee.ac.uk	Roberts, Stefan GE/R-5537-2016	Roberts, Stefan GE/0000-0002-7535-6365				BAGBY S, 1995, CELL, V82, P857, DOI 10.1016/0092-8674(95)90483-2; Bangur CS, 1997, MOL CELL BIOL, V17, P6784, DOI 10.1128/MCB.17.12.6784; BERROTERAN RW, 1994, MOL CELL BIOL, V14, P226, DOI 10.1128/MCB.14.1.226; Bushnell DA, 1996, J BIOL CHEM, V271, P20170, DOI 10.1074/jbc.271.33.20170; Fang SM, 1996, J BIOL CHEM, V271, P11703, DOI 10.1074/jbc.271.20.11703; FURTERGRAVES EM, 1994, NUCLEIC ACIDS RES, V22, P4932, DOI 10.1093/nar/22.23.4932; Ge H, 1996, METHOD ENZYMOL, V274, P57; GIARDINA C, 1993, SCIENCE, V261, P759, DOI 10.1126/science.8342041; HA I, 1993, GENE DEV, V7, P1021, DOI 10.1101/gad.7.6.1021; Hampsey M, 1998, MICROBIOL MOL BIOL R, V62, P465, DOI 10.1128/MMBR.62.2.465-503.1998; Hayashi F, 1998, BIOCHEMISTRY-US, V37, P7941, DOI 10.1021/bi9801098; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; HULL MW, 1995, GENE DEV, V9, P481, DOI 10.1101/gad.9.4.481; Knaus R, 1996, EMBO J, V15, P1933, DOI 10.1002/j.1460-2075.1996.tb00544.x; Lagrange T, 1998, GENE DEV, V12, P34, DOI 10.1101/gad.12.1.34; Leuther KK, 1996, CELL, V85, P773, DOI 10.1016/S0092-8674(00)81242-8; LI Y, 1994, SCIENCE, V263, P805, DOI 10.1126/science.8303296; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; Myer VE, 1998, J BIOL CHEM, V273, P27757, DOI 10.1074/jbc.273.43.27757; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; OSHEAGREENFIELD A, 1992, J BIOL CHEM, V267, P1391; Pardee TS, 1998, J BIOL CHEM, V273, P17859, DOI 10.1074/jbc.273.28.17859; PINTO I, 1992, CELL, V68, P977, DOI 10.1016/0092-8674(92)90040-J; PINTO I, 1994, J BIOL CHEM, V269, P30569; Qureshi SA, 1998, MOL CELL, V1, P389, DOI 10.1016/S1097-2765(00)80039-8; ROBERTS SGE, 1993, NATURE, V363, P741, DOI 10.1038/363741a0; ROBERTS SGE, 1994, NATURE, V371, P717, DOI 10.1038/371717a0; Shaw SP, 1996, MOL CELL BIOL, V16, P3651; SUN ZW, 1995, P NATL ACAD SCI USA, V92, P3127, DOI 10.1073/pnas.92.8.3127; WAMPLER SL, 1992, GENE DEV, V6, P1542, DOI 10.1101/gad.6.8.1542; Zhu WL, 1996, NAT STRUCT BIOL, V3, P122, DOI 10.1038/nsb0296-122	34	55	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					14337	14343		10.1074/jbc.274.20.14337	http://dx.doi.org/10.1074/jbc.274.20.14337			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318856	hybrid			2022-12-25	WOS:000080322200085
J	Hsieh, CM; Yet, SF; Layne, MD; Watanabe, M; Hong, AM; Perrella, MA; Lee, ME				Hsieh, CM; Yet, SF; Layne, MD; Watanabe, M; Hong, AM; Perrella, MA; Lee, ME			Genomic cloning and promoter analysis of aortic preferentially expressed gene-1 - Identification of a vascular smooth muscle-specific promoter mediated by an E box motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELIX TRANSCRIPTION FACTOR; MESSENGER-RNA; TRANSGENIC MICE; MYC PROTEINS; DNA-BINDING; IN-VIVO; CELLS; DIFFERENTIATION; ELEMENT; SM22-ALPHA	Aortic preferentially expressed gene-1 (APEG-1) was originally identified as a 1.4-kilobase (kb) transcript preferentially expressed in differentiated vascular smooth muscle cells (VSMC). Its expression is markedly down-regulated in de-differentiated VSMC, suggesting a role for APEG-1 in VSMC differentiation. We have now determined that APEG-1 is a single-copy gene in the human, rat, and mouse genomes and have mapped human APEG-1 to chromosome 2q34. To study the molecular mechanisms regulating its expression, we characterized the genomic organization and promoter of mouse APEG-1. APEG-1 spans 4.5 kb in the mouse genome and is composed of five exons. Using reporter gene transfection analysis, we found that a 2.7-kb APEG-1 5'-flanking sequence directed a high level of promoter activity only in VSMC. Its activity was minimal in five other cell types. A repressor region located within an upstream 685-base pair sequence suppressed the activity of this 2.7-kb promoter. Further deletion and mutation analyses identified an E box motif as a positive regulatory element, which was bound by nuclear protein prepared from VSMC. In conjunction with its flanking. sequence, this E box moth confers VSMC-specific enhancer activity to a heterologous SV40 promoter, To our knowledge, this is the first demonstration of an E box motif that mediates gene expression restricted to VSMC.	Harvard Univ, Sch Publ Hlth, Cardiovasc Biol Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Pulm & Crit Care, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital	Lee, ME (corresponding author), Harvard Univ, Sch Publ Hlth, Cardiovasc Biol Lab, 677 Huntington Ave, Boston, MA 02115 USA.		Yet, Shaw-Fang/B-1067-2010; Yet, Shaw-Fang/O-8583-2019	Calderwood, Audrey/0000-0001-7486-8310; Yet, Shaw-Fang/0000-0001-9097-3962; Layne, Matthew/0000-0003-0007-4870	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003194, F32HL010113] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053249] Funding Source: NIH RePORTER; NHLBI NIH HHS [F32-HL10113, KO8-HL03194] Funding Source: Medline; NIGMS NIH HHS [R01-GM53249] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMROLIA PJ, 1995, J BIOL CHEM, V270, P12892, DOI 10.1074/jbc.270.21.12892; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; DUBAND JL, 1993, DIFFERENTIATION, V55, P1, DOI 10.1111/j.1432-0436.1993.tb00027.x; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; GRECO A, 1994, J GEN VIROL, V75, P1693, DOI 10.1099/0022-1317-75-7-1693; GUNTHER S, 1982, J CELL BIOL, V92, P289, DOI 10.1083/jcb.92.2.289; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Herring BP, 1997, AM J PHYSIOL-CELL PH, V272, pC1394, DOI 10.1152/ajpcell.1997.272.4.C1394; Hsieh CM, 1996, J BIOL CHEM, V271, P17354, DOI 10.1074/jbc.271.29.17354; JACOBS Y, 1993, MOL CELL BIOL, V13, P7321, DOI 10.1128/MCB.13.12.7321; Jain MK, 1998, J BIOL CHEM, V273, P5993, DOI 10.1074/jbc.273.11.5993; JOHNSON JE, 1992, DEVELOPMENT, V114, P75; Kim S, 1997, MOL CELL BIOL, V17, P2266, DOI 10.1128/MCB.17.4.2266; LEE ME, 1990, J BIOL CHEM, V265, P10446; Li L, 1996, J CELL BIOL, V132, P849, DOI 10.1083/jcb.132.5.849; LIBBY P, 1991, LAB INVEST, V64, P5; Madsen CS, 1997, J BIOL CHEM, V272, P6332, DOI 10.1074/jbc.272.10.6332; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NELSEN B, 1992, INT REV CYTOL, V133, P121, DOI 10.1016/S0074-7696(08)61859-8; NOMURA M, 1995, J BIOL CHEM, V270, P7453, DOI 10.1074/jbc.270.13.7453; OSBOURN JK, 1995, GENE, V154, P249, DOI 10.1016/0378-1119(94)00847-L; OWENS GK, 1995, PHYSIOL REV, V75, P487; PERRELLA MA, 1994, J BIOL CHEM, V269, P14595; RITZENTHALER JD, 1991, BIOCHEM J, V280, P157, DOI 10.1042/bj2800157; ROBERTS VJ, 1993, P NATL ACAD SCI USA, V90, P7583, DOI 10.1073/pnas.90.16.7583; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Roztocil T, 1997, DEVELOPMENT, V124, P3263; Sambrook J., 2002, MOL CLONING LAB MANU; SCHWARTZ SM, 1990, PHYSIOL REV, V70, P1177, DOI 10.1152/physrev.1990.70.4.1177; SHIMIZU RT, 1995, J BIOL CHEM, V270, P7631, DOI 10.1074/jbc.270.13.7631; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; SOBUE K, 1991, J BIOL CHEM, V266, P12115; SOLWAY J, 1995, J BIOL CHEM, V270, P13460, DOI 10.1074/jbc.270.22.13460; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; Tsai JC, 1996, J CLIN INVEST, V97, P146, DOI 10.1172/JCI118383; TSAI JC, 1994, P NATL ACAD SCI USA, V91, P6369, DOI 10.1073/pnas.91.14.6369; WALTER MA, 1994, NAT GENET, V7, P22, DOI 10.1038/ng0594-22; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; Wilhide CC, 1997, BLOOD, V90, P3951, DOI 10.1182/blood.V90.10.3951; WINDER SJ, 1991, ADV EXP MED BIOL, V304, P37; YANO H, 1995, J BIOL CHEM, V270, P23661, DOI 10.1074/jbc.270.40.23661; Yet SF, 1998, J BIOL CHEM, V273, P10530, DOI 10.1074/jbc.273.17.10530; YOSHIZUMI M, 1995, J CLIN INVEST, V95, P2275, DOI 10.1172/JCI117918	48	18	19	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					14344	14351		10.1074/jbc.274.20.14344	http://dx.doi.org/10.1074/jbc.274.20.14344			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318857	hybrid			2022-12-25	WOS:000080322200086
J	Woo, ES; Rice, RL; Lazo, JS				Woo, ES; Rice, RL; Lazo, JS			Cell cycle dependent subcellular distribution of Cdc25B subtypes	ONCOGENE			English	Article						Cdc25; green fluorescent protein; nuclear localization; phosphorylation; etoposide; cell cycle	CDK REGULATION; PHOSPHATASE; MITOSIS; PHOSPHORYLATION; ACTIVATION; PHASE; TRIGGERS; BINDING; DOMAIN; ROLES	The dual specificity phosphatase and oncogene Cdc25B has been implicated in the G2/M cell cycle checkpoint, but the mode by which it is regulated remains poorly understood, Regional subcellular redistribution of proteins represents a unique potential regulatory mechanism. Thus, we examined in live cells the subcellular localization characteristics of Cdc25B(2) and Cdc25B(3) fused to green fluorescent protein. Cdc25B(2) partitioned primarily in the cytoplasm during G1 and progressively migrated to the nucleus as cells transited from S to G2/M phase. In contrast, Cdc25B(3) maintained a homogeneously staining diffuse phenotype irrespective of cell cycle phase. Treatment of the Cdc25B(2)-green fluorescent protein stable transfectants with vanadate inhibited the cell cycle dependency of intracellular distribution, while okadaic acid had little effect except in G1, suggesting regulation by at least one phosphorylation-dependent pathway. The DNA topoisomerase II poison and DNA damaging agent, etoposide, inhibited nuclear localization of Cdc25B(2) in S phase, possibly by invoking a sequestration cascade. Thus, differences in the spatial distribution of Cdc25B subtypes exist within cells and the 41 amino acid insert in the N-terminus of the Cdc25B(3) splice variant encodes an important inhibitory determinant for such regulation. The subcellular redistribution of Cdc25B(2) could be functionally important for G2/M checkpoint regulation.	Univ Pittsburgh, Inst Canc, Dept Pharmacol, Mol Therapeut Drug Discovery Program, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Lazo, JS (corresponding author), Univ Pittsburgh, Inst Canc, Dept Pharmacol, Mol Therapeut Drug Discovery Program, Pittsburgh, PA 15261 USA.				NCI NIH HHS [CA61299, CA78039] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061299, P01CA078039] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aitken A, 1996, TRENDS CELL BIOL, V6, P341, DOI 10.1016/0962-8924(96)10029-5; Baldin V, 1997, J BIOL CHEM, V272, P32731, DOI 10.1074/jbc.272.52.32731; Baldin V, 1997, ONCOGENE, V14, P2485, DOI 10.1038/sj.onc.1201063; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; Gabrielli BG, 1996, J CELL SCI, V109, P1081; Gabrielli BG, 1997, J BIOL CHEM, V272, P28607, DOI 10.1074/jbc.272.45.28607; Gabrielli BG, 1997, ONCOGENE, V15, P749, DOI 10.1038/sj.onc.1201254; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; Kruk PA, 1997, BIOCHEM BIOPH RES CO, V233, P717, DOI 10.1006/bbrc.1997.6549; Lammer C, 1998, J CELL SCI, V111, P2445; MILLAR JBA, 1991, P NATL ACAD SCI USA, V88, P10500, DOI 10.1073/pnas.88.23.10500; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; PASTAN I, 1979, METHOD ENZYMOL, V58, P233; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; STRAUSFELD U, 1994, J BIOL CHEM, V269, P5989; Woo ES, 1997, CANCER RES, V57, P4236; Xu X, 1996, J BIOL CHEM, V271, P5118; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Zeng Y, 1998, NATURE, V395, P507, DOI 10.1038/26766	25	21	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 29	1999	18	17					2770	2776		10.1038/sj.onc.1202614	http://dx.doi.org/10.1038/sj.onc.1202614			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FH	10348352	Bronze			2022-12-25	WOS:000080124900013
J	Chruscinski, AJ; Rohrer, DK; Schauble, E; Desai, KH; Bernstein, D; Kobilka, BK				Chruscinski, AJ; Rohrer, DK; Schauble, E; Desai, KH; Bernstein, D; Kobilka, BK			Targeted disruption of the beta 2 adrenergic receptor gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED RING PREPARATIONS; BETA-1-ADRENERGIC RECEPTOR; ESSENTIAL-HYPERTENSION; ADRENOCEPTOR SUBTYPE; CORONARY-ARTERIES; MICE; BETA-2-ADRENOCEPTORS; DOGS; BETA-1-ADRENOCEPTORS; STIMULATION	beta-Adrenergic receptors (beta-ARs) are members of the superfamily of G-protein-coupled receptors that mediate the effects of catecholamines in the sympathetic nervous system. Three distinct beta-AR subtypes have been identified (beta 1-AR, beta 2-AR, and beta 3-AR), In order to define further the role of the different P-AR subtypes, we have used gene targeting to inactivate selectively the beta 2-AR gene in mice. Based on intercrosses of heterozygous knockout (beta 2-AR +/-) mice, there is no prenatal lethality associated with this mutation. Adult knockout mice (beta 2-AR -/-) appear grossly normal and are fertile. Their resting heart rate and blood pressure are normal, and they have a normal chronotropic response to the beta-AR agonist isoproterenol, The hypotensive response to isoproterenol, however, is significantly blunted compared with wild type mice. Despite this defect in vasodilation, beta 2-AR -/- mice can still exercise normally and actually have a greater total exercise capacity than wild type mice. At comparable workloads, beta 2-AR -/- mice had a lower respiratory exchange ratio than wild type mice suggesting a difference in energy metabolism. beta 2-AR -/- mice become hypertensive during exercise and exhibit a greater hypertensive response to epinephrine compared with wild type mice. In summary, the primary physiologic consequences of the beta 2-AR gene disruption are observed only during the stress of exercise and are the result of alterations in both vascular tone and energy metabolism.	Stanford Univ, Howard Hughes Med Inst, Stanford, CA 94305 USA; Stanford Univ, Dept Cellular & Mol Physiol, Stanford, CA 94305 USA; Stanford Univ, Div Cardiovasc Med, Stanford, CA 94305 USA; Stanford Univ, Dept Pediat, Stanford, CA 94305 USA; Roche Biosci, Dept Mol Pharmacol, Palo Alto, CA 94304 USA	Howard Hughes Medical Institute; Stanford University; Stanford University; Stanford University; Stanford University; Roche Holding	Kobilka, BK (corresponding author), Stanford Univ, Howard Hughes Med Inst, Stanford, CA 94305 USA.	kobilka@cmgm.stanford.edu		Kobilka, Brian/0000-0001-5958-3990; Bernstein, Daniel/0000-0001-7761-5853	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007365] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM07365] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHLBORG G, 1985, AM J PHYSIOL, V248, pE540, DOI 10.1152/ajpendo.1985.248.5.E540; ALLEN JM, 1988, EMBO J, V7, P133, DOI 10.1002/j.1460-2075.1988.tb02792.x; BRODDE OE, 1991, PHARMACOL REV, V43, P203; BRODDE OE, 1992, J HYPERTENS, V10, pS133; DESAI KH, 1997, AM J PHYSIOL, pH1053; DIXON RAF, 1986, NATURE, V321, P75, DOI 10.1038/321075a0; EISEN EJ, 1981, GROWTH, V45, P100; EMORINE LJ, 1989, SCIENCE, V245, P1118, DOI 10.1126/science.2570461; FELDMAN RD, 1987, CAN J PHYSIOL PHARM, V65, P1666, DOI 10.1139/y87-261; FRIELLE T, 1987, P NATL ACAD SCI USA, V84, P7920, DOI 10.1073/pnas.84.22.7920; GOLDSTEIN DS, 1983, HYPERTENSION, V5, P86, DOI 10.1161/01.HYP.5.1.86; Hatakeyama D J, 1988, Proc West Pharmacol Soc, V31, P171; ISSEKUTZ B, 1984, J APPL PHYSIOL, V57, P1754, DOI 10.1152/jappl.1984.57.6.1754; JOYNER AL, 1993, GENE TARGETING PRACT, P33; KAUMANN AJ, 1986, N-S ARCH PHARMACOL, V332, P406, DOI 10.1007/BF00500096; LANDS A. M., 1967, LIFE SCI, V6, P2241, DOI 10.1016/0024-3205(67)90031-8; LANDS AM, 1967, NATURE, V214, P597, DOI 10.1038/214597a0; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; NYBORG NCB, 1985, J CARDIOVASC PHARM, V7, P1113, DOI 10.1097/00005344-198511000-00016; ODONNELL SR, 1984, J PHARMACOL EXP THER, V228, P733; ODONNELL SR, 1984, BRIT J PHARMACOL, V81, P637, DOI 10.1111/j.1476-5381.1984.tb16129.x; OPIE LH, 1985, AM J CARDIOL, V55, pD95, DOI 10.1016/0002-9149(85)91062-8; ROGERS P, 1980, BRIT J NUTR, V43, P83, DOI 10.1079/BJN19800066; Rohrer DK, 1999, J BIOL CHEM, V274, P16701, DOI 10.1074/jbc.274.24.16701; Rohrer DK, 1996, P NATL ACAD SCI USA, V93, P7375, DOI 10.1073/pnas.93.14.7375; Shen YT, 1996, J PHARMACOL EXP THER, V278, P1435; SHEN YT, 1994, J PHARMACOL EXP THER, V268, P466; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEIN CM, 1995, J CLIN INVEST, V96, P579, DOI 10.1172/JCI118070; Strosberg AD, 1997, ANNU REV PHARMACOL, V37, P421, DOI 10.1146/annurev.pharmtox.37.1.421; TAKEI M, 1992, JPN J PHARMACOL, V59, P23, DOI 10.1254/jjp.59.23; Timmermann B, 1998, KIDNEY INT, V53, P1455, DOI 10.1046/j.1523-1755.1998.00926.x; TODA N, 1990, J PHARMACOL EXP THER, V253, P518; VATNER SF, 1985, AM J PHYSIOL, V249, pH49, DOI 10.1152/ajpheart.1985.249.1.H49; WOOD SA, 1993, NATURE, V365, P87, DOI 10.1038/365025a0	35	241	248	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16694	16700		10.1074/jbc.274.24.16694	http://dx.doi.org/10.1074/jbc.274.24.16694			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358008	hybrid			2022-12-25	WOS:000080780400007
J	Sakata, N; Stoops, JD; Dixon, JL				Sakata, N; Stoops, JD; Dixon, JL			Cytosolic components are required for proteasomal degradation of newly synthesized apolipoprotein B in permeabilized HepG2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE TRANSFER PROTEIN; ENDOPLASMIC-RETICULUM; INTRACELLULAR DEGRADATION; CONTAINING LIPOPROTEINS; SECRETORY PROTEIN; CULTURED-CELLS; RAT-LIVER; G2 CELLS; UBIQUITIN; B100	Recent studies have proposed that post-translational degradation of apolipoprotein B100 (apoB) involves the cytosolic ubiquitin-proteasome pathway. In this study, immunocytochemistry indicated that endoplasmic reticulum (ER)-associated proteasome molecules were concentrated in perinuclear regions of digitonin-permeabilized HepG2 cells. Signals produced by antibodies that recognize both alpha- and beta-subunits of the proteasome co-localized in the ER with specific domains of apoB, The mechanism of apoB degradation in the ER by the ubiquitin-proteasome pathway was studied using pulse-chase labeling and digitonin-permeabilized cells. ApoB in permeabilized cells incubated at 37 degrees C in buffer alone was relatively stable. When permeabilized cells were incubated with both exogenous ATP and rabbit reticulocyte lysate (RRL) as a source of ubiquitin-proteasome factors, >50% of [H-3]apoB was degraded in 30 min. The degradation of apoB in the intact ER of permeabilized cells was much more rapid than that of extracted [H-3]apoB incubated with RRL and ATP in vitro, The degradation of apoB was reduced by clasto-lactacystin beta-lactone, a potent proteasome inhibitor, and by ubiquitin K48R mutant protein, an inhibitor of polyubiquitination. ApoB in HepG2 cells was ubiquitinated, and polyubiquitination of apoB was stimulated by incubation of permeabilized cells with RRL. These results suggest that newly synthesized apoB in the ER is accessible to the cytoplasmic ubiquitin-proteasome pathway and that factors in RRL stimulate polyubiquitination of apoB, leading to rapid degradation of apoB in permeabilized cells.	Univ Missouri, Dept Food Sci & Human Nutr, Columbia, MO 65211 USA	University of Missouri System; University of Missouri Columbia	Dixon, JL (corresponding author), Univ Missouri, Dept Food Sci & Human Nutr, 122 Eckles Hall, Columbia, MO 65211 USA.	DixonJ@missouri.edu	Sakata, Nobuhiro/ACN-9770-2022		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047586, R29HL047586] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-47586] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adeli K, 1997, J BIOL CHEM, V272, P22489, DOI 10.1074/jbc.272.36.22489; Baumeister W, 1997, CURR OPIN STRUC BIOL, V7, P273, DOI 10.1016/S0959-440X(97)80036-X; Benoist F, 1997, J BIOL CHEM, V272, P20435, DOI 10.1074/jbc.272.33.20435; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; Brodsky JL, 1997, TRENDS CELL BIOL, V7, P151, DOI 10.1016/S0962-8924(97)01020-9; CIECHANOVER A, 1978, BIOCHEM BIOPH RES CO, V81, P1100, DOI 10.1016/0006-291X(78)91249-4; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Dick LR, 1997, J BIOL CHEM, V272, P182; Dick LR, 1996, J BIOL CHEM, V271, P7273, DOI 10.1074/jbc.271.13.7273; DIXON JL, 1993, J LIPID RES, V34, P167; DIXON JL, 1991, J BIOL CHEM, V266, P5080; Du EZ, 1999, J BIOL CHEM, V274, P1856, DOI 10.1074/jbc.274.3.1856; Du XB, 1998, J CELL BIOL, V141, P585, DOI 10.1083/jcb.141.3.585; Enenkel C, 1998, EMBO J, V17, P6144, DOI 10.1093/emboj/17.21.6144; Fenteany G, 1998, J BIOL CHEM, V273, P8545, DOI 10.1074/jbc.273.15.8545; FINLEY D, 1994, MOL CELL BIOL, V14, P5501, DOI 10.1128/MCB.14.8.5501; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; FURUKAWA S, 1992, J BIOL CHEM, V267, P22630; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; KRUL ES, 1988, J LIPID RES, V29, P937; Liao W, 1998, J BIOL CHEM, V273, P27225, DOI 10.1074/jbc.273.42.27225; Linnik KM, 1998, J BIOL CHEM, V273, P21368, DOI 10.1074/jbc.273.33.21368; McCracken AA, 1998, ADV MOL CEL, V27, P165, DOI 10.1016/S1569-2558(08)60461-0; Mitchell DM, 1998, P NATL ACAD SCI USA, V95, P14733, DOI 10.1073/pnas.95.25.14733; Palmer A, 1996, BIOCHEM J, V316, P401, DOI 10.1042/bj3160401; Pilon M, 1997, EMBO J, V16, P4540, DOI 10.1093/emboj/16.15.4540; RIVETT AJ, 1992, J HISTOCHEM CYTOCHEM, V40, P1165, DOI 10.1177/40.8.1619280; Rivett AJ, 1998, CURR OPIN IMMUNOL, V10, P110, DOI 10.1016/S0952-7915(98)80040-X; SAKATA N, 1993, J BIOL CHEM, V268, P22967; Sakata N, 1999, BBA-MOL CELL BIOL L, V1437, P71, DOI 10.1016/S1388-1981(98)00006-7; Sommer T, 1997, FASEB J, V11, P1227, DOI 10.1096/fasebj.11.14.9409541; Weissman AM, 1997, IMMUNOL TODAY, V18, P189, DOI 10.1016/S0167-5699(97)84666-X; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Wu XJ, 1997, J BIOL CHEM, V272, P11575; Yao ZM, 1997, J LIPID RES, V38, P1937; Yeung SJ, 1996, BIOCHEMISTRY-US, V35, P13843, DOI 10.1021/bi9618777; Zhou MY, 1998, J BIOL CHEM, V273, P24649, DOI 10.1074/jbc.273.38.24649	40	15	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17068	17074		10.1074/jbc.274.24.17068	http://dx.doi.org/10.1074/jbc.274.24.17068			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358059	hybrid			2022-12-25	WOS:000080780400058
J	Goldshleger, R; Karlish, SJD				Goldshleger, R; Karlish, SJD			The energy transduction mechanism of Na,K-ATPase studied with iron-catalyzed oxidative cleavage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSPORT ADENOSINE-TRIPHOSPHATASE; SITE-DIRECTED MUTAGENESIS; MEMBRANE H+-ATPASE; (NA+ + K+)-ATPASE; ALPHA-SUBUNIT; BINDING-SITE; SARCOPLASMIC-RETICULUM; CONFORMATIONAL-CHANGES; NA+/K+-ATPASE; AMINO-ACID	This paper extends our recent report on specific iron-catalyzed oxidative cleavages of renal Na,K-ATPase and effects of E-1 <----> E-2 conformational transitions (Goldshleger, R., and Karlish, S. J. D. (1997) Proc. Natl. Acad. Sci. U.S.A. 94, 9596-9601). The experiments indicate that only peptide bonds close to a bound Fe2+ ion are cleaved, and provide evidence on proximity of the different cleavage positions in the native enzyme. A sequence HFIH near trans-membrane segment M3 appears to be involved in Fe2+ binding, Previously we hypothesized that E-2 and E-1 conformations are characterized by formation or relaxation of interactions within the alpha subunit at or near highly conserved sequences, TGES in the minor cytoplasmic loop and CSDK, MVTGD, and VNDSPALKK in the major cytoplasmic loop. This concept has been tested by examining iron-catalyzed cleavage in both non-phosphorylated and phosphorylated conformations and effects of phosphate, vanadate, and ouabain. The results imply that both E-1 <----> E-2 and E1P <----> E2P transitions are indeed associated with formation and relaxation of interactions between cytoplasmic domains, comprising the minor loop plus N-terminal tail leading into M1 and major loop, respectively. Furthermore, it appears that either non-covalently or covalently bound phosphate bind near CSDK and MVTGD, and Mg2+ ions may bind to residues within TGES and VNDSPALKK and to bound phosphate, Thus cytoplasmic domain interactions seem to occur within or near the active site. We discuss the relationship between structural changes in the cytoplasmic domain and movements of trans-membrane segments that lead to cation transport. Presumably conformation-dependent formation and relaxation of domain interactions underlie energy transduction in all P-type pumps.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Karlish, SJD (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.							ANDERSEN JP, 1995, FEBS LETT, V359, P101, DOI 10.1016/0014-5793(95)00019-6; ASKARI A, 1983, J BIOL CHEM, V258, P3453; Auer M, 1998, NATURE, V392, P840, DOI 10.1038/33967; Bar Shimon M, 1998, J BIOL CHEM, V273, P34190, DOI 10.1074/jbc.273.51.34190; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Boxenbaum N, 1998, J BIOL CHEM, V273, P23086, DOI 10.1074/jbc.273.36.23086; CAPASSO JM, 1992, J BIOL CHEM, V267, P1150; Cornelius F, 1998, BIOCHEMISTRY-US, V37, P16686, DOI 10.1021/bi981571v; Daly SE, 1997, J BIOL CHEM, V272, P6341, DOI 10.1074/jbc.272.10.6341; Daly SE, 1996, J BIOL CHEM, V271, P23683, DOI 10.1074/jbc.271.39.23683; DEMEIS L, 1980, BIOCHEMISTRY-US, V19, P4252, DOI 10.1021/bi00559a017; FAHN S, 1966, J BIOL CHEM, V241, P1882; FARLEY RA, 1984, J BIOL CHEM, V259, P9532; Fedosova NU, 1998, BIOCHEMISTRY-US, V37, P13634, DOI 10.1021/bi980703h; FORBUSH B, 1987, J BIOL CHEM, V262, P11116; FUKUSHIMA Y, 1978, J BIOL CHEM, V253, P6853; GIRARDET JL, 1993, EUR J BIOCHEM, V217, P225, DOI 10.1111/j.1432-1033.1993.tb18237.x; GLYNN IM, 1990, ANNU REV BIOCHEM, V59, P171, DOI 10.1146/annurev.bi.59.070190.001131; Goldshleger R, 1997, P NATL ACAD SCI USA, V94, P9596, DOI 10.1073/pnas.94.18.9596; GOLDSHLEGER R, 1995, BIOCHEMISTRY-US, V34, P8668, DOI 10.1021/bi00027a016; GREEN NM, 1992, ACTA PHYSIOL SCAND, V146, P59; HARLOW E, 1988, ANTIBODIES LAB MANUA, P509; HARRIS SL, 1991, J BIOL CHEM, V266, P24439; JEWELLMOTZ EA, 1993, BIOCHEMISTRY-US, V32, P13523, DOI 10.1021/bi00212a018; Jorgensen PL, 1997, ANN NY ACAD SCI, V834, P161, DOI 10.1111/j.1749-6632.1997.tb52248.x; JORGENSEN PL, 1988, METHOD ENZYMOL, V156, P29; JORGENSEN PL, 1986, BIOCHIM BIOPHYS ACTA, V860, P570, DOI 10.1016/0005-2736(86)90555-9; JORGENSEN PL, 1985, BIOCHIM BIOPHYS ACTA, V821, P319, DOI 10.1016/0005-2736(85)90102-6; Karlish SJD, 1997, ANN NY ACAD SCI, V834, P30, DOI 10.1111/j.1749-6632.1997.tb52223.x; KARLISH SJD, 1990, P NATL ACAD SCI USA, V87, P4566, DOI 10.1073/pnas.87.12.4566; KARLISH SJD, 1998, ACTA PHYSL SCAND, V163, P89; KOSO VN, 1997, BIOCHEMISTRY-US, V36, P8045; MAUNSBACH AB, 1991, SOC GEN PHY, V46, P159; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; MUNZER JS, 1994, J BIOL CHEM, V269, P16668; Nielsen JM, 1998, BIOCHEMISTRY-US, V37, P1961, DOI 10.1021/bi972524q; OHTA T, 1986, P NATL ACAD SCI USA, V83, P2071, DOI 10.1073/pnas.83.7.2071; OVCHINNIKOV YA, 1987, FEBS LETT, V217, P111, DOI 10.1016/0014-5793(87)81253-X; Pedersen PA, 1998, BIOCHEMISTRY-US, V37, P17818, DOI 10.1021/bi981898w; PLATIS IE, 1993, BIOCHEMISTRY-US, V32, P12761, DOI 10.1021/bi00210a027; POST RL, 1975, J BIOL CHEM, V250, P691; RANA TM, 1991, P NATL ACAD SCI USA, V88, P10578, DOI 10.1073/pnas.88.23.10578; ROBINSON JD, 1993, BIOCHIM BIOPHYS ACTA, V1154, P83, DOI 10.1016/0304-4157(93)90018-J; SHULL GE, 1986, BIOCHEMISTRY-US, V25, P8125, DOI 10.1021/bi00373a001; Smirnova IN, 1998, FEBS LETT, V431, P309, DOI 10.1016/S0014-5793(98)00760-1; Stokes DL, 1998, ACTA PHYSIOL SCAND, V163, P35; SWEADNER KJ, 1988, METHOD ENZYMOL, V156, P65; SWEADNER KJ, 1989, BIOCHIM BIOPHYS ACTA, V988, P185, DOI 10.1016/0304-4157(89)90019-1; TRAN CM, 1994, J BIOL CHEM, V269, P6558; TRAN CM, 1994, BIOCHEMISTRY-US, V33, P4140, DOI 10.1021/bi00180a006; URAYAMA O, 1988, BIOCHEM BIOPH RES CO, V156, P796, DOI 10.1016/S0006-291X(88)80914-8; Vilsen B, 1997, BIOCHEMISTRY-US, V36, P13312, DOI 10.1021/bi971030q; Zhang PJ, 1998, NATURE, V392, P835, DOI 10.1038/33959	53	40	40	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16213	16221		10.1074/jbc.274.23.16213	http://dx.doi.org/10.1074/jbc.274.23.16213			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347176	hybrid			2022-12-25	WOS:000080668600036
J	Sarafova, S; Siu, G				Sarafova, S; Siu, G			A potential role for Elf-1 in CD4 promoter function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL DEVELOPMENT; TRANSGENIC MICE; DNA-BINDING; TRANSCRIPTION FACTOR; POSITIVE SELECTION; ANTIGEN RECEPTOR; LYMPHOCYTE DEVELOPMENT; NEGATIVE SELECTION; LINEAGE COMMITMENT; GENE-EXPRESSION	The control of CD4 gene expression is believed to be linked directly to the signaling events that mediate T cell development and is directly dependent on the CD4 promoter. We have previously determined that this promoter contains four factor-binding sites important for its function. One of these sites, referred to as the P4 site, contains an Ets consensus recognition sequence. Using functional and biochemical analyses, we determine that Elf-1 binds to this site and specifically activates the CD4 promoter, indicating that Elf-1 is playing an important role in CD4 promoter function. In addition, a second nuclear factor binds to this region. Although there are consensus recognition sites for other factors, we demonstrate that none of these factors binds to the P4 site, nor do other known members of the Ets family. Thus, a novel transcription factor may bind to the CD4 promoter and help mediate its function.	Columbia Univ Coll Phys & Surg, Dept Microbiol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Integrated Program Cellular Mol & Biophys Studies, New York, NY 10032 USA	Columbia University; Columbia University	Siu, G (corresponding author), Columbia Univ Coll Phys & Surg, Dept Microbiol, 701 W 168th St, New York, NY 10032 USA.	siu@cusiu3.cpmc.columbia.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034925] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI34925] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adlam M, 1997, INT IMMUNOL, V9, P877, DOI 10.1093/intimm/9.6.877; ALBEROLAILA J, 1995, NATURE, V373, P620, DOI 10.1038/373620a0; AnsariLari MA, 1996, GENOME RES, V6, P314, DOI 10.1101/gr.6.4.314; BAIXERAS E, 1992, J EXP MED, V176, P327, DOI 10.1084/jem.176.2.327; Bassuk AG, 1997, ADV IMMUNOL, V64, P65, DOI 10.1016/S0065-2776(08)60887-1; BERG LJ, 1989, CELL, V58, P1035, DOI 10.1016/0092-8674(89)90502-3; BOSSELUT R, 1993, NUCLEIC ACIDS RES, V21, P5184, DOI 10.1093/nar/21.22.5184; Bruniquel D, 1997, IMMUNOGENETICS, V47, P96, DOI 10.1007/s002510050332; CHAN SH, 1993, CELL, V73, P225, DOI 10.1016/0092-8674(93)90225-F; DAVIS CB, 1993, CELL, V73, P237, DOI 10.1016/0092-8674(93)90226-G; Davis JN, 1996, GENE, V171, P265, DOI 10.1016/0378-1119(96)00013-3; DEMCZUK S, 1993, P NATL ACAD SCI USA, V90, P2574, DOI 10.1073/pnas.90.7.2574; DUNCAN DD, 1995, MOL CELL BIOL, V15, P3179; Duncan DD, 1996, IMMUNITY, V4, P301, DOI 10.1016/S1074-7613(00)80438-0; FOWLKES BJ, 1989, ADV IMMUNOL, V44, P207, DOI 10.1016/S0065-2776(08)60643-4; GEGONNE A, 1992, NEW BIOL, V4, P512; Georgopoulos K, 1997, ANNU REV IMMUNOL, V15, P155, DOI 10.1146/annurev.immunol.15.1.155; GOYAL N, 1990, MOL CELL BIOL, V10, P1041, DOI 10.1128/MCB.10.3.1041; HUARD B, 1994, IMMUNOGENETICS, V39, P213; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KAYE J, 1989, NATURE, V341, P746, DOI 10.1038/341746a0; Kim HK, 1998, MOL CELL BIOL, V18, P7166, DOI 10.1128/MCB.18.12.7166; KISIELOW P, 1988, NATURE, V335, P730, DOI 10.1038/335730a0; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; KRUISBEEK AM, 1985, J EXP MED, V161, P1029, DOI 10.1084/jem.161.5.1029; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LANCKI DW, 1983, J EXP MED, V157, P921, DOI 10.1084/jem.157.3.921; LEIDEN JM, 1992, IMMUNOL TODAY, V13, P22, DOI 10.1016/0167-5699(92)90200-Q; LITTMAN DR, 1987, ANNU REV IMMUNOL, V5, P561, DOI 10.1146/annurev.iy.05.040187.003021; LUCAS B, 1995, J EXP MED, V181, P1623, DOI 10.1084/jem.181.5.1623; LUNDBERG K, 1995, J EXP MED, V181, P1643, DOI 10.1084/jem.181.5.1643; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; ManzanoWinkler B, 1996, J BIOL CHEM, V271, P12076, DOI 10.1074/jbc.271.20.12076; Miyazaki Y, 1996, ONCOGENE, V13, P1721; NOSSAL GJV, 1994, CELL, V76, P229, DOI 10.1016/0092-8674(94)90331-X; Oettgen P, 1996, MOL CELL BIOL, V16, P5091; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; PARNES JR, 1989, ADV IMMUNOL, V44, P265, DOI 10.1016/S0065-2776(08)60644-6; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PERLMUTTER RM, 1993, CLIN IMMUNOL IMMUNOP, V67, pS44, DOI 10.1006/clin.1993.1083; PERLMUTTER RM, 1989, BIOCHIM BIOPHYS ACTA, V948, P245, DOI 10.1016/0304-419X(89)90001-2; ROBEY E, 1994, ANNU REV IMMUNOL, V12, P675, DOI 10.1146/annurev.iy.12.040194.003331; ROBEY EA, 1991, CELL, V64, P99, DOI 10.1016/0092-8674(91)90212-H; SALMON P, 1993, P NATL ACAD SCI USA, V90, P7739, DOI 10.1073/pnas.90.16.7739; SAWADA S, 1991, MOL CELL BIOL, V11, P5506, DOI 10.1128/MCB.11.11.5506; SAWADA S, 1993, MOL CELL BIOL, V13, P5620, DOI 10.1128/MCB.13.9.5620; SAWADA S, 1994, CELL, V77, P917, DOI 10.1016/0092-8674(94)90140-6; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; SHA WC, 1988, NATURE, V335, P271, DOI 10.1038/335271a0; Sharp LL, 1997, IMMUNITY, V7, P609, DOI 10.1016/S1074-7613(00)80382-9; SIU G, 1994, EMBO J, V13, P3570, DOI 10.1002/j.1460-2075.1994.tb06664.x; SIU G, 1992, MOL CELL BIOL, V12, P1592, DOI 10.1128/MCB.12.4.1592; SUZUKI H, 1995, IMMUNITY, V2, P413, DOI 10.1016/1074-7613(95)90149-3; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; TRIEBEL F, 1990, J EXP MED, V171, P1393, DOI 10.1084/jem.171.5.1393; VONBOEHMER H, 1994, CELL, V76, P219, DOI 10.1016/0092-8674(94)90330-1; VONBOEHMER H, 1993, CELL, V73, P207, DOI 10.1016/0092-8674(93)90220-K; WANG CY, 1992, J EXP MED, V175, P1391, DOI 10.1084/jem.175.5.1391; WATERMAN M L, 1990, New Biologist, V2, P621; Wilkinson DA, 1997, LEUKEMIA, V11, P86, DOI 10.1038/sj.leu.2400516; WURSTER AL, 1994, MOL CELL BIOL, V14, P6452, DOI 10.1128/MCB.14.10.6452; ZIPURSKY SL, 1994, ANNU REV NEUROSCI, V17, P373, DOI 10.1146/annurev.neuro.17.1.373	64	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16126	16134		10.1074/jbc.274.23.16126	http://dx.doi.org/10.1074/jbc.274.23.16126			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347164	hybrid			2022-12-25	WOS:000080668600024
J	Canitrot, Y; Frechet, M; Servant, L; Cazaux, C; Hoffmann, JB				Canitrot, Y; Frechet, M; Servant, L; Cazaux, C; Hoffmann, JB			Overexpression of DNA polymerase beta: a genomic instability enhancer process	FASEB JOURNAL			English	Article						DNA replication; Pol beta; mismatch repair; nucleotide excision repair	BASE-EXCISION-REPAIR; MISMATCH REPAIR; MUTATOR PHENOTYPE; MAMMALIAN-CELLS; CANCER-CELLS; IN-VITRO; REPLICATION; GENE; RECOMBINATION; HETERODIMER	DNA polymerase beta (Pol beta) is the most inaccurate of the six DNA polymerases found in mammalian cells. In a normal situation, it is expressed at a constant low level and its role is believed to be restricted to repair synthesis in the base excision repair pathway participating to the genome stability. However, excess of Pol beta, found in some human tumors, could confer an increase in spontaneous mutagenesis and result in a highly mutagenic tolerance phenotype toward bifunctional DNA crosslinking anticancer drugs, Here, we present a hypothesis on the mechanisms used by Pol beta to be a genetic instability enhancer through its overexpression, We hypothesize that an excess of pol beta perturbs the well-defined specific functions of DNA polymerases developed by the cell and propose Pol beta-mediated gap fillings during DNA transactions like repair, replication, or recombination pathways as key processes to introduce illegitimate deoxyribonucleotides or mutagenic base analogs like those produced by intracellular oxidative processes. These mechanisms may predominate during cellular nonproliferative phases in the absence of DNA replication.	IPBS, CNRS, UPR 9062, Grp Instabil Genet & Canc, F-31077 Toulouse, France	Centre National de la Recherche Scientifique (CNRS)	Hoffmann, JB (corresponding author), IPBS, CNRS, UPR 9062, Grp Instabil Genet & Canc, 205 Route Narbonne, F-31077 Toulouse, France.		Hoffmann, Jean-Sebastien/O-9183-2014	Hoffmann, Jean-Sebastien/0000-0003-2222-354X				BAMBARA RA, 1995, PROG NUCLEIC ACID RE, V51, P93, DOI 10.1016/S0079-6603(08)60877-6; Beard WA, 1998, CHEM BIOL, V5, pR7, DOI 10.1016/S1074-5521(98)90081-3; Bouayadi K, 1997, CANCER RES, V57, P110; Burgers PMJ, 1998, CHROMOSOMA, V107, P218, DOI 10.1007/s004120050300; Canitrot Y, 1998, P NATL ACAD SCI USA, V95, P12586, DOI 10.1073/pnas.95.21.12586; CANITROT Y, 1999, IN PRESS ONCOGENE, V18; Chagovetz AM, 1997, J BIOL CHEM, V272, P27501, DOI 10.1074/jbc.272.44.27501; COPELAND WC, 1992, J BIOL CHEM, V267, P21459; DRAKE JW, 1991, ANNU REV GENET, V25, P125, DOI 10.1146/annurev.ge.25.120191.001013; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Efrati E, 1997, J BIOL CHEM, V272, P2559; FORNACE AJ, 1989, MOL CELL BIOL, V9, P851, DOI 10.1128/MCB.9.2.851; Gibbs PEM, 1998, P NATL ACAD SCI USA, V95, P6876, DOI 10.1073/pnas.95.12.6876; HERENDEEN D, 1996, EUKARYOTIC DNA REPLI, P29; HOFFMANN J, 1997, INT J ONCOL, V12, P377; Hoffmann JS, 1996, J BIOL CHEM, V271, P15386, DOI 10.1074/jbc.271.26.15831; HOFFMANN JS, 1995, P NATL ACAD SCI USA, V92, P5356, DOI 10.1073/pnas.92.12.5356; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; KamathLoeb AS, 1997, J BIOL CHEM, V272, P5892, DOI 10.1074/jbc.272.9.5892; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; Kornberg A., 1992, DNA REPLICATION; KUNKEL TA, 1985, J BIOL CHEM, V260, P5787; Lawrence CW, 1996, CANCER SURV, V28, P21; Lieber MR, 1997, BIOESSAYS, V19, P233, DOI 10.1002/bies.950190309; Loeb LA, 1997, SCIENCE, V277, P1449, DOI 10.1126/science.277.5331.1449; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; Palombo F, 1996, CURR BIOL, V6, P1181, DOI 10.1016/S0960-9822(02)70685-4; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; Plug AW, 1997, P NATL ACAD SCI USA, V94, P1327, DOI 10.1073/pnas.94.4.1327; SCANLON KJ, 1989, CANCER INVEST, V7, P581, DOI 10.3109/07357908909017533; SHIJVI MKK, 1992, CELL, V69, P367; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; Stucki M, 1998, ONCOGENE, V17, P835, DOI 10.1038/sj.onc.1202001; SWEASY JB, 1992, J BIOL CHEM, V267, P1407; Torkelson J, 1997, EMBO J, V16, P3303, DOI 10.1093/emboj/16.11.3303; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; Wood RD, 1997, J BIOL CHEM, V272, P23465, DOI 10.1074/jbc.272.38.23465; Wood RD, 1996, ANNU REV BIOCHEM, V65, P135, DOI 10.1146/annurev.bi.65.070196.001031; ZMUDZKA BZ, 1988, NUCLEIC ACIDS RES, V16, P9589	39	73	82	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	1999	13	9					1107	1111		10.1096/fasebj.13.9.1107	http://dx.doi.org/10.1096/fasebj.13.9.1107			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	200NZ	10336894				2022-12-25	WOS:000080547700016
J	Hipfner, DR; Mao, QC; Qiu, W; Leslie, EM; Gao, M; Deeley, RG; Cole, SPC				Hipfner, DR; Mao, QC; Qiu, W; Leslie, EM; Gao, M; Deeley, RG; Cole, SPC			Monoclonal antibodies that inhibit the transport function of the 190-kDa multidrug resistance protein, MRP - Localization of their epitopes to the nucleotide-binding domains of the protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-TUMOR-CELLS; MOUSE P-GLYCOPROTEIN; HUMAN LUNG-CANCER; LEUKOTRIENE C-4; VINCRISTINE TRANSPORT; CASSETTE TRANSPORTER; MEMBRANE-VESICLES; EXPORT PUMP; EFFLUX PUMP; ATP	Multidrug resistance in tumor cells is often accompanied by overexpression of multidrug resistance protein (MRP), a 190-kDa transmembrane protein that belongs to the ATP-binding cassette superfamily of transport proteins. MRP mediates ATP-dependent transport of a variety of conjugated organic anions and can also transport several unmodified xenobiotics in a glutathione-dependent manner. To facilitate structure-function studies of MRP, we have generated a panel of MRP-specific monoclonal antibodies (mAbs), Four of these mAbs, QCRL-2, -3, -4, and -6, bind intracellular conformation-dependent epitopes, and we have shown that they can inhibit the transport of several MRP substrates, Binding competition and immunoprecipitation assays indicated that mAbs QCRL-4 and -6 probably recognize the same detergent-sensitive epitope in MRP, whereas mAbs QCRL-2, -3, and -4 each bind distinct, non-overlapping epitopes, Fab fragments inhibit transport as effectively as the intact mAbs, suggesting that inhibition results from direct interactions of the mAbs with MRP, Immunodot blot and immunoprecipitation analyses revealed that the minimal regions of MRP sufficient for full reactivity of mAbs QCRL-2 and -3 are amino acids 617-858 and 617-932, respectively, which encompass the NH2-proximal nucleotide-binding domain (NBD), In contrast, the epitope bound by mAb QCRL-4 localized to amino acids 1294-1531, a region that contains the COOH-proximal NBD. However, none of the mAbs inhibited photo-labeling of intact MRP with 8-azido-[alpha-P-32]ATP. This suggests that rather than preventing nucleotide binding, the mAbs inhibit transport by interfering with substrate binding or by trapping MRP in a conformation that does not allow transport to occur. Our results also demonstrate for the first time that the NBDs of MRP can be expressed as soluble polypeptides that retain a native conformation.	Queens Univ, Canc Res Labs, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Pathol, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Pharmacol & Toxicol, Kingston, ON K7L 3N6, Canada	Queens University - Canada; Queens University - Canada; Queens University - Canada	Cole, SPC (corresponding author), Queens Univ, Canc Res Labs, Botterell Hall, Kingston, ON K7L 3N6, Canada.		Cole, Susan P.C./I-6389-2017; Deeley, Roger/J-4828-2012	Cole, Susan P.C./0000-0001-6571-6884; Leslie, Elaine/0000-0003-1825-348X				Allikmets R, 1996, HUM MOL GENET, V5, P1649, DOI 10.1093/hmg/5.10.1649; ALMQUIST KC, 1995, CANCER RES, V55, P102; ARCECI RJ, 1993, CANCER RES, V53, P310; Barnouin K, 1998, BRIT J CANCER, V77, P201, DOI 10.1038/bjc.1998.34; BAUBICHONCORTAY H, 1994, J BIOL CHEM, V269, P22983; Chan HSL, 1997, J LAB CLIN MED, V130, P297, DOI 10.1016/S0022-2143(97)90025-1; Chan HSL, 1997, CANCER RES, V57, P2325; COLE SPC, 1994, CANCER RES, V54, P5902; Cole SPC, 1998, BIOESSAYS, V20, P931, DOI 10.1002/(SICI)1521-1878(199811)20:11<931::AID-BIES8>3.0.CO;2-J; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; CORNWELL MM, 1986, P NATL ACAD SCI USA, V83, P3847, DOI 10.1073/pnas.83.11.3847; Dayan G, 1996, J BIOL CHEM, V271, P11652, DOI 10.1074/jbc.271.20.11652; DEELEY RG, 1997, MOL GENETICS DRUG RE, P247; Filipits M, 1997, BRIT J CANCER, V75, P208, DOI 10.1038/bjc.1997.35; Filipits M, 1997, CLIN CANCER RES, V3, P1419; FLENS MJ, 1994, CANCER RES, V54, P4557; Flens MJ, 1996, AM J PATHOL, V148, P1237; Gao M, 1998, J BIOL CHEM, V273, P10733, DOI 10.1074/jbc.273.17.10733; Gao M, 1996, J BIOL CHEM, V271, P27782, DOI 10.1074/jbc.271.44.27782; GEORGES E, 1990, P NATL ACAD SCI USA, V87, P152, DOI 10.1073/pnas.87.1.152; GEORGES E, 1991, J CELL PHYSIOL, V148, P479, DOI 10.1002/jcp.1041480321; Gottesman MM, 1996, CURR OPIN GENET DEV, V6, P610, DOI 10.1016/S0959-437X(96)80091-8; GRANT CE, 1994, CANCER RES, V54, P357; HAMADA H, 1986, P NATL ACAD SCI USA, V83, P7785, DOI 10.1073/pnas.83.20.7785; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hipfner DR, 1997, J BIOL CHEM, V272, P23623, DOI 10.1074/jbc.272.38.23623; Hipfner DR, 1998, BRIT J CANCER, V78, P1134, DOI 10.1038/bjc.1998.642; Hipfner DR, 1996, CANCER RES, V56, P3307; HIPFNER DR, 1994, CANCER RES, V54, P5788; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; Ito K, 1998, ONCOL RES, V10, P99; Jedlitschky G, 1996, CANCER RES, V56, P988; KARTNER N, 1985, NATURE, V316, P820, DOI 10.1038/316820a0; KO YH, 1995, J BIOL CHEM, V270, P22093, DOI 10.1074/jbc.270.38.22093; Kokubu N, 1997, BIOCHEM BIOPH RES CO, V230, P398, DOI 10.1006/bbrc.1996.5970; LEIER I, 1994, EUR J BIOCHEM, V220, P599, DOI 10.1111/j.1432-1033.1994.tb18661.x; LEIER I, 1994, J BIOL CHEM, V269, P27807; LINCKE CR, 1990, CANCER RES, V50, P1779; Loe DW, 1997, MOL PHARMACOL, V51, P1034, DOI 10.1124/mol.51.6.1034; Loe DW, 1996, J BIOL CHEM, V271, P9683, DOI 10.1074/jbc.271.16.9683; Loe DW, 1998, CANCER RES, V58, P5130; Loe DW, 1996, J BIOL CHEM, V271, P9675, DOI 10.1074/jbc.271.16.9675; MECHETNER EB, 1992, P NATL ACAD SCI USA, V89, P5824, DOI 10.1073/pnas.89.13.5824; Mechetner EB, 1997, P NATL ACAD SCI USA, V94, P12908, DOI 10.1073/pnas.94.24.12908; MEYERS MB, 1989, CANCER RES, V49, P3209; MIRSKI SEL, 1987, CANCER RES, V47, P2594; MULLER M, 1994, P NATL ACAD SCI USA, V91, P13033, DOI 10.1073/pnas.91.26.13033; Renes J, 1999, BRIT J PHARMACOL, V126, P681, DOI 10.1038/sj.bjp.0702360; SHARMA S, 1995, J BIOL CHEM, V270, P14085, DOI 10.1074/jbc.270.23.14085; Sharom FJ, 1997, J MEMBRANE BIOL, V160, P161, DOI 10.1007/s002329900305; Stride BD, 1996, MOL PHARMACOL, V49, P962; Tusnady GE, 1997, FEBS LETT, V402, P1, DOI 10.1016/S0014-5793(96)01478-0; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Wright SR, 1998, CLIN CANCER RES, V4, P2279; ZAMAN GJR, 1994, P NATL ACAD SCI USA, V91, P8822, DOI 10.1073/pnas.91.19.8822	55	78	79	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15420	15426		10.1074/jbc.274.22.15420	http://dx.doi.org/10.1074/jbc.274.22.15420			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336431	hybrid			2022-12-25	WOS:000080560100020
J	Mori, K; Ogawa, Y; Ebihara, K; Tamura, N; Tashiro, K; Kuwahara, T; Mukoyama, M; Sugawara, A; Ozaki, S; Tanaka, I; Nakao, K				Mori, K; Ogawa, Y; Ebihara, K; Tamura, N; Tashiro, K; Kuwahara, T; Mukoyama, M; Sugawara, A; Ozaki, S; Tanaka, I; Nakao, K			Isolation and characterization of CA XIV, a novel membrane-bound carbonic anhydrase from mouse kidney	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL SEQUENCE TRAP; MOLECULAR-CLONING; II DEFICIENCY; CDNA CLONING; EXPRESSION; RECEPTOR; PROTEIN; LOCALIZATION; IV; EFFICIENT	Carbonic anhydrase (CA) is involved in various physiological processes such as acid-base balance and transport of carbon dioxide and ions. In this study, we have succeeded in the isolation of a novel CA from the mouse kidney by use of the signal sequence trap method. It is a 337-amino acid polypeptide with a calculated molecular mass of 37.5 kDa, consisting of a putative amino-terminal signal sequence, a CA domain, a transmembrane domain, and a short hydrophilic carboxyl terminus, which we designated CA XIV.(1) The CA domain of CA XIV is highly homologous with those of known CAs, especially extracellular CAs including CA XII, IX, VI, and IV. The expression study of an epitope-tagged protein has suggested that CA XIV is located on the plasma membrane. When expressed in COS-7 cells, CA XIV exhibits CA activity that is predominantly associated with the membrane fraction. By Northern blot analysis, the gene expression of CA XIV is most abundant in the kidney and heart, followed by the skeletal muscle, brain, lung, and liver. In situ hybridization has revealed that, in the kidney, the gene is expressed intensely in the proximal convoluted tubule, which is the major segment for bicarbonate reabsorption and also in the outer border of the inner stripe of the outer medulla. In conclusion, we have cloned a functional cDNA encoding a novel membrane-bound CA. This study will bring new insights into our understanding of carbon dioxide metabolism and acid-base balance.	Kyoto Univ, Grad Sch Med, Dept Med & Clin Sci, Sakyo Ku, Kyoto, Japan; Kyoto Univ, Ctr Mol Biol & Genet, Sakyo Ku, Kyoto 6068057, Japan; Saiseikai Nakatsu Hosp, Dept Nephrol, Kita Ku, Osaka 5300012, Japan	Kyoto University; Kyoto University	Ogawa, Y (corresponding author), Kyoto Univ, Grad Sch Med, Dept Med & Clin Sci, Sakyo Ku, 54 Shogoin Kawahara cho, Kyoto, Japan.	ogawa@kuhp.kyoto-u.ac.jp	Mori, Kiyoshi/N-1267-2014	Mori, Kiyoshi/0000-0002-7285-8351; Ogawa, Yoshihiro/0000-0002-0834-2836				ALPERN RJ, 1996, BRENNER RECTORS KIDN, P408; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BARNEA G, 1993, MOL CELL BIOL, V13, P1497, DOI 10.1128/MCB.13.3.1497; BROWN D, 1990, P NATL ACAD SCI USA, V87, P7457, DOI 10.1073/pnas.87.19.7457; BROWN D, 1983, AM J PHYSIOL, V245, pF110, DOI 10.1152/ajprenal.1983.245.1.F110; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DOBYAN DC, 1982, ANAT REC, V204, P185, DOI 10.1002/ar.1092040303; FERNLEY RT, 1988, BIOCHEMISTRY-US, V27, P2815, DOI 10.1021/bi00408a023; FLEMING RE, 1993, AM J PHYSIOL, V265, pL627, DOI 10.1152/ajplung.1993.265.6.L627; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HewettEmmett D, 1996, MOL PHYLOGENET EVOL, V5, P50, DOI 10.1006/mpev.1996.0006; Imai T, 1996, J BIOL CHEM, V271, P21514, DOI 10.1074/jbc.271.35.21514; Ivanov SV, 1998, P NATL ACAD SCI USA, V95, P12596, DOI 10.1073/pnas.95.21.12596; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mori K, 1997, FEBS LETT, V401, P218, DOI 10.1016/S0014-5793(96)01473-1; Mori K, 1997, FEBS LETT, V417, P371, DOI 10.1016/S0014-5793(97)01325-2; NAKAMURA T, 1995, GENOMICS, V30, P312, DOI 10.1006/geno.1995.9872; Nei M., 1987, MOL EVOLUT GENET, P293; NIKAIDO T, 1984, NATURE, V311, P631, DOI 10.1038/311631a0; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OKUYAMA T, 1992, P NATL ACAD SCI USA, V89, P1315, DOI 10.1073/pnas.89.4.1315; PASTOREK J, 1994, ONCOGENE, V9, P2877; PELES E, 1995, CELL, V82, P251, DOI 10.1016/0092-8674(95)90312-7; RIDDERSTRALE Y, 1992, J HISTOCHEM CYTOCHEM, V40, P1665, DOI 10.1177/40.11.1431055; SCHWARTZ MM, 1974, KIDNEY INT, V6, pA93, DOI 10.1038/ki.1974.101; SLY WS, 1985, NEW ENGL J MED, V313, P139, DOI 10.1056/NEJM198507183130302; SLY WS, 1995, ANNU REV BIOCHEM, V64, P375, DOI 10.1146/annurev.bi.64.070195.002111; SPICER SS, 1979, J HISTOCHEM CYTOCHEM, V27, P820, DOI 10.1177/27.4.109495; SUGIMOTO Y, 1994, AM J PHYSIOL, V266, pF823, DOI 10.1152/ajprenal.1994.266.5.F823; SUNDARAM V, 1986, AM J HUM GENET, V38, P125; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TASHIAN RE, 1992, ADV GENET, V30, P321, DOI 10.1016/S0065-2660(08)60323-5; TASHIAN RE, 1989, BIOESSAYS, V10, P186, DOI 10.1002/bies.950100603; TASHIRO K, 1993, SCIENCE, V261, P600, DOI 10.1126/science.8342023; Tashiro K, 1997, Methods Mol Biol, V69, P203; Tsuruoka S, 1998, AM J PHYSIOL-RENAL, V274, pF259, DOI 10.1152/ajprenal.1998.274.2.F259; Tureci O, 1998, P NATL ACAD SCI USA, V95, P7608, DOI 10.1073/pnas.95.13.7608; UCHIYAMA T, 1981, J IMMUNOL, V126, P1393; YOSHIDA T, 1995, FEBS LETT, V360, P155, DOI 10.1016/0014-5793(95)00093-O; ZHU XL, 1990, J BIOL CHEM, V265, P8795	43	106	110	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15701	15705		10.1074/jbc.274.22.15701	http://dx.doi.org/10.1074/jbc.274.22.15701			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336468	hybrid			2022-12-25	WOS:000080560100057
J	Shimamoto, N				Shimamoto, N			One-dimensional diffusion of proteins along DNA - Its biological and chemical significance revealed by single-molecule measurements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							REPRESSOR-OPERATOR INTERACTION; COLI RNA-POLYMERASE; RESTRICTION-ENDONUCLEASE ECORI; IRRADIATED ESCHERICHIA-COLI; INITIATED EXCISION REPAIR; LAC REPRESSOR; LINEAR DIFFUSION; FACILITATED DIFFUSION; ASSOCIATION KINETICS; DRIVEN MECHANISMS	Evidence for sliding of proteins along DNA has been provided by many kinetic studies, but single-molecule-based measurements have uncovered distinct problems, the solutions of which may lead us to an understanding of new mechanisms for gene regulation. Furthermore, they reveal a deep problem lying between chemistry and physics regarding the seemingly simple binding between DNA and protein. Single-molecule dynamics provides a tool to solve this problem without prejudgments or unsound assumptions.	Natl Inst Genet, Struct Biol Ctr, Mishima, Shizuoka 4118540, Japan	Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan	Shimamoto, N (corresponding author), Natl Inst Genet, Struct Biol Ctr, Mishima, Shizuoka 4118540, Japan.		Shimamoto, Nobuo/AAJ-4999-2020	Shimamoto, Nobuo/0000-0001-7579-0084				BARKLEY MD, 1981, BIOCHEMISTRY-US, V20, P3833, DOI 10.1021/bi00516a026; BELINTSEV BN, 1980, NUCLEIC ACIDS RES, V8, P1391, DOI 10.1093/nar/8.6.1391; BERG OG, 1981, BIOCHEMISTRY-US, V20, P6929, DOI 10.1021/bi00527a028; BERG OG, 1978, BIOPHYS CHEM, V8, P271, DOI 10.1016/0301-4622(78)80010-6; BERG OG, 1982, BIOPHYS CHEM, V15, P41, DOI 10.1016/0301-4622(82)87015-4; Berkhout B, 1996, J BIOL CHEM, V271, P1837, DOI 10.1074/jbc.271.4.1837; EHBRECHT HJ, 1985, J BIOL CHEM, V260, P6160; FICKERT R, 1992, J MOL BIOL, V226, P59, DOI 10.1016/0022-2836(92)90124-3; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; Gelles J, 1998, CELL, V93, P13, DOI 10.1016/S0092-8674(00)81140-X; GRUSKIN EA, 1988, J BIOL CHEM, V263, P12738; GRUSKIN EA, 1988, J BIOL CHEM, V263, P12728; Hsieh M, 1997, J BIOL CHEM, V272, P22092, DOI 10.1074/jbc.272.35.22092; JACK WE, 1982, P NATL ACAD SCI-BIOL, V79, P4010, DOI 10.1073/pnas.79.13.4010; JELTSCH A, 1994, BIOCHEMISTRY-US, V33, P10215, DOI 10.1021/bi00200a001; Jeltsch A, 1996, EMBO J, V15, P5104, DOI 10.1002/j.1460-2075.1996.tb00891.x; JELTSCH A, 1993, ANAL BIOCHEM, V213, P234, DOI 10.1006/abio.1993.1415; KABATA H, 1993, SCIENCE, V262, P1561, DOI 10.1126/science.8248804; KHOURY AM, 1990, BIOCHIM BIOPHYS ACTA, V1087, P55, DOI 10.1016/0167-4781(90)90120-Q; KIM JG, 1987, J MOL BIOL, V196, P149, DOI 10.1016/0022-2836(87)90517-1; LANGOWSKI J, 1983, NUCLEIC ACIDS RES, V11, P501, DOI 10.1093/nar/11.2.501; LEE SP, 1995, BIOCHEMISTRY-US, V34, P10215, DOI 10.1021/bi00032a015; Lieberman BA, 1997, J BIOL CHEM, V272, P1061, DOI 10.1074/jbc.272.2.1061; LLOYD RS, 1980, NUCLEIC ACIDS RES, V8, P5113, DOI 10.1093/nar/8.21.5113; LOHMAN TM, 1978, BIOPHYS CHEM, V8, P281, DOI 10.1016/0301-4622(78)80011-8; NARDONE G, 1986, J BIOL CHEM, V261, P2128; PARK CS, 1982, J BIOL CHEM, V257, P6944; RICCHETTI M, 1988, P NATL ACAD SCI USA, V85, P4610, DOI 10.1073/pnas.85.13.4610; RIGGS AD, 1970, J MOL BIOL, V53, P401, DOI 10.1016/0022-2836(70)90074-4; RUUSALA T, 1992, P NATL ACAD SCI USA, V89, P4903, DOI 10.1073/pnas.89.11.4903; SCHUCK P, 1997, ANNU REV BIOPH BIOM, V26, P539; SHIMAMOTO N, 1992, STRUCTURAL TOOLS ANA, P241; SINGER P, 1987, J BIOL CHEM, V262, P14178; SINGER PT, 1988, J BIOL CHEM, V263, P4208; Surby MA, 1996, BIOCHEMISTRY-US, V35, P2209, DOI 10.1021/bi951884f; Surby MA, 1996, BIOCHEMISTRY-US, V35, P2201, DOI 10.1021/bi951883n; TERRY BJ, 1985, J BIOL CHEM, V260, P3130; van Noort SJT, 1998, BIOPHYS J, V74, P2840, DOI 10.1016/S0006-3495(98)77991-3; VONHIPPEL PH, 1989, J BIOL CHEM, V264, P675; WASHIZU M, 1995, IEEE T IND APPL, V31, P447, DOI 10.1109/28.382102; WINTER RB, 1981, BIOCHEMISTRY-US, V20, P6961, DOI 10.1021/bi00527a030; WINTER RB, 1981, BIOCHEMISTRY-US, V20, P6948, DOI 10.1021/bi00527a029; Yang SW, 1995, EMBO J, V14, P6292, DOI 10.1002/j.1460-2075.1995.tb00319.x	44	137	138	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15293	15296		10.1074/jbc.274.22.15293	http://dx.doi.org/10.1074/jbc.274.22.15293			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336412	hybrid			2022-12-25	WOS:000080560100001
J	Budhram-Mahadeo, V; Morris, PJ; Smith, MD; Midgley, CA; Boxer, LM; Latchman, DS				Budhram-Mahadeo, V; Morris, PJ; Smith, MD; Midgley, CA; Boxer, LM; Latchman, DS			p53 suppresses the activation of the Bcl-2 promoter by the Brn-3a POU family transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; NEURONAL CELLS; FUNCTIONAL-ANALYSIS; HUMAN NEUROBLASTOMA; ESTROGEN-RECEPTOR; RESPONSE ELEMENT; ALPHA-INTERNEXIN; CELLULAR DEATH; APOPTOSIS; GROWTH	The Brn-3a POU family transcription factor has been shown to strongly activate expression of the Bcl-2 protooncogene and thereby protect neuronal cells from programmed cell death (apoptosis), This activation of the Bcl-2 promoter by Brn-3a is strongly inhibited by the p53 anti-oncogene protein. This inhibitory effect of p53 on Brn-3a-mediated transactivation is observed with nonoverlapping gene fragments containing either the Bcl-2 pi or p2 promoters but is not observed with other Brn-3a-activated promoters such as in the gene encoding alpha-internexin or with an isolated Bm-Sa binding site from the Bcl-2 promoter linked to a heterologous promoter. In contrast, p53 mutants, which are incapable of binding to DNA, do not affect Brn-3a-mediated activation of the Bcl-2 pi and p2 promoters. Moreover, Brn-3a and p53 have been shown to bind to adjacent sites in the p2 promoter and to directly interact with one another, both in vitro and in vivo, with this interaction being mediated by the POU domain of Brn-3a and the DNA binding domain of p53, The significance of these effects is discussed in terms of the antagonistic effects of Bcl-2 and p53 on the rate of apoptosis and the overexpression of Brn-3a in specific tumor cell types.	UCL, Sch Med, Windeyer Inst Med Sci, Dept Mol Pathol, London W1P 6DB, England; Univ Dundee, Dept Biochem, Dundee DD1 5EH, Scotland; Stanford Univ, Med Ctr, Dept Med, Stanford, CA 94305 USA	University of London; University College London; UCL Medical School; University of Dundee; Stanford University	Latchman, DS (corresponding author), UCL, Sch Med, Windeyer Inst Med Sci, Dept Mol Pathol, Windeyer Bldg,46 Cleveland St, London W1P 6DB, England.	windinst@ucl.ac.uk						Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; BANIAHMAD C, 1995, MOL ENDOCRINOL, V9, P34, DOI 10.1210/me.9.1.34; Budhram-Mahadeo V, 1998, MOL CELL BIOL, V18, P1029, DOI 10.1128/MCB.18.2.1029; BUDHRAMMAHADEO V, 1995, J BIOL CHEM, V270, P2853, DOI 10.1074/jbc.270.6.2853; CHEN HM, 1995, MOL CELL BIOL, V15, P3840; CHING GY, 1991, J BIOL CHEM, V266, P19459; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; GORMAN CM, 1985, DNA CLONING PRACTICA, P143; Harn HJ, 1996, HISTOPATHOLOGY, V28, P317, DOI 10.1046/j.1365-2559.1996.d01-431.x; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Hoehner JC, 1997, BRIT J CANCER, V75, P1185, DOI 10.1038/bjc.1997.203; HOEHNER JC, 1995, INT J CANCER, V62, P19, DOI 10.1002/ijc.2910620106; Ibrahim AP, 1997, BBA-GENE STRUCT EXPR, V1350, P306, DOI 10.1016/S0167-4781(96)00170-4; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Latchman DS, 1997, INT J ONCOL, V10, P1133; LeblondFrancillard M, 1997, J CLIN ENDOCR METAB, V82, P89, DOI 10.1210/jc.82.1.89; Lee WY, 1996, ANTICANCER RES, V16, P3007; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LILLYCROP KA, 1992, NUCLEIC ACIDS RES, V20, P5093, DOI 10.1093/nar/20.19.5093; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Marcellus RC, 1996, CELL GROWTH DIFFER, V7, P1643; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MIYASHITA T, 1994, CANCER RES, V54, P3131; MORRIS PJ, 1994, MOL CELL BIOL, V14, P6907, DOI 10.1128/MCB.14.10.6907; Ndisdang D, 1998, J CLIN INVEST, V101, P1687, DOI 10.1172/JCI1089; NISSIM A, 1994, EMBO J, V13, P692, DOI 10.1002/j.1460-2075.1994.tb06308.x; Oue T, 1996, J PEDIATR SURG, V31, P251, DOI 10.1016/S0022-3468(96)90009-3; PARK DJ, 1994, ONCOGENE, V9, P1899; REED JC, 1991, CANCER RES, V51, P6529; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Smith MD, 1996, INT J CANCER, V67, P653; Smith MD, 1998, J BIOL CHEM, V273, P16715, DOI 10.1074/jbc.273.27.16715; Smith MD, 1998, NUCLEIC ACIDS RES, V26, P4100, DOI 10.1093/nar/26.18.4100; THEIL T, 1993, NUCLEIC ACIDS RES, V21, P5921, DOI 10.1093/nar/21.25.5921; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; Wang TTY, 1997, CANCER LETT, V116, P61, DOI 10.1016/S0304-3835(97)00175-4; WOOD JN, 1990, P ROY SOC B-BIOL SCI, V241, P187, DOI 10.1098/rspb.1990.0084	40	128	128	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					15237	15244		10.1074/jbc.274.21.15237	http://dx.doi.org/10.1074/jbc.274.21.15237			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329733	hybrid			2022-12-25	WOS:000081965200098
J	He, GP; Kim, SW; Ro, HS				He, GP; Kim, SW; Ro, HS			Cloning and characterization of a novel zinc finger transcriptional repressor - A direct role of the zinc finger motif in repression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER BINDING-PROTEIN; GENE-EXPRESSION; ADIPOCYTE DIFFERENTIATION; FACTOR EGR-1; P2 GENE; KRUPPEL; CELLS; DOMAINS; DNA; YY1	We have identified a novel transcriptional repressor, AEBP2, that binds to a regulatory sequence (termed AE-1) located in the proximal promoter region of the aP2 gene that encodes the adipose fatty acid-binding protein. Sequence analysis of AEBP2 cDNA revealed that it encodes a protein containing three Gli-Kruppel (Cys(2)-His(2))-type zinc fingers. Northern blot analysis revealed two transcripts (4.5 and 3.5 kilobases) which were ubiquitously expressed in every mouse tissue examined. In co-transfection assays, AEBP2 repressed transcription from the homologous aP2 promoter containing multiple copies of the AE-1 sequence. Moreover, a chimeric construct encoding a fusion AEBP2 protein with the Gal4 DNA-binding domain was able to repress the transcriptional activity of a heterologous promoter containing the Gal4-binding sequence. The transcriptional repression function of AEBP2 was completely abolished when one of the conserved histidine residues and a flanking serine residue in the middle zinc finger were replaced with an arginine residue. The defective transcriptional repression function of the mutant derivative was due neither to lack of expression nor to a failure to localize to the nucleus. Moreover, both the wild-type and mutant derivative of either the histidine-tagged recombinant AEBP2 proteins or the in vitro translated Gal4-AEBP2 fusion proteins were equally able to bind to the target DNA. These results suggest that a portion of the zinc finger structure may play a direct role in transcriptional repression function, but not in DNA binding.	Dalhousie Univ, Fac Med, Dept Biochem, Halifax, NS B3H 4H7, Canada	Dalhousie University	Ro, HS (corresponding author), Dalhousie Univ, Fac Med, Dept Biochem, Sir Charles Tupper Med Bldg, Halifax, NS B3H 4H7, Canada.			Ro, Hyo-Sung/0000-0003-4411-0386				BROWN RS, 1985, FEBS LETT, V186, P271, DOI 10.1016/0014-5793(85)80723-7; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; CORNELIUS P, 1994, ANNU REV NUTR, V14, P99, DOI 10.1146/annurev.nu.14.070194.000531; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; HE GP, 1995, NATURE, V378, P92, DOI 10.1038/378092a0; HERRERA R, 1989, MOL CELL BIOL, V9, P5331, DOI 10.1128/MCB.9.12.5331; HUNT CR, 1986, P NATL ACAD SCI USA, V83, P3786, DOI 10.1073/pnas.83.11.3786; JAYNES JB, 1991, EMBO J, V10, P1427, DOI 10.1002/j.1460-2075.1991.tb07663.x; Jiang SW, 1996, J BIOL CHEM, V271, P9510, DOI 10.1074/jbc.271.16.9510; JOHNSON AD, 1995, CELL, V81, P655, DOI 10.1016/0092-8674(95)90524-3; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LEE JS, 1995, NUCLEIC ACIDS RES, V23, P925, DOI 10.1093/nar/23.6.925; LICHT JD, 1990, NATURE, V346, P76, DOI 10.1038/346076a0; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; MARGOLIN JF, 1994, P NATL ACAD SCI USA, V91, P4509, DOI 10.1073/pnas.91.10.4509; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; Ostling J, 1996, MOL CELL BIOL, V16, P753; PERROTTI D, 1995, MOL CELL BIOL, V15, P6075; RO HS, 1991, MOL CELL BIOL, V11, P2303, DOI 10.1128/MCB.11.4.2303; SAUER F, 1995, NATURE, V375, P162, DOI 10.1038/375162a0; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; Seyfert VL, 1996, ONCOGENE, V12, P2331; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; WILLIAMS AJ, 1995, J BIOL CHEM, V270, P22143, DOI 10.1074/jbc.270.38.22143; WITZGALL R, 1994, P NATL ACAD SCI USA, V91, P4514, DOI 10.1073/pnas.91.10.4514; XU L, 1994, NUCLEIC ACIDS RES, V22, P646, DOI 10.1093/nar/22.4.646; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; ZUO P, 1991, GENE DEV, V5, P254, DOI 10.1101/gad.5.2.254	34	41	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					14678	14684		10.1074/jbc.274.21.14678	http://dx.doi.org/10.1074/jbc.274.21.14678			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329662	hybrid			2022-12-25	WOS:000081965200027
J	Varlamov, O; Eng, FJ; Novikova, EG; Fricker, LD				Varlamov, O; Eng, FJ; Novikova, EG; Fricker, LD			Localization of metallocarboxypeptidase D in AtT-20 cells - Potential, role in prohormone processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B VIRUS-PARTICLES; IMMATURE SECRETORY GRANULES; TRANS-GOLGI NETWORK; OBESE FAT/FAT MICE; CARBOXYPEPTIDASE-E; INTRACELLULAR TRAFFICKING; MEMBRANE-PROTEIN; ENZYME-ACTIVITY; FAT MUTATION; VESICLES	Carboxypeptidase D (CPD) is a recently discovered metallocarboxypeptidase that is predominantly located in the trans-Golgi network (TGN), and also cycles between the cell surface and the TGN. In the present study, the intracellular distribution of CPD was examined in AtT-20 cells, a mouse anterior pituitary-derived corticotroph. CPD-containing compartments were isolated using antibodies to the CPD cytosolic tail. The immunopurified vesicles contained TGN proteins (TGN38, furin, syntaxin 6) but not lysosomal or plasma membrane proteins. The CPD containing vesicles also contained neuropeptide-processing enzymes and adrenocorticotropic hormone, a product of proopiomelanocortin proteolysis. Electron microscopic analysis revealed that CPD is present within the TGN and immature secretory granules but is virtually absent from mature granules, suggesting that CPD is actively removed from the regulated pathway during the process of granule maturation. A second major finding of the present study is that a soluble truncated form of CPD is secreted mainly via the constitutive pathway in AtT-20 cells, indicating that the lumenal domain does not contain signals for the sorting of CPD to mature secretory granules. Taken together, these data are consistent with the proposal that CPD participates in the processing of proteins within the TGN and immature secretory vesicles.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Fricker, LD (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051271] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [K02DA000194] Funding Source: NIH RePORTER; NIDA NIH HHS [K02 DA-00194] Funding Source: Medline; NIDDK NIH HHS [R01 DK-51271] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Cain BM, 1997, ENDOCRINOLOGY, V138, P4034, DOI 10.1210/en.138.9.4034; Davanger S, 1997, MOL BIOL CELL, V8, P1261, DOI 10.1091/mbc.8.7.1261; Dittie AS, 1997, EMBO J, V16, P4859, DOI 10.1093/emboj/16.16.4859; DOCHERTY K, 1983, FEBS LETT, V162, P137, DOI 10.1016/0014-5793(83)81065-5; Dong W, 1999, NEUROSCIENCE, V89, P1301, DOI 10.1016/S0306-4522(98)00381-9; Eng FJ, 1998, J BIOL CHEM, V273, P8382, DOI 10.1074/jbc.273.14.8382; Eng FJ, 1999, MOL BIOL CELL, V10, P35, DOI 10.1091/mbc.10.1.35; Fan XM, 1999, DNA CELL BIOL, V18, P121, DOI 10.1089/104454999315501; Fernandez CJ, 1997, MOL BIOL CELL, V8, P2171, DOI 10.1091/mbc.8.11.2171; Fricker LD, 1996, J BIOL CHEM, V271, P30619, DOI 10.1074/jbc.271.48.30619; FRICKER LD, 1988, ANNU REV PHYSIOL, V50, P309, DOI 10.1146/annurev.ph.50.030188.001521; FRICKER LD, 1982, P NATL ACAD SCI-BIOL, V79, P3886, DOI 10.1073/pnas.79.12.3886; FRICKER LD, 1991, PEPTIDE BIOSYNTHESIS, P199; GREENE D, 1992, BIOCHEM J, V285, P613, DOI 10.1042/bj2850613; GUEST PC, 1991, ENDOCRINOLOGY, V129, P734, DOI 10.1210/endo-129-2-734; Hohl I, 1996, J CELL SCI, V109, P2539; HOOK VYH, 1984, P NATL ACAD SCI-BIOL, V81, P2776, DOI 10.1073/pnas.81.9.2776; HORNBY PJ, 1993, NEUROENDOCRINOLOGY, V58, P555, DOI 10.1159/000126590; Klumperman J, 1998, J CELL BIOL, V141, P359, DOI 10.1083/jcb.141.2.359; KOEDAM JA, 1992, J CELL BIOL, V116, P617, DOI 10.1083/jcb.116.3.617; KUROKI K, 1995, J BIOL CHEM, V270, P15022, DOI 10.1074/jbc.270.25.15022; KUROKI K, 1994, J VIROL, V68, P2091, DOI 10.1128/JVI.68.4.2091-2096.1994; LUZIO JP, 1990, BIOCHEM J, V270, P97, DOI 10.1042/bj2700097; MATSUUCHI L, 1988, J CELL BIOL, V106, P239, DOI 10.1083/jcb.106.2.239; MILGRAM SL, 1992, J CELL BIOL, V117, P717, DOI 10.1083/jcb.117.4.717; MILGRAM SL, 1994, J CELL SCI, V107, P737; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; NAGGERT JK, 1995, NAT GENET, V10, P135, DOI 10.1038/ng0695-135; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; ORCI L, 1987, CELL, V49, P865, DOI 10.1016/0092-8674(87)90624-6; Rovere C, 1996, ENDOCRINOLOGY, V137, P2954, DOI 10.1210/en.137.7.2954; Sambrook J., 2002, MOL CLONING LAB MANU; SCHNABEL E, 1989, MOL ENDOCRINOL, V3, P1223, DOI 10.1210/mend-3-8-1223; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; SETTLE SH, 1995, P NATL ACAD SCI USA, V92, P9470, DOI 10.1073/pnas.92.21.9470; SHENNAN KIJ, 1995, J BIOL CHEM, V270, P1402, DOI 10.1074/jbc.270.3.1402; SONG LX, 1995, J BIOL CHEM, V270, P25007, DOI 10.1074/jbc.270.42.25007; Song LX, 1996, J BIOL CHEM, V271, P28884, DOI 10.1074/jbc.271.46.28884; STEINER DF, 1992, J BIOL CHEM, V267, P23435; Tan FL, 1997, BIOCHEM J, V327, P81, DOI 10.1042/bj3270081; Tanaka S, 1997, J HISTOCHEM CYTOCHEM, V45, P425, DOI 10.1177/002215549704500310; Thorens B, 1996, J CELL SCI, V109, P1311; TOOZE J, 1986, J CELL BIOL, V103, P839, DOI 10.1083/jcb.103.3.839; TOOZE SA, 1991, J CELL BIOL, V115, P1491, DOI 10.1083/jcb.115.6.1491; Udupi V, 1997, ENDOCRINOLOGY, V138, P1959, DOI 10.1210/en.138.5.1959; Varlamov O, 1998, J CELL SCI, V111, P877; Varlamov O, 1996, J BIOL CHEM, V271, P13981, DOI 10.1074/jbc.271.24.13981; Xin XN, 1997, DNA CELL BIOL, V16, P897, DOI 10.1089/dna.1997.16.897; ZHOU A, 1993, J BIOL CHEM, V268, P1763	49	67	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					14759	14767		10.1074/jbc.274.21.14759	http://dx.doi.org/10.1074/jbc.274.21.14759			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329672	hybrid			2022-12-25	WOS:000081965200037
J	Miyaki, M; Iijima, T; Konishi, M; Sakai, K; Ishii, A; Yasuno, M; Hishima, T; Koike, M; Shitara, N; Iwama, T; Utsunomiya, J; Kuroki, T; Mori, T				Miyaki, M; Iijima, T; Konishi, M; Sakai, K; Ishii, A; Yasuno, M; Hishima, T; Koike, M; Shitara, N; Iwama, T; Utsunomiya, J; Kuroki, T; Mori, T			Higher frequency of Smad4 gene mutation in human colorectal cancer with distant metastasis	ONCOGENE			English	Article						Smad4 gene; Smad genes; somatic mutation; distant metastasis; colorectal cancer	FAMILIAL ADENOMATOUS POLYPOSIS; DPC4 SMAD4; TUMORS; IDENTIFICATION; TUMORIGENESIS; CARCINOMAS	We have previously detected an increased frequency of loss of heterozygosity (LOH) on chromosome 18q during progression of colorectal carcinomas. To clarify the target of 18qLOH, mutation of Smad4 and Smad2 genes was analysed in 176 colorectal tumors with different stages, including liver metastasis, from 111 sporadic, 52 familial adenomatous polyposis (FAP) and nine hereditary nonpolyposis colorectal cancer (HNPCC) patients. Mutation of other Smad gene families in the TGF-beta signaling pathway was also examined. Twenty-one Smad4 mutations and one Smad2 mutation mere detected, whereas mutation of Smad3, 6 and 7 genes was not detected. Smad4 mutations included seven frameshift, one inframe deletion, four nonsense and nine missense mutations, 95% of which resulted in alteration of Smad4 protein regions included in homo-oligomer and hetero-oligomer formation. Frequencies of tumors with Smad4 mutation were 0/40 (0%) in adenoma, 4/39 (10%) in intramucosal carcinoma, 3/44 (7%) in primary invasive carcinoma,without distant metastasis, 6/17 (35%) in primary invasive carcinoma with distant metastasis, and 11/36 (31%) in distant metastasis (metastatic/non-metastatic: P=0.006 similar to 0.01). Loss of the other allele was observed in 19 of 20 (95%) invasive and metastasized carcinomas with Smad4 mutations. In four eases both primary and metastasized carcinomas in the same patients showed the same mutations. The present results suggest that Smad4 gene is one of true targets of 18qLOH, and that its inactivation is involved in advanced stages, such as distant metastasis, in human colorectal carcinogenesis.	Tokyo Metropolitan Komagome Hosp, Hereditary Tumor Res Project, Tokyo 1138677, Japan; Tokyo Metropolitan Komagome Hosp, Dept Surg, Tokyo 1138677, Japan; Tokyo Metropolitan Komagome Hosp, Dept Pathol, Tokyo 1138677, Japan; Tokyo Metropolitan Komagome Hosp, Dept Neurosurg, Tokyo 1138677, Japan; Showa Univ, Inst Mol Oncol, Tokyo 1428555, Japan; Kyoundo Hosp, Dept Surg, Sasaki Inst, Tokyo 1010062, Japan; Hyogo Coll Med, Nishinomiya, Hyogo 6638501, Japan	Tokyo Metropolitan Cancer & Infectious Diseases Center Komagome Hospital; Tokyo Metropolitan Cancer & Infectious Diseases Center Komagome Hospital; Tokyo Metropolitan Cancer & Infectious Diseases Center Komagome Hospital; Tokyo Metropolitan Cancer & Infectious Diseases Center Komagome Hospital; Showa University; Hyogo College of Medicine	Miyaki, M (corresponding author), Tokyo Metropolitan Komagome Hosp, Hereditary Tumor Res Project, Tokyo 1138677, Japan.		Kuroki, Toshio/A-9500-2011	Kuroki, Toshio/0000-0001-6369-4351				CHO KR, 1994, GENOMICS, V19, P525, DOI 10.1006/geno.1994.1102; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HAHN SA, 1995, CANCER RES, V55, P4670; Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086; KIKUCHIYANOSHITA R, 1992, CANCER RES, V52, P3965; KIKUCHIYANOSHITA R, 1992, CANCER RES, V52, P3801; Konishi M, 1996, GASTROENTEROLOGY, V111, P307, DOI 10.1053/gast.1996.v111.pm8690195; MacGrogan D, 1997, ONCOGENE, V15, P1111, DOI 10.1038/sj.onc.1201232; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; MIYAKI M, 1994, CANCER RES, V54, P3011; MIYAKI M, 1990, CANCER RES, V50, P7166; MIYAKI M, 1995, CRIT REV ONCOL HEMAT, V19, P1, DOI 10.1016/1040-8428(94)00129-H; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; Riggins GJ, 1996, NAT GENET, V13, P347, DOI 10.1038/ng0796-347; Schutte M, 1996, CANCER RES, V56, P2527; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; Takagi Y, 1996, GASTROENTEROLOGY, V111, P1369, DOI 10.1053/gast.1996.v111.pm8898652; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	25	329	354	1	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 20	1999	18	20					3098	3103		10.1038/sj.onc.1202642	http://dx.doi.org/10.1038/sj.onc.1202642			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	197WB	10340381	Bronze			2022-12-25	WOS:000080388000005
J	Grossberger, R; Gieffers, C; Zachariae, W; Podtelejnikova, AV; Schleiffer, A; Nasmyth, K; Mann, M; Peters, JM				Grossberger, R; Gieffers, C; Zachariae, W; Podtelejnikova, AV; Schleiffer, A; Nasmyth, K; Mann, M; Peters, JM			Characterization of the DOC1/APC10 subunit of the yeast and the human anaphase-promoting complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEIN LIGASE; END RULE PATHWAY; SACCHAROMYCES-CEREVISIAE; FISSION YEAST; RECOGNITION COMPONENT; MEDIATES ASSOCIATION; POLYACRYLAMIDE GELS; MASS-SPECTROMETRY; CRYSTAL-STRUCTURE; MITOTIC SPINDLE	The anaphase-promoting complex/cyclosome (APC) is a ubiquitin-protein ligase whose activity is essential for progression through mitosis. The vertebrate APC is thought to be composed of 8 subunits, whereas in budding yeast several additional APC-associated proteins have been identified, including a 33-kDa protein called Doc1 or Apc10, Here, we show that Doc1/Apc10 is a subunit of the yeast APC throughout the cell cycle. Mutation of Doc1/Apc10 inactivates the APC without destabilizing the complex, An ortholog of Doc1/Apc10, which we call APC10, is associated with the APC in different vertebrates, including humans and frogs. Biochemical fractionation experiments and mass spectrometric analysis of a component of the purified human APC show that APC10 is a genuine APC subunit whose cellular levels or association with the APC are not cell cycle-regulated, We have further identified an APC10 homology region, which we propose to call the DOC domain, in several protein sequences that also contain either cullin or HECT domains. Cullins are present in several ubiquitination complexes including the APC, whereas HECT domains represent the catalytic core of a different type of ubiquitin-protein ligase, DOC domains may therefore be important for reactions catalyzed by several types of ubiquitin-protein ligases.	Res Inst Mol Pathol, A-1030 Vienna, Austria; Odense Univ, Univ So Denmark, Prot Interact Lab, DK-5230 Odense M, Denmark	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); University of Southern Denmark	Peters, JM (corresponding author), Res Inst Mol Pathol, Dr Bohr Gasse 7, A-1030 Vienna, Austria.		Mann, Matthias/A-3454-2013	Mann, Matthias/0000-0003-1292-4799; Nasmyth, Kim/0000-0001-7030-4403; Schleiffer, Alexander/0000-0001-6251-2747				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; Borden KLB, 1996, CURR OPIN STRUC BIOL, V6, P395, DOI 10.1016/S0959-440X(96)80060-1; Charles JF, 1998, CURR BIOL, V8, P497, DOI 10.1016/S0960-9822(98)70201-5; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871; Fang GW, 1998, MOL CELL, V2, P163, DOI 10.1016/S1097-2765(00)80126-4; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; Guo QB, 1998, P NATL ACAD SCI USA, V95, P9172, DOI 10.1073/pnas.95.16.9172; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; HUIBREGTSE JM, 1998, UBIQUITIN BIOL CELL, P323; Hwang LH, 1997, MOL BIOL CELL, V8, P1877, DOI 10.1091/mbc.8.10.1877; IMIGER S, 1995, CELL, V81, P269; IRNIGER S, 1998, CELL, V93; Ishikawa K, 1998, DNA Res, V5, P169, DOI 10.1093/dnares/5.3.169; Ji YG, 1999, HUM MOL GENET, V8, P533, DOI 10.1093/hmg/8.3.533; Juang YL, 1997, SCIENCE, V275, P1311, DOI 10.1126/science.275.5304.1311; Kallio M, 1998, J CELL BIOL, V141, P1393, DOI 10.1083/jcb.141.6.1393; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; Kominami K, 1998, EMBO J, V17, P5388, DOI 10.1093/emboj/17.18.5388; Kramer ER, 1998, CURR BIOL, V8, P1207, DOI 10.1016/S0960-9822(07)00510-6; Kwon YT, 1998, P NATL ACAD SCI USA, V95, P7898, DOI 10.1073/pnas.95.14.7898; LAMB JR, 1994, EMBO J, V13, P4321, DOI 10.1002/j.1460-2075.1994.tb06752.x; Lehman AL, 1998, P NATL ACAD SCI USA, V95, P9436, DOI 10.1073/pnas.95.16.9436; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; Nefsky B, 1996, EMBO J, V15, P1301, DOI 10.1002/j.1460-2075.1996.tb00472.x; Nicholas K.B., 1997, EMBNEW NEWS, V4, P1; Nomura N, 1994, DNA Res, V1, P223, DOI 10.1093/dnares/1.5.223; Patton EE, 1998, GENE DEV, V12, P692, DOI 10.1101/gad.12.5.692; Patton EE, 1998, TRENDS GENET, V14, P236, DOI 10.1016/S0168-9525(98)01473-5; Peters JM, 1998, CURR OPIN CELL BIOL, V10, P759, DOI 10.1016/S0955-0674(98)80119-1; Peters JM, 1996, SCIENCE, V274, P1199, DOI 10.1126/science.274.5290.1199; Prinz S, 1998, CURR BIOL, V8, P750, DOI 10.1016/S0960-9822(98)70298-2; Renault L, 1998, NATURE, V392, P97, DOI 10.1038/32204; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; Shevchenko A, 1996, P NATL ACAD SCI USA, V93, P14440, DOI 10.1073/pnas.93.25.14440; Shevchenko A, 1997, RAPID COMMUN MASS SP, V11, P1015, DOI 10.1002/(SICI)1097-0231(19970615)11:9<1015::AID-RCM958>3.0.CO;2-H; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; SOLOVYEV VV, 1994, NUCLEIC ACIDS RES, V22, P5156, DOI 10.1093/nar/22.24.5156; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4; Varshavsky A., 1998, UBIQUITIN BIOL CELL, P223; Vorlaufer E, 1998, MOL BIOL CELL, V9, P1817, DOI 10.1091/mbc.9.7.1817; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Wassmann K, 1998, P NATL ACAD SCI USA, V95, P11193, DOI 10.1073/pnas.95.19.11193; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519; Yamada H, 1997, J CELL SCI, V110, P1793; Yu HT, 1998, SCIENCE, V279, P1219, DOI 10.1126/science.279.5354.1219; Zachariae W, 1996, SCIENCE, V274, P1201, DOI 10.1126/science.274.5290.1201; Zachariae W, 1996, MOL BIOL CELL, V7, P791, DOI 10.1091/mbc.7.5.791; Zachariae W, 1998, SCIENCE, V282, P1721, DOI 10.1126/science.282.5394.1721; Zachariae W, 1998, SCIENCE, V279, P1216, DOI 10.1126/science.279.5354.1216	62	78	83	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					14500	14507		10.1074/jbc.274.20.14500	http://dx.doi.org/10.1074/jbc.274.20.14500			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318877	hybrid			2022-12-25	WOS:000080322200106
J	Pigazzi, A; Heydrick, S; Folli, F; Benoit, S; Michelson, A; Loscalzo, J				Pigazzi, A; Heydrick, S; Folli, F; Benoit, S; Michelson, A; Loscalzo, J			Nitric oxide inhibits thrombin-receptor-activating peptide-induced phosphoinositide 3-kinase activity in human platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; BETA-GAMMA-SUBUNITS; LYN TYROSINE KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; P85 SUBUNIT; PI 3-KINASE; INTEGRIN; TRANSLOCATION; ASSOCIATION; BINDING	Although nitric oxide (NO) has potent antiplatelet actions, the signaling pathways affected by NO in the platelet are poorly understood. Since NO can induce platelet disaggregation and phosphoinositide a-kinase (PI3-kinase) activation renders aggregation irreversible, we tested the hypothesis that NO exerts its antiplatelet effects at least in part by inhibiting PI3-kinase; The results demonstrate that the NO donor S-nitrosoglutathione (S-NO-glutathione) inhibits the stimulation of PI3-kinase associated with tyrosine-phosphorylated proteins and of p85/PI3-kinase associated with the SRC family kinase member LYN following the exposure of platelets to thrombin receptor-activating peptide. The activation of LYN-associated PI3-kinase was unrelated to changes in the amount of PI3-kinase physically associated with LYN signaling complexes but did require the activation of LYN and other tyrosine kinases. The cyclic GMP-dependent kinase activator 8-bromo-cyclic GMP had similar effects on PI3-kinase activity, consistent with a model in which the cyclic nucleotide mediates the effects of NO. Additional studies showed that wortmannin and S-NO-glutathione have additive inhibitory effects on thrombin receptor-activating peptide-induced platelet aggregation and the surface expression of platelet activation markers. These data provide evidence of a distinct and novel mechanism for the inhibitory effects of NO on platelet function.	Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Boston, MA 02118 USA; Boston Univ, Sch Med, Evans Dept Med, Boston, MA 02118 USA; Univ Massachusetts, Sch Med, Dept Pediat, Worcester, MA 01605 USA; HS Raffaele, Unit Metab Dis, Milan, Italy	Boston University; Boston University; University of Massachusetts System; University of Massachusetts Worcester	Loscalzo, J (corresponding author), Boston Univ, Sch Med, Whitaker Cardiovasc Inst, 700 Albany St, Boston, MA 02118 USA.		Michelson, Alan/ABE-8487-2021; Loscalzo, Joseph/ABD-8980-2021; folli, franco/J-2795-2018	Michelson, Alan/0000-0002-1746-4819; folli, franco/0000-0001-9824-5222	NHLBI NIH HHS [HL55993, HL53919, HL48976] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL055993, R01HL053919] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARNOLD WP, 1977, P NATL ACAD SCI USA, V74, P3203, DOI 10.1073/pnas.74.8.3203; BORN GVR, 1963, J PHYSIOL-LONDON, V168, P178, DOI 10.1113/jphysiol.1963.sp007185; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CARPENTER CL, 1993, MOL CELL BIOL, V13, P1657, DOI 10.1128/MCB.13.3.1657; Chung J, 1997, J BIOL CHEM, V272, P14740, DOI 10.1074/jbc.272.23.14740; DombroskyFerlan PM, 1997, ONCOGENE, V14, P2019, DOI 10.1038/sj.onc.1201031; DORAHY DJ, 1995, BIOCHEM J, V309, P481, DOI 10.1042/bj3090481; Dorahy DJ, 1996, BIOCHEM J, V319, P67, DOI 10.1042/bj3190067; Dorahy DJ, 1996, BIOCHEM BIOPH RES CO, V218, P575, DOI 10.1006/bbrc.1996.0102; FOLLI F, 1992, J BIOL CHEM, V267, P22171; Freedman JE, 1997, J CLIN INVEST, V100, P350, DOI 10.1172/JCI119540; Frenette PS, 1996, CELL, V84, P563, DOI 10.1016/S0092-8674(00)81032-6; GEIGER J, 1992, P NATL ACAD SCI USA, V89, P1031, DOI 10.1073/pnas.89.3.1031; GOPALAKRISHNA R, 1993, J BIOL CHEM, V268, P27180; GUINEBAULT C, 1995, J CELL BIOL, V129, P831, DOI 10.1083/jcb.129.3.831; Hartwig JH, 1996, J BIOL CHEM, V271, P32986, DOI 10.1074/jbc.271.51.32986; Hazeki O, 1998, LIFE SCI, V62, P1555, DOI 10.1016/S0024-3205(98)00106-4; Hirao A, 1997, EMBO J, V16, P2342, DOI 10.1093/emboj/16.9.2342; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; KOVACSOVICS TJ, 1995, J BIOL CHEM, V270, P11358, DOI 10.1074/jbc.270.19.11358; KUCERA GL, 1990, J BIOL CHEM, V265, P5345; Kurosu H, 1997, J BIOL CHEM, V272, P24252, DOI 10.1074/jbc.272.39.24252; LAM K, 1994, J BIOL CHEM, V269, P20648; MENDELSSOHN IA, 1990, OIL CHEM POLLUT, V7, P1, DOI 10.1016/S0269-8579(05)80031-0; Michelson AD, 1996, AM J PHYSIOL-HEART C, V270, pH1640, DOI 10.1152/ajpheart.1996.270.5.H1640; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; PTASZNIK A, 1995, J BIOL CHEM, V270, P19969, DOI 10.1074/jbc.270.34.19969; QUON MJ, 1995, MOL CELL BIOL, V15, P5403; Rittenhouse SE, 1996, BLOOD, V88, P4401, DOI 10.1182/blood.V88.12.4401.bloodjournal88124401; SOTIRELLIS N, 1995, J BIOL CHEM, V270, P29773; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; Tang XW, 1997, J BIOL CHEM, V272, P14193, DOI 10.1074/jbc.272.22.14193; THOMASON PA, 1994, J BIOL CHEM, V269, P16525; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; TOKER A, 1994, J BIOL CHEM, V269, P32358; Vaandrager AB, 1996, MOL CELL BIOCHEM, V157, P23, DOI 10.1007/BF00227877; YANAGI S, 1994, EUR J BIOCHEM, V224, P329, DOI 10.1111/j.1432-1033.1994.00329.x; YATOMI Y, 1992, BIOCHEM J, V285, P745, DOI 10.1042/bj2850745; Zeng GY, 1996, J CLIN INVEST, V98, P894, DOI 10.1172/JCI118871; Zhang J, 1996, J BIOL CHEM, V271, P6265, DOI 10.1074/jbc.271.11.6265; ZHANG J, 1992, J BIOL CHEM, V267, P4686	43	71	72	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					14368	14375		10.1074/jbc.274.20.14368	http://dx.doi.org/10.1074/jbc.274.20.14368			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318860	hybrid			2022-12-25	WOS:000080322200089
J	Hall-Jackson, CA; Goedert, M; Hedge, P; Cohen, P				Hall-Jackson, CA; Goedert, M; Hedge, P; Cohen, P			Effect of SB 203580 on the activity of c-Raf in vitro and in vivo	ONCOGENE			English	Article						c-Raf; MAP kinase; SB203580; EGF; SAPK2; p38	P38 MAP KINASE; PROTEIN-KINASE; SUBSTRATE-SPECIFICITY; CELLULAR STRESSES; PLASMA-MEMBRANE; SAP KINASES; ACTIVATION; INHIBITOR; INSULIN; INTERLEUKIN-1	The inhibition of SAPK2a/p38 (a mitogen activated protein (MAP) kinase family member) by SE 203580 depends on the presence of threonine at residue 106. Nearly all other protein kinases are insensitive to this drug because a more bulky residue occupies this site (Eyers et al,, 1998), Raf is one of the few protein kinases that possesses threonine at this position, and we show that SE 203580 inhibits c-Raf with an IC50 of 2 mu M in vitro. However, SB 203580 does not suppress either growth factor or phorbol ester-induced activation of the classical MAP kinase cascade in mammalian cells. One of the reasons for this is that SE 203580 also triggers a remarkable activation of c-Raf in vivo (when measured in the absence of the drug). The SB203580-induced activation of c-Raf occurs without any increase in the GTP-loading of Ras, is not prevented by inhibitors of the MAPK cascade, protein kinase C or phosphatidylinositide 3-kinase, and is not triggered by the binding of this drug to SAPK2a/p38. The paradoxical activation of c-Raf by SE 203580 (and by another structurally unrelated c-Raf inhibitor) suggests that inhibitors of the kinase activity of c-Raf may not be effective as anti-cancer drugs.	Univ Dundee, Dept Biochem, MRC, Prot Phosphorylat Unit, Dundee DD1 5EH, Scotland; MRC, Mol Biol Lab, Cambridge CB2 2QH, England; Zeneca Pharmaceut, Macclesfield SK10 4TG, Cheshire, England	University of Dundee; MRC Laboratory Molecular Biology	Hall-Jackson, CA (corresponding author), Univ Dundee, Dept Biochem, MRC, Prot Phosphorylat Unit, MSI WTB Complex,Dow St, Dundee DD1 5EH, Scotland.							ALESSI DR, 1995, METHOD ENZYMOL, V255, P279; Alessi DR, 1997, FEBS LETT, V402, P121, DOI 10.1016/S0014-5793(96)01510-4; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Badger AM, 1996, J PHARMACOL EXP THER, V279, P1453; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; Clifton AD, 1996, FEBS LETT, V392, P209, DOI 10.1016/0014-5793(96)00816-2; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; COHEN P, 1994, BIOCHEM J, V303, P21; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Doza YN, 1998, ONCOGENE, V17, P19, DOI 10.1038/sj.onc.1202168; Eyers PA, 1998, CHEM BIOL, V5, P321, DOI 10.1016/S1074-5521(98)90170-3; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; GOULD GW, 1995, BIOCHEM J, V311, P735, DOI 10.1042/bj3110735; Gum RJ, 1998, J BIOL CHEM, V273, P15605, DOI 10.1074/jbc.273.25.15605; Hazzalin CA, 1997, ONCOGENE, V15, P2321, DOI 10.1038/sj.onc.1201403; Ishii H, 1996, SCIENCE, V272, P728, DOI 10.1126/science.272.5262.728; LAW NM, 1996, EMERGING DRUGS PROSP, P241; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Tong L, 1997, NAT STRUCT BIOL, V4, P311, DOI 10.1038/nsb0497-311; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Wilson KP, 1997, CHEM BIOL, V4, P423, DOI 10.1016/S1074-5521(97)90194-0; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116	30	131	135	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 25	1999	18	12					2047	2054		10.1038/sj.onc.1202603	http://dx.doi.org/10.1038/sj.onc.1202603			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	179TX	10321729				2022-12-25	WOS:000079346200002
J	Hahn, A; Hock, B				Hahn, A; Hock, B			Chromosome mechanics of fungi under spaceflight conditions - tetrad analysis of two-factor crosses between spore color mutants of Sordaria macrospora	FASEB JOURNAL			English	Article; Proceedings Paper	Symposium of the European-Space-Agency/National-Aeronautics-and-Space-Administration Workshop on Cell and Molecular biology Research in Space	JUN, 1998	BELGIUM NATL ACAD SCI, LEUVEN, BELGIUM	European Space Agency, NASA	BELGIUM NATL ACAD SCI	fungal genetics; sexual recombination; radiation effects	SPACE	Spore color mutants of the Sordaria macrospora Auersw, were crossed under spaceflight conditions on the space shuttle to MIR mission S/MM 05 (STS-81), The arrangement of spores of different colors in the asci allowed conclusions on the influence of spaceflight conditions on sexual recombination in fungi. Experiments on a 1-g centrifuge in space and in parallel on the ground were used for controls. The samples were analyzed microscopically on their return to earth. Each fruiting body was assessed separately. Statistical analysis of the data showed a significant increase in gene recombination frequencies caused by the heavy ion particle stream in space radiation. The lack of gravity did not influence crossing-over frequencies. Hyphae of the flown samples were assessed for DNA strand breaks. No increase in damage was found compared with the ground samples. It was shown that S. macrospora is able to repair radiation-induced DNA strand breaks within hours.	Tech Univ Munchen Weihenstephan, Dept Bot, D-85350 Freising, Germany	Technical University of Munich	Hahn, A (corresponding author), Tech Univ Munchen Weihenstephan, Dept Bot, Alte Akad 12, D-85350 Freising, Germany.							BARBIER M, 1978, LIFE SCI SPACE RES, V6, P207; Beadle GW, 1941, P NATL ACAD SCI USA, V27, P499, DOI 10.1073/pnas.27.11.499; BRUSCHI CV, 1994, BIORACK SPACELAB IML, P83; ESSER K, 1958, Z VEREBUNGSL, V89, P729, DOI 10.1007/BF00888561; FAIRBAIRN DW, 1995, MUTAT RES-REV GENET, V339, P37, DOI 10.1016/0165-1110(94)00013-3; Horneck G, 1974, Life Sci Space Res, V12, P75; HORNECK G, 1992, NUCL TRACKS RAD MEAS, V20, P185; HORNECK G, 1998, BIOSENSORS ENV DIAGN, P215; KIEFER J, 1996, BIOL MED RES SPACE, P300; KOPPEN G, 1997, COMET NEWS, V6, P2; KRANZ AR, 1987, EUROPEAN SPACE AGENC; LINDEGREN CC, 1932, B TORREY BOT CLUB, V59, P119; Manieri P, 1996, J BIOTECHNOL, V47, P71, DOI 10.1016/0168-1656(96)01365-X; MOLOWITZ R, 1976, PLANTA, V128, P143, DOI 10.1007/BF00390315; NELSON GA, 1994, ADV SPACE RES-SERIES, V14, P209, DOI 10.1016/0273-1177(94)90405-7; Nevzgodina L V, 1989, Adv Space Res, V9, P53, DOI 10.1016/0273-1177(89)90054-9; ONEILL KL, 1993, MUTAT RES, V319, P129, DOI 10.1016/0165-1218(93)90071-K; Palagyi Z, 1996, BIOTECHNOL TECH, V10, P565, DOI 10.1007/BF00157362; Peterson D D, 1977, Life Sci Space Res, V15, P151; REITZ G, 1995, ACTA ASTRONAUT, V35, P313, DOI 10.1016/0094-5765(95)98735-R; REITZ G, 1993, CLIN INVESTIGATOR, V71, P710; REITZ G, 1998, RESULTS SPACE SHUTTL; YANG CH, 1994, ADV SPACE RES, V14, P373, DOI 10.1016/0273-1177(94)90490-1; ZHAO HY, 1995, GENETICS, V139, P1045; ZIMMERMANN MW, 1994, ADV SPACE RES, V14, P47, DOI 10.1016/0273-1177(94)90449-9	25	3	5	0	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.		1999	13			S			S149	S156						8	Biochemistry & Molecular Biology; Biology; Cell Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	198CF	10352157				2022-12-25	WOS:000080403800019
J	Himpens, B; Stalmans, P; Gomez, P; Malfait, M; Vereecke, J				Himpens, B; Stalmans, P; Gomez, P; Malfait, M; Vereecke, J			Intra- and intercellular Ca2+ signaling in retinal pigment epithelial cells during mechanical stimulation	FASEB JOURNAL			English	Article; Proceedings Paper	Symposium of the European-Space-Agency/National-Aeronautics-and-Space-Administration Workshop on Cell and Molecular biology Research in Space	JUN, 1998	BELGIUM NATL ACAD SCI, LEUVEN, BELGIUM	European Space Agency, NASA	BELGIUM NATL ACAD SCI	RCS rats; gap junctions; intercellular communication; protein phosphorylation; calcium wave; confocal imaging; nucleus; cytoplasm; nucleo-cytoplasmic gradient; cytoskeleton	PROTEIN-KINASE-C; SIMULATED MICROGRAVITY; SMOOTH-MUSCLE; CALCIUM; ACTIVATION; PHOSPHORYLATION; LYMPHOCYTES; PROPAGATION	The intercellular communication (IC) was investigated between cultured rat retinal pig ment epithelial (RPE) cells isolated from Long-Evans (LE) or dystrophic Royal College of Surgeons (RCS) rats and gown in solutions containing normal and high glucose concentrations, or after modulation of protein kinase C (PKC), This was performed by studying the conduction of the free Ca2+-concentration ([Ca2+](i)) wave elicited by mechanical stimulation and by analyzing the fluorescence recovery after photobleaching (FRAP), Mechanical stimulation of LE-RPE cells triggers Ca2+ influx, mediated by stretch-sensitive cation channels followed by intracellular Ca2+ release. A regenerative [Ca2+](i) wave was found with a lower propagation rate in RCS-RPE cells, This rate could be increased by PKC downregulation, Mechanical stimulation caused a [Ca2+](i) increase in the mechanically stimulated (MS) cell followed after a delay by a [Ca2+](i) rise in the adjacent cell layers. The intercellular [Ca2+](i) wave propagation could be blocked by gap junction blockers such as halothane or PKC activation. An inhibition of die [Ca2+](i)-wave propagation similar to that induced by halothane could be observed in cells gown in solutions containing 14 mM or higher concentrations of glucose, PKC down-regulated cells gown in glucose-rich medium did not develop this inhibitory effect on gap junction communication (GJC), FRAP experiments confirmed that the observed changes were consistent with a PKC-mediated inhibitory effect of high glucose concentrations on GJC.	Catholic Univ Louvain, Physiol Lab, B-3000 Louvain, Belgium	Universite Catholique Louvain	Himpens, B (corresponding author), Catholic Univ Louvain, Physiol Lab, Herestr 49, B-3000 Louvain, Belgium.							BENNETT MVL, 1994, SOC GEN PHY, V49, P223; Cooper D, 1998, J LEUKOCYTE BIOL, V63, P550, DOI 10.1002/jlb.63.5.550; DeSmedt H, 1997, BIOCHEM J, V322, P575; Felix JA, 1998, AM J RESP CELL MOL, V18, P602, DOI 10.1165/ajrcmb.18.5.3105; GALLEMORE RP, 1994, VISUAL NEUROSCI, V11, P753, DOI 10.1017/S0952523800003059; HIMPENS B, 1994, FASEB J, V8, P879, DOI 10.1096/fasebj.8.11.8070638; HIMPENS B, 1995, J VASC RES, V32, P207, DOI 10.1159/000159095; HIMPENS B, 1995, CELL CALCIUM, V18, P111, DOI 10.1016/0143-4160(95)90002-0; HIMPENS B, 1994, CELL CALCIUM, V16, P239, DOI 10.1016/0143-4160(94)90087-6; HughesFulford M, 1996, EXP CELL RES, V224, P103, DOI 10.1006/excr.1996.0116; Janmey PA, 1998, PHYSIOL REV, V78, P763, DOI 10.1152/physrev.1998.78.3.763; Lewis ML, 1998, FASEB J, V12, P1007, DOI 10.1096/fasebj.12.11.1007; LIMOUSE M, 1991, EXP CELL RES, V197, P82, DOI 10.1016/0014-4827(91)90482-A; Maniotis AJ, 1997, P NATL ACAD SCI USA, V94, P849, DOI 10.1073/pnas.94.3.849; ROOF D, 1994, PRINCIPLES PRACTICE, P309; SANDERSON MJ, 1994, MOL CELL ENDOCRINOL, V98, P173, DOI 10.1016/0303-7207(94)90136-8; Schmitt DA, 1996, FASEB J, V10, P1627, DOI 10.1096/fasebj.10.14.9002555; SNEYD J, 1995, AM J PHYSIOL-CELL PH, V268, pC1537, DOI 10.1152/ajpcell.1995.268.6.C1537; Stalmans P, 1997, INVEST OPHTH VIS SCI, V38, P176; Stalmans P, 1998, INVEST OPHTH VIS SCI, V39, P1493; Stalmans P, 1997, INVEST OPHTH VIS SCI, V38, P1598; Wang SSH, 1995, BIOPHYS J, V69, P1683, DOI 10.1016/S0006-3495(95)80086-X	23	34	35	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.		1999	13			S			S63	S68						6	Biochemistry & Molecular Biology; Biology; Cell Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	198CF	10352146				2022-12-25	WOS:000080403800008
J	Bowers, J; Sokolsky, T; Quach, T; Alani, E				Bowers, J; Sokolsky, T; Quach, T; Alani, E			A mutation in the MSH6 subunit of the Saccharomyces cerevisiae MSH2-MSH6 complex disrupts mismatch recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BASE PAIRS; DUPLEX OLIGONUCLEOTIDES; TRANSLOCATION MECHANISM; SPECIFICALLY BINDS; HETERODUPLEX DNA; GENE-PRODUCT; HMUTS-ALPHA; PROTEIN; REPAIR; HETERODIMER	In yeast, MSH2 interacts with MSH6 to repair base pair mismatches and single nucleotide insertion/deletion mismatches and with MSH3 to recognize small loop insertion/deletion mismatches. We identified a msh6 mutation (msh6-F337A) that when overexpressed in wild type strains conferred a defect in both MSH2-MSH6- and MSH2-MSH3-dependent mismatch repair pathways. Genetic analysis suggested that this phenotype was due to msh6-F337A sequestering MSH2 and preventing it from interacting with MSH3 and MSH6. In UV cross-linking, filter binding, and gel retardation assays, the MSH2-msh6-F337A complex displayed a mismatch recognition defect. These observations, in conjunction with ATPase and dissociation rate analysis, suggested that MSH2-msh6-F337A formed an unproductive complex that was unable to stably bind to mismatch DNA.	Cornell Univ, Genet & Dev Sect, Ithaca, NY 14853 USA	Cornell University	Alani, E (corresponding author), Cornell Univ, Genet & Dev Sect, 459 Biotechnol Bldg, Ithaca, NY 14853 USA.	eea3@cornell.edu			NIGMS NIH HHS [GM53085, R01 GM053085] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053085] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1995, GENE DEV, V9, P234, DOI 10.1101/gad.9.2.234; Alani E, 1997, MOL CELL BIOL, V17, P2436, DOI 10.1128/MCB.17.5.2436; Alani E, 1996, MOL CELL BIOL, V16, P5604; Allen DJ, 1997, EMBO J, V16, P4467, DOI 10.1093/emboj/16.14.4467; AU KG, 1992, J BIOL CHEM, V267, P12142; Blackwell LJ, 1998, J BIOL CHEM, V273, P32055, DOI 10.1074/jbc.273.48.32055; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHI NW, 1994, J BIOL CHEM, V269, P29984; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; CROUSE GF, 1996, DNA DAMAGE REPAIR BI, P411; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; GIETZ RD, 1991, YEAST, V7, P253, DOI 10.1002/yea.320070307; Gradia S, 1997, CELL, V91, P995, DOI 10.1016/S0092-8674(00)80490-0; GRILLEY M, 1989, J BIOL CHEM, V264, P1000; HABER LT, 1991, EMBO J, V10, P2707, DOI 10.1002/j.1460-2075.1991.tb07815.x; Habraken Y, 1997, CURR BIOL, V7, P790, DOI 10.1016/S0960-9822(06)00337-X; Habraken Y, 1998, J BIOL CHEM, V273, P9837, DOI 10.1074/jbc.273.16.9837; Habraken Y, 1996, CURR BIOL, V6, P1185, DOI 10.1016/S0960-9822(02)70686-6; HENDERSON ST, 1992, MOL CELL BIOL, V12, P2749, DOI 10.1128/MCB.12.6.2749; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Iaccarino I, 1996, CURR BIOL, V6, P484, DOI 10.1016/S0960-9822(02)00516-X; Iaccarino I, 1998, EMBO J, V17, P2677, DOI 10.1093/emboj/17.9.2677; Johnson RE, 1996, J BIOL CHEM, V271, P7285, DOI 10.1074/jbc.271.13.7285; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; Malkov VA, 1997, J BIOL CHEM, V272, P23811, DOI 10.1074/jbc.272.38.23811; Maniatis T., 1982, MOL CLONING LAB MANU; Marsischky GT, 1996, GENE DEV, V10, P407, DOI 10.1101/gad.10.4.407; MCENTEE K, 1980, P NATL ACAD SCI-BIOL, V77, P857, DOI 10.1073/pnas.77.2.857; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; REENAN RAG, 1992, GENETICS, V132, P975; Rose MD., 1990, METHODS YEAST GENETI; STRAND M, 1995, P NATL ACAD SCI USA, V92, P10418, DOI 10.1073/pnas.92.22.10418; Studamire B, 1998, MOL CELL BIOL, V18, P7590, DOI 10.1128/MCB.18.12.7590; SU SS, 1986, P NATL ACAD SCI USA, V83, P5057, DOI 10.1073/pnas.83.14.5057; WELSH KM, 1987, J BIOL CHEM, V262, P15624; WINSTON F, 1995, YEAST, V11, P53, DOI 10.1002/yea.320110107; YOCUM RR, 1984, MOL CELL BIOL, V4, P1985, DOI 10.1128/MCB.4.10.1985	41	77	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16115	16125		10.1074/jbc.274.23.16115	http://dx.doi.org/10.1074/jbc.274.23.16115			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347163	hybrid			2022-12-25	WOS:000080668600023
J	Johnson, RE; Prakash, S; Prakash, L				Johnson, RE; Prakash, S; Prakash, L			Requirement of DNA polymerase activity of yeast Rad30 protein for its biological function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMPLE REPETITIVE SEQUENCES; ESCHERICHIA-COLI DINB; GROUP-D GENE; SACCHAROMYCES-CEREVISIAE; REPAIR; HELICASE; MUTAGENESIS; RECONSTITUTION; MECHANISM; MUTATIONS	The RAD30 gene of Saccharomyces cerevisiae encodes a DNA polymerase, Pol eta, The Rad30 protein shares homology with the yeast Rev1 and the Escherichia coli DinB and UmuC proteins. Although these proteins contain several highly conserved motifs, only Rad30 has been shown to possess a DNA polymerase activity. To determine whether the DNA polymerase activity of Rad30 was essential for its biological function, we made a mutation in the highly conserved SIDE sequence in Rad30, in which the aspartate and glutamate residues have each been changed to alanine. The mutant Rad30 protein lacks the DNA polymerase activity, and the mutant gene does not complement the rad30 Delta mutation. These findings indicate that DNA polymerase activity is indispensable for the biological function of RAD30.	Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Prakash, L (corresponding author), Univ Texas, Med Branch, Sealy Ctr Mol Sci, 6-104 Med Res Bldg,11th & Mechan St, Galveston, TX 77555 USA.		Prakash, Satya/C-6420-2013; Prakash, Louise/C-7891-2012	Prakash, Louise/0000-0001-9143-6261; Prakash, Satya/0000-0001-7228-1444	NIGMS NIH HHS [GM19261] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM019261] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; BAILLY V, 1994, GENE DEV, V8, P811, DOI 10.1101/gad.8.7.811; Bailly V, 1997, J BIOL CHEM, V272, P23360, DOI 10.1074/jbc.272.37.23360; GUZDER SN, 1995, J BIOL CHEM, V270, P17660, DOI 10.1074/jbc.270.30.17660; JOHNSON RE, 1992, MOL CELL BIOL, V12, P3807, DOI 10.1128/MCB.12.9.3807; Johnson RE, 1999, SCIENCE, V283, P1001, DOI 10.1126/science.283.5404.1001; JOHNSON RE, 1994, J BIOL CHEM, V269, P28259; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; McDonald JP, 1997, GENETICS, V147, P1557; Nelson JR, 1996, NATURE, V382, P729, DOI 10.1038/382729a0; Nelson JR, 1996, SCIENCE, V272, P1646, DOI 10.1126/science.272.5268.1646; PRAKASH S, 1993, ANNU REV GENET, V27, P33, DOI 10.1146/annurev.ge.27.120193.000341; Reuven NB, 1998, MOL CELL, V2, P191, DOI 10.1016/S1097-2765(00)80129-X; Roush AA, 1998, MOL GEN GENET, V257, P686; Smith BT, 1998, GENETICS, V148, P1599; Sung P, 1996, J BIOL CHEM, V271, P10821, DOI 10.1074/jbc.271.18.10821; SUNG P, 1987, P NATL ACAD SCI USA, V84, P8951, DOI 10.1073/pnas.84.24.8951; SUNG P, 1993, NATURE, V365, P852, DOI 10.1038/365852a0; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; Tang MJ, 1998, P NATL ACAD SCI USA, V95, P9755, DOI 10.1073/pnas.95.17.9755	20	105	106	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					15975	15977		10.1074/jbc.274.23.15975	http://dx.doi.org/10.1074/jbc.274.23.15975			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347143	hybrid			2022-12-25	WOS:000080668600003
J	Beattie, BK; Merrill, AR				Beattie, BK; Merrill, AR			A fluorescence investigation of the active site of Pseudomonas aeruginosa exotoxin A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINAMIDE ADENINE-DINUCLEOTIDE; HYDROCHLORIDE-INDUCED DENATURATION; E1 CHANNEL PEPTIDE; DIPHTHERIA-TOXIN; TRYPTOPHAN RESIDUES; CRYSTAL-STRUCTURE; ADP-RIBOSYLATION; DOMAIN-III; TRANSLOCATION; RESOLUTION	Single tryptophan mutant proteins of a catalytically active domain III recombinant protein (PE24) from Pseudomonas aeruginosa exotoxin A were prepared by site-directed mutagenesis, The binding of the dinucleotide substrate, NAD(+), to the PE24 active site was studied by exploiting intrinsic tryptophan fluorescence for the wild-type, single Trp, and tryptophan-deficient mutant proteins. Various approaches were used to study the substrate binding process, including dynamic quenching, CD spectroscopy, steady-state fluorescence emission analysis, NAD(+)-glycohydrolase activity, NAD(+) binding analysis, protein denaturation experiments, fluorescence lifetime analysis, steady-state anisotropy measurement, stopped flow fluorescence spectroscopy, and quantum yield determination, It was found that the conservative replacement of tryptophan residues with phenylalanine had little or no effect on the folded stability and enzyme activity of the PE24 protein. Dynamic quenching experiments indicated that when bound to the active site of the enzyme, the NAD(+) substrate protected Trp-558 from solvent to a large extent but had no effect on the degree of solvent exposure for tryptophans 417 and 466, Also, upon substrate binding, the anisotropy of the Trp-417(W466F/W558F) protein showed the largest increase, followed by Trp-466(W417F/W558F), and there was no effect on Trp-558(W417F/W466F). Furthermore, the intrinsic tryptophan fluorescence exhibited the highest degree of substrate-induced quenching for the wild-type protein, followed in decreasing order by Trp-417(W466F/W558F), Trp-558(W417F/W466F), and Trp-466(W417F/W558F). These data provide evidence for a structural rearrangement in the enzyme domain near Trp-417 invoked by the binding of the NAD(+) substrate.	Univ Guelph, Dept Chem & Biochem, Guelph Waterloo Ctr Grad Work Chem, Guelph, ON N1G 2W1, Canada	University of Guelph; University of Waterloo; Guelph-Waterloo Centre for Graduate Work in Chemistry & Biochemistry	Merrill, AR (corresponding author), Univ Guelph, Dept Chem & Biochem, Guelph Waterloo Ctr Grad Work Chem, Guelph, ON N1G 2W1, Canada.		Merrill, Rod/M-8313-2014					ALLURED VS, 1986, P NATL ACAD SCI USA, V83, P1320, DOI 10.1073/pnas.83.5.1320; Beattie BK, 1996, BIOCHEMISTRY-US, V35, P9042, DOI 10.1021/bi960396k; Beattie BK, 1996, BIOCHEMISTRY-US, V35, P15134, DOI 10.1021/bi961985t; Bell CE, 1997, PROTEIN SCI, V6, P2084; Bell CE, 1996, BIOCHEMISTRY-US, V35, P1137, DOI 10.1021/bi9520848; BENNETT MJ, 1994, PROTEIN SCI, V3, P1444, DOI 10.1002/pro.5560030911; BOPP LH, 1991, INFECT IMMUN, V59, P708, DOI 10.1128/IAI.59.2.708-711.1991; CREED D, 1984, PHOTOCHEM PHOTOBIOL, V39, P537; DOMENIGHINI M, 1991, MOL MICROBIOL, V5, P23, DOI 10.1111/j.1365-2958.1991.tb01822.x; EFTINK MR, 1981, ANAL BIOCHEM, V114, P199, DOI 10.1016/0003-2697(81)90474-7; IGLEWSKI BH, 1977, INFECT IMMUN, V15, P138, DOI 10.1128/IAI.15.1.138-144.1977; JINNO Y, 1989, J BIOL CHEM, V264, P15953; Li M, 1996, P NATL ACAD SCI USA, V93, P6902, DOI 10.1073/pnas.93.14.6902; LI M, 1995, P NATL ACAD SCI USA, V92, P9308, DOI 10.1073/pnas.92.20.9308; MERRILL AR, 1993, BIOCHEMISTRY-US, V32, P6974, DOI 10.1021/bi00078a023; Merrill AR, 1997, BIOCHEMISTRY-US, V36, P6874, DOI 10.1021/bi970222i; OPPENHEIMER NJ, 1981, J BIOL CHEM, V256, P8579; Parker C. A., 1968, PHOTOLUMINESCENCE SO, P220; Permyakov EA, 1993, LUMINESCENT SPECTROS; Steer BA, 1997, BIOCHEMISTRY-US, V36, P3037, DOI 10.1021/bi961926f; STEER BA, 1995, BIOCHEMISTRY-US, V34, P7225, DOI 10.1021/bi00021a038; TORY MC, 1998, BIOPHYS J, V74, pM135; WILSON BA, 1992, CURR TOP MICROBIOL I, V175, P1	23	21	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15646	15654		10.1074/jbc.274.22.15646	http://dx.doi.org/10.1074/jbc.274.22.15646			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336461	hybrid			2022-12-25	WOS:000080560100050
J	Grasberger, H; Buettner, C; Janssen, OE				Grasberger, H; Buettner, C; Janssen, OE			Modularity of serpins - A bifunctional chimera possessing alpha(1)-proteinase inhibitor and thyroxine-binding globulin properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEINASE-INHIBITORS; 3-DIMENSIONAL STRUCTURE; ALPHA-LACTALBUMIN; FOLDING UNITS; MECHANISM; LOOP; GENE; ALPHA-1-ANTITRYPSIN; POLYMERIZATION; EVOLUTION	An exciting application of protein engineering is the creation of proteins with novel functions by the retrofitting of native proteins. Such attempts might be facilitated by the idea of a mosaic architecture of proteins out of structural units. Even though numerous theoretical concepts deal with the delineation of structural "modules," their potential in the design of proteins has not yet been sufficiently exploited. To address this question we used a gain of function approach by designing modular chimeric molecules out of two structurally homologous but functionally diverse members of the superfamily of serine-proteinase inhibitors, alpha(1)-proteinase inhibitor and thyroxine-binding globulin, Substitution of two of four alpha(1)-proteinase inhibitor modules (Lys(222) to Leu(288) and Pro(362) to Lys(394), respectively), identified by cu-backbone distance analysis, with their thyroxine-binding globulin homologues resulted in a bifunctional chimera with inhibition of human leukocyte elastase and high affinity thyroxine binding. To our knowledge, this is the first report on a bifunctional chimera engineered from modules of homologous globular proteins. Our results demonstrate how a modular concept can facilitate the design of new functional proteins by swapping structural units chosen from members of a protein superfamily.	Univ Munich, Med Klin, Klinikum Innenstadt, Dept Med, D-80336 Munich, Germany	University of Munich	Janssen, OE (corresponding author), Univ Munich, Med Klin, Klinikum Innenstadt, Dept Med, Ziemssenstr 1, D-80336 Munich, Germany.		Grasberger, Helmut/C-4148-2015	Grasberger, Helmut/0000-0002-4065-4418				Bottomley SP, 1997, BIOCHEM BIOPH RES CO, V241, P264, DOI 10.1006/bbrc.1997.7805; BRUCH M, 1988, J BIOL CHEM, V263, P16626; Campbell RK, 1997, NAT BIOTECHNOL, V15, P439, DOI 10.1038/nbt0597-439; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; Carrell RW, 1996, BIOL CHEM H-S, V377, P1; Chang WSW, 1997, PROTEIN SCI, V6, P89; CHOTHIA C, 1992, NATURE, V357, P543, DOI 10.1038/357543a0; CILIBERTO G, 1985, CELL, V41, P531, DOI 10.1016/S0092-8674(85)80026-X; CRIPPEN GM, 1978, J MOL BIOL, V126, P315, DOI 10.1016/0022-2836(78)90043-8; Elliott PR, 1996, NAT STRUCT BIOL, V3, P676, DOI 10.1038/nsb0896-676; FELGNER PL, 1989, NATURE, V337, P387, DOI 10.1038/337387a0; GO M, 1981, NATURE, V291, P90, DOI 10.1038/291090a0; HAMMOND GL, 1990, ENDOCR REV, V11, P65, DOI 10.1210/edrv-11-1-65; Henikoff S, 1997, SCIENCE, V278, P609, DOI 10.1126/science.278.5338.609; HOLM L, 1994, PROTEINS, V19, P256, DOI 10.1002/prot.340190309; Hopfner KP, 1998, P NATL ACAD SCI USA, V95, P9813, DOI 10.1073/pnas.95.17.9813; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; HUNT LT, 1980, BIOCHEM BIOPH RES CO, V95, P864, DOI 10.1016/0006-291X(80)90867-0; JANSSEN OE, 1992, J BIOL CHEM, V267, P13998; KAHN MS, 1977, J BIOL CHEM, V252, P1895; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KORCEK L, 1976, J BIOL CHEM, V251, P3558; LESK AM, 1981, P NATL ACAD SCI-BIOL, V78, P4304, DOI 10.1073/pnas.78.7.4304; LEVIN EG, 1987, BLOOD, V70, P1090; LEVITT M, 1976, NATURE, V261, P552, DOI 10.1038/261552a0; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; LOMAS DA, 1995, J BIOL CHEM, V270, P16864, DOI 10.1074/jbc.270.28.16864; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; MURATA Y, 1985, J ENDOCRINOL INVEST, V8, P225, DOI 10.1007/BF03348482; MURZIN AG, 1993, TRENDS BIOCHEM SCI, V18, P403, DOI 10.1016/0968-0004(93)90132-7; Murzin AG, 1998, CURR OPIN STRUC BIOL, V8, P380, DOI 10.1016/S0959-440X(98)80073-0; NEMETHY G, 1979, P NATL ACAD SCI USA, V76, P6050, DOI 10.1073/pnas.76.12.6050; NITTA K, 1989, EUR J BIOCHEM, V182, P111, DOI 10.1111/j.1432-1033.1989.tb14806.x; Nixon AE, 1997, P NATL ACAD SCI USA, V94, P1069, DOI 10.1073/pnas.94.4.1069; ORENGO CA, 1994, NATURE, V372, P631, DOI 10.1038/372631a0; PATSTON PA, 1995, FEBS LETT, V368, P401, DOI 10.1016/0014-5793(95)00694-5; PEMBERTON PA, 1988, NATURE, V336, P257, DOI 10.1038/336257a0; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; POWELL LM, 1992, J MOL BIOL, V224, P241, DOI 10.1016/0022-2836(92)90587-A; QASBA PK, 1984, NATURE, V308, P377, DOI 10.1038/308377a0; RAO ST, 1973, J MOL BIOL, V76, P241, DOI 10.1016/0022-2836(73)90388-4; RASHIN AA, 1981, NATURE, V291, P85, DOI 10.1038/291085a0; REFETOFF S, 1994, ENDOCRINE REV MONOGR, V3, P162; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHULZE AJ, 1992, BIOCHEMISTRY-US, V31, P7560, DOI 10.1021/bi00148a017; SNYDER SM, 1976, J BIOL CHEM, V251, P6489; STEIN PE, 1995, NAT STRUCT BIOL, V2, P96, DOI 10.1038/nsb0295-96; TABACHNICK M, 1987, BIOCHEM INT, V15, P409; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; WAKASUGI K, 1994, J BIOL CHEM, V269, P18750; WEBB AC, 1991, BIOTECHNIQUES, V11, P512; WETLAUFER DB, 1973, ANNU REV BIOCHEM, V42, P135, DOI 10.1146/annurev.bi.42.070173.001031; Whisstock J, 1998, TRENDS BIOCHEM SCI, V23, P63, DOI 10.1016/S0968-0004(97)01172-9; WISTOW G, 1993, TRENDS BIOCHEM SCI, V18, P301, DOI 10.1016/0968-0004(93)90041-K; Zehfus MH, 1997, PROTEIN SCI, V6, P1210, DOI 10.1002/pro.5560060609	56	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					15046	15051		10.1074/jbc.274.21.15046	http://dx.doi.org/10.1074/jbc.274.21.15046			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329708	hybrid			2022-12-25	WOS:000081965200073
J	Pochampally, R; Fodera, B; Chen, LH; Lu, WG; Chen, JD				Pochampally, R; Fodera, B; Chen, LH; Lu, WG; Chen, JD			Activation of an MDM2-specific caspase by p53 in the absence of apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR P53; DNA-DAMAGE; CYTOCHROME-C; MDM2 ONCOPROTEIN; TRANSCRIPTIONAL ACTIVATION; PROTEOLYTIC CLEAVAGE; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; DEATH RECEPTORS; CELLS	Cells undergoing p53-mediated apoptosis activate caspase 3-like activities, resulting in the cleavage of the MDM2 oncoprotein and other apoptotic substrates such as poly(ADP-ribose) polymerase, To investigate the mechanism of p53-mediated apoptosis and to determine whether cleavage of MDM2 has a potential role in regulating p53, we examined caspase activation and cleavage of MDM2 in a cell line undergoing p53-mediated growth arrest and delayed apoptosis, We found that in H1299 cells expressing a temperature-sensitive human p53, a distinct caspase activity specific for the MDM2 cleavage site DVPD is induced by p53 prior to the onset of apoptosis and loss of viability. This is accompanied by the cleavage of MDM2 but not the apoptotic substrate poly(ADP-ribose) polymerase. The cleaved MDM2 loses the ability to promote p53 degradation and may potentially function in a dominant-negative fashion to stabilize p53, These results suggest that p53 activation may induce a positive feedback effect by cleavage of MDM2 through a unique caspase.	Louisiana State Univ, Med Ctr, Dept Microbiol, Stanley S Scott Canc Ctr, New Orleans, LA 70112 USA	Louisiana State University System	Chen, JD (corresponding author), Louisiana State Univ, Med Ctr, Dept Microbiol, Stanley S Scott Canc Ctr, 1901 Perdido St, New Orleans, LA 70112 USA.			Pochampally, Radhika/0000-0002-4263-0364	NATIONAL CANCER INSTITUTE [R01CA072915] Funding Source: NIH RePORTER; NCI NIH HHS [CA72915] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chen JD, 1996, MOL CELL BIOL, V16, P2445; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Chen LH, 1998, P NATL ACAD SCI USA, V95, P195, DOI 10.1073/pnas.95.1.195; Chen LH, 1997, J BIOL CHEM, V272, P22966, DOI 10.1074/jbc.272.36.22966; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Donato NJ, 1998, J BIOL CHEM, V273, P5067, DOI 10.1074/jbc.273.9.5067; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elenbaas B, 1996, MOL MED, V2, P439, DOI 10.1007/BF03401903; Erhardt P, 1997, J BIOL CHEM, V272, P15049, DOI 10.1074/jbc.272.24.15049; Gottlieb E, 1998, EMBO J, V17, P3587, DOI 10.1093/emboj/17.13.3587; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; JEOUNG DI, 1995, J BIOL CHEM, V270, P18367, DOI 10.1074/jbc.270.31.18367; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LANDERS JE, 1994, ONCOGENE, V9, P2745; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LUNA RMD, 1995, NATURE, V378, P203; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MITSUDOMI T, 1992, ONCOGENE, V7, P171; MIYASHITA T, 1995, CELL, V80, P293; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Pochampally R, 1998, ONCOGENE, V17, P2629, DOI 10.1038/sj.onc.1202206; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Wilhelm S, 1998, EUR J IMMUNOL, V28, P891, DOI 10.1002/(SICI)1521-4141(199803)28:03<891::AID-IMMU891>3.3.CO;2-O; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	52	61	62	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					15271	15277		10.1074/jbc.274.21.15271	http://dx.doi.org/10.1074/jbc.274.21.15271			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329737	hybrid			2022-12-25	WOS:000081965200102
J	Stock, MF; Guerrero, J; Cobb, B; Eggers, CT; Huang, TG; Li, X; Hackney, DD				Stock, MF; Guerrero, J; Cobb, B; Eggers, CT; Huang, TG; Li, X; Hackney, DD			Formation of the compact confomer of kinesin requires a COOH-terminal heavy chain domain and inhibits microtubule-stimulated ATPase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE BRAIN KINESIN; HELICAL COILED-COIL; DROSOPHILA KINESIN; CONVENTIONAL KINESIN; ENZYMATIC-PROPERTIES; ESCHERICHIA-COLI; DIMERIC KINESIN; SMOOTH-MUSCLE; NECK REGION; MOTOR	Full-length Drosophila kinesin heavy chain from position 1 to 975 was expressed in Escherichia coli (DKH975) and is a dimer, The sedimentation coefficient of DKH975 shifts from 5.4 S at 1 M NaCl to similar to 6.9 S at <0.2 Rr NaCl, This transition of DKH975 between extended and compact conformations is essentially identical to that for the heavy chain dimer of bovine kinesin (Hackney, D. D., Levitt, J. D., and Suhan, J. (1992) J. Biol. Chem, 267, 8696-8701), Thus the capacity for undergoing the 7 S/5 S transition is an intrinsic property of the heavy chains and requires neither light chains nor eukaryotic post-translational modification. DKH960 undergoes a similar transition, indicating that the extreme COOH-terminal region is not required. More extensive deletions from the COOH-terminal (DKH945 and DKH937) result in a shift in the midpoint for the transition to lower salt concentrations. DKH927 and shorter constructs remaining extended even in the absence of added salt. Thus the COOH-terminal similar to 50 amino acids are required for the formation of the compact conformation. Separately expressed COOH-terminal tail segments and NH2-terminal head/neck segments interact in a salt-dependent manner that is consistent with the compact conformer being produced by the interaction of domains from these regions of the heavy chain dimer, The microtubule-stimulated ATPase rate of DKH975 in the compact conformer is strongly inhibited compared with the rate of extended DKH894 (4 s(-1) and 35 s(-1), respectively, for k(cat) at saturating microtubules).	Carnegie Mellon Univ, Dept Biol Sci, Pittsburgh, PA 15213 USA	Carnegie Mellon University	Hackney, DD (corresponding author), Carnegie Mellon Univ, Dept Biol Sci, 4400 5th Ave, Pittsburgh, PA 15213 USA.	ddh+@andrew.cmu.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028562] Funding Source: NIH RePORTER; NINDS NIH HHS [NS28562] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BLOOM GS, 1988, BIOCHEMISTRY-US, V27, P3409, DOI 10.1021/bi00409a043; Cheng JQ, 1998, BIOCHEMISTRY-US, V37, P5288, DOI 10.1021/bi972742j; Coy D. L., 1996, Biophysical Journal, V70, pA36; DECUEVAS M, 1992, J CELL BIOL, V116, P957, DOI 10.1083/jcb.116.4.957; HACKNEY DD, 1992, J BIOL CHEM, V267, P8696; HACKNEY DD, 1991, BIOCHEM BIOPH RES CO, V174, P810, DOI 10.1016/0006-291X(91)91490-4; HACKNEY DD, 1994, J BIOL CHEM, V269, P16508; HACKNEY DD, 1991, METHOD ENZYMOL, V196, P175; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; HISANAGA S, 1989, CELL MOTIL CYTOSKEL, V12, P264, DOI 10.1002/cm.970120407; HUANG TG, 1994, J BIOL CHEM, V269, P16493; HUANG TG, 1994, J BIOL CHEM, V269, P16502; IKEBE M, 1983, BIOCHEMISTRY-US, V22, P4580, DOI 10.1021/bi00288a036; JIANG MY, 1995, BIOPHYS J, V68, pS283; Jiang W, 1997, J BIOL CHEM, V272, P7626, DOI 10.1074/jbc.272.12.7626; KOSIK KS, 1990, J BIOL CHEM, V265, P3278; Kozielski F, 1997, CELL, V91, P985, DOI 10.1016/S0092-8674(00)80489-4; KUZNETSOV SA, 1989, J BIOL CHEM, V264, P589; KUZNETSOV SA, 1988, EMBO J, V7, P353, DOI 10.1002/j.1460-2075.1988.tb02820.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE KD, 1995, J BIOL CHEM, V270, P5600, DOI 10.1074/jbc.270.10.5600; Lupas A, 1996, METHOD ENZYMOL, V266, P513; MACKNIGHT AE, 1994, DIVERSITY MYOSIN LIK; Moraga D. E., 1997, Molecular Biology of the Cell, V8, p258A; Morii H, 1997, BIOCHEMISTRY-US, V36, P1933, DOI 10.1021/bi962392l; NAVONE F, 1992, J CELL BIOL, V117, P1263, DOI 10.1083/jcb.117.6.1263; NEUHOFF V, 1988, ELECTROPHORESIS, V9, P255, DOI 10.1002/elps.1150090603; NICLAS J, 1994, NEURON, V12, P1059, DOI 10.1016/0896-6273(94)90314-X; STEINBERG G, 1995, MOL BIOL CELL, V6, P1605, DOI 10.1091/mbc.6.11.1605; STEWART RJ, 1993, P NATL ACAD SCI USA, V90, P5209, DOI 10.1073/pnas.90.11.5209; Tripet B, 1997, J BIOL CHEM, V272, P8946; TRYBUS KM, 1982, P NATL ACAD SCI-BIOL, V79, P6151, DOI 10.1073/pnas.79.20.6151; URRUTIA R, 1991, P NATL ACAD SCI USA, V88, P6701, DOI 10.1073/pnas.88.15.6701; Vale RD, 1997, ANNU REV CELL DEV BI, V13, P745, DOI 10.1146/annurev.cellbio.13.1.745; WAGNER MC, 1989, CELL MOTIL CYTOSKEL, V12, P195, DOI 10.1002/cm.970120403; WRIGHT BD, 1991, J CELL BIOL, V113, P817, DOI 10.1083/jcb.113.4.817; YANG JT, 1988, P NATL ACAD SCI USA, V85, P1864, DOI 10.1073/pnas.85.6.1864; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2	38	119	120	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					14617	14623		10.1074/jbc.274.21.14617	http://dx.doi.org/10.1074/jbc.274.21.14617			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329654	hybrid			2022-12-25	WOS:000081965200019
J	Xu, P; Jacobs, AR; Taylor, SI				Xu, P; Jacobs, AR; Taylor, SI			Interaction of insulin receptor substrate 3 with insulin receptor, insulin receptor-related receptor, insulin-like growth factor-1 receptor, and downstream signaling proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-DEPENDENT INTERACTION; PLECKSTRIN HOMOLOGY DOMAIN; TANDEM SH2 DOMAINS; PHOSPHATIDYLINOSITOL 3-KINASE; HEPATOMA-CELLS; SH2-CONTAINING PROTEIN; TYROSINE-PHOSPHATASE; DOCKING PROTEIN; 2-HYBRID SYSTEM; RAT ADIPOCYTES	Insulin receptor substrates (IRS) mediate biological actions of insulin, growth factors, and cytokines. All four mammalian IRS proteins contain pleckstrin homology (PH) and phosphotyrosine binding (PTB) domains at their N termini. However, the molecules diverge in their C-terminal sequences. IRS3 is considerably shorter than IRS1, IRS2, and IRS4, and is predicted to interact with a distinct group of downstream signaling molecules. In the present study, we investigated interactions of IRS3 with various signaling molecules. The PTB domain of mIRS3 is necessary and sufficient for binding to the juxtamembrane NPXpY motif of the insulin receptor in the yeast two-hybrid system. This interaction is stronger if the PH domain or the C-terminal phosphorylation domain is retained in the construct. As determined in a modified yeast two-hybrid system, mIRS3 bound strongly to the p85 subunit of phosphatidylinositol 3-kinase. Although high affinity interaction required the presence of at least two of the four YXXM motifs in mIRS3, there was not a requirement for specific YXXM motifs. mIRS3 also bound to SHP2, Grb2, Nck, and Shc, but less strongly than to p85. Studies in COS-7 cells demonstrated that deletion of either the PH or the PTB domain abolished insulin-stimulated phosphorylation of mIRS3. Insulin stimulation promoted the association of mIRS3 with p85, SHP2, Nck, and Shc. Despite weak association between mIRS3 and Grb2, this interaction was not increased by insulin, and may not be mediated by the SH2 domain of Grb2. Thus, in contrast to other IRS proteins, mIRS3 appears to have greater specificity for activation of the phosphatidylinositol 3-kinase pathway rather than the Grb2/Ras pathway.	NIDDK, Diabet Branch, NIH, Bethesda, MD 20892 USA; George Washington Univ, Grad Program Genet, Washington, DC 20052 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); George Washington University	Taylor, SI (corresponding author), NIDDK, Diabet Branch, NIH, Bldg 10,Rm 9S-213, Bethesda, MD 20892 USA.	simeon_taylor@nih.gov						Anai O, 1998, J BIOL CHEM, V273, P29686, DOI 10.1074/jbc.273.45.29686; Burks DJ, 1997, J BIOL CHEM, V272, P27716, DOI 10.1074/jbc.272.44.27716; CRAPARO A, 1995, J BIOL CHEM, V270, P15639, DOI 10.1074/jbc.270.26.15639; Eck MJ, 1996, NATURE, V379, P277, DOI 10.1038/379277a0; Fuller KJ, 1998, BIOTECHNIQUES, V25, P85, DOI 10.2144/98251st04; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; He WM, 1996, J BIOL CHEM, V271, P11641, DOI 10.1074/jbc.271.20.11641; HERBST JJ, 1994, BIOCHEMISTRY-US, V33, P9376, DOI 10.1021/bi00198a002; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Kaburagi Y, 1997, J BIOL CHEM, V272, P25839, DOI 10.1074/jbc.272.41.25839; Keegan K, 1996, ONCOGENE, V12, P1537; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LAVAN BE, 1993, J BIOL CHEM, V268, P5921; Lavan BE, 1997, J BIOL CHEM, V272, P11439; Lavan BE, 1997, J BIOL CHEM, V272, P21403, DOI 10.1074/jbc.272.34.21403; MARGOLIS RN, 1990, BIOCHEM BIOPH RES CO, V166, P562, DOI 10.1016/0006-291X(90)90845-E; MILARSKI KL, 1995, BIOCHEM J, V308, P579, DOI 10.1042/bj3080579; MYERS MG, 1995, J BIOL CHEM, V270, P11715, DOI 10.1074/jbc.270.20.11715; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; OSBORNE MA, 1995, BIO-TECHNOL, V13, P1474, DOI 10.1038/nbt1295-1474; Ottinger EA, 1998, J BIOL CHEM, V273, P729, DOI 10.1074/jbc.273.2.729; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PERROTTI N, 1987, P NATL ACAD SCI USA, V84, P3137, DOI 10.1073/pnas.84.10.3137; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; Ross SA, 1998, BIOCHEM BIOPH RES CO, V247, P487, DOI 10.1006/bbrc.1998.8821; SawkaVerhelle D, 1996, J BIOL CHEM, V271, P5980, DOI 10.1074/jbc.271.11.5980; SawkaVerhelle D, 1997, J BIOL CHEM, V272, P16414, DOI 10.1074/jbc.272.26.16414; Sciacchitano S, 1997, ENDOCRINOLOGY, V138, P4931, DOI 10.1210/en.138.11.4931; SmithHall J, 1997, BIOCHEMISTRY-US, V36, P8304, DOI 10.1021/bi9630974; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; TARTAREDECKERT S, 1995, J BIOL CHEM, V270, P23456, DOI 10.1074/jbc.270.40.23456; Tirode F, 1997, J BIOL CHEM, V272, P22995, DOI 10.1074/jbc.272.37.22995; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VanRenterghem B, 1998, J BIOL CHEM, V273, P29942, DOI 10.1074/jbc.273.45.29942; VOLIOVITCH H, 1995, J BIOL CHEM, V270, P18083, DOI 10.1074/jbc.270.30.18083; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; Yenush L, 1996, J BIOL CHEM, V271, P24300, DOI 10.1074/jbc.271.39.24300; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; Zhang J, 1996, ANAL BIOCHEM, V242, P68, DOI 10.1006/abio.1996.0429; ZhangSun G, 1996, ENDOCRINOLOGY, V137, P2649, DOI 10.1210/en.137.7.2649; Zhou LX, 1997, J BIOL CHEM, V272, P29829, DOI 10.1074/jbc.272.47.29829; Zhou LX, 1999, MOL ENDOCRINOL, V13, P505, DOI 10.1210/me.13.3.505; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	49	42	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					15262	15270		10.1074/jbc.274.21.15262	http://dx.doi.org/10.1074/jbc.274.21.15262			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329736	hybrid			2022-12-25	WOS:000081965200101
J	Murdock, DG; Boone, BE; Esposito, LA; Wallace, DC				Murdock, DG; Boone, BE; Esposito, LA; Wallace, DC			Up-regulation of nuclear and mitochondrial genes in the skeletal muscle of mice lacking the heart muscle isoform of the adenine nucleotide translocator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE CHAIN-REACTION; CYTOCHROME-C-OXIDASE; DIFFERENTIAL DISPLAY; SEQUENCE-ANALYSIS; IDENTIFICATION; EXPRESSION; SUBUNIT; CLONING; MUTANT; CDNA	Mice deficient in the heart/muscle specific isoform of the adenine nucleotide translocator (ANT1) exhibit many of the hallmarks of human oxidative phosphorylation (OXPHOS) disease, including a dramatic proliferation of skeletal muscle mitochondria, Because many of the genes necessary for mitochondrial biosynthesis, OXPHOS function, and response to OXPHOS disease might be expected to be up-regulated in the Ant1(-/-)mouse, we used differential display reverse transcription-polymerase chain reaction techniques in an effort to identify these genes. 17 genes were identified as upregulated in Ant1-deficient mice, and they fall into four categories: 1) nuclear and mitochondrial genes encoding OXPHOS components, 2) mitochondrial tRNA and rRNA genes, 3) genes involved in intermediary metabolism, and 4) an eclectic group of other genes. Among the latter genes, we identified the gene encoding anti-apoptotic Mcl-1, the Skd3 gene, and the WS-3 gene, which were previously unknown to be related to mitochondrial function. These results indicate that identification of genes up-regulated in the skeletal muscle of the Ant1-deficient mouse provides a novel method for identifying mammalian genes required for mitochondrial biogenesis.	Emory Univ, Sch Med, Ctr Mol Med, Atlanta, GA 30322 USA	Emory University	Wallace, DC (corresponding author), Emory Univ, Sch Med, Ctr Mol Med, 1462 Clifton Rd NE, Atlanta, GA 30322 USA.		Murdock, Deborah/C-3483-2012		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045572] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021328] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013154] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45572] Funding Source: Medline; NIA NIH HHS [AG13154] Funding Source: Medline; NINDS NIH HHS [NS21328] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BASU A, 1990, BIOCHIM BIOPHYS ACTA, V1087, P98, DOI 10.1016/0167-4781(90)90128-O; Buess M, 1997, NUCLEIC ACIDS RES, V25, P2233, DOI 10.1093/nar/25.11.2233; CHUNG AB, 1992, J BIOL CHEM, V267, P21154; CLAYTON DA, 1992, INT REV CYTOL, V141, P217, DOI 10.1016/S0074-7696(08)62067-7; Graham BH, 1997, NAT GENET, V16, P226, DOI 10.1038/ng0797-226; HEDDI A, 1994, BBA-MOL BASIS DIS, V1226, P206, DOI 10.1016/0925-4439(94)90030-2; HEDDI A, 1993, J BIOL CHEM, V268, P12156; HIRVAS L, 1991, EMBO J, V10, P1017, DOI 10.1002/j.1460-2075.1991.tb08036.x; HOOD DA, 1994, CAN J APPL PHYSIOL, V19, P12, DOI 10.1139/h94-002; HUDSON JW, 1993, BIOCHIM BIOPHYS ACTA, V1164, P197, DOI 10.1016/0167-4838(93)90248-P; Ichikawa K, 1997, GENE, V189, P277, DOI 10.1016/S0378-1119(96)00863-3; JOH T, 1987, J BIOL CHEM, V262, P15127; KELLY TM, 1993, J BIOL CHEM, V268, P19866; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; MOCZKO M, 1995, J MOL BIOL, V254, P538, DOI 10.1006/jmbi.1995.0636; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; NIELSEN PJ, 1989, NUCLEIC ACIDS RES, V17, P6723, DOI 10.1093/nar/17.16.6723; PERIER F, 1995, GENE, V152, P157, DOI 10.1016/0378-1119(94)00697-Q; Schmitt M, 1996, J CELL BIOL, V134, P1375, DOI 10.1083/jcb.134.6.1375; Schneider R, 1997, FEBS LETT, V407, P249, DOI 10.1016/S0014-5793(97)00360-8; WALKER JE, 1992, J MOL BIOL, V226, P1051, DOI 10.1016/0022-2836(92)91052-Q; Wallace D. C., 1996, P1280; Yang T, 1996, J CELL PHYSIOL, V166, P523, DOI 10.1002/(SICI)1097-4652(199603)166:3<523::AID-JCP7>3.0.CO;2-R; YANG T, 1995, J CELL BIOL, V128, P1173, DOI 10.1083/jcb.128.6.1173	24	70	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 14	1999	274	20					14429	14433		10.1074/jbc.274.20.14429	http://dx.doi.org/10.1074/jbc.274.20.14429			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	196RW	10318868	hybrid			2022-12-25	WOS:000080322200097
J	Cuddihy, AR; Wong, AHT; Tam, NWN; Li, SY; Koromilas, AE				Cuddihy, AR; Wong, AHT; Tam, NWN; Li, SY; Koromilas, AE			The double-stranded RNA activated protein kinase PKR physically associates with the tumor suppressor p53 protein and phosphorylates human p53 on serine 392 in vitro	ONCOGENE			English	Article						tumor suppressor; protein kinase; protein-protein interactions; phosphorylation	C-TERMINAL DOMAIN; NF-KAPPA-B; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; MALIGNANT TRANSFORMATION; INDUCED APOPTOSIS; NUCLEIC-ACIDS; IN-VITRO; INTERFERON; REPRESSION	The tumor suppressor p53 is a multifunctional protein that plays a critical role in modulating cellular responses upon DNA damage or other stresses, These functions of p53 are regulated both by protein-protein interactions and phosphorylation, The double-stranded RNA activated protein kinase PKR is a serine/threonine kinase that modulates protein synthesis through the phosphorylation of translation initiation factor eIF-2 alpha. PKR is an interferon (IFN)-inducible protein that is thought to mediate the anti-viral and anti-proliferative effects of IFN via its capacity to inhibit protein synthesis, Here we report that PKR physically associates with p53. The interaction of PKR with p53 is enhanced by IFNs and upon conditions that p53 acquires a wild type conformation. PKR/p53 complex formation in vitro requires the N-terminal regulatory domain of PKR and the last 30 amino acids of the C-terminus of human p53. In addition, p53 may function as a substrate of PKR since phosphorylation of human p53 on serine(392) is induced by activated PKR in vitro. These novel findings raise the possibility of a functional interaction between PKR and p53 in vivo, which may account, at least in part, for the ability of each protein to regulate gene expression at both the transcriptional and the translational levels.	McGill Univ, Dept Oncol, Montreal, PQ, Canada; McGill Univ, Dept Med, Montreal, PQ, Canada; McGill Univ, Dept Microbiol & Immunol, Montreal, PQ, Canada; McGill Univ, Dept Anat & Cell Biol, Montreal, PQ, Canada	McGill University; McGill University; McGill University; McGill University	Koromilas, AE (corresponding author), Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, 3755 Cote St Catharine Rd,Room 528-1, Montreal, PQ H3T 1E2, Canada.			Cuddihy, Andrew/0000-0002-9898-0443				Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; BALKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413; BALKALKIN G, 1995, NUCLEIC ACIDS RES, V23, P362; BARBER GN, 1995, MOL CELL BIOL, V15, P3138; BAYLE JH, 1995, P NATL ACAD SCI USA, V92, P5729, DOI 10.1073/pnas.92.12.5729; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRAIN R, 1994, ONCOGENE, V9, P1775; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; Choubey D, 1996, EMBO J, V15, P5668, DOI 10.1002/j.1460-2075.1996.tb00951.x; CHOUBEY D, 1995, J BIOL CHEM, V270, P6134, DOI 10.1074/jbc.270.11.6134; Clemens MJ, 1997, J INTERF CYTOK RES, V17, P503, DOI 10.1089/jir.1997.17.503; Datta B, 1996, J BIOL CHEM, V271, P27544, DOI 10.1074/jbc.271.44.27544; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Ewen ME, 1996, BBA-REV CANCER, V1242, P181, DOI 10.1016/0304-419X(95)00010-D; EWEN ME, 1995, GENE DEV, V9, P204, DOI 10.1101/gad.9.2.204; FONTOURA BMA, 1992, MOL CELL BIOL, V12, P5145, DOI 10.1128/MCB.12.11.5145; Fontoura BMA, 1997, MOL CELL BIOL, V17, P3146, DOI 10.1128/MCB.17.6.3146; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Fu LN, 1997, EMBO J, V16, P4117, DOI 10.1093/emboj/16.13.4117; Fu LN, 1996, EMBO J, V15, P4392, DOI 10.1002/j.1460-2075.1996.tb00812.x; GALABRU J, 1987, J BIOL CHEM, V262, P15538; GEBALLE AP, 1996, TRANSLATIONAL CONTRO, P173; GREEN SR, 1995, MOL CELL BIOL, V15, P358, DOI 10.1128/MCB.15.1.358; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HARPER JW, 1993, CELL, V75, P805; HERSHEY JWB, 1989, J BIOL CHEM, V264, P20823; HOPPESEYLER F, 1993, J VIROL, V67, P3111, DOI 10.1128/JVI.67.6.3111-3117.1993; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; HOWE JG, 1984, CELL, V37, P85; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; ISHIOKA C, 1995, ONCOGENE, V10, P1485; KATZE MG, 1991, MOL CELL BIOL, V11, P5497, DOI 10.1128/MCB.11.11.5497; Katze Michael G., 1995, Trends in Microbiology, V3, P75, DOI 10.1016/S0966-842X(00)88880-0; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; LEE C, 1994, J OBJECT-ORIENT PROG, V7, P49; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Lee SB, 1997, VIROLOGY, V231, P81, DOI 10.1006/viro.1997.8494; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Lu H, 1998, P NATL ACAD SCI USA, V95, P6399, DOI 10.1073/pnas.95.11.6399; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; Milne DM, 1996, ONCOGENE, V13, P205; Min W, 1996, MOL CELL BIOL, V16, P359; MIYASHITA T, 1995, CELL, V80, P293; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; Pfeifer GP, 1997, BBA-REV CANCER, V1333, pM1, DOI 10.1016/S0304-419X(97)00004-8; REED M, 1995, P NATL ACAD SCI USA, V92, P9455, DOI 10.1073/pnas.92.21.9455; RendeFournier R, 1997, VIROLOGY, V238, P410, DOI 10.1006/viro.1997.8824; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Steegenga WT, 1996, J MOL BIOL, V263, P103, DOI 10.1006/jmbi.1996.0560; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; Takizawa T, 1996, J VIROL, V70, P8128, DOI 10.1128/JVI.70.11.8128-8132.1996; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Wong AHT, 1997, EMBO J, V16, P1291, DOI 10.1093/emboj/16.6.1291; WU L, 1995, MOL CELL BIOL, V15, P497, DOI 10.1128/MCB.15.1.497; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; Yeung MC, 1996, P NATL ACAD SCI USA, V93, P12451, DOI 10.1073/pnas.93.22.12451; Zhu SH, 1996, J BIOL CHEM, V271, P24989, DOI 10.1074/jbc.271.40.24989	68	171	176	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	1999	18	17					2690	2702		10.1038/sj.onc.1202620	http://dx.doi.org/10.1038/sj.onc.1202620			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FH	10348343				2022-12-25	WOS:000080124900004
J	Calabro, V; Parisi, T; Di Cristofano, A; La Mantia, G				Calabro, V; Parisi, T; Di Cristofano, A; La Mantia, G			Suppression of Ras-mediated NIH3T3 transformation by p19(ARF) does not involve alterations of cell growth properties	ONCOGENE			English	Article						cellular transformation; tumor suppressor genes; cell cycle regulation; INK4a locus	CYCLE ARREST; IN-VITRO; LOCUS; P16(INK4); P16; MUTATIONS; PROTEIN; CANCER; MDM2; P53	The INK4a gene, one of the most frequently disrupted loci in human cancer, encodes two unrelated proteins, p16(INK4a) and p19(ARF), that both block cell proliferation. p16(INK4a) is a component of the Rb regulatory pathway, while p19(ARF) has been functionally related to p53, Moreover, p16(INK4a) is inactivated in many human tumors, while it has been very recently reported that p19(ARF) null mice develop tumors early in life. We show here that p19(ARF) iS able to inhibit the formation of G418-resistant colonies when transfected into human and mouse cell lines expressing wild-type p53, regardless of p16 status. Moreover its amino terminal domain encoded by exon 1 beta is still sufficient to obtain the same effect. We have analysed the ability of p19(ARF) to interfere with Ras-mediated cellular transformation in the NIH3T3 cell line. Cotransfection of p19(ARF) together with activated ras potently inhibited the formation of transformed foci in a dose-dependent manner. We have also isolated stable NIH3T3 transfectants expressing p19(ARF) and we have measured their growth properties as well as their efficiency of transformation by activated ras, Our results suggest that p19(ARF) can interfere,vith oncogene-mediated transformation, without significantly affecting NIH3T3 cell growth, at least at the levels of expression achieved in these experiments.	Univ Naples Federico II, Dept Genet Gen & Mol Biol, I-80134 Naples, Italy	University of Naples Federico II	La Mantia, G (corresponding author), Univ Naples Federico II, Dept Genet Gen & Mol Biol, Via Mezzocannone 8, I-80134 Naples, Italy.		di cristofano, antonio/AAJ-3796-2020; Calabro, Viola/H-6156-2013; Di Cristofano, Antonio/B-4148-2016	di cristofano, antonio/0000-0003-2537-3228; Calabro, Viola/0000-0002-6508-8889				Arap W, 1997, ONCOGENE, V15, P2013, DOI 10.1038/sj.onc.1201389; CALABRO V, 1996, INT J CANCER, V66, P1; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V264, P435; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Liggett WH, 1996, CANCER RES, V56, P4119; MAO L, 1995, CANCER RES, V55, P2995; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; Quelle DE, 1997, P NATL ACAD SCI USA, V94, P669, DOI 10.1073/pnas.94.2.669; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Spillare EA, 1996, MOL CARCINOGEN, V16, P53, DOI 10.1002/(SICI)1098-2744(199605)16:1<53::AID-MC7>3.0.CO;2-P; STONE S, 1995, CANCER RES, V55, P2988; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	20	14	14	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 25	1999	18	12					2157	2162		10.1038/sj.onc.1202532	http://dx.doi.org/10.1038/sj.onc.1202532			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	179TX	10321741				2022-12-25	WOS:000079346200014
J	Masse, E; Drolet, M				Masse, E; Drolet, M			Escherichia coli DNA topoisomerase I inhibits R-loop formation by relaxing transcription-induced negative supercoiling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TEMPLATE; RNA; ELONGATION; MECHANISM; MUTANTS; VITRO	It has recently been shown that RNase H overproduction can partially compensate for the growth defect due to the absence of DNA topoisomerase I in Escherichia coli (Drolet, M,, Phoenix, P,, Menzel, R,, Masse, E,, Liu, L. F,, and Crouch, R, J, (1995) Proc. Natl, Acad. Sci, U, S, A. 92, 3526-3530), This result has suggested a model in which inhibitory R-loops occur during transcription in topA mutants. Results presented in this report further support this notion and demonstrate that transcription-induced supercoliing is involved in R-loop formation, First, we show that stable R-loop formation during in vitro transcription with E, coli RNA polymerase only occurs in the presence of DNA gyrase, Second, extensive R-loop formation in vivo, revealed by the production of RNase H-sensitive hypernegatively supercolied plasmid DNAs, is observed under conditions where topA mutants fail to grow. Furthermore, we have demonstrated that the coupling of transcription and translation in bacteria is an efficient way of preventing R-loop formation.	Univ Montreal, Dept Microbiol & Immunol, Montreal, PQ H3C 3J7, Canada	Universite de Montreal	Drolet, M (corresponding author), Univ Montreal, Dept Microbiol & Immunol, CP 6128,Succursale Centreville, Montreal, PQ H3C 3J7, Canada.	Marc.Drolet@umontreal.ca	Drolet, Marc/M-1328-2019					DAUBE SS, 1994, BIOCHEMISTRY-US, V33, P340, DOI 10.1021/bi00167a044; DRLICA K, 1992, MOL MICROBIOL, V6, P425, DOI 10.1111/j.1365-2958.1992.tb01486.x; DROLET M, 1995, P NATL ACAD SCI USA, V92, P3526, DOI 10.1073/pnas.92.8.3526; DROLET M, 1994, J BIOL CHEM, V269, P2068; ITOH T, 1980, P NATL ACAD SCI-BIOL, V77, P2450, DOI 10.1073/pnas.77.5.2450; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; LYNCH AS, 1993, J BACTERIOL, V175, P1645, DOI 10.1128/JB.175.6.1645-1655.1993; Masse E, 1999, J BIOL CHEM, V274, P16654, DOI 10.1074/jbc.274.23.16654; Masse E, 1997, J BIOL CHEM, V272, P12816, DOI 10.1074/jbc.272.19.12816; MASUKATA H, 1990, CELL, V62, P331, DOI 10.1016/0092-8674(90)90370-T; Phoenix P, 1997, J BIOL CHEM, V272, P1473, DOI 10.1074/jbc.272.3.1473; PRUSS GJ, 1985, J MOL BIOL, V185, P51, DOI 10.1016/0022-2836(85)90182-2; Sambrook J., 2002, MOL CLONING LAB MANU; TSAO YP, 1989, CELL, V56, P111, DOI 10.1016/0092-8674(89)90989-6; von Hippel PH, 1998, SCIENCE, V281, P660, DOI 10.1126/science.281.5377.660; WANG JC, 1974, J MOL BIOL, V87, P797, DOI 10.1016/0022-2836(74)90085-0; WU HY, 1988, CELL, V53, P433, DOI 10.1016/0092-8674(88)90163-8	17	107	111	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16659	16664		10.1074/jbc.274.23.16659	http://dx.doi.org/10.1074/jbc.274.23.16659			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347234	hybrid			2022-12-25	WOS:000080668600094
J	Ried, S; Jager, C; Jeffers, M; Vande Woude, GF; Graeff, H; Schmitt, M; Lengyel, E				Ried, S; Jager, C; Jeffers, M; Vande Woude, GF; Graeff, H; Schmitt, M; Lengyel, E			Activation mechanisms of the urokinase-type plasminogen activator promoter by hepatocyte growth factor scatter factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; RHO-FAMILY PROTEINS; GRB2 BINDING-SITE; RAS TRANSFORMATION; MET PROTOONCOGENE; SIGNALING PATHWAY; EPITHELIAL-CELLS; OVARIAN-CANCER; ONCOGENIC RAS; PHORBOL-ESTER	Hepatocyte growth factor/scatter factor (HGF/SF) is a pleiotropic effector inducing invasion and metastasis of tumor cells that express the Met tyrosine kinase receptor, One of the effecters of HGF/SF is the urokinase-type plasminogen activator, a serine protease that facilitates tumor progression and metastasis by controlling the synthesis of the extracellular matrix degrading plasmin, Stimulation of NIH 3T3 cells that were stably trans fected with the human Met receptor (NIH 3T3-Met(hum)) with HGF/SF induced a trans-activation of the urokinase promoter and urokinase secretion. Induction of the urokinase promoter by HGF/SF via the Met receptor was blocked by co-expression of a dominant-negative Grb2 and Sos1 expression construct. Further, the expression of the catalytically inactive mutants of Ha-Ras, RhoA, c-Raf, and Erk2 or addition of the Mek1-specific inhibitor PD 098059 abrogated the stimulation of the urokinase promoter by HGF/SF. A sequence residing between -2109 and -1870 base pairs (bp) was critical for stimulation of the urokinase gene by HGF/SF. Mobility shift assays with oligonucleotides spanning an AP-1 site at -1880 bp or a combined PEA3/AP-1 site at -1967 bp showed binding of nuclear factors from NIH 3T3-Met(hum) cells. Expression of an expression plasmid that inhibits DNA binding of AP-1 proteins (A-Fos) abrogated inducible and basal activation of the urokinase promoter. Nuclear extract from unstimulated NIH 3T3-Met(hum) cells contained more JunD and showed a stronger JunD supershift with the AP-I oligonucleotides, compared with HGF/SF-stimulated cells. Consistent with the levels of JunD expression being functionally important for basal expression of the urokinase promoter, we found that overexpression of wild type JunD inhibited the induction of the urokinase promoter by HGF/SF. These data suggest that the induction of urokinase by HGF/SF is regulated by a Grb2/Sos1/Ha-Ras/c-Raf/RhoA/Mek1/ Erk2/c-Jun-dependent mitogen-activated protein kinase pathway.	Tech Univ Munich, Dept Obstet & Gynecol, D-81675 Munich, Germany; NCI, ABL Basic Res Program, NIH, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA; NCI, Div Basic Sci, NIH, Bethesda, MD 20892 USA	Technical University of Munich; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Lengyel, E (corresponding author), Tech Univ Munich, Klinikum Rechts Isar, Dept Obstet & Gynecol, Ismaninger Str 22, D-81675 Munich, Germany.		Lengyel, Ernst/D-9220-2014	Lengyel, Ernst/0000-0001-8624-1507				ALESSI DR, 1993, ONCOGENE, V8, P2015; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Besser D, 1997, ONCOGENE, V14, P705, DOI 10.1038/sj.onc.1200879; BLASI F, 1993, BIOESSAYS, V15, P105, DOI 10.1002/bies.950150206; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BROWN PH, 1993, ONCOGENE, V8, P877; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; Choong PFM, 1996, INT J CANCER, V69, P268, DOI 10.1002/(SICI)1097-0215(19960822)69:4<268::AID-IJC5>3.0.CO;2-V; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dunsmore SE, 1996, J BIOL CHEM, V271, P24576, DOI 10.1074/jbc.271.40.24576; ELLIS V, 1991, J BIOL CHEM, V266, P12752; Fixman ED, 1997, J BIOL CHEM, V272, P20167, DOI 10.1074/jbc.272.32.20167; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; HARTMANN G, 1994, J BIOL CHEM, V269, P21936; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976; Jeffers M, 1996, MOL CELL BIOL, V16, P1115; KhosraviFar R, 1998, ADV CANCER RES, V72, P57; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Klippel A, 1996, MOL CELL BIOL, V16, P4117; KUHN W, 1994, GYNECOL ONCOL, V55, P401, DOI 10.1006/gyno.1994.1313; Lengye E, 1995, ONCOGENE, V11, P2639; Lengyel E, 1997, ONCOGENE, V14, P2563, DOI 10.1038/sj.onc.1201098; LENGYEL E, 1995, J BIOL CHEM, V270, P23007, DOI 10.1074/jbc.270.39.23007; Lengyel E, 1996, J CELL BIOCHEM, V61, P430, DOI 10.1002/(SICI)1097-4644(19960601)61:3<430::AID-JCB10>3.0.CO;2-N; LIOTTA LA, 1981, CANCER RES, V41, P4629; MARTIN ME, 1988, P NATL ACAD SCI USA, V85, P5839, DOI 10.1073/pnas.85.16.5839; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NALDINI L, 1995, J BIOL CHEM, V270, P603, DOI 10.1074/jbc.270.2.603; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; NERLOV C, 1991, ONCOGENE, V6, P1583; NERLOV C, 1992, EMBO J, V11, P4573, DOI 10.1002/j.1460-2075.1992.tb05559.x; Nguyen L, 1997, J BIOL CHEM, V272, P20811, DOI 10.1074/jbc.272.33.20811; Olive M, 1997, J BIOL CHEM, V272, P18586, DOI 10.1074/jbc.272.30.18586; PEPPER MS, 1992, J BIOL CHEM, V267, P20493; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Rahimi N, 1996, J BIOL CHEM, V271, P24850, DOI 10.1074/jbc.271.40.24850; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; RORTH P, 1990, NUCLEIC ACIDS RES, V18, P5009, DOI 10.1093/nar/18.17.5009; SAKAUE M, 1995, MOL CELL BIOL, V15, P379, DOI 10.1128/MCB.15.1.379; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; Vandel L, 1996, MOL CELL BIOL, V16, P1881; VANDEL L, 1995, ONCOGENE, V10, P495; VERDE P, 1988, NUCLEIC ACIDS RES, V16, P10699, DOI 10.1093/nar/16.22.10699; WARN R, 1995, NATURE, V376, P723, DOI 10.1038/376723a0; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; WILHELM O, 1995, CLIN EXP METASTAS, V13, P296, DOI 10.1007/BF00133485; WILHELM O, 1988, CANCER RES, V48, P3507; WUN TC, 1982, J BIOL CHEM, V257, P3276; Xie YM, 1995, J BIOL CHEM, V270, P30717, DOI 10.1074/jbc.270.51.30717; YAMASHITA J, 1994, CANCER RES, V54, P1630; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	61	76	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16377	16386		10.1074/jbc.274.23.16377	http://dx.doi.org/10.1074/jbc.274.23.16377			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347197	hybrid			2022-12-25	WOS:000080668600057
J	Le, KT; Boue-Grabot, E; Archambault, V; Seguela, P				Le, KT; Boue-Grabot, E; Archambault, V; Seguela, P			Functional and biochemical evidence for heteromeric ATP-gated channels composed of P2X(1) and P2X(5) subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ION CHANNELS; SENSORY NEURONS; P-2X RECEPTOR; EXTRACELLULAR ATP; STRUCTURAL MOTIF; RAT; PURINOCEPTOR; EXPRESSION; CLONING; FAMILY	The mammalian P2X receptor gene family encodes two-transmembrane domain nonselective cation channels gated by extracellular ATP, Anatomical localization data obtained by in situ hybridization and immunocytochemistry have shown that neuronal P2X subunits are expressed in specific but overlapping distribution patterns, Therefore, the native ionotropic ATP receptors diversity most likely arises from interactions between different P2X subunits that generate hetero-multimers phenotypically distinct from homomeric channels, Rat P2X(1) and P2X(5) mRNAs are localized within common subsets of peripheral and central sensory neurons as well as spinal motoneurons. The present study demonstrates a functional association between P2X(1) and P2X(5) subunits giving rise to hybrid ATP-gated channels endowed with the pharmacology of P2X(1) and the kinetics of P2X(5). When expressed in Xenopus oocytes, hetero-oligomeric: P2X(1+5) ATP receptors were characterized by slowly desensitizing currents highly sensitive to the agonist alpha,beta-methylene ATP (EC50 = 1.1 mu M) and to the antagonist trinitrophenyl ATP (IC50 = 64 nM), observed with neither P2X(1) nor P2X(5) alone. Direct physical evidence for P2X(1+5) co-assembly was provided by reciprocal subunit-specific co-purifications between epitope-tagged P2X(1) and P2X(5) subunits transfected in HEK-293A cells.	McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, Cell Biol Excitable Tissue Grp, Montreal, PQ H3A 2B4, Canada	McGill University	Seguela, P (corresponding author), McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, Cell Biol Excitable Tissue Grp, 3801 Univ St, Montreal, PQ H3A 2B4, Canada.		Boué-Grabot, Eric/AAQ-2061-2020	Boué-Grabot, Eric/0000-0003-2187-9037				BO XN, 1995, FEBS LETT, V375, P129, DOI 10.1016/0014-5793(95)01203-Q; BRAKE AJ, 1994, NATURE, V371, P519, DOI 10.1038/371519a0; Buell G, 1996, EMBO J, V15, P55, DOI 10.1002/j.1460-2075.1996.tb00333.x; Buell G, 1996, EUR J NEUROSCI, V8, P2221, DOI 10.1111/j.1460-9568.1996.tb00745.x; CHEN CC, 1995, NATURE, V377, P428, DOI 10.1038/377428a0; Chow YW, 1998, J NEUROCHEM, V70, P2606; Collo G, 1996, J NEUROSCI, V16, P2495; Cook SP, 1997, NATURE, V387, P505, DOI 10.1038/387505a0; Funk GD, 1997, J NEUROSCI, V17, P6325; GarciaGuzman M, 1996, FEBS LETT, V388, P123, DOI 10.1016/0014-5793(96)00499-1; Gu JGG, 1997, NATURE, V389, P749, DOI 10.1038/39639; Le KT, 1998, J NEUROSCI, V18, P7152; LEWIS C, 1995, NATURE, V377, P432, DOI 10.1038/377432a0; Nicke A, 1998, EMBO J, V17, P3016, DOI 10.1093/emboj/17.11.3016; North RA, 1997, CURR OPIN NEUROBIOL, V7, P346, DOI 10.1016/S0959-4388(97)80062-1; Radford KM, 1997, J NEUROSCI, V17, P6529; Seguela P, 1996, J NEUROSCI, V16, P448; Soto F, 1996, P NATL ACAD SCI USA, V93, P3684, DOI 10.1073/pnas.93.8.3684; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; Thomas S, 1998, J PHYSIOL-LONDON, V509, P411, DOI 10.1111/j.1469-7793.1998.411bn.x; VALERA S, 1994, NATURE, V371, P516, DOI 10.1038/371516a0; Virginio C, 1998, MOL PHARMACOL, V53, P969; Vulchanova L, 1997, NEUROPHARMACOLOGY, V36, P1229, DOI 10.1016/S0028-3908(97)00126-3; Vulchanova L, 1996, P NATL ACAD SCI USA, V93, P8063, DOI 10.1073/pnas.93.15.8063; WANG C, 1996, BIOCHEM BIOPH RES CO, V230, P8063	25	79	80	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15415	15419		10.1074/jbc.274.22.15415	http://dx.doi.org/10.1074/jbc.274.22.15415			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336430	Green Published, hybrid			2022-12-25	WOS:000080560100019
J	Mani, SS; Besharse, JC; Knox, BE				Mani, SS; Besharse, JC; Knox, BE			Immediate upstream sequence of arrestin directs rod-specific expression in Xenopus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-DARK CYCLE; MOUSE S-ANTIGEN; PINEAL-GLAND; G-PROTEIN; DEVELOPMENTAL EXPRESSION; PHOTORECEPTOR CELLS; 48-KDA PROTEIN; MESSENGER-RNAS; BETA-ARRESTIN; BOVINE RETINA	Arrestins are a family of proteins that modulate G protein-coupled receptor responses with distinct arrestin genes expressed in rods and cones. To understand the regulatory mechanisms controlling rod-specific expression, the abundant Xenopus rod arrestin cDNA and a partial genomic clone, containing the immediate upstream region and amino terminus of the polypeptide, have been characterized. The deduced polypeptide has similar to 69% identity to other vertebrate rod arrestins. Southern blot analysis and polymerase chain reaction of intronic sequences demonstrated multiple alleles for rod arrestin. DNase I footprinting with retinal proteins revealed four major DNA binding sites in the proximal promoter, coinciding with consensus sequences reported in mammalian promoters. Purified bovine Crx homeodomain and mouse Nrl proteins protected a number of these sites. A dual approach of transient embryo transfections and transgenesis was used to locate transcriptional control sequences essential for rod-specific expression in Xenopus. Constructs containing -1287/+113 of 5' upstream sequence with or without intron 1 directed high level expression, specifically in rods. A construct containing only -287/+113 directed expression of green fluorescent protein solely in rod cells. These results suggest that the Crx and Nrl binding sites in the proximal promoter are the primary cis-acting sequences regulating arrestin gene expression in rods.	SUNY Hlth Sci Ctr, Dept Biochem & Mol Biol, Syracuse, NY 13210 USA; SUNY Hlth Sci Ctr, Ctr Vis Res, Dept Ophthalmol, Syracuse, NY 13210 USA; Med Coll Wisconsin, Dept Cell Biol Neurobiol & Anat, Milwaukee, WI 53226 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; Medical College of Wisconsin	Knox, BE (corresponding author), SUNY Hlth Sci Ctr, Dept Biochem & Mol Biol, 750 E Adams St, Syracuse, NY 13210 USA.	knoxb@hscsyr.edu			NATIONAL EYE INSTITUTE [R01EY009409, R55EY009409, R01EY002414] Funding Source: NIH RePORTER; NEI NIH HHS [EY02414, R01 EY002414, EY09409] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ABDULAEVA G, 1995, EUR J BIOCHEM, V234, P437, DOI 10.1111/j.1432-1033.1995.437_b.x; ABE T, 1990, EXP EYE RES, V51, P111, DOI 10.1016/0014-4835(90)90178-W; ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; Batni S, 1996, J BIOL CHEM, V271, P3179, DOI 10.1074/jbc.271.6.3179; BATNI S, 1999, IN PRESS METHODS ENZ; Blackshaw S, 1997, J NEUROSCI, V17, P8074; Boatright JH, 1997, EXP EYE RES, V64, P269, DOI 10.1006/exer.1996.0222; BOWES C, 1988, EXP EYE RES, V47, P369, DOI 10.1016/0014-4835(88)90049-8; BREITMAN ML, 1991, J BIOL CHEM, V266, P15505; Chen SM, 1996, J BIOL CHEM, V271, P28549, DOI 10.1074/jbc.271.45.28549; Chen SM, 1997, NEURON, V19, P1017, DOI 10.1016/S0896-6273(00)80394-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRAFT CM, 1995, FEBS LETT, V362, P247, DOI 10.1016/0014-5793(95)00213-S; CRAFT CM, 1990, J NEUROCHEM, V55, P1461, DOI 10.1111/j.1471-4159.1990.tb04927.x; CRAFT CM, 1994, J BIOL CHEM, V269, P4613; FARBER DB, 1991, EXP EYE RES, V53, P781, DOI 10.1016/0014-4835(91)90114-T; Ferguson SSG, 1996, CAN J PHYSIOL PHARM, V74, P1095, DOI 10.1139/y96-124; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FUCHS S, 1995, NAT GENET, V10, P360, DOI 10.1038/ng0795-360; Furukawa T, 1997, CELL, V91, P531, DOI 10.1016/S0092-8674(00)80439-0; GRAF JD, 1991, METHOD CELL BIOL, V36, P19; HARGRAVE PA, 1992, FASEB J, V6, P2323, DOI 10.1096/fasebj.6.6.1544542; Hisatomi O, 1997, FEBS LETT, V411, P12, DOI 10.1016/S0014-5793(97)00640-6; HOLT CE, 1988, NEURON, V1, P15, DOI 10.1016/0896-6273(88)90205-X; HOLT CE, 1990, NEURON, V4, P203, DOI 10.1016/0896-6273(90)90095-W; KERPPOLA TK, 1994, ONCOGENE, V9, P675; KIKUCHI T, 1993, MOL CELL BIOL, V13, P4400, DOI 10.1128/MCB.13.7.4400; KIKUCHI T, 1995, INVEST OPHTH VIS SCI, V36, pS772; Kimura A., 1998, IOVS, V39, pS47; KISELEV A, 1994, SCIENCE, V266, P1369, DOI 10.1126/science.7973725; Knox BE, 1998, FEBS LETT, V423, P117, DOI 10.1016/S0014-5793(98)00018-0; KORF B, 1989, CELL TISSUE RES, V258, P319; Kroll KL, 1996, DEVELOPMENT, V122, P3173; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; LU XP, 1994, MOL ENDOCRINOL, V8, P1774, DOI 10.1210/me.8.12.1774; MCGINNIS JF, 1992, J NEUROSCI RES, V31, P584, DOI 10.1002/jnr.490310325; NEIUWKOOP P, 1994, NORMAL TABLE XENOPUS, P53; Palczewski K, 1997, CURR OPIN NEUROBIOL, V7, P500, DOI 10.1016/S0959-4388(97)80029-3; PALCZEWSKI K, 1994, PROTEIN SCI, V3, P1355, DOI 10.1002/pro.5560030901; PARRUTI G, 1993, J BIOL CHEM, V268, P9753; RANGANATHAN R, 1995, CELL, V81, P841, DOI 10.1016/0092-8674(95)90004-7; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SAXEN L, 1995, ANN ACAD SCI A4, V23, P1; SHINOHARA T, 1987, P NATL ACAD SCI USA, V84, P6975, DOI 10.1073/pnas.84.20.6975; SHINOHARA T, 1988, PROGR RETINAL RES, V8, P51; Singh AK, 1996, EXP EYE RES, V62, P299, DOI 10.1006/exer.1996.0036; SMITH DP, 1990, P NATL ACAD SCI USA, V87, P1003, DOI 10.1073/pnas.87.3.1003; SMITH WC, 1995, J NEUROCHEM, V64, P1; STIEMKE MM, 1994, DEV BIOL, V162, P169, DOI 10.1006/dbio.1994.1076; Swofford D., 1998, PAUP PHYLOGENETIC AN; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TIMMERS AM, 1993, EXP EYE RES, V56, P257, DOI 10.1006/exer.1993.1034; TSUDA M, 1988, GENE, V73, P11, DOI 10.1016/0378-1119(88)90308-3; TSUDA M, 1991, EUR J BIOCHEM, V200, P95, DOI 10.1111/j.1432-1033.1991.tb21053.x; Xu J, 1997, NATURE, V389, P505, DOI 10.1038/39068; YAMADA T, 1990, SCIENCE, V248, P483, DOI 10.1126/science.2158671; YAMAKI K, 1987, BIOCHEM BIOPH RES CO, V142, P904, DOI 10.1016/0006-291X(87)91499-9; YAMAKI K, 1990, J BIOL CHEM, V265, P20757; ZHANG J, 1994, VISUAL NEUROSCI, V11, P1185, DOI 10.1017/S0952523800006982	60	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15590	15597		10.1074/jbc.274.22.15590	http://dx.doi.org/10.1074/jbc.274.22.15590			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336455	hybrid			2022-12-25	WOS:000080560100044
J	Bhattacharyya, U; Dhar, G; Bhaduri, A				Bhattacharyya, U; Dhar, G; Bhaduri, A			An arginine residue is essential for stretching and binding of the substrate on UDP-glucose-4-epimerase from Escherichia coli - Use of a stacked and quenched uridine nucleotide fluorophore as probe	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UDP-GALACTOSE 4-EPIMERASE; UDPGLUCOSE 4-EPIMERASE; KLUYVEROMYCES-FRAGILIS; MOLECULAR-STRUCTURE; MECHANISM; REDUCTION; ENZYME; SITE	In the previous paper we demonstrated that uridine-5'-beta-1-(5-sulfonic acid) naphthylamidate (UDPAmNS) is a stacked and quenched fluorophore that shows severalfold enhancement of fluorescence in a stretched conformation. UDPAnNS was found to be a powerful competitive inhibitor (K-i = 0.2 mM) for UDP-glucose-4-epimerase from Escherichia coli, This active site-directed fluorophore assumed a stretched conformation on the enzyme surface, as was evidenced by full enhancement of fluorescence in saturating enzyme concentration. Complete displacement of the fluorophore by UDP suggested it to bind to the substrate binding site of the active site. Analysis of inactivation kinetics in presence of alpha,beta-diones such as phenylglyoxal, cyclohaxanedione, and a,3-butadione suggested involvement of the essential arginine residue in the overall catalytic process. From spectral analysis, loss of activity could also be directly correlated with modification of only one arginine residue. Protection experiments with UDP showed the arginine residue to be located in the uridyl phosphate binding subsite, Unlike the native enzyme, the modified enzyme failed to show any enhancement of fluorescence with UDPAmNS clearly demonstrating the role of the essential arginine residue in stretching and binding of the substrate. The potential usefulness of such stacked and quenched nucleotide fluorophores has been discussed.	Indian Inst Chem Biol, Calcutta 700032, W Bengal, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Biology (IICB)	Bhaduri, A (corresponding author), Indian Inst Chem Biol, 4 Raja Sc Mullick Rd, Calcutta 700032, W Bengal, India.							ADAIR WL, 1973, J BIOL CHEM, V248, P4635; BAUER AJ, 1992, PROTEINS, V12, P372, DOI 10.1002/prot.340120409; BHATTACHARJEE H, 1992, J BIOL CHEM, V267, P11714; Dhar G, 1999, J BIOL CHEM, V274, P14568, DOI 10.1074/jbc.274.21.14568; FLENTKE GR, 1990, BIOCHEMISTRY-US, V29, P2430, DOI 10.1021/bi00461a029; Frey P. A., 1987, PYRIDINE NUCLEOTID B, V2B, P462; GABRIEL O, 1975, SUBUNIT ENZYMES BIOC, P85; HAYMAN S, 1978, BIOCHEMISTRY-US, V17, P4161, DOI 10.1021/bi00613a009; Helmreich EJM, 1996, BBA-REV BIOMEMBRANES, V1286, P285, DOI 10.1016/S0304-4157(96)00013-5; LEVY HM, 1963, J BIOL CHEM, V238, P3654; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAITRA US, 1971, P NATL ACAD SCI USA, V68, P2660, DOI 10.1073/pnas.68.11.2660; MANIATIS J, 1982, MOL CLONING LAB MANU, P466; MAS MT, 1985, BIOCHEMISTRY-US, V24, P1634, DOI 10.1021/bi00328a011; MUKHERJI S, 1986, J BIOL CHEM, V261, P4519; MUKHERJI S, 1992, J BIOL CHEM, V267, P11709; NELSESTU.GL, 1971, J BIOL CHEM, V246, P7533; PAL DK, 1971, BIOCHIM BIOPHYS ACTA, V250, P588, DOI 10.1016/0005-2744(71)90259-2; PATTHY L, 1975, J BIOL CHEM, V250, P557; RAY M, 1975, J BIOL CHEM, V250, P4373; RAY M, 1980, J BIOL CHEM, V255, P782; RIOIDAN JF, 1973, BIOCHEMISTRY-US, V12, P3915; SCHULZ GE, 1992, CURR OPIN STRUC BIOL, V2, P61; TAKAHASHI K, 1968, J BIOL CHEM, V243, P6171; TAKAHASHI K, 1977, J BIOCHEM-TOKYO, V81, P403, DOI 10.1093/oxfordjournals.jbchem.a131472; Thoden JB, 1996, BIOCHEMISTRY-US, V35, P2557, DOI 10.1021/bi952715y; Thoden JB, 1996, BIOCHEMISTRY-US, V35, P5137, DOI 10.1021/bi9601114; VANHOOKE JL, 1994, J BIOL CHEM, V269, P31496; WEE TG, 1973, J BIOL CHEM, V248, P33; WILSON DB, 1964, J BIOL CHEM, V239, P2469; WONG SS, 1977, BIOCHEMISTRY-US, V16, P298, DOI 10.1021/bi00621a022; WONG SS, 1978, BIOCHEMISTRY-US, V18, P3551; WONG YHH, 1979, BIOCHEMISTRY-US, V18, P5337, DOI 10.1021/bi00591a012	33	5	5	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					14573	14578		10.1074/jbc.274.21.14573	http://dx.doi.org/10.1074/jbc.274.21.14573			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329648	hybrid			2022-12-25	WOS:000081965200013
J	Brown, RA; Domino, J; Arcaro, A; Waterfield, MD; Shepherd, PR				Brown, RA; Domino, J; Arcaro, A; Waterfield, MD; Shepherd, PR			Insulin activates the alpha isoform of class II phosphoinositide 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; C2 DOMAIN; GLUCOSE-TRANSPORT; 3T3-L1 ADIPOCYTES; GROWTH-FACTOR; CLONING; FAMILY; CALCIUM; IRS-1	The novel class II phosphoinositide (PI) S-kinases are characterized by the presence of a C-terminal C2 domain, but little is known about their regulation, We find insulin causes a rapid 2-3-fold increase in the activity of PI S-kinase C2 alpha (PI3K-C2 alpha) in CHO-IR cells, 3T3-L1 adipocytes, and fully differentiated L5L6 myotubes. No insulin-induced activation of PI3K-C2 alpha was observed in cell types known to have low responsiveness to insulin including HEK 293 cells, 3T3-L1 preadipocytes, and undifferentiated L5L6 myoblasts, The mechanism of activation of PI3K-C2a by insulin differs from that of class Ia PI S-kinases in that insulin stimulation did not cause PI3K-C2a to associate with IRS-1 or insulin receptor, PI3K-C2a existed as a doublet, and insulin stimulation caused a redistribution from the lower molecular weight band to the higher molecular weight band, suggesting phosphorylation-induced bandshift. Consistent with this, in vitro phosphatase treatment reduced the intensity of the upper band back to that seen in unstimulated cells, This suggests that insulin-induced phosphorylation could play a role in regulation of the activity of PI3K-C2 alpha. The finding that insulin activates PI3K-C2 alpha in cell types known to possess a wide range of responses to insulin suggests that PI3K-C2 alpha is a novel component of insulin-stimulated signaling cascades.	Univ London Univ Coll, Dept Biochem & Mol Biol, London WC1E 6BT, England; Ludwig Inst Canc Res, London W1P 8BT, England	University of London; University College London; Ludwig Institute for Cancer Research	Shepherd, PR (corresponding author), Univ London Univ Coll, Dept Biochem & Mol Biol, Gower St, London WC1E 6BT, England.		Arcaro, Alexandre/G-1711-2010	Arcaro, Alexandre/0000-0001-9107-2947				Arcaro A, 1998, J BIOL CHEM, V273, P33082, DOI 10.1074/jbc.273.49.33082; Brown RA, 1997, BIOCHEM BIOPH RES CO, V233, P537, DOI 10.1006/bbrc.1997.6495; CHEUNG JY, 1987, AM J PHYSIOL, V252, pC163, DOI 10.1152/ajpcell.1987.252.2.C163; Domin J, 1997, BIOCHEM J, V326, P139, DOI 10.1042/bj3260139; Domin J, 1997, FEBS LETT, V410, P91, DOI 10.1016/S0014-5793(97)00617-0; GIORGETTI S, 1993, J BIOL CHEM, V268, P7358; HERBST JJ, 1994, BIOCHEMISTRY-US, V33, P9376, DOI 10.1021/bi00198a002; KELLY KL, 1993, J BIOL CHEM, V268, P4391; KLIP A, 1984, AM J PHYSIOL, V247, pE297, DOI 10.1152/ajpendo.1984.247.3.E297; KLIP A, 1987, J BIOL CHEM, V262, P9141; Macdougall LK, 1995, CURR BIOL, V5, P1404, DOI 10.1016/S0960-9822(95)00278-8; Misawa H, 1998, BIOCHEM BIOPH RES CO, V244, P531, DOI 10.1006/bbrc.1998.8294; Molz L, 1996, J BIOL CHEM, V271, P13892, DOI 10.1074/jbc.271.23.13892; Nave BT, 1996, BIOCHEM J, V318, P55, DOI 10.1042/bj3180055; Ono F, 1998, J BIOL CHEM, V273, P7731, DOI 10.1074/jbc.273.13.7731; Ricort JM, 1996, EUR J BIOCHEM, V239, P17, DOI 10.1111/j.1432-1033.1996.0017u.x; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Turner SJ, 1998, J BIOL CHEM, V273, P25987, DOI 10.1074/jbc.273.40.25987; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Virbasius JV, 1996, J BIOL CHEM, V271, P13304, DOI 10.1074/jbc.271.23.13304; Yang J, 1996, BIOCHEM J, V313, P125, DOI 10.1042/bj3130125; Zhang J, 1998, J BIOL CHEM, V273, P14081, DOI 10.1074/jbc.273.23.14081	24	109	111	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					14529	14532		10.1074/jbc.274.21.14529	http://dx.doi.org/10.1074/jbc.274.21.14529			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329640	hybrid			2022-12-25	WOS:000081965200005
J	Mihara, H; Maeda, M; Fujii, T; Kurihara, T; Hata, Y; Esaki, N				Mihara, H; Maeda, M; Fujii, T; Kurihara, T; Hata, Y; Esaki, N			A nifS-like gene, csdB, encodes an Escherichia coli counterpart of mammalian selenocysteine lyase - Gene cloning, purification, characterization and preliminary x-ray crystallographic studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELENOPHOSPHATE SYNTHETASE; NUCLEOTIDE-SEQUENCE; AZOTOBACTER-VINELANDII; PHYSICAL MAP; PROTEIN; ENZYME; MECHANISM; SELENIUM; IDENTIFICATION; BIOSYNTHESIS	Selenocysteine lyase is a pyridoxal 5'-phosphate (PLP)-dependent enzyme that catalyzes the exclusive decomposition of L-selenocysteine to L-alanine and elemental selenium. An open reading frame, named csdB, from Escherichia coli encodes a putative protein that is similar to selenocysteine lyase of pig Liver and cysteine desulfurase (NifS) of Azotobacter vinelandii. In this study, the csdB gene was cloned and expressed in E. coli cells. The gene product was a homodimer with the subunit M-r of 44,439, contained 1 mol of PLP as a cofactor per mol of subunit, and catalyzed the release of Se, SO2, and S from L-selenocysteine, L-cysteine sulfinic acid, and L-cysteine, respectively, to yield L-alanine; the reactivity of the substrates decreased in this order. Although the enzyme was not specific for L-selenocysteine, the high specific activity for L-selenocysteine (5.5 units/mg compared with 0.019 units/mg for L-cysteine) supports the view that the enzyme can be regarded as an E. coli counterpart of mammalian selenocysteine lyase. me crystallized CsdB, the csdB gene product, by the hanging drop vapor diffusion method. The crystals were of suitable quality for x-ray crystallography and belonged to the tetragonal space group P4(3)2(1)2 with unit cell dimensions of a = b = 128.1 Angstrom and c = 137.0 Angstrom. Consideration of the Matthews parameter V-m (3.19 Angstrom(3)/Da) accounts for the presence of a single dimer in the crystallographic asymmetric unit. A native diffraction dataset up to 2.8 Angstrom resolution was collected. This is the first crystallographic analysis of a protein of NifS/selenocysteine lyase family.	Kyoto Univ, Inst Chem Res, Uji, Kyoto 6110011, Japan	Kyoto University	Esaki, N (corresponding author), Kyoto Univ, Inst Chem Res, Uji, Kyoto 6110011, Japan.		Mihara, Hisaaki/F-2172-2010	Mihara, Hisaaki/0000-0002-5153-4403				Adams E, 1979, Methods Enzymol, V62, P407; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; ESAKI N, 1985, ARCH BIOCHEM BIOPHYS, V238, P418, DOI 10.1016/0003-9861(85)90182-1; ESAKI N, 1982, J BIOL CHEM, V257, P4386; Flint DH, 1996, J BIOL CHEM, V271, P16068; FORCHHAMMER K, 1991, J BIOL CHEM, V266, P6324; GRISHIN NV, 1995, PROTEIN SCI, V4, P1291, DOI 10.1002/pro.5560040705; HEIDER J, 1993, ADV MICROB PHYSIOL, V35, P71, DOI 10.1016/S0065-2911(08)60097-1; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KOLMAN C, 1993, J BACTERIOL, V175, P1433, DOI 10.1128/JB.175.5.1433-1442.1993; Lacourciere GM, 1998, J BIOL CHEM, V273, P30921, DOI 10.1074/jbc.273.47.30921; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE BJ, 1989, J BIOL CHEM, V264, P9724; LEINFELDER W, 1989, J BIOL CHEM, V264, P9720; LEINWEBER FJ, 1987, METHOD ENZYMOL, V143, P15; Liu SY, 1997, ARCH BIOCHEM BIOPHYS, V341, P353, DOI 10.1006/abbi.1997.9990; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Mihara H, 1997, J BIOL CHEM, V272, P22417, DOI 10.1074/jbc.272.36.22417; Mullins LS, 1997, J AM CHEM SOC, V119, P6684, DOI 10.1021/ja971074m; Nakai Y, 1998, FEBS LETT, V433, P143, DOI 10.1016/S0014-5793(98)00897-7; Neuhierl B, 1996, EUR J BIOCHEM, V239, P235, DOI 10.1111/j.1432-1033.1996.0235u.x; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; Rudd KE, 1998, MICROBIOL MOL BIOL R, V62, P985, DOI 10.1128/MMBR.62.3.985-1019.1998; SLIWKOWSKI MX, 1985, J BIOL CHEM, V260, P3140; Soda K, 1979, Adv Enzymol Relat Areas Mol Biol, V49, P1; Stadtman T C, 1979, Adv Enzymol Relat Areas Mol Biol, V48, P1; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503; SUN DX, 1993, J BACTERIOL, V175, P1423, DOI 10.1128/JB.175.5.1423-1432.1993; TANAKA H, 1987, METHOD ENZYMOL, V143, P240; TATE SS, 1971, ADV ENZYMOL RAMB, V35, P503; VERES Z, 1994, J BIOL CHEM, V269, P10597; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; ZHENG LM, 1993, P NATL ACAD SCI USA, V90, P2754, DOI 10.1073/pnas.90.7.2754; ZHENG LM, 1994, BIOCHEMISTRY-US, V33, P4714, DOI 10.1021/bi00181a031; Zheng LM, 1998, J BIOL CHEM, V273, P13264, DOI 10.1074/jbc.273.21.13264; ZINONI F, 1986, P NATL ACAD SCI USA, V83, P4650, DOI 10.1073/pnas.83.13.4650	36	100	108	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					14768	14772		10.1074/jbc.274.21.14768	http://dx.doi.org/10.1074/jbc.274.21.14768			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329673	hybrid			2022-12-25	WOS:000081965200038
J	Svetek, J; Yadav, MP; Nothnagel, EA				Svetek, J; Yadav, MP; Nothnagel, EA			Presence of a glycosylphosphatidylinositol lipid anchor on rose arabinogalactan proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSYL YARIV REAGENT; CELL-WALL; GLYCOSYL-PHOSPHATIDYLINOSITOL; SOMATIC EMBRYOGENESIS; REGULATED EXPRESSION; MEMBRANE ANCHORS; PHOSPHOLIPASE-C; PLASMA-MEMBRANE; NICOTIANA-ALATA; TOBACCO-LEAVES	Arabinogalactan proteins constitute a class of plant cell surface proteoglycans with widespread occurrence and suggested functions in various aspects of plant growth and development, including cell proliferation, expansion, marking, and death. Previous investigations of subcellular fractions from suspension-cultured cells of "Paul's Scarlet" rose (Rosa sp.) have revealed extensive structural similarity between some soluble arabinogalactan proteins from the cell wall space and some plasma membrane-associated arabinogalactan proteins, thus inspiring the present investigation of the mechanism through which these inherently water-soluble molecules are held on the plasma membrane. Several lines of evidence gained through a combination of methods including reversed-phase chromatography, treatment with phosphatidylinositol-specific phospholipase C, and chemical structural analysis now show that some rose arabinogalactan proteins carry a ceramide class glycosylphosphatidylinositol Lipid anchor. The predominant form of the ceramide is composed of tetracosanoic acid and 4-hydroxysphinganine. Plasma membrane vesicles readily shed arabinogalactan proteins by an inherent mechanism that appears to involve a phospholipase. This finding has significance toward understanding the biosynthesis, localization, and function of arabinogalactan proteins and toward stimulating other studies that may expand the currently very short List of higher plant proteins found to carry such membrane lipid anchors.	Univ Calif Riverside, Dept Bot & Plant Sci 072, Riverside, CA 92521 USA	University of California System; University of California Riverside	Nothnagel, EA (corresponding author), Univ Calif Riverside, Dept Bot & Plant Sci 072, Riverside, CA 92521 USA.	eugene.nothnagel@ucr.edu						BUTIKOFER P, 1993, J BIOL CHEM, V268, P17794; CAMPBELL AS, 1992, BIOORG MED CHEM LETT, V2, P655; CARTER HE, 1969, J LIPID RES, V10, P356; CARTER HE, 1969, BIOCHEMISTRY-US, V8, P383, DOI 10.1021/bi00829a053; CARTER HE, 1969, J LIPID RES, V10, P363; Casero PJ, 1998, PLANTA, V204, P252, DOI 10.1007/s004250050254; Cheung AY, 1996, P NATL ACAD SCI USA, V93, P3853, DOI 10.1073/pnas.93.9.3853; Ding L, 1997, PLANTA, V203, P289, DOI 10.1007/s004250050194; Du H, 1996, TRENDS CELL BIOL, V6, P411, DOI 10.1016/S0962-8924(96)20036-4; Fan JQ, 1997, J BIOL CHEM, V272, P27058, DOI 10.1074/jbc.272.43.27058; FANKHAUSER C, 1993, J BIOL CHEM, V268, P26365; Ferguson M. A. J., 1992, LIPID MODIFICATION P, P191; FOLCH J, 1957, J BIOL CHEM, V226, P497; GRIFFITH OH, 1991, METHOD ENZYMOL, V197, P493, DOI DOI 10.1016/0076-6879(91)97175-X; HAMMARST.S, 1970, J LIPID RES, V11, P175; HSIEH TCY, 1978, BIOCHEMISTRY-US, V17, P3575, DOI 10.1021/bi00610a024; Ikezawa H, 1981, METHODS ENZYMOLOGY C, P731, DOI [10.1016/0076-6879(81)71086-3, DOI 10.1016/0076-6879(81)71086-3]; Jones DR, 1998, INT J BIOCHEM CELL B, V30, P313, DOI 10.1016/S1357-2725(97)00144-1; KAUL K, 1978, BIOCHEMISTRY-US, V17, P3569, DOI 10.1021/bi00610a023; Knox JP, 1996, MEMBRANES SPECIALIZE, P93; KOMALAVILAS P, 1991, J BIOL CHEM, V266, P15956; KREUGER M, 1995, PLANTA, V197, P135, DOI 10.1007/BF00239949; Kunze M, 1997, PLANT PHYSIOL BIOCH, V35, P507; Langan KJ, 1997, PROTOPLASMA, V196, P87, DOI 10.1007/BF01281062; Li SX, 1996, PLANT MOL BIOL, V32, P641, DOI 10.1007/BF00020205; LOW MG, 1989, BIOCHIM BIOPHYS ACTA, V988, P427, DOI 10.1016/0304-4157(89)90014-2; McCabe PF, 1997, PLANT CELL, V9, P2225, DOI 10.1105/tpc.9.12.2225; MENON AK, 1994, METHOD ENZYMOL, V230, P418; Morita N, 1996, BBA-GEN SUBJECTS, V1290, P53, DOI 10.1016/0304-4165(95)00185-9; MURPHY RC, 1993, HDB LIPID RES, V7, P71; Nothnagel EA, 1997, INT REV CYTOL, V174, P195, DOI 10.1016/S0074-7696(08)62118-X; PROUDFOOT L, 1995, BIOCHEM J, V308, P45, DOI 10.1042/bj3080045; Roy S, 1998, PLANTA, V204, P450, DOI 10.1007/s004250050279; SERPE MD, 1995, PLANT PHYSIOL, V109, P1007, DOI 10.1104/pp.109.3.1007; SERPE MD, 1994, PLANTA, V193, P542, DOI 10.1007/BF02411560; Serpe MD, 1996, PLANT PHYSIOL, V112, P1261, DOI 10.1104/pp.112.3.1261; SommerKnudsen J, 1996, PLANT J, V9, P71, DOI 10.1046/j.1365-313X.1996.09010071.x; SommerKnudsen J, 1997, SEX PLANT REPROD, V10, P253, DOI 10.1007/s004970050095; Svetek J, 1996, MOL BIOL CELL, V7, P1762; Takos AM, 1997, FEBS LETT, V405, P1, DOI 10.1016/S0014-5793(97)00064-1; TARENTINO AL, 1982, J BIOL CHEM, V257, P776; Thompson HJM, 1998, PLANTA, V205, P32, DOI 10.1007/s004250050293; Toonen MAJ, 1997, PLANTA, V203, P188, DOI 10.1007/s004250050181; TRETTER V, 1991, EUR J BIOCHEM, V199, P647, DOI 10.1111/j.1432-1033.1991.tb16166.x; WANG H, 1993, PLANT CELL, V5, P1639, DOI 10.1105/tpc.5.11.1639; Willats WGT, 1996, PLANT J, V9, P919, DOI 10.1046/j.1365-313X.1996.9060919.x; Youl JJ, 1998, P NATL ACAD SCI USA, V95, P7921, DOI 10.1073/pnas.95.14.7921	47	121	125	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					14724	14733		10.1074/jbc.274.21.14724	http://dx.doi.org/10.1074/jbc.274.21.14724			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329668	hybrid			2022-12-25	WOS:000081965200033
J	Canitrot, Y; Lautier, D; Laurent, G; Frechet, M; Ahmed, A; Turhan, AG; Salles, B; Cazaux, C; Hoffmann, JS				Canitrot, Y; Lautier, D; Laurent, G; Frechet, M; Ahmed, A; Turhan, AG; Salles, B; Cazaux, C; Hoffmann, JS			Mutator phenotype of BCR-ABL transfected Ba/F3 cell lines and its association with enhanced expression of DNA polymerase beta	ONCOGENE			English	Article						bcr-abl; mutator phenotype; DNA polymerase beta	CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOCYTIC-LEUKEMIA; CLONAL EVOLUTION; BLAST CRISIS; P53 GENE; RAS; MUTATIONS; ONCOGENE; OVEREXPRESSION; TRANSFORMATION	Chronic myelogenous leukemia (CML) is characterized by the Philadelphia chromosome resulting from the translocation t(9-22) producing the chimeric 190 and 210 kDa BCR-ABL fusion proteins. Evolution of the CML to the more aggressive acute myelogenous leukemia (AML) is accompanied by increased cellular proliferation and genomic instability at the cytogenetic level. We hypothezised that genomic instability at the nucleotide level and spontaneous error in DNA replication may also contribute to the evolution of CML to AML. Murine Ba/F3 cell line was transfected with the p190 and p210-encoding BCR-ABL oncogenes, and spontaneous mutation frequency at the Na-K-ATPase and the hypoxanthine guanine phosphoribosyl transferase (HPRT) loci were measured. A significant 3-5-fold increase in mutation frequency for the transfected cells relative to the untransfected control cells was found. Furthermore, we observed that BCR-ABL transfection induced an overexpression of DNA polymerase beta, the most inaccurate of the mammalian DNA polymerases, as well as an increase in its activity, suggesting that inaccuracy of DNA replication may account for the observed mutator phenotype. These data suggest that the Philadelphia abnormality confers a mutator phenotype and may have implications for the potential role of DNA polymerase beta in this process.	CNRS, Inst Pharmacol & Biol Struct, F-31077 Toulouse, France; Inst Claudius Regaud, INSERM, F-31052 Toulouse, France; Inst Gustave Roussy, INSERM, U362, F-94805 Villejuif, France	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Claudius Regaud; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy	Hoffmann, JS (corresponding author), CNRS, Inst Pharmacol & Biol Struct, UPR 9062,205 Route Narbonne, F-31077 Toulouse, France.		Hoffmann, Jean-Sebastien/O-9183-2014; Lautier, Dominique/G-3959-2017; salles, bernard/B-8531-2008	Hoffmann, Jean-Sebastien/0000-0003-2222-354X; TURHAN, Ali/0000-0002-4861-0137				Ahmed M, 1998, ONCOGENE, V16, P489, DOI 10.1038/sj.onc.1201556; AHUJA H, 1989, P NATL ACAD SCI USA, V86, P6783, DOI 10.1073/pnas.86.17.6783; AHUJA H, 1991, J CLIN INVEST, V87, P2042, DOI 10.1172/JCI115234; BERNSTEIN R, 1988, SEMIN HEMATOL, V25, P20; Bouayadi K, 1997, CANCER RES, V57, P110; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Canitrot Y, 1998, P NATL ACAD SCI USA, V95, P12586, DOI 10.1073/pnas.95.21.12586; COLLINS SJ, 1989, BLOOD, V73, P1028; COPELAND WC, 1992, J BIOL CHEM, V267, P21459; FEINSTEIN E, 1991, P NATL ACAD SCI USA, V88, P6293, DOI 10.1073/pnas.88.14.6293; FIALKOW PJ, 1977, AM J MED, V63, P125, DOI 10.1016/0002-9343(77)90124-3; FORNACE AJ, 1989, MOL CELL BIOL, V9, P851, DOI 10.1128/MCB.9.2.851; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; Hoffmann JS, 1996, P NATL ACAD SCI USA, V93, P13766, DOI 10.1073/pnas.93.24.13766; KEDAR PS, 1990, MOL CELL BIOL, V10, P3852, DOI 10.1128/MCB.10.7.3852; KELMAN Z, 1989, BLOOD, V74, P2318; KUNKEL TA, 1985, J BIOL CHEM, V260, P5787; LANEUVILLE P, 1992, BLOOD, V80, P1788; LEMAISTRE A, 1989, BLOOD, V73, P889; LOEB LA, 1991, CANCER RES, V51, P3075; MANDANAS RA, 1993, BLOOD, V82, P1838; MASHAL R, 1990, BLOOD, V75, P180; MCCARTHY DM, 1984, LANCET, V2, P1362; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; SAWYERS CL, 1995, J EXP MED, V181, P307, DOI 10.1084/jem.181.1.307; SCANLON KJ, 1989, CANCER INVEST, V7, P581, DOI 10.3109/07357908909017533; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; WADA C, 1994, BLOOD, V83, P3449, DOI 10.1182/blood.V83.12.3449.bloodjournal83123449; WIND N, 1995, CELL, V82, P321; ZMUDZKA BZ, 1988, NUCLEIC ACIDS RES, V16, P9589	30	82	84	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 29	1999	18	17					2676	2680		10.1038/sj.onc.1202619	http://dx.doi.org/10.1038/sj.onc.1202619			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FH	10348341				2022-12-25	WOS:000080124900002
J	Li, KY; Shao, RP; Hung, MC				Li, KY; Shao, RP; Hung, MC			Collagen-homology domain 1 deletion mutant of Shc suppresses transformation mediated by neu through a MAPK-independent pathway	ONCOGENE			English	Article						tyrosine kinase receptor; neu; Shc; transformation; MAPK	EPIDERMAL GROWTH-FACTOR; ACTIVATED PROTEIN-KINASE; HUMAN-BREAST-CANCER; GUANINE-NUCLEOTIDE EXCHANGE; CYCLE-DEPENDENT REGULATION; RECEPTOR TYROSINE KINASES; EGF RECEPTOR; POINT MUTATION; OVARIAN-CANCER; PROGNOSTIC-SIGNIFICANCE	Shc proteins are implicated in coupling receptor tyrosine kinase to the mitogen-activated protein kinase (MAPK) pathway by recruiting Grb2/SOS to the plasma membrane. To better understand the role of Shc in the oncogenesis by point-mutation activated neu (p185*), we transfected a Shc mutant (Shc Delta CH1), which lacks the Grb2 binding site Y317 by deletion of collagen-homology domain 1, into p185*-transformed NIH3T3 cells. The cellular transformation phenotypes mere found to be largely suppressed by expression of Shc Delta CH1. Although Shc Delta CH1 still retained another Grb2 binding site (Y239/240), we did not detect its physical association with Grb2. We also found that Shc Delta CH1 could associate with p185*; however, this association did not interfere,vith the endogenous Shc-p185* interaction or the Shc-Grb2 interaction. In addition, p185*-mediated MAPK and Elk activation likewise were not inhibited by Shc Delta CH1 expression. Taken together, these data demonstrate that Shc Delta CH1 suppresses the transformation induced by activated neu through a MAPK-independent pathway, indicating that Shc may be involved in other signal pathway(s) critical for cellular transformation in addition to the MAPK pathway.	Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Sect Mol Cell Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Hung, MC (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Sect Mol Cell Biol, Box 79,1515 Holcombe Blvd, Houston, TX 77030 USA.		Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740	NCI NIH HHS [R01-CA77858, R01-CA58880] Funding Source: Medline; PHS HHS [16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077858, R01CA058880] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALESSI DR, 1995, METHOD ENZYMOL, V255, P279; BAAK JPA, 1991, LAB INVEST, V64, P215; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BERCHUCK A, 1990, CANCER RES, V50, P4087; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; Chen H, 1997, ONCOGENE, V14, P1965, DOI 10.1038/sj.onc.1201030; Chen YH, 1996, EMBO J, V15, P1037, DOI 10.1002/j.1460-2075.1996.tb00441.x; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIMARCO E, 1990, MOL CELL BIOL, V10, P3247, DOI 10.1128/MCB.10.6.3247; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GISHIZKY ML, 1995, P NATL ACAD SCI USA, V92, P10889, DOI 10.1073/pnas.92.24.10889; Gotoh N, 1996, EMBO J, V15, P6197, DOI 10.1002/j.1460-2075.1996.tb01008.x; Gotoh N, 1997, MOL CELL BIOL, V17, P1824, DOI 10.1128/MCB.17.4.1824; HARRISONFINDIK D, 1995, ONCOGENE, V10, P1385; HOU L, 1992, CANCER LETT, V65, P215, DOI 10.1016/0304-3835(92)90234-M; HUNG MC, 1989, P NATL ACAD SCI USA, V86, P2545, DOI 10.1073/pnas.86.8.2545; HUNG MC, 1992, CANCER LETT, V61, P95, DOI 10.1016/0304-3835(92)90166-S; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; KIYOKAWA N, 1995, P NATL ACAD SCI USA, V92, P1092, DOI 10.1073/pnas.92.4.1092; Kiyokawa N, 1997, ONCOGENE, V15, P2633, DOI 10.1038/sj.onc.1201442; LANFRANCONE L, 1995, ONCOGENE, V10, P907; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MCCANN AH, 1991, CANCER RES, V51, P3296; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; Migliaccio E, 1997, EMBO J, V16, P706, DOI 10.1093/emboj/16.4.706; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; PADHY LC, 1982, CELL, V28, P865, DOI 10.1016/0092-8674(82)90065-4; PELICCI G, 1995, ONCOGENE, V11, P899; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; REARDON DB, 1994, ONCOL REP, V1, P37; RICCI A, 1995, ONCOGENE, V11, P1519; Roche S, 1996, EMBO J, V15, P4940, DOI 10.1002/j.1460-2075.1996.tb00874.x; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SALCINI AE, 1994, ONCOGENE, V9, P2827; SAMANTA A, 1994, P NATL ACAD SCI USA, V91, P1711, DOI 10.1073/pnas.91.5.1711; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; SEGATTO O, 1993, ONCOGENE, V8, P2105; SEGATTO O, 1988, MOL CELL BIOL, V8, P5570, DOI 10.1128/MCB.8.12.5570; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERNBERG MJE, 1989, NATURE, V339, P587, DOI 10.1038/339587a0; SUEN TC, 1990, MOL CELL BIOL, V10, P6306, DOI 10.1128/MCB.10.12.6306; TOIKKANEN S, 1992, J CLIN ONCOL, V10, P1044, DOI 10.1200/JCO.1992.10.7.1044; TYSON FL, 1991, AM J OBSTET GYNECOL, V165, P640, DOI 10.1016/0002-9378(91)90300-G; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; WEINER DB, 1990, CANCER RES, V50, P421; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; Xia WY, 1997, CLIN CANCER RES, V3, P3; Xie YM, 1996, BIOCHEM BIOPH RES CO, V221, P140, DOI 10.1006/bbrc.1996.0559; XIE YM, 1995, ONCOGENE, V10, P2409; Xie YM, 1995, J BIOL CHEM, V270, P30717, DOI 10.1074/jbc.270.51.30717; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YU DH, 1991, ONCOGENE, V6, P1991	68	7	7	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 22	1999	18	16					2617	2626		10.1038/sj.onc.1202605	http://dx.doi.org/10.1038/sj.onc.1202605			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	189LU	10353605				2022-12-25	WOS:000079907100009
J	Butz, K; Whitaker, N; Denk, C; Ullmann, A; Geisen, C; Hoppe-Seyler, F				Butz, K; Whitaker, N; Denk, C; Ullmann, A; Geisen, C; Hoppe-Seyler, F			Induction of the p53-target gene GADD45 in HPV-positive cancer cells	ONCOGENE			English	Article						cervical cancer; HPV; p53; gadd45; tumor virus	HUMAN ORAL KERATINOCYTES; P53 PROTEIN; TRANSCRIPTIONAL ACTIVITY; P53-INDEPENDENT PATHWAY; ANTICANCER AGENTS; GENOTOXIC STRESS; MESSENGER-RNA; DNA-BINDING; E6; EXPRESSION	The E6 oncoprotein of human papillomaviruses (HPVs) has the potential to functionally antagonize p53. In several experimental model systems, ectopic expression of E6 can block the genotoxic induction of the growth inhibitory p53 target gene gadd45, suggesting that the inactivation of this pathway may play a major role for HPV-associated cell transformation. Here, we investigated whether this reflects the regulation of gadd45 expression in carcinoma-derived HPV-positive cells, We found that the gadd45 gene is efficiently induced by mitomycin C, cisplatin, and UV irradiation in a series of HPV-positive cervical cancer cell lines. Moreover, clear induction of gadd45 gene expression was also observed following treatment with gamma-irradiation, a pathway that is strictly dependent on functional p53, This contrasted with findings in human foreskin keratinocytes experimentally immortalized by expressing the HPV16 E6, E7, or E6/E7 oncogenes from the heterologous CMV promoter, where expression of the E6 gene was linked to a lack of gadd45 induction following gamma-irradiation. These results indicate (I) that the tumorigenic phenotype of HPV-positive cancer cells is not Linked to an inability to induce the gadd45 gene following DNA damage, (2) that experimental model systems in which the E6 gene is expressed ectopically and/or in a different cellular context do not necessarily reflect the regulation of p53-associated pathways in HPV-positive cancer cells and (3) that a pathway strictly depending on functional p53 is inducible in HPV-positive cancer cells, providing direct evidence that the endogenous p53 protein in these cells is competent to activate a cellular target gene, despite coexpression of the viral E6 oncogene.	Deutsch Krebsforschungszentrum, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Hoppe-Seyler, F (corresponding author), Deutsch Krebsforschungszentrum, Neuenheimer Feld 242, D-69120 Heidelberg, Germany.			Hoppe-Seyler, Felix/0000-0002-1864-300X				Butz K, 1998, ONCOGENE, V17, P781, DOI 10.1038/sj.onc.1201995; BUTZ K, 1995, ONCOGENE, V10, P927; Butz K, 1996, INT J CANCER, V68, P506, DOI 10.1002/(SICI)1097-0215(19961115)68:4<506::AID-IJC17>3.0.CO;2-2; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; FOSTER SA, 1994, J VIROL, V68, P5698, DOI 10.1128/JVI.68.9.5698-5705.1994; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; GUJULUVA CN, 1994, ONCOGENE, V9, P1819; HOPPESEYLER F, 1993, J VIROL, V67, P3111, DOI 10.1128/JVI.67.6.3111-3117.1993; HOPPESEYLER F, 1997, PAPILLOMAVIRUSES HUM, P71; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JACKMAN J, 1994, CANCER RES, V54, P5656; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; JOHNSON M, 1994, MOL CARCINOGEN, V11, P59, DOI 10.1002/mc.2940110202; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KEARSEY JM, 1995, ONCOGENE, V11, P1675; KEARSEY JM, 1995, SCIENCE, V270, P1003; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; Liu X, 1997, ONCOGENE, V14, P2347, DOI 10.1038/sj.onc.1201078; Loignon M, 1997, CANCER RES, V57, P3390; Lu X, 1996, ONCOGENE, V13, P413; MITSUDOMI T, 1992, NATURE, V358, P80; OConnor PM, 1997, CANCER RES, V57, P4285; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PAN HC, 1995, GENE DEV, V9, P2157, DOI 10.1101/gad.9.17.2157; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; Shin KH, 1996, ONCOGENE, V12, P1089; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; WEINBERG WC, 1995, ONCOGENE, V10, P2271; WHITAKER SJ, 1992, EUR J CANCER, V28A, P273, DOI 10.1016/0959-8049(92)90432-2; Zhan QM, 1996, DNA CELL BIOL, V15, P805, DOI 10.1089/dna.1996.15.805; ZHAN QM, 1994, CANCER RES, V54, P2755; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	35	66	67	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 8	1999	18	14					2381	2386		10.1038/sj.onc.1202557	http://dx.doi.org/10.1038/sj.onc.1202557			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184DT	10327059				2022-12-25	WOS:000079595500011
J	Felici, A; Giorgio, M; Krauzewicz, N; Della Rocca, C; Santoro, M; Rovere, P; Manni, I; Amati, P; Pozzi, L				Felici, A; Giorgio, M; Krauzewicz, N; Della Rocca, C; Santoro, M; Rovere, P; Manni, I; Amati, P; Pozzi, L			Medullary thyroid carcinomas in transgenic mice expressing a polyoma carboxyl-terminal truncated middle-T and wild type small-T antigens	ONCOGENE			English	Article						transgenic; oncogene; middle-T; medullary thyroid carcinoma	GROWTH-FACTOR RECEPTOR; TUMOR-ANTIGEN; VIRUS MUTANT; MONOCLONAL-ANTIBODIES; CELL-TRANSFORMATION; REGULATORY REGION; SARCOMA-VIRUSES; GENE; PROTEIN; ASSOCIATION	Medullary thyroid carcinoma (MTC) is a rare human tumor affecting the calcitonin-secreting c-cells of the thyroid. Here me report that two independent strains of transgenic mice expressing a Polyomavirus (Py) truncated middle-T antigen (Delta MT), consisting of the aminoterminal 304 amino acids, and the full length Py small-T antigen, developed multifocal bilateral MTCs with 100% penetrance, Occasionally one strain also developed mammary and bone tumors. Furthermore, offspring from both transgenic lines displayed pronounced waviness of the whiskers and fur, previously associated,vith defective epidermal growth factor receptor signaling, Transgene transcription, driven by the homologous early promoter/enhancer, and the corresponding translation products mere detected in tumors and in many other organs which did not develop pathologies. The subcellular distribution of Delta MT and its interactions with the adapter proteins of the SHC family have also been analysed. Our study describes a novel murine model of MTC and provides evidence that the N-terminal 304 amino acid fragment of Py middle-T antigen, possibly in co-operation with small-T antigen, acts as a potent oncogene in c-cells of the thyroid.	Ist Regina Elena, Ctr Ric Sperimentale, I-00158 Rome, Italy; Univ Rome La Sapienza, Dipartimento Biotecnol Cellulari & Ematol, I-00161 Rome, Italy; Ist Dermopat Immacolata, Dept Patol Vasc, I-00167 Rome, Italy; Royal Postgrad Med Sch, Dept Virol, London W12 0NN, England; Univ Rome La Sapienza, Dipartimento Med Sperimentale, I-00161 Rome, Italy; Univ Naples, Fac Med & Chirurg, Dipartimento Biol & Patol Cellulare & Mol, CNR,Ctr Endocrinol Oncol Sperimentale, I-80131 Naples, Italy; Ist Regina Elena, Lab Oncogenesi Mol, I-00158 Rome, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Sapienza University Rome; IRCCS Istituto Dermopatico dell'Immacolata (IDI); Imperial College London; Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	Felici, A (corresponding author), Ist Regina Elena, Ctr Ric Sperimentale, I-00158 Rome, Italy.		Manni, Isabella/ABH-6460-2020; Giorgio, Marco/I-9425-2012	Manni, Isabella/0000-0003-4823-0596; Giorgio, Marco/0000-0002-5842-6042				ANDREWS DW, 1993, MOL CELL BIOL, V13, P4703, DOI 10.1128/MCB.13.8.4703; BAETSCHER M, 1991, ONCOGENE, V6, P1133; BAUTCH VL, 1989, MOL BIOL MED, V6, P309; BAUTCH VL, 1987, CELL, V51, P529, DOI 10.1016/0092-8674(87)90122-X; BOLEN JB, 1984, J BIOL CHEM, V259, P1686; Brewster CEP, 1997, J VIROL, V71, P5512, DOI 10.1128/JVI.71.7.5512-5520.1997; Bronson R, 1997, P NATL ACAD SCI USA, V94, P7954, DOI 10.1073/pnas.94.15.7954; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; CARMICHAEL GG, 1982, P NATL ACAD SCI-BIOL, V79, P3579, DOI 10.1073/pnas.79.11.3579; CARSON EB, 1995, CANCER RES, V55, P2048; CHALIFOUR LE, 1992, MOL CARCINOGEN, V5, P178, DOI 10.1002/mc.2940050304; CHENG SH, 1988, EMBO J, V7, P3845, DOI 10.1002/j.1460-2075.1988.tb03270.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5299; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; Crew FAE, 1933, J GENET, V27, P95, DOI 10.1007/BF02984383; DAWE CJ, 1980, PHYLETIC APPROACHES; DESIMONE V, 1987, J VIROL, V61, P1615, DOI 10.1128/JVI.61.5.1615-1620.1987; DILWORTH SM, 1993, J VIROL, V67, P2235, DOI 10.1128/JVI.67.4.2235-2244.1993; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; Elliott J, 1998, ONCOGENE, V17, P1797, DOI 10.1038/sj.onc.1202083; FIMIA GM, 1995, BIOCHEM BIOPH RES CO, V207, P339, DOI 10.1006/bbrc.1995.1193; FOWLER KJ, 1995, P NATL ACAD SCI USA, V92, P1465, DOI 10.1073/pnas.92.5.1465; FREUND R, 1992, AM J PATHOL, V141, P1409; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; HARVEY M, 1995, CANCER RES, V55, P1146; HELSETH A, 1992, AM J PATHOL, V140, P1071; HOGAN B, 1986, MANIPULATING MOUSE E, P79; HORAK ID, 1989, J VIROL, V63, P2343, DOI 10.1128/JVI.63.5.2343-2347.1989; Johnston D, 1998, ONCOGENE, V16, P167, DOI 10.1038/sj.onc.1201478; KIEFER F, 1994, ADV CANCER RES, V64, P125, DOI 10.1016/S0065-230X(08)60837-4; KORNBLUTH S, 1987, NATURE, V325, P171, DOI 10.1038/325171a0; KRIPPL B, 1988, NUCLEIC ACIDS RES, V16, P8963, DOI 10.1093/nar/16.18.8963; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBEL M, 1995, CELL GROWTH DIFFER, V6, P1591; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LUETTEKE NC, 1993, CELL, V73, P263, DOI 10.1016/0092-8674(93)90228-I; LUETTEKE NC, 1994, GENE DEV, V8, P399, DOI 10.1101/gad.8.4.399; MAIONE R, 1985, EMBO J, V4, P3215, DOI 10.1002/j.1460-2075.1985.tb04068.x; MANN GB, 1993, CELL, V73, P249, DOI 10.1016/0092-8674(93)90227-H; MARKLAND W, 1987, BIOCHIM BIOPHYS ACTA, V907, P299, DOI 10.1016/0304-419X(87)90011-4; MCLAREN A, 1969, NATURE, V224, P238, DOI 10.1038/224238a0; Michiels FM, 1997, P NATL ACAD SCI USA, V94, P3330, DOI 10.1073/pnas.94.7.3330; NAKAGAWA T, 1987, P NATL ACAD SCI USA, V84, P5923, DOI 10.1073/pnas.84.16.5923; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; PAQUISFLUCKLINGER V, 1993, ONCOGENE, V8, P2087; RASSOULZADEGAN M, 1990, ONCOGENE, V5, P1507; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SCHULZ N, 1992, CANCER RES, V52, P450; SU W, 1995, J BIOL CHEM, V270, P12331, DOI 10.1074/jbc.270.21.12331; Tehranian A, 1996, AM J PATHOL, V149, P1177; TEMPLETON D, 1982, J VIROL, V41, P1014, DOI 10.1128/JVI.41.3.1014-1024.1982; Tooze J, 1980, DNA TUMOR VIRUSES; TSUZUKI T, 1995, ONCOGENE, V10, P191; WANG R, 1991, J VIROL, V65, P5174, DOI 10.1128/JVI.65.10.5174-5183.1991; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	56	3	5	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 8	1999	18	14					2387	2395		10.1038/sj.onc.1202578	http://dx.doi.org/10.1038/sj.onc.1202578			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184DT	10327060				2022-12-25	WOS:000079595500012
J	Piret, B; Schoonbroodt, S; Piette, J				Piret, B; Schoonbroodt, S; Piette, J			The ATM protein is required for sustained activation of NF-kappa B following DNA damage	ONCOGENE			English	Article						NF-kappa B; camptothecin; ataxia-telangiectasia; DNA damage; DNA-PK; ATM	DAUNORUBICIN-INDUCED APOPTOSIS; SIGNAL-TRANSDUCTION PATHWAY; ATAXIA-TELANGIECTASIA CELLS; NIJMEGEN BREAKAGE SYNDROME; NUCLEAR TYROSINE KINASE; ALPHA-INDUCED APOPTOSIS; LONG TERMINAL REPEAT; TRANSCRIPTION FACTOR; C-ABL; IONIZING-RADIATION	Cells lacking an intact ATM gene are hypersensitive to ionizing radiation and show multiple defects in the cell cycle-coupled checkpoints. DNA damage usually triggers cell cycle arrest through, among other things, the Another DNA-damage responsive factor is NF-kappa B. It is activated by various stress situations, including oxidative stress, and by DNA-damaging compounds such as topoisomerase poisons. We found that cells from Ataxia Telangiectasia patients exhibit a defect in NF-kappa B activation in response to treatment with camptothecin, a topoisomerase I poison. In AT cells, this activation is shortened or suppressed, compared to that observed in normal cells. Ectopic expression of the ATM protein in AT cells increases the activation of NF-kappa B in response to camptothecin. M059J glioblastoma cells that do not express the DNA-PK catalytic subunit respond normally to camptothecin. These results support the hypothesis that NF-kappa B is a DNA damage-responsive transcription factor and that its activation pathway by DNA damage shares some components with the one leading to p53 activation.	Univ Liege, Lab Fundamental Virol & Immunol, B-4000 Liege, Belgium	University of Liege	Piette, J (corresponding author), Univ Liege, Lab Fundamental Virol & Immunol, B23, B-4000 Liege, Belgium.							Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; ALKALAY I, 1995, P NATL ACAD SCI USA, V92, P10599, DOI 10.1073/pnas.92.23.10599; ANDERSON MT, 1994, P NATL ACAD SCI USA, V91, P11527, DOI 10.1073/pnas.91.24.11527; BAGULEY BC, 1991, ANTI-CANCER DRUG DES, V6, P1; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Basu S, 1998, BIOCHEM BIOPH RES CO, V247, P79, DOI 10.1006/bbrc.1998.8741; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bender K, 1998, EMBO J, V17, P5170, DOI 10.1093/emboj/17.17.5170; BERTONCINI CRA, 1995, NUCLEIC ACIDS RES, V23, P2995, DOI 10.1093/nar/23.15.2995; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Boulton SJ, 1998, EMBO J, V17, P1819, DOI 10.1093/emboj/17.6.1819; BRACH MA, 1991, J CLIN INVEST, V88, P691, DOI 10.1172/JCI115354; Brown L, 1997, NATURE, V387, P450, DOI 10.1038/387450a0; Cai ZZ, 1997, J BIOL CHEM, V272, P96; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Flohe L, 1997, FREE RADICAL BIO MED, V22, P1115, DOI 10.1016/S0891-5849(96)00501-1; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P14; Fritz E, 1997, P NATL ACAD SCI USA, V94, P4538, DOI 10.1073/pnas.94.9.4538; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; Gartenhaus RB, 1996, P NATL ACAD SCI USA, V93, P265, DOI 10.1073/pnas.93.1.265; Gilad S, 1996, HUM MOL GENET, V5, P433, DOI 10.1093/hmg/5.4.433; GOGA A, 1995, ONCOGENE, V11, P791; Gravel S, 1998, SCIENCE, V280, P741, DOI 10.1126/science.280.5364.741; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; Hoekstra MF, 1997, CURR OPIN GENET DEV, V7, P170, DOI 10.1016/S0959-437X(97)80125-6; Hug H, 1997, J BIOL CHEM, V272, P28191, DOI 10.1074/jbc.272.45.28191; JAFFRAY E, 1995, MOL CELL BIOL, V15, P2166; Jaffrezou JP, 1996, EMBO J, V15, P2417, DOI 10.1002/j.1460-2075.1996.tb00599.x; JASPERS NGJ, 1988, CYTOGENET CELL GENET, V49, P259, DOI 10.1159/000132673; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; Jung M, 1997, CANCER RES, V57, P24; Jung M, 1998, RADIAT RES, V149, P596, DOI 10.2307/3579906; JUNG M, 1995, SCIENCE, V268, P1619, DOI 10.1126/science.7777860; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; Le Page C, 1998, BIOCHEM BIOPH RES CO, V243, P451; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LeesMiller SP, 1996, BIOCHEM CELL BIOL, V74, P503, DOI 10.1139/o96-054; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; LEGRANDPOELS S, 1995, J BIOL CHEM, V270, P6925, DOI 10.1074/jbc.270.12.6925; Liu L, 1998, MOL CELL BIOL, V18, P4221, DOI 10.1128/MCB.18.7.4221; LIU LF, 1981, P NATL ACAD SCI-BIOL, V78, P3487, DOI 10.1073/pnas.78.6.3487; Liu WM, 1998, INT J ONCOL, V12, P793; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; Metcalfe JA, 1996, NAT GENET, V13, P350, DOI 10.1038/ng0796-350; MEYN MS, 1993, AM J HUM GENET, V53, P1206; Nitiss JL, 1996, MOL PHARMACOL, V50, P1095; PAHL HL, 1995, EMBO J, V14, P2580, DOI 10.1002/j.1460-2075.1995.tb07256.x; PANDITA TK, 1995, CYTOGENET CELL GENET, V71, P86, DOI 10.1159/000134069; PETERSON C, 1991, GENE, V107, P279, DOI 10.1016/0378-1119(91)90328-9; Piette J, 1997, BIOL CHEM, V378, P1237; Piret B, 1996, NUCLEIC ACIDS RES, V24, P4242, DOI 10.1093/nar/24.21.4242; PIRET B, 1995, EUR J BIOCHEM, V228, P447, DOI 10.1111/j.1432-1033.1995.tb20283.x; PLANCHON SM, 1995, CANCER RES, V55, P3706; Qiu XB, 1996, J BIOL CHEM, V271, P31915, DOI 10.1074/jbc.271.50.31915; QUINTO I, 1993, J BIOL CHEM, V268, P26719; REED M, 1995, P NATL ACAD SCI USA, V92, P9455, DOI 10.1073/pnas.92.21.9455; Rothenberg ML, 1997, ANN ONCOL, V8, P837, DOI 10.1023/A:1008270717294; SACHSENMAIER C, 1994, BIOCHEM PHARMACOL, V47, P129, DOI 10.1016/0006-2952(94)90446-4; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shiloh Y, 1997, ANNU REV GENET, V31, P635, DOI 10.1146/annurev.genet.31.1.635; SINGH S, 1995, J BIOL CHEM, V270, P10631, DOI 10.1074/jbc.270.18.10631; SINHA BK, 1990, FREE RADICAL BIO MED, V8, P567, DOI 10.1016/0891-5849(90)90155-C; Smilenov LB, 1997, ONCOGENE, V15, P2659, DOI 10.1038/sj.onc.1201449; STEIN B, 1989, J VIROL, V63, P4540, DOI 10.1128/JVI.63.11.4540-4544.1989; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Vaziri H, 1997, EMBO J, V16, P6018, DOI 10.1093/emboj/16.19.6018; VERHAEGEN S, 1995, BIOCHEM PHARMACOL, V50, P1021, DOI 10.1016/0006-2952(95)00233-P; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343; Wright J, 1996, AM J HUM GENET, V59, P839; Xia SJJ, 1996, MUTAT RES-DNA REPAIR, V364, P1, DOI 10.1016/0921-8777(96)00015-8; Xie GF, 1998, ONCOGENE, V16, P721, DOI 10.1038/sj.onc.1201793; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0; Zhang N, 1997, P NATL ACAD SCI USA, V94, P8021, DOI 10.1073/pnas.94.15.8021; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319	96	137	142	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 1	1999	18	13					2261	2271		10.1038/sj.onc.1202541	http://dx.doi.org/10.1038/sj.onc.1202541			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	182YE	10327072				2022-12-25	WOS:000079525100010
J	Takahashi, T; Ueno, H; Shibuya, M				Takahashi, T; Ueno, H; Shibuya, M			VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells	ONCOGENE			English	Article						vascular endothelial growth factor; tyrosine kinase receptor; signal transduction; MAP kinase cascade; protein kinase C	GROWTH-FACTOR VEGF; VASCULAR-PERMEABILITY FACTOR; RECEPTOR TYROSINE KINASE; SIGNAL-TRANSDUCTION; PC12 CELLS; HEMATOPOIETIC-CELLS; PLC-GAMMA; PHOSPHORYLATION; ANGIOGENESIS; EXPRESSION	KDR/Flk-1 tyrosine kinase, one of the two VEGF receptors induces mitogenesis and differentiation of vascular endothelial cells. We have previously reported that a major target molecule of KDR/Flk-1 kinase is PLC-gamma, and that VEGF induces activation of MAP kinase, mainly mediated by protein kinase C (PKC) in the NIH3T3 cells overexpressing KDR/Flk-1 (Takahashi and Shibuya, 1997). However, the signal transduction initiated from VEGF in endothelial cells remains to be elucidated. In primary sinusoidal endothelial cells which showed strictly VEGF-dependent growth, we found that VEGF stimulated the activation of Raf-1-MEK-MAP kinase cascade. To our surprise, an important regulator, Ras was not efficiently activated to a significant level in response to VEGF. Consistent with this, dominant-negative Ras did not block the VEGF-induced phosphorylation of MAP kinase. On the other hand, PKC-specific inhibitors severely reduced VEGF-dependent phosphorylation of MEK, activation of MAP kinase and subsequent DNA synthesis. A potent PI3 kinase inhibitor, Wortmannin, could not inhibit either of them. These results suggest that in primary endothelial cells, VEGF-induced activation of Raf-MEK-MAP kinase and DNA synthesis are mainly mediated by PKC-dependent pathway, much more than by Ras-dependent or PI3 kinase-dependent pathway.	Univ Tokyo, Inst Med Sci, Dept Genet, Minato Ku, Tokyo 1088639, Japan; Kyushu Univ, Sch Med, Dept Cardiol, Fukuoka 8120054, Japan	University of Tokyo; Kyushu University	Shibuya, M (corresponding author), Univ Tokyo, Inst Med Sci, Dept Genet, Minato Ku, Tokyo 1088639, Japan.							Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BACCARINI M, 1990, EMBO J, V9, P3649, DOI 10.1002/j.1460-2075.1990.tb07576.x; Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629; Cohen T, 1992, GROWTH FACTORS, V7, P131, DOI 10.3109/08977199209046402; CONNINGHAM SA, 1995, J BIOL CHEM, V270, P20254; CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322; DAVIET I, 1989, BIOCHEM BIOPH RES CO, V158, P584, DOI 10.1016/S0006-291X(89)80089-0; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; EICHMANN A, 1993, MECH DEVELOP, V42, P33, DOI 10.1016/0925-4773(93)90096-G; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FERRARA N, 1991, J CELL BIOCHEM, V47, P211, DOI 10.1002/jcb.240470305; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; INOGUCHI T, 1992, P NATL ACAD SCI USA, V89, P11059, DOI 10.1073/pnas.89.22.11059; IZUMI T, 1991, J BIOL CHEM, V266, P7933; JAKEMAN LB, 1992, J CLIN INVEST, V89, P244, DOI 10.1172/JCI115568; JUNG V, 1994, MOL CELL BIOL, V14, P3707, DOI 10.1128/MCB.14.6.3707; KAIPAINEN A, 1993, J EXP MED, V178, P2077, DOI 10.1084/jem.178.6.2077; Katagiri H, 1997, AM J PHYSIOL-ENDOC M, V272, pE326, DOI 10.1152/ajpendo.1997.272.2.E326; KATOH O, 1995, CANCER RES, V55, P5687; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KROLL J, 1997, J BIOL CHEM, V272, P33521; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Li YS, 1996, MOL CELL BIOL, V16, P5947; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; MONTESANO R, 1985, CELL, V42, P469, DOI 10.1016/0092-8674(85)90104-7; MORRIS PB, 1988, AM J PHYSIOL, V254, pC318, DOI 10.1152/ajpcell.1988.254.2.C318; MUROYA K, 1992, ONCOGENE, V7, P277; MUSTONEN T, 1995, J CELL BIOL, V12, P895; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PEPPER MS, 1991, BIOCHEM BIOPH RES CO, V181, P902, DOI 10.1016/0006-291X(91)91276-I; QIU MS, 1991, NEURON, V7, P937, DOI 10.1016/0896-6273(91)90339-2; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; Sawano A, 1997, BIOCHEM BIOPH RES CO, V238, P487, DOI 10.1006/bbrc.1997.7327; SEETHARAM L, 1995, ONCOGENE, V10, P135; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHEN H, 1993, BLOOD, V81, P2767; SHIBUYA M, 1990, ONCOGENE, V5, P519; Shibuya M, 1995, ADV CANCER RES, V67, P281, DOI 10.1016/S0065-230X(08)60716-2; SOZERI O, 1992, ONCOGENE, V7, P2259; Takahashi T, 1997, J BIOL CHEM, V272, P16018, DOI 10.1074/jbc.272.25.16018; Takahashi T, 1997, ONCOGENE, V14, P2079, DOI 10.1038/sj.onc.1201047; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; UNEMORI EN, 1992, J CELL PHYSIOL, V153, P557, DOI 10.1002/jcp.1041530317; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; WOLF BA, 1991, J CLIN INVEST, V87, P31, DOI 10.1172/JCI114988; Xia P, 1996, J CLIN INVEST, V98, P2018, DOI 10.1172/JCI119006; YAMANE A, 1994, ONCOGENE, V9, P2683	64	450	475	0	15	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 1	1999	18	13					2221	2230		10.1038/sj.onc.1202527	http://dx.doi.org/10.1038/sj.onc.1202527			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	182YE	10327068				2022-12-25	WOS:000079525100006
J	Doliana, R; Mongiat, M; Bucciotti, F; Giacomello, E; Deutzmann, R; Volpin, D; Bressan, GM; Colombatti, A				Doliana, R; Mongiat, M; Bucciotti, F; Giacomello, E; Deutzmann, R; Volpin, D; Bressan, GM; Colombatti, A			EMILIN, a component of the elastic fiber and a new member of the C1q/Tumor necrosis factor superfamily of proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-BINDING-PROTEIN; MOLECULAR-CLONING; GLOBULAR DOMAIN; SUBCOMPONENT C1Q; SIGNAL PEPTIDES; LEUCINE-ZIPPER; CDNA SEQUENCE; COILED-COIL; B-CHAIN; GENE	EMILIN (elastin microfibril interface located protein) is an extracellular matrix glycoprotein abundantly expressed in elastin-rich tissues such as blood vessels, skin, heart, and lung. It occurs associated with elastic fibers at the interface between amorphous elastin and microfibrils, Avian EMILIN was extracted from 19-day-old embryonic chick aortas and associated blood vessels and purified by ion-exchange chromatography and gel filtration. Tryptic peptides were generated from EMILIN and sequenced, and degenerate inosine-containing oligonucleotide primers were designed from some peptides. A set of primers allowed the amplification of a 360-base pair reverse transcription polymerase chain reaction product from chick aorta mRNA, A probe based on a human homologue selected by comparison of the chick sequence with EST data base was used to select overlapping clones from both human aorta and kidney cDNA libraries. Here we present the cDNA sequence of the entire coding region of human EMILIN encompassing an open reading frame of 1016 amino acid residues. There was a high degree of homology (76% identity and 88% similarity) between the chick C terminus and the human sequence as well as between the N terminus of the mature chick protein where 10 of 12 residues, as determined by N-terminal sequencing, were identical or similar to the deduced N terminus of human EMILIN. The domain organization of human EMILIN includes a Clq-like globular domain at the C terminus, a collagenous stalk, and a longer segment in which at least four heptad repeats and a leucine zipper can be identified with a high potential for forming coiled-coil alpha helices, At the N terminus there is a cysteine-rich sequence stretch similar to a region of multimerin, a platelet and endothelial cell component, containing a partial epidermal growth factor-like motif, The native state of the recombinantly expressed EMILIN C1q-like domain to be used in cell adhesion was determined by CD spectra analysis, which indicated a high value of beta-sheet conformation. The EMILIN C1q-like domain promoted a high cell adhesion of the leiomyosarcoma cell line SK-UT-1, whereas the fibrosarcoma cell line HT1080 was negative.	Ctr Riferimento Oncol, Div Oncol Sperimentale 2, I-33081 Aviano, Italy; Univ Regensburg, Dept Biochem Genet & Microbiol, D-8400 Regensburg, Germany; Univ Padua, Ist Istol, I-35100 Padua, Italy; Univ Udine, Dipartimento Sci & Tecnol Biomed, I-33100 Udine, Italy	IRCCS Aviano (CRO); University of Regensburg; University of Padua; Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Udine	Colombatti, A (corresponding author), Ctr Riferimento Oncol, Div Oncol Sperimentale 2, Via Pedemontana Occidentale, I-33081 Aviano, Italy.		Doliana, Roberto/AAA-1479-2019; Bucciotti, Francesco/AAZ-1255-2020; Mongiat, Maurizio/H-8297-2018; Giacomello, Emiliana/E-3080-2018	Doliana, Roberto/0000-0002-8324-7564; Bucciotti, Francesco/0000-0002-4253-855X; Mongiat, Maurizio/0000-0001-6509-0068; colombatti, alfonso/0000-0002-3676-2379; Giacomello, Emiliana/0000-0003-3329-6269	Telethon [E.0704] Funding Source: Medline	Telethon(Fondazione Telethon)		ABRAMS WR, 1995, GENOMICS, V26, P47, DOI 10.1016/0888-7543(95)80081-V; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; Bork P, 1996, CURR OPIN STRUC BIOL, V6, P366, DOI 10.1016/S0959-440X(96)80057-1; BRESSAN GM, 1993, J CELL BIOL, V121, P201, DOI 10.1083/jcb.121.1.201; BRESSAN GM, 1983, J BIOL CHEM, V258, P3262; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; Cleary E.G., 1987, CONNECTIVE TISSUE DI, V12, P55; CLEARY EG, 1996, STRUCTURE FUNCTION E, V2, P95; COLOMBATTI A, 1985, COLLAGEN REL RES, V5, P181; COLOMBATTI A, 1988, J BIOL CHEM, V263, P17534; COLOMBATTI A, 1985, J CELL BIOL, V100, P18, DOI 10.1083/jcb.100.1.18; COLOMBATTI A, 1987, COLLAGEN REL RES, V7, P259; DAGAGORDINI D, 1987, HISTOCHEM J, V19, P623, DOI 10.1007/BF01676168; Davis JG, 1997, P NATL ACAD SCI USA, V94, P707, DOI 10.1073/pnas.94.2.707; Dedio J, 1998, J IMMUNOL, V160, P3534; Frischholz S, 1998, J BIOL CHEM, V273, P4547, DOI 10.1074/jbc.273.8.4547; GHEBREHIWET B, 1994, J EXP MED, V179, P1809, DOI 10.1084/jem.179.6.1809; GIACOMELLO E, 1999, IN PRESS BIOTECHNIQU; Gibson MA, 1996, J BIOL CHEM, V271, P1096, DOI 10.1074/jbc.271.2.1096; GIBSON MA, 1995, MOL CELL BIOL, V15, P6932; GREENLEE TK, 1966, J CELL BIOL, V30, P59, DOI 10.1083/jcb.30.1.59; Hatzinikolas G, 1998, J BIOL CHEM, V273, P29309, DOI 10.1074/jbc.273.45.29309; HAYWARD CPM, 1995, J BIOL CHEM, V270, P19217, DOI 10.1074/jbc.270.33.19217; HAYWARD CPM, 1991, BLOOD, V77, P2556; HAYWARD CPM, 1995, J BIOL CHEM, V270, P18246, DOI 10.1074/jbc.270.31.18246; Henderson M, 1996, J HISTOCHEM CYTOCHEM, V44, P1389, DOI 10.1177/44.12.8985131; Hu E, 1996, J BIOL CHEM, V271, P10697, DOI 10.1074/jbc.271.18.10697; KANZAKI T, 1990, CELL, V61, P1051, DOI 10.1016/0092-8674(90)90069-Q; KAUL M, 1995, J IMMUNOL, V155, P5795; KOZAK M, 1981, NUCLEIC ACIDS RES, V9, P5233, DOI 10.1093/nar/9.20.5233; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; Lupas A, 1996, METHOD ENZYMOL, V266, P513; MENENDEZARIAS L, 1988, COMPUT APPL BIOSCI, V4, P479; MURAGAKI Y, 1991, J BIOL CHEM, V266, P7721; MURAGAKI Y, 1991, EUR J BIOCHEM, V197, P615, DOI 10.1111/j.1432-1033.1991.tb15951.x; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; PARTRIDGE SM, 1962, ADV PROTEIN CHEM, V17, P227; PEARLMAN JA, 1994, FEBS LETT, V354, P183, DOI 10.1016/0014-5793(94)01119-2; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PEERSCHKE EIB, 1993, J LEUKOCYTE BIOL, V53, P179, DOI 10.1002/jlb.53.2.179; Peerschke EIB, 1996, J IMMUNOL, V157, P4154; PEERSCHKE EIB, 1994, J IMMUNOL, V152, P5896; PERLMAN D, 1983, J MOL BIOL, V167, P391, DOI 10.1016/S0022-2836(83)80341-6; REICHENBERGER E, 1992, FEBS LETT, V311, P305, DOI 10.1016/0014-5793(92)81126-7; Reid K B, 1989, Behring Inst Mitt, P8; REID KBM, 1985, BIOCHEM J, V231, P729, DOI 10.1042/bj2310729; ROAK EF, 1995, J HISTOCHEM CYTOCHEM, V43, P401; ROSENBLOOM J, 1993, FASEB J, V7, P1208, DOI 10.1096/fasebj.7.13.8405806; Saharinen J, 1998, J BIOL CHEM, V273, P18459, DOI 10.1074/jbc.273.29.18459; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; SELLAR GC, 1991, BIOCHEM J, V274, P481, DOI 10.1042/bj2740481; Shapiro L, 1998, CURR BIOL, V8, P335, DOI 10.1016/S0960-9822(98)70133-2; SMITH KF, 1994, BIOCHEM J, V301, P249, DOI 10.1042/bj3010249; SPESSOTTO P, 1999, IN PRESS METHODS MOL; TAKAMATSU N, 1993, MOL CELL BIOL, V13, P1516, DOI 10.1128/MCB.13.3.1516; URADE Y, 1991, P NATL ACAD SCI USA, V88, P1069, DOI 10.1073/pnas.88.3.1069; YIN WS, 1995, J BIOL CHEM, V270, P10147, DOI 10.1074/jbc.270.17.10147; ZHANG H, 1994, J CELL BIOL, V124, P855, DOI 10.1083/jcb.124.5.855; Zhang SD, 1996, GENE DEV, V10, P1108, DOI 10.1101/gad.10.9.1108; ZHAO ZY, 1995, HUM MOL GENET, V4, P589, DOI 10.1093/hmg/4.4.589	62	71	75	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16773	16781		10.1074/jbc.274.24.16773	http://dx.doi.org/10.1074/jbc.274.24.16773			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358019	hybrid			2022-12-25	WOS:000080780400018
J	Serebriiskii, I; Khazak, V; Golemis, EA				Serebriiskii, I; Khazak, V; Golemis, EA			A two-hybrid dual bait system to discriminate specificity of protein interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-HYBRID SYSTEM; SACCHAROMYCES-CEREVISIAE; DIFFERENTIAL INTERACTION; 2-HYBRID SYSTEM; GENE-PRODUCT; DNA-BINDING; LEXA GENE; YEAST; REPRESSOR; AFFINITY	Biological regulatory systems require the specific organization of proteins into multicomponent complexes. Two hybrid systems have been used to identify novel components of signaling networks based on interactions with defined partner proteins. An important issue in the use of two-hybrid systems has been the degree to which interacting proteins distinguish their biological partner from evolutionarily conserved related proteins and the degree to which observed interactions are specific. We adapted the basic two-hybrid strategy to create a novel dual bait system designed to allow single-step screening of libraries for proteins that interact with protein 1 of interest, fused to DNA binding domain A (LexA), but do not interact with protein 2, fused to DNA binding domain B (lambda cI), Using the selective interactions of Ras and Krev-1(Rap1A) with Raf, RalGDS, and Krit1 as a model, we systematically compared LexA- and cI-fused baits and reporters. The LexA and cI baits reporter systems are well matched for level of bait expression and sensitivity range for interaction detection and allow effective isolation of specifically interacting protein pairs against a nonspecific background. These reagents should prove useful to refine the selectivity of library screens, to reduce the isolation of false positives in such screens, and to perform directed analyses of sequence elements governing the interaction of a single protein with multiple partners.	Fox Chase Canc Ctr, Div Basic Sci, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Golemis, EA (corresponding author), Fox Chase Canc Ctr, Div Basic Sci, 7701 Burholme Ave, Philadelphia, PA 19111 USA.			Golemis, Erica/0000-0003-3618-3673	NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER; NCI NIH HHS [CA06927] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALT FW, 1986, COLD SPRING HARB SYM, V51, P931, DOI 10.1101/SQB.1986.051.01.106; Aronheim A, 1997, MOL CELL BIOL, V17, P3094, DOI 10.1128/MCB.17.6.3094; Ausubel FM, 1998, CURRENT PROTOCOLS MO; Bartel PL, 1996, NAT GENET, V12, P72, DOI 10.1038/ng0196-72; BRENT R, 1981, P NATL ACAD SCI-BIOL, V78, P4204, DOI 10.1073/pnas.78.7.4204; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHIU MI, 1994, P NATL ACAD SCI USA, V91, P12574, DOI 10.1073/pnas.91.26.12574; Colas P, 1996, NATURE, V380, P548, DOI 10.1038/380548a0; COLEMIS EA, 1997, CURRENT PROTOCOLS MO; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Duttweiler HM, 1996, TRENDS GENET, V12, P340, DOI 10.1016/S0168-9525(96)80008-4; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; FIELDS S, 1989, NATURE, V340, P345; FINLEY RL, 1994, P NATL ACAD SCI USA, V91, P12980, DOI 10.1073/pnas.91.26.12980; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; FromontRacine M, 1997, NAT GENET, V16, P277, DOI 10.1038/ng0797-277; GOLEMIS EA, 1992, MOL CELL BIOL, V12, P3006, DOI 10.1128/MCB.12.7.3006; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; Inouye C, 1997, GENETICS, V147, P479; Jiang R, 1996, GENE DEV, V10, P3105, DOI 10.1101/gad.10.24.3105; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Licitra EJ, 1996, P NATL ACAD SCI USA, V93, P12817, DOI 10.1073/pnas.93.23.12817; LITTLE JW, 1981, P NATL ACAD SCI-BIOL, V78, P4199, DOI 10.1073/pnas.78.7.4199; MARKHAM BE, 1981, NUCLEIC ACIDS RES, V9, P4149, DOI 10.1093/nar/9.16.4149; Mendelsohn Andrew R., 1994, Current Opinion in Biotechnology, V5, P482, DOI 10.1016/0958-1669(94)90061-2; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; NELSON HCM, 1985, CELL, V42, P549, DOI 10.1016/0092-8674(85)90112-6; Osborne MA, 1996, J BIOL CHEM, V271, P29271, DOI 10.1074/jbc.271.46.29271; PTASHNE M, 1978, OPERON, P325; SAUER RT, 1982, NATURE, V298, P447, DOI 10.1038/298447a0; SenGupta DJ, 1996, P NATL ACAD SCI USA, V93, P8496, DOI 10.1073/pnas.93.16.8496; Serebriiskii I, 1997, ONCOGENE, V15, P1043, DOI 10.1038/sj.onc.1201268; Shalloway D, 1997, TRENDS CELL BIOL, V7, P215; Sherman F., 1986, METHODS YEAST GENETI; Tirode F, 1997, J BIOL CHEM, V272, P22995, DOI 10.1074/jbc.272.37.22995; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wang ZF, 1996, GENE DEV, V10, P3028, DOI 10.1101/gad.10.23.3028; Xu CW, 1997, P NATL ACAD SCI USA, V94, P12473, DOI 10.1073/pnas.94.23.12473; YANG MJ, 1995, NUCLEIC ACIDS RES, V23, P1152, DOI 10.1093/nar/23.7.1152; ZARET KS, 1985, J BACTERIOL, V162, P579, DOI 10.1128/JB.162.2.579-583.1985; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	42	73	86	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17080	17087		10.1074/jbc.274.24.17080	http://dx.doi.org/10.1074/jbc.274.24.17080			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358061	hybrid			2022-12-25	WOS:000080780400060
J	Barlic, J; Khandaker, MH; Mahon, E; Andrews, J; DeVries, ME; Mitchell, GB; Rahimpour, R; Tan, CM; Ferguson, SSG; Kelvin, DJ				Barlic, J; Khandaker, MH; Mahon, E; Andrews, J; DeVries, ME; Mitchell, GB; Rahimpour, R; Tan, CM; Ferguson, SSG; Kelvin, DJ			beta-Arrestins regulate interleukin-8-induced CXCR1 internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLED RECEPTOR INTERNALIZATION; BETA(2)-ADRENERGIC RECEPTOR; MEDIATED ENDOCYTOSIS; IL-8 RECEPTOR; PROTEIN; DYNAMIN; CHEMOKINES; CLATHRIN; DESENSITIZATION; NEUTROPHILS	The functional role of neutrophils during acute inflammatory responses is regulated by two high affinity interleukin-8 receptors (CXCR1 and CXCR2) that are rapidly desensitized and internalized upon binding their cognate chemokine ligands. The efficient re-expression of CXCR1 on the surface of neutrophils following agonist-induced internalization suggests that CXCR1 surface receptor turnover may involve regulatory pathways and intracellular factors similar to those regulating beta(2)-adrenergic receptor internalization and re-expression. To examine the internalization pathway utilized by ligand-activated CXCR1, a CXCR1-GFP construct was transiently expressed in two different cell lines, HEK 293 and RBL-2H3 cells. While interleukin-8 stimulation promoted CXCR1 sequestration in RBL-2H3 cells, receptor internalization in HEK 293 cells required co-expression of G protein-coupled receptor kinase 2 and beta-arrestin proteins. The importance of beta-arrestins in CXCR1 internalization was confirmed by the ability of a dominant negative beta-arrestin 1-V53D mutant to block internalization of CXCR1 in RBL-2H3 cells. A role for dynamin was also demonstrated by the lack of CXCR1 internalization in dynamin I-K44A dominant negative mutant-transfected RBL-2H3 cells. Agonist-promoted co-localization of transferrin and CXCR1-GFP in endosomes of RBL-2H3 cells confirmed that receptor internalization occurs via clathrin coated vesicles. Our data provides a direct Link between agonist-induced internalization of CXCR1 and a requirement for G protein-coupled receptor kinase 2, beta-arrestins, and dynamin during this process.	John P Robarts Res Inst, Lab Mol Immunol & Inflammat, London, ON N6G 2V4, Canada; Univ Western Ontario, Dept Microbiol & Immunol, London, ON N6A 5C1, Canada; Univ Western Ontario, Dept Physiol Pharmacol & Toxicol, London, ON N6A 5K8, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Kelvin, DJ (corresponding author), John P Robarts Res Inst, Lab Mol Immunol & Inflammat, London, ON N6G 2V4, Canada.		Sawant, Kirti V/H-3778-2013					Aramori I, 1997, EMBO J, V16, P4606, DOI 10.1093/emboj/16.15.4606; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CHUANG TT, 1992, J BIOL CHEM, V267, P6886; CHUNTHARAPAI A, 1995, J IMMUNOL, V155, P2587; Damke H, 1996, FEBS LETT, V389, P48, DOI 10.1016/0014-5793(96)00517-0; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Ferguson SSG, 1996, CAN J PHYSIOL PHARM, V74, P1095, DOI 10.1139/y96-124; FERNANDEZ HN, 1978, J IMMUNOL, V120, P109; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; HAMMOND MEW, 1995, J IMMUNOL, V155, P1428; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; Hirst J, 1998, BBA-MOL CELL RES, V1404, P173, DOI 10.1016/S0167-4889(98)00056-1; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; Kallal L, 1998, J BIOL CHEM, V273, P322, DOI 10.1074/jbc.273.1.322; KELVIN DJ, 1993, J LEUKOCYTE BIOL, V54, P604, DOI 10.1002/jlb.54.6.604; Khandaker MH, 1998, J IMMUNOL, V161, P1930; LEE J, 1992, J BIOL CHEM, V267, P16283; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; Muhlberg AB, 1997, EMBO J, V16, P6676, DOI 10.1093/emboj/16.22.6676; Murphy Philip M., 1996, Cytokine and Growth Factor Reviews, V7, P47, DOI 10.1016/1359-6101(96)00009-3; Murphy PM, 1997, SEMIN HEMATOL, V34, P311; Oh P, 1998, J CELL BIOL, V141, P101, DOI 10.1083/jcb.141.1.101; Ponka P, 1998, SEMIN HEMATOL, V35, P35; Prado GN, 1996, J BIOL CHEM, V271, P19186, DOI 10.1074/jbc.271.32.19186; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; Richardson RM, 1998, J BIOL CHEM, V273, P10690, DOI 10.1074/jbc.273.17.10690; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Sabroe I, 1997, J IMMUNOL, V158, P1361; SAMANTA AK, 1990, J BIOL CHEM, V265, P183; SCHIFFMANN E, 1975, P NATL ACAD SCI USA, V72, P1059, DOI 10.1073/pnas.72.3.1059; SHAM RL, 1993, BLOOD, V82, P2546; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	38	110	114	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16287	16294		10.1074/jbc.274.23.16287	http://dx.doi.org/10.1074/jbc.274.23.16287			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347185	hybrid			2022-12-25	WOS:000080668600045
J	Edwards, SW; Limbird, LE				Edwards, SW; Limbird, LE			Role for the third intracellular loop in cell surface stabilization of the alpha(2A)-adrenergic receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; MUSCARINIC ACETYLCHOLINE-RECEPTOR; AGONIST-PROMOTED DESENSITIZATION; MEMBRANE CYTOSKELETAL COMPLEX; POSTSYNAPTIC DENSITY PROTEIN; NITRIC-OXIDE SYNTHASE; CANINE KIDNEY-CELLS; EPITHELIAL-CELLS; PLASMA-MEMBRANE; DOWN-REGULATION	Previous studies have shown that alpha(2A)-adrenergic receptor (alpha(2A)-AR) retention at the basolateral surface of polarized MDCKII cells involves its third intracellular (3i loop). The present studies examining mutant alpha(2A)-ARs possessing short deletions of the 3i loop indicate that no single region can completely account for the accelerated surface turnover of the Delta 3i alpha(2A)-AR, suggesting that the entire 3i loop is involved in basolateral retention. Both wild-type and Delta 3i loop alpha(2A)-ARs are extracted from polarized Madin-Darby canine kidney (MDCK) cells with 0.2% Triton X-100 and with a similar concentration/response profile, suggesting that Triton X-100-resistant interactions of the alpha(2A)-AR with cytoskeletal proteins are not involved in receptor retention on the basolateral surface. The indistinguishable basolateral t(1/2) for either the wild-type or nonsense 3i loop alpha(2A)-AR suggests that the stabilizing properties of the alpha(2A)-AR 3i loop are not uniquely dependent on a specific sequence of amino acids. The accelerated turnover of Delta 3i alpha(2A)-AR cannot be attributed to alteration in agonist-elicited alpha(2A)-AR redistribution, because alpha(2A)-ARs are not down-regulated in response to agonist. Taken together, the present studies show that stabilization of the alpha(2A)-AR on the basolateral surface of MDCKII cells involves multiple mechanisms, with the third intracellular loop playing a central role in regulating these processes.	Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA	Vanderbilt University	Limbird, LE (corresponding author), Vanderbilt Univ, Med Ctr, Dept Pharmacol, MRBI 464, Nashville, TN 37232 USA.			Edwards, Stephen/0000-0002-7985-111X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL025182] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043879] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007628] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL25182] Funding Source: Medline; NIDDK NIH HHS [DK43879] Funding Source: Medline; NIGMS NIH HHS [GM07628] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENZEEV A, 1979, CELL, V17, P859, DOI 10.1016/0092-8674(79)90326-X; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; BROWN AM, 1993, J MEMBRANE BIOL, V131, P93, DOI 10.1007/BF02791318; CHOI KY, 1994, CELL, V78, P499; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; Daunt DA, 1997, MOL PHARMACOL, V51, P711, DOI 10.1124/mol.51.5.711; DellAcqua ML, 1997, J BIOL CHEM, V272, P12881, DOI 10.1074/jbc.272.20.12881; DHARMSATHAPHORN K, 1984, GASTROENTEROLOGY, V86, P120; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; EASON MG, 1995, J BIOL CHEM, V270, P4681, DOI 10.1074/jbc.270.9.4681; EASON MG, 1992, J BIOL CHEM, V267, P25473; Ferguson S S, 1998, Adv Pharmacol, V42, P420; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; FIELD M, 1973, AM J PHYSIOL, V225, P852; GELLAI M, 1987, J PHARMACOL EXP THER, V240, P723; GELLAI M, 1990, AM J PHYSIOL, V259, pF1, DOI 10.1152/ajprenal.1990.259.1.F1; Gether U, 1997, J BIOL CHEM, V272, P2587, DOI 10.1074/jbc.272.5.2587; Goldman PS, 1996, J BIOL CHEM, V271, P4215; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GRAESER D, 1993, MOL PHARMACOL, V43, P434; GUYER CA, 1990, J BIOL CHEM, V265, P17307; Heck DA, 1998, LIFE SCI, V62, P1467, DOI 10.1016/S0024-3205(98)00091-5; Itokawa M, 1996, MOL PHARMACOL, V49, P560; JewellMotz EA, 1997, BIOCHEMISTRY-US, V36, P8858, DOI 10.1021/bi970487x; KEEFER JR, 1993, J BIOL CHEM, V268, P11340; KEEFER JR, 1994, J BIOL CHEM, V269, P16425; KENNEDY ME, 1993, J BIOL CHEM, V268, P8003; Kusumi A, 1996, CURR OPIN CELL BIOL, V8, P566, DOI 10.1016/S0955-0674(96)80036-6; LAMEH J, 1992, J BIOL CHEM, V267, P13406; LIGGETT SB, 1992, J BIOL CHEM, V267, P4740; MCNEILL RB, 1995, J BIOL CHEM, V270, P10043, DOI 10.1074/jbc.270.17.10043; MOCHLYROSEN D, 1991, J BIOL CHEM, V266, P14866; MORO O, 1993, J BIOL CHEM, V268, P6862; NEAME SJ, 1992, EMBO J, V11, P4733, DOI 10.1002/j.1460-2075.1992.tb05578.x; NELSON WJ, 1990, J CELL BIOL, V110, P349, DOI 10.1083/jcb.110.2.349; NELSON WJ, 1989, J CELL BIOL, V108, P893, DOI 10.1083/jcb.108.3.893; NEUBIG RR, 1994, FASEB J, V8, P939, DOI 10.1096/fasebj.8.12.8088459; NORD EP, 1987, J CLIN INVEST, V80, P1755, DOI 10.1172/JCI113268; RUFFOLO RR, 1994, PHARMACOL THERAPEUT, V61, P1, DOI 10.1016/0163-7258(94)90058-2; RUFFOLO RR, 1995, J MED CHEM, V38, P3681, DOI 10.1021/jm00019a001; SAKO Y, 1994, J CELL BIOL, V125, P1251, DOI 10.1083/jcb.125.6.1251; SAKO Y, 1995, J CELL BIOL, V129, P1559, DOI 10.1083/jcb.129.6.1559; Saunders C, 1998, J BIOL CHEM, V273, P24196, DOI 10.1074/jbc.273.37.24196; STRADER CD, 1995, FASEB J, V9, P745, DOI 10.1096/fasebj.9.9.7601339; TARONE G, 1984, J CELL BIOL, V99, P512, DOI 10.1083/jcb.99.2.512; Tsuga H, 1998, J BIOL CHEM, V273, P5323, DOI 10.1074/jbc.273.9.5323; UHLEN S, 1995, PHARM COMMUN, V6, P155; Wozniak M, 1996, J BIOL CHEM, V271, P5017; Yan Z, 1997, J NEUROPHYSIOL, V77, P1003, DOI 10.1152/jn.1997.77.2.1003; YU J, 1973, Journal of Supramolecular Structure, V1, P233, DOI 10.1002/jss.400010308	51	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16331	16336		10.1074/jbc.274.23.16331	http://dx.doi.org/10.1074/jbc.274.23.16331			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347190	hybrid			2022-12-25	WOS:000080668600050
J	Goldberg, ME; Schaeffer, F; Guillou, Y; Djavadi-Ohaniance, L				Goldberg, ME; Schaeffer, F; Guillou, Y; Djavadi-Ohaniance, L			Pseudo-native motifs in the noncovalent heme-apocytochrome c complex - Evidence from antibody binding studies by enzyme-linked immunosorbent assay and microcalorimetry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EGG-WHITE LYSOZYME; CYTOCHROME-C; LIGAND-BINDING; MONOCLONAL-ANTIBODIES; P21(H-RAS) PROTEIN; SELF-ORGANIZATION; MECHANISM; EQUILIBRIUM; RESOLUTION; CONSTANT	When beef heart apocytochrome c is unfolded, it folds upon noncovalent heme binding (Dumont, M. E., Corin, A. F., and Campbell, G.A. (1994) Biochemistry, 33, 7368-7378), Here, the conformation of the heme-apocytochrome noncovalent complex is compared with that of holocytochrome c, A purification method was designed for obtaining in large amounts apocytochrome c that was shown by amino acid analysis and mass spectroscopy to be chemically intact. The apoprotein and its noncovalent complex were characterized by absorption, fluorescence, circular dichroism, and sedimentation velocity, confirming previous reports. Sedimentation-diffusion equilibrium showed that the apoprotein and its noncovalent complex with heme were monomeric, Surprisingly, whereas apocytochrome c was quite soluble, the noncovalent complex slowly formed heavy aggregates, thus precluding experiments at the concentrations needed for structural studies. Two monoclonal antibodies that bind strongly to distinct antigenic sites on native holocytochrome were used to probe the noncovalent complex conformation. For both antibodies, the affinity for the noncovalent complex was only about 5-10fold smaller than that for native holocytochrome c, and about 50-100-fold larger than that for apocytochrome c, These results indicate that the noncovalent complex, although not entirely native, carries some pseudo-native structural motifs.	Inst Pasteur, Unite Biochim Cellulaire, F-75724 Paris 15, France; Inst Pasteur, CNRS, URA 1129, Lab Resonance Magnet Nucl, F-75724 Paris, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Goldberg, ME (corresponding author), Inst Pasteur, Unite Biochim Cellulaire, 28 Rue Dr Roux, F-75724 Paris 15, France.							ALLEN MJ, 1994, BIOCHEMISTRY-US, V33, P3967, DOI 10.1021/bi00179a024; CHAFFOTTE AF, 1992, BIOCHEMISTRY-US, V31, P9694, DOI 10.1021/bi00155a024; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; CREIGHTON TE, 1988, BIOPHYS CHEM, V31, P155, DOI 10.1016/0301-4622(88)80021-8; DAMASCHUN G, 1991, INT J BIOL MACROMOL, V13, P217, DOI 10.1016/0141-8130(91)90062-Y; DJAVADIOHANIANCE L, 1986, BIOCHEMISTRY-US, V25, P2502, DOI 10.1021/bi00357a033; DUMONT ME, 1994, BIOCHEMISTRY-US, V33, P7368, DOI 10.1021/bi00189a043; ELOVE GA, 1994, BIOCHEMISTRY-US, V33, P6925, DOI 10.1021/bi00188a023; FISHER WR, 1973, J BIOL CHEM, V248, P3188; FRIGUET B, 1989, RES IMMUNOL, V140, P355, DOI 10.1016/0923-2494(89)90142-9; FRIGUET B, 1985, J IMMUNOL METHODS, V77, P305, DOI 10.1016/0022-1759(85)90044-4; FRIGUET B, 1989, PROTEIN STRUCTURE PR, P287; FURIE B, 1975, J MOL BIOL, V92, P497, DOI 10.1016/0022-2836(75)90305-8; GOLDBERG ME, 1994, PROTEIN SCI, V3, P883; GOSHORN SC, 1991, J BIOL CHEM, V266, P2134; Jaenicke R, 1998, BIOL CHEM, V379, P237; LARVOR MP, 1994, J IMMUNOL METHODS, V170, P167, DOI 10.1016/0022-1759(94)90392-1; LIN LN, 1994, BIOCHEMISTRY-US, V33, P6564, DOI 10.1021/bi00187a025; MARGOLIASH E, 1959, BIOCHEM J, V71, P570, DOI 10.1042/bj0710570; MILES EW, 1970, J BIOL CHEM, V245, P6016; Onoue K, 1965, Immunochemistry, V2, P401, DOI 10.1016/0019-2791(65)90039-X; PAUL KG, 1950, ACTA CHEM SCAND, V4, P239, DOI 10.3891/acta.chem.scand.04-0239; PTITSYN OB, 1973, DOKL AKAD NAUK SSSR+, V210, P1213; RAMAN CS, 1992, BIOCHEMISTRY-US, V31, P10370, DOI 10.1021/bi00157a027; RAMAN CS, 1995, BIOCHEMISTRY-US, V34, P5831, DOI 10.1021/bi00017a015; Roux P, 1997, J BIOL CHEM, V272, P24843, DOI 10.1074/jbc.272.40.24843; STELLWAGEN E, 1972, J BIOL CHEM, V247, P8074; STEVENS FJ, 1987, MOL IMMUNOL, V24, P1055, DOI 10.1016/0161-5890(87)90073-3; TAKANO T, 1973, J BIOL CHEM, V248, P5234; Tsai CJ, 1998, FOLD DES, V3, pR71, DOI 10.1016/S1359-0278(98)00032-7; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; WOLYNES PG, 1995, SCIENCE, V267, P1619, DOI 10.1126/science.7886447; Zhang J, 1998, BIOCHEMISTRY-US, V37, P14891, DOI 10.1021/bi981116z; Zhang J, 1998, BIOCHEMISTRY-US, V37, P14881, DOI 10.1021/bi9811157	34	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16052	16061		10.1074/jbc.274.23.16052	http://dx.doi.org/10.1074/jbc.274.23.16052			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347156	hybrid			2022-12-25	WOS:000080668600016
J	Zhang, LX; Paakkarinen, V; van Wijk, KJ; Aro, EM				Zhang, LX; Paakkarinen, V; van Wijk, KJ; Aro, EM			Co-translational assembly of the D1 protein into photosystem II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLAMYDOMONAS-REINHARDTII; ENDOPLASMIC-RETICULUM; THYLAKOID MEMBRANES; IN-VITRO; INTEGRATION; CHLOROPLAST; IDENTIFICATION; LIGHT; TRANSLOCATION; ORGANIZATION	Assembly of multi-subunit membrane protein complexes is poorly understood, In this study, we present direct evidence that the D1 protein, a multiple membrane spanning protein, assembles co-translationally into the large membrane-bound complex, photosystem II. During pulse-chase studies in intact chloroplasts, incorporation of the D1 protein occurred without transient accumulation of free labeled protein in the thylakoid membrane, and photosystem II subcomplexes contained nascent D1 intermediates of 17, 22, and 25 kDa, These N-terminal D1 intermediates could be coimmunoprecipitated with antiserum directed against the D2 protein, suggesting co-translational assembly of the D1 protein into PS II complexes. Further evidence for a co-translational assembly of the D1 protein into photosystem II was obtained by analyzing ribosome nascent chain complexes liberated from the thylakoid membrane after a short pulse labeling. Radiolabeled D1 intermediates could be immunoprecipitated under nondenaturing conditions with antisera raised against the D1 and D2 protein as well as CP47, However, when the ribosome pellets were solubilized with SDS, the interaction of these intermediates with CP47 was completely lost, but strong interaction of a 25-kDa D1 intermediate with the D2 protein still remained. Taken together, our results indicate that during the repair of photosystem II, the assembly of the newly synthesized D1 protein into photosystem II occurs co-translationally involving direct interaction of the nascent D1 chains with the D2 protein.	Univ Turku, Dept Biol, Lab Plant Physiol, FIN-20520 Turku, Finland; Univ Stockholm, Dept Biochem, Arrhenius Labs Nat Sci, S-10691 Stockholm, Sweden	University of Turku; Stockholm University	Aro, EM (corresponding author), Univ Turku, Dept Biol, Lab Plant Physiol, Biocity A,6th Floor, FIN-20520 Turku, Finland.		Aro, Eva-Mari/Q-8664-2017	Aro, Eva-Mari/0000-0002-2922-1435				ADIR N, 1990, J BIOL CHEM, V265, P12563; ANDERSSON B, 1994, ADV MOL CEL, V10, P1; ARO EM, 1993, BIOCHIM BIOPHYS ACTA, V1143, P113, DOI 10.1016/0005-2728(93)90134-2; Baena-Gonzalez E, 1999, PLANTA, V208, P196, DOI 10.1007/s004250050550; BARBATO R, 1995, EUR J BIOCHEM, V234, P459, DOI 10.1111/j.1432-1033.1995.459_b.x; BARBATO R, 1992, J CELL BIOL, V119, P315; Barber J, 1998, BBA-BIOENERGETICS, V1365, P269, DOI 10.1016/S0005-2728(98)00079-6; Borel AC, 1996, CELL, V85, P379, DOI 10.1016/S0092-8674(00)81116-2; DEVITRY C, 1989, J CELL BIOL, V109, P991, DOI 10.1083/jcb.109.3.991; DINER BA, 1996, OXYGENIC PHOTOSYNTHE, P213; Do H, 1996, CELL, V85, P369, DOI 10.1016/S0092-8674(00)81115-0; ESHAGHI S, 1998, PHOTOSYNTHESIS MECH, V2, P695; GHIRARDI ML, 1989, CURRENT RES PHOTOSYN, V2, P733; Hankamer B, 1997, ANNU REV PLANT PHYS, V48, P641, DOI 10.1146/annurev.arplant.48.1.641; ISAACS WB, 1987, P NATL ACAD SCI USA, V84, P6174, DOI 10.1073/pnas.84.17.6174; ITO K, 1984, MOL GEN GENET, V197, P204, DOI 10.1007/BF00330964; JAGENDORF AT, 1990, PLANT SCI, V71, P137, DOI 10.1016/0168-9452(90)90001-5; Kepes F, 1996, J MOL BIOL, V262, P77, DOI 10.1006/jmbi.1996.0500; KIM JM, 1991, J BIOL CHEM, V266, P14931; KLEIN RR, 1988, J CELL BIOL, V106, P289, DOI 10.1083/jcb.106.2.289; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMMON MA, 1992, J BIOL CHEM, V267, P7683; Lindquist JA, 1998, EMBO J, V17, P2186, DOI 10.1093/emboj/17.8.2186; MATTOO AK, 1981, P NATL ACAD SCI-BIOL, V78, P1572, DOI 10.1073/pnas.78.3.1572; Mothes W, 1997, CELL, V89, P523, DOI 10.1016/S0092-8674(00)80234-2; MULLET JE, 1986, EUR J BIOCHEM, V155, P331, DOI 10.1111/j.1432-1033.1986.tb09495.x; OHAD I, 1984, J CELL BIOL, V99, P481, DOI 10.1083/jcb.99.2.481; Rhee KH, 1997, NATURE, V389, P522, DOI 10.1038/39103; SATOH K, 1993, PHOTOSYNTHETIC REACT, V1, P289; vanWijk KJ, 1996, J BIOL CHEM, V271, P9627, DOI 10.1074/jbc.271.16.9627; vanWijk KJ, 1997, BIOCHEMISTRY-US, V36, P6178, DOI 10.1021/bi962921l; vanWijk KJ, 1996, FEBS LETT, V388, P89, DOI 10.1016/0014-5793(96)00540-6; VANWIJK KJ, 1995, J BIOL CHEM, V270, P25685, DOI 10.1074/jbc.270.43.25685; Xiong J, 1998, PHOTOSYNTH RES, V56, P229, DOI 10.1023/A:1006061918025; Young JC, 1996, EMBO J, V15, P172, DOI 10.1002/j.1460-2075.1996.tb00345.x	35	168	177	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16062	16067		10.1074/jbc.274.23.16062	http://dx.doi.org/10.1074/jbc.274.23.16062			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347157	hybrid			2022-12-25	WOS:000080668600017
J	Boffelli, D; Zajchowski, DA; Yang, ZY; Lawn, RM				Boffelli, D; Zajchowski, DA; Yang, ZY; Lawn, RM			Estrogen modulation of apolipoprotein(a) expression - Identification of a regulatory element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA LIPOPROTEIN(A) LEVELS; CORONARY HEART-DISEASE; TRANSGENIC MICE; POSTMENOPAUSAL WOMEN; REPLACEMENT THERAPY; TISSUE-SPECIFICITY; HUMAN PLASMINOGEN; DNA-BINDING; I GENE; RECEPTOR	Elevated plasma levels of the lipoprotein particle Lp(a) are a major risk factor for cardiovascular disease, Lp(a) plasma levels are determined by the level of expression of its characteristic protein component, apo(a), Apo(a) expression is modulated by several hormones, of which estrogens are the best known, The chromosomal region responsible for estrogen response was identified within an apo(a) enhancer located at similar to 26 kilobases from the apo(a) promoter. Although the estrogen-responsive unit contains a potential estrogen response element, binding of estrogen receptor-cu to DNA was not necessary. The receptor, activated by bound estradiol, interacts through its transactivation domains with a transcription factor necessary for the function of the enhancer, preventing its binding to DNA.	Stanford Univ, Sch Med, Falk Cardiovasc Res Ctr, Stanford, CA 94305 USA; Berlex Biosci, Dept Canc Res, Richmond, CA 94804 USA	Stanford University	Lawn, RM (corresponding author), CV Therapeut, 3172 Porter Dr, Palo Alto, CA 94304 USA.				NHLBI NIH HHS [HL50590] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050590] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Assmann G, 1996, AM J CARDIOL, V77, P1179, DOI 10.1016/S0002-9149(96)00159-2; Blobel GA, 1996, MOL CELL BIOL, V16, P1687, DOI 10.1128/mcb.16.4.1687; BOERWINKLE E, 1992, J CLIN INVEST, V90, P52, DOI 10.1172/JCI115855; Boonmark NW, 1997, J CLIN INVEST, V100, P558, DOI 10.1172/JCI119565; Bostom AG, 1996, JAMA-J AM MED ASSOC, V276, P544, DOI 10.1001/jama.276.7.544; BROWN SA, 1993, ARTERIOSCLER THROMB, V13, P1139, DOI 10.1161/01.ATV.13.8.1139; BYRNE CD, 1994, ARTERIOSCLER THROMB, V14, P534, DOI 10.1161/01.ATV.14.4.534; CHUNG JH, 1993, CELL, V74, P505, DOI 10.1016/0092-8674(93)80052-G; COHEN JC, 1993, J CLIN INVEST, V91, P1630, DOI 10.1172/JCI116370; Craig WY, 1998, CLIN CHEM, V44, P2301; ENVER T, 1990, NATURE, V344, P309, DOI 10.1038/344309a0; FARISH E, 1991, BRIT MED J, V303, P694, DOI 10.1136/bmj.303.6804.694; FEDOR M J, 1992, Current Opinion in Cell Biology, V4, P436, DOI 10.1016/0955-0674(92)90009-2; FRAZER KA, 1995, NAT GENET, V9, P424, DOI 10.1038/ng0495-424; Gerasimova TI, 1998, CELL, V92, P511, DOI 10.1016/S0092-8674(00)80944-7; GRAINGER DJ, 1994, NATURE, V370, P460, DOI 10.1038/370460a0; GRAINGER DJ, 1993, SCIENCE, V260, P1655, DOI 10.1126/science.8503012; HAJJAR KA, 1989, NATURE, V339, P303, DOI 10.1038/339303a0; Harnish DC, 1998, J BIOL CHEM, V273, P9270, DOI 10.1074/jbc.273.15.9270; HARPEL PC, 1989, P NATL ACAD SCI USA, V86, P3847, DOI 10.1073/pnas.86.10.3847; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; JENNER JL, 1993, CIRCULATION, V87, P1135, DOI 10.1161/01.CIR.87.4.1135; KIM CJ, 1994, ARTERIOSCLER THROMB, V14, P275, DOI 10.1161/01.ATV.14.2.275; KRAFT HG, 1992, HUM GENET, V90, P220; KRUST A, 1986, EMBO J, V5, P891, DOI 10.1002/j.1460-2075.1986.tb04300.x; LACKNER C, 1991, J CLIN INVEST, V87, P2153, DOI 10.1172/JCI115248; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LATCHMAN DS, 1995, EUKARYOTIC TRANSCRIP, P78; Lou XJ, 1998, P NATL ACAD SCI USA, V95, P12591, DOI 10.1073/pnas.95.21.12591; MAGNAGHI P, 1994, BIOCHEM BIOPH RES CO, V205, P930, DOI 10.1006/bbrc.1994.2754; MAGNAGHI P, 1994, HUM MOL GENET, V3, P437, DOI 10.1093/hmg/3.3.437; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; Meroni G, 1996, EUR J BIOCHEM, V236, P373, DOI 10.1111/j.1432-1033.1996.00373.x; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; MILES LA, 1989, NATURE, V339, P301, DOI 10.1038/339301a0; NISHIYORI A, 1994, J BIOL CHEM, V269, P1323; PEROMBELON YFN, 1994, J CLIN INVEST, V93, P1481, DOI 10.1172/JCI117126; Ramharack R, 1997, BIOCHEM BIOPH RES CO, V238, P48, DOI 10.1006/bbrc.1997.7240; RIDKER PM, 1993, JAMA-J AM MED ASSOC, V270, P2195, DOI 10.1001/jama.270.18.2195; RYMER J, 1993, ACTA ENDOCRINOL-COP, V128, P259, DOI 10.1530/acta.0.1280259; SCANU AM, 1990, J CLIN INVEST, V85, P1709, DOI 10.1172/JCI114625; SIMONET WS, 1993, J BIOL CHEM, V268, P8221; SOMA MR, 1993, ARCH INTERN MED, V153, P1462, DOI 10.1001/archinte.153.12.1462; Stein JH, 1997, ARCH INTERN MED, V157, P1170, DOI 10.1001/archinte.157.11.1170; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; UTERMANN G, 1987, J CLIN INVEST, V80, P458, DOI 10.1172/JCI113093; UTTERMANN G, 1989, SCIENCE, V246, P904; von Lindern M, 1998, MOL ENDOCRINOL, V12, P263, DOI 10.1210/me.12.2.263; WADE DP, 1994, J BIOL CHEM, V269, P19757; Wade DP, 1997, J BIOL CHEM, V272, P30387, DOI 10.1074/jbc.272.48.30387; WALSH A, 1993, J LIPID RES, V34, P617; YANG ZY, 1994, MOL CELL BIOL, V14, P2201, DOI 10.1128/MCB.14.3.2201; Yang ZY, 1998, J BIOL CHEM, V273, P891, DOI 10.1074/jbc.273.2.891; ZAJCHOWSKI DA, 1991, MOL ENDOCRINOL, V5, P1613, DOI 10.1210/mend-5-11-1613; Zysow BR, 1997, ARTERIOSCL THROM VAS, V17, P1741, DOI 10.1161/01.ATV.17.9.1741	55	32	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15569	15574		10.1074/jbc.274.22.15569	http://dx.doi.org/10.1074/jbc.274.22.15569			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336452	hybrid			2022-12-25	WOS:000080560100041
J	Cases, I; Perez-Martin, J; de Lorenzo, V				Cases, I; Perez-Martin, J; de Lorenzo, V			The IIA(Ntr) (PtsN) protein of Pseudomonas putida mediates the C source inhibition of the sigma(54)-dependent Pu promoter of the TOL plasmid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATABOLITE REPRESSION CONTROL; ESCHERICHIA-COLI; PHOSPHOTRANSFERASE SYSTEM; FUNCTIONAL DOMAINS; RNA-POLYMERASE; SIGMA-FACTOR; RPON OPERON; GENE; EXPRESSION; XYLR	The gene cluster adjacent to the sequence of rpoN (encoding sigma factor sigma(54)) of Pseudomonas putida has been studied with respect to the C source regulation of the Pu promoter of the upper TOL (toluene catabolism) operon. The region includes four open reading frames (ORFs), two of which (named ptsN and ptsO genes) encode proteins similar to components of the phosphoenolpyruvate:sugar phosphotransferase system. Each of the four genes was disrupted with a nonpolar insertion, and the effects in the inhibition caused by glucose on Pu activity were inspected with a lacZ reporter system. Although cells lacking ORF102, ORF284, and ptsO did not display any evident phenotype under the conditions tested, the loss of ptsN, which encodes the IIA(Ntr) protein, made Pu unresponsive to repression by glucose. The ptsN mutant had rates of glucose/gluconate consumption identical to those of the wild type, thus ruling out indirect effects mediated by the transport of the carbohydrate, A site-directed ptsN mutant in which the conserved phospho-acceptor site His(68) Of IIANtr was replaced by an aspartic acid residue made Pu blind to the presence or absence of glucose, thus supporting the notion that phosphorylation of IIA(Ntr) mediates the C source inhibition of the promoter. These data substantiate the existence of a molecular pathway for co-regulation of some sigma(54) promoters in which IIA(Ntr) is a key protein intermediate.	Ctr Nacl Biotecnol Consejo Super Invest Cient, Madrid 28049, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	de Lorenzo, V (corresponding author), Ctr Nacl Biotecnol Consejo Super Invest Cient, Campus Cantoblanco, Madrid 28049, Spain.	vdlorenzo@cnb.uam.es	Perez-Martin, Jose/K-5117-2014; Cases, Ildefonso/C-2998-2008	Perez-Martin, Jose/0000-0001-9849-7382; Cases, Ildefonso/0000-0002-8784-5174; de Lorenzo, Victor/0000-0002-6041-2731				Albus AM, 1997, J BACTERIOL, V179, P3928, DOI 10.1128/jb.179.12.3928-3935.1997; ASSINDER SJ, 1990, ADV MICROB PHYSIOL, V31, P1; BEGLEY GS, 1994, FEMS MICROBIOL LETT, V119, P389; Bertoni G, 1998, EMBO J, V17, P5120, DOI 10.1093/emboj/17.17.5120; Cases I, 1996, MOL MICROBIOL, V19, P7, DOI 10.1046/j.1365-2958.1996.345873.x; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; Collier DN, 1996, RES MICROBIOL, V147, P551, DOI 10.1016/0923-2508(96)84011-3; DELORENZO V, 1991, EMBO J, V10, P1159, DOI 10.1002/j.1460-2075.1991.tb08056.x; DELORENZO V, 1993, J BACTERIOL, V175, P6902, DOI 10.1128/jb.175.21.6902-6907.1993; DELORENZO V, 1994, TRENDS BIOTECHNOL, V12, P365, DOI 10.1016/0167-7799(94)90037-X; DELORENZO V, 1994, METHOD ENZYMOL, V235, P386; Du Y, 1996, RES MICROBIOL, V147, P129, DOI 10.1016/0923-2508(96)80212-9; Duetz WA, 1996, APPL ENVIRON MICROB, V62, P601, DOI 10.1128/AEM.62.2.601-606.1996; DUETZ WA, 1994, J BACTERIOL, V176, P2354, DOI 10.1128/JB.176.8.2354-2361.1994; EHRT S, 1994, J BACTERIOL, V176, P3493, DOI 10.1128/JB.176.12.3493-3499.1994; FERNANDEZ S, 1995, MOL MICROBIOL, V16, P205, DOI 10.1111/j.1365-2958.1995.tb02293.x; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; HOLTEL A, 1994, J BACTERIOL, V176, P1773, DOI 10.1128/jb.176.6.1773-1776.1994; HUGOUVIEUXCOTTEPATTAT N, 1990, J BACTERIOL, V172, P6651, DOI 10.1128/jb.172.12.6651-6660.1990; Janakiraman RS, 1997, J BACTERIOL, V179, P5138, DOI 10.1128/jb.179.16.5138-5147.1997; JIN SG, 1994, J BACTERIOL, V176, P1316, DOI 10.1128/jb.176.5.1316-1322.1994; JONES DHA, 1994, MICROBIOL-SGM, V140, P1035, DOI 10.1099/13500872-140-5-1035; KANIGA K, 1991, GENE, V103, P137; KOHLER T, 1989, NUCLEIC ACIDS RES, V17, P10125, DOI 10.1093/nar/17.23.10125; KOHLER T, 1989, J BACTERIOL, V171, P4326; KOHLER T, 1994, FEMS MICROBIOL LETT, V115, P177, DOI 10.1016/0378-1097(94)90010-8; KOLB A, 1993, ANNU REV BIOCHEM, V62, P749, DOI 10.1146/annurev.bi.62.070193.003533; KULLIK I, 1991, J BACTERIOL, V173, P1125, DOI 10.1128/jb.173.3.1125-1138.1991; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; MARQUES S, 1994, J BACTERIOL, V176, P2517; MERRICK MJ, 1989, MOL MICROBIOL, V3, P1765, DOI 10.1111/j.1365-2958.1989.tb00162.x; MERRICK MJ, 1995, NITROGEN FIXATION FU; Michiels J, 1998, J BACTERIOL, V180, P1729, DOI 10.1128/JB.180.7.1729-1740.1998; MORETT E, 1993, J BACTERIOL, V175, P6067, DOI 10.1128/JB.175.19.6067-6074.1993; MYERS RM, 1985, SCIENCE, V229, P242, DOI 10.1126/science.2990046; PerezMartin J, 1996, GENE, V172, P81, DOI 10.1016/0378-1119(96)00193-X; PEREZMARTIN J, 1995, P NATL ACAD SCI USA, V92, P9392, DOI 10.1073/pnas.92.20.9392; PerezMartin J, 1996, J MOL BIOL, V258, P575, DOI 10.1006/jmbi.1996.0270; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; POWELL BS, 1995, J BIOL CHEM, V270, P4822, DOI 10.1074/jbc.270.9.4822; PRENTKI P, 1984, GENE, V29, P303, DOI 10.1016/0378-1119(84)90059-3; Ramos JL, 1997, ANNU REV MICROBIOL, V51, P341, DOI 10.1146/annurev.micro.51.1.341; REIZER J, 1992, PROTEIN SCI, V1, P722, DOI 10.1002/pro.5560010604; RunyenJanecky LJ, 1997, J BACTERIOL, V179, P2802, DOI 10.1128/jb.179.9.2802-2809.1997; SAIER MH, 1989, MICROBIOL REV, V53, P109, DOI 10.1128/MMBR.53.1.109-120.1989; Saier MH, 1996, FEMS MICROBIOL LETT, V138, P97; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sanchez-Romero JM, 1998, APPL ENVIRON MICROB, V64, P4040; SAWYER MH, 1977, ARCH MICROBIOL, V112, P49, DOI 10.1007/BF00446653; Schleissner C, 1997, MICROBIOL-SGM, V143, P1595, DOI 10.1099/00221287-143-5-1595; Sze CC, 1999, MOL MICROBIOL, V31, P1217, DOI 10.1046/j.1365-2958.1999.01264.x; VICENTE M, 1973, J BACTERIOL, V116, P908, DOI 10.1128/JB.116.2.908-914.1973; WITTEKIND M, 1989, BIOCHEMISTRY-US, V28, P9908, DOI 10.1021/bi00452a005	54	88	90	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15562	15568		10.1074/jbc.274.22.15562	http://dx.doi.org/10.1074/jbc.274.22.15562			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336451	hybrid			2022-12-25	WOS:000080560100040
J	Cross, AR; Erickson, RW; Curnutte, JT				Cross, AR; Erickson, RW; Curnutte, JT			Simultaneous presence of p47(phox) and flavocytochrome b(-245), are required for the activation of NADPH oxidase by anionic amphiphiles - Evidence for an intermediate state of oxidase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY BURST OXIDASE; SUPEROXIDE-GENERATING SYSTEM; CELL-FREE SYSTEM; HUMAN-NEUTROPHILS; CYTOCHROME-B; CYTOSOLIC COMPONENT; INDEPENDENT ACTIVATION; CONFORMATIONAL-CHANGES; ELECTRON FLOW; TRANSLOCATION	We have examined the kinetics of NADPH oxidase activation induced by arachidonic acid or SDS in a cell-free system using mixtures of recombinant Phox proteins and purified flavocytochrome b(-245). Activation of oxidase activity required the simultaneous presence of p47(phox), flavocytochrome b(-245), and the anionic amphiphile. The activation of electron transfer reactions was much more rapid when iodonitrotetrazolium violet was used as electron acceptor than when oxygen alone was the acceptor. We propose that this difference represents an intermediate activation state of NADPH oxidase in which electron flow can proceed hom NADPH to enzyme flavin (and hence to iodonitrotetrazolium violet) but not from flavin to heme (or not between the hemes). A model for NADPH oxidase activation is presented that is consistent with these observations.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Genentech Inc, Dept Immunol, San Francisco, CA 94080 USA	Scripps Research Institute; Roche Holding; Genentech	Cross, AR (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, MEM-241,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NIAID NIH HHS [AI24838] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024838] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMBRUSO DR, 1990, J BIOL CHEM, V265, P924; BABIOR BM, 1988, J BIOL CHEM, V263, P1713; BABIOR BM, 1973, J CLIN INVEST, V52, P741, DOI 10.1172/JCI107236; BELLAVITE P, 1983, BIOCHIM BIOPHYS ACTA, V746, P40, DOI 10.1016/0167-4838(83)90008-0; BOKOCH GM, 1994, J BIOL CHEM, V269, P31674; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; CROSS AR, 1985, BIOCHEM J, V226, P881, DOI 10.1042/bj2260881; CROSS AR, 1984, BIOCHEM J, V223, P337, DOI 10.1042/bj2230337; Cross AR, 1999, BIOCHEM J, V338, P229, DOI 10.1042/0264-6021:3380229; CROSS AR, 1982, BIOCHEM J, V204, P479, DOI 10.1042/bj2040479; CROSS AR, 1995, J BIOL CHEM, V270, P6543, DOI 10.1074/jbc.270.12.6543; CROSS AR, 1995, J BIOL CHEM, V270, P17075, DOI 10.1074/jbc.270.29.17075; CROSS AR, 1994, J BIOL CHEM, V269, P21448; CROSS AR, 1984, P 8 INT S FLAV FLAV; ELLIS JA, 1989, BIOCHEM J, V262, P575, DOI 10.1042/bj2620575; Freeman JL, 1996, J BIOL CHEM, V271, P22578, DOI 10.1074/jbc.271.37.22578; FUJIMOTO S, 1989, J BIOL CHEM, V264, P21629; Hata K, 1998, J BIOL CHEM, V273, P4232, DOI 10.1074/jbc.273.7.4232; HEYWORTH PG, 1994, J BIOL CHEM, V269, P30749; KLEINBERG ME, 1990, J BIOL CHEM, V265, P15577; Koshkin V, 1996, J BIOL CHEM, V271, P30326, DOI 10.1074/jbc.271.48.30326; Koshkin V, 1995, BBA-BIOENERGETICS, V1232, P225, DOI 10.1016/0005-2728(95)00123-9; KOSHKIN V, 1994, FEBS LETT, V338, P285, DOI 10.1016/0014-5793(94)80285-8; OHTSUKA T, 1990, J BIOCHEM-TOKYO, V108, P169, DOI 10.1093/oxfordjournals.jbchem.a123177; Park HS, 1998, BBA-PROTEIN STRUCT M, V1387, P406, DOI 10.1016/S0167-4838(98)00152-6; QUINN MT, 1993, J BIOL CHEM, V268, P20983; QUINN MT, 1992, J BIOL CHEM, V267, P7303; ROOS D, 1997, PRIMARY IMMUNODEFICI, P318; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; SEGAL AW, 1992, BIOCHEM J, V284, P781, DOI 10.1042/bj2840781; Swain SD, 1997, J BIOL CHEM, V272, P29502, DOI 10.1074/jbc.272.47.29502; TSUNAWAKI S, 1994, BIOCHEM BIOPH RES CO, V199, P1378, DOI 10.1006/bbrc.1994.1383; UHLINGER DJ, 1994, J BIOL CHEM, V269, P22095; WIENTJES FB, 1993, BIOCHEM J, V296, P557, DOI 10.1042/bj2960557; YOSHIDA LS, 1992, BIOCHIM BIOPHYS ACTA, V1135, P245	35	55	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15519	15525		10.1074/jbc.274.22.15519	http://dx.doi.org/10.1074/jbc.274.22.15519			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336445	hybrid			2022-12-25	WOS:000080560100034
J	Patel, RP; Hogg, N; Spencer, NY; Kalyanaraman, B; Matalon, S; Darley-Usmar, VM				Patel, RP; Hogg, N; Spencer, NY; Kalyanaraman, B; Matalon, S; Darley-Usmar, VM			Biochemical characterization of human S-nitrosohemoglobin - Effects on oxygen binding and transnitrosation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; MASS-SPECTROMETRY; NITROGEN-OXIDES; HEMOGLOBIN; NITROSOGLUTATHIONE; NITROSYLATION; ACTIVATION; RECEPTOR; PROTEINS; THIOLS	S-Nitrosation of cysteine beta 93 in hemoglobin (S-nitrosohemoglobin (SNO-Hb)) occurs in vivo, and transnitrosation reactions of deoxygenated SNO-Hb are proposed as a mechanism leading to release of NO and control of blood flow. However, little is known of the oxygen binding properties of SNO-Hb or the effects of oxygen on transnitrosation between SNO-Hb and the dominant low molecular weight thiol in the red blood cell, GSH, These data are important as they would provide a biochemical framework to assess the physiological function of SNO-Hb, Our results demonstrate that SNO-Hb has a higher affinity for oxygen than native Hb, This implies that NO transfer from SNO-Hb in vivo would be limited to regions of extremely low oxygen tension if this were to occur from deoxygenated SNO-Hb. Furthermore, the kinetics of the transnitrosation reactions between GSH and SNO-Hb are relatively slow, making transfer of NO+ from SNO-Hb to GSH less likely as a mechanism to elicit vessel relaxation under conditions of low oxygen tension and over the circulatory lifetime of a given red blood cell. These data suggest that the reported oxygen-dependent promotion of S-nitrosation from SNO-Hb involves biochemical mechanisms that are not intrinsic to the Hb molecule.	Univ Alabama Birmingham, Dept Pathol, Mol & Cellular Div, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Ctr Free Rad Biol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Anesthesiol Physiol & Biophys, Birmingham, AL 35294 USA; Med Coll Wisconsin, Biophys Res Inst, Milwaukee, WI 53226 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Medical College of Wisconsin	Darley-Usmar, VM (corresponding author), Univ Alabama Birmingham, Dept Pathol, Mol & Cellular Div, Volker Hall,Rm GO19,1670 Univ Blvd, Birmingham, AL 35294 USA.	darley@path.uab.edu	Spencer, Netanya/AAS-7999-2020; Darley-Usmar, Victor/F-7656-2010	Spencer, Netanya/0000-0003-1010-5458; Patel, Rakesh/0000-0002-1526-4303; Darley-Usmar, Victor/0000-0001-8921-7086	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL031197, R01HL031197, R01HL051173] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM055792, R01GM055792] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL51173, HL31197] Funding Source: Medline; NIGMS NIH HHS [GM55792] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Antonini E., 1971, HAEMOGLOBIN MYOGLOBI; BENESCH R, 1969, NATURE, V221, P618, DOI 10.1038/221618a0; BUTT E, 1993, NEUROCHEM RES, V18, P27, DOI 10.1007/BF00966920; CRAESCU CT, 1986, J BIOL CHEM, V261, P4710; DOYLE MP, 1981, J INORG BIOCHEM, V14, P351, DOI 10.1016/S0162-0134(00)80291-3; Feelisch M., 1996, METHODS NITRIC OXIDE; Ferranti P, 1997, FEBS LETT, V400, P19, DOI 10.1016/S0014-5793(96)01258-6; FRANCIS SH, 1988, MOL PHARMACOL, V34, P506; Funai EF, 1997, BIOCHEM BIOPH RES CO, V239, P875, DOI 10.1006/bbrc.1997.7565; GASTON B, 1993, P NATL ACAD SCI USA, V90, P10957, DOI 10.1073/pnas.90.23.10957; Gow AJ, 1998, NATURE, V391, P169, DOI 10.1038/34402; HARANO K, 1984, FEBS LETT, V173, P45, DOI 10.1016/0014-5793(84)81014-5; HAYASHI A, 1973, BIOCHIM BIOPHYS ACTA, V310, P309, DOI 10.1016/0005-2795(73)90110-4; IGNARRO LJ, 1982, BIOCHIM BIOPHYS ACTA, V718, P49, DOI 10.1016/0304-4165(82)90008-3; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; KILMARTIN IV, 1976, BR MED B, V32, P209; KILMARTIN JV, 1973, P NATL ACAD SCI USA, V70, P1246, DOI 10.1073/pnas.70.4.1246; Kluge I, 1997, J NEUROCHEM, V69, P2599; Kosaka H, 1996, BIOCHEM BIOPH RES CO, V218, P749, DOI 10.1006/bbrc.1996.0133; KULCHAN MJ, 1994, AM J PHYSIOL, V267, pC753; LANCASTER JR, 1994, P NATL ACAD SCI USA, V91, P8137, DOI 10.1073/pnas.91.17.8137; LINCOLN TM, 1993, FASEB J, V7, P328, DOI 10.1096/fasebj.7.2.7680013; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; LIU X, 1988, J BIOL CHEM, V273, P1870; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; Pawloski JR, 1998, CIRCULATION, V97, P263, DOI 10.1161/01.CIR.97.3.263; RIGGS A, 1961, J BIOL CHEM, V236, P1948; Rossi R, 1997, ANAL BIOCHEM, V254, P215, DOI 10.1006/abio.1997.2424; SCHARFSTEIN JS, 1994, J CLIN INVEST, V94, P1432, DOI 10.1172/JCI117480; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; Stamler JS, 1997, SCIENCE, V276, P2034, DOI 10.1126/science.276.5321.2034; TRAYLOR TG, 1992, BIOCHEMISTRY-US, V31, P2847, DOI 10.1021/bi00126a001; Tsai AG, 1998, P NATL ACAD SCI USA, V95, P6590, DOI 10.1073/pnas.95.12.6590; WINTERBOURN CC, 1990, METHOD ENZYMOL, V186, P265; Xu L, 1998, SCIENCE, V279, P234, DOI 10.1126/science.279.5348.234	35	122	124	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15487	15492		10.1074/jbc.274.22.15487	http://dx.doi.org/10.1074/jbc.274.22.15487			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336440	hybrid			2022-12-25	WOS:000080560100029
J	Rozwarski, DA; Vilcheze, C; Sugantino, M; Bittman, R; Sacchettini, JC				Rozwarski, DA; Vilcheze, C; Sugantino, M; Bittman, R; Sacchettini, JC			Crystal structure of the Mycobacterium tuberculosis enoyl-ACP reductase, InhA, in complex with NAD(+) and a C16 fatty acyl substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARRIER-PROTEIN REDUCTASE; MYCOLIC ACID BIOSYNTHESIS; ESCHERICHIA-COLI; ISONIAZID TARGET; BRASSICA-NAPUS; 7-ALPHA-HYDROXYSTEROID DEHYDROGENASE; DRUG-RESISTANCE; CELL-WALL; GENE; FABI	Enoyl-ACP reductases participate in fatty acid biosynthesis by utilizing NADH to reduce the trans double bond between positions C2 and C3 of a fatty acyl chain linked to the acyl carrier protein. The enoyl-ACP reductase from My. cobacterium tuberculosis, known as InhA, is a member of an unusual FAS-II system that prefers longer chain fatty acyl substrates for the purpose of synthesizing mycolic acids, a major component of mycobacterial cell walls. The crystal structure of InhA in complex with NAD(+) and a C16 fatty acyl substrate, trans-2-hexadecenoyl-(N-acetylcysteamine)-thioester, reveals that the substrate binds in a general "U-shaped" conformation, with the trans double bond positioned directly adjacent to the nicotinamide ring of NAD(+). The side chain of Tyr(158) directly interacts with the thioester carbonyl oxygen of the C16 fatty acyl substrate and therefore could help stabilize the enolate intermediate, proposed to form during substrate catalysis, Hydrophobic residues, primarily from the substrate binding loop (residues 196-219), engulf the fatty acyl chain portion of the substrate. The substrate binding loop of InhA is longer than that of other enoyl-ACP reductases and creates a deeper substrate binding crevice, consistent with the ability of InhA to recognize longer chain fatty acyl substrates.	Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA; CUNY Queens Coll, Dept Chem & Biochem, Flushing, NY 11367 USA	Texas A&M University System; Texas A&M University College Station; Yeshiva University; Albert Einstein College of Medicine; City University of New York (CUNY) System; Queens College NY (CUNY)	Sacchettini, JC (corresponding author), Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI036849] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045859] Funding Source: NIH RePORTER; NIAID NIH HHS [AI36849] Funding Source: Medline; NIGMS NIH HHS [GM45859] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER ME, 1995, BIOCHEM J, V309, P1029, DOI 10.1042/bj3091029; Baldock C, 1996, SCIENCE, V274, P2107, DOI 10.1126/science.274.5295.2107; BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673; Basso LA, 1996, J AM CHEM SOC, V118, P11301, DOI 10.1021/ja962035y; Bergler H, 1996, EUR J BIOCHEM, V242, P689, DOI 10.1111/j.1432-1033.1996.0689r.x; BERGLER H, 1992, J GEN MICROBIOL, V138, P2093, DOI 10.1099/00221287-138-10-2093; BERGLER H, 1994, J BIOL CHEM, V269, P5493; Blanchard JS, 1996, ANNU REV BIOCHEM, V65, P215, DOI 10.1146/annurev.bi.65.070196.001243; Bloch K, 1977, Adv Enzymol Relat Areas Mol Biol, V45, P1; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CHRISTOPHER JA, 1998, SPOCK SOFTWARE VERSI; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; DAVIDSON LA, 1979, ANTIMICROB AGENTS CH, V16, P104, DOI 10.1128/AAC.16.1.104; DESSEN A, 1995, SCIENCE, V267, P1638, DOI 10.1126/science.7886450; Duax WL, 1996, CURR OPIN STRUC BIOL, V6, P813, DOI 10.1016/S0959-440X(96)80012-1; FAWCETT T, 1994, PLANT MOL BIOL, V26, P155, DOI 10.1007/BF00039528; FULCO AJ, 1983, PROG LIPID RES, V22, P133, DOI 10.1016/0163-7827(83)90005-X; HEATH RJ, 1995, J BIOL CHEM, V270, P26538, DOI 10.1074/jbc.270.44.26538; HEYM B, 1994, LANCET, V344, P293, DOI 10.1016/S0140-6736(94)91338-2; JOHNSSON K, 1995, J AM CHEM SOC, V117, P5009, DOI 10.1021/ja00122a038; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KATER MM, 1994, PLANT MOL BIOL, V25, P771, DOI 10.1007/BF00028873; KATER MM, 1991, PLANT MOL BIOL, V17, P895, DOI 10.1007/BF00037070; KIKUCHI S, 1992, ARCH BIOCHEM BIOPHYS, V295, P318, DOI 10.1016/0003-9861(92)90524-Z; Kleerebezem M, 1996, RES MICROBIOL, V147, P609, DOI 10.1016/0923-2508(96)84016-2; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LACAVE C, 1990, BIOCHIM BIOPHYS ACTA, V1045, P58, DOI 10.1016/0005-2760(90)90203-A; Lee RE, 1996, CURR TOP MICROBIOL, V215, P1; LOPEZMARIN LM, 1991, BIOCHIM BIOPHYS ACTA, V1086, P22, DOI 10.1016/0005-2760(91)90150-G; Mdluli K, 1998, SCIENCE, V280, P1607, DOI 10.1126/science.280.5369.1607; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Musser JM, 1996, J INFECT DIS, V173, P196, DOI 10.1093/infdis/173.1.196; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; Quemard A, 1996, J AM CHEM SOC, V118, P1561, DOI 10.1021/ja950998b; QUEMARD A, 1995, BIOCHEMISTRY-US, V34, P8235, DOI 10.1021/bi00026a004; QURESHI N, 1984, J BACTERIOL, V157, P46, DOI 10.1128/JB.157.1.46-52.1984; RAFFERTY JB, 1995, STRUCTURE, V3, P927, DOI 10.1016/S0969-2126(01)00227-1; Rock CO, 1996, BBA-LIPID LIPID MET, V1302, P1, DOI 10.1016/0005-2760(96)00056-2; ROUSE DA, 1995, ANTIMICROB AGENTS CH, V39, P2472, DOI 10.1128/AAC.39.11.2472; Rozwarski DA, 1998, SCIENCE, V279, P98, DOI 10.1126/science.279.5347.98; Sacchettini JC, 1996, RES MICROBIOL, V147, P36, DOI 10.1016/0923-2508(96)80201-4; SMITH S, 1994, FASEB J, V8, P1248, DOI 10.1096/fasebj.8.15.8001737; TAKAYAMA K, 1975, J LIPID RES, V16, P308; TAKAYAMA K, 1972, ANTIMICROB AGENTS CH, V2, P29, DOI 10.1128/AAC.2.1.29; Tanaka N, 1996, BIOCHEMISTRY-US, V35, P7715, DOI 10.1021/bi951904d; Telenti A, 1997, J CLIN MICROBIOL, V35, P719, DOI 10.1128/JCM.35.3.719-723.1997; WAKIL SJ, 1983, ANNU REV BIOCHEM, V52, P537, DOI 10.1146/annurev.bi.52.070183.002541; Wheeler PR, 1996, BIOCHEM J, V318, P451, DOI 10.1042/bj3180451; WHEELER PR, 1993, BIOCHIM BIOPHYS ACTA, V1167, P182, DOI 10.1016/0005-2760(93)90160-B; WINDER F G, 1970, Journal of General Microbiology, V63, P41; YOSHIMOTO T, 1991, J BACTERIOL, V173, P2173, DOI 10.1128/JB.173.7.2173-2179.1991; YOUNG ACM, 1994, STRUCTURE, V2, P523, DOI 10.1016/S0969-2126(00)00052-6; YOUNG DB, 1994, CURR BIOL, V4, P351, DOI 10.1016/S0960-9822(00)00077-4; Zabinski RF, 1997, J AM CHEM SOC, V119, P2331, DOI 10.1021/ja9639731	56	224	230	1	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15582	15589		10.1074/jbc.274.22.15582	http://dx.doi.org/10.1074/jbc.274.22.15582			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336454	hybrid			2022-12-25	WOS:000080560100043
J	Wallin, JJ; Rinkenberger, JL; Rao, S; Gackstetter, ER; Koshland, ME; Zwollo, P				Wallin, JJ; Rinkenberger, JL; Rao, S; Gackstetter, ER; Koshland, ME; Zwollo, P			B cell-specific activator protein prevents two activator factors from binding to the immunoglobulin J chain promoter until the antigen-driven stages of B cell development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3'ALPHA ENHANCER; GENE-EXPRESSION; BSAP; TRANSCRIPTION; DNA; DIFFERENTIATION; REPRESSOR; SEQUENCE; ELEMENT	The immunoglobulin J chain gene is inducibly transcribed in mature B cells upon antigen recognition and a signal from interleubin-2 (IL-2). B cell-specific activator protein (BSAP), a transcription factor that silences J chain transcription, has been identified as a nuclear target of the IL-2 signal, The levels of BSAP progressively decrease in response to IL-2 and this change correlates with the differentiation of B cells into antibody secreting plasma cells. Here we report the binding of the upstream stimulatory factor (USF) to an E-box motif immediately upstream from the BSAP site on the J chain promoter. Mutations in the USF binding motif significantly decrease J chain promoter activity in J chain expressing B cell lines. We also show that a functional relationship exists between USF and a second J chain positive-regulating factor, B-MEF2, using co-immunoprecipitation assays and transfections. Finally, we provide evidence that the binding of BSAP prevents USF and B-IMEF2 from interacting with the J chain promoter during the antigen-independent stages of B cell development. It is not until the levels of BSAP decrease during the antigen-driven stages of B cell development that both USF and B-IMEF2 are able to bind to their respective promoter elements and activate J chain transcription.	Coll William & Mary, Dept Biol, Williamsburg, VA 23187 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	William & Mary; University of California System; University of California Berkeley	Zwollo, P (corresponding author), Coll William & Mary, Dept Biol, Williamsburg, VA 23187 USA.	Pxzwol@facstaff.wm.edu		Wallin, Jeffrey/0000-0002-5952-3813	NATIONAL CANCER INSTITUTE [T32CA009179] Funding Source: NIH RePORTER; NCI NIH HHS [CA09179] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BLACKMAN MA, 1986, CELL, V47, P609, DOI 10.1016/0092-8674(86)90625-2; BUSSLINGER M, 1995, CURR OPIN GENET DEV, V5, P595, DOI 10.1016/0959-437X(95)80028-X; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; DURAND DB, 1987, J EXP MED, V165, P395, DOI 10.1084/jem.165.2.395; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; GROSSCHEDL R, 1985, CELL, V41, P885, DOI 10.1016/S0092-8674(85)80069-6; HALLE JP, 1995, J BIOL CHEM, V270, P21307, DOI 10.1074/jbc.270.36.21307; KOKUBO T, 1993, J BIOL CHEM, V268, P17554; KOSHLAND ME, 1985, ANNU REV IMMUNOL, V3, P425; LANSFORD RD, 1992, P NATL ACAD SCI USA, V89, P5966, DOI 10.1073/pnas.89.13.5966; MACDONALD GH, 1995, J BIOL CHEM, V270, P3527, DOI 10.1074/jbc.270.8.3527; MCFADDEN HJ, 1991, P NATL ACAD SCI USA, V88, P11027, DOI 10.1073/pnas.88.24.11027; Michaelson JS, 1996, J IMMUNOL, V156, P2349; MINIE ME, 1986, MOL CELL BIOL, V6, P4031, DOI 10.1128/MCB.6.11.4031; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; NEURATH MF, 1995, P NATL ACAD SCI USA, V92, P5336, DOI 10.1073/pnas.92.12.5336; NEURATH MF, 1995, IMMUNOL TODAY, V16, P564, DOI 10.1016/0167-5699(95)80078-6; NEURATH MF, 1994, J IMMUNOL, V153, P730; PETERSON CL, 1986, MOL CELL BIOL, V6, P4168, DOI 10.1128/MCB.6.12.4168; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; Rao E, 1997, J BIOL CHEM, V272, P6722, DOI 10.1074/jbc.272.10.6722; Rao S, 1998, J BIOL CHEM, V273, P26123, DOI 10.1074/jbc.273.40.26123; Rinkenberger JL, 1996, IMMUNITY, V5, P377, DOI 10.1016/S1074-7613(00)80263-0; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHIN MK, 1993, GENE DEV, V7, P2006, DOI 10.1101/gad.7.10.2006; STAUDT LM, 1991, ANNU REV IMMUNOL, V9, P373; STRACHAN T, 1994, CURR OPIN GENET DEV, V4, P427, DOI 10.1016/0959-437X(94)90032-9; Wallin JJ, 1998, SCIENCE, V279, P1961, DOI 10.1126/science.279.5358.1961	30	30	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15959	15965		10.1074/jbc.274.22.15959	http://dx.doi.org/10.1074/jbc.274.22.15959			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336503	hybrid			2022-12-25	WOS:000080560100092
J	Blaukat, A; Ivankovic-Dikic, I; Gronroos, E; Dolfi, F; Tokiwa, G; Vuori, K; Dikic, I				Blaukat, A; Ivankovic-Dikic, I; Gronroos, E; Dolfi, F; Tokiwa, G; Vuori, K; Dikic, I			Adaptor proteins Grb2 and Crk couple Pyk2 with activation of specific mitogen-activated protein kinase cascades	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; SRC FAMILY KINASES; TYROSINE KINASE; CELL-ADHESION; SIGNALING PATHWAY; IN-VIVO; SH3 DOMAINS; V-CRK; RECEPTOR; PHOSPHORYLATION	The protein tyrosine kinase Pyk2 acts as an upstream regulator of mitogen-activated protein (MAP) kinase cascades in response to numerous extracellular signals. The precise molecular mechanisms by which Pyk2 activates distinct MAP kinase pathways are not yet fully understood. In this report, we provide evidence that the protein tyrosine kinase Src and adaptor proteins Grb2, Crk, and p130Cas act as downstream mediators of Pyk2 leading to the activation of extracellular signal-regulated kinase (ERK) and c-Jun amino-terminal kinase (JNK). Pyk2-induced activation of Src is necessary for phosphorylation of Shc and p130Cas and their association with Grb2 and Crk, respectively, and for the activation of ERK and JNK cascades. Expression of a Grb2 mutant with a deletion of the amino-terminal Src homology 3 domain or the carboxyl-terminal tail of Sos strongly reduced Pyk2-induced ERK activation, with no apparent effect on JNK activity. Grb2 with a deleted carboxyl-terminal Src homology 3 domain partially blocked Pyk2-induced ERK and JNK pathways, whereas expression of dominant interfering mutants of p130Cas or Crk specifically inhibited JNK but not ERK activation by Pyk2. Taken together, our data reveal specific pathways that couple Pyk2 with MAP kinases: the Grb2/Sos complex connects Pyk2 to the activation of ERK, whereas adaptor proteins p130Cas and Crk link Pyk2 with the JNK pathway.	Ludwig Inst Canc Res, S-75124 Uppsala, Sweden; NYU, Med Ctr, Dept Pharmacol, New York, NY 10016 USA; Burnham Inst, La Jolla Canc Res Ctr, La Jolla, CA 92037 USA	Ludwig Institute for Cancer Research; New York University; Sanford Burnham Prebys Medical Discovery Institute	Dikic, I (corresponding author), Ludwig Inst Canc Res, Box 595,Husargatan 3, S-75124 Uppsala, Sweden.	Ivan.Dikic@licr.uu.se	Gronroos, Eva/E-9351-2013; Gronroos, Eva/P-6951-2015; Dikic, Ivan/O-4650-2015	Dikic, Ivan/0000-0001-8156-9511; Gronroos, Eva/0000-0001-8303-5409	NCI NIH HHS [CA71560] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071560] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anafi M, 1997, J BIOL CHEM, V272, P27804, DOI 10.1074/jbc.272.44.27804; Andreev J, 1999, MOL CELL BIOL, V19, P2338; Astier A, 1997, J BIOL CHEM, V272, P19719, DOI 10.1074/jbc.272.32.19719; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; Butler AA, 1997, J BIOL CHEM, V272, P27660, DOI 10.1074/jbc.272.44.27660; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Cantrell D, 1998, CURR BIOL, V8, pR535, DOI 10.1016/S0960-9822(07)00341-7; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Davis CB, 1997, J EXP MED, V186, P1793, DOI 10.1084/jem.186.10.1793; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; Dikic I, 1998, J BIOL CHEM, V273, P14301, DOI 10.1074/jbc.273.23.14301; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; Felsch JS, 1998, P NATL ACAD SCI USA, V95, P5051, DOI 10.1073/pnas.95.9.5051; Ganju RK, 1997, J EXP MED, V185, P1055, DOI 10.1084/jem.185.6.1055; Ganju RK, 1998, BLOOD, V91, P791, DOI 10.1182/blood.V91.3.791.791_791_797; GISHIZKY ML, 1995, P NATL ACAD SCI USA, V92, P10889, DOI 10.1073/pnas.92.24.10889; Gismondi A, 1997, J IMMUNOL, V159, P4729; Hatch WC, 1998, BLOOD, V91, P3967, DOI 10.1182/blood.V91.10.3967.3967_3967_3973; Hildebrand JD, 1996, MOL CELL BIOL, V16, P3169; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; Kiyokawa E, 1997, CRIT REV ONCOGENESIS, V8, P329, DOI 10.1615/CritRevOncog.v8.i4.30; Kiyokawa E, 1998, J BIOL CHEM, V273, P24479, DOI 10.1074/jbc.273.38.24479; KIYOKAWA E, GENES DEV, V2, P3331; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Lev S, 1999, MOL CELL BIOL, V19, P2278; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li X, 1998, J BIOL CHEM, V273, P9361, DOI 10.1074/jbc.273.16.9361; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; Matsuya M, 1998, J BIOL CHEM, V273, P1003, DOI 10.1074/jbc.273.2.1003; Miyazaki T, 1998, GENE DEV, V12, P770, DOI 10.1101/gad.12.6.770; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; Nakashima N, 1999, J BIOL CHEM, V274, P3001, DOI 10.1074/jbc.274.5.3001; Neet K, 1996, GENES CELLS, V1, P147, DOI 10.1046/j.1365-2443.1996.d01-234.x; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Ohba T, 1998, BIOCHEM J, V330, P1249, DOI 10.1042/bj3301249; Okazaki H, 1997, J BIOL CHEM, V272, P32443, DOI 10.1074/jbc.272.51.32443; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; Pomerance M, 1998, J BIOL CHEM, V273, P24301, DOI 10.1074/jbc.273.38.24301; Posern G, 1998, ONCOGENE, V16, P1903, DOI 10.1038/sj.onc.1201714; Qian DP, 1997, J EXP MED, V185, P1253, DOI 10.1084/jem.185.7.1253; RAABE T, 1995, EMBO J, V14, P2509, DOI 10.1002/j.1460-2075.1995.tb07248.x; Raja S, 1997, J BIOL CHEM, V272, P10941; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Salgia R, 1996, J BIOL CHEM, V271, P31222, DOI 10.1074/jbc.271.49.31222; SALGIA R, 1995, J BIOL CHEM, V270, P29145, DOI 10.1074/jbc.270.49.29145; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; Siciliano JC, 1996, J BIOL CHEM, V271, P28942, DOI 10.1074/jbc.271.46.28942; SIMON JA, 1995, CHEM BIOL, V2, P53, DOI 10.1016/1074-5521(95)90080-2; Smit L, 1996, J BIOL CHEM, V271, P8564, DOI 10.1074/jbc.271.15.8564; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Vuori K, 1996, MOL CELL BIOL, V16, P2606; WU XD, 1995, STRUCTURE, V3, P215, DOI 10.1016/S0969-2126(01)00151-4; Xie YM, 1995, J BIOL CHEM, V270, P30717, DOI 10.1074/jbc.270.51.30717; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; Zhu T, 1998, J BIOL CHEM, V273, P33864, DOI 10.1074/jbc.273.50.33864	67	179	181	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					14893	14901		10.1074/jbc.274.21.14893	http://dx.doi.org/10.1074/jbc.274.21.14893			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329689	hybrid			2022-12-25	WOS:000081965200054
J	Kasahara, M; Ohmori, M				Kasahara, M; Ohmori, M			Activation of a cyanobacterial adenylate cyclase, CyaC, by autophosphorylation and a subsequent phosphotransfer reaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PROTEIN; SPIRULINA-PLATENSIS; ANABAENA-CYLINDRICA; DIFFERENTIAL ACTIVATION; BACTERIAL CHEMOTAXIS; MYXOCOCCUS-XANTHUS; ESCHERICHIA-COLI; RAS PROTEINS; GENE; PHOSPHORYLATION	The CyaC protein, a cyanobacterial adenylate cyclase, has a unique primary structure composed of the catalytic domain of adenylate cyclase and the conserved domains of bacterial two-component regulatory systems, one transmitter domain and two receiver domains. In the present work, CyaC was produced in Escherichia coli as a histidine-tagged recombinant protein and purified to homogeneity, CyaC showed ability to autophosphorylate in vitro with the gamma-phosphate of [gamma-P-32]ATP. CyaC derivatives were constructed by site-directed mutagenesis in which the highly conserved phosphorylation sites in the transmitter domain (His(572)) and receiver domains (Asp(60) or. Asp(895)) were replaced by glutamine and alanine residues, respectively. After autophosphorylation of the CyaC derivatives, the chemical stabilities of the phosphoryl groups bound to the derivatives were determined. It was found that His(572) is the initial phosphorylation site and that the phosphoryl group once bound to His(572) is transferred to Asp(895). The enzyme activities of the CyaC derivatives defective in His572 Or Asp(895) were considerably reduced. Asp(895) is phosphorylated by acetyl [P-32]phosphate, a small phosphoryl molecule, but Asp(60) is not. Acetyl phosphate stimulates adenylate cyclase activity only when Asp(895) is intact. These results suggest that the phosphorylation of Asp(895) is essential for the activation of adenylate cyclase and that Asp(60) functions differently from Asp(895) in regulating the enzyme activity.	Univ Tokyo, Grad Sch Arts & Sci, Dept Life Sci, Tokyo 153, Japan	University of Tokyo	Ohmori, M (corresponding author), Univ Tokyo, Grad Sch Arts & Sci, Dept Life Sci, Tokyo 153, Japan.	cohmori@komaba.ecc.u-tokyo.ac.jp						BROEK D, 1985, CELL, V41, P763, DOI 10.1016/S0092-8674(85)80057-X; Buck J, 1999, P NATL ACAD SCI USA, V96, P79, DOI 10.1073/pnas.96.1.79; CHANG C, 1993, SCIENCE, V262, P539, DOI 10.1126/science.8211181; DUCLOS B, 1991, METHOD ENZYMOL, V201, P10; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; Hoch J.A., 1995, 2 COMPONENT SIGNAL T, DOI [10.1128/9781555818319, DOI 10.1128/9781555818319]; HOOD EE, 1979, BIOCHIM BIOPHYS ACTA, V588, P193, DOI 10.1016/0304-4165(79)90202-2; IGO MM, 1989, GENE DEV, V3, P598, DOI 10.1101/gad.3.5.598; IUCHI S, 1992, J BACTERIOL, V174, P5617, DOI 10.1128/JB.174.17.5617-5623.1992; IWAMI G, 1995, J BIOL CHEM, V270, P12481, DOI 10.1074/jbc.270.21.12481; Kaneko T, 1996, DNA Res, V3, P109; Kasahara M, 1997, PLANT CELL PHYSIOL, V38, P828, DOI 10.1093/oxfordjournals.pcp.a029241; Katayama M, 1997, J BACTERIOL, V179, P3588, DOI 10.1128/jb.179.11.3588-3593.1997; KATAYAMA M, 1995, J BACTERIOL, V177, P3873, DOI 10.1128/jb.177.13.3873-3878.1995; KAWABE J, 1994, J BIOL CHEM, V269, P16554; KOSHLAND DE, 1952, J AM CHEM SOC, V74, P2286, DOI 10.1021/ja01129a035; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LUKAT GS, 1992, P NATL ACAD SCI USA, V89, P718, DOI 10.1073/pnas.89.2.718; LUPAS A, 1989, J BIOL CHEM, V264, P17337; MCCLEARY WR, 1990, P NATL ACAD SCI USA, V87, P5898, DOI 10.1073/pnas.87.15.5898; MCCLEARY WR, 1994, J BIOL CHEM, V269, P31567; OHMORI K, 1992, PLANT CELL PHYSIOL, V33, P21; OHMORI M, 1989, PLANT CELL PHYSIOL, V30, P911, DOI 10.1093/oxfordjournals.pcp.a077824; OHMORI M, 1988, ARCH MICROBIOL, V150, P203, DOI 10.1007/BF00425163; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; PLAMANN L, 1995, J BACTERIOL, V177, P2014, DOI 10.1128/jb.177.8.2014-2020.1995; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; Quon KC, 1996, CELL, V84, P83, DOI 10.1016/S0092-8674(00)80995-2; REDDY P, 1985, P NATL ACAD SCI USA, V82, P8300, DOI 10.1073/pnas.82.24.8300; RUSSO FD, 1993, J MOL BIOL, V231, P261, DOI 10.1006/jmbi.1993.1281; SCHALLER GE, 1995, SCIENCE, V270, P1809, DOI 10.1126/science.270.5243.1809; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; Thomason PA, 1998, EMBO J, V17, P2838, DOI 10.1093/emboj/17.10.2838; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; UHL MA, 1994, P NATL ACAD SCI USA, V91, P1163, DOI 10.1073/pnas.91.3.1163; Yashiro K, 1996, PLANT MOL BIOL, V31, P175, DOI 10.1007/BF00020618; Yeh KC, 1997, SCIENCE, V277, P1505, DOI 10.1126/science.277.5331.1505	38	36	36	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					15167	15172		10.1074/jbc.274.21.15167	http://dx.doi.org/10.1074/jbc.274.21.15167			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329724	hybrid			2022-12-25	WOS:000081965200089
J	Zhang, YF; Pasparakis, M; Kollias, G; Simons, M				Zhang, YF; Pasparakis, M; Kollias, G; Simons, M			Myocyte-dependent regulation of endothelial cell syndecan-4 expression - Role of TNF-alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; PROTEIN-KINASE-C; HEPARAN-SULFATE PROTEOGLYCANS; MOLECULAR-CLONING; GENE-EXPRESSION; PHOSPHORYLATION; ANGIOGENESIS; ISCHEMIA	Syndecan-4 is a unique member of the syndecan gene family that has the ability to bind and activate protein kinase C-alpha. Whereas increased syndecan-4 levels have been noted in ischemic hearts, little is known regarding the regulation of its expression. To investigate the role of cardiac myocytes in induction of syndecan-4 expression, human endothelial cells (ECV304) mere exposed to a medium conditioned by primary mouse cardiac myocytes or H9c2 cells. The medium conditioned by hypoxic but not normal myocytes was able to induce syndecan-4 expression in ECV cells. Western analysis of the conditioned medium demonstrated an increased presence of tumor necrosis factor-alpha (TNF-alpha) in the medium conditioned by hypoxic but not normal myoblasts. Primary cardiac myocytes collected from the wild type C57/129 but not the homozygous TNF-alpha(-/-) knockout mice were able to induce syndecan-4 expression in ECV cells when cultured under hypoxic conditions. In vitro studies demonstrated that TNF-alpha induced endothelial cell syndecan-4 expression by both increasing syndecan-4 gene expression in an NF-KB-dependent manner and by prolonging syndecan-4 mRNA half-life. We conclude that TNF-alpha is the principal factor produced by the ischemic myocytes that is responsible for induction of endothelial cell syndecan-4 expression and that this requires both transcriptional and posttranscriptional mechanisms.	Beth Israel Deaconess Med Ctr, Div Cardiovasc, Dept Med, Angiogenesis Res Ctr, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Hellen Pasteur Inst, Genet Mol Lab, Athens 11521, Greece	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Simons, M (corresponding author), Beth Israel Deaconess Med Ctr, Div Cardiovasc, Dept Med, Angiogenesis Res Ctr, 330 Brookline Ave, Boston, MA 02215 USA.		Kollias, George/A-7079-2012; Pasparakis, Manolis/H-9292-2017; Simons, Michael/G-8553-2014; Pasparakis, Manolis/N-4350-2019	Kollias, George/0000-0003-1867-3150; Pasparakis, Manolis/0000-0002-9870-0966; Simons, Michael/0000-0003-0348-7734; Pasparakis, Manolis/0000-0002-9870-0966	NHLBI NIH HHS [R01 HL53793, P50 HL56993] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053793, P50HL056993] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Carey DJ, 1997, BIOCHEM J, V327, P1; Chandrasekar B, 1997, CLIN EXP IMMUNOL, V108, P346, DOI 10.1046/j.1365-2249.1997.d01-1017.x; Fenteany G, 1998, J BIOL CHEM, V273, P8545, DOI 10.1074/jbc.273.15.8545; GALLO RL, 1994, P NATL ACAD SCI USA, V91, P11035, DOI 10.1073/pnas.91.23.11035; Gurevitch J, 1996, J AM COLL CARDIOL, V28, P247, DOI 10.1016/0735-1097(96)00105-2; Horowitz A, 1998, J BIOL CHEM, V273, P25548, DOI 10.1074/jbc.273.40.25548; Horowitz A, 1998, J BIOL CHEM, V273, P10914, DOI 10.1074/jbc.273.18.10914; Kainulainen V, 1996, J BIOL CHEM, V271, P18759, DOI 10.1074/jbc.271.31.18759; KOJIMA T, 1992, J BIOL CHEM, V267, P4870; Li JA, 1997, CIRC RES, V81, P785; Meldrum DR, 1998, AM J PHYSIOL-REG I, V274, pR577, DOI 10.1152/ajpregu.1998.274.3.R577; MONTRUCCHIO G, 1994, J EXP MED, V180, P377, DOI 10.1084/jem.180.1.377; NIKKARI ST, 1994, AM J PATHOL, V144, P1348; Norrby K, 1996, MICROVASC RES, V52, P79, DOI 10.1006/mvre.1996.0045; Oh ES, 1997, J BIOL CHEM, V272, P11805, DOI 10.1074/jbc.272.18.11805; Oh ES, 1997, J BIOL CHEM, V272, P8133, DOI 10.1074/jbc.272.13.8133; Pasparakis M, 1996, J EXP MED, V184, P1397, DOI 10.1084/jem.184.4.1397; Rosenberg RD, 1997, J CLIN INVEST, V99, P2062, DOI 10.1172/JCI119377; Tsuzuki S, 1997, J BIOCHEM-TOKYO, V122, P17; Whiteside ST, 1997, SEMIN CANCER BIOL, V8, P75, DOI 10.1006/scbi.1997.0058	20	60	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					14786	14790		10.1074/jbc.274.21.14786	http://dx.doi.org/10.1074/jbc.274.21.14786			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329676	hybrid			2022-12-25	WOS:000081965200041
J	Pegram, M; Hsu, S; Lewis, G; Pietras, R; Beryt, M; Sliwkowski, M; Coombs, D; Baly, D; Kabbinavar, F; Slamon, D				Pegram, M; Hsu, S; Lewis, G; Pietras, R; Beryt, M; Sliwkowski, M; Coombs, D; Baly, D; Kabbinavar, F; Slamon, D			Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers	ONCOGENE			English	Article						HER-2/neu (c-erbB-2); chemotherapy; breast cancer; multiple drug effects analysis; synergy	GROWTH-FACTOR-RECEPTOR; HER2/NEU-OVEREXPRESSING METASTATIC BREAST; TUMOR NECROSIS FACTOR; MONOCLONAL-ANTIBODY; ENDOMETRIAL CANCER; OVARIAN-CANCER; ANTINEOPLASTIC AGENTS; C-ERBB-2 PROTEIN; SALIVARY-GLAND; GENE-PRODUCT	Previous studies have demonstrated a synergistic interaction between rhuMAb HER2 and the cytotoxic drug cisplatin in human breast and ovarian cancer cells. To define the nature of the interaction between rhuMAb HER2 and other classes of cytotoxic drugs, we applied multiple drug effect/combination index (CI) isobologram analysis to a variety of chemotherapeutic drug/rhuMAb HER2 combinations in vitro. Synergistic interactions at clinically relevant drug concentrations were observed for rhuMAb HER2 in combination with cisplatin (CI = 0.48, P = 0.003), thiotepa (CI = 0.67, P = 0.0008), and etoposide (CI = 0.54, P = 0.0003). Additive cytotoxic effects were observed with rhuMAb HER2 plus doxorubicin (CI = 1.16, P = 0.13), paclitaxel (CI = 0.91, P = 0.21), methotrexate (CI = 1.15, P = 0.28), and vinblastine (CI = 1.09, P = 0.26). One drug, 5-fluorouracil, was found to be antagonistic with rhuMAb HER2 in vitro (CI = 2.87, P = 0.0001). In vivo drug/rhuMAb HER2 studies were conducted with HER-2/neu-transfected, MCF7 human breast cancer xenografts in athymic mice. Combinations of rhuMAb HER2 plus cyclophosphamide, doxorubicin, paclitaxel, methotrexate, etoposide, and vinblastine in vivo resulted in a significant reduction in xenograft volume compared to chemotherapy alone (P < 0.05). Xenografts treated with rhuMAb HER2 plus 5-fluorouracil were not significantly different from 5-fluorouracil alone controls consistent with the subadditive effects observed with this combination in vitro. The synergistic interaction of rhuMAb HER2 with alkylating agents, platinum analogs and topoisomerase II inhibitors, as well as the additive interaction with taxanes, anthracyclines and some antimetabolites in HER-2/neu-overexpressing breast cancer cells demonstrates that these are rational combinations to test in human clinical trials.	Univ Calif Los Angeles, Sch Med, Dept Med, Div Hematol Oncol, Los Angeles, CA 90095 USA; Genentech Inc, San Francisco, CA 94080 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Roche Holding; Genentech	Slamon, D (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Med, Div Hematol Oncol, 11-934 Factor Bldg, Los Angeles, CA 90095 USA.			Pietras, Richard/0000-0002-2846-3192				ABOUDPIRAK E, 1988, J NATL CANCER I, V80, P1605, DOI 10.1093/jnci/80.20.1605; ARTEAGA CL, 1994, CANCER RES, V54, P3758; BASELGA J, 1993, J NATL CANCER I, V85, P1327, DOI 10.1093/jnci/85.16.1327; Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; Baselga J, 1998, CANCER RES, V58, P2825; BASELGA J, 1992, P AM ASSOC CANC RES, V33, P2947; BERCHUCK A, 1991, AM J OBSTET GYNECOL, V164, P15, DOI 10.1016/0002-9378(91)90615-X; Bible KC, 1997, CANCER RES, V57, P3375; BOVEN E, 1991, NUDE MOUSE ONCOL RES; BUICK RN, 1994, CANC CHEMOTHERAPY HD, P3; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; CHAZIN VR, 1992, ONCOGENE, V7, P1859; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; DESANTES K, 1992, CANCER RES, V52, P1916; FENDLY BM, 1990, CANCER RES, V50, P1550; FLICK DA, 1984, J IMMUNOL METHODS, V68, P167, DOI 10.1016/0022-1759(84)90147-9; GILLIES RJ, 1986, ANAL BIOCHEM, V159, P109, DOI 10.1016/0003-2697(86)90314-3; GIOVANELLA BC, 1977, P 2 INT WORKSH NUD M, P475; HANAUSKE AR, 1987, EUR J CANCER CLIN ON, V23, P545, DOI 10.1016/0277-5379(87)90318-X; HANCOCK MC, 1991, CANCER RES, V51, P4575; HETZEL DJ, 1992, GYNECOL ONCOL, V47, P179, DOI 10.1016/0090-8258(92)90103-P; Hill AV, 1913, BIOCHEM J, V7, P471, DOI 10.1042/bj0070471; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HSU S, 1997, BASIC CLIN ASPECTS B; HUDZIAK RM, 1989, MOL CELL BIOL, V9, P1165, DOI 10.1128/MCB.9.3.1165; INABA M, 1988, JPN J CANCER RES, V79, P509, DOI 10.1111/j.1349-7006.1988.tb01620.x; Klapper LN, 1997, ONCOGENE, V14, P2099, DOI 10.1038/sj.onc.1201029; LUKES AS, 1994, CANCER, V73, P2380, DOI 10.1002/1097-0142(19940501)73:9<2380::AID-CNCR2820730922>3.0.CO;2-G; MAIER LA, 1991, CANCER RES, V51, P5361; Park J W, 1992, Cancer Treat Res, V61, P193; PEGRAM M D, 1992, Proceedings of the American Association for Cancer Research Annual Meeting, V33, P442; Pegram MD, 1998, J CLIN ONCOL, V16, P2659, DOI 10.1200/JCO.1998.16.8.2659; Pegram MD, 1997, ONCOGENE, V15, P537, DOI 10.1038/sj.onc.1201222; PIETRAS RJ, 1994, ONCOGENE, V9, P1829; PRESS MF, 1994, CANCER RES, V54, P5675; Reese D., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P51; REILE H, 1990, ANAL BIOCHEM, V187, P262, DOI 10.1016/0003-2697(90)90454-H; RODRIGUEZ GC, 1993, AM J OBSTET GYNECOL, V168, P228, DOI 10.1016/S0002-9378(12)90918-7; SAFFARI B, 1995, CANCER RES, V55, P5693; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SIAS PE, 1990, J IMMUNOL METHODS, V132, P73, DOI 10.1016/0022-1759(90)90400-P; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; TANNOCK I, 1978, CANCER TREAT REP, V62, P1117; YARDEN Y, 1990, P NATL ACAD SCI USA, V87, P2569, DOI 10.1073/pnas.87.7.2569; YONEMURA Y, 1991, CANCER, V67, P2914, DOI 10.1002/1097-0142(19910601)67:11<2914::AID-CNCR2820671134>3.0.CO;2-G; ZUCKIER G, 1983, EXP CELL RES, V148, P155, DOI 10.1016/0014-4827(83)90195-7	47	533	591	2	48	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 1	1999	18	13					2241	2251		10.1038/sj.onc.1202526	http://dx.doi.org/10.1038/sj.onc.1202526			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	182YE	10327070				2022-12-25	WOS:000079525100008
J	Brizzi, MF; Dentelli, P; Rosso, A; Yarden, Y; Pegoraro, L				Brizzi, MF; Dentelli, P; Rosso, A; Yarden, Y; Pegoraro, L			STAT protein recruitment and activation in c-Kit deletion mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; COLONY-STIMULATING FACTOR; STEM-CELL FACTOR; DNA-BINDING ACTIVITY; FACTOR RECEPTOR; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; HORMONE RECEPTOR; KINASE; ASSOCIATION	Stem cell factor (SCF) and its tyrosine kinase receptor, c-Kit, play a crucial role in regulating migration and proliferation of melanoblasts, germ cells, and hemopoietic cell progenitors by activating a number of intracellular signaling molecules. Here we report that SCF stimulation of myeloid cells or fibroblasts ectopically expressing c-Kit induces physical association with and tyrosine phosphorylation of three signal transducers and activators of transcription (STATs) as follows: STAT1 alpha, STAT5A, and STAT5B. Other STAT proteins are not recruited upon SCF stimulation. Recruitment of STATs leads to their dimerization, nuclear translocation, and binding to specific promoter-responsive elements. Whereas STAT1 alpha, possibly in the form of homodimers, binds to the sis-inducible DNA element, STAT5 proteins, either as STAT5A/STAT5B or STAT5/STAT1 alpha heterodimers, bind to the prolactin-inducible element of the beta-casein promoter. The tyrosine kinase activity of Kit appears essential for STAT activation since a kinase-defective mutant lacking a kinase insert domain was inactive in STAT signaling. However, another mutant that lacked the carboxyl-terminal region retained STAT1 alpha activation and nuclear translocation but was unable to fully activate STATE proteins, although it mediated their transient phosphorylation, These results indicate that different intracellular domains of c-Kit are involved in activation of the various STAT proteins.	Univ Turin, Dipartimento Med Interna, I-10126 Turin, Italy; Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel	University of Turin; Weizmann Institute of Science	Pegoraro, L (corresponding author), Univ Turin, Dipartimento Med Interna, Corso Dogliotti 14, I-10126 Turin, Italy.		YARDEN, YOSEF/K-1467-2012; Brizzi, Maria Felice/J-7882-2016					AVANZI GC, 1990, J CELL PHYSIOL, V145, P458, DOI 10.1002/jcp.1041450310; BLECHMAN JM, 1993, J BIOL CHEM, V268, P4399; BRIZZI MF, 1994, J BIOL CHEM, V269, P31680; Brizzi MF, 1996, J BIOL CHEM, V271, P3562; Choudhury GG, 1998, J CLIN INVEST, V101, P2751, DOI 10.1172/JCI1044; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; FJETANI Y, 1997, ONCOGENE, V14, P751; Friedman MC, 1996, P NATL ACAD SCI USA, V93, P2077, DOI 10.1073/pnas.93.5.2077; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; HELM MH, 1995, SCIENCE, V267, P1347; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; Leaman DW, 1996, MOL CELL BIOL, V16, P369; Leaman DW, 1996, FASEB J, V10, P1578, DOI 10.1096/fasebj.10.14.9002549; LEBRUN JJ, 1995, J BIOL CHEM, V270, P10664, DOI 10.1074/jbc.270.18.10664; LEV S, 1992, P NATL ACAD SCI USA, V89, P678, DOI 10.1073/pnas.89.2.678; Mellitzer G, 1996, P NATL ACAD SCI USA, V93, P9600, DOI 10.1073/pnas.93.18.9600; MIYAZAWA K, 1991, EXP HEMATOL, V19, P1110; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; Novak U, 1996, J BIOL CHEM, V271, P18350, DOI 10.1074/jbc.271.31.18350; Okimoto T, 1996, ONCOGENE, V12, P1625; OShea JJ, 1997, IMMUNITY, V7, P1, DOI 10.1016/S1074-7613(00)80505-1; PEREZ A, 1997, J BIOL CHEM, V272, P25043; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; QUELLE FW, 1995, J BIOL CHEM, V270, P20775, DOI 10.1074/jbc.270.35.20775; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; RUFFJAMISON S, 1995, P NATL ACAD SCI USA, V92, P4215, DOI 10.1073/pnas.92.10.4215; Ryan JJ, 1997, EXP HEMATOL, V25, P357; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; TAUCHI T, 1994, J BIOL CHEM, V269, P25206; Valgeirsdottir S, 1998, ONCOGENE, V16, P505, DOI 10.1038/sj.onc.1201555; Vignais ML, 1996, MOL CELL BIOL, V16, P1759; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WANG YD, 1995, J BIOL CHEM, V270, P7021, DOI 10.1074/jbc.270.13.7021; Weiler SR, 1996, BLOOD, V87, P3688, DOI 10.1182/blood.V87.9.3688.bloodjournal8793688; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; Xu BXC, 1996, J BIOL CHEM, V271, P19768, DOI 10.1074/jbc.271.33.19768; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P433; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4	48	75	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16965	16972		10.1074/jbc.274.24.16965	http://dx.doi.org/10.1074/jbc.274.24.16965			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358045	hybrid			2022-12-25	WOS:000080780400044
J	Cierniewski, CS; Byzova, T; Papierak, M; Haas, TA; Niewiarowska, J; Zhang, L; Cieslak, M; Plow, EF				Cierniewski, CS; Byzova, T; Papierak, M; Haas, TA; Niewiarowska, J; Zhang, L; Cieslak, M; Plow, EF			Peptide ligands can bind to distinct sites in integrin alpha(IIb)beta(3) and elicit different functional responses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; FIBRINOGEN GAMMA-CHAIN; VONWILLEBRAND-FACTOR; GPIIB-IIIA; RECOGNITION SITE; HUMAN-PLATELETS; ALPHA-CHAIN; ADHESION RECEPTOR; CRYSTAL-STRUCTURE; BETA-3 INTEGRINS	The spatial relationship between the binding sites for two cyclic peptides, cyclo(S,S)KYGCRGDWPC (cRGD) and cyclo(S,S)KYGCHarGDWPC (cHarGD), high affinity analogs for the RGD and HLGGAKQAGDV peptide ligands, in integrin alpha(IIb)beta(3) (GPIIb-IIIa) has been characterized. For this purpose, cRGD and cHarGD were labeled with fluorescein isothiocyanate and tetramethylrhodamine B-isothiocyanate, respectively, Both cyclic peptides were potent inhibitors of fibrinogen binding to alpha(IIb)beta(3), particularly in the presence of Mn2+; IC50 values for cRGD and cHarGD were 1 and < 0.1 nM in the presence of Mn2+. Direct binding experiments and fluorescence resonance energy transfer analysis using the purified receptor showed that both peptides interacted simultaneously with distinct sites in alpha(IIb)beta(3). The distance between these sites was estimated to be 6.1 +/- 0.5 nm, Although cRGD bound preferentially to one site and cHarGD to the other, the sites were not fully specific, and each cyclic peptide or its Linear counterpart could displace the other to some extent. The binding affinity of the cHarGD site was dramatically affected by Mn2+. cRGD, but not cHarGD, bound to recombinant beta(3)-(95-373) in a cation-dependent manner, indicating that the cRGD site is located entirely within this fragment. With intact platelets, binding of c-RGD and cHarGD to alpha(IIb)beta(3) resulted in distinct conformational alterations in the receptor as indicated by the differential exposure of Ligand-induced binding site epitopes and also induced the opposite on membrane fluidity as shown by electron paramagnetic resonance analyses using 5-doxylstearic acid as a spin probe, These data support the concept the two peptide Ligands bind to distinct sites in alpha(IIb)beta(3) and initiate different functional consequences within the receptor itself and within platelets.	Cleveland Clin Fdn, Joseoph J Jacobs Ctr Thrombosis & Vasc Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Mol Cardiol, Cleveland, OH 44195 USA; Med Univ Lodz, Dept Biophys, PL-90131 Lodz, Poland; Polish Acad Sci, Ctr Mol & Macromol Res, Dept Bioorgan Chem, PL-90131 Lodz, Poland	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Medical University Lodz; Polish Academy of Sciences	Plow, EF (corresponding author), Cleveland Clin Fdn, Joseoph J Jacobs Ctr Thrombosis & Vasc Biol, 9500 Euclid Ave,NB50, Cleveland, OH 44195 USA.		Cieslak, Marcin/ABF-2494-2020	Cieslak, Marcin/0000-0002-9628-214X; Niewiarowska, Jolanta/0000-0003-0561-7766; Byzova, Tatiana/0000-0002-2615-875X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054924] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-54924] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDRIEUX A, 1991, J BIOL CHEM, V266, P14202; ANDRIEUX A, 1989, J BIOL CHEM, V264, P9258; BAJT ML, 1992, J BIOL CHEM, V267, P3789; BENNETT JS, 1988, J BIOL CHEM, V263, P12948; BRUNO J, 1992, BIOCHEMISTRY-US, V31, P7016, DOI 10.1021/bi00146a002; Byzova TV, 1997, J BIOL CHEM, V272, P27183, DOI 10.1074/jbc.272.43.27183; CHAPMAN ER, 1992, BIOCHEMISTRY-US, V31, P12819, DOI 10.1021/bi00166a016; CHARO IF, 1991, J BIOL CHEM, V266, P1415; CIERNIEWSKI CS, 1994, BIOCHEMISTRY-US, V33, P12238, DOI 10.1021/bi00206a029; DSOUZA SE, 1988, J BIOL CHEM, V263, P3943; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; DSOUZA SE, 1994, CELL, V79, P659, DOI 10.1016/0092-8674(94)90551-7; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; DU XP, 1993, J BIOL CHEM, V268, P23087; FARRELL DH, 1992, P NATL ACAD SCI USA, V89, P10729, DOI 10.1073/pnas.89.22.10729; FARRELL DH, 1994, J BIOL CHEM, V269, P226; FRELINGER AL, 1988, J BIOL CHEM, V263, P12397; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; GULINO D, 1992, J BIOL CHEM, V267, P1001; HAVERSTICK DM, 1985, BLOOD, V66, P946; HOMANDBERG GA, 1985, AM J PATHOL, V120, P327; Hu DD, 1996, J BIOL CHEM, V271, P21745, DOI 10.1074/jbc.271.36.21745; HUBBELL WL, 1971, J AM CHEM SOC, V93, P314; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; Kamata T, 1996, J BIOL CHEM, V271, P18610, DOI 10.1074/jbc.271.31.18610; LAM SCT, 1987, J BIOL CHEM, V262, P947; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Lin ECK, 1997, J BIOL CHEM, V272, P14236, DOI 10.1074/jbc.272.22.14236; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; LOFTUS JC, 1987, P NATL ACAD SCI USA, V84, P7114, DOI 10.1073/pnas.84.20.7114; MARGUERIE GA, 1980, J BIOL CHEM, V255, P154; MARGUERIE GA, 1979, J BIOL CHEM, V254, P5357; MASUMOTO A, 1993, J CELL BIOL, V123, P245, DOI 10.1083/jcb.123.1.245; Mazurov AV, 1996, FEBS LETT, V391, P84, DOI 10.1016/0014-5793(96)00709-0; MOULD AP, 1995, J BIOL CHEM, V270, P26270, DOI 10.1074/jbc.270.44.26270; MULLER B, 1993, J BIOL CHEM, V268, P6800; MUSTARD JF, 1972, BRIT J HAEMATOL, V22, P193, DOI 10.1111/j.1365-2141.1972.tb08800.x; NIEWIAROWSKI S, 1994, SEMIN HEMATOL, V31, P289; OBARA M, 1988, CELL, V53, P649, DOI 10.1016/0092-8674(88)90580-6; PARISE LV, 1985, J BIOL CHEM, V260, P698; PEERSCHKE EIB, 1987, BLOOD, V69, P950; PIETU G, 1984, NATURE, V308, P648, DOI 10.1038/308648a0; PLOW EF, 1992, SEMIN THROMB HEMOST, V18, P324, DOI 10.1055/s-2007-1002571; PLOW EF, 1987, BIOCHEM PHARMACOL, V36, P4035, DOI 10.1016/0006-2952(87)90558-2; PLOW EF, 1984, J BIOL CHEM, V259, P5388; PLOW EF, 1985, BLOOD, V66, P26; PLOW EF, 1985, P NATL ACAD SCI USA, V82, P8057, DOI 10.1073/pnas.82.23.8057; PLOW EF, 1987, BLOOD, V70, P110; PLOW EF, 1985, BLOOD, V66, P724; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; RYBAK MEM, 1989, J BIOL CHEM, V264, P14617; SANTORO SA, 1987, CELL, V48, P867, DOI 10.1016/0092-8674(87)90083-3; SCARBOROUGH RM, 1993, J BIOL CHEM, V268, P1066; SCARBOROUGH RM, 1991, J BIOL CHEM, V266, P9359; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SHATTIL SJ, 1995, THROMB HAEMOSTASIS, V74, P149; Shattil SJ, 1997, J CLIN INVEST, V100, pS91; SIMS PJ, 1991, J BIOL CHEM, V266, P7345; SMITH JW, 1990, J BIOL CHEM, V265, P12267; SMITH JW, 1994, J BIOL CHEM, V269, P960; SMYTH SS, 1993, BLOOD, V81, P2827; Suehiro K, 1996, J BIOL CHEM, V271, P10365, DOI 10.1074/jbc.271.17.10365; TANGEMANN K, 1995, FEBS LETT, V358, P179, DOI 10.1016/0014-5793(94)01411-S; TIMMONS S, 1984, P NATL ACAD SCI-BIOL, V81, P4935, DOI 10.1073/pnas.81.15.4935; TOMIYAMA Y, 1992, BLOOD, V79, P2303; Topol EJ, 1999, LANCET, V353, P227, DOI 10.1016/S0140-6736(98)11086-3; Tozer EC, 1996, J BIOL CHEM, V271, P21978, DOI 10.1074/jbc.271.36.21978; Turcatti G, 1996, J BIOL CHEM, V271, P19991, DOI 10.1074/jbc.271.33.19991; Turcatti G, 1997, J BIOL CHEM, V272, P21167, DOI 10.1074/jbc.272.34.21167; Wagner CL, 1996, BLOOD, V88, P907; Watala C, 1996, EUR J BIOCHEM, V235, P281, DOI 10.1111/j.1432-1033.1996.00281.x; WILLIAMS S, 1987, THROMB RES, V46, P457, DOI 10.1016/0049-3848(87)90133-2; Zar JH., 1999, BIOSTAT ANAL	75	79	80	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16923	16932		10.1074/jbc.274.24.16923	http://dx.doi.org/10.1074/jbc.274.24.16923			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358039	hybrid			2022-12-25	WOS:000080780400038
J	Rohrer, DK; Chruscinski, A; Schauble, EH; Bernstein, D; Kobilka, BK				Rohrer, DK; Chruscinski, A; Schauble, EH; Bernstein, D; Kobilka, BK			Cardiovascular and metabolic alterations in mice lacking both beta 1-and beta 2-adrenergic receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; BETA-1-ADRENERGIC RECEPTOR; TARGETED DISRUPTION; STIMULATION; EXERCISE; GENE; RAT; CATECHOLAMINES; PROPRANOLOL; 5-HYDROXYTRYPTAMINE	The activation state of beta-adrenergic receptors (beta-ARs) in vivo is an important determinant of hemodynamic status, cardiac performance, and metabolic rate. In order to achieve homeostasis in vivo, the cellular signals generated by beta-AR activation are integrated with signals from a number of other distinct receptors and signaling pathways. We have utilized genetic knockout models to test directly the role of beta 1- and/or beta 2-AR expression on these homeostatic control mechanisms. Despite total absence of beta 1- and beta 2-ARs, the predominant cardiovascular beta-adrenergic subtypes, basal heart rate, blood pressure, and metabolic rate do not differ from wild type controls. However, stimulation of beta-AR function by beta-AR agonists or exercise reveals significant impairments in chronotropic range, vascular reactivity, and metabolic rate. Surprisingly, the blunted chronotropic and metabolic response to exercise seen in pll beta 2-AR double knockouts fails to impact maximal exercise capacity. Integrating the results from single beta 1- and beta 2-AR knockouts as well as the beta 1-/beta 2-AR double knockout suggest that in the mouse, beta-AR stimulation of cardiac inotropy and chronotropy is mediated almost exclusively by the beta 1-AR, whereas vascular relaxation and metabolic rate are controlled by all three beta-ARs (beta 1-, beta 2-, and beta 3-AR), Compensatory alterations in cardiac muscarinic receptor density and vascular beta 3-AR responsiveness are also observed in beta 1-/beta 2-AR double knockouts. In addition to its ability to define P-AR subtype-specific functions, this genetic approach is also useful in identifying adaptive alterations that serve to maintain critical physiological setpoints such as heart rate, blood pressure, and metabolic rate when cellular signaling mechanisms are perturbed.	Stanford Univ, Howard Hughes Med Inst, Stanford, CA 94305 USA; Roche Biosci, Dept Mol Pharmacol, Palo Alto, CA 94304 USA; Stanford Univ, Dept Pediat, Div Pediat Cardiol, Stanford, CA 94305 USA	Howard Hughes Medical Institute; Stanford University; Roche Holding; Stanford University	Kobilka, BK (corresponding author), Stanford Univ, Howard Hughes Med Inst, Stanford, CA 94305 USA.	kobilka@cmgm.stanford.edu		Bernstein, Daniel/0000-0001-7761-5853; Kobilka, Brian/0000-0001-5958-3990	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007365] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM07365] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEVILACQUA M, 1989, AM J CARDIOL, V63, P853, DOI 10.1016/0002-9149(89)90056-8; BOSNJAK ZJ, 1991, ANESTHESIOLOGY, V74, P340, DOI 10.1097/00000542-199102000-00022; BOUDOULAS H, 1977, ANN INTERN MED, V87, P433, DOI 10.7326/0003-4819-87-4-433; BRISTOW MR, 1982, MOL PHARMACOL, V21, P671; BRODDE OE, 1988, J HYPERTENS, V6, pS497, DOI 10.1097/00004872-198812040-00157; BRODDE OE, 1992, BASIC RES CARDIOL, V87, P1; Cavalli A, 1997, P NATL ACAD SCI USA, V94, P11589, DOI 10.1073/pnas.94.21.11589; Chruscinski AJ, 1999, J BIOL CHEM, V274, P16694, DOI 10.1074/jbc.274.24.16694; CLAUSEN T, 1977, J PHYSIOL-LONDON, V270, P383, DOI 10.1113/jphysiol.1977.sp011958; CLINE WH, 1981, J PHARMACOL EXP THER, V216, P104; Davy M, 1997, CELL MOL LIFE SCI, V53, P263, DOI 10.1007/PL00000601; Desai KH, 1997, AM J PHYSIOL-HEART C, V272, pH1053, DOI 10.1152/ajpheart.1997.272.2.H1053; Desai KH, 1996, CIRCULATION, V94, P1800; DiBello V, 1995, INT J SPORTS MED, V16, P498, DOI 10.1055/s-2007-973044; DIXON RAF, 1986, NATURE, V321, P75, DOI 10.1038/321075a0; ELLINGSEN O, 1987, CIRC RES, V60, P540, DOI 10.1161/01.RES.60.4.540; EMORINE LJ, 1989, SCIENCE, V245, P1118, DOI 10.1126/science.2570461; ENDOH M, 1989, BASIC RES CARDIOL, V84, P69, DOI 10.1007/BF02650348; Eschenhagen T, 1996, CIRCULATION, V93, P763, DOI 10.1161/01.CIR.93.4.763; FRIELLE T, 1987, P NATL ACAD SCI USA, V84, P7920, DOI 10.1073/pnas.84.22.7920; GALBO H, 1976, J APPL PHYSIOL, V40, P855, DOI 10.1152/jappl.1976.40.6.855; Gauthier C, 1996, J CLIN INVEST, V98, P556, DOI 10.1172/JCI118823; GLAUBIGER G, 1977, BIOCHEM BIOPH RES CO, V78, P720, DOI 10.1016/0006-291X(77)90238-8; Gotshall RW, 1996, INT J SPORTS MED, V17, P17; JUHLINDANNFELT A, 1983, ACTA MED SCAND, P49; KEMMOTSU O, 1973, ANESTHESIOLOGY, V39, P470, DOI 10.1097/00000542-197311000-00003; LANDS A. M., 1967, LIFE SCI, V6, P2241, DOI 10.1016/0024-3205(67)90031-8; LANDS AM, 1967, NATURE, V214, P597, DOI 10.1038/214597a0; LINK RE, 1995, MOL PHARMACOL, V48, P48; Link RE, 1996, SCIENCE, V273, P803, DOI 10.1126/science.273.5276.803; LYNCH C, 1986, ANESTHESIOLOGY, V64, P620, DOI 10.1097/00000542-198605000-00013; MacMillan LB, 1996, SCIENCE, V273, P801, DOI 10.1126/science.273.5276.801; Malinowska B, 1997, BRIT J PHARMACOL, V122, P1307, DOI 10.1038/sj.bjp.0701516; MCLEOD AA, 1983, CIRCULATION, V67, P1076, DOI 10.1161/01.CIR.67.5.1076; OPIE LH, 1985, AM J CARDIOL, V55, pD95, DOI 10.1016/0002-9149(85)91062-8; PEPPERL DJ, 1994, HDB RECEPTORS CHANNE, P45; ROGUS EM, 1977, BIOCHIM BIOPHYS ACTA, V464, P347, DOI 10.1016/0005-2736(77)90009-8; Rohrer DK, 1998, ANNU REV PHARMACOL, V38, P351, DOI 10.1146/annurev.pharmtox.38.1.351; Rohrer DK, 1996, P NATL ACAD SCI USA, V93, P7375, DOI 10.1073/pnas.93.14.7375; Rohrer DK, 1998, AM J PHYSIOL-HEART C, V274, pH1184, DOI 10.1152/ajpheart.1998.274.4.H1184; ROHRER DK, 1998, HYPERTENSION HEART F, P129; Shen YT, 1996, J PHARMACOL EXP THER, V278, P1435; STRADER CD, 1995, FASEB J, V9, P745, DOI 10.1096/fasebj.9.9.7601339; Strosberg AD, 1995, OBES RES, V3, pS501, DOI 10.1002/j.1550-8528.1995.tb00219.x; SUSULIC VS, 1995, J BIOL CHEM, V270, P29483, DOI 10.1074/jbc.270.49.29483; Thomas AJ, 1997, METHOD INFORM MED, V36, P372; UUSITUPA M, 1982, ANN CLIN RES, V14, P165; Zaizen H, 1996, HEART VESSELS, V11, P10, DOI 10.1007/BF01744594	48	206	213	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16701	16708		10.1074/jbc.274.24.16701	http://dx.doi.org/10.1074/jbc.274.24.16701			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358009	hybrid			2022-12-25	WOS:000080780400008
J	Casse, C; Giannoni, F; Nguyen, VT; Dubois, MF; Bensaude, O				Casse, C; Giannoni, F; Nguyen, VT; Dubois, MF; Bensaude, O			The transcriptional inhibitors, actinomycin D and alpha-amanitin, activate the HIV-1 promoter and favor phosphorylation of the RNA polymerase IIC-terminal domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; NF-KAPPA-B; GENE-EXPRESSION; DNA-DAMAGE; IN-VIVO; LARGEST SUBUNIT; RIBOSOMAL-RNA; HISTONE ACETYLTRANSFERASE; TAT TRANSACTIVATION; PROTEIN-KINASE	Actinomycin D and alpha-amanitin are commonly used to inhibit transcription. Unexpectedly, however, the transcription of the human immunodeficiency virus (HIV-1) long terminal repeats (LTR) is shown to be activated at the level of elongation, in human and murine cells exposed to these drugs, whereas the Rous sarcoma virus LTR, the human cytomegalovirus immediate early gene (CMV), and the HSP70 promoters are repressed. Activation of the HIV LTR is independent of the NF kappa B and TAR sequences and coincides with an enhanced average phosphorylation of the C-terminal domain (CTD) from the largest subunit of RNA polymerase II. Both the HIV-1 LTR activation and the bulk CTD phosphorylation enhancement are prevented by several CTD kinase inhibitors, including 5,6-dichloro-1-beta-D-ribofuranosyl-benzimidazole. The efficacies of the various compounds to block CTD phosphorylation and transcription in vivo correlate with their capacities to inhibit the CDK9/ PITALRE kinase in vitro. Hence, the positive transcription elongation factor, P-TEFb, is likely to contribute to the average CTD phosphorylation in vivo and to the activation of the HIV-1 LTR induced by actinomycin D.	Ecole Normale Super, Genet Mol Lab, F-75230 Paris 05, France	UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)	Bensaude, O (corresponding author), Ecole Normale Super, Genet Mol Lab, 46 Rue Ulm, F-75230 Paris 05, France.		Giannoni, Federico/A-6577-2013	Giannoni, Federico/0000-0001-5521-512X; Bensaude, Olivier/0000-0002-0259-6608				ALCAMI J, 1995, EMBO J, V14, P1552, DOI 10.1002/j.1460-2075.1995.tb07141.x; ALONSO S, 1986, J MOL EVOL, V23, P11, DOI 10.1007/BF02100994; BACHELERIE F, 1991, NATURE, V350, P709, DOI 10.1038/350709a0; Barbeau B, 1997, J BIOL CHEM, V272, P12968, DOI 10.1074/jbc.272.20.12968; Bates S, 1996, ONCOGENE, V13, P1103; Benkirane M, 1998, J BIOL CHEM, V273, P24898, DOI 10.1074/jbc.273.38.24898; Bentley D, 1998, NATURE, V395, P21, DOI 10.1038/25616; Bieniasz PD, 1998, EMBO J, V17, P7056, DOI 10.1093/emboj/17.23.7056; BOSHART M, 1985, CELL, V41, P521, DOI 10.1016/S0092-8674(85)80025-8; BROWN FL, 1993, MOL CELL BIOL, V13, P5245, DOI 10.1128/MCB.13.9.5245; CONRADWEBB H, 1995, MOL CELL BIOL, V15, P2420; Corden JL, 1997, TRENDS BIOCHEM SCI, V22, P413, DOI 10.1016/S0968-0004(97)01125-0; Cujec TP, 1997, GENE DEV, V11, P2645, DOI 10.1101/gad.11.20.2645; Cujec TP, 1997, MOL CELL BIOL, V17, P1817, DOI 10.1128/MCB.17.4.1817; Cullen BR, 1998, CELL, V93, P685, DOI 10.1016/S0092-8674(00)81431-2; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; DEMERCOYROL L, 1989, BIOCHEM J, V258, P165, DOI 10.1042/bj2580165; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; Dubois MF, 1997, NUCLEIC ACIDS RES, V25, P694, DOI 10.1093/nar/25.4.694; DUBOIS MF, 1994, J BIOL CHEM, V269, P13331; DUBOIS MF, 1994, J CELL PHYSIOL, V158, P417, DOI 10.1002/jcp.1041580305; Dubois MF, 1999, NUCLEIC ACIDS RES, V27, P1338, DOI 10.1093/nar/27.5.1338; Dubois MF, 1998, CELL STRESS CHAPERON, V3, P147, DOI 10.1379/1466-1268(1998)003<0147:PORPIC>2.3.CO;2; EGYHAZI E, 1976, NATURE, V262, P319, DOI 10.1038/262319a0; Emerman M, 1998, SCIENCE, V280, P1880, DOI 10.1126/science.280.5371.1880; Garber ME, 1998, GENE DEV, V12, P3512, DOI 10.1101/gad.12.22.3512; GARCIA JA, 1994, PROG NUCLEIC ACID RE, V49, P157; GEELEN JLMC, 1988, J GEN VIROL, V69, P2913, DOI 10.1099/0022-1317-69-11-2913; Gorospe M, 1998, MOL CELL BIOL, V18, P1400, DOI 10.1128/MCB.18.3.1400; GUALBERTO A, 1995, MOL CELL BIOL, V15, P3450; Haaf T, 1996, EXP CELL RES, V224, P163, DOI 10.1006/excr.1996.0124; HADJIOLOVA KV, 1995, EUR J BIOCHEM, V228, P605, DOI 10.1111/j.1432-1033.1995.tb20300.x; Harris W., 1991, Horticulture in New Zealand, V2, P2; Hengartner CJ, 1998, MOL CELL, V2, P43, DOI 10.1016/S1097-2765(00)80112-4; JEANG KT, 1993, J BIOL CHEM, V268, P24940; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; Jones KA, 1997, GENE DEV, V11, P2593, DOI 10.1101/gad.11.20.2593; KEDINGER C, 1970, BIOCHEM BIOPH RES CO, V38, P165, DOI 10.1016/0006-291X(70)91099-5; Keen NJ, 1997, EMBO J, V16, P5260, DOI 10.1093/emboj/16.17.5260; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; KIDDER GM, 1985, J EXP ZOOL, V233, P155, DOI 10.1002/jez.1402330123; Kingsman SM, 1996, EUR J BIOCHEM, V240, P491, DOI 10.1111/j.1432-1033.1996.0491h.x; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; KONTERMANN RE, 1995, BIOL CHEM H-S, V376, P473, DOI 10.1515/bchm3.1995.376.8.473; KRETZREMY C, 1994, FEBS LETT, V351, P191, DOI 10.1016/S0014-5793(94)80103-7; Kumar S, 1996, J BIOL CHEM, V271, P30864, DOI 10.1074/jbc.271.48.30451; Leclerc V, 1996, MOL BIOL CELL, V7, P505, DOI 10.1091/mbc.7.4.505; Leist M, 1997, GASTROENTEROLOGY, V112, P923, DOI 10.1053/gast.1997.v112.pm9041255; LINDELL TJ, 1970, SCIENCE, V170, P447, DOI 10.1126/science.170.3956.447; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; MACIASZEK JW, 1994, J VIROL, V68, P6598, DOI 10.1128/JVI.68.10.6598-6604.1994; Mancebo HSY, 1997, GENE DEV, V11, P2633, DOI 10.1101/gad.11.20.2633; MARCINIAK RA, 1991, EMBO J, V10, P4189, DOI 10.1002/j.1460-2075.1991.tb04997.x; Marshall NF, 1998, J BIOL CHEM, V273, P31726, DOI 10.1074/jbc.273.48.31726; MCCUNE JM, 1995, CELL, V82, P183, DOI 10.1016/0092-8674(95)90305-4; MORGAN WD, 1987, MOL CELL BIOL, V7, P1129, DOI 10.1128/MCB.7.3.1129; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; Nguyen VT, 1996, NUCLEIC ACIDS RES, V24, P2924, DOI 10.1093/nar/24.15.2924; OMALLEY K, 1985, MOL CELL BIOL, V5, P3476, DOI 10.1128/MCB.5.12.3476; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; PARADA CA, 1995, J BIOL CHEM, V270, P2274, DOI 10.1074/jbc.270.5.2274; Parvin JD, 1998, CURR OPIN GENET DEV, V8, P565, DOI 10.1016/S0959-437X(98)80012-9; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; PERRY RP, 1970, J CELL PHYSIOL, V76, P127, DOI 10.1002/jcp.1040760202; Piret B, 1996, NUCLEIC ACIDS RES, V24, P4242, DOI 10.1093/nar/24.21.4242; RAYNAL F, 1984, FEBS LETT, V167, P263, DOI 10.1016/0014-5793(84)80139-8; SAKAGUCHI M, 1991, J VIROL, V65, P5448, DOI 10.1128/JVI.65.10.5448-5456.1991; Schafer H, 1998, ONCOGENE, V16, P2479, DOI 10.1038/sj.onc.1201788; SCHWARTZ O, 1990, GENE, V88, P197, DOI 10.1016/0378-1119(90)90032-M; SHELDON M, 1993, MOL CELL BIOL, V13, P1251, DOI 10.1128/MCB.13.2.1251; Shuman S, 1997, P NATL ACAD SCI USA, V94, P12758, DOI 10.1073/pnas.94.24.12758; SOBELL HM, 1985, P NATL ACAD SCI USA, V82, P5328, DOI 10.1073/pnas.82.16.5328; Svejstrup JQ, 1996, TRENDS BIOCHEM SCI, V21, P346, DOI 10.1016/0968-0004(96)10046-3; TONGSTARKSEN SE, 1987, P NATL ACAD SCI USA, V84, P6845, DOI 10.1073/pnas.84.19.6845; VALAY JG, 1995, J MOL BIOL, V249, P535, DOI 10.1006/jmbi.1995.0316; VALERIE K, 1988, NATURE, V333, P78, DOI 10.1038/333078a0; VanLint C, 1996, EMBO J, V15, P1112, DOI 10.1002/j.1460-2075.1996.tb00449.x; VLACH J, 1995, VIROLOGY, V208, P753, DOI 10.1006/viro.1995.1207; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; WEINMANN R, 1974, P NATL ACAD SCI USA, V71, P1790, DOI 10.1073/pnas.71.5.1790; Weissman JD, 1998, P NATL ACAD SCI USA, V95, P11601, DOI 10.1073/pnas.95.20.11601; Wright S, 1996, J MOL BIOL, V263, P1, DOI 10.1006/jmbi.1996.0551; Xiao H, 1997, MOL CELL BIOL, V17, P6898, DOI 10.1128/MCB.17.12.6898; YAMAIZUMI M, 1994, ONCOGENE, V9, P2775; Yamamoto T, 1997, J BIOL CHEM, V272, P30595, DOI 10.1074/jbc.272.49.30595; Yang XZ, 1997, P NATL ACAD SCI USA, V94, P12331, DOI 10.1073/pnas.94.23.12331; YANKULOV K, 1995, J BIOL CHEM, V270, P23922, DOI 10.1074/jbc.270.41.23922; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	88	83	84	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16097	16106		10.1074/jbc.274.23.16097	http://dx.doi.org/10.1074/jbc.274.23.16097			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347161	hybrid			2022-12-25	WOS:000080668600021
J	Fry, AM; Arnaud, L; Nigg, EA				Fry, AM; Arnaud, L; Nigg, EA			Activity of the human centrosomal kinase, Nek2, depends on an unusual leucine zipper dimerization motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE/THREONINE PROTEIN-KINASE; CELL-CYCLE REGULATION; NIMA-RELATED KINASES; ASPERGILLUS-NIDULANS; COILED-COIL; MITOTIC REGULATOR; GAMMA-TUBULIN; EXPRESSION PATTERN; VERTEBRATE CELLS; DNA	Nek2 is a human cell cycle-regulated kinase that is structurally related to the mitotic regulator, NIMA, of Aspergillus nidulans. Localization studies have shown that Nek2 is a core component of the centrosome, the microtubule organizing center of the cell, and functional approaches suggest a possible role for Nek2 in centrosome separation at the G(2)/m transition. Here, we have investigated the importance of an unusual leucine zipper coiled-coil motif present in the C-terminal noncatalytic domain of the Nek2 kinase. Glycerol gradient centrifugation indicated that endogenous Nek2 is present in HeLa cells as a salt-resistant 6 S complex, the predicted size of a Nek2 homodimer. Recombinant Nek2 overexpressed in insect cells also formed a 6 S complex, whereas a Nek2 mutant specifically lacking the leucine zipper motif was monomeric. Using yeast two-hybrid interaction analyses and coprecipitation assays, we found that Nek2 can indeed form homodimers both in vivo and in vitro and that this dimerization specifically required the leucine zipper motif. Moreover, deletion of the leucine zipper prevented a trans-autophosphorylation reaction on the C-terminal domain of Nek2 and strongly reduced Nek2 kinase activity on exogenous substrates. Finally, we emphasize that the Nek2 leucine zipper described here differs from classical leucine zippers in that it exhibits a radically different arrangement of hydrophobic and charged amino acids. Thus, this study reveals not only an important mechanism for the regulation of the Nek2 kinase but, furthermore, highlights an unusual organization of a leucine zipper dimerization motif.	Univ Geneva, Dept Mol Biol, CH-1211 Geneva 4, Switzerland	University of Geneva	Fry, AM (corresponding author), Univ Leicester, Dept Biochem, Adrian Bldg,Univ Rd, Leicester LE1 7RH, Leics, England.	amf5@le.ac.uk		nigg, erich/0000-0003-4835-5719				Alber T, 1992, CURR OPIN GENET DEV, V2, P205, DOI 10.1016/S0959-437X(05)80275-8; Arama E, 1998, ONCOGENE, V16, P1813, DOI 10.1038/sj.onc.1201710; CARDOZO T, 1995, PROTEINS, V23, P403, DOI 10.1002/prot.340230314; DOROW DS, 1993, EUR J BIOCHEM, V213, P701, DOI 10.1111/j.1432-1033.1993.tb17810.x; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Fry AM, 1998, J CELL BIOL, V141, P1563, DOI 10.1083/jcb.141.7.1563; FRY AM, 1995, J BIOL CHEM, V270, P12899, DOI 10.1074/jbc.270.21.12899; Fry AM, 1997, METHOD ENZYMOL, V283, P270; Fry AM, 1998, EMBO J, V17, P470, DOI 10.1093/emboj/17.2.470; Gallant P, 1995, J CELL SCI, P21; GAMM DM, 1995, J BIOL CHEM, V270, P27380, DOI 10.1074/jbc.270.45.27380; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; HARPER JW, 1993, CELL, V75, P805; HOLZMAN LB, 1994, J BIOL CHEM, V269, P30808; Kawai T, 1998, MOL CELL BIOL, V18, P1642, DOI 10.1128/MCB.18.3.1642; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; LEVEDAKOU EN, 1994, ONCOGENE, V9, P1977; Lu K P, 1995, Prog Cell Cycle Res, V1, P187; Lu KP, 1996, NATURE, V380, P544; LU KP, 1995, CELL, V81, P413, DOI 10.1016/0092-8674(95)90394-1; LU KP, 1994, EMBO J, V13, P2103, DOI 10.1002/j.1460-2075.1994.tb06486.x; LU KP, 1993, J BIOL CHEM, V268, P8769; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lupas A, 1996, METHOD ENZYMOL, V266, P513; MORITZ M, 1995, NATURE, V378, P638, DOI 10.1038/378638a0; MORRIS NR, 1975, GENET RES, V26, P237, DOI 10.1017/S0016672300016049; Moudjou M, 1996, J CELL SCI, V109, P875; MUKAI H, 1994, BIOCHEM BIOPH RES CO, V199, P897, DOI 10.1006/bbrc.1994.1313; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; Osmani SA, 1996, BIOCHEM J, V317, P633, DOI 10.1042/bj3170633; Paoletti A, 1996, J CELL SCI, V109, P3089; Rhee K, 1997, DEVELOPMENT, V124, P2167; Roe JL, 1997, J BIOL CHEM, V272, P5838, DOI 10.1074/jbc.272.9.5838; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; SCHMIDTZACHMANN MS, 1993, J CELL SCI, V105, P799; SCHULTZ SJ, 1993, CELL GROWTH DIFFER, V4, P821; SCHULTZ SJ, 1994, CELL GROWTH DIFFER, V5, P625; Tanaka K, 1997, EXP CELL RES, V237, P264, DOI 10.1006/excr.1997.3788; WERNET W, 1989, FEBS LETT, V251, P191, DOI 10.1016/0014-5793(89)81453-X; Yavuzer U, 1998, GENE DEV, V12, P2188, DOI 10.1101/gad.12.14.2188; ZHENG YX, 1995, NATURE, V378, P578, DOI 10.1038/378578a0	47	73	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16304	16310		10.1074/jbc.274.23.16304	http://dx.doi.org/10.1074/jbc.274.23.16304			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347187	hybrid, Green Published			2022-12-25	WOS:000080668600047
J	Mamiya, N; Worman, HJ				Mamiya, N; Worman, HJ			Hepatitis C virus core protein binds to a DEAD box RNA helicase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE ERYTHROID-CELLS; NON-B-HEPATITIS; INTERNAL INITIATION; NON-A; TRANSLATION; SEQUENCE; GENOME; POLIOVIRUS; YEAST; IDENTIFICATION	Approximately 4 million Americans are infected with the hepatitis C virus (HCV), making it a major cause of chronic liver disease. Because of the lack of an efficient cell culture system, little is known about the interaction between HCV and host cells. We performed a yeast two-hybrid screen of a human liver cell cDNA library with HCV core protein as bait and isolated the DEAD box protein DBX. DBX has significant amino acid sequence identity to mouse PL10, an ATP-dependent RNA helicase. The binding of DBX to HCV core protein occurred in an in vitro binding assay in the presence of 1 M NaCl or detergent. When expressed in mammalian cells, HCV core protein and DBX were co-localized at the endoplasmic reticulum, In a mutant strain of Saccharomyces cerevisiae, DBX complemented the function of Ded1p, an essential DEAD box RNA helicase. HCV core protein inhibited the growth of DBX-complemented mutant yeast but not Ded1p-expressing yeast. HCV core protein also inhibited the in vitro translation of capped but not uncapped RNA. These findings demonstrate an interaction between HCV core protein and a host cell protein involved in RNA translation and suggest a mechanism by which HCV may inhibit host cell mRNA translation.	Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Anat & Cell Biol, New York, NY 10032 USA	Columbia University; Columbia University	Worman, HJ (corresponding author), Columbia Univ Coll Phys & Surg, Dept Med, 630 W 168th St,10th Floor,Rm 508, New York, NY 10032 USA.				NCI NIH HHS [5 P30 CA13696] Funding Source: Medline; NCRR NIH HHS [1S10 RR10506] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013696] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR010506] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALTER MJ, 1995, SEMIN LIVER DIS, V15, P5, DOI 10.1055/s-2007-1007259; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; CHIEN C, 1991, P NATL ACAD SCI USA, V88, P9579; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451; Chuang RY, 1997, SCIENCE, V275, P1468, DOI 10.1126/science.275.5305.1468; Chung J, 1995, KOREAN J BIOCHEM, V27, P193; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ETCHISON D, 1982, J BIOL CHEM, V257, P4806; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FRANKE EK, 1994, NATURE, V372, P359, DOI 10.1038/372359a0; Fukushi S, 1997, J VIROL, V71, P1662, DOI 10.1128/JVI.71.2.1662-1666.1997; GEE SL, 1994, GENE, V140, P171, DOI 10.1016/0378-1119(94)90541-X; Hsieh TY, 1998, J BIOL CHEM, V273, P17651, DOI 10.1074/jbc.273.28.17651; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KATO N, 1990, P NATL ACAD SCI USA, V87, P9524, DOI 10.1073/pnas.87.24.9524; KIM DW, 1994, JPN J MED SCI BIOL, V47, P211, DOI 10.7883/yoken1952.47.211; Kim JL, 1998, STRUCTURE, V6, P89, DOI 10.1016/S0969-2126(98)00010-0; KNIPE DM, 1996, FIELDS VIROLOGY, P273; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; Lahn BT, 1997, SCIENCE, V278, P675, DOI 10.1126/science.278.5338.675; LEROY P, 1989, CELL, V57, P549, DOI 10.1016/0092-8674(89)90125-6; Liang TJ, 1998, NEW ENGL J MED, V339, P1549, DOI 10.1056/NEJM199811193392112; LUBAN J, 1993, CELL, V73, P1067, DOI 10.1016/0092-8674(93)90637-6; MAMIYA N, 1997, CURR OPIN INFECT DIS, V10, P3990; MANSELL CJ, 1995, SEMIN LIVER DIS, V15, P15, DOI 10.1055/s-2007-1007260; Matsumoto M, 1996, VIROLOGY, V218, P43, DOI 10.1006/viro.1996.0164; Matsumoto M, 1997, J VIROL, V71, P1301, DOI 10.1128/JVI.71.2.1301-1309.1997; Moradpour D, 1998, HEPATOLOGY, V28, P192, DOI 10.1002/hep.510280125; OKAMOTO H, 1991, J GEN VIROL, V72, P2697, DOI 10.1099/0022-1317-72-11-2697; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; Ray RB, 1997, J BIOL CHEM, V272, P10983; REYNOLDS JE, 1995, EMBO J, V14, P6010, DOI 10.1002/j.1460-2075.1995.tb00289.x; ROSE JK, 1978, P NATL ACAD SCI USA, V75, P2732, DOI 10.1073/pnas.75.6.2732; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; SELBY MJ, 1993, J GEN VIROL, V74, P1103, DOI 10.1099/0022-1317-74-6-1103; SOULLAM B, 1995, J CELL BIOL, V130, P15, DOI 10.1083/jcb.130.1.15; TAKAMIZAWA A, 1991, J VIROL, V65, P1105, DOI 10.1128/JVI.65.3.1105-1113.1991; Yao NH, 1997, NAT STRUCT BIOL, V4, P463, DOI 10.1038/nsb0697-463; Ye Q, 1996, J BIOL CHEM, V271, P14653, DOI 10.1074/jbc.271.25.14653; Zhu NL, 1998, J VIROL, V72, P3691, DOI 10.1128/JVI.72.5.3691-3697.1998; 1997, HEPATOLOGY, V26, pS1	42	145	157	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15751	15756		10.1074/jbc.274.22.15751	http://dx.doi.org/10.1074/jbc.274.22.15751			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336476	hybrid			2022-12-25	WOS:000080560100065
J	Oh, H; Takagi, H; Suzuma, K; Otani, A; Matsumura, M; Honda, Y				Oh, H; Takagi, H; Suzuma, K; Otani, A; Matsumura, M; Honda, Y			Hypoxia and vascular endothelial growth factor selectively up-regulate angiopoietin-2 in bovine microvascular endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; BLOOD-VESSEL FORMATION; FACTOR MESSENGER-RNA; IN-VIVO; TIE2 RECEPTOR; RETINAL NEOVASCULARIZATION; GENE-TRANSCRIPTION; FACTOR EXPRESSION; FACTOR VEGF; ANGIOGENESIS	Recent studies have shown that the angiopoietin-Tie2 system is a predominant regulator of vascular integrity. In this study, we investigated the effect of two known angiogenic stimuli, hypoxia and vascular endothelial growth factor (VEGF), on these molecules. VEGF induced both a time- and concentration-dependent increase in angiopoietin-2 (Ang2) mRNA expression in bovine microvascular endothelial cells. This up-regulation was derived primarily from an increased transcription rate as evidenced by nuclear run-on assay and mRNA decay study. The increased Ang2 expression upon VEGF treatment was almost totally abolished by inhibition of tyrosine kinase or mitogen-activated protein kinase and partially by suppression of protein kinase C. Hypoxia also directly increased Ang2 mRNA expression. In contrast, Ang1 and Tie2 responded to neither of these stimuli. The enhanced Ang2 expression following VEGF stimulation and hypoxia was accompanied by de novo protein synthesis as detected by immunoprecipitation. In a mouse model of ischemia-induced retinal neovascularization, Ang2 mRNA was up-regulated in the ischemic inner retinal layer, and remarkable expression was observed in neovascular vessels. These data suggest that both hypoxia- and VEGF-induced neovascularization might be facilitated by selective induction of Ang2, which deteriorates the integrity of preexisting vasculature.	Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University	Takagi, H (corresponding author), Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, 54 Shogoinkawara Cho, Kyoto 6068507, Japan.							Aiello LP, 1997, DIABETES, V46, P1473, DOI 10.2337/diabetes.46.9.1473; AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457; AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; ANTONELLIORLIDGE A, 1989, P NATL ACAD SCI USA, V86, P4544, DOI 10.1073/pnas.86.12.4544; Asahara T, 1998, CIRC RES, V83, P233, DOI 10.1161/01.RES.83.3.233; ASAHARA T, 1997, SCIENCE, V275, P965; ASHTON N, 1957, AM J OPHTHALMOL, V44, P7, DOI 10.1016/0002-9394(57)90426-9; BANAI S, 1994, CARDIOVASC RES, V28, P1176, DOI 10.1093/cvr/28.8.1176; Barleon B, 1997, CANCER RES, V57, P5421; BERU N, 1986, MOL CELL BIOL, V6, P2571, DOI 10.1128/MCB.6.7.2571; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; Couffinhal T, 1997, AM J PATHOL, V150, P1673; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; DUMONT DJ, 1992, ONCOGENE, V7, P1471; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; Enholm B, 1997, ONCOGENE, V14, P2475, DOI 10.1038/sj.onc.1201090; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; GOLDBERG MA, 1991, BLOOD, V77, P271; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KING GL, 1985, J CLIN INVEST, V75, P1028, DOI 10.1172/JCI111764; Koblizek TI, 1998, CURR BIOL, V8, P529, DOI 10.1016/S0960-9822(98)70205-2; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; Kukk E, 1997, BRIT J HAEMATOL, V98, P195, DOI 10.1046/j.1365-2141.1997.1732989.x; KUWABARA K, 1995, P NATL ACAD SCI USA, V92, P4606, DOI 10.1073/pnas.92.10.4606; Levy AP, 1996, J BIOL CHEM, V271, P25492, DOI 10.1074/jbc.271.41.25492; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Lin PN, 1997, J CLIN INVEST, V100, P2072, DOI 10.1172/JCI119740; Lin PN, 1998, P NATL ACAD SCI USA, V95, P8829, DOI 10.1073/pnas.95.15.8829; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Michaelson I.C., 1948, T OPHTHALMOL SOC, V68, P137; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; Namiki A, 1995, J BIOL CHEM, V270, P31189, DOI 10.1074/jbc.270.52.31189; NOMURA M, 1995, J BIOL CHEM, V270, P28316; ORLIDGE A, 1987, J CELL BIOL, V105, P1455, DOI 10.1083/jcb.105.3.1455; Otani A, 1998, CIRC RES, V82, P619, DOI 10.1161/01.RES.82.5.619; PAJUSOLA K, 1992, CANCER RES, V52, P5738; Parenti A, 1998, J BIOL CHEM, V273, P4220, DOI 10.1074/jbc.273.7.4220; PARTANEN J, 1992, MOL CELL BIOL, V12, P1698, DOI 10.1128/MCB.12.4.1698; PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; PURI MC, 1995, EMBO J, V14, P5884, DOI 10.1002/j.1460-2075.1995.tb00276.x; Risau W, 1995, ANNU REV CELL DEV BI, V11, P73, DOI 10.1146/annurev.cb.11.110195.000445; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Ristimaki A, 1998, J BIOL CHEM, V273, P8413, DOI 10.1074/jbc.273.14.8413; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; SABRI MN, 1991, AM HEART J, V121, P876, DOI 10.1016/0002-8703(91)90202-S; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; Seymour LW, 1996, LAB INVEST, V75, P427; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHIBUYA M, 1990, ONCOGENE, V5, P519; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SHWEIKI D, 1993, J CLIN INVEST, V91, P2235, DOI 10.1172/JCI116450; SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101; STEIN I, 1995, MOL CELL BIOL, V15, P5363; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Takagi H, 1996, DIABETES, V45, P1016, DOI 10.2337/diabetes.45.8.1016; TAKESHITA S, 1994, J CLIN INVEST, V93, P662, DOI 10.1172/JCI117018; TERMAN BI, 1991, ONCOGENE, V6, P1677; Vikkula M, 1996, CELL, V87, P1181, DOI 10.1016/S0092-8674(00)81814-0; Waltenberger J, 1996, CIRCULATION, V94, P1647, DOI 10.1161/01.CIR.94.7.1647; Witzenbichler B, 1998, J BIOL CHEM, V273, P18514, DOI 10.1074/jbc.273.29.18514; Wong AL, 1997, CIRC RES, V81, P567, DOI 10.1161/01.RES.81.4.567; Xia P, 1996, J CLIN INVEST, V98, P2018, DOI 10.1172/JCI119006	68	391	409	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15732	15739		10.1074/jbc.274.22.15732	http://dx.doi.org/10.1074/jbc.274.22.15732			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336473	hybrid			2022-12-25	WOS:000080560100062
J	Spencer, JA; Baron, MH; Olson, EN				Spencer, JA; Baron, MH; Olson, EN			Cooperative transcriptional activation by serum response factor and the high mobility group protein SSRP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; FACTOR GENE; TINMAN HOMOLOG; MUSCLE-CELLS; BOX PROTEIN; IN-VITRO; EXPRESSION; ALPHA; PROMOTER; ELEMENT	Serum response factor (SRF) is a MADS box transcription factor that controls a wide range of genes involved in cell proliferation and differentiation. The MADS box mediates homodimerization and binding of SRF to the consensus sequence CC(APT)(6)GG, known as a CArG box, which is found in the control regions of numerous serum-inducible and muscle-specific genes, Using a modified yeast one-hybrid screen to identify potential SRF cofactors, we found that SRF interacts with the high mobility group factor SSRP1 (structure-specific recognition protein). This interaction, which occurs in yeast and mammalian cells, is mediated through the MADS box of SRF and a basic region of SSRP1 encompassing amino acids 489-542, immediately adjacent to the high mobility group domain. SSRP1 does not bind the CArG box, but interaction of SSRP1 with SRF dramatically increases the DNA binding activity of SRF, resulting in synergistic transcriptional activation of native and artificial SRF-dependent promoters. These results reveal an important role for SSRP1 as a coregulator of SRF-dependent transcription in mammalian cells.	Univ Texas, SW Med Ctr, Dept Mol Biol & Oncol, Dallas, TX 75235 USA; SUNY, Mt Sinai Sch Med, New York, NY 10228 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Icahn School of Medicine at Mount Sinai; State University of New York (SUNY) System; SUNY Community College; SUNY Maritime College; SUNY Optometry	Olson, EN (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Biol & Oncol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042413] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARGENTIN S, 1994, MOL CELL BIOL, V14, P777, DOI 10.1128/MCB.14.1.777; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BAXEVANIS AD, 1995, NUCLEIC ACIDS RES, V23, P1604, DOI 10.1093/nar/23.9.1604; Belaguli NS, 1997, J BIOL CHEM, V272, P18222, DOI 10.1074/jbc.272.29.18222; Boonyaratanakornkit V, 1998, MOL CELL BIOL, V18, P4471, DOI 10.1128/MCB.18.8.4471; BOXER LM, 1989, MOL CELL BIOL, V9, P515, DOI 10.1128/MCB.9.2.515; Brewster NK, 1998, J BIOL CHEM, V273, P21972, DOI 10.1074/jbc.273.34.21972; BROWN SJ, 1993, SCIENCE, V261, P603, DOI 10.1126/science.8342024; BRUHN SL, 1992, P NATL ACAD SCI USA, V89, P2307, DOI 10.1073/pnas.89.6.2307; Chen CY, 1996, DEV GENET, V19, P119, DOI 10.1002/(SICI)1520-6408(1996)19:2<119::AID-DVG3>3.0.CO;2-C; Chen CY, 1996, MOL CELL BIOL, V16, P6372; Chin MT, 1998, J BIOL CHEM, V273, P9755, DOI 10.1074/jbc.273.16.9755; Croissant JD, 1996, DEV BIOL, V177, P250, DOI 10.1006/dbio.1996.0160; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; Dyer MA, 1998, MOL CELL BIOL, V18, P2617, DOI 10.1128/MCB.18.5.2617; GAUTHIERROUVIERE C, 1991, CELL REGUL, V2, P575, DOI 10.1091/mbc.2.7.575; Groisman R, 1996, J BIOL CHEM, V271, P5258; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; Hautmann MB, 1997, CIRC RES, V81, P600, DOI 10.1161/01.RES.81.4.600; Hertel L, 1997, BIOCHIMIE, V79, P717, DOI 10.1016/S0300-9084(97)86929-5; Jayaraman L, 1998, GENE DEV, V12, P462, DOI 10.1101/gad.12.4.462; JOHANSEN FE, 1993, MOL CELL BIOL, V13, P4640, DOI 10.1128/MCB.13.8.4640; JOLIET V, 1995, NATURE, V373, P632, DOI 10.1038/373632a0; Li L, 1997, DEV BIOL, V187, P311, DOI 10.1006/dbio.1997.8621; MISRA RP, 1991, MOL CELL BIOL, V11, P4545, DOI 10.1128/MCB.11.9.4545; Molkentin JD, 1996, J MOL CELL CARDIOL, V28, P1211, DOI 10.1006/jmcc.1996.0112; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; NATESAN S, 1995, MOL CELL BIOL, V15, P5975; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; OWENS GK, 1995, PHYSIOL REV, V75, P487; Paull TT, 1996, GENE DEV, V10, P2769, DOI 10.1101/gad.10.21.2769; PRYWES R, 1992, NUCLEIC ACIDS RES, V20, P513, DOI 10.1093/nar/20.3.513; SANCEAU J, 1995, J BIOL CHEM, V270, P27920, DOI 10.1074/jbc.270.46.27920; Spencer JA, 1996, J BIOL CHEM, V271, P16535, DOI 10.1074/jbc.271.28.16535; TREISMAN R, 1987, EMBO J, V6, P2711, DOI 10.1002/j.1460-2075.1987.tb02564.x; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Treisman R, 1992, CURR OPIN GENET DEV, V2, P221, DOI 10.1016/S0959-437X(05)80277-1; VANDROMME M, 1992, J CELL BIOL, V118, P1489, DOI 10.1083/jcb.118.6.1489; WATT F, 1988, NUCLEIC ACIDS RES, V16, P1471, DOI 10.1093/nar/16.4.1471; Xiang YY, 1996, CANCER LETT, V106, P271, DOI 10.1016/0304-3835(96)04332-7; Zappavigna V, 1996, EMBO J, V15, P4981, DOI 10.1002/j.1460-2075.1996.tb00878.x; Zhu C, 1997, MOL CELL BIOL, V17, P4957, DOI 10.1128/MCB.17.9.4957; ZWILLING S, 1995, EMBO J, V14, P1198, DOI 10.1002/j.1460-2075.1995.tb07103.x	44	43	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15686	15693		10.1074/jbc.274.22.15686	http://dx.doi.org/10.1074/jbc.274.22.15686			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336466	hybrid			2022-12-25	WOS:000080560100055
J	Tokumitsu, H; Takahashi, N; Eto, K; Yano, S; Soderling, TR; Muramatsu, M				Tokumitsu, H; Takahashi, N; Eto, K; Yano, S; Soderling, TR; Muramatsu, M			Substrate recognition by Ca2+/calmodulin-dependent protein kinase kinase - Role of the Arg-Pro-rich insert domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SUBUNIT; MOLECULAR-CLONING; IV KINASE; PHOSPHORYLASE-KINASE; RAT-BRAIN; ACTIVATION; CALMODULIN; CALCIUM; CASCADE; IDENTIFICATION	Mammalian Ca2+/CaM-dependent protein kinase kinase (CaM-KK) has been identified and cloned as an activator for two kinases, CaM kinase I (CaM-KI) and CaM kinase IV (CaM-KIV), and a recent report (Yano, S., Togumitsu, Il., and Soderling, T. R. (1998) Nature 396, 584-587) demonstrates that CaM-KH can also activate and phosphorylate protein kinase B (PKB), In this study, we identify a CaM-KK from Caenorhabditis elegans, and comparison of its sequence with the mammalian CaM-KK alpha and beta shows a unique Arg-Pro (RP)-rich insert in their catalytic domains relative to other protein kinases, Deletion of the RP-domain resulted in complete loss of CaM-KIV activation activity and physical interaction of CaM-KK with glutathione S-transferase-CaM-KIV (T196A). However, CaM-KK autophosphorylation and phosphorylation of a synthetic peptide substrate were normal in the RP-domain mutant. Site-directed mutagenesis of three conserved Arg in the RP-domain of CaM-KK confirmed that these positive charges are important for CaM-KIV activation. The RP-domain deletion mutant also failed to fully activate and phosphorylate CaM-KI, but this mutant was indistinguishable from wild-type CaM-KK for the phosphorylation and activation of PKB, These results indicate that the RP-domain in CaM-KK is critical for recognition of downstream CaM-kinases but not for its catalytic activity (i.e. autophosphorylation) and PKB activation.	Helix Res Inst Inc, Kisarazu, Chiba 2920812, Japan; Oregon Hlth Sci Univ, Vollum Inst, Portland, OR 97201 USA; Tokyo Med & Dent Univ, Med Res Inst, Dept Biol Cybergenet, Bunkyo Ku, Tokyo 1138510, Japan	Oregon Health & Science University; Tokyo Medical & Dental University (TMDU)	Tokumitsu, H (corresponding author), Helix Res Inst Inc, 1532-3 Yana, Kisarazu, Chiba 2920812, Japan.		Tokumitsu, Hiroshi/M-3978-2015	Tokumitsu, Hiroshi/0000-0002-2193-6794				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; ALLETA JM, 1996, J BIOL CHEM, V271, P20930; Anderson KA, 1998, J BIOL CHEM, V273, P31880, DOI 10.1074/jbc.273.48.31880; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; BUECHLER JA, 1990, BIOCHEMISTRY-US, V29, P1937, DOI 10.1021/bi00459a039; CHO FS, 1994, BBA-MOL CELL RES, V1224, P156, DOI 10.1016/0167-4889(94)90123-6; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; Edelman AM, 1996, J BIOL CHEM, V271, P10806, DOI 10.1074/jbc.271.18.10806; ENSLEN H, 1995, BIOCHEM BIOPH RES CO, V207, P1038, DOI 10.1006/bbrc.1995.1289; Enslen H, 1996, P NATL ACAD SCI USA, V93, P10803, DOI 10.1073/pnas.93.20.10803; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARIBABU B, 1995, EMBO J, V14, P3679, DOI 10.1002/j.1460-2075.1995.tb00037.x; Kitani T, 1997, J BIOCHEM-TOKYO, V122, P243; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; LEE JSC, 1994, J BIOL CHEM, V269, P2158; LIN CR, 1987, P NATL ACAD SCI USA, V84, P5962, DOI 10.1073/pnas.84.16.5962; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; NAIRN AC, 1985, ANNU REV BIOCHEM, V54, P931, DOI 10.1146/annurev.bi.54.070185.004435; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; OKUNO S, 1993, J BIOCHEM-TOKYO, V114, P167, DOI 10.1093/oxfordjournals.jbchem.a124149; OKUNO S, 1994, J BIOCHEM, V116, P923, DOI 10.1093/oxfordjournals.jbchem.a124617; Okuno S, 1997, J BIOCHEM, V122, P337; Park IK, 1995, J BIOL CHEM, V270, P30464, DOI 10.1074/jbc.270.51.30464; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Robinson MJ, 1996, J BIOL CHEM, V271, P29734, DOI 10.1074/jbc.271.47.29734; ROSKOSKI R, 1985, METHOD ENZYMOL, V99, P3; SELBERT MA, 1995, J BIOL CHEM, V270, P17616, DOI 10.1074/jbc.270.29.17616; SHOJI S, 1979, J BIOL CHEM, V254, P6211; Soderling TR, 1996, BBA-PROTEIN STRUCT M, V1297, P131, DOI 10.1016/S0167-4838(96)00105-7; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Tokumitsu H, 1996, J BIOL CHEM, V271, P5617, DOI 10.1074/jbc.271.10.5617; Tokumitsu H, 1997, BIOCHEMISTRY-US, V36, P12823, DOI 10.1021/bi971348i; TOKUMITSU H, 1994, J BIOL CHEM, V269, P28640; TOKUMITSU H, 1995, J BIOL CHEM, V270, P19320, DOI 10.1074/jbc.270.33.19320; TOMODA T, 1993, BIOCHIM BIOPHYS ACTA, V1175, P333, DOI 10.1016/0167-4889(93)90226-F; UHLER MD, 1986, P NATL ACAD SCI USA, V83, P1300, DOI 10.1073/pnas.83.5.1300; WALSH DA, 1971, J BIOL CHEM, V246, P1968; WEEKES J, 1994, EUR J BIOCHEM, V219, P751, DOI 10.1111/j.1432-1033.1994.tb18554.x; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147	46	49	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 28	1999	274	22					15803	15810		10.1074/jbc.274.22.15803	http://dx.doi.org/10.1074/jbc.274.22.15803			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	200VE	10336483	hybrid			2022-12-25	WOS:000080560100072
J	Kim, KS; Kim, KH; Storey, MK; Voelker, DR; Carman, GM				Kim, KS; Kim, KH; Storey, MK; Voelker, DR; Carman, GM			Isolation and characterization of the Saccharomyces cerevisiae EKI1 gene encoding ethanolamine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLETHANOLAMINE METHYLATION PATHWAY; MEMBRANE PHOSPHOLIPID-COMPOSITION; CDP-CHOLINE PATHWAY; TRANSFER PROTEIN; PHOSPHATIDYLSERINE DECARBOXYLASE; INOSITOL SYNTHESIS; ESCHERICHIA-COLI; NULL ALLELE; CKI GENE; YEAST	Ethanolamine kinase (ATP:ethanolamine O-phosphotransferase, EC 2.7.1.82) catalyzes the committed step of phosphatidylethanolamine synthesis via the CDP-ethanolamine pathway. The gene encoding ethanolamine kinase (EKI1) was identified from the Saccharomyces Genome Data Base (locus YDR147W) based on its homology to the Saccharomyces cerevisiae CKI1-encoded choline kinase, which also exhibits ethanolamine kinase activity. The EKI1 gene was isolated and used to construct eki1 Delta and eki1 Delta cki1 Delta mutants. A multicopy plasmid containing the EKI1 gene directed the overexpression of ethanolamine kinase activity in wild-type, eki1 Delta mutant, cki1 Delta mutant, and eki1 Delta cki1 Delta double mutant cells. The heterologous expression of the S. cerevisiae EKI1 gene in Sf-9 insect cells resulted in a 165,500-fold overexpression of ethanolamine kinase activity relative to control insect cells, The EKI1 gene product also exhibited choline kinase activity. Biochemical analyses of the enzyme expressed in insect cells, in eki1 Delta mutants, and in cki1 Delta mutants indicated that ethanolamine was the preferred substrate. The eki1 Delta mutant did not exhibit a growth phenotype, Biochemical analyses of eki1 Delta, cki1 Delta, and eki1 Delta cki1 Delta mutants showed that the EKI1 and CKI1 gene products encoded all of the ethanolamine kinase and choline kinase activities in S, cerevisiae, lit vivo labeling experiments showed that the EKI1 and CKI1 gene products had overlapping functions with respect to phospholipid synthesis. Whereas the EKI1 gene product was primarily responsible for phosphatidylethanolamine synthesis via the CDP-ethanolamine pathway, the CKI1 gene product was primarily responsible for phosphatidylcholine synthesis via the CDP-choline pathway. Unlike cki1 Delta mutants, eki1 Delta mutants did not suppress the essential function of Sec14p.	Rutgers State Univ, New Jersey Agr Expt Stn, Cook Coll, Dept Food Sci, New Brunswick, NJ 08901 USA; Natl Jewish Ctr Immunol & Resp Med, Lord & Taylor Lab Lung Biochem, Denver, CO 80206 USA; Natl Jewish Ctr Immunol & Resp Med, Anna Perahia Adatto Clin Res Ctr, Denver, CO 80206 USA	Rutgers State University New Brunswick; National Jewish Health; National Jewish Health	Carman, GM (corresponding author), Rutgers State Univ, New Jersey Agr Expt Stn, Cook Coll, Dept Food Sci, 65 Dudley Rd, New Brunswick, NJ 08901 USA.	carman@aesop.rutgers.edu			NIGMS NIH HHS [GM-32453, GM-50679] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM032453, R01GM032453, R01GM050679] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN JB, 1994, YEAST, V10, P1267, DOI 10.1002/yea.320101003; ATKINSON K, 1980, J BIOL CHEM, V255, P6653; ATKINSON KD, 1980, J BACTERIOL, V141, P558, DOI 10.1128/JB.141.2.558-564.1980; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNER S, 1987, NATURE, V329, P21, DOI 10.1038/329021a0; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; Carman GM, 1996, J BIOL CHEM, V271, P13293, DOI 10.1074/jbc.271.23.13293; CLEVES AE, 1991, CELL, V64, P789, DOI 10.1016/0092-8674(91)90508-V; CULBERTSON MR, 1975, GENETICS, V80, P23; Elabbadi N, 1997, BIOCHEM J, V324, P435, DOI 10.1042/bj3240435; ESKO JD, 1980, J BIOL CHEM, V255, P4474; Fang M, 1998, BBA-MOL CELL RES, V1404, P85, DOI 10.1016/S0167-4889(98)00049-4; Greenberg ML, 1996, MICROBIOL REV, V60, P1; GREENBERG ML, 1982, GENETICS, V100, P19; Griac P, 1996, J BIOL CHEM, V271, P25692, DOI 10.1074/jbc.271.41.25692; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HOMANN MJ, 1987, J BACTERIOL, V169, P533, DOI 10.1128/jb.169.2.533-539.1987; HOSAKA K, 1989, J BIOL CHEM, V264, P2053; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; Ishidate K, 1997, BBA-LIPID LIPID MET, V1348, P70, DOI 10.1016/S0005-2760(97)00118-5; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jacq C, 1997, NATURE, V387, P75, DOI 10.1038/387s075; Kent C, 1999, TRENDS BIOCHEM SCI, V24, P146, DOI 10.1016/S0968-0004(99)01365-1; Kim KH, 1998, J BIOL CHEM, V273, P6844, DOI 10.1074/jbc.273.12.6844; KLIG LS, 1985, J BACTERIOL, V162, P1135, DOI 10.1128/JB.162.3.1135-1141.1985; KODAKI T, 1987, J BIOL CHEM, V262, P15428; KODAKI T, 1989, EUR J BIOCHEM, V185, P243, DOI 10.1111/j.1432-1033.1989.tb15109.x; MCDONOUGH VM, 1995, J BIOL CHEM, V270, P18774, DOI 10.1074/jbc.270.32.18774; MCGEE TP, 1994, J BACTERIOL, V176, P6861, DOI 10.1128/JB.176.22.6861-6868.1994; MCGEE TP, 1994, J CELL BIOL, V124, P273, DOI 10.1083/jcb.124.3.273; MCGRAW P, 1989, GENETICS, V122, P317; McMaster CR, 1997, BBA-LIPID LIPID MET, V1348, P117, DOI 10.1016/S0005-2760(97)00098-2; MinSeok R, 1996, J BIOCHEM, V120, P1040; MORLOCK KR, 1988, J BACTERIOL, V170, P3561, DOI 10.1128/jb.170.8.3561-3566.1988; NIKAWA J, 1990, J BIOL CHEM, V265, P15996; NIKAWA JI, 1986, J BACTERIOL, V166, P328, DOI 10.1128/jb.166.1.328-330.1986; O'Reilly D., 1992, BACULOVIRUS EXPRESSI, P109; Ostrander DB, 1998, J BIOL CHEM, V273, P18992, DOI 10.1074/jbc.273.30.18992; PALTAUF F, 1992, MOL CELLULAR BIOL YE, P415; PattonVogt JL, 1997, J BIOL CHEM, V272, P20873, DOI 10.1074/jbc.272.33.20873; PAVLIDIS P, 1994, CELL, V79, P23, DOI 10.1016/0092-8674(94)90397-2; PERRELLA FW, 1988, ANAL BIOCHEM, V174, P437, DOI 10.1016/0003-2697(88)90042-5; PORTER TJ, 1992, METHOD ENZYMOL, V209, P134; REPETTO B, 1990, MOL CELL BIOL, V10, P4221, DOI 10.1128/MCB.10.8.4221; ROSENBERG M, 1990, MICROBIAL CELL SURFA, P1; ROTHSTEIN R, 1991, METHODS ENZYMOL, V194, P281; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Sha BD, 1998, NATURE, V391, P506, DOI 10.1038/35179; Sreenivas A, 1998, J BIOL CHEM, V273, P16635, DOI 10.1074/jbc.273.27.16635; SUMMERS EF, 1988, GENETICS, V120, P909; TEEGARDEN D, 1990, J BIOL CHEM, V265, P6042; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; Toke DA, 1998, J BIOL CHEM, V273, P3278, DOI 10.1074/jbc.273.6.3278; TROTTER PJ, 1995, J BIOL CHEM, V270, P6071, DOI 10.1074/jbc.270.11.6071; TROTTER PJ, 1995, J BIOL CHEM, V270, P6062, DOI 10.1074/jbc.270.11.6062; TROTTER PJ, 1993, J BIOL CHEM, V268, P21416; YAMASHITA S, 1997, BIOCHIM BIOPHYS ACTA, P63	59	67	70	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					14857	14866		10.1074/jbc.274.21.14857	http://dx.doi.org/10.1074/jbc.274.21.14857			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329685	hybrid			2022-12-25	WOS:000081965200050
J	Pages, P; Benali, N; Saint-Laurent, N; Esteve, JP; Schally, AV; Tkaczuk, J; Vaysse, N; Susini, C; Buscail, L				Pages, P; Benali, N; Saint-Laurent, N; Esteve, JP; Schally, AV; Tkaczuk, J; Vaysse, N; Susini, C; Buscail, L			sst2 somatostatin receptor mediates cell cycle arrest and induction of p27(Kip1) - Evidence for the role of SHP-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT KINASE INHIBITOR; TYROSINE PHOSPHATASE SHP-1; MAMMARY EPITHELIAL-CELLS; CDK INHIBITOR; SIGNAL-TRANSDUCTION; NEGATIVE REGULATION; GROWTH ARREST; G(1) ARREST; MOTH-EATEN; TGF-BETA	Activation of the somatostatin receptor sst2 inhibits cell proliferation by a mechanism involving the stimulation of the protein-tyrosine phosphatase SHP-1, The cell cycle regulatory events leading to sst2-mediated growth arrest are not known. Here, we report that treatment of Chinese hamster ovary cells expressing sst2 with the somatostatin analogue, RC-160, led to G(1) cell cycle arrest and inhibition of insulin-induced S-phase entry through induction of the cyclin-dependent kinase inhibitor p27(Kip1). Consequently, a decrease of p27(Kip1)-cdk2 association, an inhibition of insulin-induced cyclin E-cdk2 kinase activity, and an accumulation of hypophosphorylated retinoblastoma gene product (Rb) were observed. However, RC-160 had no effect on the p21(Waf1/Cip1) When sst2 was coexpressed with a catalytically inactive mutant SHP-1 in Chinese hamster ovary cells, mutant SHP-1 induced entry into cell cycle and down-regulation of p27(Kip1) and prevented modulation by insulin and RC-160 of p27(Kip1) expression, p27(Kip1)-cdk2 association, cyclin E-cdk2 kinase activity, and the phosphorylation state of Rb. In mouse pancreatic acini, RC-160 reverted down-regulation of p27(Kip1) induced by a mitogen, and this effect did not occur in acini from viable motheaten (me(v)/me(v)) mice expressing a mutant SHP-1 with markedly deficient enzymes. These findings provide the first evidence that sst2 induces cell cycle arrest through the up-regulation of p27(Kip1) and demonstrate that SHP-1 is required for maintaining high inhibitory levels of p27(Kip1) and is a critical target of the insulin, and somatostatin signaling cascade, leading to the modulation of p27(Kip1).	CHU Rangueil, Inst Louis Bugnard, INSERM, U151, F-31403 Toulouse, France; Tulane Univ, Dept Med, New Orleans, LA 70112 USA; Vet Affairs Med Ctr, Sch Med, New Orleans, LA 70112 USA; CHU Rangueil, Immunol Lab, F-31403 Toulouse, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Tulane University; US Department of Veterans Affairs; Veterans Health Administration (VHA); CHU de Toulouse	Susini, C (corresponding author), CHU Rangueil, Inst Louis Bugnard, INSERM, U151, F-31403 Toulouse, France.		Nathalie, Saint-Laurent/G-5487-2017	Schally, Andrew/0000-0003-1273-6747				Akiyama T, 1997, CANCER RES, V57, P1495; Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; Bouchard C, 1997, J IMMUNOL, V159, P4155; Bousquet C, 1998, J BIOL CHEM, V273, P7099, DOI 10.1074/jbc.273.12.7099; BUSCAIL L, 1995, P NATL ACAD SCI USA, V92, P1580, DOI 10.1073/pnas.92.5.1580; BUSCAIL L, 1994, P NATL ACAD SCI USA, V91, P2315, DOI 10.1073/pnas.91.6.2315; CAI RZ, 1986, P NATL ACAD SCI USA, V83, P1896, DOI 10.1073/pnas.83.6.1896; CHEUNG NW, 1995, ENDOCRINOLOGY, V136, P4174, DOI 10.1210/en.136.10.4174; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; HARPER JW, 1993, CELL, V75, P805; Harvat BL, 1997, ONCOGENE, V14, P2111, DOI 10.1038/sj.onc.1201055; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Johnson D, 1998, ONCOGENE, V16, P2017, DOI 10.1038/sj.onc.1201727; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KNUHTSEN S, 1990, J BIOL CHEM, V265, P1129; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; KOZLOWSKI M, 1993, J EXP MED, V178, P2157, DOI 10.1084/jem.178.6.2157; Kwon TK, 1996, CELL GROWTH DIFFER, V7, P1305; Kwon TK, 1996, BIOCHEM BIOPH RES CO, V220, P703, DOI 10.1006/bbrc.1996.0468; LAMBERTS SWJ, 1991, ENDOCR REV, V12, P450, DOI 10.1210/edrv-12-4-450; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LEWIN MJM, 1992, ANNU REV PHYSIOL, V54, P455, DOI 10.1146/annurev.physiol.54.1.455; LIEBOW C, 1989, P NATL ACAD SCI USA, V86, P2003, DOI 10.1073/pnas.86.6.2003; LOGSDON CD, 1983, GASTROENTEROLOGY, V85, P339; Lopez F, 1997, J BIOL CHEM, V272, P24448, DOI 10.1074/jbc.272.39.24448; Mandal M, 1998, ONCOGENE, V16, P217, DOI 10.1038/sj.onc.1201529; Mann DJ, 1997, ONCOGENE, V14, P1759, DOI 10.1038/sj.onc.1201134; Matsuo T, 1998, ONCOGENE, V16, P3337, DOI 10.1038/sj.onc.1201830; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PAGLIACCI MC, 1991, ENDOCRINOLOGY, V129, P2555, DOI 10.1210/endo-129-5-2555; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Rivard N, 1996, J BIOL CHEM, V271, P18337, DOI 10.1074/jbc.271.31.18337; Sgambato A, 1998, CANCER RES, V58, P3448; Sharma K, 1996, MOL ENDOCRINOL, V10, P1688, DOI 10.1210/me.10.12.1688; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; SRIKANT CB, 1995, BIOCHEM BIOPH RES CO, V209, P400, DOI 10.1006/bbrc.1995.1517; Sweeney KJ, 1998, ONCOGENE, V16, P2865, DOI 10.1038/sj.onc.1201814; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Weber JD, 1997, J BIOL CHEM, V272, P32966, DOI 10.1074/jbc.272.52.32966; Wu XP, 1996, ONCOGENE, V12, P1397; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	51	110	119	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					15186	15193		10.1074/jbc.274.21.15186	http://dx.doi.org/10.1074/jbc.274.21.15186			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329727	hybrid			2022-12-25	WOS:000081965200092
J	Ward, AC; Smith, L; de Koning, JP; van Aesch, Y; Touw, IP				Ward, AC; Smith, L; de Koning, JP; van Aesch, Y; Touw, IP			Multiple signals mediate proliferation, differentiation, and survival from the granulocyte colony-stimulating factor receptor in myeloid 32D cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-CSF RECEPTOR; TYROSINE-PHOSPHATASE; EXPRESSION CLONING; RAPID ACTIVATION; IN-VIVO; PROTEIN; STAT3; DOMAINS; BINDING; GROWTH	Granulocyte colony-stimulating factor (G-CSF) regulates neutrophil production through activation of its cognate receptor, the G-CSF-R Previous studies with deletion mutants have shown that the membrane-proximal cytoplasmic domain of the receptor is sufficient for mitogenic signaling, whereas the membrane-distal domain is required for differentiation signaling. However, the function of the four cytoplasmic tyrosines of the G-CSF-R in the control of proliferation, differentiation, and survival has remained unclear. Here we investigated the role of these tyrosines by expressing a tyrosine "null" mutant and single tyrosine "add back" mutants in maturation-competent myeloid 32D cells. Clones expressing the null mutant showed only minimal proliferation and differentiation, with survival also reduced at low G-CSF concentrations. Analysis of clones expressing the add-back mutants revealed that multiple tyrosines contribute to proliferation, differentiation, and survival signals from the G-CSF-R. Analysis of signaling pathways downstream of these tyrosines suggested a positive role for STAT3 activation in both differentiation and survival signaling, whereas SHP-2, Grb2 and Shc appear important for proliferation signaling. In addition, we show that a tyrosine-independent "differentiation domain" in the membrane-distal region of the G-CSF-R appears necessary but not sufficient for mediating neutrophilic differentiation in these cells.	Erasmus Univ, Inst Hematol, NL-3000 DR Rotterdam, Netherlands; Dr Daniel Den Hoed Canc Ctr, Dept Hematol, NL-3008 AE Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute	Ward, AC (corresponding author), Erasmus Univ, Inst Hematol, Room H EE 1314,POB 1738, NL-3000 DR Rotterdam, Netherlands.	ward@hema.fgg.eul.nl		Ward, Alister/0000-0001-7945-7975				Avalos BR, 1996, BLOOD, V88, P761, DOI 10.1182/blood.V88.3.761.bloodjournal883761; Barge RMY, 1996, BLOOD, V87, P2148, DOI 10.1182/blood.V87.6.2148.bloodjournal8762148; BASHEY A, 1994, BLOOD, V83, P949, DOI 10.1182/blood.V83.4.949.bloodjournal834949; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; Chakraborty A, 1999, BLOOD, V93, P15, DOI 10.1182/blood.V93.1.15.401a46_15_24; Corey SJ, 1998, J BIOL CHEM, V273, P3230, DOI 10.1074/jbc.273.6.3230; COREY SJ, 1994, P NATL ACAD SCI USA, V91, P4683, DOI 10.1073/pnas.91.11.4683; Csar XF, 1997, BIOCHEM J, V322, P79, DOI 10.1042/bj3220079; de Koning JP, 1998, BLOOD, V91, P1924, DOI 10.1182/blood.V91.6.1924.1924_1924_1933; deKoning JP, 1996, BLOOD, V87, P132; deKoning JP, 1996, BLOOD, V87, P1335, DOI 10.1182/blood.V87.4.1335.bloodjournal8741335; DEMETRI GD, 1991, BLOOD, V78, P2791; DONG F, 1995, NEW ENGL J MED, V333, P487, DOI 10.1056/NEJM199508243330804; DONG F, 1993, MOL CELL BIOL, V13, P7774, DOI 10.1128/MCB.13.12.7774; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; FUKUNAGA R, 1990, P NATL ACAD SCI USA, V87, P8702, DOI 10.1073/pnas.87.22.8702; FUKUNAGA R, 1993, CELL, V74, P1079, DOI 10.1016/0092-8674(93)90729-A; Hunter MG, 1999, BLOOD, V93, P440, DOI 10.1182/blood.V93.2.440.402k23_440_446; Hunter MG, 1998, J IMMUNOL, V160, P4979; Itoh T, 1998, MOL CELL BIOL, V18, P742, DOI 10.1128/MCB.18.2.742; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIESCHKE GJ, 1994, BLOOD, V84, P1737; Liu FL, 1996, IMMUNITY, V5, P491, DOI 10.1016/S1074-7613(00)80504-X; Longmore GD, 1998, BLOOD, V91, P870, DOI 10.1182/blood.V91.3.870.870_870_878; Nicholson SE, 1996, J BIOL CHEM, V271, P26947, DOI 10.1074/jbc.271.43.26947; NICHOLSON SE, 1995, BLOOD, V86, P3698, DOI 10.1182/blood.V86.10.3698.bloodjournal86103698; NICHOLSON SE, 1994, P NATL ACAD SCI USA, V91, P2985, DOI 10.1073/pnas.91.8.2985; NICOLA NA, 1989, ANNU REV BIOCHEM, V58, P45; Novak U, 1996, GROWTH FACTORS, V13, P251, DOI 10.3109/08977199609003226; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Shi ZQ, 1998, J BIOL CHEM, V273, P4904, DOI 10.1074/jbc.273.9.4904; Shimoda K, 1997, BLOOD, V90, P597, DOI 10.1182/blood.V90.2.597.597_597_604; Shimozaki K, 1997, J BIOL CHEM, V272, P25184, DOI 10.1074/jbc.272.40.25184; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; TAUCHI T, 1994, J BIOL CHEM, V269, P25206; Tian SS, 1996, BLOOD, V88, P4435, DOI 10.1182/blood.V88.12.4435.bloodjournal88124435; TIAN SS, 1994, BLOOD, V84, P1760; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; Vogel W, 1996, CELL GROWTH DIFFER, V7, P1589; Ward AC, 1998, BBA-MOL CELL RES, V1448, P70, DOI 10.1016/S0167-4889(98)00120-7; WARD AC, 1995, ARCH VIROL, V140, P2067, DOI 10.1007/BF01322693; Ward AC, 1998, BIOCHEM BIOPH RES CO, V251, P117, DOI 10.1006/bbrc.1998.9441; Ward AC, 1999, BLOOD, V93, P447, DOI 10.1182/blood.V93.2.447; Ward AC, 1999, BLOOD, V93, P113, DOI 10.1182/blood.V93.1.113.401k33_113_124; YOSHIKAWA A, 1995, EMBO J, V14, P5288, DOI 10.1002/j.1460-2075.1995.tb00213.x; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	50	105	105	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	1999	274	21					14956	14962		10.1074/jbc.274.21.14956	http://dx.doi.org/10.1074/jbc.274.21.14956			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	225MK	10329697	hybrid, Green Published			2022-12-25	WOS:000081965200062
J	Drabkin, HA; West, JD; Hotfilder, M; Heng, YM; Erickson, P; Calvo, R; Dalmau, J; Gemmill, RM; Sablitzky, F				Drabkin, HA; West, JD; Hotfilder, M; Heng, YM; Erickson, P; Calvo, R; Dalmau, J; Gemmill, RM; Sablitzky, F			DEF-3(g16/NY-LU-12), an RNA binding protein from the 3p21.3 homozygous deletion region in SCLC	ONCOGENE			English	Article						granulocyte differentiation; zinc finger; POZ domain	CELL LUNG-CANCER; CHROMOSOME 3P21.3; INTERACTION MOTIF; MESSENGER-RNAS; POZ-DOMAIN; GENE; HEL-N1; RECOGNITION; SPECIFICITY; ANTIBODIES	DEF-3(g16/NY-LU-12) encodes a novel RNA binding protein isolated by positional cloning from an SCLC homozygous deletion region in 3p21.3 and, in parallel, as a differentially expressed gene during myelopoiesis from FDCPmix-A4 cells, DEF-3(g16/NY-LU-12) is ubiquitously expressed during mouse embryogenesis and in adult organs while human hematopoietic tissues showed differential expression, The mouse and human proteins are highly conserved containing two RNA recognition motifs (RRMs) and other domains associated with RNA binding and protein-protein interactions. A database search identified related proteins in human, rat, C. elegans and S, pombe including the 3p21.3 co-deleted gene, LUCA15, Recombinant proteins containing the RRMs of DEF-3(g16/NY-LU-12) and LUCA15 specifically bound poly(G) RNA homopolymers in vitro. These RRMs also show similarity to those of the Hu protein family. Since anti-Hu RRM domain antibodies are associated with an anti-tumor effect and paraneoplastic encephalomyelitis, we tested sera from Hu syndrome patients with the RRMs of DEF-3(g16/NY-LU-12) and LUCA15, These were non-reactive. Thus, DEF-3(g16/NY-LU-12) and LUCA15 represent members of a novel family of RNA binding proteins with similar expression patterns and in vitro RNA binding characteristics. They are co-deleted in some lung cancers and immunologically distinct from the Hu proteins.	Univ Colorado, Hlth Sci Ctr, Div Med Oncol, Denver, CO 80262 USA; Univ Hosp Munster, Dept Expt Neurooncol, Munster, Germany; UCL, Windeyer Inst Med Sci, Dept Med, London, England; Hosp Badalona Germans Trias & Pujol, Dept Med, Barcelona, Spain; Mem Sloan Kettering Canc Ctr, Dept Neurol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Mol Neurooncol Lab, New York, NY 10021 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Munster; University of London; University College London; Hospital Germans Trias i Pujol; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Drabkin, HA (corresponding author), Univ Colorado, Hlth Sci Ctr, Div Med Oncol, 4200 E 9th Ave, Denver, CO 80262 USA.		West, James/E-2960-2010; Sablitzky, Fred/A-2276-2011	West, James/0000-0002-6004-0202; Sablitzky, Fred/0000-0001-9718-1546	NCI NIH HHS [CA58187, P30 CA 46934] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA046934, P50CA058187] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMASINO RM, 1986, ANAL BIOCHEM, V152, P304, DOI 10.1016/0003-2697(86)90413-6; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Cairns P, 1997, CANCER RES, V57, P5356; DALMAU J, 1992, MEDICINE, V71, P59, DOI 10.1097/00005792-199203000-00001; DALY MC, 1993, ONCOGENE, V8, P1721; Dong S, 1996, P NATL ACAD SCI USA, V93, P3624, DOI 10.1073/pnas.93.8.3624; GAO FB, 1994, P NATL ACAD SCI USA, V91, P11207, DOI 10.1073/pnas.91.23.11207; Graus F, 1997, J CLIN ONCOL, V15, P2866, DOI 10.1200/JCO.1997.15.8.2866; Grondin B, 1996, J BIOL CHEM, V271, P15458, DOI 10.1074/jbc.271.26.15458; Gure AO, 1998, CANCER RES, V58, P1034; Inoue A, 1996, NUCLEIC ACIDS RES, V24, P2990, DOI 10.1093/nar/24.15.2990; Kaplan J, 1997, NUCLEIC ACIDS RES, V25, P1108, DOI 10.1093/nar/25.6.1108; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KIM YJ, 1993, MOL CELL BIOL, V13, P174, DOI 10.1128/MCB.13.1.174; KOK K, 1994, CANCER RES, V54, P4183; LEVINE TD, 1993, MOL CELL BIOL, V13, P3494, DOI 10.1128/MCB.13.6.3494; NUMOTO M, 1993, NUCLEIC ACIDS RES, V21, P3767, DOI 10.1093/nar/21.16.3767; OHNO T, 1994, ONCOGENE, V9, P3087; Okano HJ, 1997, J NEUROSCI, V17, P3024; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; Roche J, 1996, ONCOGENE, V12, P1289; SEKIDO Y, 1994, CANCER RES, V54, P4988; SINGH R, 1995, SCIENCE, V268, P1173, DOI 10.1126/science.7761834; vandenBerg A, 1996, GENE CHROMOSOME CANC, V15, P64, DOI 10.1002/(SICI)1098-2264(199601)15:1<64::AID-GCC9>3.0.CO;2-2; VARELLAGARCIA M, 1997, LUNG CANCER, V18, P140; Wei MH, 1996, CANCER RES, V56, P1487; Wu L, 1997, IMMUNITY, V7, P483, DOI 10.1016/S1074-7613(00)80370-2	29	40	50	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 22	1999	18	16					2589	2597		10.1038/sj.onc.1202601	http://dx.doi.org/10.1038/sj.onc.1202601			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	189LU	10353602				2022-12-25	WOS:000079907100006
J	Wang, YC; Blandino, G; Givol, D				Wang, YC; Blandino, G; Givol, D			Induced p21(waf) expression in H1299 cell line promotes cell senescence and protects against cytotoxic effect of radiation and doxorubicin	ONCOGENE			English	Article						inducible p21(waf); senescence; anti-cancer drugs; radiation	CYCLE ARREST; HUMAN FIBROBLASTS; WILD-TYPE; APOPTOSIS; P53; P21; INDUCTION; P21(WAF1/CIP1); INHIBITOR; WAF1/CIP1	The CDK inhibitor p21(waf) is a principal mediator of p53 function but can also be transactivated by many p53-independent stimuli leading to cell growth arrest or differentiation. In order to study the function of p21(waf) in a p53-deficient environment, we established an inducible expression of p21(waf) in the p53-null lung cancer cell line H1299, based on the muristerone-regulated system. Overexpression of p211(waf) led cells to growth arrest which after several days became irreversible and the arrested cells acquired a senescent phenotype as judged by cell shape, the senescence-associated beta-gal marker and inhibition of colony formation, The effect of p21(waf) overexpression, in the absence of p53, on the cytotoxicity caused by irradiation, doxorubicin and taxol was studied. Expression of p21(waf) provided protection against the cytotoxic effect of radiation and doxorubicin but not of taxol. These results are relevant to treatment of cancer when p53 is inactive.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Givol, D (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.		Blandino, Giovanni/B-1137-2013	Blandino, Giovanni/0000-0002-6970-2241				Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CHEDID M, 1994, ONCOGENE, V9, P3021; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; ELDEIRY WS, 1993, CELL, V75, P805; Fazeli A, 1997, P NATL ACAD SCI USA, V94, P10199, DOI 10.1073/pnas.94.19.10199; Gorospe M, 1996, MOL CELL BIOL, V16, P6654; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; HARPER JW, 1993, CELL, V75, P817; Kondo Y, 1997, EXP CELL RES, V236, P51, DOI 10.1006/excr.1997.3693; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MICHIELI P, 1994, CANCER RES, V54, P3391; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Poluha W, 1996, MOL CELL BIOL, V16, P1335; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Sambrook J., 2002, MOL CLONING LAB MANU; STEINMAN RA, 1994, ONCOGENE, V9, P3389; Sugrue MM, 1997, P NATL ACAD SCI USA, V94, P9648, DOI 10.1073/pnas.94.18.9648; TAKAHASHI T, 1992, CANCER RES, V52, P2340; Uhrbom L, 1997, ONCOGENE, V15, P505, DOI 10.1038/sj.onc.1201227; Waldman T, 1997, NAT MED, V3, P1034, DOI 10.1038/nm0997-1034; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang YA, 1997, P NATL ACAD SCI USA, V94, P14590, DOI 10.1073/pnas.94.26.14590; Wang YC, 1998, ONCOGENE, V17, P1923, DOI 10.1038/sj.onc.1202113; Wouters BG, 1997, CANCER RES, V57, P4703; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZAKUT R, 1995, ONCOGENE, V11, P393	34	121	124	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 22	1999	18	16					2643	2649		10.1038/sj.onc.1202632	http://dx.doi.org/10.1038/sj.onc.1202632			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	189LU	10353608				2022-12-25	WOS:000079907100012
J	Abdel-Rahman, WM; Georgiades, IB; Curtis, LJ; Arends, MJ; Wyllie, AH				Abdel-Rahman, WM; Georgiades, IB; Curtis, LJ; Arends, MJ; Wyllie, AH			Role of BAX mutations in mismatch repair-deficient colorectal carcinogenesis	ONCOGENE			English	Article						BAX; colorectal cancer; RER; mismatch repair	TUMOR-SUPPRESSOR P53; TGF-BETA RECEPTOR; MICROSATELLITE INSTABILITY; COLON-CANCER; IN-VIVO; GENE; BCL-2; PROGRESSION; CARCINOMAS; PHENOTYPE	BAX gene mutations occur in approximately 50% of RER+ colorectal cancers. To determine the role of these mutations in tumour progression we analysed multiple different tumour sites from RER+ colorectal cancers for BAX mutations. Sixty colorectal carcinomas were analysed for microsatellite instability at loci BAT-26, L-myc, TGF beta RII, D13S160 and D2S123. Twelve out of 60 tumours (20%) were RER+, Forty-five different tumour sites from the 12 RER+ carcinomas were analysed for BAX mutations at the [(G)8] tract in exon 3, Six out of 12 (50%) RER+ tumours showed BAX mutations, four of which showed a homogenous pattern of such mutations detected in all tumour sites. In the other two cases, BAX mutations were present in some but not all tumour sites sampled from the same patient. In contrast, TGF beta RII mutations were found in 9/12 cases (75%) and in each of these were present in all the sampled sites. Two cases showed neither BAX nor TGF beta RII mutation. These data suggest that mutations in TGF beta RII may occur at a very early stage in tumour progression, perhaps in the founder clone. BAX mutations, however, are clearly not necessary for formation of the founder clone and can occur for the first time later in tumour progression.	Univ Edinburgh, Western Gen Hosp, Mol Med Ctr, Sir Alastair Currie CRC Labs, Edinburgh EH4 2XU, Midlothian, Scotland	University of Edinburgh	Wyllie, AH (corresponding author), Univ Cambridge, Dept Pathol, Tennis Court Rd, Cambridge CB2 1QP, England.			Abdel-Rahman, Wael/0000-0002-2149-1043				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Brown R, 1997, BRIT MED BULL, V53, P466; Bubb VJ, 1996, ONCOGENE, V12, P2641; Chung YJ, 1997, ONCOGENE, V15, P1719, DOI 10.1038/sj.onc.1201343; GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P118, DOI 10.1016/0006-291X(85)90390-0; Hoang JM, 1997, CANCER RES, V57, P300; Huang J, 1996, P NATL ACAD SCI USA, V93, P9049, DOI 10.1073/pnas.93.17.9049; JACOBY RF, 1995, GASTROENTEROLOGY, V109, P73, DOI 10.1016/0016-5085(95)90270-8; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Ouyang H, 1998, CLIN CANCER RES, V4, P1071; PARSONS R, 1995, CANCER RES, V55, P5548; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Samowitz WS, 1997, AM J PATHOL, V151, P33; THIBODEAU SN, 1993, AM J HUM GENET, V53, P1; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Yagi OK, 1998, GASTROENTEROLOGY, V114, P268, DOI 10.1016/S0016-5085(98)70477-9; Yamamoto H, 1998, CANCER RES, V58, P997; YOUNG J, 1995, GENE CHROMOSOME CANC, V12, P251, DOI 10.1002/gcc.2870120403; Zhou XP, 1998, GENE CHROMOSOME CANC, V21, P101, DOI 10.1002/(SICI)1098-2264(199802)21:2<101::AID-GCC4>3.0.CO;2-4	24	32	34	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 25	1999	18	12					2139	2142		10.1038/sj.onc.1202589	http://dx.doi.org/10.1038/sj.onc.1202589			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	179TX	10321738				2022-12-25	WOS:000079346200011
J	Braun, M; Buchen, B; Sievers, A				Braun, M; Buchen, B; Sievers, A			Electron microscopic analysis of gravisensing Chara rhizoids developed under microgravity conditions	FASEB JOURNAL			English	Article; Proceedings Paper	Symposium of the European-Space-Agency/National-Aeronautics-and-Space-Administration Workshop on Cell and Molecular biology Research in Space	JUN, 1998	BELGIUM NATL ACAD SCI, LEUVEN, BELGIUM	European Space Agency, NASA	BELGIUM NATL ACAD SCI	gravitropism; statolith; tip growth	TIP-GROWING CELLS; STATOLITHS; GRAVITY; MICROFILAMENTS; CYTOSKELETON; GRAVITROPISM; TRANSPORT	Tip-growing, unicellular Chara rhizoids that react gravitropically on Earth developed in microgravity, In microgravity, they grew out from the nodes of the green thallus in random orientation. Development and morphogenesis followed an endogenous program that is not affected by the gravitational field. The cell shape, the polar cytoplasmic organization, and the polar distribution of cell organelles, except for the statoliths, were not different from controls that had grown on earth (ground controls), The ultrastructure of the organelles and the microtubules were well preserved. Microtubules were excluded from the apical zone in both ground controls as well as microgravity-grown rhizoids. The statoliths (vesicles containing BaSO4 crystals in a matrix) in microgravity-grown rhizoids were spread over a larger area (up to 50 mu m basal to the tip) than the statoliths of ground controls (10-30 mu m), Some statoliths were even located in the subapical zone close to microtubules, which was not observed in ground controls. The crystals in statoliths from microgravity-gown rhizoids appeared more loosely arranged in the vesicle matrix compared with ground controls. The chemical composition of the crystals was identified as BaSO4 by X-ray microanalysis, There is evidence that the amount of BaSO4 in statoliths of rhizoids developed in microgravity is lower than in ground controls, indicating that the gravisensitivity of microgravity-developed rhizoids might be reduced compared with ground controls. Lack of gravity, however, does not affect the process of tip growth and does not inhibit the development of the structures needed for the gravity-sensing machinery.	Univ Bonn, Inst Bot, D-53115 Bonn, Germany	University of Bonn	Braun, M (corresponding author), Univ Bonn, Inst Bot, Venusbergweg 22, D-53115 Bonn, Germany.							Braun M, 1996, PROTOPLASMA, V191, P1, DOI 10.1007/BF01280820; Braun M, 1998, PLANTA, V205, P39, DOI 10.1007/s004250050294; BRAUN M, 1993, PROTOPLASMA, V174, P50, DOI 10.1007/BF01404042; Braun M, 1997, PLANTA, V203, pS11, DOI 10.1007/PL00008098; BRAUN M, 1994, EUR J CELL BIOL, V63, P289; Braun M, 1996, J BIOTECHNOL, V47, P245, DOI 10.1016/0168-1656(96)01529-5; BUCHEN B, 1993, PROTOPLASMA, V172, P38, DOI 10.1007/BF01403719; BUDER J, 1961, BER DTSCH OT GES, V74, pS14; HEJNOWICZ Z, 1981, PROTOPLASMA, V108, P117, DOI 10.1007/BF01276887; HEMMERSBACH R, 1998, ESA; KISS JZ, 1994, PLANT PHYSIOL, V105, P937, DOI 10.1104/pp.105.3.937; Laurinavicius R, 1996, Adv Space Res, V17, P91, DOI 10.1016/0273-1177(95)00617-N; LEITZ G, 1995, PLANTA, V197, P278; Miller DD, 1996, PROTOPLASMA, V195, P123, DOI 10.1007/BF01279191; SCHROTER K, 1975, PLANTA, V122, P213, DOI 10.1007/BF00385269; SIEVERS A, 1991, BOT ACTA, V104, P103, DOI 10.1111/j.1438-8677.1991.tb00204.x; Sievers A, 1996, TRENDS PLANT SCI, V1, P273; Sievers A., 1991, CYTOSKELETAL BASIS P, P169; VOLKMANN D, 1991, PLANTA, V185, P153, DOI 10.1007/BF00194056; Volkmann D, 1996, PLANT CELL ENVIRON, V19, P1195, DOI 10.1111/j.1365-3040.1996.tb00435.x; VOLKMANN D, 1990, ESA SP307, P497	21	9	9	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.		1999	13			S			S113	S120						8	Biochemistry & Molecular Biology; Biology; Cell Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	198CF	10352152				2022-12-25	WOS:000080403800014
